<SEC-DOCUMENT>0000885590-22-000025.txt : 20220510
<SEC-HEADER>0000885590-22-000025.hdr.sgml : 20220510
<ACCEPTANCE-DATETIME>20220510171744
ACCESSION NUMBER:		0000885590-22-000025
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		115
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220510
DATE AS OF CHANGE:		20220510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Bausch Health Companies Inc.
		CENTRAL INDEX KEY:			0000885590
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14956
		FILM NUMBER:		22911054

	BUSINESS ADDRESS:	
		STREET 1:		2150 ST. ELZEAR BLVD. WEST
		STREET 2:		LAVAL
		CITY:			QUEBEC
		STATE:			A8
		ZIP:			H7L 4A8
		BUSINESS PHONE:		514-744-6792

	MAIL ADDRESS:	
		STREET 1:		2150 ST. ELZEAR BLVD. WEST
		STREET 2:		LAVAL
		CITY:			QUEBEC
		STATE:			A8
		ZIP:			H7L 4A8

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Valeant Pharmaceuticals International, Inc.
		DATE OF NAME CHANGE:	20100928

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOVAIL Corp
		DATE OF NAME CHANGE:	20100416

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOVAIL CORP INTERNATIONAL
		DATE OF NAME CHANGE:	19960522
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>bhc-20220331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:9c0993e0-3c65-4e23-b478-aba95d934319,g:036e3555-df42-4f12-aaee-1876eac48ef4,d:801c461cbd33492a893c84373a8e7cbc--><html xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:bhc="http://www.bauschhealth.com/20220331" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:srt="http://fasb.org/srt/2021-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>bhc-20220331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180L2ZyYWc6ZGJjN2QwODhkZjdkNDNmZGJmOTU3OTBkMDkyNGQyNjYvdGFibGU6MmE0OTYwMTM5NmVjNDU2M2JmYmYxYTBmOTk3OTAwMGEvdGFibGVyYW5nZToyYTQ5NjAxMzk2ZWM0NTYzYmZiZjFhMGY5OTc5MDAwYV8zLTEtMS0xLTg5MDcy_9fde6d31-8274-4e83-ac65-1863b374a7bb">0000885590</ix:nonNumeric><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180L2ZyYWc6ZGJjN2QwODhkZjdkNDNmZGJmOTU3OTBkMDkyNGQyNjYvdGFibGU6MmE0OTYwMTM5NmVjNDU2M2JmYmYxYTBmOTk3OTAwMGEvdGFibGVyYW5nZToyYTQ5NjAxMzk2ZWM0NTYzYmZiZjFhMGY5OTc5MDAwYV80LTEtMS0xLTg5MDcy_b53f797b-c025-4146-bba7-00745dc95964">12/31</ix:nonNumeric><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180L2ZyYWc6ZGJjN2QwODhkZjdkNDNmZGJmOTU3OTBkMDkyNGQyNjYvdGFibGU6MmE0OTYwMTM5NmVjNDU2M2JmYmYxYTBmOTk3OTAwMGEvdGFibGVyYW5nZToyYTQ5NjAxMzk2ZWM0NTYzYmZiZjFhMGY5OTc5MDAwYV81LTEtMS0xLTg5MDcy_dcfa2248-4453-41c4-9c20-71a3bf79a011">2022</ix:nonNumeric><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180L2ZyYWc6ZGJjN2QwODhkZjdkNDNmZGJmOTU3OTBkMDkyNGQyNjYvdGFibGU6MmE0OTYwMTM5NmVjNDU2M2JmYmYxYTBmOTk3OTAwMGEvdGFibGVyYW5nZToyYTQ5NjAxMzk2ZWM0NTYzYmZiZjFhMGY5OTc5MDAwYV82LTEtMS0xLTg5MDcy_0613fda4-f14b-4b67-b529-821575e0a070">Q1</ix:nonNumeric><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180L2ZyYWc6ZGJjN2QwODhkZjdkNDNmZGJmOTU3OTBkMDkyNGQyNjYvdGFibGU6MmE0OTYwMTM5NmVjNDU2M2JmYmYxYTBmOTk3OTAwMGEvdGFibGVyYW5nZToyYTQ5NjAxMzk2ZWM0NTYzYmZiZjFhMGY5OTc5MDAwYV83LTEtMS0xLTg5MDcy_0a5d6cd0-0ade-4426-a9c2-774515b1cff5">FALSE</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="iea36229e5f1244b3b1faa248153f8623_D20220101-20220331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183MC9mcmFnOmU0ZTQ5MmIyYjc1ZDRjNDJiYzYyNjQzY2ZkZTViMWVkL3RhYmxlOjYyYWE1YWViNWUyYzQ4YTk4MTVlYzBiYTg1MjM1NjM1L3RhYmxlcmFuZ2U6NjJhYTVhZWI1ZTJjNDhhOTgxNWVjMGJhODUyMzU2MzVfMy0xLTEtMS04OTA3Mg_7c2956ef-0f5f-47fd-9406-5802ec3250d3">0.5</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="bhc-20220331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4a7b4e0ac9943a9b88f1223220896de_I20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-05-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i27191b9cf0284661bc72bab06e9a28cc_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="idc41203b79724c8b8c35295ae22f1ee5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7062f2c8d3b74170b8ed9d57d942850f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47ece7f00f6a493a9f2236a26d681928_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69f7b40936e24b94a92542e01f316976_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5e530ee58404ccc965b53fc6d73c350_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i13d8ae26fd5b445285277b95f6ab5311_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba49a57b938b4b89b6c94414674a0509_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84be42c574674323bfa1ce40efc25a3b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e97a6c789b1443ba408d058697c5cc2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdfc8eeec050428bb667d6d8a8100215_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if569d73216764720b3070f4e5764288d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7de19b3349ed480785851723d3e2ec65_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ae02726ad6f44979a1c380354d1b1ee_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77808f738d5b47f0b37ad9c848b56f22_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f4e826d5cae4c6ab418a941d7cc0de2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c0970c94f194e79b173d2e77e2e293e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfaddc1e31294937b80e601e88e11ec4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id18917e004004a1cb3c4e185b15bf4f9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f63b9f26c034375825caac2dc4a720d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib79580d46a03440a901afd4aa7cf0eae_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38bc8011408047f4b2f92fc815fe79b3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f1e816041a249bcaedd71a44ddc03c1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0925610a81344f42966f7155678bbe7d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bc0f97e922441d290fd2952ed4015ca_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f39cf0ad53f489993087fb8612e9e44_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i580f9e18b59a4b5180b3f4e43139f3fd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c28220a2c554d82874543d9cef4c95f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ec67446aa664948b24b2dd151b61e21_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida777d6fa6784748b45afb0c1b8b936f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d274a4a3e5a43ae91dfbb2934c4c5d1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i250250ab4d084a8688cdf94e83fcc6ea_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9abb088ab0824fe28335ba83a90707de_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4db7cba132fa4f3593873402ff1be811_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cf56ffa097d418fbaa7f8cee2095239_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf2c42a95b1b488c9bb882abf26775af_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c96e3e707c44ef29db8e7d1430f0ccf_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc469902b8d54318b2dc5e3d6f63767e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a3043cdb1ec4efba6e8a08d5c15f7d0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8aed8fa227084065a8e36af7e4853547_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8e74f44512b4b5ba5eadd53d7ab8369_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2671fe8b646f46afb7fa5e65ea5d1e7b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f5376ee1f8e4cf1a9859fc1a22909f3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i812289a7a0cf44b4b1eed544ad0bec6c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="country"><xbrli:measure>bhc:country</xbrli:measure></xbrli:unit><xbrli:context id="i68726a27c9ca4a3a994459eb340ec3da_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0d8e4dd5979420fbef5b45edd961b43_I20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae181339de7f48fb8794bf85314efcc0_I20210803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="company"><xbrli:measure>bhc:company</xbrli:measure></xbrli:unit><xbrli:context id="i3b5fdcedce07473f95b4d896abcc8dc6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id234e6e6761c4d3fadd602df79c36a18_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3282ac48025c402fb8242346f1697dc3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f7124918f0c4940946cbc5598b8eb93_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82cd23474eef475d818ea158ef0a033c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f025023becd4701b88a21aeb30b1551_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2702eb3989e049ee9ba259ff98e17bd5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba1bbd977ad949bb8ef314204d0f9031_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75a4cf7e52aa4b4baa6fd5cc411e8269_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib297e736b3f84933b2038cba50e4d5ed_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1d87c2977704a1e9e27fa4ce9d6f6ca_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91537bd044f94fd8a698e842e7d17804_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i445a6442a30f43b594d2d8364e5b4894_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcb261aecea64295aab4bf43ac889601_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bcf6389cdc947f7ae05710631221f68_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i697ad802318444ba908fe6471d84bff7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if292799a4efd4044b18a023be1f10b95_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fec8302d4c14f00b65fb0e31f318228_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PriceAppreciationCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia46992a39fd44a9b8ea71a5f0394d386_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f9959394a574ff69f1d9b58d938d4d3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e23891f40464cfa8e56cdb7bab0040d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9401e356d1aa4b399cc5adc2cd56f34c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic58ddf3411fb47e0af82f6f1e662bf16_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54b8dbfb41c7451caad9c7ce92634d2b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e143ff88d214dff8d83bfb996d04d80_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i038c797945244014ae7afbec7d83111e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie89ad456c68d4bbbbdbaf276e1161261_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92d2b71d6b3c41538e26137d45cf75e6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e170c61a34348efbeb9b2757d9d6ff0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cc8ac7cdffe4470a00c7b19194e2fd9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia71b36fbbd72476aa3d99cbc13954b77_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacbae26421d743459b9dfa79bcc4f94f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6300cf7309e042b48c456d1a58ee874f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39945b5b3dde4b2f9bc375faa8ded0c1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa437e0185f6406491796407827b52e0_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idba10c80ddf84c3cbaffdb663edf3e53_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PriceAppreciationCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3524eadbe1ec47a0a36751409752f55b_D20210331-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21711d9019c8476f949b23d06ee0e9c1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bhc:AssetImpairmentChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d5bc364e17040579714c24cebd52ba5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f59ac9f2ff644c89eb4f65f46c45061_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i956734b907cd48758decdff4f630c6f9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc39509affcd41d9a58e0cca4fe7e0eb_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85c368e92b024530907723a0994de3c7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:SeparationAndInitialPublicOfferingCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fb5f4d139b04ae9b628f854af7fd7ee_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:SeparationAndInitialPublicOfferingCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bdc5e2685a240ae96ca33df37493045_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i363991f4b7144460a084057864c8034f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc1a0b5922ad406796cebf7b0701a0cb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20f7343e1588476cb8e134ea3252cb58_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if45e89de6ed14de1836e660f70eb9092_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i150d2e94468344d2bba3906c337eef86_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa7390cf31be44f1986a62d20c407d5b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica75b10c2fbd403ea21ee75a6cd245bd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0cbf30c76af4d498983e82d4fdca172_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if05c08af1a034dc7980de8e6d52990be_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b499ddf7ec0496ba113157683c198d2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81fe5dde69aa4fa98b7711acbae4387f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i100091396ce9444685173217122765a6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i723c0252bb3e4eb98782b62a2ac15585_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i258050e5f8ba4ce1b2273604ec31e67f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7cdfcca5d2f4a10b641c8f4d80b31b8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5945a5ff5f34495dab13516392201c16_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b77eb6463994ae99224a58bba550905_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bhc:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b4e235324904728b762550f85fa7269_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee66331a046f4575acc6e455516cc956_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="appeal"><xbrli:measure>bhc:appeal</xbrli:measure></xbrli:unit><xbrli:context id="ia2c311dd5c6b469480afc3e5392a01db_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e2fdd6767694d7e97928c8c973cce88_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb234a60c94344e9a94bfbc00466a78a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46cf2f3899da4a21a3b37afd85cde532_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf2062d283b74ee789d97615ebc112e9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf8c5147a31443548f1f01cdff3ee173_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0fafc41fd0d46f2aafbccde9b40c90f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1d2d795d550443991566dd2c6bcf53b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f0e25e6a91b4e2e872255dda15e2d72_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bhc:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i811cc5ac0cc64328ad722d7dad5db8b1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ec8590d1fe9450a8eb2faa9ceaf5975_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0b87773b146435a838297c342e6101d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf65fa777b444e8b899db7eb8bab459d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ba0dd91cc574f9abe328ce7f85dc950_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="rate"><xbrli:measure>bhc:rate</xbrli:measure></xbrli:unit><xbrli:context id="i142e78536e92483bb3067f4b123b35c7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id92289d625924bfcb27511b3c14249c7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">bhc:MeasurementInputWeightedAverageDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib824c124997f479bbc169d1602673e5b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:AccretionForTimeValueOfMoneyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if29face7dd5e4f4f824bb78e8b24bb84_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:AccretionForTimeValueOfMoneyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbb2bee16b5a4770b40bde7992c3b661_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7beef5fa81be4f83928de85244de7710_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1ad1d6d1a0146b0848446f63d1074ab_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc49a20c1efb4682a698d499e7132490_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33581fa718c7424d96b4ece6084ce29f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69ed23fd69344f4bb9c380845d6fda6f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cfcfb06623f468794d93d4a7a2a0b37_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2b058cfe7264b67b8928b4f04d339b3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01425e632a3246ef8376661a776befbe_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i128fe797bfca49acb9c7413882eb5f28_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6778a58f66f24243ab203161f3c6127d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8420c39690874c31bfc4e99fc56813a9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdae99c37fc148b9b34c052c3f5ee437_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc94d751eecd4f2884cec4ffed6f0547_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i184da53a325548e5a9b4d68317c28bf5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7adc09fd30f54c31a00d1b781106171b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24b3278f312448edbdbbd2e5c8edb4ea_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9aa88c188d514752bb8a235164b310e8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:DiscontinuedProductLinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd413c64fca1463c942b8ada290af82b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78352536ea52411880331b5c2102a14b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:DiscontinuedProductLinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i942199177b494651b884505a5348aee8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12b373f353694a7a92ef13969e363c9c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f9c2f75c9054ca7be42d333db8aa66a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a8465040b7746bbbb02d83f214f8936_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e916e0c53bb4694a37e063fb61adc77_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56804b7aa6534ed9b555f349c187b56d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b662e8f657b4e3ab3b79a4cebde04c2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib37696822d2c4572b3c78344c1fd444a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia94fd825df534043ad9a8d3ff85daa7f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dcff32aa885494dbd4c25e336b285dd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i928ceb331757485bb004adc674715221_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab3980bb98104da18c9a7bfacb2b814c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icad79738cfa145e4ad3efae80a8f7853_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i883adcdb932a4b7facd79e34969366b7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie485ba4bcfb74a319879f1cc1994ceb1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc6abfd8107c426d88c7af70640541ed_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16fa5c63321a4379872d667cd4f09ff7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3e9f44ea7f04ab4bb12e34a4d9b198f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03d9858da1a54c6a897587b6b5079ca1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cc8090790184dbd8e5fef8bc092f80c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5df5fcbde684e86add3147c9fe2ea1c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i897d561735644b67b640f606386ea273_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03af4a3fb12d4415985732b5f1713c51_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c5165be148344bdaf507fcd8cd8faa1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff8cffb5a07d43829a8ad9375270cefc_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17fd70111a574d2ca873e85d5d905ac6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42279724503f49f38806cc3713f1dec9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c7901af22c14ac2ad3c4144a35ef0c6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05c0aa9bce2948fe95f19480427221e2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb4928a2aeb34ea08a24be593ce24cf0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05c4425257364b019ef82d6d8127a3d0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i22918d18bb77417eac5d796b8c470056_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59dd4c241bfe46cab97c7f62aa7998be_D20210331-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i813f53a5817849fa8b332b4429a806c7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:ReportingUnitsExcludingOrthoDermatologicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i352bdc0bdb3746bcab18bb34559bda96_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3d106cc00bb4068aeaadfb5a27059ab_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b7487693f3a42968a15d65a005a518a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i579bd73ae67e4680b7518c0d567bd33c_D20210331-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76fa5b74ac474ce785d33b402a51a48b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0aeee5779e6741b5a846738af963baa7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bde0da879c447c1bce8cc7c0ff990a9_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66cd53bf84e745829ac8a76a80274bef_D20210630-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-30</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i273ea466a0c24f7f9a2bc799a58a59b0_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84c7e2b9e5eb4b97857089a8cd8efa23_D20211001-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="reporting_unit"><xbrli:measure>bhc:reporting_unit</xbrli:measure></xbrli:unit><xbrli:context id="i600f2612b7b641d682431ce561c69ad9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6561f3b97934eda8c2522f1ea9ce1b7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76f9207c1db94dfbacf80f2bc2b52b0d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06779efa67a44834b0f4f24944444a1b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i782e0885b3064787aa9e926150c70157_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc86294f39b245aebaa7bec35dc0f511_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54411522c1a245de9350f74e2cd4c3d1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1632bbe90c084a8bbad28b27f64c1f85_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic53f52344dcd464f82fdd9233f9e3fbb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.50NotesDueNovember2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i488c2864915b43b0b468383a88a34995_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.50NotesDueNovember2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09bbf996de02471991c5b856e064297d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ba04ab2a63c40b39e946e401067a3d9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfa4659d82fd4e9583cb868b85c3feab_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.75NotesDueAugust2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9b94284819448b1933c562ef7aded08_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.75NotesDueAugust2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2abc875715cb4b1fa661daa27ac2f5af_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic574f713857543fe848f75d40d04e380_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i379ff2b3df7445b5b936e826c3995957_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i247336064728420fafc7c84febff7ebc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2f961c12b854470a0cc36e07e92006e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes900DueDecember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7146a1406b5149a0897a90ac7344b1bb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes900DueDecember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b4545d9fb57437bbacc0e55479da783_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes925DueApril2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f68bb5402fa40aaa3d1e8a5876a1481_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes925DueApril2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b5e0bf7441145f3a22ac4510e73101b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes850DueJanuary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia02b8e8095664970aeeda0fcc527bb86_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes850DueJanuary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5833ace0facf472a8cf1a49a6becbe8d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueJanuary2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4758100c83ee4d7f82d179bcb44516dd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueJanuary2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb63f20c4f224de380f590b991ab70bd_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueJanuary2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6a900b7cea44342b2ebea58f9a1a829_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueJanuary2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a9e5ff5b17847ae8c5b4a20045b80a7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa9fb491c6f44e0494c78843ae2d7d07_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9d48b1e660749f7a7367bb5dc150e1b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueFebruary2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ab99de7a1954ce6996bda7caf7833a8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueFebruary2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib88817449df74848a8baeff6c02361f9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes725DueMay2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4341fd255afd4b2f98811eb433952df1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes725DueMay2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51f3dd4e5a524f1bbf10cd1a0055202c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueJanuary2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ee2ed402ff54a6f843446ee188a72d8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueJanuary2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if151bdb884d34ff6b871d14b1339db96_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueFebruary2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i504ae7293b234304b31a5f5ef8da3011_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueFebruary2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if31b5959255941138da93ebd548669bb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:OtherLongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cee80bfcbe74e0c8421a1c67604dccd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:OtherLongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3baf0d17d1ce4fb09e14886b74b202be_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bhc:SeniorSecuredCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd8b2b705a834db0850fd8a5ff15144a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c325805e88f46bb919acf58b5da907e_I20180601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7609d2be3db44f5af9ae6b7c8e642b7_D20180601-20180601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i805461905703413cb5837246f45f0ab6_I20180601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f9d786ce6b041f08ba221a702f7956d_I20180601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ec4d9258ade4c988572b72ab0b9bcda_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50ea92505146474394a150389011b6f2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87085be380954b8f8d3c8aca38e1f32f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f1641e5674c4a75b682c9b185796d5c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:CanadaBankersAcceptanceRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9578b054a9c3434d956829eb311cdcd5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:CanadaBankersAcceptanceRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i615747c5edca4f728ff0d5d6e3cdb38d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb673f79152245ccaaa71c72c83aca5f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9f46032075146bb974b5459828d0837_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:BaseRateOrPrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebb71b6e150a4d3583b70be11293ebbb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88f4e8e6d2a74bb3bbf6df6210d11118_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifce02581a2a24dcf8c3af7034d61d45b_D20220331-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-31</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20665638c329437cab38c53e8d90d29b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15c4387da4984e3890700c3445ff56f7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd749185fb814c7eb0ea4622273efa10_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b1c2edd6efe487a80e89a2e9dfacbc3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie92612a0f96b4f89b84ac22fb594d512_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i891a2d21f1024827aa29f1df940ffbb3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8602535e6b14704b3f07b216531b82d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a1cfa5016e04bb3a7bc13c20a921226_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i730cebd5276140a781d756138d28a05d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3525c40548924586bbd17234ab1c71c3_I20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad4d39b309f5434c87cf47a080a1d040_I20210608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcbf9946c1974457a0c4173198dc2413_D20210608-20210608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueMarch2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-08</xbrli:startDate><xbrli:endDate>2021-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2fbd73a42e346bea819f0b583f98618_I20210608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueMarch2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95e73196dfe44ca6bb964e033fa104f5_D20210608-20210608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-08</xbrli:startDate><xbrli:endDate>2021-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88e8d3f432e14718a0ba0ed393f9efbf_D20210608-20210608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-08</xbrli:startDate><xbrli:endDate>2021-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8673b92629a48189ea708c9a312bfe5_D20210608-20210608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-08</xbrli:startDate><xbrli:endDate>2021-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if16401eb786046228b3c642b80d44636_I20220210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0fb622b80e1461e88f672d0cba387ac_D20220210-20220210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-10</xbrli:startDate><xbrli:endDate>2022-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida33ef4fd5a74725af4144c875055297_D20220210-20220210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-10</xbrli:startDate><xbrli:endDate>2022-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice4047eb87914dd280d3a5673cae9b27_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1e3d8f9146049ff9febeb80d7774565_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba4cf152a5ec43589599bfbc8c8881de_I20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A2027RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea36229e5f1244b3b1faa248153f8623_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i830e50982f6544d8ac6e50bc7bd7c443_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic655b0478ac14dac9616872cec7db523_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5551d17df34844848847e1383a62e7c3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74e0245bcf24424487c80b95aed98a9d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i673851b86a634af7b2f89d29c8e7cac4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2d66b26d13244be9ae6815748b18427_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28d956fcdc7e473694aec5169b2c17fd_I20140531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i407781f626f341f296f71f5e85d199df_D20180430-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-30</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79d17571326d4113a14289e30a432c94_D20180430-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:NonemployeeDirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-30</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9d13a041f834d2f9ed315beee256b39_D20200428-20200428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-28</xbrli:startDate><xbrli:endDate>2020-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24dd995e79e2480eb8534ebdb9b36ffe_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c3748cc38b94811b494a048524f18d4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbcf180e8ee94c498f903101c65055cf_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5189be309deb481aba3dbe709f732ab9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i302c4d997fc44f5f93fd331d80fb1d09_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c8dba5a632049539392f661e0428449_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96274aa944bb4685b39b713920d2304f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16e6e5eeaf9441738f673fb99507f4e5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9aaaf1035cf34c098a5c6e6768c0dbf4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77c337a40ebb461491bdb6dab1118617_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fc2981be2ea44a386fb0f04805428f4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf0b5e90aca84802a2fe6dfc35444ad9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TSRPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief18d16522574e578066730177201d22_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TSRPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i672f6c3b00ec46e5ae4b3d4816dbc732_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:ROTCPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbfb63fc6db643aba45a4aa4ec0c1c63_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:ROTCPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64cc50678b8b42b28c6fffa51684b252_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:SeparationPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a2ccdb6d9074d6d8d84aba34115a27e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:SeparationPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46d6cdf39c0344c9997ac487916b5ced_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia421fa8b794e48b48d28fe42bfdcba6b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27c24a8f9680457fae0e0043ab55f83c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf07a0520a7f41db853c67b1c28a17a5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib705b8700b7f48e8b664f48c1ff6c694_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bhc:MilestonePaymentRelatedToCertainProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i634a33b4555248bda810d4755ec7944f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cbb08e41ef540369a6004ec2d016b37_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0765fea13c904226bd504d19d10dcd55_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b08aef1966547e9bd168396be5172b8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c234ad885934263b7d0d458906eac06_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice3d4454e30642078b6d278363d32c89_D20151001-20151031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-10-01</xbrli:startDate><xbrli:endDate>2015-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="case"><xbrli:measure>bhc:case</xbrli:measure></xbrli:unit><xbrli:context id="i8498207cf8ab47a98694e871b43ed0ac_D20191216-20191216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-16</xbrli:startDate><xbrli:endDate>2019-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52b91cd6bf81428da787050c41b56633_D20220331-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bhc:RestrictedCashAndOtherSettlementDepositsCurrentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-31</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9003a9e8d5e4cb890f3dca99318e110_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="group"><xbrli:measure>bhc:group</xbrli:measure></xbrli:unit><xbrli:context id="i596e029672034f1ebeeeb10da808b0b3_D20150101-20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffef6edab6454226a9a750b828094eab_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="action"><xbrli:measure>bhc:action</xbrli:measure></xbrli:unit><xbrli:context id="i66e66455cad94f43bea051172349e294_D20200804-20200804"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-04</xbrli:startDate><xbrli:endDate>2020-08-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="cad"><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unit><xbrli:context id="ib9363f6177cc4981a294b2f6d18e765d_I20190215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="entity"><xbrli:measure>bhc:entity</xbrli:measure></xbrli:unit><xbrli:context id="i3e992c240c2041b78b9cd6b48dde9c97_I20210317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70e88a8ce2b644ebb754e35500783f63_D20160527-20160916"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:RICOClassActionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-05-27</xbrli:startDate><xbrli:endDate>2016-09-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c2253862a7e47b3abf3762d16caa354_D20171207-20171207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InsuranceCoverageLawsuitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-07</xbrli:startDate><xbrli:endDate>2017-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="insurance_policy_period"><xbrli:measure>bhc:insurance_policy_period</xbrli:measure></xbrli:unit><xbrli:context id="i56f9cd8d429c490aa470859df6ea769c_I20210720"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InsuranceCoverageLawsuitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="insured"><xbrli:measure>bhc:insured</xbrli:measure></xbrli:unit><xbrli:context id="i33fa032d820947a1b95a1ffae232ac03_D20210720-20210720"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InsuranceCoverageLawsuitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-20</xbrli:startDate><xbrli:endDate>2021-07-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia47d407ff7c64c98a6e296b58ca6f86d_D20190801-20200730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2020-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7afbeb4c54a7426c95c622c88ede0f55_D20190801-20200730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationNonClassComplaintsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2020-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6f99e9cc813479883c5c2dc19cb2f6b_D20190801-20200730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:PlaintiffsDirectPurchasersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2020-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3162f07bec9e4a3daa43dcea08a13f2b_D20190801-20200730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationNonClassComplaintsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:PlaintiffsDirectPurchasersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2020-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cdef9a49476491db7e461eeea893094_D20210726-20210726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-26</xbrli:startDate><xbrli:endDate>2021-07-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3feba39b7c864f9287819ae735b85819_D20200326-20200326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:NorwichPharmaceuticalsIncLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-26</xbrli:startDate><xbrli:endDate>2020-03-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a34cd34e127459a89499090f4a93cbc_D20200828-20200828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PerrigoIsraelPharmaceuticalsLtdLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-28</xbrli:startDate><xbrli:endDate>2020-08-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ce85e02604a4aa4b028657df917f434_D20200501-20200501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PadagisLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6770fa9b73a64b54b1f41da09e16bf8f_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:MSNLaboratoriesPrivateLtdLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i484e9a2b823f442e9977dce133acdc8e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PatentInfringementLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="defendant"><xbrli:measure>bhc:defendant</xbrli:measure></xbrli:unit><xbrli:context id="i65eb0cafd758435f8136a068d6e0611a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ApotexIncLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>bhc:claim</xbrli:measure></xbrli:unit><xbrli:context id="if6cd264b4a7249cea5facc5b0e2e6685_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fb0759d98f74dea9d8da712d3d4ef7b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadb1f3c2425247b1a17793d33add0cd6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccdebf1cc8224c95806abf21a3970331_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-BC</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41ce3780c3a74f4da7f954a056043ef8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-QC</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9980036908434c78bce13e0b3f16a63d_D20211101-20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1c54f63619d491e9de1d89624c515eb_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bbcfb43fc7145b0bb30d7beba40cbb8_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:DoctorsAllergyFormulaLLCLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc58c0dcbe644cedb326ae513855b55f_D20190128-20190128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:LitigationwithFormerSalixCEOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-28</xbrli:startDate><xbrli:endDate>2019-01-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c75337ca1004f2ca22a8acafcee0b80_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85cfed31dcdb4b5fbdcfd5de90d79e53_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i269760d6627c41d9af67faeb79fcc823_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7a20cee7c49437a80ead9dc6edc62bf_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ce8c1f567d4480199ab7c96956ff606_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0baff1dd72ec4f1d9be30dc22385fd78_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i515ccc73a3044997b576a1bf8db45a42_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fa555eb8f35445291ded844157a0bbf_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03406ff2404048fa81b2e21abb5623f6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i204e74587c904466ba5b4d9604c5d421_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78e30f03ea4548deae9a927c4b6a6def_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d07c8e2cb2b45138d98bfa04aca8095_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57dad9adbdcb4f9eb8980d1993b5a15e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i956efc9320ef432bad3fbea5c3f1a4fe_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81a741d98a084635a313bb4bf76f4091_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64a60b01aba54bed9371ce993d6fcde6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide4e3d656d794986bc25805dd6eafb35_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i375b53e51f9a46f689b2c28b45772369_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26543803a914471b91cfff3fec88f408_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i965c5ef9967640559f4a892e2bc019c3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fb3820e9af24cffa7541b8391ded598_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33c622ed3818484b99457a5e5ac61b94_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c9d891249204a23b5a99cff63162625_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44029f40cbcc4c10b8745e5f1b7f00ea_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i443f3d343d0a48fcb2a083c30d4f80e3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24ebf624edfd4bdf9d7fdd3ec9d063ec_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45c1beafb56d472ead9374b62bb12e0d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93b04924fc4f4e13885891185ac2968f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9bd671b035e41d69c0e38a6f82fb9cb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff23cd75a927442b8803bc3729da27ed_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fc8477c42ba432494cf231b6c0d0bc6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i124b70687528481fa21c28eb1cd32810_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08499bccbbc4410cb5590fb188cf4b8f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95c4cba1caca493b898eda95b9d55af7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia38a1019d805412a8c33d8125fa11085_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb9c9b16f92e4c9ebdac506674e51576_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ef5e2b06a5642ab9e8f2e182c325773_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4ad50d4f8264e31a30246a147683d1e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa28b372582e4ed39b7c1cf546fdc7e2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6242e90d746b4facb737eb995d4cd3a1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd97f12e125642fcb0965c4f1a9363fc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59217fa829ff402c854f159e561f67dc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i559671273f154caeb21890281cc0f5d1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6583ef0acc464c159cccb04b0fec1a1b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b20d7a1afdb4a4880e7ffd0aa66b93d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica7d291dc2bd424e9fb044bf5d42a71d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a8e341755db419cb385c32abb37fbf5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ae1c40162554d5eb82184aadef55683_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09d760aefc9346f3ba42a8f6e9e5a1c4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3e109bbefcc46d498195d4ffe5d8600_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa0b5f041d2b45cf9d22badd73f64a23_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6786806a071a4586b8fe4628dc8b3a7e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e5a66dcb11244d9adafcfbfdcfaa3fb_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ac60a867fe14187a7ad6925c72ddfcb_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87d31612ba6e4870b08c2e8bbacff14b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ec570a785a84b3e8b00f4538ffd504c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbb358ccd88b4e1582585e87263d2797_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafde2cd7b3454407911b0fdbcfa6bdd6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89351cbae84d472fbc3dabeb58d46f5f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaccd246e128b428da512aad072f4e923_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i365abf392e8246c192b779a84beb07cf_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7aa0024629f24b1e86fc6db4add48d1e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3a2b93c59aa455cb5ec35f29c61b2af_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60c320b8b80142589fb80e99cc32f396_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id78c49bd421641d9bc16ae14a49b0f38_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50631f79a17f4417939599b18339e8ad_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i305ec4b1f3cf485cace07ea69588b9d7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8080745b5f44e97ae240acceb434c81_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74bb4d5c955a430c8f54a13eb2e95dbe_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b0c293a2a6e4e71a0b1622ed24842b9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63e664ec8ede4265b16d1a42ee684fc0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54f11fd19e174e98aea8c453c247a13e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i242c0d38400b4e0ebc1e4083d039a5d2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c17a4613b5a49258f9f5b8c94015244_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i595a156d88824a07951bbc6d45f101aa_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9021db7996494bfb917eaa4217e384e5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8a36b6287944ab9a444528b83f6e58e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0910908181894cb28f6e71d1b8022f02_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia346b213e50645b0a1038d38fc86c181_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08f479ec27794028980e1c2521cd237c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>bhc:product</xbrli:measure></xbrli:unit><xbrli:context id="i2cf35ad54d7f4e3b94b6b600661263c9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CustomerTopTenProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6c16437fc1645e5bd3f51dbfd6bc45d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CustomerTopTenProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i736938c435c34b8cbf4b9a86a5c1716b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1c251a743e84e29bcdcb92c1700440f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29ca60685fd143c4ada8c74045564916_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib389f9ca07bc4c7ca630c86bb01430f2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib632e708eb9e44e5a2c76e757b159704_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id62e8ded86954413866df53834a4022f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id17ace1eafa74b49b1494fa93c34f515_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfae22764ebc4680bba6944b73990b38_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d98656df59c417aa61bfd38cf347ab8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i309adbf2ee5c4529ad9d523c886afcbc_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71f5260404d34943ae2284710ac15bcc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0efa9862b055429eb1653d07596c035a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i038caeba82944fb08a4051fbf6da7b09_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60f8953bbbe6445eb5947c90b19aab2e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e0b22a76af3426bae92c761987b0187_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifeb045fdd1fd4540bf7a4106731f2f2c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e819574885a4427b258852c7217cbb7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief192120e21c43a1a934405e935223ca_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02bac5e7352941d58218671cc5ac18ee_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i388557aa2024443c871b4d4a9a886575_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bd53359a539414b9021c46b47d84743_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff2ea0b9ea7b4ff2b1dc7c83ee9f0674_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i477436c4d44d4790b5bee0250e92a451_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee07a351938545e1bc0374c9ee03db58_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c9cbd283603466d890093b4f1ad2033_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie51fbc2dae9941b8b6e55b6fa231f07c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i704a8bd37aad403db52ecbc7efb33040_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4b0684914ec4f1b9d774361c28cb7b0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c455f78b2c24f19ab413825cf24b3b1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:AmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d795947131641bda6742f32f927ee39_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:AmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i735a4a9dd69c4f20ad6fa633744e4013_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:McKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc5628f43f5849428205c5a57a1c1fcf_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:McKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae7d7933e83c4caf870a090351b7a111_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CardinalHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbf2cc68e33744c4b8947828008ff5d9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CardinalHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2ffbb57b436490590a2819d68a36061_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9088830177c14b93899cdc2428206dd1_I20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9beb6982df2843ba905908dcf5d3e1c9_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie30ec3f614a04d42848dad1250068433_I20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b0e960b1ec848318fdc55394dac24fa_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07b15b7868704928b2944eba14639156_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic99afd1f228a44c78581651c6a9579a0_I20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i969796cd9c2a43459679467ac14382c6_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a1c85fad6244e21b4823c99ca9236cb_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6835eeba06904e7d83cc68aeeb30bc96_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaef1fd49551a4a5e99cc5c7286d61d19_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6062d01783b9476ab5d93d304f908fdb_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ed6554f1984485bbe1d859a5cce60e5_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37d22f117617444f9a62f2666aeaf23e_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebf7fa610282462e8a87798c4a0c13b7_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07c3bdbe9d364f85a235465f6572d30b_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i827cfce6b4184d368806fa2e3eab7b12_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15b198ca83624b318396f39380edc2ac_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2a157fb52da45df95151e9668b651b6_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7c0ae85a82c4cb3a319373f684bc55a_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i679d8e8de83d43b8aa7b432b14f90a83_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d5a322888ac487b9f4166843a4b2254_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a4a857f626f43fcbcdf8083edd3c4b1_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0dbac6e5e59470e9e96eab6a439d571_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4920545cfdfe43ea874d0ca5a349c081_I20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A2027TermLoanBFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a96cf695f3646188214a645c50f0e12_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A2027RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5263f4eeef0e4a1eb6008213ffca534f_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A2027TermLoanBFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00ec1ba964804053bf2cebbf5c43f522_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A2027TermLoanBFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i801aca530cc14c9b8be64fb696e6dcf5_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDORAndEURIBORRatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A2027TermLoanBFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id66d7e17675f4184972f0235d07b1e63_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A2027TermLoanBFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e33a46b9a8c458e92c2a7533b092615_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A2027TermLoanBFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedc6c37d8af5490d993ec3399bc55792_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A2027TermLoanBFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28d3080b48c44fb2a31f867511fa241f_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A2027TermLoanBFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5ba454a7b6c45a3949b8f1985ac313e_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A2027RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i053e8e2380ae405a8cf2ef0d0dac698b_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A2027RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i618e8b101a9e4651a8d45a1516a66fde_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A2027RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfc76cd45bc6474988b4e3877373db82_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A2027RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i577466297a53405f9454d33995ecba1e_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A2027RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5b37fae66ea41e88fed93726d182d6a_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A2027RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14ef51bcde474f27be0e9b588872b89a_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d6eeadd393b426393e1f0ed889d241d_I20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic809285ec99545369921696d670f6b36_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fe9c48370994d03935d785c7f1a8b8b_I20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49de6c3d04bb472d8b09e6bd0c1887d7_I20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia843743426e540ee8c98df5ca73090c9_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:NewRestatedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa22c8251ddf46939526e13e17458660_I20220118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A9.00SeniorNotesdueDecember2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-18</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i801c461cbd33492a893c84373a8e7cbc_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 45.00pt 36.00pt 45.00pt"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington,&#160;D.C. 20549</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGV4dHJlZ2lvbjphMTM1NTRlMGM4Yzk0ODgwOTc3ZDQyOTMyYzgxOGY2NF8xOTgx_fc850edd-396e-41bb-8549-adcc1867c237">10-Q</ix:nonNumeric></span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.798%"><tr><td style="width:0.1%"></td><td style="width:2.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.540%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGFibGU6MDQ2ZTQyMjAyZTA5NGEwODgzZGI4MGYxMWFkZmU5NzQvdGFibGVyYW5nZTowNDZlNDIyMDJlMDk0YTA4ODNkYjgwZjExYWRmZTk3NF8wLTAtMS0xLTg5MDcy_59bd49d1-0a2b-4b0e-89e4-1bd8978efc40">&#9746;</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-align:right;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Quarterly Period Ended</span></div></td><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGFibGU6MDQ2ZTQyMjAyZTA5NGEwODgzZGI4MGYxMWFkZmU5NzQvdGFibGVyYW5nZTowNDZlNDIyMDJlMDk0YTA4ODNkYjgwZjExYWRmZTk3NF8xLTItMS0xLTg5MDcy_9af76d0d-7891-4983-857b-924f99619e92">March 31, 2022</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OR</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGFibGU6MDQ2ZTQyMjAyZTA5NGEwODgzZGI4MGYxMWFkZmU5NzQvdGFibGVyYW5nZTowNDZlNDIyMDJlMDk0YTA4ODNkYjgwZjExYWRmZTk3NF8zLTAtMS0xLTg5MDcy_b251460b-7ab6-4417-a11d-4b1091d88d1c">&#9744;</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the transition period from&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">           &#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> to&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">           &#160;</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGV4dHJlZ2lvbjphMTM1NTRlMGM4Yzk0ODgwOTc3ZDQyOTMyYzgxOGY2NF8xOTc1_4679f6ec-b0f4-4a6e-bd02-b5e3a9240d3a">001-14956</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGV4dHJlZ2lvbjphMTM1NTRlMGM4Yzk0ODgwOTc3ZDQyOTMyYzgxOGY2NF8xOTgy_61dce745-e142-498f-b59f-70bcad273ed2">Bausch Health Companies Inc.</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.816%"><tr><td style="width:1.0%"></td><td style="width:22.429%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.330%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGFibGU6Y2QxZTY5MTM2ZGFhNGM4ZmFkYWIyODkwZWFiN2I1OGQvdGFibGVyYW5nZTpjZDFlNjkxMzZkYWE0YzhmYWRhYjI4OTBlYWI3YjU4ZF8wLTAtMS0xLTg5MDcy_54eb9144-3d04-40eb-872d-4a70a3099c48">British Columbia</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGFibGU6Y2QxZTY5MTM2ZGFhNGM4ZmFkYWIyODkwZWFiN2I1OGQvdGFibGVyYW5nZTpjZDFlNjkxMzZkYWE0YzhmYWRhYjI4OTBlYWI3YjU4ZF8wLTQtMS0xLTg5MDcy_5dc75537-ca9a-4000-bbdf-d1ccf06f81f1">Canada</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGFibGU6Y2QxZTY5MTM2ZGFhNGM4ZmFkYWIyODkwZWFiN2I1OGQvdGFibGVyYW5nZTpjZDFlNjkxMzZkYWE0YzhmYWRhYjI4OTBlYWI3YjU4ZF8wLTctMS0xLTg5MDcy_1c63e76a-636c-4605-a118-15c12012eef0">98-0448205</ix:nonNumeric></span></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGV4dHJlZ2lvbjphMTM1NTRlMGM4Yzk0ODgwOTc3ZDQyOTMyYzgxOGY2NF8xOTg2_71335e5d-2d8e-42d8-ae92-c6a97169264d">2150 St. Elz&#233;ar Blvd. West</ix:nonNumeric>, <ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGV4dHJlZ2lvbjphMTM1NTRlMGM4Yzk0ODgwOTc3ZDQyOTMyYzgxOGY2NF8xOTgz_62cfcd96-0f76-4e28-beaa-ebfcee0d2c2d">Laval</ix:nonNumeric>, <ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGV4dHJlZ2lvbjphMTM1NTRlMGM4Yzk0ODgwOTc3ZDQyOTMyYzgxOGY2NF8xOTg0_79bbbe37-adbc-47a2-931f-eac0d19dade2">Qu&#233;bec</ix:nonNumeric>, <ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGV4dHJlZ2lvbjphMTM1NTRlMGM4Yzk0ODgwOTc3ZDQyOTMyYzgxOGY2NF8xOTc2_36f4f928-8afb-42c7-b9c0-985850b4394c">Canada</ix:nonNumeric> <ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGV4dHJlZ2lvbjphMTM1NTRlMGM4Yzk0ODgwOTc3ZDQyOTMyYzgxOGY2NF8xOTg1_126ac9c6-719a-461f-8a2b-565a60ef8e9b">H7L 4A8</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of Principal Executive Offices) (Zip Code)</span></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGV4dHJlZ2lvbjphMTM1NTRlMGM4Yzk0ODgwOTc3ZDQyOTMyYzgxOGY2NF8xOTg3_f69e7f0b-b230-41e4-8dc2-9e7a02231919">514</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGV4dHJlZ2lvbjphMTM1NTRlMGM4Yzk0ODgwOTc3ZDQyOTMyYzgxOGY2NF8xOTc3_a6c33ecf-a17d-4653-8009-62033c887ab1">744-6792</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.522%"><tr><td style="width:1.0%"></td><td style="width:29.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.639%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.921%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="9" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGFibGU6MjE3YWFjYzVhNjNjNDE5NmE3Nzc0YzU2MjA2MDRlNTMvdGFibGVyYW5nZToyMTdhYWNjNWE2M2M0MTk2YTc3NzRjNTYyMDYwNGU1M18xLTAtMS0xLTg5MDcy_4ce6cff8-61e2-4f63-b164-ec8094b226bb">Common Shares, No Par Value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGFibGU6MjE3YWFjYzVhNjNjNDE5NmE3Nzc0YzU2MjA2MDRlNTMvdGFibGVyYW5nZToyMTdhYWNjNWE2M2M0MTk2YTc3NzRjNTYyMDYwNGU1M18xLTEtMS0xLTg5MDcy_72f4207e-f526-47cd-9012-8b7feaca84a1">BHC</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGFibGU6MjE3YWFjYzVhNjNjNDE5NmE3Nzc0YzU2MjA2MDRlNTMvdGFibGVyYW5nZToyMTdhYWNjNWE2M2M0MTk2YTc3NzRjNTYyMDYwNGU1M18xLTItMS0xLTg5MDcy_4c5ce663-6f50-4f9f-b460-adccfb561a1e">New York Stock Exchange</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Toronto Stock Exchange</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or&#160;15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or&#160;for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. <ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGV4dHJlZ2lvbjphMTM1NTRlMGM4Yzk0ODgwOTc3ZDQyOTMyYzgxOGY2NF8xOTc4_e2fe4a05-b930-4e47-85ba-bca1066631a1">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or&#160;for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGV4dHJlZ2lvbjphMTM1NTRlMGM4Yzk0ODgwOTc3ZDQyOTMyYzgxOGY2NF8xOTc5_ecedc55d-7973-4c76-80cb-da00cbb91369">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221;, and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.451%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGFibGU6ODRkYzYyMDg2YjUzNDdlMTg2NzM1YjQ2MDJmZjk1M2QvdGFibGVyYW5nZTo4NGRjNjIwODZiNTM0N2UxODY3MzViNDYwMmZmOTUzZF8wLTAtMS0xLTg5MDcy_8332e37a-f9cf-4327-a2da-59558098f8d7">Large accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGFibGU6ODRkYzYyMDg2YjUzNDdlMTg2NzM1YjQ2MDJmZjk1M2QvdGFibGVyYW5nZTo4NGRjNjIwODZiNTM0N2UxODY3MzViNDYwMmZmOTUzZF8wLTctMS0xLTg5MDcy_70ffb8d3-f5a1-4c4a-b930-29e02e0c2065">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGFibGU6ODRkYzYyMDg2YjUzNDdlMTg2NzM1YjQ2MDJmZjk1M2QvdGFibGVyYW5nZTo4NGRjNjIwODZiNTM0N2UxODY3MzViNDYwMmZmOTUzZF8wLTktMS0xLTg5MDcy_5331019e-1656-47dd-b0d8-6bc80c777fb5">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as&#160;defined in Rule&#160;12b-2 of the Exchange Act). Yes &#9744; No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGV4dHJlZ2lvbjphMTM1NTRlMGM4Yzk0ODgwOTc3ZDQyOTMyYzgxOGY2NF8xOTgw_ceddb37f-6c9c-4461-bf94-5fe10686e42e">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable&#160;date.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common shares, no par value&#160;&#8212; <ix:nonFraction unitRef="shares" contextRef="ie4a7b4e0ac9943a9b88f1223220896de_I20220505" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGV4dHJlZ2lvbjphMTM1NTRlMGM4Yzk0ODgwOTc3ZDQyOTMyYzgxOGY2NF8xOTI5_0a372ed0-037c-4c7c-b3c0-04278cdcb1b4">361,479,708</ix:nonFraction> shares outstanding as of May 5, 2022.</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i801c461cbd33492a893c84373a8e7cbc_7"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 45.00pt 36.00pt 45.00pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM 10-Q</span></div><div style="margin-bottom:16pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE QUARTERLY PERIOD ENDED MARCH&#160;31, 2022 </span></div><div style="margin-bottom:16pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.118%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part&#160;I.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Consolidated <a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_19">Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_22">Consolidated Balance Sheets as of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_22">March 31</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_22">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_22">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_22"> and December&#160;31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_22">1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_22">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_25">Consolidated Statements of Operations for the three</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_25"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_25">March </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_25">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_25">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_25">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_25">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_25"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_25">1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_25">2</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_28">Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_28">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_31">Consolidated Statements of Shareholders</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8217;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_31"> Deficit for the three months ended March 31, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_31">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_34">Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_34">three</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_34"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_34">March 31</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_34">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_34">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_34"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_34">1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_34">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_37">Notes to the Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_37">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_103">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_103">41</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_208">Quantitative and&#160;Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-align:right;text-indent:-27pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_208">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_211">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_211">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part&#160;II</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Information</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_220">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_220">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_223">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_223">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_226">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:40.5pt;text-align:right;text-indent:-40.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_226">87</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_229">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_229">88</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_232">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_232">88</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;5.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_235">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_235">88</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_238">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_238">88</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i801c461cbd33492a893c84373a8e7cbc_241">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i801c461cbd33492a893c84373a8e7cbc_241">90</a></span></div></td></tr></table></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="i801c461cbd33492a893c84373a8e7cbc_10"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM 10-Q</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE QUARTERLY PERIOD ENDED MARCH&#160;31, 2022 </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Introductory Note</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except where the context otherwise requires, all references in this Quarterly Report on Form&#160;10-Q for the quarterly period ended March&#160;31, 2022 (this &#8220;Form&#160;10-Q&#8221;) to&#160;the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221; or similar words or phrases are to Bausch Health Companies&#160;Inc. and its subsidiaries, taken together. In this Form&#160;10-Q, references to&#160;&#8220;$&#8221; are to United&#160;States (&#8220;U.S.&#8221;) dollars, references to &#8220;&#8364;&#8221; are to euros and references to &#8220;CAD&#8221; are to Canadian dollars. Unless otherwise indicated, the statistical and financial data contained in this Form&#160;10-Q are presented as of March&#160;31, 2022.</span></div><div id="i801c461cbd33492a893c84373a8e7cbc_13"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caution regarding forward-looking information and statements and &#8220;Safe-Harbor&#8221; statements under the U.S.&#160;Private Securities Litigation Reform Act of&#160;1995 and applicable Canadian securities laws:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">To the extent any statements made in this Form&#160;10-Q contain information that is not historical, these statements are forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended, and may be forward-looking information within the meaning defined under applicable Canadian securities laws (collectively, &#8220;forward-looking statements&#8221;).</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">These forward-looking statements relate to, among other things: our business strategy, business plans and prospects and forecasts and changes thereto; product pipeline, prospective products and product approvals, expected launches of new products, product development and future performance and results of current and anticipated products; anticipated revenues for our products; expected research and development (&#8220;R&amp;D&#8221;) and marketing spend; our expected primary cash and working capital requirements for 2022 and beyond; the Company&#8217;s plans for continued improvement in operational efficiency and the anticipated impact of such plans; our liquidity and our ability to satisfy our debt maturities as they become due; our ability to reduce debt levels; our ability to comply with the financial and other covenants contained in our Fourth Amended and Restated Credit and Guaranty Agreement, as amended by the First Incremental Amendment to the Restated Credit Agreement, dated as of November 27, 2018 and the Second Amendment to the Restated Credit Agreement, dated as of May 10, 2022 (the &#8220;2022 Restated Credit Agreement&#8221;), and senior notes indentures;the ability of our subsidiary, Bausch + Lomb Corporation (&#8220;Bausch + Lomb&#8221;), to comply with the financial and other covenants contained in its Credit and Guaranty Agreement (the &#8220;B+L Credit Agreement&#8221;, and the credit facilities thereunder, the &#8220;B+L Credit Facilities&#8221;), dated as of May 10, 2022; the impact of our distribution, fulfillment and other third-party arrangements; proposed pricing actions; exposure to foreign currency exchange rate changes and interest rate changes; the outcome of contingencies, such as litigation, subpoenas, investigations, reviews, audits and regulatory proceedings; the anticipated impact of the adoption of new accounting standards; general market conditions; our expectations regarding our financial performance, including revenues, expenses, gross margins and income&#160;taxes; our impairment assessments, including the assumptions used therein and the results thereof; the anticipated impact of the evolving COVID-19 pandemic and related responses from governments and private sector participants on the Company, its supply chain, third-party suppliers, project development timelines, costs, revenues, margins, liquidity and financial condition, the anticipated timing, speed and magnitude of recovery from these COVID-19 pandemic related impacts and the Company&#8217;s planned actions and responses to this pandemic; the Company&#8217;s plan to separate its eye health business, including the structure and timing of completing such separation transaction; and the proposed initial public offering (&#8220;IPO&#8221;) of the Company&#8217;s Solta aesthetic medical device business, including the timing of such IPO.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward-looking statements can generally be identified by the use of words such as &#8220;believe&#8221;, &#8220;anticipate&#8221;, &#8220;expect&#8221;, &#8220;intend&#8221;, &#8220;estimate&#8221;, &#8220;plan&#8221;, &#8220;continue&#8221;, &#8220;will&#8221;, &#8220;may&#8221;, &#8220;could&#8221;, &#8220;would&#8221;, &#8220;should&#8221;, &#8220;target&#8221;, &#8220;potential&#8221;, &#8220;opportunity&#8221;, &#8220;designed&#8221;, &#8220;create&#8221;, &#8220;predict&#8221;, &#8220;project&#8221;, &#8220;forecast&#8221;, &#8220;seek&#8221;, &#8220;strive&#8221;, &#8220;ongoing&#8221;, &#8220;decrease&#8221; or &#8220;increase&#8221; and variations or other similar expressions. In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements may not be appropriate for other purposes. Although we have previously indicated certain of these statements set out herein, all of the statements in this Form&#160;10-Q that contain forward-looking statements are qualified by these cautionary statements. These statements are based upon the current expectations and beliefs of management. Although we believe that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors or assumptions are applied in making such forward-looking statements, including, but not limited to, factors and assumptions regarding the items previously outlined, those factors, risks and uncertainties outlined below and the assumption that none of these factors, risks and uncertainties will cause actual results or events to differ materially from those described in such forward-looking statements. Actual results may differ materially from those expressed or implied in such statements. Important factors, risks </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and uncertainties that could cause actual results to differ materially from these expectations include, among other things, the&#160;following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, the fear of that pandemic, the availability and effectiveness of vaccines for COVID-19 (including with respect to current or future variants and subvariants), COVID-19 vaccine immunization rates, the emergence of variant and subvariant strains of COVID-19, the resurgence of the COVID-19 virus and variant and subvariant strains thereof (including, but not limited to, the recent resurgence of COVID-19 cases in China) and any resulting reinstitution of lockdowns and other restrictions, the evolving reaction of governments, private sector participants and the public to that pandemic, and the potential effects and economic impact of the pandemic and the reaction to it, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a significant adverse impact on the Company, including, but not limited to, its supply chain, third-party suppliers, project development timelines, employee base, liquidity, stock price, financial condition and costs (which may increase) and revenue and margins (both of which may decrease);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the challenges the Company faces as a result of the closing of the IPO of Bausch + Lomb (the &#8220;B+L IPO&#8221;), including the transitional services being provided by and to Bausch + Lomb, any potential, actual or perceived conflict of interest of some of our directors and officers because of their equity ownership in Bausch + Lomb and/or because they also serve as directors or officers of Bausch + Lomb and our ability to timely consolidate the financial results of the Bausch + Lomb business; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">with respect to the proposed separation of Bausch + Lomb, the risks and uncertainties include, but are not limited to, the expected benefits and costs of the separation transaction, the expected timing of completion of the separation transaction and its terms (including the Company&#8217;s expectation that the separation transaction will be completed following the expiry of customary lock-ups related to the B+L IPO and achievement of targeted debt leverage ratios, subject to receipt of applicable shareholder and other necessary approvals), the Company&#8217;s ability to complete the separation transaction considering the various conditions to the completion of the separation transaction (some of which are outside the Company&#8217;s control, including conditions related to regulatory matters and a possible shareholder vote, if applicable), that market or other conditions are no longer favorable to completing the transaction, that any regulatory or other approval (if required) is not obtained on the terms or timelines anticipated or at all, business disruption during the pendency of, or following, the separation transaction, diversion of management time on separation transaction-related issues, retention of existing management team members, the reaction of customers and other parties to the separation transaction, the qualification of the separation transaction as a tax-free transaction for Canadian and/or U.S. federal income tax purposes (including whether or not an advance ruling from the Canada Revenue Agency and/or the Internal Revenue Service will be sought or obtained), the ability of the Company and the separated entity to satisfy the conditions required to maintain the tax-free status of the separation transaction (some of which are beyond their control), other potential tax or other liabilities that may arise as a result of the separation transaction, the potential dissynergy costs resulting from the separation transaction, the impact of the separation transaction on relationships with customers, suppliers, employees and other business counterparties, general economic conditions, conditions in the markets the Company is engaged in, behavior of customers, suppliers and competitors, technological developments, as well as legal and regulatory rules affecting the Company&#8217;s business.  In particular, the Company can offer no assurance that any separation will occur at all, or that any such transaction will occur on the timelines anticipated by the Company;  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">with respect to the proposed IPO of the Company&#8217;s Solta aesthetic medical device business, the risks and uncertainties include, but are not limited to, risks relating to the expected timing of completion of such transaction (including the Company&#8217;s expectation that it will launch such IPO when financial market conditions are favorable, subject to receipt of regulatory, stock exchange and other approvals and other factors) and the Company&#8217;s ability to complete such transaction, that market or other conditions are no longer favorable to completing the transaction on a timely basis or at all, the receipt of (or failure to receive) any shareholder, stock exchange, regulatory and other approvals required in connection with the transaction and the timing of receipt of such approvals, business disruption during the pendency of, or following, such transaction, diversion of management time on transaction-related issues, retention of Solta aesthetic medical device management team members, the reaction of customers and other parties to such transaction, the impact of such transaction on relationships with customers, suppliers, employees and other business counterparties, and other events that could adversely impact the completion of such transaction, including industry or economic conditions outside of Bausch Health&#8217;s control. In particular, the Company can offer no assurance that any such transaction will occur at all, or that any such transaction will occur on the timelines, structure or terms anticipated by the Company;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">ongoing litigation and potential additional litigation, claims, challenges and/or regulatory investigations challenging or otherwise relating to the B+L IPO and the proposed separation of Bausch + Lomb and the costs, </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">expenses, use of resources, diversion of management time and efforts, liability and damages that may result therefrom;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the expense, timing and outcome of legal and governmental proceedings, investigations and information requests relating to, among other matters, our past distribution, marketing, pricing, disclosure and accounting practices (including with respect to our former relationship with Philidor Rx Services, LLC (&#8220;Philidor&#8221;)), including a number of pending non-class securities litigations (including certain pending opt-out actions in the U.S. related to the previously settled securities class action (which remains subject to an objector&#8217;s petition for rehearing of its appeal of the Court&#8217;s final approval order) and certain opt-out actions in Canada relating to the recently settled class action in Canada), certain pending lawsuits and other claims, investigations or proceedings that may be initiated or that may be asserted;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">potential additional litigation and regulatory investigations (and any costs, expenses, use of resources, diversion of management time and efforts, liability and damages that may result therefrom), negative publicity and reputational harm on our Company, products and business that may result from the past and ongoing public scrutiny of our past distribution, marketing, pricing, disclosure and accounting practices and from our former relationship with Philidor;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the past and ongoing scrutiny of our legacy business practices, including with respect to pricing, and any pricing controls or price adjustments that may be sought or imposed on our products as a result thereof; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">pricing decisions that we have implemented, or may in the future elect to implement, such as the Patient Access and Pricing Committee&#8217;s historic practice of limiting the average annual price increase for our branded prescription pharmaceutical products to single digits, or any future pricing actions we may take in 2022 or beyond following review by our Patient Access and Pricing Committee (which is responsible for the pricing of our drugs);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">legislative or policy efforts, including those that may be introduced and passed by the U.S. Congress, designed to reduce patient out-of-pocket costs for medicines, which could result in new mandatory rebates and discounts or other pricing restrictions, controls or regulations (including mandatory price reductions);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">ongoing oversight and review of our products and facilities by regulatory and governmental agencies, including periodic audits by the U.S.&#160;Food and Drug Administration (the &#8220;FDA&#8221;) and equivalent agencies outside of the U.S. and the results thereof;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">actions by the FDA or other regulatory authorities with respect to our products or facilities;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with the legal and regulatory requirements of our marketed products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our substantial debt (and potential additional future indebtedness) and current and future debt service obligations, our ability to reduce our outstanding debt levels and the resulting impact on our financial condition, cash flows and results of operations;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to comply with the financial and other covenants contained in our senior notes indentures, 2027 Revolving Credit Facility (as defined below), the 2022 Restated Credit Agreement, the B+L Credit Agreement and other current or future credit and/or debt agreements and the limitations including the ability of Bausch + Lomb to comply with its covenants and obligations under the B+L Credit Agreement, restrictions and prohibitions such covenants impose or may impose on the way we conduct our business, including prohibitions on incurring additional debt if certain financial covenants are not met, limitations on the amount of additional obligations we are able to incur pursuant to other covenants, our ability to draw under our 2027 Revolving Credit Facility, Bausch + Lomb&#8217;s ability to draw down under the revolving credit facility under the B+L Credit Agreement and restrictions on our ability to make certain investments and other restricted payments;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">any default under the terms of our senior notes indentures or the 2022 Restated Credit Agreement (and other current or future credit and/or debt agreements) and our ability, if any, to cure or obtain waivers of such default;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">any downgrade by rating agencies in our credit ratings, which may impact, among other things, our ability to raise debt and the cost of capital for additional debt issuances;</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">any reductions in, or changes in the assumptions used in, our forecasts for fiscal year 2022 or beyond, including as a result of the impacts of the COVID-19 pandemic on our business and operations, which could lead to, among other things: (i) a failure to meet the financial and/or other covenants contained in our 2018 Restated Credit Agreement, the 2022 Restated Credit Agreement, senior notes indentures and/or the B+L Credit Agreement (and other current or future credit and/or debt agreements) and/or (ii) impairment in the goodwill associated with certain of our reporting units or impairment charges related to certain of our products or other intangible assets, which impairments could be material;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the assumptions used in connection with our impairment analyses or assessments, which would lead to a change in such impairment analyses and assessments and which could result in an impairment in the goodwill associated with any of our reporting units or impairment charges related to certain of our products or other intangible assets;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the uncertainties associated with the acquisition and launch of new products, assets and businesses, including, but not limited to, our ability to provide the time, resources, expertise and funds required for the commercial launch of new products, the acceptance and demand for new products, and the impact of competitive products and&#160;pricing, which could lead to material impairment charges;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability or inability to extend the profitable life of our products, including through line extensions and other life-cycle programs;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to retain, motivate and recruit directors, executives and other key&#160;employees;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to implement effective succession planning for our executives and key employees;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">factors impacting our ability to stabilize and reposition our Ortho Dermatologics business to generate additional value, including the success of recently launched products and the approval of pipeline products (and the timing of such approvals);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">factors impacting our ability to achieve anticipated revenues for our products, including changes in anticipated marketing spend on such products and launch of competing products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">factors impacting our ability to achieve anticipated market acceptance for our products, including acceptance of the pricing, effectiveness of promotional efforts, reputation of our products and launch of competing products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the challenges and difficulties associated with managing a large complex business, which has, in the past, grown rapidly;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to compete against companies that are larger and have greater financial, technical and human resources than we do, as well as other competitive factors, such as technological advances achieved, patents obtained and new products introduced by our competitors;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively operate and grow our businesses in light of the challenges that the Company has faced and market conditions, including with respect to its substantial debt, pending investigations and legal proceedings, scrutiny of our past pricing and other practices, limitations on the way we conduct business imposed by the covenants contained in our 2018 Restated Credit Agreement, our 2022 Restated Credit Agreement, the B+L Credit Agreement, our senior notes indentures and the agreements governing our other indebtedness, and the impacts of the COVID-19 pandemic;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our products are reimbursed by government authorities, pharmacy benefit managers (&#8220;PBMs&#8221;) and other third-party payors; the impact our distribution, pricing and other practices may have on the decisions of such government authorities, PBMs and other third-party payors to reimburse our products; the impact of obtaining or maintaining such reimbursement on the price and sales of our products; and the launch and implementation of any new pharma-care or dental-care program or related spending by the Canadian federal government;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the inclusion of our products on formularies or our ability to achieve favorable formulary status, as well as the impact on the price and sales of our products in connection therewith;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the consolidation of wholesalers, retail drug chains and other customer groups and the impact of such industry consolidation on our business;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain strong relationships with physicians and other healthcare professionals;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our eligibility for benefits under tax treaties and the continued availability of low effective tax rates for the business profits of certain of our subsidiaries;</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">v</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the implementation of the Organisation for Economic Co-operation and Development inclusive framework on Base Erosion and Profit Shifting, including the global minimum corporate tax rate, by the countries in which we operate; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome of any audits by taxation authorities, which outcomes may differ from the estimates and assumptions that we may use in determining our consolidated tax provisions and accruals;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the actions of our third-party partners or service providers of research, development, manufacturing, marketing, distribution or other services, including their compliance with applicable laws and contracts, which actions may be beyond our control or influence, and the impact of such actions on our Company;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the risks associated with the international scope of our operations, including our presence in emerging markets and the challenges we face when entering and operating in new and different geographic markets (including the challenges created by new and different regulatory regimes in such countries and the need to comply with applicable anti-bribery and economic sanctions laws and regulations);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">adverse global economic conditions and credit markets and foreign currency exchange uncertainty and volatility in certain of the countries in which we do&#160;business;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the trade conflict between the U.S. and China;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the ongoing conflict between Russia and Ukraine and </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">the export controls, sanctions and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other restrictive actions that have been or may be imposed by the U.S., Canada and other countries</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">against governmental and other entities in Russia, Belarus and parts of Ukrain</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt">the impact of the United States-Mexico-Canada Agreement (&#8220;USMCA&#8221;) and any potential changes to other trade agreements;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain, maintain and license sufficient intellectual property rights over our products and enforce and defend against challenges to such intellectual property (such as in connection with the filing by Norwich Pharmaceuticals Inc. (&#8220;Norwich&#8221;) of its Abbreviated New Drug Application (&#8220;ANDA&#8221;) for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets and the Company&#8217;s related lawsuit filed against Norwich in connection therewith);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the introduction of generic, biosimilar or other competitors of our branded products and other products, including the introduction of products that compete against our products that do not have patent or data exclusivity rights;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify, finance, acquire, close and integrate acquisition targets successfully and on a timely basis and the difficulties, challenges, time and resources associated with the integration of acquired companies, businesses and products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">any divestitures of our assets or businesses and our ability to successfully complete any such divestitures on commercially reasonable terms and on a timely basis, or at all, and the impact of any such divestitures on our Company, including the reduction in the size or scope of our business or market share, loss of revenue, any loss on sale, including any resultant impairments of goodwill or other assets, or any adverse tax consequences suffered as a result of any such divestitures;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the expense, timing and outcome of pending or future legal and governmental proceedings, arbitrations, investigations, subpoenas, tax and other regulatory audits, examinations, reviews and regulatory proceedings against us or relating to us and settlements thereof;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to negotiate the terms of or obtain court approval for the settlement of certain legal and regulatory proceedings;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain components, raw materials or finished products supplied by third&#160;parties (some of which may be single-sourced) and other manufacturing and related supply difficulties, interruptions and delays;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the disruption of delivery of our products and the routine flow of manufactured goods;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">economic factors over which the Company has no control, including changes in inflation, interest rates, foreign currency rates, and the potential effect of such factors on revenues, expenses and resulting margins;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">interest rate risks associated with our floating rate debt borrowings;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively distribute our products and the effectiveness and success of our distribution arrangements;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively promote our own products and those of our co-promotion partners;</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vi</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our fulfillment arrangements with Walgreen Co., including market acceptance of, or market reaction to, such arrangements (including by customers, doctors, patients, PBMs, third-party payors and governmental agencies), and the continued compliance of such arrangements with applicable laws;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to secure and maintain third-party research, development, manufacturing, licensing, marketing or distribution arrangements;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that our products could cause, or be alleged to cause, personal injury and adverse effects, leading to potential lawsuits, product liability claims and damages and/or recalls or withdrawals of products from the&#160;market;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the mandatory or voluntary recall or withdrawal of our products from the market and the costs associated therewith;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of, and our ability to obtain and maintain, adequate insurance coverage and/or our ability to cover or insure against the total amount of the claims and liabilities we face, whether through third-party insurance or self-insurance;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our indemnity agreements, which may result in an obligation to indemnify or reimburse the relevant counterparty, which amounts may be material;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the difficulty in predicting the expense, timing and outcome within our legal and regulatory environment, including with respect to approvals by the FDA, Health Canada, European Medicines Agency (&#8220;EMA&#8221;) and similar agencies in other countries, legal and regulatory proceedings and settlements thereof, the protection afforded by our patents and other intellectual and proprietary property, successful generic challenges to our products and infringement or alleged infringement of the intellectual property of&#160;others;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the results of continuing safety and efficacy studies by industry and government agencies;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the success of preclinical and clinical trials for our drug development pipeline or delays in clinical trials that adversely impact the timely commercialization of our pipeline products, as well as other factors impacting the commercial success of our products, which could lead to material impairment charges;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">uncertainties around the successful improvement and modification of our existing products and development of new products, which may require significant expenditures and efforts;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the results of management reviews of our research and development portfolio (including following the receipt of clinical results or feedback from the FDA or other regulatory authorities), which could result in terminations of specific projects which, in turn, could lead to material impairment charges;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the seasonality of sales of certain of our products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">declines in the pricing and sales volume of certain of our products that are distributed or marketed by third parties, over which we have no or limited control;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">compliance by the Company or our third-party partners and service providers (over whom we may have limited influence), or the failure of our Company or these third parties to comply, with health care &#8220;fraud and abuse&#8221; laws and other extensive regulation of our marketing, promotional and business practices (including with respect to pricing), worldwide anti-bribery laws (including the U.S. Foreign Corrupt Practices Act and the Canadian Corruption of Foreign Public Officials Act), worldwide economic sanctions and/or export laws, worldwide environmental laws and regulation and privacy and security regulations;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the impacts of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 and potential amendment thereof and other legislative and regulatory health care reforms in the countries in which we operate, including with respect to recent government inquiries on pricing;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of any changes in or reforms to the legislation, laws, rules, regulation and guidance that apply to the Company and its businesses and products or the enactment of any new or proposed legislation, laws, rules, regulations or guidance that will impact or apply to the Company or its businesses or products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of changes in federal laws and policy that may be undertaken under the Biden administration;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">illegal distribution or sale of counterfeit versions of our products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">interruptions, breakdowns or breaches in our information technology systems; and</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:13.8pt">risks in Item 1A. &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed on February 23, 2022, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">risks under Item 1A. &#8220;Risk Factors&#8221; of Part II of this Form 10-Q </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">and risks detailed from time to time in our other filings with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) and the Canadian Securities Administrators (the&#160;&#8220;CSA&#8221;), as well as our ability to anticipate and manage the risks associated with the&#160;foregoing.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed on February 23, 2022,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">under Item&#160;1A. &#8220;Risk Factors&#8221;, u</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">nder Item 1A. &#8220;Risk Factors&#8221; of Part II of this Form 10-Q </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and in the Company&#8217;s other filings with the SEC and the CSA. When relying on our forward-looking statements to make decisions with respect to the Company, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. These forward-looking statements speak only as of the date made. We undertake no obligation to update or revise any of these forward-looking statements to reflect events or circumstances after the date of this Form&#160;10-Q or&#160;to reflect actual outcomes, except as required by law. We caution that, as it is not possible to predict or identify all relevant factors that may impact forward-looking statements, the foregoing list of important factors that may affect future results is not exhaustive and should not be considered a complete statement of all potential risks and uncertainties.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">viii</span></div></div></div><div id="i801c461cbd33492a893c84373a8e7cbc_16"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="i801c461cbd33492a893c84373a8e7cbc_19"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. Financial Statements</span></div><div id="i801c461cbd33492a893c84373a8e7cbc_22"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions, except share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:9pt;margin-top:5pt;padding-left:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.775%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMy0xLTEtMS04OTA3Mg_c94abbfe-789b-44cc-bfb6-ca88fc3a99d0">1,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMy0zLTEtMS04OTA3Mg_e80ff975-8ff1-48f6-a8b9-2840fe534dfa">582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and other settlement deposits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="bhc:RestrictedCashAndOtherSettlementDepositsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfNC0xLTEtMS04OTA3Mg_c3908cac-5c4c-4452-8477-f3954589612c">1,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="bhc:RestrictedCashAndOtherSettlementDepositsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfNC0zLTEtMS04OTA3Mg_fde993c5-8aa6-4b53-bd06-27743ef5a289">1,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfNS0xLTEtMS04OTA3Mg_92bcfc2f-0004-488b-bb22-43ba4e67bbd3">1,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfNS0zLTEtMS04OTA3Mg_572e7cc1-74b5-4cfe-8594-628130392ef7">1,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfNi0xLTEtMS04OTA3Mg_162f2991-6448-453a-9aae-c6127094abd2">1,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfNi0zLTEtMS04OTA3Mg_e8c8c12e-e098-4527-b739-006fe2399342">993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfNy0xLTEtMS04OTA3Mg_fdfb058f-eaa2-41aa-b5a2-d942f363306d">765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfNy0zLTEtMS04OTA3Mg_13fc259b-1ded-4710-97f6-c3c3a4c3f593">720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfOC0xLTEtMS04OTA3Mg_585f3567-2803-4b18-88eb-9a8721540353">5,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfOC0zLTEtMS04OTA3Mg_4938970a-dca5-40a4-87b4-d353d0971ebb">5,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfOS0xLTEtMS04OTA3Mg_8a322ad8-af2b-4855-b5a9-12bd837be95f">1,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfOS0zLTEtMS04OTA3Mg_4bcef469-a957-484b-aa49-d001ab980f97">1,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMTAtMS0xLTEtODkwNzI_7bde9ae0-b3c8-4d1b-97cb-35287f45bfcc">6,632</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMTAtMy0xLTEtODkwNzI_9914db1a-568c-48aa-b139-0a138b76f042">6,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMTEtMS0xLTEtODkwNzI_4f2d018d-0ba6-436a-83af-208747fc0258">12,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMTEtMy0xLTEtODkwNzI_6928b1ae-151e-42e8-a7df-bff66151fcb4">12,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMTItMS0xLTEtODkwNzI_abb30ddf-5232-4de9-bccd-bc18c1d0a3e5">2,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMTItMy0xLTEtODkwNzI_1ea88a75-a9fa-4179-844a-2d5fde1604eb">2,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMTMtMS0xLTEtODkwNzI_dc02fa84-bdb3-47c5-a875-3853dd8baadf">334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMTMtMy0xLTEtODkwNzI_684f4fe1-ae58-49a0-a42a-7d710d743279">340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMTQtMS0xLTEtODkwNzI_c3457ecd-1891-48a1-bde8-57b46f6c3755">29,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMTQtMy0xLTEtODkwNzI_57855ce6-02ad-46e1-9ac6-26340679be4e">29,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMTctMS0xLTEtODkwNzI_90cec72d-899c-4ce9-a5ba-6d31e808d39e">471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMTctMy0xLTEtODkwNzI_b776fe0c-c08c-4794-88b1-a39a9ab15d45">407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMTgtMS0xLTEtODkwNzI_57f029a6-8a4b-4ac4-93a5-2e68264d763e">4,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMTgtMy0xLTEtODkwNzI_1b9c42e8-6194-4225-9a54-5cb98e389358">4,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMTktMS0xLTEtODkwNzI_88b4d82f-f90a-4746-9230-1c535978749d">4,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMTktMy0xLTEtODkwNzI_e5632c36-cacf-4fb5-a51c-054511ce7181">5,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="bhc:BusinessCombinationContingentConsiderationNoncurrentLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMjAtMS0xLTEtODkwNzI_597b0325-882e-4944-8d37-485e6c8926f2">193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="bhc:BusinessCombinationContingentConsiderationNoncurrentLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMjAtMy0xLTEtODkwNzI_ed698a29-4c20-4f60-ae43-cfeeb4733056">202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMjEtMS0xLTEtODkwNzI_f4dd3fcb-2755-445b-ba0c-de60613ad7f8">23,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMjEtMy0xLTEtODkwNzI_e80c8a06-f7bd-4b16-9b45-12d158fe780e">22,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMjItMS0xLTEtODkwNzI_00ffecf8-1aa7-40d4-b9bc-b06d07ea6b1e">552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMjItMy0xLTEtODkwNzI_f4561b35-ea15-4880-81f4-0826f74073ae">529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMjMtMS0xLTEtODkwNzI_de823fe9-2054-4989-ae6e-6b650a278547">544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMjMtMy0xLTEtODkwNzI_c867397d-5d4f-4750-bc5c-5629825d6d9a">653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMjQtMS0xLTEtODkwNzI_86f9ca79-0348-452a-857e-cdd8319ec130">29,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMjQtMy0xLTEtODkwNzI_629fccf0-f24c-43f3-83db-3f1c870e2938">29,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMjUtMS0xLTEtODkwNzI_66644f4c-dd29-4bae-a55f-1e681358ca9b"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMjUtMy0xLTEtODkwNzI_068cf546-240e-441d-9013-466545604903"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deficit </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares, no par value, unlimited shares authorized, <ix:nonFraction unitRef="shares" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMjctMC0xLTEtODkwNzIvdGV4dHJlZ2lvbjpjYWZiZWVjNjNjYjk0M2RkYTViMDc0ZmFjNDhlNjZlZV82Mg_7555a972-4ef5-4965-a986-b96747406f14"><ix:nonFraction unitRef="shares" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMjctMC0xLTEtODkwNzIvdGV4dHJlZ2lvbjpjYWZiZWVjNjNjYjk0M2RkYTViMDc0ZmFjNDhlNjZlZV82Mg_dc8fc9fb-20a9-4a5b-92e1-0f7344c9e582">361,331,665</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMjctMC0xLTEtODkwNzIvdGV4dHJlZ2lvbjpjYWZiZWVjNjNjYjk0M2RkYTViMDc0ZmFjNDhlNjZlZV82OQ_b46feb3d-7289-4d49-8b56-15dada824fb2"><ix:nonFraction unitRef="shares" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMjctMC0xLTEtODkwNzIvdGV4dHJlZ2lvbjpjYWZiZWVjNjNjYjk0M2RkYTViMDc0ZmFjNDhlNjZlZV82OQ_d15dd73c-c2b9-477b-b2c8-d2b0890ce6f3">359,405,748</ix:nonFraction></ix:nonFraction> issued and outstanding at March 31, 2022 and December&#160;31, 2021, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMjctMS0xLTEtODkwNzI_7ffeb007-e769-41fe-9ac8-62c1ca849174">10,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMjctMy0xLTEtODkwNzI_da466f51-1b88-4811-af79-282f657e2e6e">10,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMjgtMS0xLTEtODkwNzI_023cb733-8914-45b3-ba3d-fbfeebb6b7a7">415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMjgtMy0xLTEtODkwNzI_9271f5e2-5473-47fe-8914-ca9ca12f7f08">462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMjktMS0xLTEtODkwNzI_3d5184b2-d88b-479e-a4c9-033aa0a2b015">9,030</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMjktMy0xLTEtODkwNzI_c57c6727-7ff3-4dc7-af0c-35fcbf344fd6">8,961</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMzAtMS0xLTEtODkwNzI_87b07e6d-8c49-436a-90e0-6ca4751fc93c">1,974</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMzAtMy0xLTEtODkwNzI_2a1e7eb3-257e-4aee-8649-a0948b007f53">1,924</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Bausch Health Companies Inc. shareholders&#8217; deficit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMzEtMS0xLTEtODkwNzI_95992186-8f0e-4ac7-bdb6-86b3ec6abd63">216</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMzEtMy0xLTEtODkwNzI_00453d6c-e592-4a86-95e3-b752fc7f0815">106</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMzItMS0xLTEtODkwNzI_f7ba6ebd-0f7d-4f05-84e0-2938533c4e6d">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMzItMy0xLTEtODkwNzI_250f4153-d8a1-4a63-aafb-ffe5301f8ffd">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deficit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMzMtMS0xLTEtODkwNzI_5b992cb2-28bf-4126-b6bd-3e02cfb360e1">141</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMzMtMy0xLTEtODkwNzI_3997b385-2e63-4e16-a19e-61b47f7411a6">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and deficit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMzQtMS0xLTEtODkwNzI_5da4a518-3d43-48c5-8e56-d13ea3c1a730">29,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMzQtMy0xLTEtODkwNzI_c9d4aecd-362e-4d16-8abd-1fdfb4054c8f">29,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i801c461cbd33492a893c84373a8e7cbc_25"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.876%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7062f2c8d3b74170b8ed9d57d942850f_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMy01LTEtMS04OTA3Mg_5ba64193-1c0b-4955-9810-dbc858729dd7">1,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47ece7f00f6a493a9f2236a26d681928_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMy03LTEtMS04OTA3Mg_93b1d4d2-f23d-474f-bcaa-0a69777c3a8f">2,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69f7b40936e24b94a92542e01f316976_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfNC01LTEtMS04OTA3Mg_a925b14a-c0bc-4aca-91c0-fc99a76032ab">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5e530ee58404ccc965b53fc6d73c350_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfNC03LTEtMS04OTA3Mg_30823265-adaa-4311-af08-9c4bd847f63d">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfNS01LTEtMS04OTA3Mg_53c7129b-bbd1-4c88-b8fe-7ffdb0c3751e">1,918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfNS03LTEtMS04OTA3Mg_4a6a43c9-f68c-444d-a5f1-0486e9d0e91e">2,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(excluding amortization and impairments of intangible assets)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7062f2c8d3b74170b8ed9d57d942850f_D20220101-20220331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfNy01LTEtMS04OTA3Mg_84ab7a50-5d54-4add-a5a4-47403cc7b0c7">543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47ece7f00f6a493a9f2236a26d681928_D20210101-20210331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfNy03LTEtMS04OTA3Mg_e1e439e4-481b-46dc-b8ee-97afb13173c7">564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of other revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69f7b40936e24b94a92542e01f316976_D20220101-20220331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfOC01LTEtMS04OTA3Mg_04cd5811-e5ab-413e-a84e-ee862d739665">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5e530ee58404ccc965b53fc6d73c350_D20210101-20210331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfOC03LTEtMS04OTA3Mg_7fa0bdad-b93d-493d-a468-2439b7cc382a">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfOS01LTEtMS04OTA3Mg_fd4cbe21-5bea-4413-8c22-a55f8ebae35f">622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfOS03LTEtMS04OTA3Mg_0574ea0b-4f92-41a4-a836-ebcb5819317f">606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMTAtNS0xLTEtODkwNzI_8fcfe739-6078-492c-9940-fdf96d9f01e5">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMTAtNy0xLTEtODkwNzI_5c61728f-0327-4153-aad2-1c46235aef89">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMTEtNS0xLTEtODkwNzI_c2924bc2-a0c7-4453-879a-b1a9ea8d3202">310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMTEtNy0xLTEtODkwNzI_1e816d96-fd2f-45da-b674-729f0798aec7">357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMTItNS0xLTEtODkwNzI_2664234f-144f-412d-81cb-1fd4eacfeaf6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMTItNy0xLTEtODkwNzI_dc1e3780-752c-4543-9cf9-5fc8c8921189">469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments, including loss on assets held for sale</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMTMtNS0xLTEtODkwNzI_ba850735-d768-43ab-aa06-29e1af563bae">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMTMtNy0xLTEtODkwNzI_1c16b15d-4e05-4c57-8388-066312c9cdf6">148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, integration, separation and IPO costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="bhc:RestructuringChargesAndInitialPublicOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMTQtNS0xLTEtODkwNzI_8173d398-50c9-41ce-a4cf-c77ff3acd458">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="bhc:RestructuringChargesAndInitialPublicOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMTQtNy0xLTEtODkwNzI_246ced12-a029-49fd-afac-48771aaacf41">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income), net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMTUtNS0xLTEtODkwNzI_448c1903-57c4-463a-9acb-66e08f7acebe">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMTUtNy0xLTEtODkwNzI_3a2f2259-059b-4fff-bd9d-81fbc7bf4856">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMTYtNS0xLTEtODkwNzI_a52721b7-5f30-4d6c-8827-11315be207be">1,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMTYtNy0xLTEtODkwNzI_764b141a-82e4-4ebd-8206-2768b4b4856f">2,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMTctNS0xLTEtODkwNzI_49aa2090-13fc-4008-baa2-f91aba5c4c57">285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMTctNy0xLTEtODkwNzI_3a3183cf-48e6-4789-ab4a-d28eb52714ab">221</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMTgtNS0xLTEtODkwNzI_3be73a39-8bb5-4710-a857-1074945e9042">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMTgtNy0xLTEtODkwNzI_057744d0-99d1-4c59-b72c-bdc25fe2ed42">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMTktNS0xLTEtODkwNzI_a560670d-2522-40f3-8da5-ce43908224a9">362</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMTktNy0xLTEtODkwNzI_0cf92165-ef56-4375-aa52-4597161dff43">368</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMjAtNS0xLTEtODkwNzI_606af6d4-5e79-4df6-80a7-13dae65e1d70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMjAtNy0xLTEtODkwNzI_32aa44c8-938d-4323-9c78-4d43d4212c70">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMjEtNS0xLTEtODkwNzI_ff05d42d-1b45-4260-be74-ee551bce807b">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMjEtNy0xLTEtODkwNzI_31d6b299-1bb9-46ab-ab5a-f8555cd06164">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before provision for income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMjItNS0xLTEtODkwNzI_39fa7a89-d0eb-4135-ac9f-b916852e337f">82</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMjItNy0xLTEtODkwNzI_b53af802-a1c4-49e5-b0fb-b23b82adb58b">591</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from (provision for) income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMjMtNS0xLTEtODkwNzI_9b5e2a8f-0ce4-4497-b3b1-3bee482dda94">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMjMtNy0xLTEtODkwNzI_9815a60a-12c3-45e7-bd14-b54a5c6101c6">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMjQtNS0xLTEtODkwNzI_dc6bc22f-ee54-41a3-b991-1daafd9b285b">66</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMjQtNy0xLTEtODkwNzI_55ca8b6b-8a11-4ebd-b403-26ad1882e46e">607</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interest</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMjUtNS0xLTEtODkwNzI_3b52565f-a418-46c3-a051-6f7102e6da9d">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMjUtNy0xLTEtODkwNzI_0ca88355-3ef7-421f-80a5-712d396b10a0">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMjYtNS0xLTEtODkwNzI_326e0352-4fa6-4c3e-af06-15e57a723c72">69</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMjYtNy0xLTEtODkwNzI_a1cfe7be-ffcf-43d4-93ab-a08af3e7505e">610</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and diluted loss per share attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMjktNS0xLTEtODkwNzI_f266d57c-b5a0-476e-a1b5-5001a199c220"><ix:nonFraction unitRef="usdPerShare" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMjktNS0xLTEtODkwNzI_f94db0b8-c47c-411f-a96f-5bb5b15b8d0b">0.19</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMjktNy0xLTEtODkwNzI_3a78cb4a-cd74-4e5a-82bb-785a086facdc"><ix:nonFraction unitRef="usdPerShare" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMjktNy0xLTEtODkwNzI_ad100ef4-2766-48cf-a11e-b7f8b7476e4d">1.71</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and diluted weighted-average common shares</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMzMtNS0xLTEtODkwNzI_e6341211-22c5-4e8d-9d08-6e5a2dfd55fc"><ix:nonFraction unitRef="shares" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMzMtNS0xLTEtODkwNzI_f6333850-e51f-4b8d-b24f-f7cdca664bba">360.8</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMzMtNy0xLTEtODkwNzI_4ad30366-a60d-45f8-87e0-3333fbc4dffa"><ix:nonFraction unitRef="shares" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMzMtNy0xLTEtODkwNzI_5d3cff9e-3265-465c-ba1f-047936d2cb35">356.8</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i801c461cbd33492a893c84373a8e7cbc_28"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.875%"><tr><td style="width:1.0%"></td><td style="width:74.936%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:1.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.195%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yOC9mcmFnOmQ0YjcwMzVlZWI4YjRiODk5MTg4YzlmMjE4YmVlN2M0L3RhYmxlOmU2NTU1ZDYzZTBkOTQ0ODZhZDRiYzQ1ZDg4YzliNTUzL3RhYmxlcmFuZ2U6ZTY1NTVkNjNlMGQ5NDQ4NmFkNGJjNDVkODhjOWI1NTNfMi01LTEtMS04OTA3Mg_e174f489-b8f6-4c39-84dc-e578aa5229b5">66</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yOC9mcmFnOmQ0YjcwMzVlZWI4YjRiODk5MTg4YzlmMjE4YmVlN2M0L3RhYmxlOmU2NTU1ZDYzZTBkOTQ0ODZhZDRiYzQ1ZDg4YzliNTUzL3RhYmxlcmFuZ2U6ZTY1NTVkNjNlMGQ5NDQ4NmFkNGJjNDVkODhjOWI1NTNfMi03LTEtMS04OTA3Mg_165bf1c6-9523-4b2c-9e72-e79d95b46384">607</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive (loss) income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yOC9mcmFnOmQ0YjcwMzVlZWI4YjRiODk5MTg4YzlmMjE4YmVlN2M0L3RhYmxlOmU2NTU1ZDYzZTBkOTQ0ODZhZDRiYzQ1ZDg4YzliNTUzL3RhYmxlcmFuZ2U6ZTY1NTVkNjNlMGQ5NDQ4NmFkNGJjNDVkODhjOWI1NTNfNC01LTEtMS04OTA3Mg_430fdb98-12f5-4b85-9173-4f7565fbdf85">56</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yOC9mcmFnOmQ0YjcwMzVlZWI4YjRiODk5MTg4YzlmMjE4YmVlN2M0L3RhYmxlOmU2NTU1ZDYzZTBkOTQ0ODZhZDRiYzQ1ZDg4YzliNTUzL3RhYmxlcmFuZ2U6ZTY1NTVkNjNlMGQ5NDQ4NmFkNGJjNDVkODhjOWI1NTNfNC03LTEtMS04OTA3Mg_d84153cc-c615-4151-9c5a-a2f43f2efdc4">124</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and postretirement benefit plan adjustments, net of income taxes</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yOC9mcmFnOmQ0YjcwMzVlZWI4YjRiODk5MTg4YzlmMjE4YmVlN2M0L3RhYmxlOmU2NTU1ZDYzZTBkOTQ0ODZhZDRiYzQ1ZDg4YzliNTUzL3RhYmxlcmFuZ2U6ZTY1NTVkNjNlMGQ5NDQ4NmFkNGJjNDVkODhjOWI1NTNfNS01LTEtMS04OTA3Mg_f69dba4e-e481-4428-af07-c932dcb4e9c6">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yOC9mcmFnOmQ0YjcwMzVlZWI4YjRiODk5MTg4YzlmMjE4YmVlN2M0L3RhYmxlOmU2NTU1ZDYzZTBkOTQ0ODZhZDRiYzQ1ZDg4YzliNTUzL3RhYmxlcmFuZ2U6ZTY1NTVkNjNlMGQ5NDQ4NmFkNGJjNDVkODhjOWI1NTNfNS03LTEtMS04OTA3Mg_66f0efbd-c6e7-4187-859f-9474301722ed">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yOC9mcmFnOmQ0YjcwMzVlZWI4YjRiODk5MTg4YzlmMjE4YmVlN2M0L3RhYmxlOmU2NTU1ZDYzZTBkOTQ0ODZhZDRiYzQ1ZDg4YzliNTUzL3RhYmxlcmFuZ2U6ZTY1NTVkNjNlMGQ5NDQ4NmFkNGJjNDVkODhjOWI1NTNfNi01LTEtMS04OTA3Mg_dda1a83d-fd22-49ad-8dfa-dc7bcd33d967">50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yOC9mcmFnOmQ0YjcwMzVlZWI4YjRiODk5MTg4YzlmMjE4YmVlN2M0L3RhYmxlOmU2NTU1ZDYzZTBkOTQ0ODZhZDRiYzQ1ZDg4YzliNTUzL3RhYmxlcmFuZ2U6ZTY1NTVkNjNlMGQ5NDQ4NmFkNGJjNDVkODhjOWI1NTNfNi03LTEtMS04OTA3Mg_d6251661-0b23-480e-b72d-cd793397aa56">123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yOC9mcmFnOmQ0YjcwMzVlZWI4YjRiODk5MTg4YzlmMjE4YmVlN2M0L3RhYmxlOmU2NTU1ZDYzZTBkOTQ0ODZhZDRiYzQ1ZDg4YzliNTUzL3RhYmxlcmFuZ2U6ZTY1NTVkNjNlMGQ5NDQ4NmFkNGJjNDVkODhjOWI1NTNfNy01LTEtMS04OTA3Mg_8ecda77c-9e44-4196-80ec-3d8f74025c48">116</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yOC9mcmFnOmQ0YjcwMzVlZWI4YjRiODk5MTg4YzlmMjE4YmVlN2M0L3RhYmxlOmU2NTU1ZDYzZTBkOTQ0ODZhZDRiYzQ1ZDg4YzliNTUzL3RhYmxlcmFuZ2U6ZTY1NTVkNjNlMGQ5NDQ4NmFkNGJjNDVkODhjOWI1NTNfNy03LTEtMS04OTA3Mg_629b8350-65d6-4890-b979-78d991f21720">730</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income attributable to noncontrolling interest</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yOC9mcmFnOmQ0YjcwMzVlZWI4YjRiODk5MTg4YzlmMjE4YmVlN2M0L3RhYmxlOmU2NTU1ZDYzZTBkOTQ0ODZhZDRiYzQ1ZDg4YzliNTUzL3RhYmxlcmFuZ2U6ZTY1NTVkNjNlMGQ5NDQ4NmFkNGJjNDVkODhjOWI1NTNfOC01LTEtMS04OTA3Mg_9b28b8dd-b385-4568-a31f-ae6504d85983">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yOC9mcmFnOmQ0YjcwMzVlZWI4YjRiODk5MTg4YzlmMjE4YmVlN2M0L3RhYmxlOmU2NTU1ZDYzZTBkOTQ0ODZhZDRiYzQ1ZDg4YzliNTUzL3RhYmxlcmFuZ2U6ZTY1NTVkNjNlMGQ5NDQ4NmFkNGJjNDVkODhjOWI1NTNfOC03LTEtMS04OTA3Mg_566ded38-aec6-4fca-8e2a-51524fd7b135">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yOC9mcmFnOmQ0YjcwMzVlZWI4YjRiODk5MTg4YzlmMjE4YmVlN2M0L3RhYmxlOmU2NTU1ZDYzZTBkOTQ0ODZhZDRiYzQ1ZDg4YzliNTUzL3RhYmxlcmFuZ2U6ZTY1NTVkNjNlMGQ5NDQ4NmFkNGJjNDVkODhjOWI1NTNfOS01LTEtMS04OTA3Mg_b5f8dde0-64e6-4336-a26f-e69a6772c7d4">119</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yOC9mcmFnOmQ0YjcwMzVlZWI4YjRiODk5MTg4YzlmMjE4YmVlN2M0L3RhYmxlOmU2NTU1ZDYzZTBkOTQ0ODZhZDRiYzQ1ZDg4YzliNTUzL3RhYmxlcmFuZ2U6ZTY1NTVkNjNlMGQ5NDQ4NmFkNGJjNDVkODhjOWI1NTNfOS03LTEtMS04OTA3Mg_14ee18a0-71d9-470e-9712-1738b4424df3">733</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i801c461cbd33492a893c84373a8e7cbc_31"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF SHAREHOLDERS&#8217; DEFICIT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.001%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bausch Health Companies&#160;Inc. Shareholders&#8217; Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss </span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Bausch Health<br/>Companies&#160;Inc.<br/>Shareholders&#8217;<br/>(Deficit) Equity</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Non-<br/>controlling<br/>Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total<br/>(Deficit)<br/>Equity</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances, January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i13d8ae26fd5b445285277b95f6ab5311_I20211231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMjUtMi0xLTEtODkwNzI_b0983265-9b7e-4a05-9ee8-658e9aa14fc9">359.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13d8ae26fd5b445285277b95f6ab5311_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMjUtNC0xLTEtODkwNzI_9698fcd9-f06f-4f90-8741-0f2e565c09b1">10,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba49a57b938b4b89b6c94414674a0509_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMjUtNi0xLTEtODkwNzI_449aa583-d253-4802-9d0f-72bbfd4943cc">462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i84be42c574674323bfa1ce40efc25a3b_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMjUtOC0xLTEtODkwNzI_cec32c7d-9367-406c-8f0d-cdaf3f2a2d11">8,961</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e97a6c789b1443ba408d058697c5cc2_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMjUtMTAtMS0xLTg5MDcy_622157d1-3e0c-41a7-b165-52a5afe89f18">1,924</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdfc8eeec050428bb667d6d8a8100215_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMjUtMTItMS0xLTg5MDcy_f6d5f99a-a06b-4a76-8743-fd6ac3ef9cc6">106</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if569d73216764720b3070f4e5764288d_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMjUtMTQtMS0xLTg5MDcy_65160cb7-ad20-4e0a-8d7c-dec9cb46d9fe">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMjUtMTYtMS0xLTg5MDcy_01f6d3bb-b658-4eb6-b352-b860cb221346">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common shares issued under share-based compensation plans</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7de19b3349ed480785851723d3e2ec65_D20220101-20220331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMjYtMi0xLTEtODkwNzI_57cfc132-ace7-4cb9-b55d-17af55c8cca6">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de19b3349ed480785851723d3e2ec65_D20220101-20220331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMjYtNC0xLTEtODkwNzI_57064e95-52f5-4ff8-9cc1-e9d516433e1d">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ae02726ad6f44979a1c380354d1b1ee_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMjYtNi0xLTEtODkwNzI_54d36600-f976-4f1b-83f8-ff26acad6e92">54</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77808f738d5b47f0b37ad9c848b56f22_D20220101-20220331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMjYtMTItMS0xLTg5MDcy_30888e98-a46e-408b-a58f-1ba4bad963cd">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMjYtMTYtMS0xLTg5MDcy_d3b02bd7-3280-4567-afc7-8619dba02bb4">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ae02726ad6f44979a1c380354d1b1ee_D20220101-20220331" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMjctNi0xLTEtODkwNzI_b20c5e5e-20fc-432a-9027-950989e92bf4">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77808f738d5b47f0b37ad9c848b56f22_D20220101-20220331" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMjctMTItMS0xLTg5MDcy_47567793-7847-41d3-aa8a-5cb444df0545">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMjctMTYtMS0xLTg5MDcy_b52da956-a337-492c-93f7-ecfda23555c5">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee withholding taxes related to share-based awards</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ae02726ad6f44979a1c380354d1b1ee_D20220101-20220331" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMjgtNi0xLTEtODkwNzI_ffa47b1c-2127-4ca7-9f52-103cc4d97618">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77808f738d5b47f0b37ad9c848b56f22_D20220101-20220331" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMjgtMTItMS0xLTg5MDcy_42123ab0-5ddb-49da-b83d-612a77bf5be3">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMjgtMTYtMS0xLTg5MDcy_e0c82ad2-d50c-4c7e-8d00-9986646d9b16">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f4e826d5cae4c6ab418a941d7cc0de2_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzEtOC0xLTEtODkwNzI_db17f732-cb3a-401e-8a00-4897a3a99d38">69</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77808f738d5b47f0b37ad9c848b56f22_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzEtMTItMS0xLTg5MDcy_400cdc28-405d-48f4-b5ad-5cfd0d9c1aba">69</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0970c94f194e79b173d2e77e2e293e_D20220101-20220331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzEtMTQtMS0xLTg5MDcy_365ffe23-254b-448a-a573-bc94e2c84b58">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzEtMTYtMS0xLTg5MDcy_3d3b7133-2d73-41d6-8eab-1e1420a33515">66</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfaddc1e31294937b80e601e88e11ec4_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzItMTAtMS0xLTg5MDcy_fadeba15-8937-4712-ada4-2ac1b2ff2d4d">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77808f738d5b47f0b37ad9c848b56f22_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzItMTItMS0xLTg5MDcy_9adfc9ff-4445-47e7-83f1-700b67b77130">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzItMTYtMS0xLTg5MDcy_bdeaefe3-d9ce-404b-87e1-654ca4a516d9">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances, March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id18917e004004a1cb3c4e185b15bf4f9_I20220331" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzMtMi0xLTEtODkwNzI_14f949ea-f1a9-4675-8dbf-04c9b8819388">361.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id18917e004004a1cb3c4e185b15bf4f9_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzMtNC0xLTEtODkwNzI_11c0bbaa-379d-4476-88a3-59d69276b343">10,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f63b9f26c034375825caac2dc4a720d_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzMtNi0xLTEtODkwNzI_7e481303-4cd2-473b-9ece-8bcf0daf8090">415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib79580d46a03440a901afd4aa7cf0eae_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzMtOC0xLTEtODkwNzI_badf3bc7-c298-4d7f-9647-e2d972ff07c8">9,030</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38bc8011408047f4b2f92fc815fe79b3_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzMtMTAtMS0xLTg5MDcy_8a42ebf0-64df-400d-81cd-86457fee3929">1,974</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f1e816041a249bcaedd71a44ddc03c1_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzMtMTItMS0xLTg5MDcy_6dc18650-7e0c-448b-bef4-36d9b5d790d9">216</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0925610a81344f42966f7155678bbe7d_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzMtMTQtMS0xLTg5MDcy_d5a1e295-e8ba-4cfa-8d2f-746c351f2cfa">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzMtMTYtMS0xLTg5MDcy_968ec850-e02f-4e1b-94ee-08de2bfa47c3">141</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances, January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6bc0f97e922441d290fd2952ed4015ca_I20201231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzYtMi0xLTEtODkwNzI_1a3a8224-395d-4746-bf22-a015cbcca59c">355.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bc0f97e922441d290fd2952ed4015ca_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzYtNC0xLTEtODkwNzI_97c9d4ef-26da-42d8-badf-6af2010a7f3c">10,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f39cf0ad53f489993087fb8612e9e44_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzYtNi0xLTEtODkwNzI_9d3ece54-a881-4fc6-be09-75c92c372a1e">454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i580f9e18b59a4b5180b3f4e43139f3fd_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzYtOC0xLTEtODkwNzI_81740f2e-f02c-4fc9-9f14-1fb75f6b98ef">8,013</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c28220a2c554d82874543d9cef4c95f_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzYtMTAtMS0xLTg5MDcy_a350ebb6-68f8-408a-93cc-dd9332f97e8e">2,133</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ec67446aa664948b24b2dd151b61e21_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzYtMTItMS0xLTg5MDcy_9a410699-2e76-4de6-b172-1ce83fb399a1">535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida777d6fa6784748b45afb0c1b8b936f_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzYtMTQtMS0xLTg5MDcy_d924ff4a-7171-4326-9443-5a535f4ac6e7">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d274a4a3e5a43ae91dfbb2934c4c5d1_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzYtMTYtMS0xLTg5MDcy_eda1a57d-0408-4b58-b270-12a28fb59648">605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common shares issued under share-based compensation plans</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i250250ab4d084a8688cdf94e83fcc6ea_D20210101-20210331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzgtMi0xLTEtODkwNzI_eb4a55a8-1947-4132-8741-5e1f0c7a0e27">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i250250ab4d084a8688cdf94e83fcc6ea_D20210101-20210331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzgtNC0xLTEtODkwNzI_538e1280-9b61-4651-b8f2-8e78aba82305">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9abb088ab0824fe28335ba83a90707de_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzgtNi0xLTEtODkwNzI_6de43cae-454a-4444-85fb-3805bab4aa63">51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4db7cba132fa4f3593873402ff1be811_D20210101-20210331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzgtMTItMS0xLTg5MDcy_36a48c24-4bfc-49df-badd-79f0f83170a5">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzgtMTYtMS0xLTg5MDcy_1b254ad8-243b-4e61-83c7-9183f8bab704">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9abb088ab0824fe28335ba83a90707de_D20210101-20210331" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzktNi0xLTEtODkwNzI_985d3d47-cdd3-41a0-97e7-cab892682f8a">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4db7cba132fa4f3593873402ff1be811_D20210101-20210331" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzktMTItMS0xLTg5MDcy_ee5289b2-8ad5-4b11-a2fd-06ab5a62fcea">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzktMTYtMS0xLTg5MDcy_6d82c93f-ea77-47b8-abf5-0c265e5f8e41">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee withholding taxes related to share-based awards</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9abb088ab0824fe28335ba83a90707de_D20210101-20210331" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfNDAtNi0xLTEtODkwNzI_7a4b46ec-0210-4676-9574-76f34db81f91">41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4db7cba132fa4f3593873402ff1be811_D20210101-20210331" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfNDAtMTItMS0xLTg5MDcy_3c364e47-6e7b-499f-aa9d-9619504a55bc">41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfNDAtMTYtMS0xLTg5MDcy_334b71d4-37e3-40b4-8de6-c6b692b61942">41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1cf56ffa097d418fbaa7f8cee2095239_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfNDItOC0xLTEtODkwNzI_d6e835e4-1f14-4ecc-a296-29a57fa52c1b">610</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4db7cba132fa4f3593873402ff1be811_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfNDItMTItMS0xLTg5MDcy_9d74eae5-b497-4d3f-a017-319d037cbbfa">610</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2c42a95b1b488c9bb882abf26775af_D20210101-20210331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzgtMTQtMS0xLTk5OTIz_d8d7e7e4-f312-4c5e-953b-8def2070c410">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfNDItMTYtMS0xLTg5MDcy_eb04ee6d-956f-46d2-a611-409f17c6a417">607</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c96e3e707c44ef29db8e7d1430f0ccf_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfNDMtMTAtMS0xLTg5MDcy_db5e3a2c-7258-4b2c-a3f8-3d2567241560">123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4db7cba132fa4f3593873402ff1be811_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfNDMtMTItMS0xLTg5MDcy_56005155-f4d1-4e83-addc-f143f97b49c8">123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfNDMtMTYtMS0xLTg5MDcy_e0a3896d-9b1d-4b7c-8a6e-5a895de6b723">123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances, March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc469902b8d54318b2dc5e3d6f63767e_I20210331" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfNDQtMi0xLTEtODkwNzI_f8201394-55ca-401b-95b9-b498c1481cbc">358.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc469902b8d54318b2dc5e3d6f63767e_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfNDQtNC0xLTEtODkwNzI_cf7a6a10-df90-49c8-b6b8-e9ea94c68a50">10,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a3043cdb1ec4efba6e8a08d5c15f7d0_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfNDQtNi0xLTEtODkwNzI_e1a835f1-4fec-4505-8a8a-6d1365649a17">393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8aed8fa227084065a8e36af7e4853547_I20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfNDQtOC0xLTEtODkwNzI_83b27980-ec90-4344-be65-dccb8cf62fbf">8,623</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8e74f44512b4b5ba5eadd53d7ab8369_I20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfNDQtMTAtMS0xLTg5MDcy_a105b798-bf4a-41f6-a69a-24867b518ed2">2,256</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2671fe8b646f46afb7fa5e65ea5d1e7b_I20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfNDQtMTItMS0xLTg5MDcy_4d81ddcf-403b-4613-abec-5437cfe1267d">197</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f5376ee1f8e4cf1a9859fc1a22909f3_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfNDQtMTQtMS0xLTg5MDcy_c81fd666-a3ac-418d-aaad-ecb6b41a9e0f">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i812289a7a0cf44b4b1eed544ad0bec6c_I20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfNDQtMTYtMS0xLTg5MDcy_083b724b-d006-422f-9c02-3fdead2ee051">124</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i801c461cbd33492a893c84373a8e7cbc_34"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 22.50pt 54.00pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:81.165%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.947%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.949%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows From Operating Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMy0xLTEtMS04OTA3Mg_e174f489-b8f6-4c39-84dc-e578aa5229b5">66</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMy0zLTEtMS04OTA3Mg_165bf1c6-9523-4b2c-9e72-e79d95b46384">607</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNS0xLTEtMS04OTA3Mg_a4e4f269-50aa-4b61-9616-d5d09e9d5278">352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNS0zLTEtMS04OTA3Mg_f7fe1e21-f87c-4c33-af06-86030aa24495">403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization and write-off of debt premiums, discounts and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNi0xLTEtMS04OTA3Mg_a4a951b3-ba40-4e25-a7f0-54f2cfb8ccd7">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNi0zLTEtMS04OTA3Mg_f4fc9b4d-db09-4af8-b499-656365659458">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset impairments, including loss on assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNy0xLTEtMS04OTA3Mg_ba850735-d768-43ab-aa06-29e1af563bae">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNy0zLTEtMS04OTA3Mg_1c16b15d-4e05-4c57-8388-066312c9cdf6">148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill impairments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfOC0xLTEtMS04OTA3Mg_2664234f-144f-412d-81cb-1fd4eacfeaf6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfOC0zLTEtMS04OTA3Mg_dc1e3780-752c-4543-9cf9-5fc8c8921189">469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfOS0xLTEtMS04OTA3Mg_1c8ef0c8-e48c-4392-a059-37d8033077ab">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" sign="-" name="bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfOS0zLTEtMS04OTA3Mg_bf249f3a-bd4c-47a4-b23e-7c79be08f7e3">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allowances for losses on trade receivable and inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="bhc:AllowancesForLossesOnAccountsReceivableAndInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMTAtMS0xLTEtODkwNzI_8b6b5551-2848-4eb3-bc48-d92dc57637c7">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="bhc:AllowancesForLossesOnAccountsReceivableAndInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMTAtMy0xLTEtODkwNzI_b9d22c23-3a57-4e22-8e7a-69d3b2af98de">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" sign="-" name="bhc:DeferredIncomeTaxNoncashExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMTEtMS0xLTEtODkwNzI_9c48af66-19a5-4461-9d95-07416247d98e">83</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" sign="-" name="bhc:DeferredIncomeTaxNoncashExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMTEtMy0xLTEtODkwNzI_c9317cc9-cc45-4064-b20d-c5f36fdc511b">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net gain on sale of assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMTItMS0xLTEtODkwNzI_ca64c6c0-e5ad-4388-b02c-a8037479f4ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMTItMy0xLTEtODkwNzI_d17ec827-ae5d-4670-9c67-469fb668360a">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reductions to accrued legal settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="bhc:GainLossRelatedToLitigationSettlementGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMTMtMS0xLTEtODkwNzI_acc35399-b48a-4966-920c-3a1318c389a0">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="bhc:GainLossRelatedToLitigationSettlementGross" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMTMtMy0xLTEtODkwNzI_3453d565-385c-4b6b-924f-229dae6bae3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments of accrued legal settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsForLegalSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMTQtMS0xLTEtODkwNzI_88a5f58b-953d-4de4-8024-1c0dbda1c7e3">360</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsForLegalSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMTQtMy0xLTEtODkwNzI_873d18b0-d025-41fb-8430-07c94ab01d8d">118</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMTUtMS0xLTEtODkwNzI_106a0a03-d679-43fd-aa38-319c7e827836">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMTUtMy0xLTEtODkwNzI_a851c784-3844-471e-a9f1-f4e99b099550">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMTYtMS0xLTEtODkwNzI_0de0909b-e85b-4a6f-8f7e-3f0835f1ff6b">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMTYtMy0xLTEtODkwNzI_aa3ef1ed-03ad-4dda-9c16-4461f3ff4f0a">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain excluded from hedge effectiveness</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="bhc:DerivativeGainExcludedComponent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMTctMS0xLTEtODkwNzI_429d6caa-ad6c-478f-a99f-573503ffc94a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="bhc:DerivativeGainExcludedComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMTctMy0xLTEtODkwNzI_73ae7d77-6f36-4e0b-824d-08edba09cd68">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMTgtMS0xLTEtODkwNzI_f47471bc-b8a3-459b-be1b-de57cb4db87a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMTgtMy0xLTEtODkwNzI_bdc9b56b-bc7f-4992-9209-1d326c608704">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMjAtMS0xLTEtODkwNzI_4e733726-341a-49f5-86a4-815685b3ddef">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMjAtMy0xLTEtODkwNzI_d6e22c3b-fd59-4eac-8533-6b6e3d2be675">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMjItMS0xLTEtODkwNzI_759afcf3-9870-41cd-8e1d-b2dd87c2c5ae">197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMjItMy0xLTEtODkwNzI_dc309121-a480-4248-b551-da95ed8189ef">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMjMtMS0xLTEtODkwNzI_67939ff1-aeaa-4b9f-a3b1-93102e4a2e6c">73</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMjMtMy0xLTEtODkwNzI_a0b1a867-2dd2-4ae1-b04c-3738006e3385">35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMjQtMS0xLTEtODkwNzI_05aaae06-6ed4-4be1-9890-bf65efe1269f">33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMjQtMy0xLTEtODkwNzI_d34f3f6b-e0d0-45c7-8535-9fc72be4c035">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable, accrued and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMjUtMS0xLTEtODkwNzI_2b941d14-9e77-467b-ae81-bf5c0648d3b1">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMjUtMy0xLTEtODkwNzI_0bca2c22-b6bb-420e-8d16-bd574023bc1d">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash (used in) provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMjYtMS0xLTEtODkwNzI_a0bf3ed9-8cae-472c-8f1b-1eacf5048a11">63</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMjYtMy0xLTEtODkwNzI_0b401b13-c968-47d6-af13-3f29aaffbe33">443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows From Investing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMjgtMS0xLTEtODkwNzI_2be1069d-3031-4c31-8531-4deb51418487">46</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMjgtMy0xLTEtODkwNzI_c13d01e1-9954-47c2-82d2-60fc28e156ba">66</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for intangible and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMjktMS0xLTEtODkwNzI_1c62fc2e-8895-4848-a953-6b258a5f5b96">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMjktMy0xLTEtODkwNzI_9e52085d-89e3-4086-984c-b3807b63e8b6">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMzAtMS0xLTEtODkwNzI_391cd965-107a-43f3-bc4c-acf60e167919">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMzAtMy0xLTEtODkwNzI_d0618f50-ff98-4d38-896e-b02f86e1428d">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMzEtMS0xLTEtODkwNzI_f994e775-14a8-49a6-98cc-d39c429f9004">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMzEtMy0xLTEtODkwNzI_96f84f0d-160d-46e0-b572-977390569e57">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale of assets and businesses, net of costs to sell</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMzItMS0xLTEtODkwNzI_40521685-1e40-4416-9e3e-b39b3f990769">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMzItMy0xLTEtODkwNzI_9ad498e7-de0b-4377-b34b-db03aebaee7d">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest settlements from cross-currency swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="bhc:InterestSettlementOnCrossCurrencySwaps" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMzMtMS0xLTEtODkwNzI_dd0ce51c-f465-4f33-b53f-e701856cc6d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="bhc:InterestSettlementOnCrossCurrencySwaps" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMzMtMy0xLTEtODkwNzI_ac09f19e-cbd7-4ef0-97cc-9c27757a4659">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMzQtMS0xLTEtODkwNzI_811955b8-e190-47a8-959c-94e5cd91fa3b">56</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMzQtMy0xLTEtODkwNzI_bcfed1bd-642c-43b6-9488-dc84f9bd9b60">56</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows From Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of long-term debt, net of discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMzYtMS0xLTEtODkwNzI_ebbf3b13-4993-41e4-84ad-57c59bfcd4c1">986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMzYtMy0xLTEtODkwNzI_06aa53b4-97d4-458a-ac37-e91749bbf8b1">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayments of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMzctMS0xLTEtODkwNzI_279eff2b-f528-4664-bd4a-1b304a60c5c9">485</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMzctMy0xLTEtODkwNzI_58fe3e6a-40a4-4227-bd29-bab3a3ea3a57">200</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments of employee withholding taxes related to share-based awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNDAtMS0xLTEtODkwNzI_ef93050b-30cd-458d-bf33-0972185f925c">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNDAtMy0xLTEtODkwNzI_09523e66-d27b-421b-ad1b-309d4ec46d83">41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments of acquisition-related contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNDEtMS0xLTEtODkwNzI_5345ae1c-c833-4301-a71c-41a3bcb5841a">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNDEtMy0xLTEtODkwNzI_a83e0244-5685-40cd-8bcf-f49b0e3dbeaa">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments of financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNDItMS0xLTEtODkwNzI_7a81767d-f490-4d0d-8bc2-d1a3228e8942">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNDItMy0xLTEtODkwNzI_b3821221-2c5a-4e0c-8f40-963938c71627">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNDMtMS0xLTEtODkwNzI_7cbda6d3-695f-4edf-acaf-44ae3dd00650">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNDMtMy0xLTEtODkwNzI_f3b44eef-ac99-49e1-ae47-f61e07f24cf8">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNDQtMS0xLTEtODkwNzI_5f96b2ba-f9e6-42f4-aaf9-b966c0558f53">468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNDQtMy0xLTEtODkwNzI_c0f87495-9a80-4252-b461-0182aafc7b58">243</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNDUtMS0xLTEtODkwNzI_9d032266-cc22-413a-9990-9028c11dcbb9">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNDUtMy0xLTEtODkwNzI_5d67d29a-d399-42b3-af62-9531a8c60455">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNDYtMS0xLTEtODkwNzI_e5f6e043-466b-4011-b98f-d13054137642">341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNDYtMy0xLTEtODkwNzI_8f99fd05-e563-437b-87fd-8386a15f4036">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNDctMS0xLTEtODkwNzI_affc4586-46bf-4391-aff9-ebf77fc084b8">2,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d274a4a3e5a43ae91dfbb2934c4c5d1_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNDctMy0xLTEtODkwNzI_2dbd7242-5f27-4b50-87c3-531075b63570">1,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash, cash equivalents and restricted cash, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNDgtMS0xLTEtODkwNzI_f926a55f-f20d-44b4-944b-afa16f9a1e43">2,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i812289a7a0cf44b4b1eed544ad0bec6c_I20210331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNDgtMy0xLTEtODkwNzI_339afb1a-546e-4644-9b15-7bf0e1da472a">1,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNDktMS0xLTEtODkwNzI_02035ebc-af37-4f96-a32b-a23e58d82f12">1,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i812289a7a0cf44b4b1eed544ad0bec6c_I20210331" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNDktMy0xLTEtODkwNzI_a5685bdb-ffc8-479d-b522-a83714b29083">679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash and other settlement deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="bhc:RestrictedCashAndOtherSettlementDepositsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNTAtMS0xLTEtODkwNzI_e41a1083-1478-49c4-9b17-8cbe308961ba">1,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i812289a7a0cf44b4b1eed544ad0bec6c_I20210331" decimals="-6" name="bhc:RestrictedCashAndOtherSettlementDepositsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNTAtMy0xLTEtODkwNzI_0ce0fb67-a17a-4fdd-b16a-e2f42d97f7f6">1,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents, held for sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNTEtMS0xLTEtOTQ3MDk_a285bd7c-ace7-4bbd-9d39-78c6255a7bb3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i812289a7a0cf44b4b1eed544ad0bec6c_I20210331" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNTEtMy0xLTEtOTQ3MDk_597ace11-d070-4ffd-af4a-91282bc0cc3f">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash, cash equivalents and restricted cash, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNTEtMS0xLTEtODkwNzI_0d902b80-dc8d-43dc-a4ad-4d2317f672b9">2,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i812289a7a0cf44b4b1eed544ad0bec6c_I20210331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNTEtMy0xLTEtODkwNzI_5229cd8d-c1d4-41e1-a251-69e5ee3d7ac9">1,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div></div><div style="height:22.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i801c461cbd33492a893c84373a8e7cbc_37"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="i801c461cbd33492a893c84373a8e7cbc_40"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180MC9mcmFnOjQ4OTVjZTllODdmMTRiMzVhZjc1M2QyNjVmMzU5NWY4L3RleHRyZWdpb246NDg5NWNlOWU4N2YxNGIzNWFmNzUzZDI2NWYzNTk1ZjhfNTkw_3a641487-a58c-469c-a6c9-a72dd5348083" continuedAt="i6dd3a51bc47346e0aef53a382ff12a38" escape="true">DESCRIPTION OF BUSINESS </ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6dd3a51bc47346e0aef53a382ff12a38">Bausch Health Companies Inc. (the&#160;&#8220;Company&#8221; or &#8220;Bausch Health&#8221;) is a multinational, specialty pharmaceutical and medical device company that develops, manufactures and markets, primarily in the therapeutic areas of eye health, gastroenterology (&#8220;GI&#8221;) and dermatology, a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (&#8220;OTC&#8221;) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices) which are marketed directly or indirectly in approximately <ix:nonFraction unitRef="country" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-2" name="us-gaap:NumberOfCountriesInWhichEntityOperates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180MC9mcmFnOjQ4OTVjZTllODdmMTRiMzVhZjc1M2QyNjVmMzU5NWY4L3RleHRyZWdpb246NDg5NWNlOWU4N2YxNGIzNWFmNzUzZDI2NWYzNTk1ZjhfNTc0_7576847f-c059-413a-b79d-766d5ebb16fe">100</ix:nonFraction> countries.</ix:continuation></span></div><div id="i801c461cbd33492a893c84373a8e7cbc_43"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180My9mcmFnOjU5YzU0MTc3NGNlOTRhOTM4Y2NhZThmNGEzYzRmMDAwL3RleHRyZWdpb246NTljNTQxNzc0Y2U5NGE5MzhjY2FlOGY0YTNjNGYwMDBfODY0Ng_956cc5e5-536b-4de8-b366-15aa5bddc2af" continuedAt="id534c186d97742dbab2f773596480c3e" escape="true">SIGNIFICANT ACCOUNTING POLICIES </ix:nonNumeric></span></div><ix:continuation id="id534c186d97742dbab2f773596480c3e" continuedAt="ic7446d37d5dd4490ad7584f2c9adfe51"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180My9mcmFnOjU5YzU0MTc3NGNlOTRhOTM4Y2NhZThmNGEzYzRmMDAwL3RleHRyZWdpb246NTljNTQxNzc0Y2U5NGE5MzhjY2FlOGY0YTNjNGYwMDBfODY3MQ_a486cfda-8995-494d-8a14-ee5dea96c3ba" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation and Use of Estimates </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Consolidated Financial Statements have been prepared by the Company in U.S. dollars and in accordance with&#160;U.S. generally accepted accounting principles (&#8220;U.S.&#160;GAAP&#8221;) for interim financial reporting, which do not conform in all respects to the requirements of U.S.&#160;GAAP for annual financial statements. Accordingly, these notes to the unaudited Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements prepared in accordance with U.S.&#160;GAAP that are contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the U.S. Securities and Exchange Commission (the&#160;&#8220;SEC&#8221;) and the Canadian Securities Administrators (the&#160;&#8220;CSA&#8221;) on February&#160;23, 2022. The unaudited Consolidated Financial Statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company&#8217;s audited Consolidated Financial Statements for the year ended December&#160;31, 2021, except for the new accounting guidance adopted during the period. The unaudited Consolidated Financial Statements reflect all normal and recurring adjustments necessary for a fair statement of the Company&#8217;s financial position and results of operations for the interim periods. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full&#160;year.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Separation of the Bausch + Lomb Eye Health Business and Initial Public Offering of Solta Medical Business</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2020, the Company announced its intentions to separate its eye health business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc. (the &#8220;B+L Separation&#8221;). On August 3, 2021, the Company announced its intentions to conduct an initial public offering (&#8220;IPO&#8221;) of its aesthetic medical device business, Global Solta (the &#8220;Solta IPO&#8221;). In January 2022, the Company completed the internal organizational design and structure of the new eye health entity, Bausch + Lomb Corporation (&#8220;Bausch + Lomb&#8221;), and the new Global Solta entity, Solta Medical Corporation (&#8220;Solta&#8221;), as previously announced. The registration statement related to the B+L IPO of Bausch + Lomb (the &#8220;B+L IPO&#8221;) was declared effective on May 5, 2022, and Bausch + Lomb&#8217;s common stock began trading on the New York Stock Exchange and the Toronto Stock Exchange, in each case under the ticker symbol &#8220;BLCO&#8221; on May 6, 2022. Prior to the effectiveness of the registration statement, Bausch + Lomb was an indirect wholly-owned subsidiary of the Company. On May 10, 2022, a wholly owned subsidiary of the Company (the &#8220;Selling Shareholder&#8221;) sold <ix:nonFraction unitRef="shares" contextRef="i68726a27c9ca4a3a994459eb340ec3da_D20220510-20220510" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180My9mcmFnOjU5YzU0MTc3NGNlOTRhOTM4Y2NhZThmNGEzYzRmMDAwL3RleHRyZWdpb246NTljNTQxNzc0Y2U5NGE5MzhjY2FlOGY0YTNjNGYwMDBfMTA0NDUzNjA0ODQwMTk_71b8a7b1-cad0-4103-8498-c8eaeea35275">35,000,000</ix:nonFraction> common shares of Bausch + Lomb, at an offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia0d8e4dd5979420fbef5b45edd961b43_I20220510" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180My9mcmFnOjU5YzU0MTc3NGNlOTRhOTM4Y2NhZThmNGEzYzRmMDAwL3RleHRyZWdpb246NTljNTQxNzc0Y2U5NGE5MzhjY2FlOGY0YTNjNGYwMDBfMTA0NDUzNjA0ODQwMzE_8de528df-0d9b-4cba-8aae-7e7a742c3db3">18.00</ix:nonFraction>, per share, pursuant to the Bausch + Lomb prospectus. The net proceeds from the B+L IPO after deducting underwriting commissions and estimated offering expenses were approximately $<ix:nonFraction unitRef="usd" contextRef="i68726a27c9ca4a3a994459eb340ec3da_D20220510-20220510" decimals="-6" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180My9mcmFnOjU5YzU0MTc3NGNlOTRhOTM4Y2NhZThmNGEzYzRmMDAwL3RleHRyZWdpb246NTljNTQxNzc0Y2U5NGE5MzhjY2FlOGY0YTNjNGYwMDBfMTA0NDUzNjA0ODQwMzk_7c8693b8-e98f-478f-a657-dc77316843cf">560</ix:nonFraction>&#160;million. The Company expects to complete the separation of Bausch + Lomb after the expiry of customary lockups related to the B+L IPO and achievement of targeted debt leverage ratios, subject to the receipt of applicable shareholder and other necessary approvals. The launch of the Solta IPO remains subject to when financial market conditions become favorable (and subject to receipt of regulatory, stock exchange and other approvals and other factors). See Note 20, &#8220;SUBSEQUENT EVENTS&#8221; for additional details regarding the B+L IPO.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The B+L Separation and the proposed Solta IPO will establish <ix:nonFraction unitRef="company" contextRef="iae181339de7f48fb8794bf85314efcc0_I20210803" decimals="INF" name="bhc:ProposedBusinessSeparationAndInitialPublicOfferingNumberOfCompaniesEstablished" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180My9mcmFnOjU5YzU0MTc3NGNlOTRhOTM4Y2NhZThmNGEzYzRmMDAwL3RleHRyZWdpb246NTljNTQxNzc0Y2U5NGE5MzhjY2FlOGY0YTNjNGYwMDBfMjA0Nw_d7afa004-35a8-46cf-98d5-e251d5182d24">three</ix:nonFraction> separate companies that include: (i) a fully integrated eye health company which will consist of the Company&#8217;s Bausch + Lomb Global Vision Care, Global Surgical, Global Consumer and Global Ophthalmic Pharmaceuticals businesses, (ii) a global provider of aesthetic medical devices which will consist of the Company&#8217;s Solta business and (iii) a diversified pharmaceutical company which will include the Company&#8217;s Salix, International (formerly International Rx), dentistry, neurology, medical dermatology and generics pharmaceutical businesses. These audited Consolidated Financial Statements do not include any adjustments to give effect to either the B+L Separation or the proposed Solta IPO.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impacts of COVID-19 Pandemic </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unprecedented nature of the COVID-19 pandemic has, and continues to, adversely impact the global economy. The COVID-19 pandemic and the reactions of governments, private sector participants and the public in an effort to contain the spread of the COVID-19 virus and/or address its impacts have had significant direct and indirect effects on businesses and </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="ic7446d37d5dd4490ad7584f2c9adfe51"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commerce. This includes, but is not limited to, disruption to supply chains, employee base and transactional activity, facilities closures and production suspensions.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which these events may continue to impact the Company&#8217;s business, financial condition, cash flows and results of operations, in particular, will depend on future developments which are highly uncertain and many of which are outside the Company&#8217;s control. Such developments include the availability and effectiveness of vaccines for the COVID-19 virus, the ultimate geographic spread and duration of the pandemic, COVID-19 vaccine immunization rates, the extent and duration of a resurgence of the COVID-19 virus and variant strains thereof, such as the delta and omicron variants, new information concerning the severity of the COVID-19 virus, the effectiveness and intensity of measures to contain the COVID-19 virus and the economic impact of the pandemic and the reactions to it. Such developments, among others, depending on their nature, duration and intensity, could have a significant adverse effect on the Company&#8217;s business, financial condition, cash flows and results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has been able to continue its operations with limited disruptions in supply and manufacturing.   Although it is difficult to predict the broad macroeconomic effects that the COVID-19 pandemic will have on industries or individual companies, the Company has assessed the possible effects and outcomes of the pandemic on, among other things, its supply chain, customers and distributors, discounts and rebates, employee base, product sustainability, research and development efforts, product pipeline and consumer demand and currently believes that its estimates are reasonable. </span></div><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180My9mcmFnOjU5YzU0MTc3NGNlOTRhOTM4Y2NhZThmNGEzYzRmMDAwL3RleHRyZWdpb246NTljNTQxNzc0Y2U5NGE5MzhjY2FlOGY0YTNjNGYwMDBfODYzOA_7b1c164f-a6fb-40e7-ac0c-c2bf6941d0df" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing the unaudited Consolidated Financial Statements, management is required to make estimates and assumptions. This includes estimates and assumptions regarding the nature, timing and extent of the impacts that the COVID-19 pandemic will have on its operations and cash flows.  The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the unaudited Consolidated Financial Statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates and the differences could be material. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company&#8217;s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company&#8217;s results of operations and financial position could be materially impacted.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180My9mcmFnOjU5YzU0MTc3NGNlOTRhOTM4Y2NhZThmNGEzYzRmMDAwL3RleHRyZWdpb246NTljNTQxNzc0Y2U5NGE5MzhjY2FlOGY0YTNjNGYwMDBfODY0Mw_955753e2-a86c-44d0-a3b7-6443a41340d3" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180My9mcmFnOjU5YzU0MTc3NGNlOTRhOTM4Y2NhZThmNGEzYzRmMDAwL3RleHRyZWdpb246NTljNTQxNzc0Y2U5NGE5MzhjY2FlOGY0YTNjNGYwMDBfODYzNA_5ed66cfe-f568-4d9c-b470-28f4ce610e84" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior year amounts to conform to the current year presentation.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Reportable Segments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the first quarter of 2022, the Company operates in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International (formerly International Rx), (iv) Solta Medical and (v) Diversified Products. Prior to the first quarter of 2022, the Company operated in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International, (iv) Ortho Dermatologics and (v) Diversified Products. Prior period presentations have been recast to conform to the current segment reporting structure. See Note 19, &#8220;SEGMENT INFORMATION&#8221; for additional information.</span></div></ix:continuation><div id="i801c461cbd33492a893c84373a8e7cbc_46"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RleHRyZWdpb246OWUyNTVmY2Q2YjIyNDgzMWJmYjkxNDk0ODZhMDBlNWNfNjUyMQ_39e26840-92b6-4e27-986b-d937e35411ab" continuedAt="i03c272f9fbf8451ba45df18cf759eca3" escape="true"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RleHRyZWdpb246OWUyNTVmY2Q2YjIyNDgzMWJmYjkxNDk0ODZhMDBlNWNfNjUyOA_3c40216f-bdf2-44dd-996f-f9a7d299705f" continuedAt="icbe64acdadb24b7c9938bde24de36653" escape="true">REVENUE RECOGNITION </ix:nonNumeric></ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i03c272f9fbf8451ba45df18cf759eca3" continuedAt="i4663ccb3002a4530968ed6061a1d3eba"><ix:continuation id="icbe64acdadb24b7c9938bde24de36653" continuedAt="i92bbafcf39ca4fb7ad8d6da3f6755396">The Company&#8217;s revenues are primarily generated from product sales, principally in the therapeutic areas of eye health, GI and dermatology, that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 19, &#8220;SEGMENT INFORMATION&#8221; for the disaggregation of revenue which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts.</ix:continuation></ix:continuation></span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i92bbafcf39ca4fb7ad8d6da3f6755396" continuedAt="i16260d79f6634af9a705c9b50ddc662b"><ix:continuation id="i4663ccb3002a4530968ed6061a1d3eba"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales Provisions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.&#160; The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers. Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company&#8217;s products. These judgments include the potential impact of the COVID-19 pandemic on, among other things, unemployment and related changes in customer health insurance levels, customer behaviors during the COVID-19 pandemic and government stimulus bills that focus on ensuring availability and access to lifesaving drugs during a public health crisis. This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or require an adjustment related to past sales, or both. If the trend in actual amounts of variable consideration varies from the Company&#8217;s prior estimates, the Company adjusts these estimates when such trend is believed to be sustainable. At that time, the Company would record the necessary adjustments which would affect net product revenue and earnings reported in the current period. The Company applies this method consistently for contracts with similar characteristics.</span></div></ix:continuation><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RleHRyZWdpb246OWUyNTVmY2Q2YjIyNDgzMWJmYjkxNDk0ODZhMDBlNWNfNjUxNg_80f56020-f7f6-415c-9817-6bb2b4d3a675" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the activity and ending balances of the Company&#8217;s variable consideration provisions for the three months ended March 31, 2022 and 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.616%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5fdcedce07473f95b4d896abcc8dc6_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfMi0yLTEtMS04OTA3Mg_f76636c2-a365-47ae-9184-7e93152eb2cb">222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id234e6e6761c4d3fadd602df79c36a18_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfMi00LTEtMS04OTA3Mg_0ed50a89-9a68-4a0d-b931-b9d0a82839d0">482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3282ac48025c402fb8242346f1697dc3_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfMi02LTEtMS04OTA3Mg_7b267480-c1cc-47db-bd7c-39d4d68a4e32">944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f7124918f0c4940946cbc5598b8eb93_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfMi04LTEtMS04OTA3Mg_4d333c50-2223-473e-8d2f-f513e198ae98">170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82cd23474eef475d818ea158ef0a033c_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfMi0xMC0xLTEtODkwNzI_a4939e6b-f0d3-4408-b751-f9ecaef7c16c">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfMi0xMi0xLTEtODkwNzI_6d568a51-da5f-49ca-a950-580b65a29d2a">1,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provisions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f025023becd4701b88a21aeb30b1551_D20220101-20220331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfMy0yLTEtMS04OTA3Mg_97fa42f0-3b65-4e26-b65f-c014a2fa4aff">134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2702eb3989e049ee9ba259ff98e17bd5_D20220101-20220331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfMy00LTEtMS04OTA3Mg_a6e46a13-3786-4594-ae9e-f9748c3eec1f">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba1bbd977ad949bb8ef314204d0f9031_D20220101-20220331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfMy02LTEtMS04OTA3Mg_28d67997-7009-41dc-a7c5-7df89a283573">581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75a4cf7e52aa4b4baa6fd5cc411e8269_D20220101-20220331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfMy04LTEtMS04OTA3Mg_57b0bebd-9122-4dc9-9292-7f3d667f1bbc">471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib297e736b3f84933b2038cba50e4d5ed_D20220101-20220331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfMy0xMC0xLTEtODkwNzI_85d5c298-143f-4213-8511-67ec0162cb13">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfMy0xMi0xLTEtODkwNzI_a74ee750-487c-4851-8226-ce060cc4b65e">1,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f025023becd4701b88a21aeb30b1551_D20220101-20220331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfNC0yLTEtMS04OTA3Mg_997f2cb0-b4c4-4aa2-b798-fb99af457b21">162</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2702eb3989e049ee9ba259ff98e17bd5_D20220101-20220331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfNC00LTEtMS04OTA3Mg_33c66881-2fa7-4eb7-b57a-abaa6ca7b05e">54</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba1bbd977ad949bb8ef314204d0f9031_D20220101-20220331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfNC02LTEtMS04OTA3Mg_a2a05830-ba6a-45e3-879b-f9c218167c96">599</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75a4cf7e52aa4b4baa6fd5cc411e8269_D20220101-20220331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfNC04LTEtMS04OTA3Mg_98862648-33ce-4cdc-b884-95f2d0673c97">359</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib297e736b3f84933b2038cba50e4d5ed_D20220101-20220331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfNC0xMC0xLTEtODkwNzI_fa92e7a0-370f-45ea-91a1-2951b9e23b68">53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfNC0xMi0xLTEtODkwNzI_ca803892-7291-42cf-8ee2-7615c685b5ec">1,227</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d87c2977704a1e9e27fa4ce9d6f6ca_I20220331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfNS0yLTEtMS04OTA3Mg_a0cf350d-dc70-4f91-a822-c2a5b241c689">194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91537bd044f94fd8a698e842e7d17804_I20220331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfNS00LTEtMS04OTA3Mg_435d1554-253f-4565-95cb-77085ea5f55e">447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i445a6442a30f43b594d2d8364e5b4894_I20220331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfNS02LTEtMS04OTA3Mg_eea67426-1d9c-4d25-9b00-1991b0d5e164">926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcb261aecea64295aab4bf43ac889601_I20220331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfNS04LTEtMS04OTA3Mg_7d82d0ba-b3e6-4886-b71c-06746109e44a">282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bcf6389cdc947f7ae05710631221f68_I20220331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfNS0xMC0xLTEtODkwNzI_4c09b570-99b0-46a8-b0d6-cf04e84f3844">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfNS0xMi0xLTEtODkwNzI_035d777e-7b9b-437f-843e-d063d20e535a">1,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $<ix:nonFraction unitRef="usd" contextRef="i697ad802318444ba908fe6471d84bff7_I20220331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RleHRyZWdpb246OWUyNTVmY2Q2YjIyNDgzMWJmYjkxNDk0ODZhMDBlNWNfNDg2MA_5aee83c6-3dcc-4d05-b930-3654c61b36d1">37</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if292799a4efd4044b18a023be1f10b95_I20220101" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RleHRyZWdpb246OWUyNTVmY2Q2YjIyNDgzMWJmYjkxNDk0ODZhMDBlNWNfNDg2Nw_ed6d4867-60d0-4522-ae86-7b6f91e9c1dd">36</ix:nonFraction>&#160;million as of March 31, 2022 and January 1, 2022, respectively, which are reflected as a reduction of Trade receivables, net in the Consolidated Balance Sheets. There were <ix:nonFraction unitRef="usd" contextRef="i5fec8302d4c14f00b65fb0e31f318228_D20220101-20220331" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RleHRyZWdpb246OWUyNTVmY2Q2YjIyNDgzMWJmYjkxNDk0ODZhMDBlNWNfMjc0ODc3OTA3ODA3MQ_974c39e0-50d3-4f2c-9fff-5b2f8db06a02">no</ix:nonFraction> price appreciation credits during the three months ended March 31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.616%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia46992a39fd44a9b8ea71a5f0394d386_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfMi0yLTEtMS04OTA3Mg_3f12321b-92e1-4a46-8385-854574f75bff">190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f9959394a574ff69f1d9b58d938d4d3_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfMi00LTEtMS04OTA3Mg_126fe7ae-59f9-45b5-957c-a1877c4a7765">575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e23891f40464cfa8e56cdb7bab0040d_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfMi02LTEtMS04OTA3Mg_35821c52-6a8c-4a30-aa36-36a852da0e40">779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9401e356d1aa4b399cc5adc2cd56f34c_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfMi04LTEtMS04OTA3Mg_3bdb9aeb-29fd-4280-b910-cd82ca48d512">184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic58ddf3411fb47e0af82f6f1e662bf16_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfMi0xMC0xLTEtODkwNzI_e51552b4-da76-4722-9c32-21b1cc80dba5">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d274a4a3e5a43ae91dfbb2934c4c5d1_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfMi0xMi0xLTEtODkwNzI_e08192bc-cba9-43ea-b229-fa243c284530">1,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provisions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b8dbfb41c7451caad9c7ce92634d2b_D20210101-20210331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfMy0yLTEtMS04OTA3Mg_3183d0d6-751f-47fe-ab9b-667141027bf9">147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e143ff88d214dff8d83bfb996d04d80_D20210101-20210331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfMy00LTEtMS04OTA3Mg_901a40b6-ea44-43b2-bdc9-d0683ab86819">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i038c797945244014ae7afbec7d83111e_D20210101-20210331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfMy02LTEtMS04OTA3Mg_e1b52ad4-4c40-4d1a-8ce4-e8244a39cefd">602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89ad456c68d4bbbbdbaf276e1161261_D20210101-20210331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfMy04LTEtMS04OTA3Mg_c5f74f87-fd43-400a-9085-946d1b26697c">462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92d2b71d6b3c41538e26137d45cf75e6_D20210101-20210331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfMy0xMC0xLTEtODkwNzI_cf3c6d3d-e673-4954-b87e-495b01ae9dc0">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfMy0xMi0xLTEtODkwNzI_5be0f588-b3b5-4360-bb5d-fd30f2f8979a">1,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54b8dbfb41c7451caad9c7ce92634d2b_D20210101-20210331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfNC0yLTEtMS04OTA3Mg_3191a2d0-e62c-4af0-8384-6b67bdfb45d0">160</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e143ff88d214dff8d83bfb996d04d80_D20210101-20210331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfNC00LTEtMS04OTA3Mg_282552cf-9679-4797-97cd-56e009d2bc97">56</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i038c797945244014ae7afbec7d83111e_D20210101-20210331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfNC02LTEtMS04OTA3Mg_3096840c-332d-46ce-9135-4ebc935ca6a2">457</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie89ad456c68d4bbbbdbaf276e1161261_D20210101-20210331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfNC04LTEtMS04OTA3Mg_661fd0b5-0189-4ad1-b2a6-7c7db785b408">483</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92d2b71d6b3c41538e26137d45cf75e6_D20210101-20210331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfNC0xMC0xLTEtODkwNzI_2b25b79c-53f6-475a-89b2-a4420d0543bc">66</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfNC0xMi0xLTEtODkwNzI_60be33e4-0766-4918-a396-04578341ed93">1,222</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e170c61a34348efbeb9b2757d9d6ff0_I20210331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfNS0yLTEtMS04OTA3Mg_1279cbd9-4d88-4312-9c78-42f091806b5a">177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc8ac7cdffe4470a00c7b19194e2fd9_I20210331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfNS00LTEtMS04OTA3Mg_64e783be-91b9-4d25-8040-b860544b91d4">553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71b36fbbd72476aa3d99cbc13954b77_I20210331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfNS02LTEtMS04OTA3Mg_c81a13ac-56ec-45a1-85da-9e4a45cd7922">924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacbae26421d743459b9dfa79bcc4f94f_I20210331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfNS04LTEtMS04OTA3Mg_acb5c7ea-2e8f-412a-9d78-0c45c3b1f867">163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6300cf7309e042b48c456d1a58ee874f_I20210331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfNS0xMC0xLTEtODkwNzI_4152ce0f-e6f6-486c-8074-89afbd261d8f">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i812289a7a0cf44b4b1eed544ad0bec6c_I20210331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfNS0xMi0xLTEtODkwNzI_a33f9a74-dffd-4b2a-8722-baa26dd5349a">1,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $<ix:nonFraction unitRef="usd" contextRef="i39945b5b3dde4b2f9bc375faa8ded0c1_I20210331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RleHRyZWdpb246OWUyNTVmY2Q2YjIyNDgzMWJmYjkxNDk0ODZhMDBlNWNfNTI0Ng_6407062c-0579-45dd-8a5f-44b90c3e6a47">34</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iaa437e0185f6406491796407827b52e0_I20210101" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RleHRyZWdpb246OWUyNTVmY2Q2YjIyNDgzMWJmYjkxNDk0ODZhMDBlNWNfNTI1Mw_bbd83688-e376-4a31-acad-50ac1004c296">32</ix:nonFraction>&#160;million as of March 31, 2021 and January 1, 2021, respectively. Included as a reduction of Distribution fees in the table above are price appreciation credits of approximately $<ix:nonFraction unitRef="usd" contextRef="idba10c80ddf84c3cbaffdb663edf3e53_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RleHRyZWdpb246OWUyNTVmY2Q2YjIyNDgzMWJmYjkxNDk0ODZhMDBlNWNfMjc0ODc3OTA3ODA2MA_30e30f03-15b1-4462-9d96-05cb618ab487">1</ix:nonFraction>&#160;million during the three months ended March 31, 2021.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i16260d79f6634af9a705c9b50ddc662b"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Contract Liabilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no contract assets for any period presented. Contract liabilities consist of deferred revenue, the balance of which is not material to any period presented. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allowance for Credit Losses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An allowance is maintained for potential credit losses. The Company estimates the current expected credit loss on its receivables based on various factors, including historical credit loss experience, customer credit worthiness, value of collaterals (if any), and any relevant current and reasonably supportable future economic factors.&#160; Additionally, the Company generally estimates the expected credit loss on a pool basis when customers are deemed to have similar risk characteristics. Trade receivable balances are written off against the allowance when it is deemed probable that the trade receivable will not be&#160;collected. Trade receivables, net are stated net of certain sales provisions and the allowance for credit losses. <ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RleHRyZWdpb246OWUyNTVmY2Q2YjIyNDgzMWJmYjkxNDk0ODZhMDBlNWNfNjUzOQ_d0be902c-d95f-49e1-b7f2-b6cdc156e42f" continuedAt="ie388c5f08c914be29e5248ea8420af4c" escape="true">The activity in the allowance for credit losses for trade receivables for the three months ended March 31, 2022 and 2021 is as follows.</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><ix:continuation id="ie388c5f08c914be29e5248ea8420af4c"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.830%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjNiZWE0YmIxMDIxZjQ4Nzg4Njc3YTA5ODhiYjJiNGM2L3RhYmxlcmFuZ2U6M2JlYTRiYjEwMjFmNDg3ODg2NzdhMDk4OGJiMmI0YzZfMS0xLTEtMS04OTA3Mg_245518aa-8620-472e-9dd8-e26099adf999">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d274a4a3e5a43ae91dfbb2934c4c5d1_I20201231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjNiZWE0YmIxMDIxZjQ4Nzg4Njc3YTA5ODhiYjJiNGM2L3RhYmxlcmFuZ2U6M2JlYTRiYjEwMjFmNDg3ODg2NzdhMDk4OGJiMmI0YzZfMS0zLTEtMS04OTA3Mg_dae1d455-2f19-4ec8-8843-57ce8831ba13">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjNiZWE0YmIxMDIxZjQ4Nzg4Njc3YTA5ODhiYjJiNGM2L3RhYmxlcmFuZ2U6M2JlYTRiYjEwMjFmNDg3ODg2NzdhMDk4OGJiMmI0YzZfMy0xLTEtMS04OTA3Mg_99b1a915-db60-44cd-96fe-8c88940a5c90">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjNiZWE0YmIxMDIxZjQ4Nzg4Njc3YTA5ODhiYjJiNGM2L3RhYmxlcmFuZ2U6M2JlYTRiYjEwMjFmNDg3ODg2NzdhMDk4OGJiMmI0YzZfMy0zLTEtMS04OTA3Mg_d76f76b8-0537-4dd9-859e-84f744fe862a">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjNiZWE0YmIxMDIxZjQ4Nzg4Njc3YTA5ODhiYjJiNGM2L3RhYmxlcmFuZ2U6M2JlYTRiYjEwMjFmNDg3ODg2NzdhMDk4OGJiMmI0YzZfNC0xLTEtMS04OTA3Mg_8ec7b04f-5c66-494d-9224-a25616e969d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjNiZWE0YmIxMDIxZjQ4Nzg4Njc3YTA5ODhiYjJiNGM2L3RhYmxlcmFuZ2U6M2JlYTRiYjEwMjFmNDg3ODg2NzdhMDk4OGJiMmI0YzZfNC0zLTEtMS04OTA3Mg_9af9bdb5-da52-4003-ae5e-498dd54ad5bd">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recoveries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjNiZWE0YmIxMDIxZjQ4Nzg4Njc3YTA5ODhiYjJiNGM2L3RhYmxlcmFuZ2U6M2JlYTRiYjEwMjFmNDg3ODg2NzdhMDk4OGJiMmI0YzZfNS0xLTEtMS04OTA3Mg_ab1ff691-abf7-41a4-98fe-6f12fe8bcfc6">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjNiZWE0YmIxMDIxZjQ4Nzg4Njc3YTA5ODhiYjJiNGM2L3RhYmxlcmFuZ2U6M2JlYTRiYjEwMjFmNDg3ODg2NzdhMDk4OGJiMmI0YzZfNS0zLTEtMS04OTA3Mg_6b411684-7bb3-4619-bddd-bd7c779e6fcc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="bhc:AccountsReceivableAllowanceForForeignExchangeAndOther" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjNiZWE0YmIxMDIxZjQ4Nzg4Njc3YTA5ODhiYjJiNGM2L3RhYmxlcmFuZ2U6M2JlYTRiYjEwMjFmNDg3ODg2NzdhMDk4OGJiMmI0YzZfNi0xLTEtMS04OTA3Mg_c1f44d57-e555-4db7-aea1-2215b78ee78f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" sign="-" name="bhc:AccountsReceivableAllowanceForForeignExchangeAndOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjNiZWE0YmIxMDIxZjQ4Nzg4Njc3YTA5ODhiYjJiNGM2L3RhYmxlcmFuZ2U6M2JlYTRiYjEwMjFmNDg3ODg2NzdhMDk4OGJiMmI0YzZfNi0zLTEtMS04OTA3Mg_1e3be402-68b1-415b-9f86-c11418bdfd68">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjNiZWE0YmIxMDIxZjQ4Nzg4Njc3YTA5ODhiYjJiNGM2L3RhYmxlcmFuZ2U6M2JlYTRiYjEwMjFmNDg3ODg2NzdhMDk4OGJiMmI0YzZfNy0xLTEtMS04OTA3Mg_d1e8815c-861b-416f-913c-8bdf0417b0a7">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i812289a7a0cf44b4b1eed544ad0bec6c_I20210331" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjNiZWE0YmIxMDIxZjQ4Nzg4Njc3YTA5ODhiYjJiNGM2L3RhYmxlcmFuZ2U6M2JlYTRiYjEwMjFmNDg3ODg2NzdhMDk4OGJiMmI0YzZfNy0zLTEtMS04OTA3Mg_8a2bb411-64aa-4956-9cc2-6080a2c0492c">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div id="i801c461cbd33492a893c84373a8e7cbc_49"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="bhc:AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180OS9mcmFnOjIyNjFkZTZhYWNjOTQ4ZWZhZmE1N2VkODVkM2ZlNzZiL3RleHRyZWdpb246MjI2MWRlNmFhY2M5NDhlZmFmYTU3ZWQ4NWQzZmU3NmJfNDQ4Mw_fb679d36-e8e7-4f39-b0f6-727bfa4f1efd" continuedAt="i17ef0ac075e9425ab3173b6afa17d361" escape="true">LICENSING AGREEMENTS AND DIVESTITURE</ix:nonNumeric></span></div><ix:continuation id="i17ef0ac075e9425ab3173b6afa17d361"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing Agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company may enter into select licensing and collaborative agreements for the commercialization and/or development of unique products. These products are sometimes investigational treatments in early stage development that target unique conditions. The ultimate outcome, including whether the product will be: (i) fully developed, (ii) approved by regulatory agencies, (iii) covered by third-party payors or (iv) profitable for distribution, is highly uncertain.  The commitment periods under these agreements vary and include customary termination provisions.  Expenses arising from commitments, if any, to fund the development and testing of these products and their promotion are recognized as incurred. Royalties due are recognized when earned and milestone payments are accrued when each milestone has been achieved and payment is probable and can be reasonably estimated.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divestiture of Amoun Pharmaceutical Company S.A.E. (&#8220;Amoun&#8221;)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2021, the Company announced that it and certain of its affiliates had entered into a definitive agreement to sell all of its equity interests in Amoun for total gross consideration of approximately $<ix:nonFraction unitRef="usd" contextRef="i3524eadbe1ec47a0a36751409752f55b_D20210331-20210331" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180OS9mcmFnOjIyNjFkZTZhYWNjOTQ4ZWZhZmE1N2VkODVkM2ZlNzZiL3RleHRyZWdpb246MjI2MWRlNmFhY2M5NDhlZmFmYTU3ZWQ4NWQzZmU3NmJfMjY2OQ_39377316-b705-481d-9a81-462c8e4b6b3f">740</ix:nonFraction>&#160;million (including the assignment to the purchasing entity of an intercompany loan granted by the Company to Amoun), subject to certain adjustments (the &#8220;Amoun Sale&#8221;). The Amoun Sale closed on July 26, 2021. As part of the Amoun Sale, cash generated by Amoun during the period from the locked-box date of January 1, 2021 through closing was for the benefit of the purchasing entity, subject to working capital during such period. Amoun manufactures, markets and distributes branded generics of human and animal health products. The Amoun business was part of the International segment (previously included within the former Bausch + Lomb/International segment) and was reclassified as held for sale as of December 31, 2020. As a result of meeting the criteria for held for sale classification, the carrying value of the Amoun business, was adjusted to its estimated fair value, less costs to sell, and the Company recognized an impairment loss of $<ix:nonFraction unitRef="usd" contextRef="i21711d9019c8476f949b23d06ee0e9c1_D20210101-20210331" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180OS9mcmFnOjIyNjFkZTZhYWNjOTQ4ZWZhZmE1N2VkODVkM2ZlNzZiL3RleHRyZWdpb246MjI2MWRlNmFhY2M5NDhlZmFmYTU3ZWQ4NWQzZmU3NmJfMTY0OTI2NzQ0NjM1NA_b84711ac-12fd-42dd-91cf-47ed2b8f1095">68</ix:nonFraction>&#160;million during the three months ended March 31, 2021, included within Asset impairments, including loss on assets held for sale in the Consolidated Statements of Operations. Revenues associated with Amoun were $<ix:nonFraction unitRef="usd" contextRef="i9d5bc364e17040579714c24cebd52ba5_D20210101-20210331" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180OS9mcmFnOjIyNjFkZTZhYWNjOTQ4ZWZhZmE1N2VkODVkM2ZlNzZiL3RleHRyZWdpb246MjI2MWRlNmFhY2M5NDhlZmFmYTU3ZWQ4NWQzZmU3NmJfODc5NjA5MzAyODI1OA_68d289af-9410-4a64-8377-37adf9c456ab">60</ix:nonFraction>&#160;million for the three months ended March 31, 2021.</span></div></ix:continuation><div id="i801c461cbd33492a893c84373a8e7cbc_52"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="bhc:RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181Mi9mcmFnOmJkYzUzMjQ5NmJmYjRiOTliZWI5NDExNzlkYTU4OWJiL3RleHRyZWdpb246YmRjNTMyNDk2YmZiNGI5OWJlYjk0MTE3OWRhNTg5YmJfMjQ5Mw_c58c0043-d56e-4317-8974-53778b022d92" continuedAt="i9511d334dcbc4417a2ecd4dadab0d796" escape="true">RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS </ix:nonNumeric></span></div><ix:continuation id="i9511d334dcbc4417a2ecd4dadab0d796" continuedAt="i995dc46512864a8281562de6df48874f"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring and Integration Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates opportunities to improve its operating results and implements cost savings programs to streamline its operations and eliminate&#160;redundant processes and expenses. Restructuring and integration costs are expenses associated with the implementation of these cost savings programs and include expenses associated with: (i)&#160;reducing headcount, (ii)&#160;eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives. The liability associated with restructuring and integration costs as of March 31, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i8f59ac9f2ff644c89eb4f65f46c45061_I20220331" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181Mi9mcmFnOmJkYzUzMjQ5NmJmYjRiOTliZWI5NDExNzlkYTU4OWJiL3RleHRyZWdpb246YmRjNTMyNDk2YmZiNGI5OWJlYjk0MTE3OWRhNTg5YmJfNzA5_e594ce7a-5f90-4f08-b884-9db6e1bfef27">15</ix:nonFraction> million.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i995dc46512864a8281562de6df48874f"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred $<ix:nonFraction unitRef="usd" contextRef="i956734b907cd48758decdff4f630c6f9_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181Mi9mcmFnOmJkYzUzMjQ5NmJmYjRiOTliZWI5NDExNzlkYTU4OWJiL3RleHRyZWdpb246YmRjNTMyNDk2YmZiNGI5OWJlYjk0MTE3OWRhNTg5YmJfNzM0_d5e1e407-d3e7-4e37-80b6-e000555f95c9">3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idc39509affcd41d9a58e0cca4fe7e0eb_D20210101-20210331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181Mi9mcmFnOmJkYzUzMjQ5NmJmYjRiOTliZWI5NDExNzlkYTU4OWJiL3RleHRyZWdpb246YmRjNTMyNDk2YmZiNGI5OWJlYjk0MTE3OWRhNTg5YmJfNzQx_4e39b9ff-760b-4d95-bfa9-4d8013072190">3</ix:nonFraction>&#160;million of restructuring and integration costs and made payments of $<ix:nonFraction unitRef="usd" contextRef="i956734b907cd48758decdff4f630c6f9_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181Mi9mcmFnOmJkYzUzMjQ5NmJmYjRiOTliZWI5NDExNzlkYTU4OWJiL3RleHRyZWdpb246YmRjNTMyNDk2YmZiNGI5OWJlYjk0MTE3OWRhNTg5YmJfODA0_96155526-eac8-4eda-a1ea-f5a091660a27">7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="idc39509affcd41d9a58e0cca4fe7e0eb_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181Mi9mcmFnOmJkYzUzMjQ5NmJmYjRiOTliZWI5NDExNzlkYTU4OWJiL3RleHRyZWdpb246YmRjNTMyNDk2YmZiNGI5OWJlYjk0MTE3OWRhNTg5YmJfODEx_1708b59a-f2ea-44aa-81c1-4e0d22e58993">5</ix:nonFraction>&#160;million during the three months ended March 31, 2022 and 2021, respectively.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Separation Costs, Separation-related Costs, IPO Costs and IPO-related Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred, and will incur, costs associated with activities to effectuate the B+L Separation and the Solta IPO. These activities include: (i) separating the Bausch + Lomb and Solta Medical businesses from the remainder of the Company and (ii) registering the Bausch + Lomb and Solta Medical businesses as independent publicly traded entities. Separation and IPO costs are incremental costs directly related to the B+L Separation and Solta IPO and include, but are not limited to: (i) legal, audit and advisory fees, (ii) talent acquisition costs and (iii) costs associated with establishing a new board of directors and related board committees for the Bausch + Lomb and Solta Medical entities. Included in Restructuring, integration, separation and IPO costs for the three months ended March 31, 2022 and 2021 are Separation and IPO costs of $<ix:nonFraction unitRef="usd" contextRef="i85c368e92b024530907723a0994de3c7_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181Mi9mcmFnOmJkYzUzMjQ5NmJmYjRiOTliZWI5NDExNzlkYTU4OWJiL3RleHRyZWdpb246YmRjNTMyNDk2YmZiNGI5OWJlYjk0MTE3OWRhNTg5YmJfMTY4Nw_821cda46-e3b6-49c9-9163-0000c6ed7ed9">10</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i4fb5f4d139b04ae9b628f854af7fd7ee_D20210101-20210331" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181Mi9mcmFnOmJkYzUzMjQ5NmJmYjRiOTliZWI5NDExNzlkYTU4OWJiL3RleHRyZWdpb246YmRjNTMyNDk2YmZiNGI5OWJlYjk0MTE3OWRhNTg5YmJfMTY5NA_38005a71-3f6c-4c1f-93b3-8843aa53dc02">9</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has also incurred, and will incur, Separation-related and IPO-related costs which are incremental costs indirectly related to the B+L Separation and Solta IPO. Separation-related and IPO-related costs include, but are not limited to: (i) IT infrastructure and software licensing costs, (ii) rebranding costs and (iii) costs associated with facility relocation and/or modification. Included in Selling, general and administrative for the three months ended March 31, 2022 and 2021 are Separation-related and IPO-related costs of $<ix:nonFraction unitRef="usd" contextRef="i85c368e92b024530907723a0994de3c7_D20220101-20220331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181Mi9mcmFnOmJkYzUzMjQ5NmJmYjRiOTliZWI5NDExNzlkYTU4OWJiL3RleHRyZWdpb246YmRjNTMyNDk2YmZiNGI5OWJlYjk0MTE3OWRhNTg5YmJfMjIyMQ_1526cf19-068a-4f92-af01-88fa884a2f61">24</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i4fb5f4d139b04ae9b628f854af7fd7ee_D20210101-20210331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181Mi9mcmFnOmJkYzUzMjQ5NmJmYjRiOTliZWI5NDExNzlkYTU4OWJiL3RleHRyZWdpb246YmRjNTMyNDk2YmZiNGI5OWJlYjk0MTE3OWRhNTg5YmJfMjIyOA_4a749985-02ab-4511-91ab-75c523dc405d">20</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent and timing of future charges for these costs cannot be reasonably estimated at this time and could be material.</span></div></ix:continuation><div id="i801c461cbd33492a893c84373a8e7cbc_55"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RleHRyZWdpb246MThlODc5ODM3YTdhNDAwNWE3OTliYjJjNjI2NGIwOTlfNzE2Mw_c543ec53-3962-42e2-9fe0-a77fc1dc2a9f" continuedAt="i2d7d78f5ca3449e6aba5e5b88082a135" escape="true">FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS</ix:nonNumeric></span></div><ix:continuation id="i2d7d78f5ca3449e6aba5e5b88082a135" continuedAt="i04a7642eaa9743048805b1a6049a643f"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are estimated based on valuation techniques and inputs categorized as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1&#160;&#8212;&#160;Quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2&#160;&#8212;&#160;Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities;&#160;and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3&#160;&#8212;&#160;Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using discounted cash flow methodologies, pricing models, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or&#160;estimation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the&#160;instrument.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RleHRyZWdpb246MThlODc5ODM3YTdhNDAwNWE3OTliYjJjNjI2NGIwOTlfNzE1Nw_960081d2-c0de-4fba-a440-713f96ab6b88" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table presents the components and classification of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.196%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bdc5e2685a240ae96ca33df37493045_I20220331" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfMy0yLTEtMS04OTA3Mg_68a5cfa6-a543-4375-82d9-22e4a76d3068">766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i363991f4b7144460a084057864c8034f_I20220331" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfMy00LTEtMS04OTA3Mg_1e839cb2-03a6-4aad-8718-a9da15d2469f">749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc1a0b5922ad406796cebf7b0701a0cb_I20220331" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfMy02LTEtMS04OTA3Mg_98e98c15-d4ee-4625-8601-b7e630b19497">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f7343e1588476cb8e134ea3252cb58_I20220331" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfMy04LTEtMS04OTA3Mg_153f2bf2-3c4d-4f3c-9386-cdd0a35e2b31">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if45e89de6ed14de1836e660f70eb9092_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfMy0xMC0xLTEtODkwNzI_533714de-eef5-40b3-b62b-7ab0fcdc9f1a">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i150d2e94468344d2bba3906c337eef86_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfMy0xMi0xLTEtODkwNzI_e0f7f5a4-db3e-4702-bab4-c83be6dafd9a">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7390cf31be44f1986a62d20c407d5b_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfMy0xNC0xLTEtODkwNzI_730897ee-c49e-4a2e-945b-c0819cfb2540">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica75b10c2fbd403ea21ee75a6cd245bd_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfMy0xNi0xLTEtODkwNzI_0910e073-606b-4809-a19f-4cb590e8fa23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and other settlement deposits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bdc5e2685a240ae96ca33df37493045_I20220331" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNC0yLTEtMS04OTA3Mg_d7173a81-beca-4746-9c20-3afd33ea1680">1,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i363991f4b7144460a084057864c8034f_I20220331" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNC00LTEtMS04OTA3Mg_da5daf34-cd75-43f9-a1df-d6fbc8d6ad18">1,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc1a0b5922ad406796cebf7b0701a0cb_I20220331" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNC02LTEtMS04OTA3Mg_6ddd6520-9786-43df-816f-e7be47ae0f7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f7343e1588476cb8e134ea3252cb58_I20220331" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNC04LTEtMS04OTA3Mg_31f5a0c1-abfa-490f-8936-76d2e45ed173">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if45e89de6ed14de1836e660f70eb9092_I20211231" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNC0xMC0xLTEtODkwNzI_29c93337-eff1-417f-8070-efb92bb0794c">1,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i150d2e94468344d2bba3906c337eef86_I20211231" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNC0xMi0xLTEtODkwNzI_df9e7cc3-64e5-4849-a0ee-536daf9245d5">1,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7390cf31be44f1986a62d20c407d5b_I20211231" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNC0xNC0xLTEtODkwNzI_61e33630-ef22-4894-ab9a-cf39eeb86c25">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica75b10c2fbd403ea21ee75a6cd245bd_I20211231" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNC0xNi0xLTEtODkwNzI_beda486f-8e50-44be-9fa6-bc51a7a842fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0cbf30c76af4d498983e82d4fdca172_I20220331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNS0yLTEtMS04OTA3Mg_1bb7f1d6-dc49-4371-8cf2-4588a5e68c95">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if05c08af1a034dc7980de8e6d52990be_I20220331" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNS00LTEtMS04OTA3Mg_1f8c830b-2967-4efc-9c85-c01b7e9c22e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b499ddf7ec0496ba113157683c198d2_I20220331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNS02LTEtMS04OTA3Mg_866ab892-b588-4b91-8afa-54cea9fe1f08"><ix:nonFraction unitRef="usd" contextRef="i81fe5dde69aa4fa98b7711acbae4387f_I20220331" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNS02LTEtMS04OTA3Mg_cb0add76-303f-47a6-96dd-8a3a6382b373">1</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i100091396ce9444685173217122765a6_I20220331" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNS04LTEtMS04OTA3Mg_1a6d6974-54d2-44e9-b1e3-64129de0a53e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i723c0252bb3e4eb98782b62a2ac15585_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNS0xMC0xLTEtODkwNzI_730ee82e-2a71-45a9-aba7-a0b26dd926bf">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i258050e5f8ba4ce1b2273604ec31e67f_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNS0xMi0xLTEtODkwNzI_fda77e76-db1e-462a-915b-48d75383fafe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7cdfcca5d2f4a10b641c8f4d80b31b8_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNS0xNC0xLTEtODkwNzI_d3442b5e-4d51-4d85-aa59-b5fbadb3b1e3">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5945a5ff5f34495dab13516392201c16_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNS0xNi0xLTEtODkwNzI_9ea71d55-92ca-4d29-bf92-cf9ee5699679">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bdc5e2685a240ae96ca33df37493045_I20220331" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNy0yLTEtMS04OTA3Mg_ecf2d9d6-d475-4f31-b525-4a8256648282">236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i363991f4b7144460a084057864c8034f_I20220331" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNy00LTEtMS04OTA3Mg_d9e0c328-25cf-4530-8a17-b460862e74f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc1a0b5922ad406796cebf7b0701a0cb_I20220331" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNy02LTEtMS04OTA3Mg_334853e9-c17a-4cdd-9387-d5bbf2715933">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f7343e1588476cb8e134ea3252cb58_I20220331" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNy04LTEtMS04OTA3Mg_b9ea3d03-5790-4dee-877a-f3e7cd5a427a">236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if45e89de6ed14de1836e660f70eb9092_I20211231" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNy0xMC0xLTEtODkwNzI_3b962e62-f4e2-4165-868e-1ea2dc364a88">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i150d2e94468344d2bba3906c337eef86_I20211231" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNy0xMi0xLTEtODkwNzI_1d058e20-5ac3-4807-817b-13c7ce4d4415">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7390cf31be44f1986a62d20c407d5b_I20211231" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNy0xNC0xLTEtODkwNzI_1f5dc323-2e3b-4841-b634-ecc9a7f5efd9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica75b10c2fbd403ea21ee75a6cd245bd_I20211231" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNy0xNi0xLTEtODkwNzI_e04b01e3-f7a2-499b-8d48-4da3100c85a7">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0cbf30c76af4d498983e82d4fdca172_I20220331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfOS0yLTEtMS04OTA3Mg_55afe13c-4cd0-4c1c-b8b9-98d25d8494ea">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if05c08af1a034dc7980de8e6d52990be_I20220331" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfOS00LTEtMS04OTA3Mg_b9ca63bf-70e5-4afc-aff2-92237513f2a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b77eb6463994ae99224a58bba550905_I20220331" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfOS02LTEtMS04OTA3Mg_41a3d573-ec67-46fc-8482-2505ce0aad6f"><ix:nonFraction unitRef="usd" contextRef="i0b499ddf7ec0496ba113157683c198d2_I20220331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfOS02LTEtMS04OTA3Mg_7a694287-5200-4576-b5bc-6c1a3d61dc2d">8</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i100091396ce9444685173217122765a6_I20220331" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfOS04LTEtMS04OTA3Mg_1defc974-5f70-40fd-bcb4-34c9dd884262">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i723c0252bb3e4eb98782b62a2ac15585_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfOS0xMC0xLTEtODkwNzI_a4982000-f151-433f-b23d-4eace0dd63bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i258050e5f8ba4ce1b2273604ec31e67f_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfOS0xMi0xLTEtODkwNzI_9d7d09e6-c0ab-4b19-abed-103382724222">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7cdfcca5d2f4a10b641c8f4d80b31b8_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfOS0xNC0xLTEtODkwNzI_559e5cb8-d8b9-421d-b92e-c2e4c1662e41">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5945a5ff5f34495dab13516392201c16_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfOS0xNi0xLTEtODkwNzI_d75ef04e-b977-4af3-ac38-c28f06ec20bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of highly liquid investments, primarily money market funds, with maturities of <ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="bhc:HighlyLiquidInvestmentsMaturityPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RleHRyZWdpb246MThlODc5ODM3YTdhNDAwNWE3OTliYjJjNjI2NGIwOTlfMTQyOA_79f465a7-13c1-482c-b93d-8b7b6ff3e53d">three months</ix:nonNumeric> or less when&#160;purchased, and are reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to their short-term nature.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i04a7642eaa9743048805b1a6049a643f" continuedAt="i6e06547520344524adec12ac474cbdb6"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, Restricted cash and other settlement deposits includes $<ix:nonFraction unitRef="usd" contextRef="i4b4e235324904728b762550f85fa7269_D20220101-20220331" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RleHRyZWdpb246MThlODc5ODM3YTdhNDAwNWE3OTliYjJjNjI2NGIwOTlfMTYyNA_897801c3-4b52-413e-9118-979b56455b05">1,210</ix:nonFraction>&#160;million of payments into an escrow fund under the terms of a settlement agreement regarding certain U.S. securities litigation (which settlement agreement is subject to <ix:nonFraction unitRef="appeal" contextRef="iee66331a046f4575acc6e455516cc956_I20220331" decimals="INF" name="bhc:LitigationSettlementNumberOfObjectorsAppeals" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RleHRyZWdpb246MThlODc5ODM3YTdhNDAwNWE3OTliYjJjNjI2NGIwOTlfMTc4OA_0dc84ce6-be01-455f-9f23-02f32325c7af">one</ix:nonFraction> objector&#8217;s appeal of the final court approval of the agreement), and is reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to its short-term nature. These payments will remain in escrow until resolution of the appeal of the final court approval of the settlement agreement, as discussed in Note 18, &#8220;LEGAL PROCEEDINGS&#8221;.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers into or out of Level 3 during the three months ended March 31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cross-currency Swaps</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company entered into cross-currency swaps, with aggregate notional amounts of $<ix:nonFraction unitRef="usd" contextRef="ia2c311dd5c6b469480afc3e5392a01db_I20191231" decimals="INF" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RleHRyZWdpb246MThlODc5ODM3YTdhNDAwNWE3OTliYjJjNjI2NGIwOTlfMjMxMg_5ae28055-7487-4e17-9b60-be54c1efa19c">1,250</ix:nonFraction> million, to mitigate fluctuation in the value of a portion of its euro-denominated net investment in its consolidated financial statements from fluctuation in exchange rates. The euro-denominated net investment being hedged was the Company&#8217;s investment in certain euro-denominated subsidiaries. The Company unwound these cross-currency swaps during November 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the unwinding of the cross-currency swaps during November 2021, there were no assets or liabilities associated with the cross-currency swaps included in the Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021.</span></div><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RleHRyZWdpb246MThlODc5ODM3YTdhNDAwNWE3OTliYjJjNjI2NGIwOTlfNzE3MA_6fda01f8-3292-4632-b241-c066d2dd5a05" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of hedging instruments on the Consolidated Statements of Comprehensive Loss and the Consolidated Statements of Operations for the three months ended March 31, 2022 and 2021:</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.792%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.105%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain recognized in Other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e2fdd6767694d7e97928c8c973cce88_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjJiNTcyOTExMTFiOTRkMWE5YWQyZDdiMDY5ZjkxZjBlL3RhYmxlcmFuZ2U6MmI1NzI5MTExMWI5NGQxYTlhZDJkN2IwNjlmOTFmMGVfMi01LTEtMS04OTA3Mg_ab9e21cd-9749-4218-b98a-d63ccb26ca4f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb234a60c94344e9a94bfbc00466a78a_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjJiNTcyOTExMTFiOTRkMWE5YWQyZDdiMDY5ZjkxZjBlL3RhYmxlcmFuZ2U6MmI1NzI5MTExMWI5NGQxYTlhZDJkN2IwNjlmOTFmMGVfMi03LTEtMS04OTA3Mg_fcbe1507-f141-4720-8113-520d0fd98c18">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain excluded from assessment of hedge effectiveness</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46cf2f3899da4a21a3b37afd85cde532_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjJiNTcyOTExMTFiOTRkMWE5YWQyZDdiMDY5ZjkxZjBlL3RhYmxlcmFuZ2U6MmI1NzI5MTExMWI5NGQxYTlhZDJkN2IwNjlmOTFmMGVfMy01LTEtMS04OTA3Mg_67b203f8-1070-4bd3-9cbe-b4f6b3d5d1a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf2062d283b74ee789d97615ebc112e9_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjJiNTcyOTExMTFiOTRkMWE5YWQyZDdiMDY5ZjkxZjBlL3RhYmxlcmFuZ2U6MmI1NzI5MTExMWI5NGQxYTlhZDJkN2IwNjlmOTFmMGVfMy03LTEtMS04OTA3Mg_5e939c60-4f90-4744-99b0-da0e15f95fc0">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location of gain of excluded component</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Expense</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No portion of the cross-currency swaps was ineffective for the three months ended March 31, 2021. During the three months ended March 31, 2022 and 2021, the Company received $<ix:nonFraction unitRef="usd" contextRef="idf8c5147a31443548f1f01cdff3ee173_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsForProceedsFromHedgeInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RleHRyZWdpb246MThlODc5ODM3YTdhNDAwNWE3OTliYjJjNjI2NGIwOTlfMzczMg_1a0b6d85-453f-4837-82f4-ae54f255e070">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ib0fafc41fd0d46f2aafbccde9b40c90f_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsForProceedsFromHedgeInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RleHRyZWdpb246MThlODc5ODM3YTdhNDAwNWE3OTliYjJjNjI2NGIwOTlfMzczOQ_be7226df-dc49-4f50-a6d2-47ba7834a390">11</ix:nonFraction>&#160;million, respectively, in interest settlements which are reported as investing activities in the Consolidated Statements of Cash Flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Contracts</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2020, the Company has been entering into foreign currency exchange contracts. As of March 31, 2022, these contracts had an aggregate outstanding notional amount of $<ix:nonFraction unitRef="usd" contextRef="ib1d2d795d550443991566dd2c6bcf53b_I20220331" decimals="INF" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RleHRyZWdpb246MThlODc5ODM3YTdhNDAwNWE3OTliYjJjNjI2NGIwOTlfNDA1NA_d9b1f054-530f-4f8a-b1e3-bf2c380c28f3">158</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s foreign currency exchange contracts are remeasured at each reporting date to reflect changes in their fair values determined using forward rates, which are observable market inputs, multiplied by the notional amount. The Company&#8217;s foreign currency exchange contracts are economically hedging the foreign exchange exposure on certain of the Company&#8217;s intercompany balances. These contracts have not been designated as an accounting hedge, and therefore the net change in their fair value is reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other. Settlements of the Company&#8217;s foreign currency exchange contracts are reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other and reported as operating activities in the Consolidated Statements of Cash Flows. </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i6e06547520344524adec12ac474cbdb6"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RleHRyZWdpb246MThlODc5ODM3YTdhNDAwNWE3OTliYjJjNjI2NGIwOTlfNzE3MQ_454d4432-7f33-4044-ae5b-62c174f7691e" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities associated with the Company&#8217;s foreign exchange contracts as included in the Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021 are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.443%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b77eb6463994ae99224a58bba550905_I20220331" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjJkYTExNTMzNGE0ZjRmMGNiZDQ0NzRlODRlNzc5MDc0L3RhYmxlcmFuZ2U6MmRhMTE1MzM0YTRmNGYwY2JkNDQ3NGU4NGU3NzkwNzRfMS0xLTEtMS04OTA3Mg_41a3d573-ec67-46fc-8482-2505ce0aad6f"><ix:nonFraction unitRef="usd" contextRef="i0b499ddf7ec0496ba113157683c198d2_I20220331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjJkYTExNTMzNGE0ZjRmMGNiZDQ0NzRlODRlNzc5MDc0L3RhYmxlcmFuZ2U6MmRhMTE1MzM0YTRmNGYwY2JkNDQ3NGU4NGU3NzkwNzRfMS0xLTEtMS04OTA3Mg_7a694287-5200-4576-b5bc-6c1a3d61dc2d">8</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f0e25e6a91b4e2e872255dda15e2d72_I20211231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjJkYTExNTMzNGE0ZjRmMGNiZDQ0NzRlODRlNzc5MDc0L3RhYmxlcmFuZ2U6MmRhMTE1MzM0YTRmNGYwY2JkNDQ3NGU4NGU3NzkwNzRfMS0zLTEtMS04OTA3Mg_e151d3a4-f30b-4690-adbd-031ab6121b8d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b499ddf7ec0496ba113157683c198d2_I20220331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjJkYTExNTMzNGE0ZjRmMGNiZDQ0NzRlODRlNzc5MDc0L3RhYmxlcmFuZ2U6MmRhMTE1MzM0YTRmNGYwY2JkNDQ3NGU4NGU3NzkwNzRfMi0xLTEtMS04OTA3Mg_866ab892-b588-4b91-8afa-54cea9fe1f08"><ix:nonFraction unitRef="usd" contextRef="i81fe5dde69aa4fa98b7711acbae4387f_I20220331" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjJkYTExNTMzNGE0ZjRmMGNiZDQ0NzRlODRlNzc5MDc0L3RhYmxlcmFuZ2U6MmRhMTE1MzM0YTRmNGYwY2JkNDQ3NGU4NGU3NzkwNzRfMi0xLTEtMS04OTA3Mg_cb0add76-303f-47a6-96dd-8a3a6382b373">1</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i811cc5ac0cc64328ad722d7dad5db8b1_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjJkYTExNTMzNGE0ZjRmMGNiZDQ0NzRlODRlNzc5MDc0L3RhYmxlcmFuZ2U6MmRhMTE1MzM0YTRmNGYwY2JkNDQ3NGU4NGU3NzkwNzRfMi0zLTEtMS04OTA3Mg_4358cbfe-50c6-40e7-a44d-4f2d7ebdff7d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1d2d795d550443991566dd2c6bcf53b_I20220331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjJkYTExNTMzNGE0ZjRmMGNiZDQ0NzRlODRlNzc5MDc0L3RhYmxlcmFuZ2U6MmRhMTE1MzM0YTRmNGYwY2JkNDQ3NGU4NGU3NzkwNzRfMy0xLTEtMS04OTA3Mg_883d8aac-6a1a-4bc1-bbaa-5ed82e287a93">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ec8590d1fe9450a8eb2faa9ceaf5975_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjJkYTExNTMzNGE0ZjRmMGNiZDQ0NzRlODRlNzc5MDc0L3RhYmxlcmFuZ2U6MmRhMTE1MzM0YTRmNGYwY2JkNDQ3NGU4NGU3NzkwNzRfMy0zLTEtMS04OTA3Mg_5d796236-1ddd-4f81-b47e-b1cf17874e26">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RleHRyZWdpb246MThlODc5ODM3YTdhNDAwNWE3OTliYjJjNjI2NGIwOTlfNzE2Ng_686db161-8775-4bf2-801a-4f7f4bcc5e4f" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of the Company&#8217;s foreign exchange contracts on the Consolidated Statements of Operations and the Consolidated Statements of Cash Flows for the three months ended March 31, 2022 and 2021:</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.443%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss related to changes in fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0b87773b146435a838297c342e6101d_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjcyMWQ3MjE3MmM5ZTQ5OTliMzNkYjRkZGQwZDI1NDQxL3RhYmxlcmFuZ2U6NzIxZDcyMTcyYzllNDk5OWIzM2RiNGRkZDBkMjU0NDFfMi01LTEtMS04OTA3Mg_069ebd5f-6380-4819-9626-0d04b716f4be">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf65fa777b444e8b899db7eb8bab459d_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjcyMWQ3MjE3MmM5ZTQ5OTliMzNkYjRkZGQwZDI1NDQxL3RhYmxlcmFuZ2U6NzIxZDcyMTcyYzllNDk5OWIzM2RiNGRkZDBkMjU0NDFfMi03LTEtMS04OTA3Mg_bd2819b8-8125-4413-b11d-3be98eb48692">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) related to settlements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0b87773b146435a838297c342e6101d_D20220101-20220331" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjcyMWQ3MjE3MmM5ZTQ5OTliMzNkYjRkZGQwZDI1NDQxL3RhYmxlcmFuZ2U6NzIxZDcyMTcyYzllNDk5OWIzM2RiNGRkZDBkMjU0NDFfMy01LTEtMS04OTA3Mg_de74c0bc-a8ac-40fc-915b-ae321d0fe2a4">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf65fa777b444e8b899db7eb8bab459d_D20210101-20210331" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjcyMWQ3MjE3MmM5ZTQ5OTliMzNkYjRkZGQwZDI1NDQxL3RhYmxlcmFuZ2U6NzIxZDcyMTcyYzllNDk5OWIzM2RiNGRkZDBkMjU0NDFfMy03LTEtMS04OTA3Mg_cd348d7a-3af4-4120-8753-cbcac2b2e30b">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition-related Contingent Consideration Obligations</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurement of contingent consideration obligations arising from business combinations is determined via a probability-weighted discounted cash flow analysis, using unobservable (Level&#160;3) inputs. These inputs may include: (i)&#160;the estimated amount and timing of projected cash flows, (ii)&#160;the probability of the achievement of the factor(s) on which the contingency is based and (iii)&#160;the risk-adjusted discount rate used to present value the probability-weighted cash&#160;flows. Significant increases or decreases in any of those inputs in isolation could result in a significantly higher or lower fair value measurement. At March&#160;31, 2022, the fair value measurements of acquisition-related contingent consideration were determined using risk-adjusted discount rates ranging from <ix:nonFraction unitRef="rate" contextRef="i5ba0dd91cc574f9abe328ce7f85dc950_I20220331" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RleHRyZWdpb246MThlODc5ODM3YTdhNDAwNWE3OTliYjJjNjI2NGIwOTlfNjEyMw_b8a4bc3f-365a-4bb0-bf43-6e95322fd392">6</ix:nonFraction>% to <ix:nonFraction unitRef="rate" contextRef="i142e78536e92483bb3067f4b123b35c7_I20220331" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RleHRyZWdpb246MThlODc5ODM3YTdhNDAwNWE3OTliYjJjNjI2NGIwOTlfNjEyOQ_4d9ec85a-361c-481d-aa91-26fa87fe1b0b">18</ix:nonFraction>%, and a weighted average risk-adjusted discount rate of <ix:nonFraction unitRef="rate" contextRef="id92289d625924bfcb27511b3c14249c7_I20220331" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RleHRyZWdpb246MThlODc5ODM3YTdhNDAwNWE3OTliYjJjNjI2NGIwOTlfNjE4Nw_5b536b38-8803-4feb-a103-c79a545e96c6">7</ix:nonFraction>%. The weighted average risk-adjusted discount rate was calculated by weighting each contract&#8217;s relative fair value at March&#160;31, 2022.</span></div><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RleHRyZWdpb246MThlODc5ODM3YTdhNDAwNWE3OTliYjJjNjI2NGIwOTlfNzE1MQ_b244da51-80cf-4b1e-8009-42e59f172f23" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level&#160;3) for the three months ended March 31, 2022 and 2021: </span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:63.132%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.547%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjlkN2Y5ZGE5NmNhNjQ4YzZiNTJiNzkwNTc1MDU1MTA1L3RhYmxlcmFuZ2U6OWQ3ZjlkYTk2Y2E2NDhjNmI1MmI3OTA1NzUwNTUxMDVfMi00LTEtMS04OTA3Mg_5baac17b-3328-464e-a93b-e8ad634d290c">241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d274a4a3e5a43ae91dfbb2934c4c5d1_I20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjlkN2Y5ZGE5NmNhNjQ4YzZiNTJiNzkwNTc1MDU1MTA1L3RhYmxlcmFuZ2U6OWQ3ZjlkYTk2Y2E2NDhjNmI1MmI3OTA1NzUwNTUxMDVfMi04LTEtMS04OTA3Mg_6b90cff4-2516-4406-b210-c932edaf76b5">328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to Acquisition-related contingent consideration:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion for the time value of money</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib824c124997f479bbc169d1602673e5b_D20220101-20220331" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjlkN2Y5ZGE5NmNhNjQ4YzZiNTJiNzkwNTc1MDU1MTA1L3RhYmxlcmFuZ2U6OWQ3ZjlkYTk2Y2E2NDhjNmI1MmI3OTA1NzUwNTUxMDVfNC0yLTEtMS04OTA3Mg_bd12fa99-54ec-4a29-a3df-8812a8446dd6">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if29face7dd5e4f4f824bb78e8b24bb84_D20210101-20210331" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjlkN2Y5ZGE5NmNhNjQ4YzZiNTJiNzkwNTc1MDU1MTA1L3RhYmxlcmFuZ2U6OWQ3ZjlkYTk2Y2E2NDhjNmI1MmI3OTA1NzUwNTUxMDVfNC02LTEtMS04OTA3Mg_4ea748d2-be20-4d94-84ca-9c093a3f718e">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments due to changes in estimates of other future payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbb2bee16b5a4770b40bde7992c3b661_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjlkN2Y5ZGE5NmNhNjQ4YzZiNTJiNzkwNTc1MDU1MTA1L3RhYmxlcmFuZ2U6OWQ3ZjlkYTk2Y2E2NDhjNmI1MmI3OTA1NzUwNTUxMDVfNS0yLTEtMS04OTA3Mg_7458dc89-be33-4350-9b36-3828c14f6484">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7beef5fa81be4f83928de85244de7710_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjlkN2Y5ZGE5NmNhNjQ4YzZiNTJiNzkwNTc1MDU1MTA1L3RhYmxlcmFuZ2U6OWQ3ZjlkYTk2Y2E2NDhjNmI1MmI3OTA1NzUwNTUxMDVfNS02LTEtMS04OTA3Mg_64a27ae0-119a-4049-bea9-738a1fa946c9">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjlkN2Y5ZGE5NmNhNjQ4YzZiNTJiNzkwNTc1MDU1MTA1L3RhYmxlcmFuZ2U6OWQ3ZjlkYTk2Y2E2NDhjNmI1MmI3OTA1NzUwNTUxMDVfNi00LTEtMS04OTA3Mg_abe0cebf-3250-45e1-be3a-4fcbd7700994">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjlkN2Y5ZGE5NmNhNjQ4YzZiNTJiNzkwNTc1MDU1MTA1L3RhYmxlcmFuZ2U6OWQ3ZjlkYTk2Y2E2NDhjNmI1MmI3OTA1NzUwNTUxMDVfNi04LTEtMS04OTA3Mg_871bb1b0-3fa6-44ce-88e6-518f17e00d96">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments/Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjlkN2Y5ZGE5NmNhNjQ4YzZiNTJiNzkwNTc1MDU1MTA1L3RhYmxlcmFuZ2U6OWQ3ZjlkYTk2Y2E2NDhjNmI1MmI3OTA1NzUwNTUxMDVfNy00LTEtMS04OTA3Mg_85348f65-9922-4bb9-adeb-d8615a6f5264">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjlkN2Y5ZGE5NmNhNjQ4YzZiNTJiNzkwNTc1MDU1MTA1L3RhYmxlcmFuZ2U6OWQ3ZjlkYTk2Y2E2NDhjNmI1MmI3OTA1NzUwNTUxMDVfNy04LTEtMS04OTA3Mg_c3384ad8-b550-424b-9086-97f42eb41581">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjlkN2Y5ZGE5NmNhNjQ4YzZiNTJiNzkwNTc1MDU1MTA1L3RhYmxlcmFuZ2U6OWQ3ZjlkYTk2Y2E2NDhjNmI1MmI3OTA1NzUwNTUxMDVfOS00LTEtMS04OTA3Mg_adddb46f-5057-49f4-88f5-10aebd6db145">236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i812289a7a0cf44b4b1eed544ad0bec6c_I20210331" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjlkN2Y5ZGE5NmNhNjQ4YzZiNTJiNzkwNTc1MDU1MTA1L3RhYmxlcmFuZ2U6OWQ3ZjlkYTk2Y2E2NDhjNmI1MmI3OTA1NzUwNTUxMDVfOS04LTEtMS04OTA3Mg_da9369ea-173c-4224-9f58-9cafcdeb332d">313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjlkN2Y5ZGE5NmNhNjQ4YzZiNTJiNzkwNTc1MDU1MTA1L3RhYmxlcmFuZ2U6OWQ3ZjlkYTk2Y2E2NDhjNmI1MmI3OTA1NzUwNTUxMDVfMTAtNC0xLTEtODkwNzI_2914f8c6-eff8-48c6-be9b-5fbb5ae53e0f">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i812289a7a0cf44b4b1eed544ad0bec6c_I20210331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjlkN2Y5ZGE5NmNhNjQ4YzZiNTJiNzkwNTc1MDU1MTA1L3RhYmxlcmFuZ2U6OWQ3ZjlkYTk2Y2E2NDhjNmI1MmI3OTA1NzUwNTUxMDVfMTAtOC0xLTEtODkwNzI_3c535b38-948a-48f8-91ed-5b5aa6e4ea5c">111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjlkN2Y5ZGE5NmNhNjQ4YzZiNTJiNzkwNTc1MDU1MTA1L3RhYmxlcmFuZ2U6OWQ3ZjlkYTk2Y2E2NDhjNmI1MmI3OTA1NzUwNTUxMDVfMTEtNC0xLTEtODkwNzI_a1693f95-aeb3-4563-adbb-52841c59c1d1">193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i812289a7a0cf44b4b1eed544ad0bec6c_I20210331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjlkN2Y5ZGE5NmNhNjQ4YzZiNTJiNzkwNTc1MDU1MTA1L3RhYmxlcmFuZ2U6OWQ3ZjlkYTk2Y2E2NDhjNmI1MmI3OTA1NzUwNTUxMDVfMTEtOC0xLTEtODkwNzI_c92b80df-5468-4fa6-9427-f9d42f2964dc">202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Long-term Debt</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of long-term debt as of March&#160;31, 2022 and December&#160;31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="id1ad1d6d1a0146b0848446f63d1074ab_I20220331" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RleHRyZWdpb246MThlODc5ODM3YTdhNDAwNWE3OTliYjJjNjI2NGIwOTlfNzAyNg_c1ffe3d6-cebe-4bfd-9ce4-b71b76e9549c">21,963</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idc49a20c1efb4682a698d499e7132490_I20211231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RleHRyZWdpb246MThlODc5ODM3YTdhNDAwNWE3OTliYjJjNjI2NGIwOTlfNzAzMw_ea6faa23-4339-440c-85d9-4185582a3e4f">22,689</ix:nonFraction> million, respectively, and was estimated using the quoted market prices for the same or similar debt issuances (Level 2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="i801c461cbd33492a893c84373a8e7cbc_58"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181OC9mcmFnOmY4YjczNTUyMjJjYzRkZWU4MDIwMGEwYTg0YmEwODcyL3RleHRyZWdpb246ZjhiNzM1NTIyMmNjNGRlZTgwMjAwYTBhODRiYTA4NzJfNTc_431e7c10-3773-493b-94a8-bb7791c2168a" continuedAt="icb7c95d1a6724323b57ebfe2e3f02f64" escape="true">INVENTORIES</ix:nonNumeric></span></div><ix:continuation id="icb7c95d1a6724323b57ebfe2e3f02f64"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181OC9mcmFnOmY4YjczNTUyMjJjYzRkZWU4MDIwMGEwYTg0YmEwODcyL3RleHRyZWdpb246ZjhiNzM1NTIyMmNjNGRlZTgwMjAwYTBhODRiYTA4NzJfNDg_7dff0b6a-187b-4875-ae89-fc7225f7cfe8" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net consist of:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:InventoryRawMaterials" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181OC9mcmFnOmY4YjczNTUyMjJjYzRkZWU4MDIwMGEwYTg0YmEwODcyL3RhYmxlOjBkNTIwNTY5ZDc5MDQwNzI5OWEyN2FlODI3Zjc5MzBlL3RhYmxlcmFuZ2U6MGQ1MjA1NjlkNzkwNDA3Mjk5YTI3YWU4MjdmNzkzMGVfMS0yLTEtMS04OTA3Mg_a57adedd-7c28-4ef5-a833-741dd3d43c07">288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:InventoryRawMaterials" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181OC9mcmFnOmY4YjczNTUyMjJjYzRkZWU4MDIwMGEwYTg0YmEwODcyL3RhYmxlOjBkNTIwNTY5ZDc5MDQwNzI5OWEyN2FlODI3Zjc5MzBlL3RhYmxlcmFuZ2U6MGQ1MjA1NjlkNzkwNDA3Mjk5YTI3YWU4MjdmNzkzMGVfMS00LTEtMS04OTA3Mg_cc49aa04-9715-444c-ac5b-658e94c6f5fb">279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:InventoryWorkInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181OC9mcmFnOmY4YjczNTUyMjJjYzRkZWU4MDIwMGEwYTg0YmEwODcyL3RhYmxlOjBkNTIwNTY5ZDc5MDQwNzI5OWEyN2FlODI3Zjc5MzBlL3RhYmxlcmFuZ2U6MGQ1MjA1NjlkNzkwNDA3Mjk5YTI3YWU4MjdmNzkzMGVfMi0yLTEtMS04OTA3Mg_ff19a958-ec73-4d5b-ac66-8631f804c3a1">121</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:InventoryWorkInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181OC9mcmFnOmY4YjczNTUyMjJjYzRkZWU4MDIwMGEwYTg0YmEwODcyL3RhYmxlOjBkNTIwNTY5ZDc5MDQwNzI5OWEyN2FlODI3Zjc5MzBlL3RhYmxlcmFuZ2U6MGQ1MjA1NjlkNzkwNDA3Mjk5YTI3YWU4MjdmNzkzMGVfMi00LTEtMS04OTA3Mg_8ba99d84-e063-47ad-aa1d-f9fc16017ed5">112</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:InventoryFinishedGoods" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181OC9mcmFnOmY4YjczNTUyMjJjYzRkZWU4MDIwMGEwYTg0YmEwODcyL3RhYmxlOjBkNTIwNTY5ZDc5MDQwNzI5OWEyN2FlODI3Zjc5MzBlL3RhYmxlcmFuZ2U6MGQ1MjA1NjlkNzkwNDA3Mjk5YTI3YWU4MjdmNzkzMGVfMy0yLTEtMS04OTA3Mg_802a470b-0b93-4f5e-bc87-d86169ce4904">636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:InventoryFinishedGoods" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181OC9mcmFnOmY4YjczNTUyMjJjYzRkZWU4MDIwMGEwYTg0YmEwODcyL3RhYmxlOjBkNTIwNTY5ZDc5MDQwNzI5OWEyN2FlODI3Zjc5MzBlL3RhYmxlcmFuZ2U6MGQ1MjA1NjlkNzkwNDA3Mjk5YTI3YWU4MjdmNzkzMGVfMy00LTEtMS04OTA3Mg_06bcddbf-25d2-44de-9b48-acb91a904e24">602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181OC9mcmFnOmY4YjczNTUyMjJjYzRkZWU4MDIwMGEwYTg0YmEwODcyL3RhYmxlOjBkNTIwNTY5ZDc5MDQwNzI5OWEyN2FlODI3Zjc5MzBlL3RhYmxlcmFuZ2U6MGQ1MjA1NjlkNzkwNDA3Mjk5YTI3YWU4MjdmNzkzMGVfNC0yLTEtMS04OTA3Mg_5a90bf87-0932-43a2-bf0b-4b38d1af2ffa">1,045</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:InventoryGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181OC9mcmFnOmY4YjczNTUyMjJjYzRkZWU4MDIwMGEwYTg0YmEwODcyL3RhYmxlOjBkNTIwNTY5ZDc5MDQwNzI5OWEyN2FlODI3Zjc5MzBlL3RhYmxlcmFuZ2U6MGQ1MjA1NjlkNzkwNDA3Mjk5YTI3YWU4MjdmNzkzMGVfNC00LTEtMS04OTA3Mg_bae9882f-7004-4894-bb92-ba133bdf50ee">993</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i801c461cbd33492a893c84373a8e7cbc_61"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMjI0MjM_a5986c73-99ec-4a9d-9ebf-a7b030a79ebd" continuedAt="i81c5292ff66a4f96beaedcc1fc0b4dc4" escape="true">INTANGIBLE ASSETS AND GOODWILL </ix:nonNumeric></span></div><ix:continuation id="i81c5292ff66a4f96beaedcc1fc0b4dc4" continuedAt="i2c9b38ca453842acbc744927a68b7724"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMjI0MjQ_5bd8549f-66a3-4fed-a463-8d9e17ceec83" escape="true"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMjI0NjM_734ede77-0685-4804-b290-897d2677215c" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of intangible assets consist of:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.126%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization<br/>and<br/>Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization<br/>and<br/>Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33581fa718c7424d96b4ece6084ce29f_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfMy0yLTEtMS04OTA3Mg_da4e8d8c-4c83-4e86-bb3b-abfa5d17541e">20,845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33581fa718c7424d96b4ece6084ce29f_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfMy00LTEtMS04OTA3Mg_368f77a3-ca92-472a-99bc-8f7ddb45ebfc">16,452</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33581fa718c7424d96b4ece6084ce29f_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfMy02LTEtMS04OTA3Mg_0dd6f281-69f9-456f-9ddb-57331e1ef1dd">4,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69ed23fd69344f4bb9c380845d6fda6f_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfMy04LTEtMS04OTA3Mg_3c1f4b81-aef0-472e-be87-9797e15d19c1">20,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69ed23fd69344f4bb9c380845d6fda6f_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfMy0xMC0xLTEtODkwNzI_8726de84-36f0-4481-b821-15c7bbada4e1">16,169</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69ed23fd69344f4bb9c380845d6fda6f_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfMy0xMi0xLTEtODkwNzI_89282ddb-121d-4eed-a3f8-81e48bd1871b">4,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfcfb06623f468794d93d4a7a2a0b37_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNC0yLTEtMS04OTA3Mg_f970c382-38a9-4d7d-8547-d331714dd92d">900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1cfcfb06623f468794d93d4a7a2a0b37_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNC00LTEtMS04OTA3Mg_5ead1493-635e-4896-9471-3d73f12355cf">489</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfcfb06623f468794d93d4a7a2a0b37_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNC02LTEtMS04OTA3Mg_aa1041c4-8d58-43b1-a0d7-31d89a3bce0f">411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2b058cfe7264b67b8928b4f04d339b3_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNC04LTEtMS04OTA3Mg_4632468f-ea3a-4ec1-8cef-885b4c193d3f">902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2b058cfe7264b67b8928b4f04d339b3_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNC0xMC0xLTEtODkwNzI_be46a53b-1386-4b82-9f71-255a18b2e6b7">473</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2b058cfe7264b67b8928b4f04d339b3_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNC0xMi0xLTEtODkwNzI_98a361b5-57d5-456c-a04e-e1a4aac18bd9">429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01425e632a3246ef8376661a776befbe_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNS0yLTEtMS04OTA3Mg_e88dc25e-5a64-45d9-832b-cc20ccf211fc">3,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01425e632a3246ef8376661a776befbe_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNS00LTEtMS04OTA3Mg_cf66fec2-5210-4dd2-8868-eb9b26768ee6">3,191</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01425e632a3246ef8376661a776befbe_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNS02LTEtMS04OTA3Mg_9b46a088-fa27-494f-b23c-292ec2684509">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i128fe797bfca49acb9c7413882eb5f28_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNS04LTEtMS04OTA3Mg_af2f1e01-83f8-45ad-b663-458cd802b2c2">3,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i128fe797bfca49acb9c7413882eb5f28_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNS0xMC0xLTEtODkwNzI_6fe9d77c-605d-435b-b391-2b27b02613c9">3,174</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i128fe797bfca49acb9c7413882eb5f28_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNS0xMi0xLTEtODkwNzI_c2e8a018-e915-4c33-a898-49d95e88a138">147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6778a58f66f24243ab203161f3c6127d_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNi0yLTEtMS04OTA3Mg_7372a158-92e3-4aa3-9d2b-f32c34ad0483">154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6778a58f66f24243ab203161f3c6127d_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNi00LTEtMS04OTA3Mg_05a38d30-13e9-45a1-8bf1-63aaae7f1360">154</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6778a58f66f24243ab203161f3c6127d_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNi02LTEtMS04OTA3Mg_941af8b7-6308-4579-bbcf-2399d77499ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8420c39690874c31bfc4e99fc56813a9_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNi04LTEtMS04OTA3Mg_9b731554-3725-4b61-841a-cc61b54b9a3d">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8420c39690874c31bfc4e99fc56813a9_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNi0xMC0xLTEtODkwNzI_783fe39d-4d10-4f0f-88e9-43cb59f5cb1d">158</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8420c39690874c31bfc4e99fc56813a9_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNi0xMi0xLTEtODkwNzI_37c96d57-6503-4367-8a22-d3dc8e33bd3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Technology and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdae99c37fc148b9b34c052c3f5ee437_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNy0yLTEtMS04OTA3Mg_b4cd772d-bd5f-4dad-827e-c68246b9e2a6">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdae99c37fc148b9b34c052c3f5ee437_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNy00LTEtMS04OTA3Mg_421901fd-75f0-4127-b7af-9ef25c2ab85b">199</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdae99c37fc148b9b34c052c3f5ee437_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNy02LTEtMS04OTA3Mg_06a22ca2-d547-4309-aab9-160694f0242c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc94d751eecd4f2884cec4ffed6f0547_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNy04LTEtMS04OTA3Mg_fe0d572f-78db-406a-9d3e-1e7908549175">207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc94d751eecd4f2884cec4ffed6f0547_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNy0xMC0xLTEtODkwNzI_112c5796-9150-4764-8d72-b94b57678077">206</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc94d751eecd4f2884cec4ffed6f0547_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNy0xMi0xLTEtODkwNzI_bc9d8173-1e4e-41f4-b123-28def67821da">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfOC0yLTEtMS04OTA3Mg_548288b0-1e77-43e9-892d-007aee9437bd">25,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfOC00LTEtMS04OTA3Mg_124c6edc-7599-4fc8-9eaa-21b8fe2e3476">20,485</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfOC02LTEtMS04OTA3Mg_55df365c-fa97-43eb-9db4-05d2bb05fb9b">4,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfOC04LTEtMS04OTA3Mg_bfcf558d-3b5d-43e9-b077-9373d020f7a3">25,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfOC0xMC0xLTEtODkwNzI_aadc8270-dde8-4258-b4a2-d968dfc23452">20,180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfOC0xMi0xLTEtODkwNzI_eb8781b7-a0e5-4f6c-9955-4525c39d5eeb">5,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bausch + Lomb Trademark</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i184da53a325548e5a9b4d68317c28bf5_I20220331" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfMTAtMi0xLTEtODkwNzI_a4d9dcd8-446d-4b4b-8678-78694bf320be">1,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i184da53a325548e5a9b4d68317c28bf5_I20220331" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfMTAtNi0xLTEtODkwNzI_7157f9c7-c1b2-4e00-ab9b-57968075ca25">1,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7adc09fd30f54c31a00d1b781106171b_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfMTAtOC0xLTEtODkwNzI_df33da77-3c58-4031-86cf-1d0fe95e5b46">1,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7adc09fd30f54c31a00d1b781106171b_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfMTAtMTItMS0xLTg5MDcy_aa6f09a3-a6a3-44e4-84f0-56f7c1ea4ae3">1,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfMTEtMi0xLTEtODkwNzI_68255282-af26-43b1-abe2-baaded50d2da">27,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfMTEtNC0xLTEtODkwNzI_e579e603-46dd-477c-8017-fc43c77325d9">20,485</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfMTEtNi0xLTEtODkwNzI_c64c37bf-013c-446c-a44d-4da980c7cb1e">6,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfMTEtOC0xLTEtODkwNzI_4c2e1ef7-219c-46e7-ad17-41bd8dab96e8">27,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfMTEtMTAtMS0xLTg5MDcy_dbc9fcc3-9d95-4030-a637-14daf974daa8">20,180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfMTEtMTItMS0xLTg5MDcy_b4db95ce-80bf-4340-a5a7-80b5a9ee08cf">6,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Impairment charges associated with these assets are included in Asset impairments in the Consolidated Statement of Operations. The Company continues to monitor the recoverability of its finite-lived intangible assets and tests the intangible assets for impairment if indicators of impairment are present. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments, including loss on assets held for sale for the three months ended March 31, 2022 were $<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfNjY3_8caa150a-eca6-461c-89c3-65548f828eda">8</ix:nonFraction>&#160;million and include: (i) impairments of $<ix:nonFraction unitRef="usd" contextRef="i24b3278f312448edbdbbd2e5c8edb4ea_D20220101-20220331" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfNzAy_06fc97db-aa35-42ca-b507-eb3964110f74">4</ix:nonFraction>&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines, and (ii) impairments of $<ix:nonFraction unitRef="usd" contextRef="i9aa88c188d514752bb8a235164b310e8_D20220101-20220331" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfOTAz_eb29eae1-cf76-479e-b515-94f440dcc34a">4</ix:nonFraction>&#160;million, in aggregate, related to the discontinuance of certain product lines.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments, including loss on assets held for sale for the three months ended March 31, 2021 were $<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMTA1MQ_2049f20d-e45d-4beb-8759-aa8faac9a3db">148</ix:nonFraction>&#160;million and include: (i) $<ix:nonFraction unitRef="usd" contextRef="ibd413c64fca1463c942b8ada290af82b_D20210101-20210331" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMTA4Ng_04d6538f-939d-4756-a3af-2f3fc2dab5dd">71</ix:nonFraction>&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines in the Ortho Dermatologics business, (ii) an adjustment of $<ix:nonFraction unitRef="usd" contextRef="i9d5bc364e17040579714c24cebd52ba5_D20210101-20210331" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMTY0OTI2NzQ4NDgwNA_eb05ff62-29e1-42f3-9f14-4b75f61f1639">68</ix:nonFraction>&#160;million due to the loss on assets held for sale in connection with the Amoun Sale and (iii) impairments of $<ix:nonFraction unitRef="usd" contextRef="i78352536ea52411880331b5c2102a14b_D20210101-20210331" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMTE3NQ_419baeeb-5755-4466-bcea-e268ef8dcf67">9</ix:nonFraction>&#160;million, in aggregate, related to the discontinuance of certain product lines. </span></div><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMjI0NTI_e1554673-252b-4722-a705-f6c3a24393ce" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense of finite-lived intangible assets for the remainder of 2022 and each of the five succeeding years ending December&#160;31 and thereafter is as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.833%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remainder of 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE5NWZjZmQ3OGNjMzQ5MWFhYjgzY2VmYjE1YmNjM2ZiL3RhYmxlcmFuZ2U6MTk1ZmNmZDc4Y2MzNDkxYWFiODNjZWZiMTViY2MzZmJfMS0yLTEtMS04OTA3Mg_54f36e78-3dfa-429a-9f2a-52640c9686e2">870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE5NWZjZmQ3OGNjMzQ5MWFhYjgzY2VmYjE1YmNjM2ZiL3RhYmxlcmFuZ2U6MTk1ZmNmZDc4Y2MzNDkxYWFiODNjZWZiMTViY2MzZmJfMS00LTEtMS04OTA3Mg_3dd28d59-aeef-4ca5-8b37-93c3169e5717">1,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE5NWZjZmQ3OGNjMzQ5MWFhYjgzY2VmYjE1YmNjM2ZiL3RhYmxlcmFuZ2U6MTk1ZmNmZDc4Y2MzNDkxYWFiODNjZWZiMTViY2MzZmJfMS02LTEtMS04OTA3Mg_9b5d99bb-b7d5-4fd8-999f-534c2d48b1f4">901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE5NWZjZmQ3OGNjMzQ5MWFhYjgzY2VmYjE1YmNjM2ZiL3RhYmxlcmFuZ2U6MTk1ZmNmZDc4Y2MzNDkxYWFiODNjZWZiMTViY2MzZmJfMS04LTEtMS04OTA3Mg_aa55363d-8438-4978-a009-06f099ecda7c">794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE5NWZjZmQ3OGNjMzQ5MWFhYjgzY2VmYjE1YmNjM2ZiL3RhYmxlcmFuZ2U6MTk1ZmNmZDc4Y2MzNDkxYWFiODNjZWZiMTViY2MzZmJfMS0xMC0xLTEtODkwNzI_8ee539f4-0f0d-48f7-9f3c-a46510ece2c9">664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE5NWZjZmQ3OGNjMzQ5MWFhYjgzY2VmYjE1YmNjM2ZiL3RhYmxlcmFuZ2U6MTk1ZmNmZDc4Y2MzNDkxYWFiODNjZWZiMTViY2MzZmJfMS0xMi0xLTEtODkwNzI_bb438c09-aac7-4b2a-9516-75205024d44f">627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE5NWZjZmQ3OGNjMzQ5MWFhYjgzY2VmYjE1YmNjM2ZiL3RhYmxlcmFuZ2U6MTk1ZmNmZDc4Y2MzNDkxYWFiODNjZWZiMTViY2MzZmJfMS0xNC0xLTEtODkwNzI_47101932-1643-4931-895d-41589f83c5c0">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE5NWZjZmQ3OGNjMzQ5MWFhYjgzY2VmYjE1YmNjM2ZiL3RhYmxlcmFuZ2U6MTk1ZmNmZDc4Y2MzNDkxYWFiODNjZWZiMTViY2MzZmJfMS0xNi0xLTEtODkwNzI_68417954-0cab-43d3-b5b1-1d6c0d26e99b">4,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i2c9b38ca453842acbc744927a68b7724" continuedAt="i1719823995924add8a5c123e3280e06e"><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMjI0Njg_482767cf-1afd-447d-b8d3-fc1a23ba3654" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amounts of goodwill during the three months ended March 31, 2022 and the year ended December&#160;31, 2021 were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.346%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.298%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.447%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.494%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Bausch + Lomb/ International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i942199177b494651b884505a5348aee8_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfMS0yLTEtMS04OTA3Mg_376d1f9f-fdd9-41f7-a013-3402dd5ccf5b">5,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12b373f353694a7a92ef13969e363c9c_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfMS02LTEtMS04OTA3Mg_874e9ae9-3022-4c3b-aafe-5e26b23e1a8c">3,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f9c2f75c9054ca7be42d333db8aa66a_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfMS0xMC0xLTEtODkwNzI_e83b06f7-3487-4492-addc-39d7e5343e59">1,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a8465040b7746bbbb02d83f214f8936_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfMS0xMi0xLTEtODkwNzI_18a24ef0-bcff-4802-bcc1-a4ea081c2796">2,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d274a4a3e5a43ae91dfbb2934c4c5d1_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfMS0xNC0xLTEtODkwNzI_2ce1595e-db00-4727-8213-76ea36db61cc">13,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Realignment of segment goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e916e0c53bb4694a37e063fb61adc77_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfMi0yLTEtMS04OTA3Mg_b3e25ae5-cc10-4138-8cbc-67a21cc98099">5,704</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56804b7aa6534ed9b555f349c187b56d_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfMi00LTEtMS05NDc3MQ_88b1bfca-004e-4646-8de1-ff0d1a840071">5,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b662e8f657b4e3ab3b79a4cebde04c2_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfMi04LTEtMS05NDc3MQ_ff8c09e0-495e-4cfb-86dd-7c96d95ddc14">887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib37696822d2c4572b3c78344c1fd444a_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfMi0xNC0xLTEtOTQ3NzE_48d62aea-7a9c-4442-a695-ac946a0be89e">578</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia94fd825df534043ad9a8d3ff85daa7f_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfMi0xNC0xLTEtODkwNzI_fc64e22b-cc79-4e75-95d2-33218a9994a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e916e0c53bb4694a37e063fb61adc77_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfMy0yLTEtMS04OTA3Mg_e23abf98-1bae-4a47-a453-4bbb6412170a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1dcff32aa885494dbd4c25e336b285dd_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfMy0xMC0xLTEtOTQ3Nzc_f3d04935-780e-439c-94b2-a040717a5274">469</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia94fd825df534043ad9a8d3ff85daa7f_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfMy0xNC0xLTEtODkwNzI_a69ed944-8172-4285-9515-b31556f17733">469</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e916e0c53bb4694a37e063fb61adc77_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfNC0yLTEtMS04OTA3Mg_920a5063-116b-406c-bbdc-c397fd8ffdde">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56804b7aa6534ed9b555f349c187b56d_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfNC00LTEtMS05NDc3OQ_c73a7c53-ef91-463f-8625-bfe035f5217a">77</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b662e8f657b4e3ab3b79a4cebde04c2_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfNC04LTEtMS05NDc4MQ_ed9dec3c-690a-4925-bb83-9c4e8e4ece5e">62</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib37696822d2c4572b3c78344c1fd444a_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfNC0xNC0xLTEtOTQ3ODM_c18613aa-fc8f-4407-bde1-9e11105146fd">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia94fd825df534043ad9a8d3ff85daa7f_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfNC0xNC0xLTEtODkwNzI_7c6762f0-7ec3-41e0-a8ca-f2d3f1da2867">118</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i928ceb331757485bb004adc674715221_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfNS0yLTEtMS04OTA3Mg_a561b6a1-8cea-49ba-bb0e-bd1d0d5b47ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab3980bb98104da18c9a7bfacb2b814c_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfNS00LTEtMS04OTA3Mg_e107eaa7-850d-4f3e-93cc-55d34dc15389">5,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icad79738cfa145e4ad3efae80a8f7853_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfNS02LTEtMS04OTA3Mg_3a27ec61-cbad-42c4-9219-58f3617a31f8">3,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i883adcdb932a4b7facd79e34969366b7_I20211231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfNS04LTEtMS04OTA3Mg_7025f5e6-474d-4a6c-b953-59506822ac67">825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie485ba4bcfb74a319879f1cc1994ceb1_I20211231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfNS0xMC0xLTEtODkwNzI_2d293676-7360-4ae0-b033-4257f37a40c1">798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6abfd8107c426d88c7af70640541ed_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfNS0xMi0xLTEtOTQ3OTA_50ad45fe-f2cb-4b1a-8727-2a61e549e4b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16fa5c63321a4379872d667cd4f09ff7_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfNS0xMi0xLTEtODkwNzI_46b940e0-26c9-4647-9086-b157116101bc">2,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfNS0xNC0xLTEtODkwNzI_17d1ac96-2afa-4753-9faf-ad70b3e22de9">12,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Realignment of segment goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3e9f44ea7f04ab4bb12e34a4d9b198f_D20220101-20220331" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfNi0yLTEtMS04OTA3Mg_4e1b1e70-6091-4457-ab6e-a2180c0460f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03d9858da1a54c6a897587b6b5079ca1_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfNi0xMC0xLTEtOTQ3OTk_9cbe4b72-816f-4bbf-a842-5d0c762bf629">798</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cc8090790184dbd8e5fef8bc092f80c_D20220101-20220331" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfNi0xMi0xLTEtOTQ4MDM_785923d3-5eeb-4709-9b02-2afd7eea92af">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5df5fcbde684e86add3147c9fe2ea1c_D20220101-20220331" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfNi0xMi0xLTEtODkwNzI_d7160b1c-4909-4064-bb90-5569ede4f672">683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfNi0xNC0xLTEtODkwNzI_04cbac96-c05a-4037-872b-287af0b374cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3e9f44ea7f04ab4bb12e34a4d9b198f_D20220101-20220331" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfNy0yLTEtMS0xMDE2ODY_e187fbc3-04ea-42e9-81ff-39a2b9adb889">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i897d561735644b67b640f606386ea273_D20220101-20220331" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfOC00LTEtMS04OTA3Mg_02edff88-706a-4720-bc6b-7fec5c527fd9">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03af4a3fb12d4415985732b5f1713c51_D20220101-20220331" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfOC04LTEtMS04OTA3Mg_c13cfeff-368f-42b1-b353-c0a373a7ce51">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5df5fcbde684e86add3147c9fe2ea1c_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfOC0xMi0xLTEtODkwNzI_843a7255-37b6-49cf-8da6-c7e9d3f0142d">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfOC0xNC0xLTEtODkwNzI_a3c31bb2-502d-47bb-81c5-71679cca1646">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c5165be148344bdaf507fcd8cd8faa1_I20220331" decimals="-6" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfOS0yLTEtMS04OTA3Mg_6fb0fcdd-593e-4bd3-be35-25494c829169">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff8cffb5a07d43829a8ad9375270cefc_I20220331" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfOS00LTEtMS04OTA3Mg_15979faf-d065-4ddc-a42d-0eb0d9297e8f">5,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17fd70111a574d2ca873e85d5d905ac6_I20220331" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfOS02LTEtMS04OTA3Mg_b0e8b958-5567-461f-be60-6012b75995c7">3,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42279724503f49f38806cc3713f1dec9_I20220331" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfOS04LTEtMS04OTA3Mg_4f04a910-a4d3-4ce5-85d8-5efba0a2994b">811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c7901af22c14ac2ad3c4144a35ef0c6_I20220331" decimals="-6" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfOS0xMC0xLTEtODkwNzI_56c0275b-5ce2-42a1-af87-02e2dd8fad49">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05c0aa9bce2948fe95f19480427221e2_I20220331" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfOC0xMi0xLTEtOTQ3OTI_f8b64629-b999-42da-b3c6-d87f94111738">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb4928a2aeb34ea08a24be593ce24cf0_I20220331" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfOS0xMi0xLTEtODkwNzI_fd9bb101-a3a3-4bcc-bdbc-c46e269052b5">3,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfOS0xNC0xLTEtODkwNzI_9f1168ef-9f8a-47c6-98e4-41f11c98c624">12,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized but is tested for impairment at least annually on October 1st at the reporting unit level. A reporting unit is the same as, or one level below, an operating segment. The Company performs its annual impairment test by first assessing qualitative factors. Where the qualitative assessment suggests that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed for that reporting unit (Step 1).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of a reporting unit refers to the price that would be received to sell the unit as a whole in an orderly transaction between market participants. The Company estimates the fair value of a reporting unit using a discounted cash flow model which utilizes Level 3 unobservable inputs. The discounted cash flow model relies on assumptions regarding revenue growth rates, gross profit, projected working capital needs, selling, general and administrative expenses, research and development expenses, capital expenditures, income tax rates, discount rates and terminal growth rates. To estimate fair value, the Company discounts the forecasted cash flows of each reporting unit. The discount rate the Company uses represents the estimated weighted average cost of capital, which reflects the overall level of inherent risk involved in its reporting unit operations and the rate of return a market participant would expect to earn. The quantitative fair value test is performed utilizing long-term growth rates and discount rates applied to the estimated cash flows in estimation of fair value. To estimate cash flows beyond the final year of its model, the Company estimates a terminal value by applying an in-perpetuity growth assumption and discount factor to determine the reporting unit&#8217;s terminal value. </span></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To forecast a reporting unit&#8217;s cash flows the Company takes into consideration economic conditions and trends, estimated future operating results, management&#8217;s and a market participant&#8217;s view of growth rates and product lives, and anticipates future economic conditions. Revenue growth rates inherent in these forecasts are based on input from internal and external market research that compare factors such as growth in global economies, recent industry trends and product life-cycles. Macroeconomic factors such as changes in economies, changes in the competitive landscape including the unexpected loss of exclusivity to the Company&#8217;s product portfolio, changes in government legislation, product life-cycles, industry consolidations and other changes beyond the Company&#8217;s control could have a positive or negative impact on achieving its targets. Accordingly, if market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future and such change could be material. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">First Quarter 2021 - Realignment of Segments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the first quarter of 2021, the Company began operating in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International, (iv) Ortho Dermatologics and (v) Diversified Products. The Bausch + Lomb segment consisted of the: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units. The Salix segment consisted of the Salix reporting unit. The International segment consisted of the International (formerly International Rx) reporting unit. The Ortho Dermatologics segment consisted of the: (i) Ortho Dermatologics and (ii) Global Solta reporting units. The Diversified Products segment consisted of the: (i) Neurology and Other, (ii) Generics and (iii) Dentistry reporting units. This realignment in segment structure resulted in a change in the Company&#8217;s former International reporting unit, which was divided between the International Bausch + Lomb reporting unit and International reporting unit. In addition, as part of the realignment of segment structure, certain products historically included in the Generics reporting unit were included in the U.S. Bausch + Lomb reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of this realignment, goodwill was reassigned to each of the aforementioned reporting units using a relative fair value approach. Goodwill previously reported in the former International reporting unit was reassigned to the International Bausch + Lomb and International reporting units, and a portion of goodwill previously reported in the former Generics reporting unit was reassigned to the U.S. Bausch + Lomb reporting unit.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i1719823995924add8a5c123e3280e06e" continuedAt="i645e1e00954f4be6b924eb32669b416d"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the change in reporting units, the Company performed a qualitative fair value assessment for its former: (i) International and (ii) Generics reporting units. Based on the qualitative fair value assessment performed, Management believed that it was more likely than not that the carrying values of its former: (i) International and (ii) Generics reporting units were less than their respective fair values and therefore, concluded a quantitative assessment was not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately following the change in reporting units, as a result of the change in composition of the net assets for its: (i) International Bausch + Lomb, (ii) International and (iii) Generics reporting units, the Company performed a quantitative fair value test. The quantitative fair value test utilized a range of long-term growth rates of <ix:nonFraction unitRef="number" contextRef="i05c4425257364b019ef82d6d8127a3d0_I20210331" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMTU0NTc_56612e34-23b1-493c-b38b-0524910b23c9">1.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i22918d18bb77417eac5d796b8c470056_I20210331" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMTU0NjM_0feed543-5287-4a77-a36b-dc440d8ac54b">3.0</ix:nonFraction>% and a range of discount rates between <ix:nonFraction unitRef="number" contextRef="i05c4425257364b019ef82d6d8127a3d0_I20210331" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMTU1MDQ_e2cc3e29-4c43-499f-876d-5fec8f2e1cc5">11.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i22918d18bb77417eac5d796b8c470056_I20210331" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMTU1MTE_f4c720d6-b6df-4e9f-a082-b9e608fa1d7b">12.25</ix:nonFraction>%, in estimation of the fair value of the reporting units. After completing the testing, the fair value of each of these reporting units exceeded its carrying value by more than <ix:nonFraction unitRef="number" contextRef="i812289a7a0cf44b4b1eed544ad0bec6c_I20210331" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMTU2OTA_6e004799-2777-4f4f-b149-635ff6b1694c">40</ix:nonFraction>%, and, therefore, there was <ix:nonFraction unitRef="usd" contextRef="i59dd4c241bfe46cab97c7f62aa7998be_D20210331-20210331" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMTU3MjA_ed520cbf-ab9a-4cc8-9316-6252aa4637ff">no</ix:nonFraction> impairment to goodwill. In addition, as the U.S. Bausch + Lomb reporting unit had a change in composition of its net assets related to certain products historically included in the Generics reporting unit now being included in the U.S. Bausch + Lomb reporting unit, the Company performed a qualitative assessment of this reporting unit. Based on the qualitative fair value assessment performed, Management believed that it was more likely than not that the carrying value of its current U.S. Bausch + Lomb reporting unit was less than its fair value and therefore, concluded a quantitative assessment was not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Interim Goodwill Impairment Testing</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the interim periods of 2021, with the exception of the Ortho Dermatologics reporting unit, no events occurred, or circumstances changed that would indicate that the fair value of any other reporting unit might be below its carrying value and therefore, <ix:nonFraction unitRef="usd" contextRef="i813f53a5817849fa8b332b4429a806c7_D20210101-20211231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMjc0ODc3OTExMjU5NA_bb8c6f3b-a6fa-45f0-b2ab-8f4950c3e211">no</ix:nonFraction> impairments were recorded.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, management identified launches of certain Ortho Dermatologics products which were not going to achieve their trajectories as forecasted once the social restrictions associated with the COVID-19 pandemic began to ease in the U.S. and offices of health care professionals could reopen. In addition, insurance coverage pressures within the U.S. continued to persist limiting patient access to topical acne and psoriasis products. In light of these developments, during the first quarter of 2021, the Company began taking steps to: (i) redirect its R&amp;D spend to eliminate projects it had identified as high cost and high risk, (ii) redirect a portion of its marketing and product development outside the U.S. to geographies where there is better patient access and (iii) reduce its cost structure to be more competitive. As a result, during the three months ended March 31, 2021, the Company revised its long-term forecasts for the Ortho Dermatologics reporting unit. Management believed that these events were indicators that there was less headroom as of March 31, 2021 as compared to the headroom calculated on the date goodwill was last tested for impairment (October 1, 2020). Therefore, a quantitative fair value test for the Ortho Dermatologics reporting unit was performed. The quantitative fair value test utilized the Company&#8217;s most recent cash flow projections as revised in the first quarter of 2021 to reflect the business changes previously discussed, including a range of potential outcomes, along with a long-term growth rate of <ix:nonFraction unitRef="number" contextRef="i352bdc0bdb3746bcab18bb34559bda96_I20210331" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMTc5Njg_5f247fd5-cfcf-4e7d-8a1e-03074df45e57">1.0</ix:nonFraction>% and a range of discount rates between <ix:nonFraction unitRef="number" contextRef="ib3d106cc00bb4068aeaadfb5a27059ab_I20210331" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMTgwMDk_eda86c98-447f-4d9f-9922-907a9a9665d5">9.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i3b7487693f3a42968a15d65a005a518a_I20210331" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMTgwMTY_7c7b6879-1705-472e-b06c-5c3ca66dfb6c">10.0</ix:nonFraction>%. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at March 31, 2021, and the Company recognized a goodwill impairment of $<ix:nonFraction unitRef="usd" contextRef="i579bd73ae67e4680b7518c0d567bd33c_D20210331-20210331" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMTgyMTk_a2bb4b41-d341-4793-a4f0-34d5572e4c04">469</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Second Quarter 2021 - Realignment of Bausch + Lomb Reporting Units</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the second quarter of 2021, the Company changed the way it reviews the financial information of its Bausch + Lomb segment. Beginning in the second quarter of 2021, management no longer reviews the financial information of its Bausch + Lomb segment on a geographic basis, but instead reviews this financial information on a business line basis. This change created a change in the reporting units of the Bausch + Lomb segment. After the change, under its business line view, the Bausch + Lomb segment consisted of the global: (i) Vision Care / Consumer Products, (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units. Prior to the second quarter of 2021, under the geographic view, the Bausch + Lomb segment consisted of the former: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units. As a result of the realignment, goodwill was reassigned to each of the aforementioned reporting units using a relative fair value approach. The change in Bausch + Lomb reporting units did not impact the reported revenues and segment profits of the Bausch + Lomb segment for any prior periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the change in its Bausch + Lomb reporting units, the Company performed a qualitative fair value assessment for its former reporting units. Based on the qualitative fair value assessment, management believed that it was more likely than not that the carrying values of its former: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units were less than their respective fair values and, therefore, concluded a quantitative assessment was not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the change in composition of net assets, the Company performed a quantitative fair value test of its new: (i) Vision Care / Consumer Products, (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units immediately following the change in the Bausch + Lomb segment. The quantitative fair value test utilized long-term growth rates of <ix:nonFraction unitRef="number" contextRef="i76fa5b74ac474ce785d33b402a51a48b_I20210630" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMjAyNzA_f7f8720c-2cc1-4233-9a1b-4171688f5761">2.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i0aeee5779e6741b5a846738af963baa7_I20210630" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMjAyNzc_7b7186a0-fda0-4ee1-93ab-d5997a1d7e8d">3.0</ix:nonFraction>% and a range of discount rates between <ix:nonFraction unitRef="number" contextRef="i76fa5b74ac474ce785d33b402a51a48b_I20210630" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMjAzMTg_1c64298f-7401-4f21-b307-13eb9b76c199"><ix:nonFraction unitRef="number" contextRef="i76fa5b74ac474ce785d33b402a51a48b_I20210630" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMjAzMTg_3e1a7d77-2e15-4a20-84f5-96cf8f9e087e">7.0</ix:nonFraction></ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i0aeee5779e6741b5a846738af963baa7_I20210630" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMjAzMjU_56b95725-45a4-4833-806e-5bd1f6650b0f"><ix:nonFraction unitRef="number" contextRef="i0aeee5779e6741b5a846738af963baa7_I20210630" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMjAzMjU_a475e520-0dfd-41d9-b634-93400caae45a">10.0</ix:nonFraction></ix:nonFraction>%, in estimation of the fair value of the reporting units. After completing </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i645e1e00954f4be6b924eb32669b416d"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the testing, the fair value of each of these reporting units exceeded its carrying value by more than <ix:nonFraction unitRef="number" contextRef="i4bde0da879c447c1bce8cc7c0ff990a9_I20210630" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMjA1MDQ_8997ecc3-e249-49e0-b07d-34a739c61b2f"><ix:nonFraction unitRef="number" contextRef="i4bde0da879c447c1bce8cc7c0ff990a9_I20210630" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMjA1MDQ_ee3cc7ba-ef47-4009-86fc-fe6141c2e168">45</ix:nonFraction></ix:nonFraction>%, and, therefore, there was <ix:nonFraction unitRef="usd" contextRef="i66cd53bf84e745829ac8a76a80274bef_D20210630-20210630" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMjA1MzQ_7ec7775a-d7fd-4ca3-a9d2-d3682b776851">no</ix:nonFraction> impairment to goodwill.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Annual Goodwill Impairment Test</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducted its annual goodwill impairment test as of October 1, 2021 by first assessing qualitative factors. Based on its qualitative assessment as of October 1, 2021, management believed that, with the exception of the Ortho Dermatologics reporting unit, it was more likely than not that the carrying amounts of its reporting units were less than their respective fair values and therefore concluded that a quantitative fair value test for those reporting units was not required. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of its qualitative assessment of the Ortho Dermatologics reporting unit as of October 1, 2021, the Company considered, among other matters, the limited headroom as a result of the impairment to the goodwill of the Ortho Dermatologics reporting unit when last tested (March 31, 2021) and macroeconomic factors such as higher than expected inflation for many commodities, volatility in many of the equity markets and pressures on market interest rates. The Company believed that these facts and circumstances may suggest that it was more likely than not that the fair value of the Ortho Dermatologics reporting unit was less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed a quantitative fair value test for the Ortho Dermatologics reporting unit as of October 1, 2021, utilizing a long-term growth rate of <ix:nonFraction unitRef="number" contextRef="i273ea466a0c24f7f9a2bc799a58a59b0_I20211001" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMTY0OTI2NzQ2ODIwMg_a96f342d-8e3c-4253-a440-5fde658ec162">1.0</ix:nonFraction>% and a discount rate of <ix:nonFraction unitRef="number" contextRef="i273ea466a0c24f7f9a2bc799a58a59b0_I20211001" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMTY0OTI2NzQ2ODIwOA_247057dc-fb07-4b95-a7c1-f317547a5c53">9.0</ix:nonFraction>%, in estimation of the fair value of this reporting unit. Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was approximately <ix:nonFraction unitRef="number" contextRef="i273ea466a0c24f7f9a2bc799a58a59b0_I20211001" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMTY0OTI2NzQ2ODIxNA_aec26595-6623-4305-b251-14165e39c499">10</ix:nonFraction>% greater than its carrying value and as a result there was <ix:nonFraction unitRef="usd" contextRef="i84c7e2b9e5eb4b97857089a8cd8efa23_D20211001-20211001" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMTY0OTI2NzQ2ODIxOA_4a3691e3-0997-4e31-b467-ffeffdda5ac4">no</ix:nonFraction> impairment to the goodwill of the reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">First Quarter 2022 - Realignment of Segments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the first quarter of 2022, the Company began operating in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International, (iv) Solta Medical and (v) Diversified Products. The Bausch + Lomb segment consists of the: (i) Vision Care / Consumer Products, (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units. The Salix segment consists of the Salix reporting unit. The International segment consists of the International reporting unit. The Solta Medical segment consists of the Global Solta reporting unit. The Diversified Products segment consists of the: (i) Neurology and Other, (ii) Generics, (iii) Ortho Dermatologics and (iv) Dentistry reporting units. As such, the new segment structure does not impact the Company&#8217;s reporting units but realigns the <ix:nonFraction unitRef="reporting_unit" contextRef="i03d9858da1a54c6a897587b6b5079ca1_D20220101-20220331" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMjc0ODc3OTExMjYwOQ_64475b6c-e5c5-4911-a540-07a779b7fd34">two</ix:nonFraction> reporting units of the former Ortho Dermatologics segment whereby the Ortho Dermatologics reporting unit is now part of the current Diversified Products segment and the Solta reporting unit is now its own operating and reportable segment, and therefore management concluded that a quantitative fair value test was not required. See Note 19, &#8220;SEGMENT INFORMATION&#8221; for additional information.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">March 31, 2022 Interim Assessment of Goodwill</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to monitor market conditions which could impact the previous valuation of Ortho Dermatologics reporting unit. During the three months ended March 31, 2022, macroeconomic factors have impacted interest rates and the U.S. inflation rate is higher than previously expected.  Given the limited headroom calculated on October 1, 2021, the Company believed that these facts and circumstances suggest the fair value of the Ortho Dermatologics reporting unit could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value test utilized the Company&#8217;s most recent cash flow projections as revised in the first quarter of 2022 and utilized a long-term growth rate of <ix:nonFraction unitRef="number" contextRef="i600f2612b7b641d682431ce561c69ad9_I20220331" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMjc0ODc3OTEzMDEyMQ_6b32980f-5024-41a6-baec-b89628cbfc8a">1</ix:nonFraction>% and a discount rate of <ix:nonFraction unitRef="number" contextRef="i600f2612b7b641d682431ce561c69ad9_I20220331" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMjc0ODc3OTEzMDEyNQ_9791a21d-54bb-4616-909c-95756fa19a5d">9</ix:nonFraction>%.  The discount rate contemplates changes in the current macroeconomic conditions noting certain inputs such as the risk free rate increased over the three months ended March 31, 2022, and was offset by decreases in other reporting unit specific risks during the same period. Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was less than <ix:nonFraction unitRef="number" contextRef="i600f2612b7b641d682431ce561c69ad9_I20220331" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMjc0ODc3OTEzMDEyOQ_a3aedd68-b811-412f-b875-c0ea735a5efd">2</ix:nonFraction>% greater than its carrying value and as a result there was <ix:nonFraction unitRef="usd" contextRef="if6561f3b97934eda8c2522f1ea9ce1b7_D20220101-20220331" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMjc0ODc3OTEzMDEzMg_07fd2a49-3c5d-40d0-8cad-cfc181a90dfa">no</ix:nonFraction> impairment to the goodwill of the reporting unit. If market conditions deteriorate requiring management to revise its assumptions such as its long-term growth or discount rates, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future and those charges could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other events occurred or circumstances changed during the period October 1, 2021 (the last time goodwill was tested for all other reporting units) through March 31, 2022 that would indicate that the fair value of any reporting unit, other than the Ortho Dermatologics reporting unit, might be below its carrying value. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated goodwill impairment charges through March&#160;31, 2022 were $<ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMjI0MjA_2b9dd7f4-c514-4b87-9903-67bd9461f03a">4,180</ix:nonFraction> million.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="i801c461cbd33492a893c84373a8e7cbc_64"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182NC9mcmFnOjU5NGZhYjcyMTcwZTQ1NjdiMDFiYTBmNjAxYmM3ZjUwL3RleHRyZWdpb246NTk0ZmFiNzIxNzBlNDU2N2IwMWJhMGY2MDFiYzdmNTBfOTc_e36297a1-d83a-4b7c-82a2-ef5f6872e875" continuedAt="i98a05a2bc3c940caa400310d000611cc" escape="true">ACCRUED AND OTHER CURRENT LIABILITIES</ix:nonNumeric></span></div><ix:continuation id="i98a05a2bc3c940caa400310d000611cc"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182NC9mcmFnOjU5NGZhYjcyMTcwZTQ1NjdiMDFiYTBmNjAxYmM3ZjUwL3RleHRyZWdpb246NTk0ZmFiNzIxNzBlNDU2N2IwMWJhMGY2MDFiYzdmNTBfOTQ_6ae97a61-e5ee-4704-829a-1d9cb3a1f252" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities consist of:</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal matters and related fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="bhc:Legalsettlementsandrelatedfees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182NC9mcmFnOjU5NGZhYjcyMTcwZTQ1NjdiMDFiYTBmNjAxYmM3ZjUwL3RhYmxlOmE2YTUyNDdiYmRmZTQ1OGRiNTU4OTAyZDQ5ZGFjYzViL3RhYmxlcmFuZ2U6YTZhNTI0N2JiZGZlNDU4ZGI1NTg5MDJkNDlkYWNjNWJfMS0yLTEtMS04OTA3Mg_c24287d0-6e4e-40b5-afa2-666a3435c2cb">1,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="bhc:Legalsettlementsandrelatedfees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182NC9mcmFnOjU5NGZhYjcyMTcwZTQ1NjdiMDFiYTBmNjAxYmM3ZjUwL3RhYmxlOmE2YTUyNDdiYmRmZTQ1OGRiNTU4OTAyZDQ5ZGFjYzViL3RhYmxlcmFuZ2U6YTZhNTI0N2JiZGZlNDU4ZGI1NTg5MDJkNDlkYWNjNWJfMS00LTEtMS04OTA3Mg_b0048e69-c094-462a-904a-646a07a90da5">1,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rebates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="bhc:AccruedProductRebateCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182NC9mcmFnOjU5NGZhYjcyMTcwZTQ1NjdiMDFiYTBmNjAxYmM3ZjUwL3RhYmxlOmE2YTUyNDdiYmRmZTQ1OGRiNTU4OTAyZDQ5ZGFjYzViL3RhYmxlcmFuZ2U6YTZhNTI0N2JiZGZlNDU4ZGI1NTg5MDJkNDlkYWNjNWJfMi0yLTEtMS04OTA3Mg_67640732-f4b8-456e-bc03-ba53550e01cf">889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="bhc:AccruedProductRebateCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182NC9mcmFnOjU5NGZhYjcyMTcwZTQ1NjdiMDFiYTBmNjAxYmM3ZjUwL3RhYmxlOmE2YTUyNDdiYmRmZTQ1OGRiNTU4OTAyZDQ5ZGFjYzViL3RhYmxlcmFuZ2U6YTZhNTI0N2JiZGZlNDU4ZGI1NTg5MDJkNDlkYWNjNWJfMi00LTEtMS04OTA3Mg_729a1416-0d0b-4c19-aeef-2f269242c8a6">908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="bhc:AccruedProductReturnCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182NC9mcmFnOjU5NGZhYjcyMTcwZTQ1NjdiMDFiYTBmNjAxYmM3ZjUwL3RhYmxlOmE2YTUyNDdiYmRmZTQ1OGRiNTU4OTAyZDQ5ZGFjYzViL3RhYmxlcmFuZ2U6YTZhNTI0N2JiZGZlNDU4ZGI1NTg5MDJkNDlkYWNjNWJfMy0yLTEtMS04OTA3Mg_9045b0ed-a73a-4ddb-af7f-674a8e9ba7ad">447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="bhc:AccruedProductReturnCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182NC9mcmFnOjU5NGZhYjcyMTcwZTQ1NjdiMDFiYTBmNjAxYmM3ZjUwL3RhYmxlOmE2YTUyNDdiYmRmZTQ1OGRiNTU4OTAyZDQ5ZGFjYzViL3RhYmxlcmFuZ2U6YTZhNTI0N2JiZGZlNDU4ZGI1NTg5MDJkNDlkYWNjNWJfMy00LTEtMS04OTA3Mg_472b1712-b570-4966-94f7-29492d6b2802">482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:InterestPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182NC9mcmFnOjU5NGZhYjcyMTcwZTQ1NjdiMDFiYTBmNjAxYmM3ZjUwL3RhYmxlOmE2YTUyNDdiYmRmZTQ1OGRiNTU4OTAyZDQ5ZGFjYzViL3RhYmxlcmFuZ2U6YTZhNTI0N2JiZGZlNDU4ZGI1NTg5MDJkNDlkYWNjNWJfNC0yLTEtMS04OTA3Mg_2b58c563-89d1-4a51-aef4-bafeb9451add">372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:InterestPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182NC9mcmFnOjU5NGZhYjcyMTcwZTQ1NjdiMDFiYTBmNjAxYmM3ZjUwL3RhYmxlOmE2YTUyNDdiYmRmZTQ1OGRiNTU4OTAyZDQ5ZGFjYzViL3RhYmxlcmFuZ2U6YTZhNTI0N2JiZGZlNDU4ZGI1NTg5MDJkNDlkYWNjNWJfNC00LTEtMS04OTA3Mg_810a6679-aef2-470a-9975-2b8d563252c5">328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefit costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182NC9mcmFnOjU5NGZhYjcyMTcwZTQ1NjdiMDFiYTBmNjAxYmM3ZjUwL3RhYmxlOmE2YTUyNDdiYmRmZTQ1OGRiNTU4OTAyZDQ5ZGFjYzViL3RhYmxlcmFuZ2U6YTZhNTI0N2JiZGZlNDU4ZGI1NTg5MDJkNDlkYWNjNWJfNS0yLTEtMS04OTA3Mg_9c65225f-f57c-4ca6-9e16-beaca42367b3">283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182NC9mcmFnOjU5NGZhYjcyMTcwZTQ1NjdiMDFiYTBmNjAxYmM3ZjUwL3RhYmxlOmE2YTUyNDdiYmRmZTQ1OGRiNTU4OTAyZDQ5ZGFjYzViL3RhYmxlcmFuZ2U6YTZhNTI0N2JiZGZlNDU4ZGI1NTg5MDJkNDlkYWNjNWJfNS00LTEtMS04OTA3Mg_2a116e60-a25c-4b8f-bd8b-d9d7ef3ab9fe">336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182NC9mcmFnOjU5NGZhYjcyMTcwZTQ1NjdiMDFiYTBmNjAxYmM3ZjUwL3RhYmxlOmE2YTUyNDdiYmRmZTQ1OGRiNTU4OTAyZDQ5ZGFjYzViL3RhYmxlcmFuZ2U6YTZhNTI0N2JiZGZlNDU4ZGI1NTg5MDJkNDlkYWNjNWJfNi0yLTEtMS04OTA3Mg_7f9f6761-42c4-444d-806f-d88504988201">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182NC9mcmFnOjU5NGZhYjcyMTcwZTQ1NjdiMDFiYTBmNjAxYmM3ZjUwL3RhYmxlOmE2YTUyNDdiYmRmZTQ1OGRiNTU4OTAyZDQ5ZGFjYzViL3RhYmxlcmFuZ2U6YTZhNTI0N2JiZGZlNDU4ZGI1NTg5MDJkNDlkYWNjNWJfNi00LTEtMS04OTA3Mg_cc1353be-e9e7-4e10-a964-a1da5a2ac168">98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182NC9mcmFnOjU5NGZhYjcyMTcwZTQ1NjdiMDFiYTBmNjAxYmM3ZjUwL3RhYmxlOmE2YTUyNDdiYmRmZTQ1OGRiNTU4OTAyZDQ5ZGFjYzViL3RhYmxlcmFuZ2U6YTZhNTI0N2JiZGZlNDU4ZGI1NTg5MDJkNDlkYWNjNWJfNy0yLTEtMS04OTA3Mg_f1f39691-c4b4-4779-a826-d508a52d9151">702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182NC9mcmFnOjU5NGZhYjcyMTcwZTQ1NjdiMDFiYTBmNjAxYmM3ZjUwL3RhYmxlOmE2YTUyNDdiYmRmZTQ1OGRiNTU4OTAyZDQ5ZGFjYzViL3RhYmxlcmFuZ2U6YTZhNTI0N2JiZGZlNDU4ZGI1NTg5MDJkNDlkYWNjNWJfNy00LTEtMS04OTA3Mg_dd6f7ad1-0c99-4464-b611-eb513df40a6b">749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182NC9mcmFnOjU5NGZhYjcyMTcwZTQ1NjdiMDFiYTBmNjAxYmM3ZjUwL3RhYmxlOmE2YTUyNDdiYmRmZTQ1OGRiNTU4OTAyZDQ5ZGFjYzViL3RhYmxlcmFuZ2U6YTZhNTI0N2JiZGZlNDU4ZGI1NTg5MDJkNDlkYWNjNWJfOC0yLTEtMS04OTA3Mg_a285d8d3-37a2-43de-a664-ba0e351fb3fb">4,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182NC9mcmFnOjU5NGZhYjcyMTcwZTQ1NjdiMDFiYTBmNjAxYmM3ZjUwL3RhYmxlOmE2YTUyNDdiYmRmZTQ1OGRiNTU4OTAyZDQ5ZGFjYzViL3RhYmxlcmFuZ2U6YTZhNTI0N2JiZGZlNDU4ZGI1NTg5MDJkNDlkYWNjNWJfOC00LTEtMS04OTA3Mg_a811e871-8e8d-468f-bdc0-ba4adfbdaa02">4,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i801c461cbd33492a893c84373a8e7cbc_67"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTk1NjY_55aa3025-0a10-4d0d-a069-31e6e7ffad0e" continuedAt="if56461a2168e4f8d9347b0581d579e22" escape="true">FINANCING ARRANGEMENTS</ix:nonNumeric></span></div><ix:continuation id="if56461a2168e4f8d9347b0581d579e22" continuedAt="i4868a71bcc024e68bcd84a16bef2ad80"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTk1Njg_56b5e9b3-9869-4929-aea4-3f32010a437e" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs consist of the following: </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Credit Facilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76f9207c1db94dfbacf80f2bc2b52b0d_I20220331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMy00LTEtMS04OTA3Mg_fe888f9c-a59f-4e58-b338-7ff63cfcda85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76f9207c1db94dfbacf80f2bc2b52b0d_I20220331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMy02LTEtMS04OTA3Mg_12eba395-1ea3-4687-acee-018dae0612b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06779efa67a44834b0f4f24944444a1b_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMy04LTEtMS04OTA3Mg_8c46ac14-5d1e-431a-9c0d-12094e427e27">285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06779efa67a44834b0f4f24944444a1b_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMy0xMC0xLTEtODkwNzI_466b4d54-4e2f-44cb-b422-467823ba4f02">285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i782e0885b3064787aa9e926150c70157_I20220331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfNC00LTEtMS04OTA3Mg_3381560e-c59a-4296-b8b0-8e7527937bcb">2,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i782e0885b3064787aa9e926150c70157_I20220331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfNC02LTEtMS04OTA3Mg_d261d49b-b2d1-48af-8d1c-8ee69c7e0fc7">2,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc86294f39b245aebaa7bec35dc0f511_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfNC04LTEtMS04OTA3Mg_f81b18e0-ea65-484e-8cf2-3685d6a2ff75">2,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc86294f39b245aebaa7bec35dc0f511_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfNC0xMC0xLTEtODkwNzI_4b282a0e-9948-4418-90f5-57cb43e98ee5">2,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54411522c1a245de9350f74e2cd4c3d1_I20220331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfNS00LTEtMS04OTA3Mg_99a2ec0c-0eae-4027-a94f-bb763cf9f8e8">994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54411522c1a245de9350f74e2cd4c3d1_I20220331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfNS02LTEtMS04OTA3Mg_3ae0111e-0da9-4d3f-ba23-d293060dc54f">985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1632bbe90c084a8bbad28b27f64c1f85_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfNS04LTEtMS04OTA3Mg_4d324e1a-9cdf-4af2-9318-2133aaacd748">994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1632bbe90c084a8bbad28b27f64c1f85_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfNS0xMC0xLTEtODkwNzI_fd07aa38-51e0-4150-9b71-d92ffb8d9536">984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic53f52344dcd464f82fdd9233f9e3fbb_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfOC0wLTEtMS04OTA3Mi90ZXh0cmVnaW9uOjkxNTc1ZGNmMmZjODRkOWE4YWUyNmI4YzA2OTg1NmU4XzQ_288a7759-a31b-4e05-9bb0-1e0206e9f449">5.50</ix:nonFraction>% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic53f52344dcd464f82fdd9233f9e3fbb_I20220331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfOC00LTEtMS04OTA3Mg_22564be4-84e4-4efc-9665-ed8bed40b965">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic53f52344dcd464f82fdd9233f9e3fbb_I20220331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfOC02LTEtMS04OTA3Mg_0eeed0b4-3f2a-45ef-9063-54b3fc65525f">1,740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i488c2864915b43b0b468383a88a34995_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfOC04LTEtMS04OTA3Mg_a8cfffbd-c2f3-4126-853d-6b27e8595f07">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i488c2864915b43b0b468383a88a34995_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfOC0xMC0xLTEtODkwNzI_463ad2f6-ab66-4ff1-9aec-a1205be46889">1,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i09bbf996de02471991c5b856e064297d_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfOS0wLTEtMS05MzQxMy90ZXh0cmVnaW9uOjVjZTk2ZmFjMjg4MzRkNzNiOTU2YzRkZWY2OWRkZTc4XzE2NDkyNjc0NDE2OTQ_15d04dec-ea40-41ab-b696-e9fc56febb54">6.125</ix:nonFraction>% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09bbf996de02471991c5b856e064297d_I20220331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfOS00LTEtMS05MzQwMw_08d7265b-76f8-4d97-b4d9-bd7578a6fd74">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09bbf996de02471991c5b856e064297d_I20220331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfOS02LTEtMS05MzQwMw_540c58ed-94b8-48bb-91ce-0cbe3c226b93">986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ba04ab2a63c40b39e946e401067a3d9_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfOS04LTEtMS05MzQwMw_70acc2e7-6981-4125-8486-d8fe1b2a6a91">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ba04ab2a63c40b39e946e401067a3d9_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfOS0xMC0xLTEtOTM0MDM_23400e97-94cb-40aa-b248-f538942df38f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icfa4659d82fd4e9583cb868b85c3feab_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfOS0wLTEtMS04OTA3Mi90ZXh0cmVnaW9uOjRlMmQ0MGRiMjBiMDRjOGFhODIyNTU2M2Q4OTU5MmJjXzQ_6901e661-c1ac-4ae7-80ef-1bb67d1f9296">5.75</ix:nonFraction>% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfa4659d82fd4e9583cb868b85c3feab_I20220331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfOS00LTEtMS04OTA3Mg_3d29c69c-9c7c-4610-9b07-6d73eda3292d">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfa4659d82fd4e9583cb868b85c3feab_I20220331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfOS02LTEtMS04OTA3Mg_7eb4757b-f5a7-48e1-92fe-275040868b29">495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9b94284819448b1933c562ef7aded08_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfOS04LTEtMS04OTA3Mg_db2c6c76-e89e-454f-87ce-2cf53911e708">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9b94284819448b1933c562ef7aded08_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfOS0xMC0xLTEtODkwNzI_c2457a1c-fdc3-4973-9a9a-d29ba53a4bf1">495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2abc875715cb4b1fa661daa27ac2f5af_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTAtMC0xLTEtODkwNzIvdGV4dHJlZ2lvbjo5YWQ1YzQ4NGQzNjc0ZjBjYmI0ZWFhNjg2MTBkYzQ1ZF80_c1f56975-77cd-434b-882b-d3b0afd97f4d">4.875</ix:nonFraction>% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abc875715cb4b1fa661daa27ac2f5af_I20220331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTAtNC0xLTEtODkwNzI_a2438bd5-b52f-4d4e-9005-b325d9a78f27">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abc875715cb4b1fa661daa27ac2f5af_I20220331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTAtNi0xLTEtODkwNzI_1efd8306-0d5b-456b-8425-948959805433">1,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic574f713857543fe848f75d40d04e380_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTAtOC0xLTEtODkwNzI_2f04d12c-0bc8-47b3-8853-8ea273d31d82">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic574f713857543fe848f75d40d04e380_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTAtMTAtMS0xLTg5MDcy_0d35d2b4-0e34-41fc-af39-8dff642c6e04">1,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i379ff2b3df7445b5b936e826c3995957_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTItMC0xLTEtODkwNzIvdGV4dHJlZ2lvbjplYjY1NDNkMjY1OTk0MWYzYWNmNjRhNWRjMjllMzUwYV80_472c0a85-35c6-46dc-b060-4e8397c0f00e">6.125</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i379ff2b3df7445b5b936e826c3995957_I20220331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTItNC0xLTEtODkwNzI_82dd316d-1315-48db-aefe-6bfbfab6db82">2,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i379ff2b3df7445b5b936e826c3995957_I20220331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTItNi0xLTEtODkwNzI_457e08d5-f170-468b-95f2-19e9d88162a2">2,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i247336064728420fafc7c84febff7ebc_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTItOC0xLTEtODkwNzI_df3e7d2e-1b93-48d0-8121-1e8175dbee9e">2,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i247336064728420fafc7c84febff7ebc_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTItMTAtMS0xLTg5MDcy_70d26337-7132-4d23-b2c7-4ebfd7f1e0b1">2,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib2f961c12b854470a0cc36e07e92006e_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTMtMC0xLTEtODkwNzIvdGV4dHJlZ2lvbjphZmU0YTZkYmJmYjI0Nzc5OTI1MDUwYWZlZWRhZjEwN180_9af6e74c-c446-46bb-b278-e8a9a54c7899">9.00</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2f961c12b854470a0cc36e07e92006e_I20220331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTMtNC0xLTEtODkwNzI_b0b679ce-70f1-412a-959c-ccc18b54ded2">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2f961c12b854470a0cc36e07e92006e_I20220331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTMtNi0xLTEtODkwNzI_ceea6daf-2622-441a-9ade-a3e141d159e0">1,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7146a1406b5149a0897a90ac7344b1bb_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTMtOC0xLTEtODkwNzI_22a0a136-5de9-437f-a520-5222d7c76e5e">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7146a1406b5149a0897a90ac7344b1bb_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTMtMTAtMS0xLTg5MDcy_a78dbe6d-9477-4ae8-82f0-a286e766acfc">1,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1b4545d9fb57437bbacc0e55479da783_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTQtMC0xLTEtODkwNzIvdGV4dHJlZ2lvbjpkNGYzNjA1MzRlODc0OWQ1OTdmYTg4NmU0ZWUxZGMyMl80_931d978d-ed36-4b0f-b5ee-6efdf4acf3fe">9.25</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b4545d9fb57437bbacc0e55479da783_I20220331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTQtNC0xLTEtODkwNzI_1416fef8-fe1f-464f-86b4-9d7941994925">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b4545d9fb57437bbacc0e55479da783_I20220331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTQtNi0xLTEtODkwNzI_dd83b562-94cf-43b7-b1b6-b0bdb25f5ae3">1,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f68bb5402fa40aaa3d1e8a5876a1481_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTQtOC0xLTEtODkwNzI_693c00f9-b02d-4067-a406-6e3da7df2e0f">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f68bb5402fa40aaa3d1e8a5876a1481_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTQtMTAtMS0xLTg5MDcy_735fcde5-6839-4903-9f04-42afb7ddeb0a">1,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6b5e0bf7441145f3a22ac4510e73101b_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTUtMC0xLTEtODkwNzIvdGV4dHJlZ2lvbjplMDE4YjZhZDgxZTE0YzA5YjZjYmJkZTVmYjJiNWY1MV80_7ee06571-bdad-420c-b27d-4820a1ffe2ac">8.50</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b5e0bf7441145f3a22ac4510e73101b_I20220331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTUtNC0xLTEtODkwNzI_c00621f0-70a9-454b-9c17-5908ea02a3b8">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b5e0bf7441145f3a22ac4510e73101b_I20220331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTUtNi0xLTEtODkwNzI_35224b34-d725-46cd-965b-21be94491e99">1,754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia02b8e8095664970aeeda0fcc527bb86_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTUtOC0xLTEtODkwNzI_2afc085d-e85e-4167-bb77-875b9a3d9e14">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia02b8e8095664970aeeda0fcc527bb86_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTUtMTAtMS0xLTg5MDcy_433b673f-5868-4426-91da-f72eb94f003b">1,754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5833ace0facf472a8cf1a49a6becbe8d_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTYtMC0xLTEtODkwNzIvdGV4dHJlZ2lvbjpkODhhZGE3OGMzMWY0YzM1YmI0NGZiYTE5Zjk4ZjZiOF80_d2abc2d7-cdfc-49b0-829d-a1f6f655b3f8">7.00</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5833ace0facf472a8cf1a49a6becbe8d_I20220331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTYtNC0xLTEtODkwNzI_a27f1d66-b6bd-45b4-9921-0ec4c4779a2e">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5833ace0facf472a8cf1a49a6becbe8d_I20220331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTYtNi0xLTEtODkwNzI_838e475f-7812-4fea-8045-6dccddff3878">743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4758100c83ee4d7f82d179bcb44516dd_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTYtOC0xLTEtODkwNzI_1260d079-b593-4ac6-910f-b4ebadd54ec6">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4758100c83ee4d7f82d179bcb44516dd_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTYtMTAtMS0xLTg5MDcy_11338064-18ee-49bc-8a0e-4162acf2aa4e">743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icb63f20c4f224de380f590b991ab70bd_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTctMC0xLTEtODkwNzIvdGV4dHJlZ2lvbjo4OTJmNTIxYjZlYmQ0YmE5YjM5YmVlODJmOTFiYzc5MV80_90a017a9-263e-496d-8eaf-1a11eddc1dc8">5.00</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb63f20c4f224de380f590b991ab70bd_I20220331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTctNC0xLTEtODkwNzI_c27b60cb-f219-4496-903a-6a32de2d515f">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb63f20c4f224de380f590b991ab70bd_I20220331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTctNi0xLTEtODkwNzI_2224737f-058c-412b-81f1-08f8a2aa299b">1,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6a900b7cea44342b2ebea58f9a1a829_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTctOC0xLTEtODkwNzI_a4b62ea0-8b2c-4bee-a62f-cd701fef4644">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6a900b7cea44342b2ebea58f9a1a829_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTctMTAtMS0xLTg5MDcy_4b7625cd-3c84-4ace-94f9-bce44cea4afb">1,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0a9e5ff5b17847ae8c5b4a20045b80a7_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTgtMC0xLTEtODkwNzIvdGV4dHJlZ2lvbjplNWEyMGZmZTFhMmQ0Y2VkYTZiZGE0YWU3Mjg1MTVmNV80_cb2775a0-d07e-4095-99c2-ce98b6dbb168">6.25</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a9e5ff5b17847ae8c5b4a20045b80a7_I20220331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTgtNC0xLTEtODkwNzI_7c52ef51-c087-466c-8c92-a279a3ea329e">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a9e5ff5b17847ae8c5b4a20045b80a7_I20220331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTgtNi0xLTEtODkwNzI_aaa6d7fb-e5cf-4ebf-8dee-e969de2fde31">1,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa9fb491c6f44e0494c78843ae2d7d07_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTgtOC0xLTEtODkwNzI_32bb3e2d-c836-4242-ac93-c7339da58e12">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa9fb491c6f44e0494c78843ae2d7d07_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTgtMTAtMS0xLTg5MDcy_0c90b3c4-fc8b-42d9-b805-c4006b36923f">1,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic9d48b1e660749f7a7367bb5dc150e1b_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTktMC0xLTEtODkwNzI_70ce870a-f4fa-4e1e-998f-038df23d8bfc">5.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9d48b1e660749f7a7367bb5dc150e1b_I20220331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTktNC0xLTEtODkwNzI_2bb64a4a-cc87-4368-95f2-80b16b3a2108">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9d48b1e660749f7a7367bb5dc150e1b_I20220331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTktNi0xLTEtODkwNzI_7094bf2d-e9eb-4485-a631-a6e797660d2c">990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ab99de7a1954ce6996bda7caf7833a8_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTktOC0xLTEtODkwNzI_86e75585-d0eb-4670-8472-9d88e34d99bc">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ab99de7a1954ce6996bda7caf7833a8_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTktMTAtMS0xLTg5MDcy_b7f83aef-de8d-42f7-bcb6-185000c3f208">990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib88817449df74848a8baeff6c02361f9_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjAtMC0xLTEtODkwNzIvdGV4dHJlZ2lvbjo3NjA5M2MwMjEyZWI0ZmUyOTcyMDk4ZDljYTBkMjNkZl80_2fe58e5e-19db-42b5-b100-14974d1356fe">7.25</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib88817449df74848a8baeff6c02361f9_I20220331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjAtNC0xLTEtODkwNzI_6fbb7bd4-5297-4638-9466-2e5dd6e5dee6">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib88817449df74848a8baeff6c02361f9_I20220331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjAtNi0xLTEtODkwNzI_6c6c9b23-a3bf-4821-864e-1abfa8de1fb4">743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4341fd255afd4b2f98811eb433952df1_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjAtOC0xLTEtODkwNzI_bf095778-aaf9-481b-8e9b-21193c55762f">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4341fd255afd4b2f98811eb433952df1_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjAtMTAtMS0xLTg5MDcy_b863272a-60f7-45d1-9893-d7019f48dbb6">742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i51f3dd4e5a524f1bbf10cd1a0055202c_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjEtMC0xLTEtODkwNzIvdGV4dHJlZ2lvbjpkMTM4MzZkNTNhMzI0NTBlYmEyODJkYzNhMGY3YTI4OF80_5497538c-5819-489d-8a26-5832d8ab6525">5.25</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51f3dd4e5a524f1bbf10cd1a0055202c_I20220331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjEtNC0xLTEtODkwNzI_5ff71bdd-b141-473c-a390-795fea864330">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51f3dd4e5a524f1bbf10cd1a0055202c_I20220331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjEtNi0xLTEtODkwNzI_1ad3cd5b-8609-4581-a423-16197760dd95">1,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee2ed402ff54a6f843446ee188a72d8_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjEtOC0xLTEtODkwNzI_bca4165a-e2de-4b9b-8b0d-42ccda86ba09">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee2ed402ff54a6f843446ee188a72d8_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjEtMTAtMS0xLTg5MDcy_d64b5077-b52c-4eed-9db9-baa8b4f3380e">1,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if151bdb884d34ff6b871d14b1339db96_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjItMC0xLTEtODkwNzI_11e715de-e8a1-4b2b-b6f4-2d2bec164e2f">5.25</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if151bdb884d34ff6b871d14b1339db96_I20220331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjItNC0xLTEtODkwNzI_0d5b9232-f5c5-4c71-9ff8-5f7816517b97">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if151bdb884d34ff6b871d14b1339db96_I20220331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjItNi0xLTEtODkwNzI_1d5ca0d5-f947-4720-9592-537eac69e906">990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i504ae7293b234304b31a5f5ef8da3011_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjItOC0xLTEtODkwNzI_b2a01c9b-b8a2-4312-93a7-84e6318f6646">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i504ae7293b234304b31a5f5ef8da3011_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjItMTAtMS0xLTg5MDcy_1f84a327-be92-44aa-9a1f-de033d7bee95">989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if31b5959255941138da93ebd548669bb_I20220331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjMtNC0xLTEtODkwNzI_87abbdf4-681a-4fe3-8ab4-ab7c6222c1ef">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if31b5959255941138da93ebd548669bb_I20220331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjMtNi0xLTEtODkwNzI_27768a34-6f3a-4884-a70f-62b0b862132d">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cee80bfcbe74e0c8421a1c67604dccd_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjMtOC0xLTEtODkwNzI_a555f3e4-2f30-4fa4-9b60-22f04d0def04">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cee80bfcbe74e0c8421a1c67604dccd_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjMtMTAtMS0xLTg5MDcy_79aa8c1a-2844-4cd7-8eb9-e2bb6ff0d806">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjQtNC0xLTEtODkwNzI_3073f3f4-f28e-4b01-bdbd-501a556d1ecb">23,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjQtNi0xLTEtODkwNzI_990b78f3-7cf0-4fee-81a9-967768f87697">23,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjQtOC0xLTEtODkwNzI_45471997-fae5-4118-a106-4b7d250597d5">22,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjQtMTAtMS0xLTg5MDcy_91885a60-bc2a-44fc-9714-53c05b2fa8bd">22,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjUtNi0xLTEtODkwNzI_18eefa7b-afc6-430a-8575-54552d86e1c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjUtMTAtMS0xLTg5MDcy_a9782ead-8094-4703-b319-4abd7cb1b0e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjYtNi0xLTEtODkwNzI_fe25b7e2-2614-40a9-b569-b866bcf656f9">23,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjYtMTAtMS0xLTg5MDcy_61cd208e-ecb5-430a-b67e-e0378871a03a">22,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Covenant Compliance</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Credit Facilities (as defined below) and the indentures governing the Senior Secured Notes and Senior Unsecured Notes contain customary affirmative and negative covenants and specified events of default. These affirmative </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i4868a71bcc024e68bcd84a16bef2ad80" continuedAt="i8c6d3e8643cd4a93a373d6b20f0f2e7e"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and negative covenants include, among other things, and subject to certain qualifications and exceptions, covenants that restrict the Company&#8217;s ability and the ability of its subsidiaries to: incur or guarantee additional indebtedness; create or permit liens on assets; pay dividends on capital stock or redeem, repurchase or retire capital stock or subordinated indebtedness; make certain investments and other restricted payments; engage in mergers, acquisitions, consolidations and amalgamations; transfer and sell certain assets; and engage in transactions with affiliates. As of March&#160;31, 2022, the amount available for restricted payments under the &#8220;builder basket&#8221; in the Company&#8217;s most restrictive indentures (as defined by those indentures) was approximately $<ix:nonFraction unitRef="usd" contextRef="i3baf0d17d1ce4fb09e14886b74b202be_I20220331" decimals="-6" name="bhc:DebtInstrumentCovenantAmountAvailableForRestrictedPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTIwMQ_58c19394-416c-4c68-9ab4-e801d9965526">13,900</ix:nonFraction>&#160;million (although such availability is subject to the Company&#8217;s compliance with a <ix:nonFraction unitRef="number" contextRef="ibd8b2b705a834db0850fd8a5ff15144a_I20220331" decimals="INF" name="bhc:DebtInstrumentCovenantTermsFixedChargeCoverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTI3OA_6c9d0336-4fc9-4a81-ac26-09326bf43ce9">2.00</ix:nonFraction>:1.00 fixed charge coverage ratio). The 2023 Revolving Credit Facility (as defined below) also contains a financial maintenance covenant that, prior to giving effect to the Second Amendment (as defined below), required the Company to maintain a first lien net leverage ratio of not greater than <ix:nonFraction unitRef="number" contextRef="ibd8b2b705a834db0850fd8a5ff15144a_I20220331" decimals="INF" name="bhc:DebtInstrumentCovenantComplianceSecuredLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTUwNw_c73c5d33-79f1-44df-831c-a939fdaef05d">4.00</ix:nonFraction>:1.00. The financial maintenance covenant may be waived or amended without the consent of the term loan facility lenders and contains a customary term loan facility standstill.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, the Company was in compliance with its financial maintenance covenant related to its debt obligations. The Company, based on its current forecast for the next twelve months from the date of issuance of these financial statements, expects to remain in compliance with its financial maintenance covenant and meet its debt service obligations over that same period. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to take steps to improve its operating results to ensure continual compliance with its financial maintenance covenant and may take other actions to reduce its debt levels to align with the Company&#8217;s long-term strategy, including divesting other businesses, refinancing debt and issuing equity or equity-linked securities as deemed appropriate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Secured Credit Facilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2018, the Company and certain of its subsidiaries as guarantors entered into the &#8220;Senior Secured Credit Facilities&#8221; under the Company&#8217;s Fourth Amended and Restated Credit and Guaranty Agreement, as amended by the First Incremental Amendment to the Restated Credit Agreement, dated as of November 27, 2018 (the &#8220;2018 Restated Credit Agreement&#8221;) with a syndicate of financial institutions and investors as lenders. Prior to the Second Amendment (as defined below), the 2018 Restated Credit Agreement provided for a revolving credit facility of $<ix:nonFraction unitRef="usd" contextRef="i6c325805e88f46bb919acf58b5da907e_I20180601" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMjk0Ng_1525bb68-ad51-451f-b1ca-1cd4ab1ea7a4">1,225</ix:nonFraction> million, maturing on the earlier of June 1, 2023 and the date that is <ix:nonNumeric contextRef="ic7609d2be3db44f5af9ae6b7c8e642b7_D20180601-20180601" name="bhc:DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMzAxNg_76965e29-82c5-4099-bf87-c4afc3fcc0c7">91</ix:nonNumeric> calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company and Bausch Health Americas, Inc. (&#8220;BHA&#8221;) in an aggregate principal amount in excess of $<ix:nonFraction unitRef="usd" contextRef="i6c325805e88f46bb919acf58b5da907e_I20180601" decimals="INF" name="bhc:DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMzIwMg_acdddc1b-1287-4332-ad63-d04f89d320d6">1,000</ix:nonFraction> million (the &#8220;2023 Revolving Credit Facility&#8221;) and term loan facilities of original principal amounts of $<ix:nonFraction unitRef="usd" contextRef="i805461905703413cb5837246f45f0ab6_I20180601" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMzMwMg_03b0b056-f70e-46d4-a8b5-aad7ab573602">4,565</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9f9d786ce6b041f08ba221a702f7956d_I20180601" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMzMwOQ_162563f5-2a9e-4280-a414-e4455821061b">1,500</ix:nonFraction> million, maturing in June 2025 (the &#8220;June 2025 Term Loan B Facility&#8221;) and November 2025 (the &#8220;November 2025 Term Loan B Facility"), respectively. Both the Company and BHA were borrowers with respect to the 2023 Revolving Credit Facility. Borrowings under the 2023 Revolving Credit Facility could be made in U.S. dollars or Canadian dollars (or if an amendment to the 2018 Restated Credit Agreement was made to replace LIBOR with an alternative benchmark rate with respect to borrowings under the Revolving Credit Facility denominated in euros, euros). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Description of Senior Secured Credit Facilities as of March 31, 2022</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following description describes the 2018 Restated Credit Agreement as in effect on March 31, 2022, prior to giving effect to the Second Amendment (as defined below). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Senior Secured Credit Facilities in U.S. dollars bear interest at a rate per annum equal to, at the Company&#8217;s option, either: (i) a base rate determined by reference to the highest of: (a) the prime rate (as defined in the 2018 Restated Credit Agreement), (b) the federal funds effective rate plus 1/2 of 1.00% or (c) the eurocurrency rate (as defined in the 2018 Restated Credit Agreement) for a period of one month plus <ix:nonFraction unitRef="number" contextRef="i9ec4d9258ade4c988572b72ab0b9bcda_D20220101-20220331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNDA5Ng_e8dcf7af-697c-40b6-a314-341f6a8111bf">1.00</ix:nonFraction>% (or if such eurocurrency rate shall not be ascertainable, <ix:nonFraction unitRef="number" contextRef="i9ec4d9258ade4c988572b72ab0b9bcda_D20220101-20220331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNDE1Nw_bcd56faa-481d-4cfe-aa50-40c5d83c88c2">1.00</ix:nonFraction>%) or (ii) a eurocurrency rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing adjusted for certain additional costs (provided, however, that the eurocurrency rate shall at no time be less than <ix:nonFraction unitRef="number" contextRef="i50ea92505146474394a150389011b6f2_D20220101-20220331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNDQyNg_382719af-f27b-47c3-8a17-81c6f39b80dd">0.00</ix:nonFraction>% per annum), in each case plus an applicable margin. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2023 Revolving Credit Facility in euros, when available, are expected to bear interest at a term benchmark rate determined by reference to the costs of funds for euro deposits for the interest period relevant to such borrowing (provided, however, that the eurocurrency rate is at no time expected to be less than <ix:nonFraction unitRef="number" contextRef="i87085be380954b8f8d3c8aca38e1f32f_D20220101-20220331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNDc3Mg_506dfa18-d17b-4b79-a349-07354cd6e5d1">0.00</ix:nonFraction>% per annum), plus an applicable margin. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2023 Revolving Credit Facility in Canadian dollars bear interest at a rate per annum equal to, at the Company&#8217;s option, either: (i) a prime rate determined by reference to the higher of: (a) the rate of interest last quoted by The Wall Street Journal as the &#8220;Canadian Prime Rate&#8221; or, if The Wall Street Journal ceases to quote such rate, the highest per annum interest rate published by the Bank of Canada as its prime rate and (b) the 1 month BA rate (as defined below) calculated daily plus <ix:nonFraction unitRef="number" contextRef="i3f1641e5674c4a75b682c9b185796d5c_D20220101-20220331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNTMyOQ_56422655-09d9-4232-aafc-a83ed2cff1d5">1.00</ix:nonFraction>% (provided, however, that the prime rate shall at no time be less than <ix:nonFraction unitRef="number" contextRef="i9578b054a9c3434d956829eb311cdcd5_D20220101-20220331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNTQwMg_bf8c8cad-55dc-4a4f-8a0d-416f3252dd13">0.00</ix:nonFraction>%) or (ii) the bankers&#8217; acceptance rate for Canadian dollar deposits in the Toronto interbank market (the &#8220;BA rate&#8221;) for the interest period relevant to such borrowing (provided, however, that the BA rate shall at no time be less than <ix:nonFraction unitRef="number" contextRef="i9578b054a9c3434d956829eb311cdcd5_D20220101-20220331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNTYzOA_446a3bb7-cff1-4a3e-8c3d-7cb57bb19118">0.00</ix:nonFraction>% per annum), in each case plus an applicable margin.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i8c6d3e8643cd4a93a373d6b20f0f2e7e" continuedAt="ie7270780bc1a4c8ab271bfc6f17877cf"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions and customary baskets set forth in the 2018 Restated Credit Agreement, the Company is required to make mandatory prepayments of the loans under the Senior Secured Credit Facilities under certain circumstances, including from: (i)&#160;<ix:nonFraction unitRef="number" contextRef="i615747c5edca4f728ff0d5d6e3cdb38d_D20220101-20220331" decimals="INF" name="bhc:DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNTk0OA_8024e04d-858b-4898-9f64-517c304a16ea">100</ix:nonFraction>% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold), (ii)&#160;<ix:nonFraction unitRef="number" contextRef="i615747c5edca4f728ff0d5d6e3cdb38d_D20220101-20220331" decimals="INF" name="bhc:DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNjExMA_c8f3d6c2-66cb-4f40-8c85-b4598611d399">100</ix:nonFraction>% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the 2018 Restated Credit Agreement), (iii)&#160;<ix:nonFraction unitRef="number" contextRef="i615747c5edca4f728ff0d5d6e3cdb38d_D20220101-20220331" decimals="INF" name="bhc:DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNjI0Nw_b9648f0b-bfe4-4bd3-b956-ff609b3a3967">50</ix:nonFraction>% of Excess Cash Flow (as&#160;defined in the 2018 Restated Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv)&#160;<ix:nonFraction unitRef="number" contextRef="i615747c5edca4f728ff0d5d6e3cdb38d_D20220101-20220331" decimals="INF" name="bhc:DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNjQwNA_86d34293-ab6d-4d5a-a942-e394b998d83e">100</ix:nonFraction>% of net cash proceeds from asset sales (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold). These mandatory prepayments may be used to satisfy future amortization.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margins for the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility are <ix:nonFraction unitRef="number" contextRef="ibb673f79152245ccaaa71c72c83aca5f_D20220101-20220331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNjYxNA_3b63623e-d6d7-4256-9a36-1e2e74cb0d33">2.00</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="if9f46032075146bb974b5459828d0837_D20220101-20220331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNjYyMQ_b5b73469-3dde-4c90-9204-bd524d2cd477">1.75</ix:nonFraction>%, respectively, with respect to base rate and prime rate borrowings and <ix:nonFraction unitRef="number" contextRef="iebb71b6e150a4d3583b70be11293ebbb_D20220101-20220331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNjY5NQ_a1ea0d0d-b6e1-4b76-bb9c-c01857b834c6">3.00</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i88f4e8e6d2a74bb3bbf6df6210d11118_D20220101-20220331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNjcwMg_559fd51a-1b4b-44b2-af05-913ba5618eeb">2.75</ix:nonFraction>%, respectively, with respect to eurocurrency rate and BA rate borrowings. As of March 31, 2022, the stated rates of interest on the Company&#8217;s borrowings under the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility were <ix:nonFraction unitRef="number" contextRef="i782e0885b3064787aa9e926150c70157_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNjg2OA_add41a76-fd12-4f0e-8d8a-1f3a11e16102">3.21</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i54411522c1a245de9350f74e2cd4c3d1_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNjg3NQ_ba860b99-5278-4b00-adf8-c86455ad8af2">2.96</ix:nonFraction>% per annum, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortization rate for both the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility is <ix:nonFraction unitRef="number" contextRef="i54411522c1a245de9350f74e2cd4c3d1_I20220331" decimals="INF" name="bhc:DebtInstrumentAnnualAmortizationRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNjk1NQ_468e20f9-f22f-4847-91fc-ae236e94726b"><ix:nonFraction unitRef="number" contextRef="i782e0885b3064787aa9e926150c70157_I20220331" decimals="INF" name="bhc:DebtInstrumentAnnualAmortizationRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNjk1NQ_d1f1b011-dd1c-47ac-9318-8ead563ca266">5.00</ix:nonFraction></ix:nonFraction>% per annum. The Company may direct that prepayments be applied to such amortization payments in order of maturity. As of March 31, 2022, there were <ix:nonFraction unitRef="usd" contextRef="ifce02581a2a24dcf8c3af7034d61d45b_D20220331-20220331" decimals="INF" name="bhc:DebtInstrumentPeriodicPaymentQuarterlyAmortization" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNzA4Nw_b11f2d71-44c6-4537-b58f-2f7b361bbe1e">no</ix:nonFraction> remaining mandatory quarterly amortization payments for the Senior Secured Credit Facilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margins for borrowings under the 2023 Revolving Credit Facility are <ix:nonFraction unitRef="number" contextRef="i20665638c329437cab38c53e8d90d29b_D20220101-20220331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNzI4MQ_b3526a1a-4451-495f-aea6-c6ab0dd3ad30">1.50</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i15c4387da4984e3890700c3445ff56f7_D20220101-20220331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNzI4NA_13fb0a9e-aa06-4241-a204-79638690aa1f">2.00</ix:nonFraction>% with respect to base rate or prime rate borrowings and <ix:nonFraction unitRef="number" contextRef="ibd749185fb814c7eb0ea4622273efa10_D20220101-20220331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNzM0Mg_ca0ff2f1-9a64-410c-85e1-c6d285b77839">2.50</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i2b1c2edd6efe487a80e89a2e9dfacbc3_D20220101-20220331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNzM0NQ_2cf8d677-c1f4-4b20-b585-e641795bdce6">3.00</ix:nonFraction>% with respect to eurocurrency rate or BA rate borrowings. As of March 31, 2022, the stated rate of interest on the 2023 Revolving Credit Facility was <ix:nonFraction unitRef="number" contextRef="i76f9207c1db94dfbacf80f2bc2b52b0d_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNzQ4MA_ebfc81d0-9400-49ce-a49d-4e136dd7be98">2.96</ix:nonFraction>% per annum. As of March&#160;31, 2022, the Company had <ix:nonFraction unitRef="usd" contextRef="i76f9207c1db94dfbacf80f2bc2b52b0d_I20220331" decimals="INF" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNzUyMA_1a992a18-b0f4-455f-9e5b-1e1befad0a00">no</ix:nonFraction> outstanding borrowings, $<ix:nonFraction unitRef="usd" contextRef="ie92612a0f96b4f89b84ac22fb594d512_I20220331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNzU0Nw_37b7c9fa-cfa1-4a8e-b4c7-d174365fd09b">54</ix:nonFraction> million of issued and outstanding letters of credit and remaining availability of $<ix:nonFraction unitRef="usd" contextRef="i76f9207c1db94dfbacf80f2bc2b52b0d_I20220331" decimals="-6" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNzYyNA_aa119e01-55a6-4396-a41e-c41c92e5296d">1,171</ix:nonFraction> million under its 2023 Revolving Credit Facility. In addition, the Company is required to pay commitment fees of <ix:nonFraction unitRef="number" contextRef="i891a2d21f1024827aa29f1df940ffbb3_D20220101-20220331" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNzczMg_8dc705e2-b071-4bb4-890c-a6ebc0a83bf3">0.25</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="ib8602535e6b14704b3f07b216531b82d_D20220101-20220331" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNzczNQ_2844464e-ee65-4884-a63a-9f90551b70c1">0.50</ix:nonFraction>% per annum with respect to the unutilized commitments under the 2023 Revolving Credit Facility, payable quarterly in arrears. The Company also is required to pay: (i) letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on eurocurrency rate borrowings under the 2023 Revolving Credit Facility on a per annum basis, payable quarterly in arrears, (ii) customary fronting fees for the issuance of letters of credit and (iii) agency&#160;fees.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2018 Restated Credit Agreement permits the incurrence of incremental credit facility borrowings up to the greater of $<ix:nonFraction unitRef="usd" contextRef="ibd8b2b705a834db0850fd8a5ff15144a_I20220331" decimals="INF" name="bhc:LineOfCreditFacilityThresholdForIncrementalBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfODM4NQ_361ba02e-c35a-4a6f-94c0-088fae091a1b">1,000</ix:nonFraction> million and <ix:nonFraction unitRef="number" contextRef="ibd8b2b705a834db0850fd8a5ff15144a_I20220331" decimals="INF" name="bhc:LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfODM5Mg_341fad45-d3dd-4fd2-8bc4-4f209389eacb">28.5</ix:nonFraction>% of Consolidated Adjusted EBITDA (non-GAAP) (as defined in the 2018 Restated Credit Agreement), subject to customary terms and conditions, as well as the incurrence of additional incremental credit facility borrowings subject to, in the case of secured debt, a secured leverage ratio of not greater than <ix:nonFraction unitRef="number" contextRef="i8a1cfa5016e04bb3a7bc13c20a921226_I20220331" decimals="INF" name="bhc:DebtInstrumentCovenantComplianceSecuredLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfODY2Mw_062b7c56-48b4-44eb-850a-4dfef41e5a6d">3.50</ix:nonFraction>:1.00, and, in the case of unsecured debt, either a total leverage ratio of not greater than <ix:nonFraction unitRef="number" contextRef="i730cebd5276140a781d756138d28a05d_I20220331" decimals="INF" name="bhc:DebtInstrumentCovenantTotalLeverageRatioMaximum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfODc0OQ_41bf1a75-8163-4483-b66c-e9afd0e4b4ba">6.50</ix:nonFraction>:1.00 or an interest coverage ratio of not less than <ix:nonFraction unitRef="number" contextRef="ibd8b2b705a834db0850fd8a5ff15144a_I20220331" decimals="INF" name="bhc:DebtInstrumentCovenantInterestCoverageRatioMinimum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfODgwMg_3c676794-b448-4bd5-9fe7-fd854efb351f">2.00</ix:nonFraction>:1.00.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As more fully discussed in Note 20, &#8220;SUBSEQUENT EVENTS&#8221;, on May 10, 2022 in connection with the B+L IPO, the Company completed a series of transactions in which among other things: (i) Bausch + Lomb entered into a new credit facility, (ii) the Company repaid certain amounts outstanding under its existing term B loans, (iii) the Company refinanced the remaining amounts outstanding under its credit facilities and (iv) the Company discharged the indenture governing the <ix:nonFraction unitRef="number" contextRef="i3525c40548924586bbd17234ab1c71c3_I20220510" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTY0OTI2NzQ0NzY1Mjc_8d665c34-d4ef-4214-8095-73452d08f215">6.125</ix:nonFraction>% Senior Unsecured Notes due 2025 (the &#8220;April 2025 Unsecured Notes&#8221; and the related indenture the &#8220;April 2025 Unsecured Notes Indenture&#8221;) with, among other sources, the net proceeds from the February 2027 Secured Notes (defined below). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Secured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes are guaranteed by each of the Company&#8217;s subsidiaries that is a guarantor under the 2018 Restated Credit Agreement and existing Senior Unsecured Notes (together, the &#8220;Note Guarantors&#8221;). In connection with the closing of the B+L IPO, the discharge of the 6.125% Notes Indenture and the related release in respect of the 2018 Restated Credit Agreement, the guarantees and related security provided by Bausch + Lomb and its subsidiaries in respect of the existing senior notes of the Company and BHA were released.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes and the guarantees related thereto are senior obligations and are secured, subject to permitted liens and certain other exceptions, by the same first priority liens that secure the Company&#8217;s obligations under the 2022 Restated Credit Agreement (as defined below) under the terms of the indentures governing the Senior Secured Notes. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes and the guarantees rank equally in right of repayment with all of the Company&#8217;s and Note Guarantors&#8217; respective existing and future unsubordinated indebtedness and senior to the Company&#8217;s and Note Guarantors&#8217; respective future subordinated indebtedness. The Senior Secured Notes and the guarantees related thereto are effectively </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">pari passu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the Company&#8217;s and the Note Guarantors&#8217; respective existing and future indebtedness secured by a first priority </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="ie7270780bc1a4c8ab271bfc6f17877cf" continuedAt="ia8819a681631490091dd11646e9f2584"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lien on the collateral securing the Senior Secured Notes and effectively senior to the Company&#8217;s and the Note Guarantors&#8217; respective existing and future indebtedness that is unsecured, including the existing Senior Unsecured Notes, or that is secured by junior liens, in each case to the extent of the value of the collateral. In addition, the Senior Secured Notes are structurally subordinated to: (i) all liabilities of any of the Company&#8217;s subsidiaries that do not guarantee the Senior Secured Notes and (ii) any of the Company&#8217;s debt that is secured by assets that are not collateral.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a change in control (as defined in the indentures governing the Senior Secured Notes), unless the Company has exercised its right to redeem all of the notes of a series, holders of the Senior Secured Notes may require the Company to repurchase such holder&#8217;s notes, in whole or in part, at a purchase price equal to <ix:nonFraction unitRef="number" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="INF" name="bhc:DebtInstrumentRedemptionPricePercentageChangeinControl" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTA3Nzk_ccade392-161d-47ca-85c7-1a3ca52b6f8e">101</ix:nonFraction>% of the principal amount thereof plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="iad4d39b309f5434c87cf47a080a1d040_I20210608" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTA4NDg_91340a77-1ad3-4aaf-8f45-18d5985800c3">4.875</ix:nonFraction>% Senior Secured Notes due 2028 - June 2021 Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 8, 2021, the Company issued $<ix:nonFraction unitRef="usd" contextRef="iad4d39b309f5434c87cf47a080a1d040_I20210608" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTA5NTQ_424d0248-d98d-4748-be20-f69396f4be4e">1,600</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="iad4d39b309f5434c87cf47a080a1d040_I20210608" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTA5ODc_91340a77-1ad3-4aaf-8f45-18d5985800c3">4.875</ix:nonFraction>% Senior Secured Notes due June 2028 (the &#8220;June 2028 Secured Notes&#8221;) in a private placement. The proceeds and cash on hand were used to: (i) repurchase a portion and redeem the remainder of $<ix:nonFraction unitRef="usd" contextRef="ibcbf9946c1974457a0c4173198dc2413_D20210608-20210608" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTExNzg_ab981e7a-a2e4-46ab-9e99-0ea2162b4a18">1,600</ix:nonFraction>&#160;million of <ix:nonFraction unitRef="number" contextRef="ia2fbd73a42e346bea819f0b583f98618_I20210608" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTExODQ_a0a48210-f14b-4c60-9d8d-6e34aabfe4bd">7.00</ix:nonFraction>% Senior Secured Notes due 2024 (the &#8220;March 2024 Secured Notes&#8221;), representing the remaining outstanding principal balance of the March 2024 Secured Notes and (ii) pay all fees and expenses associated with these transactions (collectively, the &#8220;June 2021 Refinancing Transactions&#8221;). The June 2021 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="i95e73196dfe44ca6bb964e033fa104f5_D20210608-20210608" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTE2MTY_44e3695c-02f1-47a7-9c0d-8efbbfd58f51">38</ix:nonFraction>&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#8217;s carrying value. Interest on the June 2028 Secured Notes is payable semi-annually in arrears on each June 1 and December 1.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The June 2028 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after June 1, 2024, at the redemption prices set forth in the June 2028 Secured Notes indenture. The Company may redeem some or all of the June 2028 Secured Notes prior to June 1, 2024 at a price equal to <ix:nonFraction unitRef="number" contextRef="i88e8d3f432e14718a0ba0ed393f9efbf_D20210608-20210608" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTIxNzE_46a57b00-7b3f-42fc-b415-59d558c432a5">100</ix:nonFraction>% of the principal amount thereof, plus accrued and unpaid interest to, but not including, the date of the redemption plus a &#8220;make-whole&#8221; premium. In addition, at any time prior to June 1, 2024, the Company may redeem up to <ix:nonFraction unitRef="number" contextRef="if8673b92629a48189ea708c9a312bfe5_D20210608-20210608" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTIzOTY_a4284ee9-b487-428d-9854-e00f5c170ca0">40</ix:nonFraction>% of the aggregate principal amount of the June 2028 Secured Notes using the net proceeds of certain equity offerings at the redemption price set forth in the June 2028 Secured Notes indenture.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="if16401eb786046228b3c642b80d44636_I20220210" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTY0OTI2NzQ2OTEwNg_80a190a5-0e66-4d95-8cca-08348a690ac6">6.125</ix:nonFraction>% Senior Secured Notes due 2027 - February 2022 Financing</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 10, 2022, the Company issued $<ix:nonFraction unitRef="usd" contextRef="if16401eb786046228b3c642b80d44636_I20220210" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTY0OTI2NzQ3MDA2Nw_c47df40f-d8aa-4300-9bff-d813cd303ec3">1,000</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="if16401eb786046228b3c642b80d44636_I20220210" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTA5OTUxMTY4MjExNQ_e46f2da0-472e-4620-9a97-43f4e9cede50">6.125</ix:nonFraction>% senior secured notes due February 2027 (the &#8220;February 2027 Secured Notes&#8221;). As discussed in further detail below, the proceeds from the February 2027 Secured Notes, along with proceeds from the B+L IPO, the 2027 Term Loans and the B+L Debt Financing (each as defined below) and cash on hand, were used to deposit funds sufficient to redeem in full all outstanding April 2025 Unsecured Notes and for the Credit Agreement Refinancing. The February 2027 Secured Notes accrue interest at a rate of <ix:nonFraction unitRef="number" contextRef="if16401eb786046228b3c642b80d44636_I20220210" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTA5OTUxMTY4MjEyNA_e46f2da0-472e-4620-9a97-43f4e9cede50">6.125</ix:nonFraction>% per year, payable semi-annually in arrears on each February and August. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The February 2027 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after February 2024, at the redemption prices set forth in the indenture. The Company may redeem some or all of the February 2027 Secured Notes prior to February 2024 at a price equal to <ix:nonFraction unitRef="number" contextRef="ie0fb622b80e1461e88f672d0cba387ac_D20220210-20220210" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTA0NDUzNjA1MTIzMTk_114c7f69-30c6-484f-8fad-a38cce263bfc">100</ix:nonFraction>% of the principal amount thereof plus a &#8220;make-whole&#8221; premium. Prior to February 2024, the Company may redeem up to <ix:nonFraction unitRef="number" contextRef="ida33ef4fd5a74725af4144c875055297_D20220210-20220210" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTA0NDUzNjA1MTIzMjU_c9d5b81c-c785-480a-ae71-14f6e7ebf48a">40</ix:nonFraction>% of the aggregate principal amount of the February 2027 Secured Notes using the proceeds of certain equity offerings at the redemption price set forth in the indenture.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Unsecured Notes</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Unsecured Notes issued by the Company are the Company&#8217;s senior unsecured obligations and are jointly and severally guaranteed on a senior unsecured basis by each of its subsidiaries that is a guarantor under the Senior Secured Credit Facilities. The Senior Unsecured Notes issued by BHA are senior unsecured obligations of BHA and are jointly and severally guaranteed on a senior unsecured basis by the Company and each of its subsidiaries (other than BHA) that is a guarantor under the Senior Secured Credit Facilities. Future subsidiaries of the Company and BHA, if any, may be required to guarantee the Senior Unsecured Notes. In connection with the closing of the B+L IPO, the discharge of the April 2025 Unsecured Notes Indenture and the related release in respect of the 2018 Restated Credit Agreement, the guarantees and related security provided by Bausch + Lomb and its subsidiaries in respect of the existing senior notes of the Company and BHA were released.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company experiences a change in control, the Company may be required to make an offer to repurchase each series of Senior Unsecured Notes, in whole or in part, at a purchase price equal to <ix:nonFraction unitRef="number" contextRef="ice4047eb87914dd280d3a5673cae9b27_D20220101-20220331" decimals="INF" name="bhc:DebtInstrumentRedemptionPricePercentageChangeinControl" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTM0NTE_1247d314-4881-46bc-b277-515b598f1387">101</ix:nonFraction>% of the aggregate principal amount of the Senior Unsecured Notes repurchased, plus accrued and unpaid interest.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="ia8819a681631490091dd11646e9f2584" continuedAt="i52c3668e986546dc9ae15c13de8a56cb"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Stated Rate of Interest</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average stated rate of interest for the Company&#8217;s outstanding debt obligations as of March&#160;31, 2022 and December&#160;31, 2021 was <ix:nonFraction unitRef="number" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="4" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTg3NzA_9c82a978-0810-4a9c-ae7f-bb126d350215">5.97</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="4" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTg3Nzc_a446f902-9e73-45e3-a8c6-5a5316babcce">5.88</ix:nonFraction>%, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maturities</span></div><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTk1ODE_1221231d-bd27-43b7-8ce9-e5b05f31733a" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of debt obligations for the remainder of 2022, the five succeeding years ending December&#160;31 and thereafter are as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:90.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmEyOTRjZTNjMDI1MzRkYTc5MDEyYzE1NGViYjAxNWI2L3RhYmxlcmFuZ2U6YTI5NGNlM2MwMjUzNGRhNzkwMTJjMTU0ZWJiMDE1YjZfMS0xLTEtMS04OTA3Mg_c054e93f-465a-4cd3-98db-4d5a6c9f6b0f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmEyOTRjZTNjMDI1MzRkYTc5MDEyYzE1NGViYjAxNWI2L3RhYmxlcmFuZ2U6YTI5NGNlM2MwMjUzNGRhNzkwMTJjMTU0ZWJiMDE1YjZfMi0xLTEtMS04OTA3Mg_fb13e426-e2bc-4456-8c29-89763bf50d0f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmEyOTRjZTNjMDI1MzRkYTc5MDEyYzE1NGViYjAxNWI2L3RhYmxlcmFuZ2U6YTI5NGNlM2MwMjUzNGRhNzkwMTJjMTU0ZWJiMDE1YjZfMy0xLTEtMS04OTA3Mg_fd233b9b-c50c-49e6-b437-84a7ba4601a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmEyOTRjZTNjMDI1MzRkYTc5MDEyYzE1NGViYjAxNWI2L3RhYmxlcmFuZ2U6YTI5NGNlM2MwMjUzNGRhNzkwMTJjMTU0ZWJiMDE1YjZfNC0xLTEtMS04OTA3Mg_16b1a4b5-824c-49c5-9d83-ec38dd0ff7b4">9,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmEyOTRjZTNjMDI1MzRkYTc5MDEyYzE1NGViYjAxNWI2L3RhYmxlcmFuZ2U6YTI5NGNlM2MwMjUzNGRhNzkwMTJjMTU0ZWJiMDE1YjZfNS0xLTEtMS04OTA3Mg_cb71bd2e-be07-4fff-be41-22004dd2c41a">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmEyOTRjZTNjMDI1MzRkYTc5MDEyYzE1NGViYjAxNWI2L3RhYmxlcmFuZ2U6YTI5NGNlM2MwMjUzNGRhNzkwMTJjMTU0ZWJiMDE1YjZfNi0xLTEtMS04OTA3Mg_cfcd2bd9-cd8d-499e-b1dc-717022629fa7">3,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmEyOTRjZTNjMDI1MzRkYTc5MDEyYzE1NGViYjAxNWI2L3RhYmxlcmFuZ2U6YTI5NGNlM2MwMjUzNGRhNzkwMTJjMTU0ZWJiMDE1YjZfNy0xLTEtMS04OTA3Mg_935af95a-23c6-4e46-bb0a-f1526284e0c5">9,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt obligations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmEyOTRjZTNjMDI1MzRkYTc5MDEyYzE1NGViYjAxNWI2L3RhYmxlcmFuZ2U6YTI5NGNlM2MwMjUzNGRhNzkwMTJjMTU0ZWJiMDE1YjZfOC0xLTEtMS04OTA3Mg_594d2249-1e65-418c-8d3c-469e3e2b0d59">23,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized premiums, discounts and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmEyOTRjZTNjMDI1MzRkYTc5MDEyYzE1NGViYjAxNWI2L3RhYmxlcmFuZ2U6YTI5NGNlM2MwMjUzNGRhNzkwMTJjMTU0ZWJiMDE1YjZfOS0xLTEtMS04OTA3Mg_17724e15-66a2-4a69-ba13-b712cc227310">217</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmEyOTRjZTNjMDI1MzRkYTc5MDEyYzE1NGViYjAxNWI2L3RhYmxlcmFuZ2U6YTI5NGNlM2MwMjUzNGRhNzkwMTJjMTU0ZWJiMDE1YjZfMTAtMS0xLTEtODkwNzI_990b78f3-7cf0-4fee-81a9-967768f87697">23,168</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the closing of the B+L IPO, the conditions to the Company&#8217;s previously announced redemption of its April 2025 Unsecured Notes were satisfied. On May 10, 2022, the Company caused sufficient funds for the redemption in full of the April 2025 Unsecured Notes at a redemption price of <ix:nonFraction unitRef="number" contextRef="id1e3d8f9146049ff9febeb80d7774565_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTY0OTI2NzQ0NzUwMjM_b61362b9-439c-4dd7-bf8e-fdfcc47929cd">101.021</ix:nonFraction>% of the principal amount thereof to be irrevocably deposited with the Bank of New York Mellon, N.A., as trustee under the April 2025 Unsecured Notes Indenture and the April 2025 Unsecured Notes was discharged. The April 2025 Unsecured Notes will be redeemed on May 16, 2022. In addition, as of May 10, 2022, the Company has drawn $<ix:nonFraction unitRef="usd" contextRef="iba4cf152a5ec43589599bfbc8c8881de_I20220510" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTA5OTUxMTY4NjM1OA_56c0fdb2-8a62-410f-9f4b-571bc707b6e5">350</ix:nonFraction> million on the 2027 Revolving Credit Facility (defined below).</span></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i52c3668e986546dc9ae15c13de8a56cb">This satisfaction and discharge, as well as the B+L Debt Financing, the Credit Agreement Refinancing and the borrowings under the 2027 Revolving Credit Facility (each as defined in Note 20, &#8220;SUBSEQUENT EVENTS&#8221;), are not reflected in the maturities table above.  See Note 20, &#8220;SUBSEQUENT EVENTS&#8221; for further details regarding these transactions.</ix:continuation> </span></div><div id="i801c461cbd33492a893c84373a8e7cbc_73"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RleHRyZWdpb246NjljNThhNjhjNjYyNDEwMGEzOTJmYTRjODI4N2VhZjJfNDAx_03f176de-4bd0-4095-976e-fa2c9ef6cb5c" continuedAt="i3822fd832d9543e193bdfcdd8940d855" escape="true">PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS</ix:nonNumeric></span></div><ix:continuation id="i3822fd832d9543e193bdfcdd8940d855"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors defined benefit plans and a participatory defined benefit postretirement medical and life insurance plan, which covers certain U.S. employees and employees in certain other countries. <ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RleHRyZWdpb246NjljNThhNjhjNjYyNDEwMGEzOTJmYTRjODI4N2VhZjJfMzk4_04fe13cf-8d85-4a44-8d28-86596874e099" continuedAt="icaf49c64ed9d43bc93c01ad9b104dbf8" escape="true">Net periodic (benefit) cost for the Company&#8217;s defined benefit pension plans and postretirement benefit plan for the three months ended March 31, 2022 and 2021 consists of: </ix:nonNumeric></span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><ix:continuation id="icaf49c64ed9d43bc93c01ad9b104dbf8"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.971%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.980%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Postretirement<br/>Benefit<br/>Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830e50982f6544d8ac6e50bc7bd7c443_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfMy0yLTEtMS04OTA3Mg_50e4b20d-4a2c-4ea1-a2fc-88bb50fb9efe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic655b0478ac14dac9616872cec7db523_D20210101-20210331" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfMy00LTEtMS04OTA3Mg_8c36b4c7-712e-4160-a263-61456b99dd45">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5551d17df34844848847e1383a62e7c3_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfMy02LTEtMS04OTA3Mg_03113176-6a9c-47ed-96fa-53e56b16399c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74e0245bcf24424487c80b95aed98a9d_D20210101-20210331" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfMy04LTEtMS04OTA3Mg_d87ca5c2-6209-418d-832f-fd779b5e3102">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i673851b86a634af7b2f89d29c8e7cac4_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfMy0xMC0xLTEtODkwNzI_ad1ae374-18f2-4f62-ad97-3b2bae0a6166">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2d66b26d13244be9ae6815748b18427_D20210101-20210331" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfMy0xMi0xLTEtODkwNzI_737ff188-9e3b-4bc8-97e3-c5dce6bcee73">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830e50982f6544d8ac6e50bc7bd7c443_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfNC0yLTEtMS04OTA3Mg_50922abd-6339-4f9e-a8fa-69f04078e328">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic655b0478ac14dac9616872cec7db523_D20210101-20210331" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfNC00LTEtMS04OTA3Mg_a312cf7e-6063-46da-9d5c-43276ab9980a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5551d17df34844848847e1383a62e7c3_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfNC02LTEtMS04OTA3Mg_0d118578-959a-4205-8b16-906521ed4a64">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74e0245bcf24424487c80b95aed98a9d_D20210101-20210331" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfNC04LTEtMS04OTA3Mg_d2541c4a-03b3-4630-8d09-064eb2a5aa12">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i673851b86a634af7b2f89d29c8e7cac4_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfNC0xMC0xLTEtODkwNzI_635b630e-66e7-4d85-8b99-e41ddf7ac52e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2d66b26d13244be9ae6815748b18427_D20210101-20210331" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfNC0xMi0xLTEtODkwNzI_d94cae6a-686e-4fb8-9081-72d72629b5c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i830e50982f6544d8ac6e50bc7bd7c443_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfNS0yLTEtMS04OTA3Mg_28295b3f-ca72-4576-9519-4521fd59113e">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic655b0478ac14dac9616872cec7db523_D20210101-20210331" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfNS00LTEtMS04OTA3Mg_590a1e75-3e71-4e1b-8c59-a684bc157b42">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5551d17df34844848847e1383a62e7c3_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfNS02LTEtMS04OTA3Mg_7e0df1bb-adb9-4e0c-8586-5a67d76b6387">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74e0245bcf24424487c80b95aed98a9d_D20210101-20210331" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfNS04LTEtMS04OTA3Mg_d661e4e3-12d3-46b3-bc63-187b5e1f771b">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i673851b86a634af7b2f89d29c8e7cac4_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfNS0xMC0xLTEtODkwNzI_3ff493e2-0541-450b-8591-3646705cc84d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2d66b26d13244be9ae6815748b18427_D20210101-20210331" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfNS0xMi0xLTEtODkwNzI_48df1b5e-e232-46d9-9994-1472c8a380ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service credit and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830e50982f6544d8ac6e50bc7bd7c443_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfNi0yLTEtMS04OTA3Mg_a62461af-e802-4bad-8b84-b147f41b439f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic655b0478ac14dac9616872cec7db523_D20210101-20210331" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfNi00LTEtMS04OTA3Mg_dda8221f-cd14-45c4-8bfa-c90971c9b867">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5551d17df34844848847e1383a62e7c3_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfNi02LTEtMS04OTA3Mg_65b32369-b973-4fd7-b10e-927f81403562">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74e0245bcf24424487c80b95aed98a9d_D20210101-20210331" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfNi04LTEtMS04OTA3Mg_a37b9ea4-009c-4b49-8164-644dcfffb01b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i673851b86a634af7b2f89d29c8e7cac4_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfNi0xMC0xLTEtODkwNzI_cf9bbfbe-9f7c-4439-9fb3-45e188fe69db">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2d66b26d13244be9ae6815748b18427_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfNi0xMi0xLTEtODkwNzI_edf87c5c-e2f6-4e6d-a3c9-7065755f9a69">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic (benefit) cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i830e50982f6544d8ac6e50bc7bd7c443_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfOC0yLTEtMS04OTA3Mg_f4ecc7bd-73f4-44b1-8e02-1a717cf5217c">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic655b0478ac14dac9616872cec7db523_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfOC00LTEtMS04OTA3Mg_4a3a6a7e-77a0-4f5f-bfc3-5cf04355b3df">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5551d17df34844848847e1383a62e7c3_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfOC02LTEtMS04OTA3Mg_4654f78a-0459-4c7d-8aef-c135f2ebff09">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74e0245bcf24424487c80b95aed98a9d_D20210101-20210331" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfOC04LTEtMS04OTA3Mg_1af9dc21-c6da-467d-a441-0f62b02a06cb">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i673851b86a634af7b2f89d29c8e7cac4_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfOC0xMC0xLTEtODkwNzI_0d6707ac-8303-4dc8-94c2-f4a02bb21c47">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2d66b26d13244be9ae6815748b18427_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfOC0xMi0xLTEtODkwNzI_4e8db2ea-c7a7-4a32-a120-7caedfc4086e">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div id="i801c461cbd33492a893c84373a8e7cbc_76"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RleHRyZWdpb246NTc4NWQ3MGNhMjAzNDc2MWI3MzI3ZThlZmVlYjYxYjFfNDU0Mg_c5f386bf-804e-43f9-aaa7-792fd171612e" continuedAt="i8f6d47aaf9b54280be20ecc71dd19d1b" escape="true">SHARE-BASED COMPENSATION</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8f6d47aaf9b54280be20ecc71dd19d1b" continuedAt="if80dacd8079341d59670a24038df633a">In May 2014, shareholders approved the Company&#8217;s 2014 Omnibus Incentive Plan (the &#8220;2014 Plan&#8221;) which replaced the Company&#8217;s 2011 Omnibus Incentive Plan (the &#8220;2011 Plan&#8221;) for future equity awards granted by the Company. The Company transferred the common shares available under the 2011 Plan to the 2014 Plan. The maximum number of common shares that may be issued to participants under the 2014 Plan was equal to <ix:nonFraction unitRef="shares" contextRef="i28d956fcdc7e473694aec5169b2c17fd_I20140531" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RleHRyZWdpb246NTc4NWQ3MGNhMjAzNDc2MWI3MzI3ZThlZmVlYjYxYjFfNDQ0_c345faf2-6b0d-4211-b34b-897b83620c11">18,000,000</ix:nonFraction> common shares, plus the number of common shares under the 2011 Plan reserved but unissued and not underlying outstanding awards and the number of common shares becoming available for reuse after awards are terminated, forfeited, cancelled, exchanged or surrendered under the 2011 Plan </ix:continuation></span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="if80dacd8079341d59670a24038df633a" continuedAt="i074f33a405004950ba090e66a6551154"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the Company&#8217;s 2007 Equity Compensation Plan. The Company registered <ix:nonFraction unitRef="shares" contextRef="i28d956fcdc7e473694aec5169b2c17fd_I20140531" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RleHRyZWdpb246NTc4NWQ3MGNhMjAzNDc2MWI3MzI3ZThlZmVlYjYxYjFfODA0_c3daf8e4-771d-4057-978a-5796db9edf10">20,000,000</ix:nonFraction> common shares for issuance under the 2014 Plan. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective April 30, 2018, the Company amended and restated the 2014 Plan (the &#8220;Amended and Restated 2014 Plan&#8221;). The Amended and Restated 2014 Plan includes the following amendments: (i) the number of common shares authorized for issuance under the Amended and Restated 2014 Plan has been increased by an additional <ix:nonFraction unitRef="shares" contextRef="i407781f626f341f296f71f5e85d199df_D20180430-20180430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RleHRyZWdpb246NTc4NWQ3MGNhMjAzNDc2MWI3MzI3ZThlZmVlYjYxYjFfMTE3Mg_76d00012-0179-4c3d-ba09-502684c6015f">11,900,000</ix:nonFraction> common shares, as approved by the requisite number of shareholders at the Company&#8217;s annual general meeting held on April 30, 2018, (ii) introduction of a $<ix:nonFraction unitRef="usd" contextRef="i79d17571326d4113a14289e30a432c94_D20180430-20180430" decimals="INF" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RleHRyZWdpb246NTc4NWQ3MGNhMjAzNDc2MWI3MzI3ZThlZmVlYjYxYjFfMTMyOQ_30a97619-edbe-4780-9cc5-6828e1182a2c">750,000</ix:nonFraction> aggregate fair market value limit on awards (in either equity, cash or other compensation) that can be granted in any calendar year to a participant who is a non-employee director, (iii) housekeeping changes to address changes to Section 162(m) of the Internal Revenue Code, (iv) awards are expressly subject to the Company&#8217;s clawback policy and (v) awards not assumed or substituted in connection with a Change of Control (as defined in the Amended and Restated 2014 Plan) will only vest on a pro rata basis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective April 28, 2020, the Company further amended and restated the Amended and Restated 2014 Plan (the &#8220;Further Amended and Restated 2014 Plan&#8221;). The Further Amended and Restated 2014 Plan includes the following amendments: (i) the number of common shares authorized for issuance under the Further Amended and Restated 2014 Plan has been increased by an additional <ix:nonFraction unitRef="shares" contextRef="ic9d13a041f834d2f9ed315beee256b39_D20200428-20200428" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RleHRyZWdpb246NTc4NWQ3MGNhMjAzNDc2MWI3MzI3ZThlZmVlYjYxYjFfMjIxOA_c7c3fdf4-f2bb-4a73-943e-de5df066797b">13,500,000</ix:nonFraction> common shares, as approved by the requisite number of shareholders at the Company&#8217;s annual general meeting held on April 28, 2020, (ii) the exercise price of stock options and share appreciation rights (&#8220;SARs&#8221;) will be based on the closing price of the underlying common shares on the date such stock options or SARs are granted (rather than on the last preceding trading date), (iii)&#160;additional provisions clarifying that: (a)&#160;stock options and SARs will not be eligible for the payment of dividend or dividend equivalents and (b)&#160;the Talent and Compensation Committee of the Board of Directors of the Company cannot, without shareholder approval, seek to effect any repricing of any previously granted &#8220;underwater&#8221; stock option or SAR and (iv) other housekeeping and/or clerical changes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately <ix:nonFraction unitRef="shares" contextRef="i24dd995e79e2480eb8534ebdb9b36ffe_I20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RleHRyZWdpb246NTc4NWQ3MGNhMjAzNDc2MWI3MzI3ZThlZmVlYjYxYjFfMzAyNQ_cc463b1c-6eaf-4238-8736-9a0c8a00e004">8,542,000</ix:nonFraction> common shares were available for future grants as of March&#160;31, 2022. The Company uses reserved and unissued common shares to satisfy its obligations under its share-based compensation plans.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a long-term incentive program with the objective of aligning the share-based awards granted to senior management with the Company&#8217;s focus on improving its tangible capital usage and allocation while maintaining focus on improving total shareholder return over the long-term. The share-based awards granted under this long-term incentive program consist of time-based stock options, time-based restricted share units (&#8220;RSUs&#8221;) and performance-based RSUs. Performance-based RSUs are comprised of awards that: (i) vest upon achievement of certain share price appreciation conditions that are based on total shareholder return (&#8220;TSR&#8221;), (ii) vest upon attainment of certain performance targets that are based on the Company&#8217;s return on tangible capital (&#8220;ROTC&#8221;) and (iii) vest fully or partially upon attainment of certain goals that are linked to the B+L Separation. </span></div><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RleHRyZWdpb246NTc4NWQ3MGNhMjAzNDc2MWI3MzI3ZThlZmVlYjYxYjFfNDUzNw_408fe0ed-6b3b-4456-af4a-6929c56ded5d" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components and classification of share-based compensation expenses related to stock options and RSUs for the three months ended March 31, 2022 and 2021: </span></div><div style="margin-bottom:6pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.471%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c3748cc38b94811b494a048524f18d4_D20220101-20220331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmNiODY2ZWQyYjQxZTRkNmViZTNkY2UyZjg1MGRhMDc5L3RhYmxlcmFuZ2U6Y2I4NjZlZDJiNDFlNGQ2ZWJlM2RjZTJmODUwZGEwNzlfMi01LTEtMS04OTA3Mg_ac1fda45-7bed-4d23-8de4-c87e9d4ca963">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbcf180e8ee94c498f903101c65055cf_D20210101-20210331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmNiODY2ZWQyYjQxZTRkNmViZTNkY2UyZjg1MGRhMDc5L3RhYmxlcmFuZ2U6Y2I4NjZlZDJiNDFlNGQ2ZWJlM2RjZTJmODUwZGEwNzlfMi03LTEtMS04OTA3Mg_095c84f9-b5e3-4c35-96fe-3dd2463cb2ae">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5189be309deb481aba3dbe709f732ab9_D20220101-20220331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmNiODY2ZWQyYjQxZTRkNmViZTNkY2UyZjg1MGRhMDc5L3RhYmxlcmFuZ2U6Y2I4NjZlZDJiNDFlNGQ2ZWJlM2RjZTJmODUwZGEwNzlfMy01LTEtMS04OTA3Mg_53fd21e1-c39b-48fe-921d-ddce186018a8">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i302c4d997fc44f5f93fd331d80fb1d09_D20210101-20210331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmNiODY2ZWQyYjQxZTRkNmViZTNkY2UyZjg1MGRhMDc5L3RhYmxlcmFuZ2U6Y2I4NjZlZDJiNDFlNGQ2ZWJlM2RjZTJmODUwZGEwNzlfMy03LTEtMS04OTA3Mg_8663ac0e-e642-4b5c-ac20-ef4d51f430c4">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmNiODY2ZWQyYjQxZTRkNmViZTNkY2UyZjg1MGRhMDc5L3RhYmxlcmFuZ2U6Y2I4NjZlZDJiNDFlNGQ2ZWJlM2RjZTJmODUwZGEwNzlfNC01LTEtMS04OTA3Mg_1c0d6e34-9a74-46c4-b964-676a5fcd56cd">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmNiODY2ZWQyYjQxZTRkNmViZTNkY2UyZjg1MGRhMDc5L3RhYmxlcmFuZ2U6Y2I4NjZlZDJiNDFlNGQ2ZWJlM2RjZTJmODUwZGEwNzlfNC03LTEtMS04OTA3Mg_160ef1fb-f629-479b-af6b-c5ef1dc7feb4">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c8dba5a632049539392f661e0428449_D20220101-20220331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmNiODY2ZWQyYjQxZTRkNmViZTNkY2UyZjg1MGRhMDc5L3RhYmxlcmFuZ2U6Y2I4NjZlZDJiNDFlNGQ2ZWJlM2RjZTJmODUwZGEwNzlfNi01LTEtMS04OTA3Mg_10a99658-c916-4b23-a9c5-a973569b317e">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96274aa944bb4685b39b713920d2304f_D20210101-20210331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmNiODY2ZWQyYjQxZTRkNmViZTNkY2UyZjg1MGRhMDc5L3RhYmxlcmFuZ2U6Y2I4NjZlZDJiNDFlNGQ2ZWJlM2RjZTJmODUwZGEwNzlfNi03LTEtMS04OTA3Mg_8bb09638-1075-4b01-83b7-b33c27e680d2">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16e6e5eeaf9441738f673fb99507f4e5_D20220101-20220331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmNiODY2ZWQyYjQxZTRkNmViZTNkY2UyZjg1MGRhMDc5L3RhYmxlcmFuZ2U6Y2I4NjZlZDJiNDFlNGQ2ZWJlM2RjZTJmODUwZGEwNzlfNy01LTEtMS04OTA3Mg_4340a066-2c41-4a1c-a67d-b305624f8d2c">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9aaaf1035cf34c098a5c6e6768c0dbf4_D20210101-20210331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmNiODY2ZWQyYjQxZTRkNmViZTNkY2UyZjg1MGRhMDc5L3RhYmxlcmFuZ2U6Y2I4NjZlZDJiNDFlNGQ2ZWJlM2RjZTJmODUwZGEwNzlfNy03LTEtMS04OTA3Mg_7a8f4af0-6767-417c-9900-faaff12ec366">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmNiODY2ZWQyYjQxZTRkNmViZTNkY2UyZjg1MGRhMDc5L3RhYmxlcmFuZ2U6Y2I4NjZlZDJiNDFlNGQ2ZWJlM2RjZTJmODUwZGEwNzlfOC01LTEtMS04OTA3Mg_42d93029-d404-4ffb-889f-6e497e07f488">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmNiODY2ZWQyYjQxZTRkNmViZTNkY2UyZjg1MGRhMDc5L3RhYmxlcmFuZ2U6Y2I4NjZlZDJiNDFlNGQ2ZWJlM2RjZTJmODUwZGEwNzlfOC03LTEtMS04OTA3Mg_09eb0229-1b32-4240-a9d6-dee36ceb526d">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i074f33a405004950ba090e66a6551154"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RleHRyZWdpb246NTc4NWQ3MGNhMjAzNDc2MWI3MzI3ZThlZmVlYjYxYjFfNDUyOQ_e720366f-a229-4af2-b212-ecb0ef06e6cd" escape="true"><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based awards granted for the three months ended March 31, 2022 and 2021 consist of:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c3748cc38b94811b494a048524f18d4_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmZjYzc3MzUyZWEwNjRkODQ5YzM3NDNmYTNkY2NlYmU1L3RhYmxlcmFuZ2U6ZmNjNzczNTJlYTA2NGQ4NDljMzc0M2ZhM2RjY2ViZTVfMi0xLTEtMS04OTA3Mg_429efa6f-39af-45ae-9e42-f0d06bf5c9d3">2,545,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icbcf180e8ee94c498f903101c65055cf_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmZjYzc3MzUyZWEwNjRkODQ5YzM3NDNmYTNkY2NlYmU1L3RhYmxlcmFuZ2U6ZmNjNzczNTJlYTA2NGQ4NDljMzc0M2ZhM2RjY2ViZTVfMi0zLTEtMS04OTA3Mg_d54010ce-64d6-4f38-8e62-da114e10b903">1,343,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average exercise price</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4c3748cc38b94811b494a048524f18d4_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmZjYzc3MzUyZWEwNjRkODQ5YzM3NDNmYTNkY2NlYmU1L3RhYmxlcmFuZ2U6ZmNjNzczNTJlYTA2NGQ4NDljMzc0M2ZhM2RjY2ViZTVfMy0xLTEtMS04OTA3Mg_ec298887-f573-4762-92d3-7ada76b3e9ab">24.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icbcf180e8ee94c498f903101c65055cf_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmZjYzc3MzUyZWEwNjRkODQ5YzM3NDNmYTNkY2NlYmU1L3RhYmxlcmFuZ2U6ZmNjNzczNTJlYTA2NGQ4NDljMzc0M2ZhM2RjY2ViZTVfMy0zLTEtMS04OTA3Mg_1933ee78-67c5-4b45-813b-2f054d47e855">32.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4c3748cc38b94811b494a048524f18d4_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmZjYzc3MzUyZWEwNjRkODQ5YzM3NDNmYTNkY2NlYmU1L3RhYmxlcmFuZ2U6ZmNjNzczNTJlYTA2NGQ4NDljMzc0M2ZhM2RjY2ViZTVfNC0xLTEtMS04OTA3Mg_019ec593-7518-4153-9748-e25e8c12dafd">6.63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icbcf180e8ee94c498f903101c65055cf_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmZjYzc3MzUyZWEwNjRkODQ5YzM3NDNmYTNkY2NlYmU1L3RhYmxlcmFuZ2U6ZmNjNzczNTJlYTA2NGQ4NDljMzc0M2ZhM2RjY2ViZTVfNC0zLTEtMS04OTA3Mg_2a9171d6-e3d4-446c-a152-db0cbd85e46f">11.45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time-based RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i77c337a40ebb461491bdb6dab1118617_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmZjYzc3MzUyZWEwNjRkODQ5YzM3NDNmYTNkY2NlYmU1L3RhYmxlcmFuZ2U6ZmNjNzczNTJlYTA2NGQ4NDljMzc0M2ZhM2RjY2ViZTVfNi0xLTEtMS04OTA3Mg_9c11e6d6-9e24-4a8e-8155-8b823727cb53">1,662,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3fc2981be2ea44a386fb0f04805428f4_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmZjYzc3MzUyZWEwNjRkODQ5YzM3NDNmYTNkY2NlYmU1L3RhYmxlcmFuZ2U6ZmNjNzczNTJlYTA2NGQ4NDljMzc0M2ZhM2RjY2ViZTVfNi0zLTEtMS04OTA3Mg_ca38e798-9245-4982-82d1-c02a02fdcdba">2,560,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i77c337a40ebb461491bdb6dab1118617_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmZjYzc3MzUyZWEwNjRkODQ5YzM3NDNmYTNkY2NlYmU1L3RhYmxlcmFuZ2U6ZmNjNzczNTJlYTA2NGQ4NDljMzc0M2ZhM2RjY2ViZTVfNy0xLTEtMS04OTA3Mg_47d04d5c-5733-4f5e-9e4e-3c802dd6bd10">24.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3fc2981be2ea44a386fb0f04805428f4_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmZjYzc3MzUyZWEwNjRkODQ5YzM3NDNmYTNkY2NlYmU1L3RhYmxlcmFuZ2U6ZmNjNzczNTJlYTA2NGQ4NDljMzc0M2ZhM2RjY2ViZTVfNy0zLTEtMS04OTA3Mg_e60b9bbc-b195-4e51-a6a6-26d6ed92fc11">32.45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TSR performance-based RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf0b5e90aca84802a2fe6dfc35444ad9_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmZjYzc3MzUyZWEwNjRkODQ5YzM3NDNmYTNkY2NlYmU1L3RhYmxlcmFuZ2U6ZmNjNzczNTJlYTA2NGQ4NDljMzc0M2ZhM2RjY2ViZTVfOS0xLTEtMS04OTA3Mg_04d3f3ab-a566-4c11-a28b-d9fb46c9287f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief18d16522574e578066730177201d22_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmZjYzc3MzUyZWEwNjRkODQ5YzM3NDNmYTNkY2NlYmU1L3RhYmxlcmFuZ2U6ZmNjNzczNTJlYTA2NGQ4NDljMzc0M2ZhM2RjY2ViZTVfOS0zLTEtMS04OTA3Mg_cb275227-3292-4e5d-962d-067a124ce199">400,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibf0b5e90aca84802a2fe6dfc35444ad9_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmZjYzc3MzUyZWEwNjRkODQ5YzM3NDNmYTNkY2NlYmU1L3RhYmxlcmFuZ2U6ZmNjNzczNTJlYTA2NGQ4NDljMzc0M2ZhM2RjY2ViZTVfMTAtMS0xLTEtODkwNzI_18aba2fd-0aa6-4a55-b3c1-78ea9c5c320c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ief18d16522574e578066730177201d22_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmZjYzc3MzUyZWEwNjRkODQ5YzM3NDNmYTNkY2NlYmU1L3RhYmxlcmFuZ2U6ZmNjNzczNTJlYTA2NGQ4NDljMzc0M2ZhM2RjY2ViZTVfMTAtMy0xLTEtODkwNzI_f0ae4d7d-da7d-461e-8e8b-d9c2b58d1ada">56.04</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROTC performance-based RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i672f6c3b00ec46e5ae4b3d4816dbc732_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmZjYzc3MzUyZWEwNjRkODQ5YzM3NDNmYTNkY2NlYmU1L3RhYmxlcmFuZ2U6ZmNjNzczNTJlYTA2NGQ4NDljMzc0M2ZhM2RjY2ViZTVfMTItMS0xLTEtODkwNzI_83729d98-5f97-4acb-8e1e-d90138203fa8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idbfb63fc6db643aba45a4aa4ec0c1c63_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmZjYzc3MzUyZWEwNjRkODQ5YzM3NDNmYTNkY2NlYmU1L3RhYmxlcmFuZ2U6ZmNjNzczNTJlYTA2NGQ4NDljMzc0M2ZhM2RjY2ViZTVfMTItMy0xLTEtODkwNzI_5f3df5dd-b55f-456e-ac84-fec075ee9b77">413,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i672f6c3b00ec46e5ae4b3d4816dbc732_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmZjYzc3MzUyZWEwNjRkODQ5YzM3NDNmYTNkY2NlYmU1L3RhYmxlcmFuZ2U6ZmNjNzczNTJlYTA2NGQ4NDljMzc0M2ZhM2RjY2ViZTVfMTMtMS0xLTEtODkwNzI_2a1f297a-c726-4001-ad56-a6125561242d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idbfb63fc6db643aba45a4aa4ec0c1c63_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmZjYzc3MzUyZWEwNjRkODQ5YzM3NDNmYTNkY2NlYmU1L3RhYmxlcmFuZ2U6ZmNjNzczNTJlYTA2NGQ4NDljMzc0M2ZhM2RjY2ViZTVfMTMtMy0xLTEtODkwNzI_0c2fed7a-02c5-46ba-b3af-41ee6e7bec4f">31.72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B+L Separation performance-based RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i64cc50678b8b42b28c6fffa51684b252_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmZjYzc3MzUyZWEwNjRkODQ5YzM3NDNmYTNkY2NlYmU1L3RhYmxlcmFuZ2U6ZmNjNzczNTJlYTA2NGQ4NDljMzc0M2ZhM2RjY2ViZTVfMTUtMS0xLTEtODkwNzI_50e61d9a-1477-4d4d-8737-110f3ecead7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3a2ccdb6d9074d6d8d84aba34115a27e_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmZjYzc3MzUyZWEwNjRkODQ5YzM3NDNmYTNkY2NlYmU1L3RhYmxlcmFuZ2U6ZmNjNzczNTJlYTA2NGQ4NDljMzc0M2ZhM2RjY2ViZTVfMTUtMy0xLTEtODkwNzI_dadb9747-d8b3-4bd8-973b-d84165c83599">132,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i64cc50678b8b42b28c6fffa51684b252_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmZjYzc3MzUyZWEwNjRkODQ5YzM3NDNmYTNkY2NlYmU1L3RhYmxlcmFuZ2U6ZmNjNzczNTJlYTA2NGQ4NDljMzc0M2ZhM2RjY2ViZTVfMTYtMS0xLTEtODkwNzI_bc68ae3f-e10e-44d2-a26a-86f38ab4ddce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3a2ccdb6d9074d6d8d84aba34115a27e_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmZjYzc3MzUyZWEwNjRkODQ5YzM3NDNmYTNkY2NlYmU1L3RhYmxlcmFuZ2U6ZmNjNzczNTJlYTA2NGQ4NDljMzc0M2ZhM2RjY2ViZTVfMTYtMy0xLTEtODkwNzI_7141c25d-42ba-417f-941b-29b70b88f0b5">32.56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the remaining unrecognized compensation expenses related to all outstanding non-vested stock options, time-based RSUs and performance-based RSUs amounted to $<ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RleHRyZWdpb246NTc4NWQ3MGNhMjAzNDc2MWI3MzI3ZThlZmVlYjYxYjFfNDQ1OQ_6b9cf86e-361c-4868-bb90-af845b33aefa">134</ix:nonFraction> million, which will be amortized over a weighted-average period of <ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RleHRyZWdpb246NTc4NWQ3MGNhMjAzNDc2MWI3MzI3ZThlZmVlYjYxYjFfNDUyMQ_7a2d6c9b-138f-4b47-a9a8-e7dd7bea8478">1.84</ix:nonNumeric> years.</span></div></ix:continuation><div id="i801c461cbd33492a893c84373a8e7cbc_79"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183OS9mcmFnOjA1ODA3YThkOTdkYTRlMjBhYjI1M2ExNGMyNzc2MTNjL3RleHRyZWdpb246MDU4MDdhOGQ5N2RhNGUyMGFiMjUzYTE0YzI3NzYxM2NfNDc2_2fa77d9a-6caa-478c-a522-f310f5e138ba" continuedAt="i91cf411b8d744dd4872bec76db224aad" escape="true">ACCUMULATED OTHER COMPREHENSIVE LOSS</ix:nonNumeric></span></div><ix:continuation id="i91cf411b8d744dd4872bec76db224aad"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183OS9mcmFnOjA1ODA3YThkOTdkYTRlMjBhYjI1M2ExNGMyNzc2MTNjL3RleHRyZWdpb246MDU4MDdhOGQ5N2RhNGUyMGFiMjUzYTE0YzI3NzYxM2NfNDcy_800913d3-9930-4e38-8270-9f54ce3bf2dc" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss consists of:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:69.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46d6cdf39c0344c9997ac487916b5ced_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183OS9mcmFnOjA1ODA3YThkOTdkYTRlMjBhYjI1M2ExNGMyNzc2MTNjL3RhYmxlOjBhMDZmYmExMDU0OTQxNTViYmI1YTA2ZjczZWVmNTE5L3RhYmxlcmFuZ2U6MGEwNmZiYTEwNTQ5NDE1NWJiYjVhMDZmNzNlZWY1MTlfMS0yLTEtMS04OTA3Mg_5ab5021a-68c9-4b29-be27-29f8199ba1ba">1,961</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia421fa8b794e48b48d28fe42bfdcba6b_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183OS9mcmFnOjA1ODA3YThkOTdkYTRlMjBhYjI1M2ExNGMyNzc2MTNjL3RhYmxlOjBhMDZmYmExMDU0OTQxNTViYmI1YTA2ZjczZWVmNTE5L3RhYmxlcmFuZ2U6MGEwNmZiYTEwNTQ5NDE1NWJiYjVhMDZmNzNlZWY1MTlfMS00LTEtMS04OTA3Mg_13a23286-0cf9-42b8-b929-dbbb6c31b00d">1,905</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and postretirement benefit plan adjustments, net of income taxes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27c24a8f9680457fae0e0043ab55f83c_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183OS9mcmFnOjA1ODA3YThkOTdkYTRlMjBhYjI1M2ExNGMyNzc2MTNjL3RhYmxlOjBhMDZmYmExMDU0OTQxNTViYmI1YTA2ZjczZWVmNTE5L3RhYmxlcmFuZ2U6MGEwNmZiYTEwNTQ5NDE1NWJiYjVhMDZmNzNlZWY1MTlfMi0yLTEtMS04OTA3Mg_17144cdc-4e3c-47dd-822d-98ff8ab36faa">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf07a0520a7f41db853c67b1c28a17a5_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183OS9mcmFnOjA1ODA3YThkOTdkYTRlMjBhYjI1M2ExNGMyNzc2MTNjL3RhYmxlOjBhMDZmYmExMDU0OTQxNTViYmI1YTA2ZjczZWVmNTE5L3RhYmxlcmFuZ2U6MGEwNmZiYTEwNTQ5NDE1NWJiYjVhMDZmNzNlZWY1MTlfMi00LTEtMS04OTA3Mg_6370b943-8917-4a3c-b544-ad858c62c485">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38bc8011408047f4b2f92fc815fe79b3_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183OS9mcmFnOjA1ODA3YThkOTdkYTRlMjBhYjI1M2ExNGMyNzc2MTNjL3RhYmxlOjBhMDZmYmExMDU0OTQxNTViYmI1YTA2ZjczZWVmNTE5L3RhYmxlcmFuZ2U6MGEwNmZiYTEwNTQ5NDE1NWJiYjVhMDZmNzNlZWY1MTlfMy0yLTEtMS04OTA3Mg_038ecc78-b97a-4ed4-a134-94051a310343">1,974</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e97a6c789b1443ba408d058697c5cc2_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183OS9mcmFnOjA1ODA3YThkOTdkYTRlMjBhYjI1M2ExNGMyNzc2MTNjL3RhYmxlOjBhMDZmYmExMDU0OTQxNTViYmI1YTA2ZjczZWVmNTE5L3RhYmxlcmFuZ2U6MGEwNmZiYTEwNTQ5NDE1NWJiYjVhMDZmNzNlZWY1MTlfMy00LTEtMS04OTA3Mg_14cf31a7-1f5e-4b58-9e3e-1d8ceeb9a910">1,924</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are not provided for foreign currency translation adjustments arising on the translation of the Company&#8217;s operations having a functional currency other than the U.S. dollar, except to the extent of translation adjustments related to the Company&#8217;s retained earnings for foreign jurisdictions in which the Company is not considered to be permanently reinvested.</span></div></ix:continuation><div id="i801c461cbd33492a893c84373a8e7cbc_82"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184Mi9mcmFnOjU0ZGUyZTQ1MWUwYzRjNjZhOWQ1ODFhZDYyZTVlMDBlL3RleHRyZWdpb246NTRkZTJlNDUxZTBjNGM2NmE5ZDU4MWFkNjJlNWUwMGVfMjMz_979887fc-95f0-4f23-897b-8b73ce3eafa9" continuedAt="i51f11a3d580c404ab6fcf2007ac9d410" escape="true">RESEARCH AND DEVELOPMENT</ix:nonNumeric></span></div><ix:continuation id="i51f11a3d580c404ab6fcf2007ac9d410"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Research and development are costs related to product development and quality assurance programs. Quality assurance are the costs incurred to meet evolving customer and regulatory standards. <ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="bhc:SummaryOfResearchAndDevelopmentExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184Mi9mcmFnOjU0ZGUyZTQ1MWUwYzRjNjZhOWQ1ODFhZDYyZTVlMDBlL3RleHRyZWdpb246NTRkZTJlNDUxZTBjNGM2NmE5ZDU4MWFkNjJlNWUwMGVfMjM2_53279af7-348c-407c-848c-826bc570a7bc" continuedAt="i4c0e686be4cb4f26b78d43e3cdf87b8b" escape="true">Research and development costs consist of:</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><ix:continuation id="i4c0e686be4cb4f26b78d43e3cdf87b8b"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.471%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product related research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseProductRelated" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184Mi9mcmFnOjU0ZGUyZTQ1MWUwYzRjNjZhOWQ1ODFhZDYyZTVlMDBlL3RhYmxlOjIwNTllY2VjYThjODQ2YmNhYmRhMDNiOGYwMWYyNTBiL3RhYmxlcmFuZ2U6MjA1OWVjZWNhOGM4NDZiY2FiZGEwM2I4ZjAxZjI1MGJfMi02LTEtMS04OTA3Mg_8a7ab1f8-1f26-457f-91fa-1d1fffaf8b53">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseProductRelated" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184Mi9mcmFnOjU0ZGUyZTQ1MWUwYzRjNjZhOWQ1ODFhZDYyZTVlMDBlL3RhYmxlOjIwNTllY2VjYThjODQ2YmNhYmRhMDNiOGYwMWYyNTBiL3RhYmxlcmFuZ2U6MjA1OWVjZWNhOGM4NDZiY2FiZGEwM2I4ZjAxZjI1MGJfMi04LTEtMS04OTA3Mg_bcc15aa2-a824-498f-ad97-fd9bf986701b">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality assurance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseQualityAssurance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184Mi9mcmFnOjU0ZGUyZTQ1MWUwYzRjNjZhOWQ1ODFhZDYyZTVlMDBlL3RhYmxlOjIwNTllY2VjYThjODQ2YmNhYmRhMDNiOGYwMWYyNTBiL3RhYmxlcmFuZ2U6MjA1OWVjZWNhOGM4NDZiY2FiZGEwM2I4ZjAxZjI1MGJfMy02LTEtMS04OTA3Mg_8a99d0c5-f00f-48f5-acf3-0095c9b755db">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseQualityAssurance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184Mi9mcmFnOjU0ZGUyZTQ1MWUwYzRjNjZhOWQ1ODFhZDYyZTVlMDBlL3RhYmxlOjIwNTllY2VjYThjODQ2YmNhYmRhMDNiOGYwMWYyNTBiL3RhYmxlcmFuZ2U6MjA1OWVjZWNhOGM4NDZiY2FiZGEwM2I4ZjAxZjI1MGJfMy04LTEtMS04OTA3Mg_fe460784-0190-4747-ac31-ca7042f05233">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184Mi9mcmFnOjU0ZGUyZTQ1MWUwYzRjNjZhOWQ1ODFhZDYyZTVlMDBlL3RhYmxlOjIwNTllY2VjYThjODQ2YmNhYmRhMDNiOGYwMWYyNTBiL3RhYmxlcmFuZ2U6MjA1OWVjZWNhOGM4NDZiY2FiZGEwM2I4ZjAxZjI1MGJfNC02LTEtMS04OTA3Mg_3e8fd65f-4ad0-46da-bfd4-188867175987">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184Mi9mcmFnOjU0ZGUyZTQ1MWUwYzRjNjZhOWQ1ODFhZDYyZTVlMDBlL3RhYmxlOjIwNTllY2VjYThjODQ2YmNhYmRhMDNiOGYwMWYyNTBiL3RhYmxlcmFuZ2U6MjA1OWVjZWNhOGM4NDZiY2FiZGEwM2I4ZjAxZjI1MGJfNC04LTEtMS04OTA3Mg_dc078dd2-be31-450b-bacf-efc58e30c790">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="i801c461cbd33492a893c84373a8e7cbc_85"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184NS9mcmFnOjY0ZmUxN2U3ZDJiYzQxMjFhYThiYjc5MzNhN2FhNDQxL3RleHRyZWdpb246NjRmZTE3ZTdkMmJjNDEyMWFhOGJiNzkzM2E3YWE0NDFfMTI2Mw_6f4db32e-91cc-40cb-b1b2-f0ec74e12572" continuedAt="i55a87f5cb015428d99a9f7799c3b84b4" escape="true">OTHER EXPENSE (INCOME), NET</ix:nonNumeric></span></div><ix:continuation id="i55a87f5cb015428d99a9f7799c3b84b4"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184NS9mcmFnOjY0ZmUxN2U3ZDJiYzQxMjFhYThiYjc5MzNhN2FhNDQxL3RleHRyZWdpb246NjRmZTE3ZTdkMmJjNDEyMWFhOGJiNzkzM2E3YWE0NDFfMTI1NQ_707a9f31-9b25-4def-8b40-c3b0f67549a7" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense (income), net consists of:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.471%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and other matters</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184NS9mcmFnOjY0ZmUxN2U3ZDJiYzQxMjFhYThiYjc5MzNhN2FhNDQxL3RhYmxlOjVhMzRlOTNkM2NmMjQxMmJiZjVlZDhmMDUzOTQ5M2I1L3RhYmxlcmFuZ2U6NWEzNGU5M2QzY2YyNDEyYmJmNWVkOGYwNTM5NDkzYjVfMi02LTEtMS04OTA3Mg_66af668a-788c-4a52-84ba-82424749e4de">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184NS9mcmFnOjY0ZmUxN2U3ZDJiYzQxMjFhYThiYjc5MzNhN2FhNDQxL3RhYmxlOjVhMzRlOTNkM2NmMjQxMmJiZjVlZDhmMDUzOTQ5M2I1L3RhYmxlcmFuZ2U6NWEzNGU5M2QzY2YyNDEyYmJmNWVkOGYwNTM5NDkzYjVfMi04LTEtMS04OTA3Mg_2c1ef53f-4f35-46f3-bc91-256785e46a54">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184NS9mcmFnOjY0ZmUxN2U3ZDJiYzQxMjFhYThiYjc5MzNhN2FhNDQxL3RhYmxlOjVhMzRlOTNkM2NmMjQxMmJiZjVlZDhmMDUzOTQ5M2I1L3RhYmxlcmFuZ2U6NWEzNGU5M2QzY2YyNDEyYmJmNWVkOGYwNTM5NDkzYjVfMy02LTEtMS04OTA3Mg_0f7492ad-d6f0-4ec3-92ff-7efb7443b655">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184NS9mcmFnOjY0ZmUxN2U3ZDJiYzQxMjFhYThiYjc5MzNhN2FhNDQxL3RhYmxlOjVhMzRlOTNkM2NmMjQxMmJiZjVlZDhmMDUzOTQ5M2I1L3RhYmxlcmFuZ2U6NWEzNGU5M2QzY2YyNDEyYmJmNWVkOGYwNTM5NDkzYjVfMy04LTEtMS04OTA3Mg_a354ee90-99f2-45f5-a6c8-e2288ab49451">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of assets, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184NS9mcmFnOjY0ZmUxN2U3ZDJiYzQxMjFhYThiYjc5MzNhN2FhNDQxL3RhYmxlOjVhMzRlOTNkM2NmMjQxMmJiZjVlZDhmMDUzOTQ5M2I1L3RhYmxlcmFuZ2U6NWEzNGU5M2QzY2YyNDEyYmJmNWVkOGYwNTM5NDkzYjVfNC02LTEtMS04OTA3Mg_886c4edc-e6e5-4b39-9e46-bd6f596568e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184NS9mcmFnOjY0ZmUxN2U3ZDJiYzQxMjFhYThiYjc5MzNhN2FhNDQxL3RhYmxlOjVhMzRlOTNkM2NmMjQxMmJiZjVlZDhmMDUzOTQ5M2I1L3RhYmxlcmFuZ2U6NWEzNGU5M2QzY2YyNDEyYmJmNWVkOGYwNTM5NDkzYjVfNC04LTEtMS04OTA3Mg_3113236b-2643-4342-ad83-13ec5e42f285">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184NS9mcmFnOjY0ZmUxN2U3ZDJiYzQxMjFhYThiYjc5MzNhN2FhNDQxL3RhYmxlOjVhMzRlOTNkM2NmMjQxMmJiZjVlZDhmMDUzOTQ5M2I1L3RhYmxlcmFuZ2U6NWEzNGU5M2QzY2YyNDEyYmJmNWVkOGYwNTM5NDkzYjVfNS02LTEtMS04OTA3Mg_5ef87e4f-d53f-40c6-8310-a055d64f54b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184NS9mcmFnOjY0ZmUxN2U3ZDJiYzQxMjFhYThiYjc5MzNhN2FhNDQxL3RhYmxlOjVhMzRlOTNkM2NmMjQxMmJiZjVlZDhmMDUzOTQ5M2I1L3RhYmxlcmFuZ2U6NWEzNGU5M2QzY2YyNDEyYmJmNWVkOGYwNTM5NDkzYjVfNS04LTEtMS04OTA3Mg_1a59153d-881a-4beb-a954-a211e7a6efab">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184NS9mcmFnOjY0ZmUxN2U3ZDJiYzQxMjFhYThiYjc5MzNhN2FhNDQxL3RhYmxlOjVhMzRlOTNkM2NmMjQxMmJiZjVlZDhmMDUzOTQ5M2I1L3RhYmxlcmFuZ2U6NWEzNGU5M2QzY2YyNDEyYmJmNWVkOGYwNTM5NDkzYjVfNi02LTEtMS04OTA3Mg_c40dd8ca-2631-4876-a5a0-9a9eba1c6356">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184NS9mcmFnOjY0ZmUxN2U3ZDJiYzQxMjFhYThiYjc5MzNhN2FhNDQxL3RhYmxlOjVhMzRlOTNkM2NmMjQxMmJiZjVlZDhmMDUzOTQ5M2I1L3RhYmxlcmFuZ2U6NWEzNGU5M2QzY2YyNDEyYmJmNWVkOGYwNTM5NDkzYjVfNi04LTEtMS04OTA3Mg_0f26368b-dfc9-43be-8ca1-e49f8a5e9e56">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of assets, net for the three months ended March 31, 2021, includes $<ix:nonFraction unitRef="usd" contextRef="ib705b8700b7f48e8b664f48c1ff6c694_D20210101-20210331" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184NS9mcmFnOjY0ZmUxN2U3ZDJiYzQxMjFhYThiYjc5MzNhN2FhNDQxL3RleHRyZWdpb246NjRmZTE3ZTdkMmJjNDEyMWFhOGJiNzkzM2E3YWE0NDFfMTAyNw_1be29b36-ddc4-452b-a091-419557c1b57d">25</ix:nonFraction>&#160;million related to the achievement of a milestone related to a certain product.</span></div></ix:continuation><div id="i801c461cbd33492a893c84373a8e7cbc_88"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184OC9mcmFnOjgyZWIxNTk5NmI2ZjQ5MDFhMjY0NzI0NTFiMmIyNjhlL3RleHRyZWdpb246ODJlYjE1OTk2YjZmNDkwMWEyNjQ3MjQ1MWIyYjI2OGVfNzg1MQ_f51e3c65-6489-476f-b822-e59cc90fd5e8" continuedAt="i4886afd76e804992b27a74649e6f9127" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="i4886afd76e804992b27a74649e6f9127" continuedAt="i571c16a3c2bf449d95724c94994b0ba8"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For interim financial statement purposes, U.S. GAAP income tax expense/benefit related to ordinary income is determined by applying an estimated annual effective income tax rate against a company&#8217;s ordinary income. Income tax expense/benefit related to items not characterized as ordinary income is recognized as a discrete item when incurred. The estimation of the Company&#8217;s income tax provision requires the use of management forecasts and other estimates, application of statutory income tax rates, and an evaluation of valuation allowances. The Company&#8217;s estimated annual effective income tax rate may be revised, if necessary, in each interim period.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Benefit from income taxes for the three months ended March 31, 2022 was $<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184OC9mcmFnOjgyZWIxNTk5NmI2ZjQ5MDFhMjY0NzI0NTFiMmIyNjhlL3RleHRyZWdpb246ODJlYjE1OTk2YjZmNDkwMWEyNjQ3MjQ1MWIyYjI2OGVfNzA3_9b5e2a8f-0ce4-4497-b3b1-3bee482dda94">16</ix:nonFraction> million and included: (i) $<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184OC9mcmFnOjgyZWIxNTk5NmI2ZjQ5MDFhMjY0NzI0NTFiMmIyNjhlL3RleHRyZWdpb246ODJlYjE1OTk2YjZmNDkwMWEyNjQ3MjQ1MWIyYjI2OGVfNzI4_e5324ef9-1c49-421e-bf50-c0ede4ec60a0">14</ix:nonFraction>&#160;million of income tax expense for the Company&#8217;s ordinary loss for the three months ended March 31, 2022 and (ii) $<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" sign="-" name="bhc:EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184OC9mcmFnOjgyZWIxNTk5NmI2ZjQ5MDFhMjY0NzI0NTFiMmIyNjhlL3RleHRyZWdpb246ODJlYjE1OTk2YjZmNDkwMWEyNjQ3MjQ1MWIyYjI2OGVfODA1_326a4b88-4a46-4194-a0f9-ce5d961546a8">30</ix:nonFraction> million of net income tax benefit for discrete items, which includes: (a) $<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationTaxContingencies" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184OC9mcmFnOjgyZWIxNTk5NmI2ZjQ5MDFhMjY0NzI0NTFiMmIyNjhlL3RleHRyZWdpb246ODJlYjE1OTk2YjZmNDkwMWEyNjQ3MjQ1MWIyYjI2OGVfODc0_0ca882a1-66af-40f7-a182-9f21cc909e7e">36</ix:nonFraction>&#160;million of net income tax benefit tax provision recognized for changes in uncertain tax positions, and (b) a $<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="bhc:EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184OC9mcmFnOjgyZWIxNTk5NmI2ZjQ5MDFhMjY0NzI0NTFiMmIyNjhlL3RleHRyZWdpb246ODJlYjE1OTk2YjZmNDkwMWEyNjQ3MjQ1MWIyYjI2OGVfMTIwMQ_daf72e3a-3fd7-46a2-bf09-2069667f7bec">6</ix:nonFraction>&#160;million tax provision associated with filing certain tax returns.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes for the three months ended March 31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184OC9mcmFnOjgyZWIxNTk5NmI2ZjQ5MDFhMjY0NzI0NTFiMmIyNjhlL3RleHRyZWdpb246ODJlYjE1OTk2YjZmNDkwMWEyNjQ3MjQ1MWIyYjI2OGVfMTI5Mw_9815a60a-12c3-45e7-bd14-b54a5c6101c6">16</ix:nonFraction> million and included: (i) $<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="bhc:EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184OC9mcmFnOjgyZWIxNTk5NmI2ZjQ5MDFhMjY0NzI0NTFiMmIyNjhlL3RleHRyZWdpb246ODJlYjE1OTk2YjZmNDkwMWEyNjQ3MjQ1MWIyYjI2OGVfMTMxNA_d6ee057c-398d-42fd-80e7-c756ed98a55d">49</ix:nonFraction> million of net income tax provision for discrete items, which includes: (a) a $<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="bhc:EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184OC9mcmFnOjgyZWIxNTk5NmI2ZjQ5MDFhMjY0NzI0NTFiMmIyNjhlL3RleHRyZWdpb246ODJlYjE1OTk2YjZmNDkwMWEyNjQ3MjQ1MWIyYjI2OGVfMTM4Mw_42fce428-cc73-483b-a54d-85a433aa9a26">46</ix:nonFraction>&#160;million tax provision related to potential and recognized withholding tax on intercompany dividends, (b) a $<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184OC9mcmFnOjgyZWIxNTk5NmI2ZjQ5MDFhMjY0NzI0NTFiMmIyNjhlL3RleHRyZWdpb246ODJlYjE1OTk2YjZmNDkwMWEyNjQ3MjQ1MWIyYjI2OGVfMTQ1OQ_18488f30-01b2-431a-a445-6cd374c7d36a">6</ix:nonFraction>&#160;million tax benefit associated with the filing of certain tax returns, (c) a $<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184OC9mcmFnOjgyZWIxNTk5NmI2ZjQ5MDFhMjY0NzI0NTFiMmIyNjhlL3RleHRyZWdpb246ODJlYjE1OTk2YjZmNDkwMWEyNjQ3MjQ1MWIyYjI2OGVfMTUzMg_4cd30574-9948-4e80-b3fd-605494c91c05">6</ix:nonFraction> million tax benefit related to a deduction for stock compensation (d) a $<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:IncomeTaxReconciliationTaxContingencies" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184OC9mcmFnOjgyZWIxNTk5NmI2ZjQ5MDFhMjY0NzI0NTFiMmIyNjhlL3RleHRyZWdpb246ODJlYjE1OTk2YjZmNDkwMWEyNjQ3MjQ1MWIyYjI2OGVfMTYwOA_8bd3d62d-addb-4cfd-963c-f8fc4ddc9fcf">3</ix:nonFraction> million tax provision recognized for changes in uncertain tax positions and (ii) $<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184OC9mcmFnOjgyZWIxNTk5NmI2ZjQ5MDFhMjY0NzI0NTFiMmIyNjhlL3RleHRyZWdpb246ODJlYjE1OTk2YjZmNDkwMWEyNjQ3MjQ1MWIyYjI2OGVfMTc1MQ_5e78c59f-4b49-4a34-bf04-e0ec06f2b6a8">33</ix:nonFraction>&#160;million of income tax benefit for the Company&#8217;s ordinary loss for the three months ended March 31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, the provision for income taxes will increase or decrease, respectively, in the period such determination is made except that, as a result of the 2018 adoption of guidance regarding intra-entity transfers, any change in valuation allowance surrounding the adoption of the intra-entity transfer resulting from this adoption was recorded within equity. The valuation allowance against deferred tax assets was $<ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184OC9mcmFnOjgyZWIxNTk5NmI2ZjQ5MDFhMjY0NzI0NTFiMmIyNjhlL3RleHRyZWdpb246ODJlYjE1OTk2YjZmNDkwMWEyNjQ3MjQ1MWIyYjI2OGVfMjUwMA_b8dd3a60-61c9-451f-904f-b7017cbbb614">2,252</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184OC9mcmFnOjgyZWIxNTk5NmI2ZjQ5MDFhMjY0NzI0NTFiMmIyNjhlL3RleHRyZWdpb246ODJlYjE1OTk2YjZmNDkwMWEyNjQ3MjQ1MWIyYjI2OGVfMjUwNw_6a1e609c-8158-4a2e-b70d-9476d3935380">2,222</ix:nonFraction> million as of March&#160;31, 2022 and December&#160;31, 2021, respectively. The decrease was primarily due to loss in Canada. The Company will continue to assess the need for a valuation allowance on a go-forward basis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 8, 2021, the Organisation for Economic Co-operation and Development (&#8220;OECD&#8221;)/G20 inclusive framework on Base Erosion and Profit Shifting (the &#8220;Inclusive Framework&#8221;) published a statement updating and finalizing the key components of a two-pillar plan on global tax reform originally agreed on July 1, 2021, and a timetable for implementation by 2023. The Inclusive Framework plan has now been agreed to by 141 OECD members, including several countries which did not agree to the initial plan. Under pillar one, taxing rights over multinational businesses with global turnover above &#8364;20 billion and a profit margin above 10% will generally be re-allocated to market jurisdictions. Under pillar two, the Inclusive Framework has agreed on a global minimum corporate tax rate of 15% for companies with revenue above &#8364;750 million, calculated on a country-by-country basis. On October 30, 2021, the G20 formally endorsed the new global minimum corporate tax rate rules. The Inclusive Framework agreement must now be implemented by the OECD Members who have agreed to the plan, effective in 2023. On December 20, 2021, the OECD published model rules to implement the pillar two rules, which are generally consistent with agreements reached by the Inclusive Framework in October 2021. Additional guidance is expected to be published in 2022. The Company will continue to monitor the implementation of the Inclusive Framework agreement by the countries in which we operate. While the Company is unable to predict when and how the Inclusive Framework agreement will be enacted into law in these countries, it is possible that the implementation of the </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i571c16a3c2bf449d95724c94994b0ba8"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inclusive Framework agreement, including the global minimum corporate tax rate could have a material effect on the Company&#8217;s liability for corporate taxes and the Company&#8217;s consolidated effective tax rate. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022 and December&#160;31, 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184OC9mcmFnOjgyZWIxNTk5NmI2ZjQ5MDFhMjY0NzI0NTFiMmIyNjhlL3RleHRyZWdpb246ODJlYjE1OTk2YjZmNDkwMWEyNjQ3MjQ1MWIyYjI2OGVfNDM4MA_724eb3a5-2768-4c24-ac91-6144c797e8b7">876</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184OC9mcmFnOjgyZWIxNTk5NmI2ZjQ5MDFhMjY0NzI0NTFiMmIyNjhlL3RleHRyZWdpb246ODJlYjE1OTk2YjZmNDkwMWEyNjQ3MjQ1MWIyYjI2OGVfNDM4Nw_a94816db-d2c7-4b7c-8003-79f2e1a055bb">927</ix:nonFraction> million of unrecognized tax benefits, which included $<ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184OC9mcmFnOjgyZWIxNTk5NmI2ZjQ5MDFhMjY0NzI0NTFiMmIyNjhlL3RleHRyZWdpb246ODJlYjE1OTk2YjZmNDkwMWEyNjQ3MjQ1MWIyYjI2OGVfNDQzNQ_3db16d0f-c705-4729-9621-6298d91cb136">43</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184OC9mcmFnOjgyZWIxNTk5NmI2ZjQ5MDFhMjY0NzI0NTFiMmIyNjhlL3RleHRyZWdpb246ODJlYjE1OTk2YjZmNDkwMWEyNjQ3MjQ1MWIyYjI2OGVfNDQ0Mg_350a407c-b6b8-4993-a6ad-a627a80bc84f">41</ix:nonFraction> million of interest and penalties, respectively. Of the total unrecognized tax benefits as of March&#160;31, 2022, $<ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184OC9mcmFnOjgyZWIxNTk5NmI2ZjQ5MDFhMjY0NzI0NTFiMmIyNjhlL3RleHRyZWdpb246ODJlYjE1OTk2YjZmNDkwMWEyNjQ3MjQ1MWIyYjI2OGVfNDUzNQ_86816eb3-9da4-44cf-b619-604b175b803d">196</ix:nonFraction> million would reduce the Company&#8217;s effective tax rate, if recognized. The Company believes that it is reasonably possible that the total amount of unrecognized tax benefits at March&#160;31, 2022 could decrease by approximately $<ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184OC9mcmFnOjgyZWIxNTk5NmI2ZjQ5MDFhMjY0NzI0NTFiMmIyNjhlL3RleHRyZWdpb246ODJlYjE1OTk2YjZmNDkwMWEyNjQ3MjQ1MWIyYjI2OGVfNDc0MQ_bd27c767-0664-48de-9e6b-bed935d5826f">21</ix:nonFraction> million in the next 12 months as a result of the resolution of certain tax audits and other events.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to be under examination by the Canada Revenue Agency. The Company&#8217;s position as of March&#160;31, 2022 with regard to proposed audit adjustments was updated to reflect an updated assessment received for 2015 which would primarily result in a loss of tax attributes that are subject to a full valuation allowance.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Company undertook an internal restructuring in the form of what is commonly known as a Granite Trust transaction, which resulted in a recorded capital loss (the &#8220;2017 capital loss&#8221;). In the U.S., the 2014 tax year remains open to the extent of the portion of the 2017 capital loss carried back to that year. The Internal Revenue Service (&#8220;IRS&#8221;) is continuing its examination of the Company&#8217;s annual tax filings for 2015 and 2016 and the Company&#8217;s short period tax return for the period ended September 8, 2017, which was filed as a result of the Company&#8217;s internal restructuring efforts during 2017. Recently, the Company has received a notice of proposed adjustment from the IRS that would disallow the 2017 capital loss. To date, the Company has not received an assessment from the IRS but expects to receive a notice of proposed tax deficiency. The Company intends to contest any proposed tax deficiency through the IRS administrative appeals process, and if necessary, appropriate litigation. If the Company were ultimately unsuccessful in defending its position, and all or a substantial portion of the 2017 capital loss deduction were disallowed, the Company estimates, in a worst case scenario, that it could be liable for additional income taxes (excluding penalties and interest) of up to $<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184OC9mcmFnOjgyZWIxNTk5NmI2ZjQ5MDFhMjY0NzI0NTFiMmIyNjhlL3RleHRyZWdpb246ODJlYjE1OTk2YjZmNDkwMWEyNjQ3MjQ1MWIyYjI2OGVfNjQ2NQ_e5e440b6-6ddb-42f0-bee4-ddb5772e2f10">2,100</ix:nonFraction>&#160;million, which could have an adverse effect on the Company&#8217;s financial condition and results of operations. The Company intends to vigorously defend its position, including through appropriate litigation, if necessary, and ultimately believes it will sustain its deduction of the 2017 capital loss, and, accordingly, no income tax provision has been recorded. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s U.S. affiliates remain under examination for various state tax audits in the U.S. for years 2015 through 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s subsidiaries in Germany are under audit for tax years 2014 through 2016. At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company&#8217;s Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s subsidiaries in Australia are under audit by the Australian Taxation Office for various years beginning in 2011 through 2017. At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company&#8217;s Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain affiliates of the Company in regions outside of Canada, the U.S., Germany and Australia are currently under examination by relevant taxing authorities, and all necessary accruals have been recorded, including uncertain tax benefits.  At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company&#8217;s Consolidated Financial Statements.</span></div></ix:continuation><div id="i801c461cbd33492a893c84373a8e7cbc_91"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185MS9mcmFnOmIyN2I0MDRkZDY5YzQwMjFiNmVhNjg3NGE0ZjI5NGQyL3RleHRyZWdpb246YjI3YjQwNGRkNjljNDAyMWI2ZWE2ODc0YTRmMjk0ZDJfMTI1MA_7cd7165a-c6a6-4917-be55-7f716460dec0" continuedAt="i6cf77ab167694f83a2bc421f23b496aa" escape="true">LOSS PER SHARE</ix:nonNumeric></span></div><ix:continuation id="i6cf77ab167694f83a2bc421f23b496aa" continuedAt="i08af6461028e48ec9ca723bbcbe40237"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185MS9mcmFnOmIyN2I0MDRkZDY5YzQwMjFiNmVhNjg3NGE0ZjI5NGQyL3RleHRyZWdpb246YjI3YjQwNGRkNjljNDAyMWI2ZWE2ODc0YTRmMjk0ZDJfMTI2MA_64eb8a11-5ddb-4f0d-a9ea-473e70c5a4be" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share attributable to Bausch Health Companies Inc. were calculated as follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.066%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185MS9mcmFnOmIyN2I0MDRkZDY5YzQwMjFiNmVhNjg3NGE0ZjI5NGQyL3RhYmxlOjBhMDg4ZDNlYjBlZTQ5OTBiY2Q1YWFhNDhjN2E0M2ZhL3RhYmxlcmFuZ2U6MGEwODhkM2ViMGVlNDk5MGJjZDVhYWE0OGM3YTQzZmFfMi01LTEtMS04OTA3Mg_659f2e29-9a97-4ab5-8542-86eae9db9df8">69</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185MS9mcmFnOmIyN2I0MDRkZDY5YzQwMjFiNmVhNjg3NGE0ZjI5NGQyL3RhYmxlOjBhMDg4ZDNlYjBlZTQ5OTBiY2Q1YWFhNDhjN2E0M2ZhL3RhYmxlcmFuZ2U6MGEwODhkM2ViMGVlNDk5MGJjZDVhYWE0OGM3YTQzZmFfMi03LTEtMS04OTA3Mg_369c0376-acd7-4221-b1b9-a80a0d5253dd">610</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted weighted-average common shares outstanding</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185MS9mcmFnOmIyN2I0MDRkZDY5YzQwMjFiNmVhNjg3NGE0ZjI5NGQyL3RhYmxlOjBhMDg4ZDNlYjBlZTQ5OTBiY2Q1YWFhNDhjN2E0M2ZhL3RhYmxlcmFuZ2U6MGEwODhkM2ViMGVlNDk5MGJjZDVhYWE0OGM3YTQzZmFfMy01LTEtMS04OTA3Mg_e6341211-22c5-4e8d-9d08-6e5a2dfd55fc"><ix:nonFraction unitRef="shares" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185MS9mcmFnOmIyN2I0MDRkZDY5YzQwMjFiNmVhNjg3NGE0ZjI5NGQyL3RhYmxlOjBhMDg4ZDNlYjBlZTQ5OTBiY2Q1YWFhNDhjN2E0M2ZhL3RhYmxlcmFuZ2U6MGEwODhkM2ViMGVlNDk5MGJjZDVhYWE0OGM3YTQzZmFfMy01LTEtMS04OTA3Mg_f6333850-e51f-4b8d-b24f-f7cdca664bba">360.8</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185MS9mcmFnOmIyN2I0MDRkZDY5YzQwMjFiNmVhNjg3NGE0ZjI5NGQyL3RhYmxlOjBhMDg4ZDNlYjBlZTQ5OTBiY2Q1YWFhNDhjN2E0M2ZhL3RhYmxlcmFuZ2U6MGEwODhkM2ViMGVlNDk5MGJjZDVhYWE0OGM3YTQzZmFfMy03LTEtMS04OTA3Mg_4ad30366-a60d-45f8-87e0-3333fbc4dffa"><ix:nonFraction unitRef="shares" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185MS9mcmFnOmIyN2I0MDRkZDY5YzQwMjFiNmVhNjg3NGE0ZjI5NGQyL3RhYmxlOjBhMDg4ZDNlYjBlZTQ5OTBiY2Q1YWFhNDhjN2E0M2ZhL3RhYmxlcmFuZ2U6MGEwODhkM2ViMGVlNDk5MGJjZDVhYWE0OGM3YTQzZmFfMy03LTEtMS04OTA3Mg_5d3cff9e-3265-465c-ba1f-047936d2cb35">356.8</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per share attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185MS9mcmFnOmIyN2I0MDRkZDY5YzQwMjFiNmVhNjg3NGE0ZjI5NGQyL3RhYmxlOjBhMDg4ZDNlYjBlZTQ5OTBiY2Q1YWFhNDhjN2E0M2ZhL3RhYmxlcmFuZ2U6MGEwODhkM2ViMGVlNDk5MGJjZDVhYWE0OGM3YTQzZmFfNy01LTEtMS04OTA3Mg_f266d57c-b5a0-476e-a1b5-5001a199c220"><ix:nonFraction unitRef="usdPerShare" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185MS9mcmFnOmIyN2I0MDRkZDY5YzQwMjFiNmVhNjg3NGE0ZjI5NGQyL3RhYmxlOjBhMDg4ZDNlYjBlZTQ5OTBiY2Q1YWFhNDhjN2E0M2ZhL3RhYmxlcmFuZ2U6MGEwODhkM2ViMGVlNDk5MGJjZDVhYWE0OGM3YTQzZmFfNy01LTEtMS04OTA3Mg_f94db0b8-c47c-411f-a96f-5bb5b15b8d0b">0.19</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185MS9mcmFnOmIyN2I0MDRkZDY5YzQwMjFiNmVhNjg3NGE0ZjI5NGQyL3RhYmxlOjBhMDg4ZDNlYjBlZTQ5OTBiY2Q1YWFhNDhjN2E0M2ZhL3RhYmxlcmFuZ2U6MGEwODhkM2ViMGVlNDk5MGJjZDVhYWE0OGM3YTQzZmFfNy03LTEtMS04OTA3Mg_3a78cb4a-cd74-4e5a-82bb-785a086facdc"><ix:nonFraction unitRef="usdPerShare" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185MS9mcmFnOmIyN2I0MDRkZDY5YzQwMjFiNmVhNjg3NGE0ZjI5NGQyL3RhYmxlOjBhMDg4ZDNlYjBlZTQ5OTBiY2Q1YWFhNDhjN2E0M2ZhL3RhYmxlcmFuZ2U6MGEwODhkM2ViMGVlNDk5MGJjZDVhYWE0OGM3YTQzZmFfNy03LTEtMS04OTA3Mg_ad100ef4-2766-48cf-a11e-b7f8b7476e4d">1.71</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022 and 2021, all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive. The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been approximately <ix:nonFraction unitRef="shares" contextRef="i634a33b4555248bda810d4755ec7944f_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185MS9mcmFnOmIyN2I0MDRkZDY5YzQwMjFiNmVhNjg3NGE0ZjI5NGQyL3RleHRyZWdpb246YjI3YjQwNGRkNjljNDAyMWI2ZWE2ODc0YTRmMjk0ZDJfNDQz_9c613763-c2a1-4899-936a-f1105035d027">3,600,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i5cbb08e41ef540369a6004ec2d016b37_D20210101-20210331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185MS9mcmFnOmIyN2I0MDRkZDY5YzQwMjFiNmVhNjg3NGE0ZjI5NGQyL3RleHRyZWdpb246YjI3YjQwNGRkNjljNDAyMWI2ZWE2ODc0YTRmMjk0ZDJfNDUw_397831e2-9af3-4b23-8e97-e05f73f0087e">6,657,000</ix:nonFraction> common shares for the three months ended March 31, 2022 and 2021, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022 and 2021, time-based RSUs, performance-based RSUs and stock options to purchase approximately <ix:nonFraction unitRef="shares" contextRef="i0765fea13c904226bd504d19d10dcd55_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185MS9mcmFnOmIyN2I0MDRkZDY5YzQwMjFiNmVhNjg3NGE0ZjI5NGQyL3RleHRyZWdpb246YjI3YjQwNGRkNjljNDAyMWI2ZWE2ODc0YTRmMjk0ZDJfNTky_906cd794-d875-4aa6-aed1-394408fe3412">9,332,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i1b08aef1966547e9bd168396be5172b8_D20210101-20210331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185MS9mcmFnOmIyN2I0MDRkZDY5YzQwMjFiNmVhNjg3NGE0ZjI5NGQyL3RleHRyZWdpb246YjI3YjQwNGRkNjljNDAyMWI2ZWE2ODc0YTRmMjk0ZDJfNTk5_6d1eb00a-de8b-4f32-819b-7b9f29b0a51b">4,846,000</ix:nonFraction> common shares, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method. During the three </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i08af6461028e48ec9ca723bbcbe40237">months ended March 31, 2022, an additional <ix:nonFraction unitRef="shares" contextRef="i6c234ad885934263b7d0d458906eac06_D20220101-20220331" decimals="-3" name="bhc:SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185MS9mcmFnOmIyN2I0MDRkZDY5YzQwMjFiNmVhNjg3NGE0ZjI5NGQyL3RleHRyZWdpb246YjI3YjQwNGRkNjljNDAyMWI2ZWE2ODc0YTRmMjk0ZDJfODA5_49da0c0b-5659-4da2-93aa-54bcf6100f1a"><ix:nonFraction unitRef="shares" contextRef="i6c234ad885934263b7d0d458906eac06_D20220101-20220331" decimals="-3" name="bhc:SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185MS9mcmFnOmIyN2I0MDRkZDY5YzQwMjFiNmVhNjg3NGE0ZjI5NGQyL3RleHRyZWdpb246YjI3YjQwNGRkNjljNDAyMWI2ZWE2ODc0YTRmMjk0ZDJfODA5_5f5fa1c1-662c-48e2-9bf9-603878807fe7">156,000</ix:nonFraction></ix:nonFraction> performance-based RSUs were not included in the computation of diluted earnings per share as the required performance conditions had not been met.</ix:continuation> </span></div><div id="i801c461cbd33492a893c84373a8e7cbc_94"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfNDYwMjI_969d8b27-43eb-41b9-9a97-6710d08f2bab" continuedAt="iffa0945929ac41ff9e37962a82b7c6f0" escape="true">LEGAL PROCEEDINGS</ix:nonNumeric></span></div><ix:continuation id="iffa0945929ac41ff9e37962a82b7c6f0" continuedAt="i26089d65c1a74fc6a3c063ae4f8f12d0"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company becomes involved in various legal and administrative proceedings, which include product liability, intellectual property, commercial, tax, antitrust, governmental and regulatory investigations, related private litigation and ordinary course employment-related issues. From time to time, the Company also initiates actions or files counterclaims. The Company could be subject to counterclaims or other suits in response to actions it may initiate. The Company believes that the prosecution of these actions and counterclaims is important to preserve and protect the Company, its reputation and its assets. Certain of these proceedings and actions are described in Note 20, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC and the CSA on February 23, 2022. Except as described below, there have been no material updates or developments with respect to any such proceedings or actions during the three months ended March 31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a quarterly basis, the Company evaluates developments in legal proceedings, potential settlements and other matters that could increase or decrease the amount of the liability accrued. As of March 31, 2022, the Company&#8217;s Consolidated Balance Sheets includes accrued current loss contingencies of $<ix:nonFraction unitRef="usd" contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331" decimals="-6" name="us-gaap:LitigationReserveCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMTM2Nw_b5f3d4e1-a83c-474c-b641-01e4962498fa">1,530</ix:nonFraction> million related to matters which are both probable and reasonably estimable. For all other matters, unless otherwise indicated, the Company cannot reasonably predict the outcome of these legal proceedings, nor can it estimate the amount of loss, or range of loss, if any, that may result from these proceedings. An adverse outcome in certain of these proceedings could have a material adverse effect on the Company&#8217;s business, financial condition and results of operations, and could cause the market value of its common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governmental and Regulatory Inquiries</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As referenced above, during the three months ended March 31, 2022, there have been no material updates or developments with respect to certain other proceedings or actions as described under &#8220;Governmental and Regulatory Inquiries&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 20, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC and the CSA on February 23, 2022. These matters include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigation by the U.S. Attorney&#8217;s Office for the District of Massachusetts - re OraPharma</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company received a subpoena from the U.S. Attorney&#8217;s Office for the District of Massachusetts, requesting materials including documents concerning the sales, marketing, coverage and reimbursement of Arestin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including related support services, and other matters. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is cooperating with this investigation. The Company cannot predict the outcome or the duration of this investigation or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of this investigation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities and RICO Class Actions and Related Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Securities Litigation - Opt-Out Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2019, the Company announced that it had agreed to settle, subject to final court approval, the consolidated securities class action filed in the U.S. District Court for the District of New Jersey (In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658). On January 31, 2021, the District Court issued an order granting final approval of this settlement. On February 4, 2021, Timber Hill LLC filed a notice of appeal of the Court&#8217;s final approval order, which overruled its objections to the allocation of settlement proceeds as between common stock and options. On March 1, 2021, Cathy Lochridge filed a notice of appeal of the Court&#8217;s final approval order, which overruled her objections as to the attorneys&#8217; fees awarded to class counsel. On October 14, 2021, Timber Hill LLC dismissed its appeal of the final approval order. On December 20, 2021, the Third Circuit denied Lochridge&#8217;s appeal. On January 3, 2022, Lochridge filed a petition for rehearing of the appeal en banc which remains pending.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2015, <ix:nonFraction unitRef="case" contextRef="ice3d4454e30642078b6d278363d32c89_D20151001-20151031" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfNDA2OA_131b84c7-8851-42f2-b061-6c490ee8c6a5">four</ix:nonFraction> putative securities class actions were filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. The allegations related to, among other things, allegedly false and misleading statements and/or failures to disclose information about the Company&#8217;s business and prospects, including relating to drug pricing, the Company&#8217;s use of specialty pharmacies, and the Company&#8217;s relationship with Philidor. On May 31, 2016, the court entered an order consolidating the <ix:nonFraction unitRef="case" contextRef="ice3d4454e30642078b6d278363d32c89_D20151001-20151031" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfNDYwOQ_ee414666-abe6-4e18-89f6-67f6736bf914">four</ix:nonFraction> actions under the caption In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658. On December 16, 2019, the Company, the current or former officers and directors, ValueAct, and the underwriters announced that they agreed to resolve the securities action for $<ix:nonFraction unitRef="usd" contextRef="i8498207cf8ab47a98694e871b43ed0ac_D20191216-20191216" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfNDkwOQ_fde975e5-a86d-43ad-aeff-442f77f13538">1,210</ix:nonFraction> million, subject to final court approval. This settlement received final approval from the court on January </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i26089d65c1a74fc6a3c063ae4f8f12d0" continuedAt="i375b339b4333483b81d9b48b0e82924e"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31, 2021 and will resolve and discharge all claims against the Company in the class action. As part of the settlement, the Company and the other settling defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. The settlement remains subject to appeal of the final court approval (as such appeal is further described above). In order to qualify for a settlement payment all persons and entities that purchased or otherwise acquired the Company securities during the class period must have submitted a proof of claim and release form by May 6, 2020. The settlement payments have been paid into an escrow account in accordance with the payment schedule outlined in the settlement agreement. These payments, less certain settlement expenses and attorneys&#8217; fees, will remain in escrow until resolution of the appeal of the final court approval of the settlement agreement. The opt-out litigations discussed below remain ongoing. As of March 31, 2022, Restricted cash and other settlement deposits includes an aggregate $<ix:nonFraction unitRef="usd" contextRef="i52b91cd6bf81428da787050c41b56633_D20220331-20220331" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMjc0ODc3OTE3MzA4NA_cfdf29c4-f545-4294-931e-d63339fc8047">1,210</ix:nonFraction>&#160;million of: (i) payments in the escrow fund and (ii) certain disbursements for settlement expenses and attorney&#8217;s fees. Disbursements for attorney&#8217;s fees remain refundable until resolution of the appeal of the final court approval of the settlement agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2018, a putative class action was filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. This action, captioned Timber Hill LLC, v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 18-cv-10246) (&#8220;Timber Hill&#8221;), asserts securities fraud claims under Sections 10(b) and 20(a) of the Exchange Act on behalf of a putative class of persons who purchased call options or sold put options on the Company&#8217;s common stock during the period January 4, 2013 through August 11, 2016. On June 11, 2018, this action was consolidated with In re Valeant Pharmaceuticals International, Inc. Securities Litigation, (Case No. 15-cv-07658). On January 14, 2019, the defendants filed a motion to dismiss the Timber Hill complaint. Briefing on that motion was completed on February 13, 2019. On August 15, 2019, the Court denied the motion to dismiss the Timber Hill action, holding that this complaint was a legal nullity as a result of the June 11, 2018 consolidation order.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the consolidated putative class action, <ix:nonFraction unitRef="group" contextRef="if9003a9e8d5e4cb890f3dca99318e110_D20220101-20220331" decimals="INF" name="bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfNzA1MA_1100b259-6240-44e5-837e-3fe75ed216ab">thirty-seven</ix:nonFraction> groups of individual investors in the Company&#8217;s stock and debt securities have chosen to opt out of the consolidated putative class action and filed securities actions in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. These actions were captioned previously in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed on February 23, 2022. <ix:nonFraction unitRef="case" contextRef="if9003a9e8d5e4cb890f3dca99318e110_D20220101-20220331" decimals="INF" name="us-gaap:LossContingencyClaimsDismissedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfNzUwMw_f3c037d8-d3a1-475f-b113-bc0765481aa0">Sixteen</ix:nonFraction> of the <ix:nonFraction unitRef="group" contextRef="if9003a9e8d5e4cb890f3dca99318e110_D20220101-20220331" decimals="INF" name="bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfNzUxMw_1100b259-6240-44e5-837e-3fe75ed216ab">thirty-seven</ix:nonFraction> opt-out actions have been dismissed; and the total number of remaining opt-out actions pending in the District of New Jersey is <ix:nonFraction unitRef="group" contextRef="if9003a9e8d5e4cb890f3dca99318e110_D20220101-20220331" decimals="INF" name="bhc:LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfNzY0NA_25695cb8-37d8-4cf7-9f70-8ef7adda6c2b">twenty-one</ix:nonFraction> actions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These individual shareholder actions assert claims under Sections 10(b), and 20(a) of the Exchange Act. Certain of these individual actions assert additional claims, including claims under Section 18 of the Exchange Act, Sections 11, 12(a)(2), and 15 of the Securities Act, common law fraud, negligent misrepresentation, and claims under the New Jersey Racketeer Influenced and Corrupt Organizations Act. These claims are based on alleged purchases of Company stock, options, and/or debt at various times between January 3, 2013 and August 10, 2016. The allegations in the complaints are similar to those made by plaintiffs in the putative class action. Motions to dismiss have been filed and in most cases decided in many of these individual actions. To date, the Court has dismissed state law claims including New Jersey Racketeer Influenced and Corrupt Organizations Act, common law fraud, and negligent misrepresentation claims in certain cases. On January 7, 2019, the Court entered a stipulation of voluntary dismissal in the Senzar Healthcare Master Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-02286) opt-out action, closing the case. On September 10, 2019, the Court granted defendants&#8217; motion to dismiss all claims in the Bahaa Aly v. Valeant Pharmaceuticals International, Inc. (&#8220;Aly&#8221;) (Case No. 18-cv-17393) opt-out action. On October 9, 2019, the Aly Plaintiffs filed a notice of appeal to the United States Court of Appeals for the Third Circuit. On June 16, 2021, the Court of Appeals granted plaintiffs&#8217; appeal in the Aly action. This action has been remanded to the District Court. On June 19, 2020, the Court entered stipulations of voluntary dismissal in the Catalyst, Mississippi, Connecticut, and Delaware actions. On July 13, 2020, the Court entered a stipulation of voluntary dismissal in the NYCERS action. On December 30, 2020, the Court entered a stipulation of voluntary dismissal in the BlueMountain action. On February 18, 2021, and March 10, 2021, the Court entered stipulations of voluntary dismissal in the T. Rowe, BloombergSen, Principal Funds, Pentwater, Lord Abbett, Equity Trustees, and UC Regents actions. On April 30, 2021, the Court entered a stipulation of voluntary dismissal in the Florida SBA action. On July 20, 2021, the Court entered a stipulation of voluntary dismissal in the Janus action.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disputes the claims against it in the remaining individual opt-out complaints and intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Canadian Securities Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, <ix:nonFraction unitRef="case" contextRef="i596e029672034f1ebeeeb10da808b0b3_D20150101-20151231" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMTAxOTU_f7e66203-70a7-49f9-b589-41715d19af4c">six</ix:nonFraction> putative class actions were filed and served against the Company and certain current or former officers and directors in Canada in the provinces of British Columbia, Ontario and Quebec. The Company is also aware of <ix:nonFraction unitRef="action" contextRef="iffef6edab6454226a9a750b828094eab_D20220101-20220331" decimals="INF" name="bhc:LossContingencyNewClaimsFiledButNotYetServedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMTA0MTM_b34b4600-e04a-486f-873a-9f41007c3bb2">two</ix:nonFraction> additional putative class actions that were filed with the applicable court but which have not been served on the Company and the factual allegations made in these actions are substantially similar to those outlined herein. These actions were captioned previously in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed on February 23, 2022.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i375b339b4333483b81d9b48b0e82924e" continuedAt="i025260017dff4e0ba30a227da8819664"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actions generally allege violations of Canadian provincial securities legislation on behalf of putative classes of persons who purchased or otherwise acquired securities of the Company for periods commencing as early as January 1, 2013 and ending as late as November 16, 2015. The alleged violations relate to the same matters described in the U.S. Securities Litigation description above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these putative class actions, other than the Catucci action in the Quebec Superior Court, was discontinued. In the Catucci action, on August 29, 2017, the judge granted the plaintiffs leave to proceed with their claims under the Quebec Securities Act and authorized the class proceeding. On October 26, 2017, the plaintiffs issued their Judicial Application Originating Class Proceedings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After a hearing on November 11, 2019, the court approved a settlement in the Catucci action between the class members and the Company&#8217;s auditors and the action was dismissed as against them. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 4, 2020, the Company entered into a settlement agreement with the plaintiffs in Catucci, on behalf of the class, pursuant to which it agreed to resolve the Catucci action for the amount of CAD <ix:nonFraction unitRef="cad" contextRef="i66e66455cad94f43bea051172349e294_D20200804-20200804" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMTE4Mjc_481628f0-7d19-4ede-a37f-7f58ffb6e257">94,000,000</ix:nonFraction> plus payment of an additional amount to cover notice and settlement administration costs and disbursements. As part of the settlement, the Company and the other defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. Court approval of the settlement was granted after a hearing on November 16, 2020. The Catucci action has now been dismissed against the Company, its current and former directors and officers, its underwriters and its insurers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the class proceedings described above, on April 12, 2018, the Company was served with an application for leave filed in the Quebec Superior Court of Justice to pursue an action under the Quebec Securities Act against the Company and certain current or former officers and directors. This proceeding is captioned BlackRock Asset Management Canada Limited et al. v. Valeant, et al. (Court File No. 500-11-054155-185). The allegations in the proceeding are similar to those made by plaintiffs in the Catucci class action. On June 18, 2018, the same BlackRock entities filed an originating application (Court File No. 500-17-103749-183) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is aware that certain other members of the Catucci class exercised their opt-out rights prior to the June 19, 2018 deadline. On February 15, 2019, <ix:nonFraction unitRef="entity" contextRef="ib9363f6177cc4981a294b2f6d18e765d_I20190215" decimals="INF" name="bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMTMyNTM_fd1ec1f8-4429-4303-bb3f-b561c6d58077">one</ix:nonFraction> of the entities which exercised its opt-out rights, the California State Teachers&#8217; Retirement System (&#8220;CalSTRS&#8221;), served the Company with an application in the Quebec Superior Court of Justice for leave to pursue an action under the Quebec Securities Act against the Company, certain current or former officers and directors of the Company and its auditor. That proceeding is captioned California State Teachers&#8217; Retirement System v. Bausch Health Companies Inc. et al. (Court File No. 500-11-055722-181). The allegations in the proceeding are similar to those made by the plaintiffs in the Catucci class action and in the BlackRock opt-out proceedings. On that same date, CalSTRS also served the Company with proceedings (Court File No. 500-17-106044-186) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 3, 2020, the Quebec Superior Court granted the applications of CalSTRS and BlackRock for leave to pursue their respective actions asserting claims under the Quebec Securities Act. On June 16, 2020, the Quebec Court of Appeal granted the defendants leave to appeal that decision. The appeal was heard on September 29, 2021 and, by judgment dated October 29, 2021, the appeals were dismissed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 8 and 9, 2020, respectively, CalSTRS amended its proceedings to, among other things, include a new alleged misrepresentation concerning the accounting treatment of &#8220;price appreciation credits&#8221; in respect of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the period covered by the claims. A hearing was held on February 17, 2021 with respect to whether CalSTRS would be permitted to file the proposed amended proceedings.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 9, 2021, the Quebec Superior Court granted the Company&#8217;s application to strike the new allegations from its Quebec Securities Act claim, but permitted the amendments to its claim under the Quebec Civil Code. On December 8, 2021, CalSTRS delivered its amended pleadings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 17, 2021, <ix:nonFraction unitRef="entity" contextRef="i3e992c240c2041b78b9cd6b48dde9c97_I20210317" decimals="INF" name="bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMTUxNzg_6448a0cc-e337-46d7-8221-be18a29e523a">four</ix:nonFraction> additional opt-outs from the Catucci class issued a Statement of Claim in the Ontario Superior Court of Justice. That proceeding is captioned The Bank of Korea et al. v. Valeant Pharmaceuticals International Inc. et al. (Court File No. 21-006589666-0000). In addition, these plaintiffs also served and filed a motion for leave to pursue claims under the Ontario Securities Act. The allegations in this proceeding are similar to those made by the plaintiffs in the Catucci class action and the plaintiffs in the opt-out actions described above. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that it has viable defenses in each of these actions. In each case, the Company intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RICO Class Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between May 27, 2016 and September 16, 2016, <ix:nonFraction unitRef="action" contextRef="i70e88a8ce2b644ebb754e35500783f63_D20160527-20160916" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMTU5Mjg_f4477fc8-129b-4987-bce7-7b382b5b7a01">three</ix:nonFraction> actions were filed in the U.S. District Court for the District of New Jersey against the Company and various third-parties (these actions were subsequently consolidated), alleging claims under </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i025260017dff4e0ba30a227da8819664" continuedAt="i922db311f7fd49389e6d5022a67337e5"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the federal Racketeer Influenced Corrupt Organizations Act (&#8220;RICO&#8221;) on behalf of a putative class of certain third-party payors that paid claims submitted by Philidor for certain Company-branded drugs between January 2, 2013 and November 9, 2015.&#160; The consolidated complaint alleges, among other things, that the defendants committed predicate acts of mail and wire fraud by submitting or causing to be submitted prescription reimbursement requests that misstated or omitted facts regarding: (1) the identity and licensing status of the dispensing pharmacy; (2) the resubmission of previously denied claims; (3) patient co-pay waivers; (4) the availability of generic alternatives; and (5) the insured&#8217;s consent to renew the prescription.&#160;The complaint further alleges that these acts constitute a pattern of racketeering or a racketeering conspiracy in violation of the RICO statute and caused plaintiffs and the putative class unspecified damages, which may be trebled under the RICO statute.&#160;On August 4, 2021, the Company executed a stipulation of settlement for this action and, on August 17, 2021, the Court preliminarily approved the settlement. On December 6, 2021 the Special Master overseeing this litigation issued a report and recommendation recommending final approval of the settlement, and on February 22, 2022 the settlement was approved by the district court. The time to appeal the district court&#8217;s final approval order expired on March 24, 2022. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Securities and RICO Class Actions and Related Matters</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As referenced above, during the three months ended March 31, 2022, there have been no material updates or developments with respect to certain other proceedings or actions as described under &#8220;Securities and RICO Class Actions and Related Matters&#8221; in Note 20, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC and the CSA on February 23, 2022. Such matters include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Insurance Coverage Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2017, the Company filed a lawsuit against its insurance companies that issued insurance policies covering claims made against the Company, its subsidiaries, and its directors and officers during <ix:nonFraction unitRef="insurance_policy_period" contextRef="i9c2253862a7e47b3abf3762d16caa354_D20171207-20171207" decimals="INF" name="bhc:LossContingencyNumberOfInsurancePolicyPeriods" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMTc1Nzc_c6f43704-84e8-441e-8c5d-bf91a25dd7a7">two</ix:nonFraction> distinct policy periods, (i) 2013-14 and (ii) 2015-16. The lawsuit is currently pending in the United States District Court for the District of New Jersey (Valeant Pharmaceuticals International, Inc., et al. v. AIG Insurance Company of Canada, et al.; Case No. 3:18-CV-00493). In the lawsuit, the Company seeks coverage for: (i) the costs of defending and resolving claims brought by former shareholders and debtholders of Allergan, Inc. in In re Allergan, Inc. Proxy Violation Securities Litigation and Timber Hill LLC, individually and on behalf of all others similarly situated v. Pershing Square Capital Management, L.P., et al. (the &#8220;Allergan Securities Litigation&#8221;) (under the 2013-2014 coverage period), and (ii) costs incurred and to be incurred in connection with the securities class actions and opt-out cases described in this section and the SEC Investigation and certain of the other investigations described under &#8220;Complete or Inactive Matters&#8221; in Note 20, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC and the CSA on February 24, 2021 and under &#8220;Governmental and Regulatory Inquiries&#8221; and &#8220;Complete or Inactive Matters&#8221; in Note 21, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC and the CSA on February 19, 2020 (under the 2015-2016 coverage period).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 20, 2021, the Company entered into settlement agreements with the insurers in the 2015-2016 coverage period in which the Company agreed to resolve its claims for insurance coverage in connection with the U.S. Securities Litigation and the Canadian Securities Litigation and related opt-out litigation and related investigations matters described above. On that same day, the Company entered into settlement agreements with <ix:nonFraction unitRef="insured" contextRef="i56f9cd8d429c490aa470859df6ea769c_I20210720" decimals="INF" name="bhc:LossContingencySettlementAgreementsNumberOfInsurers" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMTk1NDI_ec52029c-4a57-4d9c-89ff-3e35ff13d2a2">two</ix:nonFraction> of its insurers in the 2013-2014 coverage period in which the Company agreed to resolve its claims against those <ix:nonFraction unitRef="insured" contextRef="i56f9cd8d429c490aa470859df6ea769c_I20210720" decimals="INF" name="bhc:LossContingencySettlementAgreementsNumberOfInsurers" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMTk2NTg_06005d09-6667-4d49-be1e-2ce84ed98b02">two</ix:nonFraction> insurers only for insurance coverage in connection with the Allergan Securities Litigation. As a result of all of the settlement agreements entered into with the insurers on July 20, 2021, the Company has received an aggregate sum of $<ix:nonFraction unitRef="usd" contextRef="i33fa032d820947a1b95a1ffae232ac03_D20210720-20210720" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedFromOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMTk4OTU_6d8a89c8-de9a-4ba1-976e-27950d33e70c">213</ix:nonFraction>&#160;million. The Company&#8217;s insurance claims with respect to the Allergan Securities Litigation against the remaining insurers in the 2013-2014 coverage period remain pending.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Hound Partners Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, Hound Partners Offshore Fund, LP, Hound Partners Long Master, LP, and Hound Partners Concentrated Master, LP, filed a lawsuit against the Company in the Superior Court of New Jersey Law Division/Mercer County that asserts claims for common law fraud, negligent misrepresentation, and violations of the New Jersey Racketeer Influenced and Corrupt Organizations Act. The Company disputes the claims and intends to vigorously defend this matter.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Antitrust</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glumetza Antitrust Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between August 2019 and July 2020, <ix:nonFraction unitRef="case" contextRef="ia47d407ff7c64c98a6e296b58ca6f86d_D20190801-20200730" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMjI3OTc_f8272f83-2917-48d5-b200-4ade02e534b8">eight</ix:nonFraction> (8) putative antitrust class actions and <ix:nonFraction unitRef="case" contextRef="i7afbeb4c54a7426c95c622c88ede0f55_D20190801-20200730" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMjI4NDE_15c65db4-330a-4019-a489-b887c74f9905">four</ix:nonFraction> (4) non-class complaints naming the Company, Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc., and Santarus, Inc. (for purposes of this subsection, collectively, the &#8220;Company&#8221;), among other defendants, were filed or transferred to the Northern District of California. <ix:nonFraction unitRef="case" contextRef="ib6f99e9cc813479883c5c2dc19cb2f6b_D20190801-20200730" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMjMxMjA_50336fa9-f5d8-4800-bbaa-da28f941d542">Three</ix:nonFraction> (3) of the class actions were filed by plaintiffs seeking to represent a class of direct purchasers. The purported classes of </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i922db311f7fd49389e6d5022a67337e5" continuedAt="ia0138b8b19104698b40e107d32b73b29"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">direct purchasers filed a consolidated first amended complaint and a motion for class certification in April 2020. The court certified a direct purchaser class in August 2020. The putative class action complaints filed by end payer purchasers have all been voluntarily dismissed. <ix:nonFraction unitRef="case" contextRef="i3162f07bec9e4a3daa43dcea08a13f2b_D20190801-20200730" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMjM1MzA_0dde5229-e6b6-437c-b61c-c4c5ee9a60ac">Three</ix:nonFraction> (3) of the non-class complaints were filed by direct purchasers. The fourth non-class complaint, asserting claims based on both direct and indirect purchases, was filed by an insurer plaintiff in July 2020 and subsequently amended in September 2020. In December 2020, the court denied the Company&#8217;s motion to dismiss as to the insurer plaintiff&#8217;s direct claims but dismissed the insurer plaintiff&#8217;s indirect claims. On February 2, 2021, the insurer plaintiff&#8217;s motion for leave to amend its complaint was denied.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These actions were consolidated and coordinated in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 3:19-cv-05822-WHA (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The lawsuits alleged that a 2012 settlement of a patent litigation regarding Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or grant any other company a license to do so. The complaints alleged that the settlement agreement resulted in higher prices for Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its generic equivalent both prior to and after generic entry. Both the class and non-class plaintiffs sought damages under federal antitrust laws for claims based on direct purchases.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2021, the insurer plaintiff filed an action asserting its indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others (the &#8220;State Court Action&#8221;) (discussed in further detail below, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">see Glumetza State-Law Insurer Litigations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Defendants&#8217; demurrer in the State Court Action was heard on September 22, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 26, 2021, the Company reached an agreement in principle and, thereafter, on September 14, 2021, executed a final settlement agreement to resolve the class plaintiffs&#8217; claims for $<ix:nonFraction unitRef="usd" contextRef="i7cdef9a49476491db7e461eeea893094_D20210726-20210726" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMjUyMDE_3d853262-f6f2-4395-bbe7-a14cb5337894">300</ix:nonFraction>&#160;million, subject to court approval. On August 1, 2021, the Company also reached an agreement in principle to resolve the non-class direct purchaser plaintiffs&#8217; claims, described above, for additional consideration. A final settlement agreement with the non-class direct purchaser plaintiffs was executed on August 6, 2021. As part of the settlements, the Company admitted no liability as to the claims against it and denied all allegations of wrongdoing. On September 20, 2021, the insurer plaintiff voluntarily dismissed its claims in the consolidated federal action. By stipulation, the insurer plaintiff has asserted its direct opt-out claims in the State Court Action, resulting in the consolidation of all of its opt-out claims in the State Court Action.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 22, 2021, the court granted preliminary approval of the class settlement agreement and vacated the October 2021 trial date and all other pre-trial deadlines in the consolidated actions. On February 3, 2022, the court granted final approval of the class settlement and ordered dismissal of the class plaintiffs&#8217; claims. The deadline to appeal the final approval of the class settlement has now passed, and the settlements have resolved and discharged all asserted class and direct purchaser non-class claims against the Company in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Pricing Antitrust Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s subsidiaries, Oceanside Pharmaceuticals, Inc. (&#8220;Oceanside&#8221;), Bausch Health US, LLC (formerly Valeant Pharmaceuticals North America LLC) (&#8220;Bausch Health US&#8221;), and Bausch Health Americas, Inc. (formerly Valeant Pharmaceuticals International) (&#8220;Bausch Health Americas&#8221;) (for the purposes of this paragraph, collectively, the &#8220;Company&#8221;), are defendants in multidistrict antitrust litigation (&#8220;MDL&#8221;) entitled In re: Generic Pharmaceuticals Pricing Antitrust Litigation, pending in the United States District Court for the Eastern District of Pennsylvania (MDL 2724, 16- MD-2724). The lawsuits seek damages under federal and state antitrust laws, state consumer protection and unjust enrichment laws and allege that the Company&#8217;s subsidiaries entered into a conspiracy to fix, stabilize, and raise prices, rig bids and engage in market and customer allocation for generic pharmaceuticals. The lawsuits, which have been brought as putative class actions by direct purchasers, end payers, and indirect resellers, and as direct actions by direct purchasers, end payers, insurers, States, and various Counties, Cities, and Towns, have been consolidated into the MDL. There are also additional, separate complaints which have been consolidated in the same MDL that do not name the Company or any of its subsidiaries as a defendant. There are cases pending in the Court of Common Pleas of Philadelphia County against the Company and other defendants related to the multidistrict litigation, but no complaint has been filed in the cases. The cases have been placed in deferred status. The Company disputes the claims against it and continues to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, Bausch Health Companies Inc. and certain U.S. and Canadian subsidiaries (for the purposes of this paragraph, collectively the "Company&#8221;) have been named as defendants in a proposed class proceeding entitled Kathryn Eaton v. Teva Canada Limited, et al. in the Federal Court in Toronto, Ontario, Canada (Court File No. T-607-20). The plaintiff seeks to certify a proposed class action on behalf of persons in Canada who purchased generic drugs in the private sector, alleging that the Company and other defendants violated the Competition Act by conspiring to allocate the market, fix prices, and maintain the supply of generic drugs, and seeking damages under federal law. The proposed class action contains similar allegations to the In re: Generic Pharmaceuticals Pricing Antitrust Litigation pending in the United States Court for the Eastern District of Pennsylvania. The Company disputes the claims against it and will defend itself vigorously.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="ia0138b8b19104698b40e107d32b73b29" continuedAt="i03dbe3a53fb64caa8d095c182aa22d81"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glumetza State-Law Insurer Litigations</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2021, the insurer plaintiff from the federal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 3:19-cv-05822- WHA (N.D. Cal.) (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) (discussed in further detail above) filed an action asserting its indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others (the &#8220;State Court Action&#8221;). The State Court Action alleges that a 2012 settlement of a patent litigation regarding Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or grant any other company a license to do so. The State Court Action alleges that the settlement agreement resulted in higher prices for Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its generic equivalent both prior to and after generic entry. On September 20, 2021, the parties stipulated that the insurer plaintiff&#8217;s direct opt-out claims from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, discussed above, were deemed asserted in the State Court Action. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defendants&#8217; demurrer in the State Court Action was heard on September 22, 2021. On November 29, 2021, the court denied the motion in part and granted it in part as to certain state law claims, with leave to amend. The insurer plaintiff did not amend the complaint. Defendants&#8217; answers were filed on February 3, 2022. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2022, Health Care Service Corporation filed an action with similar substantive allegations and similar indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disputes the claims and intends to vigorously defend these matters.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Litigation/Paragraph IV Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company (and/or certain of its affiliates) is also party to certain patent infringement proceedings in the United States and Canada, including as arising from claims filed by the Company (or that the Company anticipates filing within the required time periods) in connection with Notices of Paragraph IV Certification (in the United States) and Notices of Allegation (in Canada) received from third-party generic manufacturers respecting their pending applications for generic versions of certain products sold by or on behalf of the Company, including Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 550mg, Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Injection in the United States and Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Canada, or other similar suits.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2020, the Company and Alfasigma S.p.A. (&#8220;Alfasigma&#8221;) received a Notice of Paragraph IV Certification from Norwich Pharmaceuticals Inc. (&#8220;Norwich&#8221;), in which Norwich asserted that the U.S. patents listed in the FDA&#8217;s Orange Book for the Company&#8217;s Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 550 mg, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Norwich&#8217;s generic rifaximin tablets, 550 mg, for which an Abbreviated New Drug Application (&#8220;ANDA&#8221;) has been filed by Norwich. The Company, through its subsidiaries Salix Pharmaceuticals, Inc. and Bausch Health Ireland Limited, holds the New Drug Application for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and owns or exclusively licenses (from Alfasigma) these patents.&#160;On March 26, 2020, certain of the Company&#8217;s subsidiaries and Alfasigma filed suit against Norwich in the U.S. District Court for the District of Delaware (Case No. 20-cv-00430) pursuant to the Hatch-Waxman Act, alleging infringement by Norwich of one or more claims of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a <ix:nonNumeric contextRef="i3feba39b7c864f9287819ae735b85819_D20200326-20200326" name="bhc:LossContingencyStayOfApprovalPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMzA5NTM_0813a895-a615-4575-bf33-e1f40eb7e478">30</ix:nonNumeric>-month stay of the approval of Norwich&#8217;s ANDA for rifaximin tablets, 550 mg. Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is protected by 26 patents covering the composition of matter and the use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> listed in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange&#160;Book. Trial in this matter was held in March 2022. A decision is pending. Post-trial briefing is expected to occur in the second quarter of 2022, with a decision expected in the third quarter of 2022. The Company remains confident in the strength of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and will continue to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 23, 2020, the Company received a Notice of Paragraph IV Certification from Perrigo Israel Pharmaceuticals, Ltd. (now Padagis LLC) (&#8220;Padagis&#8221;), in which Padagis asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotine) lotion, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Padagis&#8217; generic lotion, for which an ANDA has been filed by Padagis. On August 28, 2020, the Company filed suit against Padagis pursuant to the Hatch-Waxman Act, alleging infringement by Padagis of one or more claims of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a <ix:nonNumeric contextRef="i7a34cd34e127459a89499090f4a93cbc_D20200828-20200828" name="bhc:LossContingencyStayOfApprovalPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMzIxMzc_3d3f921a-d51f-4e28-882b-707a8b2b53de">30</ix:nonNumeric>-month stay of the approval of the Padagis ANDA. On September 3, 2020, this action was consolidated with the action between the Company and Padagis described below, regarding Padagis&#8217; ANDA for generic Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate) lotion. A pre-trial conference in the consolidated action has been scheduled for July 20, 2022. The Company remains confident in the strength of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related patents and will vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 20, 2020, the Company received a Notice of Paragraph IV Certification from Padagis, in which Padagis asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate) lotion, 0.01% are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Padagis&#8217; generic halobetasol propionate lotion, for which an ANDA has been filed by Padagis. On May 1, 2020, the Company filed suit against Padagis pursuant to the Hatch-Waxman Act, alleging infringement by Padagis of one or more claims of the </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i03dbe3a53fb64caa8d095c182aa22d81" continuedAt="i4ec88c6fa72747f3b872d998d887e8a3"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a <ix:nonNumeric contextRef="i7ce85e02604a4aa4b028657df917f434_D20200501-20200501" name="bhc:LossContingencyStayOfApprovalPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMzMxNTU_4a85a2a5-a6b8-4263-a238-9587045ada6c">30</ix:nonNumeric>-month stay of the approval of the Padagis ANDA for halobetasol propionate lotion. On September 3, 2020, this action was consolidated with the action between the Company and Padagis described above, regarding Padagis&#8217; ANDA for generic Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotine) lotion. A pre-trial conference in the consolidated action has been scheduled for July 20, 2022. The Company remains confident in the strength of the Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents and intends to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company commenced litigation against MSN Laboratories Private Ltd. (&#8220;MSN&#8221;) and Mylan Pharmaceuticals Inc., (&#8220;Mylan&#8221;) alleging patent infringement by MSN&#8217;s and Mylan&#8217;s filing of their ANDA for generic Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (plecanatide) 3mg tablets. This suit had been filed following receipt of a Notice of Paragraph IV Certification from each of MSN and Mylan, in which they had each asserted that the U.S. patents listed in the FDA&#8217;s Orange Book for the Company&#8217;s Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 3 mg, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of their respective generic plecanatide tablets, 3 mg. The filing of these suits triggered a <ix:nonNumeric contextRef="i6770fa9b73a64b54b1f41da09e16bf8f_D20210401-20210430" name="bhc:LossContingencyStayOfApprovalPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMzQzMDI_589b2668-18c0-42e7-afa7-da70340ff904">30</ix:nonNumeric>-month stay of the approval of the MSN and Mylan ANDAs for plecanatide tablets. The Company remains confident in the strength of the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and intends to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2021, the Company received a Notice of Paragraph IV Certification from Slayback Pharma LLC (&#8220;Slayback&#8221;), in which Slayback asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (brimonidine tartrate solution) drops (the &#8220;Lumify Patents&#8221;), are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Slayback&#8217;s generic drops, for which an ANDA has been filed by Slayback. The Company, through its affiliate Bausch + Lomb Ireland Limited, exclusively licenses the Lumify Patents from Eye Therapies, LLC (&#8220;Eye Therapies&#8221;). On September 10, 2021, B&amp;L Inc., Bausch + Lomb Ireland Limited and Eye Therapies filed suit against Slayback pursuant to the Hatch-Waxman Act, alleging infringement by Slayback of one or more claims of the Lumify Patents, thereby triggering a 30-month stay of the approval of the Slayback ANDA.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 20, 2022, B&amp;L Inc. received a Notice of Paragraph IV Certification from Lupin Ltd. (&#8220;Lupin&#8221;), in which Lupin asserted that certain of the Lumify Patents are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Lupin&#8217;s generic brimonidine tartrate solution, for which its ANDA No. 216716 has been filed by Lupin. On February 2, 2022, B&amp;L Inc., Bausch + Lomb Ireland Limited and Eye Therapies filed suit against Lupin pursuant to the Hatch-Waxman Act, alleging patent infringement by Lupin of one or more claims of the Lumify Patents, thereby triggering a 30-month stay of the approval of the Lupin ANDA.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company remains confident in the strength of the Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related patents and intends to vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, patents covering the Company&#8217;s branded pharmaceutical products may be challenged in proceedings other than court proceedings, including inter partes review (&#8220;IPR&#8221;) at the U.S. Patent &amp; Trademark Office. The proceedings operate under different standards from district court proceedings, and are often completed within 18 months of institution.&#160;IPR challenges have been brought against patents covering the Company&#8217;s branded pharmaceutical products.&#160;For example, following Acrux DDS&#8217;s IPR petition, the U.S. Patent and Trial Appeal Board (&#8220;PTAB&#8221;), in May 2017, instituted inter partes review for an Orange Book-listed patent covering Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(U.S. Patent No. 7,214,506 (the &#8220;&#8216;506 Patent&#8221;)) and, on June 6, 2018, issued a written determination invalidating such patent. An appeal of this decision was filed on August 7, 2018. On March 13, 2020, the Court of Appeals for the Federal Circuit reversed this decision and remanded the matter back to the PTAB for further proceedings. As a result of a settlement, a joint motion to terminate the proceedings was filed on November 12, 2020 and, on January 8, 2021, the PTAB granted this motion.  The &#8216;506 Patent, therefore, remains valid and enforceable and expires in 2026. Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is covered by fourteen Orange Book-listed patents owned by the Company or its licensor, which expire in the years 2028 through 2035. In August and September 2018, the Company received notices of the filing of a number of ANDAs with paragraph IV certification, and has timely filed patent infringement suits against these ANDA filers, and, in addition, the Company has also commenced certain patent infringement proceedings in Canada against <ix:nonFraction unitRef="defendant" contextRef="i484e9a2b823f442e9977dce133acdc8e_I20220331" decimals="INF" name="bhc:LossContingencyNumberOfSeparateDefendants" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMjc0ODc3OTE2NDgyNw_b8ee92dd-77fc-49d7-8734-ea058bd25d9e">four</ix:nonFraction> separate defendants. All cases in U.S. regarding Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have been settled. In Canada, <ix:nonFraction unitRef="claim" contextRef="i65eb0cafd758435f8136a068d6e0611a_I20220331" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMjc0ODc3OTE2NDgzNg_567f1a7f-4338-49d7-970b-2c1c6a5e1ca6">two</ix:nonFraction> lawsuits remain pending against Apotex Inc.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Products Liability Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2016, the Company has been named in a number of product liability lawsuits involving the Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> body powder product acquired in September 2012 from Johnson &amp; Johnson; due to dismissals, twenty-nine (<ix:nonFraction unitRef="case" contextRef="if6cd264b4a7249cea5facc5b0e2e6685_I20220331" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMzc1NjE_f3a8fda5-ccb9-45b5-8a1c-90472d897004">29</ix:nonFraction>) of such product liability suits currently remain pending. Potential liability (including its attorneys&#8217; fees and costs) arising out of these remaining suits is subject to full indemnification obligations of Johnson &amp; Johnson owed to the Company and its affiliates, and legal fees and costs will be paid by Johnson &amp; Johnson. Twenty-eight (<ix:nonFraction unitRef="case" contextRef="i0fb0759d98f74dea9d8da712d3d4ef7b_I20220331" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMzc4ODU_b4da49b0-b43f-45b7-ab87-a9518bb549b7">28</ix:nonFraction>) of these lawsuits filed by individual plaintiffs allege that the use of Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> caused the plaintiffs to develop ovarian cancer, mesothelioma or breast cancer. The allegations in these cases include failure to warn, design defect, manufacturing defect, negligence, gross negligence, breach </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i4ec88c6fa72747f3b872d998d887e8a3" continuedAt="ia2758fb2e41f443b82593ee2aae50079"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of express and implied warranties, civil conspiracy concert in action, negligent misrepresentation, wrongful death, loss of consortium and/or punitive damages. The damages sought include compensatory damages, including medical expenses, lost wages or earning capacity, loss of consortium and/or compensation for pain and suffering, mental anguish anxiety and discomfort, physical impairment and loss of enjoyment of life. Plaintiffs also seek pre- and post-judgment interest, exemplary and punitive damages, and attorneys&#8217; fees. Additionally, <ix:nonFraction unitRef="case" contextRef="iadb1f3c2425247b1a17793d33add0cd6_I20220331" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMzg3MzM_4bfe3ec0-e4cc-49c0-ac2e-c11adce8b549">two</ix:nonFraction> proposed class actions have been filed in Canada against the Company and various Johnson &amp; Johnson entities (<ix:nonFraction unitRef="case" contextRef="iccdebf1cc8224c95806abf21a3970331_I20220331" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMzg4NDU_eff7c54c-20fe-4b7b-8160-db721c5eddd4">one</ix:nonFraction> in the Supreme Court of British Columbia and <ix:nonFraction unitRef="case" contextRef="i41ce3780c3a74f4da7f954a056043ef8_I20220331" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMzg4OTM_a6e19d6a-c878-4aa1-a8f5-37982038a66a">one</ix:nonFraction> in the Superior Court of Quebec), on behalf of persons who have purchased or used Johnson &amp; Johnson&#8217;s Baby Powder or Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The class actions allege the use of the product increases certain health risks (British Columbia) or negligence in failing to properly test, failing to warn of health risks, and failing to remove the products from the market in a timely manner (Quebec). The plaintiffs in these actions are seeking awards of general, special, compensatory and punitive damages. On November 17, 2020, the British Columbia court issued a judgment declining to certify a class as to the Company or Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and at this time no appeal of that judgment has been filed. </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2021, the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plaintiff in the British Columbia class action filed a Second Amended Notice of Civil Claim and Application</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for Certification, removing the Company as a defendant; as a result, the British Columbia class action is concluded</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as to the Company.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson, through one or more subsidiaries, has purported to have completed a Texas divisional merger with respect to any talc liabilities at Johnson &amp; Johnson Consumer, Inc. (&#8220;JJCI&#8221;). LTL Management, LLC (&#8220;LTL&#8221;), the resulting entity of the divisional merger, assumed JJCI&#8217;s talc liabilities and thereafter filed for Chapter 11 bankruptcy protection in the United States Bankruptcy Court for the Western District of North Carolina. Pursuant to court orders entered in November 2021, the case was transferred to the United States District Court for the District of New Jersey, and substantially all cases related to Johnson &amp; Johnson&#8217;s talc liability were stayed for a period of sixty (<ix:nonNumeric contextRef="i9980036908434c78bce13e0b3f16a63d_D20211101-20211130" name="bhc:LossContingencyStayOfApprovalPeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMjc0ODc3OTE2NDg0NQ_305f2ead-3e5c-4b65-8ff4-a335c7ee5194">60</ix:nonNumeric>) days pursuant to a preliminary injunction. Notwithstanding the divisional merger and LTL&#8217;s bankruptcy case, the Company and its affiliates continue to have indemnification claims and rights against Johnson &amp; Johnson and LTL pursuant to the terms of the indemnification agreement entered into between JJCI and its affiliates and the Company and its affiliates, which indemnification agreement remains in effect. As a result, it is the Company&#8217;s current expectation that it will not incur any material impairments with respect to its indemnification claims as a result of the divisional merger or the bankruptcy. In December 2021, certain talc claimants filed motions to dismiss the bankruptcy case. Shortly thereafter, LTL filed a motion in the bankruptcy court to extend the <ix:nonNumeric contextRef="id1c54f63619d491e9de1d89624c515eb_D20211201-20211231" name="bhc:LossContingencyStayOfApprovalMotionToExtendPeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMjc0ODc3OTE2NDg1Mw_ec581cc6-dc93-449b-a46e-9308b79fa907">60</ix:nonNumeric>-day preliminary injunction. On February 25, 2022, the bankruptcy court entered orders denying the motions to dismiss and extending the preliminary injunction staying substantially all cases subject to the indemnification agreement related to Johnson &amp; Johnson&#8217;s talc liability through at least June 29, 2022. The order denying the motions to dismiss and the order extending the preliminary injunction are subject to appeal and the bankruptcy court certified their appeals directly to the United States Court of Appeals for the Third Circuit. A petition to authorize the direct appeal is currently pending before the Court of Appeals. Further, pursuant to a court order dated March 18, 2022, the bankruptcy court directed certain talc claimants and LTL to mediate the issues related to the case in the hopes of achieving a global resolution. The Bankruptcy Court has also indicated that it intends to order separate mediation with respect to certain consumer protection claims against LTL by various state attorneys general. On May 4, 2022, the Bankruptcy Court extended LTL&#8217;s exclusive period to file a chapter 11 plan until September 9, 2022. To the extent that any cases proceed during the pendency of the bankruptcy case, it is the Company&#8217;s expectation that Johnson &amp; Johnson, in accordance with the indemnification agreement, will continue to vigorously defend the Company in each of the remaining actions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Civil Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Securities Litigation - New Jersey Declaratory Judgment Lawsu</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">it</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 24, 2022, the Company and Bausch + Lomb were named in a declaratory judgment action in the Superior </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Court of New Jersey, Somerset County, Chancery Division, brought by certain individual investors in the Company&#8217;s common shares and debt securities who are also maintaining individual securities fraud claims against the Company and certain current or former officers and directors as part of the U.S. Securities Litigation. This newly filed action seeks a declaratory judgment that the transfer of the Company assets to Bausch + Lomb would constitute a voidable transfer under New Jersey&#8217;s Uniform Voidable Transactions Act and that Bausch + Lomb would become liable for damages awarded against the Company in the individual opt-out actions. The declaratory judgment action alleges that a transfer of assets from the Company to Bausch + Lomb would leave the Company with inadequate financial resources to satisfy these plaintiffs&#8217; alleged securities fraud damages in the underlying individual opt-out actions. None of the plaintiffs in this declaratory judgment action have obtained a judgment against the Company in the underlying individual opt-out actions and the Company disputes the claims against it in those underlying actions. The underlying individual opt-out actions assert claims under Sections 10(b) and 20(a) of the Exchange Act, and certain actions assert claims under Section 18 of the Exchange Act. The allegations in those underlying individual opt out actions are made against the Company and several of its former officers and directors only and relate to, among other things, allegedly false and misleading statements made during the 2013-2016 time period by the Company and/or failures to disclose information about the Company&#8217;s business and prospects including relating to drug pricing and the use of specialty pharmacies. On March 31, 2022, the Company and Bausch + Lomb removed the action to the U.S. District Court for the District of New Jersey.  As a result, the New Jersey Superior Court action is closed and the case is now pending in the </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="ia2758fb2e41f443b82593ee2aae50079" continuedAt="ia948ade97ab147348c0eba7a5ab7ab90"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">District of New Jersey (Case No. 22-cv-01823). On April 29, 2022, Plaintiffs filed a motion to remand. That motion will be fully briefed on June 3, 2022. Other proceedings are in abeyance pending resolution of Plaintiffs&#8217; remand motion. Both the Company and Bausch + Lomb dispute the claims in this declaratory judgment action and intend to vigorously defend this matter. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">California Proposition 65 Related Matter</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2019, plaintiffs filed a proposed class action in California state court against Bausch Health US and Johnson &amp; Johnson (Gutierrez, et al. v. Johnson &amp; Johnson, et al., Case No. 37-2019-00025810-CU-NP-CTL), asserting claims for purported violations of the California Consumer Legal Remedies Act, False Advertising Law and Unfair Competition Law in connection with their sale of talcum powder products that the plaintiffs allege violated Proposition 65 and/or the California Safe Cosmetics Act. This lawsuit was served on Bausch Health US in June 2019 and was subsequently removed to the United States District Court for the Southern District of California, where it is currently pending. Plaintiffs seek damages, disgorgement of profits, injunctive relief, and reimbursement/restitution. The Company filed a motion to dismiss Plaintiffs&#8217; claims, which was granted in April 2020 without prejudice. In May 2020, Plaintiffs filed an amended complaint and in June 2020, filed a motion for leave to amend the complaint further, which was granted. In August 2020, Plaintiffs filed the Fifth Amended Complaint. On January 22, 2021, the Court granted the motion to dismiss with prejudice. On February 19, 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit Court of Appeals. On July 1, 2021, Appellants (Plaintiffs) filed their opening brief; Appellees&#8217; response briefs were filed on October 8, 2021. This matter was stayed by the Ninth Circuit on December 7, 2021, due to the preliminary injunction entered by the bankruptcy court in the LTL bankruptcy proceeding. This stay included Appellants&#8217; reply brief deadline, which was previously due to be filed on or before December 2, 2021. On March 9, 2022, the Ninth Circuit issued an order extending the stay through July 29, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other General Civil Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As referenced above, during the three months ended March 31, 2022, there have been no material updates or developments with respect to certain proceedings or actions as described under &#8220;General Civil Actions&#8221; in Note 20, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC and the CSA on February 24, 2021. These matters include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Mexico Attorney General Consumer Protection Action</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US were named in an action brought by State of New Mexico ex rel. Hector H. Balderas, Attorney General of New Mexico, in the County of Santa Fe New Mexico First Judicial District Court (New Mexico ex rel. Balderas v. Johnson &amp; Johnson, et al., Civil Action No. D-101-CV-2020-00013, filed on January 2, 2020), alleging consumer protection claims against Johnson &amp; Johnson and Johnson &amp; Johnson Consumer Companies, Inc., the Company and Bausch Health US related to Shower to Shower&#174; and its alleged causal link to mesothelioma and other cancers. In April 2020, Bausch Health US filed a motion to dismiss, which in September 2020, the Court granted in part as to the New Mexico Medicaid Fraud Act and New Mexico Fraud Against Taxpayers Act claims and denied as to all other claims. The State of New Mexico brings claims against all defendants under the New Mexico Unfair Practices Act and other common law and equitable causes of action, alleging defendants engaged in wrongful marketing, sale and promotion of talcum powder products. The lawsuit seeks to recover the cost of the talcum powder products as well as the cost of treating asbestos-related cancers allegedly caused by those products. Bausch Health US filed its answer on November 16, 2020. On December 30, 2020 Johnson &amp; Johnson filed a Motion for Partial Judgment on the Pleadings and on January 4, 2021, Bausch Health US filed a joinder to that motion, which was denied on March 8, 2021. Trial is scheduled to begin on March 6, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Doctors Allergy Formula Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, Doctors Allergy Formula, LLC (&#8220;Doctors Allergy&#8221;), filed a lawsuit against Bausch Health Americas in the Supreme Court of the State of New York, County of New York, asserting breach of contract and related claims under a 2015 Asset Purchase Agreement, which purports to include milestone payments that Doctors Allergy alleges should have been paid by Bausch Health Americas.&#160;Doctors Allergy claims its damages are not less than $<ix:nonFraction unitRef="usd" contextRef="i6bbcfb43fc7145b0bb30d7beba40cbb8_D20180401-20180430" decimals="-6" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfNDQ3NzU_b2c2bb17-737b-4970-a55d-52690a790bd2">23</ix:nonFraction> million. Bausch Health Americas has asserted counterclaims against Doctors Allergy. Bausch Health Americas filed a motion seeking an order granting Bausch Health Americas summary judgment on its counterclaims against Plaintiff and dismissing Plaintiff&#8217;s claims against it. The motion was fully briefed as of May 2021. The Court held a hearing on the motion on January 25, 2022. The motion remains pending. Bausch Health Americas disputes the claims against it and will continue to defend itself vigorously.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="ia948ade97ab147348c0eba7a5ab7ab90"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation with Former Salix CEO</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 28, 2019, former Salix Ltd. CEO and director Carolyn Logan filed a lawsuit in the Delaware Court of Chancery, asserting claims for breach of contract and declaratory relief. On November 19, 2021, Logan amended her complaint to add a claim for breach of the implied covenant of good faith and fair dealing. The lawsuit arises out of the contractual termination of approximately $<ix:nonFraction unitRef="usd" contextRef="idc58c0dcbe644cedb326ae513855b55f_D20190128-20190128" decimals="-6" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfNDU0OTk_47d93c61-23bc-4583-a6d4-0df15975da03">30</ix:nonFraction> million in unvested equity awards following the determination by the Salix Ltd. Board of Directors that Logan intentionally engaged in wrongdoing that resulted, or would reasonably be expected to result, in material harm to Salix Ltd., or to the business or reputation of Salix Ltd. Logan seeks the restoration of the unvested equity awards and a declaration regarding certain rights related to indemnification. On June 19, 2019, the Court entered an order staying the claim for declaratory relief pending the final resolution of the breach of contract claim. Trial is scheduled to commence on September 6, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disputes the claims against it in each of these matters and intends to vigorously defend the matters.</span></div></ix:continuation><div id="i801c461cbd33492a893c84373a8e7cbc_97"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RleHRyZWdpb246MmM4ZjBlMDNkMmMyNGY4OTllNTViNDcwMjNiMmQ3YzdfNDExNg_730f7d5e-ff90-4492-b139-7fc732ad3bc4" continuedAt="ia4228be2b8af4d24ac10cb3cb4e92d35" escape="true">SEGMENT INFORMATION</ix:nonNumeric></span></div><ix:continuation id="ia4228be2b8af4d24ac10cb3cb4e92d35" continuedAt="i031ecfeb569a456fba57984a2fb8ac11"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reportable Segments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the planned separation of its Solta business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc., the Company has begun managing its operations in a manner which is consistent with the organizational structure of the two separate entities as proposed by the Solta IPO. As a result, during the first quarter of 2022, the Company&#8217;s Chief Executive Officer (&#8220;CEO&#8221;), who is the Company&#8217;s Chief Operating Decision Maker, commenced managing the business differently through changes in its operating and reportable segments, which necessitated a realignment of the Company&#8217;s historical segment structure. This realignment is consistent with how the Company&#8217;s CEO currently: (i) assesses operating performance on a regular basis, (ii) makes resource allocation decisions and (iii) designates responsibilities of his direct reports. Pursuant to these changes, effective in the first quarter of 2022, the Company operates in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International (formerly International Rx), (iv) Solta Medical and (v) Diversified Products. The new segment structure does not impact the Company&#8217;s reporting units but realigns the <ix:nonFraction unitRef="reporting_unit" contextRef="i03d9858da1a54c6a897587b6b5079ca1_D20220101-20220331" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RleHRyZWdpb246MmM4ZjBlMDNkMmMyNGY4OTllNTViNDcwMjNiMmQ3YzdfMTY0OTI2NzQ0ODkzOA_d9e5c898-70c9-4bad-be6f-127b70715657">two</ix:nonFraction> reporting units of the former Ortho Dermatologics segment whereby its medical dermatology reporting unit (Ortho Dermatologics) is now part of the current Diversified Products segment and the Solta reporting unit is now the sole reporting unit of the new Solta Medical segment. Prior period presentation of segment revenues and segment profits has been recast to conform to the current segment reporting structure.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a brief description of the Company&#8217;s segments:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Bausch + Lomb segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Bausch + Lomb Vision Care, Consumer, Surgical and Ophthalmic Pharmaceuticals products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Salix segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of sales in the U.S. of GI products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The International segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of sales, with the exception of sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Solta Medical segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Solta aesthetic medical devices. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;padding-left:14.5pt">The Diversified Products segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products, (iii) Ortho Dermatologics (dermatological) products and (iv) dentistry products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment profit is based on operating income after the elimination of intercompany transactions. Certain costs, such as Amortization of intangible assets, Asset impairments, Acquired in-process research and development costs, Restructuring, integration, separation and IPO costs and Other (income) expense, net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of the Company&#8217;s businesses and incurs certain expenses, gains and losses related to the overall management of the Company, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single&#160;segment.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i031ecfeb569a456fba57984a2fb8ac11" continuedAt="i907cf604bc944169827e610c25743035"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Revenues and Profits</span></div><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RleHRyZWdpb246MmM4ZjBlMDNkMmMyNGY4OTllNTViNDcwMjNiMmQ3YzdfNDEyNw_679295de-f258-41e2-a692-46374402e85c" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment revenues and profits were as&#160;follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.471%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c75337ca1004f2ca22a8acafcee0b80_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMy01LTEtMS04OTA3Mg_28c81470-a8c6-499f-aeed-375832832629">889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85cfed31dcdb4b5fbdcfd5de90d79e53_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMy03LTEtMS04OTA3Mg_ea7612d6-08a3-4348-9d61-f86b7eaa3ecd">881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i269760d6627c41d9af67faeb79fcc823_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfNC01LTEtMS04OTA3Mg_1b3b7729-fd6f-44b2-a433-ca86fdb61cfc">464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7a20cee7c49437a80ead9dc6edc62bf_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfNC03LTEtMS04OTA3Mg_16f510bf-5434-411e-99e0-4885582e1684">472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce8c1f567d4480199ab7c96956ff606_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfNS01LTEtMS04OTA3Mg_f2092f50-110c-471d-a655-0d3bbc6c1411">244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0baff1dd72ec4f1d9be30dc22385fd78_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfNS03LTEtMS04OTA3Mg_92b64085-c671-4899-b07a-3c44c3a8ae91">306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i515ccc73a3044997b576a1bf8db45a42_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfNi01LTEtMS04OTA3Mg_99aff6ba-50f1-4039-b571-89cce548ec51">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fa555eb8f35445291ded844157a0bbf_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfNi03LTEtMS04OTA3Mg_c22ad469-96b7-43a9-9986-b9e78342adea">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03406ff2404048fa81b2e21abb5623f6_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfNy01LTEtMS04OTA3Mg_45a238d5-4192-4024-b3b5-893da43f6024">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i204e74587c904466ba5b4d9604c5d421_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfNy03LTEtMS04OTA3Mg_279f60a8-5f63-471d-b9fb-922281511b77">296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e30f03ea4548deae9a927c4b6a6def_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfOC01LTEtMS04OTA3Mg_2e67e49d-d904-4d54-a2be-a5a6c0ab85b5">1,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d07c8e2cb2b45138d98bfa04aca8095_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfOC03LTEtMS04OTA3Mg_9b17e83d-2cea-4446-af28-7e9e4710b900">2,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c75337ca1004f2ca22a8acafcee0b80_D20220101-20220331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMTAtNS0xLTEtODkwNzI_6468c856-36ac-4c01-abab-3190f8753452">206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85cfed31dcdb4b5fbdcfd5de90d79e53_D20210101-20210331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMTAtNy0xLTEtODkwNzI_3bc09308-0b36-4455-8b47-94de44bbf69d">239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i269760d6627c41d9af67faeb79fcc823_D20220101-20220331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMTEtNS0xLTEtODkwNzI_0414dcd3-02cf-4a4e-9215-a3b793a7a6cd">322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7a20cee7c49437a80ead9dc6edc62bf_D20210101-20210331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMTEtNy0xLTEtODkwNzI_d377441e-487f-4158-b8cb-7269fcc918ea">327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce8c1f567d4480199ab7c96956ff606_D20220101-20220331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMTItNS0xLTEtODkwNzI_bc26880d-523d-4a40-a2a1-aa7f659f264c">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0baff1dd72ec4f1d9be30dc22385fd78_D20210101-20210331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMTItNy0xLTEtODkwNzI_6976b04a-6931-4037-9b39-5eb482eabf4a">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i515ccc73a3044997b576a1bf8db45a42_D20220101-20220331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMTMtNS0xLTEtODkwNzI_b7c6381a-ce7d-4779-920e-330c05026456">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fa555eb8f35445291ded844157a0bbf_D20210101-20210331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMTMtNy0xLTEtODkwNzI_d97f25c8-103a-4bc7-a422-fd3687c95807">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03406ff2404048fa81b2e21abb5623f6_D20220101-20220331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMTQtNS0xLTEtODkwNzI_e33b8cfe-8f23-4ddd-95e6-66652f177d07">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i204e74587c904466ba5b4d9604c5d421_D20210101-20210331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMTQtNy0xLTEtODkwNzI_7f490ec2-533c-475f-a953-6ff2d5f3c6d9">200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e30f03ea4548deae9a927c4b6a6def_D20220101-20220331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMTUtNS0xLTEtODkwNzI_ab612d30-ca6a-4602-bb3c-467b37a574dd">812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d07c8e2cb2b45138d98bfa04aca8095_D20210101-20210331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMTUtNy0xLTEtODkwNzI_97fbbbd2-5e9b-4496-8167-b532e89d314e">916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57dad9adbdcb4f9eb8980d1993b5a15e_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMTYtNS0xLTEtODkwNzI_fb218582-cac2-45ed-ae8d-e68fa5cba6ee">194</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i956efc9320ef432bad3fbea5c3f1a4fe_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMTYtNy0xLTEtODkwNzI_899972c4-3707-45fb-9d63-dc7ff701c650">181</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMTctNS0xLTEtODkwNzI_4eca1266-7a69-4f34-bece-a8eabced0181">310</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMTctNy0xLTEtODkwNzI_61c69000-a645-48e7-a7cf-610da29e8a4a">357</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMTgtNS0xLTEtODkwNzI_602dbbcf-87b1-4660-87ab-b672ebdd7277">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMTgtNy0xLTEtODkwNzI_27da2c62-10c1-4c4e-ba9f-84173dd35cfe">469</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments, including loss on assets held for sale</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMTktNS0xLTEtODkwNzI_0214e145-949d-4520-8425-2ddc875f4931">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMTktNy0xLTEtODkwNzI_ec59572e-8ddc-449b-8656-a6d35de5038d">148</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, integration, separation and IPO costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="bhc:RestructuringChargesAndInitialPublicOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMjAtNS0xLTEtODkwNzI_faf65571-a028-4a17-9577-1b052247daeb">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="bhc:RestructuringChargesAndInitialPublicOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMjAtNy0xLTEtODkwNzI_d26b8bbc-9fd5-4027-9d25-568c56e33e33">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMjEtNS0xLTEtODkwNzI_05f7a39d-2744-45a8-b6e1-74b9ccc66877">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMjEtNy0xLTEtODkwNzI_cb7f20be-0d13-46fb-b6eb-de6eca1604ea">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMjItNS0xLTEtODkwNzI_cd33ffa4-cded-4037-8e6d-7aa5e3b4982b">285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMjItNy0xLTEtODkwNzI_e7d934c9-3687-48e1-bd84-0e2b85c189ed">221</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMjMtNS0xLTEtODkwNzI_67cd5e54-507e-4969-b27e-9c6317b7b607">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMjMtNy0xLTEtODkwNzI_71b9777f-b5dc-4785-bb7a-679d62a02948">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMjQtNS0xLTEtODkwNzI_117d1301-b7e2-49c4-96c6-1750ba495011">362</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMjQtNy0xLTEtODkwNzI_d5e232ec-a3a6-4ff3-94f8-871648d7a13a">368</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMjUtNS0xLTEtODkwNzI_7cf72887-35fe-4ff0-8da4-4add938d166f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMjUtNy0xLTEtODkwNzI_99e3412d-7e76-48b3-90c4-d60e8ec16b80">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMjYtNS0xLTEtODkwNzI_e9c32773-2ebe-41b5-bbc5-240a70cd1fdb">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMjYtNy0xLTEtODkwNzI_a44a5c86-65ea-4c49-ad12-8286a80134e9">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before provision for income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMjctNS0xLTEtODkwNzI_b266040d-4956-4110-9b24-def10abcd19d">82</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMjctNy0xLTEtODkwNzI_6a724f17-00d4-404e-98b4-021928dd9f72">591</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i907cf604bc944169827e610c25743035" continuedAt="i9a5ed7a51c654217a2aa7f8a0e5c7186"><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues by Segment and Product Category </span></div><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RleHRyZWdpb246MmM4ZjBlMDNkMmMyNGY4OTllNTViNDcwMjNiMmQ3YzdfNDE1Nw_e2e45ff4-4a5d-4118-b271-d95152d13e6b" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by segment and product category were as&#160;follows: </span></div><div style="margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.858%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81a741d98a084635a313bb4bf76f4091_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMi0xLTEtMS04OTA3Mg_077db12a-8246-4e19-863d-8d883b953389">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64a60b01aba54bed9371ce993d6fcde6_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMi0zLTEtMS04OTA3Mg_777882ed-d374-4508-a976-94cc68373faf">464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e3d656d794986bc25805dd6eafb35_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMi01LTEtMS04OTA3Mg_5b5c232c-41d3-4f49-a2b4-06ad6d1e0de6">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i375b53e51f9a46f689b2c28b45772369_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMi03LTEtMS04OTA3Mg_e5f65ce1-bdc0-4858-b705-4fae018be475">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26543803a914471b91cfff3fec88f408_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMi05LTEtMS04OTA3Mg_72145d45-3841-492f-92f9-edd257dce5e8">205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i965c5ef9967640559f4a892e2bc019c3_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMi0xMS0xLTEtODkwNzI_06c80ad4-4e02-429b-8df3-a9a78eada263">844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fb3820e9af24cffa7541b8391ded598_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMy0xLTEtMS04OTA3Mg_e6916c58-702e-43de-b584-219e86a1ceb4">386</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33c622ed3818484b99457a5e5ac61b94_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMy0zLTEtMS04OTA3Mg_216a6dc0-24c9-452b-97f1-564865bad0d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9d891249204a23b5a99cff63162625_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMy01LTEtMS04OTA3Mg_7c0878c1-cec8-441f-ba09-e0d5bbe47435">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44029f40cbcc4c10b8745e5f1b7f00ea_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMy03LTEtMS04OTA3Mg_06f802e2-9f13-41f7-a92a-0ee9ce831998">72</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i443f3d343d0a48fcb2a083c30d4f80e3_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMy05LTEtMS04OTA3Mg_20b6a014-d4ee-4a38-876b-9b2b216a55dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24ebf624edfd4bdf9d7fdd3ec9d063ec_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMy0xMS0xLTEtODkwNzI_da48d07b-53db-438d-ac4c-1fabdcda2d4e">458</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c1beafb56d472ead9374b62bb12e0d_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNC0xLTEtMS04OTA3Mg_efbdc15a-4f03-4ec0-85a6-8c4ab3cf28d4">335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93b04924fc4f4e13885891185ac2968f_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNC0zLTEtMS04OTA3Mg_cc27986a-b08c-4d1f-a7c7-3665db491562">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9bd671b035e41d69c0e38a6f82fb9cb_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNC01LTEtMS04OTA3Mg_151a7d5d-42ec-4c7c-992b-d5da81b1801f">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff23cd75a927442b8803bc3729da27ed_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNC03LTEtMS04OTA3Mg_6042c55f-5526-4fd4-afc7-7bbf3fe90fbe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fc8477c42ba432494cf231b6c0d0bc6_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNC05LTEtMS04OTA3Mg_7a57af37-4d15-424f-994d-fa8a15eae8fc">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i124b70687528481fa21c28eb1cd32810_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNC0xMS0xLTEtODkwNzI_b40b5193-2149-4bbb-99c2-bbfa13471689">375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08499bccbbc4410cb5590fb188cf4b8f_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNS0xLTEtMS04OTA3Mg_07ca5090-130f-460f-a870-a105d1d0e2c7">52</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95c4cba1caca493b898eda95b9d55af7_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNS0zLTEtMS04OTA3Mg_c90c7b09-fc7a-44ca-a933-73c693c13c93">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia38a1019d805412a8c33d8125fa11085_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNS01LTEtMS04OTA3Mg_4d66e7f8-2e37-4f7b-a281-4d19a0a56977">133</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb9c9b16f92e4c9ebdac506674e51576_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNS03LTEtMS04OTA3Mg_d11fcab6-edce-421e-acd5-a925ecff195d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef5e2b06a5642ab9e8f2e182c325773_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNS05LTEtMS04OTA3Mg_96bf8733-5136-43ca-b425-91a0ad803a3a">36</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ad50d4f8264e31a30246a147683d1e_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNS0xMS0xLTEtODkwNzI_dbd80ea4-e7b2-4035-9db2-cc85d04c903a">221</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa28b372582e4ed39b7c1cf546fdc7e2_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNi0xLTEtMS04OTA3Mg_2febece8-c3db-4012-aca8-a4b02b3acc51">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6242e90d746b4facb737eb995d4cd3a1_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNi0zLTEtMS04OTA3Mg_5c134b97-0ff7-4e76-8147-ed2bd3804960">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd97f12e125642fcb0965c4f1a9363fc_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNi01LTEtMS04OTA3Mg_3f73dee3-5e74-45ca-a34d-14b640160fd0">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i59217fa829ff402c854f159e561f67dc_D20220101-20220331" xsi:nil="true" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNi03LTEtMS04OTA3Mg_7c2e8d29-c85c-46e0-9816-9dc615a846ba"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i559671273f154caeb21890281cc0f5d1_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNi05LTEtMS04OTA3Mg_68b88113-6342-47a8-a1ef-407efb6d14a8">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6583ef0acc464c159cccb04b0fec1a1b_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNi0xMS0xLTEtODkwNzI_2536d9a7-5faf-49c6-a87c-078b0e51c645">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i897d561735644b67b640f606386ea273_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNy0xLTEtMS04OTA3Mg_9a803344-53bd-4cb0-9334-8377f40a7455">889</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b20d7a1afdb4a4880e7ffd0aa66b93d_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNy0zLTEtMS04OTA3Mg_952f4116-7c02-47c6-b19d-4cac0cc6096d">464</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03af4a3fb12d4415985732b5f1713c51_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNy01LTEtMS04OTA3Mg_44ab95b9-8844-4dd0-aeb0-f7d860e534e3">244</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cc8090790184dbd8e5fef8bc092f80c_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNy03LTEtMS04OTA3Mg_eccf966c-2177-4ecf-8e68-7fde560493d2">72</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5df5fcbde684e86add3147c9fe2ea1c_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNy05LTEtMS04OTA3Mg_b39fc3c4-4302-4610-802b-5dfff86bcf1d">249</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNy0xMS0xLTEtODkwNzI_6a0840bb-e036-45f4-9f37-b25b5d0c242d">1,918</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica7d291dc2bd424e9fb044bf5d42a71d_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTAtMS0xLTEtODkwNzI_a0360def-68ba-4d0a-83a4-8b8d0a1e141b">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a8e341755db419cb385c32abb37fbf5_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTAtMy0xLTEtODkwNzI_88a725c8-fa9f-406a-8c83-0f4fee4e0313">470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ae1c40162554d5eb82184aadef55683_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTAtNS0xLTEtODkwNzI_cdc9b809-7c92-49f4-8a47-580b90f68340">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09d760aefc9346f3ba42a8f6e9e5a1c4_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTAtNy0xLTEtODkwNzI_b2171481-6b39-4187-8e34-dc97a77995ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3e109bbefcc46d498195d4ffe5d8600_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTAtOS0xLTEtODkwNzI_f4a9bc4a-5545-4af0-8a6f-1742ac3d0923">242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa0b5f041d2b45cf9d22badd73f64a23_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTAtMTEtMS0xLTg5MDcy_4215311f-dd5a-413c-9399-4fad304ebc66">892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6786806a071a4586b8fe4628dc8b3a7e_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTEtMS0xLTEtODkwNzI_a3805cd3-d37b-4d10-98ad-ef70f40c3844">382</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e5a66dcb11244d9adafcfbfdcfaa3fb_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTEtMy0xLTEtODkwNzI_98595771-2c99-4ea7-be86-57d2e80ed3f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ac60a867fe14187a7ad6925c72ddfcb_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTEtNS0xLTEtODkwNzI_e090b0da-3bd7-4867-a912-c4243c74cdcf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d31612ba6e4870b08c2e8bbacff14b_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTEtNy0xLTEtODkwNzI_63ebc88f-9ec1-4c1b-8564-19c108043e88">72</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec570a785a84b3e8b00f4538ffd504c_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTEtOS0xLTEtODkwNzI_9b102b30-c6ef-4e2c-8030-65629026cbf9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbb358ccd88b4e1582585e87263d2797_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTEtMTEtMS0xLTg5MDcy_8ef890df-a648-43e3-8686-47525f1e6652">454</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafde2cd7b3454407911b0fdbcfa6bdd6_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTItMS0xLTEtODkwNzI_2909f478-4280-4519-aa8f-fa720082ce86">320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89351cbae84d472fbc3dabeb58d46f5f_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTItMy0xLTEtODkwNzI_12eed38a-b915-4b24-a7de-3f38064b843f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaccd246e128b428da512aad072f4e923_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTItNS0xLTEtODkwNzI_4b33c095-553d-4df7-9f41-a91feb77605a">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i365abf392e8246c192b779a84beb07cf_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTItNy0xLTEtODkwNzI_95b1b5bd-4056-4697-8a3d-5ddfd366bb64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7aa0024629f24b1e86fc6db4add48d1e_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTItOS0xLTEtODkwNzI_0e02dc33-0aa8-4668-a191-6b657f41d045">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a2b93c59aa455cb5ec35f29c61b2af_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTItMTEtMS0xLTg5MDcy_75774a91-fd26-4cba-8fbc-969502f2bdfb">347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60c320b8b80142589fb80e99cc32f396_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTMtMS0xLTEtODkwNzI_104c227b-cee9-430b-9763-5b47ec7fa2cf">51</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id78c49bd421641d9bc16ae14a49b0f38_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTMtMy0xLTEtODkwNzI_6d3ab044-f5fe-48f0-9535-e355869b1274">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50631f79a17f4417939599b18339e8ad_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTMtNS0xLTEtODkwNzI_6856292d-a8ca-48f9-beef-46de742ccc32">212</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i305ec4b1f3cf485cace07ea69588b9d7_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTMtNy0xLTEtODkwNzI_d480eb25-b3bf-4b97-8480-d914034bdc93">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8080745b5f44e97ae240acceb434c81_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTMtOS0xLTEtODkwNzI_030dc9b2-e708-4fd5-99fa-350483560701">47</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74bb4d5c955a430c8f54a13eb2e95dbe_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTMtMTEtMS0xLTg5MDcy_54900a84-45d2-4dcb-ab3e-276ef2357e39">310</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b0c293a2a6e4e71a0b1622ed24842b9_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTQtMS0xLTEtODkwNzI_11e7f9b2-3544-490b-ad33-59caa37114e9">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e664ec8ede4265b16d1a42ee684fc0_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTQtMy0xLTEtODkwNzI_ca5190fe-b843-429b-b76d-4e1407728785">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54f11fd19e174e98aea8c453c247a13e_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTQtNS0xLTEtODkwNzI_6c217da1-5a7e-42b9-9e6f-d438a5097ff6">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i242c0d38400b4e0ebc1e4083d039a5d2_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTQtNy0xLTEtODkwNzI_80dd3256-e916-4ef8-a60b-e65d28a55453">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c17a4613b5a49258f9f5b8c94015244_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTQtOS0xLTEtODkwNzI_1c6f9a34-4e56-4a89-b2fa-da2f8351806f">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i595a156d88824a07951bbc6d45f101aa_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTQtMTEtMS0xLTg5MDcy_2da99fa2-a3e7-4cac-b6d5-425fdb33cfd6">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9021db7996494bfb917eaa4217e384e5_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTUtMS0xLTEtODkwNzI_78d1b886-b228-4478-8d7a-7a67a2422d1d">881</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8a36b6287944ab9a444528b83f6e58e_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTUtMy0xLTEtODkwNzI_3556d09a-7d0b-4bf7-99e6-8f538748ddc9">472</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0910908181894cb28f6e71d1b8022f02_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTUtNS0xLTEtODkwNzI_dd6516be-f2bb-46c6-b91f-cab1f10593f4">306</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia346b213e50645b0a1038d38fc86c181_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTUtNy0xLTEtODkwNzI_c34ed5ff-6143-4755-b1f9-29c07b12d521">72</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08f479ec27794028980e1c2521cd237c_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTUtOS0xLTEtODkwNzI_019e4ed7-c7ee-48e3-be82-9b7a174f3261">296</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTUtMTEtMS0xLTg5MDcy_42ce6560-711a-4a23-a91d-1d1fa3969756">2,027</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The top <ix:nonFraction unitRef="product" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="INF" name="bhc:ConcentrationRiskNumberOfProducts" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RleHRyZWdpb246MmM4ZjBlMDNkMmMyNGY4OTllNTViNDcwMjNiMmQ3YzdfMzcyNA_93600559-7a85-4618-aa08-c6c45b65ff6d"><ix:nonFraction unitRef="product" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="INF" name="bhc:ConcentrationRiskNumberOfProducts" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RleHRyZWdpb246MmM4ZjBlMDNkMmMyNGY4OTllNTViNDcwMjNiMmQ3YzdfMzcyNA_cfbaff55-e768-4ab4-9341-f58d4ae6bbb5">ten</ix:nonFraction></ix:nonFraction> products for the three months ended March 31, 2022 and 2021 represented <ix:nonFraction unitRef="number" contextRef="i2cf35ad54d7f4e3b94b6b600661263c9_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RleHRyZWdpb246MmM4ZjBlMDNkMmMyNGY4OTllNTViNDcwMjNiMmQ3YzdfMzc1OQ_11a0f893-958d-44fd-ba00-d277d88b30e4">44</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ia6c16437fc1645e5bd3f51dbfd6bc45d_D20210101-20210331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RleHRyZWdpb246MmM4ZjBlMDNkMmMyNGY4OTllNTViNDcwMjNiMmQ3YzdfMzc2Ng_f3896a56-d7ea-46da-a202-ec25770b14ee">40</ix:nonFraction>% of total revenues for the three months ended March 31, 2022 and 2021, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Information</span></div><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RleHRyZWdpb246MmM4ZjBlMDNkMmMyNGY4OTllNTViNDcwMjNiMmQ3YzdfNDE1MA_ee00ada9-183e-4b65-9ecb-7a8fe2f65f3e" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are attributed to a geographic region based on the location of the customer and were as&#160;follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.471%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i736938c435c34b8cbf4b9a86a5c1716b_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfMi01LTEtMS04OTA3Mg_3e9fed06-24a1-4545-af63-8f4ac47e865d">1,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1c251a743e84e29bcdcb92c1700440f_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfMi03LTEtMS04OTA3Mg_30eddfdf-e1f7-418f-b4aa-a52207273bd7">1,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29ca60685fd143c4ada8c74045564916_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfMy01LTEtMS04OTA3Mg_a1a095b2-6c51-45ed-a9c8-6c6c730083aa">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib389f9ca07bc4c7ca630c86bb01430f2_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfMy03LTEtMS04OTA3Mg_62723939-932c-4173-97d9-a9a52c98e737">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib632e708eb9e44e5a2c76e757b159704_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfNC01LTEtMS04OTA3Mg_f607b134-8587-42a9-8cd9-9f3e8fe94bd6">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id62e8ded86954413866df53834a4022f_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfNC03LTEtMS04OTA3Mg_ccfe9005-6b03-4b45-8414-ca7ab2efdabd">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id17ace1eafa74b49b1494fa93c34f515_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfNS01LTEtMS04OTA3Mg_07b9070c-06e0-497b-b535-a544a3cd5dc6">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfae22764ebc4680bba6944b73990b38_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfNS03LTEtMS04OTA3Mg_21845dd5-31b8-4aa4-9135-535ebb98207f">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d98656df59c417aa61bfd38cf347ab8_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfNi01LTEtMS04OTA3Mg_10232be6-da44-46f8-9b57-f6680be3d861">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i309adbf2ee5c4529ad9d523c886afcbc_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfNi03LTEtMS04OTA3Mg_a80d036f-8014-4182-b009-3b8e2f22ddb7">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71f5260404d34943ae2284710ac15bcc_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfNy01LTEtMS0xMDIyODE_bed595fc-068c-4207-a4eb-710d1af43cbb">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0efa9862b055429eb1653d07596c035a_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfNy03LTEtMS0xMDIyODg_af18ab54-cb95-4f29-afcf-5e99cf5572d4">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i038caeba82944fb08a4051fbf6da7b09_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfNy01LTEtMS04OTA3Mg_2f36c00f-cc73-4102-b679-d202334ab719">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60f8953bbbe6445eb5947c90b19aab2e_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfNy03LTEtMS04OTA3Mg_5cd270a0-7d00-4231-8607-cb92d69ad9d4">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e0b22a76af3426bae92c761987b0187_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfOC01LTEtMS04OTA3Mg_d4cfd68f-ced9-42bd-949c-1f9b35f22f80">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb045fdd1fd4540bf7a4106731f2f2c_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfOC03LTEtMS04OTA3Mg_a08bed21-1876-4ced-90a3-c8a8aa250378">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e819574885a4427b258852c7217cbb7_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfMTAtNS0xLTEtODkwNzI_5092b72d-e56c-43f8-8c87-dde11469d67f">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief192120e21c43a1a934405e935223ca_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfMTAtNy0xLTEtODkwNzI_ef3b2fd2-26dd-42c4-b10b-f6f446fd0cc1">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02bac5e7352941d58218671cc5ac18ee_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfMTEtNS0xLTEtODkwNzI_f1f7e57a-94a1-44e3-adb1-72d959d238c0">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i388557aa2024443c871b4d4a9a886575_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfMTEtNy0xLTEtODkwNzI_22c4bfce-b8a8-4b80-b5be-7fd13007844c">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd53359a539414b9021c46b47d84743_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfMTItNS0xLTEtODkwNzI_f5f0b262-a044-4731-b319-628f0221e15b">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff2ea0b9ea7b4ff2b1dc7c83ee9f0674_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfMTItNy0xLTEtODkwNzI_d5b3c7d0-92f5-4bf3-b3c3-40689131977d">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i477436c4d44d4790b5bee0250e92a451_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfMTMtNS0xLTEtODkwNzI_98b9a7f0-4fc1-44fd-83d8-05c1939859e9">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee07a351938545e1bc0374c9ee03db58_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfMTMtNy0xLTEtODkwNzI_7ccafa6b-89af-496d-95a8-bccf3a2de16d">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Korea</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c9cbd283603466d890093b4f1ad2033_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfMTQtNS0xLTEtMTAyMjkw_bd464926-04bc-40ec-a7d8-ed540d788faf">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie51fbc2dae9941b8b6e55b6fa231f07c_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfMTQtNy0xLTEtMTAyMjky_4448be82-3f62-4532-9eea-d4a4f1295977">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i704a8bd37aad403db52ecbc7efb33040_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfMTQtNS0xLTEtODkwNzI_816d2731-9f6e-47c4-994d-cf1fed71bd95">219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4b0684914ec4f1b9d774361c28cb7b0_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfMTQtNy0xLTEtODkwNzI_4470e357-f770-4424-9884-29bdc1379d1f">280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfMTUtNS0xLTEtODkwNzI_88e1a289-9d0e-4875-b397-5b7b17e56c6b">1,918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfMTUtNy0xLTEtODkwNzI_704e9155-5778-49e1-8472-2501314fda0d">2,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i9a5ed7a51c654217a2aa7f8a0e5c7186"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made and are reflected in the table above.</span></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major Customers</span></div><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RleHRyZWdpb246MmM4ZjBlMDNkMmMyNGY4OTllNTViNDcwMjNiMmQ3YzdfNDE0Mw_6065637b-7b2a-4c7e-88c0-8eb60cfa803d" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers that accounted for 10% or more of total revenues were as follows:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5c455f78b2c24f19ab413825cf24b3b1_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjljOTNjZTc4NzgzZTQ1MDI5ZGYzOTJmZjU0N2MyNzIwL3RhYmxlcmFuZ2U6OWM5M2NlNzg3ODNlNDUwMjlkZjM5MmZmNTQ3YzI3MjBfMi0xLTEtMS04OTA3Mg_dc001075-f30f-446c-b5d9-3235d89eeae4">18</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3d795947131641bda6742f32f927ee39_D20210101-20210331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjljOTNjZTc4NzgzZTQ1MDI5ZGYzOTJmZjU0N2MyNzIwL3RhYmxlcmFuZ2U6OWM5M2NlNzg3ODNlNDUwMjlkZjM5MmZmNTQ3YzI3MjBfMi0zLTEtMS04OTA3Mg_78a33fa8-71f0-470a-871b-65db349648a5">18</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation (including McKesson Specialty)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i735a4a9dd69c4f20ad6fa633744e4013_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjljOTNjZTc4NzgzZTQ1MDI5ZGYzOTJmZjU0N2MyNzIwL3RhYmxlcmFuZ2U6OWM5M2NlNzg3ODNlNDUwMjlkZjM5MmZmNTQ3YzI3MjBfMy0xLTEtMS04OTA3Mg_a4f7e4f6-9784-47d2-8def-2a904369882d">14</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idc5628f43f5849428205c5a57a1c1fcf_D20210101-20210331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjljOTNjZTc4NzgzZTQ1MDI5ZGYzOTJmZjU0N2MyNzIwL3RhYmxlcmFuZ2U6OWM5M2NlNzg3ODNlNDUwMjlkZjM5MmZmNTQ3YzI3MjBfMy0zLTEtMS04OTA3Mg_d9b5e8ef-d89a-4461-9d04-2d6cdb96d4e4">16</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health,&#160;Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iae7d7933e83c4caf870a090351b7a111_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjljOTNjZTc4NzgzZTQ1MDI5ZGYzOTJmZjU0N2MyNzIwL3RhYmxlcmFuZ2U6OWM5M2NlNzg3ODNlNDUwMjlkZjM5MmZmNTQ3YzI3MjBfNC0xLTEtMS04OTA3Mg_639c6239-cefc-4f5f-bb84-a220b352e6e8">13</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifbf2cc68e33744c4b8947828008ff5d9_D20210101-20210331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjljOTNjZTc4NzgzZTQ1MDI5ZGYzOTJmZjU0N2MyNzIwL3RhYmxlcmFuZ2U6OWM5M2NlNzg3ODNlNDUwMjlkZjM5MmZmNTQ3YzI3MjBfNC0zLTEtMS04OTA3Mg_ad2ceae3-db1d-43a0-9344-d36ed95a9ef7">12</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i801c461cbd33492a893c84373a8e7cbc_100"></div><div style="text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMTk0OTc_a7f1b217-5ef5-44c3-9d5f-4feac49a851f" continuedAt="ib8f4f251415f4d3fa4c8cd8969897161" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><ix:continuation id="ib8f4f251415f4d3fa4c8cd8969897161" continuedAt="id4506a97ff2e4db891a0973cef2716e4"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Initial Public Offering </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The registration statement related to the B+L IPO was declared effective on May 5, 2022, and Bausch + Lomb&#8217;s common shares began trading on the New York Stock Exchange and the Toronto Stock Exchange, in each case under the ticker symbol &#8220;BLCO&#8221;, on May 6, 2022. On May 10, 2022, the Selling Shareholder (as previously defined) sold <ix:nonFraction unitRef="shares" contextRef="i68726a27c9ca4a3a994459eb340ec3da_D20220510-20220510" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMTk0ODA_94ed8ab3-4833-4ca9-a349-3d7f5edd36a1">35,000,000</ix:nonFraction> common shares of Bausch + Lomb at an offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia0d8e4dd5979420fbef5b45edd961b43_I20220510" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzEwNDQ1MzYwNTEzOTUw_7fae6b81-bf1e-45dd-a296-c39fc01268b6">18.00</ix:nonFraction> per share. The net proceeds from the B+L IPO after deducting underwriting commissions and estimated offering expenses were approximately $<ix:nonFraction unitRef="usd" contextRef="i68726a27c9ca4a3a994459eb340ec3da_D20220510-20220510" decimals="-6" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzEwNDQ1MzYwNTEzOTY2_28c4f7d7-f44f-4c77-bf30-81424d01a72d">560</ix:nonFraction> million as of May 10, 2022. In addition, the Selling Shareholder has granted the underwriters an option for a period of <ix:nonNumeric contextRef="ib2ffbb57b436490590a2819d68a36061_D20220510-20220510" name="bhc:SaleOfStockOverAllotmentTerm" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg3MzE_4086f145-fa5f-49b5-92f4-9565b9c27a6e">30</ix:nonNumeric> days from the date of the B+L IPO to purchase up to an additional <ix:nonFraction unitRef="shares" contextRef="ib2ffbb57b436490590a2819d68a36061_D20220510-20220510" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg3MjA_9a7d0839-8472-4c99-b119-e6f9e622ca68">5,250,000</ix:nonFraction> common shares to cover over-allotments at the IPO offering price less underwriting commissions. As of May 10, 2022, the underwriters have not exercised this option. Upon the closing of the B+L IPO (but before exercise of the over-allotment option), the Company directly or indirectly holds <ix:nonFraction unitRef="shares" contextRef="i9088830177c14b93899cdc2428206dd1_I20220510" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzEwOTk1MTE2ODE3MTc_06530d08-adf8-43ad-94dd-87a8213424cd">315,000,000</ix:nonFraction> Bausch + Lomb common shares, which represents approximately <ix:nonFraction unitRef="number" contextRef="i9beb6982df2843ba905908dcf5d3e1c9_D20220510-20220510" decimals="2" name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzEwOTk1MTE2ODE3MzA_cb9f7b43-198d-4809-816e-6428e824f9f5">90</ix:nonFraction>% of Bausch + Lomb&#8217;s common shares.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financing Transactions of Bausch + Lomb</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2022, Bausch + Lomb entered into a credit agreement (the &#8220;B+L Credit Agreement&#8221;, and the credit facilities thereunder, the &#8220;B+L Credit Facilities&#8221;) providing for term loans of approximately $<ix:nonFraction unitRef="usd" contextRef="ie30ec3f614a04d42848dad1250068433_I20220510" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg3Mzk_8c912cfd-cdf6-4ff2-9073-4b87cdab60e2">2,500</ix:nonFraction>&#160;million with a <ix:nonNumeric contextRef="i9b0e960b1ec848318fdc55394dac24fa_D20220510-20220510" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg3NjM_36877417-c208-46ad-8cf4-1544ecad1554">five-year</ix:nonNumeric> term to maturity (the &#8220;B+L Term Facility&#8221;) and a <ix:nonNumeric contextRef="i07b15b7868704928b2944eba14639156_D20220510-20220510" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg3NzM_44a79dc3-4f46-409a-9f53-bfa3ee4f8ad6">five year</ix:nonNumeric> revolving credit facility of approximately $<ix:nonFraction unitRef="usd" contextRef="ic99afd1f228a44c78581651c6a9579a0_I20220510" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg3NzU_be041775-012d-434f-9a96-ba06ecd15560">500</ix:nonFraction>&#160;million (the &#8220;B+L Revolving Credit Facility&#8221; or such financing, the &#8220;B+L Debt Financing&#8221;). The B+L Credit Facilities are secured by substantially all of the assets of Bausch + Lomb and its material, wholly-owned Canadian, U.S., Dutch and Irish subsidiaries, subject to certain exceptions. The term loans are denominated in U.S. dollars, and borrowings under the revolving credit facility will be made available in U.S. dollars, euros, pounds sterling and Canadian dollars. As of May 10, 2022, the B+L Revolving Credit Facility remains undrawn.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the B+L Revolving Credit Facility in (i) U.S. dollars bear interest at a rate per annum equal to, at our option, either: (a) a term SOFR-based rate or (b) a U.S. dollar base rate, (ii) Canadian dollars bear interest at a rate per annum equal to, at our option, either: (a) CDOR or (b) a Canadian dollar prime rate, (iii) euros bear interest at a rate per annum equal to EURIBOR and (iv) pounds sterling bear interest at a rate per annum equal to SONIA (provided, however, that the term SOFR-based rate, CDOR, EURIBOR and SONIA shall be no less than <ix:nonFraction unitRef="number" contextRef="i969796cd9c2a43459679467ac14382c6_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg3ODk_979a04e8-1b6c-4370-a77c-449f99440d30">0.00</ix:nonFraction>% per annum at any time and the U.S. dollar base rate and the Canadian dollar prime rate shall be no less than <ix:nonFraction unitRef="number" contextRef="i1a1c85fad6244e21b4823c99ca9236cb_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg3OTc_d72b6c22-ae73-4fe2-8917-7f24a5172a19">1.00</ix:nonFraction>% per annum at any time), in each case, plus an applicable margin. Term SOFR-based loans are subject to a credit spread adjustment of <ix:nonFraction unitRef="number" contextRef="i6835eeba06904e7d83cc68aeeb30bc96_D20220510-20220510" decimals="INF" name="bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzE2NDkyNjc0NDg1NzQw_4278d38b-318b-4e77-b789-84fc06675e0d">0.10</ix:nonFraction>%.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margins for borrowings under the B+L Revolving Credit Facility are (i) between <ix:nonFraction unitRef="number" contextRef="iaef1fd49551a4a5e99cc5c7286d61d19_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg4MDQ_cc9958e7-7d7b-4efc-b3c8-ef9f05b5d870">0.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i6062d01783b9476ab5d93d304f908fdb_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg4MTE_fcf5d492-a087-4fbe-84d6-231226a5a129">1.75</ix:nonFraction>% with respect to U.S. dollar base rate or Canadian dollar prime rate borrowings and between <ix:nonFraction unitRef="number" contextRef="i5ed6554f1984485bbe1d859a5cce60e5_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg4MTg_27f75ac4-6662-4372-a1bf-6eed03042059">1.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i37d22f117617444f9a62f2666aeaf23e_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg4MjU_9d703785-3819-425b-b06b-a3dfafae7023">2.75</ix:nonFraction>% with respect to SOFR, EURIBOR, SONIA or CDOR borrowings based on the Company&#8217;s total net leverage ratio and (ii) after (x) Bausch + Lomb&#8217;s senior unsecured non-credit-enhanced long term indebtedness for borrowed money receives an investment grade rating from at least two of S&amp;P, Moody&#8217;s and Fitch and (y) the term loan facility has been repaid in full in cash (the &#8220;IG Trigger&#8221;), between <ix:nonFraction unitRef="number" contextRef="iebf7fa610282462e8a87798c4a0c13b7_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg4MzI_93553db0-fed0-4f04-ac98-a6d2f3104ce8">0.015</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i07c3bdbe9d364f85a235465f6572d30b_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg4NDA_3cbfa130-6bed-4119-a80d-a4fd88aa4686">0.475</ix:nonFraction>% with respect to U.S. dollar base rate or Canadian dollar prime rate borrowings and between <ix:nonFraction unitRef="number" contextRef="i827cfce6b4184d368806fa2e3eab7b12_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg4NDg_7448b5ee-e522-4a13-9cec-d5e952c4dd6b">1.015</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i15b198ca83624b318396f39380edc2ac_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg4NTY_ae0b843a-dbc0-4c22-806d-8979fe1c72b4">1.475</ix:nonFraction>% with respect to SOFR, EURIBOR, SONIA or CDOR borrowings based on the Company&#8217;s debt rating. In addition, the Company is required to pay commitment fees of <ix:nonFraction unitRef="number" contextRef="i07b15b7868704928b2944eba14639156_D20220510-20220510" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg4NjQ_f4eac893-638a-4a5e-9803-cfb760e484ea">0.25</ix:nonFraction>% per annum in respect of the unutilized commitments under the revolving credit facility, payable quarterly in arrears until the IG Trigger and a facility fee between <ix:nonFraction unitRef="number" contextRef="id2a157fb52da45df95151e9668b651b6_D20220510-20220510" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg4NzE_b667729a-58a2-4aee-8365-8bc17844c1c9">0.110</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ic7c0ae85a82c4cb3a319373f684bc55a_D20220510-20220510" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg4Nzk_d5cf685a-84b8-416d-a647-d6e421eb91ae">0.275</ix:nonFraction>% of the total revolving commitments, whether used or unused, based on the Company&#8217;s debt rating and payable quarterly in arrears. The Company is also required to pay letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on SOFR borrowings under the revolving credit facility on a per annum basis, payable quarterly in arrears, as well as customary fronting fees for the issuance of letters of credit and agency fees. </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="id4506a97ff2e4db891a0973cef2716e4" continuedAt="iff187e116bb24456866401f333879550"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the term loan facility bear interest at a rate per annum equal to, at our option, either (i) a term SOFR-based rate, plus an applicable margin of <ix:nonFraction unitRef="number" contextRef="i679d8e8de83d43b8aa7b432b14f90a83_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg4ODc_d81264f3-07fc-4c5e-8940-08ff5181cab5">3.25</ix:nonFraction>% or (ii) a U.S. dollar base rate, plus an applicable margin of <ix:nonFraction unitRef="number" contextRef="i8d5a322888ac487b9f4166843a4b2254_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg4OTU_01a4282c-2f32-4718-abb8-14bc628a4bce">2.25</ix:nonFraction>% (provided, however, that the term SOFR-based rate shall be no less than <ix:nonFraction unitRef="number" contextRef="i6a4a857f626f43fcbcdf8083edd3c4b1_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzE2NDkyNjc0NDg1NzQ3_3f96f077-6a81-4b86-bb7d-9cd3e3bb0a6a">0.50</ix:nonFraction>% per annum at any time and the U.S. dollar base rate shall not be lower than <ix:nonFraction unitRef="number" contextRef="if0dbac6e5e59470e9e96eab6a439d571_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzE2NDkyNjc0NDg1NzU0_7dc9b8d7-4c02-402d-b2ad-c7c0ad3f2e37">1.50</ix:nonFraction>% per annum at any time). Term SOFR-based loans are subject to a credit spread adjustment of <ix:nonFraction unitRef="number" contextRef="i679d8e8de83d43b8aa7b432b14f90a83_D20220510-20220510" decimals="INF" name="bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzE2NDkyNjc0NDg1NzYx_a9ee8d97-0eb9-449b-a143-683dc4beffff">0.10</ix:nonFraction>%.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions and customary baskets set forth in the B+L Credit Agreement, the Company is required to make mandatory prepayments of the loans under the B+L Term Facility under certain circumstances, including from: (i) <ix:nonFraction unitRef="number" contextRef="i07b15b7868704928b2944eba14639156_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg5MDI_6667054a-ba7c-4ff2-af22-737b97cf9494">100</ix:nonFraction>% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold), (ii) <ix:nonFraction unitRef="number" contextRef="i07b15b7868704928b2944eba14639156_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg5MDg_905e6787-dad7-40b9-9baf-6572a2ed1459">100</ix:nonFraction>% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the B+L Credit Agreement), (iii) <ix:nonFraction unitRef="number" contextRef="i07b15b7868704928b2944eba14639156_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg5MTQ_31071885-bd1c-440d-8658-edd34e02fd0b">50</ix:nonFraction>% of Excess Cash Flow (as defined in the B+L Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv) <ix:nonFraction unitRef="number" contextRef="i07b15b7868704928b2944eba14639156_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg5MTk_76d5e468-ae08-4e15-832c-aaa652008ee3">100</ix:nonFraction>% of net cash proceeds from asset sales (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold). These mandatory prepayments may be used to satisfy future amortization.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortization rate for the B+L Term Facility is <ix:nonFraction unitRef="number" contextRef="ie30ec3f614a04d42848dad1250068433_I20220510" decimals="INF" name="bhc:DebtInstrumentAnnualAmortizationRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg5MjU_28f9b26d-729f-4814-a659-ee690286d4d6">1.00</ix:nonFraction>% per annum and the first installment shall be payable on September 30, 2022. Bausch + Lomb may direct that prepayments be applied to such amortization payments in order of maturity. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Secured Credit Facilitie</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2022, the Company and certain of its subsidiaries as guarantors entered into that certain Second Amendment to the Fourth Amended and Restated Credit and Guaranty Agreement (the &#8220;Second Amendment&#8221;). The 2022 Restated Credit Agreement provides for a new term facility with an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i4920545cfdfe43ea874d0ca5a349c081_I20220510" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg5MzI_5d4ac766-14c9-4d08-a278-7d5c90cb7e95">2,500</ix:nonFraction>&#160;million (the &#8220;2027 Term Loan B Facility&#8221; and the loans thereunder the &#8220;2027 Term Loans&#8221;) maturing on February 1, 2027 and a new revolving credit facility of $<ix:nonFraction unitRef="usd" contextRef="iba4cf152a5ec43589599bfbc8c8881de_I20220510" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg5NDg_0792b5b8-5340-45bd-9293-a43c8d82303c">975</ix:nonFraction>&#160;million (the &#8220;2027 Revolving Credit Facility&#8221;) that will mature on the earlier of February 1, 2027 and the date that is <ix:nonNumeric contextRef="i1a96cf695f3646188214a645c50f0e12_D20220510-20220510" name="bhc:DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzE2NDkyNjc0NDg1NzY4_058c2c9c-71c5-4c7e-8b1f-86d60d169a3b">91</ix:nonNumeric> calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company and BHA in an aggregate principal amount in excess of $<ix:nonFraction unitRef="usd" contextRef="iba4cf152a5ec43589599bfbc8c8881de_I20220510" decimals="INF" name="bhc:DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg5NjI_cb4de2d1-189c-479b-9670-a44178f02e69">1,000</ix:nonFraction>&#160;million. After giving effect to the 2022 Restated Credit Agreement, the 2023 Revolving Credit Facility, June 2025 Term Loan B Facility and November 2025 Term Loan B Facility were refinanced (such refinancing, the &#8220;Credit Agreement Refinancing&#8221;), along with certain of the Company&#8217;s existing senior notes, using proceeds of the Credit Agreement Refinancing, the B+L IPO and the B+L Debt Financing and available cash on hand. As of May 10, 2022, the Company has drawn $<ix:nonFraction unitRef="usd" contextRef="iba4cf152a5ec43589599bfbc8c8881de_I20220510" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzE2NDkyNjc0NDg1Nzc2_56c0fdb2-8a62-410f-9f4b-571bc707b6e5">350</ix:nonFraction> million on the 2027 Revolving Credit Facility.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2027 Term Loan B Facility bear interest at a rate per annum equal to, at our option, either: (a) a term SOFR-based rate or (b) a U.S. dollar base rate, in each case, plus an applicable margin (provided, however, that the term SOFR-based rate is expected to be no less than <ix:nonFraction unitRef="number" contextRef="i5263f4eeef0e4a1eb6008213ffca534f_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg5Nzg_db8081a5-e3c1-421e-b441-3a46fabee19a">0.50</ix:nonFraction>% per annum at any time and the U.S. dollar base rate is expected to be no less than <ix:nonFraction unitRef="number" contextRef="i00ec1ba964804053bf2cebbf5c43f522_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg5ODU_85650845-55b0-4633-84df-0329fd0a83fb">1.50</ix:nonFraction>% per annum at any time). Borrowings under the 2027 Revolving Credit Facility in: (i) U.S. dollars bear interest at a rate per annum equal to, at the Company&#8217;s option, either: (a) a term SOFR-based rate or (b) a U.S. dollar base rate, (ii) Canadian dollars bear interest at a rate per annum equal to, at our option, either: (a) CDOR or (b) a Canadian dollar prime rate and (iii) euros bear interest at a rate per annum equal to EURIBOR (provided, however, that the term SOFR-based rate, CDOR and EURIBOR are expected to be no less than <ix:nonFraction unitRef="number" contextRef="i801aca530cc14c9b8be64fb696e6dcf5_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg5OTI_268dfd74-00cb-43db-b2d1-4285d89f0777">0.00</ix:nonFraction>% per annum at any time and the U.S. dollar base rate and the Canadian dollar prime rate are expected to be no less than <ix:nonFraction unitRef="number" contextRef="id66d7e17675f4184972f0235d07b1e63_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkwMDA_77524024-2006-494e-96cf-30e0bd994a27">1.00</ix:nonFraction>% per annum at any time), in each case, plus an applicable margin. Term SOFR-based loans are subject to a credit spread adjustment ranging from <ix:nonFraction unitRef="number" contextRef="i5263f4eeef0e4a1eb6008213ffca534f_D20220510-20220510" decimals="INF" name="bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzE2NDkyNjc0NDg1Nzg1_3a9139d2-2d3f-4478-8da0-859386214f90">0.10</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i9e33a46b9a8c458e92c2a7533b092615_D20220510-20220510" decimals="INF" name="bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzE2NDkyNjc0NDg1Nzky_006f532e-18b8-46de-8d90-4e0de34c4ce4">0.25</ix:nonFraction>%.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margin for borrowings under the 2027 Term Loan B Facility is <ix:nonFraction unitRef="number" contextRef="iedc6c37d8af5490d993ec3399bc55792_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkwMDc_4e447bf0-01b2-460e-89a2-6971f4943066">5.25</ix:nonFraction>% for term SOFR-based loans and <ix:nonFraction unitRef="number" contextRef="i28d3080b48c44fb2a31f867511fa241f_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkwMTQ_fcef0ca5-f9ee-4a4d-b16f-52273c5b9bbe">4.25</ix:nonFraction>% for U.S. dollar base rate loans. The applicable interest rate margin for borrowings under the 2027 Revolving Credit Facility ranges from <ix:nonFraction unitRef="number" contextRef="ib5ba454a7b6c45a3949b8f1985ac313e_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkwMjE_f5f4bd7c-fe64-420d-ac0f-25b036edccf1">3.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i053e8e2380ae405a8cf2ef0d0dac698b_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkwMjg_a555f2f6-71f7-4010-8285-8dbe479203fd">4.25</ix:nonFraction>% for term SOFR-based loans and <ix:nonFraction unitRef="number" contextRef="i618e8b101a9e4651a8d45a1516a66fde_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkwMzU_db298e49-7340-463d-a9ad-ea38728ad7a5">2.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ibfc76cd45bc6474988b4e3877373db82_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkwNDI_f343642d-2d32-4aac-8bf4-a7d53a894bb5">3.25</ix:nonFraction>% for U.S. dollar base rate loans.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is required to pay commitment fees of <ix:nonFraction unitRef="number" contextRef="i577466297a53405f9454d33995ecba1e_D20220510-20220510" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkwNDk_b4e82447-bf60-4b2f-92cd-53255abefd1c">0.25</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="ib5b37fae66ea41e88fed93726d182d6a_D20220510-20220510" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkwNTY_00270621-96b0-4960-b6d9-0e3250900a3d">0.50</ix:nonFraction>% per annum with respect to the unutilized commitments under the 2027 Revolving Credit Facility, payable quarterly in arrears. The Company also is required to pay: (i) letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on term SOFR borrowings under the 2027 Revolving Credit Facility on a per annum basis, payable quarterly in arrears, (ii) customary fronting fees for the issuance of letters of credit and (iii) agency fees.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions and customary baskets set forth in the 2022 Restated Credit Agreement, the Company is required to make mandatory prepayments of the loans under the Senior Secured Credit Facilities under certain circumstances, including from: (i) <ix:nonFraction unitRef="number" contextRef="i14ef51bcde474f27be0e9b588872b89a_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkwNjM_b8dc0d92-1e53-40be-ab58-a38996b6d714">100</ix:nonFraction>% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold), (ii) <ix:nonFraction unitRef="number" contextRef="i14ef51bcde474f27be0e9b588872b89a_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkwNjk_8a604c67-781a-4a8e-a268-24e41060d7f3">100</ix:nonFraction>% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the 2022 Restated Credit Agreement), (iii) <ix:nonFraction unitRef="number" contextRef="i14ef51bcde474f27be0e9b588872b89a_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkwNzU_e3f3d17b-2ad2-4127-ae9d-85746eb46103">50</ix:nonFraction>% of Excess Cash Flow (as defined in the 2022 Restated Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv) <ix:nonFraction unitRef="number" contextRef="i14ef51bcde474f27be0e9b588872b89a_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkwODA_ecd4c961-835a-41c2-bb32-b67f10e57e97">100</ix:nonFraction>% of net cash proceeds from asset sales (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold). These mandatory prepayments may be used to satisfy future amortization. </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="iff187e116bb24456866401f333879550"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortization rate for the 2027 Term Loan B Facility is <ix:nonFraction unitRef="number" contextRef="i4920545cfdfe43ea874d0ca5a349c081_I20220510" decimals="INF" name="bhc:DebtInstrumentAnnualAmortizationRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkwODY_78212e57-c4d9-466d-8012-ec6fd65f7102">5.00</ix:nonFraction>% per annum and the first installment shall be payable on September 30, 2022. The Company may direct that prepayments be applied to such amortization payments in order of maturity.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Restated Credit Agreement permits the incurrence of incremental credit facility borrowings up to the greater of $<ix:nonFraction unitRef="usd" contextRef="i5d6eeadd393b426393e1f0ed889d241d_I20220510" decimals="INF" name="bhc:LineOfCreditFacilityThresholdForIncrementalBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkwOTM_2ebad52b-52e8-46bd-a046-775c57bbc05d">1,000</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="number" contextRef="ic809285ec99545369921696d670f6b36_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkxMDk_fb6bcce3-0ef3-4470-b69e-8f334ae67ce0">40</ix:nonFraction>% of Consolidated Adjusted EBITDA (non-GAAP) (as defined in the 2022 Restated Credit Agreement), subject to customary terms and conditions, as well as the incurrence of additional incremental credit facility borrowings subject to, in the case of secured debt, a secured leverage ratio of not greater than <ix:nonFraction unitRef="number" contextRef="i2fe9c48370994d03935d785c7f1a8b8b_I20220510" decimals="INF" name="bhc:DebtInstrumentCovenantTermsSecuredLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkxMTQ_065eb5e8-e4cc-4d96-be82-891b577d69ef">3.50</ix:nonFraction>:1.00, and, in the case of unsecured debt, either a total leverage ratio of not greater than <ix:nonFraction unitRef="number" contextRef="i49de6c3d04bb472d8b09e6bd0c1887d7_I20220510" decimals="INF" name="bhc:DebtInstrumentCovenantTotalLeverageRatioMaximum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkxMjA_74a0ec1e-49c2-4944-bc11-71cfeef63067">6.50</ix:nonFraction>:1.00 or an interest coverage ratio of not less than <ix:nonFraction unitRef="number" contextRef="i5d6eeadd393b426393e1f0ed889d241d_I20220510" decimals="INF" name="bhc:DebtInstrumentCovenantInterestCoverageRatioMinimum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkxMjY_76e592a1-4b45-4f55-ad75-d2a5833e935f">2.00</ix:nonFraction>:1.00.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Restated Credit Agreement provides that Bausch + Lomb initially be a &#8220;excluded&#8221; subsidiary subject to the terms of the 2022 Restated Credit Agreement covenants, but does not require Bausch + Lomb to guarantee the obligations under the 2022 Restated Credit Agreement. The 2022 Restated Credit Agreement permits the Company to designate Bausch + Lomb as an &#8220;unrestricted&#8221; subsidiary under the 2022 Restated Credit Agreement and no longer subject to the terms of the covenants thereunder upon achievement of a <ix:nonFraction unitRef="number" contextRef="ia843743426e540ee8c98df5ca73090c9_D20220510-20220510" decimals="INF" name="bhc:DebtInstrumentCovenantTotalLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkxMzI_aeea666f-8f80-497e-b012-abfbf2a4ee52">7.6</ix:nonFraction>x pro forma &#8220;Remainco Total Leverage Ratio&#8221; Such designation could take place at any time after the B+L IPO. The Credit Agreement Refinancing contains provisions designed to facilitate the separation and distribution of Bausch + Lomb.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Redemption of April 2025 Unsecured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 18, 2022, the Company issued conditional notices of redemption to redeem: (i) all April 2025 Unsecured Notes conditioned upon the completion of the Credit Agreement Refinancing and (ii) $<ix:nonFraction unitRef="usd" contextRef="iaa22c8251ddf46939526e13e17458660_I20220118" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkxMzc_b350c47a-2ed4-4b57-9b54-9ffb2b6987c9">370</ix:nonFraction>&#160;million in aggregate principal amount of our outstanding <ix:nonFraction unitRef="number" contextRef="iaa22c8251ddf46939526e13e17458660_I20220118" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkxNTE_c7697313-37d8-4591-8a8c-822820e775c6">9.000</ix:nonFraction>% Senior Unsecured Notes due 2025 (the "December 2025 Unsecured Notes") conditioned upon the receipt of aggregate proceeds from: (i) the B+L IPO, (ii) the B+L Debt Financing, (iii) the Credit Agreement Refinancing and (iv) the issuance of the February 2027 Secured Notes of at least $<ix:nonFraction unitRef="usd" contextRef="iaa22c8251ddf46939526e13e17458660_I20220118" decimals="INF" name="bhc:DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkxNTk_f77e5db9-35be-4707-95ba-218de6a32fc1">7,000</ix:nonFraction>&#160;million. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the closing of the B+L IPO, the conditions of the Company&#8217;s previously announced redemption of its April 2025 Unsecured Notes were satisfied and the Company discharged the April 2025 Unsecured Notes Indenture using: (i) the proceeds from the issuance of the February 2027 Secured Notes, (ii) the proceeds from the B+L IPO, (iii) the net proceeds from the borrowings under the B+L Debt Financing and (iv) cash on hand. On May 10, 2022, the Company caused sufficient funds for the redemption in full of its April 2025 Unsecured Notes at a redemption price of <ix:nonFraction unitRef="number" contextRef="id1e3d8f9146049ff9febeb80d7774565_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkxNzU_5dce3528-39a4-45a8-937e-8bb7d87e29e3">101.021</ix:nonFraction>% of the principal amount then outstanding to be irrevocably deposited with the Bank of New York Mellon, N.A., as trustee under the April 2025 Unsecured Notes Indenture, and the April 2025 Unsecured Notes Indenture was discharged. The April 2025 Unsecured Notes will be redeemed on May 16, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2022, the Company notified the Trustee and holders of its outstanding December 2025 Unsecured Notes that the conditions to its previously announced redemption would not be satisfied, and the conditional redemption was cancelled.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the closing of the B+L IPO, the discharge of the <ix:nonFraction unitRef="number" contextRef="i3525c40548924586bbd17234ab1c71c3_I20220510" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzE2NDkyNjc0NDg1Nzk5_8d665c34-d4ef-4214-8095-73452d08f215">6.125</ix:nonFraction>% Notes Indenture and the related release in respect of the 2018 Restated Credit Agreement as described above, the guarantees and related security provided by Bausch + Lomb and its subsidiaries in respect of the existing senior notes of the Company and BHA were released.</span></div></ix:continuation><div><span><br/></span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><div id="i801c461cbd33492a893c84373a8e7cbc_103"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of&#160;Operations</span></div><div id="i801c461cbd33492a893c84373a8e7cbc_106"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTRODUCTION</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unless the context otherwise indicates, as used in this &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;the Company,&#8221; and similar terms refer to Bausch Health Companies Inc. and its subsidiaries. This &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; has been updated through May&#160;10, 2022 and should be read in conjunction with the unaudited interim Consolidated Financial Statements and the related notes included elsewhere in this Quarterly Report on Form 10-Q for the quarterly period ended March&#160;31, 2022 (this &#8220;Form 10-Q&#8221;). The matters discussed in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; contain certain forward-looking statements within the meaning of Section 27A of The Securities Act of 1933, as amended, and Section 21E of The Securities Exchange Act of 1934, as amended, and that may be forward-looking information within the meaning defined under applicable Canadian securities laws (collectively, &#8220;Forward-Looking Statements&#8221;). See &#8220;Forward-Looking Statements&#8221; at the end of this discussion. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our accompanying unaudited interim Consolidated Financial Statements as of March&#160;31, 2022 and for the three months ended March 31, 2022 and 2021 have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and the rules and regulations of the United States Securities and Exchange Commission (the &#8220;SEC&#8221;) for interim financial statements, and should be read in conjunction with our Consolidated Financial Statements for the year ended December&#160;31, 2021, which were included in our Annual Report on Form 10-K filed on February&#160;23, 2022. In our opinion, the unaudited interim Consolidated Financial Statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for a fair statement of the financial condition, results of operations and cash flows for the periods indicated. Additional company information is available on SEDAR at </span><span style="color:#0027ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.sedar.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> and on the SEC website at&#160;</span><span style="color:#0027ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. All currency amounts are expressed in U.S.&#160;dollars, unless otherwise noted.</span></div><div id="i801c461cbd33492a893c84373a8e7cbc_109"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OVERVIEW</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a global company whose mission is to improve people&#8217;s lives with our health care products. We develop, manufacture and market, primarily in the therapeutic areas of eye health, gastroenterology (&#8220;GI&#8221;) and dermatology, a broad range of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) over-the-counter (&#8220;OTC&#8221;) products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in approximately 100 countries. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of products falls into five operating and reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International (formerly Interntaional Rx), (iv) Solta Medical and (v) Diversified Products. These segments are discussed in detail in Note 19, &#8220;SEGMENT INFORMATION&#8221; to our unaudited Consolidated Financial Statements. The following is a brief description of the Company&#8217;s segments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Bausch + Lomb segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Bausch + Lomb Vision Care, Consumer, Surgical and Ophthalmic Pharmaceuticals products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Salix segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of sales in the U.S. of GI products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The International segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of sales, with the exception of sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Solta Medical segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Solta aesthetic medical devices. </span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;padding-left:14.5pt">The Diversified Products segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products, (iii) Ortho Dermatologics (dermatological) products and (iv) dentistry products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the planned separation of our Solta business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc., during the first quarter of 2022, the Company changed its segment structure in a manner which is consistent with the organizational structure of the two separate entities as proposed by the Solta IPO (as defined below). The new segment structure resulted in a change to the Company&#8217;s former Ortho Dermatologics segment whereby its medical dermatology business (Ortho Dermatologics) will now be managed by the Chief Operating Decision Maker (&#8220;CODM&#8221;) as part of the Diversified Products segment and the Solta business will be managed by the CODM as its own operating and reportable segment. Prior period presentation of segment revenues and segment profits has been recast to conform to the current reporting structure.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><div id="i801c461cbd33492a893c84373a8e7cbc_1904"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Focus on Value</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, we retained a new executive team which implemented a multi-year plan designed to transform and bring out value in our Company. The multi-year plan increased our focus on, among other factors, our: product portfolio, infrastructure, geographic footprint, capital structure and risk management.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since that time, we have been executing and continue to execute on our commitments to transform the Company and generate value. As discussed below, under the multi-year plan, we have taken actions that among other things included: (i) divesting non-core assets, (ii) making strategic investments in our core businesses and (iii) making measurable progress in improving our capital structure. These measures gave us operating flexibility and put us in a strong position to unlock the additional value to be found in our specific businesses. We believe that these and other positive actions we took to transform our Company, have helped to focus our operations, and improve our capital structure. These positive actions also presented us with an opportunity to unlock potential value across our portfolio of assets by separating our pharmaceutical, eye health and skincare businesses, and, in 2020 and 2021, we set out to create three highly attractive but dissimilar businesses. Although management believes these transactions will bring out additional value, there can be no assurance that either the B+L Separation or the Solta IPO (each of which are defined below) will be successful in doing so.</span></div><div id="i801c461cbd33492a893c84373a8e7cbc_115"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Separation of the Bausch + Lomb Eye Health Business and IPO of the Solta Medical Business</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2020, we announced our plan to separate our eye health business consisting of our Bausch + Lomb Global Vision Care, Global Consumer, Global Surgical and Global Ophthalmic Pharmaceuticals businesses into an independent publicly traded entity, Bausch + Lomb Corporation (&#8220;Bausch + Lomb&#8221;), from the remainder of Bausch Health Companies Inc. (the &#8220;B+L Separation&#8221;). In January 2022, we completed the internal organizational design and structure of the new eye health entity. The registration statement related to the IPO of Bausch + Lomb (the &#8220;B+L IPO&#8221;) was declared effective on May 5, 2022, and Bausch + Lomb&#8217;s common stock began trading on the New York Stock Exchange and the Toronto Stock Exchange, in each case under the ticker symbol &#8220;BLCO&#8221; on May 6, 2022. Prior to the effectiveness of the registration statement, Bausch + Lomb was an indirect wholly-owned subsidiary of the Company. On May 10, 2022, a wholly owned subsidiary of the Company (the &#8220;Selling Shareholder&#8221;) sold 35,000,000 common shares of Bausch + Lomb, at an offering price of $18.00, per share, pursuant to the Bausch + Lomb prospectus. In addition, the Selling Shareholder has granted the underwriters an option for a period of 30 days from the date of the B+L IPO to purchase up to an additional 5,250,000 common shares to cover over-allotments at the IPO offering price less underwriting commissions. As of May 10, 2022, the underwriters have not exercised this option. We expect to complete the separation of Bausch + Lomb after the expiry of customary lockups related to the B+L IPO and achievement of targeted debt leverage ratios, subject to the receipt of applicable shareholder and other necessary approvals. See Note 20, &#8220;SUBSEQUENT EVENTS&#8221; to our unaudited interim Consolidated Financial Statements for additional information.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time of our announcement of the B+L Separation, we emphasized that it is important that the post-separation entities be well capitalized, with appropriate leverage and with access to additional capital, if and when needed, to provide each entity with the ability to independently allocate capital to areas that will strengthen their own competitive positions in their respective lines of business and position each entity for sustainable growth. Therefore, we see the appropriate capitalization and leverage of these businesses post-separation as a key to maximizing value across our portfolio of assets and, so, it is a primary objective of our plan of separation. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also previously stated that all options for achieving the appropriate capitalization and leverage for these entities post-separation were being considered. Management remains focused on the capitalizations of the post-separation entities and has considered and continues to consider alternative means of achieving the appropriate outcome, including dispositions in our business that we believe represent attractive opportunities for the Company and are in line with our plan of separation. This informed our decision to divest Amoun Pharmaceutical Company S.A.E. (&#8220;Amoun&#8221;) on July 26, 2021 and, as discussed below, use the net proceeds to repay certain debt obligations. It has also informed, in part, our decision to pursue an initial public offering (&#8220;IPO&#8221;) of our Solta aesthetic medical device business (&#8220;Solta Medical&#8221;) (the &#8220;Solta IPO&#8221;), which we announced on August 3, 2021. Since announcing the Solta IPO, we began executing on those plans and, at the end of 2021, had substantially completed the internal objectives necessary to facilitate the Solta IPO. We believe that the Solta IPO, when and if complete, will allow us to unlock the value of this high-growth business and give us ownership of a valuable financial asset that would compare more favorably to other aesthetic medical device companies. We continue to monitor market conditions and aim to launch the Solta IPO when financial market conditions are favorable (subject to receipt of regulatory, stock exchange and other approvals and other factors). Until such time, we continue to manage the Solta business along with our diverse portfolio of gastroenterology, hepatology, dermatology, neurology and other therapeutics, with our commitment to bring out additional value for our shareholders.  However, there can be no assurance as to when we will complete either the B+L Separation or the Solta IPO, if at all.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in further detail below, the proceeds from the B+L IPO, along with those from the offering of the February 2027 Secured Notes, the B+L Debt Financing and the 2027 Term Loans (each as defined below), along with cash on hand, were used to repay and refinance a portion of our existing debt. In addition, we intend to use the proceeds from any potential </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future offers of Bausch + Lomb common shares and the Solta IPO to further repay, to the extent possible, a portion of our existing debt, thereby improving our capitalization and leverage. We believe the B+L Separation and the Solta IPO, if consummated, provides us with an attractive opportunity for liquidity to support the appropriate capitalization and leverage of the Bausch + Lomb entity, the Solta Medical entity and the remainder of Bausch Health Companies Inc., which we refer to as &#8220;Bausch Pharma&#8221; and will assume a new name upon completion of the B+L Separation. However, management continues to explore a number of alternative capitalization structures in order to properly capitalize the three entities. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The B+L Separation and the Solta IPO will establish three separate companies that include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Bausch + Lomb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - a fully integrated, pure play eye health company built on the iconic Bausch + Lomb brand and long history of innovation; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Solta Medical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - a leading global aesthetic medical device company focused on the development, manufacture and sale of innovative technologies that provide aesthetic and therapeutic benefits; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Bausch Pharma</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - a diversified pharmaceutical company with leading positions in gastroenterology, hepatology, dermatology, neurology and international pharmaceuticals. The remaining pharmaceutical entity will comprise a diversified portfolio of our leading durable brands across the Salix, International, dentistry, neurology, medical dermatology and generics businesses. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the B+L Separation and the Solta IPO will result in three highly attractive but dissimilar businesses. As separate entities, management believes that each company will be better positioned to individually focus on its core businesses to drive additional growth, more effectively allocate capital and better manage its respective capital needs.  Further, these transactions allow us and the market to compare the operating results of each entity with other &#8220;pure play&#8221; peer companies. Although management believes these transactions will bring out additional value, there can be no assurance that either the B+L Separation or the Solta IPO will be successful in doing so.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although an IPO of the Solta Medical businesses is among the alternate capital structures being considered, this Form 10-Q does not constitute an offer to sell, or the solicitation of an offer to buy, any securities of Solta Medical. As of the date of this filing, the determination of the capitalization of the three entities continues to evolve, and we do not have a definitive timetable to finalize the respective capital structures. We continue to monitor market conditions and aim to launch the Solta IPO when financial market conditions are favorable (and subject to receipt of regulatory, stock exchange, and other approvals). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the capitalization and leverage ratios of each entity, there are considerations, approvals and conditions, including market conditions, that will determine the ultimate timing and structure of these transactions, including regulatory approvals, final approval by our board of directors, any shareholder vote requirements that may be applicable, compliance with U.S. and Canadian securities laws and stock exchange rules, receipt of any applicable opinions and/or rulings with respect to the Canadian and U.S. federal income tax treatment of such transactions and determination of the pro forma capitalization of each of the three entities. The failure to satisfy all of the required conditions could delay the completion of these transactions for a significant period of time or prevent them from occurring at all. We will need to complete a number of additional steps that will depend on the ultimate structure of the transactions (in addition to obtaining the regulatory approvals and satisfying the conditions described above) before we can complete the B+L Separation and/or launch the Solta IPO. As a result, there can be no assurance as to the timing of the completion of either of these transactions or their structure or terms, and the information in this Form 10-Q relating to each transaction is preliminary and may change as the transactions progress and any such changes and their impact on the Company, or any of the companies that result from the consummation of any of these transactions, may be material.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 1A. &#8220;Risk Factors &#8212; Risk Relating to the B+L Separation and the Solta IPO&#8221; of our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC and the CSA on February&#160;23, 2022, for additional risks relating to the B+L Separation and the Solta IPO.</span></div><div id="i801c461cbd33492a893c84373a8e7cbc_112"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Setting Up Our Company to Unlock Value</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To position ourselves to unlock the value we see in our individual businesses, we have sought to right-size our portfolio of assets and provide financial flexibility. The Company has focused on the following growth drivers, that remain a focus of our growth strategies today:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">on May 10, 2022 in connection with the B+L IPO, the Company completed a series of transactions in which among other things: (i) Bausch + Lomb entered into a new credit facility, (ii) the Company repaid certain amounts outstanding under its existing term B loans, (iii) the Company refinanced the remaining amounts outstanding under its credit facilities and (iv) the Company discharged the indenture governing the 6.125% Senior Unsecured Notes due 2025 (the &#8220;April 2025 Unsecured Notes&#8221; and the related indenture the &#8220;April 2025 Unsecured Notes </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indenture&#8221;) with, among other sources, the net proceeds from the February 2027 Secured Notes (as defined below). We believe these transactions bring us one step closer to meeting our commitment to properly capitalize the three entities post-separation while improving our overall capitalization and leverage. These actions are discussed in more detail in Item &#8220;&#8212; Liquidity and Capital Resources &#8212; Liquidity and Debt &#8212; Long-term Debt&#8221;;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">divested non-core assets in order to narrow the Company&#8217;s activities to our core businesses where we believe we have an existing and sustainable competitive edge and the ability to generate operational efficiencies. To date, we received approximately $4,100 million in net proceeds from these divestitures, which includes the sale of Amoun Pharmaceutical Company S.A.E. (&#8220;Amoun&#8221;), as discussed below, which we divested on July 26, 2021;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">made strategic investments in our core businesses in order to support recent revenue growth and prepare for additional growth opportunities we plan to capitalize on for our core businesses;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">made measurable progress in improving our capital structure as we have repaid approximately $9,500&#160;million in long-term debt obligations (net of additional borrowings, amounts refinanced, excluding the $1,210 million financing of the U.S. Securities Litigation settlement discussed below) during the period of January 1, 2016 through March 31, 2022, using the proceeds from the divestiture of non-core assets, proceeds from the B+L Debt Financing (as defined and discussed below), cash on-hand, cash generated from our operations and improved working capital management; and </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">resolved many of the Company's legacy litigation matters originating back to 2015 and prior, including the most significant legacy legal matter, the U.S. Securities Litigation settlement discussed below, significantly reducing related possible disruptions and other uncertainties to our operations. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that these and other actions we have taken to transform our Company, have helped focus our operations, unlocked value across our product portfolios, improved our capital structure and mitigated certain risks associated with legacy litigation matters.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that these measures, along with our continued commitment to improving people's lives through our health products, help position us to unlock potential value across our portfolio of assets by separating our pharmaceutical, eye health and skincare businesses. Although management believes these transactions will bring out additional value, there can be no assurance that either the B+L Separation or the Solta IPO will be successful in doing so.</span></div><div id="i801c461cbd33492a893c84373a8e7cbc_118"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Divest Assets to Improve Our Capital Structure and Simplify Our Business</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to better focus on our core businesses, we continue to evaluate opportunities to simplify our operations and improve our capital structure, including dispositions of various assets. For example, on July 26, 2021, we completed the sale of Amoun for total gross consideration of approximately $740&#160;million, subject to certain adjustments (the &#8220;Amoun Sale&#8221;). Amoun, which was part of the International segment, manufactures, markets and distributes branded generics of human and animal health products. The Amoun business was part of the International segment (previously included within the former Bausch + Lomb/International segment). Revenues associated with Amoun were $68&#160;million for the three months ended March 31, 2021, $157&#160;million for the period of January 1, 2021 through July 26, 2021 and were $247&#160;million for the year 2020. On July 30, 2021 and August 3, 2021, the Company made aggregate payments of $600&#160;million, to repay $469&#160;million of its June 2025 Term Loan B Facility and $131&#160;million of its November 2025 Term Loan B Facility (each defined below), using the net proceeds from the Amoun Sale and cash on hand.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to consider further dispositions of various assets in line with this strategy. While we anticipate that any future divestiture activities will be on non-core assets, consistent with our duties to our shareholders and other stakeholders, we will consider dispositions in core areas that we believe represent attractive opportunities for the Company. See Note 4, &#8220;LICENSING AGREEMENTS AND DIVESTITURE&#8221; to our unaudited interim Consolidated Financial Statements for additional information.</span></div><div id="i801c461cbd33492a893c84373a8e7cbc_124"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Focus on Core Businesses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to focus on our core businesses we have: (i) directed capital allocation to drive growth within our core businesses, (ii) made measurable progress in effectively managing our capital structure, (iii) increased our efforts to improve patient access and (iv) continued to invest in sustainable growth drivers to position us for long-term growth.</span></div><div id="i801c461cbd33492a893c84373a8e7cbc_127"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Direct Capital Allocation to Drive Growth Within Our Core Businesses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our capital allocation is driven by our long-term growth strategies.  We have been aggressively allocating resources to promote our core businesses globally through: (i) R&amp;D investment, (ii) strategic licensing agreements and (iii) strategic investments in our infrastructure. The outcome of this process allows us to better drive value in our product portfolio and generate operational efficiencies.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><div id="i801c461cbd33492a893c84373a8e7cbc_133"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">R&amp;D Investment</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continuously search for new product opportunities through internal development and strategic licensing agreements, that, if successful, will allow us to leverage our commercial footprint, particularly our sales force, and supplement our existing product portfolio and address specific unmet needs in the market. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal R&amp;D organization focuses on the development of products through clinical trials. As of December 31, 2021, approximately 1,300 dedicated R&amp;D and quality assurance employees in 25 R&amp;D facilities were involved in our R&amp;D efforts internally. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, we have approximately 180 projects in our global pipeline. Certain core internal R&amp;D projects that have received a significant portion of our R&amp;D investment in current and prior periods are listed below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch + Lomb</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">SiHy Daily - A silicone hydrogel daily disposable contact lens designed to provide clear vision throughout the day. In September 2018, we launched SiHy Daily in Japan under the branded name AQUALOX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY.&#160; In August 2020, we launched SiHy Daily in the U.S. under the branded name Bausch + Lomb INFUSE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SiHy Daily Disposable contact lens.  In the fourth quarter of 2020, SiHy Daily was launched in Australia, Hong Kong and Canada under the branded name Bausch + Lomb Ultra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY. SiHy Daily has also received regulatory approval in China, New Zealand, Japan, South Korea, Europe, Singapore and Malaysia, where it will be branded as Bausch + Lomb Ultra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY, and in the second quarter of 2021, we launched SiHy Daily in South Korea and Singapore as Bausch + Lomb Ultra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (brimonidine tartrate ophthalmic solution, 0.025%) - An OTC eye drop developed as an ocular redness reliever. We launched this product in the U.S. in May 2018. Currently, we have several line extensions under development and expect Phase 3 clinical studies to commence in 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Biotrue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday for Astigmatism - A daily disposable contact lens for astigmatic patients. The Biotrue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday contact lens incorporates Surface Active Technology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to provide a dehydration barrier.&#160; The Biotrue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday for Astigmatism also includes evolved peri-ballast geometry to deliver stability and comfort for the astigmatic patient.&#160;We launched this product in December 2016 and launched an extended power range and further extended power ranges in each of the years 2017 through 2020. Biotrue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday for Astigmatism has also received regulatory approval in China.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">New Ophthalmic Viscosurgical Device (&#8220;OVD&#8221;) product - A formulation to protect corneal endothelium during phacoemulsification process during a cataract surgery and to help chamber maintenance and lubrication during intraocular lens delivery.  In January 2020, we commenced an FDA clinical study for the cohesive OVD product (StableVisc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), and the study report is expected in June 2022. In addition, in March 2021, we received Premarket Approval from the FDA for Clearvisc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> dispersive OVD, which we launched in the U.S. in June 2021.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10pt">enVista</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Trifocal intraocular lens - An innovative lens design.  We initiated an investigative device exemption study for this product in May 2018 and initiated the last phase of this three-phase study in the fourth quarter of 2020. We completed enrollment during the first quarter of 2022 for the Canadian study and expect to complete enrollment during the first half of 2022 for the U.S. study.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">SimplifEYE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> preloaded intraocular lens injector platform for enVista intraocular lens - We have received approvals from the European Union and Canada and received FDA clearance for the injector and launched this platform in October 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Extended depth of focus intraocular lens - Currently under development; however, the timing and completion of development was delayed due to COVID-19 pandemic-related matters. Once development is completed, and if approved, we anticipate that this product could be launched in 2024.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Bausch + Lomb ULTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> monthly silicone hydrogel lens - Specifically designed to address the lifestyle and vision needs of patients with MoistureSeal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology, which maintains 95% of contact lens moisture for a full 16 hours. In the second quarter of 2020, Bausch + Lomb ULTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> received a seven day extended wear indication approval from the European Union and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">received regulatory approval</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from the National</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical Products Administration in China.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Bausch + Lomb ULTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Multifocal for Astigmatism contact lens - The first and only multifocal toric lens available as a standard offering in the eye care professional&#8217;s fit set. The new monthly silicone hydrogel lens, which was specifically designed to address the lifestyle and vision needs of patients with both astigmatism and presbyopia, combines the Company's unique 3-Zone Progressive</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;multifocal design with the stability of its OpticAlign</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;toric </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with MoistureSeal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology to provide eye care professionals and their patients an advanced contact lens technology that offers the convenience of same-day fitting during the initial lens exam.&#160;Bausch + Lomb ULTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Multifocal for Astigmatism was launched in June 2019 and received European Union regulatory approval in the second quarter of 2020. In July 2021, we launched an extended parameter range of this product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Renu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Advanced Multi-Purpose Solution (&#8220;MPS&#8221;) - Contains a triple disinfectant system that kills 99.9% of germs, and has a dual surfactant system that provides up to 20 hours of moisture.  Renu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Advanced MPS is FDA cleared with indications for use to condition, clean, remove protein, disinfect, rinse and store soft contact lenses including those composed of silicone hydrogels.  Renu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Advanced MPS has gained regulatory approvals in Korea, India, Mexico, Indonesia, Malaysia, Singapore and, during the second quarter of 2020, the European Union. In 2021, Renu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Advanced MPS was launched in Greece and gained regulatory approvals in China and Taiwan.  We anticipate launches in China, Taiwan, Czech Republic, Israel, Poland, Slovakia, the Middle East and Africa region and the Latin American region during 2022 and launches in additional regions in 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Zen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Multifocal Scleral Lens for presbyopia - In January 2019, we launched this product exclusively available with Zenlens</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Zen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> RC scleral lenses and will allow eye care professionals to fit presbyopic patients with regular and irregular corneas and those with ocular surface disease, such as dry eye.  The Zen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Multifocal Scleral Lens incorporates decentered optics, enabling the near power to be positioned over the visual axis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Tangible</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Hydra-PEG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - A high-water polymer coating that is bonded to the surface of a contact lens and designed to address contact lens discomfort and dry eye. We launched this product in March 2019. Tangible</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Hydra-PEG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> coating technology in combination with our Boston</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> materials and Zenlens</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> family of scleral lenses will help eye care professionals provide a better lens wearing experience for their patients with challenging vision needs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gastrointestinal</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10pt">Rifaximin - Top line results from a Phase 2 study for the treatment of overt hepatic encephalopathy with a new formulation (SSD IR) of rifaximin showed a treatment benefit. Patients receiving 40 mg twice daily showed a statistically significant separation from placebo. The top line results from this Phase 2 study will help inform further research on potential new indications for rifaximin. A Phase 3 study has commenced (RED-C) with patients actively enrolling for the prevention of the first episode of Hepatic Encephalopathy.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Rifaximin - Rifaximin recently received orphan drug designation for sickle cell disease. A novel dosage formulation is planned to be studied for the treatment of sickle cell disease and clinical sites began enrolling into the trial at the end of 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Rifaximin - Development of a fit for purpose Patient Reported Outcomes tool for small intestinal bacterial overgrowth, or &#8220;SIBO&#8221;, is continuing in 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Rifaximin - We have entered into an agreement with Cedars Sinai Medical Center to evaluate a new formulation of rifaximin for the treatment of IBS-D.  Two preclinical studies have been completed.  A Proof of Concept study, that was paused due to COVID-19 pandemic related factors, has recommenced and is fully enrolled. Based on recent FDA comments dated February 10, 2022, the program is being assessed and related timelines reviewed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Envive</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In October 2020, we launched, on a limited basis, a probiotic supplement that was developed to address gastrointestinal disturbances.  In April 2021, we expanded the launch to additional territories in the U.S.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Amiselimod (S1P modulator) - We commenced a Phase 2 study during the first half of 2021 to evaluate Amiselimod (S1P modulator) for the treatment of mild to moderate ulcerative colitis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Solta Medical</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Clear + Brilliant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Touch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Next generation Clear + Brilliant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;laser that is designed to deliver a customized and more comprehensive treatment protocol by providing patients of all ages and skin types the benefits of two wavelengths. This product was launched in the U.S. in March 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dermatology</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Arazlo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(tazarotene) Lotion, 0.045% (formerly Internal Development Project (&#8220;IDP&#8221;)-123) - In June 2020, we launched this acne product containing lower concentration of tazarotene in a lotion form to help reduce irritation while maintaining efficacy.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">IDP-120 - An acne product with a fixed combination of mutually incompatible ingredients: benzoyl peroxide and tretinoin.  Phase 3 clinical studies have been completed and met the primary endpoints. We are currently evaluating next steps for this project.  </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">IDP-126 - An acne product with a fixed combination of benzoyl peroxide, clindamycin phosphate and adapalene. Phase 3 clinical studies initiated in December 2019 were paused due to COVID-19 pandemic related factors, but resumed in June 2020. Both Phase 3 studies have been completed and have met their primary endpoints. A comparative bridging safety and efficacy study was delayed until 2021 due to COVID-19. The bridging study is ongoing. We anticipate filing a New Drug Application (&#8220;NDA&#8221;) in the the fourth quarter of 2022.</span></div><div id="i801c461cbd33492a893c84373a8e7cbc_136"></div><div style="margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Strategic Licensing Agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To supplement our internal R&amp;D initiatives and to build-out and refresh our product portfolio, we also search for opportunities to augment our pipeline through arrangements that allow us to gain access to unique products and investigational treatments, by strategically aligning ourselves with other innovative product solutions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company will enter into select licensing and collaborative agreements for the commercialization and/or development of unique products primarily in the U.S. and Canada. These products are sometimes investigational treatments in early stage development that target unique conditions.  The ultimate outcome, including whether the product will be: (i) fully developed, (ii) approved by the FDA or other regulators, (iii) covered by third-party payors or (iv) profitable for distribution, is highly uncertain. Under certain agreements, the Company may be required to make payments contingent upon the achievement of specific developmental, regulatory, or commercial milestones.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, we announced that we had entered into two exclusive license agreements which present us with unique developmental opportunities to address the unmet need of treatment for myopia in children. The first of these two licensing agreements is with Eyenovia, Inc. for the development and commercialization in the United States and Canada of an investigational microdose formulation of atropine ophthalmic solution, which is being investigated for the reduction of pediatric myopia progression, also known as nearsightedness, in children ages 3-12. We expect to complete enrollment for a Phase 3 study during the second half of 2022. If approved by the FDA, we believe this investigational product could potentially change the treatment paradigm for the reduction of myopia progression in children. The second is an exclusive global licensing agreement with BHVI for a myopia control contact lens design developed by BHVI. The Company plans to pair BHVI&#8217;s novel contact lens design with our leading contact lens technologies to develop potential contact lens treatments designed to slow the progression of myopia in children.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we announced that we had acquired an exclusive license from Novaliq GmbH for the commercialization and development in the U.S. and Canada of the investigational treatment NOV03 (perfluorohexyloctane), a first-in-class investigational drug with a novel mechanism of action to treat dry eye diseases (&#8220;DED&#8221;) associated with Meibomian gland dysfunction (&#8220;MGD&#8221;). In an Open Label Safety study, NOV03 has achieved its enrollment target.  In April 2021, we announced statistically significant topline data from the first of two Phase 3 studies and in September 2021, we announced statistically significant topline data from the second Phase 3 study. We anticipate filing an NDA in the first half of 2022. If approved by the FDA, we believe the addition of this investigational treatment for DED will help build upon our strong portfolio of integrated eye health products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, we acquired an exclusive license from Clearside Biomedical, Inc. (&#8220;Clearside&#8221;) for the commercialization and development of Xipere</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (triamcinolone acetonide suprachoroidal injectable suspension) in the U.S. and Canada. Xipere</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a proprietary suspension of the corticosteroid triamcinolone acetonide formulated for suprachoroidal administration via Clearside&#8217;s proprietary SCS Microinjector</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In October 2021, the FDA approved Xipere</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for suprachoroidal use for the treatment of macular edema associated with uveitis. We launched Xipere</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the U.S. in the first quarter of 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, we entered into an exclusive licensing agreement with Mitsubishi Tanabe Pharma Corporation to develop and commercialize MT-1303 (amiselimod), a late-stage oral compound that targets the sphingosine 1-phosphate receptor that plays a role in autoimmune diseases, such as inflammatory bowel disease and ulcerative colitis. We have completed a thorough QTC study, which evaluated the cardiac safety profile of the compound. Topline results were positive and we commenced a Phase 2 study in the first half of 2021.</span></div><div id="i801c461cbd33492a893c84373a8e7cbc_139"></div><div style="margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Strategic Investments in our Infrastructure</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In support of our core businesses, we have and continue to make strategic investments in our infrastructure, the most significant of which are at our Waterford facility in Ireland, our Rochester facility in New York and our Lynchburg facility in Virginia. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To meet the forecasted demand for our Biotrue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday range of contact lenses, in July 2017, we placed into service a $175 million multi-year strategic expansion project of the Waterford facility.  The emphasis of the expansion project was to: (i) develop new technology to manufacture, automatically inspect and package contact lenses, (ii) bring that technology to full validation and (iii) increase the size of the Waterford facility.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To address the expected global demand for our Bausch + Lomb ULTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> range of contact lenses, in December 2017, we completed a multi-year, $220 million strategic upgrade to our Rochester facility.  The upgrade increased production capacity in support of our Bausch + Lomb Ultra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and SiHy Daily AQUALOX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product lines and better supports the production of other well-established contact lenses, such as our PureVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, PureVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2 (SVS, Toric, and Multifocal), SofLens</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 38 and SilSoft</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To address the expected global demand for our SiHy Daily disposable contact lenses, in November 2018, we initiated $300 million of additional expansion projects to add multiple production lines to our Rochester and Waterford facilities. The first phase of the production line installation program has been completed, and in early 2022, we commenced commercial production of certain of our latest contact lenses, Bausch + Lomb INFUSE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and Bausch + Lomb ULTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> ONE DAY, at our Rochester facility.  We expect to complete the expansion programs at our Rochester and Waterford facilities in the second half of 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, we announced plans to invest an additional $90 million to increase capacity at our Waterford facility to meet the expected demand for our Biotrue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday range of daily disposable contact lenses.  The new production lines are expected to be completed in 2023. If completed as planned, the recently announced expansion of our Waterford facility will be the fifth major expansion of our Bausch + Lomb manufacturing facilities in support of our efforts to increase market share in the contact lens market in the seven years ending 2023. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the investments in our Waterford, Rochester and Lynchburg facilities and related expansion of labor forces further demonstrates the growth potential we see in our Bausch + Lomb products and our eye health business.</span></div><div id="i801c461cbd33492a893c84373a8e7cbc_142"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Effectively Managing Our Capital Structure  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to effectively manage our capital structure by: (i) executing on our plan for the B+L Separation and Solta IPO, (ii) reducing our debt through repayments, (iii) extending the maturities of debt through refinancing and (iv) focusing on our credit ratings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since announcing our plans for the B+L Separation and the Solta IPO, we emphasized that it is important that the post-separation entities be well capitalized, with appropriate leverage and with access to additional capital, if and when needed, to provide each entity with the ability to independently allocate capital to areas that will strengthen their own competitive positions in their respective lines of business and position each entity for sustainable growth. Therefore, we see the appropriate capitalization and leverage of these businesses post-separation as a key to maximizing value across our portfolio of assets and, so, it is a primary objective of our plan of separation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Repayments and Other Financing Transactions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; In 2016, our new executive team committed to improving our Company&#8217;s capital structure and, since that time, we have been executing and continue to execute on that commitment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of a series of debt repayments and transactions since making that commitment, the Company positioned itself to add value through the B+L Separation and Solta IPO, while at the same time providing for the appropriate capitalization and leverage of these businesses post-separation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">B+L IPO and Debt Financing - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2022 in connection with the B+L IPO, the Company completed a series of transactions in which among other things: (i) Bausch + Lomb entered into a new credit facility, (ii) the Company repaid certain amounts outstanding under its existing term B loans, (iii) the Company refinanced the remaining amounts outstanding under its credit facilities and (iv) the Company discharged the April 2025 Unsecured Notes Indenture with, among other sources, the net proceeds from $1,000&#160;million aggregate principal amount of 6.125% senior secured notes due February 2027 (the &#8220;February 2027 Secured Notes&#8221;) issued February 10, 2022. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2022, the Selling Shareholder sold 35,000,000 Bausch + Lomb common shares, at an offering price of $18.00 per share. The net proceeds from the B+L IPO after deducting underwriting commissions and estimated offering expenses were approximately $560 million as of May 10, 2022. In addition, on May 10, 2022 we discharged the April 2025 Unsecured Notes Indenture using: (i) the net proceeds from the issuance of the February 2027 Secured Notes, (ii) net proceeds from the B+L IPO, (iii) the net proceeds received in connection with the B+L Debt Financing as defined in Item &#8220;&#8212; Liquidity and Capital Resources &#8212; Liquidity and Debt &#8212; Long-term Debt&#8221; and (iv) cash on hand.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe these transactions bring us one step closer to meeting our commitment to properly capitalize the three entities post-separation while improving our overall capitalization and leverage. See Item &#8220;&#8212; Liquidity and Capital Resources &#8212; Liquidity and Debt &#8212; Long-term Debt&#8221; and Note 20, &#8220;SUBSEQUENT EVENTS&#8221; to our unaudited interim Consolidated Financial Statements for further details related to these transactions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Repayments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Excluding the impact of the $1,210 million financing of the U.S. Securities Litigation settlement (discussed in the subsequent section titled &#8220;OFF-BALANCE SHEET ARRANGEMENTS AND CONTRACTUAL OBLIGATIONS&#8221;) we have repaid (net of additional borrowings) approximately $9,500&#160;million of long-term debt during the </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period January 1, 2016 through March 31, 2022 using the net cash proceeds from divestitures of non-core assets, cash on-hand, cash generated from operations and cash generated from tighter working capital management. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Focus on Capitalization of the Post-separation Entities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the B+L Separation and Solta IPO, we have emphasized that it is important that the post-separation entities be well capitalized, with appropriate leverage and with access to additional capital, if and when needed, to provide each entity with the ability to independently allocate capital to areas that will strengthen their own competitive positions in their respective lines of business and position each entity for sustainable growth. Therefore, we see the appropriate capitalization and leverage of these new entities post-separation as a key to bringing out the maximum value across our portfolio of assets and, so, it is a primary objective of our plan of separation. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The B+L IPO, the B+L Debt Financing and the Credit Agreement Refinancing closed on the date of this filing, May 10, 2022. We continue to monitor market conditions and aim to launch the Solta IPO when financial market conditions are favorable, subject to receipt of regulatory, stock exchange and other approvals, and, in 2022, took certain actions to, and announced others that we believe will, bring us closer to reaching our targeted capitalizations of the post-separation entities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Continue to Manage our Capital Structure</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Notes Issuance and Credit Agreement Refinancing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; On February 10, 2022, the Company issued $1,000 million aggregate principal amount of February 2027 Secured Notes and, on May 10, 2022, the Company refinanced its existing 2018 Restated Credit Agreement with a second amendment to the 2018 Restated Credit Agreement, as defined and discussed in further detail, under Item &#8220;&#8212; Liquidity and Capital Resources &#8212; Liquidity and Debt &#8212; Long-term Debt&#8221;. The 2022 Restated Credit Agreement consists of new term loans of $2,500 million and a revolving credit facility of $975 million. These transactions, along with cash on hand, allowed us to: (i) replace our existing revolving credit facility which matured in 2023, with a revolving credit facility that matures in 2027, (ii) redeem in full all of our outstanding April 2025 Unsecured Notes, and (iii) replace our June 2025 Term Loan Facility and November 2025 Term Loan Facility with the 2027 Term Loan B Facility. In addition, on May 10, 2022, Bausch + Lomb entered into the B+L Credit Agreement. The B+L Credit Agreement provides for a five-year term loan facility in an initial principal amount of $2,500 million, and also provides for a five-year revolving credit facility in the amount of $500 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor our capital structure and to evaluate other opportunities to simplify our business and improve our capital structure, giving us the ability to better focus on our core businesses and prepare us for post-separation. Also, the Company regularly evaluates market conditions, its liquidity profile and various financing alternatives for opportunities to enhance its capital structure. If the Company determines that conditions are favorable, the Company may refinance or repurchase existing debt or issue additional debt, equity or equity-linked securities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to complete the separation of Bausch + Lomb after the expiry of customary lockups related to the B+L IPO and achievement of targeted debt leverage ratios, subject to the receipt of applicable shareholder and other necessary approvals and market conditions. We continue to monitor market conditions and aim to launch the Solta IPO when financial market conditions are favorable (subject to receipt of regulatory, stock exchange and other approvals and other factors). However, there can be no assurance as to when we will complete either the B+L Separation or the Solta IPO, if at all. Until such time, we continue to manage these businesses along with our diverse portfolio of gastroenterology, hepatology, dermatology, neurology and other therapeutics, with our continued commitment to bring out additional value for our shareholders. Nothing in this Form 10-Q shall constitute an offer to sell or the solicitation of an offer to buy any securities of the Bausch + Lomb or Solta entities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, &#8220;FINANCING ARRANGEMENTS&#8221; to our unaudited interim Consolidated Financial Statements and &#8220;Management&#8217;s Discussion and Analysis - Liquidity and Capital Resources: Long-term Debt&#8221; for additional discussion of these matters. Cash requirements for future debt repayments including interest can be found in &#8220;Management's Discussion and Analysis - Off-Balance Sheet Arrangements and Contractual Obligations.&#8221;</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><div id="i801c461cbd33492a893c84373a8e7cbc_145"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improve Patient Access</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Improving patient access to our products, as well as making them more affordable, is a key element of our business strategy.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patient Access and Pricing Committee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In 2016, we formed the Patient Access and Pricing Committee which is responsible for setting, changing and monitoring the pricing of our products and evaluating contract arrangements that determine the placement of our products on drug formularies.  The Patient Access and Pricing Committee considers new to market product pricing, price changes and their impact across channels on patient accessibility and affordability. Since its inception, the Patient Access and Pricing Committee has limited the average annual price increase for our branded prescription pharmaceutical products to single digits. Future pricing changes and programs could affect the average realized pricing for our products and may have a significant impact on our revenues and profits.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch Health Patient Assistance Program - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to supporting patients who have lost employment health benefits due to the COVID-19 pandemic, and because it is essential that our patients continue their prescribed treatments, we are proud to offer certain of our prescription medicines through our Bausch Health Patient Assistance Program.  In the face of the COVID-19 pandemic, some people have financial obstacles that keep them from obtaining and continuing their prescribed treatments. The purpose of the Bausch Health Patient Assistance Program is to provide eligible unemployed patients in the U.S., who meet stated qualifications and have lost their health insurance due to the COVID-19 pandemic, with certain of our prescription products where their financial circumstances or insurance status would otherwise interfere with their ability to access such products. If approved, patients receive their Bausch Health Companies Inc. prescription product(s) at no cost to them for up to one year, and may be able to reapply to the program annually if they continue to meet eligibility requirements and have a valid prescription.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash-pay Prescription Program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In February 2019, we launched Dermatology.com, a cash-pay product acquisition program offering certain branded Ortho Dermatologics products directly to patients. In March 2020, the name Dermatology.com was removed as the cash-pay product program name, with the name Dermatology.com limited to only online usage, including future digital teledermatology and e-commerce offerings. The cash-pay program is designed to address the affordability and availability of certain branded dermatology products, when insurers and pharmacy benefit managers are no longer offering those branded prescription pharmaceutical products under their designated pharmacy benefit offerings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Walgreens Fulfillment Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In the beginning of 2016, we launched a brand fulfillment arrangement with Walgreen Co. (&#8220;Walgreens&#8221;). Under the terms of the brand fulfillment arrangement, as amended in July 2019, we made certain dermatology and ophthalmology products available to eligible patients through patient access and co-pay assistance programs at Walgreens U.S. retail pharmacy locations, as well as participating independent retail pharmacies.</span></div><div id="i801c461cbd33492a893c84373a8e7cbc_148"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Invest in Sustainable Growth Drivers to Position us for Long-Term Growth</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are constantly challenged by the changing dynamics of our industry to innovate and bring new products to market.  We have divested certain businesses where we saw limited growth opportunities, so that we can be more aggressive in redirecting our R&amp;D spend and other corporate investments to innovate within our core businesses where we believe we can be most profitable and where we aim to be an industry leader. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that we have a well-established product portfolio that is diversified within our core businesses and provides a sustainable revenue stream to fund our operations. However, our future success is also dependent upon our ability to continually refresh our pipeline, to provide a rotation of product launches that meet new and changing demands and replace other products that have lost momentum.  We believe we have a robust pipeline that not only provides for the next generation of our existing products, but is also poised to bring new products to market.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Invest in our Eye Health Business - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a fully integrated eye health business with a legacy of over 165 years, Bausch + Lomb has an established line of contact lenses, intraocular lenses and other medical devices, surgical systems and devices, vitamin and mineral supplements, lens care products, prescription eye-medications and other consumer products that positions us to compete in all areas of the eye health market. As part of our global Bausch + Lomb business strategy, we continually look for key trends in the eye health market to meet changing consumer/patient needs and identify areas for investment to extend our market share through new launches and effective pricing. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For instance, there is an increasing rate of myopia, and importantly, myopia is a potential risk factor for glaucoma, macular degeneration and retinal detachment. We continue to see increased demand for new eye health products that address conditions brought on by factors such as increased screen time, lack of outdoor activities and academic pressures, as well as conditions brought on by an aging population (for example, as more and more baby-boomers in the U.S. are reaching the age of 65).  To extend our market share in eye health, we continually seek to identify new products tailored to address these key trends for development internally with our own R&amp;D team to generate organic growth. Recent product launches include </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biotrue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday daily disposable contact lenses, the next generation of Bausch + Lomb ULTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contact lenses, SiHy Daily contact lenses (branded as AQUALOX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY in Japan, Bausch + Lomb INFUSE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SiHy Daily Disposable in the U.S. and Bausch + Lomb Ultra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY in Australia, Hong Kong, Canada and South Korea and Singapore), Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (an eye redness treatment), Vyzulta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (a pressure lowering eye drop for patients with angle glaucoma or ocular hypertension), Ocuvite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Eye Performance (vitamins to protect the eye from stressors such as sunlight and blue light emitted from digital devices) and SimplifEYE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (preloaded intraocular lens injector platform for enVista intraocular lens).  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also license selective molecules or technology in leveraging our own R&amp;D expertise through development, as well as seek out external product development opportunities. As previously discussed, we acquired a global exclusive license for a myopia control contact lens design developed by BHVI, which we plan to pair with our leading contact lens technologies to develop potential contact lens treatments designed to slow the progression of myopia in children, and exclusive licenses for the commercialization and development in the U.S. and Canada of: (i) a microdose formulation of atropine ophthalmic solution, which is being investigated for the reduction of pediatric myopia progression in children ages 3-12; (ii) Xipere</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which was approved by the FDA in October 2021 and launched in the first quarter of 2022, and is the first treatment available in the U.S. that utilizes the suprachoroidal space to treat patients suffering from macular edema associated with uveitis; and (iii) NOV03, an investigational drug with a novel mechanism of action to treat DED associated with MGD which has demonstrated statistically significant topline data in two Phase 3 studies. We also acquired the U.S. rights to EM-100, which was launched in February 2021 as Alaway</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Preservative-Free and is the first OTC preservative-free formulation eye drop for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair, and dander in adults and children 3 years of age and older. We believe investments in these investigational treatments, if approved by the FDA, will complement, and help build upon, our strong portfolio of integrated eye health products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously discussed, we have also made strategic investments in our infrastructure, the most significant of which were at our Waterford facility in Ireland to meet the forecasted demand for our Biotrue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday lenses, our Rochester facility in New York to address the expected global demand for our Bausch + Lomb ULTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contact lens and our Lynchburg facility in Virginia to be our main point of distribution for medical devices in the U.S. During late 2018, we began investing in additional expansion projects at the Waterford and Rochester facilities in order to address the expected global demand for our SiHy Daily disposable contact lenses, which we launched in Japan in September 2018, under the branded name AQUALOX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY, in the U.S. in August 2020, under the branded name Bausch + Lomb INFUSE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SiHy Daily Disposable contact lens, and in Australia, Hong Kong and Canada in the fourth quarter of 2020 and in South Korea and Singapore in the second quarter of 2021, under the branded name Bausch + Lomb Ultra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our recent product launches, licensing arrangements and the investments in our Waterford, Rochester and Lynchburg facilities demonstrate the growth potential we see in our Bausch + Lomb products and our eye health business and that these investments will position us to further extend our market share in the eye health market.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leveraging our Salix Infrastructure - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strongly believe in our GI product portfolio and we have implemented initiatives, including increasing our marketing presence and identifying additional opportunities outside our existing GI portfolio, to further capitalize on the value of the infrastructure we built around these products to extend our market share. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2017, we hired approximately 250 trained and experienced sales force representatives and managers to create, bolster and sustain deep relationships with primary care physicians (&#8220;PCP&#8221;). With approximately 70% of IBS-D patients initially presenting symptoms to a PCP, we continue to believe that the dedicated PCP sales force is better positioned to reach more patients in need of IBS-D treatment. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This initiative provided us with positive results, as we experienced consistent growth in demand for our GI products throughout 2017 through 2021, which was evident by our growth in Salix revenues of 32% when comparing 2021 to 2017. These results encouraged us to seek out ways to bring out further value through leveraging our existing sales force and in 2019, we identified and executed on certain opportunities which we describe below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Strategic Acquisition - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, we completed the acquisition of certain assets of Synergy Pharmaceuticals Inc. (&#8220;Synergy&#8221;), whereby we acquired the worldwide rights to the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product, a once-daily tablet for adults with chronic idiopathic constipation, or CIC and irritable bowel syndrome with constipation, or IBS-C. We believe that the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product complements our existing Salix products and allows us to effectively leverage our existing GI sales force. In order to drive growth of the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product, we have increased the number of sales force representatives for the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product. We believe this has been successful as Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues were $24 million and $21 million for the three months ended March 31, 2022 and 2021, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licensing Arrangement - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously discussed, in April 2019, we entered into a licensing agreement to develop and commercialize MT-1303 (amiselimod), a late-stage oral compound that targets the sphingosine 1-phosphate receptor that plays a role in autoimmune diseases, such as inflammatory bowel disease and ulcerative colitis.  This license presents a unique developmental opportunity to address unmet needs of individuals suffering with certain </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GI and liver diseases and, if developed and approved by the FDA, will allow us to further utilize our existing sales force and infrastructure to extend our market share in the future and create value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in Next Generation Formulations - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product increased approximately 11%, 2% and 22% in 2021, 2020 and 2019, respectively. In order to extend growth in Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we continue to directly invest in next generation formulations of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and rifaximin, the principal semi-synthetic antibiotic used in our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product.  In addition to three R&amp;D programs in progress, we have another R&amp;D program planned for a next generation formulation of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) which would address a new indication.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the acquisition and licensing opportunities discussed above will be accretive to our business by providing us access to products and investigational compounds that are a natural pairing to our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> business, allowing us to effectively leverage our existing infrastructure and sales force. We believe these opportunities, coupled with our investment in next generation formulations, will allow our GI franchise to continue to further extend market share.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in Our Solta Aesthetic Medical Device Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - As of January 2022, we have positioned the Solta Medical business to move forward with the Solta IPO.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor market conditions and aim to launch the Solta IPO when financial market conditions are favorable, subject to receipt of regulatory, stock exchange and other approvals. However, there can be no assurance as to when we will complete the Solta IPO, if at all. Until such time, we continue to manage our Solta business with our continued commitment to bring out additional value for our shareholders. We continue to make investments in our Solta portfolio and anticipate building out our Solta sales force, particularly in Europe, to address the growing demand for our Solta aesthetic medical devices.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we launched our next generation Thermage FLX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product in the U.S., a fourth-generation non-invasive treatment option using a radiofrequency platform designed to optimize key functional characteristics and improve patient outcomes. Next generation Thermage FLX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was launched in the U.S., Hong Kong, Japan, Korea, Taiwan, Philippines, Singapore, Indonesia, Malaysia, China, Thailand, Vietnam, Australia and various parts of Europe as part of our Solta aesthetic medical devices portfolio. These launches have been successful as next generation Thermage FLX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues were $154&#160;million and $142&#160;million for the years 2021 and 2020, respectively. We plan to continue to expand into other regions, paced by country-specific regulatory registrations. Consistent with our business strategy to continually update and improve our technology, in 2021, we launched, in the U.S., our next generation Clear + Brilliant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Touch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> system which is designed to deliver a customized and more comprehensive treatment protocol by providing patients of all ages and skin types the benefits of two wavelengths. The launch of our next generation Clear + Brilliant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Touch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> system in the U.S. is expected to serve as a foundation for future launches in Asia and Europe.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reposition the Ortho Dermatologics Business to Generate Additional Value - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Ortho Dermatologics business continues to work towards improving the treatment options for medical dermatology patients needing topical acne and psoriasis products. We continue to explore additional strategic e-commerce and partnership expansion opportunities which can enable increased accessibility for patients and we continue to invest in our on-market products and evaluate various opportunities for our key medical dermatology pipeline products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In support of the complete dermatology portfolio, we continue to take a number of actions that we believe will help our efforts to stabilize our dermatology business. These actions include: (i) building on our legacy brands to improve and meet today&#8217;s physician relevance and customer service, (ii) appointing new leadership, (iii) making key investments in our core medical device and dermatological products portfolios, (iv) optimizing our go to market strategy by building on our relationships with prescribers of our products to balance our sales portfolio with the business&#8217; profitability, (v) refocusing our operational and promotional resources and (vi) improving patient access to our Ortho Dermatologics products through our cash-pay prescription program previously discussed. In addition, we made significant investments to build out our psoriasis and acne portfolios as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Psoriasis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In response to the increasing number of reported cases of psoriasis in the U.S., we launched Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in June 2019 and launched Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in November 2018, which align well with our topical portfolio of psoriasis treatments. Although we continue to support a diverse portfolio of topical and injectable biologics, in order to provide a diverse choice of psoriasis treatments to doctors and patients, we believe some patients prefer topical products as an alternative to injectable biologics.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acne</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In support of our established acne product portfolio, we have developed and launched several products, which include Arazlo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(tazarotene) Lotion (launched in the U.S. in June 2020), Altreno</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(launched in the U.S. in October 2018), the first lotion (rather than a gel or cream) product containing tretinoin for the treatment of acne, and Retin-A Micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 0.06% (launched in the U.S. in January 2018). We also have a unique acne project in our pipeline that, if approved by the FDA, we believe will further innovate and advance the treatment of acne.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><div id="i801c461cbd33492a893c84373a8e7cbc_151"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Trends</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the actions previously outlined, the events described below have affected and may affect our business trends. The matters discussed in this section contain Forward-Looking Statements. Please see &#8220;Forward-Looking Statements&#8221; for additional information.</span></div><div id="i801c461cbd33492a893c84373a8e7cbc_1868"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Russia-Ukraine War</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, Russia invaded Ukraine. As military activity proceeds and sanctions are imposed against Russia, Belarus and specific areas of Ukraine, the war is increasingly affecting economic and global financial markets and exacerbating ongoing economic challenges, including issues such as rising inflation and global supply-chain disruption.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues attributable to Russia for the three months ended March 31, 2022 and 2021 were $25 million and $31 million, respectively. Our revenues attributable to Ukraine for the three months ended March 31, 2022 and 2021 were $2 million and $2 million, respectively. Our revenues attributable to Belarus for the three months ended March 31, 2022 and 2021 were $2 million and $2 million, respectively. As the geopolitical situation in Eastern Europe continues to intensify, political events and sanctions are continually changing, and we continue to assess the impact that the Russia-Ukraine war will have on our businesses. These impacts may include but are not limited to: (i) interruptions or stoppage of production, (ii) damage or loss of inventories, (iii) supply-chain and product distribution disruptions in Eastern Europe, (iv) volatility in commodity prices and currencies, (v) disruption in banking systems and capital markets, (vi) reductions in sales and earnings of business in affected areas, (vii) increased costs and (viii) cyberattacks.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, these challenges have begun to impact, but have not yet had a material impact on our operations; however, we anticipate that the ongoing conflict in this region and the sanctions and other actions by the global community in response will continue to hinder our ability to conduct business with customers and vendors in this region. For example, we expect to experience further disruption and delays in the supply of our products to our customers in Russia, Belarus and Ukraine. We may also experience further decreased demand for our products in these countries as a result of the conflict and invasion. In addition, we expect to experience difficulties in collecting receivables from such customers. If we continue to be hampered in our ability to conduct business with new or existing customers and vendors in this region, our business, and operations, including our revenues, profitability and cash flows, could be adversely impacted. Furthermore, if the sanctions and other retaliatory measures imposed by the global community change, we may be required to cease or suspend our operations in the region or, should the conflict worsen, we may voluntarily elect to do so. We cannot provide assurance that current sanctions or potential future changes in these sanctions or other measures will not have a material impact on our operations in Russia, Belarus and Ukraine. The disruption to or suspension of our business and operations in Russia, Belarus and Ukraine may have a material adverse impact on our business, financial condition, cash flows and results of operations. We will continue to monitor the impacts of the Russia-Ukraine war on macroeconomic conditions and continually assess the effect these matters may have on our businesses. </span></div><div id="i801c461cbd33492a893c84373a8e7cbc_121"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impacts of COVID-19 Pandemic </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unprecedented nature of the COVID-19 pandemic has, and continues to, adversely impact the global economy. The COVID-19 pandemic and the reactions of governments, private sector participants and the public in an effort to contain the spread of the COVID-19 virus and/or address its impacts have had significant direct and indirect effects on businesses and commerce. This includes, but is not limited to, disruption to supply chains, employee base and transactional activity, facilities closures and production suspensions. Our revenues were most negatively impacted during our second quarter of 2020 by certain social restrictions and other precautionary measures taken in response to the COVID-19 pandemic. However, as governments began lifting social restrictions, allowing offices of certain health care providers to reopen and certain surgeries and elective medical procedures to proceed, the negative trend in the revenues of certain businesses began to level off and stabilize prior to our third quarter of 2020. After the launch of effective vaccines in December 2020, infection rates began to decline, signaling the beginning of a recovery from the COVID-19 pandemic.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues gradually returned to pre-pandemic levels for many of our businesses and geographies throughout 2021. However, in some regions, including China (as further described below), we continue to experience negative impacts of the COVID-19 pandemic on our business in those regions. The rates of recovery for each business will vary by geography and will be dependent upon, among other things, the availability and effectiveness of vaccines for the COVID-19 virus and variant and subvariant strains thereof, government responses, rates of economic recovery, precautionary measures taken by patients and customers, the rate at which remaining social restrictions are lifted and, once lifted, the presumption that social restrictions will not be materially reenacted in the event of a resurgence of the virus or variant and subvariant strains thereof and other actions taken in response to the COVID-19 pandemic.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outbreak of the omicron variant in China has resulted in government enforced lockdowns and other social restrictions, which impacted our ability to conduct business as usual in certain regions in China, particularly Shanghai. The lockdowns in China have impacted the demand for certain products, particularly our consumer, vision care and Solta </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products, as shelter in place orders limit the demand and need for the use of contact lenses and related products.  Our revenues in China for the three months ended March 31, 2022 and 2021 were $103 million and $110 million, respectively, a decrease of $7 million and, in part, reflects the challenges created by the surge of the omicron variant in China. Additionally, government enforced lockdowns have caused certain businesses to suspend operations, creating distribution and other logistic issues for the distribution of our products and the sourcing for a limited number of raw materials.  Through the date of this filing, we have dealt with these issues in China with only a minimal impact on our manufacturing and distribution processes.  However, as the impacts of global reaction to the COVID-19 pandemic remains a fluid situation, we continue to monitor the impacts on our businesses of the COVID-19 virus and variant and subvariant strains thereof in order to timely address new issues if and when they arise.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a further discussion of these and other COVID-19 related risks, see Item 1A. &#8220;Risk Factors&#8212; Risk Relating to COVID-19&#8221; of our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC and the CSA on February&#160;23, 2022.</span></div><div id="i801c461cbd33492a893c84373a8e7cbc_154"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Tax Reform</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, U.S. President Joseph Biden proposed changes to the U.S. tax system. Since that date, both houses of Congress have released their own proposals for changes to the U.S. tax system, which differ in a number of respects from the President&#8217;s proposal. The proposals under discussion have included changes to the U.S. corporate tax system that would increase U.S. corporate tax rates, although the most recent proposals do not include any such rate increase, and changes that would raise the tax rate on and make other changes to the taxation of Global Intangible Low Tax Income earned by foreign subsidiaries. Also under consideration are modifications to the Base Erosion and Anti-Abuse Tax, which would tax certain payments, including some that are related to inventory, made to affiliates that are subject to an effective tax rate of less than specified rates. Certain proposals also include limitations on the participation exemption for foreign dividends received and interest expense. In addition, certain proposals include limitations on the deduction of interest expense and carryforwards of unused interest expense, as well as an excise tax on certain pharmaceutical products that are non-compliant with the proposed drug pricing legislation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable to predict which, if any, U.S. tax reform proposals will be enacted into law, and what effects any enacted legislation might have on our liability for U.S. corporate tax. However, it is possible that the enactment of changes in the U.S. corporate tax system could have a material adverse effect on our liability for U.S. corporate tax and our consolidated effective tax rate.</span></div><div id="i801c461cbd33492a893c84373a8e7cbc_157"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Global Minimum Corporate Tax Rate</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 8, 2021, the Organisation for Economic Co-operation and Development (&#8220;OECD&#8221;)/G20 inclusive framework on Base Erosion and Profit Shifting (the &#8220;Inclusive Framework&#8221;) published a statement updating and finalizing the key components of a two-pillar plan on global tax reform originally agreed on July 1, 2021, and a timetable for implementation by 2023. The Inclusive Framework plan has now been agreed to by 141 OECD members, including several countries which did not agree to the initial plan. Under pillar one, a portion of the residual profits of multinational businesses with global turnover above &#8364;20 billion and a profit margin above 10% will be allocated to market countries where such allocated profits would be taxed. Under pillar two, the Inclusive Framework has agreed on a global minimum corporate tax rate of 15% for companies with revenue above &#8364;750 million, calculated on a country-by-country basis. On October 30, 2021, the G20 formally endorsed the new global minimum corporate tax rate rules. The Inclusive Framework agreement must now be implemented by the OECD Members who have agreed to the plan, effective in 2023. On December 20, 2021, the OECD published model rules to implement the pillar two rules, which are generally consistent with the agreement reached by the Inclusive Framework in October 2021.  Additional guidance is expected to be published in 2022. We will continue to monitor the implementation of the Inclusive Framework agreement by the countries in which we operate. While we are unable to predict when and how the Inclusive Framework agreement will be enacted into law in these countries, and it is possible that the implementation of the Inclusive Framework agreement, including the global minimum corporate tax rate could have a material effect on our liability for corporate taxes and our consolidated effective tax rate.</span></div><div id="i801c461cbd33492a893c84373a8e7cbc_160"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Care Reform</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal and state governments continue to propose and pass legislation designed to regulate the health care industry. In March&#160;2010, the Patient Protection and Affordable Care Act (the &#8220;ACA&#8221;) was enacted in the U.S.&#160;The ACA contains several provisions that impact our business, including: (i) an increase in the minimum Medicaid rebate to states participating in the Medicaid program, (ii) the extension of the Medicaid rebates to Managed Care Organizations that dispense drugs to Medicaid beneficiaries, (iii) the expansion of the 340(B) Public Health Services drug pricing program, which provides outpatient drugs at reduced rates, to include additional hospitals, clinics and health care centers and (iv) a fee payable to the federal government based on our prior-calendar-year share relative to other companies of branded prescription drug sales to specified government programs.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in 2013, federal subsidies began to be phased in for brand-name prescription drugs filled in the Medicare Part D coverage gap. The ACA also included provisions designed to increase the number of Americans covered by health insurance. In 2014, the ACA&#8217;s private health insurance exchanges began to operate. The ACA also allows states to expand Medicaid coverage with most of the expansion&#8217;s cost paid for by the federal government.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2021 and 2020, we incurred costs of $13 million and $21 million, respectively, related to the annual fee assessed on prescription drug manufacturers and importers that sell branded prescription drugs to specified U.S.&#160;government programs (e.g.,&#160;Medicare and Medicaid). For 2021 and 2020, we also incurred costs of $94 million and $131 million, respectively, on Medicare Part&#160;D utilization incurred by beneficiaries whose prescription drug costs cause them to be subject to the Medicare Part&#160;D coverage gap (i.e.,&#160;the &#8220;donut&#160;hole&#8221;). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial impact of the ACA will be affected by certain additional developments over the next few years, including pending implementation guidance and certain health care reform proposals. Additionally, policy efforts designed specifically to reduce patient out-of-pocket costs for medicines could result in new mandatory rebates and discounts or other pricing restrictions. Also, it is possible, as discussed further below, that legislation will be passed by Congress repealing the ACA in whole or in part.  Adoption of legislation at the federal or state level could materially affect demand for, or pricing of, our products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we faced uncertainties due to federal legislative and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the ACA. However, we believe there is low likelihood of repeal of the ACA, given the recent failure of the Senate&#8217;s multiple attempts to repeal various combinations of ACA provisions and the recent change in administration. There is no assurance that any replacement or administrative modifications of the ACA will not adversely affect our business and financial results, particularly if the replacing legislation reduces incentives for employer-sponsored insurance coverage, and we cannot predict how future federal or state legislative or administrative changes relating to the reform will affect our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the U.S. Department of Health and Human Services announced a preliminary plan to allow for the importation of certain lower-cost drugs from Canada. The preliminary plan excludes insulin, biological drugs, controlled substances and intravenous drugs. The preliminary plan relies on individual states to develop proposals for safe importation of those drugs from Canada and submit those proposals to the federal government for approval. Although the preliminary plan has some support from the prior administration, at this time, studies to evaluate the related costs and benefits, evaluate the reasonableness of the logistics, and measure the public reaction of such a plan have not been performed. While we do not believe this will have a significant impact on our future cash flows, we cannot provide assurance as to the effect or impact of such a plan.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Government of Canada (Health Canada) published in the Canada Gazette the new pricing regulation for patented drugs. These regulations were scheduled to become effective on July 1, 2021, but have been delayed until July 1, 2022. The new regulations will, among other things, change the mechanics of establishing the pricing for products submitted for approval after August 21, 2019 and the number and composition of reference countries used to determine if a drug&#8217;s price is excessive. While we do not believe this will have a significant impact on our future cash flows, as additional facts materialize, we cannot provide assurance as to the ultimate content, timing, effect or impact of such regulations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, former U.S. President Donald Trump signed four Executive Orders related to drug pricing, including orders addressing: (i) Part D rebate reform, (ii) the provision of deeply discounted insulin and/or an EpiPen to patients of Federally Qualified Health Centers, (iii) drug importation from Canada and (iv) most favored nation pricing for Medicare. In November 2020, former U.S. President Donald Trump announced the Most Favored Nation Model for Medicare Part B Payment which was to be implemented by the Centers for Medicare &amp; Medicaid Services Innovation on January 1, 2021; however, it has not been implemented, as it is currently being challenged in court. It is also uncertain whether the Biden administration intends to reverse these measures or adopt similar policy initiatives. However, U.S. President Joseph Biden and several members of the current U.S. Congress have indicated that lowering drug prices is a legislative and political priority, and some have introduced proposals that seek to address drug pricing.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, as part of a series of drug pricing-related rules issued by the Trump Administration, the Center for Medicare &amp; Medicaid Services issued a Final Rule that makes significant modifications to the Medicaid Drug Rebate Program regulations in several areas, including with respect to the definition of key terms &#8220;line extension&#8221; and &#8220;new formulation&#8221; and best price reporting relating to certain value-based purchasing arrangements (which took effect on January 1, 2022) and the price reporting treatment of manufacturer-sponsored patient benefit programs (which take effect on January 1, 2023).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the U.S. Congress enacted the American Rescue Plan Act of 2021. One of the provisions included within the American Rescue Plan Act of 2021 eliminated the Maximum Rebate Amount for Single Source drugs and </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innovator Multiple Source drugs in the Medicaid Drug Rebate Program.  We are currently reviewing this legislation, the impact of which is uncertain at this time.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative efforts relating to drug pricing have been enacted and others have been proposed at the U.S. federal and state levels. For instance, certain states have enacted legislation related to prescription drug pricing transparency. Several states have passed importation legislation and Florida is working with the U.S. government to implement an importation program from Canada. We also anticipate that Congress, state legislatures and third-party payors may continue to review and assess alternative health care delivery and payment systems and may in the future propose and adopt legislation or policy changes or implementations affecting additional fundamental changes in the health care delivery system. We continually review newly enacted and proposed U.S. federal and state legislation, as well as proposed rulemaking and guidance published by the Department of Health and Human Services and the FDA; however, at this time, it is unclear the effect these matters may have on our businesses.</span></div><div id="i801c461cbd33492a893c84373a8e7cbc_163"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Competition and Loss of Exclusivity</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our products face the expiration of their patent or regulatory exclusivity in 2022 or in later years, following which we anticipate generic competition of these products. In addition, in certain cases, as a result of negotiated settlements of some of our patent infringement proceedings against generic competitors, we have granted licenses to such generic companies, which will permit them to enter the market with their generic products prior to the expiration of our applicable patent or regulatory exclusivity. Finally, for certain of our products that lost patent or regulatory exclusivity in prior years, we anticipate that generic competitors may launch in 2022 or in later years. Following a loss of exclusivity (&#8220;LOE&#8221;) of and/or generic competition for a product, we would anticipate that product sales for such product would decrease significantly shortly following the LOE or entry of a generic competitor. Where we have the rights, we may elect to launch an authorized generic (&#8220;AG&#8221;) of such product (either ourselves or through a third-party) prior to, upon or following generic entry, which may mitigate the anticipated decrease in product sales; however, even with launch of an authorized generic, the decline in product sales of such product would still be expected to be significant, and the effect on our future revenues could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of our products already face generic competition.  Prior to and during 2021, in the U.S., these products include, among others, Ammonul</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Apriso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Benzaclin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Bepreve</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Bupap</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Cuprimine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Demser</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Edecrin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Elidel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Istalol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Isuprel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Locoid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lotion, Lotemax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Gel, Lotemax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Suspension, Mephyton</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Migranal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MoviPrep</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Nitropress</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Solodyn</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Syprine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Timoptic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Ocudose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Uceris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Tablet, Virazole</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Wellbutrin&#160;XL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Xenazine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zegerid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Zovirax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cream.  In Canada, these products include, among others, Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Wellbutrin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;XL and Zovirax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ointment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 LOE Branded Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Branded products that began facing generic competition in the U.S. during 2021 included Lotemax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Gel, Bepreve</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Clindagel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and certain other products. These products accounted for less than 1% of our total revenues in 2020. We believe the entry into the market of generic competition generally would have an adverse impact on the volume and/or pricing of the affected products, however we are unable to predict the magnitude or timing of this impact.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 through 2026 LOE Branded Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Based on current patent expiration dates, settlement agreements and/or competitive information, we have identified branded products that we believe could begin facing potential LOE and/or generic competition in the U.S. during the years 2022 through 2026.  These products and year of expected LOE include, but are not limited to, Noritate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (2022), Targretin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Gel (2022), Xerese</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2022)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and certain other products that are subject to settlement agreements which could impact their exclusivity during the years 2022 through 2026.&#160;In aggregate, these products accounted for 2% of our total revenues in 2021. These dates may change based on, among other things, successful challenge to our patents, settlement of existing or future patent litigation and at-risk generic launches. We believe the entry into the market of generic competition generally would have an adverse impact on the volume and/or pricing of the affected products, however we are unable to predict the magnitude or timing of this impact.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, for a number of our products (including Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 550mg, Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Injection in the U.S. and Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Canada), we have commenced (or anticipate commencing) and have (or may have) ongoing infringement proceedings against potential generic competitors in the U.S. and Canada. If we are not successful in these proceedings, we may face increased generic competition for these products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Lotion, 0.01% (Glenmark)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In December 2019, the Company announced that it had reached an agreement to resolve&#160;the&#160;outstanding&#160;intellectual&#160;property&#160;litigation&#160;with&#160;Glenmark&#160;Pharmaceuticals,&#160;Ltd. (&#8220;Glenmark&#8221;). Under the terms of the agreement, the Company will grant Glenmark a non-exclusive license to its intellectual property relating to Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. and, beginning in 2026 (or earlier under certain circumstances), Glenmark will have the option to market a royalty-free generic version of Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lotion, should it receive approval from the FDA. The parties have agreed to dismiss all litigation related to Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lotion, and all intellectual property protecting Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lotion remains intact.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Lotion, 0.01% (Padagis) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- On March 20, 2020, the Company received a Notice of Paragraph IV Certification from Perrigo Israel Pharmaceuticals, Ltd. (now Padagis LLC) (&#8220;Padagis&#8221;), in which Padagis asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate) lotion, 0.01% are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Padagis&#8217; generic halobetasol propionate lotion, for which an Abbreviated New Drug Application (&#8220;ANDA&#8221;) has been filed by Padagis.&#160; On May 1, 2020, the Company filed suit against Padagis pursuant to the Hatch-Waxman Act, alleging infringement by Padagis of one or more claims of the Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents, thereby triggering a 30-month stay of the approval of the Padagis ANDA for halobetasol propionate lotion.&#160;On September 3, 2020, this action was consolidated with the action between the Company and Padagis described below, regarding Padagis&#8217; ANDA for generic Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotine) lotion. A pre-trial conference in the consolidated action has been scheduled for July 20, 2022. The Company remains confident in the strength of the Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and intends to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Lotion (Padagis) - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 23, 2020, the Company received a Notice of Paragraph IV Certification from Padagis, in which Padagis asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotine) lotion, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Padagis&#8217; generic lotion, for which an ANDA has been filed by Padagis.  On August 28, 2020, the Company filed suit against Padagis pursuant to the Hatch-Waxman Act, alleging infringement by Padagis of one or more claims of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a 30-month stay of the approval of the Padagis ANDA.  On September 3, 2020, this action was consolidated with the action between the Company and Padagis described above, regarding Padagis&#8217; ANDA for generic Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate) lotion. A pre-trial conference in the consolidated action has been scheduled for July 20, 2022. We remain confident in the strength of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and will vigorously defend our intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> 550mg Patent Litigation (Actavis) - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2016, the Company initiated litigation against Actavis Laboratories FL, Inc. (&#8220;Actavis&#8221;), which alleged infringement by Actavis of one or more claims of each of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents. On September 12, 2018, we announced that we had reached an agreement with Actavis that resolved the existing litigation and eliminated the pending challenges to our intellectual property protecting Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets. As part of the agreement, the parties agreed to dismiss all litigation related to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin), Actavis acknowledged the validity of the licensed patents for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets and all intellectual property protecting Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets will remain intact and enforceable until expiry in 2029. The agreement also grants Actavis a non-exclusive license to the intellectual property relating to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets in the United States beginning January 1, 2028 (or earlier under certain circumstances). The Company will not make any financial payments or other transfers of value as part of the agreement. In addition, under the terms of the agreement, beginning January 1, 2028 (or earlier under certain circumstances), Actavis will have the option to: (1) market a royalty-free generic version of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tablets, 550 mg, should it receive approval from the FDA on its ANDA, or (2) market an authorized generic version of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tablets, 550 mg, in which case, we will receive a share of the economics from Actavis on its sales of such an authorized generic. Actavis will be able to commence such marketing earlier if another generic rifaximin product is granted approval and such other generic rifaximin product begins to be sold or distributed before January 1, 2028.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">550mg Patent Litigation (Sandoz) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- In October 2019, the Company announced that it and its licensor, Alfasigma, had commenced litigation against Sandoz Inc. (&#8220;Sandoz&#8221;), a Novartis division, alleging patent infringement of 14 patents by Sandoz&#8217;s filing of its ANDA for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets. On May 6, 2020, the Company announced that an agreement had been reached with Sandoz that resolved this litigation. Under the terms of the agreement, the parties agreed to dismiss all litigation related to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(rifaximin), Sandoz acknowledged the validity of the licensed patents for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(rifaximin) 550 mg tablets and all intellectual property protecting Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(rifaximin) 550 mg tablets will remain intact and enforceable until expiry in October 2029. The agreement also grants Sandoz a non-exclusive license to the intellectual property relating to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(rifaximin) 550 mg tablets in the United States beginning January 1, 2028 (or earlier under certain circumstances). Under the terms of the agreement, beginning January 1, 2028 (or earlier under certain circumstances), Sandoz will have the right to market a royalty-free generic version of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(rifaximin) 550 mg tablets, should it receive approval from the FDA on its ANDA. Sandoz will be able to commence such marketing earlier if another generic rifaximin product is granted approval and such other generic rifaximin product begins to be sold or distributed in the U.S. before January 1, 2028. The Company did not make any financial payments or other transfers of value as part of this agreement with Sandoz.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">550mg Patent Litigation (Norwich) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- On March 26, 2020, the Company and its licensor, Alfasigma, filed suit against Norwich Pharmaceuticals Inc. (&#8220;Norwich&#8221;), alleging infringement by Norwich of one or more claims of the 23 Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents by Norwich&#8217;s filing of its ANDA for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets.  On November 13, 2020, an additional three patents alleged to be infringed by Norwich were added to the suit.  Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 550mg is protected by 26 patents covering the composition of matter and the use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> listed in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange&#160;Book. Trial in this matter was held in March 2022. A decision is pending. Post-trial briefing is expected to occur in the second quarter of 2022, with a decision expected in the third quarter of </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022. The Company remains confident in the strength of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and will continue to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">200mg and 550mg Patent Litigation (Sun) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- In April 2019, the Company and its licensor, Alfasigma, commenced litigation against Sun Pharmaceutical Industries Ltd. (&#8220;Sun&#8221;), alleging patent infringement by Sun&#8217;s filing of its ANDA for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 200 mg tablets. This suit had been filed following receipt of a Notice of Paragraph IV Certification from Sun, in which Sun asserted that the U.S. patents listed in the FDA&#8217;s Orange Book for the Company&#8217;s Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 200 mg, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of Sun&#8217;s generic rifaximin tablets, 200 mg. Subsequently, on August 10, 2020, the Company received an additional Notice of Paragraph IV Certification from Sun, in which Sun asserted that the U.S. patents listed in the FDA&#8217;s Orange Book for the Company&#8217;s Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 550 mg, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of Sun&#8217;s generic rifaximin tablets, 550 mg, for which an ANDA had been filed by Sun. On September 22, 2020, the Company announced that an agreement had been reached with Sun that resolved the outstanding intellectual property disputes with Sun regarding Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 200 mg and 550 mg tablets. Under the terms of the agreement, the parties agreed to dismiss all litigation related to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) and all intellectual property protecting Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 200 mg and 550 mg tablets will remain intact and enforceable until expiry in July and October 2029, respectively. The agreement also grants Sun a non-exclusive license to the intellectual property relating to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 200 mg and 550 mg tablets in the U.S. beginning January 1, 2028 (or earlier under certain circumstances). Under the terms of the agreement, beginning January 1, 2028 (or earlier under certain circumstances), Sun will have the right to market royalty-free generic versions of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 200 mg and 550 mg tablets, should it receive approval from the FDA on its ANDAs. Sun will be able to commence such marketing earlier if another generic rifaximin product is granted approval and such other generic rifaximin product begins to be sold or distributed in the U.S. before January 1, 2028. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Tablets Patent Litigation (Actavis)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - On December 6, 2016, the Company initiated litigation against Actavis, which alleged infringement by Actavis of one or more claims of U.S.&#160;Patent No. 8,524,276 (the &#8220;&#8216;276 Patent&#8221;), which protects the formulation of RELISTOR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets. Actavis had challenged the validity of such patent and alleged non-infringement by its generic version of such product. In July 2019, we announced that the U.S. District Court of New Jersey had upheld the validity of, and determined that Actavis infringed, the &#8216;276 Patent, expiring in March 2031. Actavis appealed this decision to the U.S. Court of Appeals for the Federal Circuit. In March 2021, the Company and Actavis reached a settlement agreement and the appeal was dismissed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Injection Patent Litigation (Gland)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - On February 22, 2022, the Company commenced litigation against Gland Pharma Limited (&#8220;Gland&#8221;) alleging patent infringement by Gland&#8217;s filing of its ANDA No. 216836, referencing Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (methynaltrexone bromide injection, vials) and its ANDA No. 216965, referencing Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (methynaltrexone bromide injection, pre-filled syringes).  This suit had been filed following receipt of two Notices of Paragraph IV Certification from Gland, in which it had asserted that the U.S. patents listed in the FDA&#8217;s Orange Book for the Company&#8217;s Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> methynaltrexone bromide injection, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of its generic methynaltrexone bromide injection.  The filing of this suit triggered a 30-month stay of the approval of the Gland ANDA for its methynaltrexone bromide injection. The Company remains confident in the strength of the Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and will continue to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> 3mg Tablets Patent Litigation (MSN and Mylan)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In March 2021, the Company received Notices of Paragraph IV Certification from MSN Laboratories Private Ltd. (&#8220;MSN&#8221;) and Mylan Pharmaceuticals Inc., (&#8220;Mylan&#8221;) in which MSN and Mylan asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (plecanatide) 3mg tablets, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of their generic plecanatide tablets, for which each of MSN and Mylan had filed an ANDA.  In April 2021, the Company filed suit against MSN and Mylan, alleging infringement of one or more claims of the patents listed for Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. The Company remains confident in the strength of the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and will continue to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Ophthalmic Solution Patent Litigation (Slayback)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - On August 16, 2021, the Company received a Notice of Paragraph IV Certification from Slayback Pharma LLC (&#8220;Slayback&#8221;), in which Slayback asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (brimonidine tartrate solution) drops (the &#8220;Lumify Patents&#8221;), are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Slayback&#8217;s generic drops, for which an Abbreviated New Drug Application (&#8220;ANDA&#8221;) has been filed by Slayback. The Company, through its affiliate Bausch + Lomb Ireland Limited, exclusively licenses the Lumify Patents from Eye Therapies, LLC (&#8220;Eye Therapies&#8221;). On September 10, 2021, B&amp;L Inc., Bausch + Lomb Ireland Limited and Eye Therapies filed suit against Slayback pursuant to the Hatch-Waxman Act, alleging infringement by Slayback of one or more claims of the Lumify </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents, thereby triggering a 30-month stay of the approval of the Slayback ANDA. The Company remains confident in the strength of the Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents and intends to vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Ophthalmic Solution Patent Litigation (Lupin)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; On January 20, 2022, B&amp;L Inc. received a Notice of Paragraph IV Certification from Lupin Ltd. (&#8220;Lupin&#8221;), in which Lupin asserted that certain of the Lumify Patents are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Lupin&#8217;s generic brimonidine tartrate solution, for which its ANDA No. 216716 has been filed by Lupin. On February 2, 2022, B&amp;L Inc., Bausch + Lomb Ireland Limited and Eye Therapies filed suit against Lupin pursuant to the Hatch-Waxman Act, alleging patent infringement by Lupin of one or more claims of the Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a 30-month stay of the approval of the Lupin ANDA. As noted above, the Company remains confident in the strength of the Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents and intends to vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Competition to Uceris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, a generic competitor launched a product which will directly compete with our Uceris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Tablet product. As disclosed in our prior filings, the Company initiated various infringement proceedings against this generic competitor. The Court construed the claims of the asserted patents on August 2, 2019 and, on October 24, 2019, the Company agreed to a judgment that the asserted patents did not cover the generic tablets under the Court&#8217;s claim construction, while reserving its right to appeal the claim construction. On November 22, 2019, the Company filed a Notice of Appeal with respect to the claim construction in the Court of Appeals for the Federal Circuit.  On December 18, 2020, the Court of Appeals for the Federal Circuit affirmed the District Court&#8217;s claim construction. The ultimate impact of this generic competitor on our future revenues cannot be predicted; however, Uceris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Tablet revenues for the three months ended March 31, 2022 and 2021 were approximately $2 million and $2 million, respectively, and for the years 2021, 2020 and 2019 were approximately $10&#160;million, $15&#160;million and $20&#160;million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Competition to Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2018, the U.S. Patent and Trial Appeal Board (&#8220;PTAB&#8221;) completed its inter partes review for an Orange Book-listed patent covering Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (U.S. Patent No 7,214,506 (the &#8220;&#8216;506 Patent&#8221;)) and issued a written determination invalidating such patent.&#160; On March 13, 2020, the Court of Appeals for the Federal Circuit reversed this decision and remanded the matter back to the PTAB for further proceedings.&#160; As a result of a settlement, a joint motion to terminate the proceedings was filed on November 12, 2020 and, on January 8, 2021, the PTAB granted this motion.   The &#8216;506 Patent, therefore, remains valid and enforceable and expires in 2026. Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues for the three months ended March 31, 2022 and 2021 were approximately $24 million and $24 million, respectively, and for the years 2021, 2020 and 2019 were approximately $100 million, $111 million and $110 million, respectively. Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is covered by fourteen additional Orange Book-listed patents owned by the Company or its licensor, which expire in the years 2028 through 2035. In August and September 2018, the Company received notices of the filing of a number of ANDAs with paragraph IV certification, and has timely filed patent infringement suits against these ANDA filers, and, in addition, the Company has also commenced certain patent infringement proceedings in Canada against three separate defendants. All cases in the U.S. regarding Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have been settled. In Canada, two lawsuits remain pending against Apotex, Inc.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Litigation - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AREDS and PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AREDS 2 are OTC eye vitamin and mineral supplements containing nutrient formulas recommended by the National Eye Institute to reduce the risk of progression of intermediate to advanced AMD. PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products accounted for 3% of our total revenues in 2021.  The PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> U.S. formulation patent expired in March 2021, but a patent covering methods of using the formulation remains in force into 2026. The Company has filed patent infringement proceedings against 16 defendants claiming infringement of these patents and, in certain circumstances, related unfair competition and false advertising causes of action. Eleven of these proceedings were subsequently settled; two resulted in entry of a default. One defendant filed a declaratory judgment action after the Company filed its suit, seeking declaratory judgment related to patent claims as well as false advertising and unfair competition claims. As of the date of this filing, there are three ongoing matters. The Company remains confident in the strength of these patents and will continue to vigorously pursue these matters and defend its intellectual property. While the Company cannot predict the magnitude or timing of the impact from the PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patent expiry, this is an OTC product and thus, the impact is not expected to be as significant as the LOE of a branded pharmaceutical product. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 18, &#8220;LEGAL PROCEEDINGS&#8221; to our unaudited interim Consolidated Financial Statements elsewhere in this Form 10-Q, as well as Note 20, "LEGAL PROCEEDINGS&#8221; of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC and the CSA on February&#160;23, 2022 for further details regarding certain infringement proceedings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risks of generic competition are a fact of the health care industry and are not specific to our operations or product portfolio.  These risks are not avoidable, but we believe they are manageable.  To manage these risks, our leadership team continually evaluates the impact that generic competition may have on future profitability and operations.  In addition to aggressively defending the Company&#8217;s patents and other intellectual property, our leadership team makes operational and investment decisions regarding these products and businesses at risk, not the least of which are decisions regarding our pipeline. Our leadership team actively manages the Company&#8217;s pipeline in order to identify innovative and realizable projects </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">aligned with our core businesses that are expected to provide incremental and sustainable revenues and growth into the future.  We believe that our current pipeline is strong enough to meet these objectives and provide future sources of revenues, in our core businesses, sufficient enough to sustain our growth and corporate health as other products in our established portfolio face generic competition and lose momentum.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that we have a well-established product portfolio that is diversified within our core businesses. We also believe that we have a robust pipeline that not only provides for the next generation of our existing products, but also brings new solutions into the market.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 1A &#8220;Risk Factors&#8221; of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC and the CSA on February&#160;23, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information on our competition risks.</span></div><div id="i801c461cbd33492a893c84373a8e7cbc_166"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the normal course of business, our products, devices and facilities are the subject of ongoing oversight and review by regulatory and governmental agencies, including general, for cause and pre-approval inspections by the relevant competent authorities where we have business operations. Through the date of this filing, all of our global operations and facilities have the relevant operational good manufacturing practices certificates and all Company products and operating sites are in good compliance standing with all relevant notified bodies and global health authorities. Further, all sites under FDA jurisdiction are rated as either No Action Indicated (where there was no Form 483 observation) or Voluntary Action Indicated (&#8220;VAI&#8221;) (where there was a Form 483 with one or more observations). In the case of VAI inspection outcomes, the FDA has accepted our responses to the issues cited, which will be verified when the agency makes its next inspection of those specific facilities. </span></div><div id="i801c461cbd33492a893c84373a8e7cbc_169"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL PERFORMANCE HIGHLIGHTS</span></div><div style="margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides selected unaudited financial information for the three months ended March 31, 2022 and 2021: </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.221%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,918&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,027&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(591)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(610)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per share attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.71)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Performance</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of the Three Months Ended March 31, 2022 Compared to the Three Months Ended March 31, 2021 </span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Revenue for the three months ended March 31, 2022 and 2021 was $1,918 million and $2,027 million, respectively, a decrease of $109 million, or 5%. The decrease was primarily due to: (i) the impact of our divestiture of Amoun on July 26, 2021, (ii) the net decrease in volumes primarily driven by our Diversified Products and Salix segments and (iii) the unfavorable impact of foreign currencies, primarily in Europe and Asia. These decreases were partially offset by an increase in net realized pricing, primarily driven by our Salix segment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income for the three months ended March 31, 2022 was $285 million as compared to an operating loss of $221&#160;million for the three months ended March 31, 2021, an increase in our operating results of $506 million and reflects, among other factors:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.53pt">a decrease in contribution (Product sales revenue less Cost of goods sold, excluding amortization and impairments of intangible assets) of $84 million primarily due to: (i) the decrease net in volumes discussed above, (ii) the impact of our divestiture of Amoun on July 26, 2021 and (iii) the unfavorable impact of foreign currencies, partially offset by the increase in net realized pricing, discussed above;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.53pt">an increase in SG&amp;A of $16 million primarily attributable to: (i) higher selling, advertising and promotion expenses, (ii) higher compensation expense and (iii) an increase in separation-related and IPO-related costs, partially offset by: (i) the impact of our divestiture of Amoun on July 26, 2021 and (ii) the favorable impact of foreign currencies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:12.53pt">an increase in R&amp;D of $15 million primarily attributable to lower R&amp;D spend in 2021, as certain R&amp;D activities and clinical trials which were suspended in response to the COVID-19 pandemic in 2020 did not normalize until later in 2021, and higher spend on certain Bausch + Lomb and Salix projects;</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in Amortization of intangible assets of $47 million primarily attributable to fully amortized intangible assets no longer being amortized in 2022;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in Goodwill impairments of $469 million related to the impairment of the goodwill of the Ortho Dermatologics reporting unit during the three months ended March 31, 2021 as a result of revised forecasts due to: (i) certain products that continue to experience longer launch cycles than originally anticipated, in part due to COVID-19 pandemic factors, and (ii) other changes to its product pipeline;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in Asset impairments, including loss on assets held for sale of $140 million attributable to: (i) an adjustment to the loss on assets held for sale in connection with the Amoun Sale during 2021 and (ii) lower impairments to certain products; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.53pt">an unfavorable change in Other expense (income), net of $32 million, primarily attributable to the net gain on sale of assets during the three months ended March 31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income for the three months ended March 31, 2022 was $285 million as compared to an operating loss of $221&#160;million for the three months ended March 31, 2021 and included non-cash charges for Depreciation and amortization of intangible assets of $352 million and $403 million, Goodwill impairments of $0 and $469 million, Asset impairments, including loss on assets held for sale, of $8 million and $148 million and Share-based compensation of $32&#160;million and $31&#160;million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before income taxes for the three months ended March 31, 2022 and 2021 was $82 million and $591&#160;million, respectively, a decrease of $509 million. The decrease in our Loss before income taxes is primarily attributable to: (i) the increase in our operating results of $506 million, as previously discussed, (ii) a decrease in Interest expense of $6 million and (iii) the decrease in Loss on extinguishment of debt of $5&#160;million, partially offset by an unfavorable net change in Foreign exchange and other of $8&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to Bausch Health Companies Inc. for the three months ended March 31, 2022 and 2021 was $69&#160;million and $610&#160;million, respectively, an increase in our results of $541 million. The increase in our results was primarily due to the decrease in our Loss before income taxes of $509 million, as previously discussed, and the favorable change in income taxes of $32 million.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><div id="i801c461cbd33492a893c84373a8e7cbc_175"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our unaudited operating results for the three months ended March 31, 2022 and 2021 were as follows:</span></div><div style="margin-bottom:0.8pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.626%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:2.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,003&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,918&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,027&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of goods sold (excluding amortization and impairments of intangible assets)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of other revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill impairments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset impairments, including loss on assets held for sale</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring, integration, separation and IPO costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expense (income), net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,633&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(615)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(221)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(362)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(368)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before provision for income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(591)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit from (provision for) income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(607)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interest</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(610)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="i801c461cbd33492a893c84373a8e7cbc_178"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Three Months Ended March 31, 2022 Compared to the Three Months Ended March 31, 2021 </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenues are primarily generated from product sales, principally in the therapeutic areas of eye health, GI and dermatology, that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues were $1,918 million and $2,027 million for the three months ended March 31, 2022 and 2021, respectively, a decrease of $109 million, or 5%. The decrease was due to: (i) the impact of divestitures and discontinuations of $72 million, primarily attributable to our divestiture of Amoun on July 26, 2021, (ii) the net decrease in volumes of $60 million primarily in our Diversified Products and Salix segments and (iii) the unfavorable impact of foreign currencies of $41 million, primarily in Europe and Asia. These decreases were partially offset by an increase in net realized pricing of $64&#160;million, primarily in our Salix segment. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in our segment revenues and segment profits for the three months ended March 31, 2022, are discussed in further detail in the respective subsequent section &#8220; &#8212; Reportable Segment Revenues and Profits&#8221;.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Discounts and Allowances, Chargebacks and Distribution Fees</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at net product sales.&#160;Provisions for these deductions are recognized concurrently with the recognition of gross product sales. These provisions include cash discounts and allowances, chargebacks, and distribution fees, which are paid or credited to direct customers, as well as rebates and returns, which can be paid or credited to direct and indirect customers. As more fully discussed in Note 3, &#8220;REVENUE RECOGNITION&#8221; to our unaudited interim Consolidated Financial Statements, the Company continually monitors the provisions for these deductions and evaluates the estimates used as additional information becomes available.  Price appreciation credits are generated when we increase a product&#8217;s wholesaler acquisition cost (&#8220;WAC&#8221;) under our contracts with certain wholesalers. Under such contracts, we are entitled to credits from such wholesalers for the impact of that WAC increase on inventory on hand at the wholesalers. In wholesaler contracts, such credits are offset against the total distribution service fees we pay on all of our products to each such wholesaler. In addition, some payor contracts require discounting if a price increase or series of price increases in a contract period exceeds a negotiated threshold. Provision balances relating to amounts payable to direct customers are netted against trade receivables and balances relating to indirect customers are included in accrued liabilities.&#160; </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We actively manage these offerings, focusing on the incremental costs of our patient assistance programs, the level of discounting to non-retail accounts and identifying opportunities to minimize product returns. We also concentrate on managing our relationships with our payors and wholesalers, reviewing the ranges of our offerings and being disciplined as to the amount and type of incentives we negotiate.  Provisions recorded to reduce gross product sales to net product sales and revenues for the three months ended March 31, 2022 and 2021 were as follows: </span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.810%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.021%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,154&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,303&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions to reduce gross product sales to net product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Returns</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chargebacks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provisions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,898&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,003&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,918&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,027&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash discounts and allowances, returns, rebates, chargebacks and distribution fees as a percentage of gross product sales were 39.8% and 39.4% for the three months ended March 31, 2022 and 2021, respectively, an increase of 0.4 percentage points and includes:  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">discounts and allowances as a percentage of gross product sales were lower primarily driven by lower gross product sales and lower discount rates for certain generic products, such as Apriso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG, Tobramycin / Dexamethasone, Migranal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG and Flunisolide</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG partially offset by: (i) higher discounts for Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG, and (ii) the impact of higher gross product sales and discount rates for other generics, such as Latanoprost;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">returns as a percentage of gross product sales were lower as the Company&#8217;s improving return experience was offset by reductions in variable consideration for sales returns related to past sales in 2022 as compared to 2021. Over the last several years, the Company has increased its focus on maximizing operational efficiencies and continues to take actions to reduce product returns, including, but not limited to: (i) monitoring and reducing customer inventory levels, (ii) instituting disciplined pricing policies and (iii) improving contracting. These actions have had the effect of improving the sales return experience, primarily related to branded and generic products; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">rebates as a percentage of gross product sales were higher primarily due to an increase in gross product sales and higher rebate rates for certain branded products, such as Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Aplenzin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Arazlo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, partially offset by lower gross product sales and lower rebate rates for certain branded products, such as Wellbutrin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">chargebacks as a percentage of gross product sales were higher primarily due to higher chargeback rates for certain products, such as Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SLX and Latanoprost, partially offset by lower gross product sales of certain generics, such as Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG, Targretin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG and Syprine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AG; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">distribution service fees as a percentage of gross product sales were lower primarily due to lower gross product sales of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Price appreciation credits are offset against the distribution service fees we pay wholesalers and were $0 and $1 million for the three months ended March 31, 2022 and 2021, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Goods Sold (excluding amortization and impairments of intangible assets)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold primarily includes: manufacturing and packaging; the cost of products we purchase from third parties; royalty payments we make to third parties; depreciation of manufacturing facilities and equipment; and lower of cost or market adjustments to inventories. Cost of goods sold typically vary between periods as a result of product mix, volume, royalties, changes in foreign currency and inflation. Cost of goods sold excludes the amortization and impairments of intangible assets. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold was $543 million and $564 million for the three months ended March 31, 2022 and 2021, respectively, a decrease of $21 million, or 4%. The decrease was primarily driven by: (i) the impact of the divestiture of Amoun on July 26, 2021 and (ii) the favorable impact of foreign currencies. These decreases were partially offset by: (i) product mix and (ii) higher manufacturing variances, primarily as a result of inflationary pressures related to certain manufacturing costs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold as a percentage of product sales revenue were 28.6% and 28.2% for the three months ended March 31, 2022 and 2021, respectively, an increase of 0.4 percentage points.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses primarily include: employee compensation associated with sales and marketing, finance, legal, information technology, human resources and other administrative functions; certain outside legal fees and consultancy costs; product promotion expenses; overhead and occupancy costs; depreciation of corporate facilities and equipment; and other general and administrative costs. Also included in SG&amp;A expenses for the three months ended March 31, 2022 are Separation-related and IPO-related costs. The Company has incurred, and will incur, Separation-related and IPO-related costs which are incremental costs indirectly related to the B+L Separation and Solta IPO. Separation-related and IPO-related costs include, but are not limited to: (i) IT infrastructure and software licensing costs, (ii) rebranding costs and (iii) costs associated with facility relocation and/or modification.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses were $622 million and $606 million for the three months ended March 31, 2022 and 2021, respectively, an increase of $16 million, or 3%. The increase was primarily attributable to: (i) higher selling, advertising and promotion expenses, (ii) higher compensation expense and (iii) an increase in separation-related and IPO-related costs, partially offset by: (i) the impact of our divestiture of Amoun on July 26, 2021 and (ii) the favorable impact of foreign currencies.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Research and development are costs related to our product development and quality assurance programs. Expenses related to product development include: employee compensation costs; overhead and occupancy costs; depreciation of research and development facilities and equipment; clinical trial costs; clinical manufacturing and scale-up costs; and other third-party development costs. Quality assurance are the costs incurred to meet evolving customer and regulatory standards and include: employee compensation costs; overhead and occupancy costs; amortization of software; and other third-party costs. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses were $127 million and $112 million for the three months ended March 31, 2022 and 2021, respectively, an increase of $15 million, or 13%. R&amp;D expenses as a percentage of Product sales were approximately 7% and 6% for the three months ended March 31, 2022 and 2021, respectively. The increase was primarily due to: (i) the result of lower R&amp;D spend in early 2021 as our R&amp;D activities gradually recovered from the impacts of the COVID-19 pandemic as discussed below and (ii) higher spend on certain Bausch + Lomb and Salix projects. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2020, certain of our R&amp;D activities were limited and others, including new patient enrollments in clinical trials, were temporarily paused, as most trial sites were not able to accept new patients due to government-mandated shutdowns. During our third quarter of 2020, many of these trial sites began to reopen.  During 2021, the pace of new patient enrollments and the increase these activities and related R&amp;D spend gradually increased until they approached a normalized spend rate toward the end of 2021. As of the date of this filing, we have not had to make material changes to our development timelines </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the pause in our clinical trials has not had a material impact on our operating results; however, a resurgence of the virus could result in unanticipated delays in our ability to conduct new patient enrollments and create other delays which could have a significant adverse effect on our future operating results.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amortization of Intangible Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives are amortized using the straight-line method over their estimated useful lives, generally 2 to 20 years. Management continually assesses the useful lives related to the Company&#8217;s long-lived assets to reflect the most current assumptions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets was $310 million and $357 million for the three months ended March 31, 2022 and 2021, respectively, a decrease of $47 million.  The decrease was primarily attributable to fully amortized intangible assets no longer being amortized in 2022.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8, &#8220;INTANGIBLE ASSETS AND GOODWILL&#8221; to our unaudited interim Consolidated Financial Statements for further details related to the Amortization of intangible assets. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill Impairments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized but is tested for impairment at least annually on October 1st at the reporting unit level. A reporting unit is the same as, or one level below, an operating segment. The Company performs its annual impairment test by first assessing qualitative factors. Where the qualitative assessment suggests that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed for that reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill impairments were and $0 and $469 million for the three months ended March 31, 2022 and 2021, respectively, a decrease of $469 million. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">March 31, 2021</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, it became apparent that recent Ortho Dermatologics product launches were not going to achieve their forecasted trajectories that were expected once the offices of health care professionals could reopen as social restrictions associated with the COVID-19 pandemic began to ease in the U.S. In addition, insurance coverage pressures within the U.S. continued to persist limiting patient access to topical acne and psoriasis products. In light of these developments, during the first quarter of 2021, the Company began taking steps to: (i) redirect its R&amp;D spend to eliminate projects it had identified as high cost and high risk, (ii) redirect a portion of its marketing and product development outside the U.S. to geographies where there is better patient access and (iii) reduce its cost structure to be more competitive. As result, during the three months ended March 31, 2021, the Company revised its long-term forecasts for the Ortho Dermatologics reporting unit. Management believes that these events are indicators that there is less headroom as of March 31, 2021 as compared to the headroom calculated on the date goodwill was last tested for impairment (October 1, 2020). Therefore, a quantitative fair value test for the Ortho Dermatologics reporting unit was performed. The quantitative fair value test utilized the Company&#8217;s most recent cash flow projections as revised in the first quarter of 2021 to reflect the business changes previously discussed, including a range of potential outcomes, along with a long-term growth rate of 1.0% and a range of discount rates between 9.0% and 10.0%. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at March 31, 2021, and the Company recognized a goodwill impairment of $469 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">March 31, 2022</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to monitor market conditions which could impact the previous valuation of Ortho Dermatologics reporting unit. During the three months ended March 31, 2022, macroeconomic factors have impacted interest rates and the U.S. inflation rate is higher than previously expected.  Given the limited headroom calculated on October 1, 2021, the Company believed that these facts and circumstances suggest the fair value of the Ortho Dermatologics reporting unit could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value test utilized the Company&#8217;s most recent cash flow projections as revised in the first quarter of 2022 and utilized a long-term growth rate of 1% and a discount rate of 9%.  The discount rate contemplates changes in the current macroeconomic conditions noting certain inputs such as the risk free rate increased over the three months ended March 31, 2022, and was offset by decreases in other reporting unit specific risks during the same period. Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was less than 2% greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit. If market conditions deteriorate requiring management to revise its assumptions such as its long-term growth or discount rates, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future and those charges could be material.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8, &#8220;INTANGIBLE ASSETS AND GOODWILL&#8221; to our unaudited interim Consolidated Financial Statements for further details related to the Amortization of intangible assets. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Impairments, Including Loss on Assets Held for Sale</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Impairment charges associated with these assets are included in Asset impairments in the Consolidated Statement of Operations. The Company continues to monitor the recoverability of its finite-lived intangible assets and tests the intangible assets for impairment if indicators of impairment are present.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments, including loss on assets held for sale were $8 million and $148 million for the three months ended March 31, 2022 and 2021, respectively, a decrease of $140 million. Asset impairments, including loss on assets held for sale for the three months ended March 31, 2022 were $8 million and include: (i) impairments of $4&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines, and (ii) impairments of $4&#160;million, in aggregate, related to the discontinuance of certain product lines. Asset impairments, including loss on assets held for sale for the three months ended March 31, 2021 were $148&#160;million and include: (i) $71&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines in the Ortho Dermatologics business, (ii) an adjustment of $68&#160;million due to the loss on assets held for sale in connection with the Amoun Sale and (iii) impairments of $9&#160;million, in aggregate, related to the discontinuance of certain product lines.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8, &#8220;INTANGIBLE ASSETS AND GOODWILL&#8221; to our unaudited interim Consolidated Financial Statements for further details related to our intangible assets.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring, Integration, Separation and IPO Costs </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring, integration separation and IPO costs were $13 million and $12 million for the three months ended March 31, 2022 and 2021, respectively, an increase of $1 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring and Integration Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates opportunities to improve its operating results and implements cost savings programs to streamline its operations and eliminate&#160;redundant processes and expenses. Restructuring and integration costs are expenses associated with the implementation of these cost savings programs and include expenses associated with: (i)&#160;reducing headcount, (ii)&#160;eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring and integration costs were $3 million and $3 million for the three months ended March 31, 2022 and 2021, respectively. The Company continues to evaluate opportunities to streamline its operations and identify additional cost savings globally. Although a specific plan does not exist at this time, the Company may identify and take additional exit and cost-rationalization restructuring actions in the future, the costs of which could be material. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Separation and IPO Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred, and will incur, costs associated with activities to effectuate the B+L Separation and the Solta IPO. These activities include: (i) separating the Bausch + Lomb and Solta Medical businesses from the remainder of the Company and (ii) registering the Bausch + Lomb and Solta Medical businesses as independent publicly traded entities. Separation and IPO costs are incremental costs directly related to the B+L Separation and Solta IPO and include, but are not limited to: (i) legal, audit and advisory fees, (ii) talent acquisition costs and (iii) costs associated with establishing a new board of directors and related board committees for the Bausch + Lomb and Solta Medical entities. Separation and IPO costs were $10&#160;million and $9 million for the three months ended March 31, 2022 and 2021, respectively. The extent and timing of future charges for these costs cannot be reasonably estimated at this time and could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 5, &#8220;RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS&#8221; to our unaudited interim Consolidated Financial Statements for further details regarding these actions. </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other expense (income), net</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense (income), net for the three months ended March 31, 2022 and 2021 consists of the following:</span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.471%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and other matters</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of assets, net for the three months ended March 31, 2021, includes $25&#160;million related to the achievement of a milestone related to a certain product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Operating Income and Expense</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense primarily consists of interest payments due, amortization of debt premiums, discounts and deferred issuance costs on indebtedness under our credit facilities and notes and the amortization of amounts excluded from the assessment of hedge effectiveness over the term of the Company&#8217;s cross-currency swaps during 2021. In November 2021, we entered into a transaction to unwind our cross-currency swaps.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense was $362 million and $368 million, and included non-cash amortization and write-offs of debt premiums, discounts and deferred issuance costs of $14 million and $13 million, for the three months ended March 31, 2022 and 2021, respectively. Interest expense for the three months ended March 31, 2022 decreased $6 million, or 2%, as compared to the three months ended March 31, 2021. The weighted average stated rate of interest as of March&#160;31, 2022 and 2021 was 5.97% and 6.00%, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, &#8220;FINANCING ARRANGEMENTS&#8221; to our unaudited interim Consolidated Financial Statements for further details.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss on Extinguishment of Debt </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on extinguishment of debt represents the differences between the amounts paid to settle extinguished debts and the carrying value of the related extinguished debt. Loss on extinguishment of debt was $0 and $5 million for the three months ended March 31, 2022 and 2021, respectively, primarily associated with debt repayments made during the three months ended March 31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, &#8220;FINANCING ARRANGEMENTS&#8221; to our unaudited interim Consolidated Financial Statements for further details.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Exchange and Other </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange and other primarily includes: (i) translation gains/losses on intercompany loans and third-party liabilities and (ii) the gain/loss due to foreign currency exchange contracts. Foreign exchange and other was a loss of $7&#160;million and a gain of $1&#160;million for the three months ended March 31, 2022 and 2021, respectively, an unfavorable net change of $8&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Benefit from income taxes was $16 million and a provision of $16 million for the three months ended March 31, 2022 and 2021, respectively, a favorable change of $32&#160;million. </span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective income tax rate for the three months ended March 31, 2022 differs from the statutory Canadian income tax rate primarily due to: (i) the recording of valuation allowance on entities for which no tax benefit of losses is expected, (ii) the tax benefit generated from our annualized mix of earnings by jurisdiction and (iii) the discrete treatment of certain tax matters, primarily related to: (a) changes in uncertain tax positions, (b) adjustments for book to income tax return provisions and (c) a tax deduction for stock compensation. </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective income tax rate for the three months ended March 31, 2021 differs from the statutory Canadian income tax rate primarily due to: (i) the tax benefit generated from our annualized mix of earnings by jurisdiction, (ii) the recording of valuation allowance on entities for which no tax benefit of losses is expected and (iii) the discrete treatment of certain tax matters, primarily related to: (a) potential and recognized withholding taxes on intercompany dividends, (b) adjustments for book to income tax return provisions, (c) tax deduction for stock compensation and (d) changes in uncertain tax positions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 16, &#8220;INCOME TAXES&#8221; to our unaudited interim Consolidated Financial Statements for further details.</span></div><div id="i801c461cbd33492a893c84373a8e7cbc_181"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reportable Segment Revenues and Profits</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a brief description of the Company&#8217;s segments: </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Bausch + Lomb segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Bausch + Lomb Vision Care, Consumer, Surgical and Ophthalmic Pharmaceuticals products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Salix segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of sales in the U.S. of GI products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The International segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of sales, with the exception of sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Solta Medical segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Solta aesthetic medical devices.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Diversified Products segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products, (iii) Ortho Dermatologics (dermatological) products and (iv) dentistry products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment profit is based on operating income after the elimination of intercompany transactions. Certain costs, such as Amortization of intangible assets, Asset impairments, Acquired in-process research and development costs, Restructuring, integration, separation and IPO costs and Other (income) expense, net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance. See Note 19, &#8220;SEGMENT INFORMATION&#8221; to our unaudited interim Consolidated Financial Statements for a reconciliation of segment profit to Loss before provision for income taxes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents segment revenues, segment revenues as a percentage of total revenues, and the period-over-period changes in segment revenues for the three months ended March 31, 2022 and 2021.  The following table also presents segment profits, segment profits as a percentage of segment revenues and the period-over-period changes in segment profits for the three months ended March 31, 2022 and 2021.</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.542%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.090%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,918&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,027&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment Profits / Segment Profit Margins</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment profits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Organic Revenues and Organic Growth Rates (non-GAAP)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organic growth, a non-GAAP measure, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of recent acquisitions, divestitures and discontinuations. Organic revenue growth (non-GAAP) is growth in GAAP Revenue (its most directly comparable GAAP financial measure), adjusted for certain items, of businesses that have been owned for one or more years. Organic revenue (non-GAAP) is impacted by changes in product volumes and price. The price component is made up of two key drivers: (i) changes in product gross selling price and (ii) changes in sales deductions. The Company uses organic revenue (non-GAAP) and organic revenue growth (non-GAAP) to assess performance of its reportable segments, and the Company in total, without the impact of foreign currency exchange fluctuations and recent acquisitions, divestitures and product discontinuations. The Company believes that such measures are useful to investors as they provide a supplemental period-to-period comparison.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP measures are not standardized measures under the financial reporting framework used to prepare the Company&#8217;s financial statements and might not be comparable to similar financial measures disclosed by other issuers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organic revenue growth, a non-GAAP measure, reflects adjustments for: (i) the impact of period-over-period changes in foreign currency exchange rates on revenues and (ii) the revenues associated with acquisitions, divestitures and discontinuations of businesses divested and/or discontinued.  These adjustments are determined as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign currency exchange rates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Although changes in foreign currency exchange rates are part of our business, they are not within management&#8217;s control. Changes in foreign currency exchange rates, however, can mask positive or negative trends in the underlying business performance. The impact for changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions, divestitures and discontinuations:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In order to present period-over-period organic revenues (non-GAAP) on a comparable basis, revenues associated with acquisitions, divestitures and discontinuations are adjusted to include only revenues from those businesses and assets owned during both periods. Accordingly, organic revenue growth (non-GAAP) excludes from the current period, all revenues attributable to each acquisition for twelve months subsequent to the day of acquisition, as there are no revenues from those businesses and assets included in the comparable prior period. Organic revenue growth (non-GAAP) excludes from the prior period (but not the current period), all revenues attributable to each divestiture and discontinuance during the twelve months prior to the day of divestiture or discontinuance, as there are no revenues from those businesses and assets included in the comparable current period. There were no acquisitions during the twelve month period ended March&#160;31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of GAAP revenues to organic revenues (non-GAAP) and the period-over-period changes in organic revenue (Non-GAAP) for the three months ended March 31, 2022 and 2021 by segment.</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.072%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.006%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Change in<br/>Organic Revenue (Non-GAAP)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Revenue<br/>as<br/>Reported</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Changes in Exchange Rates</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Organic Revenue (Non-GAAP)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Revenue<br/>as<br/>Reported</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Divestitures and Discontinuations</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Organic Revenue (Non-GAAP)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Pct.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">889&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">918&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,918&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,959&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,027&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,955&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Bausch + Lomb Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch + Lomb Segment Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bausch + Lomb segment has a diversified product line with no single product group representing 10% or more of its product sales. The Bausch + Lomb segment revenue was $889 million and $881 million for the three months ended March 31, 2022 and 2021, respectively, an increase of $8 million, or 1%. The increase was attributable to increases in volumes in each of our Bausch + Lomb reporting units. The Bausch + Lomb segment volumes increased $47 million in the aggregate primarily due to: (i) increased demand for Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Biotrue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within U.S. Consumer and (ii) increased demand of consumables and intraocular lenses within Global Surgical, partially offset by: (i) a decrease in volume for the International Vision Care business, primarily driven by the impact of the COVID-19 pandemic in China and (ii) the impact of generic competition as certain products, such as Lotemax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Gel and Bepreve</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, lost exclusivity. This overall increase in volumes was partially offset by: (i) the unfavorable impact of foreign currencies of $29 million, primarily in Europe and Asia, (ii) a decrease in net realized pricing of $7 million primarily due to higher sales deductions in our Ophthalmology </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business in the U.S. and (iii) the impact of divestitures and discontinuations of $3 million, related to the discontinuation of certain products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch + Lomb Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bausch + Lomb segment profit for the three months ended March 31, 2022 and 2021 was $206&#160;million and $239&#160;million, respectively, a decrease of $33 million, or 14%. The decrease was primarily driven by: (i) higher SG&amp;A expenses within U.S. Consumer and Surgical, (ii) the unfavorable impact of foreign currencies, (iii) the decrease in net realized pricing, as previously discussed, and (iv) higher manufacturing variances, primarily as a result of inflationary pressures related to certain manufacturing costs. These decreases were partially offset by the increase in volumes, as previously discussed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Salix Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salix Segment Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Salix segment includes our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line. Revenues from our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line accounted for approximately 80% and 78% of the Salix segment revenues for the three months ended March 31, 2022 and 2021, respectively. No other single product group represents 10% or more of the Salix segment product sales. Salix segment revenue for the three months ended March 31, 2022 and 2021 was $464 million and $472 million, respectively, a decrease of $8 million, or 2%. The decrease is primarily driven by a decrease in volumes of $53 million primarily attributable to: (i) the inventory balancing of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by our wholesalers during the three months ended March 31, 2021 and (ii) the impact of generic competition as certain products, such as Apriso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, lost exclusivity, partially offset by an increase in net realized pricing of $45 million, primarily driven by Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salix Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Salix segment profit for the three months ended March 31, 2022 and 2021 was $322&#160;million and $327&#160;million, respectively, a decrease of $5&#160;million, or 2%. The decrease was primarily driven by an increase in: (i) selling expenses and advertising and promotion expenses and (ii) R&amp;D expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">International Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International Segment Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The International segment has a diversified product line with no single product group representing 10% or more of its product sales. The International segment revenue was $244 million and $306 million for the three months ended March 31, 2022 and 2021, respectively, a decrease of $62 million, or 20%. The decrease was primarily attributable to: (i) the impact of divestitures and discontinuations of $69 million, primarily attributable to our divestiture of Amoun on July 26, 2021 and (ii) the unfavorable impact of foreign currencies of $12 million, primarily in Europe. Revenues associated with Amoun were $68&#160;million for the three months ended March 31, 2021. These decreases were partially offset by: (i) an increase in net realized pricing of $11 million, primarily in Canada and (ii) an increase in volumes of $8 million, primarily in Europe. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The International segment profit for the three months ended March 31, 2022 and 2021 was $91 million and $109&#160;million, respectively, a decrease of $18 million, or 17%. The decrease was primarily attributable to: (i) our divestiture of Amoun on July 26, 2021, (ii) higher manufacturing variances and (iii) the unfavorable impact of foreign currencies.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Solta Medical Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Solta Medical Segment Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Solta Medical segment includes the Thermage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">product line, which accounted for approximately 78% of the Solta segment revenues for the three months ended March 31, 2022. No other single product group represents 10% or more of the Solta segment revenues. The Solta Medical segment revenue for the three months ended March 31, 2022 and 2021 was $72&#160;million and $72&#160;million, respectively, as the increase in net realized pricing of $5&#160;million was partially offset by a decrease in volume of $5&#160;million, primarily driven by the impact of the COVID-19 pandemic in China.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Solta Medical Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Solta Medical segment profit for the three months ended March 31, 2022 and 2021 was $35 million and $41&#160;million, respectively, a decrease of $6 million, or 15%. The decrease was primarily driven by: (i) an increase in SG&amp;A expenses and (ii) an increase in R&amp;D.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Diversified Products Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diversified Products Segment Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Diversified Products segment revenue for the three months ended March 31, 2022 and 2021 was $249 million and $296 million, respectively, a decrease of $47 million, or 16%. The decrease was primarily driven by: (i) a decrease in volume of $57 million, primarily driven by our Neurology and Other business, partially offset by an increase in net realized pricing of $10 million, primarily in our Neurology and Other business, partially offset by our Ortho Dermatologics business. The decrease in volume in our Neurology and Other business was primarily due to lower demand of Pepcid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Ativan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Mysoline</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Wellbutrin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diversified Products Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Diversified Products segment profit for the three months ended March 31, 2022 and 2021 was $158 million and $200&#160;million, respectively, a decrease of $42 million, or 21%. The decrease was primarily driven by: (i) a decrease in contribution primarily attributable to the net decrease in revenues, as previously discussed, and (ii) an increase in advertising and promotion expenses.</span></div><div id="i801c461cbd33492a893c84373a8e7cbc_190"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.830%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(607)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash provided by operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(923)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash (used in) provided by operating activities before changes in operating assets and liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(382)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(506)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(243)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate on cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents, restricted cash and cash held for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,460&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,947&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">513&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $63 million for the three months ended March 31, 2022, as compared to Net cash provided by operating activities of $443 million for the three months ended March 31, 2021, a decrease of $506 million. The decrease was attributable to: (i) the decrease in Cash (used in) provided by operating activities before changes in operating assets and liabilities and (ii) Changes in operating assets and liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating activities before changes in operating assets and liabilities was $79 million for the three months ended March 31, 2022, as compared to Cash provided by operating activities before changes in operating assets and liabilities of $303 million for the three months ended March 31, 2021, respectively, a decrease in cash of $382 million.  The decrease is primarily attributable to payments of accrued legal settlements related to the Glumetza Antitrust Litigation and a RICO class action matter during 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in operating assets and liabilities resulted in a net increase in cash of $16 million for the three months ended March 31, 2022, as compared to a net increase of $140 million for the three months ended March 31, 2021, respectively, representing a net decrease in cash of $124 million. During the three months ended March 31, 2022, Changes in operating assets and liabilities was positively impacted by: (i) the collection of trade receivables of $197 million and (ii) an increase in accrued interest due to timing of payments of $44&#160;million, partially offset by: (i) the timing of other payments in the ordinary course of business of $152&#160;million and (ii) an increase in inventories of $73 million. During the three months ended March 31, 2021, Changes in operating assets and liabilities was positively impacted by: (i) the timing of other payments in the ordinary course of business of $84&#160;million, (ii) the collection of trade receivables of $60 million and (iii) an increase in accrued interest due to timing of payments of $31&#160;million and was partially offset by an increase in inventories of $35 million.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $56 million for the three months ended March 31, 2022 and was primarily driven by Purchases of property, plant and equipment of $46 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $56 million for the three months ended March 31, 2021 and was driven by Purchases of property, plant and equipment of $66 million, partially offset by Interest settlements from cross-currency swaps of $11 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $468 million for the three months ended March 31, 2022 and was primarily driven by the issuance of long-term debt, net of discounts, of $986 million of February 2027 Secured Notes, partially offset by: (i) the repayment of long-term debt of $485 million related to: (i) the repayment of the outstanding balance under its 2023 Revolving Credit Facility and (ii) the repayment of long-term debt of $200 million of its June 2025 Term Loan B Facility.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities was $243 million for the three months ended March 31, 2021 and was primarily driven by the prepayment of $200 million of 7.00% Senior Secured Notes due 2024 using cash on hand and cash generated from operations during 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, &#8220;FINANCING ARRANGEMENTS&#8221; to our unaudited interim Consolidated Financial Statements for additional information regarding the financing activities described above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Debt</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Sources of Liquidity</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of liquidity are our cash and cash equivalents, cash collected from customers, funds as available from our revolving credit facility, issuances of long-term debt and issuances of equity and equity-linked securities. We believe these sources will be sufficient to meet our current liquidity needs for at least the twelve months following the issuance of this Form 10-Q.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously discussed, in January 2022, we had substantially completed the internal objectives to facilitate the IPOs and related separation of the B+L and Solta Medical businesses. The registration statement related to the B+L IPO was declared effective on May 5, 2022, and Bausch + Lomb&#8217;s common stock began trading on the New York Stock Exchange and the Toronto Stock Exchange, in each case under the ticker symbol &#8220;BLCO&#8221; on May 6, 2022. Prior to the effectiveness of the registration statement, Bausch + Lomb was an indirect wholly-owned subsidiary of the Company. On May 10, 2022, the Selling Shareholder sold 35,000,000 common shares of Bausch + Lomb at an offering price of $18.00 per share, pursuant to the Bausch + Lomb prospectus. The net proceeds from the B+L IPO after deducting underwriting commissions and estimated offering expenses were approximately $560 million as of May 10, 2022. In addition, the Selling Shareholder granted the underwriters an option for a period of 30 days from the date of the B+L IPO to purchase up to an additional 5,250,000 common shares to cover over-allotments at the B+L IPO offering price less underwriting commissions. As of May 10, 2022, the underwriters have not exercised any portion of this option. Upon the closing of the B+L IPO (but before exercise of the over-allotment option), we hold 315,000,000 shares of Bausch + Lomb common stock, which represents approximately 90% of Bausch + Lomb&#8217;s common shares.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the B+L IPO, we expect to complete the separation of Bausch + Lomb after the expiry of customary lockups related to the B+L IPO and achievement of targeted debt leverage ratios, subject to the receipt of applicable shareholder and other necessary approvals and market conditions. We continue to monitor market conditions and aim to launch the Solta IPO when financial market conditions are favorable (subject to receipt of regulatory, stock exchange and other approvals and other factors). Until such time, we continue to manage the Solta business along with our diverse portfolio of gastroenterology, hepatology, dermatology, neurology and other therapeutics, with our continued commitment to bring out additional value for our shareholders. Nothing in this Form 10-Q shall constitute an offer to sell or the solicitation of an offer to buy any securities of the Bausch + Lomb or Solta entities. However, there can be no assurance as to when we will complete either the B+L Separation or the Solta IPO, if at all.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly evaluates market conditions, its liquidity profile, and various financing alternatives for opportunities to enhance its capital structure. If opportunities are favorable, the Company may refinance or repurchase existing debt or issue equity or equity-linked securities.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-term Debt</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt, net of unamortized premiums, discounts and issuance costs was $23,168 million and $22,654 million as of March&#160;31, 2022 and December&#160;31, 2021, respectively.  Aggregate contractual principal amounts due under our debt obligations were $23,385 million and $22,870 million as of March&#160;31, 2022 and December&#160;31, 2021, respectively, an increase of $515 million. The increase is attributable to the debt issuance previously discussed under &#8220;Cash Flows - Financing Activities&#8221; during the three months ended March 31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Secured Credit Facilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2018, the Company and certain of its subsidiaries as guarantors entered into the &#8220;Senior Secured Credit Facilities&#8221; under the Company&#8217;s Fourth Amended and Restated Credit and Guaranty Agreement, as amended by the First Incremental Amendment to the Restated Credit Agreement, dated as of November 27, 2018 (the &#8220;2018 Restated Credit Agreement&#8221;) with a syndicate of financial institutions and investors as lenders. The 2018 Restated Credit Agreement provided for a revolving credit facility of $1,225 million (the &#8220;2023 Revolving Credit Facility&#8221;) and term loan facilities of original principal amounts of $4,565 million and $1,500 million, maturing in June 2025 (the &#8220;June 2025 Term Loan B Facility&#8221;) and November 2025 (the &#8220;November 2025 Term Loan B Facility&#8221;), respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Financing Transactions </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2022 in connection with the B+L IPO, the Company completed a series of transactions in which among other things: (i) Bausch + Lomb entered into a new credit facility, (ii) the Company repaid certain amounts outstanding under its existing term B loans, (iii) the Company refinanced the remaining amounts outstanding under its credit facilities and (iv) the Company discharged the April 2025 Unsecured Notes Indenture with, among other sources, the net proceeds from the February 2027 Secured Notes. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Description of Senior Secured Credit Facilities as of May 10, 2022</span></div><div style="margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline">Bausch + Lomb Credit Facilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2022, Bausch + Lomb entered into a credit agreement (the &#8220;B+L Credit Agreement&#8221;, and the credit facilities thereunder, the &#8220;B+L Credit Facilities&#8221;) providing for term loans of approximately $2,500 million with a five-year term to maturity (the &#8220;B+L Term Facility&#8221;) and a five year revolving credit facility of approximately $500 million (the &#8220;B+L Revolving Credit Facility&#8221; and such financing, the &#8220;B+L Debt Financing&#8221;). The B+L Credit Facilities are secured by substantially all of the assets of Bausch + Lomb and its material, wholly-owned Canadian, U.S., Dutch and Irish subsidiaries, subject to certain exceptions. The term loans are denominated in U.S. dollars, and borrowings under the revolving credit facility will be made available in U.S. dollars, euros, pounds sterling and Canadian dollars. </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the B+L Revolving Credit Facility in (i) U.S. dollars bear interest at a rate per annum equal to, at our option, either (a) a term SOFR-based rate or (b) a U.S. dollar base rate, (ii) Canadian dollars bear interest at a rate per annum equal to, at our option, either (a) CDOR or (b) a Canadian dollar prime rate, (iii) euros bear interest at a rate per annum equal to EURIBOR and (iv) pounds sterling bear interest at a rate per annum equal to SONIA (provided, however, that the term SOFR-based rate, CDOR, EURIBOR and SONIA shall be no less than 0.00% per annum at any time and the U.S. dollar base rate and the Canadian dollar prime rate shall be no less than 1.00% per annum at any time), in each case, plus an applicable margin. Term SOFR-based loans are subject to a credit spread adjustment of 0.10%.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margins for borrowings under the B+L Revolving Credit Facility are (i) between 0.75% to 1.75% with respect to U.S. dollar base rate or Canadian dollar prime rate borrowings and between 1.75% to 2.75% with respect to SOFR, EURIBOR, SONIA or CDOR borrowings based on the company&#8217;s total net leverage ratio and (ii) after (x) Bausch + Lomb&#8217;s senior unsecured non-credit-enhanced long term indebtedness for borrowed money receives an investment grade rating from at least two of S&amp;P, Moody&#8217;s and Fitch and (y) the term loan facility has been repaid in full in cash (the &#8220;IG Trigger&#8221;), between 0.015% to 0.475% with respect to U.S. dollar base rate or Canadian dollar prime rate borrowings and between 1.015% to 1.475% with respect to SOFR, EURIBOR, SONIA or CDOR borrowings based on the Company&#8217;s debt rating. In addition, we are required to pay commitment fees of 0.25% per annum in respect of the unutilized commitments under the revolving credit facility, payable quarterly in arrears until the IG Trigger and a facility fee between 0.110% to 0.275% of the total revolving commitments, whether used or unused, based on the Company&#8217;s debt rating and payable quarterly in arrears. We are also required to pay letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on SOFR borrowings under the revolving credit facility on a per annum basis, payable quarterly in arrears, as well as customary fronting fees for the issuance of letters of credit and agency fees. As of the date of this filing, May 10, 2022, the B+L Revolving Credit Facility remains undrawn. </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the term loan facility bear interest at a rate per annum equal to, at our option, either (i) a term SOFR-based rate, plus an applicable margin of 3.25% or (ii) a U.S. dollar base rate, plus an applicable margin of 2.25% provided, </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">however, that the term SOFR-based rate shall be no less than 0.50% per annum at any time and the U.S. dollar base rate shall not be lower than 1.50% per annum at any time). Term SOFR-based loans are subject to a credit spread adjustment of 0.10%.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions and customary baskets set forth in the B+L Credit Agreement, the Company is required to make mandatory prepayments of the loans under the B+L Term Facility under certain circumstances, including from: (i) 100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold), (ii) 100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the B+L Credit Agreement), (iii) 50% of Excess Cash Flow (as defined in the B+L Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv) 100% of net cash proceeds from asset sales (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold). These mandatory prepayments may be used to satisfy future amortization.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortization rate for the B+L Term Facility is 1.00% per annum and the first installment shall be payable on September 30, 2022. Bausch + Lomb may direct that prepayments be applied to such amortization payments in order of maturity. provided, however, that the term SOFR-based rate shall be no less than 0.50% per annum at any time and the U.S. dollar base rate shall not be lower than 1.50% per annum at any time). Term SOFR-based loans are subject to a credit spread adjustment of 0.10%.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Senior Secured Credit Facilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2022, the Company and certain of its subsidiaries as guarantors entered into that certain Second Amendment to the Fourth Amended and Restated Credit and Guaranty Agreement (the &#8220;Second Amendment&#8221;). The 2022 Restated Credit Agreement provides for a new term facility with an aggregate principal amount of $2,500 million (the &#8220;2027 Term Loan B Facility&#8221; and the loans thereunder the &#8220;2027 Term Loan&#8221;) maturing on February 1, 2027 and a new revolving credit facility of $975 million (the &#8220;2027 Revolving Credit Facility&#8221;) that will mature on the earlier of February 1, 2027 and the date that is 91 calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company and BHA in an aggregate principal amount in excess of $1,000 million. After giving effect to the 2022 Restated Credit Agreement, the 2023 Revolving Credit Facility, June 2025 Term Loan B Facility and November 2025 Term Loan B Facility were refinanced (such refinancing, the &#8220;Credit Agreement Refinancing&#8221;), along with certain of the Company&#8217;s existing senior notes, using proceeds of the B+L IPO, the Credit Agreement Refinancing and the B+L Debt Financing, and available cash on hand. As of the date of this filing, May 10, 2022, the Company has drawn $350 million on the 2027 Revolving Credit Facility.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Restated Credit Agreement provides that Bausch + Lomb initially be a &#8220;excluded&#8221; subsidiary subject to the terms of the 2022 Restated Credit Agreement covenants, but does not require Bausch + Lomb to guarantee the obligations under the 2022 Restated Credit Agreement. The 2022 Restated Credit Agreement permits the Company to designate Bausch + Lomb as an &#8220;unrestricted&#8221; subsidiary under the 2022 Restated Credit Agreement and no longer subject to the terms of the covenants thereunder upon achievement of a 7.6x pro forma &#8220;Remainco Total Leverage Ratio&#8221; Such designation could take place at any time after the B+L IPO. The Credit Agreement Refinancing contains provisions designed to facilitate the separation and distribution of Bausch + Lomb.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Secured Notes</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes are guaranteed by each of the Company&#8217;s subsidiaries that is a guarantor under the 2022 Restated Credit Agreement and existing Senior Unsecured Notes (together, the &#8220;Note Guarantors&#8221;). In connection with the closing of the B+L IPO, the discharge of the 6.125% Notes Indenture and the related release under the 2018 Restated Credit Agreement described above, the guarantees and related security provided by Bausch + Lomb and its subsidiaries in respect of the existing senior notes of the Company and BHA were released.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes and the guarantees related thereto are senior obligations and are secured, subject to permitted liens and certain other exceptions, by the same first priority liens that secure the Company&#8217;s obligations under the 2022 Restated Credit Agreement under the terms of the indentures governing the Senior Secured Notes. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes and the guarantees rank equally in right of repayment with all of the Company&#8217;s and Note Guarantors&#8217; respective existing and future unsubordinated indebtedness and senior to the Company&#8217;s and Note Guarantors&#8217; respective future subordinated indebtedness. The Senior Secured Notes and the guarantees related thereto are effectively </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">pari passu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the Company&#8217;s and the Note Guarantors&#8217; respective existing and future indebtedness secured by a first priority lien on the collateral securing the Senior Secured Notes and effectively senior to the Company&#8217;s and the Note Guarantors&#8217; respective existing and future indebtedness that is unsecured, including the existing Senior Unsecured Notes, or that is secured by junior liens, in each case to the extent of the value of the collateral. In addition, the Senior Secured Notes are structurally subordinated to: (i) all liabilities of any of the Company&#8217;s subsidiaries that do not guarantee the Senior Secured Notes and (ii) any of the Company&#8217;s debt that is secured by assets that are not collateral.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a change in control (as defined in the indentures governing the Senior Secured Notes), unless the Company has exercised its right to redeem all of the notes of a series, holders of the Senior Secured Notes may require the Company to repurchase such holder&#8217;s notes, in whole or in part, at a purchase price equal to 101% of the principal amount thereof plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate principal amount of our Senior Secured Notes as of March 31, 2022 and December&#160;31, 2021 was $4,850&#160;million and $3,850&#160;million, respectively, an increase of $1,000&#160;million representing the issuance of February 2027 Secured Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Unsecured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Unsecured Notes issued by the Company are the Company&#8217;s senior unsecured obligations and are jointly and severally guaranteed on a senior unsecured basis by each of its subsidiaries that is a guarantor under the Senior Secured Credit Facilities. The Senior Unsecured Notes issued by BHA are senior unsecured obligations of BHA and are jointly and severally guaranteed on a senior unsecured basis by the Company and each of its subsidiaries (other than BHA) that is a guarantor under the Senior Secured Credit Facilities. Future subsidiaries of the Company and BHA, if any, may be required to guarantee the Senior Unsecured Notes. In connection with the closing of the B+L IPO, the discharge of the 6.125% Notes Indenture and the related release under the 2018 Restated Credit Agreement described above, the guarantees and related security provided by Bausch + Lomb and its subsidiaries in respect of the existing senior notes of the Company and BHA were released. On a non-consolidated basis, the non-guarantor subsidiaries (which, for the avoidance of doubt, does not give effect to the release of the guarantees in connection with closing of the B+L IPO) had total assets of $2,227 million and total liabilities of $915 million as of March&#160;31, 2022, and revenues of $388 million and operating income of $74 million for the three months ended March 31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company experiences a change in control, the Company may be required to make an offer to repurchase each series of Senior Unsecured Notes, in whole or in part, at a purchase price equal to 101% of the aggregate principal amount of the Senior Unsecured Notes repurchased, plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 18, 2022, we issued conditional notices of redemption to redeem: (i) all April 2025 Unsecured Notes conditioned upon the completion of the Credit Agreement Refinancing and (ii) $370 million in aggregate principal amount of our outstanding 9.000% Senior Unsecured Notes due 2025 (the &#8220;December 2025 Unsecured Notes&#8221;) conditioned upon the receipt of aggregate proceeds from: (i) the B+L IPO, (ii) the B+L Debt Financing, (iii) the Credit Agreement Refinancing and (iv) the issuance of the February 2027 Secured Notes of at least $7,000 million. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the closing of the B+L IPO, the conditions of the Company&#8217;s previously announced redemption of its April 2025 Unsecured Notes were satisfied and the Company discharged the April 2025 Unsecured Notes Indenture using: (i) the proceeds from the issuance of the February 2027 Secured Notes, (ii) the proceeds from the B+L IPO, (iii) the net proceeds from the borrowings under the B+L Debt Financing and (iv) cash on hand. On May 10, 2022, the Company caused sufficient funds for the redemption in full of its April 2025 Unsecured Notes at a redemption price of 101.021% of the principal amount then outstanding to be irrevocably deposited with the Bank of New York Mellon, N.A., as trustee under the April 2025 Unsecured Notes Indenture, and the April 2025 Unsecured Notes Indenture was discharged. The April 2025 Unsecured Notes will be redeemed on May 16, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2022, the Company notified the Trustee and holders of its outstanding December 2025 Unsecured Notes that the conditions to its previously announced redemption would not be satisfied, and the conditional redemption was cancelled.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate principal amount of our Senior Unsecured Notes as of March 31, 2022 and December&#160;31, 2021 was $14,900&#160;million and $14,900&#160;million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Covenant Compliance</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any inability to comply with the covenants under the terms of our 2022 Restated Credit Agreement, Senior Secured Notes indentures or Senior Unsecured Notes indentures could lead to a default or an event of default for which we may need to seek relief from our lenders and noteholders in order to waive the associated default or event of default and avoid a potential acceleration of the related indebtedness or cross-default or cross-acceleration to other debt. There can be no assurance that we would be able to obtain such relief on commercially reasonable terms or otherwise and we may be required to incur significant additional costs. In addition, the lenders under our 2022 Restated Credit Agreement, holders of our Senior Secured Notes and holders of our Senior Unsecured Notes may impose additional operating and financial restrictions on us as a condition to granting any such waiver.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2017 through the date of this filing, the Company completed several actions which included repaying debt with proceeds from divestitures and cash flows from operations, as well as refinancing debt with near-term maturities. These </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">actions have reduced the Company&#8217;s debt balance and positively affected the Company&#8217;s ability to comply with its financial maintenance covenant. As of March&#160;31, 2022, the Company was in compliance with its financial maintenance covenant related to its outstanding debt. The Company, based on its current forecast, expects to remain in compliance with the financial maintenance covenant and meet its debt service obligations for at least the twelve months following the date of issuance of this Form 10-Q. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to take steps to improve its operating results to ensure continual compliance with its financial maintenance covenant and take other actions to reduce its debt levels to align with the Company&#8217;s long-term strategy. The Company may consider taking other actions, including divesting other businesses, refinancing debt and issuing equity or equity-linked securities including secondary offerings of the common shares of Bausch + Lomb and Solta Medical, as deemed appropriate, to provide additional coverage in complying with the financial maintenance covenant and meeting its debt service obligations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Focus on Capitalization of the Post-separation Entities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the B+L Separation and Solta IPO, we have emphasized that it is important that the post-separation entities be well-capitalized, with appropriate leverage and with access to additional capital, if and when needed, to provide each entity with the ability to independently allocate capital to areas that will strengthen their own competitive positions in their respective lines of business and position each entity for sustainable growth. Therefore, we see the appropriate capitalization and leverage of these businesses post-separation as a key to bringing out the maximum value across our portfolio of assets and it is a primary objective of our plan of separation. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Weighted Average Interest Rate</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average stated rate of interest of the Company&#8217;s outstanding debt as of March&#160;31, 2022 and December&#160;31, 2021 was 5.97% and 5.88%, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, &#8220;FINANCING ARRANGEMENTS&#8221; to our unaudited interim Consolidated Financial Statements for further details.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Ratings </span></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of May&#160;10, 2022, the credit ratings and outlook from Moody&#8217;s, Standard &amp; Poor&#8217;s and Fitch for certain outstanding obligations of the Company were as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.316%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rating Agency</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Corporate Rating</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Rating&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Senior Unsecured Rating</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Outlook</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Moody&#8217;s&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ba2/Ba3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Negative</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Standard &amp; Poor&#8217;s</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B+</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BB</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Negative</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fitch</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BB</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Negative</span></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a part of the financing transactions launched in January 2022 discussed above, Moody&#8217;s assigned a Ba3 rating to the $2,500 million of term B loans and the $975 million revolving credit facility as anticipated by the Credit Agreement Refinancing and to the newly issued February 2027 Secured Notes. The Ba3 rating is one notch lower than Moody&#8217;s rating of Ba2 for our existing senior secured debt. Following the completion of the Credit Agreement Refinancing on the date of this filing, May 10, 2022, Moody&#8217;s anticipates downgrading its ratings on our existing senior secured notes to Ba3 from Ba2, consistent with the Ba3 rating assigned to the $2,500 million of term B loans and the $975 million revolving credit facility as anticipated by the Credit Agreement Refinancing and to the newly issued February 2027 Secured Notes.</span></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any downgrade in our corporate credit ratings or other credit ratings may increase our cost of borrowing and may negatively impact our ability to raise additional debt capital.</span></div><div id="i801c461cbd33492a893c84373a8e7cbc_193"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OFF-BALANCE SHEET ARRANGEMENTS AND CONTRACTUAL OBLIGATIONS </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no off-balance sheet arrangements that have a material current effect or that are reasonably likely to have a material effect on our results of operations, financial condition, capital expenditures, liquidity, or capital resources. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A substantial portion of our cash requirements for the remainder of 2022 are for debt service. Our other future cash requirements relate to working capital, capital expenditures, business development transactions (contingent consideration), restructuring, integration and separation costs, benefit obligations and litigation settlements. In addition, we may use cash to enter into licensing arrangements and/or to make strategic acquisitions. We are considering further acquisition opportunities within our core therapeutic areas, some of which could be sizable.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our working capital requirements, as of March&#160;31, 2022, we expect our primary cash requirements during the remainder of 2022 to include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Debt repayments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Based on our debt portfolio as of May 10, 2022, we anticipate making mandatory amortization payments of approximately $75 million and interest payments of approximately $1,150&#160;million during the period April 1, 2022 through December 31, 2022.  In addition, as discussed above, on May 10, 2022 we deposited funds sufficient to redeem all outstanding amounts of our April 2025 Unsecured Notes using the proceeds from: (i) the issuance of the February 2027 Secured Notes, (ii) the B+L IPO, (iii) the B+L Debt Financing and (iv) cash on hand. We may also elect to make additional principal payments under certain circumstances. Further, in the ordinary course of business, we may borrow and repay additional amounts under our credit facilities using cash on hand, cash generated from operations and cash provided from the sale of common stock and additional debt financings in connection with the B+L Separation and the Solta IPO;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">IT Infrastructure Investment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We expect to make payments of approximately $55&#160;million for licensing, maintenance and capitalizable costs associated with our IT infrastructure improvement projects during the remainder of 2022;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Capital expenditures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We expect to make payments of approximately $230 million for property, plant and equipment during the remainder of 2022;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Contingent consideration payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We expect to make contingent consideration and other development/approval/sales-based milestone payments of approximately $30&#160;million during the remainder of 2022;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Restructuring and integration payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We expect to make payments of $5&#160;million during the remainder of 2022 for employee separation costs and lease termination obligations associated with restructuring and integration actions we have taken through March&#160;31, 2022;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Benefit obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We expect to make aggregate payments under our pension and postretirement obligations of $9&#160;million during the remainder of 2022; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Litigation Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;In the ordinary course of business, the Company is involved in litigation, claims, government inquiries, investigations, charges and proceedings.  As of March 31, 2022, the Company&#8217;s Consolidated Balance Sheet includes accrued current loss contingencies of $1,530 million related to matters which are both probable and reasonably estimable, of which $1,211 million is expected to be payable during the period April 1, 2022 through December 31, 2022; however, a reliable estimate of the period in which the remaining loss contingencies will be payable, if&#160;ever, cannot be made. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Securities Litigation for $1,210&#160;million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- The amounts which can be expected to be payable during the period April 1, 2022 through December 31, 2022 include inter alia the agreement to resolve the U.S. Securities litigation for $1,210 million.  Final court approval of this settlement was granted in January 2021 but is subject to an objector&#8217;s appeal of the Court&#8217;s final approval order. The settlement resolves and discharges all claims against the Company in the class action. As part of the settlement, the Company and the other settling defendants admitted no liability as to the claims against them and deny all allegations of wrongdoing. This settlement resolves the most significant of the Company&#8217;s remaining legacy legal matters and eliminates a material uncertainty regarding our Company. As of March 31, 2022, Restricted cash and other settlement deposits includes $1,210&#160;million of payments into an escrow fund under the terms of a settlement agreement regarding the U.S. Securities Litigation. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 18, &#8220;LEGAL PROCEEDINGS&#8221; to our unaudited interim Consolidated Financial Statements for further details on this and other matters. Our ability to successfully defend the Company against pending and future litigation may impact future cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Costs of B+L Separation and Solta IPO</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred, and will incur, costs associated with activities to complete the B+L Separation and the Solta IPO. These activities include the costs of: (i) separating the Bausch + Lomb and the Solta Medical businesses from the remainder of the Company and (ii) registering the Bausch + Lomb and the Solta Medical businesses as independent publicly traded entities. Separation and IPO costs are incremental costs directly related to the B+L Separation and Solta IPO and include, but are not limited to: (i) legal, audit and advisory fees, (ii) talent acquisition costs and (iii) costs associated with establishing new boards of directors and related board committees for the Bausch + Lomb and Solta Medical entities. The Company has also incurred, and will incur, Separation-related and IPO-related costs which are incremental costs indirectly related to the B+L Separation and Solta IPO. These costs include, but are not limited to: (i) IT infrastructure and software licensing costs, (ii) rebranding costs and (iii) costs associated with facility relocation and/or modification. The extent and timing of future charges for these costs cannot be reasonably estimated at this time and could be material.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Cost Savings Programs </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to evaluate opportunities to improve our operating results and may initiate additional cost savings programs to streamline our operations and eliminate&#160;redundant processes and expenses. These cost savings programs may include, but are not limited to: (i)&#160;reducing headcount, (ii)&#160;eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives. The expenses associated with the implementation of these cost savings programs could be material and may impact our cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Licensing Payments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company may enter into select licensing and collaborative agreements for the commercialization and/or development of unique products primarily in the U.S. and Canada. In connection with these agreements, the Company may pay an upfront fee to secure the agreement. See Note 4, &#8220;LICENSING AGREEMENTS AND DIVESTITURE&#8221; to our unaudited interim Consolidated Financial Statements. Payments associated with the upfront fee for these agreements cannot be reasonably estimated at this time and could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unrecognized Tax Benefits</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, the Company had unrecognized tax benefits totaling $876 million, of which, $21&#160;million is expected to be realized during the remainder of 2022, however a reliable estimate of the period in which the remaining uncertain tax positions will be payable, if&#160;ever, cannot be made. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no other material changes to the contractual obligations disclosed in Item 7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212; Off-Balance Sheet Arrangements and Contractual Obligations&#8221; included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC and the CSA on February&#160;23, 2022.</span></div><div id="i801c461cbd33492a893c84373a8e7cbc_196"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUTSTANDING SHARE DATA</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common shares trade on the New&#160;York Stock Exchange and the Toronto Stock Exchange under the symbol &#8220;BHC&#8221;. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At May 5, 2022, we had 361,479,708 issued and outstanding common shares. In addition, as of May 5, 2022, we had outstanding 11,178,289 stock options and 4,566,000 time-based restricted share units that each represent the right of a holder to receive one of the Company&#8217;s common shares, and 1,771,199 performance-based restricted share units that represent the right of a holder to receive a number of the Company&#8217;s common shares up to a specified maximum. A maximum of 2,648,908 common shares could be issued upon vesting of the performance-based restricted share units outstanding.</span></div><div id="i801c461cbd33492a893c84373a8e7cbc_199"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING POLICIES AND ESTIMATES</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical accounting policies and estimates are those policies and estimates that are most important and material to the preparation of our Consolidated Financial Statements, and which require management&#8217;s most subjective and complex judgment due to the need to select policies from among alternatives available, and to make estimates about matters that are inherently uncertain. Management has reassessed the critical accounting policies and estimates as disclosed in Item 7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212; Critical Accounting Policies and Estimates&#8221; included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC and the CSA on February&#160;23, 2022, and determined that there were no significant changes in our critical accounting policies and estimates during the three months ended March 31, 2022, except for: (i) estimates and assumptions regarding the nature, timing and extent that the COVID-19 pandemic had on the Company&#8217;s operations and cash flows as discussed in Note 2, &#8220;SIGNIFICANT ACCOUNTING POLICIES&#8221; to our unaudited interim Consolidated Financial Statements, (ii) the impact that the current year segment and reporting unit realignments had on the Company&#8217;s allocation of goodwill as discussed in Note 8, &#8220;INTANGIBLE ASSETS AND GOODWILL&#8221; to our unaudited interim Consolidated Financial Statements and (iii) the estimates associated with the fair value of Ortho Dermatologics reporting unit in testing goodwill for impairment as discussed in Note 8, &#8220;INTANGIBLE ASSETS AND GOODWILL&#8221; to our unaudited interim Consolidated Financial Statements.</span></div><div id="i801c461cbd33492a893c84373a8e7cbc_202"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEW ACCOUNTING STANDARDS </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><div id="i801c461cbd33492a893c84373a8e7cbc_205"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caution regarding forward-looking information and statements and &#8220;Safe-Harbor&#8221; statements under the U.S.&#160;Private Securities Litigation Reform Act of&#160;1995 and applicable Canadian securities laws:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent any statements made in this Form&#160;10-Q contain information that is not historical, these statements are forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended, and may be forward-looking information within the meaning defined under applicable Canadian securities laws (collectively, &#8220;forward-looking statements&#8221;).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements relate to, among other things: our business strategy, business plans and prospects and forecasts and changes thereto; product pipeline, prospective products and product approvals, expected launches of new products, product development and future performance and results of current and anticipated products; anticipated revenues for our products; expected research and development (&#8220;R&amp;D&#8221;) and marketing spend; our expected primary cash and working capital requirements for 2022 and beyond; the Company&#8217;s plans for continued improvement in operational efficiency and the anticipated impact of such plans; our liquidity and our ability to satisfy our debt maturities as they become due; our ability to reduce debt levels; our ability to comply with the financial and other covenants contained in our Fourth Amended and Restated Credit and Guaranty Agreement, as amended by the First Incremental Amendment to the Restated Credit Agreement, dated as of November 27, 2018 and the Second Amendment to the Restated Credit Agreement, dated as of May 10, 2022 (the &#8220;2022 Restated Credit Agreement&#8221;), and senior notes indentures;the ability of our subsidiary, Bausch + Lomb Corporation (&#8220;Bausch + Lomb&#8221;), to comply with the financial and other covenants contained in its Credit and Guaranty Agreement (the &#8220;B+L Credit Agreement&#8221;, and the credit facilities thereunder, the &#8220;B+L Credit Facilities&#8221;), dated as of May 10, 2022; the impact of our distribution, fulfillment and other third-party arrangements; proposed pricing actions; exposure to foreign currency exchange rate changes and interest rate changes; the outcome of contingencies, such as litigation, subpoenas, investigations, reviews, audits and regulatory proceedings; the anticipated impact of the adoption of new accounting standards; general market conditions; our expectations regarding our financial performance, including revenues, expenses, gross margins and income&#160;taxes; our impairment assessments, including the assumptions used therein and the results thereof; the anticipated impact of the evolving COVID-19 pandemic and related responses from governments and private sector participants on the Company, its supply chain, third-party suppliers, project development timelines, costs, revenues, margins, liquidity and financial condition, the anticipated timing, speed and magnitude of recovery from these COVID-19 pandemic related impacts and the Company&#8217;s planned actions and responses to this pandemic; the Company&#8217;s plan to separate its eye health business, including the structure and timing of completing such separation transaction; and the proposed initial public offering (&#8220;IPO&#8221;) of the Company&#8217;s Solta aesthetic medical device business, including the timing of such IPO.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements can generally be identified by the use of words such as &#8220;believe&#8221;, &#8220;anticipate&#8221;, &#8220;expect&#8221;, &#8220;intend&#8221;, &#8220;estimate&#8221;, &#8220;plan&#8221;, &#8220;continue&#8221;, &#8220;will&#8221;, &#8220;may&#8221;, &#8220;could&#8221;, &#8220;would&#8221;, &#8220;should&#8221;, &#8220;target&#8221;, &#8220;potential&#8221;, &#8220;opportunity&#8221;, &#8220;designed&#8221;, &#8220;create&#8221;, &#8220;predict&#8221;, &#8220;project&#8221;, &#8220;forecast&#8221;, &#8220;seek&#8221;, &#8220;strive&#8221;, &#8220;ongoing&#8221;, &#8220;decrease&#8221; or &#8220;increase&#8221; and variations or other similar expressions. In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements may not be appropriate for other purposes. Although we have previously indicated certain of these statements set out herein, all of the statements in this Form&#160;10-Q that contain forward-looking statements are qualified by these cautionary statements. These statements are based upon the current expectations and beliefs of management. Although we believe that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors or assumptions are applied in making such forward-looking statements, including, but not limited to, factors and assumptions regarding the items previously outlined, those factors, risks and uncertainties outlined below and the assumption that none of these factors, risks and uncertainties will cause actual results or events to differ materially from those described in such forward-looking statements. Actual results may differ materially from those expressed or implied in such statements. Important factors, risks and uncertainties that could cause actual results to differ materially from these expectations include, among other things, the&#160;following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, the fear of that pandemic, the availability and effectiveness of vaccines for COVID-19 (including with respect to current or future variants and subvariants), COVID-19 vaccine immunization rates, the emergence of variant and subvariant strains of COVID-19, the resurgence of the COVID-19 virus and variant and subvariant strains thereof (including, but not limited to, the recent resurgence of COVID-19 cases in China) and any resulting reinstitution of lockdowns and other restrictions, the evolving reaction of governments, private sector participants and the public to that pandemic, and the potential effects and economic impact of the pandemic and the reaction to it, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a significant adverse impact on the Company, including, but not limited to, its supply chain, third-party suppliers, project development timelines, employee base, </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liquidity, stock price, financial condition and costs (which may increase) and revenue and margins (both of which may decrease);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the challenges the Company faces as a result of the closing of the IPO of Bausch + Lomb (the &#8220;B+L IPO&#8221;), including the transitional services being provided by and to Bausch + Lomb, any potential, actual or perceived conflict of interest of some of our directors and officers because of their equity ownership in Bausch + Lomb and/or because they also serve as directors or officers of Bausch + Lomb and our ability to timely consolidate the financial results of the Bausch + Lomb business; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">with respect to the proposed separation of Bausch + Lomb, the risks and uncertainties include, but are not limited to, the expected benefits and costs of the separation transaction, the expected timing of completion of the separation transaction and its terms (including the Company&#8217;s expectation that the separation transaction will be completed following the expiry of customary lock-ups related to the B+L IPO and achievement of targeted debt leverage ratios, subject to receipt of applicable shareholder and other necessary approvals), the Company&#8217;s ability to complete the separation transaction considering the various conditions to the completion of the separation transaction (some of which are outside the Company&#8217;s control, including conditions related to regulatory matters and a possible shareholder vote, if applicable), that market or other conditions are no longer favorable to completing the transaction, that any regulatory or other approval (if required) is not obtained on the terms or timelines anticipated or at all, business disruption during the pendency of, or following, the separation transaction, diversion of management time on separation transaction-related issues, retention of existing management team members, the reaction of customers and other parties to the separation transaction, the qualification of the separation transaction as a tax-free transaction for Canadian and/or U.S. federal income tax purposes (including whether or not an advance ruling from the Canada Revenue Agency and/or the Internal Revenue Service will be sought or obtained), the ability of the Company and the separated entity to satisfy the conditions required to maintain the tax-free status of the separation transaction (some of which are beyond their control), other potential tax or other liabilities that may arise as a result of the separation transaction, the potential dissynergy costs resulting from the separation transaction, the impact of the separation transaction on relationships with customers, suppliers, employees and other business counterparties, general economic conditions, conditions in the markets the Company is engaged in, behavior of customers, suppliers and competitors, technological developments, as well as legal and regulatory rules affecting the Company&#8217;s business.  In particular, the Company can offer no assurance that any separation will occur at all, or that any such transaction will occur on the timelines anticipated by the Company; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">with respect to the proposed IPO of the Company&#8217;s Solta aesthetic medical device business, the risks and uncertainties include, but are not limited to, risks relating to the expected timing of completion of such transaction (including the Company&#8217;s expectation that it will launch such IPO when financial market conditions are favorable, subject to receipt of regulatory, stock exchange and other approvals and other factors) and the Company&#8217;s ability to complete such transaction, that market or other conditions are no longer favorable to completing the transaction on a timely basis or at all, the receipt of (or failure to receive) any shareholder, stock exchange, regulatory and other approvals required in connection with the transaction and the timing of receipt of such approvals, business disruption during the pendency of, or following, such transaction, diversion of management time on transaction-related issues, retention of Solta aesthetic medical device management team members, the reaction of customers and other parties to such transaction, the impact of such transaction on relationships with customers, suppliers, employees and other business counterparties, and other events that could adversely impact the completion of such transaction, including industry or economic conditions outside of Bausch Health&#8217;s control. In particular, the Company can offer no assurance that any such transaction will occur at all, or that any such transaction will occur on the timelines, structure or terms anticipated by the Company;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ongoing litigation and potential additional litigation, claims, challenges and/or regulatory investigations challenging or otherwise relating to the B+L IPO and the proposed separation of Bausch + Lomb and the costs, expenses, use of resources, diversion of management time and efforts, liability and damages that may result therefrom;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expense, timing and outcome of legal and governmental proceedings, investigations and information requests relating to, among other matters, our past distribution, marketing, pricing, disclosure and accounting practices (including with respect to our former relationship with Philidor Rx Services, LLC (&#8220;Philidor&#8221;)), including a number of pending non-class securities litigations (including certain pending opt-out actions in the U.S. related to the previously settled securities class action (which remains subject to an objector&#8217;s petition for rehearing of its appeal of the Court&#8217;s final approval order) and certain opt-out actions in Canada relating to the recently settled class action in Canada), certain pending lawsuits and other claims, investigations or proceedings that may be initiated or that may be asserted;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential additional litigation and regulatory investigations (and any costs, expenses, use of resources, diversion of management time and efforts, liability and damages that may result therefrom), negative publicity and reputational </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">harm on our Company, products and business that may result from the past and ongoing public scrutiny of our past distribution, marketing, pricing, disclosure and accounting practices and from our former relationship with Philidor;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the past and ongoing scrutiny of our legacy business practices, including with respect to pricing, and any pricing controls or price adjustments that may be sought or imposed on our products as a result thereof; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing decisions that we have implemented, or may in the future elect to implement, such as the Patient Access and Pricing Committee&#8217;s historic practice of limiting the average annual price increase for our branded prescription pharmaceutical products to single digits, or any future pricing actions we may take in 2022 or beyond following review by our Patient Access and Pricing Committee (which is responsible for the pricing of our drugs);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">legislative or policy efforts, including those that may be introduced and passed by the U.S. Congress, designed to reduce patient out-of-pocket costs for medicines, which could result in new mandatory rebates and discounts or other pricing restrictions, controls or regulations (including mandatory price reductions);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ongoing oversight and review of our products and facilities by regulatory and governmental agencies, including periodic audits by the U.S.&#160;Food and Drug Administration (the &#8220;FDA&#8221;) and equivalent agencies outside of the U.S. and the results thereof;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actions by the FDA or other regulatory authorities with respect to our products or facilities;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with the legal and regulatory requirements of our marketed products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our substantial debt (and potential additional future indebtedness) and current and future debt service obligations, our ability to reduce our outstanding debt levels and the resulting impact on our financial condition, cash flows and results of operations;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to comply with the financial and other covenants contained in our senior notes indentures, 2027 Revolving Credit Facility (as defined below), the 2022 Restated Credit Agreement, the B+L Credit Agreement and other current or future credit and/or debt agreements and the limitations including the ability of Bausch + Lomb to comply with its covenants and obligations under the B+L Credit Agreement, restrictions and prohibitions such covenants impose or may impose on the way we conduct our business, including prohibitions on incurring additional debt if certain financial covenants are not met, limitations on the amount of additional obligations we are able to incur pursuant to other covenants, our ability to draw under our 2027 Revolving Credit Facility, Bausch + Lomb&#8217;s ability to draw down under the revolving credit facility under the B+L Credit Agreement and restrictions on our ability to make certain investments and other restricted payments;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any default under the terms of our senior notes indentures or the 2022 Restated Credit Agreement (and other current or future credit and/or debt agreements) and our ability, if any, to cure or obtain waivers of such default;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any downgrade by rating agencies in our credit ratings, which may impact, among other things, our ability to raise debt and the cost of capital for additional debt issuances;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any reductions in, or changes in the assumptions used in, our forecasts for fiscal year 2022 or beyond, including as a result of the impacts of the COVID-19 pandemic on our business and operations, which could lead to, among other things: (i) a failure to meet the financial and/or other covenants contained in our 2018 Restated Credit Agreement, the 2022 Restated Credit Agreement, senior notes indentures and/or the B+L Credit Agreement (and other current or future credit and/or debt agreements) and/or (ii) impairment in the goodwill associated with certain of our reporting units or impairment charges related to certain of our products or other intangible assets, which impairments could be material;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the assumptions used in connection with our impairment analyses or assessments, which would lead to a change in such impairment analyses and assessments and which could result in an impairment in the goodwill associated with any of our reporting units or impairment charges related to certain of our products or other intangible assets;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the uncertainties associated with the acquisition and launch of new products, assets and businesses, including, but not limited to, our ability to provide the time, resources, expertise and funds required for the commercial launch of new products, the acceptance and demand for new products, and the impact of competitive products and&#160;pricing, which could lead to material impairment charges;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability or inability to extend the profitable life of our products, including through line extensions and other life-cycle programs;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to retain, motivate and recruit directors, executives and other key&#160;employees;</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to implement effective succession planning for our executives and key employees;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">factors impacting our ability to stabilize and reposition our Ortho Dermatologics business to generate additional value, including the success of recently launched products and the approval of pipeline products (and the timing of such approvals);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">factors impacting our ability to achieve anticipated revenues for our products, including changes in anticipated marketing spend on such products and launch of competing products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">factors impacting our ability to achieve anticipated market acceptance for our products, including acceptance of the pricing, effectiveness of promotional efforts, reputation of our products and launch of competing products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the challenges and difficulties associated with managing a large complex business, which has, in the past, grown rapidly;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to compete against companies that are larger and have greater financial, technical and human resources than we do, as well as other competitive factors, such as technological advances achieved, patents obtained and new products introduced by our competitors;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively operate and grow our businesses in light of the challenges that the Company has faced and market conditions, including with respect to its substantial debt, pending investigations and legal proceedings, scrutiny of our past pricing and other practices, limitations on the way we conduct business imposed by the covenants contained in our 2018 Restated Credit Agreement, our 2022 Restated Credit Agreement, the B+L Credit Agreement, our senior notes indentures and the agreements governing our other indebtedness, and the impacts of the COVID-19 pandemic;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our products are reimbursed by government authorities, pharmacy benefit managers (&#8220;PBMs&#8221;) and other third-party payors; the impact our distribution, pricing and other practices may have on the decisions of such government authorities, PBMs and other third-party payors to reimburse our products; the impact of obtaining or maintaining such reimbursement on the price and sales of our products; and the launch and implementation of any new pharma-care or dental-care program or related spending by the Canadian federal government;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inclusion of our products on formularies or our ability to achieve favorable formulary status, as well as the impact on the price and sales of our products in connection therewith;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the consolidation of wholesalers, retail drug chains and other customer groups and the impact of such industry consolidation on our business;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain strong relationships with physicians and other healthcare professionals;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our eligibility for benefits under tax treaties and the continued availability of low effective tax rates for the business profits of certain of our subsidiaries;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the implementation of the Organisation for Economic Co-operation and Development inclusive framework on Base Erosion and Profit Shifting, including the global minimum corporate tax rate, by the countries in which we operate; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome of any audits by taxation authorities, which outcomes may differ from the estimates and assumptions that we may use in determining our consolidated tax provisions and accruals;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the actions of our third-party partners or service providers of research, development, manufacturing, marketing, distribution or other services, including their compliance with applicable laws and contracts, which actions may be beyond our control or influence, and the impact of such actions on our Company;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risks associated with the international scope of our operations, including our presence in emerging markets and the challenges we face when entering and operating in new and different geographic markets (including the challenges created by new and different regulatory regimes in such countries and the need to comply with applicable anti-bribery and economic sanctions laws and regulations);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse global economic conditions and credit markets and foreign currency exchange uncertainty and volatility in certain of the countries in which we do&#160;business;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the trade conflict between the U.S. and China;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the ongoing conflict between Russia and Ukraine and the export controls, sanctions and other restrictive actions that have been or may be imposed by the U.S., Canada and other countries against governmental and other entities in Russia, Belarus and parts of Ukraine;</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the United States-Mexico-Canada Agreement (&#8220;USMCA&#8221;) and any potential changes to other trade agreements;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain, maintain and license sufficient intellectual property rights over our products and enforce and defend against challenges to such intellectual property (such as in connection with the filing by Norwich Pharmaceuticals Inc. (&#8220;Norwich&#8221;) of its Abbreviated New Drug Application (&#8220;ANDA&#8221;) for Xifaxan&#174; (rifaximin) 550 mg tablets and the Company&#8217;s related lawsuit filed against Norwich in connection therewith);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the introduction of generic, biosimilar or other competitors of our branded products and other products, including the introduction of products that compete against our products that do not have patent or data exclusivity rights;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify, finance, acquire, close and integrate acquisition targets successfully and on a timely basis and the difficulties, challenges, time and resources associated with the integration of acquired companies, businesses and products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any divestitures of our assets or businesses and our ability to successfully complete any such divestitures on commercially reasonable terms and on a timely basis, or at all, and the impact of any such divestitures on our Company, including the reduction in the size or scope of our business or market share, loss of revenue, any loss on sale, including any resultant impairments of goodwill or other assets, or any adverse tax consequences suffered as a result of any such divestitures;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expense, timing and outcome of pending or future legal and governmental proceedings, arbitrations, investigations, subpoenas, tax and other regulatory audits, examinations, reviews and regulatory proceedings against us or relating to us and settlements thereof;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to negotiate the terms of or obtain court approval for the settlement of certain legal and regulatory proceedings;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain components, raw materials or finished products supplied by third&#160;parties (some of which may be single-sourced) and other manufacturing and related supply difficulties, interruptions and delays;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the disruption of delivery of our products and the routine flow of manufactured goods;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic factors over which the Company has no control, including changes in inflation, interest rates, foreign currency rates, and the potential effect of such factors on revenues, expenses and resulting margins;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interest rate risks associated with our floating rate debt borrowings;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively distribute our products and the effectiveness and success of our distribution arrangements;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively promote our own products and those of our co-promotion partners;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our fulfillment arrangements with Walgreen Co., including market acceptance of, or market reaction to, such arrangements (including by customers, doctors, patients, PBMs, third-party payors and governmental agencies), and the continued compliance of such arrangements with applicable laws;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to secure and maintain third-party research, development, manufacturing, licensing, marketing or distribution arrangements;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that our products could cause, or be alleged to cause, personal injury and adverse effects, leading to potential lawsuits, product liability claims and damages and/or recalls or withdrawals of products from the&#160;market;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the mandatory or voluntary recall or withdrawal of our products from the market and the costs associated therewith;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of, and our ability to obtain and maintain, adequate insurance coverage and/or our ability to cover or insure against the total amount of the claims and liabilities we face, whether through third-party insurance or self-insurance;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our indemnity agreements, which may result in an obligation to indemnify or reimburse the relevant counterparty, which amounts may be material;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the difficulty in predicting the expense, timing and outcome within our legal and regulatory environment, including with respect to approvals by the FDA, Health Canada, European Medicines Agency (&#8220;EMA&#8221;) and similar agencies in other countries, legal and regulatory proceedings and settlements thereof, the protection afforded by our patents and other intellectual and proprietary property, successful generic challenges to our products and infringement or alleged infringement of the intellectual property of&#160;others;</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of continuing safety and efficacy studies by industry and government agencies;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of preclinical and clinical trials for our drug development pipeline or delays in clinical trials that adversely impact the timely commercialization of our pipeline products, as well as other factors impacting the commercial success of our products, which could lead to material impairment charges;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">uncertainties around the successful improvement and modification of our existing products and development of new products, which may require significant expenditures and efforts;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of management reviews of our research and development portfolio (including following the receipt of clinical results or feedback from the FDA or other regulatory authorities), which could result in terminations of specific projects which, in turn, could lead to material impairment charges;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the seasonality of sales of certain of our products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">declines in the pricing and sales volume of certain of our products that are distributed or marketed by third parties, over which we have no or limited control;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance by the Company or our third-party partners and service providers (over whom we may have limited influence), or the failure of our Company or these third parties to comply, with health care &#8220;fraud and abuse&#8221; laws and other extensive regulation of our marketing, promotional and business practices (including with respect to pricing), worldwide anti-bribery laws (including the U.S. Foreign Corrupt Practices Act and the Canadian Corruption of Foreign Public Officials Act), worldwide economic sanctions and/or export laws, worldwide environmental laws and regulation and privacy and security regulations;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impacts of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 and potential amendment thereof and other legislative and regulatory health care reforms in the countries in which we operate, including with respect to recent government inquiries on pricing;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of any changes in or reforms to the legislation, laws, rules, regulation and guidance that apply to the Company and its businesses and products or the enactment of any new or proposed legislation, laws, rules, regulations or guidance that will impact or apply to the Company or its businesses or products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of changes in federal laws and policy that may be undertaken under the Biden administration;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">illegal distribution or sale of counterfeit versions of our products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruptions, breakdowns or breaches in our information technology systems; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">risks in Item 1A. &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed on February 23, 2022, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">risks under Item 1A. &#8220;Risk Factors&#8221; of Part II of this Form 10-Q </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and risks detailed from time to time in our other filings with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) and the Canadian Securities Administrators (the&#160;&#8220;CSA&#8221;), as well as our ability to anticipate and manage the risks associated with the&#160;foregoing.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed on February 23, 2022, under Item&#160;1A. &#8220;Risk Factors&#8221;, under Item 1A. &#8220;Risk Factors&#8221; of Part II of this Form 10-Q and in the Company&#8217;s other filings with the SEC and the CSA. When relying on our forward-looking statements to make decisions with respect to the Company, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. These forward-looking statements speak only as of the date made. We undertake no obligation to update or revise any of these forward-looking statements to reflect events or circumstances after the date of this Form&#160;10-Q or&#160;to reflect actual outcomes, except as required by law. We caution that, as it is not possible to predict or identify all relevant factors that may impact forward-looking statements, the foregoing list of important factors that may affect future results is not exhaustive and should not be considered a complete statement of all potential risks and uncertainties.</span></div><div id="i801c461cbd33492a893c84373a8e7cbc_208"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.&#160;Quantitative and&#160;Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as indicated below under &#8220;&#8212; Interest Rate Risk&#8221; and &#8220;&#8212; Inflation Risk&#8221;, there have been no material changes to our exposures to market risks as disclosed in Item 7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212; Quantitative and Qualitative Disclosures About Market Risks&#8221; included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC and the CSA on February&#160;23, 2022.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, we had $19,762&#160;million and $3,623&#160;million principal amount of issued fixed rate debt and variable rate debt, respectively. The estimated fair value of our issued fixed rate debt as of March&#160;31, 2022 was $18,373&#160;million. If interest rates were to increase by 100 basis-points, the fair value of our issued fixed rate debt would decrease by approximately $634&#160;million. If interest rates were to decrease by 100 basis-points, the fair value of our issued fixed rate debt would increase by approximately $599&#160;million. We are subject to interest rate risk on our variable rate debt as changes in interest rates could adversely affect earnings and cash flows. A 100 basis-points increase in interest rates would have an annualized pre-tax effect of approximately $36&#160;million in our Consolidated Statements of Operations and Cash Flows, based on current outstanding borrowings and effective interest rates on our variable rate debt. While our variable-rate debt may impact earnings and cash flows as interest rates change, it is not subject to changes in fair value. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inflation Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to price control restrictions on our pharmaceutical products in a number of countries in which we operate. As a result, our ability to raise prices in a timely fashion in anticipation of inflation may be limited in some markets.</span></div><div id="i801c461cbd33492a893c84373a8e7cbc_211"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;Controls and&#160;Procedures</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer (&#8220;CEO&#8221;) and Chief Financial Officer (&#8220;CFO&#8221;), has evaluated the effectiveness of our disclosure controls and procedures as of March&#160;31, 2022. Based on this evaluation, our CEO and CFO concluded that our disclosure controls and procedures were effective as of March&#160;31, 2022. </span></div><div id="i801c461cbd33492a893c84373a8e7cbc_214"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in the Company&#8217;s internal controls over financial reporting that occurred during the three months ended March 31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><div id="i801c461cbd33492a893c84373a8e7cbc_217"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i801c461cbd33492a893c84373a8e7cbc_220"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;Legal Proceedings</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information concerning legal proceedings, reference is made to Note 18, &#8220;LEGAL PROCEEDINGS&#8221; of notes to&#160;the unaudited interim Consolidated Financial Statements included elsewhere in this Form&#160;10-Q.</span></div><div id="i801c461cbd33492a893c84373a8e7cbc_223"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A.&#160;Risk Factors</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:109%">Except as set forth below, there have been no material changes to the risk factors as disclosed in Item 1A. &#8220;Risk Factors&#8221; included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC and the CSA on February&#160;23, 2022. The following risk factor sets forth are additional risks affecting the Company from those originally presented in the Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">As a result of the current conflict between Russia and Ukraine, including the recent invasion of Ukraine by Russia, the current and any future responses by the global community to such conflict and any counter responses by the Russian government or other entities or individuals, and the potential expansion of the conflict to other countries, we have begun to experience and may continue to experience an adverse impact on our business and operations in this region, as well as on our business and operations generally, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 24, 2022, Russia launched a military invasion of Ukraine. The ongoing military conflict between Ukraine and Russia has provoked strong reactions from the United States, the UK, the EU, Canada and various other countries around the world, including the imposition of export controls and broad financial and economic sanctions against Russia, Belarus and specific areas of Ukraine. Additional sanctions or other measures may be imposed by the global community, and counteractive measures may be taken by the Russian government, other entities in Russia or governments or other entities outside of Russia.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the full year ended December 31, 2021 and the quarter ended March 31, 2022, we derived approximately 2% and 1% of our revenues from sales of our products in Russia, respectively, less than 1% of our revenues from sales of our products in Ukraine, and less than 1% of our revenues from sales of our products in Belarus. As of the date of this filing, the conflict between Ukraine and Russia has begun to impact our business in the region, and we are continuously monitoring developments to assess any potential future impact that may arise. Given the nature of our products, we do not believe that the current sanctions and other measures imposed by the United States and other countries preclude us from conducting business in the region. However, we anticipate that the ongoing conflict in this region and the sanctions and other actions by the global community in response may continue to hinder our ability to conduct business with customers and vendors in this region. For example, we have experienced and may in the future experience disruption and delays in the supply of our products to our customers in Russia, Belarus and Ukraine. We have experienced and may in the future also experience decreased demand for our products in these countries as a result of the conflict and invasion. In addition, we may experience difficulties in collecting receivables from such customers. If we are hampered in our ability to conduct business with new or existing customers and vendors in this region, our business, and operations, including our revenues, profitability and cash flows, could be adversely impacted. Furthermore, if the sanctions and other retaliatory measures imposed by the global community change, we may be required to cease or suspend our operations in the region or, should the conflict worsen, we may voluntarily elect to do so. We cannot provide assurance that current sanctions or potential future changes in these sanctions or other measures will not have a material impact on our operations in Russia, Belarus and Ukraine. The disruption to, or suspension of, our business and operations in Russia, Belarus and Ukraine would adversely impact our business, financial condition, cash flows and results of operations in this region which may, in turn, materially adversely impact our overall business, financial condition, cash flows and results of operations, which impact could be material, and could cause the market value of our common shares to decline. Finally, we are also subject to risks if exchange controls were to be imposed that would limit the repatriation of profits from our operations in Russia. While we do not rely on profits or dividends from our Russian operations to fund our debt repayment or other business activities generally, as our operations from Russia primarily involve the sale of products purchased from our affiliates located outside of Russia, any exchange controls that would limit the purchase of or payment for products or goods from outside of Russia may have an adverse impact on our operations in Russia or the way we conduct business in Russia.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the precise effects of the ongoing military conflict and sanctions on the Russian and global economies remain uncertain, they have already resulted in significant volatility in financial markets and depreciation of the Russian ruble and the Ukrainian hryvnia against the U.S. dollar, as well as in an increase in energy and commodity prices globally. Should the conflict continue or escalate, there may be various economic and security consequences including, but not limited to, supply shortages of different kinds, further increases in prices of commodities, including piped gas, oil and agricultural goods, reduced consumer purchasing power, significant disruptions in logistics infrastructure, telecommunications services and risks relating to the unavailability of information technology systems and infrastructure. The resulting impacts to the global economy, financial markets, inflation, interest rates and unemployment, among others, could adversely impact economic and </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial conditions, and may disrupt the global economy&#8217;s ongoing recovery following the COVID-19 pandemic. Other potential consequences include, but are not limited to, growth in the number of popular uprisings in the region, increased political discontent, especially in the regions most affected by the conflict or economic sanctions, increase in cyberterrorism activities and attacks, displacement of persons to regions close to the areas of conflict and an increase in the number of refugees fleeing across Europe, among other unforeseen social and humanitarian effects.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as a result of the ongoing conflict between Russia and Ukraine, we may experience other risks, difficulties and challenges in the way we conduct our business and operations generally. For example, there may be an increased risk of cybersecurity attacks due to the current conflict between Russia and Ukraine, including cyber security attacks perpetrated by Russia or others at its direction in response to economic sanctions and other actions taken against Russia as a result of its invasion of Ukraine. Any increase in such attacks on us or our third-party providers or other systems could adversely affect our network systems or other operations. In order to address the risks associated with cybersecurity attacks from the region (including state-sponsored cybersecurity attacks), we have taken action to consolidate network traffic from Russia and Belarus through a single point, which is designed to allow us to more closely inspect that traffic. In addition, if required, this consolidation provides a single point to quickly and efficiently disconnect the region from our corporate network. At this time, to the best of our knowledge, we do not believe we have experienced any cyberattacks that are related to the conflict between Russia and Ukraine. Although we have taken steps to enhance our protections against such attacks, we may not be able to address these cybersecurity threats proactively or implement adequate preventative measures and there can be no assurance that we will promptly detect and address any such disruption or security breach, if at all. In addition, as a result of the risk of collectability of receivables from our customers in Russia, Belarus and Ukraine, we may be required to adjust our accounting practices relating to revenue recognition in this region, with the result that we may not be able to recognize revenue from these customers until collected. We may also suffer reputational harm as a result of our continued operations in Russia, which may adversely impact our sales and other businesses in other countries. Finally, we have one global clinical trail involving Russia, Ukraine and Belarus with patients enrolled. We continue to support the existing patients, but have no plans to enroll new patients at this time. Plans for any additional trails involving Russia, Ukraine and Belarus have been postponed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A protracted conflict between Ukraine and Russia, any escalation of that conflict, and the financial and economic sanctions and import and/or export controls imposed on Russia by the U.S., the UK, the EU, Canada and others, and the above-mentioned adverse effect on our operations (both in this region and generally) and on the wider global economy and market conditions could, in turn, have a material adverse impact on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">The B+L Separation, including the Distribution, is subject to challenge and could be subject to further challenges in the future, any of which could delay or prevent the consummation of such transactions or cause them to occur on worse terms than we currently expect.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The B+L Separation, including a distribution of all or a portion of our remaining equity interest in Bausch + Lomb to our shareholders (the &#8220;Distribution&#8221;), is subject to challenge, which could delay or prevent the consummation of such transactions or cause them to occur on worse terms than we currently expect. For example, in March 2022, the Company and Bausch + Lomb were named in a declaratory judgment action in the Superior Court of New Jersey, Somerset County, Chancery Division (which was subsequently removed to the U.S. District Court for the District of New Jersey), brought by certain individual investors in the Company&#8217;s common shares and debt securities who are also maintaining individual securities fraud claims against the Company and certain of its current or former officers and directors. This newly filed action seeks a declaratory judgment that the transfer of assets from the Company to Bausch + Lomb would constitute a voidable transfer under New Jersey&#8217;s Uniform Voidable Transactions Act and that Bausch + Lomb would become liable for damages awarded against the Company in the individual opt-out actions. In addition, the Company could, in the future, face additional legal proceedings and investigations and inquiries by governmental agencies relating to these or similar matters. For more information regarding legal proceedings, see Note 18, &#8220;LEGAL PROCEEDINGS&#8221; to our unaudited interim Consolidated Financial Statements elsewhere in this Form 10-Q. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable to predict the outcome of any such proceedings, investigations and inquiries, but we may incur significant costs and diversion of management attention as a result of these matters, regardless of the outcome. Some or all of these proceedings, investigations and inquiries may lead to damages, settlement payments, fines, penalties, consent orders or other administrative sanctions against us. Furthermore, publicity surrounding these proceedings, investigations and inquiries or any enforcement action as a result thereof, even if ultimately resolved favorably for us could result in additional investigations and legal proceedings. As a result, these proceedings, investigations and inquiries could have a material adverse effect on our reputation, business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div id="i801c461cbd33492a893c84373a8e7cbc_226"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no sales of equity securities by the Company during the three months ended March 31, 2022.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><div id="i801c461cbd33492a893c84373a8e7cbc_229"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3. Defaults Upon Senior Securities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i801c461cbd33492a893c84373a8e7cbc_232"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;Mine Safety Disclosures</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i801c461cbd33492a893c84373a8e7cbc_235"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5.&#160;Other Information</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i801c461cbd33492a893c84373a8e7cbc_238"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.&#160;Exhibits </span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"></td><td style="width:8.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.126%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522034549/d293207dex41.htm">4.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522034549/d293207dex41.htm">Indenture, dated as of February 10, 2022, by and among Bausch Health Companies Inc., the guarantors named therein, The Bank of New York Mellon, N.A., as trustee and the notes collateral agents party thereto, governing the 6.125% Senior Secured Notes due 2027, originally filed as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on February 10, 2022, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000088559022000010/exhibit10202021ye.htm">10.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000088559022000010/exhibit10202021ye.htm">Amended and Restated Employment Agreement, dated February 18, 2022, between Bausch Health Companies Inc. and Thomas Appio, originally filed as Exhibit 10.20 on the Company&#8217;s Annual Report on Form 10-K filed on February 23, 2022, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522090302/d338836dex991.htm">10.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522090302/d338836dex991.htm">Master Separation Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation, dated as of March 30, 2022, originally filed as Exhibit 99.1 to the Company&#8217;s Current Report on Form 8-K filed on March 30, 2022, which is incorporated by reference herein.&#8224;#</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522125782/d283951dex992.htm">10.3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522125782/d283951dex992.htm">Amendment to Master Separation Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation, dated as of April 28, 2022, originally filed as Exhibit 99.2 to the Company&#8217;s Current Report on Form 8-K filed on April 28, 2022, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522090302/d338836dex992.htm">10.4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522090302/d338836dex992.htm">Transition Services Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation, dated as of March 30, 2022, originally filed as Exhibit 99.2 to the Company&#8217;s Current Report on Form 8-K filed on March 30, 2022, which is incorporated by reference herein &#8224;#</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522090302/d338836dex993.htm">10.5</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522090302/d338836dex993.htm">Tax Matters Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation, dated as of March 30, 2022, originally filed as Exhibit 99.3 to the Company&#8217;s Current Report on Form 8-K filed on March 30, 2022, which is incorporated by reference herein &#8224;#</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522125782/d283951dex993.htm">10.6</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522125782/d283951dex993.htm">Amendment to Tax Matters Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation, dated as of April 28, 2022, originally filed as Exhibit 99.3 to the Company&#8217;s Current Report on Form 8-K filed on April 28, 2022, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522090302/d338836dex994.htm">10.7</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522090302/d338836dex994.htm">Employee Matters Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation, dated as of March 30, 2022, originally filed as Exhibit 99.4 to the Company&#8217;s Current Report on Form 8-K filed on March 30, 2022, which is incorporated by reference herein &#8224;#</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522090302/d338836dex995.htm">10.8</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522090302/d338836dex995.htm">Intellectual Property Matters Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation, dated as of March 30, 2022, originally filed as Exhibit 99.5 to the Company&#8217;s Current Report on Form 8-K filed on March 30, 2022, which is incorporated by reference herein &#8224;#</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522090302/d338836dex996.htm">10.9</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522090302/d338836dex996.htm">Real Estate Matters Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation, dated as of March 30, 2022, originally filed as Exhibit 99.6 to the Company&#8217;s Current Report on Form 8-K filed on March 30, 2022, which is incorporated by reference herein &#8224;#</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522090302/d338836dex997.htm">10.10</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522090302/d338836dex997.htm">Registration Rights Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation, dated as of March 30, 2022, originally filed as Exhibit 99.7 to the Company&#8217;s Current Report on Form 8-K filed on March 30, 2022, which is incorporated by reference herein #</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001860742/000119312522090313/d178785dex1010.htm">10.11</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001860742/000119312522090313/d178785dex1010.htm">Loan Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation, dated as of January 1, 2022, originally filed as Exhibit 10.10 </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001860742/000119312522090313/d178785dex1010.htm">to</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001860742/000119312522090313/d178785dex1010.htm"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001860742/000119312522090313/d178785dex1010.htm">Bausch + Lomb Corporation&#8217;s Registration Statement on Form S-1 filed on April 28, 2022, which is</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001860742/000119312522090313/d178785dex1010.htm"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001860742/000119312522090313/d178785dex1010.htm">incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522125782/d283951dex991.htm">10.12</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522125782/d283951dex991.htm">Arrangement Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation and the other parties thereto, dated as of April 28, 2022, originally filed as Exhibit 99.1 to the Company&#8217;s Current Report on Form 8-K filed on April 28, 2022, which is incorporated by reference herein.&#8224;#</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1013formofrsugranta.htm">10.13</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="exhibit1013formofrsugranta.htm">Form of RSU Grant Agreement &#8224;&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1014formofoptiongra.htm">10.14</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="exhibit1014formofoptiongra.htm">Form of Option Grant Agreement &#8224;&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001860742/000119312522090313/d178785dex1018.htm">10.15</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001860742/000119312522090313/d178785dex1018.htm">Assignment, Assumption and Amendment Agreement between Bausch Health Companies Inc., Bausch + Lomb Corporation and Joseph Papa dated as of January 3, 2022, originally filed as Exhibit 10.18 to Bausch + Lomb Corporation&#8217;s Registration Statement on Form S-1 filed on April 28, 2022, which is incorporated by reference herein. &#8224;&#8224;</a></span></div></td></tr></table></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"></td><td style="width:8.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.126%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001860742/000119312522090313/d178785dex1019.htm">10.16</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001860742/000119312522090313/d178785dex1019.htm">Assignment, Assumption and Amendment Agreement between Bausch Health Companies Inc., Bausch + Lomb Corporation and Sam A. Eldessouky dated as of January 3, 2022, originally filed as Exhibit 10.19 to Bausch + Lomb Corporation&#8217;s Registration Statement on Form S-1 filed on April 28, 2022, which is incorporated by reference herein. &#8224;&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001860742/000119312522090313/d178785dex1020.htm">10.17</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001860742/000119312522090313/d178785dex1020.htm">Assignment, Assumption and Amendment Agreement between Bausch Health Companies Inc., Bausch + Lomb Corporation and Christina M. Ackermann dated as of January 3, 2022, originally filed as Exhibit 10.20 to Bausch + Lomb Corporation&#8217;s Registration on Statement Form S-1 filed on April 28, 2022, which is incorporated by reference herein. &#8224;&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001860742/000119312522090313/d178785dex1021.htm">10.18</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001860742/000119312522090313/d178785dex1021.htm">Assignment, Assumption and Amendment Agreement between Bausch Health Companies Inc., Bausch + Lomb Corporation and Joseph F. Gordon dated as of January 3, 2022, originally filed as Exhibit 10.21 to Bausch + Lomb Corporation&#8217;s Registration Statement on Form S-1  filed on April 28, 2022, which is incorporated by reference herein. &#8224;&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522146413/d298928dex101.htm">10.19</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522146413/d298928dex101.htm">Second Amendment, dated as of May 10, 2022, among Bausch Health Companies Inc., Bausch Health Americas, Inc., certain other subsidiaries of the Company as subsidiary guarantors, each of the financial institutions named therein as lenders and issuing banks and Barclays Bank PLC, as Administrative Agent, originally filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on May 10, 2022, which is incorporated by reference herein</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522146413/d298928dex101.htm">.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522146413/d298928dex102.htm">10.20</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522146413/d298928dex102.htm">Credit Agreement, dated as of May 10, 2022, among Bausch + Lomb Corporation, certain subsidiaries of the Company as subsidiary guarantors, each of the financial institutions named therein as lenders and issuing banks, Citibank, N.A., as Revolving Facility Administrative Agent and Goldman Sachs Bank USA, as Term Facility Administrative Agent, originally filed as Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on May 10, 2022, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311q12022.htm">31.1*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311q12022.htm">Certification of the Chief Executive Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312q12022.htm">31.2*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312q12022.htm">Certification of the Chief Financial Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321q12022.htm">32.1*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321q12022.htm">Certificate of the Chief Executive Officer of Bausch Health Companies&#160;Inc. pursuant to 18&#160;U.S.C. &#167;&#160;1350 as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322q12022.htm">32.2*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322q12022.htm">Certificate of the Chief Financial Officer of Bausch Health Companies Inc. pursuant to 18&#160;U.S.C. &#167;&#160;1350 as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:174%">____________________________________</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*     Filed herewith.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish supplementally a copy of any omitted exhibit or schedule upon request by the Securities and Exchange Commission.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#    Portions of this exhibit have been omitted because they are both (i) not material and (ii) would likely cause competitive harm to Bausch Health Companies Inc. if publicly disclosed.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8224;&#8224;   Management contract or compensatory plan arrangement.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><div id="i801c461cbd33492a893c84373a8e7cbc_241"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.240%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Bausch Health Companies&#160;Inc.</span></div><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 10, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ THOMAS J. APPIO</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas J. Appio<br/>Chief Executive Officer<br/>(Principal Executive Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 10, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ TOM VADAKETH</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tom Vadaketh<br/>Executive Vice President, <br/>Chief Financial Officer <br/>(Principal Financial Officer)</span></td></tr></table></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><div id="i801c461cbd33492a893c84373a8e7cbc_244"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="-sec-extract:summary;margin-bottom:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO EXHIBITS </span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"></td><td style="width:8.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.126%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522034549/d293207dex41.htm">4.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522034549/d293207dex41.htm">Indenture, dated as of February 10, 2022, by and among Bausch Health Companies Inc., the guarantors named therein, The Bank of New York Mellon, N.A., as trustee and the notes collateral agents party thereto, governing the 6.125% Senior Secured Notes due 2027, originally filed as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on February 10, 2022, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000088559022000010/exhibit10202021ye.htm">10.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000088559022000010/exhibit10202021ye.htm">Amended and Restated Employment Agreement, dated February 18, 2022, between Bausch Health Companies Inc. and Thomas Appio, originally filed as Exhibit 10.20 on the Company&#8217;s Annual Report on Form 10-K filed on February 23, 2022, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522090302/d338836dex991.htm">10.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522090302/d338836dex991.htm">Master Separation Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation, dated as of March 30, 2022, originally filed as Exhibit 99.1 to the Company&#8217;s Current Report on Form 8-K filed on March 30, 2022, which is incorporated by reference herein.&#8224;#</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522125782/d283951dex992.htm">10.3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522125782/d283951dex992.htm">Amendment to Master Separation Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation, dated as of April 28, 2022, originally filed as Exhibit 99.2 to the Company&#8217;s Current Report on Form 8-K filed on April 28, 2022, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522090302/d338836dex992.htm">10.4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522090302/d338836dex992.htm">Transition Services Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation, dated as of March 30, 2022, originally filed as Exhibit 99.2 to the Company&#8217;s Current Report on Form 8-K filed on March 30, 2022, which is incorporated by reference herein &#8224;#</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522090302/d338836dex993.htm">10.5</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522090302/d338836dex993.htm">Tax Matters Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation, dated as of March 30, 2022, originally filed as Exhibit 99.3 to the Company&#8217;s Current Report on Form 8-K filed on March 30, 2022, which is incorporated by reference herein &#8224;#</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522125782/d283951dex993.htm">10.6</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522125782/d283951dex993.htm">Amendment to Tax Matters Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation, dated as of</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522125782/d283951dex993.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522125782/d283951dex993.htm">April 28, 2022, originally filed as Exhibit 99.3 to the Company&#8217;s Current Report on Form 8-K filed on April 28, 2022, which is incorporated by reference herein</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522125782/d283951dex993.htm">.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522090302/d338836dex994.htm">10.7</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522090302/d338836dex994.htm">Employee Matters Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation, dated as of March 30, 2022, originally filed as Exhibit 99.4 to the Company&#8217;s Current Report on Form 8-K filed on March 30, 2022, which is incorporated by reference herein &#8224;#</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522090302/d338836dex995.htm">10.8</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522090302/d338836dex995.htm">Intellectual Property Matters Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation, dated as of March 30, 2022, originally filed as Exhibit 99.5 to the Company&#8217;s Current Report on Form 8-K filed on March 30, 2022, which is incorporated by reference herein &#8224;#</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522090302/d338836dex996.htm">10.9</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522090302/d338836dex996.htm">Real Estate Matters Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation, dated as of March 30, 2022, originally filed as Exhibit 99.6 to the Company&#8217;s Current Report on Form 8-K filed on March 30, 2022, which is incorporated by reference herein &#8224;#</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522090302/d338836dex997.htm">10.10</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522090302/d338836dex997.htm">Registration Rights Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation, dated as of March 30, 2022, originally filed as Exhibit 99.7 to the Company&#8217;s Current Report on Form 8-K filed on March 30, 2022, which is incorporated by reference herein #</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001860742/000119312522090313/d178785dex1010.htm">10.11</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001860742/000119312522090313/d178785dex1010.htm">Loan Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation, dated as of January 1, 2022, originally filed as Exhibit 10.10 to Bausch + Lomb Corporation&#8217;s Registration Statement on Form S-1 filed on April 28, 2022, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522125782/d283951dex991.htm">10.12</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522125782/d283951dex991.htm">Arrangement Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation and the other parties thereto, dated as of April 28, 2022, originally filed as Exhibit 99.1 to the Company&#8217;s Current Report on Form 8-K filed on April 28, 2022, which is incorporated by reference herein.&#8224;#</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1013formofrsugranta.htm">10.13</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="exhibit1013formofrsugranta.htm">Form of RSU Grant Agreement &#8224;&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1014formofoptiongra.htm">10.14</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="exhibit1014formofoptiongra.htm">Form of Option Grant Agreement &#8224;&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001860742/000119312522090313/d178785dex1018.htm">10.15</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001860742/000119312522090313/d178785dex1018.htm">Assignment, Assumption and Amendment Agreement between Bausch Health Companies Inc., Bausch + Lomb Corporation and Joseph Papa dated as of January 3, 2022, originally filed as Exhibit 10.18 to Bausch + Lomb Corporation&#8217;s Registration Statement on Form S-1 filed on April 28, 2022, which is incorporated by reference herein. &#8224;&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001860742/000119312522090313/d178785dex1019.htm">10.16</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001860742/000119312522090313/d178785dex1019.htm">Assignment, Assumption and Amendment Agreement between Bausch Health Companies Inc., Bausch + Lomb Corporation and Sam A. Eldessouky dated as of January 3, 2022, originally filed as Exhibit 10.19 to Bausch + Lomb Corporation&#8217;s Registration Statement on Form S-1 filed on April 28, 2022, which is incorporated by reference herein. &#8224;&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001860742/000119312522090313/d178785dex1020.htm">10.17</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001860742/000119312522090313/d178785dex1020.htm">Assignment, Assumption and Amendment Agreement between Bausch Health Companies Inc., Bausch + Lomb Corporation and Christina M. Ackermann dated as of January 3, 2022, originally filed as Exhibit 10.20 to Bausch + Lomb Corporation&#8217;s Registration on Statement Form S-1 filed on April 28, 2022, which is incorporated by reference herein. &#8224;&#8224;</a></span></div></td></tr></table></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"></td><td style="width:8.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.126%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001860742/000119312522090313/d178785dex1021.htm">10.18</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001860742/000119312522090313/d178785dex1021.htm">Assignment, Assumption and Amendment Agreement between Bausch Health Companies Inc., Bausch + Lomb Corporation and Joseph F. Gordon dated as of January 3, 2022, originally filed as Exhibit 10.21 to Bausch + Lomb Corporation&#8217;s Registration Statement on Form S-1 filed on April 28, 2022, which is incorporated by reference herein. &#8224;&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522146413/d298928dex101.htm">10.19</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522146413/d298928dex101.htm">Second Amendment, dated as of May 10, 2022, among Bausch Health Companies Inc., Bausch Health Americas, Inc., certain other subsidiaries of the Company as subsidiary guarantors, each of the financial institutions named therein as lenders and issuing banks and Barclays Bank PLC, as Administrative Agent, originally filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on May 10, 2022, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522146413/d298928dex102.htm">10.20</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522146413/d298928dex102.htm">Credit Agreement, dated as of May 10, 2022, among Bausch + Lomb Corporation, certain subsidiaries of the Company as subsidiary guarantors, each of the financial institutions named therein as lenders and issuing banks, Citibank, N.A., as Revolving Facility Administrative Agent and Goldman Sachs Bank USA, as Term Facility Administrative Agent, originally filed as Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on May 10, 2022, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311q12022.htm">31.1*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311q12022.htm">Certification of the Chief Executive Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312q12022.htm">31.2*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312q12022.htm">Certification of the Chief Financial Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321q12022.htm">32.1*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321q12022.htm">Certificate of the Chief Executive Officer of Bausch Health Companies&#160;Inc. pursuant to 18&#160;U.S.C. &#167;&#160;1350 as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322q12022.htm">32.2*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322q12022.htm">Certificate of the Chief Financial Officer of Bausch Health Companies Inc. pursuant to 18&#160;U.S.C. &#167;&#160;1350 as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:174%">____________________________________</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">*     Filed herewith.</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8224;&#160;&#160;&#160;&#160;Management contract or compensatory plan or arrangement.</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8224;&#8224;   Management contract or compensatory plan arrangement.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>2
<FILENAME>exhibit1013formofrsugranta.htm
<DESCRIPTION>EX-10.13
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i0efd7316443b43009adffd68ac181e8e_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit 10.13</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Bausch Health Companies Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Form of Restricted Share Unit Award Agreement <br>(Restricted Share Units)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(2014 Omnibus Incentive Plan, as amended and restated, effective as of April 28, 2020)</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Bausch Health Companies Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), pursuant to Section 7(c)(v) of the Company&#8217;s 2014 Omnibus Incentive Plan, as amended and restated, effective as of April 28, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), hereby awards to you a Restricted Share Unit Award in the form of restricted share units (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Restricted Share Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), payable in common shares of the Company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Common Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), covering the number of Common Shares set forth below.  This Award is subject to all of the terms and conditions as set forth herein (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and in the Plan, which is incorporated herein in its entirety.  Capitalized terms not otherwise defined herein shall have the meanings set forth in the Plan.  In the event of any conflict between the terms in the Agreement and the Plan, the terms of the Plan shall control.  For the avoidance of doubt, any terms contained in the Agreement but are not in the Plan shall not constitute a conflict and such terms in the Agreement shall control.  </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.112%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:133%">Participant&#58;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:133%">Date of Grant&#58;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:133%">Number of Shares Subject to Award&#58;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.75pt solid #000000;border-right:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The details of your Award are as follows.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Consideration for this Award is satisfied by your services to the Company and its Subsidiaries complying with the terms of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">In General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to the provisions of the Plan and this Agreement, one-third of the Award shall vest on each of the first three anniversaries of the Date of Grant (each such anniversary, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Vesting Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> you are employed by the Company or one of its Subsidiaries through the applicable Vesting Date and continue to comply with the restrictive covenants in Sections 8 and 9.  Vesting will cease upon your Termination of Service (except as set forth below in Sections 2(b) through (e)).  Any Restricted Share Units that did not become vested prior to your Termination of Service or that do not become vested according to the provisions in this Section 2 shall be forfeited immediately following the date of your Termination of Service.    Settlement of vested Awards shall be pursuant to Section 3 below.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Vesting Acceleration Upon Termination of Service due to Death or Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding the foregoing and any other provisions of the Plan to the contrary, in the event of your Termination of Service by the Company due to your death or Disability, then any unvested portion of your Restricted Share Units will vest on the date of your Termination of Service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Vesting Acceleration Upon Termination of Service without Cause or for Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding the foregoing and any other provisions of the Plan to the contrary, in the event of your Termination of Service by the Company without Cause or by you for Good Reason, then an additional number of your Restricted Share Units will vest as of the date of your Termination of Service, equal to the number of your unvested Restricted Share Units multiplied by a fraction, the numerator of which is the number of days from the prior Vesting Date through the date of your Termination of Service, and the denominator of which is 365, conditioned on you (i) having been employed at the Company or one of its Subsidiaries for </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at least twelve (12) months following the Date of Grant&#59; (ii) delivering to the Company, and failing to revoke, a signed release of claims acceptable to the Company within fifty-five (55) days following the date of your Termination of Service and (iii) comply with the restrictive covenants in Sections 8 and 9&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that, in the event your Termination of Service occurs as a result of the entity for which you are employed ceasing to qualify as a Subsidiary prior to the twelve (12)-month anniversary of the Date of Grant, the requirement to be employed by the Company or one of its Subsidiaries for at least twelve (12) months as set forth in clause (i) above shall not apply and one-third (1&#47;3) of the Restricted Shares Units will vest as of the date of such Termination of Service and will convert into Common Shares in accordance with Section 3 hereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Divestiture Treatment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Vesting Acceleration Upon Termination of Service due to Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Notwithstanding the foregoing and any other provisions of the Plan to the contrary, in the event of your Termination of Service due to your Retirement (as defined below), then any unvested portion of your Restricted Share Units will vest on the date of your Termination of Service&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that (i) as of the date of your Termination of Service, you have been employed by the Company or one of its Subsidiaries for at least twelve (12) months following the Date of Grant, subject to Divestiture Treatment if your Termination of Service occurs as a result of the entity for which you are employed ceasing to qualify as a Subsidiary prior to such date and (ii) conditioned on you complying with the restrictive covenants in Sections 8 and 9. Unless otherwise defined in your employment or service agreement, &#8220;Retirement&#8221; means your Termination of Service with the Company on or after the date on which you attain age 55 and your age plus your years of service with the Company and its Subsidiaries total at least 65, and you have not otherwise been terminated for Cause (and your Retirement has not occurred at a time when grounds for a Termination of Service for Cause exist). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Vesting Acceleration Upon Termination of Service without Cause or for Good Reason in Connection with a Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding the foregoing and any other provisions of the Plan to the contrary, in the event of your Termination of Service (x) by the Company without Cause or (y) by you for Good Reason, in either case within twelve (12) months following a Change of Control (or during the six month period prior to a Change of Control if such termination was in contemplation of, and directly related to, the Change of Control), then any portion of your unvested Restricted Share Units that was not cancelled in connection with such Change of Control will vest on the date of your Termination of Service (or on the date of the Change of Control if such Termination of Service occurs during the six month period prior to a Change of Control), conditioned on you delivering to the Company, and failing to revoke, a signed release of claims acceptable to the Company within fifty-five (55) days following the date of your Termination of Service and you complying with the restrictive covenants in Sections 8 and 9.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:24.03pt">Termination of Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Termination of Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the cessation of your employment relationship such that you are no longer an employee of the Company or any Subsidiary&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that the transfer of your employment from the Company to a Subsidiary, from a Subsidiary to the Company, from one Subsidiary to another Subsidiary or, unless the Committee determines otherwise, the cessation of employee status but the continuation of the performance of services for the Company or a Subsidiary as a director or consultant shall not be deemed a cessation of service that would constitute a Termination of Service&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that a Termination of Service shall be deemed to occur if you are employed by, or performing services for, a Subsidiary when such Subsidiary ceases to be a Subsidiary, unless your employment or service continues with the Company or another Subsidiary.  Notwithstanding the foregoing, to the extent this Award is subject to Section 409A of the Code (and not exempt therefrom), a Termination of Service occurs when you experience a Separation of Service.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Distribution of Common Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company will deliver to you a number of Common Shares equal to the sum of (i) the number of Restricted Share Units subject to your Award that become vested in accordance with the terms of this Agreement, plus (ii) any Restricted Share Units resulting from dividend equivalents credited with respect to such Restricted Share Units in accordance with Section 6 of this Agreement, as soon as practicable (but, subject to Section 7(c)(vi) of the Plan regarding blackout restrictions, in any event no later than sixty (60) days) following the date on which such Restricted Share Units become vested&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that, notwithstanding anything in the Plan or this Agreement to the contrary, any remaining right to a distribution of the Common Shares will be forfeited in the event of your Termination of Service by the Company for Cause prior to the date on which the Common Shares are distributed to you or if you violate any post-employment obligation that you may have to the Company or any of its Subsidiaries (including the restrictive covenants set forth in Sections 8 and 9). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Number of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The number of Common Shares subject to your Award may be adjusted from time to time in accordance with Section 6(e) of the Plan.  The Company will establish a bookkeeping account to reflect the number of Restricted Share Units standing to your credit from time to time.  However, you will not be deemed to be the holder of, or to have any of the rights of a shareholder with respect to, any Common Shares subject to your Award (including but not limited to shareholder voting rights) unless and until the shares have been delivered to you in accordance with Section 3 of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Common Share Ownership Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You agree to comply with any Common Share ownership requirements adopted by the Company applicable to you, which shall be on the same terms as similarly situated executives of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Dividend Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The bookkeeping account maintained for your Award shall, until the final Vesting Date or the termination and cancellation or forfeiture of the Restricted Share Units pursuant to the terms of this Agreement, be allocated additional Restricted Share Units on the payment date of dividends on the Company&#8217;s Common Shares.  Such dividends will be converted into a number of additional Common Shares covered by the Restricted Share Units equal to the quotient of (i) the aggregate amount or value of the dividends paid with respect to that number of Common Shares equal to the number of shares covered by the Restricted Share Units divided by (ii) the Market Price per Common Share on the payment date for such dividend.  Any such additional Restricted Share Units shall have the same Vesting Dates and shall vest in accordance with the same terms as the Restricted Share Units granted under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Disclosure and Ownership of Intellectual Property. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Company Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You acknowledge and agree that any intellectual property, including, without limitation, works, materials, inventions, invention disclosures, invention registrations, patent rights, trademarks, service marks, trade names, trade dress, logos, domain names, copyrights, design rights, mask works, software, apparatus, technology, data, trade secrets, know-how and all other intellectual property and proprietary rights recognized by any applicable law of any jurisdiction, that you create, discover, conceive, reduce to practice, develop or acquire during the course of your employment or service, either alone or jointly with others, (i) using any equipment, supplies, facilities, trade secrets, know-how or other Confidential Information of the Company or any of its affiliates, (ii) that results from any work performed for the Company or any of its affiliates and&#47;or (iii) that otherwise relates to the Company&#8217;s or any of its affiliates&#8217; business or actual or demonstrably anticipated research or development (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Company Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is and shall remain the exclusive property of the Company or the affiliate of the Company, as applicable, that is your employer (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) whether registered or otherwise exploited or not.  In furtherance of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">foregoing, you hereby assign, transfer, convey and deliver to the Employer your entire right, title and interest in and to any and all such Company Intellectual Property.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Work Made for Hire</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You acknowledge and agree that, with respect to any Company Intellectual Property that may qualify as a Work Made For Hire as defined in 17 U.S.C. &#167; 101 or other applicable law, such Company Intellectual Property is and will be deemed a Work Made for Hire and the Employer will have the sole and exclusive right to the copyright (or, in the event that any such Company Intellectual Property does not qualify as a Work Made for Hire, the copyright and all other rights thereto are hereby automatically assigned to the Employer as above).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You agree to record all activities undertaken in the course of your employment and to disclose promptly in writing to the Employer any and all Company Intellectual Property.  You agree that you will give the Company or any of its affiliates all reasonable assistance and execute all documents necessary to assist with enabling the Company or any of its affiliates to prosecute, perfect, register, record, enforce and defend any and all of their rights in and to any Company Intellectual Property and Confidential Information.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Non-Assignable Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If your principal work location is in California, Illinois, Kansas, Minnesota or Washington State, the provisions regarding your assignment of Company Intellectual Property to the Employer in Sections 7(a) and (b) of this Agreement may not apply to certain inventions (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Non-Assignable Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) as specified in the statutory code of the applicable state.  You acknowledge having received notification regarding such Non-Assignable Inventions pursuant to such states&#8217; codes.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Prior Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If, in the course of your employment with the Employer, you use any intellectual property that is solely or jointly owned by you or licensed to you, with the right to sub-license (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Prior Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), you hereby grant to the Company and its affiliates a worldwide, non-exclusive, irrevocable, perpetual, fully paid-up and royalty-free license (with rights to sublicense through multiple tiers of sublicensees) to use, reproduce, modify, make derivative works of, publicly perform, publicly display, make, have made, sell, offer for sale, import and otherwise exploit such Prior Intellectual Property for any purpose.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:24.03pt">Waiver of Moral Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. To the extent you may do so under applicable law, you hereby waive and agree never to assert any Moral Rights that you may have in or with respect to any Company Intellectual Property, even after termination of any work on behalf of the Company or its affiliates. As used in this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Moral Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any rights to claim authorship of a work, to object to or prevent the modification or destruction of a work, or to withdraw from circulation or control the publication or distribution of a work, and any similar right, existing under any applicable law of any jurisdiction, regardless of whether or not such right is denominated or generally referred to as a &#8220;moral right.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">This Section 7 shall survive your Termination of Service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Records and Confidential Data. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In consideration of the Restricted Share Units issued to you pursuant to this Agreement, you agree to be bound by the covenant of confidentiality set forth in this Section 8 with respect to any and all Confidential Information (as defined below) disclosed or made available to you or of which you have otherwise become aware, whether before, on or after the date hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Ownership&#59; Recognition of Company&#8217;s Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You acknowledge that in connection with the performance of your duties, the Company will make available to you, or you will have access to, certain Confidential Information of the Company and its affiliates. You </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">acknowledge and agree that any and all Confidential Information you learned or obtained during the course of your employment by the Company or any of its affiliates or otherwise, whether developed by you alone or in conjunction with others or otherwise, shall be and is the sole and exclusive property of the Employer. No license or other right to any Confidential Information is granted to you under this Agreement.  To the extent that you acquire any right, title or interest in or to any Confidential Information, you hereby assign, transfer, convey and deliver to the Employer all such right, title and interest in and to such Confidential Information.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You (i)&#160;will keep all Confidential Information strictly confidential, (ii)&#160;will not use Confidential Information in any manner which is detrimental to the Company or its affiliates, (iii)&#160;will not use Confidential Information other than in connection with the discharge of your duties to the Company and its affiliates, (iv)&#160;will safeguard any and all Confidential Information from unauthorized disclosure, and (v)&#160;will not disclose, publish, use, transfer or otherwise disseminate any Confidential Information to any person or entity without the Employer&#8217;s express prior written consent, except as may be necessary to perform your duties as an employee of the Company or its affiliates for the benefit of the Company or its affiliates. You may, however, disclose Confidential Information to the extent it is in response to a valid order of a court or other governmental authority or to otherwise comply with applicable law&#59; provided that, subject to Section 8(e), you shall first give notice to the Employer and reasonably cooperate with the Employer to obtain a protective order or other measures preserving the confidential treatment of such Confidential Information and requiring that the information or documents so disclosed be used only for the purposes for which the order was issued or is otherwise required by applicable law. For the avoidance of doubt, nothing in this Section 8(b) shall prevent you from exercising any legally protected whistleblower rights (including under Rule 21F under the Exchange Act).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Disposition of Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Following your Termination of Service or upon the Company&#8217;s request, you will return to the Company all copies of any and all Confidential Information in your custody, possession or control (including all copies of any analyses, compilations, studies or other documents prepared by you or for your use containing or reflecting any Confidential Information). Alternatively, with the Company&#8217;s prior written consent, you may destroy such Confidential Information. Within five (5) business days of your Termination of Service or such request by the Company, you shall deliver to the Company a document certifying that such written Confidential Information has been returned or destroyed in accordance with this Section 8(c).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Confidential Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any and all non-public, proprietary or other confidential information of the Company or its affiliates disclosed to you, to which you have access, or of which you otherwise become aware, in each case whether in oral, written, graphic or machine readable form, including, without limitation, (i)&#160;know-how, trade secrets, inventions, discoveries, concepts, information, works, materials, processes, methods, data, software, programs, apparatus, designs and the like, and any other intellectual property the value of which is contingent upon maintaining the confidentiality thereof, (ii)&#160;information regarding the business of the Company or its affiliates, including its products, services, budgets, contracts, reports, investigations, experiments, research, work in progress, drawings, designs, plans, proposals, codes, marketing and sales programs, client lists, client mailing lists, supplier lists, financial projections, cost summaries, pricing formulae, marketing studies relating to prospective business opportunities, and all other concepts, ideas, materials, or information prepared or performed for or by the Company or its affiliates, (iii)&#160;information regarding the skills and compensation of the employees, contractors, and any other service providers of the Company or its affiliates, (iv)&#160;the existence of any business discussions, negotiations, or agreements between the Company or its affiliates and any third party, (v)&#160;all documents and other work product generated by you which contain, comment upon, or relate in any way to any information disclosed by the Company or its </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">affiliates, (vi) all third-party information held in confidence by the Company or its affiliates, and (vii) the terms and conditions of this Agreement. For purposes of this Agreement, the Confidential Information shall not include and your obligation shall not extend to (i) information which is generally available to the public and (ii) information obtained by you other than pursuant to or in connection with your employment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Defend Trade Secrets Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Pursuant to Section 7 of the Defend Trade Secrets Act of 2016 (which added 18 U.S.C. &#167; 1833(b)), you and the Company acknowledge and agree that you shall not have criminal or civil liability under any federal or state trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a federal, State, or local government official, either directly or indirectly, or to an attorney and (ii) solely for the purpose of reporting or investigating a suspected violation of law&#59; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. In addition and without limiting the preceding sentence, if you file a lawsuit for retaliation by the Company for reporting a suspected violation of law, you may disclose the trade secret to your attorney and may use the trade secret information in the court proceeding, if you (x) file any document containing the trade secret under seal and (y) do not disclose the trade secret, except pursuant to court order. Nothing in this Agreement is intended to conflict with 18 U.S.C. &#167;1833(b) or create liability for disclosures of trade secrets that are expressly allowed by such Section.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:24.03pt">Whistleblower Protections</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Without limiting the generality of the foregoing, nothing in this Agreement precludes or otherwise limits your ability to (i) communicate directly with and provide information, including documents, not otherwise protected from disclosure by any applicable law or privilege to the Securities and Exchange Commission (the &#8220;SEC&#8221;) or any other federal, state or local governmental agency or commission (&#8220;Government Agency&#8221;) or self-regulatory organization regarding possible legal violations, without disclosure to the Company, or (ii) disclose information which is required to be disclosed by applicable law, regulation, or order or requirement (including without limitation, by deposition, interrogatory, requests for documents, subpoena, civil investigative demand or similar process) of courts, administrative agencies, the SEC, any Government Agency or self-regulatory organizations, provided that you provide the Company with prior notice of the contemplated disclosure and cooperates with the Company in seeking a protective order or other appropriate protection of such information. The Company may not retaliate against you for any of these activities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">This Section 8 shall survive your Termination of Service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Covenant Not to Solicit, Not to Compete and Not to Disparage. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In consideration of the Restricted Share Units issued to you pursuant to this Agreement, you agree to be bound by the covenants of non-solicitation, non-competition and non-disparagement set forth in this Section 9.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Covenant Not to Solicit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. To protect the Confidential Information and other trade secrets of the Company and its affiliates, you agree, during your employment and for a period of twelve (12) months thereafter (or, if greater, the period set forth in your employment or service agreement), not to solicit, hire or participate in or assist in any way in the solicitation or hire of any employees of the Company or any of its Subsidiaries (or any person who was an employee of the Company or any of its Subsidiaries during the 6-month period preceding such action). For purposes of this covenant, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">solicit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means directly or indirectly influencing or attempting to influence employees of the Company to become employed with any other person, partnership, firm, corporation or other entity. You agree that the covenants contained in this Section 9(a) are reasonable and desirable to protect the Confidential Information of the Company and its affiliates, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that solicitation through general advertising or the provision of references shall not constitute a breach of such obligations.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Covenant Not to Compete</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. To protect the Confidential Information and other trade secrets of the Company and its affiliates, you agree, during the period of your employment and for a period of twelve (12) months thereafter (or, if greater, the period set forth in your employment or service agreement) not to engage in Prohibited Activities (as defined below) in any country in which the Company or its affiliates conduct business, or plan to conduct business, during the period of your employment. For the purposes of this Agreement, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Prohibited Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means directly or indirectly engaging as an owner, employee, consultant or agent of any entity that derives more than 10% of its consolidated revenue from the development, manufacturing, marketing and&#47;or distribution (directly or indirectly) of branded or generic prescription or non-prescription pharmaceuticals or medical devices for treatments in the fields of neurology, dermatology, gastroenterology, ophthalmology or dentistry&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that Prohibited Activities shall not mean (i) your investment in securities of a publicly-traded company equal to less than five (5%) percent of such company&#8217;s outstanding voting securities or (ii) serving as a member of a board of directors of a company provided that, for the avoidance of doubt, you comply with the obligations set forth in Sections 8 and 9(a) of this Agreement. You agree that the covenants contained in this Section 9(b) are reasonable and desirable to protect the Confidential Information of the Company and its affiliates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Non-Disparagement Covenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You agree not to make written or oral statements about the Company or its affiliates or their directors, executive officers or non-executive officer employees that are negative or disparaging. The Company and its affiliates shall not, and the Company and its affiliates shall instruct their directors and executive officers to not, make written or oral statements about you that are negative or disparaging. Notwithstanding the foregoing, nothing in this Agreement shall preclude you, the Company and its affiliates, and the Company&#8217;s or any of its affiliate&#8217;s directors and executive officers from communicating or testifying truthfully to the extent required by law to any federal, state, provincial or local governmental agency or in response to a subpoena to testify issued by a court of competent jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">Your obligations under this Section 9 shall survive your Termination of Service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Severability of Restrictive Covenants. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">It is the intent and desire of you and the Company that the restrictive provisions of this Agreement be enforced to the fullest extent permissible under the laws and public policies as applied in each jurisdiction in which enforcement is sought. If any particular provision of Section 8 or 9 shall be determined to be invalid or unenforceable, such provision shall be amended, without any action on the part of either party hereto, to delete therefrom the portion so determined to be invalid or unenforceable, such deletion to apply only with respect to the operation of such covenant in the particular jurisdiction in which such adjudication is made.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Remedies for Breach of Obligations Under Sections 8 and 9.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You acknowledge that the Company will suffer irreparable injury, not readily susceptible of valuation in monetary damages, if you breach any obligation under Sections 8 or 9. Accordingly, you agree that the Company will be entitled, in addition to any other available remedies, to obtain preliminary and permanent injunctive relief against any breach or prospective breach by you of your obligations under Sections 8 or 9. Without limiting other forms of relief available to the Company, in the event of your breach of any of your obligations under Sections 8 or 9, your Award will be forfeited for no consideration and, if payment in respect of your Award has been made, you will be obligated to return the proceeds to the Company. You agree that process in any or all of those actions or proceedings may be served by registered mail, addressed to the last address provided by you to the Company, or in any other manner authorized by law.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Clawback. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement is subject to Section 11 of the Plan and any policy the Company adopts regarding the recovery of incentive compensation and any additional clawback provisions as required by law and applicable listing rules.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Compliance with Section 409A of the Internal Revenue Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Award is intended to comply with Section 409A of the Code to the extent subject thereto or to otherwise be exempt from Section 409A of the Code, and shall be interpreted in accordance with this intent and Section 409A of the Code and treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the Date of Grant.  Notwithstanding any provision in the Plan to the contrary, no payment or distribution under this Plan that constitutes an item of deferred compensation under Section 409A of the Code and becomes payable by reason of your Termination of Service with the Company shall be made to you until your Termination of Service constitutes a separation from service within the meaning of Section 409A of the Code.  For purposes of this Award, each amount to be paid or benefit to be provided shall be construed as a separate identified payment for purposes of Section 409A of the Code. Notwithstanding any provision in the Plan to the contrary, if you are a specified employee within the meaning of section 409A of the Code, then to the extent necessary to avoid the imposition of taxes under Section 409A of the Code, you shall not be entitled to any payments upon a termination of your employment or service until the earlier of&#58;  (i) the expiration of the six (6)-month period measured from the date of your separation from service or (ii) the date of your death.  Upon the expiration of the applicable waiting period set forth in the preceding sentence, all payments and benefits deferred pursuant to this Section 13 (whether they would have otherwise been payable in a single lump sum or in installments in the absence of such deferral) shall be paid to you in a lump sum as soon as practicable, but in no event later than sixty (60) calendar days, following such expired period, and any remaining payments due under this Award will be paid in accordance with the normal payment dates specified for them herein.  Notwithstanding any provision of the Plan to the contrary, in no event shall the Company or any affiliate be liable to you on account of an Award&#8217;s failure to (i) qualify for favorable U.S. or foreign tax treatment or (ii) avoid adverse tax treatment under U.S. or foreign law, including, without limitation, Section 409A of the Code.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Securities Law Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You may not be issued any Common Shares under your Award unless the Common Shares are either (i) then registered under the Securities Act of 1933, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or (ii) the Company has determined that such issuance would be exempt from the registration requirements of the Securities Act.  Your Award must also comply with other applicable laws and regulations governing the Award, and you shall not receive such shares if the Company determines that such receipt would not be in material compliance with such laws and regulations.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Restrictive Legends</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Common Shares issued under your Award shall be endorsed with appropriate legends, if any, determined by the Company. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as otherwise permitted by the Committee in accordance with the terms of the Plan, your Award is not transferable, except by will or by the laws of descent and distribution.  Notwithstanding the foregoing, by delivering written notice to the Company, in the form prescribed by the Company, you may designate a third party who, in the event of your death, will thereafter be entitled to receive any distribution of Common Shares pursuant to Section 3 of this Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Award Not a Service Contract</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Your Award is not an employment or service contract, and nothing in your Award will be deemed to create in any way whatsoever any obligation on your part to continue in the service of the Company or an affiliate, or on the part of the Company or an affiliate to continue such service.  In addition, nothing in your Award will obligate the Company or an affiliate, their respective shareholders, boards of directors or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">employees to continue any relationship that you might have as an employee of the Company or an affiliate. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Unsecured Obligation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Your Award is unfunded, and as a holder of a vested Restricted Share Unit, and you will be considered an unsecured creditor of the Company with respect to the Company&#8217;s obligation, if any, to issue Common Shares pursuant to this Agreement. You will not have voting or any other rights as a shareholder of the Company with respect to the Common Shares subject to your Award until such Common Shares are delivered to you pursuant to Section 3 of this Agreement. Upon such delivery, you will obtain full voting and other rights as a shareholder of the Company. Nothing contained in this Agreement, and no action taken pursuant to its provisions, will create or be construed to create a trust of any kind or a fiduciary relationship between you and the Company or any other person.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Withholding Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  On or before the time you receive a distribution of Common Shares pursuant to your Award, or at any time thereafter as requested by the Company, you hereby authorize any required withholding from the Common Shares, payroll and any other amounts payable or issuable to you and&#47;or otherwise agree to make adequate provision in cash for any sums that can be withheld to satisfy the federal, state, local and foreign tax withholding obligations of the Company or any affiliate which arise in connection with your Award (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Withholding Taxes&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).  The Company shall (i) withhold, from Common Shares otherwise issuable upon settlement of the Award, a portion of the  Common Shares with an aggregate Market Price (measured as of the date Common Shares are delivered pursuant to Section 3) equal to the amount of the applicable withholding taxes&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that the number of such Common Shares so withheld shall not exceed the maximum amount that can be withheld to satisfy the Company&#8217;s required tax withholding obligations and (ii) make a cash payment equal to such fair market value directly to the appropriate taxing authorities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notices provided for in your Award or the Plan shall be given in writing and shall be deemed effectively given upon receipt or, in the case of notices delivered by the Company to you, five (5) days after deposit in the United States mail, postage prepaid, addressed to you at the last address you provided to the Company. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The headings of the Sections in this Agreement are inserted for convenience only and will not be deemed to constitute a part of this Agreement or to affect the meaning of this Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Nothing in this Agreement shall restrict the Committee&#8217;s (or its applicable delegate&#8217;s) ability to exercise its discretionary authority pursuant to Section 4 of the Plan&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that no such action may, without your consent, adversely affect your rights under your Award and this Agreement.  Without limiting the foregoing, the Board (or appropriate committee thereof) reserves the right to change, by written notice to you, the provisions of this Agreement in any way it may deem necessary or advisable to carry out the purpose of the grant as a result of any change in applicable laws or regulations or any future law, regulation, ruling, or judicial decision&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that any such change will be applicable only to rights relating to that portion of the Award which is then subject to restrictions as provided herein. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Miscellaneous. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The rights and obligations of the Company under your Award will be transferable by the Company to any one or more persons or entities, and all covenants and agreements hereunder will inure to the benefit of, and be enforceable by the Company&#8217;s successors and assigns. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">You agree upon request to execute any further documents or instruments necessary or desirable in the sole determination of the Company to carry out the purposes or intent of your Award. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">You acknowledge and agree that you have reviewed your Award in its entirety, have had an opportunity to obtain the advice of counsel prior to executing and accepting your Award and fully understand all provisions of your Award.  This Agreement and the Plan contain the entire agreement and understanding among the parties as to the subject matter hereof, and supersede any other agreements or representations, oral or otherwise, express or implied, with respect to the subject matter hereof (including, without limitation, the provisions in your employment letter with respect thereto).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">This Agreement will be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental agencies or national securities exchanges as may be required. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">All obligations of the Company under the Plan and this Agreement will be binding on any successor to the Company, whether the existence of such successor is the result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the business and&#47;or assets of the Company. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Governing Plan Document</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Your Award is subject to all the provisions of the Plan, the provisions of which are hereby made a part of your Award, and is further subject to all interpretations, amendments, rules and regulations which may from time to time be promulgated and adopted pursuant to the Plan.  In the event of any conflict between the provisions of your Award and those of the Plan, the provisions of the Plan will control&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> for avoidance of doubt, terms contained in the Agreement but not in the Plan shall not constitute a conflict and such terms in the Agreement shall control.  The Committee will have the power to interpret the Plan and this Agreement and to adopt such rules for the administration, interpretation, and application of the Plan as are consistent therewith and to interpret or revoke any such rules.  All actions taken and all interpretations and determinations made by the Committee will be final and binding upon you, the Company, and all other interested persons.  No member of the Board or the Committee will be personally liable for any action, determination, or interpretation made in good faith with respect to the Plan or this Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">25.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Effect on Other Employee Benefit Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The value of the Award subject to this Agreement will not be included as compensation, earnings, salaries, or other similar terms used when calculating the employee&#8217;s benefits under any employee benefit plan sponsored by the Company or any affiliate except as such plan otherwise expressly provides.  The Company expressly reserves its rights to amend, modify, or terminate any of the Company&#8217;s or any affiliate&#8217;s employee benefit plans. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">26.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Choice of Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The interpretation, performance and enforcement of this Agreement will be governed by the laws of the Province of Ontario and the laws of Canada. Each of the parties submits to the exclusive jurisdiction of the state courts within the State of New Jersey. In any issue, claim, demand, action, cause of action, suit or proceeding arising out of, or relating to, this Agreement, each of the parties agrees that all claims in respect of the action or proceeding may be heard and determined in any such court, and agrees not to bring any action or proceeding arising out of, relating to, based on or in connection with this Agreement in any other court. Each of the parties waives any defense of inconvenient forum to the maintenance of any action or proceeding so brought and waives any bond, surety or other security that might be required of any other party with respect thereto.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">27.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If all or any part of this Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity will not invalidate any portion of this Agreement or the Plan not declared to be unlawful or invalid.  Any Section of this Agreement (or part of such a Section) so declared to be unlawful or invalid will, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">28.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Appendices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any provisions in this Agreement, the Restricted Share Units shall be subject to any special terms and conditions for employees outside the United States set forth in Appendix A and Appendix B attached hereto (the &#8220;Appendices&#8221;).  Further, if you relocate to one of the countries included in Appendix B, the special terms and conditions for such country will apply to you to the extent that the Company determines that the application of such terms and conditions is necessary or advisable for legal or administrative reasons.  The Appendices constitutes part of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">29.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">CKNOWLEDGEMENTS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. By accepting this Award, you hereby consent to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third-party designated by the Company.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>3
<FILENAME>exhibit1014formofoptiongra.htm
<DESCRIPTION>EX-10.14
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ifa66dd6786b54093a37228fe8e8d9af9_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit 10.14</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BAUSCH HEALTH COMPANIES INC.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FORM OF STOCK OPTION GRANT AGREEMENT<br>(NONSTATUTORY STOCK OPTION)<br>(2014 Omnibus Incentive Plan, as amended and restated, effective as of April 28, 2020)<br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Bausch Health Companies Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), pursuant to Section 7(a) of the Company&#8217;s 2014 Omnibus Incentive Plan, as amended and restated, effective as of April 28, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), hereby grants to you an option to purchase the number of Common Shares set forth below (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  This Award is subject to all of the terms and conditions as set forth herein (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and in the Plan, which is incorporated herein in its entirety.  Capitalized terms not otherwise defined herein shall have the meanings set forth in the Plan.  In the event of any conflict between the terms in the Agreement and the Plan, the terms of the Plan shall control.  For the avoidance of doubt, any terms contained in the Agreement but are not in the Plan shall not constitute a conflict and such terms in the Agreement shall control.</font></div><div><font><br></font></div><div style="padding-left:31.69pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.538%"><tr><td style="width:1.0%"></td><td style="width:52.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Option Holder&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Grant Date&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Number of Common Shares Subject to Option&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Exercise Price (Per Share)&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Expiration Date&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Type of Grant&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Nonstatutory Stock Option</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exercise Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;&#160;&#160;&#160;&#160; Same as Vesting Schedule  &#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Vesting Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58; &#160;&#160;&#160;&#160;This Award shall vest in accordance with the following vesting</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;schedule, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that you are employed by the Company or one of its Subsidiaries &#160;&#160;&#160;&#160;on the applicable anniversary of the Grant Date (each such anniversary, a &#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Vesting Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><br>&#160;&#160;&#160;&#160;-- 1&#47;3rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">of the Common Shares subject to the Option vest on the first anniversary of the &#160;&#160;&#160;&#160;Grant Date.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;-- 1&#47;3rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">of the Common Shares subject to the Option vest on the second anniversary of &#160;&#160;&#160;&#160;the Grant Date.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;-- 1&#47;3rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">of the Common Shares subject to the Option vest on the third anniversary of &#160;&#160;&#160;&#160;the Grant Date.</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Payment&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;By one or a combination of the following methods of payment (described in the &#160;&#160;&#160;&#160;Agreement)&#58;</font></div><div style="padding-left:126pt;text-indent:-36pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Cash or check</font></div><div style="padding-left:126pt;text-indent:-36pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Bank draft or money order payable to the Company</font></div><div style="padding-left:126pt;text-indent:-36pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Pursuant to a Regulation T program (cashless exercise) if the shares are publicly traded</font></div><div style="padding-left:126pt;text-indent:-36pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Delivery of already-owned shares if the shares are publicly traded</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-36pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Net exercise</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The details of your Award are as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Vesting.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">In General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to the provisions of the Plan and the limitations contained herein, your Award will vest as provided above&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> you are employed by the Company or one of its Subsidiaries through the applicable Vesting Date and continue to comply </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with the restrictive covenants in Sections 11 and 12&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that vesting will cease upon your Termination of Service (except as set forth below in Section 1(b) through (d)), and any unvested portion of your Option will be forfeited (and, in the case of your Termination of Service for Cause, the vested portion of your Option will also be forfeited). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Vesting Acceleration Upon Termination of Service due to Death or Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding the foregoing and any other provisions of the Plan to the contrary, in the event of your Termination of Service due to your death or Disability, then any unvested portion of your Option will vest on the date of your Termination of Service. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Vesting Acceleration Upon Termination of Service without Cause or for Good Reason in Connection with a Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding the foregoing and any other provisions of the Plan to the contrary, in the event of your Termination of Service by the Company without Cause or by you for Good Reason, in either case, within twelve (12) months following a Change of Control (or during the six month period prior to a Change of Control if such Termination of Service was in contemplation of, and directly related to, the Change of Control), then any portion of your Option that was not cancelled in connection with such Change of Control in exchange for a cash payment will vest on the date of your Termination of Service, conditioned on you delivering to the Company, and failing to revoke, a signed release of claims acceptable to the Company within fifty-five (55) days following the date of your Termination of Service and you complying with the restrictive covenants in Sections 11 and 12.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Vesting Acceleration Upon Termination of Service due to Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Notwithstanding the foregoing and any other provisions of the Plan to the contrary, in the event of your Termination of Service due to your Retirement (as defined below), then any unvested portion of your Option will vest on the date of your Termination of Service&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that you have been employed by the Company for at least twelve (12) months following the Grant Date (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that, in the event your Termination of Service occurs as a result of the entity for which you are employed ceasing to qualify as a Subsidiary prior to the twelve (12)-month anniversary of the Grant Date, the requirement to be employed by the Company or one of its Subsidiaries for at least twelve (12) months following the Grant Date shall not apply and one-third (1&#47;3) of the Options will vest as of the date of such Termination of Service) and conditioned on you complying with the restrictive covenants in Sections 11 and 12. Unless otherwise defined in your employment or service agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means your Termination of Service on or after the date on which you attain age 55 and your age plus your years of service with the Company and its Subsidiaries total at least 65, and you have not otherwise been terminated for Cause (and your Retirement has not occurred at a time when grounds for a Termination of Service for Cause exist).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Termination of Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Termination of Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the cessation of your employment relationship such that you are no longer an employee of the Company or any Subsidiary&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that the transfer of your employment from the Company to a Subsidiary, from a Subsidiary to the Company, from one Subsidiary to another Subsidiary or, unless the Committee determines otherwise, the cessation of employee status but the continuation of the performance of services for the Company or a Subsidiary as a director or consultant shall not be deemed a cessation of service that would constitute a Termination of Service&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that a Termination of Service shall be deemed to occur if you are employed by, or performing services for, a Subsidiary when such Subsidiary ceases to be a Subsidiary, unless your employment or service continues with the Company or another Subsidiary.  Notwithstanding the foregoing, to the extent this Award is subject to Section 409A of the Code (and not exempt therefrom), a Termination of Service occurs when you experience a Separation of Service.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Number of Shares and Exercise Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The number of Common Shares subject to your Option and your exercise price per share referenced above may be adjusted from time to time in accordance with Section 6(e) of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Method of Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Payment of the exercise price is due in full upon exercise of all or any part of your Option.  You may elect to make payment of the exercise price of your Option in cash or by check or in any other manner permitted by the Company or set forth above, which may include one or more of the following&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Bank draft or money order payable to the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">Provided that at the time of exercise the Common Shares are publicly traded and quoted regularly in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">The Wall Street Journal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of Common Shares, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Provided that at the time of exercise the Common Shares are publicly traded and quoted regularly in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">The Wall Street Journal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, by delivery to the Company (either by actual delivery or attestation) of already-owned Common Shares either that you have held for the period required to avoid a charge to the Company&#8217;s reported earnings (generally six (6) months) or that you did not acquire, directly or indirectly from the Company, that are owned free and clear of any liens, claims, encumbrances or security interests, and that are valued at Market Price on the date of exercise.  &#8220;Delivery&#8221; for these purposes, in the sole discretion of the Company at the time you exercise your Option, shall include delivery to the Company of your attestation of ownership of such Common Shares in a form approved by the Company.  Notwithstanding the foregoing, you may not exercise your Option by tender to the Company of Common Shares to the extent such tender would violate the provisions of any law, regulation or agreement restricting the redemption of the Company&#8217;s stock. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">By a &#8220;net exercise&#8221; arrangement pursuant to which the Company will reduce the number of Common Shares issued upon exercise of your Option by the largest whole number of Common Shares with a Market Price that does not exceed the aggregate exercise price&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that the Company shall accept a cash or other payment from you to the extent of any remaining balance of the aggregate exercise price not satisfied by such reduction in the number of whole Common Shares to be issued&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided further, however, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Common Shares will no longer be outstanding under your Option and will not be exercisable thereafter to the extent that (i) Common Shares are used to pay the exercise price pursuant to the &#8220;net exercise,&#8221; (ii) Common Shares are delivered to you as a result of such exercise, and (iii) Common Shares are withheld to satisfy tax withholding obligations.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Whole Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You may exercise your Option only for whole Common Shares.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Securities Law Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything to the contrary contained herein, you may not exercise your Option unless the Common Shares issuable upon such exercise are then registered under the Securities Act of 1933, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or if such Common Shares are not then so registered the Company has determined that such exercise and issuance would be exempt from the registration requirements of the Securities Act. The exercise of your Option must also comply with other applicable laws and regulations governing your Option, and you may not exercise your Option if the Company determines that such exercise would not be in material compliance with such laws and regulations.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You may not exercise your Option before it becomes vested and exercisable or after the expiration of its term.  The term of your Option commences on the Grant Date and, except as provided otherwise in Section 7(a) of the Plan, expires upon the earliest of the following&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the Expiration Date indicated above&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">your Termination of Service, in the event of your Termination of Service by the Company for Cause&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">three (3) months following your Termination of Service by the Company without Cause&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">six (6) months following your Termination of Service by the Company due to your death or Disability, or upon the expiration of your employment term following a notice of non-renewal of your employment or service agreement by the Company&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">two (2) years following your Termination of Service due to your Retirement&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">three (3) months following your Termination of Service for any reason other than those specifically enumerated in this Section 6&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that (i) if, during any part of the three (3) month, six (6) month or two (2) year periods set forth in Section 6(c), (d) or (e), respectively, your Option is not exercisable solely because of the condition set forth in Section 5, your Option shall not expire until the earlier of the Expiration Date or until it shall have been exercisable for an aggregate period of three (3) months, six (6) months or two (2) years after your Termination of Service, as applicable (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that in no event shall your Option be exercisable at any time following the Expiration Date).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You may exercise the vested portion of your Option during its term by delivering a notice (in a form designated by the Company) together with the exercise price to the Company&#8217;s Plan administrator, or to such other person as the Company may designate, during regular business hours, together with such additional documents as the Company may then require.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Restrictions on Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Your Option shall not be transferable except by will or by the laws of descent and distribution and shall be exercisable during your lifetime only by you&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that the Board may, in its sole discretion, permit you to transfer your Option in a manner consistent with applicable tax and securities laws upon your request.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Domestic Relations Orders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding the foregoing, your Option may be transferred pursuant to a domestic relations order.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Beneficiary Designation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding the foregoing, you may, by delivering written notice to the Company, in a form provided by or otherwise satisfactory to the Company, designate a third party who, in the event of your death, shall thereafter be entitled to exercise your Option.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon the occurrence of a Change of Control, at the election of the Committee in its discretion, your Option shall either be (i) cancelled in exchange for a payment in cash, securities, rights and&#47;or other property, in an amount equal to the value of the Option, which shall be determined by reference to (A) in the case of any merger transaction, the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">consideration received by holders of Common Shares in the transaction constituting the Change of Control or (B) in the case of any other event that constitutes a Change of Control, the Market Price of a Common Share on the date such Change of Control occurs (in each case, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">minus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> the applicable exercise price per Common Share) or (ii) converted into an option in respect of the common stock of the acquiring or surviving entity (or its parent) (in a merger or otherwise) on the basis of the relative values of such stock and the Common Shares at the time of the Change of Control&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that clause (ii) shall only be applicable if the common stock of the acquiring or surviving entity (or its parent), as applicable, is publicly traded on an established securities market on the date on which such Change of Control is effected.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Disclosure and Ownership of Intellectual Property. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Company Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You acknowledge and agree that any intellectual property, including, without limitation, works, materials, inventions, invention disclosures, invention registrations, patent rights, trademarks, service marks, trade names, trade dress, logos, domain names, copyrights, design rights, mask works, software, apparatus, technology, data, trade secrets, know-how and all other intellectual property and proprietary rights recognized by any applicable law of any jurisdiction, that you create, discover, conceive, reduce to practice, develop or acquire during the course of your employment, either alone or jointly with others, (i) using any equipment, supplies, facilities, trade secrets, know-how or other Confidential Information of the Company or any of its affiliates, (ii) that results from any work performed for the Company or any of its affiliates and&#47;or (iii) that otherwise relates to the Company&#8217;s or any of its affiliates&#8217; business or actual or demonstrably anticipated research or development (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Company Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is and shall remain the exclusive property of the Company or the affiliate of the Company, as applicable, that is your employer (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) whether registered or otherwise exploited or not.  In furtherance of the foregoing, you hereby assign, transfer, convey and deliver to the Employer your entire right, title and interest in and to any and all such Company Intellectual Property.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Work Made for Hire</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You acknowledge and agree that, with respect to any Company Intellectual Property that may qualify as a Work Made For Hire as defined in 17 U.S.C. &#167; 101 or other applicable law, such Company Intellectual Property is and will be deemed a Work Made for Hire and the Employer will have the sole and exclusive right to the copyright (or, in the event that any such Company Intellectual Property does not qualify as a Work Made for Hire, the copyright and all other rights thereto are hereby automatically assigned to the Employer as above).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You agree to record all activities undertaken in the course of your employment and to disclose promptly in writing to the Employer any and all Company Intellectual Property.  You agree that you will give the Company or any of its affiliates all reasonable assistance and execute all documents necessary to assist with enabling the Company or any of its affiliates to prosecute, perfect, register, record, enforce and defend any and all of their rights in and to any Company Intellectual Property and Confidential Information.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Non-Assignable Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If your principal work location is in California, Illinois, Kansas, Minnesota or Washington State, the provisions regarding your assignment of Company Intellectual Property to the Employer in Sections 10(a) and (b) of this Agreement may not apply to certain inventions (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Non-Assignable Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) as specified in the statutory code of the applicable state.  You acknowledge having received notification regarding such Non-Assignable Inventions pursuant to such states&#8217; codes.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Prior Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If, in the course of your employment with the Employer, you use any intellectual property that is solely or jointly owned by you or licensed to you, with the right to sub-license (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Prior Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), you hereby </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">grant to the Company and its affiliates a worldwide, non-exclusive, irrevocable, perpetual, fully paid-up and royalty-free license (with rights to sublicense through multiple tiers of sublicensees) to use, reproduce, modify, make derivative works of, publicly perform, publicly display, make, have made, sell, offer for sale, import and otherwise exploit such Prior Intellectual Property for any purpose.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:24.03pt">Waiver of Moral Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. To the extent you may do so under applicable law, you hereby waive and agree never to assert any Moral Rights that you may have in or with respect to any Company Intellectual Property, even after termination of any work on behalf of the Company or its affiliates. As used in this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Moral Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any rights to claim authorship of a work, to object to or prevent the modification or destruction of a work, or to withdraw from circulation or control the publication or distribution of a work, and any similar right, existing under any applicable law of any jurisdiction, regardless of whether or not such right is denominated or generally referred to as a &#8220;moral right.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">This Section 10 shall survive your Termination of Service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Records and Confidential Data. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In consideration of the Stock Options issued to you pursuant to this Agreement, you agree to be bound by the covenant of confidentiality set forth in this Section 11 with respect to any and all Confidential Information (as defined below) disclosed or made available to you or of which you have otherwise become aware, whether before, on or after the date hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Ownership&#59; Recognition of Company&#8217;s Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You acknowledge that in connection with the performance of your duties, the Company will make available to you, or you will have access to, certain Confidential Information of the Company and its affiliates. You acknowledge and agree that any and all Confidential Information you learned or obtained during the course of your employment or service by the Company or any of its affiliates or otherwise, whether developed by you alone or in conjunction with others or otherwise, shall be and is the sole and exclusive property of the Employer. No license or other right to any Confidential Information is granted to you under this Agreement.  To the extent that you acquire any right, title or interest in or to any Confidential Information, you hereby assign, transfer, convey and deliver to the Employer all such right, title and interest in and to such Confidential Information.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You (i)&#160;will keep all Confidential Information strictly confidential, (ii)&#160;will not use Confidential Information in any manner which is detrimental to the Company or its affiliates, (iii)&#160;will not use Confidential Information other than in connection with the discharge of your duties to the Company and its affiliates, (iv)&#160;will safeguard any and all Confidential Information from unauthorized disclosure, and (v)&#160;will not disclose, publish, use, transfer or otherwise disseminate any Confidential Information to any person or entity without the Employer&#8217;s express prior written consent, except as may be necessary to perform your duties as an employee of the Company or its affiliates for the benefit of the Company or its affiliates. You may, however, disclose Confidential Information to the extent it is in response to a valid order of a court or other governmental authority or to otherwise comply with applicable law&#59; provided that, subject to Section 11(e), you shall first give notice to the Employer and reasonably cooperate with the Employer to obtain a protective order or other measures preserving the confidential treatment of such Confidential Information and requiring that the information or documents so disclosed be used only for the purposes for which the order was issued or is otherwise required by applicable law. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Disposition of Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Following your Termination of Service or upon the Company&#8217;s request, you will return to the Company all copies of any and all Confidential Information in your custody, possession or control (including all copies of any analyses, compilations, studies or other documents prepared by you or for your use containing or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reflecting any Confidential Information). Alternatively, with the Company&#8217;s prior written consent, you may destroy such Confidential Information. Within five (5) business days of your Termination of Service or such request by the Company, you shall deliver to the Company a document certifying that such written Confidential Information has been returned or destroyed in accordance with this Section 11(c).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Confidential Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any and all non-public, proprietary or other confidential information of the Company or its affiliates disclosed to you, to which you have access, or of which you otherwise become aware, in each case whether in oral, written, graphic or machine readable form, including, without limitation, (i)&#160;know-how, trade secrets, inventions, discoveries, concepts, information, works, materials, processes, methods, data, software, programs, apparatus, designs and the like, and any other intellectual property the value of which is contingent upon maintaining the confidentiality thereof, (ii)&#160;information regarding the business of the Company or its affiliates, including its products, services, budgets, contracts, reports, investigations, experiments, research, work in progress, drawings, designs, plans, proposals, codes, marketing and sales programs, client lists, client mailing lists, supplier lists, financial projections, cost summaries, pricing formulae, marketing studies relating to prospective business opportunities, and all other concepts, ideas, materials, or information prepared or performed for or by the Company or its affiliates, (iii)&#160;information regarding the skills and compensation of the employees, contractors, and any other service providers of the Company or its affiliates, (iv)&#160;the existence of any business discussions, negotiations, or agreements between the Company or its affiliates and any third party, (v)&#160;all documents and other work product generated by you which contain, comment upon, or relate in any way to any information disclosed by the Company or its affiliates, (vi) all third-party information held in confidence by the Company or its affiliates, and (vii) the terms and conditions of this Agreement. For purposes of this Agreement, the Confidential Information shall not include and your obligation shall not extend to (i) information which is generally available to the public and (ii) information obtained by you other than pursuant to or in connection with your employment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Defend Trade Secrets Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Pursuant to Section 7 of the Defend Trade Secrets Act of 2016 (which added 18 U.S.C. &#167; 1833(b)), you and the Company acknowledge and agree that you shall not have criminal or civil liability under any federal or state trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a federal, State, or local government official, either directly or indirectly, or to an attorney and (ii) solely for the purpose of reporting or investigating a suspected violation of law&#59; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. In addition and without limiting the preceding sentence, if you file a lawsuit for retaliation by the Company for reporting a suspected violation of law, you may disclose the trade secret to your attorney and may use the trade secret information in the court proceeding, if you (x) file any document containing the trade secret under seal and (y) do not disclose the trade secret, except pursuant to court order. Nothing in this Agreement is intended to conflict with 18 U.S.C. &#167;1833(b) or create liability for disclosures of trade secrets that are expressly allowed by such Section.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:24.03pt">Whistleblower Protections</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Without limiting the generality of the foregoing, nothing in this Agreement precludes or otherwise limits your ability to (A) communicate directly with and provide information, including documents, not otherwise protected from disclosure by any applicable law or privilege to the Securities and Exchange Commission (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or any other federal, state or local governmental agency or commission (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Government Agency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or self-regulatory organization regarding possible legal violations, without disclosure to the Company, or (B) disclose information which is required to be disclosed by applicable law, regulation, or order or requirement (including without limitation, by deposition, interrogatory, requests for documents, subpoena, civil investigative demand or similar process) of courts, administrative agencies, the SEC, any Government Agency or self-</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">regulatory organizations, provided that you provide the Company with prior notice of the contemplated disclosure and cooperates with the Company in seeking a protective order or other appropriate protection of such information. The Company may not retaliate against you for any of these activities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">This Section 11 shall survive your Termination of Service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Covenant Not to Solicit, Not to Compete and Not to Disparage. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In consideration of the Options issued to you pursuant to this Agreement, you agree to be bound by the covenants of non-solicitation, non-competition and non-disparagement set forth in this Section 12.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Covenant Not to Solicit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. To protect the Confidential Information and other trade secrets of the Company and its affiliates, you agree, during your employment and for a period of twelve (12) months thereafter (or, if greater, the period set forth in your employment or service agreement) not to solicit, hire or participate in or assist in any way in the solicitation or hire of any employees of the Company or any of its Subsidiaries (or any person who was an employee of the Company or any of its Subsidiaries during the 6-month period preceding such action). For purposes of this covenant, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">solicit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means directly or indirectly influencing or attempting to influence employees of the Company to become employed with any other person, partnership, firm, corporation or other entity. You agree that the covenants contained in this Section 12(a) are reasonable and desirable to protect the Confidential Information of the Company and its affiliates, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that solicitation through general advertising or the provision of references shall not constitute a breach of such obligations.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Covenant Not to Compete</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. To protect the Confidential Information and other trade secrets of the Company and its affiliates, you agree, during the period of your employment and for a period of twelve (12) months thereafter (or, if greater, the period set forth in your employment or service agreement), not to engage in Prohibited Activities (as defined below) in any country in which the Company or its affiliates conduct business, or plan to conduct business, during the period of your employment. For the purposes of this Agreement, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Prohibited Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means directly or indirectly engaging as an owner, employee, consultant or agent of any entity that derives more than 10% of its consolidated revenue from the development, manufacturing, marketing and&#47;or distribution (directly or indirectly) of branded or generic prescription or non-prescription pharmaceuticals or medical devices for treatments in the fields of neurology, dermatology, gastroenterology, ophthalmology or dentistry&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that Prohibited Activities shall not mean (i) your investment in securities of a publicly-traded company equal to less than five (5%) percent of such company&#8217;s outstanding voting securities or (ii) serving as a member of a board of directors of a company provided that, for the avoidance of doubt, you comply with the obligations set forth in Sections 11 and 12(a) of this Agreement. You agree that the covenants contained in this Section 12(b) are reasonable and desirable to protect the Confidential Information of the Company and its affiliates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Non-Disparagement Covenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You agree not to make written or oral statements about the Company or its affiliates or their directors, executive officers or non-executive officer employees that are negative or disparaging. The Company and its affiliates shall not, and the Company and its affiliates shall instruct their directors and executive officers to not, make written or oral statements about you that are negative or disparaging. Notwithstanding the foregoing, nothing in this Agreement shall preclude you, the Company and its affiliates, and the Company&#8217;s or any of its affiliate&#8217;s directors and executive officers from communicating or testifying truthfully to the extent required by law to any federal, state, provincial or local governmental agency or in response to a subpoena to testify issued by a court of competent jurisdiction.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">Your obligations under this Section 12 shall survive your Termination of Service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Severability of Restrictive Covenants. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">It is the intent and desire of you and the Company that the restrictive provisions of this Agreement be enforced to the fullest extent permissible under the laws and public policies as applied in each jurisdiction in which enforcement is sought. If any particular provision of Section 11 or 12 shall be determined to be invalid or unenforceable, such provision shall be amended, without any action on the part of either party hereto, to delete therefrom the portion so determined to be invalid or unenforceable, such deletion to apply only with respect to the operation of such covenant in the particular jurisdiction in which such adjudication is made. Any provision of Section 11 or 12 (or part of such a Section) so declared to be unlawful or invalid will, if possible, be construed in a manner that will give effect to the terms of such Section or part of such Section to the fullest extent possible while remaining lawful and valid.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Remedies for Breach of Obligations Under Sections 11 and 12.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You acknowledge that the Company will suffer irreparable injury, not readily susceptible of valuation in monetary damages, if you breach any obligation under Sections 11 or 12. Accordingly, you agree that the Company will be entitled, in addition to any other available remedies, to obtain preliminary and permanent injunctive relief against any breach or prospective breach by you of your obligations under Sections 11 or 12. Without limiting other forms of relief available to Company, in the event of your breach of any of your obligations under Sections 11 or 12, your Award will be forfeited for no consideration and, if payment in respect of your Award has been made, you will be obligated to return the proceeds to the Company. You agree that process in any or all of those actions or proceedings may be served by registered mail, addressed to the last address provided by you to the Company, or in any other manner authorized by law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Clawback. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement is subject to Section 11 of the Plan and any policy the Company adopts regarding the recovery of incentive compensation and any additional clawback provisions as required by law and applicable listing rules.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Option not a Service Contract</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Your Option is not an employment or service contract, and nothing in your Option will be deemed to create in any way whatsoever any obligation on your part to continue in the service of the Company or an affiliate, or on the part of the Company or an affiliate to continue such service.  In addition, nothing in your Option will obligate the Company or an affiliate, their respective shareholders, boards of directors or employees to continue any relationship that you might have as an employee of the Company or an affiliate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Common Share Ownership Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You agree to comply with, and be subject to the terms of, any Common Share ownership requirements adopted by the Company applicable to you, which shall be on the same terms as similarly situated executives of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Withholding Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">At the time you exercise your Option, in whole or in part, or at any time thereafter as requested by the Company, you hereby authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for (including by means of a &#8220;cashless exercise&#8221; pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board to the extent permitted by the Company), any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company, if any, which arise in connection with the exercise of your Option.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">The Company shall withhold from fully vested Common Shares otherwise issuable to you upon the exercise of your Option a number of whole Common Shares having a Market Price, determined by the Company as of the date of exercise, equal to an amount up to the maximum amount of tax that can be withheld by law (or such other amount as may be permitted by applicable law and accounting standards).  Any adverse consequences to you arising in connection with such share withholding procedure shall be your sole responsibility.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notices provided for in your Option or the Plan shall be given in writing and shall be deemed effectively given upon your receipt or, in the case of notices delivered by the Company to you, five (5) days after deposit in the United States mail, postage prepaid, addressed to you at the last address you provided to the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The headings of the Sections in this Agreement are inserted for convenience only and shall not be deemed to constitute a part of this Agreement or to affect the meaning of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Nothing in this Agreement shall restrict the Committee&#8217;s (or its applicable delegate&#8217;s) ability to exercise its discretionary authority pursuant to Section 4 of the Plan&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that no such action may, without your consent, adversely affect your rights under your Option.  Without limiting the foregoing, the Board (or appropriate committee thereof) reserves the right to change, by written notice to you, the provisions of this Agreement in any way it may deem necessary or advisable to carry out the purpose of the grant as a result of any change in applicable laws or regulations or any future law, regulation, ruling, or judicial decision&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that any such change will be applicable only to rights relating to that portion of the Award which is then subject to restrictions as provided herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The rights and obligations of the Company under your Option shall be transferable to any one or more persons or entities, and all covenants and agreements hereunder shall inure to the benefit of, and be enforceable by the Company&#8217;s successors and assigns. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">You agree upon request to execute any further documents or instruments necessary or desirable in the sole determination of the Company to carry out the purposes or intent of your Option.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">You acknowledge and agree that you have reviewed your Option in its entirety, have had an opportunity to obtain the advice of counsel prior to executing and accepting your Option and fully understand all provisions of your Option.  This Agreement and the Plan contain the entire agreement and understanding among the parties as to the subject matter hereof, and supersede any other agreements or representations, oral or otherwise, express or implied, with respect to the subject matter hereof (including, without limitation, the provisions in your employment letter with respect thereto). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">This Agreement will be subject to all applicable laws, rules and regulations, and to such approvals by any governmental agencies or national securities exchanges as may be required.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">All obligations of the Company under the Plan and this Agreement will be binding on any successor to the Company, whether the existence of such successor is the result of a direct or indirect purchase, merger, consolidation or otherwise, of all or substantially all of the business and&#47;or assets of the Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Governing Plan Document</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Your Option is subject to all the provisions of the Plan, the provisions of which are hereby made a part of your Option, and is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan.  In the event of any conflict between the provisions of your Option and those of the Plan, the provisions of the Plan shall control&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, for avoidance of doubt, terms contained in the Agreement but not in the Plan shall not constitute a conflict and such terms in the Agreement shall control. The Committee will have the power to interpret the Plan and this Agreement and to adopt such rules for the administration, interpretation and application of the Plan as are consistent therewith and to interpret or revoke any such rules.  All actions taken and all interpretations and determinations made by the Committee will be final and binding upon you, the Company and all other interested persons.  No member of the Board or the Committee will be personally liable for any action, determination or interpretation made in good faith with respect to the Plan or this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Effect on Other Employee Benefit Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The value of the Award subject to this Agreement will not be included as compensation, earnings, salaries or other similar terms used when calculating the employee&#8217;s benefits under any employee benefit plan sponsored by the Company or any affiliate except as such plan otherwise expressly provides.  The Company expressly reserves its rights to amend, modify or terminate any of the Company&#8217;s or any affiliate&#8217;s employee benefit plans.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">25.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Choice of Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The interpretation, performance and enforcement of this Agreement will be governed by the laws of the Province of Ontario and the laws of Canada. Each of the parties submits to the exclusive jurisdiction of the state courts within the State of New Jersey. In any issue, claim, demand, action, cause of action, suit or proceeding arising out of, or relating to, this Agreement, each of the parties agrees that all claims in respect of the action or proceeding may be heard and determined in any such court, and agrees not to bring any action or proceeding arising out of, relating to, based on or in connection with this Agreement in any other court. Each of the parties waives any defense of inconvenient forum to the maintenance of any action or proceeding so brought and waives any bond, surety or other security that might be required of any other party with respect thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">26.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If all or any part of this Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity will not invalidate any portion of this Agreement or the Plan not declared to be unlawful or invalid.  Any Section of this Agreement (or part of such a Section) so declared to be unlawful or invalid will, if possible, be construed in a manner that will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">27.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Appendices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any provisions in this Agreement, the Option shall be subject to any special terms and conditions for employees outside the United States set forth in Appendix A and Appendix B attached hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Appendices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Further, if you relocate to one of the countries included in Appendix B, the special terms and conditions for such country will apply to you to the extent that the Company determines that the application of such terms and conditions is necessary or advisable for legal or administrative reasons.  The Appendices constitutes part of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">28.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">CKNOWLEDGEMENTS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. By accepting this Award, you hereby consent to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third-party designated by the Company.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>exhibit311q12022.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i3c8a1b0b2dab4a949a63a7ae1ae36e39_1"></div><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt;margin-top:10pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO RULE 13a-14(a)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Thomas J. Appio, certify that&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form&#160;10-Q of Bausch Health Companies&#160;Inc. (the&#160;&#8220;Company&#8221;)&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this&#160;report&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this&#160;report&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The Company's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as&#160;defined in Exchange Act Rules&#160;13a-15(e) and&#160;15d-15(e)) and internal control over financial reporting (as&#160;defined in Exchange Act Rules&#160;13a-15(f) and&#160;15d-15(f)) for the Company and&#160;have&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being&#160;prepared&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;Evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;Disclosed in this report any change in the Company&#8217;s internal control over financial reporting that occurred during the Company's most recent fiscal quarter (the Company's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The Company's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company&#8217;s auditors and the audit committee of the Company&#8217;s board of directors (or&#160;persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company&#8217;s ability to record, process, summarize and report financial information&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal control over financial reporting.</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:4.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.727%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.314%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 10, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; THOMAS J. APPIO</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas J. Appio</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer<br>(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>exhibit312q12022.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iaf9b3583c22c40368a69af98e3839f84_1"></div><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt;margin-top:10pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO RULE 13a-14(a)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Tom Vadaketh, certify that&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form&#160;10-Q of Bausch Health Companies&#160;Inc. (the&#160;&#8220;Company&#8221;)&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this&#160;report&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this&#160;report&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The Company&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as&#160;defined in Exchange Act Rules&#160;13a-15(e) and&#160;15d-15(e)) and internal control over financial reporting (as&#160;defined in Exchange Act Rules&#160;13a-15(f) and&#160;15d-15(f)) for the Company and&#160;have&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being&#160;prepared&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;Evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;Disclosed in this report any change in the Company&#8217;s internal control over financial reporting that occurred during the Company&#8217;s most recent fiscal quarter (the Company's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The Company&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company&#8217;s auditors and the audit committee of the Company&#8217;s board of directors (or&#160;persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company&#8217;s ability to record, process, summarize and report financial information&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal control over financial reporting.</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:4.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.727%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.314%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 10, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; TOM VADAKETH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Tom Vadaketh</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Chief Financial Officer<br>(Principal Financial Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>exhibit321q12022.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i8fbed72c200240a0aea8299f08625c65_1"></div><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt;margin-top:10pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18&#160;U.S.C. &#167;&#160;1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Thomas J. Appio, Chief Executive Officer of Bausch Health Companies&#160;Inc. (the&#160;&#8220;Company&#8221;), certify, pursuant to 18&#160;U.S.C. &#167;&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to my&#160;knowledge&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;The Quarterly Report on Form&#160;10-Q of the Company for the quarter ended March&#160;31, 2022 (the&#160;&#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the&#160;Company.</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.988%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.382%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 10, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; THOMAS J. APPIO</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas J. Appio</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer<br>(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Report pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the&#160;&#8220;Exchange Act&#8221;). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by&#160;reference.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the U.S.&#160;Securities and Exchange Commission or its staff upon&#160;request.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>exhibit322q12022.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i5d6be34e33164e91bf35274bd0782ab6_1"></div><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt;margin-top:10pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18&#160;U.S.C. &#167;&#160;1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Tom Vadaketh, Executive Vice-President, Chief Financial Officer of Bausch Health Companies&#160;Inc. (the&#160;&#8220;Company&#8221;), certify, pursuant to 18&#160;U.S.C. &#167;&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to my&#160;knowledge&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;The Quarterly Report on Form&#160;10-Q of the Company for the quarter ended March&#160;31, 2022 (the&#160;&#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the&#160;Company.</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.988%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.382%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 10, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; TOM VADAKETH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Tom Vadaketh</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Chief Financial Officer<br>(Principal Financial Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Report pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the&#160;&#8220;Exchange Act&#8221;). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by&#160;reference.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the U.S.&#160;Securities and Exchange Commission or its staff upon&#160;request.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>bhc-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:9c0993e0-3c65-4e23-b478-aba95d934319,g:036e3555-df42-4f12-aaee-1876eac48ef4-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:bhc="http://www.bauschhealth.com/20220331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.bauschhealth.com/20220331">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bhc-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bhc-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bhc-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bhc-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://www.bauschhealth.com/role/DocumentandEntityInformation">
        <link:definition>0001001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
        <link:definition>1004005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT" roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT">
        <link:definition>1005006 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' DEFICIT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESS" roleURI="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS">
        <link:definition>2101101 - Disclosure - DESCRIPTION OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESSNarrativeDetails" roleURI="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails">
        <link:definition>2402401 - Disclosure - DESCRIPTION OF BUSINESS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>2103102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>2204201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails">
        <link:definition>2405402 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITION" roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITION">
        <link:definition>2106103 - Disclosure - REVENUE RECOGNITION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITIONTables" roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONTables">
        <link:definition>2307301 - Disclosure - REVENUE RECOGNITION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITIONNarrativeDetails" roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails">
        <link:definition>2408403 - Disclosure - REVENUE RECOGNITION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITIONVariableConsiderationProvisionsDetails" roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails">
        <link:definition>2409404 - Disclosure - REVENUE RECOGNITION - Variable Consideration Provisions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails" roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails">
        <link:definition>2410405 - Disclosure - REVENUE RECOGNITION - Activity in Allowance for Credit Losses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LICENSINGAGREEMENTSANDDIVESTITURE" roleURI="http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURE">
        <link:definition>2111104 - Disclosure - LICENSING AGREEMENTS AND DIVESTITURE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails" roleURI="http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails">
        <link:definition>2412406 - Disclosure - LICENSING AGREEMENTS AND DIVESTITURE - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS" roleURI="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS">
        <link:definition>2113105 - Disclosure - RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails" roleURI="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails">
        <link:definition>2414407 - Disclosure - RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS">
        <link:definition>2115106 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables">
        <link:definition>2316302 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>2417408 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails">
        <link:definition>2418409 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails">
        <link:definition>2419410 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails">
        <link:definition>2420411 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails">
        <link:definition>2421412 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Currency Exchange Contracts, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails">
        <link:definition>2422413 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included in Consolidated Balance Sheets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails">
        <link:definition>2423414 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included on Consolidated Statements of Operations and Consolidated Statements of Cash Flows (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails">
        <link:definition>2424415 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails">
        <link:definition>2425416 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Reconciliation of Contingent Consideration Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails">
        <link:definition>2426417 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured on a Non-Recurring Basis and Fair Value of Long-term Debt, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIES" roleURI="http://www.bauschhealth.com/role/INVENTORIES">
        <link:definition>2127107 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIESTables" roleURI="http://www.bauschhealth.com/role/INVENTORIESTables">
        <link:definition>2328303 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIESComponentsofInventoriesDetails" roleURI="http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails">
        <link:definition>2429418 - Disclosure - INVENTORIES - Components of Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILL" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL">
        <link:definition>2130108 - Disclosure - INTANGIBLE ASSETS AND GOODWILL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLTables" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables">
        <link:definition>2331304 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails">
        <link:definition>2432419 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Major Components of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLNarrativeDetails" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails">
        <link:definition>2433420 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails">
        <link:definition>2434421 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails">
        <link:definition>2435422 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Changes in Carrying Amount of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDANDOTHERCURRENTLIABILITIES" roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES">
        <link:definition>2136109 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDANDOTHERCURRENTLIABILITIESTables" roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables">
        <link:definition>2337305 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails" roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails">
        <link:definition>2438423 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES - Summary of Accrued and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTS" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS">
        <link:definition>2139110 - Disclosure - FINANCING ARRANGEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSTables" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables">
        <link:definition>2340306 - Disclosure - FINANCING ARRANGEMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails">
        <link:definition>2441424 - Disclosure - FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSCovenantComplianceDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails">
        <link:definition>2442425 - Disclosure - FINANCING ARRANGEMENTS - Covenant Compliance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails">
        <link:definition>2443426 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSSeniorSecuredNotesDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails">
        <link:definition>2444427 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails">
        <link:definition>2445428 - Disclosure - FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails">
        <link:definition>2446429 - Disclosure - FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails">
        <link:definition>2447430 - Disclosure - FINANCING ARRANGEMENTS - Aggregate Maturities of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSMaturitiesNarrativeDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesNarrativeDetails">
        <link:definition>2448431 - Disclosure - FINANCING ARRANGEMENTS - Maturities, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS">
        <link:definition>2149111 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables">
        <link:definition>2350307 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails">
        <link:definition>2451432 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATION" roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION">
        <link:definition>2152112 - Disclosure - SHARE-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONTables" roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables">
        <link:definition>2353308 - Disclosure - SHARE-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONNarrativeDetails" roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>2454433 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails">
        <link:definition>2455434 - Disclosure - SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails" roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails">
        <link:definition>2456435 - Disclosure - SHARE-BASED COMPENSATION - Summary of Share-Based Compensation Award Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCUMULATEDOTHERCOMPREHENSIVELOSS" roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS">
        <link:definition>2157113 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCUMULATEDOTHERCOMPREHENSIVELOSSTables" roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables">
        <link:definition>2358309 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails" roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails">
        <link:definition>2459436 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS - Summary of Components of Accumulated Other Comprehensive Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESEARCHANDDEVELOPMENT" roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT">
        <link:definition>2160114 - Disclosure - RESEARCH AND DEVELOPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESEARCHANDDEVELOPMENTTables" roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables">
        <link:definition>2361310 - Disclosure - RESEARCH AND DEVELOPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails" roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails">
        <link:definition>2462437 - Disclosure - RESEARCH AND DEVELOPMENT - Summary of Research and Development (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHEREXPENSEINCOMENET" roleURI="http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENET">
        <link:definition>2163115 - Disclosure - OTHER EXPENSE (INCOME), NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHEREXPENSEINCOMENETTables" roleURI="http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETTables">
        <link:definition>2364311 - Disclosure - OTHER EXPENSE (INCOME), NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHEREXPENSEINCOMENETSummaryofOtherExpenseNetDetails" roleURI="http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETSummaryofOtherExpenseNetDetails">
        <link:definition>2465438 - Disclosure - OTHER EXPENSE (INCOME), NET - Summary of Other Expense, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHEREXPENSEINCOMENETNarrativeDetails" roleURI="http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails">
        <link:definition>2466439 - Disclosure - OTHER EXPENSE (INCOME), NET - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://www.bauschhealth.com/role/INCOMETAXES">
        <link:definition>2167116 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESNarrativeDetails" roleURI="http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails">
        <link:definition>2468440 - Disclosure - INCOME TAXES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LOSSPERSHARE" roleURI="http://www.bauschhealth.com/role/LOSSPERSHARE">
        <link:definition>2169117 - Disclosure - LOSS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LOSSPERSHARETables" roleURI="http://www.bauschhealth.com/role/LOSSPERSHARETables">
        <link:definition>2370312 - Disclosure - LOSS PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails" roleURI="http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails">
        <link:definition>2471441 - Disclosure - LOSS PER SHARE - Schedule of Calculation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LOSSPERSHARENarrativeDetails" roleURI="http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails">
        <link:definition>2472442 - Disclosure - LOSS PER SHARE - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEGALPROCEEDINGS" roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGS">
        <link:definition>2173118 - Disclosure - LEGAL PROCEEDINGS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEGALPROCEEDINGSLegalProceedsandGovernmentalandRegulatoryInquiriesDetails" roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSLegalProceedsandGovernmentalandRegulatoryInquiriesDetails">
        <link:definition>2474443 - Disclosure - LEGAL PROCEEDINGS - Legal Proceeds and Governmental and Regulatory Inquiries (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails" roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails">
        <link:definition>2475444 - Disclosure - LEGAL PROCEEDINGS - Securities and RICO Class Actions and Related Matters (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEGALPROCEEDINGSAntitrustDetails" roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails">
        <link:definition>2476445 - Disclosure - LEGAL PROCEEDINGS - Antitrust (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEGALPROCEEDINGSIntellectualPropertyDetails" roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails">
        <link:definition>2477446 - Disclosure - LEGAL PROCEEDINGS - Intellectual Property (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEGALPROCEEDINGSProductLiabilityDetails" roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails">
        <link:definition>2478447 - Disclosure - LEGAL PROCEEDINGS - Product Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEGALPROCEEDINGSGeneralCivilActionsDetails" roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails">
        <link:definition>2479448 - Disclosure - LEGAL PROCEEDINGS - General Civil Actions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATION" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATION">
        <link:definition>2180119 - Disclosure - SEGMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONTables" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables">
        <link:definition>2381313 - Disclosure - SEGMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONNarrativeDetails" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails">
        <link:definition>2482449 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONSegmentRevenuesandProfitDetails" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails">
        <link:definition>2483450 - Disclosure - SEGMENT INFORMATION - Segment Revenues and Profit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONDisaggregationofRevenueDetails" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails">
        <link:definition>2484451 - Disclosure - SEGMENT INFORMATION - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONNarrativeDetails_1" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1">
        <link:definition>2485452 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONRevenuebyGeographicAreaDetails" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails">
        <link:definition>2486453 - Disclosure - SEGMENT INFORMATION - Revenue by Geographic Area (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONMajorCustomersDetails" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails">
        <link:definition>2487454 - Disclosure - SEGMENT INFORMATION - Major Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTS" roleURI="http://www.bauschhealth.com/role/SUBSEQUENTEVENTS">
        <link:definition>2188120 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTSNarrativeDetails" roleURI="http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails">
        <link:definition>2489455 - Disclosure - SUBSEQUENT EVENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" abstract="false" name="LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_ApotexIncLitigationMember" abstract="true" name="ApotexIncLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ProposedBusinessSeparationAndInitialPublicOfferingNumberOfCompaniesEstablished" abstract="false" name="ProposedBusinessSeparationAndInitialPublicOfferingNumberOfCompaniesEstablished" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_GlumetzaAntitrustLitigationMember" abstract="true" name="GlumetzaAntitrustLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" abstract="false" name="DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet" abstract="false" name="DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_NonemployeeDirectorMember" abstract="true" name="NonemployeeDirectorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" abstract="false" name="DebtInstrumentCovenantTermsFixedChargeCoverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bhc_CanadianSecuritiesLitigationMember" abstract="true" name="CanadianSecuritiesLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SOFRCDORAndEURIBORRatesMember" abstract="true" name="SOFRCDORAndEURIBORRatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" abstract="false" name="RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" abstract="true" name="ViolationofCanadianProvincialSecuritiesLegislationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DiscontinuedProductLinesMember" abstract="true" name="DiscontinuedProductLinesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember" abstract="true" name="PerrigoIsraelPharmaceuticalsLtdLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_CardinalHealthIncMember" abstract="true" name="CardinalHealthIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate" abstract="false" name="DebtInstrumentCreditSpreadAdjustmentOnVariableRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_RICOClassActionsMember" abstract="true" name="RICOClassActionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ReserveForCustomerReturnsMember" abstract="true" name="ReserveForCustomerReturnsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" abstract="false" name="DebtInstrumentRedemptionPricePercentageChangeinControl" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" abstract="false" name="DebtInstrumentCovenantTotalLeverageRatioMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bhc_TermLoanDueMay2027Member" abstract="true" name="TermLoanDueMay2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ReportingUnitsExcludingOrthoDermatologicsMember" abstract="true" name="ReportingUnitsExcludingOrthoDermatologicsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentAnnualAmortizationRatePercentage" abstract="false" name="DebtInstrumentAnnualAmortizationRatePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_SeniorSecured5.50NotesDueNovember2025Member" abstract="true" name="SeniorSecured5.50NotesDueNovember2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" abstract="false" name="GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SeniorNotes6125DueApril2025Member" abstract="true" name="SeniorNotes6125DueApril2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorSecured5.75NotesDueAugust2027Member" abstract="true" name="SeniorSecured5.75NotesDueAugust2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" abstract="false" name="SummaryOfValuationAndQualifyingAccountsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember" abstract="true" name="RestrictedCashAndOtherSettlementDepositsCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" abstract="false" name="DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_SeniorNotes700DueMarch2024Member" abstract="true" name="SeniorNotes700DueMarch2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_CustomerTopTenProductsMember" abstract="true" name="CustomerTopTenProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LitigationSettlementNumberOfObjectorsAppeals" abstract="false" name="LitigationSettlementNumberOfObjectorsAppeals" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_SeniorNotes625DueFebruary2029Member" abstract="true" name="SeniorNotes625DueFebruary2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_BauschLombInternationalMember" abstract="true" name="BauschLombInternationalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet" abstract="false" name="DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_SeniorNotes850DueJanuary2027Member" abstract="true" name="SeniorNotes850DueJanuary2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ReserveForChargebacksMember" abstract="true" name="ReserveForChargebacksMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SOFRCDOREURIBORAndSONIARatesMember" abstract="true" name="SOFRCDOREURIBORAndSONIARatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" abstract="true" name="EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_PadagisLitigationMember" abstract="true" name="PadagisLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" abstract="true" name="GlumetzaAntitrustLitigationNonClassComplaintsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" abstract="false" name="BusinessCombinationContingentConsiderationNoncurrentLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_A2027RevolvingCreditFacilityMember" abstract="true" name="A2027RevolvingCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_InsuranceCoverageLawsuitMember" abstract="true" name="InsuranceCoverageLawsuitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_PatentInfringementLitigationMember" abstract="true" name="PatentInfringementLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ReserveForDiscountsAndAllowancesMember" abstract="true" name="ReserveForDiscountsAndAllowancesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" abstract="false" name="DebtInstrumentCovenantInterestCoverageRatioMinimum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bhc_ShowerToShowerProductLiabilityLitigationMember" abstract="true" name="ShowerToShowerProductLiabilityLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" abstract="false" name="ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_CanadaBankersAcceptanceRateMember" abstract="true" name="CanadaBankersAcceptanceRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_PharmaceuticalProductsMember" abstract="true" name="PharmaceuticalProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SaleOfStockOverAllotmentTerm" abstract="false" name="SaleOfStockOverAllotmentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_ReserveForRebatesAdvertisingCreditsPortionMember" abstract="true" name="ReserveForRebatesAdvertisingCreditsPortionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" abstract="false" name="DebtInstrumentPeriodicPaymentQuarterlyAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_NorwichPharmaceuticalsIncLitigationMember" abstract="true" name="NorwichPharmaceuticalsIncLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" abstract="true" name="FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bhc_SeniorSecuredCreditFacilityMember" abstract="true" name="SeniorSecuredCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorSecured4875NotesDueJune2028Member" abstract="true" name="SeniorSecured4875NotesDueJune2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" abstract="false" name="SummaryOfResearchAndDevelopmentExpenseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_LossContingencyStayOfApprovalMotionToExtendPeriod" abstract="false" name="LossContingencyStayOfApprovalMotionToExtendPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_ValeantUSSecuritiesLitigationMember" abstract="true" name="ValeantUSSecuritiesLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_GainLossRelatedToLitigationSettlementGross" abstract="false" name="GainLossRelatedToLitigationSettlementGross" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_UnitedStatesandPuertoRicoMember" abstract="true" name="UnitedStatesandPuertoRicoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LitigationwithFormerSalixCEOMember" abstract="true" name="LitigationwithFormerSalixCEOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes725DueMay2029Member" abstract="true" name="SeniorNotes725DueMay2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AmounPharmaceuticalCompanySAEMember" abstract="true" name="AmounPharmaceuticalCompanySAEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember" abstract="true" name="USDollarBaseRateAndCanadianDollarPrimeRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AccruedAndOtherCurrentLiabilitiesMember" abstract="true" name="AccruedAndOtherCurrentLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OvertheCounterProductsMember" abstract="true" name="OvertheCounterProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SeniorNotes900DueDecember2025Member" abstract="true" name="SeniorNotes900DueDecember2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_RestructuringAndIntegrationCostsMember" abstract="true" name="RestructuringAndIntegrationCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_InterestSettlementOnCrossCurrencySwaps" abstract="false" name="InterestSettlementOnCrossCurrencySwaps" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SeniorNotes500DueJanuary2028Member" abstract="true" name="SeniorNotes500DueJanuary2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" abstract="false" name="RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_MeasurementInputWeightedAverageDiscountRateMember" abstract="true" name="MeasurementInputWeightedAverageDiscountRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_PartnerRelationshipsMember" abstract="true" name="PartnerRelationshipsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" abstract="false" name="LossContingencyNewClaimsFiledButNotYetServedNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_RevolvingCreditFacilityDueJune2023Member" abstract="true" name="RevolvingCreditFacilityDueJune2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_PlaintiffsDirectPurchasersMember" abstract="true" name="PlaintiffsDirectPurchasersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AmerisourceBergenCorporationMember" abstract="true" name="AmerisourceBergenCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LossContingencySettlementAgreementsNumberOfInsurers" abstract="false" name="LossContingencySettlementAgreementsNumberOfInsurers" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_BaseRateOrPrimeRateMember" abstract="true" name="BaseRateOrPrimeRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ConcentrationRiskNumberOfProducts" abstract="false" name="ConcentrationRiskNumberOfProducts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_BrandedandOtherGenericProductsMember" abstract="true" name="BrandedandOtherGenericProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_TimeBasedRSUMember" abstract="true" name="TimeBasedRSUMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OtherCountriesMember" abstract="true" name="OtherCountriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ScheduleOfOtherIncomeAndExpensesTable" abstract="true" name="ScheduleOfOtherIncomeAndExpensesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="bhc_A2027TermLoanBFacilityMember" abstract="true" name="A2027TermLoanBFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ResearchAndDevelopmentExpenseQualityAssurance" abstract="false" name="ResearchAndDevelopmentExpenseQualityAssurance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" abstract="false" name="AccountsReceivableAllowanceForForeignExchangeAndOther" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount" abstract="false" name="SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bhc_BauschLombMember" abstract="true" name="BauschLombMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_TermLoanBFacilityDueJune2025Member" abstract="true" name="TermLoanBFacilityDueJune2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_Legalsettlementsandrelatedfees" abstract="false" name="Legalsettlementsandrelatedfees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DerivativeGainExcludedComponent" abstract="false" name="DerivativeGainExcludedComponent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" abstract="false" name="LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet" abstract="false" name="DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_LossContingencyNumberOfSeparateDefendants" abstract="false" name="LossContingencyNumberOfSeparateDefendants" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_McKessonCorporationMember" abstract="true" name="McKessonCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_RestructuringChargesAndInitialPublicOfferingCosts" abstract="false" name="RestructuringChargesAndInitialPublicOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_PerformanceBasedRestrictedStockUnitsMember" abstract="true" name="PerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DeferredIncomeTaxNoncashExpenseBenefit" abstract="false" name="DeferredIncomeTaxNoncashExpenseBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_TSRPerformanceBasedRestrictedStockUnitsMember" abstract="true" name="TSRPerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" abstract="false" name="DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_NewRestatedCreditAgreementMember" abstract="true" name="NewRestatedCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" abstract="false" name="BusinessAcquisitionContingentConsiderationFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" abstract="false" name="LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_ResearchAndDevelopmentExpenseProductRelated" abstract="false" name="ResearchAndDevelopmentExpenseProductRelated" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" abstract="false" name="UnrecognizedTaxBenefitsIncludingInterestAndPenalties" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_ProductBrandsMember" abstract="true" name="ProductBrandsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_MSNLaboratoriesPrivateLtdLitigationMember" abstract="true" name="MSNLaboratoriesPrivateLtdLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_RevolvingCreditFacilityDueMay2027Member" abstract="true" name="RevolvingCreditFacilityDueMay2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorSecuredCreditFacilitiesMember" abstract="true" name="SeniorSecuredCreditFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeparationAndInitialPublicOfferingCostsMember" abstract="true" name="SeparationAndInitialPublicOfferingCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ReserveForRebatesMember" abstract="true" name="ReserveForRebatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SalixSegmentMember" abstract="true" name="SalixSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" abstract="false" name="DebtInstrumentCovenantTermsSecuredLeverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bhc_OmnibusIncentivePlan2014Member" abstract="true" name="OmnibusIncentivePlan2014Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_A9.00SeniorNotesdueDecember2025Member" abstract="true" name="A9.00SeniorNotesdueDecember2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet" abstract="false" name="DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_SeniorNotes700DueJanuary2028Member" abstract="true" name="SeniorNotes700DueJanuary2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DoctorsAllergyFormulaLLCLitigationMember" abstract="true" name="DoctorsAllergyFormulaLLCLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" abstract="false" name="AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SeniorNotes925DueApril2026Member" abstract="true" name="SeniorNotes925DueApril2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LossContingencyStayOfApprovalPeriod" abstract="false" name="LossContingencyStayOfApprovalPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio" abstract="false" name="DebtInstrumentCovenantComplianceSecuredLeverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bhc_DeviceProductsMember" abstract="true" name="DeviceProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorSecured6125NotesDueFebruary2027Member" abstract="true" name="SeniorSecured6125NotesDueFebruary2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantTotalLeverageRatio" abstract="false" name="DebtInstrumentCovenantTotalLeverageRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_MilestonePaymentRelatedToCertainProductMember" abstract="true" name="MilestonePaymentRelatedToCertainProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" abstract="false" name="LineOfCreditFacilityThresholdForIncrementalBorrowings" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" abstract="false" name="LossContingencyPlaintiffsNumberofGroupsofInvestors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_RevenuesNetMember" abstract="true" name="RevenuesNetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ReserveForDistributionFeesMember" abstract="true" name="ReserveForDistributionFeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" abstract="true" name="ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_PriceAppreciationCreditMember" abstract="true" name="PriceAppreciationCreditMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" abstract="false" name="LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_SoltaMedicalSegmentMember" abstract="true" name="SoltaMedicalSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_TermLoanBFacilityDueNovember2025Member" abstract="true" name="TermLoanBFacilityDueNovember2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes525DueJanuary2030Member" abstract="true" name="SeniorNotes525DueJanuary2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AssetImpairmentChargesMember" abstract="true" name="AssetImpairmentChargesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OrthoDermatologicsReportingUnitMember" abstract="true" name="OrthoDermatologicsReportingUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OrthoDermatologicsSegmentMember" abstract="true" name="OrthoDermatologicsSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments" abstract="false" name="DebtInstrumentCovenantAmountAvailableForRestrictedPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_ReportingUnitImpairmentTestLongTermGrowthRate" abstract="false" name="ReportingUnitImpairmentTestLongTermGrowthRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_RestrictedCashAndOtherSettlementDepositsCurrent" abstract="false" name="RestrictedCashAndOtherSettlementDepositsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember" abstract="true" name="FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes500DueFebruary2029Member" abstract="true" name="SeniorNotes500DueFebruary2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" abstract="false" name="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_LossContingencyNumberOfInsurancePolicyPeriods" abstract="false" name="LossContingencyNumberOfInsurancePolicyPeriods" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_SeniorNotes525DueFebruary2031Member" abstract="true" name="SeniorNotes525DueFebruary2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OtherLongTermDebtMember" abstract="true" name="OtherLongTermDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OtherRevenuesMember" abstract="true" name="OtherRevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AccruedProductReturnCurrent" abstract="false" name="AccruedProductReturnCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" abstract="false" name="LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_OutLicensedTechnologyMember" abstract="true" name="OutLicensedTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" abstract="false" name="AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_ScheduleOfOtherIncomeAndExpensesLineItems" abstract="true" name="ScheduleOfOtherIncomeAndExpensesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable" abstract="true" name="ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="bhc_HighlyLiquidInvestmentsMaturityPeriod" abstract="false" name="HighlyLiquidInvestmentsMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" abstract="true" name="ROTCPerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate" abstract="false" name="LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" abstract="false" name="LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_InternationalRxMember" abstract="true" name="InternationalRxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AccruedProductRebateCurrent" abstract="false" name="AccruedProductRebateCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_AllowancesForLossesOnAccountsReceivableAndInventories" abstract="false" name="AllowancesForLossesOnAccountsReceivableAndInventories" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA" abstract="false" name="LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_SeparationPerformanceBasedRestrictedStockUnitsMember" abstract="true" name="SeparationPerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AccretionForTimeValueOfMoneyMember" abstract="true" name="AccretionForTimeValueOfMoneyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DiversifiedProductsSegmentMember" abstract="true" name="DiversifiedProductsSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>bhc-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:9c0993e0-3c65-4e23-b478-aba95d934319,g:036e3555-df42-4f12-aaee-1876eac48ef4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="bhc-20220331.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4c509a59-f177-4f81-aeb5-fb696d4c1fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_290cbb44-8cff-4b4f-81ba-cd120b485248" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4c509a59-f177-4f81-aeb5-fb696d4c1fc3" xlink:to="loc_us-gaap_CommonStockValue_290cbb44-8cff-4b4f-81ba-cd120b485248" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_a87f9184-8dbd-4f5d-924e-3f5dd46cac95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4c509a59-f177-4f81-aeb5-fb696d4c1fc3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_a87f9184-8dbd-4f5d-924e-3f5dd46cac95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c7026f21-4f2e-487d-885d-2c61d53cd6bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4c509a59-f177-4f81-aeb5-fb696d4c1fc3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c7026f21-4f2e-487d-885d-2c61d53cd6bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d0f1b35b-06e6-4036-9c21-4d92fcbc05e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4c509a59-f177-4f81-aeb5-fb696d4c1fc3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d0f1b35b-06e6-4036-9c21-4d92fcbc05e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b1af0eb4-c3ef-42d4-91fa-2e24e35521d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_163f6466-ef9a-41b6-90d4-915516645ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b1af0eb4-c3ef-42d4-91fa-2e24e35521d7" xlink:to="loc_us-gaap_AssetsCurrent_163f6466-ef9a-41b6-90d4-915516645ae7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_54bb804d-09b2-4426-95e5-0a4cfe0790b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b1af0eb4-c3ef-42d4-91fa-2e24e35521d7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_54bb804d-09b2-4426-95e5-0a4cfe0790b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_121e629f-119b-4868-8ed6-70f9b6777dba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b1af0eb4-c3ef-42d4-91fa-2e24e35521d7" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_121e629f-119b-4868-8ed6-70f9b6777dba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_73609652-ef91-4b15-a9b1-3460e9c05358" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b1af0eb4-c3ef-42d4-91fa-2e24e35521d7" xlink:to="loc_us-gaap_Goodwill_73609652-ef91-4b15-a9b1-3460e9c05358" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_3909a862-7d3e-4eff-875a-a4b5a33fdb45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b1af0eb4-c3ef-42d4-91fa-2e24e35521d7" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_3909a862-7d3e-4eff-875a-a4b5a33fdb45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_fe028d81-e643-49bb-8339-7813c0efd847" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b1af0eb4-c3ef-42d4-91fa-2e24e35521d7" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_fe028d81-e643-49bb-8339-7813c0efd847" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_6319084f-b5fb-4c9d-97e6-a6863cc03633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_1e08ecdd-a380-4d0b-9303-4d122219ff99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6319084f-b5fb-4c9d-97e6-a6863cc03633" xlink:to="loc_us-gaap_Liabilities_1e08ecdd-a380-4d0b-9303-4d122219ff99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_251c0ead-7fc8-42df-8af2-28c4a8a095c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6319084f-b5fb-4c9d-97e6-a6863cc03633" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_251c0ead-7fc8-42df-8af2-28c4a8a095c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_ac0869f5-fd84-461e-8d35-d4f6a9549254" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6319084f-b5fb-4c9d-97e6-a6863cc03633" xlink:to="loc_us-gaap_CommitmentsAndContingencies_ac0869f5-fd84-461e-8d35-d4f6a9549254" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0f397586-081b-4ef1-adc1-4413e181c1c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8f535a6f-174b-4cc8-8978-d4d25b859590" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0f397586-081b-4ef1-adc1-4413e181c1c1" xlink:to="loc_us-gaap_LiabilitiesCurrent_8f535a6f-174b-4cc8-8978-d4d25b859590" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_5d6484b5-2027-486d-9953-7c439e5e938a" xlink:href="bhc-20220331.xsd#bhc_BusinessCombinationContingentConsiderationNoncurrentLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0f397586-081b-4ef1-adc1-4413e181c1c1" xlink:to="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_5d6484b5-2027-486d-9953-7c439e5e938a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_8dadd970-c6ef-4ba9-b424-00ae4e12b304" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0f397586-081b-4ef1-adc1-4413e181c1c1" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_8dadd970-c6ef-4ba9-b424-00ae4e12b304" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_baa2f16d-696b-47a7-9cb5-1a719d5a9116" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0f397586-081b-4ef1-adc1-4413e181c1c1" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_baa2f16d-696b-47a7-9cb5-1a719d5a9116" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_c6809303-abd8-48f4-b1ae-ebfc232bf368" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0f397586-081b-4ef1-adc1-4413e181c1c1" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_c6809303-abd8-48f4-b1ae-ebfc232bf368" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f51d7d1e-c2b2-4538-b0dc-6162875f82fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5b0fa472-4106-439a-b9e5-f2d945e8b15f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f51d7d1e-c2b2-4538-b0dc-6162875f82fc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5b0fa472-4106-439a-b9e5-f2d945e8b15f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_c6d402b9-8eac-4a3d-bc47-4d28c8340b68" xlink:href="bhc-20220331.xsd#bhc_RestrictedCashAndOtherSettlementDepositsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f51d7d1e-c2b2-4538-b0dc-6162875f82fc" xlink:to="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_c6d402b9-8eac-4a3d-bc47-4d28c8340b68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_e8715092-d48c-411e-841c-55b112ca4316" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f51d7d1e-c2b2-4538-b0dc-6162875f82fc" xlink:to="loc_us-gaap_ReceivablesNetCurrent_e8715092-d48c-411e-841c-55b112ca4316" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_5e188dd0-a788-4520-8466-a48a2c45dea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f51d7d1e-c2b2-4538-b0dc-6162875f82fc" xlink:to="loc_us-gaap_InventoryNet_5e188dd0-a788-4520-8466-a48a2c45dea0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_946193e0-40ef-449a-9d81-3584af3a1d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f51d7d1e-c2b2-4538-b0dc-6162875f82fc" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_946193e0-40ef-449a-9d81-3584af3a1d4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3ab2c61d-756e-4789-beaa-168bdfdabf1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5d8184eb-ccd4-4a59-b451-3b3f616ee024" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3ab2c61d-756e-4789-beaa-168bdfdabf1c" xlink:to="loc_us-gaap_StockholdersEquity_5d8184eb-ccd4-4a59-b451-3b3f616ee024" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_cd9c61f6-11f3-4931-bba7-17877fe5b975" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3ab2c61d-756e-4789-beaa-168bdfdabf1c" xlink:to="loc_us-gaap_MinorityInterest_cd9c61f6-11f3-4931-bba7-17877fe5b975" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_92694b5a-7e0c-49fa-893f-692313e48a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0d2ed90a-83ba-4714-af3b-0717a06a729b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_92694b5a-7e0c-49fa-893f-692313e48a2b" xlink:to="loc_us-gaap_AccountsPayableCurrent_0d2ed90a-83ba-4714-af3b-0717a06a729b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c3183085-34bf-4ca9-aa6a-5934a9d1e2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_92694b5a-7e0c-49fa-893f-692313e48a2b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c3183085-34bf-4ca9-aa6a-5934a9d1e2a5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="bhc-20220331.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b51663da-fbb3-4c52-8747-d67b0fd72c65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ca77113c-7174-48c5-b718-f229c09295de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_b51663da-fbb3-4c52-8747-d67b0fd72c65" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ca77113c-7174-48c5-b718-f229c09295de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_52ecd834-dd83-4cc8-83e1-53b80857c470" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_b51663da-fbb3-4c52-8747-d67b0fd72c65" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_52ecd834-dd83-4cc8-83e1-53b80857c470" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ab381326-876d-4960-9bbb-27c7f45fe17e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1a017640-761c-42ae-9cea-9403f99ce636" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ab381326-876d-4960-9bbb-27c7f45fe17e" xlink:to="loc_us-gaap_ProfitLoss_1a017640-761c-42ae-9cea-9403f99ce636" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_451d20b9-47c6-476a-b464-6b30483d8857" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ab381326-876d-4960-9bbb-27c7f45fe17e" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_451d20b9-47c6-476a-b464-6b30483d8857" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_3fcf960d-14ef-4ff9-b580-141b43cf2e40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_ef58f410-828c-42de-9614-b0ece8c53686" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3fcf960d-14ef-4ff9-b580-141b43cf2e40" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_ef58f410-828c-42de-9614-b0ece8c53686" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_76675ab7-e72c-44b8-97a3-25ebe38c6651" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3fcf960d-14ef-4ff9-b580-141b43cf2e40" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_76675ab7-e72c-44b8-97a3-25ebe38c6651" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_60dd0ede-8655-4e72-9ba2-513cb7813011" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3fcf960d-14ef-4ff9-b580-141b43cf2e40" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_60dd0ede-8655-4e72-9ba2-513cb7813011" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_b835d434-b141-4bd0-8bcc-40b07f5f6668" xlink:href="bhc-20220331.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3fcf960d-14ef-4ff9-b580-141b43cf2e40" xlink:to="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_b835d434-b141-4bd0-8bcc-40b07f5f6668" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_2c7d762d-2cb3-424f-80fb-d82925ece88a" xlink:href="bhc-20220331.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3fcf960d-14ef-4ff9-b580-141b43cf2e40" xlink:to="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_2c7d762d-2cb3-424f-80fb-d82925ece88a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_f3d1f783-fb4e-4a76-8753-50f6f1dd8096" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3fcf960d-14ef-4ff9-b580-141b43cf2e40" xlink:to="loc_us-gaap_AssetImpairmentCharges_f3d1f783-fb4e-4a76-8753-50f6f1dd8096" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_8dc10f00-f77e-461c-a4bc-48d4eeb6e5da" xlink:href="bhc-20220331.xsd#bhc_RestructuringChargesAndInitialPublicOfferingCosts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3fcf960d-14ef-4ff9-b580-141b43cf2e40" xlink:to="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_8dc10f00-f77e-461c-a4bc-48d4eeb6e5da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_fb0d48cb-585c-4ad1-a3a6-89f34e0395ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3fcf960d-14ef-4ff9-b580-141b43cf2e40" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_fb0d48cb-585c-4ad1-a3a6-89f34e0395ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_cefd21a9-e4ae-4d7d-93ea-bfdc19367de1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fc9c616c-d2bb-4a22-bae5-04f594c10b49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_cefd21a9-e4ae-4d7d-93ea-bfdc19367de1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fc9c616c-d2bb-4a22-bae5-04f594c10b49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_ebdcbf31-9139-4d15-9f2f-c067d9def601" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_cefd21a9-e4ae-4d7d-93ea-bfdc19367de1" xlink:to="loc_us-gaap_CostsAndExpenses_ebdcbf31-9139-4d15-9f2f-c067d9def601" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2acad0ae-5fdf-48ec-b75b-0b944860adc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_11434fcb-cf12-4d3b-87d9-253e490435d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2acad0ae-5fdf-48ec-b75b-0b944860adc6" xlink:to="loc_us-gaap_OperatingIncomeLoss_11434fcb-cf12-4d3b-87d9-253e490435d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_dd053bea-212f-45dc-a816-8075e644955e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2acad0ae-5fdf-48ec-b75b-0b944860adc6" xlink:to="loc_us-gaap_InvestmentIncomeInterest_dd053bea-212f-45dc-a816-8075e644955e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_83b4f602-9b20-41a1-be90-084e066f022c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2acad0ae-5fdf-48ec-b75b-0b944860adc6" xlink:to="loc_us-gaap_InterestExpenseDebt_83b4f602-9b20-41a1-be90-084e066f022c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_91927363-2b14-4e54-8ec3-9594273e4dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2acad0ae-5fdf-48ec-b75b-0b944860adc6" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_91927363-2b14-4e54-8ec3-9594273e4dc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_a15376d6-5cde-4694-a51f-a8f42d9ab69c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2acad0ae-5fdf-48ec-b75b-0b944860adc6" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_a15376d6-5cde-4694-a51f-a8f42d9ab69c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="bhc-20220331.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_94a3c7fc-d8bf-4c0f-8290-35146f1baa1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_9ed6c1c9-82f6-4fe0-8a56-301102288b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_94a3c7fc-d8bf-4c0f-8290-35146f1baa1f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_9ed6c1c9-82f6-4fe0-8a56-301102288b0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_1f1f25eb-e4e8-4faf-bb3c-0d789b4113a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_94a3c7fc-d8bf-4c0f-8290-35146f1baa1f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_1f1f25eb-e4e8-4faf-bb3c-0d789b4113a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0615eb64-792f-4858-b1f7-5b9faf0af89d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_803e5a40-681e-4868-b2d2-0e5b8e53b634" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0615eb64-792f-4858-b1f7-5b9faf0af89d" xlink:to="loc_us-gaap_ProfitLoss_803e5a40-681e-4868-b2d2-0e5b8e53b634" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7ebdb3c8-caae-49fe-a241-fcce84b9eba5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0615eb64-792f-4858-b1f7-5b9faf0af89d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7ebdb3c8-caae-49fe-a241-fcce84b9eba5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_31907ae0-67ce-4b49-be6b-10720291ee61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_521278d1-a0a8-4b07-8a61-539d8eb18e42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_31907ae0-67ce-4b49-be6b-10720291ee61" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_521278d1-a0a8-4b07-8a61-539d8eb18e42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_b80d6738-bd61-40fc-a25e-47730526b155" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_31907ae0-67ce-4b49-be6b-10720291ee61" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_b80d6738-bd61-40fc-a25e-47730526b155" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="bhc-20220331.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_41a29e19-d821-4bd3-9d16-127df822adab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_ccb63dd2-2b9d-46b2-afbb-8a5c5a772019" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_41a29e19-d821-4bd3-9d16-127df822adab" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_ccb63dd2-2b9d-46b2-afbb-8a5c5a772019" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_c248071f-4ee4-4340-a9f7-ca90edb9880f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_41a29e19-d821-4bd3-9d16-127df822adab" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_c248071f-4ee4-4340-a9f7-ca90edb9880f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_03bbe964-dbba-4ba0-b8e7-31c4767ed32b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_41a29e19-d821-4bd3-9d16-127df822adab" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_03bbe964-dbba-4ba0-b8e7-31c4767ed32b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_2154d6cc-1536-4a47-871a-8f27aa7310bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_41a29e19-d821-4bd3-9d16-127df822adab" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_2154d6cc-1536-4a47-871a-8f27aa7310bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_5c54de5c-082c-4d28-9d62-1a063e8252ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_41a29e19-d821-4bd3-9d16-127df822adab" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_5c54de5c-082c-4d28-9d62-1a063e8252ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_91d7ad72-6454-4510-bc65-8a9d5bde495d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_41a29e19-d821-4bd3-9d16-127df822adab" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_91d7ad72-6454-4510-bc65-8a9d5bde495d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c1172210-e30e-4deb-8b1e-e3721995b035" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_86628f7e-4137-4883-8893-bc7af720765e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c1172210-e30e-4deb-8b1e-e3721995b035" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_86628f7e-4137-4883-8893-bc7af720765e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_7b5e43a2-9bd2-462b-9fe6-ad27c7bad192" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c1172210-e30e-4deb-8b1e-e3721995b035" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_7b5e43a2-9bd2-462b-9fe6-ad27c7bad192" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_a6b59471-b5a4-40e2-8e68-8f213d252cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c1172210-e30e-4deb-8b1e-e3721995b035" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_a6b59471-b5a4-40e2-8e68-8f213d252cf7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_0b849af0-741a-441e-a493-db12136d19dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c1172210-e30e-4deb-8b1e-e3721995b035" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_0b849af0-741a-441e-a493-db12136d19dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_00559501-bb82-4b1c-bc71-ff67e3cd3709" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c1172210-e30e-4deb-8b1e-e3721995b035" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_00559501-bb82-4b1c-bc71-ff67e3cd3709" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InterestSettlementOnCrossCurrencySwaps_1d0455a3-81ed-4e6b-99bc-8a9cd8d762bf" xlink:href="bhc-20220331.xsd#bhc_InterestSettlementOnCrossCurrencySwaps"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c1172210-e30e-4deb-8b1e-e3721995b035" xlink:to="loc_bhc_InterestSettlementOnCrossCurrencySwaps_1d0455a3-81ed-4e6b-99bc-8a9cd8d762bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2159d7cb-f44e-4429-9862-7a6c9a697213" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7f90a488-5c73-4328-841a-c6e2f4c5d0cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2159d7cb-f44e-4429-9862-7a6c9a697213" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7f90a488-5c73-4328-841a-c6e2f4c5d0cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b352cce5-10a2-4185-a420-ac3c563b7475" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2159d7cb-f44e-4429-9862-7a6c9a697213" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b352cce5-10a2-4185-a420-ac3c563b7475" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8ba7cebe-15ff-4acf-8ef8-b0c9d3d1c739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2159d7cb-f44e-4429-9862-7a6c9a697213" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8ba7cebe-15ff-4acf-8ef8-b0c9d3d1c739" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_44dfd358-661a-4e2d-84af-515b87d8fdfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2159d7cb-f44e-4429-9862-7a6c9a697213" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_44dfd358-661a-4e2d-84af-515b87d8fdfa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07cd5cbf-eb6e-43ab-9949-2fd075615a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5196b4aa-f952-40c5-9d0e-c7d8d0f298ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07cd5cbf-eb6e-43ab-9949-2fd075615a1e" xlink:to="loc_us-gaap_ProfitLoss_5196b4aa-f952-40c5-9d0e-c7d8d0f298ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_6c38c4c4-3607-4d8d-b163-5629c7b1c001" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07cd5cbf-eb6e-43ab-9949-2fd075615a1e" xlink:to="loc_us-gaap_DepreciationAndAmortization_6c38c4c4-3607-4d8d-b163-5629c7b1c001" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_729b62cf-3fa3-45ae-9596-f05900026fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07cd5cbf-eb6e-43ab-9949-2fd075615a1e" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_729b62cf-3fa3-45ae-9596-f05900026fa2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_84e8c132-9b0c-4556-83ae-0da3de853459" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07cd5cbf-eb6e-43ab-9949-2fd075615a1e" xlink:to="loc_us-gaap_AssetImpairmentCharges_84e8c132-9b0c-4556-83ae-0da3de853459" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_8389395a-0314-4a3b-8fac-1c8cc42dfc14" xlink:href="bhc-20220331.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07cd5cbf-eb6e-43ab-9949-2fd075615a1e" xlink:to="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_8389395a-0314-4a3b-8fac-1c8cc42dfc14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_36b50573-775e-4c9b-ba91-988b1d3f0bb7" xlink:href="bhc-20220331.xsd#bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07cd5cbf-eb6e-43ab-9949-2fd075615a1e" xlink:to="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_36b50573-775e-4c9b-ba91-988b1d3f0bb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_2d9cd124-2a9f-4810-bc69-81e2b97cf782" xlink:href="bhc-20220331.xsd#bhc_AllowancesForLossesOnAccountsReceivableAndInventories"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07cd5cbf-eb6e-43ab-9949-2fd075615a1e" xlink:to="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_2d9cd124-2a9f-4810-bc69-81e2b97cf782" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit_65506645-62f3-4cd2-aa2d-dfc17a07876e" xlink:href="bhc-20220331.xsd#bhc_DeferredIncomeTaxNoncashExpenseBenefit"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07cd5cbf-eb6e-43ab-9949-2fd075615a1e" xlink:to="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit_65506645-62f3-4cd2-aa2d-dfc17a07876e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_4d5f8c21-0385-4c27-94ed-23b92116f0bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07cd5cbf-eb6e-43ab-9949-2fd075615a1e" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_4d5f8c21-0385-4c27-94ed-23b92116f0bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainLossRelatedToLitigationSettlementGross_bb04a835-03b9-4fd6-89c3-a5377987b691" xlink:href="bhc-20220331.xsd#bhc_GainLossRelatedToLitigationSettlementGross"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07cd5cbf-eb6e-43ab-9949-2fd075615a1e" xlink:to="loc_bhc_GainLossRelatedToLitigationSettlementGross_bb04a835-03b9-4fd6-89c3-a5377987b691" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_3650cf54-1a4c-4ced-b0de-f6206efacd84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07cd5cbf-eb6e-43ab-9949-2fd075615a1e" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_3650cf54-1a4c-4ced-b0de-f6206efacd84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7ca41ceb-6335-443f-9cda-ee69ffcab638" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07cd5cbf-eb6e-43ab-9949-2fd075615a1e" xlink:to="loc_us-gaap_ShareBasedCompensation_7ca41ceb-6335-443f-9cda-ee69ffcab638" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_53cb4d00-9495-494b-ba27-53f5e6de2c67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07cd5cbf-eb6e-43ab-9949-2fd075615a1e" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_53cb4d00-9495-494b-ba27-53f5e6de2c67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DerivativeGainExcludedComponent_64f58463-aa02-4d3d-bd79-e55bcee04eb9" xlink:href="bhc-20220331.xsd#bhc_DerivativeGainExcludedComponent"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07cd5cbf-eb6e-43ab-9949-2fd075615a1e" xlink:to="loc_bhc_DerivativeGainExcludedComponent_64f58463-aa02-4d3d-bd79-e55bcee04eb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a52b8e3e-8aa8-4445-8614-71f15d3a99a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07cd5cbf-eb6e-43ab-9949-2fd075615a1e" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a52b8e3e-8aa8-4445-8614-71f15d3a99a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_d4cd4470-9b7d-4466-997b-fedf20b44e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07cd5cbf-eb6e-43ab-9949-2fd075615a1e" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_d4cd4470-9b7d-4466-997b-fedf20b44e1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8701b4d0-6568-4d46-b2a8-6aa75fa1fb0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07cd5cbf-eb6e-43ab-9949-2fd075615a1e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8701b4d0-6568-4d46-b2a8-6aa75fa1fb0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_1813d458-e4d6-4ed2-a319-cb43cb95e0a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="18" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07cd5cbf-eb6e-43ab-9949-2fd075615a1e" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_1813d458-e4d6-4ed2-a319-cb43cb95e0a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e0b76181-7d54-48cb-9a9f-53064236fca7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="19" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07cd5cbf-eb6e-43ab-9949-2fd075615a1e" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e0b76181-7d54-48cb-9a9f-53064236fca7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_92cac2a3-5669-4a62-a7f4-a1c37249b107" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="20" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07cd5cbf-eb6e-43ab-9949-2fd075615a1e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_92cac2a3-5669-4a62-a7f4-a1c37249b107" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2cecf0aa-8bd4-4975-a481-e734d417b2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_90e05307-be33-4bc6-bb9a-a37181008fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2cecf0aa-8bd4-4975-a481-e734d417b2e9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_90e05307-be33-4bc6-bb9a-a37181008fb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_73a95bdd-4d18-456c-b0b1-f5679733cbf5" xlink:href="bhc-20220331.xsd#bhc_RestrictedCashAndOtherSettlementDepositsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2cecf0aa-8bd4-4975-a481-e734d417b2e9" xlink:to="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_73a95bdd-4d18-456c-b0b1-f5679733cbf5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_92d5694b-5499-45bf-b751-8474f156f5a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2cecf0aa-8bd4-4975-a481-e734d417b2e9" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_92d5694b-5499-45bf-b751-8474f156f5a0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_35e15338-c863-4edb-93c0-5a814f3555ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_d846e823-1503-493b-952b-d32dc562ea62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilities_35e15338-c863-4edb-93c0-5a814f3555ef" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_d846e823-1503-493b-952b-d32dc562ea62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_24329412-3878-4b88-b399-cc06d1cf3418" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilities_35e15338-c863-4edb-93c0-5a814f3555ef" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_24329412-3878-4b88-b399-cc06d1cf3418" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e0027440-8d3a-41e2-8795-b8965f303fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_63c1bde9-81ce-4d6a-ba4c-5b5e28bc0d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e0027440-8d3a-41e2-8795-b8965f303fa6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_63c1bde9-81ce-4d6a-ba4c-5b5e28bc0d2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_c730522b-c386-4bee-967c-281d46db3d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e0027440-8d3a-41e2-8795-b8965f303fa6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_c730522b-c386-4bee-967c-281d46db3d7b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#INVENTORIESComponentsofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_adb89b9c-20a3-4d5f-b404-958a7f4a8952" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_68f42e48-204e-4c7e-a1d8-1b09bc7e734a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_adb89b9c-20a3-4d5f-b404-958a7f4a8952" xlink:to="loc_us-gaap_InventoryRawMaterials_68f42e48-204e-4c7e-a1d8-1b09bc7e734a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_88ab0c98-a827-4970-8fbd-6a5459c695bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_adb89b9c-20a3-4d5f-b404-958a7f4a8952" xlink:to="loc_us-gaap_InventoryWorkInProcess_88ab0c98-a827-4970-8fbd-6a5459c695bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_d0fa03af-7502-41cd-93d3-0c9a1da926cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_adb89b9c-20a3-4d5f-b404-958a7f4a8952" xlink:to="loc_us-gaap_InventoryFinishedGoods_d0fa03af-7502-41cd-93d3-0c9a1da926cb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_4bf29a15-3d56-4a9b-8a9d-e22eda868705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_289f5bad-638f-4d57-b39a-bbfe2797f184" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_4bf29a15-3d56-4a9b-8a9d-e22eda868705" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_289f5bad-638f-4d57-b39a-bbfe2797f184" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_a6ca9417-09b1-445f-9086-c60ed09054f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_4bf29a15-3d56-4a9b-8a9d-e22eda868705" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_a6ca9417-09b1-445f-9086-c60ed09054f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_21704498-ea4e-401c-b6a8-e2259b2c490e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_27e163cd-749e-46e1-9559-79c8dbda61b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_21704498-ea4e-401c-b6a8-e2259b2c490e" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_27e163cd-749e-46e1-9559-79c8dbda61b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_bff63160-e369-4853-be00-58d4dc2b7042" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_21704498-ea4e-401c-b6a8-e2259b2c490e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_bff63160-e369-4853-be00-58d4dc2b7042" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_837b4e4d-18ae-4bf3-b7dc-925ea6bddb25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d2a50acc-53c1-4e09-b228-0fa4b48ebaa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_837b4e4d-18ae-4bf3-b7dc-925ea6bddb25" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d2a50acc-53c1-4e09-b228-0fa4b48ebaa6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f7ed1c1e-88e6-4bb7-a09c-9707c21f33d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_837b4e4d-18ae-4bf3-b7dc-925ea6bddb25" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f7ed1c1e-88e6-4bb7-a09c-9707c21f33d9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_eb6167e1-dcdd-4efb-8370-8fc42841de82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_cded8891-1e58-424d-a309-14df8588f5c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_eb6167e1-dcdd-4efb-8370-8fc42841de82" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_cded8891-1e58-424d-a309-14df8588f5c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_28a1405b-427f-46a1-a6ef-6096c9e72b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_eb6167e1-dcdd-4efb-8370-8fc42841de82" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_28a1405b-427f-46a1-a6ef-6096c9e72b7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_8269bc7d-915e-4b7d-93c3-c0e6807ef24f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_eb6167e1-dcdd-4efb-8370-8fc42841de82" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_8269bc7d-915e-4b7d-93c3-c0e6807ef24f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_bdd01ea3-45eb-4000-9e8e-71053959a090" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_eb6167e1-dcdd-4efb-8370-8fc42841de82" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_bdd01ea3-45eb-4000-9e8e-71053959a090" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_d294dc04-12a6-40cb-a50a-fe04da364055" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_eb6167e1-dcdd-4efb-8370-8fc42841de82" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_d294dc04-12a6-40cb-a50a-fe04da364055" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_c0ba2a58-a6c2-454d-9311-56b61df59e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_eb6167e1-dcdd-4efb-8370-8fc42841de82" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_c0ba2a58-a6c2-454d-9311-56b61df59e2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_dc2869e4-ec9f-435f-9a85-c024d98febde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_eb6167e1-dcdd-4efb-8370-8fc42841de82" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_dc2869e4-ec9f-435f-9a85-c024d98febde" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_964ac101-9334-4c7e-8bfc-1bc40c6990b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_Legalsettlementsandrelatedfees_379269c5-ad53-4855-b611-95c003de1516" xlink:href="bhc-20220331.xsd#bhc_Legalsettlementsandrelatedfees"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_964ac101-9334-4c7e-8bfc-1bc40c6990b0" xlink:to="loc_bhc_Legalsettlementsandrelatedfees_379269c5-ad53-4855-b611-95c003de1516" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductRebateCurrent_f0d8d9be-1bba-4e15-833f-d782ce91b890" xlink:href="bhc-20220331.xsd#bhc_AccruedProductRebateCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_964ac101-9334-4c7e-8bfc-1bc40c6990b0" xlink:to="loc_bhc_AccruedProductRebateCurrent_f0d8d9be-1bba-4e15-833f-d782ce91b890" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductReturnCurrent_69fe703b-a5df-4c10-8b8e-aca49c1304e8" xlink:href="bhc-20220331.xsd#bhc_AccruedProductReturnCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_964ac101-9334-4c7e-8bfc-1bc40c6990b0" xlink:to="loc_bhc_AccruedProductReturnCurrent_69fe703b-a5df-4c10-8b8e-aca49c1304e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_13fcd886-7ac9-49b4-a8bc-a048cd45389c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_964ac101-9334-4c7e-8bfc-1bc40c6990b0" xlink:to="loc_us-gaap_InterestPayableCurrent_13fcd886-7ac9-49b4-a8bc-a048cd45389c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_63041091-4499-4847-bc4c-6a30d8aa3d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_964ac101-9334-4c7e-8bfc-1bc40c6990b0" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_63041091-4499-4847-bc4c-6a30d8aa3d1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_e5ae0bc2-6412-4fcb-a6b6-9d22f74cf425" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_964ac101-9334-4c7e-8bfc-1bc40c6990b0" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_e5ae0bc2-6412-4fcb-a6b6-9d22f74cf425" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e8f7e0d7-afb8-48e8-9623-aaed4eeeee07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_964ac101-9334-4c7e-8bfc-1bc40c6990b0" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e8f7e0d7-afb8-48e8-9623-aaed4eeeee07" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_ffce1f0a-d10d-4221-9c56-4623a8e2c15c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_ab4285a2-68fc-40da-a37d-3eeb67e94725" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_ffce1f0a-d10d-4221-9c56-4623a8e2c15c" xlink:to="loc_us-gaap_LongTermDebtCurrent_ab4285a2-68fc-40da-a37d-3eeb67e94725" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_9ba00782-bec9-45f1-b149-abe957d20985" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_ffce1f0a-d10d-4221-9c56-4623a8e2c15c" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_9ba00782-bec9-45f1-b149-abe957d20985" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d4181aff-3705-4353-8c44-9c064d33af63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_bdede2e6-77bc-4f3b-a8ab-ab0b8f759ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_d4181aff-3705-4353-8c44-9c064d33af63" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_bdede2e6-77bc-4f3b-a8ab-ab0b8f759ab5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_a4a576d7-6663-458b-adba-72a6a70ae6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_d4181aff-3705-4353-8c44-9c064d33af63" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_a4a576d7-6663-458b-adba-72a6a70ae6e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_9f08bb85-e408-421f-a1d0-ff5568ca7463" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_1041fc2c-e09b-44d0-978c-b69d9f2c9547" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_9f08bb85-e408-421f-a1d0-ff5568ca7463" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_1041fc2c-e09b-44d0-978c-b69d9f2c9547" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_1e0e2cc1-385f-4535-8a56-ef12e0eb486d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_9f08bb85-e408-421f-a1d0-ff5568ca7463" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_1e0e2cc1-385f-4535-8a56-ef12e0eb486d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_640249c0-0193-487f-895a-8ca9822a3245" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_9f08bb85-e408-421f-a1d0-ff5568ca7463" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_640249c0-0193-487f-895a-8ca9822a3245" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_83d009ca-a6a2-46f9-97c8-45f6d1f0cd97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_9f08bb85-e408-421f-a1d0-ff5568ca7463" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_83d009ca-a6a2-46f9-97c8-45f6d1f0cd97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_a0cc226b-99fd-48ff-ad70-6623a3830aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_9f08bb85-e408-421f-a1d0-ff5568ca7463" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_a0cc226b-99fd-48ff-ad70-6623a3830aa8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_78e6ccb3-9884-4357-a4fc-577734014e89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_9f08bb85-e408-421f-a1d0-ff5568ca7463" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_78e6ccb3-9884-4357-a4fc-577734014e89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_e989d250-6d92-4454-a790-9f63e7f12aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_9f08bb85-e408-421f-a1d0-ff5568ca7463" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_e989d250-6d92-4454-a790-9f63e7f12aaf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_1304c123-fce4-481e-8f1d-12398227e115" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_92d2720d-5489-4e1b-ae7f-189750dcc412" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_1304c123-fce4-481e-8f1d-12398227e115" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_92d2720d-5489-4e1b-ae7f-189750dcc412" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_fcdadd9f-1211-4d20-873b-4469c40ab5fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_1304c123-fce4-481e-8f1d-12398227e115" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_fcdadd9f-1211-4d20-873b-4469c40ab5fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_3a559c72-3c2b-43d4-9fec-93ad525c5ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_1304c123-fce4-481e-8f1d-12398227e115" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_3a559c72-3c2b-43d4-9fec-93ad525c5ba4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_ff7fd196-a688-43c2-963a-87ea69be687b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_1304c123-fce4-481e-8f1d-12398227e115" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_ff7fd196-a688-43c2-963a-87ea69be687b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_913fcf78-2f32-441c-a4e9-aefcc541e0b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseProductRelated_3be70ee2-363f-4143-9856-75eebf57c7b3" xlink:href="bhc-20220331.xsd#bhc_ResearchAndDevelopmentExpenseProductRelated"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_913fcf78-2f32-441c-a4e9-aefcc541e0b4" xlink:to="loc_bhc_ResearchAndDevelopmentExpenseProductRelated_3be70ee2-363f-4143-9856-75eebf57c7b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance_0f6cb05a-0c14-4d35-93ca-6a3d68c612c1" xlink:href="bhc-20220331.xsd#bhc_ResearchAndDevelopmentExpenseQualityAssurance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_913fcf78-2f32-441c-a4e9-aefcc541e0b4" xlink:to="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance_0f6cb05a-0c14-4d35-93ca-6a3d68c612c1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETSummaryofOtherExpenseNetDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#OTHEREXPENSEINCOMENETSummaryofOtherExpenseNetDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETSummaryofOtherExpenseNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_67757566-35d6-4652-a4e9-4c959a22e8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_3f4fcfa2-7317-4fb8-a0cd-65fc3c82dd94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_67757566-35d6-4652-a4e9-4c959a22e8e4" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_3f4fcfa2-7317-4fb8-a0cd-65fc3c82dd94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_d99ebb18-58b1-4107-8a19-39e4b365bdd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_67757566-35d6-4652-a4e9-4c959a22e8e4" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_d99ebb18-58b1-4107-8a19-39e4b365bdd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_b1226837-8e64-4783-a89a-721033ace49c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_67757566-35d6-4652-a4e9-4c959a22e8e4" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_b1226837-8e64-4783-a89a-721033ace49c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_92af8f21-1216-4010-9931-592fa1104c58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_67757566-35d6-4652-a4e9-4c959a22e8e4" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_92af8f21-1216-4010-9931-592fa1104c58" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>bhc-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:9c0993e0-3c65-4e23-b478-aba95d934319,g:036e3555-df42-4f12-aaee-1876eac48ef4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="bhc-20220331.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended" id="i81920a84809146f684331a0d0b90a433_CONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_65010916-608e-4387-824a-1cafaaee8b70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_39d815b3-dc0d-44c2-8593-f2187d7bb108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_65010916-608e-4387-824a-1cafaaee8b70" xlink:to="loc_us-gaap_RevenuesAbstract_39d815b3-dc0d-44c2-8593-f2187d7bb108" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_037c638c-477a-42b4-9200-e8f256045036" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_39d815b3-dc0d-44c2-8593-f2187d7bb108" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_037c638c-477a-42b4-9200-e8f256045036" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_419942d1-ab15-4fcb-9814-16b9bb046103" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_65010916-608e-4387-824a-1cafaaee8b70" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_419942d1-ab15-4fcb-9814-16b9bb046103" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_03711797-14a9-46d3-9300-19d682299797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_419942d1-ab15-4fcb-9814-16b9bb046103" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_03711797-14a9-46d3-9300-19d682299797" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_89fd2310-a56b-47cf-8372-1c9a21fbabb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_419942d1-ab15-4fcb-9814-16b9bb046103" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_89fd2310-a56b-47cf-8372-1c9a21fbabb2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_45ab53fe-bb86-4dfa-8da0-90b06cd556ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_419942d1-ab15-4fcb-9814-16b9bb046103" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_45ab53fe-bb86-4dfa-8da0-90b06cd556ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_e9126f39-edc9-473a-95c8-351ac99f51de" xlink:href="bhc-20220331.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_419942d1-ab15-4fcb-9814-16b9bb046103" xlink:to="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_e9126f39-edc9-473a-95c8-351ac99f51de" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_1a66cd9c-e0f0-4997-b5cc-a5369410aafc" xlink:href="bhc-20220331.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_419942d1-ab15-4fcb-9814-16b9bb046103" xlink:to="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_1a66cd9c-e0f0-4997-b5cc-a5369410aafc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_cdaafb8b-160d-44b9-9da8-7895491729ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_419942d1-ab15-4fcb-9814-16b9bb046103" xlink:to="loc_us-gaap_AssetImpairmentCharges_cdaafb8b-160d-44b9-9da8-7895491729ea" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_0640bf88-abf6-4952-8b62-2a3a6c042a87" xlink:href="bhc-20220331.xsd#bhc_RestructuringChargesAndInitialPublicOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_419942d1-ab15-4fcb-9814-16b9bb046103" xlink:to="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_0640bf88-abf6-4952-8b62-2a3a6c042a87" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_a2d4a5fe-8421-4def-91af-603f5615a409" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_419942d1-ab15-4fcb-9814-16b9bb046103" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_a2d4a5fe-8421-4def-91af-603f5615a409" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_03bb86f4-1ad6-44dd-bc1c-ef9405025e93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_419942d1-ab15-4fcb-9814-16b9bb046103" xlink:to="loc_us-gaap_CostsAndExpenses_03bb86f4-1ad6-44dd-bc1c-ef9405025e93" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d7225b53-2fe2-4542-91df-bdb2afa0ce48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_65010916-608e-4387-824a-1cafaaee8b70" xlink:to="loc_us-gaap_OperatingIncomeLoss_d7225b53-2fe2-4542-91df-bdb2afa0ce48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_b33c480f-3569-4858-932b-0796482dd612" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_65010916-608e-4387-824a-1cafaaee8b70" xlink:to="loc_us-gaap_InvestmentIncomeInterest_b33c480f-3569-4858-932b-0796482dd612" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_10683039-95b3-4a4c-949e-21b3f9cde736" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_65010916-608e-4387-824a-1cafaaee8b70" xlink:to="loc_us-gaap_InterestExpenseDebt_10683039-95b3-4a4c-949e-21b3f9cde736" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3abf24eb-5b14-4132-a24b-86f21ff2a6f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_65010916-608e-4387-824a-1cafaaee8b70" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3abf24eb-5b14-4132-a24b-86f21ff2a6f1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_743b810d-a9f2-4d67-9e8b-be6f92eb12a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_65010916-608e-4387-824a-1cafaaee8b70" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_743b810d-a9f2-4d67-9e8b-be6f92eb12a3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_12266bb7-0fa4-4402-ad6a-0d38624539c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_65010916-608e-4387-824a-1cafaaee8b70" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_12266bb7-0fa4-4402-ad6a-0d38624539c3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ff40b580-00b5-4729-a920-8feb3dec5d53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_65010916-608e-4387-824a-1cafaaee8b70" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ff40b580-00b5-4729-a920-8feb3dec5d53" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_3fb328f7-b358-4e5c-ab37-e0609bf2adae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_65010916-608e-4387-824a-1cafaaee8b70" xlink:to="loc_us-gaap_ProfitLoss_3fb328f7-b358-4e5c-ab37-e0609bf2adae" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7648cc3e-ad0f-4bcf-a367-1e607906612c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_65010916-608e-4387-824a-1cafaaee8b70" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7648cc3e-ad0f-4bcf-a367-1e607906612c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_46bd7ea0-fc74-4f89-817e-8a05b648105e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_65010916-608e-4387-824a-1cafaaee8b70" xlink:to="loc_us-gaap_NetIncomeLoss_46bd7ea0-fc74-4f89-817e-8a05b648105e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_4f69119e-55b0-4a14-a065-cabea5181fed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_65010916-608e-4387-824a-1cafaaee8b70" xlink:to="loc_us-gaap_EarningsPerShareBasic_4f69119e-55b0-4a14-a065-cabea5181fed" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_973c6156-2c30-41f9-b28b-3ad12c153ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_65010916-608e-4387-824a-1cafaaee8b70" xlink:to="loc_us-gaap_EarningsPerShareDiluted_973c6156-2c30-41f9-b28b-3ad12c153ac9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4d30cfc8-9c5e-439d-82b4-683dc96ceeac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_65010916-608e-4387-824a-1cafaaee8b70" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4d30cfc8-9c5e-439d-82b4-683dc96ceeac" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_65bd1869-7fcb-4922-b2de-af7e39aae3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_65010916-608e-4387-824a-1cafaaee8b70" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_65bd1869-7fcb-4922-b2de-af7e39aae3b8" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_024bfce1-92ff-41ac-b64c-4508366e477f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_65010916-608e-4387-824a-1cafaaee8b70" xlink:to="loc_us-gaap_StatementTable_024bfce1-92ff-41ac-b64c-4508366e477f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c1489988-b0c1-47b0-ad59-ca7575ff117c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_024bfce1-92ff-41ac-b64c-4508366e477f" xlink:to="loc_srt_ProductOrServiceAxis_c1489988-b0c1-47b0-ad59-ca7575ff117c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c1489988-b0c1-47b0-ad59-ca7575ff117c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c1489988-b0c1-47b0-ad59-ca7575ff117c" xlink:to="loc_srt_ProductsAndServicesDomain_c1489988-b0c1-47b0-ad59-ca7575ff117c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c5eb3c43-e1de-4b7b-a38d-38d2585ad57c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c1489988-b0c1-47b0-ad59-ca7575ff117c" xlink:to="loc_srt_ProductsAndServicesDomain_c5eb3c43-e1de-4b7b-a38d-38d2585ad57c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_a4b9a7d8-55f7-4da4-a2aa-88193a0e1ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c5eb3c43-e1de-4b7b-a38d-38d2585ad57c" xlink:to="loc_us-gaap_ProductMember_a4b9a7d8-55f7-4da4-a2aa-88193a0e1ca5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_0d859ea6-3446-4967-aee9-58b47ec4a27d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c5eb3c43-e1de-4b7b-a38d-38d2585ad57c" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_0d859ea6-3446-4967-aee9-58b47ec4a27d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT" xlink:type="simple" xlink:href="bhc-20220331.xsd#CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT" xlink:type="extended" id="ia351e38849004803902c32413e70c5f8_CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e5cdd979-eb98-4fac-a3de-ec14d5f667ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_98970c94-5835-4211-8dbe-21db5cd06757" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e5cdd979-eb98-4fac-a3de-ec14d5f667ab" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_98970c94-5835-4211-8dbe-21db5cd06757" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_e19acd90-a6e1-4ca6-acb0-881dea7cb9f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_98970c94-5835-4211-8dbe-21db5cd06757" xlink:to="loc_us-gaap_CommonStockSharesIssued_e19acd90-a6e1-4ca6-acb0-881dea7cb9f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6134f356-e461-4ffc-a48d-522fc275c4f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_98970c94-5835-4211-8dbe-21db5cd06757" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6134f356-e461-4ffc-a48d-522fc275c4f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2016e685-7653-497b-8218-8f3ba61ae506" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_98970c94-5835-4211-8dbe-21db5cd06757" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2016e685-7653-497b-8218-8f3ba61ae506" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_332805fb-babc-4ae6-a6ed-af81d4dc9378" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_98970c94-5835-4211-8dbe-21db5cd06757" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_332805fb-babc-4ae6-a6ed-af81d4dc9378" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_01b981be-8c84-4112-94fd-53cf2f9bf68f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_98970c94-5835-4211-8dbe-21db5cd06757" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_01b981be-8c84-4112-94fd-53cf2f9bf68f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_e2e9b77c-378f-49da-b1c8-a58fad6dae14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_98970c94-5835-4211-8dbe-21db5cd06757" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_e2e9b77c-378f-49da-b1c8-a58fad6dae14" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1ae83e17-6b5c-43f5-af0d-376b224b42aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_98970c94-5835-4211-8dbe-21db5cd06757" xlink:to="loc_us-gaap_ProfitLoss_1ae83e17-6b5c-43f5-af0d-376b224b42aa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6fb9348a-76bd-438e-9952-e27e19e15b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_98970c94-5835-4211-8dbe-21db5cd06757" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6fb9348a-76bd-438e-9952-e27e19e15b1b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_697007da-099e-490e-be73-b3d4a7304103" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e029dceb-deb4-4870-9dba-d876e190fc14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2e5ee966-0fab-4b5a-ba23-ac26015a3157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e5cdd979-eb98-4fac-a3de-ec14d5f667ab" xlink:to="loc_us-gaap_StatementTable_2e5ee966-0fab-4b5a-ba23-ac26015a3157" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c641c4f4-7801-4417-9b4a-55ca81447f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2e5ee966-0fab-4b5a-ba23-ac26015a3157" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c641c4f4-7801-4417-9b4a-55ca81447f7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c641c4f4-7801-4417-9b4a-55ca81447f7e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c641c4f4-7801-4417-9b4a-55ca81447f7e" xlink:to="loc_us-gaap_EquityComponentDomain_c641c4f4-7801-4417-9b4a-55ca81447f7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f205e545-954a-462f-b64b-b859d69620f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c641c4f4-7801-4417-9b4a-55ca81447f7e" xlink:to="loc_us-gaap_EquityComponentDomain_f205e545-954a-462f-b64b-b859d69620f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_1a938a1e-74c9-4b82-bebe-5507bb6ec261" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f205e545-954a-462f-b64b-b859d69620f1" xlink:to="loc_us-gaap_ParentMember_1a938a1e-74c9-4b82-bebe-5507bb6ec261" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_affa6b83-c7e6-4fa2-9931-37c7f9647477" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_1a938a1e-74c9-4b82-bebe-5507bb6ec261" xlink:to="loc_us-gaap_CommonStockMember_affa6b83-c7e6-4fa2-9931-37c7f9647477" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8381dd7b-2adf-4e03-baeb-9380b5c8a068" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_1a938a1e-74c9-4b82-bebe-5507bb6ec261" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8381dd7b-2adf-4e03-baeb-9380b5c8a068" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_7786fa3f-9c36-4b11-8fa2-40678c0ea775" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_1a938a1e-74c9-4b82-bebe-5507bb6ec261" xlink:to="loc_us-gaap_RetainedEarningsMember_7786fa3f-9c36-4b11-8fa2-40678c0ea775" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c9536ec5-9ed7-4ad6-b9b9-d1c4728c6920" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_1a938a1e-74c9-4b82-bebe-5507bb6ec261" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c9536ec5-9ed7-4ad6-b9b9-d1c4728c6920" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_6c107469-5662-48d4-941b-3a2b1ea92287" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f205e545-954a-462f-b64b-b859d69620f1" xlink:to="loc_us-gaap_NoncontrollingInterestMember_6c107469-5662-48d4-941b-3a2b1ea92287" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended" id="i0485bfe5112242918bc254dc67f02ef9_SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_6b5b214c-16fa-4212-ad5a-5a2d3ff1330e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2b0c5d2e-36dd-45c2-b926-108786b6b674" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6b5b214c-16fa-4212-ad5a-5a2d3ff1330e" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2b0c5d2e-36dd-45c2-b926-108786b6b674" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_40cdb97b-900d-466f-923e-fe1a76ee5107" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6b5b214c-16fa-4212-ad5a-5a2d3ff1330e" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_40cdb97b-900d-466f-923e-fe1a76ee5107" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_fdc45fc4-3e99-4832-91c3-372bb8784ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6b5b214c-16fa-4212-ad5a-5a2d3ff1330e" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_fdc45fc4-3e99-4832-91c3-372bb8784ab6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProposedBusinessSeparationAndInitialPublicOfferingNumberOfCompaniesEstablished_5b2e2f21-7834-45d6-9257-2bf3fbc48501" xlink:href="bhc-20220331.xsd#bhc_ProposedBusinessSeparationAndInitialPublicOfferingNumberOfCompaniesEstablished"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6b5b214c-16fa-4212-ad5a-5a2d3ff1330e" xlink:to="loc_bhc_ProposedBusinessSeparationAndInitialPublicOfferingNumberOfCompaniesEstablished_5b2e2f21-7834-45d6-9257-2bf3fbc48501" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_08b0d6e5-988c-4a9f-ace7-b80058928443" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6b5b214c-16fa-4212-ad5a-5a2d3ff1330e" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_08b0d6e5-988c-4a9f-ace7-b80058928443" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_10e18035-c4c4-4f12-adf2-533d44ff85ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_08b0d6e5-988c-4a9f-ace7-b80058928443" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_10e18035-c4c4-4f12-adf2-533d44ff85ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_10e18035-c4c4-4f12-adf2-533d44ff85ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_10e18035-c4c4-4f12-adf2-533d44ff85ba" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_10e18035-c4c4-4f12-adf2-533d44ff85ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20b3cda0-7749-460c-9866-1fdc76100991" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_10e18035-c4c4-4f12-adf2-533d44ff85ba" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20b3cda0-7749-460c-9866-1fdc76100991" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_d1566604-6ef7-4b2b-aa46-74de7ca0663a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20b3cda0-7749-460c-9866-1fdc76100991" xlink:to="loc_us-gaap_IPOMember_d1566604-6ef7-4b2b-aa46-74de7ca0663a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_fb4feb72-344c-4b80-bb98-bca4835ea0e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_08b0d6e5-988c-4a9f-ace7-b80058928443" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_fb4feb72-344c-4b80-bb98-bca4835ea0e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fb4feb72-344c-4b80-bb98-bca4835ea0e2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fb4feb72-344c-4b80-bb98-bca4835ea0e2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fb4feb72-344c-4b80-bb98-bca4835ea0e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_19549c7e-2af5-4b65-b442-b2f249ce0dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fb4feb72-344c-4b80-bb98-bca4835ea0e2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_19549c7e-2af5-4b65-b442-b2f249ce0dcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_32e4ff49-c9e9-438f-b873-25bfb85b5d07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_19549c7e-2af5-4b65-b442-b2f249ce0dcc" xlink:to="loc_us-gaap_SubsequentEventMember_32e4ff49-c9e9-438f-b873-25bfb85b5d07" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#REVENUERECOGNITIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails" xlink:type="extended" id="ief7aad23dd6448f1b9de91b85b8d529e_REVENUERECOGNITIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_160d9f66-d810-4f31-9a04-4b4bb00d9f85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_b7512493-252d-4346-ae63-ad038359b02f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_160d9f66-d810-4f31-9a04-4b4bb00d9f85" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_b7512493-252d-4346-ae63-ad038359b02f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_e697231b-1b18-4541-a0fc-b4e88ac9d674" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_160d9f66-d810-4f31-9a04-4b4bb00d9f85" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_e697231b-1b18-4541-a0fc-b4e88ac9d674" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ae5bd9c1-a980-4fbc-bf6a-9042565ab473" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_160d9f66-d810-4f31-9a04-4b4bb00d9f85" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ae5bd9c1-a980-4fbc-bf6a-9042565ab473" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_f3b87a3b-ad55-41b5-9d6f-46dcd53b4b14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_160d9f66-d810-4f31-9a04-4b4bb00d9f85" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_f3b87a3b-ad55-41b5-9d6f-46dcd53b4b14" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_c7587be2-6d1d-4182-8939-8cf39049ff83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_f3b87a3b-ad55-41b5-9d6f-46dcd53b4b14" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_c7587be2-6d1d-4182-8939-8cf39049ff83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_c7587be2-6d1d-4182-8939-8cf39049ff83_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_c7587be2-6d1d-4182-8939-8cf39049ff83" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_c7587be2-6d1d-4182-8939-8cf39049ff83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_c958ef5c-cf84-47e3-a9e1-b3c5d7c8551f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_c7587be2-6d1d-4182-8939-8cf39049ff83" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_c958ef5c-cf84-47e3-a9e1-b3c5d7c8551f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForCustomerReturnsMember_859b6ae2-eee1-4653-88ff-bbddeec45a2b" xlink:href="bhc-20220331.xsd#bhc_ReserveForCustomerReturnsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_c958ef5c-cf84-47e3-a9e1-b3c5d7c8551f" xlink:to="loc_bhc_ReserveForCustomerReturnsMember_859b6ae2-eee1-4653-88ff-bbddeec45a2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_018e878e-845e-45c5-817c-1d4aa8c7ebe5" xlink:href="bhc-20220331.xsd#bhc_ReserveForRebatesAdvertisingCreditsPortionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_c958ef5c-cf84-47e3-a9e1-b3c5d7c8551f" xlink:to="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_018e878e-845e-45c5-817c-1d4aa8c7ebe5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9882f6b8-1d88-4f97-8194-636eeb54ce90" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_f3b87a3b-ad55-41b5-9d6f-46dcd53b4b14" xlink:to="loc_srt_ProductOrServiceAxis_9882f6b8-1d88-4f97-8194-636eeb54ce90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9882f6b8-1d88-4f97-8194-636eeb54ce90_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9882f6b8-1d88-4f97-8194-636eeb54ce90" xlink:to="loc_srt_ProductsAndServicesDomain_9882f6b8-1d88-4f97-8194-636eeb54ce90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ca0b3ee0-36d5-4c44-88ba-559b9bc9e3f7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9882f6b8-1d88-4f97-8194-636eeb54ce90" xlink:to="loc_srt_ProductsAndServicesDomain_ca0b3ee0-36d5-4c44-88ba-559b9bc9e3f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PriceAppreciationCreditMember_58c8e21b-5ad7-49ba-86d6-b7b32726a9f3" xlink:href="bhc-20220331.xsd#bhc_PriceAppreciationCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ca0b3ee0-36d5-4c44-88ba-559b9bc9e3f7" xlink:to="loc_bhc_PriceAppreciationCreditMember_58c8e21b-5ad7-49ba-86d6-b7b32726a9f3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#REVENUERECOGNITIONVariableConsiderationProvisionsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails" xlink:type="extended" id="if955465f68544cb7b9677073309985dd_REVENUERECOGNITIONVariableConsiderationProvisionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_cbbffff5-cf32-4e93-8b09-3b1730a824ec" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_df5fc563-3cab-49e1-9bd4-ddcd6e5d9db3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_cbbffff5-cf32-4e93-8b09-3b1730a824ec" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_df5fc563-3cab-49e1-9bd4-ddcd6e5d9db3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_c6523d66-75b6-4906-a7fc-78ec0830bce5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_df5fc563-3cab-49e1-9bd4-ddcd6e5d9db3" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_c6523d66-75b6-4906-a7fc-78ec0830bce5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_3fb40d66-76f8-4c20-9716-9759bc7d406d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_df5fc563-3cab-49e1-9bd4-ddcd6e5d9db3" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_3fb40d66-76f8-4c20-9716-9759bc7d406d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_4a63c24f-dd10-4c40-88ee-17425ac8d185" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_df5fc563-3cab-49e1-9bd4-ddcd6e5d9db3" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_4a63c24f-dd10-4c40-88ee-17425ac8d185" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_82b04090-22fd-4896-aeca-3665c450ed37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_5fa5620f-3fd4-4ca9-bb7c-f463211bc458" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_cbbffff5-cf32-4e93-8b09-3b1730a824ec" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_5fa5620f-3fd4-4ca9-bb7c-f463211bc458" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_0847324f-b48f-4520-a94d-4a8921c0d0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_5fa5620f-3fd4-4ca9-bb7c-f463211bc458" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_0847324f-b48f-4520-a94d-4a8921c0d0e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_0847324f-b48f-4520-a94d-4a8921c0d0e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_0847324f-b48f-4520-a94d-4a8921c0d0e4" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_0847324f-b48f-4520-a94d-4a8921c0d0e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_6dd19b86-8734-412e-b72c-174305a67429" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_0847324f-b48f-4520-a94d-4a8921c0d0e4" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_6dd19b86-8734-412e-b72c-174305a67429" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDiscountsAndAllowancesMember_294cb3c9-9005-4aaf-83da-043b3d9b52d2" xlink:href="bhc-20220331.xsd#bhc_ReserveForDiscountsAndAllowancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_6dd19b86-8734-412e-b72c-174305a67429" xlink:to="loc_bhc_ReserveForDiscountsAndAllowancesMember_294cb3c9-9005-4aaf-83da-043b3d9b52d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForCustomerReturnsMember_2ae1a6d9-bfbc-46f7-aeff-c25fe6104f55" xlink:href="bhc-20220331.xsd#bhc_ReserveForCustomerReturnsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_6dd19b86-8734-412e-b72c-174305a67429" xlink:to="loc_bhc_ReserveForCustomerReturnsMember_2ae1a6d9-bfbc-46f7-aeff-c25fe6104f55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesMember_fce5c354-57bf-46a6-8ac3-7d36eced3104" xlink:href="bhc-20220331.xsd#bhc_ReserveForRebatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_6dd19b86-8734-412e-b72c-174305a67429" xlink:to="loc_bhc_ReserveForRebatesMember_fce5c354-57bf-46a6-8ac3-7d36eced3104" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForChargebacksMember_11396261-17ef-4f57-a1f9-312abb979759" xlink:href="bhc-20220331.xsd#bhc_ReserveForChargebacksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_6dd19b86-8734-412e-b72c-174305a67429" xlink:to="loc_bhc_ReserveForChargebacksMember_11396261-17ef-4f57-a1f9-312abb979759" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDistributionFeesMember_270bcffa-c70b-454e-84d4-2534a063452b" xlink:href="bhc-20220331.xsd#bhc_ReserveForDistributionFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_6dd19b86-8734-412e-b72c-174305a67429" xlink:to="loc_bhc_ReserveForDistributionFeesMember_270bcffa-c70b-454e-84d4-2534a063452b" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails" xlink:type="extended" id="iba779ed627a7492f9d1d9c8514dd40b6_LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_3039674f-dcb2-4600-b888-bbffcdea18f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_4bd698d0-029e-4af3-a1e8-6acab09231c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3039674f-dcb2-4600-b888-bbffcdea18f3" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_4bd698d0-029e-4af3-a1e8-6acab09231c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_dc9a9fea-ac12-47bb-b2f5-84b91727cc36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3039674f-dcb2-4600-b888-bbffcdea18f3" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_dc9a9fea-ac12-47bb-b2f5-84b91727cc36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_f48dd0d1-a307-424f-961c-ae7ae504fec6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3039674f-dcb2-4600-b888-bbffcdea18f3" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_f48dd0d1-a307-424f-961c-ae7ae504fec6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4f3ea81a-8d02-428d-aa53-b307d3a0df1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3039674f-dcb2-4600-b888-bbffcdea18f3" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4f3ea81a-8d02-428d-aa53-b307d3a0df1e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_880a5a91-4015-4c56-a717-79b68e147a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4f3ea81a-8d02-428d-aa53-b307d3a0df1e" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_880a5a91-4015-4c56-a717-79b68e147a0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_880a5a91-4015-4c56-a717-79b68e147a0f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_880a5a91-4015-4c56-a717-79b68e147a0f" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_880a5a91-4015-4c56-a717-79b68e147a0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_36fbaa00-5d81-4d9a-9dd7-b394edaabad4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_880a5a91-4015-4c56-a717-79b68e147a0f" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_36fbaa00-5d81-4d9a-9dd7-b394edaabad4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_871d80ae-8934-4f8d-8892-3896e7ca558e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_36fbaa00-5d81-4d9a-9dd7-b394edaabad4" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_871d80ae-8934-4f8d-8892-3896e7ca558e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b589f63f-c742-4014-9c28-cc3cc7dda805" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4f3ea81a-8d02-428d-aa53-b307d3a0df1e" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b589f63f-c742-4014-9c28-cc3cc7dda805" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b589f63f-c742-4014-9c28-cc3cc7dda805_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b589f63f-c742-4014-9c28-cc3cc7dda805" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b589f63f-c742-4014-9c28-cc3cc7dda805_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_13e8b6de-f51f-40dc-a1d8-6eddefcdfcfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b589f63f-c742-4014-9c28-cc3cc7dda805" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_13e8b6de-f51f-40dc-a1d8-6eddefcdfcfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmounPharmaceuticalCompanySAEMember_18ce41cc-57f4-456a-958e-06896efd2415" xlink:href="bhc-20220331.xsd#bhc_AmounPharmaceuticalCompanySAEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_13e8b6de-f51f-40dc-a1d8-6eddefcdfcfd" xlink:to="loc_bhc_AmounPharmaceuticalCompanySAEMember_18ce41cc-57f4-456a-958e-06896efd2415" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_414a63de-d4d0-4548-aec0-57e2efe7296f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4f3ea81a-8d02-428d-aa53-b307d3a0df1e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_414a63de-d4d0-4548-aec0-57e2efe7296f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_414a63de-d4d0-4548-aec0-57e2efe7296f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_414a63de-d4d0-4548-aec0-57e2efe7296f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_414a63de-d4d0-4548-aec0-57e2efe7296f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_14bf4a29-6678-4b76-9e57-39a6a33d926b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_414a63de-d4d0-4548-aec0-57e2efe7296f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_14bf4a29-6678-4b76-9e57-39a6a33d926b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetImpairmentChargesMember_0ba2add0-eb61-4416-a06a-3d6949a7fad1" xlink:href="bhc-20220331.xsd#bhc_AssetImpairmentChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_14bf4a29-6678-4b76-9e57-39a6a33d926b" xlink:to="loc_bhc_AssetImpairmentChargesMember_0ba2add0-eb61-4416-a06a-3d6949a7fad1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails" xlink:type="extended" id="i1ea139288b8f4a04a68d09ac8350dcfb_RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_3a8484fc-643a-4a95-ba51-372655bec545" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_ffec1b05-b555-4377-be99-5ffe0857fa9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3a8484fc-643a-4a95-ba51-372655bec545" xlink:to="loc_us-gaap_RestructuringReserve_ffec1b05-b555-4377-be99-5ffe0857fa9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_3dd1c136-dd0f-4da5-b0a1-8992ed839fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3a8484fc-643a-4a95-ba51-372655bec545" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_3dd1c136-dd0f-4da5-b0a1-8992ed839fb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_21cd064f-2ff7-4a43-b26f-c87e02898a27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3a8484fc-643a-4a95-ba51-372655bec545" xlink:to="loc_us-gaap_PaymentsForRestructuring_21cd064f-2ff7-4a43-b26f-c87e02898a27" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_e6c76885-4dab-4ff1-bcfa-9829925d3f72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3a8484fc-643a-4a95-ba51-372655bec545" xlink:to="loc_us-gaap_RestructuringCharges_e6c76885-4dab-4ff1-bcfa-9829925d3f72" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_184458b8-a50f-4a14-9995-374bb0a230ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3a8484fc-643a-4a95-ba51-372655bec545" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_184458b8-a50f-4a14-9995-374bb0a230ac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_430fb5d3-81b5-43c9-a353-181c422be04d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3a8484fc-643a-4a95-ba51-372655bec545" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_430fb5d3-81b5-43c9-a353-181c422be04d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_cda1ddfc-edad-44d2-b440-0ea499c13e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_430fb5d3-81b5-43c9-a353-181c422be04d" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_cda1ddfc-edad-44d2-b440-0ea499c13e2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_cda1ddfc-edad-44d2-b440-0ea499c13e2e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_cda1ddfc-edad-44d2-b440-0ea499c13e2e" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_cda1ddfc-edad-44d2-b440-0ea499c13e2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_a7ff044f-42a5-4bb2-91d6-b38e834bd28a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_cda1ddfc-edad-44d2-b440-0ea499c13e2e" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_a7ff044f-42a5-4bb2-91d6-b38e834bd28a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringAndIntegrationCostsMember_3a9351d4-15b6-495e-9055-95e852f52efb" xlink:href="bhc-20220331.xsd#bhc_RestructuringAndIntegrationCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_a7ff044f-42a5-4bb2-91d6-b38e834bd28a" xlink:to="loc_bhc_RestructuringAndIntegrationCostsMember_3a9351d4-15b6-495e-9055-95e852f52efb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeparationAndInitialPublicOfferingCostsMember_cea6d590-a130-478d-99ad-70cd72e294d9" xlink:href="bhc-20220331.xsd#bhc_SeparationAndInitialPublicOfferingCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_a7ff044f-42a5-4bb2-91d6-b38e834bd28a" xlink:to="loc_bhc_SeparationAndInitialPublicOfferingCostsMember_cea6d590-a130-478d-99ad-70cd72e294d9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended" id="ifc0b3cb868204f3a9805f8b8e637fd57_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2bba3422-4026-400a-a98f-1f6d30cd3ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_b7ed430d-36e2-495c-98df-eec2bd17f4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2bba3422-4026-400a-a98f-1f6d30cd3ac8" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_b7ed430d-36e2-495c-98df-eec2bd17f4c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0f421b02-9003-4800-aef8-044005895d34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b7ed430d-36e2-495c-98df-eec2bd17f4c1" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0f421b02-9003-4800-aef8-044005895d34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure_ac162127-6e4a-4d5c-8b09-dc07f08c2f6f" xlink:href="bhc-20220331.xsd#bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b7ed430d-36e2-495c-98df-eec2bd17f4c1" xlink:to="loc_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure_ac162127-6e4a-4d5c-8b09-dc07f08c2f6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_2fa7d25b-34c3-49a4-bced-330b4781a335" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b7ed430d-36e2-495c-98df-eec2bd17f4c1" xlink:to="loc_us-gaap_DerivativeAssets_2fa7d25b-34c3-49a4-bced-330b4781a335" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_9266d65f-35c4-484a-8cfc-f92730109e19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2bba3422-4026-400a-a98f-1f6d30cd3ac8" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_9266d65f-35c4-484a-8cfc-f92730109e19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_35c49cc1-fca0-4197-8d20-f8077cf9b80b" xlink:href="bhc-20220331.xsd#bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_9266d65f-35c4-484a-8cfc-f92730109e19" xlink:to="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_35c49cc1-fca0-4197-8d20-f8077cf9b80b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_706fc3cf-fb00-465a-ba23-28efcf14f24f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_9266d65f-35c4-484a-8cfc-f92730109e19" xlink:to="loc_us-gaap_DerivativeLiabilities_706fc3cf-fb00-465a-ba23-28efcf14f24f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1fd2c534-6cd3-48f5-87dd-5d7261c1eeea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2bba3422-4026-400a-a98f-1f6d30cd3ac8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1fd2c534-6cd3-48f5-87dd-5d7261c1eeea" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6c81b7f9-2d7f-4d03-986f-f68e3067e0e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1fd2c534-6cd3-48f5-87dd-5d7261c1eeea" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6c81b7f9-2d7f-4d03-986f-f68e3067e0e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_6c81b7f9-2d7f-4d03-986f-f68e3067e0e9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6c81b7f9-2d7f-4d03-986f-f68e3067e0e9" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_6c81b7f9-2d7f-4d03-986f-f68e3067e0e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_a098ec99-06a2-4728-8977-ffc2b83fb6ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6c81b7f9-2d7f-4d03-986f-f68e3067e0e9" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_a098ec99-06a2-4728-8977-ffc2b83fb6ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_c1df14d0-b61d-45a2-9c25-9cd3f41291b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_a098ec99-06a2-4728-8977-ffc2b83fb6ce" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_c1df14d0-b61d-45a2-9c25-9cd3f41291b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6adf0fbb-4423-426c-8bbc-12295e603e9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1fd2c534-6cd3-48f5-87dd-5d7261c1eeea" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6adf0fbb-4423-426c-8bbc-12295e603e9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6adf0fbb-4423-426c-8bbc-12295e603e9d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6adf0fbb-4423-426c-8bbc-12295e603e9d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6adf0fbb-4423-426c-8bbc-12295e603e9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a1a57398-9efd-44c9-b5e0-0466bd591426" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6adf0fbb-4423-426c-8bbc-12295e603e9d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a1a57398-9efd-44c9-b5e0-0466bd591426" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c060cad4-89ea-4957-83f9-0e51635af84d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a1a57398-9efd-44c9-b5e0-0466bd591426" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c060cad4-89ea-4957-83f9-0e51635af84d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_c3610794-ea68-49b0-afb4-46bc25be5901" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a1a57398-9efd-44c9-b5e0-0466bd591426" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_c3610794-ea68-49b0-afb4-46bc25be5901" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9c48aeb2-5f79-49b8-af9b-158dc7cbd440" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a1a57398-9efd-44c9-b5e0-0466bd591426" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9c48aeb2-5f79-49b8-af9b-158dc7cbd440" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5af69d7c-9d1d-4311-9af4-fbaa9b270a84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1fd2c534-6cd3-48f5-87dd-5d7261c1eeea" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5af69d7c-9d1d-4311-9af4-fbaa9b270a84" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_5af69d7c-9d1d-4311-9af4-fbaa9b270a84_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5af69d7c-9d1d-4311-9af4-fbaa9b270a84" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_5af69d7c-9d1d-4311-9af4-fbaa9b270a84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d749efa7-97e4-4516-8dd4-e8a496631314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5af69d7c-9d1d-4311-9af4-fbaa9b270a84" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d749efa7-97e4-4516-8dd4-e8a496631314" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_a4076401-0ed3-4c24-b292-9f42eab145f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d749efa7-97e4-4516-8dd4-e8a496631314" xlink:to="loc_us-gaap_ForeignExchangeContractMember_a4076401-0ed3-4c24-b292-9f42eab145f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_5e30caa3-046b-4aad-a968-6c8d7671bd42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1fd2c534-6cd3-48f5-87dd-5d7261c1eeea" xlink:to="loc_us-gaap_HedgingDesignationAxis_5e30caa3-046b-4aad-a968-6c8d7671bd42" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_5e30caa3-046b-4aad-a968-6c8d7671bd42_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_5e30caa3-046b-4aad-a968-6c8d7671bd42" xlink:to="loc_us-gaap_HedgingDesignationDomain_5e30caa3-046b-4aad-a968-6c8d7671bd42_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_3a344582-46a1-457d-8a64-a9ab80990753" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_5e30caa3-046b-4aad-a968-6c8d7671bd42" xlink:to="loc_us-gaap_HedgingDesignationDomain_3a344582-46a1-457d-8a64-a9ab80990753" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_171b1dbc-c928-44fb-9770-805e0d3a1f06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_3a344582-46a1-457d-8a64-a9ab80990753" xlink:to="loc_us-gaap_NondesignatedMember_171b1dbc-c928-44fb-9770-805e0d3a1f06" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails" xlink:type="extended" id="i62df441b41fc4bd7bfcbcf0e059fc67e_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8ccec2cb-8fdd-4918-a0b4-370e96d2248f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod_e814b628-4e79-413e-8a73-29d500044d71" xlink:href="bhc-20220331.xsd#bhc_HighlyLiquidInvestmentsMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8ccec2cb-8fdd-4918-a0b4-370e96d2248f" xlink:to="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod_e814b628-4e79-413e-8a73-29d500044d71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_c742815c-2d87-4a66-9575-1df9962a71ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8ccec2cb-8fdd-4918-a0b4-370e96d2248f" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_c742815c-2d87-4a66-9575-1df9962a71ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LitigationSettlementNumberOfObjectorsAppeals_fa95b63d-e520-4dd2-89a0-727c15f8789d" xlink:href="bhc-20220331.xsd#bhc_LitigationSettlementNumberOfObjectorsAppeals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8ccec2cb-8fdd-4918-a0b4-370e96d2248f" xlink:to="loc_bhc_LitigationSettlementNumberOfObjectorsAppeals_fa95b63d-e520-4dd2-89a0-727c15f8789d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2e7837ae-af5e-416f-95e0-84224b1380da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8ccec2cb-8fdd-4918-a0b4-370e96d2248f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2e7837ae-af5e-416f-95e0-84224b1380da" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_6292dede-1981-442e-bf65-fdaeb9cb8b15" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2e7837ae-af5e-416f-95e0-84224b1380da" xlink:to="loc_srt_LitigationCaseAxis_6292dede-1981-442e-bf65-fdaeb9cb8b15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_6292dede-1981-442e-bf65-fdaeb9cb8b15_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_6292dede-1981-442e-bf65-fdaeb9cb8b15" xlink:to="loc_srt_LitigationCaseTypeDomain_6292dede-1981-442e-bf65-fdaeb9cb8b15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_24960ac3-39df-4246-8de1-aa9ee252c4c3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_6292dede-1981-442e-bf65-fdaeb9cb8b15" xlink:to="loc_srt_LitigationCaseTypeDomain_24960ac3-39df-4246-8de1-aa9ee252c4c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember_106909eb-54d3-4495-b774-bf04940fc7f0" xlink:href="bhc-20220331.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_24960ac3-39df-4246-8de1-aa9ee252c4c3" xlink:to="loc_bhc_ValeantUSSecuritiesLitigationMember_106909eb-54d3-4495-b774-bf04940fc7f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_f29c3a53-28bb-462a-85e0-d2e6190da6e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2e7837ae-af5e-416f-95e0-84224b1380da" xlink:to="loc_us-gaap_LitigationStatusAxis_f29c3a53-28bb-462a-85e0-d2e6190da6e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_f29c3a53-28bb-462a-85e0-d2e6190da6e6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_f29c3a53-28bb-462a-85e0-d2e6190da6e6" xlink:to="loc_us-gaap_LitigationStatusDomain_f29c3a53-28bb-462a-85e0-d2e6190da6e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_6d8eb47f-4003-4cbb-af57-fad15f0dd7f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_f29c3a53-28bb-462a-85e0-d2e6190da6e6" xlink:to="loc_us-gaap_LitigationStatusDomain_6d8eb47f-4003-4cbb-af57-fad15f0dd7f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_49bd3dd3-4079-4d7b-bd3f-fc1416cb0255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_6d8eb47f-4003-4cbb-af57-fad15f0dd7f7" xlink:to="loc_us-gaap_SettledLitigationMember_49bd3dd3-4079-4d7b-bd3f-fc1416cb0255" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_cd79da1d-ccd1-4cfe-a7ff-ad9d901cf3a5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2e7837ae-af5e-416f-95e0-84224b1380da" xlink:to="loc_srt_StatementGeographicalAxis_cd79da1d-ccd1-4cfe-a7ff-ad9d901cf3a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_cd79da1d-ccd1-4cfe-a7ff-ad9d901cf3a5_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_cd79da1d-ccd1-4cfe-a7ff-ad9d901cf3a5" xlink:to="loc_srt_SegmentGeographicalDomain_cd79da1d-ccd1-4cfe-a7ff-ad9d901cf3a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d9aa3066-5b57-4672-a1ca-bf4982bc3723" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_cd79da1d-ccd1-4cfe-a7ff-ad9d901cf3a5" xlink:to="loc_srt_SegmentGeographicalDomain_d9aa3066-5b57-4672-a1ca-bf4982bc3723" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_9dd4501c-abfc-4874-89d0-79c809207aff" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_NJ"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d9aa3066-5b57-4672-a1ca-bf4982bc3723" xlink:to="loc_stpr_NJ_9dd4501c-abfc-4874-89d0-79c809207aff" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails" xlink:type="extended" id="i95715d6c94cc474cbe679e1002c378c4_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1ce88668-e0a5-486d-8760-61677b5ac3c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_fe637791-9720-4349-8df5-3a3732412a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1ce88668-e0a5-486d-8760-61677b5ac3c7" xlink:to="loc_us-gaap_DerivativeNotionalAmount_fe637791-9720-4349-8df5-3a3732412a9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_82af953d-c838-49a1-80b8-973608a1e6b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1ce88668-e0a5-486d-8760-61677b5ac3c7" xlink:to="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_82af953d-c838-49a1-80b8-973608a1e6b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3326dfb2-6aa9-46f0-8331-5090c81c3ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1ce88668-e0a5-486d-8760-61677b5ac3c7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3326dfb2-6aa9-46f0-8331-5090c81c3ed9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_cd7c0201-3dd8-409d-873c-edd75b276ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3326dfb2-6aa9-46f0-8331-5090c81c3ed9" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_cd7c0201-3dd8-409d-873c-edd75b276ddb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_cd7c0201-3dd8-409d-873c-edd75b276ddb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_cd7c0201-3dd8-409d-873c-edd75b276ddb" xlink:to="loc_us-gaap_HedgingRelationshipDomain_cd7c0201-3dd8-409d-873c-edd75b276ddb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_2a749a0a-9316-4179-b3ba-fb3eccff2952" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_cd7c0201-3dd8-409d-873c-edd75b276ddb" xlink:to="loc_us-gaap_HedgingRelationshipDomain_2a749a0a-9316-4179-b3ba-fb3eccff2952" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_0b0ae4fa-d7fc-454c-985f-e636425bb0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_2a749a0a-9316-4179-b3ba-fb3eccff2952" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_0b0ae4fa-d7fc-454c-985f-e636425bb0ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_cffafc49-8092-4483-b835-8c2c17bb5255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3326dfb2-6aa9-46f0-8331-5090c81c3ed9" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_cffafc49-8092-4483-b835-8c2c17bb5255" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_cffafc49-8092-4483-b835-8c2c17bb5255_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_cffafc49-8092-4483-b835-8c2c17bb5255" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_cffafc49-8092-4483-b835-8c2c17bb5255_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c114e80f-7fc0-4a26-9300-f251c0b764e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_cffafc49-8092-4483-b835-8c2c17bb5255" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c114e80f-7fc0-4a26-9300-f251c0b764e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_ad0321d5-8256-449a-840e-c7a25114acde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c114e80f-7fc0-4a26-9300-f251c0b764e1" xlink:to="loc_us-gaap_CurrencySwapMember_ad0321d5-8256-449a-840e-c7a25114acde" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_1c6d0215-5a07-4371-8f6d-150c4eb1f716" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3326dfb2-6aa9-46f0-8331-5090c81c3ed9" xlink:to="loc_us-gaap_HedgingDesignationAxis_1c6d0215-5a07-4371-8f6d-150c4eb1f716" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_1c6d0215-5a07-4371-8f6d-150c4eb1f716_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_1c6d0215-5a07-4371-8f6d-150c4eb1f716" xlink:to="loc_us-gaap_HedgingDesignationDomain_1c6d0215-5a07-4371-8f6d-150c4eb1f716_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_5b84faa6-60cf-4ec6-91ed-6bb033edd114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_1c6d0215-5a07-4371-8f6d-150c4eb1f716" xlink:to="loc_us-gaap_HedgingDesignationDomain_5b84faa6-60cf-4ec6-91ed-6bb033edd114" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_a20244f9-3021-4db3-9442-e132fe66e20c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_5b84faa6-60cf-4ec6-91ed-6bb033edd114" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_a20244f9-3021-4db3-9442-e132fe66e20c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" xlink:type="extended" id="if4f566e812f644d086484ee0622850bf_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a0355357-2f6b-4079-9382-81873c95c7fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_2c96a059-149e-4008-834f-de1171732610" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a0355357-2f6b-4079-9382-81873c95c7fa" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_2c96a059-149e-4008-834f-de1171732610" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_8adb3673-31c4-4958-95db-1cb410d0d521" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a0355357-2f6b-4079-9382-81873c95c7fa" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_8adb3673-31c4-4958-95db-1cb410d0d521" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7d4405f9-bda0-438a-a203-f717b2ab4d16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a0355357-2f6b-4079-9382-81873c95c7fa" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7d4405f9-bda0-438a-a203-f717b2ab4d16" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f385ad84-666c-4942-8432-0a56e46d3483" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7d4405f9-bda0-438a-a203-f717b2ab4d16" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f385ad84-666c-4942-8432-0a56e46d3483" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_f385ad84-666c-4942-8432-0a56e46d3483_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f385ad84-666c-4942-8432-0a56e46d3483" xlink:to="loc_us-gaap_HedgingRelationshipDomain_f385ad84-666c-4942-8432-0a56e46d3483_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_c1265ebb-3bc5-4902-9a88-a646445d6526" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f385ad84-666c-4942-8432-0a56e46d3483" xlink:to="loc_us-gaap_HedgingRelationshipDomain_c1265ebb-3bc5-4902-9a88-a646445d6526" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_d08ab361-471d-459a-ae78-dd6dc2659fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_c1265ebb-3bc5-4902-9a88-a646445d6526" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_d08ab361-471d-459a-ae78-dd6dc2659fbb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_21f377e3-52ca-4d56-929d-ab4c1c5d67ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7d4405f9-bda0-438a-a203-f717b2ab4d16" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_21f377e3-52ca-4d56-929d-ab4c1c5d67ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_21f377e3-52ca-4d56-929d-ab4c1c5d67ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_21f377e3-52ca-4d56-929d-ab4c1c5d67ff" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_21f377e3-52ca-4d56-929d-ab4c1c5d67ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_abec377b-7769-4fd3-8747-183cb5380870" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_21f377e3-52ca-4d56-929d-ab4c1c5d67ff" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_abec377b-7769-4fd3-8747-183cb5380870" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_545f9b86-8618-4207-84fa-a175409e822f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_abec377b-7769-4fd3-8747-183cb5380870" xlink:to="loc_us-gaap_CurrencySwapMember_545f9b86-8618-4207-84fa-a175409e822f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_73ebfb02-6fb9-4ad2-82be-2d5ef66b2afc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7d4405f9-bda0-438a-a203-f717b2ab4d16" xlink:to="loc_us-gaap_HedgingDesignationAxis_73ebfb02-6fb9-4ad2-82be-2d5ef66b2afc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_73ebfb02-6fb9-4ad2-82be-2d5ef66b2afc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_73ebfb02-6fb9-4ad2-82be-2d5ef66b2afc" xlink:to="loc_us-gaap_HedgingDesignationDomain_73ebfb02-6fb9-4ad2-82be-2d5ef66b2afc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_64819721-c430-4e72-a80a-21bb2ab76049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_73ebfb02-6fb9-4ad2-82be-2d5ef66b2afc" xlink:to="loc_us-gaap_HedgingDesignationDomain_64819721-c430-4e72-a80a-21bb2ab76049" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_dba81803-4cce-4d7e-8409-8a3a155e8b04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_64819721-c430-4e72-a80a-21bb2ab76049" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_dba81803-4cce-4d7e-8409-8a3a155e8b04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c453ce59-642f-4872-93b1-923252295fce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7d4405f9-bda0-438a-a203-f717b2ab4d16" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c453ce59-642f-4872-93b1-923252295fce" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c453ce59-642f-4872-93b1-923252295fce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c453ce59-642f-4872-93b1-923252295fce" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c453ce59-642f-4872-93b1-923252295fce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5f47822f-36dd-4f72-9983-03baa997c9da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c453ce59-642f-4872-93b1-923252295fce" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5f47822f-36dd-4f72-9983-03baa997c9da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_527c132d-a250-4886-afce-c6c7c0eeb4bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5f47822f-36dd-4f72-9983-03baa997c9da" xlink:to="loc_us-gaap_InterestExpenseMember_527c132d-a250-4886-afce-c6c7c0eeb4bf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails" xlink:type="extended" id="i002861134d5c47878e308bd3b9f9a18a_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_136e712c-f6a3-4d1e-aaca-22265cdc4ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_c734a9bb-2a15-4d09-babe-d0f643cba2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_136e712c-f6a3-4d1e-aaca-22265cdc4ec8" xlink:to="loc_us-gaap_DerivativeNotionalAmount_c734a9bb-2a15-4d09-babe-d0f643cba2cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f074ac5d-a937-411e-8992-ea229ffd4f86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_136e712c-f6a3-4d1e-aaca-22265cdc4ec8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f074ac5d-a937-411e-8992-ea229ffd4f86" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_294b7ec8-53fa-44f9-96e4-d85fad7e168c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f074ac5d-a937-411e-8992-ea229ffd4f86" xlink:to="loc_us-gaap_HedgingDesignationAxis_294b7ec8-53fa-44f9-96e4-d85fad7e168c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_294b7ec8-53fa-44f9-96e4-d85fad7e168c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_294b7ec8-53fa-44f9-96e4-d85fad7e168c" xlink:to="loc_us-gaap_HedgingDesignationDomain_294b7ec8-53fa-44f9-96e4-d85fad7e168c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_b048d63f-2d56-4a33-875e-502006135e29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_294b7ec8-53fa-44f9-96e4-d85fad7e168c" xlink:to="loc_us-gaap_HedgingDesignationDomain_b048d63f-2d56-4a33-875e-502006135e29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_afc3b2b5-1974-46ed-afff-857dd74d562e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_b048d63f-2d56-4a33-875e-502006135e29" xlink:to="loc_us-gaap_NondesignatedMember_afc3b2b5-1974-46ed-afff-857dd74d562e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_365bf202-f9c3-40d5-b550-f829c2cd7c09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f074ac5d-a937-411e-8992-ea229ffd4f86" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_365bf202-f9c3-40d5-b550-f829c2cd7c09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_365bf202-f9c3-40d5-b550-f829c2cd7c09_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_365bf202-f9c3-40d5-b550-f829c2cd7c09" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_365bf202-f9c3-40d5-b550-f829c2cd7c09_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_00e2ba63-4e92-4e00-84c4-b118b8851342" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_365bf202-f9c3-40d5-b550-f829c2cd7c09" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_00e2ba63-4e92-4e00-84c4-b118b8851342" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_42fde316-4f21-493d-ac60-f5f173866ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_00e2ba63-4e92-4e00-84c4-b118b8851342" xlink:to="loc_us-gaap_ForeignExchangeContractMember_42fde316-4f21-493d-ac60-f5f173866ee1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="extended" id="i204a9bdcfcea4f22b852837d95736e39_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3f5f0330-68a8-4088-a5f5-6420262743be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_710a0ef4-3f2f-42d6-9253-dcf2b813fdcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3f5f0330-68a8-4088-a5f5-6420262743be" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_710a0ef4-3f2f-42d6-9253-dcf2b813fdcd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_2ef088d9-6f13-4826-b8c6-0303cc3f1b75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3f5f0330-68a8-4088-a5f5-6420262743be" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_2ef088d9-6f13-4826-b8c6-0303cc3f1b75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_20f7c77c-28c2-4fb6-999c-ba5209654508" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3f5f0330-68a8-4088-a5f5-6420262743be" xlink:to="loc_us-gaap_DerivativeLiabilities_20f7c77c-28c2-4fb6-999c-ba5209654508" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_deeb0cc7-a30f-4441-80f5-712ced1b4478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3f5f0330-68a8-4088-a5f5-6420262743be" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_deeb0cc7-a30f-4441-80f5-712ced1b4478" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_6f27d52e-c2a8-47f1-814c-3b15dec5952b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_deeb0cc7-a30f-4441-80f5-712ced1b4478" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_6f27d52e-c2a8-47f1-814c-3b15dec5952b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6f27d52e-c2a8-47f1-814c-3b15dec5952b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6f27d52e-c2a8-47f1-814c-3b15dec5952b" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6f27d52e-c2a8-47f1-814c-3b15dec5952b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_bd600520-5e53-409b-b906-8edbec721c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6f27d52e-c2a8-47f1-814c-3b15dec5952b" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_bd600520-5e53-409b-b906-8edbec721c6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedAndOtherCurrentLiabilitiesMember_5c5e1293-2c8a-4f24-b983-459f44400155" xlink:href="bhc-20220331.xsd#bhc_AccruedAndOtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_bd600520-5e53-409b-b906-8edbec721c6f" xlink:to="loc_bhc_AccruedAndOtherCurrentLiabilitiesMember_5c5e1293-2c8a-4f24-b983-459f44400155" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_ded7f7e8-ccf6-4e75-9c1f-376d84f3f99c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_bd600520-5e53-409b-b906-8edbec721c6f" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_ded7f7e8-ccf6-4e75-9c1f-376d84f3f99c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_052680fc-721b-43ab-b80a-3c1cf0dc4c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_deeb0cc7-a30f-4441-80f5-712ced1b4478" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_052680fc-721b-43ab-b80a-3c1cf0dc4c0f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_052680fc-721b-43ab-b80a-3c1cf0dc4c0f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_052680fc-721b-43ab-b80a-3c1cf0dc4c0f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_052680fc-721b-43ab-b80a-3c1cf0dc4c0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c16a61d1-102b-400b-9f4c-705f8f35b103" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_052680fc-721b-43ab-b80a-3c1cf0dc4c0f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c16a61d1-102b-400b-9f4c-705f8f35b103" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_732d768e-738a-4d6e-ad41-38ec57f099f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c16a61d1-102b-400b-9f4c-705f8f35b103" xlink:to="loc_us-gaap_ForeignExchangeContractMember_732d768e-738a-4d6e-ad41-38ec57f099f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_9aff30dd-0878-4855-b6ae-f617f8994a52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_deeb0cc7-a30f-4441-80f5-712ced1b4478" xlink:to="loc_us-gaap_HedgingDesignationAxis_9aff30dd-0878-4855-b6ae-f617f8994a52" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_9aff30dd-0878-4855-b6ae-f617f8994a52_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_9aff30dd-0878-4855-b6ae-f617f8994a52" xlink:to="loc_us-gaap_HedgingDesignationDomain_9aff30dd-0878-4855-b6ae-f617f8994a52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_da7619c8-0de2-4a43-a775-b76e632c5e58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_9aff30dd-0878-4855-b6ae-f617f8994a52" xlink:to="loc_us-gaap_HedgingDesignationDomain_da7619c8-0de2-4a43-a775-b76e632c5e58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_643a19e0-822d-4141-b7ff-38f5e077239d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_da7619c8-0de2-4a43-a775-b76e632c5e58" xlink:to="loc_us-gaap_NondesignatedMember_643a19e0-822d-4141-b7ff-38f5e077239d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails" xlink:type="extended" id="i481358e980e0438badffdf9b6b191fb2_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_af6821c9-b460-4162-99cb-95d336ea23b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_641ede62-9d42-44e7-a778-5aeea8ca2a78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_af6821c9-b460-4162-99cb-95d336ea23b1" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_641ede62-9d42-44e7-a778-5aeea8ca2a78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain_c618a612-c3a6-44de-8cf3-44568cd04244" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_af6821c9-b460-4162-99cb-95d336ea23b1" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain_c618a612-c3a6-44de-8cf3-44568cd04244" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_20519ff2-068a-466c-bc62-edad7c2acda8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_af6821c9-b460-4162-99cb-95d336ea23b1" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_20519ff2-068a-466c-bc62-edad7c2acda8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bc63fd1b-4fef-452b-ab11-b78e238b869b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_af6821c9-b460-4162-99cb-95d336ea23b1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bc63fd1b-4fef-452b-ab11-b78e238b869b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_58736d89-9135-4b71-80a4-6652b08c06fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bc63fd1b-4fef-452b-ab11-b78e238b869b" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_58736d89-9135-4b71-80a4-6652b08c06fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_58736d89-9135-4b71-80a4-6652b08c06fd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_58736d89-9135-4b71-80a4-6652b08c06fd" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_58736d89-9135-4b71-80a4-6652b08c06fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_3ee7f267-6c03-4126-8c5d-917a22c13465" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_58736d89-9135-4b71-80a4-6652b08c06fd" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_3ee7f267-6c03-4126-8c5d-917a22c13465" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_7cdbf61e-5344-446d-8edc-f5328b64cbe3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_3ee7f267-6c03-4126-8c5d-917a22c13465" xlink:to="loc_us-gaap_ForeignExchangeContractMember_7cdbf61e-5344-446d-8edc-f5328b64cbe3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_ecc107ac-8611-4177-9126-e371b0ab6d58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bc63fd1b-4fef-452b-ab11-b78e238b869b" xlink:to="loc_us-gaap_HedgingDesignationAxis_ecc107ac-8611-4177-9126-e371b0ab6d58" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_ecc107ac-8611-4177-9126-e371b0ab6d58_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_ecc107ac-8611-4177-9126-e371b0ab6d58" xlink:to="loc_us-gaap_HedgingDesignationDomain_ecc107ac-8611-4177-9126-e371b0ab6d58_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_47e19143-da67-43d8-8098-e408353c1669" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_ecc107ac-8611-4177-9126-e371b0ab6d58" xlink:to="loc_us-gaap_HedgingDesignationDomain_47e19143-da67-43d8-8098-e408353c1669" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_21646295-f4ed-4fb9-bc91-5ea6bc46a51c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_47e19143-da67-43d8-8098-e408353c1669" xlink:to="loc_us-gaap_NondesignatedMember_21646295-f4ed-4fb9-bc91-5ea6bc46a51c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails" xlink:type="extended" id="i5599d85301ad4a5994e6e9a6d793eddb_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_69a38f5b-4ad8-4743-8619-2dc8afc76a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_4d8aa0db-8047-4cb2-941f-b2adce6efc3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_69a38f5b-4ad8-4743-8619-2dc8afc76a0a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_4d8aa0db-8047-4cb2-941f-b2adce6efc3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ae3015c8-a8be-4cb6-baf2-b32aef21fbf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_69a38f5b-4ad8-4743-8619-2dc8afc76a0a" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ae3015c8-a8be-4cb6-baf2-b32aef21fbf8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f8198652-6ee6-4732-bbfa-e6a1cdca1486" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ae3015c8-a8be-4cb6-baf2-b32aef21fbf8" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f8198652-6ee6-4732-bbfa-e6a1cdca1486" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f8198652-6ee6-4732-bbfa-e6a1cdca1486_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f8198652-6ee6-4732-bbfa-e6a1cdca1486" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f8198652-6ee6-4732-bbfa-e6a1cdca1486_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2c457bd2-c518-48a3-95cb-7aba2d639068" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f8198652-6ee6-4732-bbfa-e6a1cdca1486" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2c457bd2-c518-48a3-95cb-7aba2d639068" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_54355aa7-360f-45c6-9371-0f9d3bf7cc35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_2c457bd2-c518-48a3-95cb-7aba2d639068" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_54355aa7-360f-45c6-9371-0f9d3bf7cc35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_b90ac752-b68c-49ca-b4d8-3c49f8e4644b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ae3015c8-a8be-4cb6-baf2-b32aef21fbf8" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_b90ac752-b68c-49ca-b4d8-3c49f8e4644b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_b90ac752-b68c-49ca-b4d8-3c49f8e4644b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_b90ac752-b68c-49ca-b4d8-3c49f8e4644b" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_b90ac752-b68c-49ca-b4d8-3c49f8e4644b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_27af258a-0321-405a-876d-6cf47579adba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_b90ac752-b68c-49ca-b4d8-3c49f8e4644b" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_27af258a-0321-405a-876d-6cf47579adba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_c4fdb36f-0fce-4b85-b05e-06fc8d18cdfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_27af258a-0321-405a-876d-6cf47579adba" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_c4fdb36f-0fce-4b85-b05e-06fc8d18cdfb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember_a645db56-63d0-46b4-9c3d-a873612a569a" xlink:href="bhc-20220331.xsd#bhc_MeasurementInputWeightedAverageDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_27af258a-0321-405a-876d-6cf47579adba" xlink:to="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember_a645db56-63d0-46b4-9c3d-a873612a569a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_689d9743-f655-4bc4-8fbd-5f454ca2411e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ae3015c8-a8be-4cb6-baf2-b32aef21fbf8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_689d9743-f655-4bc4-8fbd-5f454ca2411e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_689d9743-f655-4bc4-8fbd-5f454ca2411e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_689d9743-f655-4bc4-8fbd-5f454ca2411e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_689d9743-f655-4bc4-8fbd-5f454ca2411e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8cf6588-cd64-455b-a32f-6d0b3a74ca9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_689d9743-f655-4bc4-8fbd-5f454ca2411e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8cf6588-cd64-455b-a32f-6d0b3a74ca9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_efe212e6-2afe-4a9c-8a5e-4215e8f5797e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8cf6588-cd64-455b-a32f-6d0b3a74ca9e" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_efe212e6-2afe-4a9c-8a5e-4215e8f5797e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b5f15366-868a-4e3c-a414-9edcbc5c853c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ae3015c8-a8be-4cb6-baf2-b32aef21fbf8" xlink:to="loc_srt_RangeAxis_b5f15366-868a-4e3c-a414-9edcbc5c853c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b5f15366-868a-4e3c-a414-9edcbc5c853c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b5f15366-868a-4e3c-a414-9edcbc5c853c" xlink:to="loc_srt_RangeMember_b5f15366-868a-4e3c-a414-9edcbc5c853c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ad1ba158-2e8e-4539-a061-f2a0daf9f375" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b5f15366-868a-4e3c-a414-9edcbc5c853c" xlink:to="loc_srt_RangeMember_ad1ba158-2e8e-4539-a061-f2a0daf9f375" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d8bc6650-8354-4342-b368-aecd9963aef3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ad1ba158-2e8e-4539-a061-f2a0daf9f375" xlink:to="loc_srt_MinimumMember_d8bc6650-8354-4342-b368-aecd9963aef3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_98679aed-6592-4324-9426-44d439bfe4f5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ad1ba158-2e8e-4539-a061-f2a0daf9f375" xlink:to="loc_srt_MaximumMember_98679aed-6592-4324-9426-44d439bfe4f5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails" xlink:type="extended" id="i09b248c88a7b43ceb5fe6ee0213f1682_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_d09552e3-b40b-45c7-9e3c-cb48f4883436" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1689085a-9b2e-47e3-adde-2667874a56a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_d09552e3-b40b-45c7-9e3c-cb48f4883436" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1689085a-9b2e-47e3-adde-2667874a56a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_c38c16b3-27a7-488b-beba-925d089c07cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1689085a-9b2e-47e3-adde-2667874a56a7" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_c38c16b3-27a7-488b-beba-925d089c07cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_8a8998b2-9f21-43d7-924b-481e4e804c17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1689085a-9b2e-47e3-adde-2667874a56a7" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_8a8998b2-9f21-43d7-924b-481e4e804c17" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_fea8a957-e553-4d1c-a722-ab3c66845b88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1689085a-9b2e-47e3-adde-2667874a56a7" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_fea8a957-e553-4d1c-a722-ab3c66845b88" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_90e3b410-fe90-4144-90ef-fa042489f55a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_4eb7a745-e628-4c5e-adca-bd7716de51cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1689085a-9b2e-47e3-adde-2667874a56a7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_4eb7a745-e628-4c5e-adca-bd7716de51cf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_513f90ce-eca4-4ad5-b7db-bc593e24948b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1689085a-9b2e-47e3-adde-2667874a56a7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_513f90ce-eca4-4ad5-b7db-bc593e24948b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_b2a80eca-a34d-4d04-ad7a-d4df4c658140" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_d09552e3-b40b-45c7-9e3c-cb48f4883436" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_b2a80eca-a34d-4d04-ad7a-d4df4c658140" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_667fe0fd-2bb2-48c5-a484-7fbe5262f85f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_b2a80eca-a34d-4d04-ad7a-d4df4c658140" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_667fe0fd-2bb2-48c5-a484-7fbe5262f85f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_667fe0fd-2bb2-48c5-a484-7fbe5262f85f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_667fe0fd-2bb2-48c5-a484-7fbe5262f85f" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_667fe0fd-2bb2-48c5-a484-7fbe5262f85f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_fe929824-8baa-45a3-96c0-1423f5b8d1d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_667fe0fd-2bb2-48c5-a484-7fbe5262f85f" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_fe929824-8baa-45a3-96c0-1423f5b8d1d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccretionForTimeValueOfMoneyMember_bd0c8f82-57e8-47b1-8824-2844e45f4c02" xlink:href="bhc-20220331.xsd#bhc_AccretionForTimeValueOfMoneyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_fe929824-8baa-45a3-96c0-1423f5b8d1d4" xlink:to="loc_bhc_AccretionForTimeValueOfMoneyMember_bd0c8f82-57e8-47b1-8824-2844e45f4c02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember_e054bbd3-6841-406d-a0db-2cb8a6f715ce" xlink:href="bhc-20220331.xsd#bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_fe929824-8baa-45a3-96c0-1423f5b8d1d4" xlink:to="loc_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember_e054bbd3-6841-406d-a0db-2cb8a6f715ce" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails" xlink:type="extended" id="i9b0887843ff14db5a5e0b27d9273856c_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c6c2048d-822a-4888-a675-5288c1f04208" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_75383699-21ef-4f20-b80f-1a0060aa520c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c6c2048d-822a-4888-a675-5288c1f04208" xlink:to="loc_us-gaap_DebtInstrumentFairValue_75383699-21ef-4f20-b80f-1a0060aa520c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_86c3c363-f6d5-422e-bb66-20c18d70b88a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c6c2048d-822a-4888-a675-5288c1f04208" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_86c3c363-f6d5-422e-bb66-20c18d70b88a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7ba1048d-43a5-4aaf-8e7f-ebad5f50ccd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_86c3c363-f6d5-422e-bb66-20c18d70b88a" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7ba1048d-43a5-4aaf-8e7f-ebad5f50ccd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7ba1048d-43a5-4aaf-8e7f-ebad5f50ccd4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7ba1048d-43a5-4aaf-8e7f-ebad5f50ccd4" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7ba1048d-43a5-4aaf-8e7f-ebad5f50ccd4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f7f28da0-97f6-49ed-a517-abd960ac587f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7ba1048d-43a5-4aaf-8e7f-ebad5f50ccd4" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f7f28da0-97f6-49ed-a517-abd960ac587f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_0051e69a-2791-4ab8-b163-c70a922ecd07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_f7f28da0-97f6-49ed-a517-abd960ac587f" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_0051e69a-2791-4ab8-b163-c70a922ecd07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fac6238d-2aeb-443e-88c7-9d4521bae3cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_86c3c363-f6d5-422e-bb66-20c18d70b88a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fac6238d-2aeb-443e-88c7-9d4521bae3cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fac6238d-2aeb-443e-88c7-9d4521bae3cb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fac6238d-2aeb-443e-88c7-9d4521bae3cb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fac6238d-2aeb-443e-88c7-9d4521bae3cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_623924f8-3248-4404-8d4b-8f1823ccf3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fac6238d-2aeb-443e-88c7-9d4521bae3cb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_623924f8-3248-4404-8d4b-8f1823ccf3a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_71fed5b0-a193-4574-8078-8ffc36fd0b47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_623924f8-3248-4404-8d4b-8f1823ccf3a9" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_71fed5b0-a193-4574-8078-8ffc36fd0b47" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails" xlink:type="extended" id="ia0b34d7777fa4c26a767e585f481409d_INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_6e3a5e04-14dd-4491-adc8-5fe5d2e051bf" xlink:href="bhc-20220331.xsd#bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2dfc191c-6597-4496-80d1-c7d3d874a4f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_6e3a5e04-14dd-4491-adc8-5fe5d2e051bf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2dfc191c-6597-4496-80d1-c7d3d874a4f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_747145c7-2939-4768-8694-765278c6ffb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2dfc191c-6597-4496-80d1-c7d3d874a4f2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_747145c7-2939-4768-8694-765278c6ffb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d3ad6071-2b4b-4e58-b19a-cc1a8d3f7e24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2dfc191c-6597-4496-80d1-c7d3d874a4f2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d3ad6071-2b4b-4e58-b19a-cc1a8d3f7e24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_746db2c9-da81-4c06-9fa3-c6ae1a3bbb6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2dfc191c-6597-4496-80d1-c7d3d874a4f2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_746db2c9-da81-4c06-9fa3-c6ae1a3bbb6b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_9fd79cb3-b0ce-492f-bfe7-6177c40a62d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_6e3a5e04-14dd-4491-adc8-5fe5d2e051bf" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_9fd79cb3-b0ce-492f-bfe7-6177c40a62d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_5423e267-11f8-4773-8b00-2e171621635c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_9fd79cb3-b0ce-492f-bfe7-6177c40a62d9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_5423e267-11f8-4773-8b00-2e171621635c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_264a6d9c-e431-4379-a585-fd76b1cab33c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_6e3a5e04-14dd-4491-adc8-5fe5d2e051bf" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_264a6d9c-e431-4379-a585-fd76b1cab33c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_18191860-f1d5-4780-bd41-69f96eb80518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_264a6d9c-e431-4379-a585-fd76b1cab33c" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_18191860-f1d5-4780-bd41-69f96eb80518" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_bd28a97d-c945-4a56-b739-b7f788f2b107" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_264a6d9c-e431-4379-a585-fd76b1cab33c" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_bd28a97d-c945-4a56-b739-b7f788f2b107" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_5d5d3da3-c974-4c23-95bd-109798ce217d" xlink:href="bhc-20220331.xsd#bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_6e3a5e04-14dd-4491-adc8-5fe5d2e051bf" xlink:to="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_5d5d3da3-c974-4c23-95bd-109798ce217d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7e63fdd2-834b-4334-a28b-9a9d7d8dad0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_5d5d3da3-c974-4c23-95bd-109798ce217d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7e63fdd2-834b-4334-a28b-9a9d7d8dad0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7e63fdd2-834b-4334-a28b-9a9d7d8dad0e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7e63fdd2-834b-4334-a28b-9a9d7d8dad0e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7e63fdd2-834b-4334-a28b-9a9d7d8dad0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9d0e1af6-a2d4-4b2c-ae8d-e67b772db65c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7e63fdd2-834b-4334-a28b-9a9d7d8dad0e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9d0e1af6-a2d4-4b2c-ae8d-e67b772db65c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProductBrandsMember_d40588fa-13e8-42f2-98a5-e1c411e33554" xlink:href="bhc-20220331.xsd#bhc_ProductBrandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9d0e1af6-a2d4-4b2c-ae8d-e67b772db65c" xlink:to="loc_bhc_ProductBrandsMember_d40588fa-13e8-42f2-98a5-e1c411e33554" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_266133ed-088f-4565-a7a5-811dd8866b32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9d0e1af6-a2d4-4b2c-ae8d-e67b772db65c" xlink:to="loc_us-gaap_TradeNamesMember_266133ed-088f-4565-a7a5-811dd8866b32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember_b0359e5f-25fb-4192-95fd-c923ba62253a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9d0e1af6-a2d4-4b2c-ae8d-e67b772db65c" xlink:to="loc_us-gaap_ContractualRightsMember_b0359e5f-25fb-4192-95fd-c923ba62253a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PartnerRelationshipsMember_424b79f8-f339-4801-aa1c-4067017e2993" xlink:href="bhc-20220331.xsd#bhc_PartnerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9d0e1af6-a2d4-4b2c-ae8d-e67b772db65c" xlink:to="loc_bhc_PartnerRelationshipsMember_424b79f8-f339-4801-aa1c-4067017e2993" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OutLicensedTechnologyMember_62dcd71b-1525-4881-96a8-b16a1ded12ff" xlink:href="bhc-20220331.xsd#bhc_OutLicensedTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9d0e1af6-a2d4-4b2c-ae8d-e67b772db65c" xlink:to="loc_bhc_OutLicensedTechnologyMember_62dcd71b-1525-4881-96a8-b16a1ded12ff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e2dc856b-821f-4764-91d9-823cb064f379" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_5d5d3da3-c974-4c23-95bd-109798ce217d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e2dc856b-821f-4764-91d9-823cb064f379" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e2dc856b-821f-4764-91d9-823cb064f379_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e2dc856b-821f-4764-91d9-823cb064f379" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e2dc856b-821f-4764-91d9-823cb064f379_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_76d57f4a-4722-45a6-96f7-4247249d4c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e2dc856b-821f-4764-91d9-823cb064f379" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_76d57f4a-4722-45a6-96f7-4247249d4c9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_52868946-d4e7-480f-a786-c2ce2761f96d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_76d57f4a-4722-45a6-96f7-4247249d4c9c" xlink:to="loc_us-gaap_TrademarksMember_52868946-d4e7-480f-a786-c2ce2761f96d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#INTANGIBLEASSETSANDGOODWILLNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" xlink:type="extended" id="ibec3eb8b3398436fa5c7c73365184cb1_INTANGIBLEASSETSANDGOODWILLNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_2dd605d7-21cd-48eb-9e12-37bddc489f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_c0973203-f8cb-40d9-94de-816f5661eaf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_2dd605d7-21cd-48eb-9e12-37bddc489f8d" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_c0973203-f8cb-40d9-94de-816f5661eaf5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_27b7d152-78ca-478e-8027-08eea953eb33" xlink:href="bhc-20220331.xsd#bhc_ReportingUnitImpairmentTestLongTermGrowthRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_2dd605d7-21cd-48eb-9e12-37bddc489f8d" xlink:to="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_27b7d152-78ca-478e-8027-08eea953eb33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_99f05375-db36-4c22-94ce-a0eace819890" xlink:href="bhc-20220331.xsd#bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_2dd605d7-21cd-48eb-9e12-37bddc489f8d" xlink:to="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_99f05375-db36-4c22-94ce-a0eace819890" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_af99cfed-15e2-47b2-b5e6-eede6223b078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_2dd605d7-21cd-48eb-9e12-37bddc489f8d" xlink:to="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_af99cfed-15e2-47b2-b5e6-eede6223b078" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_ae0c6779-a74c-4361-a57b-c58c6aab94ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_2dd605d7-21cd-48eb-9e12-37bddc489f8d" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_ae0c6779-a74c-4361-a57b-c58c6aab94ed" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_2dc87077-e132-440d-946d-3a5ec0f6f6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_2dd605d7-21cd-48eb-9e12-37bddc489f8d" xlink:to="loc_us-gaap_NumberOfReportingUnits_2dc87077-e132-440d-946d-3a5ec0f6f6bb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_d656e7b6-ba03-45e9-af49-45b4d534bb32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_2dd605d7-21cd-48eb-9e12-37bddc489f8d" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_d656e7b6-ba03-45e9-af49-45b4d534bb32" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_56f23012-bcdc-4013-a9aa-6c9d988cf330" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_2dd605d7-21cd-48eb-9e12-37bddc489f8d" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_56f23012-bcdc-4013-a9aa-6c9d988cf330" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c1accd3e-6d66-4114-83d0-35847d35f3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_56f23012-bcdc-4013-a9aa-6c9d988cf330" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c1accd3e-6d66-4114-83d0-35847d35f3a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c1accd3e-6d66-4114-83d0-35847d35f3a7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c1accd3e-6d66-4114-83d0-35847d35f3a7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c1accd3e-6d66-4114-83d0-35847d35f3a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a4560ab7-8390-4a97-974d-b1724f1f4e56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c1accd3e-6d66-4114-83d0-35847d35f3a7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a4560ab7-8390-4a97-974d-b1724f1f4e56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProductBrandsMember_bdf0004c-7f07-4357-ac7b-eba037895c18" xlink:href="bhc-20220331.xsd#bhc_ProductBrandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a4560ab7-8390-4a97-974d-b1724f1f4e56" xlink:to="loc_bhc_ProductBrandsMember_bdf0004c-7f07-4357-ac7b-eba037895c18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiscontinuedProductLinesMember_0f1740e0-ac02-4397-a325-a384e76fee23" xlink:href="bhc-20220331.xsd#bhc_DiscontinuedProductLinesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a4560ab7-8390-4a97-974d-b1724f1f4e56" xlink:to="loc_bhc_DiscontinuedProductLinesMember_0f1740e0-ac02-4397-a325-a384e76fee23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_c6c8a7c0-12b4-47ea-9d5d-08d233b3e84a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_56f23012-bcdc-4013-a9aa-6c9d988cf330" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_c6c8a7c0-12b4-47ea-9d5d-08d233b3e84a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_c6c8a7c0-12b4-47ea-9d5d-08d233b3e84a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_c6c8a7c0-12b4-47ea-9d5d-08d233b3e84a" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_c6c8a7c0-12b4-47ea-9d5d-08d233b3e84a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_06f7be50-2033-49f7-8287-e0fba3b49b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_c6c8a7c0-12b4-47ea-9d5d-08d233b3e84a" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_06f7be50-2033-49f7-8287-e0fba3b49b7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_0dcefa4d-7af0-41d4-b78b-5c6da25137df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_06f7be50-2033-49f7-8287-e0fba3b49b7f" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_0dcefa4d-7af0-41d4-b78b-5c6da25137df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0e142ecf-2ce2-446d-9974-fdd7c5ca2e1e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_56f23012-bcdc-4013-a9aa-6c9d988cf330" xlink:to="loc_srt_RangeAxis_0e142ecf-2ce2-446d-9974-fdd7c5ca2e1e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0e142ecf-2ce2-446d-9974-fdd7c5ca2e1e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0e142ecf-2ce2-446d-9974-fdd7c5ca2e1e" xlink:to="loc_srt_RangeMember_0e142ecf-2ce2-446d-9974-fdd7c5ca2e1e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9a35f94b-a1f4-4051-86c9-812ae323351a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0e142ecf-2ce2-446d-9974-fdd7c5ca2e1e" xlink:to="loc_srt_RangeMember_9a35f94b-a1f4-4051-86c9-812ae323351a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cfda77c2-1c74-4bfd-bccc-a878562d5518" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9a35f94b-a1f4-4051-86c9-812ae323351a" xlink:to="loc_srt_MinimumMember_cfda77c2-1c74-4bfd-bccc-a878562d5518" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b674a0b8-2ea5-42b1-969d-1e36189dc499" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9a35f94b-a1f4-4051-86c9-812ae323351a" xlink:to="loc_srt_MaximumMember_b674a0b8-2ea5-42b1-969d-1e36189dc499" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_eba662f3-480f-464d-8e51-b214435e7dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_56f23012-bcdc-4013-a9aa-6c9d988cf330" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_eba662f3-480f-464d-8e51-b214435e7dbb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_eba662f3-480f-464d-8e51-b214435e7dbb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_eba662f3-480f-464d-8e51-b214435e7dbb" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_eba662f3-480f-464d-8e51-b214435e7dbb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d6ddace7-263f-4d22-ab39-dfddcf8f99e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_eba662f3-480f-464d-8e51-b214435e7dbb" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d6ddace7-263f-4d22-ab39-dfddcf8f99e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmounPharmaceuticalCompanySAEMember_d305f1e2-363a-40bb-aab9-51a5cb573ad7" xlink:href="bhc-20220331.xsd#bhc_AmounPharmaceuticalCompanySAEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d6ddace7-263f-4d22-ab39-dfddcf8f99e6" xlink:to="loc_bhc_AmounPharmaceuticalCompanySAEMember_d305f1e2-363a-40bb-aab9-51a5cb573ad7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_7517badd-69ca-4551-a0b4-173179832267" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_56f23012-bcdc-4013-a9aa-6c9d988cf330" xlink:to="loc_us-gaap_ReportingUnitAxis_7517badd-69ca-4551-a0b4-173179832267" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_7517badd-69ca-4551-a0b4-173179832267_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_7517badd-69ca-4551-a0b4-173179832267" xlink:to="loc_us-gaap_ReportingUnitDomain_7517badd-69ca-4551-a0b4-173179832267_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_89f94550-f0fc-491c-9f3d-6c9c95f987ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_7517badd-69ca-4551-a0b4-173179832267" xlink:to="loc_us-gaap_ReportingUnitDomain_89f94550-f0fc-491c-9f3d-6c9c95f987ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitsExcludingOrthoDermatologicsMember_0b7056b4-90cb-4127-8801-f8b092237145" xlink:href="bhc-20220331.xsd#bhc_ReportingUnitsExcludingOrthoDermatologicsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_89f94550-f0fc-491c-9f3d-6c9c95f987ea" xlink:to="loc_bhc_ReportingUnitsExcludingOrthoDermatologicsMember_0b7056b4-90cb-4127-8801-f8b092237145" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsReportingUnitMember_b5912bd8-6e36-4582-900b-fa825284898b" xlink:href="bhc-20220331.xsd#bhc_OrthoDermatologicsReportingUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_89f94550-f0fc-491c-9f3d-6c9c95f987ea" xlink:to="loc_bhc_OrthoDermatologicsReportingUnitMember_b5912bd8-6e36-4582-900b-fa825284898b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_52cbdae8-7965-45fd-9a5c-5913fc6b6278" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_56f23012-bcdc-4013-a9aa-6c9d988cf330" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_52cbdae8-7965-45fd-9a5c-5913fc6b6278" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_52cbdae8-7965-45fd-9a5c-5913fc6b6278_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_52cbdae8-7965-45fd-9a5c-5913fc6b6278" xlink:to="loc_us-gaap_SegmentDomain_52cbdae8-7965-45fd-9a5c-5913fc6b6278_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f7b25396-98ef-4971-9a75-91b214a78984" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_52cbdae8-7965-45fd-9a5c-5913fc6b6278" xlink:to="loc_us-gaap_SegmentDomain_f7b25396-98ef-4971-9a75-91b214a78984" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember_835385bc-9ff9-4b97-9666-651b756f0317" xlink:href="bhc-20220331.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f7b25396-98ef-4971-9a75-91b214a78984" xlink:to="loc_bhc_OrthoDermatologicsSegmentMember_835385bc-9ff9-4b97-9666-651b756f0317" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails" xlink:type="extended" id="ie7f8b578e78048d59bd643834cb05d60_INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_17719fb5-8922-4145-aa23-6167f5d6d9ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_ce1db7f8-f786-4d95-9b27-0e813980a624" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_17719fb5-8922-4145-aa23-6167f5d6d9ca" xlink:to="loc_us-gaap_GoodwillRollForward_ce1db7f8-f786-4d95-9b27-0e813980a624" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_91757fd0-8484-4aad-8a19-d19b4bcbff6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_ce1db7f8-f786-4d95-9b27-0e813980a624" xlink:to="loc_us-gaap_Goodwill_91757fd0-8484-4aad-8a19-d19b4bcbff6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_8ea53d1c-ddce-4f74-a829-69254c7dab81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_ce1db7f8-f786-4d95-9b27-0e813980a624" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_8ea53d1c-ddce-4f74-a829-69254c7dab81" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_77a5081c-be19-440f-9a2e-2264b38b7878" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_ce1db7f8-f786-4d95-9b27-0e813980a624" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_77a5081c-be19-440f-9a2e-2264b38b7878" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_d73d8c63-c2e8-440e-99be-a356b9de0659" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_ce1db7f8-f786-4d95-9b27-0e813980a624" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_d73d8c63-c2e8-440e-99be-a356b9de0659" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e77111bf-bb69-4362-8e78-be905abb6715" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_1c1d0579-a7ba-4e39-b781-238eeea29eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_17719fb5-8922-4145-aa23-6167f5d6d9ca" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_1c1d0579-a7ba-4e39-b781-238eeea29eaf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_33b28974-f304-499e-8701-5b4430c96b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1c1d0579-a7ba-4e39-b781-238eeea29eaf" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_33b28974-f304-499e-8701-5b4430c96b2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_33b28974-f304-499e-8701-5b4430c96b2b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_33b28974-f304-499e-8701-5b4430c96b2b" xlink:to="loc_us-gaap_SegmentDomain_33b28974-f304-499e-8701-5b4430c96b2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f21dab73-2e1b-4b37-a005-83ab6a6cec01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_33b28974-f304-499e-8701-5b4430c96b2b" xlink:to="loc_us-gaap_SegmentDomain_f21dab73-2e1b-4b37-a005-83ab6a6cec01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombInternationalMember_f1b38306-60db-4752-bcd0-a8ae1be54ea0" xlink:href="bhc-20220331.xsd#bhc_BauschLombInternationalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f21dab73-2e1b-4b37-a005-83ab6a6cec01" xlink:to="loc_bhc_BauschLombInternationalMember_f1b38306-60db-4752-bcd0-a8ae1be54ea0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_94982457-3e8e-4a9b-aa65-d107490b5079" xlink:href="bhc-20220331.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f21dab73-2e1b-4b37-a005-83ab6a6cec01" xlink:to="loc_bhc_BauschLombMember_94982457-3e8e-4a9b-aa65-d107490b5079" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_6dab353e-e333-4594-8673-17ad271ef881" xlink:href="bhc-20220331.xsd#bhc_SalixSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f21dab73-2e1b-4b37-a005-83ab6a6cec01" xlink:to="loc_bhc_SalixSegmentMember_6dab353e-e333-4594-8673-17ad271ef881" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_8c6019ff-2206-4596-a0bd-6de3fc022bbd" xlink:href="bhc-20220331.xsd#bhc_InternationalRxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f21dab73-2e1b-4b37-a005-83ab6a6cec01" xlink:to="loc_bhc_InternationalRxMember_8c6019ff-2206-4596-a0bd-6de3fc022bbd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember_edcbfb53-f383-4203-8f19-944e881f683d" xlink:href="bhc-20220331.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f21dab73-2e1b-4b37-a005-83ab6a6cec01" xlink:to="loc_bhc_OrthoDermatologicsSegmentMember_edcbfb53-f383-4203-8f19-944e881f683d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SoltaMedicalSegmentMember_3edd19ee-2b33-432d-9c2a-18c39cff2ea0" xlink:href="bhc-20220331.xsd#bhc_SoltaMedicalSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f21dab73-2e1b-4b37-a005-83ab6a6cec01" xlink:to="loc_bhc_SoltaMedicalSegmentMember_3edd19ee-2b33-432d-9c2a-18c39cff2ea0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_cc210104-ab70-4d12-9ed3-c9d180046935" xlink:href="bhc-20220331.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f21dab73-2e1b-4b37-a005-83ab6a6cec01" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_cc210104-ab70-4d12-9ed3-c9d180046935" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="extended" id="i7bb89376694444078b931591cf0f1116_FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c8c69b84-f9b5-4771-b4cc-aadec9b8b031" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5a99021e-4645-407e-966a-b29e7b1977fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c8c69b84-f9b5-4771-b4cc-aadec9b8b031" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5a99021e-4645-407e-966a-b29e7b1977fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_e2dece69-19e9-4b15-9d3b-e1b8c37b979c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c8c69b84-f9b5-4771-b4cc-aadec9b8b031" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_e2dece69-19e9-4b15-9d3b-e1b8c37b979c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d2cac51b-66a8-4d59-82e6-0e0eecda2b36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c8c69b84-f9b5-4771-b4cc-aadec9b8b031" xlink:to="loc_us-gaap_LongTermDebt_d2cac51b-66a8-4d59-82e6-0e0eecda2b36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_76ed68c1-ef61-432f-91b7-077849f5ffa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c8c69b84-f9b5-4771-b4cc-aadec9b8b031" xlink:to="loc_us-gaap_LongTermDebtCurrent_76ed68c1-ef61-432f-91b7-077849f5ffa1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_76e99020-3690-4cb0-83fa-3bc7ea569fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c8c69b84-f9b5-4771-b4cc-aadec9b8b031" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_76e99020-3690-4cb0-83fa-3bc7ea569fdb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ad10f7c2-e6cf-4d42-90b4-dbc73a745917" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c8c69b84-f9b5-4771-b4cc-aadec9b8b031" xlink:to="loc_us-gaap_DebtInstrumentTable_ad10f7c2-e6cf-4d42-90b4-dbc73a745917" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_ae6be763-902a-4d40-beb7-b434e2456b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ad10f7c2-e6cf-4d42-90b4-dbc73a745917" xlink:to="loc_us-gaap_CreditFacilityAxis_ae6be763-902a-4d40-beb7-b434e2456b6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_ae6be763-902a-4d40-beb7-b434e2456b6d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_ae6be763-902a-4d40-beb7-b434e2456b6d" xlink:to="loc_us-gaap_CreditFacilityDomain_ae6be763-902a-4d40-beb7-b434e2456b6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_8faed696-ed7d-46fc-8c31-8f5e64867236" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_ae6be763-902a-4d40-beb7-b434e2456b6d" xlink:to="loc_us-gaap_CreditFacilityDomain_8faed696-ed7d-46fc-8c31-8f5e64867236" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_294b42ee-c177-49af-9181-6658ad64b717" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_8faed696-ed7d-46fc-8c31-8f5e64867236" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_294b42ee-c177-49af-9181-6658ad64b717" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_0191e2b3-d441-4046-aefc-afb3a54a2db0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ad10f7c2-e6cf-4d42-90b4-dbc73a745917" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_0191e2b3-d441-4046-aefc-afb3a54a2db0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0191e2b3-d441-4046-aefc-afb3a54a2db0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0191e2b3-d441-4046-aefc-afb3a54a2db0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0191e2b3-d441-4046-aefc-afb3a54a2db0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_12808e4b-20fc-40e9-bc6d-519fb9e6ec4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0191e2b3-d441-4046-aefc-afb3a54a2db0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_12808e4b-20fc-40e9-bc6d-519fb9e6ec4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_c235c933-4918-426a-abd0-fea28579b99c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_12808e4b-20fc-40e9-bc6d-519fb9e6ec4e" xlink:to="loc_us-gaap_SecuredDebtMember_c235c933-4918-426a-abd0-fea28579b99c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_d6674337-610f-47e6-a9fe-015aec9d332f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_12808e4b-20fc-40e9-bc6d-519fb9e6ec4e" xlink:to="loc_us-gaap_UnsecuredDebtMember_d6674337-610f-47e6-a9fe-015aec9d332f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_959339cf-9ce9-4039-9853-b93f444a575a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ad10f7c2-e6cf-4d42-90b4-dbc73a745917" xlink:to="loc_us-gaap_DebtInstrumentAxis_959339cf-9ce9-4039-9853-b93f444a575a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_959339cf-9ce9-4039-9853-b93f444a575a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_959339cf-9ce9-4039-9853-b93f444a575a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_959339cf-9ce9-4039-9853-b93f444a575a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5ebf8c0c-2ffe-40c7-8ed6-990710edd27d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_959339cf-9ce9-4039-9853-b93f444a575a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5ebf8c0c-2ffe-40c7-8ed6-990710edd27d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member_5fd8bcf2-d3cc-45b3-b1ee-ca446e0bf73f" xlink:href="bhc-20220331.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5ebf8c0c-2ffe-40c7-8ed6-990710edd27d" xlink:to="loc_bhc_RevolvingCreditFacilityDueJune2023Member_5fd8bcf2-d3cc-45b3-b1ee-ca446e0bf73f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025Member_26e9eaff-a24a-41e5-91f6-e470a3184329" xlink:href="bhc-20220331.xsd#bhc_TermLoanBFacilityDueJune2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5ebf8c0c-2ffe-40c7-8ed6-990710edd27d" xlink:to="loc_bhc_TermLoanBFacilityDueJune2025Member_26e9eaff-a24a-41e5-91f6-e470a3184329" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueNovember2025Member_7f087db4-4337-4e92-afc8-e365eab92a01" xlink:href="bhc-20220331.xsd#bhc_TermLoanBFacilityDueNovember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5ebf8c0c-2ffe-40c7-8ed6-990710edd27d" xlink:to="loc_bhc_TermLoanBFacilityDueNovember2025Member_7f087db4-4337-4e92-afc8-e365eab92a01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member_ccb6fc8a-f4d1-4412-ba48-9f6dd4cddf70" xlink:href="bhc-20220331.xsd#bhc_SeniorSecured5.50NotesDueNovember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5ebf8c0c-2ffe-40c7-8ed6-990710edd27d" xlink:to="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member_ccb6fc8a-f4d1-4412-ba48-9f6dd4cddf70" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_86db8a5e-e9f6-4d2d-8ded-8794d58a823a" xlink:href="bhc-20220331.xsd#bhc_SeniorSecured6125NotesDueFebruary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5ebf8c0c-2ffe-40c7-8ed6-990710edd27d" xlink:to="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_86db8a5e-e9f6-4d2d-8ded-8794d58a823a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_5e569365-1f1a-4501-8583-79aa9562e12f" xlink:href="bhc-20220331.xsd#bhc_SeniorSecured5.75NotesDueAugust2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5ebf8c0c-2ffe-40c7-8ed6-990710edd27d" xlink:to="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_5e569365-1f1a-4501-8583-79aa9562e12f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured4875NotesDueJune2028Member_26c69438-e0ac-4036-801e-fce73f85b4e7" xlink:href="bhc-20220331.xsd#bhc_SeniorSecured4875NotesDueJune2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5ebf8c0c-2ffe-40c7-8ed6-990710edd27d" xlink:to="loc_bhc_SeniorSecured4875NotesDueJune2028Member_26c69438-e0ac-4036-801e-fce73f85b4e7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member_8000bbd2-9c59-4e61-ae3b-9fbe8a45a552" xlink:href="bhc-20220331.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5ebf8c0c-2ffe-40c7-8ed6-990710edd27d" xlink:to="loc_bhc_SeniorNotes6125DueApril2025Member_8000bbd2-9c59-4e61-ae3b-9fbe8a45a552" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes900DueDecember2025Member_40693e95-8b05-4440-8ab2-510d05bf89ed" xlink:href="bhc-20220331.xsd#bhc_SeniorNotes900DueDecember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5ebf8c0c-2ffe-40c7-8ed6-990710edd27d" xlink:to="loc_bhc_SeniorNotes900DueDecember2025Member_40693e95-8b05-4440-8ab2-510d05bf89ed" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes925DueApril2026Member_9584713e-0658-4757-af72-1be408d93508" xlink:href="bhc-20220331.xsd#bhc_SeniorNotes925DueApril2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5ebf8c0c-2ffe-40c7-8ed6-990710edd27d" xlink:to="loc_bhc_SeniorNotes925DueApril2026Member_9584713e-0658-4757-af72-1be408d93508" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes850DueJanuary2027Member_644f3c10-7ae8-409f-bdb9-339da3d8a63c" xlink:href="bhc-20220331.xsd#bhc_SeniorNotes850DueJanuary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5ebf8c0c-2ffe-40c7-8ed6-990710edd27d" xlink:to="loc_bhc_SeniorNotes850DueJanuary2027Member_644f3c10-7ae8-409f-bdb9-339da3d8a63c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueJanuary2028Member_a12e323b-0df4-454a-9240-1003a33cb0be" xlink:href="bhc-20220331.xsd#bhc_SeniorNotes700DueJanuary2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5ebf8c0c-2ffe-40c7-8ed6-990710edd27d" xlink:to="loc_bhc_SeniorNotes700DueJanuary2028Member_a12e323b-0df4-454a-9240-1003a33cb0be" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueJanuary2028Member_e7b998f7-2ae8-46ca-9ffe-869a7b4452e5" xlink:href="bhc-20220331.xsd#bhc_SeniorNotes500DueJanuary2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5ebf8c0c-2ffe-40c7-8ed6-990710edd27d" xlink:to="loc_bhc_SeniorNotes500DueJanuary2028Member_e7b998f7-2ae8-46ca-9ffe-869a7b4452e5" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes625DueFebruary2029Member_c6e1403e-e5a4-4120-a9c0-2ce61f43f6b6" xlink:href="bhc-20220331.xsd#bhc_SeniorNotes625DueFebruary2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5ebf8c0c-2ffe-40c7-8ed6-990710edd27d" xlink:to="loc_bhc_SeniorNotes625DueFebruary2029Member_c6e1403e-e5a4-4120-a9c0-2ce61f43f6b6" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueFebruary2029Member_0163fa4a-9e4b-4b04-9f52-8a8cf3dee0ab" xlink:href="bhc-20220331.xsd#bhc_SeniorNotes500DueFebruary2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5ebf8c0c-2ffe-40c7-8ed6-990710edd27d" xlink:to="loc_bhc_SeniorNotes500DueFebruary2029Member_0163fa4a-9e4b-4b04-9f52-8a8cf3dee0ab" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes725DueMay2029Member_8bd8c5d1-e411-4c9e-82d1-2f998a332794" xlink:href="bhc-20220331.xsd#bhc_SeniorNotes725DueMay2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5ebf8c0c-2ffe-40c7-8ed6-990710edd27d" xlink:to="loc_bhc_SeniorNotes725DueMay2029Member_8bd8c5d1-e411-4c9e-82d1-2f998a332794" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueJanuary2030Member_f683d8cf-486c-45e5-83fe-a50470817e7b" xlink:href="bhc-20220331.xsd#bhc_SeniorNotes525DueJanuary2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5ebf8c0c-2ffe-40c7-8ed6-990710edd27d" xlink:to="loc_bhc_SeniorNotes525DueJanuary2030Member_f683d8cf-486c-45e5-83fe-a50470817e7b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueFebruary2031Member_3206d16a-4342-43b2-9d03-b7dc6855be3a" xlink:href="bhc-20220331.xsd#bhc_SeniorNotes525DueFebruary2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5ebf8c0c-2ffe-40c7-8ed6-990710edd27d" xlink:to="loc_bhc_SeniorNotes525DueFebruary2031Member_3206d16a-4342-43b2-9d03-b7dc6855be3a" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherLongTermDebtMember_8948606b-2d02-4e44-a65b-b905dd8d58b7" xlink:href="bhc-20220331.xsd#bhc_OtherLongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5ebf8c0c-2ffe-40c7-8ed6-990710edd27d" xlink:to="loc_bhc_OtherLongTermDebtMember_8948606b-2d02-4e44-a65b-b905dd8d58b7" xlink:type="arc" order="18"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#FINANCINGARRANGEMENTSCovenantComplianceDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails" xlink:type="extended" id="if26f13f9cba14c138728d27d8cc74847_FINANCINGARRANGEMENTSCovenantComplianceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_443a50fc-020a-426d-b6f2-b5d6314e092f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments_3e1083d4-c059-4232-8b69-3f06a4a38527" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_443a50fc-020a-426d-b6f2-b5d6314e092f" xlink:to="loc_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments_3e1083d4-c059-4232-8b69-3f06a4a38527" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_66c51218-abe7-420b-ba51-5cb1abec0ca2" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_443a50fc-020a-426d-b6f2-b5d6314e092f" xlink:to="loc_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_66c51218-abe7-420b-ba51-5cb1abec0ca2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_e019da7a-003d-4417-b9db-1f26fa0d2115" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_443a50fc-020a-426d-b6f2-b5d6314e092f" xlink:to="loc_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_e019da7a-003d-4417-b9db-1f26fa0d2115" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b4930bee-e2da-4a43-909f-c7b796263e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_443a50fc-020a-426d-b6f2-b5d6314e092f" xlink:to="loc_us-gaap_DebtInstrumentTable_b4930bee-e2da-4a43-909f-c7b796263e8f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_4ae6c649-3e14-418a-8a2f-ef37d85c09ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b4930bee-e2da-4a43-909f-c7b796263e8f" xlink:to="loc_us-gaap_CreditFacilityAxis_4ae6c649-3e14-418a-8a2f-ef37d85c09ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_4ae6c649-3e14-418a-8a2f-ef37d85c09ef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_4ae6c649-3e14-418a-8a2f-ef37d85c09ef" xlink:to="loc_us-gaap_CreditFacilityDomain_4ae6c649-3e14-418a-8a2f-ef37d85c09ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c612d28b-3f78-4732-9942-ab8faec9ac11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_4ae6c649-3e14-418a-8a2f-ef37d85c09ef" xlink:to="loc_us-gaap_CreditFacilityDomain_c612d28b-3f78-4732-9942-ab8faec9ac11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredCreditFacilityMember_31d15862-d65a-4426-9d4d-0f001da8add9" xlink:href="bhc-20220331.xsd#bhc_SeniorSecuredCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_c612d28b-3f78-4732-9942-ab8faec9ac11" xlink:to="loc_bhc_SeniorSecuredCreditFacilityMember_31d15862-d65a-4426-9d4d-0f001da8add9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_5ada53c8-a3bd-4a7d-b5f5-36e9a109e810" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_c612d28b-3f78-4732-9942-ab8faec9ac11" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_5ada53c8-a3bd-4a7d-b5f5-36e9a109e810" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" xlink:type="extended" id="i4305caed4c0d48ce93c6a2511668df88_FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_740c021d-77e8-4129-bc06-057e5edfac2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_c9e52b4d-d10f-4bb2-bd90-655ac1519881" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_740c021d-77e8-4129-bc06-057e5edfac2a" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_c9e52b4d-d10f-4bb2-bd90-655ac1519881" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_1e37bc24-35b9-4de7-85fe-f4b7b165c74a" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_740c021d-77e8-4129-bc06-057e5edfac2a" xlink:to="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_1e37bc24-35b9-4de7-85fe-f4b7b165c74a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_4fa186b0-d0ae-404c-9650-9bc28e73a7d8" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_740c021d-77e8-4129-bc06-057e5edfac2a" xlink:to="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_4fa186b0-d0ae-404c-9650-9bc28e73a7d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_ad7c14c6-1696-47f3-ab00-4a4bb8348591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_740c021d-77e8-4129-bc06-057e5edfac2a" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_ad7c14c6-1696-47f3-ab00-4a4bb8348591" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8e89a6fa-5506-443e-af4e-5bef04038597" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_740c021d-77e8-4129-bc06-057e5edfac2a" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8e89a6fa-5506-443e-af4e-5bef04038597" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet_bd1e0e7d-9223-471d-acd6-2937098d97b4" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_740c021d-77e8-4129-bc06-057e5edfac2a" xlink:to="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet_bd1e0e7d-9223-471d-acd6-2937098d97b4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet_7b679cb8-8f4b-4a51-8a35-0ebf234718b7" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_740c021d-77e8-4129-bc06-057e5edfac2a" xlink:to="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet_7b679cb8-8f4b-4a51-8a35-0ebf234718b7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet_84a02d79-2ad2-4552-953d-46efb907ef1a" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_740c021d-77e8-4129-bc06-057e5edfac2a" xlink:to="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet_84a02d79-2ad2-4552-953d-46efb907ef1a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet_3ea8beec-255e-4b08-a904-24a9839e3d69" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_740c021d-77e8-4129-bc06-057e5edfac2a" xlink:to="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet_3ea8beec-255e-4b08-a904-24a9839e3d69" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3ed590bd-339a-423b-be61-345dc25b0994" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_740c021d-77e8-4129-bc06-057e5edfac2a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3ed590bd-339a-423b-be61-345dc25b0994" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage_ac392ef0-76bb-4dd2-b169-47fafe37d2d9" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentAnnualAmortizationRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_740c021d-77e8-4129-bc06-057e5edfac2a" xlink:to="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage_ac392ef0-76bb-4dd2-b169-47fafe37d2d9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_d6a8edb8-8446-45dd-ba15-e517d10b9b20" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_740c021d-77e8-4129-bc06-057e5edfac2a" xlink:to="loc_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_d6a8edb8-8446-45dd-ba15-e517d10b9b20" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_1a1e31ef-5702-4296-859e-b4173eae4dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_740c021d-77e8-4129-bc06-057e5edfac2a" xlink:to="loc_us-gaap_LongTermDebt_1a1e31ef-5702-4296-859e-b4173eae4dc6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_473f974c-b172-48bd-afa5-206371bdc63d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_740c021d-77e8-4129-bc06-057e5edfac2a" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_473f974c-b172-48bd-afa5-206371bdc63d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_b9bc1160-2cd1-434c-97c3-c9555a286e83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_740c021d-77e8-4129-bc06-057e5edfac2a" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_b9bc1160-2cd1-434c-97c3-c9555a286e83" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_6e53b5da-ef7c-4243-a31d-801ae48f069f" xlink:href="bhc-20220331.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_740c021d-77e8-4129-bc06-057e5edfac2a" xlink:to="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_6e53b5da-ef7c-4243-a31d-801ae48f069f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA_ff3f345c-6d78-4889-82de-8c0d821d9eb4" xlink:href="bhc-20220331.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_740c021d-77e8-4129-bc06-057e5edfac2a" xlink:to="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA_ff3f345c-6d78-4889-82de-8c0d821d9eb4" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_74fddee3-7040-40eb-8923-9a943d827a52" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_740c021d-77e8-4129-bc06-057e5edfac2a" xlink:to="loc_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_74fddee3-7040-40eb-8923-9a943d827a52" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_ec9b006b-c51c-40a2-ac01-42777cfec7fa" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_740c021d-77e8-4129-bc06-057e5edfac2a" xlink:to="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_ec9b006b-c51c-40a2-ac01-42777cfec7fa" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_4b8ad4d4-abe9-4fc9-9df5-b62374498fa0" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_740c021d-77e8-4129-bc06-057e5edfac2a" xlink:to="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_4b8ad4d4-abe9-4fc9-9df5-b62374498fa0" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_959483dc-a387-4650-a0f5-863d4994a4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_740c021d-77e8-4129-bc06-057e5edfac2a" xlink:to="loc_us-gaap_DebtInstrumentTable_959483dc-a387-4650-a0f5-863d4994a4c1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_11fb8ab4-dafd-412b-aaff-6873ba1867d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_959483dc-a387-4650-a0f5-863d4994a4c1" xlink:to="loc_us-gaap_CreditFacilityAxis_11fb8ab4-dafd-412b-aaff-6873ba1867d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_11fb8ab4-dafd-412b-aaff-6873ba1867d1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_11fb8ab4-dafd-412b-aaff-6873ba1867d1" xlink:to="loc_us-gaap_CreditFacilityDomain_11fb8ab4-dafd-412b-aaff-6873ba1867d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2479ca4e-de08-4fc2-a9b9-287928f89d65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_11fb8ab4-dafd-412b-aaff-6873ba1867d1" xlink:to="loc_us-gaap_CreditFacilityDomain_2479ca4e-de08-4fc2-a9b9-287928f89d65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_09d15960-e2fb-4002-8552-99c0c8686aee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_2479ca4e-de08-4fc2-a9b9-287928f89d65" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_09d15960-e2fb-4002-8552-99c0c8686aee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_0178f03a-7cc5-41f7-a362-2529dd60c36b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_2479ca4e-de08-4fc2-a9b9-287928f89d65" xlink:to="loc_us-gaap_LetterOfCreditMember_0178f03a-7cc5-41f7-a362-2529dd60c36b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_870cc282-1c08-485b-aa8a-4027b0f63a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_959483dc-a387-4650-a0f5-863d4994a4c1" xlink:to="loc_us-gaap_DebtInstrumentAxis_870cc282-1c08-485b-aa8a-4027b0f63a3a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_870cc282-1c08-485b-aa8a-4027b0f63a3a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_870cc282-1c08-485b-aa8a-4027b0f63a3a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_870cc282-1c08-485b-aa8a-4027b0f63a3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d8f8e06d-0b00-4ba7-bd53-9e2b638927b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_870cc282-1c08-485b-aa8a-4027b0f63a3a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d8f8e06d-0b00-4ba7-bd53-9e2b638927b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member_a1626c78-1f37-4bc6-bbd4-2759374f2724" xlink:href="bhc-20220331.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d8f8e06d-0b00-4ba7-bd53-9e2b638927b7" xlink:to="loc_bhc_RevolvingCreditFacilityDueJune2023Member_a1626c78-1f37-4bc6-bbd4-2759374f2724" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025Member_e38792de-fe7e-490d-a1d9-4d6069d1ad59" xlink:href="bhc-20220331.xsd#bhc_TermLoanBFacilityDueJune2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d8f8e06d-0b00-4ba7-bd53-9e2b638927b7" xlink:to="loc_bhc_TermLoanBFacilityDueJune2025Member_e38792de-fe7e-490d-a1d9-4d6069d1ad59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueNovember2025Member_911fbc21-4e82-45ed-8d31-8bd7e5ddc0c3" xlink:href="bhc-20220331.xsd#bhc_TermLoanBFacilityDueNovember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d8f8e06d-0b00-4ba7-bd53-9e2b638927b7" xlink:to="loc_bhc_TermLoanBFacilityDueNovember2025Member_911fbc21-4e82-45ed-8d31-8bd7e5ddc0c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredCreditFacilitiesMember_9846e146-7d6c-4c0d-83ca-d317776c8ca7" xlink:href="bhc-20220331.xsd#bhc_SeniorSecuredCreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d8f8e06d-0b00-4ba7-bd53-9e2b638927b7" xlink:to="loc_bhc_SeniorSecuredCreditFacilitiesMember_9846e146-7d6c-4c0d-83ca-d317776c8ca7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member_20e88844-c61b-4d75-b4b5-785644e75a75" xlink:href="bhc-20220331.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d8f8e06d-0b00-4ba7-bd53-9e2b638927b7" xlink:to="loc_bhc_SeniorNotes6125DueApril2025Member_20e88844-c61b-4d75-b4b5-785644e75a75" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_6d1f2a9c-ab82-44e7-9095-5cbf0df58a73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_959483dc-a387-4650-a0f5-863d4994a4c1" xlink:to="loc_us-gaap_VariableRateAxis_6d1f2a9c-ab82-44e7-9095-5cbf0df58a73" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_6d1f2a9c-ab82-44e7-9095-5cbf0df58a73_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_6d1f2a9c-ab82-44e7-9095-5cbf0df58a73" xlink:to="loc_us-gaap_VariableRateDomain_6d1f2a9c-ab82-44e7-9095-5cbf0df58a73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_31b2d2b1-ea6f-4d41-9297-046140588046" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_6d1f2a9c-ab82-44e7-9095-5cbf0df58a73" xlink:to="loc_us-gaap_VariableRateDomain_31b2d2b1-ea6f-4d41-9297-046140588046" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_d7054216-2fb4-451a-b640-8b7ce5d98d38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_31b2d2b1-ea6f-4d41-9297-046140588046" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_d7054216-2fb4-451a-b640-8b7ce5d98d38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_7d87e8fa-9449-4da8-8e63-5be96aa2f14d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_31b2d2b1-ea6f-4d41-9297-046140588046" xlink:to="loc_us-gaap_EurodollarMember_7d87e8fa-9449-4da8-8e63-5be96aa2f14d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CanadaBankersAcceptanceRateMember_e6de009f-b4cb-48f9-96c6-591e045faac7" xlink:href="bhc-20220331.xsd#bhc_CanadaBankersAcceptanceRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_31b2d2b1-ea6f-4d41-9297-046140588046" xlink:to="loc_bhc_CanadaBankersAcceptanceRateMember_e6de009f-b4cb-48f9-96c6-591e045faac7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_eef4b0e6-97a7-42a2-81cc-ed7819d95ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_31b2d2b1-ea6f-4d41-9297-046140588046" xlink:to="loc_us-gaap_BaseRateMember_eef4b0e6-97a7-42a2-81cc-ed7819d95ff2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BaseRateOrPrimeRateMember_f7972786-347f-476d-80b1-45fb5973ba5d" xlink:href="bhc-20220331.xsd#bhc_BaseRateOrPrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_31b2d2b1-ea6f-4d41-9297-046140588046" xlink:to="loc_bhc_BaseRateOrPrimeRateMember_f7972786-347f-476d-80b1-45fb5973ba5d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9a14f9b8-1a45-40d4-b5a5-0542ee7935fc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_959483dc-a387-4650-a0f5-863d4994a4c1" xlink:to="loc_srt_RangeAxis_9a14f9b8-1a45-40d4-b5a5-0542ee7935fc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9a14f9b8-1a45-40d4-b5a5-0542ee7935fc_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9a14f9b8-1a45-40d4-b5a5-0542ee7935fc" xlink:to="loc_srt_RangeMember_9a14f9b8-1a45-40d4-b5a5-0542ee7935fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_20a3a662-706d-4f2e-9397-a48e1ed4e4a4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9a14f9b8-1a45-40d4-b5a5-0542ee7935fc" xlink:to="loc_srt_RangeMember_20a3a662-706d-4f2e-9397-a48e1ed4e4a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b504a8e1-f694-48d5-8d85-6b488b1fb67a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_20a3a662-706d-4f2e-9397-a48e1ed4e4a4" xlink:to="loc_srt_MinimumMember_b504a8e1-f694-48d5-8d85-6b488b1fb67a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b825f45a-1ff1-4e4d-8c91-324d79a648bf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_20a3a662-706d-4f2e-9397-a48e1ed4e4a4" xlink:to="loc_srt_MaximumMember_b825f45a-1ff1-4e4d-8c91-324d79a648bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_887028b3-5301-473c-82a4-dc73356fa2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_959483dc-a387-4650-a0f5-863d4994a4c1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_887028b3-5301-473c-82a4-dc73356fa2c2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_887028b3-5301-473c-82a4-dc73356fa2c2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_887028b3-5301-473c-82a4-dc73356fa2c2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_887028b3-5301-473c-82a4-dc73356fa2c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_98578d0a-00f0-4b2f-9f1e-e663293321e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_887028b3-5301-473c-82a4-dc73356fa2c2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_98578d0a-00f0-4b2f-9f1e-e663293321e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_a2d6b086-cc11-4b48-97c7-f273f4224832" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_98578d0a-00f0-4b2f-9f1e-e663293321e8" xlink:to="loc_us-gaap_SecuredDebtMember_a2d6b086-cc11-4b48-97c7-f273f4224832" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_c8c48c28-41d6-4a13-a81b-10f7befb928e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_98578d0a-00f0-4b2f-9f1e-e663293321e8" xlink:to="loc_us-gaap_UnsecuredDebtMember_c8c48c28-41d6-4a13-a81b-10f7befb928e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_884599bb-bd51-413a-b9a2-715f658e0a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_959483dc-a387-4650-a0f5-863d4994a4c1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_884599bb-bd51-413a-b9a2-715f658e0a2e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_884599bb-bd51-413a-b9a2-715f658e0a2e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_884599bb-bd51-413a-b9a2-715f658e0a2e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_884599bb-bd51-413a-b9a2-715f658e0a2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7420a233-9bd7-4686-b332-8a8b6fd63611" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_884599bb-bd51-413a-b9a2-715f658e0a2e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7420a233-9bd7-4686-b332-8a8b6fd63611" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_75f4a5d4-d9cf-4bc5-9e3d-b1f5ccb13ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7420a233-9bd7-4686-b332-8a8b6fd63611" xlink:to="loc_us-gaap_SubsequentEventMember_75f4a5d4-d9cf-4bc5-9e3d-b1f5ccb13ce9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails" xlink:type="extended" id="i2344eb473c634b4893da5cd1d8d5ca6f_FINANCINGARRANGEMENTSSeniorSecuredNotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_68745f80-583c-47a7-906b-40e2e362de55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_7524026a-69e4-432f-9d85-13399d9f6274" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentRedemptionPricePercentageChangeinControl"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_68745f80-583c-47a7-906b-40e2e362de55" xlink:to="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_7524026a-69e4-432f-9d85-13399d9f6274" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_10cc3a27-68d7-4df4-8ba2-535a46c4d3a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_68745f80-583c-47a7-906b-40e2e362de55" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_10cc3a27-68d7-4df4-8ba2-535a46c4d3a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_adeca1fa-b6db-4027-b414-10f4b63c12b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_68745f80-583c-47a7-906b-40e2e362de55" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_adeca1fa-b6db-4027-b414-10f4b63c12b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_d3b9d340-ae51-4873-97a9-3bd48b33e1fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_68745f80-583c-47a7-906b-40e2e362de55" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_d3b9d340-ae51-4873-97a9-3bd48b33e1fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_121dd9e0-db85-4ad3-9433-415b80357ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_68745f80-583c-47a7-906b-40e2e362de55" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_121dd9e0-db85-4ad3-9433-415b80357ae9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_4b36f349-3766-495c-bdac-14d4078e9a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_68745f80-583c-47a7-906b-40e2e362de55" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_4b36f349-3766-495c-bdac-14d4078e9a9c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_ba0a9cec-50cb-4144-986a-52e675154023" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_68745f80-583c-47a7-906b-40e2e362de55" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_ba0a9cec-50cb-4144-986a-52e675154023" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_fe27e51f-787e-4f2c-89f5-a6c9e05b109b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_68745f80-583c-47a7-906b-40e2e362de55" xlink:to="loc_us-gaap_DebtInstrumentTable_fe27e51f-787e-4f2c-89f5-a6c9e05b109b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a6376f59-c1f9-4da6-b3a2-796d96d5cdd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_fe27e51f-787e-4f2c-89f5-a6c9e05b109b" xlink:to="loc_us-gaap_DebtInstrumentAxis_a6376f59-c1f9-4da6-b3a2-796d96d5cdd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a6376f59-c1f9-4da6-b3a2-796d96d5cdd2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_a6376f59-c1f9-4da6-b3a2-796d96d5cdd2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a6376f59-c1f9-4da6-b3a2-796d96d5cdd2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f768184d-9cc5-40f2-b5d9-5e721f676279" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_a6376f59-c1f9-4da6-b3a2-796d96d5cdd2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f768184d-9cc5-40f2-b5d9-5e721f676279" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured4875NotesDueJune2028Member_8e81f32e-a93d-4a31-ad93-37923b68003c" xlink:href="bhc-20220331.xsd#bhc_SeniorSecured4875NotesDueJune2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f768184d-9cc5-40f2-b5d9-5e721f676279" xlink:to="loc_bhc_SeniorSecured4875NotesDueJune2028Member_8e81f32e-a93d-4a31-ad93-37923b68003c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueMarch2024Member_c334a842-c641-47f2-bf07-fd235b7ad144" xlink:href="bhc-20220331.xsd#bhc_SeniorNotes700DueMarch2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f768184d-9cc5-40f2-b5d9-5e721f676279" xlink:to="loc_bhc_SeniorNotes700DueMarch2024Member_c334a842-c641-47f2-bf07-fd235b7ad144" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_63a132c0-d34b-434f-9e36-c7bc700a3bb4" xlink:href="bhc-20220331.xsd#bhc_SeniorSecured6125NotesDueFebruary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f768184d-9cc5-40f2-b5d9-5e721f676279" xlink:to="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_63a132c0-d34b-434f-9e36-c7bc700a3bb4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_30136b3f-4029-47fb-b12a-20c39b84e27d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_fe27e51f-787e-4f2c-89f5-a6c9e05b109b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_30136b3f-4029-47fb-b12a-20c39b84e27d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_30136b3f-4029-47fb-b12a-20c39b84e27d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_30136b3f-4029-47fb-b12a-20c39b84e27d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_30136b3f-4029-47fb-b12a-20c39b84e27d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_747291dd-ab9e-459b-8d72-94c859b566d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_30136b3f-4029-47fb-b12a-20c39b84e27d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_747291dd-ab9e-459b-8d72-94c859b566d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_3568228d-7c75-4a96-8e3c-6a1c38129361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_747291dd-ab9e-459b-8d72-94c859b566d5" xlink:to="loc_us-gaap_SecuredDebtMember_3568228d-7c75-4a96-8e3c-6a1c38129361" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_b5304fde-a287-44bf-aa09-5fbb7ba10639" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_747291dd-ab9e-459b-8d72-94c859b566d5" xlink:to="loc_us-gaap_UnsecuredDebtMember_b5304fde-a287-44bf-aa09-5fbb7ba10639" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_2335dfa6-acb0-49da-a3ec-8be9138f7a41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_fe27e51f-787e-4f2c-89f5-a6c9e05b109b" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_2335dfa6-acb0-49da-a3ec-8be9138f7a41" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2335dfa6-acb0-49da-a3ec-8be9138f7a41_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_2335dfa6-acb0-49da-a3ec-8be9138f7a41" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2335dfa6-acb0-49da-a3ec-8be9138f7a41_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e6895af6-09e9-4955-9fde-bc6722562e77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_2335dfa6-acb0-49da-a3ec-8be9138f7a41" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e6895af6-09e9-4955-9fde-bc6722562e77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_62c751fb-d30e-46e5-8d03-326ba3d8cf94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e6895af6-09e9-4955-9fde-bc6722562e77" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_62c751fb-d30e-46e5-8d03-326ba3d8cf94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_8a0a73db-6143-4bae-be56-45d5cb520191" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e6895af6-09e9-4955-9fde-bc6722562e77" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_8a0a73db-6143-4bae-be56-45d5cb520191" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3b0e2a92-0cdf-42cd-aff1-02977aea22b1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_fe27e51f-787e-4f2c-89f5-a6c9e05b109b" xlink:to="loc_srt_RangeAxis_3b0e2a92-0cdf-42cd-aff1-02977aea22b1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3b0e2a92-0cdf-42cd-aff1-02977aea22b1_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3b0e2a92-0cdf-42cd-aff1-02977aea22b1" xlink:to="loc_srt_RangeMember_3b0e2a92-0cdf-42cd-aff1-02977aea22b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1bbd7ed8-1a3e-4ec2-a0da-2271a2ef6132" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3b0e2a92-0cdf-42cd-aff1-02977aea22b1" xlink:to="loc_srt_RangeMember_1bbd7ed8-1a3e-4ec2-a0da-2271a2ef6132" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a4d90005-ba78-4420-a4bb-a852f8ac5d4e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1bbd7ed8-1a3e-4ec2-a0da-2271a2ef6132" xlink:to="loc_srt_MaximumMember_a4d90005-ba78-4420-a4bb-a852f8ac5d4e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" xlink:type="extended" id="i5b995bb49c6a4bd09eb0c96e5254a435_FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_051c7b61-be79-4d25-a0ca-c70d0fb9b580" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_df1b7eda-f47d-4954-9257-7eda04b50cd3" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentRedemptionPricePercentageChangeinControl"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_051c7b61-be79-4d25-a0ca-c70d0fb9b580" xlink:to="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_df1b7eda-f47d-4954-9257-7eda04b50cd3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c66d41a4-f034-4849-8bbe-b2a8595f08c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_051c7b61-be79-4d25-a0ca-c70d0fb9b580" xlink:to="loc_us-gaap_DebtInstrumentTable_c66d41a4-f034-4849-8bbe-b2a8595f08c8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e4cf9c14-d6bb-456b-a200-38f31a94418b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c66d41a4-f034-4849-8bbe-b2a8595f08c8" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e4cf9c14-d6bb-456b-a200-38f31a94418b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e4cf9c14-d6bb-456b-a200-38f31a94418b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e4cf9c14-d6bb-456b-a200-38f31a94418b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e4cf9c14-d6bb-456b-a200-38f31a94418b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_be621669-a9ac-484d-9b82-7a88228da410" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e4cf9c14-d6bb-456b-a200-38f31a94418b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_be621669-a9ac-484d-9b82-7a88228da410" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_efb96914-58cf-4a44-ab3a-698aba42995a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_be621669-a9ac-484d-9b82-7a88228da410" xlink:to="loc_us-gaap_UnsecuredDebtMember_efb96914-58cf-4a44-ab3a-698aba42995a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#FINANCINGARRANGEMENTSMaturitiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesNarrativeDetails" xlink:type="extended" id="i205e8e90c5b648d4a4385f07eca12b39_FINANCINGARRANGEMENTSMaturitiesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_78fc73fc-9070-4382-a229-a3f3cbe7f596" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_949b2970-e594-48d4-ad70-a63e02304549" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_78fc73fc-9070-4382-a229-a3f3cbe7f596" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_949b2970-e594-48d4-ad70-a63e02304549" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_4c9a687d-d50b-4e35-9b53-2c50cb9835e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_78fc73fc-9070-4382-a229-a3f3cbe7f596" xlink:to="loc_us-gaap_LongTermDebt_4c9a687d-d50b-4e35-9b53-2c50cb9835e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9ddbbcfd-6151-492b-9549-811bdf52f344" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_78fc73fc-9070-4382-a229-a3f3cbe7f596" xlink:to="loc_us-gaap_DebtInstrumentTable_9ddbbcfd-6151-492b-9549-811bdf52f344" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8aac522d-ad7a-4c58-808b-9d6190b6fe6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9ddbbcfd-6151-492b-9549-811bdf52f344" xlink:to="loc_us-gaap_DebtInstrumentAxis_8aac522d-ad7a-4c58-808b-9d6190b6fe6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8aac522d-ad7a-4c58-808b-9d6190b6fe6c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_8aac522d-ad7a-4c58-808b-9d6190b6fe6c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8aac522d-ad7a-4c58-808b-9d6190b6fe6c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fa58d10e-7711-4f2c-bd3d-bd90093f08eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_8aac522d-ad7a-4c58-808b-9d6190b6fe6c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fa58d10e-7711-4f2c-bd3d-bd90093f08eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member_450e8029-e968-47e2-80fd-b085406d4a4c" xlink:href="bhc-20220331.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fa58d10e-7711-4f2c-bd3d-bd90093f08eb" xlink:to="loc_bhc_SeniorNotes6125DueApril2025Member_450e8029-e968-47e2-80fd-b085406d4a4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A2027RevolvingCreditFacilityMember_95cf15a3-2d27-41dc-9766-f71b85e6b92f" xlink:href="bhc-20220331.xsd#bhc_A2027RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fa58d10e-7711-4f2c-bd3d-bd90093f08eb" xlink:to="loc_bhc_A2027RevolvingCreditFacilityMember_95cf15a3-2d27-41dc-9766-f71b85e6b92f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7f40cbd4-76c6-4bfb-b68e-b2052b40972c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9ddbbcfd-6151-492b-9549-811bdf52f344" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7f40cbd4-76c6-4bfb-b68e-b2052b40972c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7f40cbd4-76c6-4bfb-b68e-b2052b40972c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7f40cbd4-76c6-4bfb-b68e-b2052b40972c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7f40cbd4-76c6-4bfb-b68e-b2052b40972c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_08d62093-7eaf-4286-b8d7-544a2da93eee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7f40cbd4-76c6-4bfb-b68e-b2052b40972c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_08d62093-7eaf-4286-b8d7-544a2da93eee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_027db724-0b90-40db-9d86-fac60a9fc5d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_08d62093-7eaf-4286-b8d7-544a2da93eee" xlink:to="loc_us-gaap_UnsecuredDebtMember_027db724-0b90-40db-9d86-fac60a9fc5d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1507f369-cc80-4042-aab4-8e05601789a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9ddbbcfd-6151-492b-9549-811bdf52f344" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1507f369-cc80-4042-aab4-8e05601789a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1507f369-cc80-4042-aab4-8e05601789a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1507f369-cc80-4042-aab4-8e05601789a9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1507f369-cc80-4042-aab4-8e05601789a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_cee88b80-c6e8-4be5-8760-cb1e13a2665e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1507f369-cc80-4042-aab4-8e05601789a9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_cee88b80-c6e8-4be5-8760-cb1e13a2665e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_e2980d1b-0944-4f1b-bd99-c9c3e9c751cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_cee88b80-c6e8-4be5-8760-cb1e13a2665e" xlink:to="loc_us-gaap_SubsequentEventMember_e2980d1b-0944-4f1b-bd99-c9c3e9c751cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_5a00909c-3808-44c0-9e17-f10cf035defd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9ddbbcfd-6151-492b-9549-811bdf52f344" xlink:to="loc_us-gaap_CreditFacilityAxis_5a00909c-3808-44c0-9e17-f10cf035defd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_5a00909c-3808-44c0-9e17-f10cf035defd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_5a00909c-3808-44c0-9e17-f10cf035defd" xlink:to="loc_us-gaap_CreditFacilityDomain_5a00909c-3808-44c0-9e17-f10cf035defd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_01802e42-5ece-4463-9c3a-5f074e7746bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_5a00909c-3808-44c0-9e17-f10cf035defd" xlink:to="loc_us-gaap_CreditFacilityDomain_01802e42-5ece-4463-9c3a-5f074e7746bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_059293d9-4b2f-47c1-8b77-133e9ffcae5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_01802e42-5ece-4463-9c3a-5f074e7746bf" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_059293d9-4b2f-47c1-8b77-133e9ffcae5b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended" id="i3b666b5011f641308baaccc0b5d15875_PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fd8f7f8d-556f-430d-8767-b07eabe75e93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_e703ae8c-72aa-4ac9-9cbb-b8dced68d7be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fd8f7f8d-556f-430d-8767-b07eabe75e93" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_e703ae8c-72aa-4ac9-9cbb-b8dced68d7be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_524112bb-14ef-491f-9104-38aa1d913f85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fd8f7f8d-556f-430d-8767-b07eabe75e93" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_524112bb-14ef-491f-9104-38aa1d913f85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_75b7661e-1433-4ad1-a5de-7e7f071baa81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fd8f7f8d-556f-430d-8767-b07eabe75e93" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_75b7661e-1433-4ad1-a5de-7e7f071baa81" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_f714c52f-81b8-480d-a3de-80f40d479bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fd8f7f8d-556f-430d-8767-b07eabe75e93" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_f714c52f-81b8-480d-a3de-80f40d479bd2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_bc805c30-f8a4-4ccc-8eaa-5a829801a1c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fd8f7f8d-556f-430d-8767-b07eabe75e93" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_bc805c30-f8a4-4ccc-8eaa-5a829801a1c5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8323ef80-21c6-4e4c-a7cc-dfa1e1a90283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fd8f7f8d-556f-430d-8767-b07eabe75e93" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8323ef80-21c6-4e4c-a7cc-dfa1e1a90283" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_741348fc-d2ba-4766-b02e-3b29046eaee4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8323ef80-21c6-4e4c-a7cc-dfa1e1a90283" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_741348fc-d2ba-4766-b02e-3b29046eaee4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_741348fc-d2ba-4766-b02e-3b29046eaee4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_741348fc-d2ba-4766-b02e-3b29046eaee4" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_741348fc-d2ba-4766-b02e-3b29046eaee4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_d5cb7c3e-2558-49bc-9ead-82e4a6e2b655" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_741348fc-d2ba-4766-b02e-3b29046eaee4" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_d5cb7c3e-2558-49bc-9ead-82e4a6e2b655" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_d5a7a138-2a9b-44cc-b015-8ec2f0835d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_d5cb7c3e-2558-49bc-9ead-82e4a6e2b655" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_d5a7a138-2a9b-44cc-b015-8ec2f0835d1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_72d26c6a-969e-4a83-8939-da4d92912693" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_d5cb7c3e-2558-49bc-9ead-82e4a6e2b655" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_72d26c6a-969e-4a83-8939-da4d92912693" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_a05d244d-0f5c-47b8-89b9-1f5d91bb5f57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8323ef80-21c6-4e4c-a7cc-dfa1e1a90283" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_a05d244d-0f5c-47b8-89b9-1f5d91bb5f57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_a05d244d-0f5c-47b8-89b9-1f5d91bb5f57_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_a05d244d-0f5c-47b8-89b9-1f5d91bb5f57" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_a05d244d-0f5c-47b8-89b9-1f5d91bb5f57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_e3ebd7f5-bba3-4f6a-a48b-5f12cc0128cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_a05d244d-0f5c-47b8-89b9-1f5d91bb5f57" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_e3ebd7f5-bba3-4f6a-a48b-5f12cc0128cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_ee247367-d742-46e6-9636-e6639256faf3" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_e3ebd7f5-bba3-4f6a-a48b-5f12cc0128cd" xlink:to="loc_country_US_ee247367-d742-46e6-9636-e6639256faf3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_1962db70-4f6e-4165-8772-cbd20c2275d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_e3ebd7f5-bba3-4f6a-a48b-5f12cc0128cd" xlink:to="loc_us-gaap_ForeignPlanMember_1962db70-4f6e-4165-8772-cbd20c2275d6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#SHAREBASEDCOMPENSATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended" id="ia2c383558e60415baa87902c107ac1cd_SHAREBASEDCOMPENSATIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5187fcb7-82c2-4426-988c-0772b6da6acc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c14f0a66-9c17-4952-980a-94519cc78b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5187fcb7-82c2-4426-988c-0772b6da6acc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c14f0a66-9c17-4952-980a-94519cc78b1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2f2361be-b7c9-4be3-93df-32a6626a127b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5187fcb7-82c2-4426-988c-0772b6da6acc" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2f2361be-b7c9-4be3-93df-32a6626a127b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_676bae80-1aae-40a5-b299-4d26cd60c140" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5187fcb7-82c2-4426-988c-0772b6da6acc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_676bae80-1aae-40a5-b299-4d26cd60c140" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant_249302e7-691b-48a5-81e9-2307e4b36c67" xlink:href="bhc-20220331.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5187fcb7-82c2-4426-988c-0772b6da6acc" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant_249302e7-691b-48a5-81e9-2307e4b36c67" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_35cbd0d8-1aac-4ee6-a7b9-564b8adb222f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5187fcb7-82c2-4426-988c-0772b6da6acc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_35cbd0d8-1aac-4ee6-a7b9-564b8adb222f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_78ce20e0-e212-4545-b477-0ae5bc8bd440" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5187fcb7-82c2-4426-988c-0772b6da6acc" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_78ce20e0-e212-4545-b477-0ae5bc8bd440" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0037a6a8-844e-4c16-9263-fd8c11dee840" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5187fcb7-82c2-4426-988c-0772b6da6acc" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0037a6a8-844e-4c16-9263-fd8c11dee840" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_26eee06e-9701-4bf6-8eb5-45ea0f585655" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5187fcb7-82c2-4426-988c-0772b6da6acc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_26eee06e-9701-4bf6-8eb5-45ea0f585655" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_63db97a6-1ad5-4d48-bca5-04315982d3fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_26eee06e-9701-4bf6-8eb5-45ea0f585655" xlink:to="loc_us-gaap_PlanNameAxis_63db97a6-1ad5-4d48-bca5-04315982d3fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_63db97a6-1ad5-4d48-bca5-04315982d3fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_63db97a6-1ad5-4d48-bca5-04315982d3fc" xlink:to="loc_us-gaap_PlanNameDomain_63db97a6-1ad5-4d48-bca5-04315982d3fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_23ab9c91-ecae-435c-be30-b955d6f74453" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_63db97a6-1ad5-4d48-bca5-04315982d3fc" xlink:to="loc_us-gaap_PlanNameDomain_23ab9c91-ecae-435c-be30-b955d6f74453" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OmnibusIncentivePlan2014Member_050e493b-a033-4248-b783-a9b629bad577" xlink:href="bhc-20220331.xsd#bhc_OmnibusIncentivePlan2014Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_23ab9c91-ecae-435c-be30-b955d6f74453" xlink:to="loc_bhc_OmnibusIncentivePlan2014Member_050e493b-a033-4248-b783-a9b629bad577" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_213ec7a0-f0f0-40a3-9d6c-db7106377c43" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_26eee06e-9701-4bf6-8eb5-45ea0f585655" xlink:to="loc_srt_TitleOfIndividualAxis_213ec7a0-f0f0-40a3-9d6c-db7106377c43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_213ec7a0-f0f0-40a3-9d6c-db7106377c43_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_213ec7a0-f0f0-40a3-9d6c-db7106377c43" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_213ec7a0-f0f0-40a3-9d6c-db7106377c43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_270833de-d0ff-4777-9175-a365be93dba4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_213ec7a0-f0f0-40a3-9d6c-db7106377c43" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_270833de-d0ff-4777-9175-a365be93dba4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NonemployeeDirectorMember_de475f34-7ac0-4ce4-be0a-6af4e233a6a4" xlink:href="bhc-20220331.xsd#bhc_NonemployeeDirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_270833de-d0ff-4777-9175-a365be93dba4" xlink:to="loc_bhc_NonemployeeDirectorMember_de475f34-7ac0-4ce4-be0a-6af4e233a6a4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" xlink:type="extended" id="ibefe607d045d4ba4a056d4f5c2f54209_SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4b7ab1c5-2058-4d91-83ee-168bf4182a66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6216c0f1-ac1a-4a96-a329-3eab0668b520" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4b7ab1c5-2058-4d91-83ee-168bf4182a66" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6216c0f1-ac1a-4a96-a329-3eab0668b520" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_833224ea-8d91-43b8-a594-cb267d633169" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4b7ab1c5-2058-4d91-83ee-168bf4182a66" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_833224ea-8d91-43b8-a594-cb267d633169" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_07d7d71a-a82f-4b8e-9b33-925b92d27a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_833224ea-8d91-43b8-a594-cb267d633169" xlink:to="loc_us-gaap_AwardTypeAxis_07d7d71a-a82f-4b8e-9b33-925b92d27a4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_07d7d71a-a82f-4b8e-9b33-925b92d27a4e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_07d7d71a-a82f-4b8e-9b33-925b92d27a4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_07d7d71a-a82f-4b8e-9b33-925b92d27a4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e7a2a5a7-8f76-463d-8078-cf0d4a98ae3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_07d7d71a-a82f-4b8e-9b33-925b92d27a4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e7a2a5a7-8f76-463d-8078-cf0d4a98ae3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e6796200-8e02-4046-832e-bfd89b2fe92d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e7a2a5a7-8f76-463d-8078-cf0d4a98ae3c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e6796200-8e02-4046-832e-bfd89b2fe92d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_34d63737-429e-4876-a04b-e01559439f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e7a2a5a7-8f76-463d-8078-cf0d4a98ae3c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_34d63737-429e-4876-a04b-e01559439f0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_08672b36-8e75-4173-abde-15286b0168f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_833224ea-8d91-43b8-a594-cb267d633169" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_08672b36-8e75-4173-abde-15286b0168f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_08672b36-8e75-4173-abde-15286b0168f0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_08672b36-8e75-4173-abde-15286b0168f0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_08672b36-8e75-4173-abde-15286b0168f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7bdc9b49-6f59-4e6b-aa4d-f0f4a9d15f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_08672b36-8e75-4173-abde-15286b0168f0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7bdc9b49-6f59-4e6b-aa4d-f0f4a9d15f5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_29cadd3f-2301-4e5f-ab4d-674e89518520" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7bdc9b49-6f59-4e6b-aa4d-f0f4a9d15f5d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_29cadd3f-2301-4e5f-ab4d-674e89518520" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6cb054b1-7cf1-48cc-88c9-f5ecc066d296" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7bdc9b49-6f59-4e6b-aa4d-f0f4a9d15f5d" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6cb054b1-7cf1-48cc-88c9-f5ecc066d296" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails" xlink:type="extended" id="i7644e7266752458ea5b9b0646b024fdd_SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a6baeef-8779-48e8-845d-117d2a796ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_98d48764-f431-4172-b823-2d469ffba435" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a6baeef-8779-48e8-845d-117d2a796ddc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_98d48764-f431-4172-b823-2d469ffba435" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_7f7b6a55-f5cf-4520-848d-c63243afb78e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_98d48764-f431-4172-b823-2d469ffba435" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_7f7b6a55-f5cf-4520-848d-c63243afb78e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f8524f27-aecd-404a-9b1f-e318b0b53e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_98d48764-f431-4172-b823-2d469ffba435" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f8524f27-aecd-404a-9b1f-e318b0b53e9f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e3f5a590-3436-46c6-abea-5277a9921f28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_98d48764-f431-4172-b823-2d469ffba435" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e3f5a590-3436-46c6-abea-5277a9921f28" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_90eab49f-6439-4908-bdf3-6ff5e66fd1b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a6baeef-8779-48e8-845d-117d2a796ddc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_90eab49f-6439-4908-bdf3-6ff5e66fd1b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c4d4e6c3-77cf-49f0-99fa-eb108773c6dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_90eab49f-6439-4908-bdf3-6ff5e66fd1b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c4d4e6c3-77cf-49f0-99fa-eb108773c6dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1e087d03-d97b-45fa-8ab9-9fc6faf90f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_90eab49f-6439-4908-bdf3-6ff5e66fd1b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1e087d03-d97b-45fa-8ab9-9fc6faf90f5d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_10d94ae8-519a-4f24-a488-c56b23b69937" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a6baeef-8779-48e8-845d-117d2a796ddc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_10d94ae8-519a-4f24-a488-c56b23b69937" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_32a3838b-84df-40fe-9b07-a2c909dd74d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_10d94ae8-519a-4f24-a488-c56b23b69937" xlink:to="loc_us-gaap_AwardTypeAxis_32a3838b-84df-40fe-9b07-a2c909dd74d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_32a3838b-84df-40fe-9b07-a2c909dd74d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_32a3838b-84df-40fe-9b07-a2c909dd74d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_32a3838b-84df-40fe-9b07-a2c909dd74d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_818a1866-1940-4fbf-95ce-e0bc46d060e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_32a3838b-84df-40fe-9b07-a2c909dd74d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_818a1866-1940-4fbf-95ce-e0bc46d060e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2e2a0d82-2545-401f-a2bb-c6e3d52fd038" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_818a1866-1940-4fbf-95ce-e0bc46d060e3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2e2a0d82-2545-401f-a2bb-c6e3d52fd038" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TimeBasedRSUMember_d8cc1194-af8b-4733-8312-fd9e6d0cbe2d" xlink:href="bhc-20220331.xsd#bhc_TimeBasedRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_818a1866-1940-4fbf-95ce-e0bc46d060e3" xlink:to="loc_bhc_TimeBasedRSUMember_d8cc1194-af8b-4733-8312-fd9e6d0cbe2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_398a2b66-3c3c-4e40-9402-8240bc2d0334" xlink:href="bhc-20220331.xsd#bhc_TSRPerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_818a1866-1940-4fbf-95ce-e0bc46d060e3" xlink:to="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_398a2b66-3c3c-4e40-9402-8240bc2d0334" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_fa02b923-a304-45a4-a822-34916a929d7b" xlink:href="bhc-20220331.xsd#bhc_ROTCPerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_818a1866-1940-4fbf-95ce-e0bc46d060e3" xlink:to="loc_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_fa02b923-a304-45a4-a822-34916a929d7b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeparationPerformanceBasedRestrictedStockUnitsMember_cba0e527-53d7-4e12-995c-6caf32ce959c" xlink:href="bhc-20220331.xsd#bhc_SeparationPerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_818a1866-1940-4fbf-95ce-e0bc46d060e3" xlink:to="loc_bhc_SeparationPerformanceBasedRestrictedStockUnitsMember_cba0e527-53d7-4e12-995c-6caf32ce959c" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails" xlink:type="extended" id="i8455e34690a946e3bf81454a7ae5d082_ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_d03f30bd-faaa-4b8f-ac49-a4aa27db2a32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f14fc061-f38f-4ce7-9a34-05c7192280fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_d03f30bd-faaa-4b8f-ac49-a4aa27db2a32" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f14fc061-f38f-4ce7-9a34-05c7192280fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_1daf6c5c-a806-4ac2-91d6-cab00d2670c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_d03f30bd-faaa-4b8f-ac49-a4aa27db2a32" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_1daf6c5c-a806-4ac2-91d6-cab00d2670c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e99d947e-5fa1-4b2d-a548-3213a1722329" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_1daf6c5c-a806-4ac2-91d6-cab00d2670c2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e99d947e-5fa1-4b2d-a548-3213a1722329" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e99d947e-5fa1-4b2d-a548-3213a1722329_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e99d947e-5fa1-4b2d-a548-3213a1722329" xlink:to="loc_us-gaap_EquityComponentDomain_e99d947e-5fa1-4b2d-a548-3213a1722329_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_172cc74c-e3d1-436b-99a5-44cc04b2028a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e99d947e-5fa1-4b2d-a548-3213a1722329" xlink:to="loc_us-gaap_EquityComponentDomain_172cc74c-e3d1-436b-99a5-44cc04b2028a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_246f3e90-6a1c-4184-80c1-f81bb00f0396" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_172cc74c-e3d1-436b-99a5-44cc04b2028a" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_246f3e90-6a1c-4184-80c1-f81bb00f0396" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_76ab93e3-f9b6-47a0-93c1-d6e2f0ade1bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_172cc74c-e3d1-436b-99a5-44cc04b2028a" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_76ab93e3-f9b6-47a0-93c1-d6e2f0ade1bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_52dccc36-7ec5-4815-81de-de405e8be752" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_172cc74c-e3d1-436b-99a5-44cc04b2028a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_52dccc36-7ec5-4815-81de-de405e8be752" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#OTHEREXPENSEINCOMENETNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails" xlink:type="extended" id="i32866928b1254941882a0bfeaee459a7_OTHEREXPENSEINCOMENETNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_ca62fcda-165c-48f8-bfe8-a536b6e6c095" xlink:href="bhc-20220331.xsd#bhc_ScheduleOfOtherIncomeAndExpensesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_d227d73a-562e-4b1d-8a2a-be3dc5d41770" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_ca62fcda-165c-48f8-bfe8-a536b6e6c095" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_d227d73a-562e-4b1d-8a2a-be3dc5d41770" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_461debd5-ea99-48b0-8c80-41cd8e61b49f" xlink:href="bhc-20220331.xsd#bhc_ScheduleOfOtherIncomeAndExpensesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_ca62fcda-165c-48f8-bfe8-a536b6e6c095" xlink:to="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_461debd5-ea99-48b0-8c80-41cd8e61b49f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_981dbba9-d5ca-4d62-a026-2eeb890edf9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_461debd5-ea99-48b0-8c80-41cd8e61b49f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_981dbba9-d5ca-4d62-a026-2eeb890edf9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_981dbba9-d5ca-4d62-a026-2eeb890edf9f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_981dbba9-d5ca-4d62-a026-2eeb890edf9f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_981dbba9-d5ca-4d62-a026-2eeb890edf9f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_af346f4c-5ea7-4720-b3d4-39dc58d47f99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_981dbba9-d5ca-4d62-a026-2eeb890edf9f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_af346f4c-5ea7-4720-b3d4-39dc58d47f99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MilestonePaymentRelatedToCertainProductMember_c519ae69-a322-4f5a-beef-6cef9515c8a4" xlink:href="bhc-20220331.xsd#bhc_MilestonePaymentRelatedToCertainProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_af346f4c-5ea7-4720-b3d4-39dc58d47f99" xlink:to="loc_bhc_MilestonePaymentRelatedToCertainProductMember_c519ae69-a322-4f5a-beef-6cef9515c8a4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#LOSSPERSHARENarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails" xlink:type="extended" id="i87105a6c47594f8e8c1621b2e4796ea5_LOSSPERSHARENarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f5c02481-d470-4787-9dee-17504e3cedd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c96c5ec0-16f3-4911-8271-a00e2152b7af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f5c02481-d470-4787-9dee-17504e3cedd6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c96c5ec0-16f3-4911-8271-a00e2152b7af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount_94998ac8-aff8-474e-943f-dd4e8b246f35" xlink:href="bhc-20220331.xsd#bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f5c02481-d470-4787-9dee-17504e3cedd6" xlink:to="loc_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount_94998ac8-aff8-474e-943f-dd4e8b246f35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e5b4311b-2430-4868-8904-a976c29a3a89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f5c02481-d470-4787-9dee-17504e3cedd6" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e5b4311b-2430-4868-8904-a976c29a3a89" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3ef68141-e27c-4a31-9983-29997852b3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e5b4311b-2430-4868-8904-a976c29a3a89" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3ef68141-e27c-4a31-9983-29997852b3d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3ef68141-e27c-4a31-9983-29997852b3d8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3ef68141-e27c-4a31-9983-29997852b3d8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3ef68141-e27c-4a31-9983-29997852b3d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2cefaca5-0159-46c0-8973-ed6c29d20a31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3ef68141-e27c-4a31-9983-29997852b3d8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2cefaca5-0159-46c0-8973-ed6c29d20a31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_436e9d78-2b68-47c8-94a7-f91c64716501" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2cefaca5-0159-46c0-8973-ed6c29d20a31" xlink:to="loc_us-gaap_StockCompensationPlanMember_436e9d78-2b68-47c8-94a7-f91c64716501" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_a14e7238-cb50-4546-9a98-723dc427f65e" xlink:href="bhc-20220331.xsd#bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2cefaca5-0159-46c0-8973-ed6c29d20a31" xlink:to="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_a14e7238-cb50-4546-9a98-723dc427f65e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_2f2cc469-b4fd-484f-9ba9-01406cba6fb2" xlink:href="bhc-20220331.xsd#bhc_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2cefaca5-0159-46c0-8973-ed6c29d20a31" xlink:to="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_2f2cc469-b4fd-484f-9ba9-01406cba6fb2" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails" xlink:type="extended" id="ia920cf45bf9f4e11ae669161dcee812b_LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_4fe04344-cb78-49c0-8c8f-04c6c6a2a3c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_f536e2f6-319c-4541-97ef-06da2a4b6a25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4fe04344-cb78-49c0-8c8f-04c6c6a2a3c5" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_f536e2f6-319c-4541-97ef-06da2a4b6a25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_1585e0c3-758b-466c-987c-8cc1ad47ff49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4fe04344-cb78-49c0-8c8f-04c6c6a2a3c5" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_1585e0c3-758b-466c-987c-8cc1ad47ff49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_6f70f239-25cf-47ef-9baa-d21d1e724d71" xlink:href="bhc-20220331.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4fe04344-cb78-49c0-8c8f-04c6c6a2a3c5" xlink:to="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_6f70f239-25cf-47ef-9baa-d21d1e724d71" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_7667d508-9586-4709-9888-4e05ac29de4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4fe04344-cb78-49c0-8c8f-04c6c6a2a3c5" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_7667d508-9586-4709-9888-4e05ac29de4a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_dd995969-c1f6-4731-bc20-9564c2d5eb57" xlink:href="bhc-20220331.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4fe04344-cb78-49c0-8c8f-04c6c6a2a3c5" xlink:to="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_dd995969-c1f6-4731-bc20-9564c2d5eb57" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_d3580f8b-82a3-4018-a062-77e337262d33" xlink:href="bhc-20220331.xsd#bhc_LossContingencyNewClaimsFiledButNotYetServedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4fe04344-cb78-49c0-8c8f-04c6c6a2a3c5" xlink:to="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_d3580f8b-82a3-4018-a062-77e337262d33" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_37e2e9d1-eee1-49ba-8d8f-e67d66d768a7" xlink:href="bhc-20220331.xsd#bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4fe04344-cb78-49c0-8c8f-04c6c6a2a3c5" xlink:to="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_37e2e9d1-eee1-49ba-8d8f-e67d66d768a7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods_26bf7dbc-4d6b-4a8e-8afc-83a0fdc3d5c0" xlink:href="bhc-20220331.xsd#bhc_LossContingencyNumberOfInsurancePolicyPeriods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4fe04344-cb78-49c0-8c8f-04c6c6a2a3c5" xlink:to="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods_26bf7dbc-4d6b-4a8e-8afc-83a0fdc3d5c0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencySettlementAgreementsNumberOfInsurers_f456fb0a-1963-4493-9740-c67dc82016d7" xlink:href="bhc-20220331.xsd#bhc_LossContingencySettlementAgreementsNumberOfInsurers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4fe04344-cb78-49c0-8c8f-04c6c6a2a3c5" xlink:to="loc_bhc_LossContingencySettlementAgreementsNumberOfInsurers_f456fb0a-1963-4493-9740-c67dc82016d7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_30d1e737-9a86-45f3-bb96-7e18b11880dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4fe04344-cb78-49c0-8c8f-04c6c6a2a3c5" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_30d1e737-9a86-45f3-bb96-7e18b11880dd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_df241bfc-a21f-42e5-9280-e56e3eb59621" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_4fe04344-cb78-49c0-8c8f-04c6c6a2a3c5" xlink:to="loc_us-gaap_LossContingenciesTable_df241bfc-a21f-42e5-9280-e56e3eb59621" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_27267259-ea34-46d1-9254-98b8ac84a264" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_df241bfc-a21f-42e5-9280-e56e3eb59621" xlink:to="loc_srt_LitigationCaseAxis_27267259-ea34-46d1-9254-98b8ac84a264" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_27267259-ea34-46d1-9254-98b8ac84a264_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_27267259-ea34-46d1-9254-98b8ac84a264" xlink:to="loc_srt_LitigationCaseTypeDomain_27267259-ea34-46d1-9254-98b8ac84a264_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_209c850f-6077-48cf-b0c7-aae29d79d0e6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_27267259-ea34-46d1-9254-98b8ac84a264" xlink:to="loc_srt_LitigationCaseTypeDomain_209c850f-6077-48cf-b0c7-aae29d79d0e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember_27be20b5-d79e-4433-801d-4c975aaaf1be" xlink:href="bhc-20220331.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_209c850f-6077-48cf-b0c7-aae29d79d0e6" xlink:to="loc_bhc_ValeantUSSecuritiesLitigationMember_27be20b5-d79e-4433-801d-4c975aaaf1be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CanadianSecuritiesLitigationMember_9d62c1e2-3ea2-4eaf-83b6-4cd369c903fc" xlink:href="bhc-20220331.xsd#bhc_CanadianSecuritiesLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_209c850f-6077-48cf-b0c7-aae29d79d0e6" xlink:to="loc_bhc_CanadianSecuritiesLitigationMember_9d62c1e2-3ea2-4eaf-83b6-4cd369c903fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RICOClassActionsMember_f5b908d8-becb-4014-8329-e51762c93b35" xlink:href="bhc-20220331.xsd#bhc_RICOClassActionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_209c850f-6077-48cf-b0c7-aae29d79d0e6" xlink:to="loc_bhc_RICOClassActionsMember_f5b908d8-becb-4014-8329-e51762c93b35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InsuranceCoverageLawsuitMember_a3f52384-ee98-4ddd-b52b-c03e73c4cb52" xlink:href="bhc-20220331.xsd#bhc_InsuranceCoverageLawsuitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_209c850f-6077-48cf-b0c7-aae29d79d0e6" xlink:to="loc_bhc_InsuranceCoverageLawsuitMember_a3f52384-ee98-4ddd-b52b-c03e73c4cb52" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_4f45f34d-dbf5-4f9e-a263-c372810a0cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_df241bfc-a21f-42e5-9280-e56e3eb59621" xlink:to="loc_us-gaap_LitigationStatusAxis_4f45f34d-dbf5-4f9e-a263-c372810a0cbf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_4f45f34d-dbf5-4f9e-a263-c372810a0cbf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_4f45f34d-dbf5-4f9e-a263-c372810a0cbf" xlink:to="loc_us-gaap_LitigationStatusDomain_4f45f34d-dbf5-4f9e-a263-c372810a0cbf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_3f1a4fd2-fb80-4add-a9bc-bb75b26d3c41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_4f45f34d-dbf5-4f9e-a263-c372810a0cbf" xlink:to="loc_us-gaap_LitigationStatusDomain_3f1a4fd2-fb80-4add-a9bc-bb75b26d3c41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_e7c91465-7ea0-4d76-ab58-35c8b1983247" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_3f1a4fd2-fb80-4add-a9bc-bb75b26d3c41" xlink:to="loc_us-gaap_SettledLitigationMember_e7c91465-7ea0-4d76-ab58-35c8b1983247" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_34ac4332-421e-495f-8ddb-cf1c88f130b6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_df241bfc-a21f-42e5-9280-e56e3eb59621" xlink:to="loc_srt_StatementGeographicalAxis_34ac4332-421e-495f-8ddb-cf1c88f130b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_34ac4332-421e-495f-8ddb-cf1c88f130b6_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_34ac4332-421e-495f-8ddb-cf1c88f130b6" xlink:to="loc_srt_SegmentGeographicalDomain_34ac4332-421e-495f-8ddb-cf1c88f130b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_fc1c7d8e-892a-4147-a1d6-617e5d5df36e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_34ac4332-421e-495f-8ddb-cf1c88f130b6" xlink:to="loc_srt_SegmentGeographicalDomain_fc1c7d8e-892a-4147-a1d6-617e5d5df36e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_5a393443-bdca-4f0c-99d1-7adb2344b42c" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_NJ"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_fc1c7d8e-892a-4147-a1d6-617e5d5df36e" xlink:to="loc_stpr_NJ_5a393443-bdca-4f0c-99d1-7adb2344b42c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_022eb1b7-acbd-40ca-a793-eca2d28e156c" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_fc1c7d8e-892a-4147-a1d6-617e5d5df36e" xlink:to="loc_country_CA_022eb1b7-acbd-40ca-a793-eca2d28e156c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_355f8c99-bb85-4084-b15e-9a1688da50ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_df241bfc-a21f-42e5-9280-e56e3eb59621" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_355f8c99-bb85-4084-b15e-9a1688da50ed" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_355f8c99-bb85-4084-b15e-9a1688da50ed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_355f8c99-bb85-4084-b15e-9a1688da50ed" xlink:to="loc_us-gaap_LossContingencyNatureDomain_355f8c99-bb85-4084-b15e-9a1688da50ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_115643de-3bb4-4baf-a873-f536ae4b0de8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_355f8c99-bb85-4084-b15e-9a1688da50ed" xlink:to="loc_us-gaap_LossContingencyNatureDomain_115643de-3bb4-4baf-a873-f536ae4b0de8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember_3bef9727-f53c-409f-a9a9-99f56178b1e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnfavorableRegulatoryActionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_115643de-3bb4-4baf-a873-f536ae4b0de8" xlink:to="loc_us-gaap_UnfavorableRegulatoryActionMember_3bef9727-f53c-409f-a9a9-99f56178b1e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_f837a843-996d-4c20-afac-a227dd8fc8a0" xlink:href="bhc-20220331.xsd#bhc_ViolationofCanadianProvincialSecuritiesLegislationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_115643de-3bb4-4baf-a873-f536ae4b0de8" xlink:to="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_f837a843-996d-4c20-afac-a227dd8fc8a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8bc7d217-9235-4cd7-9353-95276cdc41fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_df241bfc-a21f-42e5-9280-e56e3eb59621" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_8bc7d217-9235-4cd7-9353-95276cdc41fa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8bc7d217-9235-4cd7-9353-95276cdc41fa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8bc7d217-9235-4cd7-9353-95276cdc41fa" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8bc7d217-9235-4cd7-9353-95276cdc41fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_732eb03a-f33e-4a7a-8626-8686344ec391" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8bc7d217-9235-4cd7-9353-95276cdc41fa" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_732eb03a-f33e-4a7a-8626-8686344ec391" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember_6ac3cec4-d32b-4945-b57d-1fe0011fea8d" xlink:href="bhc-20220331.xsd#bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_732eb03a-f33e-4a7a-8626-8686344ec391" xlink:to="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember_6ac3cec4-d32b-4945-b57d-1fe0011fea8d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#LEGALPROCEEDINGSAntitrustDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails" xlink:type="extended" id="i36863674754243779e2645553517fecd_LEGALPROCEEDINGSAntitrustDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_fb7918df-19b0-4c02-ad2d-e75b98e7687f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_50d84bdd-e671-40fd-a501-e71032216ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_fb7918df-19b0-4c02-ad2d-e75b98e7687f" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_50d84bdd-e671-40fd-a501-e71032216ae8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_51bfaaee-72d2-4ed4-a4dc-12807b2cc99d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_fb7918df-19b0-4c02-ad2d-e75b98e7687f" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_51bfaaee-72d2-4ed4-a4dc-12807b2cc99d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_867d4f82-7316-4980-a9ab-e2a66a6b2134" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_fb7918df-19b0-4c02-ad2d-e75b98e7687f" xlink:to="loc_us-gaap_LossContingenciesTable_867d4f82-7316-4980-a9ab-e2a66a6b2134" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_4209ec83-91eb-4def-a912-943fca849dd2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_867d4f82-7316-4980-a9ab-e2a66a6b2134" xlink:to="loc_srt_LitigationCaseAxis_4209ec83-91eb-4def-a912-943fca849dd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_4209ec83-91eb-4def-a912-943fca849dd2_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_4209ec83-91eb-4def-a912-943fca849dd2" xlink:to="loc_srt_LitigationCaseTypeDomain_4209ec83-91eb-4def-a912-943fca849dd2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_aec7e7a2-1651-4a6a-8728-06bbdecd1683" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_4209ec83-91eb-4def-a912-943fca849dd2" xlink:to="loc_srt_LitigationCaseTypeDomain_aec7e7a2-1651-4a6a-8728-06bbdecd1683" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationMember_2d15f6a8-39b6-4a38-b4ca-8b1fd11d55be" xlink:href="bhc-20220331.xsd#bhc_GlumetzaAntitrustLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_aec7e7a2-1651-4a6a-8728-06bbdecd1683" xlink:to="loc_bhc_GlumetzaAntitrustLitigationMember_2d15f6a8-39b6-4a38-b4ca-8b1fd11d55be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_5287b9cf-0c98-4c9a-8804-c6cf162d1b03" xlink:href="bhc-20220331.xsd#bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_aec7e7a2-1651-4a6a-8728-06bbdecd1683" xlink:to="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_5287b9cf-0c98-4c9a-8804-c6cf162d1b03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_88cbbcff-9ed8-4d5a-b350-ba9e7a68ac58" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_867d4f82-7316-4980-a9ab-e2a66a6b2134" xlink:to="loc_srt_CounterpartyNameAxis_88cbbcff-9ed8-4d5a-b350-ba9e7a68ac58" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88cbbcff-9ed8-4d5a-b350-ba9e7a68ac58_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_88cbbcff-9ed8-4d5a-b350-ba9e7a68ac58" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88cbbcff-9ed8-4d5a-b350-ba9e7a68ac58_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_63091421-7e44-4d0f-81ac-9229b1829617" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_88cbbcff-9ed8-4d5a-b350-ba9e7a68ac58" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_63091421-7e44-4d0f-81ac-9229b1829617" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PlaintiffsDirectPurchasersMember_d016bfe2-575e-4876-b49c-a529b3184eb1" xlink:href="bhc-20220331.xsd#bhc_PlaintiffsDirectPurchasersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_63091421-7e44-4d0f-81ac-9229b1829617" xlink:to="loc_bhc_PlaintiffsDirectPurchasersMember_d016bfe2-575e-4876-b49c-a529b3184eb1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_8a11e1c6-8e75-4b60-9e64-0adf576690ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_867d4f82-7316-4980-a9ab-e2a66a6b2134" xlink:to="loc_us-gaap_LitigationStatusAxis_8a11e1c6-8e75-4b60-9e64-0adf576690ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_8a11e1c6-8e75-4b60-9e64-0adf576690ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_8a11e1c6-8e75-4b60-9e64-0adf576690ba" xlink:to="loc_us-gaap_LitigationStatusDomain_8a11e1c6-8e75-4b60-9e64-0adf576690ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_7c490094-6054-4aba-a895-a39b4a019e89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_8a11e1c6-8e75-4b60-9e64-0adf576690ba" xlink:to="loc_us-gaap_LitigationStatusDomain_7c490094-6054-4aba-a895-a39b4a019e89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_5c6f83b5-0d6a-4691-9f23-e90c663ab703" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_7c490094-6054-4aba-a895-a39b4a019e89" xlink:to="loc_us-gaap_PendingLitigationMember_5c6f83b5-0d6a-4691-9f23-e90c663ab703" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#LEGALPROCEEDINGSIntellectualPropertyDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails" xlink:type="extended" id="i9e18ebaf59704b82b46823d699ff87fc_LEGALPROCEEDINGSIntellectualPropertyDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_83ab2696-868c-4b59-87ca-2053ec76a09a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalPeriod_8050687e-48ec-4fc3-b41f-99e22ce453f4" xlink:href="bhc-20220331.xsd#bhc_LossContingencyStayOfApprovalPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_83ab2696-868c-4b59-87ca-2053ec76a09a" xlink:to="loc_bhc_LossContingencyStayOfApprovalPeriod_8050687e-48ec-4fc3-b41f-99e22ce453f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfSeparateDefendants_bab32558-59d9-4000-be43-3a7ba9762b7d" xlink:href="bhc-20220331.xsd#bhc_LossContingencyNumberOfSeparateDefendants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_83ab2696-868c-4b59-87ca-2053ec76a09a" xlink:to="loc_bhc_LossContingencyNumberOfSeparateDefendants_bab32558-59d9-4000-be43-3a7ba9762b7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_3cc51201-25f9-4568-a8b4-139bc3433b93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_83ab2696-868c-4b59-87ca-2053ec76a09a" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_3cc51201-25f9-4568-a8b4-139bc3433b93" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_1d74ea00-8803-4492-85bd-63bd59307dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_83ab2696-868c-4b59-87ca-2053ec76a09a" xlink:to="loc_us-gaap_LossContingenciesTable_1d74ea00-8803-4492-85bd-63bd59307dc1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_25a2928b-56be-41be-a955-7759fcef0272" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1d74ea00-8803-4492-85bd-63bd59307dc1" xlink:to="loc_srt_LitigationCaseAxis_25a2928b-56be-41be-a955-7759fcef0272" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_25a2928b-56be-41be-a955-7759fcef0272_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_25a2928b-56be-41be-a955-7759fcef0272" xlink:to="loc_srt_LitigationCaseTypeDomain_25a2928b-56be-41be-a955-7759fcef0272_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_2e115637-229d-4181-bfc3-d5e071553817" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_25a2928b-56be-41be-a955-7759fcef0272" xlink:to="loc_srt_LitigationCaseTypeDomain_2e115637-229d-4181-bfc3-d5e071553817" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NorwichPharmaceuticalsIncLitigationMember_52f5fbf5-d9c6-4faa-82c4-cfdd15e2a68b" xlink:href="bhc-20220331.xsd#bhc_NorwichPharmaceuticalsIncLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_2e115637-229d-4181-bfc3-d5e071553817" xlink:to="loc_bhc_NorwichPharmaceuticalsIncLitigationMember_52f5fbf5-d9c6-4faa-82c4-cfdd15e2a68b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember_35f1fddc-5d2c-4f65-be09-4ada3cd525f8" xlink:href="bhc-20220331.xsd#bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_2e115637-229d-4181-bfc3-d5e071553817" xlink:to="loc_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember_35f1fddc-5d2c-4f65-be09-4ada3cd525f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PadagisLitigationMember_f0ee6c80-01ce-442b-82c5-284b8fab16fd" xlink:href="bhc-20220331.xsd#bhc_PadagisLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_2e115637-229d-4181-bfc3-d5e071553817" xlink:to="loc_bhc_PadagisLitigationMember_f0ee6c80-01ce-442b-82c5-284b8fab16fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember_3af5a748-9b3b-4555-88ad-6ea51ad19c1e" xlink:href="bhc-20220331.xsd#bhc_MSNLaboratoriesPrivateLtdLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_2e115637-229d-4181-bfc3-d5e071553817" xlink:to="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember_3af5a748-9b3b-4555-88ad-6ea51ad19c1e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PatentInfringementLitigationMember_1eb1c1da-20ef-4ee1-aee3-5b030e612b9e" xlink:href="bhc-20220331.xsd#bhc_PatentInfringementLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_2e115637-229d-4181-bfc3-d5e071553817" xlink:to="loc_bhc_PatentInfringementLitigationMember_1eb1c1da-20ef-4ee1-aee3-5b030e612b9e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ApotexIncLitigationMember_de5b35bf-f7b5-4981-9ca3-3b7a5702af31" xlink:href="bhc-20220331.xsd#bhc_ApotexIncLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_2e115637-229d-4181-bfc3-d5e071553817" xlink:to="loc_bhc_ApotexIncLitigationMember_de5b35bf-f7b5-4981-9ca3-3b7a5702af31" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d27b2664-97dd-4498-abba-024b1bd0e91c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1d74ea00-8803-4492-85bd-63bd59307dc1" xlink:to="loc_srt_StatementGeographicalAxis_d27b2664-97dd-4498-abba-024b1bd0e91c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d27b2664-97dd-4498-abba-024b1bd0e91c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_d27b2664-97dd-4498-abba-024b1bd0e91c" xlink:to="loc_srt_SegmentGeographicalDomain_d27b2664-97dd-4498-abba-024b1bd0e91c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_cd0abc11-dfb0-456c-8845-7d897c27fdce" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_d27b2664-97dd-4498-abba-024b1bd0e91c" xlink:to="loc_srt_SegmentGeographicalDomain_cd0abc11-dfb0-456c-8845-7d897c27fdce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_8a4a8ccd-c270-4e5f-8a54-c7c5fe336760" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_cd0abc11-dfb0-456c-8845-7d897c27fdce" xlink:to="loc_country_CA_8a4a8ccd-c270-4e5f-8a54-c7c5fe336760" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_0d647012-9e47-45d4-88a1-870f7b41a124" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1d74ea00-8803-4492-85bd-63bd59307dc1" xlink:to="loc_us-gaap_LitigationStatusAxis_0d647012-9e47-45d4-88a1-870f7b41a124" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_0d647012-9e47-45d4-88a1-870f7b41a124_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_0d647012-9e47-45d4-88a1-870f7b41a124" xlink:to="loc_us-gaap_LitigationStatusDomain_0d647012-9e47-45d4-88a1-870f7b41a124_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_24c8f524-6487-43be-b37f-682010e2eb23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_0d647012-9e47-45d4-88a1-870f7b41a124" xlink:to="loc_us-gaap_LitigationStatusDomain_24c8f524-6487-43be-b37f-682010e2eb23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_78c2f47a-192b-4b98-a0a8-1dfa54070258" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_24c8f524-6487-43be-b37f-682010e2eb23" xlink:to="loc_us-gaap_PendingLitigationMember_78c2f47a-192b-4b98-a0a8-1dfa54070258" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#LEGALPROCEEDINGSProductLiabilityDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails" xlink:type="extended" id="i30416699ac2040fda3af718737376225_LEGALPROCEEDINGSProductLiabilityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_724711d0-3b5d-4a0f-b126-c281c67d8f36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_cc9e0262-9c9e-4940-a13b-af21d8865699" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_724711d0-3b5d-4a0f-b126-c281c67d8f36" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_cc9e0262-9c9e-4940-a13b-af21d8865699" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalPeriod_77006759-86d2-4231-847e-28047a2d746d" xlink:href="bhc-20220331.xsd#bhc_LossContingencyStayOfApprovalPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_724711d0-3b5d-4a0f-b126-c281c67d8f36" xlink:to="loc_bhc_LossContingencyStayOfApprovalPeriod_77006759-86d2-4231-847e-28047a2d746d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod_513f669e-de38-418f-9c3f-659cacd2aa03" xlink:href="bhc-20220331.xsd#bhc_LossContingencyStayOfApprovalMotionToExtendPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_724711d0-3b5d-4a0f-b126-c281c67d8f36" xlink:to="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod_513f669e-de38-418f-9c3f-659cacd2aa03" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_7213c0c1-1e78-4485-914d-fac14633a541" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_724711d0-3b5d-4a0f-b126-c281c67d8f36" xlink:to="loc_us-gaap_LossContingenciesTable_7213c0c1-1e78-4485-914d-fac14633a541" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_232e9ad3-069c-404a-9758-bf30f79ec201" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_7213c0c1-1e78-4485-914d-fac14633a541" xlink:to="loc_srt_LitigationCaseAxis_232e9ad3-069c-404a-9758-bf30f79ec201" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_232e9ad3-069c-404a-9758-bf30f79ec201_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_232e9ad3-069c-404a-9758-bf30f79ec201" xlink:to="loc_srt_LitigationCaseTypeDomain_232e9ad3-069c-404a-9758-bf30f79ec201_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_ddf35cad-4337-48ae-853c-a871d2e790f8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_232e9ad3-069c-404a-9758-bf30f79ec201" xlink:to="loc_srt_LitigationCaseTypeDomain_ddf35cad-4337-48ae-853c-a871d2e790f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowerToShowerProductLiabilityLitigationMember_ed2b2b64-1197-4f35-9119-aa248d341abf" xlink:href="bhc-20220331.xsd#bhc_ShowerToShowerProductLiabilityLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_ddf35cad-4337-48ae-853c-a871d2e790f8" xlink:to="loc_bhc_ShowerToShowerProductLiabilityLitigationMember_ed2b2b64-1197-4f35-9119-aa248d341abf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_6bd174c6-945e-4f56-aaed-dce812e932dd" xlink:href="bhc-20220331.xsd#bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ShowerToShowerProductLiabilityLitigationMember_ed2b2b64-1197-4f35-9119-aa248d341abf" xlink:to="loc_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_6bd174c6-945e-4f56-aaed-dce812e932dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember_dc19b3b6-18e7-4f23-9b57-0826d0b04827" xlink:href="bhc-20220331.xsd#bhc_MSNLaboratoriesPrivateLtdLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_ddf35cad-4337-48ae-853c-a871d2e790f8" xlink:to="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember_dc19b3b6-18e7-4f23-9b57-0826d0b04827" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_8259f5ca-5e8b-4b8f-a3b3-1076f50363ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_7213c0c1-1e78-4485-914d-fac14633a541" xlink:to="loc_us-gaap_LitigationStatusAxis_8259f5ca-5e8b-4b8f-a3b3-1076f50363ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_8259f5ca-5e8b-4b8f-a3b3-1076f50363ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_8259f5ca-5e8b-4b8f-a3b3-1076f50363ac" xlink:to="loc_us-gaap_LitigationStatusDomain_8259f5ca-5e8b-4b8f-a3b3-1076f50363ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_feed1825-1aa1-4f23-b308-52f8e1f28600" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_8259f5ca-5e8b-4b8f-a3b3-1076f50363ac" xlink:to="loc_us-gaap_LitigationStatusDomain_feed1825-1aa1-4f23-b308-52f8e1f28600" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_c5562413-dd88-4644-b051-e1e98f27b9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_feed1825-1aa1-4f23-b308-52f8e1f28600" xlink:to="loc_us-gaap_PendingLitigationMember_c5562413-dd88-4644-b051-e1e98f27b9bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_2c361429-025d-48af-9ffb-0bf6d948ab5f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_7213c0c1-1e78-4485-914d-fac14633a541" xlink:to="loc_srt_StatementGeographicalAxis_2c361429-025d-48af-9ffb-0bf6d948ab5f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2c361429-025d-48af-9ffb-0bf6d948ab5f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_2c361429-025d-48af-9ffb-0bf6d948ab5f" xlink:to="loc_srt_SegmentGeographicalDomain_2c361429-025d-48af-9ffb-0bf6d948ab5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_76537cf6-0d06-48b5-ae79-ec35e942d767" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_2c361429-025d-48af-9ffb-0bf6d948ab5f" xlink:to="loc_srt_SegmentGeographicalDomain_76537cf6-0d06-48b5-ae79-ec35e942d767" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_e58ae4e9-97a6-44c2-a76f-ad262628d2d9" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_76537cf6-0d06-48b5-ae79-ec35e942d767" xlink:to="loc_country_CA_e58ae4e9-97a6-44c2-a76f-ad262628d2d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-BC_79b3ca35-d3dd-4efa-8d7e-05c4eab59617" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA-BC"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_76537cf6-0d06-48b5-ae79-ec35e942d767" xlink:to="loc_stpr_CA-BC_79b3ca35-d3dd-4efa-8d7e-05c4eab59617" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-QC_e4f3c302-35a6-4a6e-af93-aebb64ca7afa" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA-QC"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_76537cf6-0d06-48b5-ae79-ec35e942d767" xlink:to="loc_stpr_CA-QC_e4f3c302-35a6-4a6e-af93-aebb64ca7afa" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#LEGALPROCEEDINGSGeneralCivilActionsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails" xlink:type="extended" id="id98873b0f68645b4acaf5defd80636ed_LEGALPROCEEDINGSGeneralCivilActionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_7ec0bf38-8a0d-49c2-89ba-feae3cdfb73b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_93e17c62-6d28-44cf-9562-eab9a202cbf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7ec0bf38-8a0d-49c2-89ba-feae3cdfb73b" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_93e17c62-6d28-44cf-9562-eab9a202cbf3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_1aca6900-18c0-428f-9628-b4ba989de427" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_7ec0bf38-8a0d-49c2-89ba-feae3cdfb73b" xlink:to="loc_us-gaap_LossContingenciesTable_1aca6900-18c0-428f-9628-b4ba989de427" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_88306435-1fec-4460-9cb0-8058269d1487" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1aca6900-18c0-428f-9628-b4ba989de427" xlink:to="loc_srt_LitigationCaseAxis_88306435-1fec-4460-9cb0-8058269d1487" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_88306435-1fec-4460-9cb0-8058269d1487_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_88306435-1fec-4460-9cb0-8058269d1487" xlink:to="loc_srt_LitigationCaseTypeDomain_88306435-1fec-4460-9cb0-8058269d1487_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_ed6dac39-1a8c-45f2-a68b-5918f3c86606" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_88306435-1fec-4460-9cb0-8058269d1487" xlink:to="loc_srt_LitigationCaseTypeDomain_ed6dac39-1a8c-45f2-a68b-5918f3c86606" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember_a808eab2-e921-4de8-b652-36324ed80fed" xlink:href="bhc-20220331.xsd#bhc_DoctorsAllergyFormulaLLCLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_ed6dac39-1a8c-45f2-a68b-5918f3c86606" xlink:to="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember_a808eab2-e921-4de8-b652-36324ed80fed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LitigationwithFormerSalixCEOMember_cf60f000-7505-4a6b-8941-a587d2d074b8" xlink:href="bhc-20220331.xsd#bhc_LitigationwithFormerSalixCEOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_ed6dac39-1a8c-45f2-a68b-5918f3c86606" xlink:to="loc_bhc_LitigationwithFormerSalixCEOMember_cf60f000-7505-4a6b-8941-a587d2d074b8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#SEGMENTINFORMATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="extended" id="i803ff69596b5458eaa7f78b9a8a82faf_SEGMENTINFORMATIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_c4afe95a-eec9-4010-a0c3-eab370712b43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_0dd577a2-2f57-4e0e-be31-1ba85b4f6d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c4afe95a-eec9-4010-a0c3-eab370712b43" xlink:to="loc_us-gaap_NumberOfReportingUnits_0dd577a2-2f57-4e0e-be31-1ba85b4f6d8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_17fa6b4b-b03f-47ed-9d50-32b6fc797b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c4afe95a-eec9-4010-a0c3-eab370712b43" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_17fa6b4b-b03f-47ed-9d50-32b6fc797b3c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_51d5ee9b-af98-4384-84d0-4ce927128ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_17fa6b4b-b03f-47ed-9d50-32b6fc797b3c" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_51d5ee9b-af98-4384-84d0-4ce927128ec2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_51d5ee9b-af98-4384-84d0-4ce927128ec2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_51d5ee9b-af98-4384-84d0-4ce927128ec2" xlink:to="loc_us-gaap_SegmentDomain_51d5ee9b-af98-4384-84d0-4ce927128ec2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b2e14643-acc2-41b3-9db0-40eb079c20e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_51d5ee9b-af98-4384-84d0-4ce927128ec2" xlink:to="loc_us-gaap_SegmentDomain_b2e14643-acc2-41b3-9db0-40eb079c20e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember_25d1f358-7fe1-4faa-b42d-3d3d5f3dff71" xlink:href="bhc-20220331.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b2e14643-acc2-41b3-9db0-40eb079c20e7" xlink:to="loc_bhc_OrthoDermatologicsSegmentMember_25d1f358-7fe1-4faa-b42d-3d3d5f3dff71" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails" xlink:type="extended" id="i2708a443186443efb16f86a9eed432fc_SEGMENTINFORMATIONSegmentRevenuesandProfitDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_c326c755-66e9-43dd-8ba3-39b29594bb62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_172fd5a8-a228-445a-84bd-35a18383c183" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c326c755-66e9-43dd-8ba3-39b29594bb62" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_172fd5a8-a228-445a-84bd-35a18383c183" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f9559b47-34c1-425a-b244-3fd72817bbb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c326c755-66e9-43dd-8ba3-39b29594bb62" xlink:to="loc_us-gaap_OperatingIncomeLoss_f9559b47-34c1-425a-b244-3fd72817bbb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_2f93c272-5aa5-4a20-9d89-e3e5798a91c8" xlink:href="bhc-20220331.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c326c755-66e9-43dd-8ba3-39b29594bb62" xlink:to="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_2f93c272-5aa5-4a20-9d89-e3e5798a91c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_016fa26f-5b60-47eb-8912-1d75cefc5446" xlink:href="bhc-20220331.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c326c755-66e9-43dd-8ba3-39b29594bb62" xlink:to="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_016fa26f-5b60-47eb-8912-1d75cefc5446" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_617381f2-7838-4547-a5a4-070ad9d58f72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c326c755-66e9-43dd-8ba3-39b29594bb62" xlink:to="loc_us-gaap_AssetImpairmentCharges_617381f2-7838-4547-a5a4-070ad9d58f72" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_146ea648-9cf9-499c-b625-61715d374d50" xlink:href="bhc-20220331.xsd#bhc_RestructuringChargesAndInitialPublicOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c326c755-66e9-43dd-8ba3-39b29594bb62" xlink:to="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_146ea648-9cf9-499c-b625-61715d374d50" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_f48e8cb2-9a0e-4951-a778-f84f3ba4af96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c326c755-66e9-43dd-8ba3-39b29594bb62" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_f48e8cb2-9a0e-4951-a778-f84f3ba4af96" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_e6e1fc64-aa5e-4856-b634-a6b67e5c8bac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c326c755-66e9-43dd-8ba3-39b29594bb62" xlink:to="loc_us-gaap_InvestmentIncomeInterest_e6e1fc64-aa5e-4856-b634-a6b67e5c8bac" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_955499d4-eaf2-43bc-89d7-1eb26ed5c64c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c326c755-66e9-43dd-8ba3-39b29594bb62" xlink:to="loc_us-gaap_InterestExpenseDebt_955499d4-eaf2-43bc-89d7-1eb26ed5c64c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0a68e17b-87e7-45f8-bab6-d180565ca12d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c326c755-66e9-43dd-8ba3-39b29594bb62" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0a68e17b-87e7-45f8-bab6-d180565ca12d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_27ab77ce-0823-420b-ae0b-a24b31b09411" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c326c755-66e9-43dd-8ba3-39b29594bb62" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_27ab77ce-0823-420b-ae0b-a24b31b09411" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_29639269-cba9-4796-8898-f2521d38c426" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c326c755-66e9-43dd-8ba3-39b29594bb62" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_29639269-cba9-4796-8898-f2521d38c426" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ca7a5a03-b5a2-4df2-8197-14ea4befc5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c326c755-66e9-43dd-8ba3-39b29594bb62" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ca7a5a03-b5a2-4df2-8197-14ea4befc5e7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_e49e094d-e8ad-4fbe-95e1-9a062ef00eaa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ca7a5a03-b5a2-4df2-8197-14ea4befc5e7" xlink:to="loc_srt_ConsolidationItemsAxis_e49e094d-e8ad-4fbe-95e1-9a062ef00eaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_e49e094d-e8ad-4fbe-95e1-9a062ef00eaa_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_e49e094d-e8ad-4fbe-95e1-9a062ef00eaa" xlink:to="loc_srt_ConsolidationItemsDomain_e49e094d-e8ad-4fbe-95e1-9a062ef00eaa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_1e71d05a-74bd-4188-aeb4-43c817950fa0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_e49e094d-e8ad-4fbe-95e1-9a062ef00eaa" xlink:to="loc_srt_ConsolidationItemsDomain_1e71d05a-74bd-4188-aeb4-43c817950fa0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_677398d0-7610-4317-a4e8-0a05a9471d25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_1e71d05a-74bd-4188-aeb4-43c817950fa0" xlink:to="loc_us-gaap_OperatingSegmentsMember_677398d0-7610-4317-a4e8-0a05a9471d25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_ba78f658-48c4-4e4e-bbdc-cf5c3c743022" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_1e71d05a-74bd-4188-aeb4-43c817950fa0" xlink:to="loc_us-gaap_CorporateNonSegmentMember_ba78f658-48c4-4e4e-bbdc-cf5c3c743022" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_0b6d630f-9bd8-4cd0-95d5-d9e8b91606f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ca7a5a03-b5a2-4df2-8197-14ea4befc5e7" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_0b6d630f-9bd8-4cd0-95d5-d9e8b91606f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0b6d630f-9bd8-4cd0-95d5-d9e8b91606f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0b6d630f-9bd8-4cd0-95d5-d9e8b91606f2" xlink:to="loc_us-gaap_SegmentDomain_0b6d630f-9bd8-4cd0-95d5-d9e8b91606f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ebc2e478-1fc2-453b-bb19-d694cd99b3b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0b6d630f-9bd8-4cd0-95d5-d9e8b91606f2" xlink:to="loc_us-gaap_SegmentDomain_ebc2e478-1fc2-453b-bb19-d694cd99b3b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_e4c1a2b9-0ef9-459e-ab80-230fc7c7762b" xlink:href="bhc-20220331.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ebc2e478-1fc2-453b-bb19-d694cd99b3b7" xlink:to="loc_bhc_BauschLombMember_e4c1a2b9-0ef9-459e-ab80-230fc7c7762b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_3886b8eb-98c4-4714-bc6d-464275a35400" xlink:href="bhc-20220331.xsd#bhc_SalixSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ebc2e478-1fc2-453b-bb19-d694cd99b3b7" xlink:to="loc_bhc_SalixSegmentMember_3886b8eb-98c4-4714-bc6d-464275a35400" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_e9eafd2e-c6fb-4dda-82a0-6259cbecefd2" xlink:href="bhc-20220331.xsd#bhc_InternationalRxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ebc2e478-1fc2-453b-bb19-d694cd99b3b7" xlink:to="loc_bhc_InternationalRxMember_e9eafd2e-c6fb-4dda-82a0-6259cbecefd2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SoltaMedicalSegmentMember_0ae5238d-da70-4182-bb07-7e59e1fb9ca5" xlink:href="bhc-20220331.xsd#bhc_SoltaMedicalSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ebc2e478-1fc2-453b-bb19-d694cd99b3b7" xlink:to="loc_bhc_SoltaMedicalSegmentMember_0ae5238d-da70-4182-bb07-7e59e1fb9ca5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_bfba17a0-0503-46fc-95b2-d74827ee9ecf" xlink:href="bhc-20220331.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ebc2e478-1fc2-453b-bb19-d694cd99b3b7" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_bfba17a0-0503-46fc-95b2-d74827ee9ecf" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#SEGMENTINFORMATIONDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails" xlink:type="extended" id="i3e4338ec35544f55bf4dbb41055bc984_SEGMENTINFORMATIONDisaggregationofRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_68c6fa1a-f366-4962-8dba-5b1613bbe85b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ca311aac-fb2b-4f3e-850c-ed9703831a41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_68c6fa1a-f366-4962-8dba-5b1613bbe85b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ca311aac-fb2b-4f3e-850c-ed9703831a41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_28b61d48-ca7b-4728-a882-48d1abc6f46e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_68c6fa1a-f366-4962-8dba-5b1613bbe85b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_28b61d48-ca7b-4728-a882-48d1abc6f46e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_b9f934b9-7f7c-448c-909c-32d9b3f8f572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_28b61d48-ca7b-4728-a882-48d1abc6f46e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_b9f934b9-7f7c-448c-909c-32d9b3f8f572" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b9f934b9-7f7c-448c-909c-32d9b3f8f572_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b9f934b9-7f7c-448c-909c-32d9b3f8f572" xlink:to="loc_us-gaap_SegmentDomain_b9f934b9-7f7c-448c-909c-32d9b3f8f572_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e29a7066-2391-4883-88fb-ab6028f4d9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b9f934b9-7f7c-448c-909c-32d9b3f8f572" xlink:to="loc_us-gaap_SegmentDomain_e29a7066-2391-4883-88fb-ab6028f4d9bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_c7f1bd02-e63b-4b51-a434-994188a4f9bc" xlink:href="bhc-20220331.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e29a7066-2391-4883-88fb-ab6028f4d9bf" xlink:to="loc_bhc_BauschLombMember_c7f1bd02-e63b-4b51-a434-994188a4f9bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_8737b91f-6935-4abb-a041-b4fed3e797c9" xlink:href="bhc-20220331.xsd#bhc_SalixSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e29a7066-2391-4883-88fb-ab6028f4d9bf" xlink:to="loc_bhc_SalixSegmentMember_8737b91f-6935-4abb-a041-b4fed3e797c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_c34e4d36-8134-4311-8e00-2ed1e85ea218" xlink:href="bhc-20220331.xsd#bhc_InternationalRxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e29a7066-2391-4883-88fb-ab6028f4d9bf" xlink:to="loc_bhc_InternationalRxMember_c34e4d36-8134-4311-8e00-2ed1e85ea218" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SoltaMedicalSegmentMember_c9ffb8ab-c773-4c1e-b769-fb60083a744d" xlink:href="bhc-20220331.xsd#bhc_SoltaMedicalSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e29a7066-2391-4883-88fb-ab6028f4d9bf" xlink:to="loc_bhc_SoltaMedicalSegmentMember_c9ffb8ab-c773-4c1e-b769-fb60083a744d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_5d5e1117-b6f9-4e1f-a541-469b59f9f54d" xlink:href="bhc-20220331.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e29a7066-2391-4883-88fb-ab6028f4d9bf" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_5d5e1117-b6f9-4e1f-a541-469b59f9f54d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_93a8e142-231c-4bfe-b31c-c504df9768d4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_28b61d48-ca7b-4728-a882-48d1abc6f46e" xlink:to="loc_srt_ProductOrServiceAxis_93a8e142-231c-4bfe-b31c-c504df9768d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_93a8e142-231c-4bfe-b31c-c504df9768d4_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_93a8e142-231c-4bfe-b31c-c504df9768d4" xlink:to="loc_srt_ProductsAndServicesDomain_93a8e142-231c-4bfe-b31c-c504df9768d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e43ba4da-f377-4e6a-b92c-622ab39f57b8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_93a8e142-231c-4bfe-b31c-c504df9768d4" xlink:to="loc_srt_ProductsAndServicesDomain_e43ba4da-f377-4e6a-b92c-622ab39f57b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PharmaceuticalProductsMember_c869f8b1-0439-4abe-8e61-7d6dcb891259" xlink:href="bhc-20220331.xsd#bhc_PharmaceuticalProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e43ba4da-f377-4e6a-b92c-622ab39f57b8" xlink:to="loc_bhc_PharmaceuticalProductsMember_c869f8b1-0439-4abe-8e61-7d6dcb891259" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeviceProductsMember_39b2a539-3dea-4bed-857c-f12373c37a64" xlink:href="bhc-20220331.xsd#bhc_DeviceProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e43ba4da-f377-4e6a-b92c-622ab39f57b8" xlink:to="loc_bhc_DeviceProductsMember_39b2a539-3dea-4bed-857c-f12373c37a64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OvertheCounterProductsMember_064092c4-72e8-4e01-8800-1b1bb9f6ac81" xlink:href="bhc-20220331.xsd#bhc_OvertheCounterProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e43ba4da-f377-4e6a-b92c-622ab39f57b8" xlink:to="loc_bhc_OvertheCounterProductsMember_064092c4-72e8-4e01-8800-1b1bb9f6ac81" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BrandedandOtherGenericProductsMember_614ecd01-da25-4c16-9ba2-3b88b4047ed8" xlink:href="bhc-20220331.xsd#bhc_BrandedandOtherGenericProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e43ba4da-f377-4e6a-b92c-622ab39f57b8" xlink:to="loc_bhc_BrandedandOtherGenericProductsMember_614ecd01-da25-4c16-9ba2-3b88b4047ed8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherRevenuesMember_7cdcc599-d144-4046-8b65-c8f8b43fad6c" xlink:href="bhc-20220331.xsd#bhc_OtherRevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e43ba4da-f377-4e6a-b92c-622ab39f57b8" xlink:to="loc_bhc_OtherRevenuesMember_7cdcc599-d144-4046-8b65-c8f8b43fad6c" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1" xlink:type="simple" xlink:href="bhc-20220331.xsd#SEGMENTINFORMATIONNarrativeDetails_1"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1" xlink:type="extended" id="ic9a03c78bfaf49bca653b2ce35c6e3dc_SEGMENTINFORMATIONNarrativeDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_083b6f67-be8e-4e27-9f9d-f96c2ee1ae8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ConcentrationRiskNumberOfProducts_21469a8a-9e3f-491a-9c90-cd4a61bbf5ff" xlink:href="bhc-20220331.xsd#bhc_ConcentrationRiskNumberOfProducts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_083b6f67-be8e-4e27-9f9d-f96c2ee1ae8b" xlink:to="loc_bhc_ConcentrationRiskNumberOfProducts_21469a8a-9e3f-491a-9c90-cd4a61bbf5ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_e81362a7-a0e8-4a55-a0e7-46d8d1f907ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_083b6f67-be8e-4e27-9f9d-f96c2ee1ae8b" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_e81362a7-a0e8-4a55-a0e7-46d8d1f907ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_26ad6364-4cb3-4208-893d-b78a39f13457" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_083b6f67-be8e-4e27-9f9d-f96c2ee1ae8b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_26ad6364-4cb3-4208-893d-b78a39f13457" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_80293b26-ffe3-4cad-9ca0-6787bf005fae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_26ad6364-4cb3-4208-893d-b78a39f13457" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_80293b26-ffe3-4cad-9ca0-6787bf005fae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_80293b26-ffe3-4cad-9ca0-6787bf005fae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_80293b26-ffe3-4cad-9ca0-6787bf005fae" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_80293b26-ffe3-4cad-9ca0-6787bf005fae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_8611f2dc-b8d0-4e0e-8fc0-f012b00e8b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_80293b26-ffe3-4cad-9ca0-6787bf005fae" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_8611f2dc-b8d0-4e0e-8fc0-f012b00e8b0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_3295b804-8f01-4bca-b603-e1c7f0622f20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_8611f2dc-b8d0-4e0e-8fc0-f012b00e8b0d" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_3295b804-8f01-4bca-b603-e1c7f0622f20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0af8da91-e1b3-43d0-b4a6-11a85fd23623" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_26ad6364-4cb3-4208-893d-b78a39f13457" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0af8da91-e1b3-43d0-b4a6-11a85fd23623" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0af8da91-e1b3-43d0-b4a6-11a85fd23623_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0af8da91-e1b3-43d0-b4a6-11a85fd23623" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0af8da91-e1b3-43d0-b4a6-11a85fd23623_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0006940e-8348-48e2-83da-5ad424ab7218" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0af8da91-e1b3-43d0-b4a6-11a85fd23623" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0006940e-8348-48e2-83da-5ad424ab7218" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuesNetMember_28dba4fd-42be-4a39-bd37-4ef7c48ecb2e" xlink:href="bhc-20220331.xsd#bhc_RevenuesNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0006940e-8348-48e2-83da-5ad424ab7218" xlink:to="loc_bhc_RevenuesNetMember_28dba4fd-42be-4a39-bd37-4ef7c48ecb2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_272ef305-2ec3-4625-9337-8ce09d4bd9f7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_26ad6364-4cb3-4208-893d-b78a39f13457" xlink:to="loc_srt_MajorCustomersAxis_272ef305-2ec3-4625-9337-8ce09d4bd9f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_272ef305-2ec3-4625-9337-8ce09d4bd9f7_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_272ef305-2ec3-4625-9337-8ce09d4bd9f7" xlink:to="loc_srt_NameOfMajorCustomerDomain_272ef305-2ec3-4625-9337-8ce09d4bd9f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_07987b98-aea8-4417-830b-4a230e293e91" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_272ef305-2ec3-4625-9337-8ce09d4bd9f7" xlink:to="loc_srt_NameOfMajorCustomerDomain_07987b98-aea8-4417-830b-4a230e293e91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CustomerTopTenProductsMember_4849ea50-44a5-4a79-84ab-0489a57a51e6" xlink:href="bhc-20220331.xsd#bhc_CustomerTopTenProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_07987b98-aea8-4417-830b-4a230e293e91" xlink:to="loc_bhc_CustomerTopTenProductsMember_4849ea50-44a5-4a79-84ab-0489a57a51e6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails" xlink:type="extended" id="icfa4f406da0347acbeb8476728738548_SEGMENTINFORMATIONRevenuebyGeographicAreaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_e1321855-7be1-4132-bc03-df1e5efcdb02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c94e814b-f0fa-4a55-a69e-287a4e24cb3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_e1321855-7be1-4132-bc03-df1e5efcdb02" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c94e814b-f0fa-4a55-a69e-287a4e24cb3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_200b8cf4-b09c-4b5d-ae36-08446a6f3ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_e1321855-7be1-4132-bc03-df1e5efcdb02" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_200b8cf4-b09c-4b5d-ae36-08446a6f3ce0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_00540f8f-18f9-4821-b641-bd5f805b1169" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_200b8cf4-b09c-4b5d-ae36-08446a6f3ce0" xlink:to="loc_srt_StatementGeographicalAxis_00540f8f-18f9-4821-b641-bd5f805b1169" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_00540f8f-18f9-4821-b641-bd5f805b1169_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_00540f8f-18f9-4821-b641-bd5f805b1169" xlink:to="loc_srt_SegmentGeographicalDomain_00540f8f-18f9-4821-b641-bd5f805b1169_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_5d21fcd3-1fa8-4b6e-a264-3710cc3500a9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_00540f8f-18f9-4821-b641-bd5f805b1169" xlink:to="loc_srt_SegmentGeographicalDomain_5d21fcd3-1fa8-4b6e-a264-3710cc3500a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnitedStatesandPuertoRicoMember_3a05e27f-b237-4e4d-bcd8-20299877368a" xlink:href="bhc-20220331.xsd#bhc_UnitedStatesandPuertoRicoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5d21fcd3-1fa8-4b6e-a264-3710cc3500a9" xlink:to="loc_bhc_UnitedStatesandPuertoRicoMember_3a05e27f-b237-4e4d-bcd8-20299877368a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_d036f6c6-72d0-4a5e-8eca-4edd2f1c5cc0" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5d21fcd3-1fa8-4b6e-a264-3710cc3500a9" xlink:to="loc_country_CN_d036f6c6-72d0-4a5e-8eca-4edd2f1c5cc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_33fe174a-2bb3-47bf-968d-9d199ec23cce" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5d21fcd3-1fa8-4b6e-a264-3710cc3500a9" xlink:to="loc_country_CA_33fe174a-2bb3-47bf-968d-9d199ec23cce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_PL_21992bab-0957-435e-8377-15411ccbf16e" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_PL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5d21fcd3-1fa8-4b6e-a264-3710cc3500a9" xlink:to="loc_country_PL_21992bab-0957-435e-8377-15411ccbf16e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_MX_69a5ec53-c7b8-416b-adfd-5b228a5ce079" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_MX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5d21fcd3-1fa8-4b6e-a264-3710cc3500a9" xlink:to="loc_country_MX_69a5ec53-c7b8-416b-adfd-5b228a5ce079" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_e6c54616-2263-49fc-af4f-76b170699f7f" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_FR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5d21fcd3-1fa8-4b6e-a264-3710cc3500a9" xlink:to="loc_country_FR_e6c54616-2263-49fc-af4f-76b170699f7f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_184f2d76-bb6e-4d15-8488-a4690ff2c917" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5d21fcd3-1fa8-4b6e-a264-3710cc3500a9" xlink:to="loc_country_JP_184f2d76-bb6e-4d15-8488-a4690ff2c917" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_c72644bf-ebc3-4335-aca6-13a56d43b665" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_DE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5d21fcd3-1fa8-4b6e-a264-3710cc3500a9" xlink:to="loc_country_DE_c72644bf-ebc3-4335-aca6-13a56d43b665" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_ae83220c-eb85-4080-9e6b-7e4143946e26" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_GB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5d21fcd3-1fa8-4b6e-a264-3710cc3500a9" xlink:to="loc_country_GB_ae83220c-eb85-4080-9e6b-7e4143946e26" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_RU_88a2873a-daa0-48c9-abbc-ebbc30514863" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_RU"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5d21fcd3-1fa8-4b6e-a264-3710cc3500a9" xlink:to="loc_country_RU_88a2873a-daa0-48c9-abbc-ebbc30514863" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_ES_56765115-f52c-43d5-8460-48fac6e71b7a" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_ES"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5d21fcd3-1fa8-4b6e-a264-3710cc3500a9" xlink:to="loc_country_ES_56765115-f52c-43d5-8460-48fac6e71b7a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IT_67dd5307-5ef5-42ce-a07b-bb1ebc15c099" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IT"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5d21fcd3-1fa8-4b6e-a264-3710cc3500a9" xlink:to="loc_country_IT_67dd5307-5ef5-42ce-a07b-bb1ebc15c099" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_KR_c60e0158-e142-4760-bbd8-2fc10b4ef203" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_KR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5d21fcd3-1fa8-4b6e-a264-3710cc3500a9" xlink:to="loc_country_KR_c60e0158-e142-4760-bbd8-2fc10b4ef203" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherCountriesMember_df250629-3dc8-406d-865c-42f045061d76" xlink:href="bhc-20220331.xsd#bhc_OtherCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5d21fcd3-1fa8-4b6e-a264-3710cc3500a9" xlink:to="loc_bhc_OtherCountriesMember_df250629-3dc8-406d-865c-42f045061d76" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#SEGMENTINFORMATIONMajorCustomersDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails" xlink:type="extended" id="i884af06c64c84939b5adff7b4dc02da8_SEGMENTINFORMATIONMajorCustomersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_b2879924-d98a-49a9-b694-49051936743d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_922fdd25-acda-4552-8179-b17c0949f26e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_b2879924-d98a-49a9-b694-49051936743d" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_922fdd25-acda-4552-8179-b17c0949f26e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_ab96c8c0-2208-48e1-9644-7f6cc3df0bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_b2879924-d98a-49a9-b694-49051936743d" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_ab96c8c0-2208-48e1-9644-7f6cc3df0bc6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d61d320a-94f7-4b89-b12d-f1dcdff76eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_ab96c8c0-2208-48e1-9644-7f6cc3df0bc6" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d61d320a-94f7-4b89-b12d-f1dcdff76eb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d61d320a-94f7-4b89-b12d-f1dcdff76eb9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d61d320a-94f7-4b89-b12d-f1dcdff76eb9" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d61d320a-94f7-4b89-b12d-f1dcdff76eb9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_67be24c9-e7c5-406c-91bb-8bb9f8d74508" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d61d320a-94f7-4b89-b12d-f1dcdff76eb9" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_67be24c9-e7c5-406c-91bb-8bb9f8d74508" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuesNetMember_5195138d-8adb-4fd5-8e89-08edcd4b10bb" xlink:href="bhc-20220331.xsd#bhc_RevenuesNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_67be24c9-e7c5-406c-91bb-8bb9f8d74508" xlink:to="loc_bhc_RevenuesNetMember_5195138d-8adb-4fd5-8e89-08edcd4b10bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_d1ef6929-41e2-49a5-ae2d-1808567a562e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_ab96c8c0-2208-48e1-9644-7f6cc3df0bc6" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_d1ef6929-41e2-49a5-ae2d-1808567a562e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_d1ef6929-41e2-49a5-ae2d-1808567a562e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_d1ef6929-41e2-49a5-ae2d-1808567a562e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_d1ef6929-41e2-49a5-ae2d-1808567a562e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_2a4c8037-8f37-4b32-96f4-4080ab66ec3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_d1ef6929-41e2-49a5-ae2d-1808567a562e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_2a4c8037-8f37-4b32-96f4-4080ab66ec3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_bb70e757-d2af-47ea-8a81-2f0a41f3d840" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_2a4c8037-8f37-4b32-96f4-4080ab66ec3f" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_bb70e757-d2af-47ea-8a81-2f0a41f3d840" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_f6edafb9-8a4d-421c-99a3-be9b97c42782" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_ab96c8c0-2208-48e1-9644-7f6cc3df0bc6" xlink:to="loc_srt_MajorCustomersAxis_f6edafb9-8a4d-421c-99a3-be9b97c42782" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f6edafb9-8a4d-421c-99a3-be9b97c42782_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_f6edafb9-8a4d-421c-99a3-be9b97c42782" xlink:to="loc_srt_NameOfMajorCustomerDomain_f6edafb9-8a4d-421c-99a3-be9b97c42782_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_77fc6a7c-8e9e-410d-92c7-4771170e5475" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_f6edafb9-8a4d-421c-99a3-be9b97c42782" xlink:to="loc_srt_NameOfMajorCustomerDomain_77fc6a7c-8e9e-410d-92c7-4771170e5475" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmerisourceBergenCorporationMember_e022232b-73b9-4eaa-add7-4c399ca39d63" xlink:href="bhc-20220331.xsd#bhc_AmerisourceBergenCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_77fc6a7c-8e9e-410d-92c7-4771170e5475" xlink:to="loc_bhc_AmerisourceBergenCorporationMember_e022232b-73b9-4eaa-add7-4c399ca39d63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_McKessonCorporationMember_aa244ad2-9324-4265-b5b6-6c13b9588872" xlink:href="bhc-20220331.xsd#bhc_McKessonCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_77fc6a7c-8e9e-410d-92c7-4771170e5475" xlink:to="loc_bhc_McKessonCorporationMember_aa244ad2-9324-4265-b5b6-6c13b9588872" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CardinalHealthIncMember_d12c9114-fb55-4ebb-a214-c025448367c7" xlink:href="bhc-20220331.xsd#bhc_CardinalHealthIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_77fc6a7c-8e9e-410d-92c7-4771170e5475" xlink:to="loc_bhc_CardinalHealthIncMember_d12c9114-fb55-4ebb-a214-c025448367c7" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#SUBSEQUENTEVENTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails" xlink:type="extended" id="i426ecc4b48d1408c9faa5124b1454843_SUBSEQUENTEVENTSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1ca3f34a-5c40-4bdf-bd36-43933fc3062b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1ca3f34a-5c40-4bdf-bd36-43933fc3062b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_aae43ae6-999b-40d3-a8ee-d8ccd884bcda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_aae43ae6-999b-40d3-a8ee-d8ccd884bcda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_7fe775ed-be18-4f34-8da4-5cd801d7423a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_7fe775ed-be18-4f34-8da4-5cd801d7423a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SaleOfStockOverAllotmentTerm_cf58ed8b-256b-457e-ab8f-27629a239d50" xlink:href="bhc-20220331.xsd#bhc_SaleOfStockOverAllotmentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_bhc_SaleOfStockOverAllotmentTerm_cf58ed8b-256b-457e-ab8f-27629a239d50" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0ad84a24-525f-4c8f-b2f0-dd0e2a2e98c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0ad84a24-525f-4c8f-b2f0-dd0e2a2e98c9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_58745114-2e6f-43b6-b40c-96bcf996d2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_58745114-2e6f-43b6-b40c-96bcf996d2a0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_644351ec-e4e6-4fd9-a91c-597bb8d04e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_644351ec-e4e6-4fd9-a91c-597bb8d04e4a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_ec36e496-4076-4b21-99c1-3b7ca0754d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_us-gaap_DebtInstrumentTerm_ec36e496-4076-4b21-99c1-3b7ca0754d5b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7f446d81-959e-47da-bd4a-409b082cd1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7f446d81-959e-47da-bd4a-409b082cd1f4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a0b4f3cc-a8f7-48a0-9860-1ae590208275" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a0b4f3cc-a8f7-48a0-9860-1ae590208275" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate_3a76d91c-82e9-4f47-8e7b-fe33180ac0ad" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate_3a76d91c-82e9-4f47-8e7b-fe33180ac0ad" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_6a0d0ce8-30ce-49ed-87a0-f0c21e384eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_6a0d0ce8-30ce-49ed-87a0-f0c21e384eb5" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_8ff7ff8a-7220-4612-9b15-b0db3d5f28b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_8ff7ff8a-7220-4612-9b15-b0db3d5f28b1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_82b9056e-57cb-48db-8e80-5c5cda4d3bd7" xlink:href="bhc-20220331.xsd#bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_82b9056e-57cb-48db-8e80-5c5cda4d3bd7" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_80d9e107-673c-4a25-9cfd-a20084d172e5" xlink:href="bhc-20220331.xsd#bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_80d9e107-673c-4a25-9cfd-a20084d172e5" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_110349c3-79e9-4fad-905f-f7fc5d0f5d95" xlink:href="bhc-20220331.xsd#bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_110349c3-79e9-4fad-905f-f7fc5d0f5d95" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_21d61000-d362-48e7-9a05-343225646dc3" xlink:href="bhc-20220331.xsd#bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_21d61000-d362-48e7-9a05-343225646dc3" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage_19009f38-175b-4edb-9cdc-161c782b96e2" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentAnnualAmortizationRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage_19009f38-175b-4edb-9cdc-161c782b96e2" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_ab8cbbb8-58b7-44dd-b844-be448af239b1" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_ab8cbbb8-58b7-44dd-b844-be448af239b1" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_3f62a578-5664-4b8b-bb18-df0adee1c4ad" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_3f62a578-5664-4b8b-bb18-df0adee1c4ad" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_c2255894-125b-4420-b04d-8fe964b41dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_us-gaap_LongTermDebt_c2255894-125b-4420-b04d-8fe964b41dc9" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_69846a0d-c50c-4cc2-9f2a-76b5781bd4c9" xlink:href="bhc-20220331.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_69846a0d-c50c-4cc2-9f2a-76b5781bd4c9" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate_a4d911f2-c410-4b0c-9f4b-9e81985a9d24" xlink:href="bhc-20220331.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate_a4d911f2-c410-4b0c-9f4b-9e81985a9d24" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_588bf587-a914-4a50-8a74-8452c21dd15b" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_588bf587-a914-4a50-8a74-8452c21dd15b" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_caa1bf98-9c9b-4d60-bdfe-9b10525fb40a" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_caa1bf98-9c9b-4d60-bdfe-9b10525fb40a" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_a61854d1-0836-459a-9106-b68cc270256a" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_a61854d1-0836-459a-9106-b68cc270256a" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatio_d9e24e19-c2a5-4675-853e-caaf6390570c" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_bhc_DebtInstrumentCovenantTotalLeverageRatio_d9e24e19-c2a5-4675-853e-caaf6390570c" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_62b97a6c-f6d2-4e6f-9f27-0786fb0cd1dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_62b97a6c-f6d2-4e6f-9f27-0786fb0cd1dd" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_68e39599-4762-43ef-88b9-89ba274ca0f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_68e39599-4762-43ef-88b9-89ba274ca0f3" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet_3c59bf34-967e-48c5-8316-8dbd47dad667" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet_3c59bf34-967e-48c5-8316-8dbd47dad667" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_ff7a55b7-b566-4fef-8e16-6e5ee73ec08e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_ff7a55b7-b566-4fef-8e16-6e5ee73ec08e" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_784af6f8-d8a6-4c8c-b07f-6c846718bc32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_us-gaap_SubsequentEventTable_784af6f8-d8a6-4c8c-b07f-6c846718bc32" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b2cbb03d-cee7-4e30-8fc9-59a12a7b8d96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_784af6f8-d8a6-4c8c-b07f-6c846718bc32" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b2cbb03d-cee7-4e30-8fc9-59a12a7b8d96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b2cbb03d-cee7-4e30-8fc9-59a12a7b8d96_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b2cbb03d-cee7-4e30-8fc9-59a12a7b8d96" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b2cbb03d-cee7-4e30-8fc9-59a12a7b8d96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_37931007-55d3-4b8e-9dfc-828a58a77e10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b2cbb03d-cee7-4e30-8fc9-59a12a7b8d96" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_37931007-55d3-4b8e-9dfc-828a58a77e10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_581f4b18-4843-46a9-86bc-82081ba888b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_37931007-55d3-4b8e-9dfc-828a58a77e10" xlink:to="loc_us-gaap_SubsequentEventMember_581f4b18-4843-46a9-86bc-82081ba888b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_920282b7-2240-440d-802f-4b94fd887cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_784af6f8-d8a6-4c8c-b07f-6c846718bc32" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_920282b7-2240-440d-802f-4b94fd887cc9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_920282b7-2240-440d-802f-4b94fd887cc9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_920282b7-2240-440d-802f-4b94fd887cc9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_920282b7-2240-440d-802f-4b94fd887cc9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b014ddc9-4b82-46eb-ab04-ca75ac88bf0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_920282b7-2240-440d-802f-4b94fd887cc9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b014ddc9-4b82-46eb-ab04-ca75ac88bf0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_13b1b809-a7d1-4531-81c3-b7a60ef03a39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b014ddc9-4b82-46eb-ab04-ca75ac88bf0c" xlink:to="loc_us-gaap_IPOMember_13b1b809-a7d1-4531-81c3-b7a60ef03a39" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_aae312bb-52a9-44e7-a83e-e59c4a4203dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b014ddc9-4b82-46eb-ab04-ca75ac88bf0c" xlink:to="loc_us-gaap_OverAllotmentOptionMember_aae312bb-52a9-44e7-a83e-e59c4a4203dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_f98823a9-5728-42a0-83f6-6a9bab3d08c4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_784af6f8-d8a6-4c8c-b07f-6c846718bc32" xlink:to="loc_srt_OwnershipAxis_f98823a9-5728-42a0-83f6-6a9bab3d08c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_f98823a9-5728-42a0-83f6-6a9bab3d08c4_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_f98823a9-5728-42a0-83f6-6a9bab3d08c4" xlink:to="loc_srt_OwnershipDomain_f98823a9-5728-42a0-83f6-6a9bab3d08c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_78a30c62-9f46-4e64-a150-b19e60a15e01" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_f98823a9-5728-42a0-83f6-6a9bab3d08c4" xlink:to="loc_srt_OwnershipDomain_78a30c62-9f46-4e64-a150-b19e60a15e01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_52f97f4b-5c30-4429-b18a-a15b0532f3ae" xlink:href="bhc-20220331.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_78a30c62-9f46-4e64-a150-b19e60a15e01" xlink:to="loc_bhc_BauschLombMember_52f97f4b-5c30-4429-b18a-a15b0532f3ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5dd2b2ca-c82a-43e8-a02e-139423264a78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_784af6f8-d8a6-4c8c-b07f-6c846718bc32" xlink:to="loc_us-gaap_DebtInstrumentAxis_5dd2b2ca-c82a-43e8-a02e-139423264a78" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5dd2b2ca-c82a-43e8-a02e-139423264a78_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_5dd2b2ca-c82a-43e8-a02e-139423264a78" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5dd2b2ca-c82a-43e8-a02e-139423264a78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_06783882-a53b-487b-9626-3eb015012651" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_5dd2b2ca-c82a-43e8-a02e-139423264a78" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_06783882-a53b-487b-9626-3eb015012651" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanDueMay2027Member_b39fc61b-9efb-4c51-acd4-87de9651d800" xlink:href="bhc-20220331.xsd#bhc_TermLoanDueMay2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06783882-a53b-487b-9626-3eb015012651" xlink:to="loc_bhc_TermLoanDueMay2027Member_b39fc61b-9efb-4c51-acd4-87de9651d800" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueMay2027Member_5bb50652-78d6-40cb-a358-e5f53064ca10" xlink:href="bhc-20220331.xsd#bhc_RevolvingCreditFacilityDueMay2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06783882-a53b-487b-9626-3eb015012651" xlink:to="loc_bhc_RevolvingCreditFacilityDueMay2027Member_5bb50652-78d6-40cb-a358-e5f53064ca10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A2027TermLoanBFacilityMember_2af8af55-96e3-4e8c-bba3-0c13828d8f3e" xlink:href="bhc-20220331.xsd#bhc_A2027TermLoanBFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06783882-a53b-487b-9626-3eb015012651" xlink:to="loc_bhc_A2027TermLoanBFacilityMember_2af8af55-96e3-4e8c-bba3-0c13828d8f3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A2027RevolvingCreditFacilityMember_e6fc7817-ca59-42ce-b50b-f6c7d39673ab" xlink:href="bhc-20220331.xsd#bhc_A2027RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06783882-a53b-487b-9626-3eb015012651" xlink:to="loc_bhc_A2027RevolvingCreditFacilityMember_e6fc7817-ca59-42ce-b50b-f6c7d39673ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredCreditFacilitiesMember_4259245e-8808-4e11-b381-b650af37ef41" xlink:href="bhc-20220331.xsd#bhc_SeniorSecuredCreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06783882-a53b-487b-9626-3eb015012651" xlink:to="loc_bhc_SeniorSecuredCreditFacilitiesMember_4259245e-8808-4e11-b381-b650af37ef41" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NewRestatedCreditAgreementMember_74d80a46-ecd2-4e19-9a26-b3e7e0e007e0" xlink:href="bhc-20220331.xsd#bhc_NewRestatedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06783882-a53b-487b-9626-3eb015012651" xlink:to="loc_bhc_NewRestatedCreditAgreementMember_74d80a46-ecd2-4e19-9a26-b3e7e0e007e0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A9.00SeniorNotesdueDecember2025Member_a18e92fd-06bb-4a3a-8e86-36b47fab2af5" xlink:href="bhc-20220331.xsd#bhc_A9.00SeniorNotesdueDecember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06783882-a53b-487b-9626-3eb015012651" xlink:to="loc_bhc_A9.00SeniorNotesdueDecember2025Member_a18e92fd-06bb-4a3a-8e86-36b47fab2af5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member_e8ac776a-2f5a-42ae-938f-5f0c834d85b6" xlink:href="bhc-20220331.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06783882-a53b-487b-9626-3eb015012651" xlink:to="loc_bhc_SeniorNotes6125DueApril2025Member_e8ac776a-2f5a-42ae-938f-5f0c834d85b6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_85374657-ec02-4971-8863-f4fe99e08891" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_784af6f8-d8a6-4c8c-b07f-6c846718bc32" xlink:to="loc_us-gaap_CreditFacilityAxis_85374657-ec02-4971-8863-f4fe99e08891" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_85374657-ec02-4971-8863-f4fe99e08891_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_85374657-ec02-4971-8863-f4fe99e08891" xlink:to="loc_us-gaap_CreditFacilityDomain_85374657-ec02-4971-8863-f4fe99e08891_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_1b546b38-8c3d-497c-b8a5-ed28011743b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_85374657-ec02-4971-8863-f4fe99e08891" xlink:to="loc_us-gaap_CreditFacilityDomain_1b546b38-8c3d-497c-b8a5-ed28011743b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_36ba573e-9317-47de-aa2c-c3cbc7d38870" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_1b546b38-8c3d-497c-b8a5-ed28011743b6" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_36ba573e-9317-47de-aa2c-c3cbc7d38870" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_c587a1e6-af38-434f-a9b3-96512e98c1ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_784af6f8-d8a6-4c8c-b07f-6c846718bc32" xlink:to="loc_us-gaap_VariableRateAxis_c587a1e6-af38-434f-a9b3-96512e98c1ad" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_c587a1e6-af38-434f-a9b3-96512e98c1ad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_c587a1e6-af38-434f-a9b3-96512e98c1ad" xlink:to="loc_us-gaap_VariableRateDomain_c587a1e6-af38-434f-a9b3-96512e98c1ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_113b144e-993d-4648-9265-1d2a807dfa43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_c587a1e6-af38-434f-a9b3-96512e98c1ad" xlink:to="loc_us-gaap_VariableRateDomain_113b144e-993d-4648-9265-1d2a807dfa43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SOFRCDOREURIBORAndSONIARatesMember_114cdf85-092d-4211-ad64-db48dff72a70" xlink:href="bhc-20220331.xsd#bhc_SOFRCDOREURIBORAndSONIARatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_113b144e-993d-4648-9265-1d2a807dfa43" xlink:to="loc_bhc_SOFRCDOREURIBORAndSONIARatesMember_114cdf85-092d-4211-ad64-db48dff72a70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember_6b23431c-cb92-454b-b0a4-e09c8673a080" xlink:href="bhc-20220331.xsd#bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_113b144e-993d-4648-9265-1d2a807dfa43" xlink:to="loc_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember_6b23431c-cb92-454b-b0a4-e09c8673a080" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_6f663ef3-98ac-415b-8537-8b624b6e840e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_113b144e-993d-4648-9265-1d2a807dfa43" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_6f663ef3-98ac-415b-8537-8b624b6e840e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_e4b917ac-517b-434a-91ca-e09bc7df063d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_113b144e-993d-4648-9265-1d2a807dfa43" xlink:to="loc_us-gaap_BaseRateMember_e4b917ac-517b-434a-91ca-e09bc7df063d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SOFRCDORAndEURIBORRatesMember_98c32a7a-21c8-4f01-9afd-8a31311607b9" xlink:href="bhc-20220331.xsd#bhc_SOFRCDORAndEURIBORRatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_113b144e-993d-4648-9265-1d2a807dfa43" xlink:to="loc_bhc_SOFRCDORAndEURIBORRatesMember_98c32a7a-21c8-4f01-9afd-8a31311607b9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b1c9b8cf-865a-4ea7-8f36-619239f1873d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_784af6f8-d8a6-4c8c-b07f-6c846718bc32" xlink:to="loc_srt_RangeAxis_b1c9b8cf-865a-4ea7-8f36-619239f1873d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b1c9b8cf-865a-4ea7-8f36-619239f1873d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b1c9b8cf-865a-4ea7-8f36-619239f1873d" xlink:to="loc_srt_RangeMember_b1c9b8cf-865a-4ea7-8f36-619239f1873d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1d201478-0f3e-40d5-be95-4ad0bf96f50a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b1c9b8cf-865a-4ea7-8f36-619239f1873d" xlink:to="loc_srt_RangeMember_1d201478-0f3e-40d5-be95-4ad0bf96f50a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ab9c0381-59aa-41f2-a7ad-8f451c61563b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1d201478-0f3e-40d5-be95-4ad0bf96f50a" xlink:to="loc_srt_MinimumMember_ab9c0381-59aa-41f2-a7ad-8f451c61563b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d9307493-cdef-46b8-a447-031b538650e6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1d201478-0f3e-40d5-be95-4ad0bf96f50a" xlink:to="loc_srt_MaximumMember_d9307493-cdef-46b8-a447-031b538650e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3644f496-1479-4e2c-937e-7da342e9e671" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_784af6f8-d8a6-4c8c-b07f-6c846718bc32" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3644f496-1479-4e2c-937e-7da342e9e671" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3644f496-1479-4e2c-937e-7da342e9e671_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3644f496-1479-4e2c-937e-7da342e9e671" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3644f496-1479-4e2c-937e-7da342e9e671_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_33c6177a-4be6-48ff-945b-168fae10cd07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3644f496-1479-4e2c-937e-7da342e9e671" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_33c6177a-4be6-48ff-945b-168fae10cd07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_434a0b42-a953-46d3-acc4-41cde34b2521" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_33c6177a-4be6-48ff-945b-168fae10cd07" xlink:to="loc_us-gaap_SecuredDebtMember_434a0b42-a953-46d3-acc4-41cde34b2521" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_18a3cdde-9a61-4119-8317-a3cf4e319624" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_33c6177a-4be6-48ff-945b-168fae10cd07" xlink:to="loc_us-gaap_UnsecuredDebtMember_18a3cdde-9a61-4119-8317-a3cf4e319624" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>bhc-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:9c0993e0-3c65-4e23-b478-aba95d934319,g:036e3555-df42-4f12-aaee-1876eac48ef4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_HedgingDesignationDomain_99e78267-cbba-487b-b483-0b0db5c0ba78_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_580640f9-f8b7-444d-8baf-48a3c11f8bea_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_078d2680-babe-4761-8fac-08ca8e3f29ca_terseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEGAL PROCEEDINGS</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_eaf21a3e-be6d-410e-af53-e6c375fe3db5_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_5c1e0ae0-3462-4d33-a233-fe21e685fa36_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c1ceb7a0-a794-4f6b-87da-0525edecaf88_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_1bbcd9c5-97aa-465b-be54-92abad54e200_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Bausch Health Companies Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_9bf8b8bb-1099-4a79-8150-df691512a946_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Bausch Health Companies Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount_521d3378-b9bb-4da3-a49e-27eedf7718dd_terseLabel_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax provision (benefit) for discrete items</link:label>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount_label_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Discrete Items, Amount</link:label>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount_documentation_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Discrete Items, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" xlink:href="bhc-20220331.xsd#bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" xlink:to="lab_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_fb1aa369-0b98-4619-bf16-c97debdedd08_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_0aae774f-4d54-436f-96c5-ae00a88e3a8d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_f2a58376-cafc-4115-9686-9bf514c283d8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e9f386ca-ad37-4452-ac7c-d1371148e67d_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization and Impairments</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_8660ee88-1652-4779-9476-4fb2c0ab028e_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LitigationSettlementNumberOfObjectorsAppeals_b3fe804c-9234-44b6-bb78-4c966f4f7122_terseLabel_en-US" xlink:label="lab_bhc_LitigationSettlementNumberOfObjectorsAppeals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement, escrow fund included in restricted cash, number of objectors' appeals</link:label>
    <link:label id="lab_bhc_LitigationSettlementNumberOfObjectorsAppeals_label_en-US" xlink:label="lab_bhc_LitigationSettlementNumberOfObjectorsAppeals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Number of Objectors' Appeals</link:label>
    <link:label id="lab_bhc_LitigationSettlementNumberOfObjectorsAppeals_documentation_en-US" xlink:label="lab_bhc_LitigationSettlementNumberOfObjectorsAppeals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Number of Objectors' Appeals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LitigationSettlementNumberOfObjectorsAppeals" xlink:href="bhc-20220331.xsd#bhc_LitigationSettlementNumberOfObjectorsAppeals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LitigationSettlementNumberOfObjectorsAppeals" xlink:to="lab_bhc_LitigationSettlementNumberOfObjectorsAppeals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_ee0381ae-4d0f-42e1-bc0e-78e8eb6b637f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of long-term debt maturities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_ab3453c5-74f6-4b9e-8ea7-8a72d028a8a8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency exchange contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_f0243b18-156e-4eca-9c3a-dab1d3a83633_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA-BC_6c73393e-8aca-444d-9a42-b9ddf5a6624d_terseLabel_en-US" xlink:label="lab_stpr_CA-BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BRITISH COLUMBIA</link:label>
    <link:label id="lab_stpr_CA-BC_label_en-US" xlink:label="lab_stpr_CA-BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BRITISH COLUMBIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-BC" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA-BC"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA-BC" xlink:to="lab_stpr_CA-BC" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CanadianSecuritiesLitigationMember_aa97886b-5c5f-4b60-bbda-3eb94731a9eb_terseLabel_en-US" xlink:label="lab_bhc_CanadianSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canadian Securities Litigation</link:label>
    <link:label id="lab_bhc_CanadianSecuritiesLitigationMember_label_en-US" xlink:label="lab_bhc_CanadianSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canadian Securities Litigation [Member]</link:label>
    <link:label id="lab_bhc_CanadianSecuritiesLitigationMember_documentation_en-US" xlink:label="lab_bhc_CanadianSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canadian Securities Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CanadianSecuritiesLitigationMember" xlink:href="bhc-20220331.xsd#bhc_CanadianSecuritiesLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CanadianSecuritiesLitigationMember" xlink:to="lab_bhc_CanadianSecuritiesLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_ad59b75f-6210-4246-b497-6de23f4ad9c9_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_3dfbbee0-43e1-4b92-b1c8-5d3d1c829e9e_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_d7d7dceb-5aab-408d-a370-33f411c73e58_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_1f6d9f74-2051-4a17-99b8-f3a8617c69b3_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of acquisition-related contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_cf620e18-65b3-4e81-9519-62ff027c8c45_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and postretirement benefit plan adjustments, net of income taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_0432d183-0d9d-4207-9831-9e6b83f9b196_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_971d6f97-aba6-4193-a318-76ad565b6136_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_3b6ed409-8ad9-4647-a668-61e04bf9ed04_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_8551ef4f-3fe2-4d87-9459-7416b65e275e_terseLabel_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_label_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Noncurrent Liability</link:label>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_documentation_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Noncurrent Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:href="bhc-20220331.xsd#bhc_BusinessCombinationContingentConsiderationNoncurrentLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:to="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_406a2a57-140c-4f7c-950b-0e0f26a843c0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e6a8d0b-5110-4724-a354-43a2967191c5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_703dd144-48f0-4718-8454-d5b723090bc3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_ec3ba76b-ef4d-4aaa-b7cd-5d8ecd6996ae_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_60c89049-4625-4c38-bf68-e1f06a41a5ee_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for future grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_c0bf8d09-692f-4e46-8bda-55ae1bf51414_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments or receipts in settlement of cross-currency swaps</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Hedge, Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_21410f3f-7785-4178-b53b-33ffb8f6b88f_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0d557638-f484-4a50-b968-cfb36d99cbeb_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_e682e2c6-7f5d-424d-86dd-7f513e610a3c_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_00b558f1-802c-4744-b929-f70fd9b6ab2b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_a8b7b686-4ff6-40c3-8006-4e7c4e9b833c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of other expense (income), net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_d26d27a5-42ef-41b9-9c7d-a90baa368955_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_83072402-6848-4fee-8830-289dfecbc1bd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_84c5c813-64c1-4bb7-aa2d-76d516a391b1_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_f81c9390-ba12-417e-b209-a6c2451da271_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TermLoanDueMay2027Member_383124eb-333d-460a-9916-e76ebdd7dff3_terseLabel_en-US" xlink:label="lab_bhc_TermLoanDueMay2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Due May 2027</link:label>
    <link:label id="lab_bhc_TermLoanDueMay2027Member_label_en-US" xlink:label="lab_bhc_TermLoanDueMay2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Due May 2027 [Member]</link:label>
    <link:label id="lab_bhc_TermLoanDueMay2027Member_documentation_en-US" xlink:label="lab_bhc_TermLoanDueMay2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Due May 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanDueMay2027Member" xlink:href="bhc-20220331.xsd#bhc_TermLoanDueMay2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TermLoanDueMay2027Member" xlink:to="lab_bhc_TermLoanDueMay2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_985f8f39-ee34-4464-8dc2-db9c7c26a754_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gain on sale of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_5c760ead-8f01-4024-b19f-a46396e7e2cf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of assets, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_c936e388-1fca-42c3-b281-ac7d5de255e2_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone achievement, included in net (loss) gain on sale of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_c49d142e-6c69-4513-ac29-ddbe3f87f98d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_d0467894-8f87-4bd8-a48b-1ed599d143b9_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember_1c2da14a-a564-4653-a751-75998c1eb652_terseLabel_en-US" xlink:label="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Doctors Allergy Formula, LLC Litigation</link:label>
    <link:label id="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember_label_en-US" xlink:label="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Doctors Allergy Formula, LLC Litigation [Member]</link:label>
    <link:label id="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember_documentation_en-US" xlink:label="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Doctors Allergy Formula, LLC Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:href="bhc-20220331.xsd#bhc_DoctorsAllergyFormulaLLCLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:to="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet_aeb9e569-f0ed-4e3b-8eff-f8704bdb8757_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt covenant, mandatory prepayments, percentage net cash proceeds, property and asset losses</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Mandatory Prepayments, Percentage Net Cash Proceeds, Property And Asset Losses, If Circumstances Met</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Mandatory Prepayments, Percentage Net Cash Proceeds, Property And Asset Losses, If Circumstances Met</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet" xlink:to="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_47758951-26d9-4ae7-94d5-16e1b421f679_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TermLoanBFacilityDueNovember2025Member_71189c2b-01e6-4b67-a821-0beccde22ef3_terseLabel_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due November 2025</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueNovember2025Member_label_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due November 2025 [Member]</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueNovember2025Member_documentation_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due November 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueNovember2025Member" xlink:href="bhc-20220331.xsd#bhc_TermLoanBFacilityDueNovember2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TermLoanBFacilityDueNovember2025Member" xlink:to="lab_bhc_TermLoanBFacilityDueNovember2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0a484706-724f-4837-9549-4e62ac3ac573_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_1f4416a5-96b6-4daf-b6b0-b03fdffd2d33_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AmerisourceBergenCorporationMember_cfaa9f56-d1fe-4786-96c1-aa29a32974e3_terseLabel_en-US" xlink:label="lab_bhc_AmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Corporation</link:label>
    <link:label id="lab_bhc_AmerisourceBergenCorporationMember_label_en-US" xlink:label="lab_bhc_AmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amerisource Bergen Corporation [Member]</link:label>
    <link:label id="lab_bhc_AmerisourceBergenCorporationMember_documentation_en-US" xlink:label="lab_bhc_AmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the major customer of the entity, AmerisourceBergen Corporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmerisourceBergenCorporationMember" xlink:href="bhc-20220331.xsd#bhc_AmerisourceBergenCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AmerisourceBergenCorporationMember" xlink:to="lab_bhc_AmerisourceBergenCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_9600de20-d091-45a9-b12c-acb4452ae914_verboseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets to be Disposed of</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReportingUnitsExcludingOrthoDermatologicsMember_9ca7dd45-bb5d-433a-bdf5-2d4caac1253c_terseLabel_en-US" xlink:label="lab_bhc_ReportingUnitsExcludingOrthoDermatologicsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Units Excluding Ortho Dermatologics</link:label>
    <link:label id="lab_bhc_ReportingUnitsExcludingOrthoDermatologicsMember_label_en-US" xlink:label="lab_bhc_ReportingUnitsExcludingOrthoDermatologicsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Units Excluding Ortho Dermatologics [Member]</link:label>
    <link:label id="lab_bhc_ReportingUnitsExcludingOrthoDermatologicsMember_documentation_en-US" xlink:label="lab_bhc_ReportingUnitsExcludingOrthoDermatologicsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Units Excluding Ortho Dermatologics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitsExcludingOrthoDermatologicsMember" xlink:href="bhc-20220331.xsd#bhc_ReportingUnitsExcludingOrthoDermatologicsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReportingUnitsExcludingOrthoDermatologicsMember" xlink:to="lab_bhc_ReportingUnitsExcludingOrthoDermatologicsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers_495d3efb-8a21-4bd6-88e8-7a62133d2e89_terseLabel_en-US" xlink:label="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement agreements, number of insurers</link:label>
    <link:label id="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers_label_en-US" xlink:label="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Settlement Agreements, Number Of Insurers</link:label>
    <link:label id="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers_documentation_en-US" xlink:label="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Settlement Agreements, Number Of Insurers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencySettlementAgreementsNumberOfInsurers" xlink:href="bhc-20220331.xsd#bhc_LossContingencySettlementAgreementsNumberOfInsurers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencySettlementAgreementsNumberOfInsurers" xlink:to="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e3702ae1-7275-49ea-9da2-c7761518f861_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive effect of potential common shares (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_11d7b827-1cd8-4be5-bacc-d57d3b531d47_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the components of inventories, net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_82c15420-3e8a-4fe9-91bc-58a8467ddb7f_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_477b4c80-6795-41e9-9005-a5482df8b6a5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_82ce1980-e2f5-4583-b8de-bbc090e28f4e_terseLabel_en-US" xlink:label="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_45cbca6e-1b4d-42ce-9fe6-11e3a45800d3_negatedLabel_en-US" xlink:label="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_label_en-US" xlink:label="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets Excluding Amortization Allocated to Revenues Cost of Good Sold</link:label>
    <link:label id="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_documentation_en-US" xlink:label="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of intangible asset amortization expense excluding amortization allocated to alliance and royalty revenue and cost of goods sold during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:href="bhc-20220331.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:to="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_d8482da0-a768-4e5f-bfbc-8df131aa83ea_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility fee (as a percent)</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c47b1b77-f23d-4ff3-ab56-0bcd390a2695_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember_50d42f29-dfd9-40a2-84b2-06a905b911cd_terseLabel_en-US" xlink:label="lab_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Dollar Base Rate and Canadian Dollar Prime Rate</link:label>
    <link:label id="lab_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember_label_en-US" xlink:label="lab_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Dollar Base Rate and Canadian Dollar Prime Rate [Member]</link:label>
    <link:label id="lab_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember_documentation_en-US" xlink:label="lab_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Dollar Base Rate and Canadian Dollar Prime Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember" xlink:href="bhc-20220331.xsd#bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember" xlink:to="lab_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_9c49f0d7-75f2-4f06-a4da-9044ab99ff8e_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate</link:label>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_label_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:to="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_8123089f-79d3-4b2b-ad4f-3832d0d9d15d_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9757f091-0956-4169-8c6f-7d42ab5340d2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_afd7adc3-3658-4063-99c7-69ede28fbd21_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss related to changes in fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_ef8839d2-8ae0-44c0-8cb6-b4d3330a550e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f003482-e7f9-4029-b4f3-3db490d641e9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_52cd7d81-8dd2-4e3f-b57b-be0fe8212e2a_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_bbf04dcc-8a7b-44ce-af91-774e1b58bbe5_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_5be4d2f3-b8c2-46a1-9223-7df272b1860b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance_490c561b-394e-49c1-834f-3082ff605249_terseLabel_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quality assurance</link:label>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance_label_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Quality Assurance</link:label>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance_documentation_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Quality Assurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:href="bhc-20220331.xsd#bhc_ResearchAndDevelopmentExpenseQualityAssurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:to="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_cd5ad83a-7e90-43b8-970f-2dd90866dcd2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_efa91b5b-10bc-42b2-894d-93665295f959_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_c2cda4e3-3aae-464b-a78c-9ba421c13bc8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrecurring adjustment</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Nonrecurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_ba2472d8-7059-4e1a-9ca0-1122e1c0a639_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated goodwill impairment charges</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_60e78bad-712f-4ce4-ae37-57fe6469c14f_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefit, amount possible to decrease in next twelve months</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9d9bc2a8-9936-44b9-97ba-385d37e7f0b0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2ca74bdc-8041-4c3b-b93b-9f48dde87dd6_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_65018767-31dd-45c2-813f-7b057e038ff5_totalLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_a3289638-5a0b-4f4f-8762-9824b42f92a3_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_646c7e07-9cf2-4ff1-a2c0-bcca9b27ca8c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INTANGIBLE ASSETS AND GOODWILL</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes725DueMay2029Member_2c881c8f-3197-4fff-829c-cd5624e97bb6_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes725DueMay2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.25 % Senior Notes Due May 2029</link:label>
    <link:label id="lab_bhc_SeniorNotes725DueMay2029Member_label_en-US" xlink:label="lab_bhc_SeniorNotes725DueMay2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 7.25%, Due May 2029 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes725DueMay2029Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes725DueMay2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes 7.25 Percent Due May 2029 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes725DueMay2029Member" xlink:href="bhc-20220331.xsd#bhc_SeniorNotes725DueMay2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes725DueMay2029Member" xlink:to="lab_bhc_SeniorNotes725DueMay2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember_124bfdf0-66a6-458f-8611-1b3d4124fa97_terseLabel_en-US" xlink:label="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash And Other Settlement Deposits, Current</link:label>
    <link:label id="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember_label_en-US" xlink:label="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash And Other Settlement Deposits, Current [Member]</link:label>
    <link:label id="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember_documentation_en-US" xlink:label="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash And Other Settlement Deposits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember" xlink:href="bhc-20220331.xsd#bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember" xlink:to="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_e7ca77b1-ab3b-49b3-85a4-43894d278f07_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate brands</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_b925246d-a221-44c2-af85-81b7d6b5b516_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_df8440af-e3f2-40b7-bd46-49e866b91f04_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">B+L IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_770f7bdf-c3f2-4be8-acfe-de86a2701656_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2754c760-289a-4900-8b0d-a23f90e0d6f7_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_bde92ff9-304e-4ec9-90d1-d18d31debdb1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CN_662d0169-2a6d-405d-828c-cb0a35feccee_terseLabel_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">China</link:label>
    <link:label id="lab_country_CN_label_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CN" xlink:to="lab_country_CN" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2228b73d-06d1-4213-9889-aac74486a2a5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_857e11fd-eb9b-4f17-bd85-fad1bc4ce5db_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b6054ef1-46d6-4484-b23d-a145eed799da_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of contingent payment obligations measured on a recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_6065ebd8-30c2-40db-9315-22a22f004671_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of prior service credit and other</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_c4dc0881-d719-43f6-bef6-1a53d142e86a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, contingent consideration obligations, discount rate</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_f1a33ede-80ab-40e3-a8e8-48944fd5f95c_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Notes</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_fa55fa33-0f13-497e-a5a6-26f58e7b5d4a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_3ea3b1cb-0ee7-4aea-8363-976ee384de8a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchased principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchased Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_country_DE_9eef98da-d39b-4ad3-90d5-a39ba5f8966f_terseLabel_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Germany</link:label>
    <link:label id="lab_country_DE_label_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GERMANY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_DE"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_DE" xlink:to="lab_country_DE" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod_002b5a39-1072-41ee-a8f9-058381aadff3_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stay of approval, motion to extend, period</link:label>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod_label_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Stay Of Approval, Motion To Extend, Period</link:label>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod_documentation_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Stay Of Approval, Motion To Extend, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod" xlink:href="bhc-20220331.xsd#bhc_LossContingencyStayOfApprovalMotionToExtendPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod" xlink:to="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4f41d3f1-0cdf-4ba9-8492-d047c7bfb855_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_ce3e58f3-6a43-493b-9f2e-091fe148e889_terseLabel_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average interest rate</link:label>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Weighted Average Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_50e8920a-e1c4-4856-9aa4-f8730e3f6542_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit_46d81fb4-73b1-474a-8cae-275c1bed25a8_terseLabel_en-US" xlink:label="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit_label_en-US" xlink:label="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Noncash Expense (Benefit)</link:label>
    <link:label id="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit_documentation_en-US" xlink:label="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The noncash component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:href="bhc-20220331.xsd#bhc_DeferredIncomeTaxNoncashExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:to="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a43c63d1-49cc-4c53-b31e-938967a1b087_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_6c291bc8-734f-4e72-8c52-82639a96f5a2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RESEARCH AND DEVELOPMENT</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research, Development, and Computer Software Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_d4431a86-42a6-4342-baa0-dafe6da533b2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SOFRCDORAndEURIBORRatesMember_8fbd780d-e53f-46b9-a664-abfba8d8c06e_terseLabel_en-US" xlink:label="lab_bhc_SOFRCDORAndEURIBORRatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR, CDOR and EURIBOR Rates</link:label>
    <link:label id="lab_bhc_SOFRCDORAndEURIBORRatesMember_label_en-US" xlink:label="lab_bhc_SOFRCDORAndEURIBORRatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR, CDOR and EURIBOR Rates [Member]</link:label>
    <link:label id="lab_bhc_SOFRCDORAndEURIBORRatesMember_documentation_en-US" xlink:label="lab_bhc_SOFRCDORAndEURIBORRatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR, CDOR and EURIBOR Rates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SOFRCDORAndEURIBORRatesMember" xlink:href="bhc-20220331.xsd#bhc_SOFRCDORAndEURIBORRatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SOFRCDORAndEURIBORRatesMember" xlink:to="lab_bhc_SOFRCDORAndEURIBORRatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member_5fe3ec3c-a93e-49bd-be72-87c1145546c2_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.125% Senior Notes Due February 2027</link:label>
    <link:label id="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member_label_en-US" xlink:label="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 6.125% Notes Due February 2027 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 6.125% Notes Due February 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member" xlink:href="bhc-20220331.xsd#bhc_SeniorSecured6125NotesDueFebruary2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member" xlink:to="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_c9fba720-6654-4d91-853d-3e8e02d8650e_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining borrowings</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c313af70-a6c1-465e-983b-94a54090d7a6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components and classification of share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_2f0e1537-1e1a-415a-a2c9-77542d322011_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion included in Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_5e4be135-915d-4b65-8b2d-17ca30db12b9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic loss per share attributable to Bausch Health Companies Inc. (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForChargebacksMember_612a3f3d-3266-49d5-9a9b-8cf01c5186ef_terseLabel_en-US" xlink:label="lab_bhc_ReserveForChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks</link:label>
    <link:label id="lab_bhc_ReserveForChargebacksMember_label_en-US" xlink:label="lab_bhc_ReserveForChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Chargebacks [Member]</link:label>
    <link:label id="lab_bhc_ReserveForChargebacksMember_documentation_en-US" xlink:label="lab_bhc_ReserveForChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Chargebacks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForChargebacksMember" xlink:href="bhc-20220331.xsd#bhc_ReserveForChargebacksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForChargebacksMember" xlink:to="lab_bhc_ReserveForChargebacksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_83f6dc06-08c5-4aaa-937e-b01730f86fc7_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of lawsuits pending</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d1167742-0569-414f-b05d-d33826ed9968_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_NonemployeeDirectorMember_fccafd2e-66b7-439e-8a20-4a0f0573be19_terseLabel_en-US" xlink:label="lab_bhc_NonemployeeDirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-employee Director</link:label>
    <link:label id="lab_bhc_NonemployeeDirectorMember_label_en-US" xlink:label="lab_bhc_NonemployeeDirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonemployee Director [Member]</link:label>
    <link:label id="lab_bhc_NonemployeeDirectorMember_documentation_en-US" xlink:label="lab_bhc_NonemployeeDirectorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonemployee Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NonemployeeDirectorMember" xlink:href="bhc-20220331.xsd#bhc_NonemployeeDirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_NonemployeeDirectorMember" xlink:to="lab_bhc_NonemployeeDirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_1cdecb63-0c68-40fe-ad29-d32454fd7493_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUE RECOGNITION</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember_c65ef608-8b05-43e3-ae78-d0ccfe014e34_terseLabel_en-US" xlink:label="lab_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value adjustments due to changes in estimates of other future payments</link:label>
    <link:label id="lab_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember_label_en-US" xlink:label="lab_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustments, Changes In Estimates Of Other Future Payments [Member]</link:label>
    <link:label id="lab_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember_documentation_en-US" xlink:label="lab_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustments, Changes In Estimates Of Other Future Payments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember" xlink:href="bhc-20220331.xsd#bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember" xlink:to="lab_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_d6797a05-0b60-42c2-b4b8-b3ea323c1098_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_283e4acd-991b-4ac9-bdb6-bbaa6e9ebe61_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_70c80898-214d-4fb0-85b5-9cdb70b96510_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_18952dbd-bdf9-4030-af00-220309f330ab_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_9b994ebe-e9c1-417d-83dd-a188f254f9f2_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OtherLongTermDebtMember_bdc1a589-51c6-486a-8362-b0dc9f3abe24_terseLabel_en-US" xlink:label="lab_bhc_OtherLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_bhc_OtherLongTermDebtMember_label_en-US" xlink:label="lab_bhc_OtherLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Debt [Member]</link:label>
    <link:label id="lab_bhc_OtherLongTermDebtMember_documentation_en-US" xlink:label="lab_bhc_OtherLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents long-term debt obligations not elsewhere enumerated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherLongTermDebtMember" xlink:href="bhc-20220331.xsd#bhc_OtherLongTermDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OtherLongTermDebtMember" xlink:to="lab_bhc_OtherLongTermDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_7eb6a1ae-53a7-4677-a5c3-1ae1bd8b6173_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CA_880a50a7-5eda-41ef-bc69-4ec438de7870_terseLabel_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada</link:label>
    <link:label id="lab_country_CA_label_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CANADA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CA" xlink:to="lab_country_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_a9ef4252-93f7-4954-931e-7f820ea9fd42_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_8e77c120-c5fe-47ab-be58-bfa8f163d6c7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BauschLombMember_2c08dd4a-5042-4239-8e72-763b0adee4a6_terseLabel_en-US" xlink:label="lab_bhc_BauschLombMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch + Lomb</link:label>
    <link:label id="lab_bhc_BauschLombMember_a5c128f6-e71e-4b31-9683-5db0fc10036f_verboseLabel_en-US" xlink:label="lab_bhc_BauschLombMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch + Lomb</link:label>
    <link:label id="lab_bhc_BauschLombMember_label_en-US" xlink:label="lab_bhc_BauschLombMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch + Lomb [Member]</link:label>
    <link:label id="lab_bhc_BauschLombMember_documentation_en-US" xlink:label="lab_bhc_BauschLombMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch + Lomb</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember" xlink:href="bhc-20220331.xsd#bhc_BauschLombMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BauschLombMember" xlink:to="lab_bhc_BauschLombMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_f6ce13fb-8ec8-4c5a-a190-6f2e73bba901_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitDomain_e0dd9fb2-c25f-411e-b0eb-f40aa8c28209_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitDomain_label_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitDomain" xlink:to="lab_us-gaap_ReportingUnitDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_b77fa25f-21ea-4efa-b391-2ea3688cedfb_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_InternationalRxMember_06d57d4e-b29a-4e7e-8131-a09dee76e216_terseLabel_en-US" xlink:label="lab_bhc_InternationalRxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_bhc_InternationalRxMember_045c7524-f500-4a32-bbed-1e3a9c497df2_verboseLabel_en-US" xlink:label="lab_bhc_InternationalRxMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_bhc_InternationalRxMember_label_en-US" xlink:label="lab_bhc_InternationalRxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Rx [Member]</link:label>
    <link:label id="lab_bhc_InternationalRxMember_documentation_en-US" xlink:label="lab_bhc_InternationalRxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Rx</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember" xlink:href="bhc-20220331.xsd#bhc_InternationalRxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_InternationalRxMember" xlink:to="lab_bhc_InternationalRxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyNumberOfSeparateDefendants_29ffe29c-bdb3-40d7-8b13-5651625ef214_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyNumberOfSeparateDefendants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of separate defendants</link:label>
    <link:label id="lab_bhc_LossContingencyNumberOfSeparateDefendants_label_en-US" xlink:label="lab_bhc_LossContingencyNumberOfSeparateDefendants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Separate Defendants</link:label>
    <link:label id="lab_bhc_LossContingencyNumberOfSeparateDefendants_documentation_en-US" xlink:label="lab_bhc_LossContingencyNumberOfSeparateDefendants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Separate Defendants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfSeparateDefendants" xlink:href="bhc-20220331.xsd#bhc_LossContingencyNumberOfSeparateDefendants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyNumberOfSeparateDefendants" xlink:to="lab_bhc_LossContingencyNumberOfSeparateDefendants" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseProductRelated_f7395f5a-0b67-4f5b-bc17-6a4065940d67_terseLabel_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product related research and development</link:label>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseProductRelated_label_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Product Related</link:label>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseProductRelated_documentation_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Product Related</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:href="bhc-20220331.xsd#bhc_ResearchAndDevelopmentExpenseProductRelated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:to="lab_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecuredCreditFacilitiesMember_53373c44-451a-46b3-bad8-4545f89c0a24_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecuredCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facilities</link:label>
    <link:label id="lab_bhc_SeniorSecuredCreditFacilitiesMember_label_en-US" xlink:label="lab_bhc_SeniorSecuredCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facilities [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecuredCreditFacilitiesMember_documentation_en-US" xlink:label="lab_bhc_SeniorSecuredCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredCreditFacilitiesMember" xlink:href="bhc-20220331.xsd#bhc_SeniorSecuredCreditFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecuredCreditFacilitiesMember" xlink:to="lab_bhc_SeniorSecuredCreditFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_b470eeef-ca02-4570-9efb-16f99672d3c0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee withholding taxes related to share-based awards</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_92ecb7e0-bc25-4695-9bd3-4b2238cde494_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_35abaa92-8832-4c27-a996-3d272f473997_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_35ae8bb7-1f9c-411c-84f3-2ed1c751bd02_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember_f2273492-fd99-4b90-8531-2af7791ac51c_terseLabel_en-US" xlink:label="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued And Other Current Liabilities [Member]</link:label>
    <link:label id="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember_documentation_en-US" xlink:label="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued And Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedAndOtherCurrentLiabilitiesMember" xlink:href="bhc-20220331.xsd#bhc_AccruedAndOtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccruedAndOtherCurrentLiabilitiesMember" xlink:to="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_68980ce4-d060-4f4b-8c3b-7f26fa9e8670_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recoveries</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Recovery</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_81254eaf-b39b-463a-876d-8da8fd156c3f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_daa07665-bcd2-49c4-9862-7dfaf5cf398e_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_85a90d76-4bc0-461d-a296-00ed3569472e_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_7d8743f3-d1bc-44c5-91f0-38db743f745c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of revenue attributed to a geographic region</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_d89ae190-38dc-4dee-9b10-623aa7f28c89_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_1e019875-a488-435b-8798-ec235354351e_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt obligations</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_4b6fa7c4-871c-443f-a518-7431033354ab_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in the carrying amount of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_d0475efc-4f39-42d2-ab11-ac169d13d4db_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitAxis_24bfa35f-9fee-4973-840d-78b9308754aa_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitAxis_label_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitAxis" xlink:to="lab_us-gaap_ReportingUnitAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_f72dcfff-a1ba-4277-88db-a5f3077cff5d_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_62833e5b-23c4-4597-a988-1c9b3998e499_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_b1b4d142-e11d-4eab-9c0c-e3763ff8a2e7_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term debt and other</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_99045c39-5a85-463c-b2c7-be89fee4ef7b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_08c83e64-ef71-4096-b04f-799ffc89231d_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount drawn under credit facility</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate_dde80328-24d4-4ebd-8048-8c4a581fe069_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit spread adjustment (as a percent)</link:label>
    <link:label id="lab_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate_label_en-US" xlink:label="lab_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Credit Spread Adjustment on Variable Rate</link:label>
    <link:label id="lab_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Credit Spread Adjustment on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate" xlink:to="lab_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_d9862aa7-2070-4364-b673-560f994b5c78_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7f73b565-1d20-4b74-8e11-947c62bedc8d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_359c5b6f-b121-4836-88b4-363e4f4d1f87_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange loss</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_ccf0094f-6f0b-4101-a346-ef425ef256ca_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of groups of investors filing action, remain pending</link:label>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_label_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Plaintiffs, Number of Groups of Investors, Pending</link:label>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_documentation_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Plaintiffs, Number of Groups of Investors, Pending</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:href="bhc-20220331.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:to="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_a234fa43-bb9d-4c9a-841b-2f3a951ca320_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_bc3658fe-bd41-48cc-a95b-f041107d92dd_negatedLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_26e08519-6440-465a-9ca6-2a4f4c1d05e6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_84985345-adee-4c2d-9596-9524891d9f7a_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Smaller Reporting Company</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_19db607a-5894-4af4-928b-e70d053d3736_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CustomerTopTenProductsMember_d7413deb-e630-4d01-b68a-b035abd3a0d3_terseLabel_en-US" xlink:label="lab_bhc_CustomerTopTenProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer, Top Ten Products</link:label>
    <link:label id="lab_bhc_CustomerTopTenProductsMember_label_en-US" xlink:label="lab_bhc_CustomerTopTenProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer, Top Ten Products [Member]</link:label>
    <link:label id="lab_bhc_CustomerTopTenProductsMember_documentation_en-US" xlink:label="lab_bhc_CustomerTopTenProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer, Top Ten Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CustomerTopTenProductsMember" xlink:href="bhc-20220331.xsd#bhc_CustomerTopTenProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CustomerTopTenProductsMember" xlink:to="lab_bhc_CustomerTopTenProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_f480af86-6d4e-4c74-8ff1-3422c8c0d378_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate_b45b451d-6a11-490b-b2a3-ea01d6ac8398_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental borrowings interest rate</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility Threshold For Incremental Borrowings Interest Rate</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility Threshold For Incremental Borrowings Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate" xlink:href="bhc-20220331.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate" xlink:to="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_591f0091-0f90-45a5-a1a0-669cb0c92410_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PendingLitigationMember_19045a21-5ad0-4346-8cae-2ec802227c1e_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember" xlink:to="lab_us-gaap_PendingLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_4584a5b0-5e0e-41a7-ab25-ca2a7453634a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_23c151e3-bf0e-4dfe-8e47-91400acdd4fe_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax provision (benefit) related to stock compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_947d18bc-3fe0-4455-a032-5e7ed3d6b821_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion of unrecognized tax benefits, if recognized, would reduce the Company's effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_e80b4fc7-f361-4f6e-bbbf-25bbdd23d942_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_c88e96d3-9bde-4ce3-8b28-b5874adc2a72_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_6a89afc7-4761-492f-98b5-c9884ba99875_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LOSS PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_cd4c072f-6ceb-4869-9ef9-9d551827efb2_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignPlanMember_f9bdf6d1-c560-48f5-818b-997e7de79b5e_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-U.S. Plans</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember" xlink:to="lab_us-gaap_ForeignPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_35333ee7-b370-4886-af8d-84b667123b23_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_51ee460c-017e-44be-984d-aa27ddb35957_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_eeb6c4a8-1867-4d29-95a0-4c71c3fc4a90_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of cash proceeds from incurrence of debt</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Percentage of Net Proceeds from Incurrence of Debt Payable as Mandatory Pre-payments</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of net cash proceeds from the incurrence of debt payable as mandatory prepayments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" xlink:href="bhc-20220331.xsd#bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" xlink:to="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_816e8131-a469-49b5-ada8-fc1f9dd249c4_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6bed2f0b-615b-4d41-bd9b-c4a0694993bf_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_96864e3b-9633-4892-8f64-ee7da105a8e6_terseLabel_en-US" xlink:label="lab_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived and Indefinite Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_documentation_en-US" xlink:label="lab_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:href="bhc-20220331.xsd#bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:to="lab_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_4c1a62e7-d087-4465-af7a-21d282d3a215_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes625DueFebruary2029Member_b8d964d8-ec66-4cb2-91a3-c9b5ecb92e25_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes625DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.25% Senior Notes Due February 2029</link:label>
    <link:label id="lab_bhc_SeniorNotes625DueFebruary2029Member_label_en-US" xlink:label="lab_bhc_SeniorNotes625DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 6.25%, Due February 2029 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes625DueFebruary2029Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes625DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 6.25%, Due February 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes625DueFebruary2029Member" xlink:href="bhc-20220331.xsd#bhc_SeniorNotes625DueFebruary2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes625DueFebruary2029Member" xlink:to="lab_bhc_SeniorNotes625DueFebruary2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_4d94e746-eb3d-4160-b3f3-30c8e66084ff_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_455c2435-9826-46d0-94b9-4bfed2d71d25_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_2a9bc23c-dcf1-4728-8443-65d36d402137_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_de959a18-98da-4519-ae56-4f018d60c67d_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation and IPO-related costs included in selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6fe935ce-581b-4b11-b36d-37712a0d0a04_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_87fbc0b5-03da-46e7-9e69-f22bcbb2e6c8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_395d186e-c962-47b8-9a32-34df50e82a08_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts_46d64cf2-62a4-414e-af84-0e3ae7f17cff_terseLabel_en-US" xlink:label="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, integration, separation and IPO costs</link:label>
    <link:label id="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts_6c97599b-1679-4065-ab4f-3542376b7080_negatedTerseLabel_en-US" xlink:label="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, integration, separation and IPO costs</link:label>
    <link:label id="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts_label_en-US" xlink:label="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges And Initial Public Offering Costs</link:label>
    <link:label id="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts_documentation_en-US" xlink:label="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges And Initial Public Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:href="bhc-20220331.xsd#bhc_RestructuringChargesAndInitialPublicOfferingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:to="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_country_FR_13a1a6e8-6961-4c2f-a084-713737716b55_terseLabel_en-US" xlink:label="lab_country_FR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">France</link:label>
    <link:label id="lab_country_FR_label_en-US" xlink:label="lab_country_FR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FRANCE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_FR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_FR" xlink:to="lab_country_FR" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_870f4a71-7350-47b6-8973-b5bbbbe981aa_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DerivativeGainExcludedComponent_2f4aae39-ebe6-4369-88e4-2db741b8a68c_negatedTerseLabel_en-US" xlink:label="lab_bhc_DerivativeGainExcludedComponent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain excluded from hedge effectiveness</link:label>
    <link:label id="lab_bhc_DerivativeGainExcludedComponent_label_en-US" xlink:label="lab_bhc_DerivativeGainExcludedComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain, Excluded Component</link:label>
    <link:label id="lab_bhc_DerivativeGainExcludedComponent_documentation_en-US" xlink:label="lab_bhc_DerivativeGainExcludedComponent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain, Excluded Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DerivativeGainExcludedComponent" xlink:href="bhc-20220331.xsd#bhc_DerivativeGainExcludedComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DerivativeGainExcludedComponent" xlink:to="lab_bhc_DerivativeGainExcludedComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccruedProductReturnCurrent_a90f687c-730a-4cc0-9900-4a5df377e03e_terseLabel_en-US" xlink:label="lab_bhc_AccruedProductReturnCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product returns</link:label>
    <link:label id="lab_bhc_AccruedProductReturnCurrent_label_en-US" xlink:label="lab_bhc_AccruedProductReturnCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Product Return Current</link:label>
    <link:label id="lab_bhc_AccruedProductReturnCurrent_documentation_en-US" xlink:label="lab_bhc_AccruedProductReturnCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for product returns. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductReturnCurrent" xlink:href="bhc-20220331.xsd#bhc_AccruedProductReturnCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccruedProductReturnCurrent" xlink:to="lab_bhc_AccruedProductReturnCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_2b204d37-af1e-40b8-b0e4-0b79f8bbdd36_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_ce90ea67-a476-44c5-82a8-b59f2523652c_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities associated with restructuring, integration and separation costs</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_5767ab5d-18f2-460d-803f-b0490979120b_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages sought</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_5acb2d94-7461-4c17-b858-62add3090323_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of suits filed but not yet served</link:label>
    <link:label id="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_label_en-US" xlink:label="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency New Claims Filed But Not Yet Served Number</link:label>
    <link:label id="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_documentation_en-US" xlink:label="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency New Claims Filed But Not Yet Served Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:href="bhc-20220331.xsd#bhc_LossContingencyNewClaimsFiledButNotYetServedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:to="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_6afc1ce3-ddef-4b23-8347-72a5d952a095_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation and benefit costs</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_ef0c85f2-37a5-4e22-b479-1617510aedf2_terseLabel_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting unit, impairment test, long-term growth rate</link:label>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_label_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Impairment Test, Long-Term Growth Rate</link:label>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_documentation_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Impairment Test, Long-Term Growth Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:href="bhc-20220331.xsd#bhc_ReportingUnitImpairmentTestLongTermGrowthRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:to="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_d842c408-247d-4a4b-b827-c48d68adf274_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_country_GB_da231a55-07d8-493a-87b1-3d7ab9d8f999_terseLabel_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom</link:label>
    <link:label id="lab_country_GB_label_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED KINGDOM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_GB"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_GB" xlink:to="lab_country_GB" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_21b3f686-47f0-4a23-ae68-15119762bfc6_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_6855585a-0822-48d7-a24a-83c890f52105_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_45293f16-8d21-4daa-8678-afaa42f7e59c_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of net cash proceeds of insurance and condemnation proceeds for property or asset losses</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Percentage of Net Cash Proceeds of Insurance and Condemnation Proceeds from Property or Asset Losses Payable as Mandatory Prepayments</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of net cash proceeds of insurance and condemnation proceeds for property or asset (losses) which is payable as mandatory prepayment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" xlink:href="bhc-20220331.xsd#bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" xlink:to="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_61db5330-ed8d-4717-b9be-d8dac76221e0_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_525e7d26-3573-4dd0-8885-7c18c1e85cf7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FINANCING ARRANGEMENTS</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SaleOfStockOverAllotmentTerm_2a53aa98-f95e-45c0-8163-ab76ba225580_terseLabel_en-US" xlink:label="lab_bhc_SaleOfStockOverAllotmentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriters option to purchase additional shares, term</link:label>
    <link:label id="lab_bhc_SaleOfStockOverAllotmentTerm_label_en-US" xlink:label="lab_bhc_SaleOfStockOverAllotmentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Over-Allotment, Term</link:label>
    <link:label id="lab_bhc_SaleOfStockOverAllotmentTerm_documentation_en-US" xlink:label="lab_bhc_SaleOfStockOverAllotmentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Over-Allotment, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SaleOfStockOverAllotmentTerm" xlink:href="bhc-20220331.xsd#bhc_SaleOfStockOverAllotmentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SaleOfStockOverAllotmentTerm" xlink:to="lab_bhc_SaleOfStockOverAllotmentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForDistributionFeesMember_0af79ede-bce0-4f65-8418-cd5bbd341424_terseLabel_en-US" xlink:label="lab_bhc_ReserveForDistributionFeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution Fees</link:label>
    <link:label id="lab_bhc_ReserveForDistributionFeesMember_label_en-US" xlink:label="lab_bhc_ReserveForDistributionFeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Distribution Fees [Member]</link:label>
    <link:label id="lab_bhc_ReserveForDistributionFeesMember_documentation_en-US" xlink:label="lab_bhc_ReserveForDistributionFeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Distribution Fees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDistributionFeesMember" xlink:href="bhc-20220331.xsd#bhc_ReserveForDistributionFeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForDistributionFeesMember" xlink:to="lab_bhc_ReserveForDistributionFeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c1733af0-c73e-41e8-976c-ad7b96c8991d_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHARE-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_c86b7134-9ed2-4c9e-b303-17c85ee907fd_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured leverage ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Secured Leverage Ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Secured Leverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio" xlink:to="lab_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_e407e113-0a1f-4853-9553-c5105e1c555b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_0d5621cd-7ffa-4522-b38c-2e75aca8e4d9_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVENTORIES</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_85b20032-4069-4642-bc19-39eb290b56ce_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits related to interest and penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_52797b5c-ef0f-4a20-8b97-56e12484f3a8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_country_ES_d3ddab36-6abd-4408-afb2-206c0031d269_terseLabel_en-US" xlink:label="lab_country_ES" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spain</link:label>
    <link:label id="lab_country_ES_label_en-US" xlink:label="lab_country_ES" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPAIN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_ES" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_ES"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_ES" xlink:to="lab_country_ES" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_ad07473c-a987-40e3-a046-d3b7ef5c84e4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OvertheCounterProductsMember_bb07dfc5-5f7e-4d95-8ab7-6fe8faa35939_terseLabel_en-US" xlink:label="lab_bhc_OvertheCounterProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTC</link:label>
    <link:label id="lab_bhc_OvertheCounterProductsMember_label_en-US" xlink:label="lab_bhc_OvertheCounterProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over the Counter Products [Member]</link:label>
    <link:label id="lab_bhc_OvertheCounterProductsMember_documentation_en-US" xlink:label="lab_bhc_OvertheCounterProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over the Counter Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OvertheCounterProductsMember" xlink:href="bhc-20220331.xsd#bhc_OvertheCounterProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OvertheCounterProductsMember" xlink:to="lab_bhc_OvertheCounterProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_92be516f-03c4-437d-973a-94a8bf20cecf_terseLabel_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits including interest and penalties</link:label>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_label_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Including Interest and Penalties</link:label>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_documentation_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The gross amount of unrecognized tax benefits including interest and penalties pertaining to uncertain tax positions taken in tax returns as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:href="bhc-20220331.xsd#bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:to="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_c32f512a-1a52-453f-9748-cf14ebb07f9a_terseLabel_en-US" xlink:label="lab_bhc_ScheduleOfOtherIncomeAndExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Income And Expenses [Line Items]</link:label>
    <link:label id="lab_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_label_en-US" xlink:label="lab_bhc_ScheduleOfOtherIncomeAndExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Income And Expenses [Line Items]</link:label>
    <link:label id="lab_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_documentation_en-US" xlink:label="lab_bhc_ScheduleOfOtherIncomeAndExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Schedule Of Other Income And Expenses [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems" xlink:href="bhc-20220331.xsd#bhc_ScheduleOfOtherIncomeAndExpensesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems" xlink:to="lab_bhc_ScheduleOfOtherIncomeAndExpensesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_751dbffa-6128-4c61-a7cb-5b1c5f90629e_terseLabel_en-US" xlink:label="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TSR performance-based RSUs</link:label>
    <link:label id="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TSR Performance-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TSR Performance-Based Restricted Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:href="bhc-20220331.xsd#bhc_TSRPerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_a6d2ac7a-2d26-415f-848d-5ce95d1511a7_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_a1c1adbd-acec-4b3d-8d75-a4cca261e75b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of revenues by segment and product category</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_4485f1b8-33d8-4b06-8a31-4885633734e9_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_1c77d99c-5554-4bcd-a7b2-33355daeea45_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange and other</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_d43efd8d-798c-4747-b151-592c449d63f3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, no par value, unlimited shares authorized, 361,331,665 and 359,405,748 issued and outstanding at March 31, 2022 and December&#160;31, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_e73f2797-33c6-4819-8704-69fc980e3ba6_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AmounPharmaceuticalCompanySAEMember_853fb110-807d-4263-b811-d5a1b5e1ff00_terseLabel_en-US" xlink:label="lab_bhc_AmounPharmaceuticalCompanySAEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amoun</link:label>
    <link:label id="lab_bhc_AmounPharmaceuticalCompanySAEMember_label_en-US" xlink:label="lab_bhc_AmounPharmaceuticalCompanySAEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amoun Pharmaceutical Company S.A.E [Member]</link:label>
    <link:label id="lab_bhc_AmounPharmaceuticalCompanySAEMember_documentation_en-US" xlink:label="lab_bhc_AmounPharmaceuticalCompanySAEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amoun Pharmaceutical Company S.A.E</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmounPharmaceuticalCompanySAEMember" xlink:href="bhc-20220331.xsd#bhc_AmounPharmaceuticalCompanySAEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AmounPharmaceuticalCompanySAEMember" xlink:to="lab_bhc_AmounPharmaceuticalCompanySAEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5e1e54ba-1f71-465c-84a0-305db16d0154_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average service period over which compensation cost is expected to be recognized (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_e13fe9a4-2af1-4937-9d6d-30d2878f3429_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A2027RevolvingCreditFacilityMember_64b02e36-ec62-4763-9c6e-21192e63d423_terseLabel_en-US" xlink:label="lab_bhc_A2027RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027 Revolving Credit Facility</link:label>
    <link:label id="lab_bhc_A2027RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_bhc_A2027RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027 Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_bhc_A2027RevolvingCreditFacilityMember_documentation_en-US" xlink:label="lab_bhc_A2027RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027 Revolving Credit Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A2027RevolvingCreditFacilityMember" xlink:href="bhc-20220331.xsd#bhc_A2027RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A2027RevolvingCreditFacilityMember" xlink:to="lab_bhc_A2027RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_4817fd79-0f2e-4096-914d-ee7d90950670_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_1e67915e-a2d4-4934-a62c-72808c1d7511_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postretirement Benefit Plan</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_907f6ae7-6d0d-43fb-bfb0-25b5e04bae7c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 18)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualRightsMember_2bab8646-20b0-488f-9700-ccf5e300615e_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product rights/patents</link:label>
    <link:label id="lab_us-gaap_ContractualRightsMember_label_en-US" xlink:label="lab_us-gaap_ContractualRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualRightsMember" xlink:to="lab_us-gaap_ContractualRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_7f71393b-ac0d-48b4-b324-8207ff5f339d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_Legalsettlementsandrelatedfees_2f5b9863-6e27-401a-bc85-a0d553ab535c_terseLabel_en-US" xlink:label="lab_bhc_Legalsettlementsandrelatedfees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal matters and related fees</link:label>
    <link:label id="lab_bhc_Legalsettlementsandrelatedfees_label_en-US" xlink:label="lab_bhc_Legalsettlementsandrelatedfees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal settlements and related fees</link:label>
    <link:label id="lab_bhc_Legalsettlementsandrelatedfees_documentation_en-US" xlink:label="lab_bhc_Legalsettlementsandrelatedfees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal settlements and related fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_Legalsettlementsandrelatedfees" xlink:href="bhc-20220331.xsd#bhc_Legalsettlementsandrelatedfees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_Legalsettlementsandrelatedfees" xlink:to="lab_bhc_Legalsettlementsandrelatedfees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_8d76be3d-35c3-4a88-8c8e-d3a553e8e816_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of assets and businesses, net of costs to sell</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses, Net of Cash Divested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5765ef58-dd03-448b-b45f-de1512301a7a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_976d5639-9368-42e1-8fff-129ca7405dfe_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_d7b7f3a5-9091-42b0-b683-21be2e278203_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternate term, number of days prior to scheduled maturity in excess of principal amount threshold</link:label>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_label_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold</link:label>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:to="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ProposedBusinessSeparationAndInitialPublicOfferingNumberOfCompaniesEstablished_39909612-e389-438c-bda3-65402e42bdaa_terseLabel_en-US" xlink:label="lab_bhc_ProposedBusinessSeparationAndInitialPublicOfferingNumberOfCompaniesEstablished" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proposed business separation and initial public offering, number of companies established</link:label>
    <link:label id="lab_bhc_ProposedBusinessSeparationAndInitialPublicOfferingNumberOfCompaniesEstablished_label_en-US" xlink:label="lab_bhc_ProposedBusinessSeparationAndInitialPublicOfferingNumberOfCompaniesEstablished" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proposed Business Separation And Initial Public Offering, Number Of Companies Established</link:label>
    <link:label id="lab_bhc_ProposedBusinessSeparationAndInitialPublicOfferingNumberOfCompaniesEstablished_documentation_en-US" xlink:label="lab_bhc_ProposedBusinessSeparationAndInitialPublicOfferingNumberOfCompaniesEstablished" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proposed Business Separation And Initial Public Offering, Number Of Companies Established</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProposedBusinessSeparationAndInitialPublicOfferingNumberOfCompaniesEstablished" xlink:href="bhc-20220331.xsd#bhc_ProposedBusinessSeparationAndInitialPublicOfferingNumberOfCompaniesEstablished"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ProposedBusinessSeparationAndInitialPublicOfferingNumberOfCompaniesEstablished" xlink:to="lab_bhc_ProposedBusinessSeparationAndInitialPublicOfferingNumberOfCompaniesEstablished" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_39dd16dd-8cc5-47d5-9f88-746ccfda087b_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of financing costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_74623091-098a-44e5-ada6-2981b22cbcc4_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_6dda4158-a9ad-48bb-a5f4-3ef306957a76_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of share-based awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_1dca4282-7953-4bbf-9f4c-ce563f59b02a_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_eab8fab8-e7a0-40c3-98a9-f120f6cd3762_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_56c7b730-c20f-4fda-92fd-ebe172e037cb_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_caaaab95-2ead-46ec-b0ba-0d8a5136b130_terseLabel_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting unit, impairment test, estimated cash flows, discount rate</link:label>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_label_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate</link:label>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_documentation_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:href="bhc-20220331.xsd#bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:to="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_58e5cd2c-0bab-4173-91bd-04b849300676_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c590907c-ab59-46d4-a2e9-a6ee256f562b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_1df11c04-5edd-4b35-aba7-03eeb114b609_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_aff2db69-6800-47b8-966c-20eb22bd245c_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod_00dcefd3-86a4-4e0c-a572-2bf9eaaa7e3b_terseLabel_en-US" xlink:label="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Highly liquid investments, maturity period (or less)</link:label>
    <link:label id="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod_label_en-US" xlink:label="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Highly Liquid Investments, Maturity Period</link:label>
    <link:label id="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod_documentation_en-US" xlink:label="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Highly Liquid Investments, Maturity Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:href="bhc-20220331.xsd#bhc_HighlyLiquidInvestmentsMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:to="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_1704989d-eda7-40a3-a308-05bbce9f74ac_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_1cd0df33-992c-406a-bc3d-802243533d14_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of annual excess cash flow</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Percentage of Consolidated Excess Cash Flow Payable as Mandatory Prepayments</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of annual excess cash flow with any excess amounts after the prepayment of the loans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" xlink:href="bhc-20220331.xsd#bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" xlink:to="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_74df616c-cc88-47e9-a3d3-9bb97093117c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RICOClassActionsMember_92d4c5a9-7984-4d29-80ec-67447df9e38e_terseLabel_en-US" xlink:label="lab_bhc_RICOClassActionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RICO Class Actions</link:label>
    <link:label id="lab_bhc_RICOClassActionsMember_label_en-US" xlink:label="lab_bhc_RICOClassActionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RICO Class Actions [Member]</link:label>
    <link:label id="lab_bhc_RICOClassActionsMember_documentation_en-US" xlink:label="lab_bhc_RICOClassActionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RICO Class Actions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RICOClassActionsMember" xlink:href="bhc-20220331.xsd#bhc_RICOClassActionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RICOClassActionsMember" xlink:to="lab_bhc_RICOClassActionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_dd43a0f2-1140-4672-983d-95d5c29c4399_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold, net proceeds</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember_71740b93-1161-4d64-bcbf-cb82b9b9aa6a_terseLabel_en-US" xlink:label="lab_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Perrigo Israel Pharmaceuticals, Ltd. Litigation</link:label>
    <link:label id="lab_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember_label_en-US" xlink:label="lab_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Perrigo Israel Pharmaceuticals, Ltd. Litigation [Member]</link:label>
    <link:label id="lab_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember_documentation_en-US" xlink:label="lab_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Perrigo Israel Pharmaceuticals, Ltd. Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember" xlink:href="bhc-20220331.xsd#bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember" xlink:to="lab_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther_827426de-76c5-46c8-b77d-2d305769343f_negatedTerseLabel_en-US" xlink:label="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange and other</link:label>
    <link:label id="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther_label_en-US" xlink:label="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance For Foreign Exchange And Other</link:label>
    <link:label id="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther_documentation_en-US" xlink:label="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance For Foreign Exchange And Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:href="bhc-20220331.xsd#bhc_AccountsReceivableAllowanceForForeignExchangeAndOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:to="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_0ba38212-786b-49a2-888d-a8491a5e0c29_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured leverage ratio (not greater than)</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Secured Leverage Ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Secured Leverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" xlink:to="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet_c002f4c9-8cb5-4a9e-b339-e460c2f69801_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt covenant, mandatory prepayments, percentage net cash proceeds, incurrence of debt</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Mandatory Prepayments, Percentage Net Cash Proceeds, Incurrence Of Debt, If Circumstances Met</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Mandatory Prepayments, Percentage Net Cash Proceeds, Incurrence Of Debt, If Circumstances Met</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet" xlink:to="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f1f20fb4-cb06-4f07-a95f-0b6d1b209d86_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_0861a426-682d-45f5-8caf-b93e7a22d540_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ba76c2f8-f927-4fbd-9631-aa717eda8851_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_52e6e38d-dbc0-4abc-b707-e66de672ccc8_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_bf06a8eb-f816-493b-85c0-7df0eecd9956_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_45bbece7-fd6c-4c18-84dc-f4f79593eac6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_88df2d50-f52a-41a6-b37c-bbf061571fc9_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price appreciation credits</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForCustomerReturnsMember_98869b4d-f5fe-4a95-ac25-b227a02ff7ed_terseLabel_en-US" xlink:label="lab_bhc_ReserveForCustomerReturnsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns</link:label>
    <link:label id="lab_bhc_ReserveForCustomerReturnsMember_label_en-US" xlink:label="lab_bhc_ReserveForCustomerReturnsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Customer Returns [Member]</link:label>
    <link:label id="lab_bhc_ReserveForCustomerReturnsMember_documentation_en-US" xlink:label="lab_bhc_ReserveForCustomerReturnsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Customer Returns [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForCustomerReturnsMember" xlink:href="bhc-20220331.xsd#bhc_ReserveForCustomerReturnsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForCustomerReturnsMember" xlink:to="lab_bhc_ReserveForCustomerReturnsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount_44cee631-8df2-409c-ae44-18463fab6f0f_terseLabel_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision related to filing certain tax returns</link:label>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount_label_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Expense Filing Tax Returns, Amount</link:label>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount_documentation_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Expense Filing Tax Returns, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" xlink:href="bhc-20220331.xsd#bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" xlink:to="lab_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_630779d4-74d0-4a99-84df-f14614e4d1bf_terseLabel_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Litigation, Non-Class Complaints</link:label>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_label_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Litigation, Non-Class Complaints [Member]</link:label>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_documentation_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Litigation, Non-Class Complaints [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:href="bhc-20220331.xsd#bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:to="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_7949a9d6-1592-4e5c-a702-8cbd1ef4e982_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BrandedandOtherGenericProductsMember_e2d21b3a-1bd4-44c5-b588-32ca7e8dbe1e_terseLabel_en-US" xlink:label="lab_bhc_BrandedandOtherGenericProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Branded and Other Generics</link:label>
    <link:label id="lab_bhc_BrandedandOtherGenericProductsMember_label_en-US" xlink:label="lab_bhc_BrandedandOtherGenericProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Branded and Other Generic Products [Member]</link:label>
    <link:label id="lab_bhc_BrandedandOtherGenericProductsMember_documentation_en-US" xlink:label="lab_bhc_BrandedandOtherGenericProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Branded and Other Generic Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BrandedandOtherGenericProductsMember" xlink:href="bhc-20220331.xsd#bhc_BrandedandOtherGenericProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BrandedandOtherGenericProductsMember" xlink:to="lab_bhc_BrandedandOtherGenericProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_cd2780dc-443b-4390-a603-0a6708488e81_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_ae94cb9d-009a-4b6b-bfb5-c2ff944aaec0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_4d89500c-73c6-4409-a13c-1e1e1096e726_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_f8223788-596b-444a-9c6c-8abf42fb92e7_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_f6d168ba-c18e-4462-b2cf-ba9a68ad19c0_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_2e441b7b-c882-47c4-bf18-2525a3ed7b1c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain recognized in Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_3070b4b9-ca31-46f1-a80f-c1239409f506_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_53487530-cb6e-4866-be6e-38df35180036_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_MilestonePaymentRelatedToCertainProductMember_6cb815b1-9ebb-490b-a729-521344a57781_terseLabel_en-US" xlink:label="lab_bhc_MilestonePaymentRelatedToCertainProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Related To Certain Product</link:label>
    <link:label id="lab_bhc_MilestonePaymentRelatedToCertainProductMember_label_en-US" xlink:label="lab_bhc_MilestonePaymentRelatedToCertainProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Related To Certain Product [Member]</link:label>
    <link:label id="lab_bhc_MilestonePaymentRelatedToCertainProductMember_documentation_en-US" xlink:label="lab_bhc_MilestonePaymentRelatedToCertainProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Related To Certain Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MilestonePaymentRelatedToCertainProductMember" xlink:href="bhc-20220331.xsd#bhc_MilestonePaymentRelatedToCertainProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_MilestonePaymentRelatedToCertainProductMember" xlink:to="lab_bhc_MilestonePaymentRelatedToCertainProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_d29f3117-7030-4bcc-8c37-bae6174dd582_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_2f48a802-189d-47e4-8a2a-dc6c0faf64c1_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEGMENT INFORMATION</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_ac9c3396-2729-4a60-8c3e-1663e6616e4d_terseLabel_en-US" xlink:label="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROTC performance-based RSUs</link:label>
    <link:label id="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROTC Performance-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROTC Performance-Based Restricted Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" xlink:href="bhc-20220331.xsd#bhc_ROTCPerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_fdaf621a-3a85-4a5b-abdc-039d2c7e8d9d_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_ccc1518e-eb63-4742-9433-10758e2e9f98_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes525DueJanuary2030Member_92edd922-fefd-4d17-bcf8-b64ee6ed0975_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes525DueJanuary2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.25% Senior Notes Due January 2030</link:label>
    <link:label id="lab_bhc_SeniorNotes525DueJanuary2030Member_label_en-US" xlink:label="lab_bhc_SeniorNotes525DueJanuary2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.25%, Due January 2030 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes525DueJanuary2030Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes525DueJanuary2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.25% Senior Notes Due January 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueJanuary2030Member" xlink:href="bhc-20220331.xsd#bhc_SeniorNotes525DueJanuary2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes525DueJanuary2030Member" xlink:to="lab_bhc_SeniorNotes525DueJanuary2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes700DueMarch2024Member_65ecd604-1fb4-49b7-a6de-7ae53eb0f89d_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes700DueMarch2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.00% Senior Notes, Due March 2024</link:label>
    <link:label id="lab_bhc_SeniorNotes700DueMarch2024Member_label_en-US" xlink:label="lab_bhc_SeniorNotes700DueMarch2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 7.00%, Due March 2024 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes700DueMarch2024Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes700DueMarch2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 7.00%, Due March 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueMarch2024Member" xlink:href="bhc-20220331.xsd#bhc_SeniorNotes700DueMarch2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes700DueMarch2024Member" xlink:to="lab_bhc_SeniorNotes700DueMarch2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_e1f7fbfa-01df-4998-8be7-4a2fc16242c6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RestructuringAndIntegrationCostsMember_37970676-34b8-454b-97e7-a3dd4f8e744f_terseLabel_en-US" xlink:label="lab_bhc_RestructuringAndIntegrationCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Integration Costs</link:label>
    <link:label id="lab_bhc_RestructuringAndIntegrationCostsMember_label_en-US" xlink:label="lab_bhc_RestructuringAndIntegrationCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Integration Costs [Member]</link:label>
    <link:label id="lab_bhc_RestructuringAndIntegrationCostsMember_documentation_en-US" xlink:label="lab_bhc_RestructuringAndIntegrationCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Integration Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringAndIntegrationCostsMember" xlink:href="bhc-20220331.xsd#bhc_RestructuringAndIntegrationCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RestructuringAndIntegrationCostsMember" xlink:to="lab_bhc_RestructuringAndIntegrationCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_833ae108-8e36-4484-b297-cfe1c993473b_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a0bbfe68-c15f-4684-8fa4-1a1a53809272_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_e24eed6a-0d6c-4950-b551-c92feb2c2e7b_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_2328cfb7-fc22-4479-8af8-fa0a40e1e975_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_b58d2c4b-e915-4779-a1d8-58d324e1b3d2_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_87f9ab00-2e36-46d8-af1f-81440f9af75d_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0d262e2a-05e1-4256-802a-e8e84e1ebf43_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments_58c3c682-002f-4e30-934a-9992af345981_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount available for restricted payments</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Amount Available For Restricted Payments</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Amount Available For Restricted Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments" xlink:to="lab_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_2a5d01f2-bc7b-46a2-b286-99fcc81cdf64_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate amount to be received</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded from Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PerformanceBasedRestrictedStockUnitsMember_d61fb52a-a9fc-4982-915f-3248c0223a0c_terseLabel_en-US" xlink:label="lab_bhc_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Restricted Stock Units</link:label>
    <link:label id="lab_bhc_PerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_bhc_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_bhc_PerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_bhc_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerformanceBasedRestrictedStockUnitsMember" xlink:href="bhc-20220331.xsd#bhc_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_bhc_PerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_a9bf9044-f43a-4e9f-8589-b5969758e189_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_InterestSettlementOnCrossCurrencySwaps_11cf82c4-b7b7-4eda-8dc9-0383e79e6e00_terseLabel_en-US" xlink:label="lab_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest settlements from cross-currency swaps</link:label>
    <link:label id="lab_bhc_InterestSettlementOnCrossCurrencySwaps_label_en-US" xlink:label="lab_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Settlement On Cross-Currency Swaps</link:label>
    <link:label id="lab_bhc_InterestSettlementOnCrossCurrencySwaps_documentation_en-US" xlink:label="lab_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Settlement On Cross-Currency Swaps</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:href="bhc-20220331.xsd#bhc_InterestSettlementOnCrossCurrencySwaps"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:to="lab_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_197c2f0d-e8ee-4e8b-99e7-89b139a14fd2_terseLabel_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_label_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements Change in Amount of Contingent Consideration Asset Cash</link:label>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_documentation_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represents the cash-flow impact of any change, including any differences arising upon settlement, recognized during the reporting period in the value of an asset or assets, arising from an item of contingent consideration, recognized in a business combination.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:href="bhc-20220331.xsd#bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:to="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:type="arc" order="1"/>
    <link:label id="lab_country_KR_c45eaf87-c7f8-4832-a4be-c71a2458a11b_terseLabel_en-US" xlink:label="lab_country_KR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">South Korea</link:label>
    <link:label id="lab_country_KR_label_en-US" xlink:label="lab_country_KR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KOREA, REPUBLIC OF</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_KR" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_KR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_KR" xlink:to="lab_country_KR" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PharmaceuticalProductsMember_d17ecf77-ac21-4fce-932b-124b413c4141_terseLabel_en-US" xlink:label="lab_bhc_PharmaceuticalProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceuticals</link:label>
    <link:label id="lab_bhc_PharmaceuticalProductsMember_label_en-US" xlink:label="lab_bhc_PharmaceuticalProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Products [Member]</link:label>
    <link:label id="lab_bhc_PharmaceuticalProductsMember_documentation_en-US" xlink:label="lab_bhc_PharmaceuticalProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PharmaceuticalProductsMember" xlink:href="bhc-20220331.xsd#bhc_PharmaceuticalProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PharmaceuticalProductsMember" xlink:to="lab_bhc_PharmaceuticalProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecured4875NotesDueJune2028Member_f9f27d92-8ec5-4584-8059-b5bfcd0ff5d9_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecured4875NotesDueJune2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.875% Senior Notes Due June 2028</link:label>
    <link:label id="lab_bhc_SeniorSecured4875NotesDueJune2028Member_label_en-US" xlink:label="lab_bhc_SeniorSecured4875NotesDueJune2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 4.875% Notes Due June 2028 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecured4875NotesDueJune2028Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecured4875NotesDueJune2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 4.875% Notes Due June 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured4875NotesDueJune2028Member" xlink:href="bhc-20220331.xsd#bhc_SeniorSecured4875NotesDueJune2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecured4875NotesDueJune2028Member" xlink:to="lab_bhc_SeniorSecured4875NotesDueJune2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueJune2023Member_17b486cb-c64d-4b70-b86f-2d1bda5e1c95_terseLabel_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due June 2023</link:label>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueJune2023Member_label_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due June 2023 [Member]</link:label>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueJune2023Member_documentation_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due June 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:href="bhc-20220331.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:to="lab_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3d42de1c-643b-4b2c-97bf-7c34d93841e2_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_IT_e97d4373-25c7-48ff-a80e-340d0b613e2e_terseLabel_en-US" xlink:label="lab_country_IT" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Italy</link:label>
    <link:label id="lab_country_IT_label_en-US" xlink:label="lab_country_IT" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ITALY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_IT" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IT"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IT" xlink:to="lab_country_IT" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PartnerRelationshipsMember_10494104-0cfe-4d50-acad-ab01f40f7246_terseLabel_en-US" xlink:label="lab_bhc_PartnerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner relationships</link:label>
    <link:label id="lab_bhc_PartnerRelationshipsMember_label_en-US" xlink:label="lab_bhc_PartnerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner Relationships [Member]</link:label>
    <link:label id="lab_bhc_PartnerRelationshipsMember_documentation_en-US" xlink:label="lab_bhc_PartnerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to existing arrangements with various other entities, for which the entity provides regulatory, compliance, sales, marketing and distribution functions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PartnerRelationshipsMember" xlink:href="bhc-20220331.xsd#bhc_PartnerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PartnerRelationshipsMember" xlink:to="lab_bhc_PartnerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_96f45c4a-f6b3-4818-8de1-e02bb115f3d3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairments, including loss on assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_729b5cdf-be7e-4814-b783-3a71f9be5e92_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairments, including loss on assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_77f701ca-7d32-4cd6-b6d3-b737bba458c9_negatedLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairments, including loss on assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_6d4352f5-6d81-4699-99f5-4c7c31221750_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate notional amounts</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_1e9dbcee-4d85-4f81-a8df-26624e3d141a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit related to filing of certain tax returns</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_8cfff137-111e-4a0e-ab5d-4567dd39a5ef_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense (income), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_NorwichPharmaceuticalsIncLitigationMember_0fe2ef0d-170d-4457-9f8c-2a613a7a7e19_terseLabel_en-US" xlink:label="lab_bhc_NorwichPharmaceuticalsIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Norwich Pharmaceuticals Inc. Litigation</link:label>
    <link:label id="lab_bhc_NorwichPharmaceuticalsIncLitigationMember_label_en-US" xlink:label="lab_bhc_NorwichPharmaceuticalsIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Norwich Pharmaceuticals Inc. Litigation [Member]</link:label>
    <link:label id="lab_bhc_NorwichPharmaceuticalsIncLitigationMember_documentation_en-US" xlink:label="lab_bhc_NorwichPharmaceuticalsIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Norwich Pharmaceuticals Inc. Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NorwichPharmaceuticalsIncLitigationMember" xlink:href="bhc-20220331.xsd#bhc_NorwichPharmaceuticalsIncLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_NorwichPharmaceuticalsIncLitigationMember" xlink:to="lab_bhc_NorwichPharmaceuticalsIncLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_0c4caf53-1154-47e3-b69a-93c3fe2d247e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percentage of principal amount that can be redeemed</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member_9b0f8f4b-c2c0-4c73-a5bc-255411adaf96_verboseLabel_en-US" xlink:label="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.75% Senior Notes Due August 2027</link:label>
    <link:label id="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member_label_en-US" xlink:label="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 5.75% Notes Due August 2027 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 5.75% Notes Due August 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:href="bhc-20220331.xsd#bhc_SeniorSecured5.75NotesDueAugust2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:to="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0851c22a-8d26-4780-82e2-96278e5b9d0f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PlaintiffsDirectPurchasersMember_055f3ff1-9e7f-41d9-a3ac-6876d9b2e445_terseLabel_en-US" xlink:label="lab_bhc_PlaintiffsDirectPurchasersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiffs, Direct Purchasers</link:label>
    <link:label id="lab_bhc_PlaintiffsDirectPurchasersMember_label_en-US" xlink:label="lab_bhc_PlaintiffsDirectPurchasersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiffs, Direct Purchasers [Member]</link:label>
    <link:label id="lab_bhc_PlaintiffsDirectPurchasersMember_documentation_en-US" xlink:label="lab_bhc_PlaintiffsDirectPurchasersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiffs, Direct Purchasers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PlaintiffsDirectPurchasersMember" xlink:href="bhc-20220331.xsd#bhc_PlaintiffsDirectPurchasersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PlaintiffsDirectPurchasersMember" xlink:to="lab_bhc_PlaintiffsDirectPurchasersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_65291332-4ada-4183-8e4b-166b652d8500_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_68d1f4d7-44d8-4786-8f5e-53c278969424_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b2b7742b-64d1-415a-86f5-70e2560b351e_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_66aba8e7-dcb8-450c-be66-3d4451265d83_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OtherRevenuesMember_3545e290-c3b2-449e-a307-3ff8eab35a37_terseLabel_en-US" xlink:label="lab_bhc_OtherRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_bhc_OtherRevenuesMember_label_en-US" xlink:label="lab_bhc_OtherRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenues [Member]</link:label>
    <link:label id="lab_bhc_OtherRevenuesMember_documentation_en-US" xlink:label="lab_bhc_OtherRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherRevenuesMember" xlink:href="bhc-20220331.xsd#bhc_OtherRevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OtherRevenuesMember" xlink:to="lab_bhc_OtherRevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_a21f27a5-07a6-42a4-8108-519bb741192d_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes850DueJanuary2027Member_64773420-d70c-4821-8a23-cfd6a77c091f_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes850DueJanuary2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">8.50% Senior Notes Due January 2027</link:label>
    <link:label id="lab_bhc_SeniorNotes850DueJanuary2027Member_label_en-US" xlink:label="lab_bhc_SeniorNotes850DueJanuary2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 8.50%, Due January 2027 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes850DueJanuary2027Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes850DueJanuary2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">8.50% Senior Notes Due January 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes850DueJanuary2027Member" xlink:href="bhc-20220331.xsd#bhc_SeniorNotes850DueJanuary2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes850DueJanuary2027Member" xlink:to="lab_bhc_SeniorNotes850DueJanuary2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_d69d929e-5530-4258-b1dd-659c36406357_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock_0d8d8c56-7f68-4ace-8a64-dbd5984c7c13_terseLabel_en-US" xlink:label="lab_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LICENSING AGREEMENTS AND DIVESTITURE</link:label>
    <link:label id="lab_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock_label_en-US" xlink:label="lab_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, Licensing Agreements, And Assets Held For Sale Disclosures [Text Block]</link:label>
    <link:label id="lab_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock_documentation_en-US" xlink:label="lab_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, Licensing Agreements, And Assets Held For Sale Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" xlink:href="bhc-20220331.xsd#bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" xlink:to="lab_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_2a1d0391-e212-489b-bb2f-9975bebf9715_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_826b9f2f-dd17-4a7e-a3dd-58d49e479a60_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_c7bc03b0-4560-4668-9b69-6e9682546c73_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c93b72ea-4b2c-4ac5-863a-f1dc7b7ad35c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2bf03a5f-9aac-430e-8143-4ced7a796608_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c297909f-9f34-4760-906e-7076c480d0f3_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OrthoDermatologicsReportingUnitMember_56a556ed-abe5-46e2-8e01-7867112bc39e_terseLabel_en-US" xlink:label="lab_bhc_OrthoDermatologicsReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ortho Dermatologics Reporting Unit</link:label>
    <link:label id="lab_bhc_OrthoDermatologicsReportingUnitMember_label_en-US" xlink:label="lab_bhc_OrthoDermatologicsReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ortho Dermatologics Reporting Unit [Member]</link:label>
    <link:label id="lab_bhc_OrthoDermatologicsReportingUnitMember_documentation_en-US" xlink:label="lab_bhc_OrthoDermatologicsReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ortho Dermatologics Reporting Unit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsReportingUnitMember" xlink:href="bhc-20220331.xsd#bhc_OrthoDermatologicsReportingUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OrthoDermatologicsReportingUnitMember" xlink:to="lab_bhc_OrthoDermatologicsReportingUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_f3c5a342-3def-4bc6-9a18-42fac13f12e1_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_a035298e-2fe6-44a1-9ab1-a05520382715_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of customers that accounted for 10% or more of total revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_7e293a13-6022-429b-988f-3f8435b2af3a_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_f4838937-7654-43f8-8766-80ad749799b9_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Bausch Health Companies Inc. shareholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SettledLitigationMember_f77c5621-8ed6-4f8c-b060-4688c76f5985_terseLabel_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation</link:label>
    <link:label id="lab_us-gaap_SettledLitigationMember_label_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SettledLitigationMember" xlink:to="lab_us-gaap_SettledLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_0e8a7478-6730-425d-aacf-2972d6aa8c71_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_9e9c1eb6-3212-4811-bada-4a15bccccbb3_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_c4360c5c-c22f-4852-8527-bdcc128b83da_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_8b351073-7cc3-4be8-a8de-481277d95a38_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage_3ad0d2e5-aa75-40a9-ae7f-90e7ed178667_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual amortization rate (as a percent)</link:label>
    <link:label id="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage_label_en-US" xlink:label="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Annual Amortization Rate, Percentage</link:label>
    <link:label id="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Annual Amortization Rate, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentAnnualAmortizationRatePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:to="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_c9c79b64-35dd-42d4-948e-8afe368ce012_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments/Settlements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2383fd91-eb39-4334-836b-86fe02afff67_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, accrued and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_a5070612-5883-4477-a27a-47399de8724a_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_76fcc11f-8593-4e51-94b2-dd0aa65cb502_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_a1d7b9fa-3e9b-4d68-a4b1-246e110a1917_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A9.00SeniorNotesdueDecember2025Member_477225ff-0997-47c9-a6e8-8ea37f0f2bfc_terseLabel_en-US" xlink:label="lab_bhc_A9.00SeniorNotesdueDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.00% Senior Notes due December 2025</link:label>
    <link:label id="lab_bhc_A9.00SeniorNotesdueDecember2025Member_label_en-US" xlink:label="lab_bhc_A9.00SeniorNotesdueDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.00% Senior Notes due December 2025 [Member]</link:label>
    <link:label id="lab_bhc_A9.00SeniorNotesdueDecember2025Member_documentation_en-US" xlink:label="lab_bhc_A9.00SeniorNotesdueDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.00% Senior Notes due December 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A9.00SeniorNotesdueDecember2025Member" xlink:href="bhc-20220331.xsd#bhc_A9.00SeniorNotesdueDecember2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A9.00SeniorNotesdueDecember2025Member" xlink:to="lab_bhc_A9.00SeniorNotesdueDecember2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_4fc639f2-3e91-4c7b-aae8-ca74cd63f662_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_f222fa19-2e94-4f8e-9f7a-5d605a5a53e5_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes500DueJanuary2028Member_1af32b76-a8cd-4759-a046-edc6fc54c3c3_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes500DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.00% Senior Notes Due January 2028</link:label>
    <link:label id="lab_bhc_SeniorNotes500DueJanuary2028Member_label_en-US" xlink:label="lab_bhc_SeniorNotes500DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.00%, Due January 2028 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes500DueJanuary2028Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes500DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.00% Senior Notes Due January 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueJanuary2028Member" xlink:href="bhc-20220331.xsd#bhc_SeniorNotes500DueJanuary2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes500DueJanuary2028Member" xlink:to="lab_bhc_SeniorNotes500DueJanuary2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PriceAppreciationCreditMember_b92edc0a-2f40-4503-a43b-f29b768006bd_terseLabel_en-US" xlink:label="lab_bhc_PriceAppreciationCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price Appreciation Credit</link:label>
    <link:label id="lab_bhc_PriceAppreciationCreditMember_label_en-US" xlink:label="lab_bhc_PriceAppreciationCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price Appreciation Credit [Member]</link:label>
    <link:label id="lab_bhc_PriceAppreciationCreditMember_documentation_en-US" xlink:label="lab_bhc_PriceAppreciationCreditMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price Appreciation Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PriceAppreciationCreditMember" xlink:href="bhc-20220331.xsd#bhc_PriceAppreciationCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PriceAppreciationCreditMember" xlink:to="lab_bhc_PriceAppreciationCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EurodollarMember_d2cd4b56-cb99-40b4-8d79-ef76ebcf14d0_terseLabel_en-US" xlink:label="lab_us-gaap_EurodollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eurocurrency rate</link:label>
    <link:label id="lab_us-gaap_EurodollarMember_label_en-US" xlink:label="lab_us-gaap_EurodollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eurodollar [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EurodollarMember" xlink:to="lab_us-gaap_EurodollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_e9a60754-b0f3-4661-b48c-3ee368f2fe1f_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_e774b7f6-7f81-45ff-9ae0-cc685428ded9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the components of Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_082fee5a-ddba-4a02-9ff6-94187a84a190_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_532e1c88-4512-4355-b5c0-2b94adc5151c_terseLabel_en-US" xlink:label="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and other settlement deposits</link:label>
    <link:label id="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_2bc91163-466f-41d2-97a6-1921bbb615ab_verboseLabel_en-US" xlink:label="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and other settlement deposits</link:label>
    <link:label id="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_label_en-US" xlink:label="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash And Other Settlement Deposits, Current</link:label>
    <link:label id="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_documentation_en-US" xlink:label="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash And Other Settlement Deposits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent" xlink:href="bhc-20220331.xsd#bhc_RestrictedCashAndOtherSettlementDepositsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent" xlink:to="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_b346164e-765b-4a80-bedb-ef19404f02b7_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_ae759507-c799-4d53-aa53-86765dc704f8_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCUMULATED OTHER COMPREHENSIVE LOSS</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShowerToShowerProductLiabilityLitigationMember_016b839f-d3bb-4b77-aeba-da70195bf49c_terseLabel_en-US" xlink:label="lab_bhc_ShowerToShowerProductLiabilityLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower to Shower Product Liability Litigation</link:label>
    <link:label id="lab_bhc_ShowerToShowerProductLiabilityLitigationMember_label_en-US" xlink:label="lab_bhc_ShowerToShowerProductLiabilityLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower To Shower Product Liability Litigation [Member]</link:label>
    <link:label id="lab_bhc_ShowerToShowerProductLiabilityLitigationMember_documentation_en-US" xlink:label="lab_bhc_ShowerToShowerProductLiabilityLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower to Shower Product Liability Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowerToShowerProductLiabilityLitigationMember" xlink:href="bhc-20220331.xsd#bhc_ShowerToShowerProductLiabilityLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShowerToShowerProductLiabilityLitigationMember" xlink:to="lab_bhc_ShowerToShowerProductLiabilityLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_bcb7ca25-9d6f-46e3-a957-32252e674f38_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_3434294b-4334-47b8-a0ca-8fd71e56521b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock_0eed4249-95f3-4c2d-a8a7-7a81192064a0_terseLabel_en-US" xlink:label="lab_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS</link:label>
    <link:label id="lab_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock_label_en-US" xlink:label="lab_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Related Activities And Initial Public Offering Costs Disclosure [Text Block]</link:label>
    <link:label id="lab_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock_documentation_en-US" xlink:label="lab_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Related Activities And Initial Public Offering Costs Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" xlink:href="bhc-20220331.xsd#bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" xlink:to="lab_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember_8ed98ed4-a8b9-436f-be3e-72a80f97a6de_terseLabel_en-US" xlink:label="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Weighted Average Risk-Adjusted Discount Rate</link:label>
    <link:label id="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember_label_en-US" xlink:label="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Weighted-Average Discount Rate [Member]</link:label>
    <link:label id="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember_documentation_en-US" xlink:label="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Weighted-Average Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:href="bhc-20220331.xsd#bhc_MeasurementInputWeightedAverageDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:to="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_397c0fc9-036f-4731-a5ac-7bf7fffcbb7e_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic (benefit) cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_20d1ed12-101e-4326-b985-2bd221264e58_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet_a1587c67-108f-477e-8c02-a5f9e2d50748_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt covenant, redemption and discharge condition, amount, if circumstances met</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Redemption And Discharge Condition, Amount, If Circumstances Met</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Redemption And Discharge Condition, Amount, If Circumstances Met</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" xlink:to="lab_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ScheduleOfOtherIncomeAndExpensesTable_818b6181-9adf-43b1-8869-91004fa8f846_terseLabel_en-US" xlink:label="lab_bhc_ScheduleOfOtherIncomeAndExpensesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Income And Expenses [Table]</link:label>
    <link:label id="lab_bhc_ScheduleOfOtherIncomeAndExpensesTable_label_en-US" xlink:label="lab_bhc_ScheduleOfOtherIncomeAndExpensesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Income And Expenses [Table]</link:label>
    <link:label id="lab_bhc_ScheduleOfOtherIncomeAndExpensesTable_documentation_en-US" xlink:label="lab_bhc_ScheduleOfOtherIncomeAndExpensesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Income And Expenses [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable" xlink:href="bhc-20220331.xsd#bhc_ScheduleOfOtherIncomeAndExpensesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable" xlink:to="lab_bhc_ScheduleOfOtherIncomeAndExpensesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_country_PL_53439431-d472-48bf-ab67-5f01b58cded6_terseLabel_en-US" xlink:label="lab_country_PL" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Poland</link:label>
    <link:label id="lab_country_PL_label_en-US" xlink:label="lab_country_PL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">POLAND</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_PL" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_PL"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_PL" xlink:to="lab_country_PL" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ConcentrationRiskNumberOfProducts_75254d62-e328-44c6-af8b-70f2c1a5336e_terseLabel_en-US" xlink:label="lab_bhc_ConcentrationRiskNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of products represented of total revenue</link:label>
    <link:label id="lab_bhc_ConcentrationRiskNumberOfProducts_label_en-US" xlink:label="lab_bhc_ConcentrationRiskNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Number Of Products</link:label>
    <link:label id="lab_bhc_ConcentrationRiskNumberOfProducts_documentation_en-US" xlink:label="lab_bhc_ConcentrationRiskNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Number Of Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ConcentrationRiskNumberOfProducts" xlink:href="bhc-20220331.xsd#bhc_ConcentrationRiskNumberOfProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ConcentrationRiskNumberOfProducts" xlink:to="lab_bhc_ConcentrationRiskNumberOfProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_c1237870-cd8b-405b-83d3-eca492e662d6_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_f1db83f0-d063-41fb-bc7b-669311ac9555_terseLabel_en-US" xlink:label="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of research and development</link:label>
    <link:label id="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_label_en-US" xlink:label="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Research And Development Expense [Table Text Block]</link:label>
    <link:label id="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_documentation_en-US" xlink:label="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Research And Development Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:href="bhc-20220331.xsd#bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:to="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_84f31b79-e558-4e71-80a0-a3306a475499_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segment</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_5256910d-49eb-4d59-bc0d-6bd16d8f8c9b_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options and RSUs</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_da528598-81fa-4efc-bf36-59df330806a1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_8f7aea10-b7c3-47d2-9497-8494a80133ab_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_36b64f32-cc74-466d-a7b5-2e7a638c2e33_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_d0f54d4b-bb15-41bb-afef-bb135a085154_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fee (as a percent)</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_6146b1da-9f00-40fe-a1f7-d15682aaae0e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_938b6e06-2b81-45d8-9195-fdd55896b28e_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_f4c2391e-1867-4ddf-b2f8-77343bd3aa98_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales return provisions</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_438284b8-4216-43db-9698-b8defa76e793_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current period provisions</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_0bd1d45c-6e42-4156-b192-21c479add71e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_6a5123ec-ca8b-46a2-a118-646b2e5f1116_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_9faa8278-4dbf-4819-8e55-27d9a420bf9a_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_bd549269-aa6e-4fa1-906a-65b410fe01c3_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_e2f9c39d-f08a-44c1-941a-29e6579c35c3_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of groups of investors filing action</link:label>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_label_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Plaintiffs, Number of Groups of Investors</link:label>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_documentation_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Plaintiffs, Number of Groups of Investors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:href="bhc-20220331.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:to="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes925DueApril2026Member_b884655e-c7aa-4131-98f2-5a74a94349f2_verboseLabel_en-US" xlink:label="lab_bhc_SeniorNotes925DueApril2026Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.25% Senior Notes Due April 2026</link:label>
    <link:label id="lab_bhc_SeniorNotes925DueApril2026Member_label_en-US" xlink:label="lab_bhc_SeniorNotes925DueApril2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 9.25%, Due April 2026 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes925DueApril2026Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes925DueApril2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.25% Senior Notes Due April 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes925DueApril2026Member" xlink:href="bhc-20220331.xsd#bhc_SeniorNotes925DueApril2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes925DueApril2026Member" xlink:to="lab_bhc_SeniorNotes925DueApril2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_e58b8a52-0538-4dbf-9369-ec267e052bd8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfCountriesInWhichEntityOperates_bbc98ada-64e0-47cf-9a9f-1140661bc031_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of countries in which entity operates</link:label>
    <link:label id="lab_us-gaap_NumberOfCountriesInWhichEntityOperates_label_en-US" xlink:label="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Countries in which Entity Operates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:to="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_83defcc0-d6bf-4d7d-ab54-93ca41226120_terseLabel_en-US" xlink:label="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
    <link:label id="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_label_en-US" xlink:label="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration Fair Value Disclosure</link:label>
    <link:label id="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_documentation_en-US" xlink:label="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, as of the balance sheet date, of potential payments under the contingent consideration arrangement which may include cash and shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:href="bhc-20220331.xsd#bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:to="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_4243a9d3-2cbe-41ea-b974-96759babd584_terseLabel_en-US" xlink:label="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time-based RSUs, Performance-based RSUs and Stock Options</link:label>
    <link:label id="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options, Time-Based Restricted Stock Units, and Performance-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options, Time-Based Restricted Stock Units, and Performance-Based Restricted Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:href="bhc-20220331.xsd#bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_fc6c9cf1-f802-4e29-99f1-7d3cf023da39_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed charge coverage ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Fixed Charge Coverage Ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Fixed Charge Coverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" xlink:to="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_8730480e-41e5-4b8f-94ca-496a3f1fb63c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments and credits</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_eb544993-b6db-44d4-a632-61a224808bb2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_18254650-31a1-4b09-bc4d-90be15cbd5dd_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_InsuranceCoverageLawsuitMember_6c9e7fbd-f51b-428e-930e-4eabe7d854ee_terseLabel_en-US" xlink:label="lab_bhc_InsuranceCoverageLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Coverage Lawsuit</link:label>
    <link:label id="lab_bhc_InsuranceCoverageLawsuitMember_label_en-US" xlink:label="lab_bhc_InsuranceCoverageLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Coverage Lawsuit [Member]</link:label>
    <link:label id="lab_bhc_InsuranceCoverageLawsuitMember_documentation_en-US" xlink:label="lab_bhc_InsuranceCoverageLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Coverage Lawsuit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InsuranceCoverageLawsuitMember" xlink:href="bhc-20220331.xsd#bhc_InsuranceCoverageLawsuitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_InsuranceCoverageLawsuitMember" xlink:to="lab_bhc_InsuranceCoverageLawsuitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b4c3d7e9-a4c4-4c9f-a558-917b86423c54_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_69493fbf-5fd1-4724-a9bc-bfe41a138a89_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit from (provision for) income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_08e11f0e-d9f3-4e57-b9cf-09ca2e517089_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision (benefit) from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_94af10e0-240e-477e-85a5-fc1ca99268b0_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4371ec1e-333d-4002-9978-4ff44f4243fe_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e26efb86-94ec-465f-bd8b-d4ca9ab2e299_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b76a0136-962a-4013-8b38-600ced628a58_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_be88d767-1ece-4342-b4be-7aad969ea1d4_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realignment of segment goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_24113a67-5e9e-45a1-b1d9-18f378b880ee_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price percentage to change in control (as a percent)</link:label>
    <link:label id="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_label_en-US" xlink:label="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage, Change in Control</link:label>
    <link:label id="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage, Change in Control</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentRedemptionPricePercentageChangeinControl"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:to="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet_9ea76ba3-f669-4252-a6f0-c0fbac75f70f_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt covenant, mandatory prepayments, percentage net cash proceeds, asset sales</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Mandatory Prepayments, Percentage Net Cash Proceeds, Asset Sales, If Circumstances Met</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Mandatory Prepayments, Percentage Net Cash Proceeds, Asset Sales, If Circumstances Met</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet" xlink:to="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_c5dc1c8d-3447-406c-976c-d35b63e8723b_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_6506c2bf-3f2e-4338-af7e-256c1d9357d7_terseLabel_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes</link:label>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_9f3c9c33-b376-4db8-a8ec-1c7ea16efd33_verboseLabel_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Debt</link:label>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnsecuredDebtMember" xlink:to="lab_us-gaap_UnsecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e7d28801-eef8-4215-8a78-8c6b31c9e141_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of long-term debt, net of discounts</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_2e01883e-1c5e-499e-a88e-5202b0e63d67_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims dismissed</link:label>
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Dismissed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyClaimsDismissedNumber" xlink:to="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_7af3da5e-14b5-4893-9218-78cdbb52c8e7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9e84fb58-e75a-4f94-a954-47ba0a2f404a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income Loss [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_48dd5b44-fb86-404f-88ac-f7f036992988_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_65207838-3931-4260-be1a-a4b6b9d66ba8_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_ec05e694-a79f-49fa-be95-e0dda06643e0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cc3d0702-5bf1-49ee-8ea6-08f16645c1f5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_19e94c31-ab47-4d58-8131-2bbf993bc750_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_2b435dfd-f145-4440-a942-28d260abd387_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_17812dec-c2e5-4b21-b792-603ada78f3a0_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_6ad63f38-89fa-42a2-be7a-a7461d130169_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_d99b149b-0bbf-4b4d-a5c4-a645933cd22e_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_country_MX_ddd290db-7590-40a2-ad91-f29605288f64_terseLabel_en-US" xlink:label="lab_country_MX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mexico</link:label>
    <link:label id="lab_country_MX_label_en-US" xlink:label="lab_country_MX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MEXICO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_MX" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_MX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_MX" xlink:to="lab_country_MX" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SalixSegmentMember_28ea26ac-52b6-4c8b-b202-ef1e483d6945_terseLabel_en-US" xlink:label="lab_bhc_SalixSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salix</link:label>
    <link:label id="lab_bhc_SalixSegmentMember_label_en-US" xlink:label="lab_bhc_SalixSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salix Segment [Member]</link:label>
    <link:label id="lab_bhc_SalixSegmentMember_documentation_en-US" xlink:label="lab_bhc_SalixSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salix Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember" xlink:href="bhc-20220331.xsd#bhc_SalixSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SalixSegmentMember" xlink:to="lab_bhc_SalixSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AssetImpairmentChargesMember_78b666eb-2f56-4925-a90f-5be2e4109bf1_terseLabel_en-US" xlink:label="lab_bhc_AssetImpairmentChargesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairments, including loss on assets held for sale</link:label>
    <link:label id="lab_bhc_AssetImpairmentChargesMember_label_en-US" xlink:label="lab_bhc_AssetImpairmentChargesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges [Member]</link:label>
    <link:label id="lab_bhc_AssetImpairmentChargesMember_documentation_en-US" xlink:label="lab_bhc_AssetImpairmentChargesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetImpairmentChargesMember" xlink:href="bhc-20220331.xsd#bhc_AssetImpairmentChargesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AssetImpairmentChargesMember" xlink:to="lab_bhc_AssetImpairmentChargesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_880e08d9-8ee4-4acb-b407-afa3c41dc2a4_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes525DueFebruary2031Member_74ff3f41-f840-439e-9c35-ab7525c66c06_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes525DueFebruary2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.25% Senior Notes Due February 2031</link:label>
    <link:label id="lab_bhc_SeniorNotes525DueFebruary2031Member_label_en-US" xlink:label="lab_bhc_SeniorNotes525DueFebruary2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.25%, Due February 2031 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes525DueFebruary2031Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes525DueFebruary2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.25%, Due February 2031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueFebruary2031Member" xlink:href="bhc-20220331.xsd#bhc_SeniorNotes525DueFebruary2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes525DueFebruary2031Member" xlink:to="lab_bhc_SeniorNotes525DueFebruary2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_d0f1e9df-c28a-49e0-a6ca-567f2c78032f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of segment revenues and profit</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_f2577335-63ae-47f9-a080-0c17f2d29784_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A2027TermLoanBFacilityMember_37c352e1-c58f-411b-aca8-a2a3c5bfd11a_terseLabel_en-US" xlink:label="lab_bhc_A2027TermLoanBFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027 Term Loan B Facility</link:label>
    <link:label id="lab_bhc_A2027TermLoanBFacilityMember_label_en-US" xlink:label="lab_bhc_A2027TermLoanBFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027 Term Loan B Facility [Member]</link:label>
    <link:label id="lab_bhc_A2027TermLoanBFacilityMember_documentation_en-US" xlink:label="lab_bhc_A2027TermLoanBFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027 Term Loan B Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A2027TermLoanBFacilityMember" xlink:href="bhc-20220331.xsd#bhc_A2027TermLoanBFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A2027TermLoanBFacilityMember" xlink:to="lab_bhc_A2027TermLoanBFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecuredCreditFacilityMember_e33a5396-cd7b-42de-889f-0feba01f40e9_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecuredCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facility</link:label>
    <link:label id="lab_bhc_SeniorSecuredCreditFacilityMember_label_en-US" xlink:label="lab_bhc_SeniorSecuredCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facility [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecuredCreditFacilityMember_documentation_en-US" xlink:label="lab_bhc_SeniorSecuredCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredCreditFacilityMember" xlink:href="bhc-20220331.xsd#bhc_SeniorSecuredCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecuredCreditFacilityMember" xlink:to="lab_bhc_SeniorSecuredCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_85ade2b1-30fb-4893-88f3-107ff30f1ccc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dcc276b4-8f24-4ed2-8d17-12fa14d1da5e_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_6060c591-2232-4e98-a502-d1a660daab98_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_af9c89c1-7c80-4c58-b228-d80f59b655ec_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest coverage ratio (not less than)</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:to="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_f574936f-90a0-40a2-ad58-49a4070b1bc5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_4ce0d2fd-20b3-4bdf-bcc0-8bd9d517d062_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion of long-term debt and other</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_a016b1c6-cb3e-446d-8465-4c7f57ec8649_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_c8258633-b8e1-49ed-bb75-07952a599a34_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_98da2185-4bc1-4838-af9c-e8d97f5f8edb_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_a523b960-756d-4ba4-9bc9-524f55e160ab_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER EXPENSE (INCOME), NET</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Other Expense Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalPeriod_9978c779-f5e1-4552-94b4-2a5da3febddc_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stay of approval, period</link:label>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalPeriod_label_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Stay Of Approval, Period</link:label>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalPeriod_documentation_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Stay Of Approval, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalPeriod" xlink:href="bhc-20220331.xsd#bhc_LossContingencyStayOfApprovalPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyStayOfApprovalPeriod" xlink:to="lab_bhc_LossContingencyStayOfApprovalPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8c0f7b8a-0d8c-426f-ad13-851e5fda34b8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_a378d0b1-8287-4379-908d-2adb6b5e958b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_946f18dc-9e4c-4805-b1bf-e6f9cdb9e2a5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares issued under share-based compensation plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_77a6a9ef-63b7-44a8-8a60-5c3865431526_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly remaining amortization payments</link:label>
    <link:label id="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_label_en-US" xlink:label="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Quarterly Amortization</link:label>
    <link:label id="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Quarterly Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" xlink:to="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_72cf8262-e02d-460a-bff6-1bd41bc540ab_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TermLoanBFacilityDueJune2025Member_6b0d4e57-c752-4f2b-ab4e-95c643db064e_verboseLabel_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due June 2025</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueJune2025Member_label_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due June 2025 [Member]</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueJune2025Member_documentation_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due June 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025Member" xlink:href="bhc-20220331.xsd#bhc_TermLoanBFacilityDueJune2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TermLoanBFacilityDueJune2025Member" xlink:to="lab_bhc_TermLoanBFacilityDueJune2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_31e4b657-19d7-4bcd-a987-5a938d06204e_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_22cb6b70-fb3e-46cb-8c52-f04f2796e845_terseLabel_en-US" xlink:label="lab_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite Lived and Indefinite Lived Intangible Asset by Major Class [Table]</link:label>
    <link:label id="lab_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_label_en-US" xlink:label="lab_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite Lived and Indefinite Lived Intangible Asset by Major Class [Table]</link:label>
    <link:label id="lab_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_documentation_en-US" xlink:label="lab_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of the carrying value of amortizable and nonamortizable intangibles assets, in total and by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable" xlink:href="bhc-20220331.xsd#bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable" xlink:to="lab_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio_29a40a68-b1d0-43de-ad86-a242183f9dc7_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total leverage ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Total Leverage Ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Total Leverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatio" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantTotalLeverageRatio" xlink:to="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_7528d99f-aee3-4d19-ad5e-eb5af0f41add_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_2d3d574f-c5d2-45df-8f00-716e30051b30_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_6351929b-ae4c-4a11-9314-790a2349bad0_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TimeBasedRSUMember_f5a20b5b-e027-4360-a8c5-90210e55bfed_terseLabel_en-US" xlink:label="lab_bhc_TimeBasedRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time-based RSUs</link:label>
    <link:label id="lab_bhc_TimeBasedRSUMember_label_en-US" xlink:label="lab_bhc_TimeBasedRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based RSU [Member]</link:label>
    <link:label id="lab_bhc_TimeBasedRSUMember_documentation_en-US" xlink:label="lab_bhc_TimeBasedRSUMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents stock awards in the form of time-based restricted stock units (RSUs) to certain directors, officers and other eligible employees pursuant to the company's incentive compensation plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TimeBasedRSUMember" xlink:href="bhc-20220331.xsd#bhc_TimeBasedRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TimeBasedRSUMember" xlink:to="lab_bhc_TimeBasedRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_28526e68-ce0e-49ed-b07e-4f95a4780161_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Finite-lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_d15da1ce-4b6a-4ed1-aa61-5c8c3af0faff_verboseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement, escrow fund included in restricted cash and other settlement deposits</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_cef70bfc-f92c-4df0-9561-babb7d91c839_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement, agreed to pay</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GainLossRelatedToLitigationSettlementGross_89f4a026-e881-49ef-a793-6560a2df9784_negatedLabel_en-US" xlink:label="lab_bhc_GainLossRelatedToLitigationSettlementGross" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions to accrued legal settlements</link:label>
    <link:label id="lab_bhc_GainLossRelatedToLitigationSettlementGross_label_en-US" xlink:label="lab_bhc_GainLossRelatedToLitigationSettlementGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related To Litigation Settlement, Gross</link:label>
    <link:label id="lab_bhc_GainLossRelatedToLitigationSettlementGross_documentation_en-US" xlink:label="lab_bhc_GainLossRelatedToLitigationSettlementGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement, Gross payments not offset by insurance proceeds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainLossRelatedToLitigationSettlementGross" xlink:href="bhc-20220331.xsd#bhc_GainLossRelatedToLitigationSettlementGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GainLossRelatedToLitigationSettlementGross" xlink:to="lab_bhc_GainLossRelatedToLitigationSettlementGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_3001371c-b9d0-48ec-8313-ac94b592075c_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs incurred</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Incurred Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:to="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_827965bf-0780-4f3c-ae58-f47313cf0b45_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares issued under share-based compensation plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_cf11a36f-4dec-4e38-bd89-e5ae2829dcbf_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_958eb25d-2bf7-4308-aaf3-ac24029ae7ff_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of reporting value, greater than its carrying value</link:label>
    <link:label id="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_label_en-US" xlink:label="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:to="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_12fa9b43-2e5a-4b88-9b1d-0af0b9b27687_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_37203186-c478-4e56-a9f6-d03aea578547_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the components and classification of share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForDiscountsAndAllowancesMember_cfeab57c-bf64-4216-8cbf-360346880c3f_terseLabel_en-US" xlink:label="lab_bhc_ReserveForDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounts and Allowances</link:label>
    <link:label id="lab_bhc_ReserveForDiscountsAndAllowancesMember_label_en-US" xlink:label="lab_bhc_ReserveForDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Discounts And Allowances [Member]</link:label>
    <link:label id="lab_bhc_ReserveForDiscountsAndAllowancesMember_documentation_en-US" xlink:label="lab_bhc_ReserveForDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Discounts And Allowances [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDiscountsAndAllowancesMember" xlink:href="bhc-20220331.xsd#bhc_ReserveForDiscountsAndAllowancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForDiscountsAndAllowancesMember" xlink:to="lab_bhc_ReserveForDiscountsAndAllowancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_b163afda-9bbc-4cca-86bb-4c1614c20684_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_2ec42645-244a-435b-97da-366a8d7d08d6_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_ed6c3967-0044-4aa2-bf24-9da9e86d65b6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeparationPerformanceBasedRestrictedStockUnitsMember_cd33cc4d-1826-42a3-96c3-94e1ed67c663_terseLabel_en-US" xlink:label="lab_bhc_SeparationPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">B+L Separation performance-based RSUs</link:label>
    <link:label id="lab_bhc_SeparationPerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_bhc_SeparationPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation Performance-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_bhc_SeparationPerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_bhc_SeparationPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation Performance-Based Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeparationPerformanceBasedRestrictedStockUnitsMember" xlink:href="bhc-20220331.xsd#bhc_SeparationPerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeparationPerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_bhc_SeparationPerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_1aa1fa76-7bb1-432f-bacb-cc54f5e69dc6_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bf9decf1-ab20-4dae-b197-523b332505a1_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_a9f6d3fc-44f0-491c-aef8-03049d91082f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods_2cff694b-c03f-40a7-9828-1a94d694e85e_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of distinct insurance policy periods</link:label>
    <link:label id="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods_label_en-US" xlink:label="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Insurance Policy Periods</link:label>
    <link:label id="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods_documentation_en-US" xlink:label="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Insurance Policy Periods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:href="bhc-20220331.xsd#bhc_LossContingencyNumberOfInsurancePolicyPeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:to="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes500DueFebruary2029Member_3354761e-ef48-4106-a399-523860d3ab14_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes500DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.00% Senior Notes Due February 2029</link:label>
    <link:label id="lab_bhc_SeniorNotes500DueFebruary2029Member_label_en-US" xlink:label="lab_bhc_SeniorNotes500DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.00%, Due February 2029 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes500DueFebruary2029Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes500DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.00%, Due February 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueFebruary2029Member" xlink:href="bhc-20220331.xsd#bhc_SeniorNotes500DueFebruary2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes500DueFebruary2029Member" xlink:to="lab_bhc_SeniorNotes500DueFebruary2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_b3d6ffb5-057b-4be4-8fa8-a20f3230fd2b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance against deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_37983df4-a718-49b7-a069-98ae1a616d49_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_b2cb6e99-3e34-44ee-949a-afd68c0a7f73_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_b0269f01-5cf8-477c-a21e-23d978d0742f_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_f2d53cf7-a0fd-4d83-b6a5-c05defa9d220_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_1ec29574-b2d1-4b7d-aca4-aeceaa6dc8be_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue associated with products for disposal</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_0a735f90-0ee9-475f-975f-9b3da44d4df7_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount_d96a49bd-b885-4367-8d5a-49c62dee1b42_terseLabel_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision related to withholding tax, intercompany dividends</link:label>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount_label_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Withholding Tax, Intercompany Dividends, Amount</link:label>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount_documentation_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Withholding Tax, Intercompany Dividends, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount" xlink:href="bhc-20220331.xsd#bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount" xlink:to="lab_bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_b67d5078-ac79-4400-a6d5-4a009e965c01_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost-rationalization and integration initiatives</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_f2cb2075-a877-44bd-bb1b-8f3ad3bcc7d0_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_f73be12b-8fe9-4458-8121-8714404aa6a9_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5430c00c-e88f-49b5-8334-a924c08cdc46_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of calculation of net loss per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2cad4d8c-5690-4145-916f-270e6849ee9a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes700DueJanuary2028Member_5d37af11-3008-42b5-8f8d-e71ca29b3750_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes700DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.00 % Senior Notes Due January 2028</link:label>
    <link:label id="lab_bhc_SeniorNotes700DueJanuary2028Member_label_en-US" xlink:label="lab_bhc_SeniorNotes700DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 7.00%, Due January 2028 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes700DueJanuary2028Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes700DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes 7.00 Percent Due January 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueJanuary2028Member" xlink:href="bhc-20220331.xsd#bhc_SeniorNotes700DueJanuary2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes700DueJanuary2028Member" xlink:to="lab_bhc_SeniorNotes700DueJanuary2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_f3b11c21-cfba-446c-a8c4-1b835c454104_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_626593b8-cf5b-44ff-9c8f-4ddc11c1ec57_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_496c9ba8-5dee-4f9b-a51e-631304c92b1c_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_a544f08a-aefb-4302-a565-d957e2c7af39_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation and other matters</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_881c482e-de3f-49d5-9bd4-5f65bf8acf87_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_047f4c40-6769-4433-a9a8-326c4deb4ee6_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_8d883ebf-5d69-4fc0-87f0-88f3212581ee_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_48e1f001-3d1f-488b-90dd-fb60eb26545f_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_ba8ab18b-1c72-4051-a8d0-18e95bdb589e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCRUED AND OTHER CURRENT LIABILITIES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_da84a27d-ecc7-4b67-8ade-2bf3436bf31d_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non- controlling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_fc763060-1533-48d8-a624-4adc2a13445f_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DeviceProductsMember_775b0fcd-2cbf-4a2a-960a-18172784406f_terseLabel_en-US" xlink:label="lab_bhc_DeviceProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Devices</link:label>
    <link:label id="lab_bhc_DeviceProductsMember_label_en-US" xlink:label="lab_bhc_DeviceProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Device Products [Member]</link:label>
    <link:label id="lab_bhc_DeviceProductsMember_documentation_en-US" xlink:label="lab_bhc_DeviceProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Device Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeviceProductsMember" xlink:href="bhc-20220331.xsd#bhc_DeviceProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DeviceProductsMember" xlink:to="lab_bhc_DeviceProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_7bf4847b-15f2-441b-993e-61c5f9e4a2df_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_eb4bc52a-f7ef-4a11-a95f-f4d7bfd1300d_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate on debt (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_b926bfd9-3cef-453b-af87-e127d18a81c8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of activity in allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_a60db1c3-e18f-4214-8808-0a0f4cecceaf_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d227829a-4b8e-4cd6-87d5-10df00ebf0d1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8c332bb8-725d-4564-9ca1-e06d2b2a3ae4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_a54016dd-6877-4cfe-919a-16e17ae66693_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_84a42d46-7274-4930-a644-6b2c3d95266c_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_6eb769d1-a1ac-4ab6-995b-92a0fcb2036e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_30a1a8fc-82e0-404c-958b-3976a372bf24_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_02aa1083-e7d9-4ece-ab40-6bbbec431182_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet_ac29db40-e35f-4c7c-bd3f-de03a20c40cc_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt covenant, mandatory prepayments, percentage of consolidated excess cash flow</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Mandatory Prepayments, Percentage Of Consolidated Excess Cash Flow, If Circumstances Met</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Mandatory Prepayments, Percentage Of Consolidated Excess Cash Flow, If Circumstances Met</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet" xlink:to="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_87b86852-6714-40c8-a0eb-78bb3aacf785_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of long-term debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_UnitedStatesandPuertoRicoMember_74aa26d0-3ae8-4b5a-9654-116ef192d44f_terseLabel_en-US" xlink:label="lab_bhc_UnitedStatesandPuertoRicoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. and Puerto Rico</link:label>
    <link:label id="lab_bhc_UnitedStatesandPuertoRicoMember_label_en-US" xlink:label="lab_bhc_UnitedStatesandPuertoRicoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States and Puerto Rico [Member]</link:label>
    <link:label id="lab_bhc_UnitedStatesandPuertoRicoMember_documentation_en-US" xlink:label="lab_bhc_UnitedStatesandPuertoRicoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States and Puerto Rico [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnitedStatesandPuertoRicoMember" xlink:href="bhc-20220331.xsd#bhc_UnitedStatesandPuertoRicoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_UnitedStatesandPuertoRicoMember" xlink:to="lab_bhc_UnitedStatesandPuertoRicoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_cfbd7fd4-3c76-4912-a9ad-52f95f7491ca_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5e736534-b437-439c-8083-7a799734c08a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_aa5dcb0d-e457-42ab-a2ef-f2a340a87e29_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_9a15c1ec-6f52-4f34-8964-8eb978c97813_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DiversifiedProductsSegmentMember_0d907689-1595-4be6-8e7f-44788b6f05af_terseLabel_en-US" xlink:label="lab_bhc_DiversifiedProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diversified Products</link:label>
    <link:label id="lab_bhc_DiversifiedProductsSegmentMember_label_en-US" xlink:label="lab_bhc_DiversifiedProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diversified Products Segment [Member]</link:label>
    <link:label id="lab_bhc_DiversifiedProductsSegmentMember_documentation_en-US" xlink:label="lab_bhc_DiversifiedProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diversified Products Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember" xlink:href="bhc-20220331.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DiversifiedProductsSegmentMember" xlink:to="lab_bhc_DiversifiedProductsSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_70054825-41ec-4626-a283-643bf554205e_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_b9879df7-e5d7-4f8e-a836-cef1c16ef08c_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternate term, principal amount maturity threshold</link:label>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_label_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Alternate Term, Principal Amount Maturity Threshold</link:label>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Alternate Term, Principal Amount Maturity Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:to="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccruedProductRebateCurrent_3f08c3af-ba90-4b99-9fc7-f2702c285b7f_terseLabel_en-US" xlink:label="lab_bhc_AccruedProductRebateCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product rebates</link:label>
    <link:label id="lab_bhc_AccruedProductRebateCurrent_label_en-US" xlink:label="lab_bhc_AccruedProductRebateCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Product Rebate Current</link:label>
    <link:label id="lab_bhc_AccruedProductRebateCurrent_documentation_en-US" xlink:label="lab_bhc_AccruedProductRebateCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the current portion of accrued product rebates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductRebateCurrent" xlink:href="bhc-20220331.xsd#bhc_AccruedProductRebateCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccruedProductRebateCurrent" xlink:to="lab_bhc_AccruedProductRebateCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_56c49796-cf8e-4576-9280-d11831af4aff_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic weighted-average common shares (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cea66be7-2999-4f94-9b6d-92d527d934c7_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic weighted-average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_f92a0aea-bd89-4323-84db-742620a353d7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted loss per share attributable to Bausch Health Companies Inc. (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_73b9bd04-4106-49e4-adfb-1a59fb06313b_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_e63e0e0e-966f-4bbc-8d24-182012d304ec_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and write-off of debt premiums, discounts and issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_942859b9-1bd4-4267-a130-7877697a57fb_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price of shares sold (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_e308549a-da37-45a4-946e-cd2c406273b4_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_225d848d-eb5f-4047-b8c9-2c0c6b4d85b5_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_0caf6291-013c-4a02-b82c-2dc5eb785523_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_d069a77a-0cf0-4820-945c-f63b1d71d806_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain excluded from assessment of hedge effectiveness</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_dd9b3484-c1e7-41c8-af7c-57dd4c69f092_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseMember_626fcb4f-71c7-422f-9710-cdc2c1895824_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseMember_label_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseMember" xlink:to="lab_us-gaap_InterestExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_RU_41c3782d-d093-4090-934d-f2cd122fbade_terseLabel_en-US" xlink:label="lab_country_RU" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Russia</link:label>
    <link:label id="lab_country_RU_label_en-US" xlink:label="lab_country_RU" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RUSSIAN FEDERATION</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_RU" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_RU"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_RU" xlink:to="lab_country_RU" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_8fd84547-9565-4df4-851a-4501f9d9a4e4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_NJ_727e7543-c0f9-4fc3-9db7-e5ce9e80b96f_terseLabel_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW JERSEY</link:label>
    <link:label id="lab_stpr_NJ_b196beea-2f3a-42bb-979b-bcc3bcbd1c54_verboseLabel_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Jersey</link:label>
    <link:label id="lab_stpr_NJ_label_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW JERSEY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_NJ"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NJ" xlink:to="lab_stpr_NJ" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_bdfd4d85-88b3-4bc7-b87d-e40bd4bb3271_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_b6dfc56b-6533-48ff-bed1-1df6b1243061_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to Bausch Health Companies Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_8f9be050-ed7a-4762-bd3f-e2ce4f805ffd_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_1dc67c90-a313-4208-b9fe-7ef8791cb3ca_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_ed5f9cdd-3538-4818-a3e5-fad854ba86db_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_2960e0e4-5b4d-4348-8989-10e9db09572b_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived intangible assets:</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_baf5cdac-9f14-4a35-90bc-94c4ccb0bb2e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_McKessonCorporationMember_069347a4-e5c8-4c90-a525-ba9f24902150_terseLabel_en-US" xlink:label="lab_bhc_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation (including McKesson Specialty)</link:label>
    <link:label id="lab_bhc_McKessonCorporationMember_label_en-US" xlink:label="lab_bhc_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mc Kesson Corporation [Member]</link:label>
    <link:label id="lab_bhc_McKessonCorporationMember_documentation_en-US" xlink:label="lab_bhc_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the major customer of the entity, McKesson Corporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_McKessonCorporationMember" xlink:href="bhc-20220331.xsd#bhc_McKessonCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_McKessonCorporationMember" xlink:to="lab_bhc_McKessonCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock_41d16d57-95df-4372-b50b-69222f544f04_terseLabel_en-US" xlink:label="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of variable consideration provisions</link:label>
    <link:label id="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock_label_en-US" xlink:label="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Valuation And Qualifying Accounts [Table Text Block]</link:label>
    <link:label id="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock_documentation_en-US" xlink:label="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Valuation And Qualifying Accounts [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:href="bhc-20220331.xsd#bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:to="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_4c1ae2f1-adf3-43e0-9138-52a827a839f7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_3534f128-f908-448c-8a6f-268be2d1e8fc_terseLabel_en-US" xlink:label="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairments</link:label>
    <link:label id="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_852706df-d6f8-4a87-b639-faaeab90f097_verboseLabel_en-US" xlink:label="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairments</link:label>
    <link:label id="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_8d4ce08d-cf96-49a0-872c-93604bd08409_negatedTerseLabel_en-US" xlink:label="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairments</link:label>
    <link:label id="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_label_en-US" xlink:label="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss, Not Included In Asset Impairment Charges</link:label>
    <link:label id="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_documentation_en-US" xlink:label="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss, Not Included In Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:href="bhc-20220331.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:to="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_e103b821-0b7d-4c87-92d2-bce2b6ff05b3_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, integration, separation, and IPO costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_c920de0c-ed07-469c-a51b-2a430464f30b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_58fc4d87-33f2-4113-84a8-13cd358fe6ef_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_de393358-5da9-4009-b733-8720de76b1e5_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch Health Companies&#160;Inc. Shareholders&#8217; (Deficit) Equity</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_75410c36-fffe-4104-b8f3-5305efcb4aff_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_0bee831f-bd52-4561-aee4-c578fce7d00c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_eeb8a658-1f29-459f-b57e-c17588957751_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of components and classification of financial assets and liabilities measured at fair value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccretionForTimeValueOfMoneyMember_fb93d0ee-106c-49a8-9e81-a72d590c6b0d_terseLabel_en-US" xlink:label="lab_bhc_AccretionForTimeValueOfMoneyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion for the time value of money</link:label>
    <link:label id="lab_bhc_AccretionForTimeValueOfMoneyMember_label_en-US" xlink:label="lab_bhc_AccretionForTimeValueOfMoneyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion For Time Value Of Money [Member]</link:label>
    <link:label id="lab_bhc_AccretionForTimeValueOfMoneyMember_documentation_en-US" xlink:label="lab_bhc_AccretionForTimeValueOfMoneyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion For Time Value Of Money [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccretionForTimeValueOfMoneyMember" xlink:href="bhc-20220331.xsd#bhc_AccretionForTimeValueOfMoneyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccretionForTimeValueOfMoneyMember" xlink:to="lab_bhc_AccretionForTimeValueOfMoneyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_6539ae4f-7e7f-4f55-ab29-1f63a688860c_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current accrued loss contingencies</link:label>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_label_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserveCurrent" xlink:to="lab_us-gaap_LitigationReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes6125DueApril2025Member_ef9dd635-e106-4235-8681-bb1498b869d4_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes6125DueApril2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.125% Senior Notes Due April 2025</link:label>
    <link:label id="lab_bhc_SeniorNotes6125DueApril2025Member_label_en-US" xlink:label="lab_bhc_SeniorNotes6125DueApril2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 6.125%, Due April 2025 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes6125DueApril2025Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes6125DueApril2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.125% Senior Notes due April 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member" xlink:href="bhc-20220331.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes6125DueApril2025Member" xlink:to="lab_bhc_SeniorNotes6125DueApril2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a7cb4c08-dfb1-4058-9f1b-e858cb097c6a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_39c084ad-f111-41af-a0c2-96e7d84fcd42_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_34eec8dc-d0ed-477f-af50-ade4802172db_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_4eb24bff-19b9-46fe-8cf2-6b3564bd9afb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnfavorableRegulatoryActionMember_c0e5b74e-3935-472a-9452-498a1d65677d_terseLabel_en-US" xlink:label="lab_us-gaap_UnfavorableRegulatoryActionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfavorable Regulatory Action</link:label>
    <link:label id="lab_us-gaap_UnfavorableRegulatoryActionMember_label_en-US" xlink:label="lab_us-gaap_UnfavorableRegulatoryActionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfavorable Regulatory Action [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnfavorableRegulatoryActionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnfavorableRegulatoryActionMember" xlink:to="lab_us-gaap_UnfavorableRegulatoryActionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_5e4b896b-e5cf-4cbd-926c-6971a9308fef_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense (income), net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_34d5257e-e2e7-40bb-9668-942fab7e0988_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_2767d5f8-77dd-4fd8-a63d-7269141a564e_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of shares held</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Percentage of Ownership after Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:to="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_a5e55113-ff68-4bbd-a78f-aa444827eb30_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_ca19ca6c-9f64-4947-82e8-f5cf6ef711d9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_367871d0-4328-4155-9b02-e96a223e747f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of effect of hedging instruments on financial statements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Investment Hedges, Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SoltaMedicalSegmentMember_27d3a24c-b849-40f8-ab44-334c5e959855_terseLabel_en-US" xlink:label="lab_bhc_SoltaMedicalSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solta Medical</link:label>
    <link:label id="lab_bhc_SoltaMedicalSegmentMember_label_en-US" xlink:label="lab_bhc_SoltaMedicalSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solta Medical Segment [Member]</link:label>
    <link:label id="lab_bhc_SoltaMedicalSegmentMember_documentation_en-US" xlink:label="lab_bhc_SoltaMedicalSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solta Medical Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SoltaMedicalSegmentMember" xlink:href="bhc-20220331.xsd#bhc_SoltaMedicalSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SoltaMedicalSegmentMember" xlink:to="lab_bhc_SoltaMedicalSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_3e0556de-f14e-47a3-8919-10ea36f76af3_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_3ef7f21e-b2d3-4604-95d3-61f9a44fce94_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant_ca6f778b-e395-459a-9e05-1f6acc8fb280_terseLabel_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate fair market value on awards granted during any calendar year</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant_label_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Plan Modification, Fair Market Value Limit On Annual Grant</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant_documentation_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Plan Modification, Fair Market Value Limit On Annual Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant" xlink:href="bhc-20220331.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant" xlink:to="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_404037d4-9b69-487b-b96d-d43bc469954c_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reporting units</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits" xlink:to="lab_us-gaap_NumberOfReportingUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_028cdc83-dfdd-46f5-9188-0c241cd88d2a_terseLabel_en-US" xlink:label="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates, Advertising Credits Portion</link:label>
    <link:label id="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_label_en-US" xlink:label="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Rebates, Advertising Credits Portion [Member]</link:label>
    <link:label id="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_documentation_en-US" xlink:label="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Rebates, Advertising Credits Portion [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:href="bhc-20220331.xsd#bhc_ReserveForRebatesAdvertisingCreditsPortionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:to="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_92cabff3-58d6-438a-86a2-dcb9b9d872c8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash proceeds from divestiture</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_c0b19117-f81a-404a-ba27-4418bd24b7b6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for intangible and other assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_1eb1a801-1e3d-4969-b4a6-e94a5613aa15_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_5fab837b-7245-4c4a-803f-6db1b4cb976f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d6ffd4c2-6b49-43b3-80cb-fc70289107ba_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive shares not included in the computation of diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_6f6dd505-ae84-40a6-885f-080d43444dfb_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_eb8d5c3e-1f3a-4784-b00e-186ae5937650_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure_8ac88235-6b2a-4d44-86ea-1aa9803b3220_terseLabel_en-US" xlink:label="lab_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and other settlement deposits</link:label>
    <link:label id="lab_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure_label_en-US" xlink:label="lab_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash And Cash Equivalents And Other Settlement Deposits, Fair Value Disclosure</link:label>
    <link:label id="lab_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure_documentation_en-US" xlink:label="lab_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash And Cash Equivalents And Other Settlement Deposits, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" xlink:href="bhc-20220331.xsd#bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" xlink:to="lab_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BauschLombInternationalMember_9185ac25-dfa4-4e0e-a557-07ff1b2a5c9f_terseLabel_en-US" xlink:label="lab_bhc_BauschLombInternationalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch + Lomb/ International</link:label>
    <link:label id="lab_bhc_BauschLombInternationalMember_label_en-US" xlink:label="lab_bhc_BauschLombInternationalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch + Lomb/International [Member]</link:label>
    <link:label id="lab_bhc_BauschLombInternationalMember_documentation_en-US" xlink:label="lab_bhc_BauschLombInternationalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch Lomb/International [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombInternationalMember" xlink:href="bhc-20220331.xsd#bhc_BauschLombInternationalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BauschLombInternationalMember" xlink:to="lab_bhc_BauschLombInternationalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_07f77916-5e4a-4db2-8795-f3393f736106_terseLabel_en-US" xlink:label="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Violation of Canadian Provincial Securities Legislation</link:label>
    <link:label id="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_label_en-US" xlink:label="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Violation of Canadian Provincial Securities Legislation [Member]</link:label>
    <link:label id="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_documentation_en-US" xlink:label="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Violation of Canadian Provincial Securities Legislation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:href="bhc-20220331.xsd#bhc_ViolationofCanadianProvincialSecuritiesLegislationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:to="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_d7cbf38e-fce6-4ff5-bd62-266440b870bb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_ae06cc56-8025-4aad-8f28-6f7af052e12a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ProductBrandsMember_d3a32e8a-dca4-48d4-99e8-930f57a8b90d_terseLabel_en-US" xlink:label="lab_bhc_ProductBrandsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product brands</link:label>
    <link:label id="lab_bhc_ProductBrandsMember_label_en-US" xlink:label="lab_bhc_ProductBrandsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Brands [Member]</link:label>
    <link:label id="lab_bhc_ProductBrandsMember_documentation_en-US" xlink:label="lab_bhc_ProductBrandsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the rights to non-patented product brands.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProductBrandsMember" xlink:href="bhc-20220331.xsd#bhc_ProductBrandsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ProductBrandsMember" xlink:to="lab_bhc_ProductBrandsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_fab4676a-b571-441e-9c12-26ee8ae3c1f0_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_402c3e32-c443-40a7-aa53-f18369a44e32_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_f44f4d7b-1d7f-4100-a031-cfa26b62cf53_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of entities, exercised opt-out right, pursuing action</link:label>
    <link:label id="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_label_en-US" xlink:label="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action</link:label>
    <link:label id="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_documentation_en-US" xlink:label="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:href="bhc-20220331.xsd#bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:to="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_15cadfb2-fd4b-4298-9de0-7b6213fcb90d_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_665e47c6-e93c-4fe1-a241-4a4d32bceac2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_8b8821c0-9195-48ee-aa43-d24026850c48_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold for incremental borrowings</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Threshold For Incremental Borrowings</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Threshold For Incremental Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:href="bhc-20220331.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:to="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CanadaBankersAcceptanceRateMember_095af6d0-023e-4efd-9de8-5a8f1d1e8340_terseLabel_en-US" xlink:label="lab_bhc_CanadaBankersAcceptanceRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada Bankers Acceptance Rate</link:label>
    <link:label id="lab_bhc_CanadaBankersAcceptanceRateMember_label_en-US" xlink:label="lab_bhc_CanadaBankersAcceptanceRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada Bankers Acceptance Rate [Member]</link:label>
    <link:label id="lab_bhc_CanadaBankersAcceptanceRateMember_documentation_en-US" xlink:label="lab_bhc_CanadaBankersAcceptanceRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada Bankers Acceptance Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CanadaBankersAcceptanceRateMember" xlink:href="bhc-20220331.xsd#bhc_CanadaBankersAcceptanceRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CanadaBankersAcceptanceRateMember" xlink:to="lab_bhc_CanadaBankersAcceptanceRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OutLicensedTechnologyMember_53181c95-6c9c-48bc-83de-8018b5066617_terseLabel_en-US" xlink:label="lab_bhc_OutLicensedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology and other</link:label>
    <link:label id="lab_bhc_OutLicensedTechnologyMember_label_en-US" xlink:label="lab_bhc_OutLicensedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Out Licensed Technology [Member]</link:label>
    <link:label id="lab_bhc_OutLicensedTechnologyMember_documentation_en-US" xlink:label="lab_bhc_OutLicensedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the rights to receive cash flows under an out-license arrangement (for example, license fees, milestone payments and royalties).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OutLicensedTechnologyMember" xlink:href="bhc-20220331.xsd#bhc_OutLicensedTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OutLicensedTechnologyMember" xlink:to="lab_bhc_OutLicensedTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_d182aca0-43b0-4467-9866-e5c2c0670d88_terseLabel_en-US" xlink:label="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowances for losses on trade receivable and inventories</link:label>
    <link:label id="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_label_en-US" xlink:label="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowances for Losses on Accounts Receivable and Inventories</link:label>
    <link:label id="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_documentation_en-US" xlink:label="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of the current period expense charged against operations (1) for the purpose of reducing receivables to an amount that approximates their net realizable value and (2) the charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:href="bhc-20220331.xsd#bhc_AllowancesForLossesOnAccountsReceivableAndInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:to="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_d2c8bd91-7174-4fc0-8114-5e84ae2e648e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossLiability_510acd5b-f96e-4f03-b977-714b7379d146_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:to="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueMay2027Member_4f2d9176-3b51-45a6-ad64-cb93ca2912c5_terseLabel_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueMay2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due May 2027</link:label>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueMay2027Member_label_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueMay2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due May 2027 [Member]</link:label>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueMay2027Member_documentation_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueMay2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due May 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueMay2027Member" xlink:href="bhc-20220331.xsd#bhc_RevolvingCreditFacilityDueMay2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RevolvingCreditFacilityDueMay2027Member" xlink:to="lab_bhc_RevolvingCreditFacilityDueMay2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_1fe497d2-4657-4868-9d7c-163ce1a8fbf0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of estimated aggregate amortization expense for each of the five succeeding years</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2ee5beef-3769-4a73-946f-7cb0d56be09f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_12de3396-2987-4480-878a-b7056d993eb9_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of unamortized debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_656c130f-b2dc-4964-844e-83e4641c03ad_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_547e3ad4-decd-4d96-917f-ce6d8ebc8da7_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_e8991071-efaf-48c6-87c9-d5fecf148874_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_e102ff3f-3d23-4cc9-944a-04bff4b68094_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_9b2445ab-51e8-4d32-bda6-7f8ae803510e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency exchange contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_43837f06-7418-426d-b090-dc42705dc148_periodStartLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_47e8f460-11fb-4c5e-b97b-392773d8192a_periodEndLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_1acd7c6b-c191-4d8b-b1c1-775544b94998_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksMember_3be2a77f-2a18-47d4-bcf4-24f72000e529_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch + Lomb Trademark</link:label>
    <link:label id="lab_us-gaap_TrademarksMember_label_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksMember" xlink:to="lab_us-gaap_TrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_dd0f2cf9-f5cb-4bb1-9c84-c88d339bef7d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_385c1ef4-fa61-4d59-8735-e45c8bedbdac_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency exchange contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock_5e54348d-49f4-4643-8ed0-28ba07f84155_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of foreign exchange contracts on the Consolidated Statements of Operations and Consolidated Statements of Cash Flows</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments Included in Trading Activities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_2f4f5f36-c2d0-401e-b403-fda22216b553_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total leverage ratio (not greater than)</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Total Leverage Ratio, Maximum</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Total Leverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:to="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BaseRateOrPrimeRateMember_2856836a-5ef4-4ff9-848f-a13ba209b9a1_terseLabel_en-US" xlink:label="lab_bhc_BaseRateOrPrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate or Prime Rate</link:label>
    <link:label id="lab_bhc_BaseRateOrPrimeRateMember_label_en-US" xlink:label="lab_bhc_BaseRateOrPrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate Or Prime Rate [Member]</link:label>
    <link:label id="lab_bhc_BaseRateOrPrimeRateMember_documentation_en-US" xlink:label="lab_bhc_BaseRateOrPrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate Or Prime Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BaseRateOrPrimeRateMember" xlink:href="bhc-20220331.xsd#bhc_BaseRateOrPrimeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BaseRateOrPrimeRateMember" xlink:to="lab_bhc_BaseRateOrPrimeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_f775abb3-16f1-4dec-994a-653e946f1eec_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_ec93373d-b98c-4e35-87f3-44e2d77f325f_terseLabel_en-US" xlink:label="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower to Shower Product Liability Litigation, Alleging Caused Ovarian Cancer, Mesothelioma or Breast Cancer</link:label>
    <link:label id="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_label_en-US" xlink:label="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower To Shower Product Liability Litigation, Alleging Caused Ovarian Cancer, Mesothelioma Or Breast Cancer [Member]</link:label>
    <link:label id="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_documentation_en-US" xlink:label="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower To Shower Product Liability Litigation, Alleging Caused Ovarian Cancer, Mesothelioma Or Breast Cancer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" xlink:href="bhc-20220331.xsd#bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" xlink:to="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes900DueDecember2025Member_171f548b-8982-4771-bad6-c7c37232e6b0_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes900DueDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.00% Senior Notes Due December 2025</link:label>
    <link:label id="lab_bhc_SeniorNotes900DueDecember2025Member_label_en-US" xlink:label="lab_bhc_SeniorNotes900DueDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 9.00%, Due December 2025 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes900DueDecember2025Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes900DueDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.00% Senior Notes due December 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes900DueDecember2025Member" xlink:href="bhc-20220331.xsd#bhc_SeniorNotes900DueDecember2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes900DueDecember2025Member" xlink:to="lab_bhc_SeniorNotes900DueDecember2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_67ffdfc3-5aee-4d0e-8ed2-2a5cf5b31a00_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_1ba3d7e1-0385-4a92-954b-6849e7ce7fa1_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_28646750-bd58-42ba-9a18-5b943247f615_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of possible loss, income tax examination (up to)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:to="lab_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_c6e90477-601c-496e-8c1f-0a898fa7bb0b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_1391b020-3ae2-4ab2-a50e-c76bc7f9d945_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_8d9b5329-892d-4d4a-84a3-cd2617b07c13_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_cd667aba-71a1-4cca-a792-43da2f6db711_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain_e68e75d2-a349-4baf-8d45-b47505abb60c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain related to settlements</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_80193ba2-d099-4ac9-97d1-f0cc1c3fc893_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_227c8c56-11ab-49a0-9fd2-432e3cf692d2_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_b1887d3a-93bf-42e2-9f71-077f01435264_netLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_36f5acc3-73b8-4c49-b40b-6dd8cbaffcf9_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_f0233562-2d57-4fe5-853d-8c3085c58970_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_140d2bfc-7f46-425c-9f3b-5d8b503916aa_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_1eaedb61-465c-4501-a467-3f36d7cdfb69_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_NewRestatedCreditAgreementMember_dd05b15b-7bba-4525-9ad6-4e7d8e5169a9_terseLabel_en-US" xlink:label="lab_bhc_NewRestatedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Restated Credit Agreement</link:label>
    <link:label id="lab_bhc_NewRestatedCreditAgreementMember_label_en-US" xlink:label="lab_bhc_NewRestatedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Restated Credit Agreement [Member]</link:label>
    <link:label id="lab_bhc_NewRestatedCreditAgreementMember_documentation_en-US" xlink:label="lab_bhc_NewRestatedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Restated Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NewRestatedCreditAgreementMember" xlink:href="bhc-20220331.xsd#bhc_NewRestatedCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_NewRestatedCreditAgreementMember" xlink:to="lab_bhc_NewRestatedCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6bfeb655-6ded-4e9a-adad-2e8d57c0d445_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4484ac25-93ef-4b35-aee2-d4e7ed0b691d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_38f8650d-50ba-46a9-8571-770b02ccd02f_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CardinalHealthIncMember_901c4637-a1bd-4d4e-8e9a-0193c776b598_terseLabel_en-US" xlink:label="lab_bhc_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health,&#160;Inc.</link:label>
    <link:label id="lab_bhc_CardinalHealthIncMember_label_en-US" xlink:label="lab_bhc_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health Inc [Member]</link:label>
    <link:label id="lab_bhc_CardinalHealthIncMember_documentation_en-US" xlink:label="lab_bhc_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the major customer of the entity, Cardinal Health, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CardinalHealthIncMember" xlink:href="bhc-20220331.xsd#bhc_CardinalHealthIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CardinalHealthIncMember" xlink:to="lab_bhc_CardinalHealthIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_6e2ded1d-defa-4aef-9767-f581ed5bdc18_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Plan</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DiscontinuedProductLinesMember_f95e5b77-cb9f-44d7-af40-f59acd415b9b_terseLabel_en-US" xlink:label="lab_bhc_DiscontinuedProductLinesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Product Lines</link:label>
    <link:label id="lab_bhc_DiscontinuedProductLinesMember_label_en-US" xlink:label="lab_bhc_DiscontinuedProductLinesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Product Lines [Member]</link:label>
    <link:label id="lab_bhc_DiscontinuedProductLinesMember_documentation_en-US" xlink:label="lab_bhc_DiscontinuedProductLinesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Product Lines</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiscontinuedProductLinesMember" xlink:href="bhc-20220331.xsd#bhc_DiscontinuedProductLinesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DiscontinuedProductLinesMember" xlink:to="lab_bhc_DiscontinuedProductLinesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_970d53af-b918-495e-a4bf-96abce64dcd5_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_31b4d169-5d43-4eb2-aeaa-0e8a620995e4_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_7c96fb32-c03d-4a1e-9cef-d74cbb01f52d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_96ca7d00-c9e5-491e-8076-41aafcfcdec6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_0b506480-98b1-4a92-9d2f-34bd613396fb_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_c63461a7-c616-40be-ab7b-9b1987defacf_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_ad5b7b8e-1bec-47d7-a9ee-04ab2810a023_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_8aae2f52-b906-49f7-8ac6-a16beb1be4de_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_4f2ee9de-da6d-4a5b-9e7b-e60cd3f2e4a5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PatentInfringementLitigationMember_934c70dc-af71-4fa6-bfd9-71dd0edad7e4_terseLabel_en-US" xlink:label="lab_bhc_PatentInfringementLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Infringement Litigation</link:label>
    <link:label id="lab_bhc_PatentInfringementLitigationMember_label_en-US" xlink:label="lab_bhc_PatentInfringementLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Infringement Litigation [Member]</link:label>
    <link:label id="lab_bhc_PatentInfringementLitigationMember_documentation_en-US" xlink:label="lab_bhc_PatentInfringementLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Infringement Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PatentInfringementLitigationMember" xlink:href="bhc-20220331.xsd#bhc_PatentInfringementLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PatentInfringementLitigationMember" xlink:to="lab_bhc_PatentInfringementLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_3d0b10a3-29d4-49bd-9f81-c0ab539468ea_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets:</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_425b4644-c63b-472e-a79e-5529b1591460_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, held for sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_79de1453-a638-42ee-93c3-097d97ae7532_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_a51f1beb-51d7-499e-8b07-fbc432057ccd_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OrthoDermatologicsSegmentMember_ce271aea-6dec-4c62-b86d-7cb96b45fd84_verboseLabel_en-US" xlink:label="lab_bhc_OrthoDermatologicsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ortho Dermatologics</link:label>
    <link:label id="lab_bhc_OrthoDermatologicsSegmentMember_label_en-US" xlink:label="lab_bhc_OrthoDermatologicsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ortho Dermatologics Segment [Member]</link:label>
    <link:label id="lab_bhc_OrthoDermatologicsSegmentMember_documentation_en-US" xlink:label="lab_bhc_OrthoDermatologicsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ortho Dermatologics Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember" xlink:href="bhc-20220331.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OrthoDermatologicsSegmentMember" xlink:to="lab_bhc_OrthoDermatologicsSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_12aa4ef4-f4fc-4f0b-bab1-503b78f1d089_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_f1d7e50d-4caf-441c-9b01-297dab214cb5_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_c2af7f17-a1bd-4b5d-92f3-708cf2621af2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_4e43103b-e8a4-48e1-8c1e-2a4891d8d063_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_edcc996c-c11a-4b8d-8899-e05bd192abe3_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted weighted-average common shares (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ea3847b0-dcff-4a79-b659-9ea12d3bf1a1_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted weighted-average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_38f282a9-2a52-466c-9bda-f81ff41174e2_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_044d22a3-5e57-4372-bfc1-b9893364395e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_3d43cae4-70d6-419b-8d0e-13a59326240a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationMember_d7c74c0e-90eb-4011-8d62-677eb872839f_terseLabel_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Litigation</link:label>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationMember_label_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Litigation [Member]</link:label>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationMember_documentation_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Class Actions Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationMember" xlink:href="bhc-20220331.xsd#bhc_GlumetzaAntitrustLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GlumetzaAntitrustLitigationMember" xlink:to="lab_bhc_GlumetzaAntitrustLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_362433c8-2c9a-4fc7-a700-1ec0cdfc4534_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_5ee0875a-86a5-4e3a-b80e-25f7595948a8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_ba9c2305-af12-422b-98aa-37e4ed1468fd_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_54ae7e82-2f88-4555-a087-0d98f9b1f221_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_b6c703c5-70ff-4944-9104-4cc18c9f083d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_2e8e2e56-7683-403d-b230-edc8f6374f01_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-offs</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_18426e7e-ef76-449e-819f-e7c47fe046b8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of net periodic benefit cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeparationAndInitialPublicOfferingCostsMember_8f0009ad-d1e5-4785-abf1-49d97bd4b8c1_terseLabel_en-US" xlink:label="lab_bhc_SeparationAndInitialPublicOfferingCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation and IPO Costs</link:label>
    <link:label id="lab_bhc_SeparationAndInitialPublicOfferingCostsMember_label_en-US" xlink:label="lab_bhc_SeparationAndInitialPublicOfferingCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation And Initial Public Offering Costs [Member]</link:label>
    <link:label id="lab_bhc_SeparationAndInitialPublicOfferingCostsMember_documentation_en-US" xlink:label="lab_bhc_SeparationAndInitialPublicOfferingCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation And Initial Public Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeparationAndInitialPublicOfferingCostsMember" xlink:href="bhc-20220331.xsd#bhc_SeparationAndInitialPublicOfferingCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeparationAndInitialPublicOfferingCostsMember" xlink:to="lab_bhc_SeparationAndInitialPublicOfferingCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_396d7455-f8d9-46d3-8e2a-5b4db5770d09_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_772174fb-d0db-4d6f-86ba-115123204b72_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OmnibusIncentivePlan2014Member_9238ff2f-f995-4ec3-8a45-0f10692b0daf_terseLabel_en-US" xlink:label="lab_bhc_OmnibusIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Plan</link:label>
    <link:label id="lab_bhc_OmnibusIncentivePlan2014Member_label_en-US" xlink:label="lab_bhc_OmnibusIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omnibus Incentive Plan 2014 [Member]</link:label>
    <link:label id="lab_bhc_OmnibusIncentivePlan2014Member_documentation_en-US" xlink:label="lab_bhc_OmnibusIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omnibus Incentive Plan 2014 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OmnibusIncentivePlan2014Member" xlink:href="bhc-20220331.xsd#bhc_OmnibusIncentivePlan2014Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OmnibusIncentivePlan2014Member" xlink:to="lab_bhc_OmnibusIncentivePlan2014Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrencySwapMember_767622bf-43bf-4dbe-939b-70b00c0ec1c1_terseLabel_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency Swap</link:label>
    <link:label id="lab_us-gaap_CurrencySwapMember_label_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrencySwapMember" xlink:to="lab_us-gaap_CurrencySwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OtherCountriesMember_ae512578-9f41-4196-818e-441700db34c6_terseLabel_en-US" xlink:label="lab_bhc_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_bhc_OtherCountriesMember_label_en-US" xlink:label="lab_bhc_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Countries [Member]</link:label>
    <link:label id="lab_bhc_OtherCountriesMember_documentation_en-US" xlink:label="lab_bhc_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Countries [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherCountriesMember" xlink:href="bhc-20220331.xsd#bhc_OtherCountriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OtherCountriesMember" xlink:to="lab_bhc_OtherCountriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SOFRCDOREURIBORAndSONIARatesMember_b0585b58-5d51-4a5c-92aa-5a8cf70d3067_terseLabel_en-US" xlink:label="lab_bhc_SOFRCDOREURIBORAndSONIARatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR, CDOR, EURIBOR and SONIA Rates</link:label>
    <link:label id="lab_bhc_SOFRCDOREURIBORAndSONIARatesMember_label_en-US" xlink:label="lab_bhc_SOFRCDOREURIBORAndSONIARatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR, CDOR, EURIBOR and SONIA Rates [Member]</link:label>
    <link:label id="lab_bhc_SOFRCDOREURIBORAndSONIARatesMember_documentation_en-US" xlink:label="lab_bhc_SOFRCDOREURIBORAndSONIARatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR, CDOR, EURIBOR and SONIA Rates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SOFRCDOREURIBORAndSONIARatesMember" xlink:href="bhc-20220331.xsd#bhc_SOFRCDOREURIBORAndSONIARatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SOFRCDOREURIBORAndSONIARatesMember" xlink:to="lab_bhc_SOFRCDOREURIBORAndSONIARatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_3385347b-31b0-4d55-bdc7-0219b56ebdcd_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_72e515f4-59bf-42a4-9ce1-3b20b8098304_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_4ba6d427-4392-4ecd-ae58-d35e0fbcfc8b_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_ea05a024-a113-454b-afa2-4b38aa2dea6c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_78e4bfca-7568-4450-a1bf-766ae9ee4122_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_549e3289-b069-4cfd-ad75-6aa683b8d0e2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_a4af1921-d7ec-4639-ae4e-0c83ca2a97f1_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9ae48778-4a75-4692-a3cf-4a43f085ee9f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_acb546e5-fb7a-476b-8168-8642e4489d2e_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_bf30e9c7-6d28-484a-94e2-6cfc3faed01d_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_fa44548b-87ae-4a93-986b-277289d11e39_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_07a7805d-ade3-4ed8-a44e-c80f0c975220_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of employee withholding taxes related to share-based awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member_6de950e1-c318-407f-960c-99b9384fa551_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Senior Notes Due November 2025</link:label>
    <link:label id="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member_label_en-US" xlink:label="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 5.50% Notes Due November 2025 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 5.50% Notes Due November 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:href="bhc-20220331.xsd#bhc_SeniorSecured5.50NotesDueNovember2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:to="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_2c988f0d-5941-4d14-b360-f8cafe62b475_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LitigationwithFormerSalixCEOMember_0bec5e89-f3ac-4e13-b454-c97399b22574_terseLabel_en-US" xlink:label="lab_bhc_LitigationwithFormerSalixCEOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation with Former Salix CEO</link:label>
    <link:label id="lab_bhc_LitigationwithFormerSalixCEOMember_label_en-US" xlink:label="lab_bhc_LitigationwithFormerSalixCEOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation with Former Salix CEO [Member]</link:label>
    <link:label id="lab_bhc_LitigationwithFormerSalixCEOMember_documentation_en-US" xlink:label="lab_bhc_LitigationwithFormerSalixCEOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation with Former Salix CEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LitigationwithFormerSalixCEOMember" xlink:href="bhc-20220331.xsd#bhc_LitigationwithFormerSalixCEOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LitigationwithFormerSalixCEOMember" xlink:to="lab_bhc_LitigationwithFormerSalixCEOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_a15e87ee-337c-4b4c-84db-d994be5ca94f_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_4126308f-e539-405b-8a04-9e47aeb4000e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange and other</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_7fec559e-0459-480d-8ade-1141a2c183f2_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_dce9645b-98eb-491a-bdab-52b591a56f80_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_f20049dc-110a-4b1f-b8bc-c80c3d42cd15_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment reporting information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_9ec06a34-a88d-4adf-b504-201e2e53824a_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_33db85e1-a163-4e58-8e97-fc8373c5933f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized premiums, discounts and issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForRebatesMember_219b7c99-447c-48fe-8d75-80d728c8f0a5_terseLabel_en-US" xlink:label="lab_bhc_ReserveForRebatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates</link:label>
    <link:label id="lab_bhc_ReserveForRebatesMember_label_en-US" xlink:label="lab_bhc_ReserveForRebatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Rebates [Member]</link:label>
    <link:label id="lab_bhc_ReserveForRebatesMember_documentation_en-US" xlink:label="lab_bhc_ReserveForRebatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Rebates [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesMember" xlink:href="bhc-20220331.xsd#bhc_ReserveForRebatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForRebatesMember" xlink:to="lab_bhc_ReserveForRebatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_ebeb853d-5536-498e-99ff-d47269434528_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_b857d971-1f0d-4d22-a6ab-11d40cea2e1e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of accrued legal settlements</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_e07599c1-1cdc-4ace-9637-43f7d6105ebb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ApotexIncLitigationMember_3f9a5058-9609-40fa-8dce-652507e61e90_terseLabel_en-US" xlink:label="lab_bhc_ApotexIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apotex Inc. Litigation</link:label>
    <link:label id="lab_bhc_ApotexIncLitigationMember_label_en-US" xlink:label="lab_bhc_ApotexIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apotex Inc. Litigation [Member]</link:label>
    <link:label id="lab_bhc_ApotexIncLitigationMember_documentation_en-US" xlink:label="lab_bhc_ApotexIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apotex Inc. Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ApotexIncLitigationMember" xlink:href="bhc-20220331.xsd#bhc_ApotexIncLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ApotexIncLitigationMember" xlink:to="lab_bhc_ApotexIncLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember_48f25b5d-e25b-48f9-b0ad-7c72365cabf9_terseLabel_en-US" xlink:label="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MSN Laboratories Private Ltd. Litigation</link:label>
    <link:label id="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember_label_en-US" xlink:label="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MSN Laboratories Private Ltd. Litigation [Member]</link:label>
    <link:label id="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember_documentation_en-US" xlink:label="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MSN Laboratories Private Ltd. Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember" xlink:href="bhc-20220331.xsd#bhc_MSNLaboratoriesPrivateLtdLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember" xlink:to="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_122c97d2-e42d-45bf-bb38-b55b345e0340_terseLabel_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Funds</link:label>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_label_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fed Funds Effective Rate Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:to="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_f04e38e4-9591-40b7-bff0-f1a22f65e9d4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA-QC_f2400f3d-2183-4c17-a64f-f312681fa2d6_terseLabel_en-US" xlink:label="lab_stpr_CA-QC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">QUEBEC</link:label>
    <link:label id="lab_stpr_CA-QC_label_en-US" xlink:label="lab_stpr_CA-QC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">QUEBEC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-QC" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA-QC"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA-QC" xlink:to="lab_stpr_CA-QC" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_563eec79-3487-4d0f-9b58-2b9f08e8e160_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_da05e126-efd6-405b-8ad3-c2dbb6f05d05_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining unrecognized compensation expense related to non-vested awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_21a2bd78-ad6f-47c0-8fd8-78e88e9c4516_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount_b13703b7-e48b-4fdc-be3a-f9cd7e282efb_terseLabel_en-US" xlink:label="lab_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excluded from computation of earnings per share, performance conditions not met (in shares)</link:label>
    <link:label id="lab_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount_label_en-US" xlink:label="lab_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Excluded From Computation Of Earnings Per Share, Performance Conditions Not Met, Amount</link:label>
    <link:label id="lab_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount_documentation_en-US" xlink:label="lab_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Excluded From Computation Of Earnings Per Share, Performance Conditions Not Met, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount" xlink:href="bhc-20220331.xsd#bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount" xlink:to="lab_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_455809d3-b4dd-4e77-87e2-651b6f780ce2_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of suits filed</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_b314d1e5-701e-4d15-9709-d71c849f6d75_verboseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of putative antitrust class actions filed</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_26662d9f-0947-4ef9-ad61-a0d58f67e4c3_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_fbb6039d-625f-4afa-b317-dc286e7bdd6f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit) on ordinary loss</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_00d94fd0-a7fb-4e5d-a725-3cec11afcdf2_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ValeantUSSecuritiesLitigationMember_bcbb5952-159b-467b-bd24-54c2ab29e11c_terseLabel_en-US" xlink:label="lab_bhc_ValeantUSSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Securities Litigation</link:label>
    <link:label id="lab_bhc_ValeantUSSecuritiesLitigationMember_label_en-US" xlink:label="lab_bhc_ValeantUSSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valeant US Securities Litigation [Member]</link:label>
    <link:label id="lab_bhc_ValeantUSSecuritiesLitigationMember_documentation_en-US" xlink:label="lab_bhc_ValeantUSSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valeant US Securities Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember" xlink:href="bhc-20220331.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ValeantUSSecuritiesLitigationMember" xlink:to="lab_bhc_ValeantUSSecuritiesLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_458b54c3-7e3e-4de7-a8f6-fa55c446d024_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_89ebbcac-ed28-4545-bd48-be5c0d6705dd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss related to settlements</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_4bd0041f-c230-46df-b620-69f1ff1c8d2f_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_fb1bbcc4-1ed6-4060-9023-06af144c5d86_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_Goodwill_a13fb507-c77a-4e01-b2c8-62db9ee5aaf9_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the end of the period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_5255b2a5-d0f8-4d04-b684-443a335a0c89_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_63fb09fd-7b0e-4328-8e23-4ec5d6b44c8b_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cooperative advertising credits included in rebates</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_f06af95e-4918-43f5-9e71-2e2a1d8396db_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve beginning balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_5d6b6ed0-1118-45bc-8245-8f593b02d407_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve ending balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_0468736a-a00e-4063-a18d-d6861581c655_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_ecc61d83-b4bf-4b82-9cfb-97d570e2d94c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of changes in the carrying amount of goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_7d831dad-d4e1-4330-b052-9ae66412619a_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DESCRIPTION OF BUSINESS</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1d0c30a1-e0f2-4eb2-91d1-de80307944b3_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_c74aa8b0-9cad-49a0-97eb-814266ef657d_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of cash proceeds from asset sales outside the ordinary course of business payable as mandatory prepayments</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Percentage of Net Cash Proceeds from Asset Sales Outside Ordinary Course of Business Payable as Mandatory Prepayments</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of net cash proceeds from asset sales outside ordinary course of business payable as mandatory prepayments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" xlink:href="bhc-20220331.xsd#bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" xlink:to="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_45d4cfa0-1e5a-4dbd-962b-0c7dd1a1ba14_terseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_64c0a45e-b39d-44cb-a614-fcf8fcb09163_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_f8efa7a7-c04f-47ed-92b5-f851357ce2af_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of assets and liabilities associated with derivatives, included in the Consolidated Balance Sheets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA_f7cd5231-da30-49a6-b1a8-7f946123be74_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold for incremental borrowings, percentage of adjusted EBITDA</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Threshold For Incremental Borrowings, Percentage Of Adjusted EBITDA</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Threshold For Incremental Borrowings, Percentage Of Adjusted EBITDA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA" xlink:href="bhc-20220331.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA" xlink:to="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PadagisLitigationMember_7024d2b3-4b5d-4c61-be0b-ee753b44d437_terseLabel_en-US" xlink:label="lab_bhc_PadagisLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Padagis Litigation</link:label>
    <link:label id="lab_bhc_PadagisLitigationMember_label_en-US" xlink:label="lab_bhc_PadagisLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Padagis Litigation [Member]</link:label>
    <link:label id="lab_bhc_PadagisLitigationMember_documentation_en-US" xlink:label="lab_bhc_PadagisLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Padagis Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PadagisLitigationMember" xlink:href="bhc-20220331.xsd#bhc_PadagisLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PadagisLitigationMember" xlink:to="lab_bhc_PadagisLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_b2acf085-36b7-4b1c-bdcc-bd36df072aae_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_0cb36886-0258-49e0-b2a0-bc1efc83d511_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_2603bebf-e37a-4299-92af-e4a903a9765f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and postretirement benefit plan adjustments, net of income taxes</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RevenuesNetMember_9c6cc77e-ab64-4f15-b9e4-47b29423626c_terseLabel_en-US" xlink:label="lab_bhc_RevenuesNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_bhc_RevenuesNetMember_label_en-US" xlink:label="lab_bhc_RevenuesNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues Net [Member]</link:label>
    <link:label id="lab_bhc_RevenuesNetMember_documentation_en-US" xlink:label="lab_bhc_RevenuesNetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate net revenues during the period in the normal course of business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuesNetMember" xlink:href="bhc-20220331.xsd#bhc_RevenuesNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RevenuesNetMember" xlink:to="lab_bhc_RevenuesNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_775c52cc-654a-420a-a99a-e5f0ac1819c9_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax provision (benefit) related to changes in uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>bhc-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:9c0993e0-3c65-4e23-b478-aba95d934319,g:036e3555-df42-4f12-aaee-1876eac48ef4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.bauschhealth.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="bhc-20220331.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_20d1e7eb-f53c-489b-ad16-dfda6b392c19" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_3f1aec5a-81d8-47ec-a9f0-360cef02e48f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20d1e7eb-f53c-489b-ad16-dfda6b392c19" xlink:to="loc_dei_DocumentType_3f1aec5a-81d8-47ec-a9f0-360cef02e48f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_95dcf258-d5d3-4b5f-aee9-8a25045b2fe0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20d1e7eb-f53c-489b-ad16-dfda6b392c19" xlink:to="loc_dei_DocumentQuarterlyReport_95dcf258-d5d3-4b5f-aee9-8a25045b2fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_f6b687e4-1999-423b-a20a-1adcbecbc5b2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20d1e7eb-f53c-489b-ad16-dfda6b392c19" xlink:to="loc_dei_DocumentPeriodEndDate_f6b687e4-1999-423b-a20a-1adcbecbc5b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_0e85997d-7de0-4947-a36d-3caefc0f6002" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20d1e7eb-f53c-489b-ad16-dfda6b392c19" xlink:to="loc_dei_DocumentTransitionReport_0e85997d-7de0-4947-a36d-3caefc0f6002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_d52b21f7-08ae-4d11-ade9-2c44900b8043" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20d1e7eb-f53c-489b-ad16-dfda6b392c19" xlink:to="loc_dei_EntityFileNumber_d52b21f7-08ae-4d11-ade9-2c44900b8043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_a310c223-2da6-4df6-bba3-2cad295c5557" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20d1e7eb-f53c-489b-ad16-dfda6b392c19" xlink:to="loc_dei_EntityRegistrantName_a310c223-2da6-4df6-bba3-2cad295c5557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_d643fcad-be8c-4b0c-b6c9-f70e781fb5ac" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20d1e7eb-f53c-489b-ad16-dfda6b392c19" xlink:to="loc_dei_EntityIncorporationStateCountryCode_d643fcad-be8c-4b0c-b6c9-f70e781fb5ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_9b8480dd-319f-427b-91ab-c631639b6d38" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20d1e7eb-f53c-489b-ad16-dfda6b392c19" xlink:to="loc_dei_EntityAddressCountry_9b8480dd-319f-427b-91ab-c631639b6d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_b50a44ed-5b7c-4980-86ba-934227e9ecee" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20d1e7eb-f53c-489b-ad16-dfda6b392c19" xlink:to="loc_dei_EntityTaxIdentificationNumber_b50a44ed-5b7c-4980-86ba-934227e9ecee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_f722647e-fa95-4a2f-8002-f15983cf83bf" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20d1e7eb-f53c-489b-ad16-dfda6b392c19" xlink:to="loc_dei_EntityAddressAddressLine1_f722647e-fa95-4a2f-8002-f15983cf83bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_d373fd97-04b0-47be-8cca-923b8e1c19de" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20d1e7eb-f53c-489b-ad16-dfda6b392c19" xlink:to="loc_dei_EntityAddressCityOrTown_d373fd97-04b0-47be-8cca-923b8e1c19de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_fcdc326a-80cf-4635-abdf-d854808e0d43" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20d1e7eb-f53c-489b-ad16-dfda6b392c19" xlink:to="loc_dei_EntityAddressStateOrProvince_fcdc326a-80cf-4635-abdf-d854808e0d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_4f2ae008-5ef4-4ba9-a850-9e61017ee97c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20d1e7eb-f53c-489b-ad16-dfda6b392c19" xlink:to="loc_dei_EntityAddressPostalZipCode_4f2ae008-5ef4-4ba9-a850-9e61017ee97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_acd837e5-980e-4ffc-8d56-f53ad75d6fd8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20d1e7eb-f53c-489b-ad16-dfda6b392c19" xlink:to="loc_dei_CityAreaCode_acd837e5-980e-4ffc-8d56-f53ad75d6fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_229e89b0-d8af-4c93-8ad9-28f20519ff8b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20d1e7eb-f53c-489b-ad16-dfda6b392c19" xlink:to="loc_dei_LocalPhoneNumber_229e89b0-d8af-4c93-8ad9-28f20519ff8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_b0c6f175-5f6a-42ca-a6ae-eff3ce0ce2d3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20d1e7eb-f53c-489b-ad16-dfda6b392c19" xlink:to="loc_dei_Security12bTitle_b0c6f175-5f6a-42ca-a6ae-eff3ce0ce2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_0e05c4b5-4e89-465c-a32c-dc0fda11a8d8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20d1e7eb-f53c-489b-ad16-dfda6b392c19" xlink:to="loc_dei_TradingSymbol_0e05c4b5-4e89-465c-a32c-dc0fda11a8d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_32d495bc-477d-4e0d-ba3f-eab3b895141d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20d1e7eb-f53c-489b-ad16-dfda6b392c19" xlink:to="loc_dei_SecurityExchangeName_32d495bc-477d-4e0d-ba3f-eab3b895141d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_2bd69dca-f38c-4543-b71d-07989f4264fe" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20d1e7eb-f53c-489b-ad16-dfda6b392c19" xlink:to="loc_dei_EntityCurrentReportingStatus_2bd69dca-f38c-4543-b71d-07989f4264fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_5284866b-1263-479d-bd5b-dd2a8ef463ac" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20d1e7eb-f53c-489b-ad16-dfda6b392c19" xlink:to="loc_dei_EntityInteractiveDataCurrent_5284866b-1263-479d-bd5b-dd2a8ef463ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_edbfa370-0f7f-4feb-b139-7e37f87c65f0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20d1e7eb-f53c-489b-ad16-dfda6b392c19" xlink:to="loc_dei_EntityFilerCategory_edbfa370-0f7f-4feb-b139-7e37f87c65f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_2dbafa60-b7d5-44ac-bcb4-3d156cb61114" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20d1e7eb-f53c-489b-ad16-dfda6b392c19" xlink:to="loc_dei_EntitySmallBusiness_2dbafa60-b7d5-44ac-bcb4-3d156cb61114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_f17b02a8-ea37-4db7-933e-599c2d47017e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20d1e7eb-f53c-489b-ad16-dfda6b392c19" xlink:to="loc_dei_EntityEmergingGrowthCompany_f17b02a8-ea37-4db7-933e-599c2d47017e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_3b444d11-2741-4597-a018-a949b497fb09" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20d1e7eb-f53c-489b-ad16-dfda6b392c19" xlink:to="loc_dei_EntityShellCompany_3b444d11-2741-4597-a018-a949b497fb09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_958ffa18-008e-4bfb-89fe-8116d602b032" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20d1e7eb-f53c-489b-ad16-dfda6b392c19" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_958ffa18-008e-4bfb-89fe-8116d602b032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_4f60a1e9-95e5-4074-ba7b-80d5961f34f9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20d1e7eb-f53c-489b-ad16-dfda6b392c19" xlink:to="loc_dei_EntityCentralIndexKey_4f60a1e9-95e5-4074-ba7b-80d5961f34f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_3084dd64-ec42-4846-aeab-9862adc788d9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20d1e7eb-f53c-489b-ad16-dfda6b392c19" xlink:to="loc_dei_CurrentFiscalYearEndDate_3084dd64-ec42-4846-aeab-9862adc788d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_b8f5382b-5db1-4586-8fbf-5eda41bc9aa7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20d1e7eb-f53c-489b-ad16-dfda6b392c19" xlink:to="loc_dei_DocumentFiscalYearFocus_b8f5382b-5db1-4586-8fbf-5eda41bc9aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_7c3e6436-b29a-476c-a4d5-f1f3e946f802" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20d1e7eb-f53c-489b-ad16-dfda6b392c19" xlink:to="loc_dei_DocumentFiscalPeriodFocus_7c3e6436-b29a-476c-a4d5-f1f3e946f802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_718ce36e-cf94-42e9-8c72-fac5fcfdef92" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20d1e7eb-f53c-489b-ad16-dfda6b392c19" xlink:to="loc_dei_AmendmentFlag_718ce36e-cf94-42e9-8c72-fac5fcfdef92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="bhc-20220331.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0160c4ca-140c-4a03-8019-da726d6d3db2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_9e5edc05-5e67-4494-8f0a-bf4f9faf5860" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0160c4ca-140c-4a03-8019-da726d6d3db2" xlink:to="loc_us-gaap_AssetsAbstract_9e5edc05-5e67-4494-8f0a-bf4f9faf5860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_6666da72-6a28-4596-a553-6ccea3dbd322" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9e5edc05-5e67-4494-8f0a-bf4f9faf5860" xlink:to="loc_us-gaap_AssetsCurrentAbstract_6666da72-6a28-4596-a553-6ccea3dbd322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d372c55b-1852-45bd-af5e-05de6be14e41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6666da72-6a28-4596-a553-6ccea3dbd322" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d372c55b-1852-45bd-af5e-05de6be14e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_3cc558c2-09a9-474b-8696-a960bcd0ce95" xlink:href="bhc-20220331.xsd#bhc_RestrictedCashAndOtherSettlementDepositsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6666da72-6a28-4596-a553-6ccea3dbd322" xlink:to="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_3cc558c2-09a9-474b-8696-a960bcd0ce95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_103f3e86-c35a-4ab9-9200-ee1313cdffcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6666da72-6a28-4596-a553-6ccea3dbd322" xlink:to="loc_us-gaap_ReceivablesNetCurrent_103f3e86-c35a-4ab9-9200-ee1313cdffcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_74e84ae9-c872-42b0-b48e-b9fc6af41e74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6666da72-6a28-4596-a553-6ccea3dbd322" xlink:to="loc_us-gaap_InventoryNet_74e84ae9-c872-42b0-b48e-b9fc6af41e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3b7cc637-9315-487b-920d-d3c1d85fa383" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6666da72-6a28-4596-a553-6ccea3dbd322" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3b7cc637-9315-487b-920d-d3c1d85fa383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8b1e385b-8fdb-42e2-8cd8-da56cb3efdd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6666da72-6a28-4596-a553-6ccea3dbd322" xlink:to="loc_us-gaap_AssetsCurrent_8b1e385b-8fdb-42e2-8cd8-da56cb3efdd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_71e2d25e-aac8-4289-9c44-cc7a40330a46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9e5edc05-5e67-4494-8f0a-bf4f9faf5860" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_71e2d25e-aac8-4289-9c44-cc7a40330a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a039eb34-ccbe-477a-b8de-9cdd116bb4d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9e5edc05-5e67-4494-8f0a-bf4f9faf5860" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a039eb34-ccbe-477a-b8de-9cdd116bb4d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_172d83b1-c99e-4187-b939-ffa9f7fd161b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9e5edc05-5e67-4494-8f0a-bf4f9faf5860" xlink:to="loc_us-gaap_Goodwill_172d83b1-c99e-4187-b939-ffa9f7fd161b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_6ee1887c-769c-4b6e-b4ee-57c1dac790db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9e5edc05-5e67-4494-8f0a-bf4f9faf5860" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_6ee1887c-769c-4b6e-b4ee-57c1dac790db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_0150238e-9674-485d-b5bf-ac283958b51e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9e5edc05-5e67-4494-8f0a-bf4f9faf5860" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_0150238e-9674-485d-b5bf-ac283958b51e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_66d9cfd0-d4b3-40d2-92a1-464b6eb29b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9e5edc05-5e67-4494-8f0a-bf4f9faf5860" xlink:to="loc_us-gaap_Assets_66d9cfd0-d4b3-40d2-92a1-464b6eb29b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_a66f0588-26f0-45af-924a-334e691be899" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0160c4ca-140c-4a03-8019-da726d6d3db2" xlink:to="loc_us-gaap_LiabilitiesAbstract_a66f0588-26f0-45af-924a-334e691be899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_5a00132e-05bf-4c9f-a120-cb031c8a29a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a66f0588-26f0-45af-924a-334e691be899" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_5a00132e-05bf-4c9f-a120-cb031c8a29a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_8724d92f-efeb-45cc-a746-15229217578b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5a00132e-05bf-4c9f-a120-cb031c8a29a7" xlink:to="loc_us-gaap_AccountsPayableCurrent_8724d92f-efeb-45cc-a746-15229217578b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_e39073c0-2af5-4b31-8270-34a012e07617" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5a00132e-05bf-4c9f-a120-cb031c8a29a7" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_e39073c0-2af5-4b31-8270-34a012e07617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_436d8a45-10c9-4470-92ff-64b52c163f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5a00132e-05bf-4c9f-a120-cb031c8a29a7" xlink:to="loc_us-gaap_LiabilitiesCurrent_436d8a45-10c9-4470-92ff-64b52c163f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_4aac3569-738f-4438-8552-9be810feba71" xlink:href="bhc-20220331.xsd#bhc_BusinessCombinationContingentConsiderationNoncurrentLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a66f0588-26f0-45af-924a-334e691be899" xlink:to="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_4aac3569-738f-4438-8552-9be810feba71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1200dc82-625e-4b4b-a8ce-c93b91200166" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a66f0588-26f0-45af-924a-334e691be899" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_1200dc82-625e-4b4b-a8ce-c93b91200166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_65bfc287-fe70-46e1-8347-88fc108a089c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a66f0588-26f0-45af-924a-334e691be899" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_65bfc287-fe70-46e1-8347-88fc108a089c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_a366eb20-2807-4f48-98f0-14cfeda3f698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a66f0588-26f0-45af-924a-334e691be899" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_a366eb20-2807-4f48-98f0-14cfeda3f698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_bceafac9-bc97-4b80-b713-bc8b137f5bde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a66f0588-26f0-45af-924a-334e691be899" xlink:to="loc_us-gaap_Liabilities_bceafac9-bc97-4b80-b713-bc8b137f5bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_ff67245c-b6d2-42f2-8809-26fe1d3fd532" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0160c4ca-140c-4a03-8019-da726d6d3db2" xlink:to="loc_us-gaap_CommitmentsAndContingencies_ff67245c-b6d2-42f2-8809-26fe1d3fd532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_5fa1d6fd-4da7-433c-a724-cecbcb246438" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0160c4ca-140c-4a03-8019-da726d6d3db2" xlink:to="loc_us-gaap_StockholdersEquityAbstract_5fa1d6fd-4da7-433c-a724-cecbcb246438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_a62a7ae2-303d-45e9-987e-5be820c94f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5fa1d6fd-4da7-433c-a724-cecbcb246438" xlink:to="loc_us-gaap_CommonStockValue_a62a7ae2-303d-45e9-987e-5be820c94f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_db30dfd5-de5a-4a5e-86f6-f451685ca201" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5fa1d6fd-4da7-433c-a724-cecbcb246438" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_db30dfd5-de5a-4a5e-86f6-f451685ca201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_53cc7dcb-775b-4dbd-9e91-0902f6ee738e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5fa1d6fd-4da7-433c-a724-cecbcb246438" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_53cc7dcb-775b-4dbd-9e91-0902f6ee738e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ad74b7b3-ecea-4f6f-8b1c-727a4f589afb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5fa1d6fd-4da7-433c-a724-cecbcb246438" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ad74b7b3-ecea-4f6f-8b1c-727a4f589afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b0a48aeb-cafe-4174-9617-b395458f38c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5fa1d6fd-4da7-433c-a724-cecbcb246438" xlink:to="loc_us-gaap_StockholdersEquity_b0a48aeb-cafe-4174-9617-b395458f38c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_73c66986-7e8b-4562-910d-3ef414701616" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5fa1d6fd-4da7-433c-a724-cecbcb246438" xlink:to="loc_us-gaap_MinorityInterest_73c66986-7e8b-4562-910d-3ef414701616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_93b5b7f5-2c22-4753-9e48-b4e70a89c5d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5fa1d6fd-4da7-433c-a724-cecbcb246438" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_93b5b7f5-2c22-4753-9e48-b4e70a89c5d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_816c0c88-9bab-485f-8a4c-f49f61615a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0160c4ca-140c-4a03-8019-da726d6d3db2" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_816c0c88-9bab-485f-8a4c-f49f61615a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="bhc-20220331.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_cf940086-d8d7-4586-acab-322ae8296984" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_33529049-9b80-4902-a3e2-2ecafc1c3654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cf940086-d8d7-4586-acab-322ae8296984" xlink:to="loc_us-gaap_CommonStockSharesIssued_33529049-9b80-4902-a3e2-2ecafc1c3654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_cbd89c2f-ded7-4801-b4a6-ebe8fd0ad97a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cf940086-d8d7-4586-acab-322ae8296984" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_cbd89c2f-ded7-4801-b4a6-ebe8fd0ad97a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="bhc-20220331.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_3607da6b-55be-4139-b94e-531d6d12614c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_024bfce1-92ff-41ac-b64c-4508366e477f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3607da6b-55be-4139-b94e-531d6d12614c" xlink:to="loc_us-gaap_StatementTable_024bfce1-92ff-41ac-b64c-4508366e477f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c1489988-b0c1-47b0-ad59-ca7575ff117c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_024bfce1-92ff-41ac-b64c-4508366e477f" xlink:to="loc_srt_ProductOrServiceAxis_c1489988-b0c1-47b0-ad59-ca7575ff117c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c5eb3c43-e1de-4b7b-a38d-38d2585ad57c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c1489988-b0c1-47b0-ad59-ca7575ff117c" xlink:to="loc_srt_ProductsAndServicesDomain_c5eb3c43-e1de-4b7b-a38d-38d2585ad57c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_a4b9a7d8-55f7-4da4-a2aa-88193a0e1ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c5eb3c43-e1de-4b7b-a38d-38d2585ad57c" xlink:to="loc_us-gaap_ProductMember_a4b9a7d8-55f7-4da4-a2aa-88193a0e1ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_0d859ea6-3446-4967-aee9-58b47ec4a27d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c5eb3c43-e1de-4b7b-a38d-38d2585ad57c" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_0d859ea6-3446-4967-aee9-58b47ec4a27d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_65010916-608e-4387-824a-1cafaaee8b70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_024bfce1-92ff-41ac-b64c-4508366e477f" xlink:to="loc_us-gaap_StatementLineItems_65010916-608e-4387-824a-1cafaaee8b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_39d815b3-dc0d-44c2-8593-f2187d7bb108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_65010916-608e-4387-824a-1cafaaee8b70" xlink:to="loc_us-gaap_RevenuesAbstract_39d815b3-dc0d-44c2-8593-f2187d7bb108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_037c638c-477a-42b4-9200-e8f256045036" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_39d815b3-dc0d-44c2-8593-f2187d7bb108" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_037c638c-477a-42b4-9200-e8f256045036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_419942d1-ab15-4fcb-9814-16b9bb046103" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_65010916-608e-4387-824a-1cafaaee8b70" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_419942d1-ab15-4fcb-9814-16b9bb046103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_03711797-14a9-46d3-9300-19d682299797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_419942d1-ab15-4fcb-9814-16b9bb046103" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_03711797-14a9-46d3-9300-19d682299797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_89fd2310-a56b-47cf-8372-1c9a21fbabb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_419942d1-ab15-4fcb-9814-16b9bb046103" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_89fd2310-a56b-47cf-8372-1c9a21fbabb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_45ab53fe-bb86-4dfa-8da0-90b06cd556ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_419942d1-ab15-4fcb-9814-16b9bb046103" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_45ab53fe-bb86-4dfa-8da0-90b06cd556ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_e9126f39-edc9-473a-95c8-351ac99f51de" xlink:href="bhc-20220331.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_419942d1-ab15-4fcb-9814-16b9bb046103" xlink:to="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_e9126f39-edc9-473a-95c8-351ac99f51de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_1a66cd9c-e0f0-4997-b5cc-a5369410aafc" xlink:href="bhc-20220331.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_419942d1-ab15-4fcb-9814-16b9bb046103" xlink:to="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_1a66cd9c-e0f0-4997-b5cc-a5369410aafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_cdaafb8b-160d-44b9-9da8-7895491729ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_419942d1-ab15-4fcb-9814-16b9bb046103" xlink:to="loc_us-gaap_AssetImpairmentCharges_cdaafb8b-160d-44b9-9da8-7895491729ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_0640bf88-abf6-4952-8b62-2a3a6c042a87" xlink:href="bhc-20220331.xsd#bhc_RestructuringChargesAndInitialPublicOfferingCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_419942d1-ab15-4fcb-9814-16b9bb046103" xlink:to="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_0640bf88-abf6-4952-8b62-2a3a6c042a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_a2d4a5fe-8421-4def-91af-603f5615a409" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_419942d1-ab15-4fcb-9814-16b9bb046103" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_a2d4a5fe-8421-4def-91af-603f5615a409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_03bb86f4-1ad6-44dd-bc1c-ef9405025e93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_419942d1-ab15-4fcb-9814-16b9bb046103" xlink:to="loc_us-gaap_CostsAndExpenses_03bb86f4-1ad6-44dd-bc1c-ef9405025e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d7225b53-2fe2-4542-91df-bdb2afa0ce48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_65010916-608e-4387-824a-1cafaaee8b70" xlink:to="loc_us-gaap_OperatingIncomeLoss_d7225b53-2fe2-4542-91df-bdb2afa0ce48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_b33c480f-3569-4858-932b-0796482dd612" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_65010916-608e-4387-824a-1cafaaee8b70" xlink:to="loc_us-gaap_InvestmentIncomeInterest_b33c480f-3569-4858-932b-0796482dd612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_10683039-95b3-4a4c-949e-21b3f9cde736" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_65010916-608e-4387-824a-1cafaaee8b70" xlink:to="loc_us-gaap_InterestExpenseDebt_10683039-95b3-4a4c-949e-21b3f9cde736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3abf24eb-5b14-4132-a24b-86f21ff2a6f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_65010916-608e-4387-824a-1cafaaee8b70" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3abf24eb-5b14-4132-a24b-86f21ff2a6f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_743b810d-a9f2-4d67-9e8b-be6f92eb12a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_65010916-608e-4387-824a-1cafaaee8b70" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_743b810d-a9f2-4d67-9e8b-be6f92eb12a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_12266bb7-0fa4-4402-ad6a-0d38624539c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_65010916-608e-4387-824a-1cafaaee8b70" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_12266bb7-0fa4-4402-ad6a-0d38624539c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ff40b580-00b5-4729-a920-8feb3dec5d53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_65010916-608e-4387-824a-1cafaaee8b70" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ff40b580-00b5-4729-a920-8feb3dec5d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_3fb328f7-b358-4e5c-ab37-e0609bf2adae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_65010916-608e-4387-824a-1cafaaee8b70" xlink:to="loc_us-gaap_ProfitLoss_3fb328f7-b358-4e5c-ab37-e0609bf2adae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7648cc3e-ad0f-4bcf-a367-1e607906612c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_65010916-608e-4387-824a-1cafaaee8b70" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7648cc3e-ad0f-4bcf-a367-1e607906612c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_46bd7ea0-fc74-4f89-817e-8a05b648105e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_65010916-608e-4387-824a-1cafaaee8b70" xlink:to="loc_us-gaap_NetIncomeLoss_46bd7ea0-fc74-4f89-817e-8a05b648105e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_4f69119e-55b0-4a14-a065-cabea5181fed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_65010916-608e-4387-824a-1cafaaee8b70" xlink:to="loc_us-gaap_EarningsPerShareBasic_4f69119e-55b0-4a14-a065-cabea5181fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_973c6156-2c30-41f9-b28b-3ad12c153ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_65010916-608e-4387-824a-1cafaaee8b70" xlink:to="loc_us-gaap_EarningsPerShareDiluted_973c6156-2c30-41f9-b28b-3ad12c153ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4d30cfc8-9c5e-439d-82b4-683dc96ceeac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_65010916-608e-4387-824a-1cafaaee8b70" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4d30cfc8-9c5e-439d-82b4-683dc96ceeac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_65bd1869-7fcb-4922-b2de-af7e39aae3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_65010916-608e-4387-824a-1cafaaee8b70" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_65bd1869-7fcb-4922-b2de-af7e39aae3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="bhc-20220331.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_bce0dd62-6a18-4b42-a56c-50fa2bb4a4ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_682c761c-52bf-423d-8041-9abbc019c499" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_bce0dd62-6a18-4b42-a56c-50fa2bb4a4ba" xlink:to="loc_us-gaap_ProfitLoss_682c761c-52bf-423d-8041-9abbc019c499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c5869aac-6b2d-4c7c-9eeb-24bdc4efeedf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_bce0dd62-6a18-4b42-a56c-50fa2bb4a4ba" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c5869aac-6b2d-4c7c-9eeb-24bdc4efeedf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_58bef6d7-a5ea-4fd8-86e7-70a69606ae56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c5869aac-6b2d-4c7c-9eeb-24bdc4efeedf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_58bef6d7-a5ea-4fd8-86e7-70a69606ae56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_f173158d-33c0-46c8-b94e-e90572717d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c5869aac-6b2d-4c7c-9eeb-24bdc4efeedf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_f173158d-33c0-46c8-b94e-e90572717d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5bec3748-b019-4936-97d8-47dce41a3987" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c5869aac-6b2d-4c7c-9eeb-24bdc4efeedf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5bec3748-b019-4936-97d8-47dce41a3987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_7d9bf043-816e-445c-b666-6ae3449b8b13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_bce0dd62-6a18-4b42-a56c-50fa2bb4a4ba" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_7d9bf043-816e-445c-b666-6ae3449b8b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_8b6ddc50-3af4-42cc-b0a9-4480c0ae7108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_bce0dd62-6a18-4b42-a56c-50fa2bb4a4ba" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_8b6ddc50-3af4-42cc-b0a9-4480c0ae7108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_6eef1cdf-fd1e-4e72-b9a5-dafa8ce0299e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_bce0dd62-6a18-4b42-a56c-50fa2bb4a4ba" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_6eef1cdf-fd1e-4e72-b9a5-dafa8ce0299e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT" xlink:type="simple" xlink:href="bhc-20220331.xsd#CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_f8ffdf70-2a9d-4712-9c76-6c6feb0676bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2e5ee966-0fab-4b5a-ba23-ac26015a3157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_f8ffdf70-2a9d-4712-9c76-6c6feb0676bb" xlink:to="loc_us-gaap_StatementTable_2e5ee966-0fab-4b5a-ba23-ac26015a3157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c641c4f4-7801-4417-9b4a-55ca81447f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2e5ee966-0fab-4b5a-ba23-ac26015a3157" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c641c4f4-7801-4417-9b4a-55ca81447f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f205e545-954a-462f-b64b-b859d69620f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c641c4f4-7801-4417-9b4a-55ca81447f7e" xlink:to="loc_us-gaap_EquityComponentDomain_f205e545-954a-462f-b64b-b859d69620f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_1a938a1e-74c9-4b82-bebe-5507bb6ec261" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f205e545-954a-462f-b64b-b859d69620f1" xlink:to="loc_us-gaap_ParentMember_1a938a1e-74c9-4b82-bebe-5507bb6ec261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_affa6b83-c7e6-4fa2-9931-37c7f9647477" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_1a938a1e-74c9-4b82-bebe-5507bb6ec261" xlink:to="loc_us-gaap_CommonStockMember_affa6b83-c7e6-4fa2-9931-37c7f9647477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8381dd7b-2adf-4e03-baeb-9380b5c8a068" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_1a938a1e-74c9-4b82-bebe-5507bb6ec261" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8381dd7b-2adf-4e03-baeb-9380b5c8a068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_7786fa3f-9c36-4b11-8fa2-40678c0ea775" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_1a938a1e-74c9-4b82-bebe-5507bb6ec261" xlink:to="loc_us-gaap_RetainedEarningsMember_7786fa3f-9c36-4b11-8fa2-40678c0ea775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c9536ec5-9ed7-4ad6-b9b9-d1c4728c6920" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_1a938a1e-74c9-4b82-bebe-5507bb6ec261" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c9536ec5-9ed7-4ad6-b9b9-d1c4728c6920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_6c107469-5662-48d4-941b-3a2b1ea92287" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f205e545-954a-462f-b64b-b859d69620f1" xlink:to="loc_us-gaap_NoncontrollingInterestMember_6c107469-5662-48d4-941b-3a2b1ea92287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e5cdd979-eb98-4fac-a3de-ec14d5f667ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2e5ee966-0fab-4b5a-ba23-ac26015a3157" xlink:to="loc_us-gaap_StatementLineItems_e5cdd979-eb98-4fac-a3de-ec14d5f667ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_98970c94-5835-4211-8dbe-21db5cd06757" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e5cdd979-eb98-4fac-a3de-ec14d5f667ab" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_98970c94-5835-4211-8dbe-21db5cd06757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_e19acd90-a6e1-4ca6-acb0-881dea7cb9f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_98970c94-5835-4211-8dbe-21db5cd06757" xlink:to="loc_us-gaap_CommonStockSharesIssued_e19acd90-a6e1-4ca6-acb0-881dea7cb9f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6134f356-e461-4ffc-a48d-522fc275c4f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_98970c94-5835-4211-8dbe-21db5cd06757" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6134f356-e461-4ffc-a48d-522fc275c4f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2016e685-7653-497b-8218-8f3ba61ae506" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_98970c94-5835-4211-8dbe-21db5cd06757" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2016e685-7653-497b-8218-8f3ba61ae506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_332805fb-babc-4ae6-a6ed-af81d4dc9378" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_98970c94-5835-4211-8dbe-21db5cd06757" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_332805fb-babc-4ae6-a6ed-af81d4dc9378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_01b981be-8c84-4112-94fd-53cf2f9bf68f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_98970c94-5835-4211-8dbe-21db5cd06757" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_01b981be-8c84-4112-94fd-53cf2f9bf68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_e2e9b77c-378f-49da-b1c8-a58fad6dae14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_98970c94-5835-4211-8dbe-21db5cd06757" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_e2e9b77c-378f-49da-b1c8-a58fad6dae14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1ae83e17-6b5c-43f5-af0d-376b224b42aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_98970c94-5835-4211-8dbe-21db5cd06757" xlink:to="loc_us-gaap_ProfitLoss_1ae83e17-6b5c-43f5-af0d-376b224b42aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6fb9348a-76bd-438e-9952-e27e19e15b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_98970c94-5835-4211-8dbe-21db5cd06757" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6fb9348a-76bd-438e-9952-e27e19e15b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_697007da-099e-490e-be73-b3d4a7304103" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_98970c94-5835-4211-8dbe-21db5cd06757" xlink:to="loc_us-gaap_CommonStockSharesIssued_697007da-099e-490e-be73-b3d4a7304103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e029dceb-deb4-4870-9dba-d876e190fc14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_98970c94-5835-4211-8dbe-21db5cd06757" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e029dceb-deb4-4870-9dba-d876e190fc14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="bhc-20220331.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_a9cb652f-9978-4545-9c62-985464423728" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1cf4d15-223d-4594-82f3-ed29600cb5fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a9cb652f-9978-4545-9c62-985464423728" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1cf4d15-223d-4594-82f3-ed29600cb5fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8cfde293-e230-41bd-8b7a-9a5aa5735707" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1cf4d15-223d-4594-82f3-ed29600cb5fa" xlink:to="loc_us-gaap_ProfitLoss_8cfde293-e230-41bd-8b7a-9a5aa5735707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1893dbef-d038-4d7e-9c62-8b3be2b580c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1cf4d15-223d-4594-82f3-ed29600cb5fa" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1893dbef-d038-4d7e-9c62-8b3be2b580c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_641e395c-2499-4989-9830-a9fe39f220dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1893dbef-d038-4d7e-9c62-8b3be2b580c1" xlink:to="loc_us-gaap_DepreciationAndAmortization_641e395c-2499-4989-9830-a9fe39f220dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_54e4a109-9b55-4423-8d2a-2acb6ab1469c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1893dbef-d038-4d7e-9c62-8b3be2b580c1" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_54e4a109-9b55-4423-8d2a-2acb6ab1469c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_c2d72006-45a3-4b80-829e-e6fd8f9dea5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1893dbef-d038-4d7e-9c62-8b3be2b580c1" xlink:to="loc_us-gaap_AssetImpairmentCharges_c2d72006-45a3-4b80-829e-e6fd8f9dea5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_42f9bb66-94e5-4368-805f-5288e34b8cca" xlink:href="bhc-20220331.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1893dbef-d038-4d7e-9c62-8b3be2b580c1" xlink:to="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_42f9bb66-94e5-4368-805f-5288e34b8cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_68261be1-309e-4569-b334-ba4507cba910" xlink:href="bhc-20220331.xsd#bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1893dbef-d038-4d7e-9c62-8b3be2b580c1" xlink:to="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_68261be1-309e-4569-b334-ba4507cba910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_3ae12c46-3aa1-4c7b-a20c-b095e962cabb" xlink:href="bhc-20220331.xsd#bhc_AllowancesForLossesOnAccountsReceivableAndInventories"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1893dbef-d038-4d7e-9c62-8b3be2b580c1" xlink:to="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_3ae12c46-3aa1-4c7b-a20c-b095e962cabb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit_26322804-5899-4113-bb57-d62ebb1d3851" xlink:href="bhc-20220331.xsd#bhc_DeferredIncomeTaxNoncashExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1893dbef-d038-4d7e-9c62-8b3be2b580c1" xlink:to="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit_26322804-5899-4113-bb57-d62ebb1d3851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_55eb906f-eb41-4bd7-8e55-930324d4d10d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1893dbef-d038-4d7e-9c62-8b3be2b580c1" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_55eb906f-eb41-4bd7-8e55-930324d4d10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainLossRelatedToLitigationSettlementGross_a8504c47-c2ad-445a-9677-40e161c183be" xlink:href="bhc-20220331.xsd#bhc_GainLossRelatedToLitigationSettlementGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1893dbef-d038-4d7e-9c62-8b3be2b580c1" xlink:to="loc_bhc_GainLossRelatedToLitigationSettlementGross_a8504c47-c2ad-445a-9677-40e161c183be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_a750f48a-f30d-41dc-8c3a-7f70328c95dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1893dbef-d038-4d7e-9c62-8b3be2b580c1" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_a750f48a-f30d-41dc-8c3a-7f70328c95dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7eaa77b8-350d-4419-914b-13ba3aa711b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1893dbef-d038-4d7e-9c62-8b3be2b580c1" xlink:to="loc_us-gaap_ShareBasedCompensation_7eaa77b8-350d-4419-914b-13ba3aa711b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_dc7d3f7a-9faf-42b6-a5e5-1e39fc87a8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1893dbef-d038-4d7e-9c62-8b3be2b580c1" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_dc7d3f7a-9faf-42b6-a5e5-1e39fc87a8a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DerivativeGainExcludedComponent_f9bed1ef-d678-4918-a0d1-3b45620399ad" xlink:href="bhc-20220331.xsd#bhc_DerivativeGainExcludedComponent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1893dbef-d038-4d7e-9c62-8b3be2b580c1" xlink:to="loc_bhc_DerivativeGainExcludedComponent_f9bed1ef-d678-4918-a0d1-3b45620399ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1fabb22b-ca61-4946-a563-bc0907c1e56b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1893dbef-d038-4d7e-9c62-8b3be2b580c1" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1fabb22b-ca61-4946-a563-bc0907c1e56b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_77d84028-2ec1-468e-888d-77fe38fcb4b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1893dbef-d038-4d7e-9c62-8b3be2b580c1" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_77d84028-2ec1-468e-888d-77fe38fcb4b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a955c704-6d97-46cb-afea-ab4ad4977799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1893dbef-d038-4d7e-9c62-8b3be2b580c1" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a955c704-6d97-46cb-afea-ab4ad4977799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7b76b6ce-127a-4fe5-9440-7caa4496670b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a955c704-6d97-46cb-afea-ab4ad4977799" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7b76b6ce-127a-4fe5-9440-7caa4496670b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_11b1d2a9-45a0-471d-b23f-e0c77dec962a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a955c704-6d97-46cb-afea-ab4ad4977799" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_11b1d2a9-45a0-471d-b23f-e0c77dec962a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2b87a1c4-ce4e-4eb8-b291-5bba48c0c567" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a955c704-6d97-46cb-afea-ab4ad4977799" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2b87a1c4-ce4e-4eb8-b291-5bba48c0c567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_386b0bfa-f2d8-403b-a4e3-cca8bbdfe953" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a955c704-6d97-46cb-afea-ab4ad4977799" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_386b0bfa-f2d8-403b-a4e3-cca8bbdfe953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_768cb897-b3e3-4425-bb84-7300ef3350bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1cf4d15-223d-4594-82f3-ed29600cb5fa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_768cb897-b3e3-4425-bb84-7300ef3350bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6a6f4ef3-6609-4ca1-a916-63b593ba8a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a9cb652f-9978-4545-9c62-985464423728" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6a6f4ef3-6609-4ca1-a916-63b593ba8a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_75a61d65-218e-455b-97e3-3f037af4bd93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6a6f4ef3-6609-4ca1-a916-63b593ba8a3b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_75a61d65-218e-455b-97e3-3f037af4bd93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_0bb51bcc-ffb8-4aa3-a568-4bc4091d128f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6a6f4ef3-6609-4ca1-a916-63b593ba8a3b" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_0bb51bcc-ffb8-4aa3-a568-4bc4091d128f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_db7c9000-0f23-4011-9b76-f878d93e9fef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6a6f4ef3-6609-4ca1-a916-63b593ba8a3b" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_db7c9000-0f23-4011-9b76-f878d93e9fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_746aa9ad-a525-4597-89f7-0285e201f8bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6a6f4ef3-6609-4ca1-a916-63b593ba8a3b" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_746aa9ad-a525-4597-89f7-0285e201f8bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_2e2cb120-c49b-4fdf-a070-4bfff7f84eba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6a6f4ef3-6609-4ca1-a916-63b593ba8a3b" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_2e2cb120-c49b-4fdf-a070-4bfff7f84eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InterestSettlementOnCrossCurrencySwaps_72b6619f-1bde-43e8-92a4-c0512f4835e0" xlink:href="bhc-20220331.xsd#bhc_InterestSettlementOnCrossCurrencySwaps"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6a6f4ef3-6609-4ca1-a916-63b593ba8a3b" xlink:to="loc_bhc_InterestSettlementOnCrossCurrencySwaps_72b6619f-1bde-43e8-92a4-c0512f4835e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_153bdb9a-fcd9-465f-a1fe-ee7bb03b05a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6a6f4ef3-6609-4ca1-a916-63b593ba8a3b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_153bdb9a-fcd9-465f-a1fe-ee7bb03b05a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_811958ea-ca53-40a0-9344-3140d0df6e03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a9cb652f-9978-4545-9c62-985464423728" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_811958ea-ca53-40a0-9344-3140d0df6e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_064ac5c7-c987-42e3-b5ef-c0beb4d2f609" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_811958ea-ca53-40a0-9344-3140d0df6e03" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_064ac5c7-c987-42e3-b5ef-c0beb4d2f609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_da3ce71e-3963-43d5-9a05-3cbbb543890b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_811958ea-ca53-40a0-9344-3140d0df6e03" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_da3ce71e-3963-43d5-9a05-3cbbb543890b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_900fed38-263c-48e4-ba6f-24f880281739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_811958ea-ca53-40a0-9344-3140d0df6e03" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_900fed38-263c-48e4-ba6f-24f880281739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_addae489-9209-4130-90de-7d250f78c747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_811958ea-ca53-40a0-9344-3140d0df6e03" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_addae489-9209-4130-90de-7d250f78c747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_0aa2fe47-8701-4790-aba2-728ed0828e51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_811958ea-ca53-40a0-9344-3140d0df6e03" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_0aa2fe47-8701-4790-aba2-728ed0828e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_20188649-5dbd-4036-affc-053bb2673398" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_811958ea-ca53-40a0-9344-3140d0df6e03" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_20188649-5dbd-4036-affc-053bb2673398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_912fb8a2-4e24-4b87-a903-462c1f969208" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_811958ea-ca53-40a0-9344-3140d0df6e03" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_912fb8a2-4e24-4b87-a903-462c1f969208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_850b774f-d845-4e73-a63e-c20bd0be599f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a9cb652f-9978-4545-9c62-985464423728" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_850b774f-d845-4e73-a63e-c20bd0be599f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_982538ba-e110-471c-a71a-fc42ea306037" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a9cb652f-9978-4545-9c62-985464423728" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_982538ba-e110-471c-a71a-fc42ea306037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7bce58a5-ddda-4132-86a9-38e1696d1d48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a9cb652f-9978-4545-9c62-985464423728" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7bce58a5-ddda-4132-86a9-38e1696d1d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9494fc5c-1eb0-49f0-8c06-22d79ecb2358" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a9cb652f-9978-4545-9c62-985464423728" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9494fc5c-1eb0-49f0-8c06-22d79ecb2358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a32fab93-3d96-45e2-9d3d-a83c3a4cc231" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a9cb652f-9978-4545-9c62-985464423728" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a32fab93-3d96-45e2-9d3d-a83c3a4cc231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_d3cfa1cd-2131-47b4-9eb8-8348086f7cad" xlink:href="bhc-20220331.xsd#bhc_RestrictedCashAndOtherSettlementDepositsCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a9cb652f-9978-4545-9c62-985464423728" xlink:to="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_d3cfa1cd-2131-47b4-9eb8-8348086f7cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_15d6abf6-71a4-4e5d-813b-b37e1b2155dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a9cb652f-9978-4545-9c62-985464423728" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_15d6abf6-71a4-4e5d-813b-b37e1b2155dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6bccac70-7573-4397-b11f-8e348c253ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a9cb652f-9978-4545-9c62-985464423728" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6bccac70-7573-4397-b11f-8e348c253ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS" xlink:type="simple" xlink:href="bhc-20220331.xsd#DESCRIPTIONOFBUSINESS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d34affa9-fd59-4430-a1b6-45eb6f55a6cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_d2f2f781-c5d4-4dbd-bc71-dc454c275aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d34affa9-fd59-4430-a1b6-45eb6f55a6cd" xlink:to="loc_us-gaap_NatureOfOperations_d2f2f781-c5d4-4dbd-bc71-dc454c275aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#DESCRIPTIONOFBUSINESSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8980233a-a364-45f8-967d-f643457eea6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_884575d6-aa55-48ff-86d5-d412a42ff287" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8980233a-a364-45f8-967d-f643457eea6f" xlink:to="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_884575d6-aa55-48ff-86d5-d412a42ff287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="bhc-20220331.xsd#SIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9aa713eb-4e6f-4f71-bd9b-0bef79ad4947" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_6454f22f-116a-45ea-98f3-81a43062a4d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9aa713eb-4e6f-4f71-bd9b-0bef79ad4947" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_6454f22f-116a-45ea-98f3-81a43062a4d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="bhc-20220331.xsd#SIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_25cc8d66-167b-4c93-aa5f-190a330379d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f58b31eb-eab2-4226-977c-dad7b91668ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_25cc8d66-167b-4c93-aa5f-190a330379d5" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f58b31eb-eab2-4226-977c-dad7b91668ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_4b393019-3394-4451-bb26-25b21b683160" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_25cc8d66-167b-4c93-aa5f-190a330379d5" xlink:to="loc_us-gaap_UseOfEstimates_4b393019-3394-4451-bb26-25b21b683160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_693c21cc-6b32-46a2-a3ed-2c22a3f01b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_25cc8d66-167b-4c93-aa5f-190a330379d5" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_693c21cc-6b32-46a2-a3ed-2c22a3f01b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_aeab0737-b412-4b4a-b6a1-93d3b972fd29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_25cc8d66-167b-4c93-aa5f-190a330379d5" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_aeab0737-b412-4b4a-b6a1-93d3b972fd29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_505e0345-85d0-4f73-8bae-cbd44ea956cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_25cc8d66-167b-4c93-aa5f-190a330379d5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_505e0345-85d0-4f73-8bae-cbd44ea956cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_541e82c3-1f63-4fb8-a23d-e551d1acbf75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_08b0d6e5-988c-4a9f-ace7-b80058928443" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_541e82c3-1f63-4fb8-a23d-e551d1acbf75" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_08b0d6e5-988c-4a9f-ace7-b80058928443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_10e18035-c4c4-4f12-adf2-533d44ff85ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_08b0d6e5-988c-4a9f-ace7-b80058928443" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_10e18035-c4c4-4f12-adf2-533d44ff85ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20b3cda0-7749-460c-9866-1fdc76100991" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_10e18035-c4c4-4f12-adf2-533d44ff85ba" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20b3cda0-7749-460c-9866-1fdc76100991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_d1566604-6ef7-4b2b-aa46-74de7ca0663a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20b3cda0-7749-460c-9866-1fdc76100991" xlink:to="loc_us-gaap_IPOMember_d1566604-6ef7-4b2b-aa46-74de7ca0663a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_fb4feb72-344c-4b80-bb98-bca4835ea0e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_08b0d6e5-988c-4a9f-ace7-b80058928443" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_fb4feb72-344c-4b80-bb98-bca4835ea0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_19549c7e-2af5-4b65-b442-b2f249ce0dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fb4feb72-344c-4b80-bb98-bca4835ea0e2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_19549c7e-2af5-4b65-b442-b2f249ce0dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_32e4ff49-c9e9-438f-b873-25bfb85b5d07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_19549c7e-2af5-4b65-b442-b2f249ce0dcc" xlink:to="loc_us-gaap_SubsequentEventMember_32e4ff49-c9e9-438f-b873-25bfb85b5d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_6b5b214c-16fa-4212-ad5a-5a2d3ff1330e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_08b0d6e5-988c-4a9f-ace7-b80058928443" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_6b5b214c-16fa-4212-ad5a-5a2d3ff1330e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2b0c5d2e-36dd-45c2-b926-108786b6b674" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6b5b214c-16fa-4212-ad5a-5a2d3ff1330e" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2b0c5d2e-36dd-45c2-b926-108786b6b674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_40cdb97b-900d-466f-923e-fe1a76ee5107" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6b5b214c-16fa-4212-ad5a-5a2d3ff1330e" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_40cdb97b-900d-466f-923e-fe1a76ee5107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_fdc45fc4-3e99-4832-91c3-372bb8784ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6b5b214c-16fa-4212-ad5a-5a2d3ff1330e" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_fdc45fc4-3e99-4832-91c3-372bb8784ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProposedBusinessSeparationAndInitialPublicOfferingNumberOfCompaniesEstablished_5b2e2f21-7834-45d6-9257-2bf3fbc48501" xlink:href="bhc-20220331.xsd#bhc_ProposedBusinessSeparationAndInitialPublicOfferingNumberOfCompaniesEstablished"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6b5b214c-16fa-4212-ad5a-5a2d3ff1330e" xlink:to="loc_bhc_ProposedBusinessSeparationAndInitialPublicOfferingNumberOfCompaniesEstablished_5b2e2f21-7834-45d6-9257-2bf3fbc48501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITION" xlink:type="simple" xlink:href="bhc-20220331.xsd#REVENUERECOGNITION"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/REVENUERECOGNITION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ae860c43-ab83-4423-9069-6e8c16c6acbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_3868c8ea-a18d-4956-9b2c-0ba08341df65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ae860c43-ab83-4423-9069-6e8c16c6acbd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_3868c8ea-a18d-4956-9b2c-0ba08341df65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONTables" xlink:type="simple" xlink:href="bhc-20220331.xsd#REVENUERECOGNITIONTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/REVENUERECOGNITIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_725072bf-6764-418e-8766-f0e5161d5436" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock_70df7bd5-dd12-49e2-9f64-a6ae5613a490" xlink:href="bhc-20220331.xsd#bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_725072bf-6764-418e-8766-f0e5161d5436" xlink:to="loc_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock_70df7bd5-dd12-49e2-9f64-a6ae5613a490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_506cd0fb-6be1-41d7-a9e3-05315fa7f95b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_725072bf-6764-418e-8766-f0e5161d5436" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_506cd0fb-6be1-41d7-a9e3-05315fa7f95b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#REVENUERECOGNITIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e8759961-34e8-44ec-a3a2-dcbf305b0e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_f3b87a3b-ad55-41b5-9d6f-46dcd53b4b14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e8759961-34e8-44ec-a3a2-dcbf305b0e1b" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_f3b87a3b-ad55-41b5-9d6f-46dcd53b4b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_c7587be2-6d1d-4182-8939-8cf39049ff83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_f3b87a3b-ad55-41b5-9d6f-46dcd53b4b14" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_c7587be2-6d1d-4182-8939-8cf39049ff83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_c958ef5c-cf84-47e3-a9e1-b3c5d7c8551f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_c7587be2-6d1d-4182-8939-8cf39049ff83" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_c958ef5c-cf84-47e3-a9e1-b3c5d7c8551f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForCustomerReturnsMember_859b6ae2-eee1-4653-88ff-bbddeec45a2b" xlink:href="bhc-20220331.xsd#bhc_ReserveForCustomerReturnsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_c958ef5c-cf84-47e3-a9e1-b3c5d7c8551f" xlink:to="loc_bhc_ReserveForCustomerReturnsMember_859b6ae2-eee1-4653-88ff-bbddeec45a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_018e878e-845e-45c5-817c-1d4aa8c7ebe5" xlink:href="bhc-20220331.xsd#bhc_ReserveForRebatesAdvertisingCreditsPortionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_c958ef5c-cf84-47e3-a9e1-b3c5d7c8551f" xlink:to="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_018e878e-845e-45c5-817c-1d4aa8c7ebe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9882f6b8-1d88-4f97-8194-636eeb54ce90" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_f3b87a3b-ad55-41b5-9d6f-46dcd53b4b14" xlink:to="loc_srt_ProductOrServiceAxis_9882f6b8-1d88-4f97-8194-636eeb54ce90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ca0b3ee0-36d5-4c44-88ba-559b9bc9e3f7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9882f6b8-1d88-4f97-8194-636eeb54ce90" xlink:to="loc_srt_ProductsAndServicesDomain_ca0b3ee0-36d5-4c44-88ba-559b9bc9e3f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PriceAppreciationCreditMember_58c8e21b-5ad7-49ba-86d6-b7b32726a9f3" xlink:href="bhc-20220331.xsd#bhc_PriceAppreciationCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ca0b3ee0-36d5-4c44-88ba-559b9bc9e3f7" xlink:to="loc_bhc_PriceAppreciationCreditMember_58c8e21b-5ad7-49ba-86d6-b7b32726a9f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_160d9f66-d810-4f31-9a04-4b4bb00d9f85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_f3b87a3b-ad55-41b5-9d6f-46dcd53b4b14" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_160d9f66-d810-4f31-9a04-4b4bb00d9f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_b7512493-252d-4346-ae63-ad038359b02f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_160d9f66-d810-4f31-9a04-4b4bb00d9f85" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_b7512493-252d-4346-ae63-ad038359b02f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_e697231b-1b18-4541-a0fc-b4e88ac9d674" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_160d9f66-d810-4f31-9a04-4b4bb00d9f85" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_e697231b-1b18-4541-a0fc-b4e88ac9d674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ae5bd9c1-a980-4fbc-bf6a-9042565ab473" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_160d9f66-d810-4f31-9a04-4b4bb00d9f85" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ae5bd9c1-a980-4fbc-bf6a-9042565ab473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#REVENUERECOGNITIONVariableConsiderationProvisionsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8bb422f8-3665-43ab-841b-0898c8a20010" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_5fa5620f-3fd4-4ca9-bb7c-f463211bc458" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8bb422f8-3665-43ab-841b-0898c8a20010" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_5fa5620f-3fd4-4ca9-bb7c-f463211bc458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_0847324f-b48f-4520-a94d-4a8921c0d0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_5fa5620f-3fd4-4ca9-bb7c-f463211bc458" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_0847324f-b48f-4520-a94d-4a8921c0d0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_6dd19b86-8734-412e-b72c-174305a67429" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_0847324f-b48f-4520-a94d-4a8921c0d0e4" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_6dd19b86-8734-412e-b72c-174305a67429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDiscountsAndAllowancesMember_294cb3c9-9005-4aaf-83da-043b3d9b52d2" xlink:href="bhc-20220331.xsd#bhc_ReserveForDiscountsAndAllowancesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_6dd19b86-8734-412e-b72c-174305a67429" xlink:to="loc_bhc_ReserveForDiscountsAndAllowancesMember_294cb3c9-9005-4aaf-83da-043b3d9b52d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForCustomerReturnsMember_2ae1a6d9-bfbc-46f7-aeff-c25fe6104f55" xlink:href="bhc-20220331.xsd#bhc_ReserveForCustomerReturnsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_6dd19b86-8734-412e-b72c-174305a67429" xlink:to="loc_bhc_ReserveForCustomerReturnsMember_2ae1a6d9-bfbc-46f7-aeff-c25fe6104f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesMember_fce5c354-57bf-46a6-8ac3-7d36eced3104" xlink:href="bhc-20220331.xsd#bhc_ReserveForRebatesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_6dd19b86-8734-412e-b72c-174305a67429" xlink:to="loc_bhc_ReserveForRebatesMember_fce5c354-57bf-46a6-8ac3-7d36eced3104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForChargebacksMember_11396261-17ef-4f57-a1f9-312abb979759" xlink:href="bhc-20220331.xsd#bhc_ReserveForChargebacksMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_6dd19b86-8734-412e-b72c-174305a67429" xlink:to="loc_bhc_ReserveForChargebacksMember_11396261-17ef-4f57-a1f9-312abb979759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDistributionFeesMember_270bcffa-c70b-454e-84d4-2534a063452b" xlink:href="bhc-20220331.xsd#bhc_ReserveForDistributionFeesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_6dd19b86-8734-412e-b72c-174305a67429" xlink:to="loc_bhc_ReserveForDistributionFeesMember_270bcffa-c70b-454e-84d4-2534a063452b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_cbbffff5-cf32-4e93-8b09-3b1730a824ec" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_5fa5620f-3fd4-4ca9-bb7c-f463211bc458" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_cbbffff5-cf32-4e93-8b09-3b1730a824ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_df5fc563-3cab-49e1-9bd4-ddcd6e5d9db3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_cbbffff5-cf32-4e93-8b09-3b1730a824ec" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_df5fc563-3cab-49e1-9bd4-ddcd6e5d9db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_c6523d66-75b6-4906-a7fc-78ec0830bce5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_df5fc563-3cab-49e1-9bd4-ddcd6e5d9db3" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_c6523d66-75b6-4906-a7fc-78ec0830bce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_3fb40d66-76f8-4c20-9716-9759bc7d406d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_df5fc563-3cab-49e1-9bd4-ddcd6e5d9db3" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_3fb40d66-76f8-4c20-9716-9759bc7d406d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_4a63c24f-dd10-4c40-88ee-17425ac8d185" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_df5fc563-3cab-49e1-9bd4-ddcd6e5d9db3" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_4a63c24f-dd10-4c40-88ee-17425ac8d185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_82b04090-22fd-4896-aeca-3665c450ed37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_df5fc563-3cab-49e1-9bd4-ddcd6e5d9db3" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_82b04090-22fd-4896-aeca-3665c450ed37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_de67e151-1127-42da-bef3-93e5cd6551a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_fb806ec0-aadd-4819-9242-24bd544d9d46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_de67e151-1127-42da-bef3-93e5cd6551a3" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_fb806ec0-aadd-4819-9242-24bd544d9d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_73b8f932-b746-44a1-a70f-e635bdc8c106" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_fb806ec0-aadd-4819-9242-24bd544d9d46" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_73b8f932-b746-44a1-a70f-e635bdc8c106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_6d6956a3-09ef-4b5f-ab67-af6fd2cd0404" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_fb806ec0-aadd-4819-9242-24bd544d9d46" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_6d6956a3-09ef-4b5f-ab67-af6fd2cd0404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_f2d62448-7b0e-40bc-9b48-412171ecfdd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_fb806ec0-aadd-4819-9242-24bd544d9d46" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_f2d62448-7b0e-40bc-9b48-412171ecfdd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_f1696f04-c3b7-4dce-857a-66d47ec7af6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_fb806ec0-aadd-4819-9242-24bd544d9d46" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_f1696f04-c3b7-4dce-857a-66d47ec7af6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther_509b9d2a-06ae-4545-ad0d-8c01ae19c040" xlink:href="bhc-20220331.xsd#bhc_AccountsReceivableAllowanceForForeignExchangeAndOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_fb806ec0-aadd-4819-9242-24bd544d9d46" xlink:to="loc_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther_509b9d2a-06ae-4545-ad0d-8c01ae19c040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_ef9866e9-f7a2-4668-9694-ca10ef0c6495" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_fb806ec0-aadd-4819-9242-24bd544d9d46" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_ef9866e9-f7a2-4668-9694-ca10ef0c6495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURE" xlink:type="simple" xlink:href="bhc-20220331.xsd#LICENSINGAGREEMENTSANDDIVESTITURE"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_8297b557-74ed-4288-b767-99d741fae375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock_52697be5-3a95-4814-814a-db2af158a575" xlink:href="bhc-20220331.xsd#bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_8297b557-74ed-4288-b767-99d741fae375" xlink:to="loc_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock_52697be5-3a95-4814-814a-db2af158a575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_8a7eefdb-6a88-4312-b162-cec3c69b0a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4f3ea81a-8d02-428d-aa53-b307d3a0df1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_8a7eefdb-6a88-4312-b162-cec3c69b0a2a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4f3ea81a-8d02-428d-aa53-b307d3a0df1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_880a5a91-4015-4c56-a717-79b68e147a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4f3ea81a-8d02-428d-aa53-b307d3a0df1e" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_880a5a91-4015-4c56-a717-79b68e147a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_36fbaa00-5d81-4d9a-9dd7-b394edaabad4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_880a5a91-4015-4c56-a717-79b68e147a0f" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_36fbaa00-5d81-4d9a-9dd7-b394edaabad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_871d80ae-8934-4f8d-8892-3896e7ca558e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_36fbaa00-5d81-4d9a-9dd7-b394edaabad4" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_871d80ae-8934-4f8d-8892-3896e7ca558e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b589f63f-c742-4014-9c28-cc3cc7dda805" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4f3ea81a-8d02-428d-aa53-b307d3a0df1e" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b589f63f-c742-4014-9c28-cc3cc7dda805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_13e8b6de-f51f-40dc-a1d8-6eddefcdfcfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b589f63f-c742-4014-9c28-cc3cc7dda805" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_13e8b6de-f51f-40dc-a1d8-6eddefcdfcfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmounPharmaceuticalCompanySAEMember_18ce41cc-57f4-456a-958e-06896efd2415" xlink:href="bhc-20220331.xsd#bhc_AmounPharmaceuticalCompanySAEMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_13e8b6de-f51f-40dc-a1d8-6eddefcdfcfd" xlink:to="loc_bhc_AmounPharmaceuticalCompanySAEMember_18ce41cc-57f4-456a-958e-06896efd2415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_414a63de-d4d0-4548-aec0-57e2efe7296f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4f3ea81a-8d02-428d-aa53-b307d3a0df1e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_414a63de-d4d0-4548-aec0-57e2efe7296f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_14bf4a29-6678-4b76-9e57-39a6a33d926b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_414a63de-d4d0-4548-aec0-57e2efe7296f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_14bf4a29-6678-4b76-9e57-39a6a33d926b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetImpairmentChargesMember_0ba2add0-eb61-4416-a06a-3d6949a7fad1" xlink:href="bhc-20220331.xsd#bhc_AssetImpairmentChargesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_14bf4a29-6678-4b76-9e57-39a6a33d926b" xlink:to="loc_bhc_AssetImpairmentChargesMember_0ba2add0-eb61-4416-a06a-3d6949a7fad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_3039674f-dcb2-4600-b888-bbffcdea18f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4f3ea81a-8d02-428d-aa53-b307d3a0df1e" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_3039674f-dcb2-4600-b888-bbffcdea18f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_4bd698d0-029e-4af3-a1e8-6acab09231c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3039674f-dcb2-4600-b888-bbffcdea18f3" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_4bd698d0-029e-4af3-a1e8-6acab09231c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_dc9a9fea-ac12-47bb-b2f5-84b91727cc36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3039674f-dcb2-4600-b888-bbffcdea18f3" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_dc9a9fea-ac12-47bb-b2f5-84b91727cc36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_f48dd0d1-a307-424f-961c-ae7ae504fec6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3039674f-dcb2-4600-b888-bbffcdea18f3" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_f48dd0d1-a307-424f-961c-ae7ae504fec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS" xlink:type="simple" xlink:href="bhc-20220331.xsd#RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5589913c-12fb-4fe6-9138-297ad116ad78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock_6a47960d-b74f-4726-a280-5febf1115155" xlink:href="bhc-20220331.xsd#bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5589913c-12fb-4fe6-9138-297ad116ad78" xlink:to="loc_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock_6a47960d-b74f-4726-a280-5febf1115155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_a090eaec-4c46-4ec3-bf2e-be2cb37a2d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_430fb5d3-81b5-43c9-a353-181c422be04d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_a090eaec-4c46-4ec3-bf2e-be2cb37a2d1a" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_430fb5d3-81b5-43c9-a353-181c422be04d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_cda1ddfc-edad-44d2-b440-0ea499c13e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_430fb5d3-81b5-43c9-a353-181c422be04d" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_cda1ddfc-edad-44d2-b440-0ea499c13e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_a7ff044f-42a5-4bb2-91d6-b38e834bd28a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_cda1ddfc-edad-44d2-b440-0ea499c13e2e" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_a7ff044f-42a5-4bb2-91d6-b38e834bd28a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringAndIntegrationCostsMember_3a9351d4-15b6-495e-9055-95e852f52efb" xlink:href="bhc-20220331.xsd#bhc_RestructuringAndIntegrationCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_a7ff044f-42a5-4bb2-91d6-b38e834bd28a" xlink:to="loc_bhc_RestructuringAndIntegrationCostsMember_3a9351d4-15b6-495e-9055-95e852f52efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeparationAndInitialPublicOfferingCostsMember_cea6d590-a130-478d-99ad-70cd72e294d9" xlink:href="bhc-20220331.xsd#bhc_SeparationAndInitialPublicOfferingCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_a7ff044f-42a5-4bb2-91d6-b38e834bd28a" xlink:to="loc_bhc_SeparationAndInitialPublicOfferingCostsMember_cea6d590-a130-478d-99ad-70cd72e294d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_3a8484fc-643a-4a95-ba51-372655bec545" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_430fb5d3-81b5-43c9-a353-181c422be04d" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_3a8484fc-643a-4a95-ba51-372655bec545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_ffec1b05-b555-4377-be99-5ffe0857fa9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3a8484fc-643a-4a95-ba51-372655bec545" xlink:to="loc_us-gaap_RestructuringReserve_ffec1b05-b555-4377-be99-5ffe0857fa9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_3dd1c136-dd0f-4da5-b0a1-8992ed839fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3a8484fc-643a-4a95-ba51-372655bec545" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_3dd1c136-dd0f-4da5-b0a1-8992ed839fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_21cd064f-2ff7-4a43-b26f-c87e02898a27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3a8484fc-643a-4a95-ba51-372655bec545" xlink:to="loc_us-gaap_PaymentsForRestructuring_21cd064f-2ff7-4a43-b26f-c87e02898a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_e6c76885-4dab-4ff1-bcfa-9829925d3f72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3a8484fc-643a-4a95-ba51-372655bec545" xlink:to="loc_us-gaap_RestructuringCharges_e6c76885-4dab-4ff1-bcfa-9829925d3f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_184458b8-a50f-4a14-9995-374bb0a230ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3a8484fc-643a-4a95-ba51-372655bec545" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_184458b8-a50f-4a14-9995-374bb0a230ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS" xlink:type="simple" xlink:href="bhc-20220331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_53ee1281-ac28-4a57-9f29-45756d558bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_6cff5b66-b7e0-4d8c-ad01-cc5b0f1c10ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_53ee1281-ac28-4a57-9f29-45756d558bd4" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_6cff5b66-b7e0-4d8c-ad01-cc5b0f1c10ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables" xlink:type="simple" xlink:href="bhc-20220331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_93de4fc6-fe77-4036-85aa-1d59eaf69871" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_66186507-e62a-4c9f-b77e-1d41d9c2ed19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_93de4fc6-fe77-4036-85aa-1d59eaf69871" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_66186507-e62a-4c9f-b77e-1d41d9c2ed19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_4ee976d6-04d9-4427-8118-5dc3a88586ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_93de4fc6-fe77-4036-85aa-1d59eaf69871" xlink:to="loc_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_4ee976d6-04d9-4427-8118-5dc3a88586ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_91105d39-9f82-4315-b9d1-c8931fd43f78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_93de4fc6-fe77-4036-85aa-1d59eaf69871" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_91105d39-9f82-4315-b9d1-c8931fd43f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock_bce1b1f7-ee59-4a65-be3d-77a73263cec0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_93de4fc6-fe77-4036-85aa-1d59eaf69871" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock_bce1b1f7-ee59-4a65-be3d-77a73263cec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_93059dc1-36ba-4115-b6c4-28a81b097c07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_93de4fc6-fe77-4036-85aa-1d59eaf69871" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_93059dc1-36ba-4115-b6c4-28a81b097c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e5c49108-6d8d-41f5-b44e-82206b68e4da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1fd2c534-6cd3-48f5-87dd-5d7261c1eeea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e5c49108-6d8d-41f5-b44e-82206b68e4da" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1fd2c534-6cd3-48f5-87dd-5d7261c1eeea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6c81b7f9-2d7f-4d03-986f-f68e3067e0e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1fd2c534-6cd3-48f5-87dd-5d7261c1eeea" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6c81b7f9-2d7f-4d03-986f-f68e3067e0e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_a098ec99-06a2-4728-8977-ffc2b83fb6ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6c81b7f9-2d7f-4d03-986f-f68e3067e0e9" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_a098ec99-06a2-4728-8977-ffc2b83fb6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_c1df14d0-b61d-45a2-9c25-9cd3f41291b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_a098ec99-06a2-4728-8977-ffc2b83fb6ce" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_c1df14d0-b61d-45a2-9c25-9cd3f41291b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6adf0fbb-4423-426c-8bbc-12295e603e9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1fd2c534-6cd3-48f5-87dd-5d7261c1eeea" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6adf0fbb-4423-426c-8bbc-12295e603e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a1a57398-9efd-44c9-b5e0-0466bd591426" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6adf0fbb-4423-426c-8bbc-12295e603e9d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a1a57398-9efd-44c9-b5e0-0466bd591426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c060cad4-89ea-4957-83f9-0e51635af84d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a1a57398-9efd-44c9-b5e0-0466bd591426" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c060cad4-89ea-4957-83f9-0e51635af84d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_c3610794-ea68-49b0-afb4-46bc25be5901" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a1a57398-9efd-44c9-b5e0-0466bd591426" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_c3610794-ea68-49b0-afb4-46bc25be5901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9c48aeb2-5f79-49b8-af9b-158dc7cbd440" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a1a57398-9efd-44c9-b5e0-0466bd591426" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9c48aeb2-5f79-49b8-af9b-158dc7cbd440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5af69d7c-9d1d-4311-9af4-fbaa9b270a84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1fd2c534-6cd3-48f5-87dd-5d7261c1eeea" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5af69d7c-9d1d-4311-9af4-fbaa9b270a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d749efa7-97e4-4516-8dd4-e8a496631314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5af69d7c-9d1d-4311-9af4-fbaa9b270a84" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d749efa7-97e4-4516-8dd4-e8a496631314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_a4076401-0ed3-4c24-b292-9f42eab145f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d749efa7-97e4-4516-8dd4-e8a496631314" xlink:to="loc_us-gaap_ForeignExchangeContractMember_a4076401-0ed3-4c24-b292-9f42eab145f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_5e30caa3-046b-4aad-a968-6c8d7671bd42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1fd2c534-6cd3-48f5-87dd-5d7261c1eeea" xlink:to="loc_us-gaap_HedgingDesignationAxis_5e30caa3-046b-4aad-a968-6c8d7671bd42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_3a344582-46a1-457d-8a64-a9ab80990753" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_5e30caa3-046b-4aad-a968-6c8d7671bd42" xlink:to="loc_us-gaap_HedgingDesignationDomain_3a344582-46a1-457d-8a64-a9ab80990753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_171b1dbc-c928-44fb-9770-805e0d3a1f06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_3a344582-46a1-457d-8a64-a9ab80990753" xlink:to="loc_us-gaap_NondesignatedMember_171b1dbc-c928-44fb-9770-805e0d3a1f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2bba3422-4026-400a-a98f-1f6d30cd3ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1fd2c534-6cd3-48f5-87dd-5d7261c1eeea" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2bba3422-4026-400a-a98f-1f6d30cd3ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_b7ed430d-36e2-495c-98df-eec2bd17f4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2bba3422-4026-400a-a98f-1f6d30cd3ac8" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_b7ed430d-36e2-495c-98df-eec2bd17f4c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0f421b02-9003-4800-aef8-044005895d34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b7ed430d-36e2-495c-98df-eec2bd17f4c1" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0f421b02-9003-4800-aef8-044005895d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure_ac162127-6e4a-4d5c-8b09-dc07f08c2f6f" xlink:href="bhc-20220331.xsd#bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b7ed430d-36e2-495c-98df-eec2bd17f4c1" xlink:to="loc_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure_ac162127-6e4a-4d5c-8b09-dc07f08c2f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_2fa7d25b-34c3-49a4-bced-330b4781a335" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b7ed430d-36e2-495c-98df-eec2bd17f4c1" xlink:to="loc_us-gaap_DerivativeAssets_2fa7d25b-34c3-49a4-bced-330b4781a335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_9266d65f-35c4-484a-8cfc-f92730109e19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2bba3422-4026-400a-a98f-1f6d30cd3ac8" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_9266d65f-35c4-484a-8cfc-f92730109e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_35c49cc1-fca0-4197-8d20-f8077cf9b80b" xlink:href="bhc-20220331.xsd#bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_9266d65f-35c4-484a-8cfc-f92730109e19" xlink:to="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_35c49cc1-fca0-4197-8d20-f8077cf9b80b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_706fc3cf-fb00-465a-ba23-28efcf14f24f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_9266d65f-35c4-484a-8cfc-f92730109e19" xlink:to="loc_us-gaap_DerivativeLiabilities_706fc3cf-fb00-465a-ba23-28efcf14f24f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f72789b6-d7ad-4db2-b2f0-1516d2d191f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2e7837ae-af5e-416f-95e0-84224b1380da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f72789b6-d7ad-4db2-b2f0-1516d2d191f2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2e7837ae-af5e-416f-95e0-84224b1380da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_6292dede-1981-442e-bf65-fdaeb9cb8b15" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2e7837ae-af5e-416f-95e0-84224b1380da" xlink:to="loc_srt_LitigationCaseAxis_6292dede-1981-442e-bf65-fdaeb9cb8b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_24960ac3-39df-4246-8de1-aa9ee252c4c3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_6292dede-1981-442e-bf65-fdaeb9cb8b15" xlink:to="loc_srt_LitigationCaseTypeDomain_24960ac3-39df-4246-8de1-aa9ee252c4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember_106909eb-54d3-4495-b774-bf04940fc7f0" xlink:href="bhc-20220331.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_24960ac3-39df-4246-8de1-aa9ee252c4c3" xlink:to="loc_bhc_ValeantUSSecuritiesLitigationMember_106909eb-54d3-4495-b774-bf04940fc7f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_f29c3a53-28bb-462a-85e0-d2e6190da6e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2e7837ae-af5e-416f-95e0-84224b1380da" xlink:to="loc_us-gaap_LitigationStatusAxis_f29c3a53-28bb-462a-85e0-d2e6190da6e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_6d8eb47f-4003-4cbb-af57-fad15f0dd7f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_f29c3a53-28bb-462a-85e0-d2e6190da6e6" xlink:to="loc_us-gaap_LitigationStatusDomain_6d8eb47f-4003-4cbb-af57-fad15f0dd7f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_49bd3dd3-4079-4d7b-bd3f-fc1416cb0255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_6d8eb47f-4003-4cbb-af57-fad15f0dd7f7" xlink:to="loc_us-gaap_SettledLitigationMember_49bd3dd3-4079-4d7b-bd3f-fc1416cb0255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_cd79da1d-ccd1-4cfe-a7ff-ad9d901cf3a5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2e7837ae-af5e-416f-95e0-84224b1380da" xlink:to="loc_srt_StatementGeographicalAxis_cd79da1d-ccd1-4cfe-a7ff-ad9d901cf3a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d9aa3066-5b57-4672-a1ca-bf4982bc3723" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_cd79da1d-ccd1-4cfe-a7ff-ad9d901cf3a5" xlink:to="loc_srt_SegmentGeographicalDomain_d9aa3066-5b57-4672-a1ca-bf4982bc3723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_9dd4501c-abfc-4874-89d0-79c809207aff" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_NJ"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d9aa3066-5b57-4672-a1ca-bf4982bc3723" xlink:to="loc_stpr_NJ_9dd4501c-abfc-4874-89d0-79c809207aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8ccec2cb-8fdd-4918-a0b4-370e96d2248f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2e7837ae-af5e-416f-95e0-84224b1380da" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8ccec2cb-8fdd-4918-a0b4-370e96d2248f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod_e814b628-4e79-413e-8a73-29d500044d71" xlink:href="bhc-20220331.xsd#bhc_HighlyLiquidInvestmentsMaturityPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8ccec2cb-8fdd-4918-a0b4-370e96d2248f" xlink:to="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod_e814b628-4e79-413e-8a73-29d500044d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_c742815c-2d87-4a66-9575-1df9962a71ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8ccec2cb-8fdd-4918-a0b4-370e96d2248f" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_c742815c-2d87-4a66-9575-1df9962a71ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LitigationSettlementNumberOfObjectorsAppeals_fa95b63d-e520-4dd2-89a0-727c15f8789d" xlink:href="bhc-20220331.xsd#bhc_LitigationSettlementNumberOfObjectorsAppeals"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8ccec2cb-8fdd-4918-a0b4-370e96d2248f" xlink:to="loc_bhc_LitigationSettlementNumberOfObjectorsAppeals_fa95b63d-e520-4dd2-89a0-727c15f8789d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e8e0a537-41dd-4761-87d7-718052a008bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3326dfb2-6aa9-46f0-8331-5090c81c3ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e8e0a537-41dd-4761-87d7-718052a008bc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3326dfb2-6aa9-46f0-8331-5090c81c3ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_cd7c0201-3dd8-409d-873c-edd75b276ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3326dfb2-6aa9-46f0-8331-5090c81c3ed9" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_cd7c0201-3dd8-409d-873c-edd75b276ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_2a749a0a-9316-4179-b3ba-fb3eccff2952" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_cd7c0201-3dd8-409d-873c-edd75b276ddb" xlink:to="loc_us-gaap_HedgingRelationshipDomain_2a749a0a-9316-4179-b3ba-fb3eccff2952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_0b0ae4fa-d7fc-454c-985f-e636425bb0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_2a749a0a-9316-4179-b3ba-fb3eccff2952" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_0b0ae4fa-d7fc-454c-985f-e636425bb0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_cffafc49-8092-4483-b835-8c2c17bb5255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3326dfb2-6aa9-46f0-8331-5090c81c3ed9" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_cffafc49-8092-4483-b835-8c2c17bb5255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c114e80f-7fc0-4a26-9300-f251c0b764e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_cffafc49-8092-4483-b835-8c2c17bb5255" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c114e80f-7fc0-4a26-9300-f251c0b764e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_ad0321d5-8256-449a-840e-c7a25114acde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c114e80f-7fc0-4a26-9300-f251c0b764e1" xlink:to="loc_us-gaap_CurrencySwapMember_ad0321d5-8256-449a-840e-c7a25114acde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_1c6d0215-5a07-4371-8f6d-150c4eb1f716" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3326dfb2-6aa9-46f0-8331-5090c81c3ed9" xlink:to="loc_us-gaap_HedgingDesignationAxis_1c6d0215-5a07-4371-8f6d-150c4eb1f716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_5b84faa6-60cf-4ec6-91ed-6bb033edd114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_1c6d0215-5a07-4371-8f6d-150c4eb1f716" xlink:to="loc_us-gaap_HedgingDesignationDomain_5b84faa6-60cf-4ec6-91ed-6bb033edd114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_a20244f9-3021-4db3-9442-e132fe66e20c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_5b84faa6-60cf-4ec6-91ed-6bb033edd114" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_a20244f9-3021-4db3-9442-e132fe66e20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1ce88668-e0a5-486d-8760-61677b5ac3c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3326dfb2-6aa9-46f0-8331-5090c81c3ed9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1ce88668-e0a5-486d-8760-61677b5ac3c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_fe637791-9720-4349-8df5-3a3732412a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1ce88668-e0a5-486d-8760-61677b5ac3c7" xlink:to="loc_us-gaap_DerivativeNotionalAmount_fe637791-9720-4349-8df5-3a3732412a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_82af953d-c838-49a1-80b8-973608a1e6b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1ce88668-e0a5-486d-8760-61677b5ac3c7" xlink:to="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_82af953d-c838-49a1-80b8-973608a1e6b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e573c0f0-569c-4489-b374-41d58fc5e69b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7d4405f9-bda0-438a-a203-f717b2ab4d16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e573c0f0-569c-4489-b374-41d58fc5e69b" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7d4405f9-bda0-438a-a203-f717b2ab4d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f385ad84-666c-4942-8432-0a56e46d3483" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7d4405f9-bda0-438a-a203-f717b2ab4d16" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f385ad84-666c-4942-8432-0a56e46d3483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_c1265ebb-3bc5-4902-9a88-a646445d6526" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f385ad84-666c-4942-8432-0a56e46d3483" xlink:to="loc_us-gaap_HedgingRelationshipDomain_c1265ebb-3bc5-4902-9a88-a646445d6526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_d08ab361-471d-459a-ae78-dd6dc2659fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_c1265ebb-3bc5-4902-9a88-a646445d6526" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_d08ab361-471d-459a-ae78-dd6dc2659fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_21f377e3-52ca-4d56-929d-ab4c1c5d67ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7d4405f9-bda0-438a-a203-f717b2ab4d16" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_21f377e3-52ca-4d56-929d-ab4c1c5d67ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_abec377b-7769-4fd3-8747-183cb5380870" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_21f377e3-52ca-4d56-929d-ab4c1c5d67ff" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_abec377b-7769-4fd3-8747-183cb5380870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_545f9b86-8618-4207-84fa-a175409e822f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_abec377b-7769-4fd3-8747-183cb5380870" xlink:to="loc_us-gaap_CurrencySwapMember_545f9b86-8618-4207-84fa-a175409e822f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_73ebfb02-6fb9-4ad2-82be-2d5ef66b2afc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7d4405f9-bda0-438a-a203-f717b2ab4d16" xlink:to="loc_us-gaap_HedgingDesignationAxis_73ebfb02-6fb9-4ad2-82be-2d5ef66b2afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_64819721-c430-4e72-a80a-21bb2ab76049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_73ebfb02-6fb9-4ad2-82be-2d5ef66b2afc" xlink:to="loc_us-gaap_HedgingDesignationDomain_64819721-c430-4e72-a80a-21bb2ab76049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_dba81803-4cce-4d7e-8409-8a3a155e8b04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_64819721-c430-4e72-a80a-21bb2ab76049" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_dba81803-4cce-4d7e-8409-8a3a155e8b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c453ce59-642f-4872-93b1-923252295fce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7d4405f9-bda0-438a-a203-f717b2ab4d16" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c453ce59-642f-4872-93b1-923252295fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5f47822f-36dd-4f72-9983-03baa997c9da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c453ce59-642f-4872-93b1-923252295fce" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5f47822f-36dd-4f72-9983-03baa997c9da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_527c132d-a250-4886-afce-c6c7c0eeb4bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5f47822f-36dd-4f72-9983-03baa997c9da" xlink:to="loc_us-gaap_InterestExpenseMember_527c132d-a250-4886-afce-c6c7c0eeb4bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a0355357-2f6b-4079-9382-81873c95c7fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7d4405f9-bda0-438a-a203-f717b2ab4d16" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a0355357-2f6b-4079-9382-81873c95c7fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_2c96a059-149e-4008-834f-de1171732610" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a0355357-2f6b-4079-9382-81873c95c7fa" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_2c96a059-149e-4008-834f-de1171732610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_8adb3673-31c4-4958-95db-1cb410d0d521" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a0355357-2f6b-4079-9382-81873c95c7fa" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_8adb3673-31c4-4958-95db-1cb410d0d521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6b4884c8-b48a-4561-8e5e-02a6e8fe6ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f074ac5d-a937-411e-8992-ea229ffd4f86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6b4884c8-b48a-4561-8e5e-02a6e8fe6ad2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f074ac5d-a937-411e-8992-ea229ffd4f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_294b7ec8-53fa-44f9-96e4-d85fad7e168c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f074ac5d-a937-411e-8992-ea229ffd4f86" xlink:to="loc_us-gaap_HedgingDesignationAxis_294b7ec8-53fa-44f9-96e4-d85fad7e168c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_b048d63f-2d56-4a33-875e-502006135e29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_294b7ec8-53fa-44f9-96e4-d85fad7e168c" xlink:to="loc_us-gaap_HedgingDesignationDomain_b048d63f-2d56-4a33-875e-502006135e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_afc3b2b5-1974-46ed-afff-857dd74d562e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_b048d63f-2d56-4a33-875e-502006135e29" xlink:to="loc_us-gaap_NondesignatedMember_afc3b2b5-1974-46ed-afff-857dd74d562e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_365bf202-f9c3-40d5-b550-f829c2cd7c09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f074ac5d-a937-411e-8992-ea229ffd4f86" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_365bf202-f9c3-40d5-b550-f829c2cd7c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_00e2ba63-4e92-4e00-84c4-b118b8851342" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_365bf202-f9c3-40d5-b550-f829c2cd7c09" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_00e2ba63-4e92-4e00-84c4-b118b8851342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_42fde316-4f21-493d-ac60-f5f173866ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_00e2ba63-4e92-4e00-84c4-b118b8851342" xlink:to="loc_us-gaap_ForeignExchangeContractMember_42fde316-4f21-493d-ac60-f5f173866ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_136e712c-f6a3-4d1e-aaca-22265cdc4ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f074ac5d-a937-411e-8992-ea229ffd4f86" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_136e712c-f6a3-4d1e-aaca-22265cdc4ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_c734a9bb-2a15-4d09-babe-d0f643cba2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_136e712c-f6a3-4d1e-aaca-22265cdc4ec8" xlink:to="loc_us-gaap_DerivativeNotionalAmount_c734a9bb-2a15-4d09-babe-d0f643cba2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_195a7596-a1c3-4ed3-adac-149c71aee6f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_deeb0cc7-a30f-4441-80f5-712ced1b4478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_195a7596-a1c3-4ed3-adac-149c71aee6f9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_deeb0cc7-a30f-4441-80f5-712ced1b4478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_6f27d52e-c2a8-47f1-814c-3b15dec5952b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_deeb0cc7-a30f-4441-80f5-712ced1b4478" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_6f27d52e-c2a8-47f1-814c-3b15dec5952b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_bd600520-5e53-409b-b906-8edbec721c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6f27d52e-c2a8-47f1-814c-3b15dec5952b" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_bd600520-5e53-409b-b906-8edbec721c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedAndOtherCurrentLiabilitiesMember_5c5e1293-2c8a-4f24-b983-459f44400155" xlink:href="bhc-20220331.xsd#bhc_AccruedAndOtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_bd600520-5e53-409b-b906-8edbec721c6f" xlink:to="loc_bhc_AccruedAndOtherCurrentLiabilitiesMember_5c5e1293-2c8a-4f24-b983-459f44400155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_ded7f7e8-ccf6-4e75-9c1f-376d84f3f99c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_bd600520-5e53-409b-b906-8edbec721c6f" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_ded7f7e8-ccf6-4e75-9c1f-376d84f3f99c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_052680fc-721b-43ab-b80a-3c1cf0dc4c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_deeb0cc7-a30f-4441-80f5-712ced1b4478" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_052680fc-721b-43ab-b80a-3c1cf0dc4c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c16a61d1-102b-400b-9f4c-705f8f35b103" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_052680fc-721b-43ab-b80a-3c1cf0dc4c0f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c16a61d1-102b-400b-9f4c-705f8f35b103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_732d768e-738a-4d6e-ad41-38ec57f099f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c16a61d1-102b-400b-9f4c-705f8f35b103" xlink:to="loc_us-gaap_ForeignExchangeContractMember_732d768e-738a-4d6e-ad41-38ec57f099f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_9aff30dd-0878-4855-b6ae-f617f8994a52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_deeb0cc7-a30f-4441-80f5-712ced1b4478" xlink:to="loc_us-gaap_HedgingDesignationAxis_9aff30dd-0878-4855-b6ae-f617f8994a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_da7619c8-0de2-4a43-a775-b76e632c5e58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_9aff30dd-0878-4855-b6ae-f617f8994a52" xlink:to="loc_us-gaap_HedgingDesignationDomain_da7619c8-0de2-4a43-a775-b76e632c5e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_643a19e0-822d-4141-b7ff-38f5e077239d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_da7619c8-0de2-4a43-a775-b76e632c5e58" xlink:to="loc_us-gaap_NondesignatedMember_643a19e0-822d-4141-b7ff-38f5e077239d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3f5f0330-68a8-4088-a5f5-6420262743be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_deeb0cc7-a30f-4441-80f5-712ced1b4478" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3f5f0330-68a8-4088-a5f5-6420262743be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_710a0ef4-3f2f-42d6-9253-dcf2b813fdcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3f5f0330-68a8-4088-a5f5-6420262743be" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_710a0ef4-3f2f-42d6-9253-dcf2b813fdcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_2ef088d9-6f13-4826-b8c6-0303cc3f1b75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3f5f0330-68a8-4088-a5f5-6420262743be" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_2ef088d9-6f13-4826-b8c6-0303cc3f1b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_20f7c77c-28c2-4fb6-999c-ba5209654508" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3f5f0330-68a8-4088-a5f5-6420262743be" xlink:to="loc_us-gaap_DerivativeLiabilities_20f7c77c-28c2-4fb6-999c-ba5209654508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_30801273-ea45-4b37-b2ce-f559af60df84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bc63fd1b-4fef-452b-ab11-b78e238b869b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_30801273-ea45-4b37-b2ce-f559af60df84" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bc63fd1b-4fef-452b-ab11-b78e238b869b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_58736d89-9135-4b71-80a4-6652b08c06fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bc63fd1b-4fef-452b-ab11-b78e238b869b" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_58736d89-9135-4b71-80a4-6652b08c06fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_3ee7f267-6c03-4126-8c5d-917a22c13465" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_58736d89-9135-4b71-80a4-6652b08c06fd" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_3ee7f267-6c03-4126-8c5d-917a22c13465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_7cdbf61e-5344-446d-8edc-f5328b64cbe3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_3ee7f267-6c03-4126-8c5d-917a22c13465" xlink:to="loc_us-gaap_ForeignExchangeContractMember_7cdbf61e-5344-446d-8edc-f5328b64cbe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_ecc107ac-8611-4177-9126-e371b0ab6d58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bc63fd1b-4fef-452b-ab11-b78e238b869b" xlink:to="loc_us-gaap_HedgingDesignationAxis_ecc107ac-8611-4177-9126-e371b0ab6d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_47e19143-da67-43d8-8098-e408353c1669" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_ecc107ac-8611-4177-9126-e371b0ab6d58" xlink:to="loc_us-gaap_HedgingDesignationDomain_47e19143-da67-43d8-8098-e408353c1669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_21646295-f4ed-4fb9-bc91-5ea6bc46a51c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_47e19143-da67-43d8-8098-e408353c1669" xlink:to="loc_us-gaap_NondesignatedMember_21646295-f4ed-4fb9-bc91-5ea6bc46a51c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_af6821c9-b460-4162-99cb-95d336ea23b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bc63fd1b-4fef-452b-ab11-b78e238b869b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_af6821c9-b460-4162-99cb-95d336ea23b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_641ede62-9d42-44e7-a778-5aeea8ca2a78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_af6821c9-b460-4162-99cb-95d336ea23b1" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_641ede62-9d42-44e7-a778-5aeea8ca2a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain_c618a612-c3a6-44de-8cf3-44568cd04244" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_af6821c9-b460-4162-99cb-95d336ea23b1" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain_c618a612-c3a6-44de-8cf3-44568cd04244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_20519ff2-068a-466c-bc62-edad7c2acda8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_af6821c9-b460-4162-99cb-95d336ea23b1" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_20519ff2-068a-466c-bc62-edad7c2acda8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3f7424eb-1aea-4448-9631-f381a3bedfa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ae3015c8-a8be-4cb6-baf2-b32aef21fbf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3f7424eb-1aea-4448-9631-f381a3bedfa1" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ae3015c8-a8be-4cb6-baf2-b32aef21fbf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f8198652-6ee6-4732-bbfa-e6a1cdca1486" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ae3015c8-a8be-4cb6-baf2-b32aef21fbf8" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f8198652-6ee6-4732-bbfa-e6a1cdca1486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2c457bd2-c518-48a3-95cb-7aba2d639068" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f8198652-6ee6-4732-bbfa-e6a1cdca1486" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2c457bd2-c518-48a3-95cb-7aba2d639068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_54355aa7-360f-45c6-9371-0f9d3bf7cc35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_2c457bd2-c518-48a3-95cb-7aba2d639068" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_54355aa7-360f-45c6-9371-0f9d3bf7cc35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_b90ac752-b68c-49ca-b4d8-3c49f8e4644b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ae3015c8-a8be-4cb6-baf2-b32aef21fbf8" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_b90ac752-b68c-49ca-b4d8-3c49f8e4644b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_27af258a-0321-405a-876d-6cf47579adba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_b90ac752-b68c-49ca-b4d8-3c49f8e4644b" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_27af258a-0321-405a-876d-6cf47579adba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_c4fdb36f-0fce-4b85-b05e-06fc8d18cdfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_27af258a-0321-405a-876d-6cf47579adba" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_c4fdb36f-0fce-4b85-b05e-06fc8d18cdfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember_a645db56-63d0-46b4-9c3d-a873612a569a" xlink:href="bhc-20220331.xsd#bhc_MeasurementInputWeightedAverageDiscountRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_27af258a-0321-405a-876d-6cf47579adba" xlink:to="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember_a645db56-63d0-46b4-9c3d-a873612a569a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_689d9743-f655-4bc4-8fbd-5f454ca2411e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ae3015c8-a8be-4cb6-baf2-b32aef21fbf8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_689d9743-f655-4bc4-8fbd-5f454ca2411e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8cf6588-cd64-455b-a32f-6d0b3a74ca9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_689d9743-f655-4bc4-8fbd-5f454ca2411e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8cf6588-cd64-455b-a32f-6d0b3a74ca9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_efe212e6-2afe-4a9c-8a5e-4215e8f5797e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8cf6588-cd64-455b-a32f-6d0b3a74ca9e" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_efe212e6-2afe-4a9c-8a5e-4215e8f5797e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b5f15366-868a-4e3c-a414-9edcbc5c853c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ae3015c8-a8be-4cb6-baf2-b32aef21fbf8" xlink:to="loc_srt_RangeAxis_b5f15366-868a-4e3c-a414-9edcbc5c853c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ad1ba158-2e8e-4539-a061-f2a0daf9f375" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b5f15366-868a-4e3c-a414-9edcbc5c853c" xlink:to="loc_srt_RangeMember_ad1ba158-2e8e-4539-a061-f2a0daf9f375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d8bc6650-8354-4342-b368-aecd9963aef3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ad1ba158-2e8e-4539-a061-f2a0daf9f375" xlink:to="loc_srt_MinimumMember_d8bc6650-8354-4342-b368-aecd9963aef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_98679aed-6592-4324-9426-44d439bfe4f5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ad1ba158-2e8e-4539-a061-f2a0daf9f375" xlink:to="loc_srt_MaximumMember_98679aed-6592-4324-9426-44d439bfe4f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_69a38f5b-4ad8-4743-8619-2dc8afc76a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ae3015c8-a8be-4cb6-baf2-b32aef21fbf8" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_69a38f5b-4ad8-4743-8619-2dc8afc76a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_4d8aa0db-8047-4cb2-941f-b2adce6efc3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_69a38f5b-4ad8-4743-8619-2dc8afc76a0a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_4d8aa0db-8047-4cb2-941f-b2adce6efc3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6dd97d3a-181c-4c79-bc40-cb59454cf25f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_b2a80eca-a34d-4d04-ad7a-d4df4c658140" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6dd97d3a-181c-4c79-bc40-cb59454cf25f" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_b2a80eca-a34d-4d04-ad7a-d4df4c658140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_667fe0fd-2bb2-48c5-a484-7fbe5262f85f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_b2a80eca-a34d-4d04-ad7a-d4df4c658140" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_667fe0fd-2bb2-48c5-a484-7fbe5262f85f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_fe929824-8baa-45a3-96c0-1423f5b8d1d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_667fe0fd-2bb2-48c5-a484-7fbe5262f85f" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_fe929824-8baa-45a3-96c0-1423f5b8d1d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccretionForTimeValueOfMoneyMember_bd0c8f82-57e8-47b1-8824-2844e45f4c02" xlink:href="bhc-20220331.xsd#bhc_AccretionForTimeValueOfMoneyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_fe929824-8baa-45a3-96c0-1423f5b8d1d4" xlink:to="loc_bhc_AccretionForTimeValueOfMoneyMember_bd0c8f82-57e8-47b1-8824-2844e45f4c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember_e054bbd3-6841-406d-a0db-2cb8a6f715ce" xlink:href="bhc-20220331.xsd#bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_fe929824-8baa-45a3-96c0-1423f5b8d1d4" xlink:to="loc_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember_e054bbd3-6841-406d-a0db-2cb8a6f715ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_d09552e3-b40b-45c7-9e3c-cb48f4883436" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_b2a80eca-a34d-4d04-ad7a-d4df4c658140" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_d09552e3-b40b-45c7-9e3c-cb48f4883436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1689085a-9b2e-47e3-adde-2667874a56a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_d09552e3-b40b-45c7-9e3c-cb48f4883436" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1689085a-9b2e-47e3-adde-2667874a56a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_c38c16b3-27a7-488b-beba-925d089c07cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1689085a-9b2e-47e3-adde-2667874a56a7" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_c38c16b3-27a7-488b-beba-925d089c07cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_8a8998b2-9f21-43d7-924b-481e4e804c17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1689085a-9b2e-47e3-adde-2667874a56a7" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_8a8998b2-9f21-43d7-924b-481e4e804c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_fea8a957-e553-4d1c-a722-ab3c66845b88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1689085a-9b2e-47e3-adde-2667874a56a7" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_fea8a957-e553-4d1c-a722-ab3c66845b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_90e3b410-fe90-4144-90ef-fa042489f55a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1689085a-9b2e-47e3-adde-2667874a56a7" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_90e3b410-fe90-4144-90ef-fa042489f55a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_4eb7a745-e628-4c5e-adca-bd7716de51cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1689085a-9b2e-47e3-adde-2667874a56a7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_4eb7a745-e628-4c5e-adca-bd7716de51cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_513f90ce-eca4-4ad5-b7db-bc593e24948b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1689085a-9b2e-47e3-adde-2667874a56a7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_513f90ce-eca4-4ad5-b7db-bc593e24948b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1ea18848-a423-4090-b036-88611a2b8e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_86c3c363-f6d5-422e-bb66-20c18d70b88a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1ea18848-a423-4090-b036-88611a2b8e2b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_86c3c363-f6d5-422e-bb66-20c18d70b88a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7ba1048d-43a5-4aaf-8e7f-ebad5f50ccd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_86c3c363-f6d5-422e-bb66-20c18d70b88a" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7ba1048d-43a5-4aaf-8e7f-ebad5f50ccd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f7f28da0-97f6-49ed-a517-abd960ac587f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7ba1048d-43a5-4aaf-8e7f-ebad5f50ccd4" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f7f28da0-97f6-49ed-a517-abd960ac587f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_0051e69a-2791-4ab8-b163-c70a922ecd07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_f7f28da0-97f6-49ed-a517-abd960ac587f" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_0051e69a-2791-4ab8-b163-c70a922ecd07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fac6238d-2aeb-443e-88c7-9d4521bae3cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_86c3c363-f6d5-422e-bb66-20c18d70b88a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fac6238d-2aeb-443e-88c7-9d4521bae3cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_623924f8-3248-4404-8d4b-8f1823ccf3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fac6238d-2aeb-443e-88c7-9d4521bae3cb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_623924f8-3248-4404-8d4b-8f1823ccf3a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_71fed5b0-a193-4574-8078-8ffc36fd0b47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_623924f8-3248-4404-8d4b-8f1823ccf3a9" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_71fed5b0-a193-4574-8078-8ffc36fd0b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c6c2048d-822a-4888-a675-5288c1f04208" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_86c3c363-f6d5-422e-bb66-20c18d70b88a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c6c2048d-822a-4888-a675-5288c1f04208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_75383699-21ef-4f20-b80f-1a0060aa520c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c6c2048d-822a-4888-a675-5288c1f04208" xlink:to="loc_us-gaap_DebtInstrumentFairValue_75383699-21ef-4f20-b80f-1a0060aa520c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INVENTORIES" xlink:type="simple" xlink:href="bhc-20220331.xsd#INVENTORIES"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INVENTORIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_2f1c0a96-fdd1-4d15-a236-1e0715c89666" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_562eb316-04a9-4a70-a90d-19a349e92e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_2f1c0a96-fdd1-4d15-a236-1e0715c89666" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_562eb316-04a9-4a70-a90d-19a349e92e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INVENTORIESTables" xlink:type="simple" xlink:href="bhc-20220331.xsd#INVENTORIESTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INVENTORIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_fa39712c-1a1a-4dd3-9c03-f0881bb97aff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_a112d787-8302-4231-909b-b9fecded5a21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_fa39712c-1a1a-4dd3-9c03-f0881bb97aff" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_a112d787-8302-4231-909b-b9fecded5a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#INVENTORIESComponentsofInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_061ad1b8-c042-462c-9c6b-1030cc66eebc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_372d16c4-b71c-4a96-b73b-f217ec225738" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_061ad1b8-c042-462c-9c6b-1030cc66eebc" xlink:to="loc_us-gaap_InventoryRawMaterials_372d16c4-b71c-4a96-b73b-f217ec225738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_880a448e-513e-43ee-bc4a-b0c20306a260" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_061ad1b8-c042-462c-9c6b-1030cc66eebc" xlink:to="loc_us-gaap_InventoryWorkInProcess_880a448e-513e-43ee-bc4a-b0c20306a260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_8bd1573b-bca5-4829-84df-d878ecf83231" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_061ad1b8-c042-462c-9c6b-1030cc66eebc" xlink:to="loc_us-gaap_InventoryFinishedGoods_8bd1573b-bca5-4829-84df-d878ecf83231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_fc3d4430-fa92-4131-9224-50f8f6775df8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_061ad1b8-c042-462c-9c6b-1030cc66eebc" xlink:to="loc_us-gaap_InventoryGross_fc3d4430-fa92-4131-9224-50f8f6775df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL" xlink:type="simple" xlink:href="bhc-20220331.xsd#INTANGIBLEASSETSANDGOODWILL"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6b6630ad-a380-4123-af38-fd457782ce9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_4cd54f82-bfbb-4493-9e00-5a50e6467684" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6b6630ad-a380-4123-af38-fd457782ce9d" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_4cd54f82-bfbb-4493-9e00-5a50e6467684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables" xlink:type="simple" xlink:href="bhc-20220331.xsd#INTANGIBLEASSETSANDGOODWILLTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d26dc53b-0a42-4185-8e82-7874267a35b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_cb9d758a-824c-4adc-a958-92d037dddea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d26dc53b-0a42-4185-8e82-7874267a35b7" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_cb9d758a-824c-4adc-a958-92d037dddea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_284761c8-f522-4b30-9129-37d5ad0a7aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d26dc53b-0a42-4185-8e82-7874267a35b7" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_284761c8-f522-4b30-9129-37d5ad0a7aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_9b3c2fee-ba31-41d7-8de2-1f9cdb942a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d26dc53b-0a42-4185-8e82-7874267a35b7" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_9b3c2fee-ba31-41d7-8de2-1f9cdb942a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_25a7096e-8f22-4a42-aa60-7e49bf8f0b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d26dc53b-0a42-4185-8e82-7874267a35b7" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_25a7096e-8f22-4a42-aa60-7e49bf8f0b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cbc860f6-c9f3-4e27-b6d2-1483733af2f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_5d5d3da3-c974-4c23-95bd-109798ce217d" xlink:href="bhc-20220331.xsd#bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cbc860f6-c9f3-4e27-b6d2-1483733af2f8" xlink:to="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_5d5d3da3-c974-4c23-95bd-109798ce217d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7e63fdd2-834b-4334-a28b-9a9d7d8dad0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_5d5d3da3-c974-4c23-95bd-109798ce217d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7e63fdd2-834b-4334-a28b-9a9d7d8dad0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9d0e1af6-a2d4-4b2c-ae8d-e67b772db65c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7e63fdd2-834b-4334-a28b-9a9d7d8dad0e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9d0e1af6-a2d4-4b2c-ae8d-e67b772db65c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProductBrandsMember_d40588fa-13e8-42f2-98a5-e1c411e33554" xlink:href="bhc-20220331.xsd#bhc_ProductBrandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9d0e1af6-a2d4-4b2c-ae8d-e67b772db65c" xlink:to="loc_bhc_ProductBrandsMember_d40588fa-13e8-42f2-98a5-e1c411e33554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_266133ed-088f-4565-a7a5-811dd8866b32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9d0e1af6-a2d4-4b2c-ae8d-e67b772db65c" xlink:to="loc_us-gaap_TradeNamesMember_266133ed-088f-4565-a7a5-811dd8866b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember_b0359e5f-25fb-4192-95fd-c923ba62253a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9d0e1af6-a2d4-4b2c-ae8d-e67b772db65c" xlink:to="loc_us-gaap_ContractualRightsMember_b0359e5f-25fb-4192-95fd-c923ba62253a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PartnerRelationshipsMember_424b79f8-f339-4801-aa1c-4067017e2993" xlink:href="bhc-20220331.xsd#bhc_PartnerRelationshipsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9d0e1af6-a2d4-4b2c-ae8d-e67b772db65c" xlink:to="loc_bhc_PartnerRelationshipsMember_424b79f8-f339-4801-aa1c-4067017e2993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OutLicensedTechnologyMember_62dcd71b-1525-4881-96a8-b16a1ded12ff" xlink:href="bhc-20220331.xsd#bhc_OutLicensedTechnologyMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9d0e1af6-a2d4-4b2c-ae8d-e67b772db65c" xlink:to="loc_bhc_OutLicensedTechnologyMember_62dcd71b-1525-4881-96a8-b16a1ded12ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e2dc856b-821f-4764-91d9-823cb064f379" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_5d5d3da3-c974-4c23-95bd-109798ce217d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e2dc856b-821f-4764-91d9-823cb064f379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_76d57f4a-4722-45a6-96f7-4247249d4c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e2dc856b-821f-4764-91d9-823cb064f379" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_76d57f4a-4722-45a6-96f7-4247249d4c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_52868946-d4e7-480f-a786-c2ce2761f96d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_76d57f4a-4722-45a6-96f7-4247249d4c9c" xlink:to="loc_us-gaap_TrademarksMember_52868946-d4e7-480f-a786-c2ce2761f96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_6e3a5e04-14dd-4491-adc8-5fe5d2e051bf" xlink:href="bhc-20220331.xsd#bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_5d5d3da3-c974-4c23-95bd-109798ce217d" xlink:to="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_6e3a5e04-14dd-4491-adc8-5fe5d2e051bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2dfc191c-6597-4496-80d1-c7d3d874a4f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_6e3a5e04-14dd-4491-adc8-5fe5d2e051bf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2dfc191c-6597-4496-80d1-c7d3d874a4f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_747145c7-2939-4768-8694-765278c6ffb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2dfc191c-6597-4496-80d1-c7d3d874a4f2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_747145c7-2939-4768-8694-765278c6ffb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d3ad6071-2b4b-4e58-b19a-cc1a8d3f7e24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2dfc191c-6597-4496-80d1-c7d3d874a4f2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d3ad6071-2b4b-4e58-b19a-cc1a8d3f7e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_746db2c9-da81-4c06-9fa3-c6ae1a3bbb6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2dfc191c-6597-4496-80d1-c7d3d874a4f2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_746db2c9-da81-4c06-9fa3-c6ae1a3bbb6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_9fd79cb3-b0ce-492f-bfe7-6177c40a62d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_6e3a5e04-14dd-4491-adc8-5fe5d2e051bf" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_9fd79cb3-b0ce-492f-bfe7-6177c40a62d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_5423e267-11f8-4773-8b00-2e171621635c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_9fd79cb3-b0ce-492f-bfe7-6177c40a62d9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_5423e267-11f8-4773-8b00-2e171621635c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_264a6d9c-e431-4379-a585-fd76b1cab33c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_6e3a5e04-14dd-4491-adc8-5fe5d2e051bf" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_264a6d9c-e431-4379-a585-fd76b1cab33c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_18191860-f1d5-4780-bd41-69f96eb80518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_264a6d9c-e431-4379-a585-fd76b1cab33c" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_18191860-f1d5-4780-bd41-69f96eb80518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_bd28a97d-c945-4a56-b739-b7f788f2b107" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_264a6d9c-e431-4379-a585-fd76b1cab33c" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_bd28a97d-c945-4a56-b739-b7f788f2b107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#INTANGIBLEASSETSANDGOODWILLNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6563b773-d7c2-4eb7-864a-684108054a88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_56f23012-bcdc-4013-a9aa-6c9d988cf330" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6563b773-d7c2-4eb7-864a-684108054a88" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_56f23012-bcdc-4013-a9aa-6c9d988cf330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c1accd3e-6d66-4114-83d0-35847d35f3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_56f23012-bcdc-4013-a9aa-6c9d988cf330" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c1accd3e-6d66-4114-83d0-35847d35f3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a4560ab7-8390-4a97-974d-b1724f1f4e56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c1accd3e-6d66-4114-83d0-35847d35f3a7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a4560ab7-8390-4a97-974d-b1724f1f4e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProductBrandsMember_bdf0004c-7f07-4357-ac7b-eba037895c18" xlink:href="bhc-20220331.xsd#bhc_ProductBrandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a4560ab7-8390-4a97-974d-b1724f1f4e56" xlink:to="loc_bhc_ProductBrandsMember_bdf0004c-7f07-4357-ac7b-eba037895c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiscontinuedProductLinesMember_0f1740e0-ac02-4397-a325-a384e76fee23" xlink:href="bhc-20220331.xsd#bhc_DiscontinuedProductLinesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a4560ab7-8390-4a97-974d-b1724f1f4e56" xlink:to="loc_bhc_DiscontinuedProductLinesMember_0f1740e0-ac02-4397-a325-a384e76fee23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_c6c8a7c0-12b4-47ea-9d5d-08d233b3e84a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_56f23012-bcdc-4013-a9aa-6c9d988cf330" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_c6c8a7c0-12b4-47ea-9d5d-08d233b3e84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_06f7be50-2033-49f7-8287-e0fba3b49b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_c6c8a7c0-12b4-47ea-9d5d-08d233b3e84a" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_06f7be50-2033-49f7-8287-e0fba3b49b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_0dcefa4d-7af0-41d4-b78b-5c6da25137df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_06f7be50-2033-49f7-8287-e0fba3b49b7f" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_0dcefa4d-7af0-41d4-b78b-5c6da25137df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0e142ecf-2ce2-446d-9974-fdd7c5ca2e1e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_56f23012-bcdc-4013-a9aa-6c9d988cf330" xlink:to="loc_srt_RangeAxis_0e142ecf-2ce2-446d-9974-fdd7c5ca2e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9a35f94b-a1f4-4051-86c9-812ae323351a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0e142ecf-2ce2-446d-9974-fdd7c5ca2e1e" xlink:to="loc_srt_RangeMember_9a35f94b-a1f4-4051-86c9-812ae323351a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cfda77c2-1c74-4bfd-bccc-a878562d5518" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9a35f94b-a1f4-4051-86c9-812ae323351a" xlink:to="loc_srt_MinimumMember_cfda77c2-1c74-4bfd-bccc-a878562d5518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b674a0b8-2ea5-42b1-969d-1e36189dc499" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9a35f94b-a1f4-4051-86c9-812ae323351a" xlink:to="loc_srt_MaximumMember_b674a0b8-2ea5-42b1-969d-1e36189dc499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_eba662f3-480f-464d-8e51-b214435e7dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_56f23012-bcdc-4013-a9aa-6c9d988cf330" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_eba662f3-480f-464d-8e51-b214435e7dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d6ddace7-263f-4d22-ab39-dfddcf8f99e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_eba662f3-480f-464d-8e51-b214435e7dbb" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d6ddace7-263f-4d22-ab39-dfddcf8f99e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmounPharmaceuticalCompanySAEMember_d305f1e2-363a-40bb-aab9-51a5cb573ad7" xlink:href="bhc-20220331.xsd#bhc_AmounPharmaceuticalCompanySAEMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d6ddace7-263f-4d22-ab39-dfddcf8f99e6" xlink:to="loc_bhc_AmounPharmaceuticalCompanySAEMember_d305f1e2-363a-40bb-aab9-51a5cb573ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_7517badd-69ca-4551-a0b4-173179832267" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_56f23012-bcdc-4013-a9aa-6c9d988cf330" xlink:to="loc_us-gaap_ReportingUnitAxis_7517badd-69ca-4551-a0b4-173179832267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_89f94550-f0fc-491c-9f3d-6c9c95f987ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_7517badd-69ca-4551-a0b4-173179832267" xlink:to="loc_us-gaap_ReportingUnitDomain_89f94550-f0fc-491c-9f3d-6c9c95f987ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitsExcludingOrthoDermatologicsMember_0b7056b4-90cb-4127-8801-f8b092237145" xlink:href="bhc-20220331.xsd#bhc_ReportingUnitsExcludingOrthoDermatologicsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_89f94550-f0fc-491c-9f3d-6c9c95f987ea" xlink:to="loc_bhc_ReportingUnitsExcludingOrthoDermatologicsMember_0b7056b4-90cb-4127-8801-f8b092237145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsReportingUnitMember_b5912bd8-6e36-4582-900b-fa825284898b" xlink:href="bhc-20220331.xsd#bhc_OrthoDermatologicsReportingUnitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_89f94550-f0fc-491c-9f3d-6c9c95f987ea" xlink:to="loc_bhc_OrthoDermatologicsReportingUnitMember_b5912bd8-6e36-4582-900b-fa825284898b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_52cbdae8-7965-45fd-9a5c-5913fc6b6278" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_56f23012-bcdc-4013-a9aa-6c9d988cf330" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_52cbdae8-7965-45fd-9a5c-5913fc6b6278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f7b25396-98ef-4971-9a75-91b214a78984" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_52cbdae8-7965-45fd-9a5c-5913fc6b6278" xlink:to="loc_us-gaap_SegmentDomain_f7b25396-98ef-4971-9a75-91b214a78984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember_835385bc-9ff9-4b97-9666-651b756f0317" xlink:href="bhc-20220331.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f7b25396-98ef-4971-9a75-91b214a78984" xlink:to="loc_bhc_OrthoDermatologicsSegmentMember_835385bc-9ff9-4b97-9666-651b756f0317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_2dd605d7-21cd-48eb-9e12-37bddc489f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_56f23012-bcdc-4013-a9aa-6c9d988cf330" xlink:to="loc_us-gaap_GoodwillLineItems_2dd605d7-21cd-48eb-9e12-37bddc489f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_c0973203-f8cb-40d9-94de-816f5661eaf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_2dd605d7-21cd-48eb-9e12-37bddc489f8d" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_c0973203-f8cb-40d9-94de-816f5661eaf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_27b7d152-78ca-478e-8027-08eea953eb33" xlink:href="bhc-20220331.xsd#bhc_ReportingUnitImpairmentTestLongTermGrowthRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_2dd605d7-21cd-48eb-9e12-37bddc489f8d" xlink:to="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_27b7d152-78ca-478e-8027-08eea953eb33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_99f05375-db36-4c22-94ce-a0eace819890" xlink:href="bhc-20220331.xsd#bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_2dd605d7-21cd-48eb-9e12-37bddc489f8d" xlink:to="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_99f05375-db36-4c22-94ce-a0eace819890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_af99cfed-15e2-47b2-b5e6-eede6223b078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_2dd605d7-21cd-48eb-9e12-37bddc489f8d" xlink:to="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_af99cfed-15e2-47b2-b5e6-eede6223b078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_ae0c6779-a74c-4361-a57b-c58c6aab94ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_2dd605d7-21cd-48eb-9e12-37bddc489f8d" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_ae0c6779-a74c-4361-a57b-c58c6aab94ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_2dc87077-e132-440d-946d-3a5ec0f6f6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_2dd605d7-21cd-48eb-9e12-37bddc489f8d" xlink:to="loc_us-gaap_NumberOfReportingUnits_2dc87077-e132-440d-946d-3a5ec0f6f6bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_d656e7b6-ba03-45e9-af49-45b4d534bb32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_2dd605d7-21cd-48eb-9e12-37bddc489f8d" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_d656e7b6-ba03-45e9-af49-45b4d534bb32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4b13a583-f0d2-4ac1-85df-c5dc6b1c48b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_7110654e-3532-4981-b95d-d74e3e4ff0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4b13a583-f0d2-4ac1-85df-c5dc6b1c48b3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_7110654e-3532-4981-b95d-d74e3e4ff0ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e095ac43-a612-4fac-8f2e-58e71f23a31d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4b13a583-f0d2-4ac1-85df-c5dc6b1c48b3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e095ac43-a612-4fac-8f2e-58e71f23a31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_4fd27c27-4860-4f55-b70b-af15f3b4f316" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4b13a583-f0d2-4ac1-85df-c5dc6b1c48b3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_4fd27c27-4860-4f55-b70b-af15f3b4f316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_7cc92b25-b1df-4c62-91db-a3826cf5bee6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4b13a583-f0d2-4ac1-85df-c5dc6b1c48b3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_7cc92b25-b1df-4c62-91db-a3826cf5bee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ce03c1e1-7771-4823-9908-4fc699c938ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4b13a583-f0d2-4ac1-85df-c5dc6b1c48b3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ce03c1e1-7771-4823-9908-4fc699c938ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_ece50e27-4552-411c-804e-a34809ecafc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4b13a583-f0d2-4ac1-85df-c5dc6b1c48b3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_ece50e27-4552-411c-804e-a34809ecafc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_2ecad589-1c52-4c60-9836-1775e364663c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4b13a583-f0d2-4ac1-85df-c5dc6b1c48b3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_2ecad589-1c52-4c60-9836-1775e364663c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b6f2476c-a1bf-4efb-839c-0154184c3a56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4b13a583-f0d2-4ac1-85df-c5dc6b1c48b3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b6f2476c-a1bf-4efb-839c-0154184c3a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_290d9839-7d2e-4bf7-b79d-2e3d8620bcac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_1c1d0579-a7ba-4e39-b781-238eeea29eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_290d9839-7d2e-4bf7-b79d-2e3d8620bcac" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_1c1d0579-a7ba-4e39-b781-238eeea29eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_33b28974-f304-499e-8701-5b4430c96b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1c1d0579-a7ba-4e39-b781-238eeea29eaf" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_33b28974-f304-499e-8701-5b4430c96b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f21dab73-2e1b-4b37-a005-83ab6a6cec01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_33b28974-f304-499e-8701-5b4430c96b2b" xlink:to="loc_us-gaap_SegmentDomain_f21dab73-2e1b-4b37-a005-83ab6a6cec01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombInternationalMember_f1b38306-60db-4752-bcd0-a8ae1be54ea0" xlink:href="bhc-20220331.xsd#bhc_BauschLombInternationalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f21dab73-2e1b-4b37-a005-83ab6a6cec01" xlink:to="loc_bhc_BauschLombInternationalMember_f1b38306-60db-4752-bcd0-a8ae1be54ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_94982457-3e8e-4a9b-aa65-d107490b5079" xlink:href="bhc-20220331.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f21dab73-2e1b-4b37-a005-83ab6a6cec01" xlink:to="loc_bhc_BauschLombMember_94982457-3e8e-4a9b-aa65-d107490b5079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_6dab353e-e333-4594-8673-17ad271ef881" xlink:href="bhc-20220331.xsd#bhc_SalixSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f21dab73-2e1b-4b37-a005-83ab6a6cec01" xlink:to="loc_bhc_SalixSegmentMember_6dab353e-e333-4594-8673-17ad271ef881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_8c6019ff-2206-4596-a0bd-6de3fc022bbd" xlink:href="bhc-20220331.xsd#bhc_InternationalRxMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f21dab73-2e1b-4b37-a005-83ab6a6cec01" xlink:to="loc_bhc_InternationalRxMember_8c6019ff-2206-4596-a0bd-6de3fc022bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember_edcbfb53-f383-4203-8f19-944e881f683d" xlink:href="bhc-20220331.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f21dab73-2e1b-4b37-a005-83ab6a6cec01" xlink:to="loc_bhc_OrthoDermatologicsSegmentMember_edcbfb53-f383-4203-8f19-944e881f683d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SoltaMedicalSegmentMember_3edd19ee-2b33-432d-9c2a-18c39cff2ea0" xlink:href="bhc-20220331.xsd#bhc_SoltaMedicalSegmentMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f21dab73-2e1b-4b37-a005-83ab6a6cec01" xlink:to="loc_bhc_SoltaMedicalSegmentMember_3edd19ee-2b33-432d-9c2a-18c39cff2ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_cc210104-ab70-4d12-9ed3-c9d180046935" xlink:href="bhc-20220331.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f21dab73-2e1b-4b37-a005-83ab6a6cec01" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_cc210104-ab70-4d12-9ed3-c9d180046935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_17719fb5-8922-4145-aa23-6167f5d6d9ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1c1d0579-a7ba-4e39-b781-238eeea29eaf" xlink:to="loc_us-gaap_GoodwillLineItems_17719fb5-8922-4145-aa23-6167f5d6d9ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_ce1db7f8-f786-4d95-9b27-0e813980a624" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_17719fb5-8922-4145-aa23-6167f5d6d9ca" xlink:to="loc_us-gaap_GoodwillRollForward_ce1db7f8-f786-4d95-9b27-0e813980a624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_91757fd0-8484-4aad-8a19-d19b4bcbff6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_ce1db7f8-f786-4d95-9b27-0e813980a624" xlink:to="loc_us-gaap_Goodwill_91757fd0-8484-4aad-8a19-d19b4bcbff6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_8ea53d1c-ddce-4f74-a829-69254c7dab81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_ce1db7f8-f786-4d95-9b27-0e813980a624" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_8ea53d1c-ddce-4f74-a829-69254c7dab81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_77a5081c-be19-440f-9a2e-2264b38b7878" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_ce1db7f8-f786-4d95-9b27-0e813980a624" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_77a5081c-be19-440f-9a2e-2264b38b7878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_d73d8c63-c2e8-440e-99be-a356b9de0659" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_ce1db7f8-f786-4d95-9b27-0e813980a624" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_d73d8c63-c2e8-440e-99be-a356b9de0659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e77111bf-bb69-4362-8e78-be905abb6715" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_ce1db7f8-f786-4d95-9b27-0e813980a624" xlink:to="loc_us-gaap_Goodwill_e77111bf-bb69-4362-8e78-be905abb6715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES" xlink:type="simple" xlink:href="bhc-20220331.xsd#ACCRUEDANDOTHERCURRENTLIABILITIES"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_4bd24f11-51a3-4644-91e3-1e09b2eaeb36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_fdca2ef8-6af6-40b3-aa81-c8950f5cb0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4bd24f11-51a3-4644-91e3-1e09b2eaeb36" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_fdca2ef8-6af6-40b3-aa81-c8950f5cb0a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables" xlink:type="simple" xlink:href="bhc-20220331.xsd#ACCRUEDANDOTHERCURRENTLIABILITIESTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_869113a6-5891-4827-8e80-0ff314dd8c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_173aa788-c315-4c50-9f71-17050fbd1618" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_869113a6-5891-4827-8e80-0ff314dd8c0e" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_173aa788-c315-4c50-9f71-17050fbd1618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_fb15e422-e6d3-4fb3-aebd-54f3a26a9b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_Legalsettlementsandrelatedfees_57f183d5-b660-4582-9fe4-b84c5034e961" xlink:href="bhc-20220331.xsd#bhc_Legalsettlementsandrelatedfees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_fb15e422-e6d3-4fb3-aebd-54f3a26a9b9a" xlink:to="loc_bhc_Legalsettlementsandrelatedfees_57f183d5-b660-4582-9fe4-b84c5034e961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductRebateCurrent_bd60bbbd-c176-4265-9e84-d74aff7eb2c1" xlink:href="bhc-20220331.xsd#bhc_AccruedProductRebateCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_fb15e422-e6d3-4fb3-aebd-54f3a26a9b9a" xlink:to="loc_bhc_AccruedProductRebateCurrent_bd60bbbd-c176-4265-9e84-d74aff7eb2c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductReturnCurrent_22893e48-0e5b-45cd-b808-890e61277def" xlink:href="bhc-20220331.xsd#bhc_AccruedProductReturnCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_fb15e422-e6d3-4fb3-aebd-54f3a26a9b9a" xlink:to="loc_bhc_AccruedProductReturnCurrent_22893e48-0e5b-45cd-b808-890e61277def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_7f5f3eac-5532-4f2b-a550-8c155a7e0ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_fb15e422-e6d3-4fb3-aebd-54f3a26a9b9a" xlink:to="loc_us-gaap_InterestPayableCurrent_7f5f3eac-5532-4f2b-a550-8c155a7e0ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_1998218d-9e2f-44a0-a428-88b2e36a77d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_fb15e422-e6d3-4fb3-aebd-54f3a26a9b9a" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_1998218d-9e2f-44a0-a428-88b2e36a77d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_de08d1a3-b0f4-4109-bc81-9da64f783a88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_fb15e422-e6d3-4fb3-aebd-54f3a26a9b9a" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_de08d1a3-b0f4-4109-bc81-9da64f783a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_90dca3af-9eff-4a0e-b802-9cd7340f4d27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_fb15e422-e6d3-4fb3-aebd-54f3a26a9b9a" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_90dca3af-9eff-4a0e-b802-9cd7340f4d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_22160844-d8fa-49a8-b6fe-6196bc1d559e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_fb15e422-e6d3-4fb3-aebd-54f3a26a9b9a" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_22160844-d8fa-49a8-b6fe-6196bc1d559e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS" xlink:type="simple" xlink:href="bhc-20220331.xsd#FINANCINGARRANGEMENTS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d723817a-3971-4d4f-823b-27ca41344b68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_6032eeaf-8d80-4016-a4d2-603532ec7fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d723817a-3971-4d4f-823b-27ca41344b68" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_6032eeaf-8d80-4016-a4d2-603532ec7fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables" xlink:type="simple" xlink:href="bhc-20220331.xsd#FINANCINGARRANGEMENTSTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2185c110-1991-44ac-b732-9dbe0263ff82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_3f767ef0-c330-4b8b-b14a-79ed5faa9959" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2185c110-1991-44ac-b732-9dbe0263ff82" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_3f767ef0-c330-4b8b-b14a-79ed5faa9959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_109e852c-4baf-42eb-b150-e833e6128ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2185c110-1991-44ac-b732-9dbe0263ff82" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_109e852c-4baf-42eb-b150-e833e6128ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_231f2c1b-7a8e-42f4-90a9-ad53e826691f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ad10f7c2-e6cf-4d42-90b4-dbc73a745917" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_231f2c1b-7a8e-42f4-90a9-ad53e826691f" xlink:to="loc_us-gaap_DebtInstrumentTable_ad10f7c2-e6cf-4d42-90b4-dbc73a745917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_ae6be763-902a-4d40-beb7-b434e2456b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ad10f7c2-e6cf-4d42-90b4-dbc73a745917" xlink:to="loc_us-gaap_CreditFacilityAxis_ae6be763-902a-4d40-beb7-b434e2456b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_8faed696-ed7d-46fc-8c31-8f5e64867236" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_ae6be763-902a-4d40-beb7-b434e2456b6d" xlink:to="loc_us-gaap_CreditFacilityDomain_8faed696-ed7d-46fc-8c31-8f5e64867236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_294b42ee-c177-49af-9181-6658ad64b717" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_8faed696-ed7d-46fc-8c31-8f5e64867236" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_294b42ee-c177-49af-9181-6658ad64b717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_0191e2b3-d441-4046-aefc-afb3a54a2db0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ad10f7c2-e6cf-4d42-90b4-dbc73a745917" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_0191e2b3-d441-4046-aefc-afb3a54a2db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_12808e4b-20fc-40e9-bc6d-519fb9e6ec4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0191e2b3-d441-4046-aefc-afb3a54a2db0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_12808e4b-20fc-40e9-bc6d-519fb9e6ec4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_c235c933-4918-426a-abd0-fea28579b99c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_12808e4b-20fc-40e9-bc6d-519fb9e6ec4e" xlink:to="loc_us-gaap_SecuredDebtMember_c235c933-4918-426a-abd0-fea28579b99c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_d6674337-610f-47e6-a9fe-015aec9d332f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_12808e4b-20fc-40e9-bc6d-519fb9e6ec4e" xlink:to="loc_us-gaap_UnsecuredDebtMember_d6674337-610f-47e6-a9fe-015aec9d332f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_959339cf-9ce9-4039-9853-b93f444a575a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ad10f7c2-e6cf-4d42-90b4-dbc73a745917" xlink:to="loc_us-gaap_DebtInstrumentAxis_959339cf-9ce9-4039-9853-b93f444a575a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5ebf8c0c-2ffe-40c7-8ed6-990710edd27d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_959339cf-9ce9-4039-9853-b93f444a575a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5ebf8c0c-2ffe-40c7-8ed6-990710edd27d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member_5fd8bcf2-d3cc-45b3-b1ee-ca446e0bf73f" xlink:href="bhc-20220331.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5ebf8c0c-2ffe-40c7-8ed6-990710edd27d" xlink:to="loc_bhc_RevolvingCreditFacilityDueJune2023Member_5fd8bcf2-d3cc-45b3-b1ee-ca446e0bf73f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025Member_26e9eaff-a24a-41e5-91f6-e470a3184329" xlink:href="bhc-20220331.xsd#bhc_TermLoanBFacilityDueJune2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5ebf8c0c-2ffe-40c7-8ed6-990710edd27d" xlink:to="loc_bhc_TermLoanBFacilityDueJune2025Member_26e9eaff-a24a-41e5-91f6-e470a3184329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueNovember2025Member_7f087db4-4337-4e92-afc8-e365eab92a01" xlink:href="bhc-20220331.xsd#bhc_TermLoanBFacilityDueNovember2025Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5ebf8c0c-2ffe-40c7-8ed6-990710edd27d" xlink:to="loc_bhc_TermLoanBFacilityDueNovember2025Member_7f087db4-4337-4e92-afc8-e365eab92a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member_ccb6fc8a-f4d1-4412-ba48-9f6dd4cddf70" xlink:href="bhc-20220331.xsd#bhc_SeniorSecured5.50NotesDueNovember2025Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5ebf8c0c-2ffe-40c7-8ed6-990710edd27d" xlink:to="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member_ccb6fc8a-f4d1-4412-ba48-9f6dd4cddf70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_86db8a5e-e9f6-4d2d-8ded-8794d58a823a" xlink:href="bhc-20220331.xsd#bhc_SeniorSecured6125NotesDueFebruary2027Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5ebf8c0c-2ffe-40c7-8ed6-990710edd27d" xlink:to="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_86db8a5e-e9f6-4d2d-8ded-8794d58a823a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_5e569365-1f1a-4501-8583-79aa9562e12f" xlink:href="bhc-20220331.xsd#bhc_SeniorSecured5.75NotesDueAugust2027Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5ebf8c0c-2ffe-40c7-8ed6-990710edd27d" xlink:to="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_5e569365-1f1a-4501-8583-79aa9562e12f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured4875NotesDueJune2028Member_26c69438-e0ac-4036-801e-fce73f85b4e7" xlink:href="bhc-20220331.xsd#bhc_SeniorSecured4875NotesDueJune2028Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5ebf8c0c-2ffe-40c7-8ed6-990710edd27d" xlink:to="loc_bhc_SeniorSecured4875NotesDueJune2028Member_26c69438-e0ac-4036-801e-fce73f85b4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member_8000bbd2-9c59-4e61-ae3b-9fbe8a45a552" xlink:href="bhc-20220331.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5ebf8c0c-2ffe-40c7-8ed6-990710edd27d" xlink:to="loc_bhc_SeniorNotes6125DueApril2025Member_8000bbd2-9c59-4e61-ae3b-9fbe8a45a552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes900DueDecember2025Member_40693e95-8b05-4440-8ab2-510d05bf89ed" xlink:href="bhc-20220331.xsd#bhc_SeniorNotes900DueDecember2025Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5ebf8c0c-2ffe-40c7-8ed6-990710edd27d" xlink:to="loc_bhc_SeniorNotes900DueDecember2025Member_40693e95-8b05-4440-8ab2-510d05bf89ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes925DueApril2026Member_9584713e-0658-4757-af72-1be408d93508" xlink:href="bhc-20220331.xsd#bhc_SeniorNotes925DueApril2026Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5ebf8c0c-2ffe-40c7-8ed6-990710edd27d" xlink:to="loc_bhc_SeniorNotes925DueApril2026Member_9584713e-0658-4757-af72-1be408d93508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes850DueJanuary2027Member_644f3c10-7ae8-409f-bdb9-339da3d8a63c" xlink:href="bhc-20220331.xsd#bhc_SeniorNotes850DueJanuary2027Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5ebf8c0c-2ffe-40c7-8ed6-990710edd27d" xlink:to="loc_bhc_SeniorNotes850DueJanuary2027Member_644f3c10-7ae8-409f-bdb9-339da3d8a63c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueJanuary2028Member_a12e323b-0df4-454a-9240-1003a33cb0be" xlink:href="bhc-20220331.xsd#bhc_SeniorNotes700DueJanuary2028Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5ebf8c0c-2ffe-40c7-8ed6-990710edd27d" xlink:to="loc_bhc_SeniorNotes700DueJanuary2028Member_a12e323b-0df4-454a-9240-1003a33cb0be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueJanuary2028Member_e7b998f7-2ae8-46ca-9ffe-869a7b4452e5" xlink:href="bhc-20220331.xsd#bhc_SeniorNotes500DueJanuary2028Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5ebf8c0c-2ffe-40c7-8ed6-990710edd27d" xlink:to="loc_bhc_SeniorNotes500DueJanuary2028Member_e7b998f7-2ae8-46ca-9ffe-869a7b4452e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes625DueFebruary2029Member_c6e1403e-e5a4-4120-a9c0-2ce61f43f6b6" xlink:href="bhc-20220331.xsd#bhc_SeniorNotes625DueFebruary2029Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5ebf8c0c-2ffe-40c7-8ed6-990710edd27d" xlink:to="loc_bhc_SeniorNotes625DueFebruary2029Member_c6e1403e-e5a4-4120-a9c0-2ce61f43f6b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueFebruary2029Member_0163fa4a-9e4b-4b04-9f52-8a8cf3dee0ab" xlink:href="bhc-20220331.xsd#bhc_SeniorNotes500DueFebruary2029Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5ebf8c0c-2ffe-40c7-8ed6-990710edd27d" xlink:to="loc_bhc_SeniorNotes500DueFebruary2029Member_0163fa4a-9e4b-4b04-9f52-8a8cf3dee0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes725DueMay2029Member_8bd8c5d1-e411-4c9e-82d1-2f998a332794" xlink:href="bhc-20220331.xsd#bhc_SeniorNotes725DueMay2029Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5ebf8c0c-2ffe-40c7-8ed6-990710edd27d" xlink:to="loc_bhc_SeniorNotes725DueMay2029Member_8bd8c5d1-e411-4c9e-82d1-2f998a332794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueJanuary2030Member_f683d8cf-486c-45e5-83fe-a50470817e7b" xlink:href="bhc-20220331.xsd#bhc_SeniorNotes525DueJanuary2030Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5ebf8c0c-2ffe-40c7-8ed6-990710edd27d" xlink:to="loc_bhc_SeniorNotes525DueJanuary2030Member_f683d8cf-486c-45e5-83fe-a50470817e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueFebruary2031Member_3206d16a-4342-43b2-9d03-b7dc6855be3a" xlink:href="bhc-20220331.xsd#bhc_SeniorNotes525DueFebruary2031Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5ebf8c0c-2ffe-40c7-8ed6-990710edd27d" xlink:to="loc_bhc_SeniorNotes525DueFebruary2031Member_3206d16a-4342-43b2-9d03-b7dc6855be3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherLongTermDebtMember_8948606b-2d02-4e44-a65b-b905dd8d58b7" xlink:href="bhc-20220331.xsd#bhc_OtherLongTermDebtMember"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5ebf8c0c-2ffe-40c7-8ed6-990710edd27d" xlink:to="loc_bhc_OtherLongTermDebtMember_8948606b-2d02-4e44-a65b-b905dd8d58b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c8c69b84-f9b5-4771-b4cc-aadec9b8b031" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ad10f7c2-e6cf-4d42-90b4-dbc73a745917" xlink:to="loc_us-gaap_DebtInstrumentLineItems_c8c69b84-f9b5-4771-b4cc-aadec9b8b031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5a99021e-4645-407e-966a-b29e7b1977fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c8c69b84-f9b5-4771-b4cc-aadec9b8b031" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5a99021e-4645-407e-966a-b29e7b1977fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_e2dece69-19e9-4b15-9d3b-e1b8c37b979c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c8c69b84-f9b5-4771-b4cc-aadec9b8b031" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_e2dece69-19e9-4b15-9d3b-e1b8c37b979c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d2cac51b-66a8-4d59-82e6-0e0eecda2b36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c8c69b84-f9b5-4771-b4cc-aadec9b8b031" xlink:to="loc_us-gaap_LongTermDebt_d2cac51b-66a8-4d59-82e6-0e0eecda2b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_76ed68c1-ef61-432f-91b7-077849f5ffa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c8c69b84-f9b5-4771-b4cc-aadec9b8b031" xlink:to="loc_us-gaap_LongTermDebtCurrent_76ed68c1-ef61-432f-91b7-077849f5ffa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_76e99020-3690-4cb0-83fa-3bc7ea569fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c8c69b84-f9b5-4771-b4cc-aadec9b8b031" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_76e99020-3690-4cb0-83fa-3bc7ea569fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#FINANCINGARRANGEMENTSCovenantComplianceDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b3e9534c-4ed6-41d1-bbcd-efa69cfcc3cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b4930bee-e2da-4a43-909f-c7b796263e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b3e9534c-4ed6-41d1-bbcd-efa69cfcc3cc" xlink:to="loc_us-gaap_DebtInstrumentTable_b4930bee-e2da-4a43-909f-c7b796263e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_4ae6c649-3e14-418a-8a2f-ef37d85c09ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b4930bee-e2da-4a43-909f-c7b796263e8f" xlink:to="loc_us-gaap_CreditFacilityAxis_4ae6c649-3e14-418a-8a2f-ef37d85c09ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c612d28b-3f78-4732-9942-ab8faec9ac11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_4ae6c649-3e14-418a-8a2f-ef37d85c09ef" xlink:to="loc_us-gaap_CreditFacilityDomain_c612d28b-3f78-4732-9942-ab8faec9ac11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredCreditFacilityMember_31d15862-d65a-4426-9d4d-0f001da8add9" xlink:href="bhc-20220331.xsd#bhc_SeniorSecuredCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_c612d28b-3f78-4732-9942-ab8faec9ac11" xlink:to="loc_bhc_SeniorSecuredCreditFacilityMember_31d15862-d65a-4426-9d4d-0f001da8add9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_5ada53c8-a3bd-4a7d-b5f5-36e9a109e810" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_c612d28b-3f78-4732-9942-ab8faec9ac11" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_5ada53c8-a3bd-4a7d-b5f5-36e9a109e810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_443a50fc-020a-426d-b6f2-b5d6314e092f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b4930bee-e2da-4a43-909f-c7b796263e8f" xlink:to="loc_us-gaap_DebtInstrumentLineItems_443a50fc-020a-426d-b6f2-b5d6314e092f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments_3e1083d4-c059-4232-8b69-3f06a4a38527" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_443a50fc-020a-426d-b6f2-b5d6314e092f" xlink:to="loc_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments_3e1083d4-c059-4232-8b69-3f06a4a38527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_66c51218-abe7-420b-ba51-5cb1abec0ca2" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_443a50fc-020a-426d-b6f2-b5d6314e092f" xlink:to="loc_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_66c51218-abe7-420b-ba51-5cb1abec0ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_e019da7a-003d-4417-b9db-1f26fa0d2115" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_443a50fc-020a-426d-b6f2-b5d6314e092f" xlink:to="loc_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_e019da7a-003d-4417-b9db-1f26fa0d2115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2945dc57-f4f9-4fed-a2b5-f7288fa2b155" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_959483dc-a387-4650-a0f5-863d4994a4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2945dc57-f4f9-4fed-a2b5-f7288fa2b155" xlink:to="loc_us-gaap_DebtInstrumentTable_959483dc-a387-4650-a0f5-863d4994a4c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_11fb8ab4-dafd-412b-aaff-6873ba1867d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_959483dc-a387-4650-a0f5-863d4994a4c1" xlink:to="loc_us-gaap_CreditFacilityAxis_11fb8ab4-dafd-412b-aaff-6873ba1867d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2479ca4e-de08-4fc2-a9b9-287928f89d65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_11fb8ab4-dafd-412b-aaff-6873ba1867d1" xlink:to="loc_us-gaap_CreditFacilityDomain_2479ca4e-de08-4fc2-a9b9-287928f89d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_09d15960-e2fb-4002-8552-99c0c8686aee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_2479ca4e-de08-4fc2-a9b9-287928f89d65" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_09d15960-e2fb-4002-8552-99c0c8686aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_0178f03a-7cc5-41f7-a362-2529dd60c36b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_2479ca4e-de08-4fc2-a9b9-287928f89d65" xlink:to="loc_us-gaap_LetterOfCreditMember_0178f03a-7cc5-41f7-a362-2529dd60c36b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_870cc282-1c08-485b-aa8a-4027b0f63a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_959483dc-a387-4650-a0f5-863d4994a4c1" xlink:to="loc_us-gaap_DebtInstrumentAxis_870cc282-1c08-485b-aa8a-4027b0f63a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d8f8e06d-0b00-4ba7-bd53-9e2b638927b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_870cc282-1c08-485b-aa8a-4027b0f63a3a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d8f8e06d-0b00-4ba7-bd53-9e2b638927b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member_a1626c78-1f37-4bc6-bbd4-2759374f2724" xlink:href="bhc-20220331.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d8f8e06d-0b00-4ba7-bd53-9e2b638927b7" xlink:to="loc_bhc_RevolvingCreditFacilityDueJune2023Member_a1626c78-1f37-4bc6-bbd4-2759374f2724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025Member_e38792de-fe7e-490d-a1d9-4d6069d1ad59" xlink:href="bhc-20220331.xsd#bhc_TermLoanBFacilityDueJune2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d8f8e06d-0b00-4ba7-bd53-9e2b638927b7" xlink:to="loc_bhc_TermLoanBFacilityDueJune2025Member_e38792de-fe7e-490d-a1d9-4d6069d1ad59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueNovember2025Member_911fbc21-4e82-45ed-8d31-8bd7e5ddc0c3" xlink:href="bhc-20220331.xsd#bhc_TermLoanBFacilityDueNovember2025Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d8f8e06d-0b00-4ba7-bd53-9e2b638927b7" xlink:to="loc_bhc_TermLoanBFacilityDueNovember2025Member_911fbc21-4e82-45ed-8d31-8bd7e5ddc0c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredCreditFacilitiesMember_9846e146-7d6c-4c0d-83ca-d317776c8ca7" xlink:href="bhc-20220331.xsd#bhc_SeniorSecuredCreditFacilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d8f8e06d-0b00-4ba7-bd53-9e2b638927b7" xlink:to="loc_bhc_SeniorSecuredCreditFacilitiesMember_9846e146-7d6c-4c0d-83ca-d317776c8ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member_20e88844-c61b-4d75-b4b5-785644e75a75" xlink:href="bhc-20220331.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d8f8e06d-0b00-4ba7-bd53-9e2b638927b7" xlink:to="loc_bhc_SeniorNotes6125DueApril2025Member_20e88844-c61b-4d75-b4b5-785644e75a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_6d1f2a9c-ab82-44e7-9095-5cbf0df58a73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_959483dc-a387-4650-a0f5-863d4994a4c1" xlink:to="loc_us-gaap_VariableRateAxis_6d1f2a9c-ab82-44e7-9095-5cbf0df58a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_31b2d2b1-ea6f-4d41-9297-046140588046" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_6d1f2a9c-ab82-44e7-9095-5cbf0df58a73" xlink:to="loc_us-gaap_VariableRateDomain_31b2d2b1-ea6f-4d41-9297-046140588046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_d7054216-2fb4-451a-b640-8b7ce5d98d38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_31b2d2b1-ea6f-4d41-9297-046140588046" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_d7054216-2fb4-451a-b640-8b7ce5d98d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_7d87e8fa-9449-4da8-8e63-5be96aa2f14d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_31b2d2b1-ea6f-4d41-9297-046140588046" xlink:to="loc_us-gaap_EurodollarMember_7d87e8fa-9449-4da8-8e63-5be96aa2f14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CanadaBankersAcceptanceRateMember_e6de009f-b4cb-48f9-96c6-591e045faac7" xlink:href="bhc-20220331.xsd#bhc_CanadaBankersAcceptanceRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_31b2d2b1-ea6f-4d41-9297-046140588046" xlink:to="loc_bhc_CanadaBankersAcceptanceRateMember_e6de009f-b4cb-48f9-96c6-591e045faac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_eef4b0e6-97a7-42a2-81cc-ed7819d95ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_31b2d2b1-ea6f-4d41-9297-046140588046" xlink:to="loc_us-gaap_BaseRateMember_eef4b0e6-97a7-42a2-81cc-ed7819d95ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BaseRateOrPrimeRateMember_f7972786-347f-476d-80b1-45fb5973ba5d" xlink:href="bhc-20220331.xsd#bhc_BaseRateOrPrimeRateMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_31b2d2b1-ea6f-4d41-9297-046140588046" xlink:to="loc_bhc_BaseRateOrPrimeRateMember_f7972786-347f-476d-80b1-45fb5973ba5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9a14f9b8-1a45-40d4-b5a5-0542ee7935fc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_959483dc-a387-4650-a0f5-863d4994a4c1" xlink:to="loc_srt_RangeAxis_9a14f9b8-1a45-40d4-b5a5-0542ee7935fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_20a3a662-706d-4f2e-9397-a48e1ed4e4a4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9a14f9b8-1a45-40d4-b5a5-0542ee7935fc" xlink:to="loc_srt_RangeMember_20a3a662-706d-4f2e-9397-a48e1ed4e4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b504a8e1-f694-48d5-8d85-6b488b1fb67a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_20a3a662-706d-4f2e-9397-a48e1ed4e4a4" xlink:to="loc_srt_MinimumMember_b504a8e1-f694-48d5-8d85-6b488b1fb67a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b825f45a-1ff1-4e4d-8c91-324d79a648bf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_20a3a662-706d-4f2e-9397-a48e1ed4e4a4" xlink:to="loc_srt_MaximumMember_b825f45a-1ff1-4e4d-8c91-324d79a648bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_887028b3-5301-473c-82a4-dc73356fa2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_959483dc-a387-4650-a0f5-863d4994a4c1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_887028b3-5301-473c-82a4-dc73356fa2c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_98578d0a-00f0-4b2f-9f1e-e663293321e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_887028b3-5301-473c-82a4-dc73356fa2c2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_98578d0a-00f0-4b2f-9f1e-e663293321e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_a2d6b086-cc11-4b48-97c7-f273f4224832" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_98578d0a-00f0-4b2f-9f1e-e663293321e8" xlink:to="loc_us-gaap_SecuredDebtMember_a2d6b086-cc11-4b48-97c7-f273f4224832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_c8c48c28-41d6-4a13-a81b-10f7befb928e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_98578d0a-00f0-4b2f-9f1e-e663293321e8" xlink:to="loc_us-gaap_UnsecuredDebtMember_c8c48c28-41d6-4a13-a81b-10f7befb928e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_884599bb-bd51-413a-b9a2-715f658e0a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_959483dc-a387-4650-a0f5-863d4994a4c1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_884599bb-bd51-413a-b9a2-715f658e0a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7420a233-9bd7-4686-b332-8a8b6fd63611" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_884599bb-bd51-413a-b9a2-715f658e0a2e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7420a233-9bd7-4686-b332-8a8b6fd63611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_75f4a5d4-d9cf-4bc5-9e3d-b1f5ccb13ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7420a233-9bd7-4686-b332-8a8b6fd63611" xlink:to="loc_us-gaap_SubsequentEventMember_75f4a5d4-d9cf-4bc5-9e3d-b1f5ccb13ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_740c021d-77e8-4129-bc06-057e5edfac2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_959483dc-a387-4650-a0f5-863d4994a4c1" xlink:to="loc_us-gaap_DebtInstrumentLineItems_740c021d-77e8-4129-bc06-057e5edfac2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_c9e52b4d-d10f-4bb2-bd90-655ac1519881" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_740c021d-77e8-4129-bc06-057e5edfac2a" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_c9e52b4d-d10f-4bb2-bd90-655ac1519881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_1e37bc24-35b9-4de7-85fe-f4b7b165c74a" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_740c021d-77e8-4129-bc06-057e5edfac2a" xlink:to="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_1e37bc24-35b9-4de7-85fe-f4b7b165c74a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_4fa186b0-d0ae-404c-9650-9bc28e73a7d8" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_740c021d-77e8-4129-bc06-057e5edfac2a" xlink:to="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_4fa186b0-d0ae-404c-9650-9bc28e73a7d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_ad7c14c6-1696-47f3-ab00-4a4bb8348591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_740c021d-77e8-4129-bc06-057e5edfac2a" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_ad7c14c6-1696-47f3-ab00-4a4bb8348591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8e89a6fa-5506-443e-af4e-5bef04038597" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_740c021d-77e8-4129-bc06-057e5edfac2a" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8e89a6fa-5506-443e-af4e-5bef04038597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet_bd1e0e7d-9223-471d-acd6-2937098d97b4" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_740c021d-77e8-4129-bc06-057e5edfac2a" xlink:to="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet_bd1e0e7d-9223-471d-acd6-2937098d97b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet_7b679cb8-8f4b-4a51-8a35-0ebf234718b7" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_740c021d-77e8-4129-bc06-057e5edfac2a" xlink:to="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet_7b679cb8-8f4b-4a51-8a35-0ebf234718b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet_84a02d79-2ad2-4552-953d-46efb907ef1a" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_740c021d-77e8-4129-bc06-057e5edfac2a" xlink:to="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet_84a02d79-2ad2-4552-953d-46efb907ef1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet_3ea8beec-255e-4b08-a904-24a9839e3d69" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_740c021d-77e8-4129-bc06-057e5edfac2a" xlink:to="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet_3ea8beec-255e-4b08-a904-24a9839e3d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3ed590bd-339a-423b-be61-345dc25b0994" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_740c021d-77e8-4129-bc06-057e5edfac2a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3ed590bd-339a-423b-be61-345dc25b0994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage_ac392ef0-76bb-4dd2-b169-47fafe37d2d9" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentAnnualAmortizationRatePercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_740c021d-77e8-4129-bc06-057e5edfac2a" xlink:to="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage_ac392ef0-76bb-4dd2-b169-47fafe37d2d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_d6a8edb8-8446-45dd-ba15-e517d10b9b20" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_740c021d-77e8-4129-bc06-057e5edfac2a" xlink:to="loc_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_d6a8edb8-8446-45dd-ba15-e517d10b9b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_1a1e31ef-5702-4296-859e-b4173eae4dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_740c021d-77e8-4129-bc06-057e5edfac2a" xlink:to="loc_us-gaap_LongTermDebt_1a1e31ef-5702-4296-859e-b4173eae4dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_473f974c-b172-48bd-afa5-206371bdc63d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_740c021d-77e8-4129-bc06-057e5edfac2a" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_473f974c-b172-48bd-afa5-206371bdc63d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_b9bc1160-2cd1-434c-97c3-c9555a286e83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_740c021d-77e8-4129-bc06-057e5edfac2a" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_b9bc1160-2cd1-434c-97c3-c9555a286e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_6e53b5da-ef7c-4243-a31d-801ae48f069f" xlink:href="bhc-20220331.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_740c021d-77e8-4129-bc06-057e5edfac2a" xlink:to="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_6e53b5da-ef7c-4243-a31d-801ae48f069f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA_ff3f345c-6d78-4889-82de-8c0d821d9eb4" xlink:href="bhc-20220331.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_740c021d-77e8-4129-bc06-057e5edfac2a" xlink:to="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA_ff3f345c-6d78-4889-82de-8c0d821d9eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_74fddee3-7040-40eb-8923-9a943d827a52" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_740c021d-77e8-4129-bc06-057e5edfac2a" xlink:to="loc_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_74fddee3-7040-40eb-8923-9a943d827a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_ec9b006b-c51c-40a2-ac01-42777cfec7fa" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_740c021d-77e8-4129-bc06-057e5edfac2a" xlink:to="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_ec9b006b-c51c-40a2-ac01-42777cfec7fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_4b8ad4d4-abe9-4fc9-9df5-b62374498fa0" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_740c021d-77e8-4129-bc06-057e5edfac2a" xlink:to="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_4b8ad4d4-abe9-4fc9-9df5-b62374498fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_c536e864-70c2-40c8-be1e-26ab4e442a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_fe27e51f-787e-4f2c-89f5-a6c9e05b109b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c536e864-70c2-40c8-be1e-26ab4e442a3c" xlink:to="loc_us-gaap_DebtInstrumentTable_fe27e51f-787e-4f2c-89f5-a6c9e05b109b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a6376f59-c1f9-4da6-b3a2-796d96d5cdd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fe27e51f-787e-4f2c-89f5-a6c9e05b109b" xlink:to="loc_us-gaap_DebtInstrumentAxis_a6376f59-c1f9-4da6-b3a2-796d96d5cdd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f768184d-9cc5-40f2-b5d9-5e721f676279" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_a6376f59-c1f9-4da6-b3a2-796d96d5cdd2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f768184d-9cc5-40f2-b5d9-5e721f676279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured4875NotesDueJune2028Member_8e81f32e-a93d-4a31-ad93-37923b68003c" xlink:href="bhc-20220331.xsd#bhc_SeniorSecured4875NotesDueJune2028Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f768184d-9cc5-40f2-b5d9-5e721f676279" xlink:to="loc_bhc_SeniorSecured4875NotesDueJune2028Member_8e81f32e-a93d-4a31-ad93-37923b68003c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueMarch2024Member_c334a842-c641-47f2-bf07-fd235b7ad144" xlink:href="bhc-20220331.xsd#bhc_SeniorNotes700DueMarch2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f768184d-9cc5-40f2-b5d9-5e721f676279" xlink:to="loc_bhc_SeniorNotes700DueMarch2024Member_c334a842-c641-47f2-bf07-fd235b7ad144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_63a132c0-d34b-434f-9e36-c7bc700a3bb4" xlink:href="bhc-20220331.xsd#bhc_SeniorSecured6125NotesDueFebruary2027Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f768184d-9cc5-40f2-b5d9-5e721f676279" xlink:to="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_63a132c0-d34b-434f-9e36-c7bc700a3bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_30136b3f-4029-47fb-b12a-20c39b84e27d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fe27e51f-787e-4f2c-89f5-a6c9e05b109b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_30136b3f-4029-47fb-b12a-20c39b84e27d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_747291dd-ab9e-459b-8d72-94c859b566d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_30136b3f-4029-47fb-b12a-20c39b84e27d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_747291dd-ab9e-459b-8d72-94c859b566d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_3568228d-7c75-4a96-8e3c-6a1c38129361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_747291dd-ab9e-459b-8d72-94c859b566d5" xlink:to="loc_us-gaap_SecuredDebtMember_3568228d-7c75-4a96-8e3c-6a1c38129361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_b5304fde-a287-44bf-aa09-5fbb7ba10639" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_747291dd-ab9e-459b-8d72-94c859b566d5" xlink:to="loc_us-gaap_UnsecuredDebtMember_b5304fde-a287-44bf-aa09-5fbb7ba10639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_2335dfa6-acb0-49da-a3ec-8be9138f7a41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fe27e51f-787e-4f2c-89f5-a6c9e05b109b" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_2335dfa6-acb0-49da-a3ec-8be9138f7a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e6895af6-09e9-4955-9fde-bc6722562e77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_2335dfa6-acb0-49da-a3ec-8be9138f7a41" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e6895af6-09e9-4955-9fde-bc6722562e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_62c751fb-d30e-46e5-8d03-326ba3d8cf94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e6895af6-09e9-4955-9fde-bc6722562e77" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_62c751fb-d30e-46e5-8d03-326ba3d8cf94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_8a0a73db-6143-4bae-be56-45d5cb520191" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e6895af6-09e9-4955-9fde-bc6722562e77" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_8a0a73db-6143-4bae-be56-45d5cb520191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3b0e2a92-0cdf-42cd-aff1-02977aea22b1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fe27e51f-787e-4f2c-89f5-a6c9e05b109b" xlink:to="loc_srt_RangeAxis_3b0e2a92-0cdf-42cd-aff1-02977aea22b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1bbd7ed8-1a3e-4ec2-a0da-2271a2ef6132" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3b0e2a92-0cdf-42cd-aff1-02977aea22b1" xlink:to="loc_srt_RangeMember_1bbd7ed8-1a3e-4ec2-a0da-2271a2ef6132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a4d90005-ba78-4420-a4bb-a852f8ac5d4e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1bbd7ed8-1a3e-4ec2-a0da-2271a2ef6132" xlink:to="loc_srt_MaximumMember_a4d90005-ba78-4420-a4bb-a852f8ac5d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_68745f80-583c-47a7-906b-40e2e362de55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fe27e51f-787e-4f2c-89f5-a6c9e05b109b" xlink:to="loc_us-gaap_DebtInstrumentLineItems_68745f80-583c-47a7-906b-40e2e362de55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_7524026a-69e4-432f-9d85-13399d9f6274" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentRedemptionPricePercentageChangeinControl"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_68745f80-583c-47a7-906b-40e2e362de55" xlink:to="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_7524026a-69e4-432f-9d85-13399d9f6274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_10cc3a27-68d7-4df4-8ba2-535a46c4d3a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_68745f80-583c-47a7-906b-40e2e362de55" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_10cc3a27-68d7-4df4-8ba2-535a46c4d3a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_adeca1fa-b6db-4027-b414-10f4b63c12b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_68745f80-583c-47a7-906b-40e2e362de55" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_adeca1fa-b6db-4027-b414-10f4b63c12b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_d3b9d340-ae51-4873-97a9-3bd48b33e1fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_68745f80-583c-47a7-906b-40e2e362de55" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_d3b9d340-ae51-4873-97a9-3bd48b33e1fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_121dd9e0-db85-4ad3-9433-415b80357ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_68745f80-583c-47a7-906b-40e2e362de55" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_121dd9e0-db85-4ad3-9433-415b80357ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_4b36f349-3766-495c-bdac-14d4078e9a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_68745f80-583c-47a7-906b-40e2e362de55" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_4b36f349-3766-495c-bdac-14d4078e9a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_ba0a9cec-50cb-4144-986a-52e675154023" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_68745f80-583c-47a7-906b-40e2e362de55" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_ba0a9cec-50cb-4144-986a-52e675154023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5388fb5b-290c-4a57-99df-e46fa3863845" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c66d41a4-f034-4849-8bbe-b2a8595f08c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5388fb5b-290c-4a57-99df-e46fa3863845" xlink:to="loc_us-gaap_DebtInstrumentTable_c66d41a4-f034-4849-8bbe-b2a8595f08c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e4cf9c14-d6bb-456b-a200-38f31a94418b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c66d41a4-f034-4849-8bbe-b2a8595f08c8" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e4cf9c14-d6bb-456b-a200-38f31a94418b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_be621669-a9ac-484d-9b82-7a88228da410" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e4cf9c14-d6bb-456b-a200-38f31a94418b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_be621669-a9ac-484d-9b82-7a88228da410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_efb96914-58cf-4a44-ab3a-698aba42995a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_be621669-a9ac-484d-9b82-7a88228da410" xlink:to="loc_us-gaap_UnsecuredDebtMember_efb96914-58cf-4a44-ab3a-698aba42995a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_051c7b61-be79-4d25-a0ca-c70d0fb9b580" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c66d41a4-f034-4849-8bbe-b2a8595f08c8" xlink:to="loc_us-gaap_DebtInstrumentLineItems_051c7b61-be79-4d25-a0ca-c70d0fb9b580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_df1b7eda-f47d-4954-9257-7eda04b50cd3" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentRedemptionPricePercentageChangeinControl"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_051c7b61-be79-4d25-a0ca-c70d0fb9b580" xlink:to="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_df1b7eda-f47d-4954-9257-7eda04b50cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b6acbad8-c239-4736-bfec-fb37f9aa84e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_3ec69731-6578-4f35-b6a8-57057f1e94aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b6acbad8-c239-4736-bfec-fb37f9aa84e2" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_3ec69731-6578-4f35-b6a8-57057f1e94aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b7ca7ca1-f1aa-4042-92b9-db5a70d78209" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_2a085687-0e24-46ec-81cb-f8749309e399" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b7ca7ca1-f1aa-4042-92b9-db5a70d78209" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_2a085687-0e24-46ec-81cb-f8749309e399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_1eef3d80-bfcc-4993-b150-72bd5e8ff584" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b7ca7ca1-f1aa-4042-92b9-db5a70d78209" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_1eef3d80-bfcc-4993-b150-72bd5e8ff584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_0fd6f30f-08b8-48f4-9bcf-28a992c0dd9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b7ca7ca1-f1aa-4042-92b9-db5a70d78209" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_0fd6f30f-08b8-48f4-9bcf-28a992c0dd9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_b58e16b4-a9e4-49c5-a99d-380aeffea8c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b7ca7ca1-f1aa-4042-92b9-db5a70d78209" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_b58e16b4-a9e4-49c5-a99d-380aeffea8c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_5a42182b-9845-4482-8efe-e1cf81fa8f58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b7ca7ca1-f1aa-4042-92b9-db5a70d78209" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_5a42182b-9845-4482-8efe-e1cf81fa8f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_65dd4f62-659d-42b7-b32d-48a1d2926d55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b7ca7ca1-f1aa-4042-92b9-db5a70d78209" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_65dd4f62-659d-42b7-b32d-48a1d2926d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_0c7ed1e4-4dab-4390-a752-777bfc5853b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b7ca7ca1-f1aa-4042-92b9-db5a70d78209" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_0c7ed1e4-4dab-4390-a752-777bfc5853b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_1a2f93b5-470a-4116-bf3c-a77d58dab0bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b7ca7ca1-f1aa-4042-92b9-db5a70d78209" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_1a2f93b5-470a-4116-bf3c-a77d58dab0bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_ee5b142c-bc57-4d58-93ce-6ea7f2a31e24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b7ca7ca1-f1aa-4042-92b9-db5a70d78209" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_ee5b142c-bc57-4d58-93ce-6ea7f2a31e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_edd6e596-a15d-4dce-8452-89b6467ac11d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b7ca7ca1-f1aa-4042-92b9-db5a70d78209" xlink:to="loc_us-gaap_LongTermDebt_edd6e596-a15d-4dce-8452-89b6467ac11d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#FINANCINGARRANGEMENTSMaturitiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a6256ef3-3230-4abd-a688-4d45807bd0d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9ddbbcfd-6151-492b-9549-811bdf52f344" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a6256ef3-3230-4abd-a688-4d45807bd0d2" xlink:to="loc_us-gaap_DebtInstrumentTable_9ddbbcfd-6151-492b-9549-811bdf52f344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8aac522d-ad7a-4c58-808b-9d6190b6fe6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9ddbbcfd-6151-492b-9549-811bdf52f344" xlink:to="loc_us-gaap_DebtInstrumentAxis_8aac522d-ad7a-4c58-808b-9d6190b6fe6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fa58d10e-7711-4f2c-bd3d-bd90093f08eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8aac522d-ad7a-4c58-808b-9d6190b6fe6c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fa58d10e-7711-4f2c-bd3d-bd90093f08eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member_450e8029-e968-47e2-80fd-b085406d4a4c" xlink:href="bhc-20220331.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fa58d10e-7711-4f2c-bd3d-bd90093f08eb" xlink:to="loc_bhc_SeniorNotes6125DueApril2025Member_450e8029-e968-47e2-80fd-b085406d4a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A2027RevolvingCreditFacilityMember_95cf15a3-2d27-41dc-9766-f71b85e6b92f" xlink:href="bhc-20220331.xsd#bhc_A2027RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fa58d10e-7711-4f2c-bd3d-bd90093f08eb" xlink:to="loc_bhc_A2027RevolvingCreditFacilityMember_95cf15a3-2d27-41dc-9766-f71b85e6b92f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7f40cbd4-76c6-4bfb-b68e-b2052b40972c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9ddbbcfd-6151-492b-9549-811bdf52f344" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7f40cbd4-76c6-4bfb-b68e-b2052b40972c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_08d62093-7eaf-4286-b8d7-544a2da93eee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7f40cbd4-76c6-4bfb-b68e-b2052b40972c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_08d62093-7eaf-4286-b8d7-544a2da93eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_027db724-0b90-40db-9d86-fac60a9fc5d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_08d62093-7eaf-4286-b8d7-544a2da93eee" xlink:to="loc_us-gaap_UnsecuredDebtMember_027db724-0b90-40db-9d86-fac60a9fc5d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1507f369-cc80-4042-aab4-8e05601789a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9ddbbcfd-6151-492b-9549-811bdf52f344" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1507f369-cc80-4042-aab4-8e05601789a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_cee88b80-c6e8-4be5-8760-cb1e13a2665e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1507f369-cc80-4042-aab4-8e05601789a9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_cee88b80-c6e8-4be5-8760-cb1e13a2665e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_e2980d1b-0944-4f1b-bd99-c9c3e9c751cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_cee88b80-c6e8-4be5-8760-cb1e13a2665e" xlink:to="loc_us-gaap_SubsequentEventMember_e2980d1b-0944-4f1b-bd99-c9c3e9c751cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_5a00909c-3808-44c0-9e17-f10cf035defd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9ddbbcfd-6151-492b-9549-811bdf52f344" xlink:to="loc_us-gaap_CreditFacilityAxis_5a00909c-3808-44c0-9e17-f10cf035defd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_01802e42-5ece-4463-9c3a-5f074e7746bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_5a00909c-3808-44c0-9e17-f10cf035defd" xlink:to="loc_us-gaap_CreditFacilityDomain_01802e42-5ece-4463-9c3a-5f074e7746bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_059293d9-4b2f-47c1-8b77-133e9ffcae5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_01802e42-5ece-4463-9c3a-5f074e7746bf" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_059293d9-4b2f-47c1-8b77-133e9ffcae5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_78fc73fc-9070-4382-a229-a3f3cbe7f596" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9ddbbcfd-6151-492b-9549-811bdf52f344" xlink:to="loc_us-gaap_DebtInstrumentLineItems_78fc73fc-9070-4382-a229-a3f3cbe7f596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_949b2970-e594-48d4-ad70-a63e02304549" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_78fc73fc-9070-4382-a229-a3f3cbe7f596" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_949b2970-e594-48d4-ad70-a63e02304549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_4c9a687d-d50b-4e35-9b53-2c50cb9835e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_78fc73fc-9070-4382-a229-a3f3cbe7f596" xlink:to="loc_us-gaap_LongTermDebt_4c9a687d-d50b-4e35-9b53-2c50cb9835e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS" xlink:type="simple" xlink:href="bhc-20220331.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c8bbb1eb-813c-48f7-800d-3f9e230bac3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_ce9f02c9-b36f-4f3b-b072-9cfdb01781a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c8bbb1eb-813c-48f7-800d-3f9e230bac3c" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_ce9f02c9-b36f-4f3b-b072-9cfdb01781a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables" xlink:type="simple" xlink:href="bhc-20220331.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f371e950-b1d9-47b9-aab4-2b78c8c7ed0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_fd2c451f-d53c-467f-b0cb-d46184bd68db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f371e950-b1d9-47b9-aab4-2b78c8c7ed0c" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_fd2c451f-d53c-467f-b0cb-d46184bd68db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0c5c49a1-4816-4ff1-9f1c-87de33b4c5bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8323ef80-21c6-4e4c-a7cc-dfa1e1a90283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0c5c49a1-4816-4ff1-9f1c-87de33b4c5bd" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8323ef80-21c6-4e4c-a7cc-dfa1e1a90283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_741348fc-d2ba-4766-b02e-3b29046eaee4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8323ef80-21c6-4e4c-a7cc-dfa1e1a90283" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_741348fc-d2ba-4766-b02e-3b29046eaee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_d5cb7c3e-2558-49bc-9ead-82e4a6e2b655" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_741348fc-d2ba-4766-b02e-3b29046eaee4" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_d5cb7c3e-2558-49bc-9ead-82e4a6e2b655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_d5a7a138-2a9b-44cc-b015-8ec2f0835d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_d5cb7c3e-2558-49bc-9ead-82e4a6e2b655" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_d5a7a138-2a9b-44cc-b015-8ec2f0835d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_72d26c6a-969e-4a83-8939-da4d92912693" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_d5cb7c3e-2558-49bc-9ead-82e4a6e2b655" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_72d26c6a-969e-4a83-8939-da4d92912693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_a05d244d-0f5c-47b8-89b9-1f5d91bb5f57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8323ef80-21c6-4e4c-a7cc-dfa1e1a90283" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_a05d244d-0f5c-47b8-89b9-1f5d91bb5f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_e3ebd7f5-bba3-4f6a-a48b-5f12cc0128cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_a05d244d-0f5c-47b8-89b9-1f5d91bb5f57" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_e3ebd7f5-bba3-4f6a-a48b-5f12cc0128cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_ee247367-d742-46e6-9636-e6639256faf3" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_e3ebd7f5-bba3-4f6a-a48b-5f12cc0128cd" xlink:to="loc_country_US_ee247367-d742-46e6-9636-e6639256faf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_1962db70-4f6e-4165-8772-cbd20c2275d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_e3ebd7f5-bba3-4f6a-a48b-5f12cc0128cd" xlink:to="loc_us-gaap_ForeignPlanMember_1962db70-4f6e-4165-8772-cbd20c2275d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fd8f7f8d-556f-430d-8767-b07eabe75e93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8323ef80-21c6-4e4c-a7cc-dfa1e1a90283" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fd8f7f8d-556f-430d-8767-b07eabe75e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_e703ae8c-72aa-4ac9-9cbb-b8dced68d7be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fd8f7f8d-556f-430d-8767-b07eabe75e93" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_e703ae8c-72aa-4ac9-9cbb-b8dced68d7be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_524112bb-14ef-491f-9104-38aa1d913f85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fd8f7f8d-556f-430d-8767-b07eabe75e93" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_524112bb-14ef-491f-9104-38aa1d913f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_75b7661e-1433-4ad1-a5de-7e7f071baa81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fd8f7f8d-556f-430d-8767-b07eabe75e93" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_75b7661e-1433-4ad1-a5de-7e7f071baa81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_f714c52f-81b8-480d-a3de-80f40d479bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fd8f7f8d-556f-430d-8767-b07eabe75e93" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_f714c52f-81b8-480d-a3de-80f40d479bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_bc805c30-f8a4-4ccc-8eaa-5a829801a1c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fd8f7f8d-556f-430d-8767-b07eabe75e93" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_bc805c30-f8a4-4ccc-8eaa-5a829801a1c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION" xlink:type="simple" xlink:href="bhc-20220331.xsd#SHAREBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b395c681-dc0d-4472-88f4-a47337719375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_e096bdc7-4c6c-4cc1-aa28-d4f52e74c294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b395c681-dc0d-4472-88f4-a47337719375" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_e096bdc7-4c6c-4cc1-aa28-d4f52e74c294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="bhc-20220331.xsd#SHAREBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1a172947-a37a-480d-bb54-2ee0e5d23be4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_7b619111-fb3f-47ec-8429-99b4a21074cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1a172947-a37a-480d-bb54-2ee0e5d23be4" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_7b619111-fb3f-47ec-8429-99b4a21074cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_4645462f-1ea5-4939-bce3-12b4c0fcc69c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1a172947-a37a-480d-bb54-2ee0e5d23be4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_4645462f-1ea5-4939-bce3-12b4c0fcc69c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#SHAREBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_950d83dc-d14d-4e41-8a27-a835faa558c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_26eee06e-9701-4bf6-8eb5-45ea0f585655" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_950d83dc-d14d-4e41-8a27-a835faa558c6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_26eee06e-9701-4bf6-8eb5-45ea0f585655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_63db97a6-1ad5-4d48-bca5-04315982d3fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_26eee06e-9701-4bf6-8eb5-45ea0f585655" xlink:to="loc_us-gaap_PlanNameAxis_63db97a6-1ad5-4d48-bca5-04315982d3fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_23ab9c91-ecae-435c-be30-b955d6f74453" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_63db97a6-1ad5-4d48-bca5-04315982d3fc" xlink:to="loc_us-gaap_PlanNameDomain_23ab9c91-ecae-435c-be30-b955d6f74453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OmnibusIncentivePlan2014Member_050e493b-a033-4248-b783-a9b629bad577" xlink:href="bhc-20220331.xsd#bhc_OmnibusIncentivePlan2014Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_23ab9c91-ecae-435c-be30-b955d6f74453" xlink:to="loc_bhc_OmnibusIncentivePlan2014Member_050e493b-a033-4248-b783-a9b629bad577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_213ec7a0-f0f0-40a3-9d6c-db7106377c43" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_26eee06e-9701-4bf6-8eb5-45ea0f585655" xlink:to="loc_srt_TitleOfIndividualAxis_213ec7a0-f0f0-40a3-9d6c-db7106377c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_270833de-d0ff-4777-9175-a365be93dba4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_213ec7a0-f0f0-40a3-9d6c-db7106377c43" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_270833de-d0ff-4777-9175-a365be93dba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NonemployeeDirectorMember_de475f34-7ac0-4ce4-be0a-6af4e233a6a4" xlink:href="bhc-20220331.xsd#bhc_NonemployeeDirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_270833de-d0ff-4777-9175-a365be93dba4" xlink:to="loc_bhc_NonemployeeDirectorMember_de475f34-7ac0-4ce4-be0a-6af4e233a6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5187fcb7-82c2-4426-988c-0772b6da6acc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_26eee06e-9701-4bf6-8eb5-45ea0f585655" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5187fcb7-82c2-4426-988c-0772b6da6acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c14f0a66-9c17-4952-980a-94519cc78b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5187fcb7-82c2-4426-988c-0772b6da6acc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c14f0a66-9c17-4952-980a-94519cc78b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2f2361be-b7c9-4be3-93df-32a6626a127b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5187fcb7-82c2-4426-988c-0772b6da6acc" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2f2361be-b7c9-4be3-93df-32a6626a127b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_676bae80-1aae-40a5-b299-4d26cd60c140" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5187fcb7-82c2-4426-988c-0772b6da6acc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_676bae80-1aae-40a5-b299-4d26cd60c140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant_249302e7-691b-48a5-81e9-2307e4b36c67" xlink:href="bhc-20220331.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5187fcb7-82c2-4426-988c-0772b6da6acc" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant_249302e7-691b-48a5-81e9-2307e4b36c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_35cbd0d8-1aac-4ee6-a7b9-564b8adb222f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5187fcb7-82c2-4426-988c-0772b6da6acc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_35cbd0d8-1aac-4ee6-a7b9-564b8adb222f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_78ce20e0-e212-4545-b477-0ae5bc8bd440" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5187fcb7-82c2-4426-988c-0772b6da6acc" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_78ce20e0-e212-4545-b477-0ae5bc8bd440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0037a6a8-844e-4c16-9263-fd8c11dee840" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5187fcb7-82c2-4426-988c-0772b6da6acc" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0037a6a8-844e-4c16-9263-fd8c11dee840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_12b1e2bf-d530-46ec-b6d6-d0e6d75fe401" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_833224ea-8d91-43b8-a594-cb267d633169" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_12b1e2bf-d530-46ec-b6d6-d0e6d75fe401" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_833224ea-8d91-43b8-a594-cb267d633169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_07d7d71a-a82f-4b8e-9b33-925b92d27a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_833224ea-8d91-43b8-a594-cb267d633169" xlink:to="loc_us-gaap_AwardTypeAxis_07d7d71a-a82f-4b8e-9b33-925b92d27a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e7a2a5a7-8f76-463d-8078-cf0d4a98ae3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_07d7d71a-a82f-4b8e-9b33-925b92d27a4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e7a2a5a7-8f76-463d-8078-cf0d4a98ae3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e6796200-8e02-4046-832e-bfd89b2fe92d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e7a2a5a7-8f76-463d-8078-cf0d4a98ae3c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e6796200-8e02-4046-832e-bfd89b2fe92d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_34d63737-429e-4876-a04b-e01559439f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e7a2a5a7-8f76-463d-8078-cf0d4a98ae3c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_34d63737-429e-4876-a04b-e01559439f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_08672b36-8e75-4173-abde-15286b0168f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_833224ea-8d91-43b8-a594-cb267d633169" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_08672b36-8e75-4173-abde-15286b0168f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7bdc9b49-6f59-4e6b-aa4d-f0f4a9d15f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_08672b36-8e75-4173-abde-15286b0168f0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7bdc9b49-6f59-4e6b-aa4d-f0f4a9d15f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_29cadd3f-2301-4e5f-ab4d-674e89518520" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7bdc9b49-6f59-4e6b-aa4d-f0f4a9d15f5d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_29cadd3f-2301-4e5f-ab4d-674e89518520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6cb054b1-7cf1-48cc-88c9-f5ecc066d296" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7bdc9b49-6f59-4e6b-aa4d-f0f4a9d15f5d" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6cb054b1-7cf1-48cc-88c9-f5ecc066d296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4b7ab1c5-2058-4d91-83ee-168bf4182a66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_833224ea-8d91-43b8-a594-cb267d633169" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4b7ab1c5-2058-4d91-83ee-168bf4182a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6216c0f1-ac1a-4a96-a329-3eab0668b520" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4b7ab1c5-2058-4d91-83ee-168bf4182a66" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6216c0f1-ac1a-4a96-a329-3eab0668b520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7eafce63-71a7-40b9-a060-9d19bc439347" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_10d94ae8-519a-4f24-a488-c56b23b69937" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7eafce63-71a7-40b9-a060-9d19bc439347" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_10d94ae8-519a-4f24-a488-c56b23b69937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_32a3838b-84df-40fe-9b07-a2c909dd74d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_10d94ae8-519a-4f24-a488-c56b23b69937" xlink:to="loc_us-gaap_AwardTypeAxis_32a3838b-84df-40fe-9b07-a2c909dd74d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_818a1866-1940-4fbf-95ce-e0bc46d060e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_32a3838b-84df-40fe-9b07-a2c909dd74d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_818a1866-1940-4fbf-95ce-e0bc46d060e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2e2a0d82-2545-401f-a2bb-c6e3d52fd038" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_818a1866-1940-4fbf-95ce-e0bc46d060e3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2e2a0d82-2545-401f-a2bb-c6e3d52fd038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TimeBasedRSUMember_d8cc1194-af8b-4733-8312-fd9e6d0cbe2d" xlink:href="bhc-20220331.xsd#bhc_TimeBasedRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_818a1866-1940-4fbf-95ce-e0bc46d060e3" xlink:to="loc_bhc_TimeBasedRSUMember_d8cc1194-af8b-4733-8312-fd9e6d0cbe2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_398a2b66-3c3c-4e40-9402-8240bc2d0334" xlink:href="bhc-20220331.xsd#bhc_TSRPerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_818a1866-1940-4fbf-95ce-e0bc46d060e3" xlink:to="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_398a2b66-3c3c-4e40-9402-8240bc2d0334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_fa02b923-a304-45a4-a822-34916a929d7b" xlink:href="bhc-20220331.xsd#bhc_ROTCPerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_818a1866-1940-4fbf-95ce-e0bc46d060e3" xlink:to="loc_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_fa02b923-a304-45a4-a822-34916a929d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeparationPerformanceBasedRestrictedStockUnitsMember_cba0e527-53d7-4e12-995c-6caf32ce959c" xlink:href="bhc-20220331.xsd#bhc_SeparationPerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_818a1866-1940-4fbf-95ce-e0bc46d060e3" xlink:to="loc_bhc_SeparationPerformanceBasedRestrictedStockUnitsMember_cba0e527-53d7-4e12-995c-6caf32ce959c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a6baeef-8779-48e8-845d-117d2a796ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_10d94ae8-519a-4f24-a488-c56b23b69937" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a6baeef-8779-48e8-845d-117d2a796ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_98d48764-f431-4172-b823-2d469ffba435" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a6baeef-8779-48e8-845d-117d2a796ddc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_98d48764-f431-4172-b823-2d469ffba435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_7f7b6a55-f5cf-4520-848d-c63243afb78e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_98d48764-f431-4172-b823-2d469ffba435" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_7f7b6a55-f5cf-4520-848d-c63243afb78e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f8524f27-aecd-404a-9b1f-e318b0b53e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_98d48764-f431-4172-b823-2d469ffba435" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f8524f27-aecd-404a-9b1f-e318b0b53e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e3f5a590-3436-46c6-abea-5277a9921f28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_98d48764-f431-4172-b823-2d469ffba435" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e3f5a590-3436-46c6-abea-5277a9921f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_90eab49f-6439-4908-bdf3-6ff5e66fd1b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a6baeef-8779-48e8-845d-117d2a796ddc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_90eab49f-6439-4908-bdf3-6ff5e66fd1b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c4d4e6c3-77cf-49f0-99fa-eb108773c6dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_90eab49f-6439-4908-bdf3-6ff5e66fd1b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c4d4e6c3-77cf-49f0-99fa-eb108773c6dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1e087d03-d97b-45fa-8ab9-9fc6faf90f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_90eab49f-6439-4908-bdf3-6ff5e66fd1b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1e087d03-d97b-45fa-8ab9-9fc6faf90f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="bhc-20220331.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_40041a34-f6ee-4da2-86f3-6ea4abb61a57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_1855ef3d-878a-4b65-800e-4b8ef1fce7d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_40041a34-f6ee-4da2-86f3-6ea4abb61a57" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_1855ef3d-878a-4b65-800e-4b8ef1fce7d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables" xlink:type="simple" xlink:href="bhc-20220331.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSSTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_6b16ac45-5291-4784-aca9-bd4148b173c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_5ccdced9-01ca-48cb-8edd-111af1dcf589" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_6b16ac45-5291-4784-aca9-bd4148b173c7" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_5ccdced9-01ca-48cb-8edd-111af1dcf589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_e8f91764-62a8-44d7-b9e1-4fdc0a5504fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_1daf6c5c-a806-4ac2-91d6-cab00d2670c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_e8f91764-62a8-44d7-b9e1-4fdc0a5504fd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_1daf6c5c-a806-4ac2-91d6-cab00d2670c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e99d947e-5fa1-4b2d-a548-3213a1722329" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_1daf6c5c-a806-4ac2-91d6-cab00d2670c2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e99d947e-5fa1-4b2d-a548-3213a1722329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_172cc74c-e3d1-436b-99a5-44cc04b2028a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e99d947e-5fa1-4b2d-a548-3213a1722329" xlink:to="loc_us-gaap_EquityComponentDomain_172cc74c-e3d1-436b-99a5-44cc04b2028a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_246f3e90-6a1c-4184-80c1-f81bb00f0396" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_172cc74c-e3d1-436b-99a5-44cc04b2028a" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_246f3e90-6a1c-4184-80c1-f81bb00f0396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_76ab93e3-f9b6-47a0-93c1-d6e2f0ade1bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_172cc74c-e3d1-436b-99a5-44cc04b2028a" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_76ab93e3-f9b6-47a0-93c1-d6e2f0ade1bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_52dccc36-7ec5-4815-81de-de405e8be752" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_172cc74c-e3d1-436b-99a5-44cc04b2028a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_52dccc36-7ec5-4815-81de-de405e8be752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_d03f30bd-faaa-4b8f-ac49-a4aa27db2a32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_1daf6c5c-a806-4ac2-91d6-cab00d2670c2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_d03f30bd-faaa-4b8f-ac49-a4aa27db2a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f14fc061-f38f-4ce7-9a34-05c7192280fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_d03f30bd-faaa-4b8f-ac49-a4aa27db2a32" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f14fc061-f38f-4ce7-9a34-05c7192280fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT" xlink:type="simple" xlink:href="bhc-20220331.xsd#RESEARCHANDDEVELOPMENT"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_9c9d68f6-4fdd-4f14-b9e9-5c68dfae716b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_05107c7d-b675-41b0-9f1b-c865b6a93f89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_9c9d68f6-4fdd-4f14-b9e9-5c68dfae716b" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_05107c7d-b675-41b0-9f1b-c865b6a93f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables" xlink:type="simple" xlink:href="bhc-20220331.xsd#RESEARCHANDDEVELOPMENTTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_2402c10a-5b6c-4a29-8210-6832c79d731c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_1f7edfe3-7985-4fca-be00-486bf00ee2da" xlink:href="bhc-20220331.xsd#bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_2402c10a-5b6c-4a29-8210-6832c79d731c" xlink:to="loc_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_1f7edfe3-7985-4fca-be00-486bf00ee2da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_381afb3d-f556-4039-ba2e-7cff8d34a8d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseProductRelated_43ac5806-5789-4206-8b41-62c6329ba44c" xlink:href="bhc-20220331.xsd#bhc_ResearchAndDevelopmentExpenseProductRelated"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_381afb3d-f556-4039-ba2e-7cff8d34a8d8" xlink:to="loc_bhc_ResearchAndDevelopmentExpenseProductRelated_43ac5806-5789-4206-8b41-62c6329ba44c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance_e02c6934-c7c8-4ee1-8e19-045b6be8af50" xlink:href="bhc-20220331.xsd#bhc_ResearchAndDevelopmentExpenseQualityAssurance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_381afb3d-f556-4039-ba2e-7cff8d34a8d8" xlink:to="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance_e02c6934-c7c8-4ee1-8e19-045b6be8af50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_7ca7b8e8-2eaa-4b8a-b165-31ae6bddb123" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_381afb3d-f556-4039-ba2e-7cff8d34a8d8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_7ca7b8e8-2eaa-4b8a-b165-31ae6bddb123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENET" xlink:type="simple" xlink:href="bhc-20220331.xsd#OTHEREXPENSEINCOMENET"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENET" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_118803e7-2339-4e79-96d3-424a899b5a73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_56435013-a2af-418e-9347-33a90a1ea65d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_118803e7-2339-4e79-96d3-424a899b5a73" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_56435013-a2af-418e-9347-33a90a1ea65d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETTables" xlink:type="simple" xlink:href="bhc-20220331.xsd#OTHEREXPENSEINCOMENETTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_59cf6ae0-7d1f-43f6-b1cd-26fd6060c836" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_0427217f-ddf7-40b3-b9a0-b7eaba2b8c38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_59cf6ae0-7d1f-43f6-b1cd-26fd6060c836" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_0427217f-ddf7-40b3-b9a0-b7eaba2b8c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETSummaryofOtherExpenseNetDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#OTHEREXPENSEINCOMENETSummaryofOtherExpenseNetDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETSummaryofOtherExpenseNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_ceb771ec-0dbc-4c6f-9093-3178259bcf02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_5566dfde-2ca4-41e2-ab64-34f4c4710a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_ceb771ec-0dbc-4c6f-9093-3178259bcf02" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_5566dfde-2ca4-41e2-ab64-34f4c4710a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_a65e0456-54d5-48ca-aaa6-4c864c9eb7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_ceb771ec-0dbc-4c6f-9093-3178259bcf02" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_a65e0456-54d5-48ca-aaa6-4c864c9eb7a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_e9a9b279-6419-4d3c-9274-03972eb1262f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_ceb771ec-0dbc-4c6f-9093-3178259bcf02" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_e9a9b279-6419-4d3c-9274-03972eb1262f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_8265bbef-bf81-4dc2-a207-79142cd4d23c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_ceb771ec-0dbc-4c6f-9093-3178259bcf02" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_8265bbef-bf81-4dc2-a207-79142cd4d23c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_0a2b97f4-28f0-41a6-af9e-aca7bb1de05d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_ceb771ec-0dbc-4c6f-9093-3178259bcf02" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_0a2b97f4-28f0-41a6-af9e-aca7bb1de05d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#OTHEREXPENSEINCOMENETNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_c8911811-c3ea-4b8e-b14a-3cdd9cdb1dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_461debd5-ea99-48b0-8c80-41cd8e61b49f" xlink:href="bhc-20220331.xsd#bhc_ScheduleOfOtherIncomeAndExpensesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_c8911811-c3ea-4b8e-b14a-3cdd9cdb1dcf" xlink:to="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_461debd5-ea99-48b0-8c80-41cd8e61b49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_981dbba9-d5ca-4d62-a026-2eeb890edf9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_461debd5-ea99-48b0-8c80-41cd8e61b49f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_981dbba9-d5ca-4d62-a026-2eeb890edf9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_af346f4c-5ea7-4720-b3d4-39dc58d47f99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_981dbba9-d5ca-4d62-a026-2eeb890edf9f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_af346f4c-5ea7-4720-b3d4-39dc58d47f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MilestonePaymentRelatedToCertainProductMember_c519ae69-a322-4f5a-beef-6cef9515c8a4" xlink:href="bhc-20220331.xsd#bhc_MilestonePaymentRelatedToCertainProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_af346f4c-5ea7-4720-b3d4-39dc58d47f99" xlink:to="loc_bhc_MilestonePaymentRelatedToCertainProductMember_c519ae69-a322-4f5a-beef-6cef9515c8a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_ca62fcda-165c-48f8-bfe8-a536b6e6c095" xlink:href="bhc-20220331.xsd#bhc_ScheduleOfOtherIncomeAndExpensesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_461debd5-ea99-48b0-8c80-41cd8e61b49f" xlink:to="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_ca62fcda-165c-48f8-bfe8-a536b6e6c095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_d227d73a-562e-4b1d-8a2a-be3dc5d41770" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_ca62fcda-165c-48f8-bfe8-a536b6e6c095" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_d227d73a-562e-4b1d-8a2a-be3dc5d41770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXES" xlink:type="simple" xlink:href="bhc-20220331.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_83e9d8e6-056f-4631-91d1-2b0899bf9d40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_7cc5e6cb-924f-4890-a090-e58f385f48f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_83e9d8e6-056f-4631-91d1-2b0899bf9d40" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_7cc5e6cb-924f-4890-a090-e58f385f48f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#INCOMETAXESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_80414028-a80c-4169-abad-8cb5ea6b6a16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8c0a3c9d-bdd1-4065-9f53-6ee056ec4251" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_80414028-a80c-4169-abad-8cb5ea6b6a16" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8c0a3c9d-bdd1-4065-9f53-6ee056ec4251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_7944f16b-f689-4da5-9932-25ba47690295" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_80414028-a80c-4169-abad-8cb5ea6b6a16" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_7944f16b-f689-4da5-9932-25ba47690295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount_276ce5c0-cddb-401b-a27b-eb4612a714e1" xlink:href="bhc-20220331.xsd#bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_80414028-a80c-4169-abad-8cb5ea6b6a16" xlink:to="loc_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount_276ce5c0-cddb-401b-a27b-eb4612a714e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_072d098b-32b8-4eef-ab26-c5bef2e7a480" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_80414028-a80c-4169-abad-8cb5ea6b6a16" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_072d098b-32b8-4eef-ab26-c5bef2e7a480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount_a3437deb-47a2-445b-9a13-1445593c3d33" xlink:href="bhc-20220331.xsd#bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_80414028-a80c-4169-abad-8cb5ea6b6a16" xlink:to="loc_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount_a3437deb-47a2-445b-9a13-1445593c3d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount_3a0d51ea-449c-4378-a992-558d4054ab8a" xlink:href="bhc-20220331.xsd#bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_80414028-a80c-4169-abad-8cb5ea6b6a16" xlink:to="loc_bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount_3a0d51ea-449c-4378-a992-558d4054ab8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_3d5a6e09-814e-4ef1-a755-cbcfa15f3de6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_80414028-a80c-4169-abad-8cb5ea6b6a16" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_3d5a6e09-814e-4ef1-a755-cbcfa15f3de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_8bc66513-e873-4eee-b529-6e8afd75364d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_80414028-a80c-4169-abad-8cb5ea6b6a16" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_8bc66513-e873-4eee-b529-6e8afd75364d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_e981e52f-8d1e-442f-bc38-6ce9233962da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_80414028-a80c-4169-abad-8cb5ea6b6a16" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_e981e52f-8d1e-442f-bc38-6ce9233962da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_f7599fbf-06b8-4867-bb7a-a7f19b72388f" xlink:href="bhc-20220331.xsd#bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_80414028-a80c-4169-abad-8cb5ea6b6a16" xlink:to="loc_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_f7599fbf-06b8-4867-bb7a-a7f19b72388f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_7c262b85-9e12-4e35-9258-3c154fb2efc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_80414028-a80c-4169-abad-8cb5ea6b6a16" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_7c262b85-9e12-4e35-9258-3c154fb2efc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_3cc98306-9c6b-4e6b-91f5-d1ca18622dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_80414028-a80c-4169-abad-8cb5ea6b6a16" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_3cc98306-9c6b-4e6b-91f5-d1ca18622dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_a71c9966-3f3a-4121-b70d-b9b3760a3b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_80414028-a80c-4169-abad-8cb5ea6b6a16" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_a71c9966-3f3a-4121-b70d-b9b3760a3b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_e1d72b94-0e31-4c93-bbde-957c2063e1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_80414028-a80c-4169-abad-8cb5ea6b6a16" xlink:to="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_e1d72b94-0e31-4c93-bbde-957c2063e1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LOSSPERSHARE" xlink:type="simple" xlink:href="bhc-20220331.xsd#LOSSPERSHARE"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LOSSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_071af72e-4e2c-4733-808d-f8175bc4822d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_967a720a-abb0-4508-9082-1d1b8f48eada" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_071af72e-4e2c-4733-808d-f8175bc4822d" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_967a720a-abb0-4508-9082-1d1b8f48eada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LOSSPERSHARETables" xlink:type="simple" xlink:href="bhc-20220331.xsd#LOSSPERSHARETables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LOSSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_77ed5200-6222-44db-ab38-20a0b477d675" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_df602911-ba75-44c5-9b75-4502c9569e86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_77ed5200-6222-44db-ab38-20a0b477d675" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_df602911-ba75-44c5-9b75-4502c9569e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0d2133e6-2765-43c2-b4d6-5e5dc6d93950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_23573080-646f-4f87-9456-86419f48c178" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0d2133e6-2765-43c2-b4d6-5e5dc6d93950" xlink:to="loc_us-gaap_NetIncomeLoss_23573080-646f-4f87-9456-86419f48c178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_de4b0d97-be58-4d16-9ec8-067502eb4a07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0d2133e6-2765-43c2-b4d6-5e5dc6d93950" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_de4b0d97-be58-4d16-9ec8-067502eb4a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0dc1bc23-7c91-43e1-872d-05c019c833ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0d2133e6-2765-43c2-b4d6-5e5dc6d93950" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0dc1bc23-7c91-43e1-872d-05c019c833ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_492cec4b-a18b-4661-94ff-a2e6faacd4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0d2133e6-2765-43c2-b4d6-5e5dc6d93950" xlink:to="loc_us-gaap_EarningsPerShareBasic_492cec4b-a18b-4661-94ff-a2e6faacd4c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_26e3be82-f82f-4fcd-89dc-6fd30dedbac3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0d2133e6-2765-43c2-b4d6-5e5dc6d93950" xlink:to="loc_us-gaap_EarningsPerShareDiluted_26e3be82-f82f-4fcd-89dc-6fd30dedbac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#LOSSPERSHARENarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8cc120cd-cb06-4d5e-acbf-7db7e397f39f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e5b4311b-2430-4868-8904-a976c29a3a89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8cc120cd-cb06-4d5e-acbf-7db7e397f39f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e5b4311b-2430-4868-8904-a976c29a3a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3ef68141-e27c-4a31-9983-29997852b3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e5b4311b-2430-4868-8904-a976c29a3a89" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3ef68141-e27c-4a31-9983-29997852b3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2cefaca5-0159-46c0-8973-ed6c29d20a31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3ef68141-e27c-4a31-9983-29997852b3d8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2cefaca5-0159-46c0-8973-ed6c29d20a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_436e9d78-2b68-47c8-94a7-f91c64716501" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2cefaca5-0159-46c0-8973-ed6c29d20a31" xlink:to="loc_us-gaap_StockCompensationPlanMember_436e9d78-2b68-47c8-94a7-f91c64716501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_a14e7238-cb50-4546-9a98-723dc427f65e" xlink:href="bhc-20220331.xsd#bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2cefaca5-0159-46c0-8973-ed6c29d20a31" xlink:to="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_a14e7238-cb50-4546-9a98-723dc427f65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_2f2cc469-b4fd-484f-9ba9-01406cba6fb2" xlink:href="bhc-20220331.xsd#bhc_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2cefaca5-0159-46c0-8973-ed6c29d20a31" xlink:to="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_2f2cc469-b4fd-484f-9ba9-01406cba6fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f5c02481-d470-4787-9dee-17504e3cedd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e5b4311b-2430-4868-8904-a976c29a3a89" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f5c02481-d470-4787-9dee-17504e3cedd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c96c5ec0-16f3-4911-8271-a00e2152b7af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f5c02481-d470-4787-9dee-17504e3cedd6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c96c5ec0-16f3-4911-8271-a00e2152b7af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount_94998ac8-aff8-474e-943f-dd4e8b246f35" xlink:href="bhc-20220331.xsd#bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f5c02481-d470-4787-9dee-17504e3cedd6" xlink:to="loc_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount_94998ac8-aff8-474e-943f-dd4e8b246f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGS" xlink:type="simple" xlink:href="bhc-20220331.xsd#LEGALPROCEEDINGS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4944aef2-24c8-43f3-a3eb-5c1f5f8b7ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_43a43e3a-2176-4735-9830-9a053e643cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4944aef2-24c8-43f3-a3eb-5c1f5f8b7ff3" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_43a43e3a-2176-4735-9830-9a053e643cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSLegalProceedsandGovernmentalandRegulatoryInquiriesDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#LEGALPROCEEDINGSLegalProceedsandGovernmentalandRegulatoryInquiriesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSLegalProceedsandGovernmentalandRegulatoryInquiriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ae59750c-ee00-43c0-8617-3f733f88212b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_6db2a97f-d493-4206-aab5-d317e45fc38d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ae59750c-ee00-43c0-8617-3f733f88212b" xlink:to="loc_us-gaap_LitigationReserveCurrent_6db2a97f-d493-4206-aab5-d317e45fc38d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f6014236-44eb-4c28-a27d-782322fa2367" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_df241bfc-a21f-42e5-9280-e56e3eb59621" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f6014236-44eb-4c28-a27d-782322fa2367" xlink:to="loc_us-gaap_LossContingenciesTable_df241bfc-a21f-42e5-9280-e56e3eb59621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_27267259-ea34-46d1-9254-98b8ac84a264" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_df241bfc-a21f-42e5-9280-e56e3eb59621" xlink:to="loc_srt_LitigationCaseAxis_27267259-ea34-46d1-9254-98b8ac84a264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_209c850f-6077-48cf-b0c7-aae29d79d0e6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_27267259-ea34-46d1-9254-98b8ac84a264" xlink:to="loc_srt_LitigationCaseTypeDomain_209c850f-6077-48cf-b0c7-aae29d79d0e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember_27be20b5-d79e-4433-801d-4c975aaaf1be" xlink:href="bhc-20220331.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_209c850f-6077-48cf-b0c7-aae29d79d0e6" xlink:to="loc_bhc_ValeantUSSecuritiesLitigationMember_27be20b5-d79e-4433-801d-4c975aaaf1be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CanadianSecuritiesLitigationMember_9d62c1e2-3ea2-4eaf-83b6-4cd369c903fc" xlink:href="bhc-20220331.xsd#bhc_CanadianSecuritiesLitigationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_209c850f-6077-48cf-b0c7-aae29d79d0e6" xlink:to="loc_bhc_CanadianSecuritiesLitigationMember_9d62c1e2-3ea2-4eaf-83b6-4cd369c903fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RICOClassActionsMember_f5b908d8-becb-4014-8329-e51762c93b35" xlink:href="bhc-20220331.xsd#bhc_RICOClassActionsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_209c850f-6077-48cf-b0c7-aae29d79d0e6" xlink:to="loc_bhc_RICOClassActionsMember_f5b908d8-becb-4014-8329-e51762c93b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InsuranceCoverageLawsuitMember_a3f52384-ee98-4ddd-b52b-c03e73c4cb52" xlink:href="bhc-20220331.xsd#bhc_InsuranceCoverageLawsuitMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_209c850f-6077-48cf-b0c7-aae29d79d0e6" xlink:to="loc_bhc_InsuranceCoverageLawsuitMember_a3f52384-ee98-4ddd-b52b-c03e73c4cb52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_4f45f34d-dbf5-4f9e-a263-c372810a0cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_df241bfc-a21f-42e5-9280-e56e3eb59621" xlink:to="loc_us-gaap_LitigationStatusAxis_4f45f34d-dbf5-4f9e-a263-c372810a0cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_3f1a4fd2-fb80-4add-a9bc-bb75b26d3c41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_4f45f34d-dbf5-4f9e-a263-c372810a0cbf" xlink:to="loc_us-gaap_LitigationStatusDomain_3f1a4fd2-fb80-4add-a9bc-bb75b26d3c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_e7c91465-7ea0-4d76-ab58-35c8b1983247" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_3f1a4fd2-fb80-4add-a9bc-bb75b26d3c41" xlink:to="loc_us-gaap_SettledLitigationMember_e7c91465-7ea0-4d76-ab58-35c8b1983247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_34ac4332-421e-495f-8ddb-cf1c88f130b6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_df241bfc-a21f-42e5-9280-e56e3eb59621" xlink:to="loc_srt_StatementGeographicalAxis_34ac4332-421e-495f-8ddb-cf1c88f130b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_fc1c7d8e-892a-4147-a1d6-617e5d5df36e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_34ac4332-421e-495f-8ddb-cf1c88f130b6" xlink:to="loc_srt_SegmentGeographicalDomain_fc1c7d8e-892a-4147-a1d6-617e5d5df36e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_5a393443-bdca-4f0c-99d1-7adb2344b42c" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_NJ"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_fc1c7d8e-892a-4147-a1d6-617e5d5df36e" xlink:to="loc_stpr_NJ_5a393443-bdca-4f0c-99d1-7adb2344b42c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_022eb1b7-acbd-40ca-a793-eca2d28e156c" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_fc1c7d8e-892a-4147-a1d6-617e5d5df36e" xlink:to="loc_country_CA_022eb1b7-acbd-40ca-a793-eca2d28e156c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_355f8c99-bb85-4084-b15e-9a1688da50ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_df241bfc-a21f-42e5-9280-e56e3eb59621" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_355f8c99-bb85-4084-b15e-9a1688da50ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_115643de-3bb4-4baf-a873-f536ae4b0de8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_355f8c99-bb85-4084-b15e-9a1688da50ed" xlink:to="loc_us-gaap_LossContingencyNatureDomain_115643de-3bb4-4baf-a873-f536ae4b0de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember_3bef9727-f53c-409f-a9a9-99f56178b1e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnfavorableRegulatoryActionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_115643de-3bb4-4baf-a873-f536ae4b0de8" xlink:to="loc_us-gaap_UnfavorableRegulatoryActionMember_3bef9727-f53c-409f-a9a9-99f56178b1e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_f837a843-996d-4c20-afac-a227dd8fc8a0" xlink:href="bhc-20220331.xsd#bhc_ViolationofCanadianProvincialSecuritiesLegislationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_115643de-3bb4-4baf-a873-f536ae4b0de8" xlink:to="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_f837a843-996d-4c20-afac-a227dd8fc8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8bc7d217-9235-4cd7-9353-95276cdc41fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_df241bfc-a21f-42e5-9280-e56e3eb59621" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_8bc7d217-9235-4cd7-9353-95276cdc41fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_732eb03a-f33e-4a7a-8626-8686344ec391" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8bc7d217-9235-4cd7-9353-95276cdc41fa" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_732eb03a-f33e-4a7a-8626-8686344ec391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember_6ac3cec4-d32b-4945-b57d-1fe0011fea8d" xlink:href="bhc-20220331.xsd#bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_732eb03a-f33e-4a7a-8626-8686344ec391" xlink:to="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember_6ac3cec4-d32b-4945-b57d-1fe0011fea8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_4fe04344-cb78-49c0-8c8f-04c6c6a2a3c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_df241bfc-a21f-42e5-9280-e56e3eb59621" xlink:to="loc_us-gaap_LossContingenciesLineItems_4fe04344-cb78-49c0-8c8f-04c6c6a2a3c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_f536e2f6-319c-4541-97ef-06da2a4b6a25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4fe04344-cb78-49c0-8c8f-04c6c6a2a3c5" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_f536e2f6-319c-4541-97ef-06da2a4b6a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_1585e0c3-758b-466c-987c-8cc1ad47ff49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4fe04344-cb78-49c0-8c8f-04c6c6a2a3c5" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_1585e0c3-758b-466c-987c-8cc1ad47ff49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_6f70f239-25cf-47ef-9baa-d21d1e724d71" xlink:href="bhc-20220331.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4fe04344-cb78-49c0-8c8f-04c6c6a2a3c5" xlink:to="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_6f70f239-25cf-47ef-9baa-d21d1e724d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_7667d508-9586-4709-9888-4e05ac29de4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4fe04344-cb78-49c0-8c8f-04c6c6a2a3c5" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_7667d508-9586-4709-9888-4e05ac29de4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_dd995969-c1f6-4731-bc20-9564c2d5eb57" xlink:href="bhc-20220331.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4fe04344-cb78-49c0-8c8f-04c6c6a2a3c5" xlink:to="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_dd995969-c1f6-4731-bc20-9564c2d5eb57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_d3580f8b-82a3-4018-a062-77e337262d33" xlink:href="bhc-20220331.xsd#bhc_LossContingencyNewClaimsFiledButNotYetServedNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4fe04344-cb78-49c0-8c8f-04c6c6a2a3c5" xlink:to="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_d3580f8b-82a3-4018-a062-77e337262d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_37e2e9d1-eee1-49ba-8d8f-e67d66d768a7" xlink:href="bhc-20220331.xsd#bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4fe04344-cb78-49c0-8c8f-04c6c6a2a3c5" xlink:to="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_37e2e9d1-eee1-49ba-8d8f-e67d66d768a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods_26bf7dbc-4d6b-4a8e-8afc-83a0fdc3d5c0" xlink:href="bhc-20220331.xsd#bhc_LossContingencyNumberOfInsurancePolicyPeriods"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4fe04344-cb78-49c0-8c8f-04c6c6a2a3c5" xlink:to="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods_26bf7dbc-4d6b-4a8e-8afc-83a0fdc3d5c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencySettlementAgreementsNumberOfInsurers_f456fb0a-1963-4493-9740-c67dc82016d7" xlink:href="bhc-20220331.xsd#bhc_LossContingencySettlementAgreementsNumberOfInsurers"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4fe04344-cb78-49c0-8c8f-04c6c6a2a3c5" xlink:to="loc_bhc_LossContingencySettlementAgreementsNumberOfInsurers_f456fb0a-1963-4493-9740-c67dc82016d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_30d1e737-9a86-45f3-bb96-7e18b11880dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4fe04344-cb78-49c0-8c8f-04c6c6a2a3c5" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_30d1e737-9a86-45f3-bb96-7e18b11880dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#LEGALPROCEEDINGSAntitrustDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c502f427-78ce-4b53-9799-1e24e80d9529" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_867d4f82-7316-4980-a9ab-e2a66a6b2134" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c502f427-78ce-4b53-9799-1e24e80d9529" xlink:to="loc_us-gaap_LossContingenciesTable_867d4f82-7316-4980-a9ab-e2a66a6b2134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_4209ec83-91eb-4def-a912-943fca849dd2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_867d4f82-7316-4980-a9ab-e2a66a6b2134" xlink:to="loc_srt_LitigationCaseAxis_4209ec83-91eb-4def-a912-943fca849dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_aec7e7a2-1651-4a6a-8728-06bbdecd1683" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_4209ec83-91eb-4def-a912-943fca849dd2" xlink:to="loc_srt_LitigationCaseTypeDomain_aec7e7a2-1651-4a6a-8728-06bbdecd1683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationMember_2d15f6a8-39b6-4a38-b4ca-8b1fd11d55be" xlink:href="bhc-20220331.xsd#bhc_GlumetzaAntitrustLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_aec7e7a2-1651-4a6a-8728-06bbdecd1683" xlink:to="loc_bhc_GlumetzaAntitrustLitigationMember_2d15f6a8-39b6-4a38-b4ca-8b1fd11d55be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_5287b9cf-0c98-4c9a-8804-c6cf162d1b03" xlink:href="bhc-20220331.xsd#bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_aec7e7a2-1651-4a6a-8728-06bbdecd1683" xlink:to="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_5287b9cf-0c98-4c9a-8804-c6cf162d1b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_88cbbcff-9ed8-4d5a-b350-ba9e7a68ac58" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_867d4f82-7316-4980-a9ab-e2a66a6b2134" xlink:to="loc_srt_CounterpartyNameAxis_88cbbcff-9ed8-4d5a-b350-ba9e7a68ac58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_63091421-7e44-4d0f-81ac-9229b1829617" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_88cbbcff-9ed8-4d5a-b350-ba9e7a68ac58" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_63091421-7e44-4d0f-81ac-9229b1829617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PlaintiffsDirectPurchasersMember_d016bfe2-575e-4876-b49c-a529b3184eb1" xlink:href="bhc-20220331.xsd#bhc_PlaintiffsDirectPurchasersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_63091421-7e44-4d0f-81ac-9229b1829617" xlink:to="loc_bhc_PlaintiffsDirectPurchasersMember_d016bfe2-575e-4876-b49c-a529b3184eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_8a11e1c6-8e75-4b60-9e64-0adf576690ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_867d4f82-7316-4980-a9ab-e2a66a6b2134" xlink:to="loc_us-gaap_LitigationStatusAxis_8a11e1c6-8e75-4b60-9e64-0adf576690ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_7c490094-6054-4aba-a895-a39b4a019e89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_8a11e1c6-8e75-4b60-9e64-0adf576690ba" xlink:to="loc_us-gaap_LitigationStatusDomain_7c490094-6054-4aba-a895-a39b4a019e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_5c6f83b5-0d6a-4691-9f23-e90c663ab703" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_7c490094-6054-4aba-a895-a39b4a019e89" xlink:to="loc_us-gaap_PendingLitigationMember_5c6f83b5-0d6a-4691-9f23-e90c663ab703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_fb7918df-19b0-4c02-ad2d-e75b98e7687f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_867d4f82-7316-4980-a9ab-e2a66a6b2134" xlink:to="loc_us-gaap_LossContingenciesLineItems_fb7918df-19b0-4c02-ad2d-e75b98e7687f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_50d84bdd-e671-40fd-a501-e71032216ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_fb7918df-19b0-4c02-ad2d-e75b98e7687f" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_50d84bdd-e671-40fd-a501-e71032216ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_51bfaaee-72d2-4ed4-a4dc-12807b2cc99d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_fb7918df-19b0-4c02-ad2d-e75b98e7687f" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_51bfaaee-72d2-4ed4-a4dc-12807b2cc99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#LEGALPROCEEDINGSIntellectualPropertyDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c82e0776-1c1f-40ff-ae74-4ab8e01c2bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_1d74ea00-8803-4492-85bd-63bd59307dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c82e0776-1c1f-40ff-ae74-4ab8e01c2bb8" xlink:to="loc_us-gaap_LossContingenciesTable_1d74ea00-8803-4492-85bd-63bd59307dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_25a2928b-56be-41be-a955-7759fcef0272" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1d74ea00-8803-4492-85bd-63bd59307dc1" xlink:to="loc_srt_LitigationCaseAxis_25a2928b-56be-41be-a955-7759fcef0272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_2e115637-229d-4181-bfc3-d5e071553817" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_25a2928b-56be-41be-a955-7759fcef0272" xlink:to="loc_srt_LitigationCaseTypeDomain_2e115637-229d-4181-bfc3-d5e071553817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NorwichPharmaceuticalsIncLitigationMember_52f5fbf5-d9c6-4faa-82c4-cfdd15e2a68b" xlink:href="bhc-20220331.xsd#bhc_NorwichPharmaceuticalsIncLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_2e115637-229d-4181-bfc3-d5e071553817" xlink:to="loc_bhc_NorwichPharmaceuticalsIncLitigationMember_52f5fbf5-d9c6-4faa-82c4-cfdd15e2a68b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember_35f1fddc-5d2c-4f65-be09-4ada3cd525f8" xlink:href="bhc-20220331.xsd#bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_2e115637-229d-4181-bfc3-d5e071553817" xlink:to="loc_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember_35f1fddc-5d2c-4f65-be09-4ada3cd525f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PadagisLitigationMember_f0ee6c80-01ce-442b-82c5-284b8fab16fd" xlink:href="bhc-20220331.xsd#bhc_PadagisLitigationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_2e115637-229d-4181-bfc3-d5e071553817" xlink:to="loc_bhc_PadagisLitigationMember_f0ee6c80-01ce-442b-82c5-284b8fab16fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember_3af5a748-9b3b-4555-88ad-6ea51ad19c1e" xlink:href="bhc-20220331.xsd#bhc_MSNLaboratoriesPrivateLtdLitigationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_2e115637-229d-4181-bfc3-d5e071553817" xlink:to="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember_3af5a748-9b3b-4555-88ad-6ea51ad19c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PatentInfringementLitigationMember_1eb1c1da-20ef-4ee1-aee3-5b030e612b9e" xlink:href="bhc-20220331.xsd#bhc_PatentInfringementLitigationMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_2e115637-229d-4181-bfc3-d5e071553817" xlink:to="loc_bhc_PatentInfringementLitigationMember_1eb1c1da-20ef-4ee1-aee3-5b030e612b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ApotexIncLitigationMember_de5b35bf-f7b5-4981-9ca3-3b7a5702af31" xlink:href="bhc-20220331.xsd#bhc_ApotexIncLitigationMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_2e115637-229d-4181-bfc3-d5e071553817" xlink:to="loc_bhc_ApotexIncLitigationMember_de5b35bf-f7b5-4981-9ca3-3b7a5702af31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d27b2664-97dd-4498-abba-024b1bd0e91c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1d74ea00-8803-4492-85bd-63bd59307dc1" xlink:to="loc_srt_StatementGeographicalAxis_d27b2664-97dd-4498-abba-024b1bd0e91c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_cd0abc11-dfb0-456c-8845-7d897c27fdce" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_d27b2664-97dd-4498-abba-024b1bd0e91c" xlink:to="loc_srt_SegmentGeographicalDomain_cd0abc11-dfb0-456c-8845-7d897c27fdce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_8a4a8ccd-c270-4e5f-8a54-c7c5fe336760" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_cd0abc11-dfb0-456c-8845-7d897c27fdce" xlink:to="loc_country_CA_8a4a8ccd-c270-4e5f-8a54-c7c5fe336760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_0d647012-9e47-45d4-88a1-870f7b41a124" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1d74ea00-8803-4492-85bd-63bd59307dc1" xlink:to="loc_us-gaap_LitigationStatusAxis_0d647012-9e47-45d4-88a1-870f7b41a124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_24c8f524-6487-43be-b37f-682010e2eb23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_0d647012-9e47-45d4-88a1-870f7b41a124" xlink:to="loc_us-gaap_LitigationStatusDomain_24c8f524-6487-43be-b37f-682010e2eb23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_78c2f47a-192b-4b98-a0a8-1dfa54070258" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_24c8f524-6487-43be-b37f-682010e2eb23" xlink:to="loc_us-gaap_PendingLitigationMember_78c2f47a-192b-4b98-a0a8-1dfa54070258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_83ab2696-868c-4b59-87ca-2053ec76a09a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1d74ea00-8803-4492-85bd-63bd59307dc1" xlink:to="loc_us-gaap_LossContingenciesLineItems_83ab2696-868c-4b59-87ca-2053ec76a09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalPeriod_8050687e-48ec-4fc3-b41f-99e22ce453f4" xlink:href="bhc-20220331.xsd#bhc_LossContingencyStayOfApprovalPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_83ab2696-868c-4b59-87ca-2053ec76a09a" xlink:to="loc_bhc_LossContingencyStayOfApprovalPeriod_8050687e-48ec-4fc3-b41f-99e22ce453f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfSeparateDefendants_bab32558-59d9-4000-be43-3a7ba9762b7d" xlink:href="bhc-20220331.xsd#bhc_LossContingencyNumberOfSeparateDefendants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_83ab2696-868c-4b59-87ca-2053ec76a09a" xlink:to="loc_bhc_LossContingencyNumberOfSeparateDefendants_bab32558-59d9-4000-be43-3a7ba9762b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_3cc51201-25f9-4568-a8b4-139bc3433b93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_83ab2696-868c-4b59-87ca-2053ec76a09a" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_3cc51201-25f9-4568-a8b4-139bc3433b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#LEGALPROCEEDINGSProductLiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5b24505a-502c-4f66-a216-a46c952b9a19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_7213c0c1-1e78-4485-914d-fac14633a541" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5b24505a-502c-4f66-a216-a46c952b9a19" xlink:to="loc_us-gaap_LossContingenciesTable_7213c0c1-1e78-4485-914d-fac14633a541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_232e9ad3-069c-404a-9758-bf30f79ec201" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7213c0c1-1e78-4485-914d-fac14633a541" xlink:to="loc_srt_LitigationCaseAxis_232e9ad3-069c-404a-9758-bf30f79ec201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_ddf35cad-4337-48ae-853c-a871d2e790f8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_232e9ad3-069c-404a-9758-bf30f79ec201" xlink:to="loc_srt_LitigationCaseTypeDomain_ddf35cad-4337-48ae-853c-a871d2e790f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowerToShowerProductLiabilityLitigationMember_ed2b2b64-1197-4f35-9119-aa248d341abf" xlink:href="bhc-20220331.xsd#bhc_ShowerToShowerProductLiabilityLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_ddf35cad-4337-48ae-853c-a871d2e790f8" xlink:to="loc_bhc_ShowerToShowerProductLiabilityLitigationMember_ed2b2b64-1197-4f35-9119-aa248d341abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_6bd174c6-945e-4f56-aaed-dce812e932dd" xlink:href="bhc-20220331.xsd#bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShowerToShowerProductLiabilityLitigationMember_ed2b2b64-1197-4f35-9119-aa248d341abf" xlink:to="loc_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_6bd174c6-945e-4f56-aaed-dce812e932dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember_dc19b3b6-18e7-4f23-9b57-0826d0b04827" xlink:href="bhc-20220331.xsd#bhc_MSNLaboratoriesPrivateLtdLitigationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_ddf35cad-4337-48ae-853c-a871d2e790f8" xlink:to="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember_dc19b3b6-18e7-4f23-9b57-0826d0b04827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_8259f5ca-5e8b-4b8f-a3b3-1076f50363ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7213c0c1-1e78-4485-914d-fac14633a541" xlink:to="loc_us-gaap_LitigationStatusAxis_8259f5ca-5e8b-4b8f-a3b3-1076f50363ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_feed1825-1aa1-4f23-b308-52f8e1f28600" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_8259f5ca-5e8b-4b8f-a3b3-1076f50363ac" xlink:to="loc_us-gaap_LitigationStatusDomain_feed1825-1aa1-4f23-b308-52f8e1f28600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_c5562413-dd88-4644-b051-e1e98f27b9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_feed1825-1aa1-4f23-b308-52f8e1f28600" xlink:to="loc_us-gaap_PendingLitigationMember_c5562413-dd88-4644-b051-e1e98f27b9bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_2c361429-025d-48af-9ffb-0bf6d948ab5f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7213c0c1-1e78-4485-914d-fac14633a541" xlink:to="loc_srt_StatementGeographicalAxis_2c361429-025d-48af-9ffb-0bf6d948ab5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_76537cf6-0d06-48b5-ae79-ec35e942d767" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_2c361429-025d-48af-9ffb-0bf6d948ab5f" xlink:to="loc_srt_SegmentGeographicalDomain_76537cf6-0d06-48b5-ae79-ec35e942d767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_e58ae4e9-97a6-44c2-a76f-ad262628d2d9" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_76537cf6-0d06-48b5-ae79-ec35e942d767" xlink:to="loc_country_CA_e58ae4e9-97a6-44c2-a76f-ad262628d2d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-BC_79b3ca35-d3dd-4efa-8d7e-05c4eab59617" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA-BC"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_76537cf6-0d06-48b5-ae79-ec35e942d767" xlink:to="loc_stpr_CA-BC_79b3ca35-d3dd-4efa-8d7e-05c4eab59617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-QC_e4f3c302-35a6-4a6e-af93-aebb64ca7afa" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA-QC"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_76537cf6-0d06-48b5-ae79-ec35e942d767" xlink:to="loc_stpr_CA-QC_e4f3c302-35a6-4a6e-af93-aebb64ca7afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_724711d0-3b5d-4a0f-b126-c281c67d8f36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7213c0c1-1e78-4485-914d-fac14633a541" xlink:to="loc_us-gaap_LossContingenciesLineItems_724711d0-3b5d-4a0f-b126-c281c67d8f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_cc9e0262-9c9e-4940-a13b-af21d8865699" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_724711d0-3b5d-4a0f-b126-c281c67d8f36" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_cc9e0262-9c9e-4940-a13b-af21d8865699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalPeriod_77006759-86d2-4231-847e-28047a2d746d" xlink:href="bhc-20220331.xsd#bhc_LossContingencyStayOfApprovalPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_724711d0-3b5d-4a0f-b126-c281c67d8f36" xlink:to="loc_bhc_LossContingencyStayOfApprovalPeriod_77006759-86d2-4231-847e-28047a2d746d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod_513f669e-de38-418f-9c3f-659cacd2aa03" xlink:href="bhc-20220331.xsd#bhc_LossContingencyStayOfApprovalMotionToExtendPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_724711d0-3b5d-4a0f-b126-c281c67d8f36" xlink:to="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod_513f669e-de38-418f-9c3f-659cacd2aa03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#LEGALPROCEEDINGSGeneralCivilActionsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_37c8c39a-4d2b-4df1-a572-b8347c585968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_1aca6900-18c0-428f-9628-b4ba989de427" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_37c8c39a-4d2b-4df1-a572-b8347c585968" xlink:to="loc_us-gaap_LossContingenciesTable_1aca6900-18c0-428f-9628-b4ba989de427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_88306435-1fec-4460-9cb0-8058269d1487" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1aca6900-18c0-428f-9628-b4ba989de427" xlink:to="loc_srt_LitigationCaseAxis_88306435-1fec-4460-9cb0-8058269d1487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_ed6dac39-1a8c-45f2-a68b-5918f3c86606" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_88306435-1fec-4460-9cb0-8058269d1487" xlink:to="loc_srt_LitigationCaseTypeDomain_ed6dac39-1a8c-45f2-a68b-5918f3c86606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember_a808eab2-e921-4de8-b652-36324ed80fed" xlink:href="bhc-20220331.xsd#bhc_DoctorsAllergyFormulaLLCLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_ed6dac39-1a8c-45f2-a68b-5918f3c86606" xlink:to="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember_a808eab2-e921-4de8-b652-36324ed80fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LitigationwithFormerSalixCEOMember_cf60f000-7505-4a6b-8941-a587d2d074b8" xlink:href="bhc-20220331.xsd#bhc_LitigationwithFormerSalixCEOMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_ed6dac39-1a8c-45f2-a68b-5918f3c86606" xlink:to="loc_bhc_LitigationwithFormerSalixCEOMember_cf60f000-7505-4a6b-8941-a587d2d074b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_7ec0bf38-8a0d-49c2-89ba-feae3cdfb73b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1aca6900-18c0-428f-9628-b4ba989de427" xlink:to="loc_us-gaap_LossContingenciesLineItems_7ec0bf38-8a0d-49c2-89ba-feae3cdfb73b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_93e17c62-6d28-44cf-9562-eab9a202cbf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7ec0bf38-8a0d-49c2-89ba-feae3cdfb73b" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_93e17c62-6d28-44cf-9562-eab9a202cbf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATION" xlink:type="simple" xlink:href="bhc-20220331.xsd#SEGMENTINFORMATION"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_e9e8a09c-02ce-4236-ac4d-d4d83daa13f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_6c280df8-42a3-4e3c-97d3-2072bc1c0c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e9e8a09c-02ce-4236-ac4d-d4d83daa13f6" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_6c280df8-42a3-4e3c-97d3-2072bc1c0c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables" xlink:type="simple" xlink:href="bhc-20220331.xsd#SEGMENTINFORMATIONTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_406d5bc1-dada-49ce-924f-6b839260c277" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_762af464-de2b-46c2-bf3b-6aab55378a45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_406d5bc1-dada-49ce-924f-6b839260c277" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_762af464-de2b-46c2-bf3b-6aab55378a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_e7a24df9-cc66-4689-8c99-3a8849ba3c83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_406d5bc1-dada-49ce-924f-6b839260c277" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_e7a24df9-cc66-4689-8c99-3a8849ba3c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_b641f632-99a5-4614-a64b-4745e31109b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_406d5bc1-dada-49ce-924f-6b839260c277" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_b641f632-99a5-4614-a64b-4745e31109b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_a90231ce-662c-4c3e-be2c-04a22e83d175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_406d5bc1-dada-49ce-924f-6b839260c277" xlink:to="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_a90231ce-662c-4c3e-be2c-04a22e83d175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#SEGMENTINFORMATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_cdba3eac-2202-4024-8f3e-6337a5bbb95d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_17fa6b4b-b03f-47ed-9d50-32b6fc797b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cdba3eac-2202-4024-8f3e-6337a5bbb95d" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_17fa6b4b-b03f-47ed-9d50-32b6fc797b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_51d5ee9b-af98-4384-84d0-4ce927128ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_17fa6b4b-b03f-47ed-9d50-32b6fc797b3c" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_51d5ee9b-af98-4384-84d0-4ce927128ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b2e14643-acc2-41b3-9db0-40eb079c20e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_51d5ee9b-af98-4384-84d0-4ce927128ec2" xlink:to="loc_us-gaap_SegmentDomain_b2e14643-acc2-41b3-9db0-40eb079c20e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember_25d1f358-7fe1-4faa-b42d-3d3d5f3dff71" xlink:href="bhc-20220331.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b2e14643-acc2-41b3-9db0-40eb079c20e7" xlink:to="loc_bhc_OrthoDermatologicsSegmentMember_25d1f358-7fe1-4faa-b42d-3d3d5f3dff71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_c4afe95a-eec9-4010-a0c3-eab370712b43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_17fa6b4b-b03f-47ed-9d50-32b6fc797b3c" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_c4afe95a-eec9-4010-a0c3-eab370712b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_0dd577a2-2f57-4e0e-be31-1ba85b4f6d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c4afe95a-eec9-4010-a0c3-eab370712b43" xlink:to="loc_us-gaap_NumberOfReportingUnits_0dd577a2-2f57-4e0e-be31-1ba85b4f6d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_78b29449-16e4-4d63-b6dd-67e7e225b8cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ca7a5a03-b5a2-4df2-8197-14ea4befc5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_78b29449-16e4-4d63-b6dd-67e7e225b8cf" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ca7a5a03-b5a2-4df2-8197-14ea4befc5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_e49e094d-e8ad-4fbe-95e1-9a062ef00eaa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ca7a5a03-b5a2-4df2-8197-14ea4befc5e7" xlink:to="loc_srt_ConsolidationItemsAxis_e49e094d-e8ad-4fbe-95e1-9a062ef00eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_1e71d05a-74bd-4188-aeb4-43c817950fa0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_e49e094d-e8ad-4fbe-95e1-9a062ef00eaa" xlink:to="loc_srt_ConsolidationItemsDomain_1e71d05a-74bd-4188-aeb4-43c817950fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_677398d0-7610-4317-a4e8-0a05a9471d25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_1e71d05a-74bd-4188-aeb4-43c817950fa0" xlink:to="loc_us-gaap_OperatingSegmentsMember_677398d0-7610-4317-a4e8-0a05a9471d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_ba78f658-48c4-4e4e-bbdc-cf5c3c743022" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_1e71d05a-74bd-4188-aeb4-43c817950fa0" xlink:to="loc_us-gaap_CorporateNonSegmentMember_ba78f658-48c4-4e4e-bbdc-cf5c3c743022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_0b6d630f-9bd8-4cd0-95d5-d9e8b91606f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ca7a5a03-b5a2-4df2-8197-14ea4befc5e7" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_0b6d630f-9bd8-4cd0-95d5-d9e8b91606f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ebc2e478-1fc2-453b-bb19-d694cd99b3b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0b6d630f-9bd8-4cd0-95d5-d9e8b91606f2" xlink:to="loc_us-gaap_SegmentDomain_ebc2e478-1fc2-453b-bb19-d694cd99b3b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_e4c1a2b9-0ef9-459e-ab80-230fc7c7762b" xlink:href="bhc-20220331.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ebc2e478-1fc2-453b-bb19-d694cd99b3b7" xlink:to="loc_bhc_BauschLombMember_e4c1a2b9-0ef9-459e-ab80-230fc7c7762b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_3886b8eb-98c4-4714-bc6d-464275a35400" xlink:href="bhc-20220331.xsd#bhc_SalixSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ebc2e478-1fc2-453b-bb19-d694cd99b3b7" xlink:to="loc_bhc_SalixSegmentMember_3886b8eb-98c4-4714-bc6d-464275a35400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_e9eafd2e-c6fb-4dda-82a0-6259cbecefd2" xlink:href="bhc-20220331.xsd#bhc_InternationalRxMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ebc2e478-1fc2-453b-bb19-d694cd99b3b7" xlink:to="loc_bhc_InternationalRxMember_e9eafd2e-c6fb-4dda-82a0-6259cbecefd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SoltaMedicalSegmentMember_0ae5238d-da70-4182-bb07-7e59e1fb9ca5" xlink:href="bhc-20220331.xsd#bhc_SoltaMedicalSegmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ebc2e478-1fc2-453b-bb19-d694cd99b3b7" xlink:to="loc_bhc_SoltaMedicalSegmentMember_0ae5238d-da70-4182-bb07-7e59e1fb9ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_bfba17a0-0503-46fc-95b2-d74827ee9ecf" xlink:href="bhc-20220331.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ebc2e478-1fc2-453b-bb19-d694cd99b3b7" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_bfba17a0-0503-46fc-95b2-d74827ee9ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_c326c755-66e9-43dd-8ba3-39b29594bb62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ca7a5a03-b5a2-4df2-8197-14ea4befc5e7" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_c326c755-66e9-43dd-8ba3-39b29594bb62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_172fd5a8-a228-445a-84bd-35a18383c183" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c326c755-66e9-43dd-8ba3-39b29594bb62" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_172fd5a8-a228-445a-84bd-35a18383c183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f9559b47-34c1-425a-b244-3fd72817bbb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c326c755-66e9-43dd-8ba3-39b29594bb62" xlink:to="loc_us-gaap_OperatingIncomeLoss_f9559b47-34c1-425a-b244-3fd72817bbb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_2f93c272-5aa5-4a20-9d89-e3e5798a91c8" xlink:href="bhc-20220331.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c326c755-66e9-43dd-8ba3-39b29594bb62" xlink:to="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_2f93c272-5aa5-4a20-9d89-e3e5798a91c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_016fa26f-5b60-47eb-8912-1d75cefc5446" xlink:href="bhc-20220331.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c326c755-66e9-43dd-8ba3-39b29594bb62" xlink:to="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_016fa26f-5b60-47eb-8912-1d75cefc5446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_617381f2-7838-4547-a5a4-070ad9d58f72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c326c755-66e9-43dd-8ba3-39b29594bb62" xlink:to="loc_us-gaap_AssetImpairmentCharges_617381f2-7838-4547-a5a4-070ad9d58f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_146ea648-9cf9-499c-b625-61715d374d50" xlink:href="bhc-20220331.xsd#bhc_RestructuringChargesAndInitialPublicOfferingCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c326c755-66e9-43dd-8ba3-39b29594bb62" xlink:to="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_146ea648-9cf9-499c-b625-61715d374d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_f48e8cb2-9a0e-4951-a778-f84f3ba4af96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c326c755-66e9-43dd-8ba3-39b29594bb62" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_f48e8cb2-9a0e-4951-a778-f84f3ba4af96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_e6e1fc64-aa5e-4856-b634-a6b67e5c8bac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c326c755-66e9-43dd-8ba3-39b29594bb62" xlink:to="loc_us-gaap_InvestmentIncomeInterest_e6e1fc64-aa5e-4856-b634-a6b67e5c8bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_955499d4-eaf2-43bc-89d7-1eb26ed5c64c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c326c755-66e9-43dd-8ba3-39b29594bb62" xlink:to="loc_us-gaap_InterestExpenseDebt_955499d4-eaf2-43bc-89d7-1eb26ed5c64c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0a68e17b-87e7-45f8-bab6-d180565ca12d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c326c755-66e9-43dd-8ba3-39b29594bb62" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0a68e17b-87e7-45f8-bab6-d180565ca12d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_27ab77ce-0823-420b-ae0b-a24b31b09411" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c326c755-66e9-43dd-8ba3-39b29594bb62" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_27ab77ce-0823-420b-ae0b-a24b31b09411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_29639269-cba9-4796-8898-f2521d38c426" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c326c755-66e9-43dd-8ba3-39b29594bb62" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_29639269-cba9-4796-8898-f2521d38c426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#SEGMENTINFORMATIONDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_86443c95-3a34-4941-b09e-8bca8c1cfe98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_28b61d48-ca7b-4728-a882-48d1abc6f46e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_86443c95-3a34-4941-b09e-8bca8c1cfe98" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_28b61d48-ca7b-4728-a882-48d1abc6f46e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_b9f934b9-7f7c-448c-909c-32d9b3f8f572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_28b61d48-ca7b-4728-a882-48d1abc6f46e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_b9f934b9-7f7c-448c-909c-32d9b3f8f572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e29a7066-2391-4883-88fb-ab6028f4d9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b9f934b9-7f7c-448c-909c-32d9b3f8f572" xlink:to="loc_us-gaap_SegmentDomain_e29a7066-2391-4883-88fb-ab6028f4d9bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_c7f1bd02-e63b-4b51-a434-994188a4f9bc" xlink:href="bhc-20220331.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e29a7066-2391-4883-88fb-ab6028f4d9bf" xlink:to="loc_bhc_BauschLombMember_c7f1bd02-e63b-4b51-a434-994188a4f9bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_8737b91f-6935-4abb-a041-b4fed3e797c9" xlink:href="bhc-20220331.xsd#bhc_SalixSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e29a7066-2391-4883-88fb-ab6028f4d9bf" xlink:to="loc_bhc_SalixSegmentMember_8737b91f-6935-4abb-a041-b4fed3e797c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_c34e4d36-8134-4311-8e00-2ed1e85ea218" xlink:href="bhc-20220331.xsd#bhc_InternationalRxMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e29a7066-2391-4883-88fb-ab6028f4d9bf" xlink:to="loc_bhc_InternationalRxMember_c34e4d36-8134-4311-8e00-2ed1e85ea218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SoltaMedicalSegmentMember_c9ffb8ab-c773-4c1e-b769-fb60083a744d" xlink:href="bhc-20220331.xsd#bhc_SoltaMedicalSegmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e29a7066-2391-4883-88fb-ab6028f4d9bf" xlink:to="loc_bhc_SoltaMedicalSegmentMember_c9ffb8ab-c773-4c1e-b769-fb60083a744d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_5d5e1117-b6f9-4e1f-a541-469b59f9f54d" xlink:href="bhc-20220331.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e29a7066-2391-4883-88fb-ab6028f4d9bf" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_5d5e1117-b6f9-4e1f-a541-469b59f9f54d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_93a8e142-231c-4bfe-b31c-c504df9768d4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_28b61d48-ca7b-4728-a882-48d1abc6f46e" xlink:to="loc_srt_ProductOrServiceAxis_93a8e142-231c-4bfe-b31c-c504df9768d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e43ba4da-f377-4e6a-b92c-622ab39f57b8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_93a8e142-231c-4bfe-b31c-c504df9768d4" xlink:to="loc_srt_ProductsAndServicesDomain_e43ba4da-f377-4e6a-b92c-622ab39f57b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PharmaceuticalProductsMember_c869f8b1-0439-4abe-8e61-7d6dcb891259" xlink:href="bhc-20220331.xsd#bhc_PharmaceuticalProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e43ba4da-f377-4e6a-b92c-622ab39f57b8" xlink:to="loc_bhc_PharmaceuticalProductsMember_c869f8b1-0439-4abe-8e61-7d6dcb891259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeviceProductsMember_39b2a539-3dea-4bed-857c-f12373c37a64" xlink:href="bhc-20220331.xsd#bhc_DeviceProductsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e43ba4da-f377-4e6a-b92c-622ab39f57b8" xlink:to="loc_bhc_DeviceProductsMember_39b2a539-3dea-4bed-857c-f12373c37a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OvertheCounterProductsMember_064092c4-72e8-4e01-8800-1b1bb9f6ac81" xlink:href="bhc-20220331.xsd#bhc_OvertheCounterProductsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e43ba4da-f377-4e6a-b92c-622ab39f57b8" xlink:to="loc_bhc_OvertheCounterProductsMember_064092c4-72e8-4e01-8800-1b1bb9f6ac81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BrandedandOtherGenericProductsMember_614ecd01-da25-4c16-9ba2-3b88b4047ed8" xlink:href="bhc-20220331.xsd#bhc_BrandedandOtherGenericProductsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e43ba4da-f377-4e6a-b92c-622ab39f57b8" xlink:to="loc_bhc_BrandedandOtherGenericProductsMember_614ecd01-da25-4c16-9ba2-3b88b4047ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherRevenuesMember_7cdcc599-d144-4046-8b65-c8f8b43fad6c" xlink:href="bhc-20220331.xsd#bhc_OtherRevenuesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e43ba4da-f377-4e6a-b92c-622ab39f57b8" xlink:to="loc_bhc_OtherRevenuesMember_7cdcc599-d144-4046-8b65-c8f8b43fad6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_68c6fa1a-f366-4962-8dba-5b1613bbe85b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_28b61d48-ca7b-4728-a882-48d1abc6f46e" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_68c6fa1a-f366-4962-8dba-5b1613bbe85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ca311aac-fb2b-4f3e-850c-ed9703831a41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_68c6fa1a-f366-4962-8dba-5b1613bbe85b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ca311aac-fb2b-4f3e-850c-ed9703831a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1" xlink:type="simple" xlink:href="bhc-20220331.xsd#SEGMENTINFORMATIONNarrativeDetails_1"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_c37e87f2-a6b5-43b6-b45b-75c90bec25f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_26ad6364-4cb3-4208-893d-b78a39f13457" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c37e87f2-a6b5-43b6-b45b-75c90bec25f5" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_26ad6364-4cb3-4208-893d-b78a39f13457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_80293b26-ffe3-4cad-9ca0-6787bf005fae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_26ad6364-4cb3-4208-893d-b78a39f13457" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_80293b26-ffe3-4cad-9ca0-6787bf005fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_8611f2dc-b8d0-4e0e-8fc0-f012b00e8b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_80293b26-ffe3-4cad-9ca0-6787bf005fae" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_8611f2dc-b8d0-4e0e-8fc0-f012b00e8b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_3295b804-8f01-4bca-b603-e1c7f0622f20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_8611f2dc-b8d0-4e0e-8fc0-f012b00e8b0d" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_3295b804-8f01-4bca-b603-e1c7f0622f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0af8da91-e1b3-43d0-b4a6-11a85fd23623" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_26ad6364-4cb3-4208-893d-b78a39f13457" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0af8da91-e1b3-43d0-b4a6-11a85fd23623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0006940e-8348-48e2-83da-5ad424ab7218" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0af8da91-e1b3-43d0-b4a6-11a85fd23623" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0006940e-8348-48e2-83da-5ad424ab7218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuesNetMember_28dba4fd-42be-4a39-bd37-4ef7c48ecb2e" xlink:href="bhc-20220331.xsd#bhc_RevenuesNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0006940e-8348-48e2-83da-5ad424ab7218" xlink:to="loc_bhc_RevenuesNetMember_28dba4fd-42be-4a39-bd37-4ef7c48ecb2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_272ef305-2ec3-4625-9337-8ce09d4bd9f7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_26ad6364-4cb3-4208-893d-b78a39f13457" xlink:to="loc_srt_MajorCustomersAxis_272ef305-2ec3-4625-9337-8ce09d4bd9f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_07987b98-aea8-4417-830b-4a230e293e91" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_272ef305-2ec3-4625-9337-8ce09d4bd9f7" xlink:to="loc_srt_NameOfMajorCustomerDomain_07987b98-aea8-4417-830b-4a230e293e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CustomerTopTenProductsMember_4849ea50-44a5-4a79-84ab-0489a57a51e6" xlink:href="bhc-20220331.xsd#bhc_CustomerTopTenProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_07987b98-aea8-4417-830b-4a230e293e91" xlink:to="loc_bhc_CustomerTopTenProductsMember_4849ea50-44a5-4a79-84ab-0489a57a51e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_083b6f67-be8e-4e27-9f9d-f96c2ee1ae8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_26ad6364-4cb3-4208-893d-b78a39f13457" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_083b6f67-be8e-4e27-9f9d-f96c2ee1ae8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ConcentrationRiskNumberOfProducts_21469a8a-9e3f-491a-9c90-cd4a61bbf5ff" xlink:href="bhc-20220331.xsd#bhc_ConcentrationRiskNumberOfProducts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_083b6f67-be8e-4e27-9f9d-f96c2ee1ae8b" xlink:to="loc_bhc_ConcentrationRiskNumberOfProducts_21469a8a-9e3f-491a-9c90-cd4a61bbf5ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_e81362a7-a0e8-4a55-a0e7-46d8d1f907ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_083b6f67-be8e-4e27-9f9d-f96c2ee1ae8b" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_e81362a7-a0e8-4a55-a0e7-46d8d1f907ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_f3df7787-e59e-4a15-9b83-fb1b4759faf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_200b8cf4-b09c-4b5d-ae36-08446a6f3ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f3df7787-e59e-4a15-9b83-fb1b4759faf9" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_200b8cf4-b09c-4b5d-ae36-08446a6f3ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_00540f8f-18f9-4821-b641-bd5f805b1169" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_200b8cf4-b09c-4b5d-ae36-08446a6f3ce0" xlink:to="loc_srt_StatementGeographicalAxis_00540f8f-18f9-4821-b641-bd5f805b1169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_5d21fcd3-1fa8-4b6e-a264-3710cc3500a9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_00540f8f-18f9-4821-b641-bd5f805b1169" xlink:to="loc_srt_SegmentGeographicalDomain_5d21fcd3-1fa8-4b6e-a264-3710cc3500a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnitedStatesandPuertoRicoMember_3a05e27f-b237-4e4d-bcd8-20299877368a" xlink:href="bhc-20220331.xsd#bhc_UnitedStatesandPuertoRicoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_5d21fcd3-1fa8-4b6e-a264-3710cc3500a9" xlink:to="loc_bhc_UnitedStatesandPuertoRicoMember_3a05e27f-b237-4e4d-bcd8-20299877368a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_d036f6c6-72d0-4a5e-8eca-4edd2f1c5cc0" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_5d21fcd3-1fa8-4b6e-a264-3710cc3500a9" xlink:to="loc_country_CN_d036f6c6-72d0-4a5e-8eca-4edd2f1c5cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_33fe174a-2bb3-47bf-968d-9d199ec23cce" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_5d21fcd3-1fa8-4b6e-a264-3710cc3500a9" xlink:to="loc_country_CA_33fe174a-2bb3-47bf-968d-9d199ec23cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_PL_21992bab-0957-435e-8377-15411ccbf16e" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_PL"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_5d21fcd3-1fa8-4b6e-a264-3710cc3500a9" xlink:to="loc_country_PL_21992bab-0957-435e-8377-15411ccbf16e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_MX_69a5ec53-c7b8-416b-adfd-5b228a5ce079" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_MX"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_5d21fcd3-1fa8-4b6e-a264-3710cc3500a9" xlink:to="loc_country_MX_69a5ec53-c7b8-416b-adfd-5b228a5ce079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_e6c54616-2263-49fc-af4f-76b170699f7f" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_FR"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_5d21fcd3-1fa8-4b6e-a264-3710cc3500a9" xlink:to="loc_country_FR_e6c54616-2263-49fc-af4f-76b170699f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_184f2d76-bb6e-4d15-8488-a4690ff2c917" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_5d21fcd3-1fa8-4b6e-a264-3710cc3500a9" xlink:to="loc_country_JP_184f2d76-bb6e-4d15-8488-a4690ff2c917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_c72644bf-ebc3-4335-aca6-13a56d43b665" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_DE"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_5d21fcd3-1fa8-4b6e-a264-3710cc3500a9" xlink:to="loc_country_DE_c72644bf-ebc3-4335-aca6-13a56d43b665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_ae83220c-eb85-4080-9e6b-7e4143946e26" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_GB"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_5d21fcd3-1fa8-4b6e-a264-3710cc3500a9" xlink:to="loc_country_GB_ae83220c-eb85-4080-9e6b-7e4143946e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_RU_88a2873a-daa0-48c9-abbc-ebbc30514863" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_RU"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_5d21fcd3-1fa8-4b6e-a264-3710cc3500a9" xlink:to="loc_country_RU_88a2873a-daa0-48c9-abbc-ebbc30514863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_ES_56765115-f52c-43d5-8460-48fac6e71b7a" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_ES"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_5d21fcd3-1fa8-4b6e-a264-3710cc3500a9" xlink:to="loc_country_ES_56765115-f52c-43d5-8460-48fac6e71b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IT_67dd5307-5ef5-42ce-a07b-bb1ebc15c099" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IT"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_5d21fcd3-1fa8-4b6e-a264-3710cc3500a9" xlink:to="loc_country_IT_67dd5307-5ef5-42ce-a07b-bb1ebc15c099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_KR_c60e0158-e142-4760-bbd8-2fc10b4ef203" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_KR"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_5d21fcd3-1fa8-4b6e-a264-3710cc3500a9" xlink:to="loc_country_KR_c60e0158-e142-4760-bbd8-2fc10b4ef203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherCountriesMember_df250629-3dc8-406d-865c-42f045061d76" xlink:href="bhc-20220331.xsd#bhc_OtherCountriesMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_5d21fcd3-1fa8-4b6e-a264-3710cc3500a9" xlink:to="loc_bhc_OtherCountriesMember_df250629-3dc8-406d-865c-42f045061d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_e1321855-7be1-4132-bc03-df1e5efcdb02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_200b8cf4-b09c-4b5d-ae36-08446a6f3ce0" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_e1321855-7be1-4132-bc03-df1e5efcdb02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c94e814b-f0fa-4a55-a69e-287a4e24cb3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_e1321855-7be1-4132-bc03-df1e5efcdb02" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c94e814b-f0fa-4a55-a69e-287a4e24cb3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#SEGMENTINFORMATIONMajorCustomersDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_92acee2e-d943-46e3-a547-5168013fa9ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_ab96c8c0-2208-48e1-9644-7f6cc3df0bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_92acee2e-d943-46e3-a547-5168013fa9ba" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_ab96c8c0-2208-48e1-9644-7f6cc3df0bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d61d320a-94f7-4b89-b12d-f1dcdff76eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_ab96c8c0-2208-48e1-9644-7f6cc3df0bc6" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d61d320a-94f7-4b89-b12d-f1dcdff76eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_67be24c9-e7c5-406c-91bb-8bb9f8d74508" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d61d320a-94f7-4b89-b12d-f1dcdff76eb9" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_67be24c9-e7c5-406c-91bb-8bb9f8d74508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuesNetMember_5195138d-8adb-4fd5-8e89-08edcd4b10bb" xlink:href="bhc-20220331.xsd#bhc_RevenuesNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_67be24c9-e7c5-406c-91bb-8bb9f8d74508" xlink:to="loc_bhc_RevenuesNetMember_5195138d-8adb-4fd5-8e89-08edcd4b10bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_d1ef6929-41e2-49a5-ae2d-1808567a562e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_ab96c8c0-2208-48e1-9644-7f6cc3df0bc6" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_d1ef6929-41e2-49a5-ae2d-1808567a562e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_2a4c8037-8f37-4b32-96f4-4080ab66ec3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_d1ef6929-41e2-49a5-ae2d-1808567a562e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_2a4c8037-8f37-4b32-96f4-4080ab66ec3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_bb70e757-d2af-47ea-8a81-2f0a41f3d840" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_2a4c8037-8f37-4b32-96f4-4080ab66ec3f" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_bb70e757-d2af-47ea-8a81-2f0a41f3d840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_f6edafb9-8a4d-421c-99a3-be9b97c42782" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_ab96c8c0-2208-48e1-9644-7f6cc3df0bc6" xlink:to="loc_srt_MajorCustomersAxis_f6edafb9-8a4d-421c-99a3-be9b97c42782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_77fc6a7c-8e9e-410d-92c7-4771170e5475" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_f6edafb9-8a4d-421c-99a3-be9b97c42782" xlink:to="loc_srt_NameOfMajorCustomerDomain_77fc6a7c-8e9e-410d-92c7-4771170e5475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmerisourceBergenCorporationMember_e022232b-73b9-4eaa-add7-4c399ca39d63" xlink:href="bhc-20220331.xsd#bhc_AmerisourceBergenCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_77fc6a7c-8e9e-410d-92c7-4771170e5475" xlink:to="loc_bhc_AmerisourceBergenCorporationMember_e022232b-73b9-4eaa-add7-4c399ca39d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_McKessonCorporationMember_aa244ad2-9324-4265-b5b6-6c13b9588872" xlink:href="bhc-20220331.xsd#bhc_McKessonCorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_77fc6a7c-8e9e-410d-92c7-4771170e5475" xlink:to="loc_bhc_McKessonCorporationMember_aa244ad2-9324-4265-b5b6-6c13b9588872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CardinalHealthIncMember_d12c9114-fb55-4ebb-a214-c025448367c7" xlink:href="bhc-20220331.xsd#bhc_CardinalHealthIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_77fc6a7c-8e9e-410d-92c7-4771170e5475" xlink:to="loc_bhc_CardinalHealthIncMember_d12c9114-fb55-4ebb-a214-c025448367c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_b2879924-d98a-49a9-b694-49051936743d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_ab96c8c0-2208-48e1-9644-7f6cc3df0bc6" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_b2879924-d98a-49a9-b694-49051936743d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_922fdd25-acda-4552-8179-b17c0949f26e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_b2879924-d98a-49a9-b694-49051936743d" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_922fdd25-acda-4552-8179-b17c0949f26e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="bhc-20220331.xsd#SUBSEQUENTEVENTS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SUBSEQUENTEVENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_b709c77f-b790-441b-a321-32f2650225ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_65b5b4c3-38df-490b-8787-b6cfd8cc007b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_b709c77f-b790-441b-a321-32f2650225ad" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_65b5b4c3-38df-490b-8787-b6cfd8cc007b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220331.xsd#SUBSEQUENTEVENTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_acecd397-b95f-4754-8c3c-4ffaaab023a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_784af6f8-d8a6-4c8c-b07f-6c846718bc32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_acecd397-b95f-4754-8c3c-4ffaaab023a6" xlink:to="loc_us-gaap_SubsequentEventTable_784af6f8-d8a6-4c8c-b07f-6c846718bc32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b2cbb03d-cee7-4e30-8fc9-59a12a7b8d96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_784af6f8-d8a6-4c8c-b07f-6c846718bc32" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b2cbb03d-cee7-4e30-8fc9-59a12a7b8d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_37931007-55d3-4b8e-9dfc-828a58a77e10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b2cbb03d-cee7-4e30-8fc9-59a12a7b8d96" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_37931007-55d3-4b8e-9dfc-828a58a77e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_581f4b18-4843-46a9-86bc-82081ba888b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_37931007-55d3-4b8e-9dfc-828a58a77e10" xlink:to="loc_us-gaap_SubsequentEventMember_581f4b18-4843-46a9-86bc-82081ba888b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_920282b7-2240-440d-802f-4b94fd887cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_784af6f8-d8a6-4c8c-b07f-6c846718bc32" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_920282b7-2240-440d-802f-4b94fd887cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b014ddc9-4b82-46eb-ab04-ca75ac88bf0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_920282b7-2240-440d-802f-4b94fd887cc9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b014ddc9-4b82-46eb-ab04-ca75ac88bf0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_13b1b809-a7d1-4531-81c3-b7a60ef03a39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b014ddc9-4b82-46eb-ab04-ca75ac88bf0c" xlink:to="loc_us-gaap_IPOMember_13b1b809-a7d1-4531-81c3-b7a60ef03a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_aae312bb-52a9-44e7-a83e-e59c4a4203dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b014ddc9-4b82-46eb-ab04-ca75ac88bf0c" xlink:to="loc_us-gaap_OverAllotmentOptionMember_aae312bb-52a9-44e7-a83e-e59c4a4203dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_f98823a9-5728-42a0-83f6-6a9bab3d08c4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_784af6f8-d8a6-4c8c-b07f-6c846718bc32" xlink:to="loc_srt_OwnershipAxis_f98823a9-5728-42a0-83f6-6a9bab3d08c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_78a30c62-9f46-4e64-a150-b19e60a15e01" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_f98823a9-5728-42a0-83f6-6a9bab3d08c4" xlink:to="loc_srt_OwnershipDomain_78a30c62-9f46-4e64-a150-b19e60a15e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_52f97f4b-5c30-4429-b18a-a15b0532f3ae" xlink:href="bhc-20220331.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_78a30c62-9f46-4e64-a150-b19e60a15e01" xlink:to="loc_bhc_BauschLombMember_52f97f4b-5c30-4429-b18a-a15b0532f3ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5dd2b2ca-c82a-43e8-a02e-139423264a78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_784af6f8-d8a6-4c8c-b07f-6c846718bc32" xlink:to="loc_us-gaap_DebtInstrumentAxis_5dd2b2ca-c82a-43e8-a02e-139423264a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_06783882-a53b-487b-9626-3eb015012651" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_5dd2b2ca-c82a-43e8-a02e-139423264a78" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_06783882-a53b-487b-9626-3eb015012651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanDueMay2027Member_b39fc61b-9efb-4c51-acd4-87de9651d800" xlink:href="bhc-20220331.xsd#bhc_TermLoanDueMay2027Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06783882-a53b-487b-9626-3eb015012651" xlink:to="loc_bhc_TermLoanDueMay2027Member_b39fc61b-9efb-4c51-acd4-87de9651d800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueMay2027Member_5bb50652-78d6-40cb-a358-e5f53064ca10" xlink:href="bhc-20220331.xsd#bhc_RevolvingCreditFacilityDueMay2027Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06783882-a53b-487b-9626-3eb015012651" xlink:to="loc_bhc_RevolvingCreditFacilityDueMay2027Member_5bb50652-78d6-40cb-a358-e5f53064ca10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A2027TermLoanBFacilityMember_2af8af55-96e3-4e8c-bba3-0c13828d8f3e" xlink:href="bhc-20220331.xsd#bhc_A2027TermLoanBFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06783882-a53b-487b-9626-3eb015012651" xlink:to="loc_bhc_A2027TermLoanBFacilityMember_2af8af55-96e3-4e8c-bba3-0c13828d8f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A2027RevolvingCreditFacilityMember_e6fc7817-ca59-42ce-b50b-f6c7d39673ab" xlink:href="bhc-20220331.xsd#bhc_A2027RevolvingCreditFacilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06783882-a53b-487b-9626-3eb015012651" xlink:to="loc_bhc_A2027RevolvingCreditFacilityMember_e6fc7817-ca59-42ce-b50b-f6c7d39673ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredCreditFacilitiesMember_4259245e-8808-4e11-b381-b650af37ef41" xlink:href="bhc-20220331.xsd#bhc_SeniorSecuredCreditFacilitiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06783882-a53b-487b-9626-3eb015012651" xlink:to="loc_bhc_SeniorSecuredCreditFacilitiesMember_4259245e-8808-4e11-b381-b650af37ef41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NewRestatedCreditAgreementMember_74d80a46-ecd2-4e19-9a26-b3e7e0e007e0" xlink:href="bhc-20220331.xsd#bhc_NewRestatedCreditAgreementMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06783882-a53b-487b-9626-3eb015012651" xlink:to="loc_bhc_NewRestatedCreditAgreementMember_74d80a46-ecd2-4e19-9a26-b3e7e0e007e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A9.00SeniorNotesdueDecember2025Member_a18e92fd-06bb-4a3a-8e86-36b47fab2af5" xlink:href="bhc-20220331.xsd#bhc_A9.00SeniorNotesdueDecember2025Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06783882-a53b-487b-9626-3eb015012651" xlink:to="loc_bhc_A9.00SeniorNotesdueDecember2025Member_a18e92fd-06bb-4a3a-8e86-36b47fab2af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member_e8ac776a-2f5a-42ae-938f-5f0c834d85b6" xlink:href="bhc-20220331.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06783882-a53b-487b-9626-3eb015012651" xlink:to="loc_bhc_SeniorNotes6125DueApril2025Member_e8ac776a-2f5a-42ae-938f-5f0c834d85b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_85374657-ec02-4971-8863-f4fe99e08891" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_784af6f8-d8a6-4c8c-b07f-6c846718bc32" xlink:to="loc_us-gaap_CreditFacilityAxis_85374657-ec02-4971-8863-f4fe99e08891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_1b546b38-8c3d-497c-b8a5-ed28011743b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_85374657-ec02-4971-8863-f4fe99e08891" xlink:to="loc_us-gaap_CreditFacilityDomain_1b546b38-8c3d-497c-b8a5-ed28011743b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_36ba573e-9317-47de-aa2c-c3cbc7d38870" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_1b546b38-8c3d-497c-b8a5-ed28011743b6" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_36ba573e-9317-47de-aa2c-c3cbc7d38870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_c587a1e6-af38-434f-a9b3-96512e98c1ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_784af6f8-d8a6-4c8c-b07f-6c846718bc32" xlink:to="loc_us-gaap_VariableRateAxis_c587a1e6-af38-434f-a9b3-96512e98c1ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_113b144e-993d-4648-9265-1d2a807dfa43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_c587a1e6-af38-434f-a9b3-96512e98c1ad" xlink:to="loc_us-gaap_VariableRateDomain_113b144e-993d-4648-9265-1d2a807dfa43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SOFRCDOREURIBORAndSONIARatesMember_114cdf85-092d-4211-ad64-db48dff72a70" xlink:href="bhc-20220331.xsd#bhc_SOFRCDOREURIBORAndSONIARatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_113b144e-993d-4648-9265-1d2a807dfa43" xlink:to="loc_bhc_SOFRCDOREURIBORAndSONIARatesMember_114cdf85-092d-4211-ad64-db48dff72a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember_6b23431c-cb92-454b-b0a4-e09c8673a080" xlink:href="bhc-20220331.xsd#bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_113b144e-993d-4648-9265-1d2a807dfa43" xlink:to="loc_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember_6b23431c-cb92-454b-b0a4-e09c8673a080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_6f663ef3-98ac-415b-8537-8b624b6e840e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_113b144e-993d-4648-9265-1d2a807dfa43" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_6f663ef3-98ac-415b-8537-8b624b6e840e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_e4b917ac-517b-434a-91ca-e09bc7df063d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_113b144e-993d-4648-9265-1d2a807dfa43" xlink:to="loc_us-gaap_BaseRateMember_e4b917ac-517b-434a-91ca-e09bc7df063d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SOFRCDORAndEURIBORRatesMember_98c32a7a-21c8-4f01-9afd-8a31311607b9" xlink:href="bhc-20220331.xsd#bhc_SOFRCDORAndEURIBORRatesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_113b144e-993d-4648-9265-1d2a807dfa43" xlink:to="loc_bhc_SOFRCDORAndEURIBORRatesMember_98c32a7a-21c8-4f01-9afd-8a31311607b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b1c9b8cf-865a-4ea7-8f36-619239f1873d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_784af6f8-d8a6-4c8c-b07f-6c846718bc32" xlink:to="loc_srt_RangeAxis_b1c9b8cf-865a-4ea7-8f36-619239f1873d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1d201478-0f3e-40d5-be95-4ad0bf96f50a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b1c9b8cf-865a-4ea7-8f36-619239f1873d" xlink:to="loc_srt_RangeMember_1d201478-0f3e-40d5-be95-4ad0bf96f50a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ab9c0381-59aa-41f2-a7ad-8f451c61563b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1d201478-0f3e-40d5-be95-4ad0bf96f50a" xlink:to="loc_srt_MinimumMember_ab9c0381-59aa-41f2-a7ad-8f451c61563b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d9307493-cdef-46b8-a447-031b538650e6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1d201478-0f3e-40d5-be95-4ad0bf96f50a" xlink:to="loc_srt_MaximumMember_d9307493-cdef-46b8-a447-031b538650e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3644f496-1479-4e2c-937e-7da342e9e671" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_784af6f8-d8a6-4c8c-b07f-6c846718bc32" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3644f496-1479-4e2c-937e-7da342e9e671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_33c6177a-4be6-48ff-945b-168fae10cd07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3644f496-1479-4e2c-937e-7da342e9e671" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_33c6177a-4be6-48ff-945b-168fae10cd07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_434a0b42-a953-46d3-acc4-41cde34b2521" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_33c6177a-4be6-48ff-945b-168fae10cd07" xlink:to="loc_us-gaap_SecuredDebtMember_434a0b42-a953-46d3-acc4-41cde34b2521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_18a3cdde-9a61-4119-8317-a3cf4e319624" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_33c6177a-4be6-48ff-945b-168fae10cd07" xlink:to="loc_us-gaap_UnsecuredDebtMember_18a3cdde-9a61-4119-8317-a3cf4e319624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_784af6f8-d8a6-4c8c-b07f-6c846718bc32" xlink:to="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1ca3f34a-5c40-4bdf-bd36-43933fc3062b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1ca3f34a-5c40-4bdf-bd36-43933fc3062b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_aae43ae6-999b-40d3-a8ee-d8ccd884bcda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_aae43ae6-999b-40d3-a8ee-d8ccd884bcda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_7fe775ed-be18-4f34-8da4-5cd801d7423a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_7fe775ed-be18-4f34-8da4-5cd801d7423a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SaleOfStockOverAllotmentTerm_cf58ed8b-256b-457e-ab8f-27629a239d50" xlink:href="bhc-20220331.xsd#bhc_SaleOfStockOverAllotmentTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_bhc_SaleOfStockOverAllotmentTerm_cf58ed8b-256b-457e-ab8f-27629a239d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0ad84a24-525f-4c8f-b2f0-dd0e2a2e98c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0ad84a24-525f-4c8f-b2f0-dd0e2a2e98c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_58745114-2e6f-43b6-b40c-96bcf996d2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_58745114-2e6f-43b6-b40c-96bcf996d2a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_644351ec-e4e6-4fd9-a91c-597bb8d04e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_644351ec-e4e6-4fd9-a91c-597bb8d04e4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_ec36e496-4076-4b21-99c1-3b7ca0754d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_us-gaap_DebtInstrumentTerm_ec36e496-4076-4b21-99c1-3b7ca0754d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7f446d81-959e-47da-bd4a-409b082cd1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7f446d81-959e-47da-bd4a-409b082cd1f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a0b4f3cc-a8f7-48a0-9860-1ae590208275" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a0b4f3cc-a8f7-48a0-9860-1ae590208275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate_3a76d91c-82e9-4f47-8e7b-fe33180ac0ad" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate_3a76d91c-82e9-4f47-8e7b-fe33180ac0ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_6a0d0ce8-30ce-49ed-87a0-f0c21e384eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_6a0d0ce8-30ce-49ed-87a0-f0c21e384eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_8ff7ff8a-7220-4612-9b15-b0db3d5f28b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_8ff7ff8a-7220-4612-9b15-b0db3d5f28b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_82b9056e-57cb-48db-8e80-5c5cda4d3bd7" xlink:href="bhc-20220331.xsd#bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_82b9056e-57cb-48db-8e80-5c5cda4d3bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_80d9e107-673c-4a25-9cfd-a20084d172e5" xlink:href="bhc-20220331.xsd#bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_80d9e107-673c-4a25-9cfd-a20084d172e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_110349c3-79e9-4fad-905f-f7fc5d0f5d95" xlink:href="bhc-20220331.xsd#bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_110349c3-79e9-4fad-905f-f7fc5d0f5d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_21d61000-d362-48e7-9a05-343225646dc3" xlink:href="bhc-20220331.xsd#bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_21d61000-d362-48e7-9a05-343225646dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage_19009f38-175b-4edb-9cdc-161c782b96e2" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentAnnualAmortizationRatePercentage"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage_19009f38-175b-4edb-9cdc-161c782b96e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_ab8cbbb8-58b7-44dd-b844-be448af239b1" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_ab8cbbb8-58b7-44dd-b844-be448af239b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_3f62a578-5664-4b8b-bb18-df0adee1c4ad" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_3f62a578-5664-4b8b-bb18-df0adee1c4ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_c2255894-125b-4420-b04d-8fe964b41dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_us-gaap_LongTermDebt_c2255894-125b-4420-b04d-8fe964b41dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_69846a0d-c50c-4cc2-9f2a-76b5781bd4c9" xlink:href="bhc-20220331.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_69846a0d-c50c-4cc2-9f2a-76b5781bd4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate_a4d911f2-c410-4b0c-9f4b-9e81985a9d24" xlink:href="bhc-20220331.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate_a4d911f2-c410-4b0c-9f4b-9e81985a9d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_588bf587-a914-4a50-8a74-8452c21dd15b" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_588bf587-a914-4a50-8a74-8452c21dd15b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_caa1bf98-9c9b-4d60-bdfe-9b10525fb40a" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_caa1bf98-9c9b-4d60-bdfe-9b10525fb40a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_a61854d1-0836-459a-9106-b68cc270256a" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_a61854d1-0836-459a-9106-b68cc270256a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatio_d9e24e19-c2a5-4675-853e-caaf6390570c" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatio"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_bhc_DebtInstrumentCovenantTotalLeverageRatio_d9e24e19-c2a5-4675-853e-caaf6390570c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_62b97a6c-f6d2-4e6f-9f27-0786fb0cd1dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_62b97a6c-f6d2-4e6f-9f27-0786fb0cd1dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_68e39599-4762-43ef-88b9-89ba274ca0f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_68e39599-4762-43ef-88b9-89ba274ca0f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet_3c59bf34-967e-48c5-8316-8dbd47dad667" xlink:href="bhc-20220331.xsd#bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet_3c59bf34-967e-48c5-8316-8dbd47dad667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_ff7a55b7-b566-4fef-8e16-6e5ee73ec08e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9c47c740-c032-4b30-89f5-d039ef1f5f17" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_ff7a55b7-b566-4fef-8e16-6e5ee73ec08e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425354064920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>May 05, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-14956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Bausch Health Companies Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">A1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0448205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2150 St. Elz&#233;ar Blvd. West<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Laval<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">QC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">H7L 4A8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">744-6792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Shares, No Par Value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BHC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Smaller Reporting Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">361,479,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000885590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425354530808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,249<span></span>
</td>
<td class="nump">$ 582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_RestrictedCashAndOtherSettlementDepositsCurrent', window );">Restricted cash and other settlement deposits</a></td>
<td class="nump">1,211<span></span>
</td>
<td class="nump">1,537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">1,566<span></span>
</td>
<td class="nump">1,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">1,045<span></span>
</td>
<td class="nump">993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">765<span></span>
</td>
<td class="nump">720<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">5,836<span></span>
</td>
<td class="nump">5,607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">1,579<span></span>
</td>
<td class="nump">1,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">6,632<span></span>
</td>
<td class="nump">6,948<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">12,427<span></span>
</td>
<td class="nump">12,457<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">2,282<span></span>
</td>
<td class="nump">2,252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">334<span></span>
</td>
<td class="nump">340<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">29,090<span></span>
</td>
<td class="nump">29,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">471<span></span>
</td>
<td class="nump">407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">4,303<span></span>
</td>
<td class="nump">4,791<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,774<span></span>
</td>
<td class="nump">5,198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">193<span></span>
</td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-current portion of long-term debt</a></td>
<td class="nump">23,168<span></span>
</td>
<td class="nump">22,654<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities, net</a></td>
<td class="nump">552<span></span>
</td>
<td class="nump">529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">544<span></span>
</td>
<td class="nump">653<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">29,231<span></span>
</td>
<td class="nump">29,236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 18)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common shares, no par value, unlimited shares authorized, 361,331,665 and 359,405,748 issued and outstanding at March 31, 2022 and December&#160;31, 2021, respectively</a></td>
<td class="nump">10,373<span></span>
</td>
<td class="nump">10,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">415<span></span>
</td>
<td class="nump">462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(9,030)<span></span>
</td>
<td class="num">(8,961)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,974)<span></span>
</td>
<td class="num">(1,924)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Bausch Health Companies Inc. shareholders&#8217; deficit</a></td>
<td class="num">(216)<span></span>
</td>
<td class="num">(106)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total deficit</a></td>
<td class="num">(141)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and deficit</a></td>
<td class="nump">$ 29,090<span></span>
</td>
<td class="nump">$ 29,202<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Noncurrent Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_BusinessCombinationContingentConsiderationNoncurrentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RestrictedCashAndOtherSettlementDepositsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted Cash And Other Settlement Deposits, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RestrictedCashAndOtherSettlementDepositsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425357425240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, issued (in shares)</a></td>
<td class="nump">361,331,665<span></span>
</td>
<td class="nump">359,405,748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, outstanding (in shares)</a></td>
<td class="nump">361,331,665<span></span>
</td>
<td class="nump">359,405,748<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425354405512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 1,918<span></span>
</td>
<td class="nump">$ 2,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">622<span></span>
</td>
<td class="nump">606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold', window );">Amortization of intangible assets</a></td>
<td class="nump">310<span></span>
</td>
<td class="nump">357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges', window );">Goodwill impairments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairments, including loss on assets held for sale</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_RestructuringChargesAndInitialPublicOfferingCosts', window );">Restructuring, integration, separation and IPO costs</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other expense (income), net</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total expenses</a></td>
<td class="nump">1,633<span></span>
</td>
<td class="nump">2,248<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="nump">285<span></span>
</td>
<td class="num">(221)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="num">(362)<span></span>
</td>
<td class="num">(368)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange and other</a></td>
<td class="num">(7)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">(82)<span></span>
</td>
<td class="num">(591)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit from (provision for) income taxes</a></td>
<td class="nump">16<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(66)<span></span>
</td>
<td class="num">(607)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interest</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Bausch Health Companies Inc.</a></td>
<td class="num">$ (69)<span></span>
</td>
<td class="num">$ (610)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per share attributable to Bausch Health Companies Inc. (in usd per share)</a></td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (1.71)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per share attributable to Bausch Health Companies Inc. (in usd per share)</a></td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (1.71)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted-average common shares (in shares)</a></td>
<td class="nump">360.8<span></span>
</td>
<td class="nump">356.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted-average common shares (in shares)</a></td>
<td class="nump">360.8<span></span>
</td>
<td class="nump">356.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 1,898<span></span>
</td>
<td class="nump">$ 2,003<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues</a></td>
<td class="nump">543<span></span>
</td>
<td class="nump">564<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible asset amortization expense excluding amortization allocated to alliance and royalty revenue and cost of goods sold during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill, Impairment Loss, Not Included In Asset Impairment Charges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RestructuringChargesAndInitialPublicOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring Charges And Initial Public Offering Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RestructuringChargesAndInitialPublicOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425354520232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (66)<span></span>
</td>
<td class="num">$ (607)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive (loss) income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(56)<span></span>
</td>
<td class="num">(124)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent', window );">Pension and postretirement benefit plan adjustments, net of income taxes</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(50)<span></span>
</td>
<td class="num">(123)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">(116)<span></span>
</td>
<td class="num">(730)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income attributable to noncontrolling interest</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Bausch Health Companies Inc.</a></td>
<td class="num">$ (119)<span></span>
</td>
<td class="num">$ (733)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425355170424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF SHAREHOLDERS' DEFICIT - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Bausch Health Companies&#160;Inc. Shareholders&#8217; (Deficit) Equity</div></th>
<th class="th"><div>Common Shares</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Non- controlling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">355,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 605<span></span>
</td>
<td class="nump">$ 535<span></span>
</td>
<td class="nump">$ 10,227<span></span>
</td>
<td class="nump">$ 454<span></span>
</td>
<td class="num">$ (8,013)<span></span>
</td>
<td class="num">$ (2,133)<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common shares issued under share-based compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common shares issued under share-based compensation plans</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Employee withholding taxes related to share-based awards</a></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="num">(607)<span></span>
</td>
<td class="num">(610)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(610)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(123)<span></span>
</td>
<td class="num">(123)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(123)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">358,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Mar. 31, 2021</a></td>
<td class="num">$ (124)<span></span>
</td>
<td class="num">(197)<span></span>
</td>
<td class="nump">$ 10,289<span></span>
</td>
<td class="nump">393<span></span>
</td>
<td class="num">(8,623)<span></span>
</td>
<td class="num">(2,256)<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning Balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">359,405,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 31, 2021</a></td>
<td class="num">$ (34)<span></span>
</td>
<td class="num">(106)<span></span>
</td>
<td class="nump">$ 10,317<span></span>
</td>
<td class="nump">462<span></span>
</td>
<td class="num">(8,961)<span></span>
</td>
<td class="num">(1,924)<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common shares issued under share-based compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common shares issued under share-based compensation plans</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Employee withholding taxes related to share-based awards</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="num">(66)<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">$ (50)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balance (in shares) at Mar. 31, 2022</a></td>
<td class="nump">361,331,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">361,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Mar. 31, 2022</a></td>
<td class="num">$ (141)<span></span>
</td>
<td class="num">$ (216)<span></span>
</td>
<td class="nump">$ 10,373<span></span>
</td>
<td class="nump">$ 415<span></span>
</td>
<td class="num">$ (9,030)<span></span>
</td>
<td class="num">$ (1,974)<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425355070088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (66)<span></span>
</td>
<td class="num">$ (607)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization of intangible assets</a></td>
<td class="nump">352<span></span>
</td>
<td class="nump">403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization and write-off of debt premiums, discounts and issuance costs</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairments, including loss on assets held for sale</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges', window );">Goodwill impairments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">3<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AllowancesForLossesOnAccountsReceivableAndInventories', window );">Allowances for losses on trade receivable and inventories</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DeferredIncomeTaxNoncashExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(83)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Net gain on sale of assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_GainLossRelatedToLitigationSettlementGross', window );">Reductions to accrued legal settlements</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments of accrued legal settlements</a></td>
<td class="num">(360)<span></span>
</td>
<td class="num">(118)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Foreign exchange loss</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DerivativeGainExcludedComponent', window );">Gain excluded from hedge effectiveness</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">10<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade receivables</a></td>
<td class="nump">197<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(73)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(33)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued and other liabilities</a></td>
<td class="num">(75)<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
<td class="num">(63)<span></span>
</td>
<td class="nump">443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(46)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Payments for intangible and other assets</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sale of marketable securities</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested', window );">Proceeds from sale of assets and businesses, net of costs to sell</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_InterestSettlementOnCrossCurrencySwaps', window );">Interest settlements from cross-currency swaps</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(56)<span></span>
</td>
<td class="num">(56)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Issuance of long-term debt, net of discounts</a></td>
<td class="nump">986<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="num">(485)<span></span>
</td>
<td class="num">(200)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments of employee withholding taxes related to share-based awards</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payments of acquisition-related contingent consideration</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of financing costs</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">468<span></span>
</td>
<td class="num">(243)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">341<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">2,119<span></span>
</td>
<td class="nump">1,816<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">2,460<span></span>
</td>
<td class="nump">1,947<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">1,249<span></span>
</td>
<td class="nump">679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_RestrictedCashAndOtherSettlementDepositsCurrent', window );">Restricted cash and other settlement deposits</a></td>
<td class="nump">1,211<span></span>
</td>
<td class="nump">1,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents', window );">Cash and cash equivalents, held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">$ 2,460<span></span>
</td>
<td class="nump">$ 1,947<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AllowancesForLossesOnAccountsReceivableAndInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the current period expense charged against operations (1) for the purpose of reducing receivables to an amount that approximates their net realizable value and (2) the charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AllowancesForLossesOnAccountsReceivableAndInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the cash-flow impact of any change, including any differences arising upon settlement, recognized during the reporting period in the value of an asset or assets, arising from an item of contingent consideration, recognized in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DeferredIncomeTaxNoncashExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncash component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DeferredIncomeTaxNoncashExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DerivativeGainExcludedComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative, Gain, Excluded Component</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DerivativeGainExcludedComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_GainLossRelatedToLitigationSettlementGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) Related to Litigation Settlement, Gross payments not offset by insurance proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_GainLossRelatedToLitigationSettlementGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill, Impairment Loss, Not Included In Asset Impairment Charges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_InterestSettlementOnCrossCurrencySwaps">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest Settlement On Cross-Currency Swaps</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_InterestSettlementOnCrossCurrencySwaps</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RestrictedCashAndOtherSettlementDepositsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted Cash And Other Settlement Deposits, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RestrictedCashAndOtherSettlementDepositsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the cash inflow during the period from the sale of a component of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425356785880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">DESCRIPTION OF BUSINESS</a></td>
<td class="text">DESCRIPTION OF BUSINESS Bausch Health Companies Inc. (the&#160;&#8220;Company&#8221; or &#8220;Bausch Health&#8221;) is a multinational, specialty pharmaceutical and medical device company that develops, manufactures and markets, primarily in the therapeutic areas of eye health, gastroenterology (&#8220;GI&#8221;) and dermatology, a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (&#8220;OTC&#8221;) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices) which are marketed directly or indirectly in approximately 100 countries.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425356785880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SIGNIFICANT ACCOUNTING POLICIES <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation and Use of Estimates </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Consolidated Financial Statements have been prepared by the Company in U.S. dollars and in accordance with&#160;U.S. generally accepted accounting principles (&#8220;U.S.&#160;GAAP&#8221;) for interim financial reporting, which do not conform in all respects to the requirements of U.S.&#160;GAAP for annual financial statements. Accordingly, these notes to the unaudited Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements prepared in accordance with U.S.&#160;GAAP that are contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the U.S. Securities and Exchange Commission (the&#160;&#8220;SEC&#8221;) and the Canadian Securities Administrators (the&#160;&#8220;CSA&#8221;) on February&#160;23, 2022. The unaudited Consolidated Financial Statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company&#8217;s audited Consolidated Financial Statements for the year ended December&#160;31, 2021, except for the new accounting guidance adopted during the period. The unaudited Consolidated Financial Statements reflect all normal and recurring adjustments necessary for a fair statement of the Company&#8217;s financial position and results of operations for the interim periods. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full&#160;year.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Separation of the Bausch + Lomb Eye Health Business and Initial Public Offering of Solta Medical Business</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2020, the Company announced its intentions to separate its eye health business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc. (the &#8220;B+L Separation&#8221;). On August 3, 2021, the Company announced its intentions to conduct an initial public offering (&#8220;IPO&#8221;) of its aesthetic medical device business, Global Solta (the &#8220;Solta IPO&#8221;). In January 2022, the Company completed the internal organizational design and structure of the new eye health entity, Bausch + Lomb Corporation (&#8220;Bausch + Lomb&#8221;), and the new Global Solta entity, Solta Medical Corporation (&#8220;Solta&#8221;), as previously announced. The registration statement related to the B+L IPO of Bausch + Lomb (the &#8220;B+L IPO&#8221;) was declared effective on May 5, 2022, and Bausch + Lomb&#8217;s common stock began trading on the New York Stock Exchange and the Toronto Stock Exchange, in each case under the ticker symbol &#8220;BLCO&#8221; on May 6, 2022. Prior to the effectiveness of the registration statement, Bausch + Lomb was an indirect wholly-owned subsidiary of the Company. On May 10, 2022, a wholly owned subsidiary of the Company (the &#8220;Selling Shareholder&#8221;) sold 35,000,000 common shares of Bausch + Lomb, at an offering price of $18.00, per share, pursuant to the Bausch + Lomb prospectus. The net proceeds from the B+L IPO after deducting underwriting commissions and estimated offering expenses were approximately $560&#160;million. The Company expects to complete the separation of Bausch + Lomb after the expiry of customary lockups related to the B+L IPO and achievement of targeted debt leverage ratios, subject to the receipt of applicable shareholder and other necessary approvals. The launch of the Solta IPO remains subject to when financial market conditions become favorable (and subject to receipt of regulatory, stock exchange and other approvals and other factors). See Note 20, &#8220;SUBSEQUENT EVENTS&#8221; for additional details regarding the B+L IPO.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The B+L Separation and the proposed Solta IPO will establish three separate companies that include: (i) a fully integrated eye health company which will consist of the Company&#8217;s Bausch + Lomb Global Vision Care, Global Surgical, Global Consumer and Global Ophthalmic Pharmaceuticals businesses, (ii) a global provider of aesthetic medical devices which will consist of the Company&#8217;s Solta business and (iii) a diversified pharmaceutical company which will include the Company&#8217;s Salix, International (formerly International Rx), dentistry, neurology, medical dermatology and generics pharmaceutical businesses. These audited Consolidated Financial Statements do not include any adjustments to give effect to either the B+L Separation or the proposed Solta IPO.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impacts of COVID-19 Pandemic </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unprecedented nature of the COVID-19 pandemic has, and continues to, adversely impact the global economy. The COVID-19 pandemic and the reactions of governments, private sector participants and the public in an effort to contain the spread of the COVID-19 virus and/or address its impacts have had significant direct and indirect effects on businesses and </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commerce. This includes, but is not limited to, disruption to supply chains, employee base and transactional activity, facilities closures and production suspensions.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which these events may continue to impact the Company&#8217;s business, financial condition, cash flows and results of operations, in particular, will depend on future developments which are highly uncertain and many of which are outside the Company&#8217;s control. Such developments include the availability and effectiveness of vaccines for the COVID-19 virus, the ultimate geographic spread and duration of the pandemic, COVID-19 vaccine immunization rates, the extent and duration of a resurgence of the COVID-19 virus and variant strains thereof, such as the delta and omicron variants, new information concerning the severity of the COVID-19 virus, the effectiveness and intensity of measures to contain the COVID-19 virus and the economic impact of the pandemic and the reactions to it. Such developments, among others, depending on their nature, duration and intensity, could have a significant adverse effect on the Company&#8217;s business, financial condition, cash flows and results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has been able to continue its operations with limited disruptions in supply and manufacturing.   Although it is difficult to predict the broad macroeconomic effects that the COVID-19 pandemic will have on industries or individual companies, the Company has assessed the possible effects and outcomes of the pandemic on, among other things, its supply chain, customers and distributors, discounts and rebates, employee base, product sustainability, research and development efforts, product pipeline and consumer demand and currently believes that its estimates are reasonable. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing the unaudited Consolidated Financial Statements, management is required to make estimates and assumptions. This includes estimates and assumptions regarding the nature, timing and extent of the impacts that the COVID-19 pandemic will have on its operations and cash flows.  The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the unaudited Consolidated Financial Statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates and the differences could be material. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company&#8217;s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company&#8217;s results of operations and financial position could be materially impacted.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior year amounts to conform to the current year presentation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Reportable Segments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the first quarter of 2022, the Company operates in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International (formerly International Rx), (iv) Solta Medical and (v) Diversified Products. Prior to the first quarter of 2022, the Company operated in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International, (iv) Ortho Dermatologics and (v) Diversified Products. Prior period presentations have been recast to conform to the current segment reporting structure. See Note 19, &#8220;SEGMENT INFORMATION&#8221; for additional information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425358360056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUE RECOGNITION</a></td>
<td class="text">REVENUE RECOGNITION The Company&#8217;s revenues are primarily generated from product sales, principally in the therapeutic areas of eye health, GI and dermatology, that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 19, &#8220;SEGMENT INFORMATION&#8221; for the disaggregation of revenue which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts.<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales Provisions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.&#160; The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers. Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company&#8217;s products. These judgments include the potential impact of the COVID-19 pandemic on, among other things, unemployment and related changes in customer health insurance levels, customer behaviors during the COVID-19 pandemic and government stimulus bills that focus on ensuring availability and access to lifesaving drugs during a public health crisis. This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or require an adjustment related to past sales, or both. If the trend in actual amounts of variable consideration varies from the Company&#8217;s prior estimates, the Company adjusts these estimates when such trend is believed to be sustainable. At that time, the Company would record the necessary adjustments which would affect net product revenue and earnings reported in the current period. The Company applies this method consistently for contracts with similar characteristics.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the activity and ending balances of the Company&#8217;s variable consideration provisions for the three months ended March 31, 2022 and 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.616%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">944&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,863&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provisions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(162)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(599)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(359)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,227)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">926&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,892&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $37 million and $36&#160;million as of March 31, 2022 and January 1, 2022, respectively, which are reflected as a reduction of Trade receivables, net in the Consolidated Balance Sheets. There were no price appreciation credits during the three months ended March 31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.616%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provisions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(160)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(457)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(483)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,222)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">553&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">924&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,891&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $34 million and $32&#160;million as of March 31, 2021 and January 1, 2021, respectively. Included as a reduction of Distribution fees in the table above are price appreciation credits of approximately $1&#160;million during the three months ended March 31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Contract Liabilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no contract assets for any period presented. Contract liabilities consist of deferred revenue, the balance of which is not material to any period presented. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allowance for Credit Losses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An allowance is maintained for potential credit losses. The Company estimates the current expected credit loss on its receivables based on various factors, including historical credit loss experience, customer credit worthiness, value of collaterals (if any), and any relevant current and reasonably supportable future economic factors.&#160; Additionally, the Company generally estimates the expected credit loss on a pool basis when customers are deemed to have similar risk characteristics. Trade receivable balances are written off against the allowance when it is deemed probable that the trade receivable will not be&#160;collected. Trade receivables, net are stated net of certain sales provisions and the allowance for credit losses. The activity in the allowance for credit losses for trade receivables for the three months ended March 31, 2022 and 2021 is as follows.</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.447%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.830%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recoveries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425357156360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSING AGREEMENTS AND DIVESTITURE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock', window );">LICENSING AGREEMENTS AND DIVESTITURE</a></td>
<td class="text">LICENSING AGREEMENTS AND DIVESTITURE<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing Agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company may enter into select licensing and collaborative agreements for the commercialization and/or development of unique products. These products are sometimes investigational treatments in early stage development that target unique conditions. The ultimate outcome, including whether the product will be: (i) fully developed, (ii) approved by regulatory agencies, (iii) covered by third-party payors or (iv) profitable for distribution, is highly uncertain.  The commitment periods under these agreements vary and include customary termination provisions.  Expenses arising from commitments, if any, to fund the development and testing of these products and their promotion are recognized as incurred. Royalties due are recognized when earned and milestone payments are accrued when each milestone has been achieved and payment is probable and can be reasonably estimated.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divestiture of Amoun Pharmaceutical Company S.A.E. (&#8220;Amoun&#8221;)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2021, the Company announced that it and certain of its affiliates had entered into a definitive agreement to sell all of its equity interests in Amoun for total gross consideration of approximately $740&#160;million (including the assignment to the purchasing entity of an intercompany loan granted by the Company to Amoun), subject to certain adjustments (the &#8220;Amoun Sale&#8221;). The Amoun Sale closed on July 26, 2021. As part of the Amoun Sale, cash generated by Amoun during the period from the locked-box date of January 1, 2021 through closing was for the benefit of the purchasing entity, subject to working capital during such period. Amoun manufactures, markets and distributes branded generics of human and animal health products. The Amoun business was part of the International segment (previously included within the former Bausch + Lomb/International segment) and was reclassified as held for sale as of December 31, 2020. As a result of meeting the criteria for held for sale classification, the carrying value of the Amoun business, was adjusted to its estimated fair value, less costs to sell, and the Company recognized an impairment loss of $68&#160;million during the three months ended March 31, 2021, included within Asset impairments, including loss on assets held for sale in the Consolidated Statements of Operations. Revenues associated with Amoun were $60&#160;million for the three months ended March 31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisitions, Licensing Agreements, And Assets Held For Sale Disclosures [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425357213592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock', window );">RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS</a></td>
<td class="text">RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring and Integration Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates opportunities to improve its operating results and implements cost savings programs to streamline its operations and eliminate&#160;redundant processes and expenses. Restructuring and integration costs are expenses associated with the implementation of these cost savings programs and include expenses associated with: (i)&#160;reducing headcount, (ii)&#160;eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives. The liability associated with restructuring and integration costs as of March 31, 2022 was $15 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred $3 million and $3&#160;million of restructuring and integration costs and made payments of $7&#160;million and $5&#160;million during the three months ended March 31, 2022 and 2021, respectively.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Separation Costs, Separation-related Costs, IPO Costs and IPO-related Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred, and will incur, costs associated with activities to effectuate the B+L Separation and the Solta IPO. These activities include: (i) separating the Bausch + Lomb and Solta Medical businesses from the remainder of the Company and (ii) registering the Bausch + Lomb and Solta Medical businesses as independent publicly traded entities. Separation and IPO costs are incremental costs directly related to the B+L Separation and Solta IPO and include, but are not limited to: (i) legal, audit and advisory fees, (ii) talent acquisition costs and (iii) costs associated with establishing a new board of directors and related board committees for the Bausch + Lomb and Solta Medical entities. Included in Restructuring, integration, separation and IPO costs for the three months ended March 31, 2022 and 2021 are Separation and IPO costs of $10&#160;million and $9&#160;million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has also incurred, and will incur, Separation-related and IPO-related costs which are incremental costs indirectly related to the B+L Separation and Solta IPO. Separation-related and IPO-related costs include, but are not limited to: (i) IT infrastructure and software licensing costs, (ii) rebranding costs and (iii) costs associated with facility relocation and/or modification. Included in Selling, general and administrative for the three months ended March 31, 2022 and 2021 are Separation-related and IPO-related costs of $24&#160;million and $20&#160;million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent and timing of future charges for these costs cannot be reasonably estimated at this time and could be material.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring And Related Activities And Initial Public Offering Costs Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425358388632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are estimated based on valuation techniques and inputs categorized as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1&#160;&#8212;&#160;Quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2&#160;&#8212;&#160;Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities;&#160;and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3&#160;&#8212;&#160;Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using discounted cash flow methodologies, pricing models, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or&#160;estimation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the&#160;instrument.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table presents the components and classification of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.196%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and other settlement deposits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of highly liquid investments, primarily money market funds, with maturities of three months or less when&#160;purchased, and are reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to their short-term nature.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, Restricted cash and other settlement deposits includes $1,210&#160;million of payments into an escrow fund under the terms of a settlement agreement regarding certain U.S. securities litigation (which settlement agreement is subject to one objector&#8217;s appeal of the final court approval of the agreement), and is reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to its short-term nature. These payments will remain in escrow until resolution of the appeal of the final court approval of the settlement agreement, as discussed in Note 18, &#8220;LEGAL PROCEEDINGS&#8221;.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers into or out of Level 3 during the three months ended March 31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cross-currency Swaps</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company entered into cross-currency swaps, with aggregate notional amounts of $1,250 million, to mitigate fluctuation in the value of a portion of its euro-denominated net investment in its consolidated financial statements from fluctuation in exchange rates. The euro-denominated net investment being hedged was the Company&#8217;s investment in certain euro-denominated subsidiaries. The Company unwound these cross-currency swaps during November 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the unwinding of the cross-currency swaps during November 2021, there were no assets or liabilities associated with the cross-currency swaps included in the Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of hedging instruments on the Consolidated Statements of Comprehensive Loss and the Consolidated Statements of Operations for the three months ended March 31, 2022 and 2021:</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.792%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.585%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.105%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain recognized in Other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain excluded from assessment of hedge effectiveness</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location of gain of excluded component</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Expense</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No portion of the cross-currency swaps was ineffective for the three months ended March 31, 2021. During the three months ended March 31, 2022 and 2021, the Company received $0 and $11&#160;million, respectively, in interest settlements which are reported as investing activities in the Consolidated Statements of Cash Flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Contracts</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2020, the Company has been entering into foreign currency exchange contracts. As of March 31, 2022, these contracts had an aggregate outstanding notional amount of $158&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s foreign currency exchange contracts are remeasured at each reporting date to reflect changes in their fair values determined using forward rates, which are observable market inputs, multiplied by the notional amount. The Company&#8217;s foreign currency exchange contracts are economically hedging the foreign exchange exposure on certain of the Company&#8217;s intercompany balances. These contracts have not been designated as an accounting hedge, and therefore the net change in their fair value is reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other. Settlements of the Company&#8217;s foreign currency exchange contracts are reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other and reported as operating activities in the Consolidated Statements of Cash Flows. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities associated with the Company&#8217;s foreign exchange contracts as included in the Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021 are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.443%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of the Company&#8217;s foreign exchange contracts on the Consolidated Statements of Operations and the Consolidated Statements of Cash Flows for the three months ended March 31, 2022 and 2021:</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.443%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss related to changes in fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) related to settlements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition-related Contingent Consideration Obligations</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurement of contingent consideration obligations arising from business combinations is determined via a probability-weighted discounted cash flow analysis, using unobservable (Level&#160;3) inputs. These inputs may include: (i)&#160;the estimated amount and timing of projected cash flows, (ii)&#160;the probability of the achievement of the factor(s) on which the contingency is based and (iii)&#160;the risk-adjusted discount rate used to present value the probability-weighted cash&#160;flows. Significant increases or decreases in any of those inputs in isolation could result in a significantly higher or lower fair value measurement. At March&#160;31, 2022, the fair value measurements of acquisition-related contingent consideration were determined using risk-adjusted discount rates ranging from 6% to 18%, and a weighted average risk-adjusted discount rate of 7%. The weighted average risk-adjusted discount rate was calculated by weighting each contract&#8217;s relative fair value at March&#160;31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level&#160;3) for the three months ended March 31, 2022 and 2021: </span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:63.132%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.843%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.547%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to Acquisition-related contingent consideration:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion for the time value of money</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments due to changes in estimates of other future payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments/Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Long-term Debt</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of long-term debt as of March&#160;31, 2022 and December&#160;31, 2021 was $21,963 million and $22,689 million, respectively, and was estimated using the quoted market prices for the same or similar debt issuances (Level 2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425357262104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text">INVENTORIES<div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net consist of:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.740%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,045&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425357259512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS AND GOODWILL</a></td>
<td class="text">INTANGIBLE ASSETS AND GOODWILL <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of intangible assets consist of:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization<br/>and<br/>Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization<br/>and<br/>Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,452)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(489)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,174)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Technology and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(199)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,419&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,485)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,934&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,180)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bausch + Lomb Trademark</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,117&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,485)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,632&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,128&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,180)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,948&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Impairment charges associated with these assets are included in Asset impairments in the Consolidated Statement of Operations. The Company continues to monitor the recoverability of its finite-lived intangible assets and tests the intangible assets for impairment if indicators of impairment are present. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments, including loss on assets held for sale for the three months ended March 31, 2022 were $8&#160;million and include: (i) impairments of $4&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines, and (ii) impairments of $4&#160;million, in aggregate, related to the discontinuance of certain product lines.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments, including loss on assets held for sale for the three months ended March 31, 2021 were $148&#160;million and include: (i) $71&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines in the Ortho Dermatologics business, (ii) an adjustment of $68&#160;million due to the loss on assets held for sale in connection with the Amoun Sale and (iii) impairments of $9&#160;million, in aggregate, related to the discontinuance of certain product lines. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense of finite-lived intangible assets for the remainder of 2022 and each of the five succeeding years ending December&#160;31 and thereafter is as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.833%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remainder of 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,023&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">794&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">627&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,934&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amounts of goodwill during the three months ended March 31, 2022 and the year ended December&#160;31, 2021 were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.346%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.298%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.447%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.494%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Bausch + Lomb/ International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,044&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Realignment of segment goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,704)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(578)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,357&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,457&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Realignment of segment goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(798)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,292&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">811&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,050&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,427&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized but is tested for impairment at least annually on October 1st at the reporting unit level. A reporting unit is the same as, or one level below, an operating segment. The Company performs its annual impairment test by first assessing qualitative factors. Where the qualitative assessment suggests that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed for that reporting unit (Step 1).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of a reporting unit refers to the price that would be received to sell the unit as a whole in an orderly transaction between market participants. The Company estimates the fair value of a reporting unit using a discounted cash flow model which utilizes Level 3 unobservable inputs. The discounted cash flow model relies on assumptions regarding revenue growth rates, gross profit, projected working capital needs, selling, general and administrative expenses, research and development expenses, capital expenditures, income tax rates, discount rates and terminal growth rates. To estimate fair value, the Company discounts the forecasted cash flows of each reporting unit. The discount rate the Company uses represents the estimated weighted average cost of capital, which reflects the overall level of inherent risk involved in its reporting unit operations and the rate of return a market participant would expect to earn. The quantitative fair value test is performed utilizing long-term growth rates and discount rates applied to the estimated cash flows in estimation of fair value. To estimate cash flows beyond the final year of its model, the Company estimates a terminal value by applying an in-perpetuity growth assumption and discount factor to determine the reporting unit&#8217;s terminal value. </span></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To forecast a reporting unit&#8217;s cash flows the Company takes into consideration economic conditions and trends, estimated future operating results, management&#8217;s and a market participant&#8217;s view of growth rates and product lives, and anticipates future economic conditions. Revenue growth rates inherent in these forecasts are based on input from internal and external market research that compare factors such as growth in global economies, recent industry trends and product life-cycles. Macroeconomic factors such as changes in economies, changes in the competitive landscape including the unexpected loss of exclusivity to the Company&#8217;s product portfolio, changes in government legislation, product life-cycles, industry consolidations and other changes beyond the Company&#8217;s control could have a positive or negative impact on achieving its targets. Accordingly, if market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future and such change could be material. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">First Quarter 2021 - Realignment of Segments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the first quarter of 2021, the Company began operating in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International, (iv) Ortho Dermatologics and (v) Diversified Products. The Bausch + Lomb segment consisted of the: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units. The Salix segment consisted of the Salix reporting unit. The International segment consisted of the International (formerly International Rx) reporting unit. The Ortho Dermatologics segment consisted of the: (i) Ortho Dermatologics and (ii) Global Solta reporting units. The Diversified Products segment consisted of the: (i) Neurology and Other, (ii) Generics and (iii) Dentistry reporting units. This realignment in segment structure resulted in a change in the Company&#8217;s former International reporting unit, which was divided between the International Bausch + Lomb reporting unit and International reporting unit. In addition, as part of the realignment of segment structure, certain products historically included in the Generics reporting unit were included in the U.S. Bausch + Lomb reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of this realignment, goodwill was reassigned to each of the aforementioned reporting units using a relative fair value approach. Goodwill previously reported in the former International reporting unit was reassigned to the International Bausch + Lomb and International reporting units, and a portion of goodwill previously reported in the former Generics reporting unit was reassigned to the U.S. Bausch + Lomb reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the change in reporting units, the Company performed a qualitative fair value assessment for its former: (i) International and (ii) Generics reporting units. Based on the qualitative fair value assessment performed, Management believed that it was more likely than not that the carrying values of its former: (i) International and (ii) Generics reporting units were less than their respective fair values and therefore, concluded a quantitative assessment was not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately following the change in reporting units, as a result of the change in composition of the net assets for its: (i) International Bausch + Lomb, (ii) International and (iii) Generics reporting units, the Company performed a quantitative fair value test. The quantitative fair value test utilized a range of long-term growth rates of 1.0% to 3.0% and a range of discount rates between 11.0% and 12.25%, in estimation of the fair value of the reporting units. After completing the testing, the fair value of each of these reporting units exceeded its carrying value by more than 40%, and, therefore, there was no impairment to goodwill. In addition, as the U.S. Bausch + Lomb reporting unit had a change in composition of its net assets related to certain products historically included in the Generics reporting unit now being included in the U.S. Bausch + Lomb reporting unit, the Company performed a qualitative assessment of this reporting unit. Based on the qualitative fair value assessment performed, Management believed that it was more likely than not that the carrying value of its current U.S. Bausch + Lomb reporting unit was less than its fair value and therefore, concluded a quantitative assessment was not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Interim Goodwill Impairment Testing</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the interim periods of 2021, with the exception of the Ortho Dermatologics reporting unit, no events occurred, or circumstances changed that would indicate that the fair value of any other reporting unit might be below its carrying value and therefore, no impairments were recorded.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, management identified launches of certain Ortho Dermatologics products which were not going to achieve their trajectories as forecasted once the social restrictions associated with the COVID-19 pandemic began to ease in the U.S. and offices of health care professionals could reopen. In addition, insurance coverage pressures within the U.S. continued to persist limiting patient access to topical acne and psoriasis products. In light of these developments, during the first quarter of 2021, the Company began taking steps to: (i) redirect its R&amp;D spend to eliminate projects it had identified as high cost and high risk, (ii) redirect a portion of its marketing and product development outside the U.S. to geographies where there is better patient access and (iii) reduce its cost structure to be more competitive. As a result, during the three months ended March 31, 2021, the Company revised its long-term forecasts for the Ortho Dermatologics reporting unit. Management believed that these events were indicators that there was less headroom as of March 31, 2021 as compared to the headroom calculated on the date goodwill was last tested for impairment (October 1, 2020). Therefore, a quantitative fair value test for the Ortho Dermatologics reporting unit was performed. The quantitative fair value test utilized the Company&#8217;s most recent cash flow projections as revised in the first quarter of 2021 to reflect the business changes previously discussed, including a range of potential outcomes, along with a long-term growth rate of 1.0% and a range of discount rates between 9.0% and 10.0%. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at March 31, 2021, and the Company recognized a goodwill impairment of $469&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Second Quarter 2021 - Realignment of Bausch + Lomb Reporting Units</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the second quarter of 2021, the Company changed the way it reviews the financial information of its Bausch + Lomb segment. Beginning in the second quarter of 2021, management no longer reviews the financial information of its Bausch + Lomb segment on a geographic basis, but instead reviews this financial information on a business line basis. This change created a change in the reporting units of the Bausch + Lomb segment. After the change, under its business line view, the Bausch + Lomb segment consisted of the global: (i) Vision Care / Consumer Products, (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units. Prior to the second quarter of 2021, under the geographic view, the Bausch + Lomb segment consisted of the former: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units. As a result of the realignment, goodwill was reassigned to each of the aforementioned reporting units using a relative fair value approach. The change in Bausch + Lomb reporting units did not impact the reported revenues and segment profits of the Bausch + Lomb segment for any prior periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the change in its Bausch + Lomb reporting units, the Company performed a qualitative fair value assessment for its former reporting units. Based on the qualitative fair value assessment, management believed that it was more likely than not that the carrying values of its former: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units were less than their respective fair values and, therefore, concluded a quantitative assessment was not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the change in composition of net assets, the Company performed a quantitative fair value test of its new: (i) Vision Care / Consumer Products, (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units immediately following the change in the Bausch + Lomb segment. The quantitative fair value test utilized long-term growth rates of 2.0% and 3.0% and a range of discount rates between 7.0% and 10.0%, in estimation of the fair value of the reporting units. After completing </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the testing, the fair value of each of these reporting units exceeded its carrying value by more than 45%, and, therefore, there was no impairment to goodwill.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Annual Goodwill Impairment Test</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducted its annual goodwill impairment test as of October 1, 2021 by first assessing qualitative factors. Based on its qualitative assessment as of October 1, 2021, management believed that, with the exception of the Ortho Dermatologics reporting unit, it was more likely than not that the carrying amounts of its reporting units were less than their respective fair values and therefore concluded that a quantitative fair value test for those reporting units was not required. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of its qualitative assessment of the Ortho Dermatologics reporting unit as of October 1, 2021, the Company considered, among other matters, the limited headroom as a result of the impairment to the goodwill of the Ortho Dermatologics reporting unit when last tested (March 31, 2021) and macroeconomic factors such as higher than expected inflation for many commodities, volatility in many of the equity markets and pressures on market interest rates. The Company believed that these facts and circumstances may suggest that it was more likely than not that the fair value of the Ortho Dermatologics reporting unit was less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed a quantitative fair value test for the Ortho Dermatologics reporting unit as of October 1, 2021, utilizing a long-term growth rate of 1.0% and a discount rate of 9.0%, in estimation of the fair value of this reporting unit. Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was approximately 10% greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">First Quarter 2022 - Realignment of Segments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the first quarter of 2022, the Company began operating in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International, (iv) Solta Medical and (v) Diversified Products. The Bausch + Lomb segment consists of the: (i) Vision Care / Consumer Products, (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units. The Salix segment consists of the Salix reporting unit. The International segment consists of the International reporting unit. The Solta Medical segment consists of the Global Solta reporting unit. The Diversified Products segment consists of the: (i) Neurology and Other, (ii) Generics, (iii) Ortho Dermatologics and (iv) Dentistry reporting units. As such, the new segment structure does not impact the Company&#8217;s reporting units but realigns the two reporting units of the former Ortho Dermatologics segment whereby the Ortho Dermatologics reporting unit is now part of the current Diversified Products segment and the Solta reporting unit is now its own operating and reportable segment, and therefore management concluded that a quantitative fair value test was not required. See Note 19, &#8220;SEGMENT INFORMATION&#8221; for additional information.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">March 31, 2022 Interim Assessment of Goodwill</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to monitor market conditions which could impact the previous valuation of Ortho Dermatologics reporting unit. During the three months ended March 31, 2022, macroeconomic factors have impacted interest rates and the U.S. inflation rate is higher than previously expected.  Given the limited headroom calculated on October 1, 2021, the Company believed that these facts and circumstances suggest the fair value of the Ortho Dermatologics reporting unit could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value test utilized the Company&#8217;s most recent cash flow projections as revised in the first quarter of 2022 and utilized a long-term growth rate of 1% and a discount rate of 9%.  The discount rate contemplates changes in the current macroeconomic conditions noting certain inputs such as the risk free rate increased over the three months ended March 31, 2022, and was offset by decreases in other reporting unit specific risks during the same period. Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was less than 2% greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit. If market conditions deteriorate requiring management to revise its assumptions such as its long-term growth or discount rates, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future and those charges could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other events occurred or circumstances changed during the period October 1, 2021 (the last time goodwill was tested for all other reporting units) through March 31, 2022 that would indicate that the fair value of any reporting unit, other than the Ortho Dermatologics reporting unit, might be below its carrying value. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated goodwill impairment charges through March&#160;31, 2022 were $4,180 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425357332520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED AND OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">ACCRUED AND OTHER CURRENT LIABILITIES</a></td>
<td class="text">ACCRUED AND OTHER CURRENT LIABILITIES<div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities consist of:</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.740%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal matters and related fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,530&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rebates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefit costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,303&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,791&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425357226312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">FINANCING ARRANGEMENTS</a></td>
<td class="text">FINANCING ARRANGEMENTS<div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs consist of the following: </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.849%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Credit Facilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,577&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.50% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.125% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.75% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.875% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,581&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.125%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.00%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.25%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.50%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.00%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.25%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.25%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.25%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,385&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,654&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,168&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Covenant Compliance</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Credit Facilities (as defined below) and the indentures governing the Senior Secured Notes and Senior Unsecured Notes contain customary affirmative and negative covenants and specified events of default. These affirmative </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and negative covenants include, among other things, and subject to certain qualifications and exceptions, covenants that restrict the Company&#8217;s ability and the ability of its subsidiaries to: incur or guarantee additional indebtedness; create or permit liens on assets; pay dividends on capital stock or redeem, repurchase or retire capital stock or subordinated indebtedness; make certain investments and other restricted payments; engage in mergers, acquisitions, consolidations and amalgamations; transfer and sell certain assets; and engage in transactions with affiliates. As of March&#160;31, 2022, the amount available for restricted payments under the &#8220;builder basket&#8221; in the Company&#8217;s most restrictive indentures (as defined by those indentures) was approximately $13,900&#160;million (although such availability is subject to the Company&#8217;s compliance with a 2.00:1.00 fixed charge coverage ratio). The 2023 Revolving Credit Facility (as defined below) also contains a financial maintenance covenant that, prior to giving effect to the Second Amendment (as defined below), required the Company to maintain a first lien net leverage ratio of not greater than 4.00:1.00. The financial maintenance covenant may be waived or amended without the consent of the term loan facility lenders and contains a customary term loan facility standstill.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, the Company was in compliance with its financial maintenance covenant related to its debt obligations. The Company, based on its current forecast for the next twelve months from the date of issuance of these financial statements, expects to remain in compliance with its financial maintenance covenant and meet its debt service obligations over that same period. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to take steps to improve its operating results to ensure continual compliance with its financial maintenance covenant and may take other actions to reduce its debt levels to align with the Company&#8217;s long-term strategy, including divesting other businesses, refinancing debt and issuing equity or equity-linked securities as deemed appropriate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Secured Credit Facilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2018, the Company and certain of its subsidiaries as guarantors entered into the &#8220;Senior Secured Credit Facilities&#8221; under the Company&#8217;s Fourth Amended and Restated Credit and Guaranty Agreement, as amended by the First Incremental Amendment to the Restated Credit Agreement, dated as of November 27, 2018 (the &#8220;2018 Restated Credit Agreement&#8221;) with a syndicate of financial institutions and investors as lenders. Prior to the Second Amendment (as defined below), the 2018 Restated Credit Agreement provided for a revolving credit facility of $1,225 million, maturing on the earlier of June 1, 2023 and the date that is 91 calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company and Bausch Health Americas, Inc. (&#8220;BHA&#8221;) in an aggregate principal amount in excess of $1,000 million (the &#8220;2023 Revolving Credit Facility&#8221;) and term loan facilities of original principal amounts of $4,565 million and $1,500 million, maturing in June 2025 (the &#8220;June 2025 Term Loan B Facility&#8221;) and November 2025 (the &#8220;November 2025 Term Loan B Facility"), respectively. Both the Company and BHA were borrowers with respect to the 2023 Revolving Credit Facility. Borrowings under the 2023 Revolving Credit Facility could be made in U.S. dollars or Canadian dollars (or if an amendment to the 2018 Restated Credit Agreement was made to replace LIBOR with an alternative benchmark rate with respect to borrowings under the Revolving Credit Facility denominated in euros, euros). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Description of Senior Secured Credit Facilities as of March 31, 2022</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following description describes the 2018 Restated Credit Agreement as in effect on March 31, 2022, prior to giving effect to the Second Amendment (as defined below). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Senior Secured Credit Facilities in U.S. dollars bear interest at a rate per annum equal to, at the Company&#8217;s option, either: (i) a base rate determined by reference to the highest of: (a) the prime rate (as defined in the 2018 Restated Credit Agreement), (b) the federal funds effective rate plus 1/2 of 1.00% or (c) the eurocurrency rate (as defined in the 2018 Restated Credit Agreement) for a period of one month plus 1.00% (or if such eurocurrency rate shall not be ascertainable, 1.00%) or (ii) a eurocurrency rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing adjusted for certain additional costs (provided, however, that the eurocurrency rate shall at no time be less than 0.00% per annum), in each case plus an applicable margin. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2023 Revolving Credit Facility in euros, when available, are expected to bear interest at a term benchmark rate determined by reference to the costs of funds for euro deposits for the interest period relevant to such borrowing (provided, however, that the eurocurrency rate is at no time expected to be less than 0.00% per annum), plus an applicable margin. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2023 Revolving Credit Facility in Canadian dollars bear interest at a rate per annum equal to, at the Company&#8217;s option, either: (i) a prime rate determined by reference to the higher of: (a) the rate of interest last quoted by The Wall Street Journal as the &#8220;Canadian Prime Rate&#8221; or, if The Wall Street Journal ceases to quote such rate, the highest per annum interest rate published by the Bank of Canada as its prime rate and (b) the 1 month BA rate (as defined below) calculated daily plus 1.00% (provided, however, that the prime rate shall at no time be less than 0.00%) or (ii) the bankers&#8217; acceptance rate for Canadian dollar deposits in the Toronto interbank market (the &#8220;BA rate&#8221;) for the interest period relevant to such borrowing (provided, however, that the BA rate shall at no time be less than 0.00% per annum), in each case plus an applicable margin.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions and customary baskets set forth in the 2018 Restated Credit Agreement, the Company is required to make mandatory prepayments of the loans under the Senior Secured Credit Facilities under certain circumstances, including from: (i)&#160;100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold), (ii)&#160;100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the 2018 Restated Credit Agreement), (iii)&#160;50% of Excess Cash Flow (as&#160;defined in the 2018 Restated Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv)&#160;100% of net cash proceeds from asset sales (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold). These mandatory prepayments may be used to satisfy future amortization.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margins for the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility are 2.00% and 1.75%, respectively, with respect to base rate and prime rate borrowings and 3.00% and 2.75%, respectively, with respect to eurocurrency rate and BA rate borrowings. As of March 31, 2022, the stated rates of interest on the Company&#8217;s borrowings under the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility were 3.21% and 2.96% per annum, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortization rate for both the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility is 5.00% per annum. The Company may direct that prepayments be applied to such amortization payments in order of maturity. As of March 31, 2022, there were no remaining mandatory quarterly amortization payments for the Senior Secured Credit Facilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margins for borrowings under the 2023 Revolving Credit Facility are 1.50%-2.00% with respect to base rate or prime rate borrowings and 2.50%-3.00% with respect to eurocurrency rate or BA rate borrowings. As of March 31, 2022, the stated rate of interest on the 2023 Revolving Credit Facility was 2.96% per annum. As of March&#160;31, 2022, the Company had no outstanding borrowings, $54 million of issued and outstanding letters of credit and remaining availability of $1,171 million under its 2023 Revolving Credit Facility. In addition, the Company is required to pay commitment fees of 0.25%-0.50% per annum with respect to the unutilized commitments under the 2023 Revolving Credit Facility, payable quarterly in arrears. The Company also is required to pay: (i) letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on eurocurrency rate borrowings under the 2023 Revolving Credit Facility on a per annum basis, payable quarterly in arrears, (ii) customary fronting fees for the issuance of letters of credit and (iii) agency&#160;fees.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2018 Restated Credit Agreement permits the incurrence of incremental credit facility borrowings up to the greater of $1,000 million and 28.5% of Consolidated Adjusted EBITDA (non-GAAP) (as defined in the 2018 Restated Credit Agreement), subject to customary terms and conditions, as well as the incurrence of additional incremental credit facility borrowings subject to, in the case of secured debt, a secured leverage ratio of not greater than 3.50:1.00, and, in the case of unsecured debt, either a total leverage ratio of not greater than 6.50:1.00 or an interest coverage ratio of not less than 2.00:1.00.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As more fully discussed in Note 20, &#8220;SUBSEQUENT EVENTS&#8221;, on May 10, 2022 in connection with the B+L IPO, the Company completed a series of transactions in which among other things: (i) Bausch + Lomb entered into a new credit facility, (ii) the Company repaid certain amounts outstanding under its existing term B loans, (iii) the Company refinanced the remaining amounts outstanding under its credit facilities and (iv) the Company discharged the indenture governing the 6.125% Senior Unsecured Notes due 2025 (the &#8220;April 2025 Unsecured Notes&#8221; and the related indenture the &#8220;April 2025 Unsecured Notes Indenture&#8221;) with, among other sources, the net proceeds from the February 2027 Secured Notes (defined below). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Secured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes are guaranteed by each of the Company&#8217;s subsidiaries that is a guarantor under the 2018 Restated Credit Agreement and existing Senior Unsecured Notes (together, the &#8220;Note Guarantors&#8221;). In connection with the closing of the B+L IPO, the discharge of the 6.125% Notes Indenture and the related release in respect of the 2018 Restated Credit Agreement, the guarantees and related security provided by Bausch + Lomb and its subsidiaries in respect of the existing senior notes of the Company and BHA were released.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes and the guarantees related thereto are senior obligations and are secured, subject to permitted liens and certain other exceptions, by the same first priority liens that secure the Company&#8217;s obligations under the 2022 Restated Credit Agreement (as defined below) under the terms of the indentures governing the Senior Secured Notes. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes and the guarantees rank equally in right of repayment with all of the Company&#8217;s and Note Guarantors&#8217; respective existing and future unsubordinated indebtedness and senior to the Company&#8217;s and Note Guarantors&#8217; respective future subordinated indebtedness. The Senior Secured Notes and the guarantees related thereto are effectively </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">pari passu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the Company&#8217;s and the Note Guarantors&#8217; respective existing and future indebtedness secured by a first priority </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lien on the collateral securing the Senior Secured Notes and effectively senior to the Company&#8217;s and the Note Guarantors&#8217; respective existing and future indebtedness that is unsecured, including the existing Senior Unsecured Notes, or that is secured by junior liens, in each case to the extent of the value of the collateral. In addition, the Senior Secured Notes are structurally subordinated to: (i) all liabilities of any of the Company&#8217;s subsidiaries that do not guarantee the Senior Secured Notes and (ii) any of the Company&#8217;s debt that is secured by assets that are not collateral.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a change in control (as defined in the indentures governing the Senior Secured Notes), unless the Company has exercised its right to redeem all of the notes of a series, holders of the Senior Secured Notes may require the Company to repurchase such holder&#8217;s notes, in whole or in part, at a purchase price equal to 101% of the principal amount thereof plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">4.875% Senior Secured Notes due 2028 - June 2021 Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 8, 2021, the Company issued $1,600&#160;million aggregate principal amount of 4.875% Senior Secured Notes due June 2028 (the &#8220;June 2028 Secured Notes&#8221;) in a private placement. The proceeds and cash on hand were used to: (i) repurchase a portion and redeem the remainder of $1,600&#160;million of 7.00% Senior Secured Notes due 2024 (the &#8220;March 2024 Secured Notes&#8221;), representing the remaining outstanding principal balance of the March 2024 Secured Notes and (ii) pay all fees and expenses associated with these transactions (collectively, the &#8220;June 2021 Refinancing Transactions&#8221;). The June 2021 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $38&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#8217;s carrying value. Interest on the June 2028 Secured Notes is payable semi-annually in arrears on each June 1 and December 1.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The June 2028 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after June 1, 2024, at the redemption prices set forth in the June 2028 Secured Notes indenture. The Company may redeem some or all of the June 2028 Secured Notes prior to June 1, 2024 at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest to, but not including, the date of the redemption plus a &#8220;make-whole&#8221; premium. In addition, at any time prior to June 1, 2024, the Company may redeem up to 40% of the aggregate principal amount of the June 2028 Secured Notes using the net proceeds of certain equity offerings at the redemption price set forth in the June 2028 Secured Notes indenture.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">6.125% Senior Secured Notes due 2027 - February 2022 Financing</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 10, 2022, the Company issued $1,000&#160;million aggregate principal amount of 6.125% senior secured notes due February 2027 (the &#8220;February 2027 Secured Notes&#8221;). As discussed in further detail below, the proceeds from the February 2027 Secured Notes, along with proceeds from the B+L IPO, the 2027 Term Loans and the B+L Debt Financing (each as defined below) and cash on hand, were used to deposit funds sufficient to redeem in full all outstanding April 2025 Unsecured Notes and for the Credit Agreement Refinancing. The February 2027 Secured Notes accrue interest at a rate of 6.125% per year, payable semi-annually in arrears on each February and August. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The February 2027 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after February 2024, at the redemption prices set forth in the indenture. The Company may redeem some or all of the February 2027 Secured Notes prior to February 2024 at a price equal to 100% of the principal amount thereof plus a &#8220;make-whole&#8221; premium. Prior to February 2024, the Company may redeem up to 40% of the aggregate principal amount of the February 2027 Secured Notes using the proceeds of certain equity offerings at the redemption price set forth in the indenture.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Unsecured Notes</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Unsecured Notes issued by the Company are the Company&#8217;s senior unsecured obligations and are jointly and severally guaranteed on a senior unsecured basis by each of its subsidiaries that is a guarantor under the Senior Secured Credit Facilities. The Senior Unsecured Notes issued by BHA are senior unsecured obligations of BHA and are jointly and severally guaranteed on a senior unsecured basis by the Company and each of its subsidiaries (other than BHA) that is a guarantor under the Senior Secured Credit Facilities. Future subsidiaries of the Company and BHA, if any, may be required to guarantee the Senior Unsecured Notes. In connection with the closing of the B+L IPO, the discharge of the April 2025 Unsecured Notes Indenture and the related release in respect of the 2018 Restated Credit Agreement, the guarantees and related security provided by Bausch + Lomb and its subsidiaries in respect of the existing senior notes of the Company and BHA were released.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company experiences a change in control, the Company may be required to make an offer to repurchase each series of Senior Unsecured Notes, in whole or in part, at a purchase price equal to 101% of the aggregate principal amount of the Senior Unsecured Notes repurchased, plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Stated Rate of Interest</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average stated rate of interest for the Company&#8217;s outstanding debt obligations as of March&#160;31, 2022 and December&#160;31, 2021 was 5.97% and 5.88%, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maturities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of debt obligations for the remainder of 2022, the five succeeding years ending December&#160;31 and thereafter are as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:90.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.383%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt obligations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,385&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized premiums, discounts and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,168&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the closing of the B+L IPO, the conditions to the Company&#8217;s previously announced redemption of its April 2025 Unsecured Notes were satisfied. On May 10, 2022, the Company caused sufficient funds for the redemption in full of the April 2025 Unsecured Notes at a redemption price of 101.021% of the principal amount thereof to be irrevocably deposited with the Bank of New York Mellon, N.A., as trustee under the April 2025 Unsecured Notes Indenture and the April 2025 Unsecured Notes was discharged. The April 2025 Unsecured Notes will be redeemed on May 16, 2022. In addition, as of May 10, 2022, the Company has drawn $350 million on the 2027 Revolving Credit Facility (defined below).</span></div>This satisfaction and discharge, as well as the B+L Debt Financing, the Credit Agreement Refinancing and the borrowings under the 2027 Revolving Credit Facility (each as defined in Note 20, &#8220;SUBSEQUENT EVENTS&#8221;), are not reflected in the maturities table above.  See Note 20, &#8220;SUBSEQUENT EVENTS&#8221; for further details regarding these transactions.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425357156360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS</a></td>
<td class="text">PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors defined benefit plans and a participatory defined benefit postretirement medical and life insurance plan, which covers certain U.S. employees and employees in certain other countries. Net periodic (benefit) cost for the Company&#8217;s defined benefit pension plans and postretirement benefit plan for the three months ended March 31, 2022 and 2021 consists of: </span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.971%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.980%"/><td style="width:0.1%"/></tr><tr style="height:20pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Postretirement<br/>Benefit<br/>Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service credit and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic (benefit) cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425357364808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">SHARE-BASED COMPENSATION</a></td>
<td class="text">SHARE-BASED COMPENSATIONIn May 2014, shareholders approved the Company&#8217;s 2014 Omnibus Incentive Plan (the &#8220;2014 Plan&#8221;) which replaced the Company&#8217;s 2011 Omnibus Incentive Plan (the &#8220;2011 Plan&#8221;) for future equity awards granted by the Company. The Company transferred the common shares available under the 2011 Plan to the 2014 Plan. The maximum number of common shares that may be issued to participants under the 2014 Plan was equal to 18,000,000 common shares, plus the number of common shares under the 2011 Plan reserved but unissued and not underlying outstanding awards and the number of common shares becoming available for reuse after awards are terminated, forfeited, cancelled, exchanged or surrendered under the 2011 Plan <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the Company&#8217;s 2007 Equity Compensation Plan. The Company registered 20,000,000 common shares for issuance under the 2014 Plan. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective April 30, 2018, the Company amended and restated the 2014 Plan (the &#8220;Amended and Restated 2014 Plan&#8221;). The Amended and Restated 2014 Plan includes the following amendments: (i) the number of common shares authorized for issuance under the Amended and Restated 2014 Plan has been increased by an additional 11,900,000 common shares, as approved by the requisite number of shareholders at the Company&#8217;s annual general meeting held on April 30, 2018, (ii) introduction of a $750,000 aggregate fair market value limit on awards (in either equity, cash or other compensation) that can be granted in any calendar year to a participant who is a non-employee director, (iii) housekeeping changes to address changes to Section 162(m) of the Internal Revenue Code, (iv) awards are expressly subject to the Company&#8217;s clawback policy and (v) awards not assumed or substituted in connection with a Change of Control (as defined in the Amended and Restated 2014 Plan) will only vest on a pro rata basis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective April 28, 2020, the Company further amended and restated the Amended and Restated 2014 Plan (the &#8220;Further Amended and Restated 2014 Plan&#8221;). The Further Amended and Restated 2014 Plan includes the following amendments: (i) the number of common shares authorized for issuance under the Further Amended and Restated 2014 Plan has been increased by an additional 13,500,000 common shares, as approved by the requisite number of shareholders at the Company&#8217;s annual general meeting held on April 28, 2020, (ii) the exercise price of stock options and share appreciation rights (&#8220;SARs&#8221;) will be based on the closing price of the underlying common shares on the date such stock options or SARs are granted (rather than on the last preceding trading date), (iii)&#160;additional provisions clarifying that: (a)&#160;stock options and SARs will not be eligible for the payment of dividend or dividend equivalents and (b)&#160;the Talent and Compensation Committee of the Board of Directors of the Company cannot, without shareholder approval, seek to effect any repricing of any previously granted &#8220;underwater&#8221; stock option or SAR and (iv) other housekeeping and/or clerical changes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 8,542,000 common shares were available for future grants as of March&#160;31, 2022. The Company uses reserved and unissued common shares to satisfy its obligations under its share-based compensation plans.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a long-term incentive program with the objective of aligning the share-based awards granted to senior management with the Company&#8217;s focus on improving its tangible capital usage and allocation while maintaining focus on improving total shareholder return over the long-term. The share-based awards granted under this long-term incentive program consist of time-based stock options, time-based restricted share units (&#8220;RSUs&#8221;) and performance-based RSUs. Performance-based RSUs are comprised of awards that: (i) vest upon achievement of certain share price appreciation conditions that are based on total shareholder return (&#8220;TSR&#8221;), (ii) vest upon attainment of certain performance targets that are based on the Company&#8217;s return on tangible capital (&#8220;ROTC&#8221;) and (iii) vest fully or partially upon attainment of certain goals that are linked to the B+L Separation. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components and classification of share-based compensation expenses related to stock options and RSUs for the three months ended March 31, 2022 and 2021: </span></div><div style="margin-bottom:6pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.471%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based awards granted for the three months ended March 31, 2022 and 2021 consist of:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,545,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,343,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average exercise price</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time-based RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,662,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,560,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TSR performance-based RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROTC performance-based RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B+L Separation performance-based RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the remaining unrecognized compensation expenses related to all outstanding non-vested stock options, time-based RSUs and performance-based RSUs amounted to $134 million, which will be amortized over a weighted-average period of 1.84 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425354033816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCUMULATED OTHER COMPREHENSIVE LOSS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">ACCUMULATED OTHER COMPREHENSIVE LOSS</a></td>
<td class="text">ACCUMULATED OTHER COMPREHENSIVE LOSS<div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss consists of:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:69.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,961)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,905)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and postretirement benefit plan adjustments, net of income taxes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,974)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,924)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are not provided for foreign currency translation adjustments arising on the translation of the Company&#8217;s operations having a functional currency other than the U.S. dollar, except to the extent of translation adjustments related to the Company&#8217;s retained earnings for foreign jurisdictions in which the Company is not considered to be permanently reinvested.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI http://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425357164904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND DEVELOPMENT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">RESEARCH AND DEVELOPMENT</a></td>
<td class="text">RESEARCH AND DEVELOPMENT<div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Research and development are costs related to product development and quality assurance programs. Quality assurance are the costs incurred to meet evolving customer and regulatory standards. Research and development costs consist of:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.471%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product related research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality assurance</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 730<br> -URI http://asc.fasb.org/subtopic&amp;trid=2197926<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425357258152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER EXPENSE (INCOME), NET<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">OTHER EXPENSE (INCOME), NET</a></td>
<td class="text">OTHER EXPENSE (INCOME), NET<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense (income), net consists of:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.471%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and other matters</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of assets, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of assets, net for the three months ended March 31, 2021, includes $25&#160;million related to the achievement of a milestone related to a certain product.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -URI http://asc.fasb.org/topic&amp;trid=2122503<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 610<br> -URI http://asc.fasb.org/topic&amp;trid=49130413<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425354033816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For interim financial statement purposes, U.S. GAAP income tax expense/benefit related to ordinary income is determined by applying an estimated annual effective income tax rate against a company&#8217;s ordinary income. Income tax expense/benefit related to items not characterized as ordinary income is recognized as a discrete item when incurred. The estimation of the Company&#8217;s income tax provision requires the use of management forecasts and other estimates, application of statutory income tax rates, and an evaluation of valuation allowances. The Company&#8217;s estimated annual effective income tax rate may be revised, if necessary, in each interim period.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Benefit from income taxes for the three months ended March 31, 2022 was $16 million and included: (i) $14&#160;million of income tax expense for the Company&#8217;s ordinary loss for the three months ended March 31, 2022 and (ii) $30 million of net income tax benefit for discrete items, which includes: (a) $36&#160;million of net income tax benefit tax provision recognized for changes in uncertain tax positions, and (b) a $6&#160;million tax provision associated with filing certain tax returns.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes for the three months ended March 31, 2021 was $16 million and included: (i) $49 million of net income tax provision for discrete items, which includes: (a) a $46&#160;million tax provision related to potential and recognized withholding tax on intercompany dividends, (b) a $6&#160;million tax benefit associated with the filing of certain tax returns, (c) a $6 million tax benefit related to a deduction for stock compensation (d) a $3 million tax provision recognized for changes in uncertain tax positions and (ii) $33&#160;million of income tax benefit for the Company&#8217;s ordinary loss for the three months ended March 31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, the provision for income taxes will increase or decrease, respectively, in the period such determination is made except that, as a result of the 2018 adoption of guidance regarding intra-entity transfers, any change in valuation allowance surrounding the adoption of the intra-entity transfer resulting from this adoption was recorded within equity. The valuation allowance against deferred tax assets was $2,252 million and $2,222 million as of March&#160;31, 2022 and December&#160;31, 2021, respectively. The decrease was primarily due to loss in Canada. The Company will continue to assess the need for a valuation allowance on a go-forward basis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 8, 2021, the Organisation for Economic Co-operation and Development (&#8220;OECD&#8221;)/G20 inclusive framework on Base Erosion and Profit Shifting (the &#8220;Inclusive Framework&#8221;) published a statement updating and finalizing the key components of a two-pillar plan on global tax reform originally agreed on July 1, 2021, and a timetable for implementation by 2023. The Inclusive Framework plan has now been agreed to by 141 OECD members, including several countries which did not agree to the initial plan. Under pillar one, taxing rights over multinational businesses with global turnover above &#8364;20 billion and a profit margin above 10% will generally be re-allocated to market jurisdictions. Under pillar two, the Inclusive Framework has agreed on a global minimum corporate tax rate of 15% for companies with revenue above &#8364;750 million, calculated on a country-by-country basis. On October 30, 2021, the G20 formally endorsed the new global minimum corporate tax rate rules. The Inclusive Framework agreement must now be implemented by the OECD Members who have agreed to the plan, effective in 2023. On December 20, 2021, the OECD published model rules to implement the pillar two rules, which are generally consistent with agreements reached by the Inclusive Framework in October 2021. Additional guidance is expected to be published in 2022. The Company will continue to monitor the implementation of the Inclusive Framework agreement by the countries in which we operate. While the Company is unable to predict when and how the Inclusive Framework agreement will be enacted into law in these countries, it is possible that the implementation of the </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inclusive Framework agreement, including the global minimum corporate tax rate could have a material effect on the Company&#8217;s liability for corporate taxes and the Company&#8217;s consolidated effective tax rate. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022 and December&#160;31, 2021, the Company had $876 million and $927 million of unrecognized tax benefits, which included $43 million and $41 million of interest and penalties, respectively. Of the total unrecognized tax benefits as of March&#160;31, 2022, $196 million would reduce the Company&#8217;s effective tax rate, if recognized. The Company believes that it is reasonably possible that the total amount of unrecognized tax benefits at March&#160;31, 2022 could decrease by approximately $21 million in the next 12 months as a result of the resolution of certain tax audits and other events.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to be under examination by the Canada Revenue Agency. The Company&#8217;s position as of March&#160;31, 2022 with regard to proposed audit adjustments was updated to reflect an updated assessment received for 2015 which would primarily result in a loss of tax attributes that are subject to a full valuation allowance.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Company undertook an internal restructuring in the form of what is commonly known as a Granite Trust transaction, which resulted in a recorded capital loss (the &#8220;2017 capital loss&#8221;). In the U.S., the 2014 tax year remains open to the extent of the portion of the 2017 capital loss carried back to that year. The Internal Revenue Service (&#8220;IRS&#8221;) is continuing its examination of the Company&#8217;s annual tax filings for 2015 and 2016 and the Company&#8217;s short period tax return for the period ended September 8, 2017, which was filed as a result of the Company&#8217;s internal restructuring efforts during 2017. Recently, the Company has received a notice of proposed adjustment from the IRS that would disallow the 2017 capital loss. To date, the Company has not received an assessment from the IRS but expects to receive a notice of proposed tax deficiency. The Company intends to contest any proposed tax deficiency through the IRS administrative appeals process, and if necessary, appropriate litigation. If the Company were ultimately unsuccessful in defending its position, and all or a substantial portion of the 2017 capital loss deduction were disallowed, the Company estimates, in a worst case scenario, that it could be liable for additional income taxes (excluding penalties and interest) of up to $2,100&#160;million, which could have an adverse effect on the Company&#8217;s financial condition and results of operations. The Company intends to vigorously defend its position, including through appropriate litigation, if necessary, and ultimately believes it will sustain its deduction of the 2017 capital loss, and, accordingly, no income tax provision has been recorded. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s U.S. affiliates remain under examination for various state tax audits in the U.S. for years 2015 through 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s subsidiaries in Germany are under audit for tax years 2014 through 2016. At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company&#8217;s Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s subsidiaries in Australia are under audit by the Australian Taxation Office for various years beginning in 2011 through 2017. At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company&#8217;s Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain affiliates of the Company in regions outside of Canada, the U.S., Germany and Australia are currently under examination by relevant taxing authorities, and all necessary accruals have been recorded, including uncertain tax benefits.  At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company&#8217;s Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425357176136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">LOSS PER SHARE</a></td>
<td class="text">LOSS PER SHARE<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share attributable to Bausch Health Companies Inc. were calculated as follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.066%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.574%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(610)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted weighted-average common shares outstanding</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360.8&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356.8&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per share attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.19)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.71)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022 and 2021, all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive. The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been approximately 3,600,000 and 6,657,000 common shares for the three months ended March 31, 2022 and 2021, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022 and 2021, time-based RSUs, performance-based RSUs and stock options to purchase approximately 9,332,000 and 4,846,000 common shares, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method. During the three </span></div>months ended March 31, 2022, an additional 156,000 performance-based RSUs were not included in the computation of diluted earnings per share as the required performance conditions had not been met.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425357246568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">LEGAL PROCEEDINGS</a></td>
<td class="text">LEGAL PROCEEDINGS<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company becomes involved in various legal and administrative proceedings, which include product liability, intellectual property, commercial, tax, antitrust, governmental and regulatory investigations, related private litigation and ordinary course employment-related issues. From time to time, the Company also initiates actions or files counterclaims. The Company could be subject to counterclaims or other suits in response to actions it may initiate. The Company believes that the prosecution of these actions and counterclaims is important to preserve and protect the Company, its reputation and its assets. Certain of these proceedings and actions are described in Note 20, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC and the CSA on February 23, 2022. Except as described below, there have been no material updates or developments with respect to any such proceedings or actions during the three months ended March 31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a quarterly basis, the Company evaluates developments in legal proceedings, potential settlements and other matters that could increase or decrease the amount of the liability accrued. As of March 31, 2022, the Company&#8217;s Consolidated Balance Sheets includes accrued current loss contingencies of $1,530 million related to matters which are both probable and reasonably estimable. For all other matters, unless otherwise indicated, the Company cannot reasonably predict the outcome of these legal proceedings, nor can it estimate the amount of loss, or range of loss, if any, that may result from these proceedings. An adverse outcome in certain of these proceedings could have a material adverse effect on the Company&#8217;s business, financial condition and results of operations, and could cause the market value of its common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governmental and Regulatory Inquiries</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As referenced above, during the three months ended March 31, 2022, there have been no material updates or developments with respect to certain other proceedings or actions as described under &#8220;Governmental and Regulatory Inquiries&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 20, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC and the CSA on February 23, 2022. These matters include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigation by the U.S. Attorney&#8217;s Office for the District of Massachusetts - re OraPharma</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company received a subpoena from the U.S. Attorney&#8217;s Office for the District of Massachusetts, requesting materials including documents concerning the sales, marketing, coverage and reimbursement of Arestin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including related support services, and other matters. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is cooperating with this investigation. The Company cannot predict the outcome or the duration of this investigation or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of this investigation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities and RICO Class Actions and Related Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Securities Litigation - Opt-Out Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2019, the Company announced that it had agreed to settle, subject to final court approval, the consolidated securities class action filed in the U.S. District Court for the District of New Jersey (In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658). On January 31, 2021, the District Court issued an order granting final approval of this settlement. On February 4, 2021, Timber Hill LLC filed a notice of appeal of the Court&#8217;s final approval order, which overruled its objections to the allocation of settlement proceeds as between common stock and options. On March 1, 2021, Cathy Lochridge filed a notice of appeal of the Court&#8217;s final approval order, which overruled her objections as to the attorneys&#8217; fees awarded to class counsel. On October 14, 2021, Timber Hill LLC dismissed its appeal of the final approval order. On December 20, 2021, the Third Circuit denied Lochridge&#8217;s appeal. On January 3, 2022, Lochridge filed a petition for rehearing of the appeal en banc which remains pending.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2015, four putative securities class actions were filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. The allegations related to, among other things, allegedly false and misleading statements and/or failures to disclose information about the Company&#8217;s business and prospects, including relating to drug pricing, the Company&#8217;s use of specialty pharmacies, and the Company&#8217;s relationship with Philidor. On May 31, 2016, the court entered an order consolidating the four actions under the caption In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658. On December 16, 2019, the Company, the current or former officers and directors, ValueAct, and the underwriters announced that they agreed to resolve the securities action for $1,210 million, subject to final court approval. This settlement received final approval from the court on January </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31, 2021 and will resolve and discharge all claims against the Company in the class action. As part of the settlement, the Company and the other settling defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. The settlement remains subject to appeal of the final court approval (as such appeal is further described above). In order to qualify for a settlement payment all persons and entities that purchased or otherwise acquired the Company securities during the class period must have submitted a proof of claim and release form by May 6, 2020. The settlement payments have been paid into an escrow account in accordance with the payment schedule outlined in the settlement agreement. These payments, less certain settlement expenses and attorneys&#8217; fees, will remain in escrow until resolution of the appeal of the final court approval of the settlement agreement. The opt-out litigations discussed below remain ongoing. As of March 31, 2022, Restricted cash and other settlement deposits includes an aggregate $1,210&#160;million of: (i) payments in the escrow fund and (ii) certain disbursements for settlement expenses and attorney&#8217;s fees. Disbursements for attorney&#8217;s fees remain refundable until resolution of the appeal of the final court approval of the settlement agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2018, a putative class action was filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. This action, captioned Timber Hill LLC, v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 18-cv-10246) (&#8220;Timber Hill&#8221;), asserts securities fraud claims under Sections 10(b) and 20(a) of the Exchange Act on behalf of a putative class of persons who purchased call options or sold put options on the Company&#8217;s common stock during the period January 4, 2013 through August 11, 2016. On June 11, 2018, this action was consolidated with In re Valeant Pharmaceuticals International, Inc. Securities Litigation, (Case No. 15-cv-07658). On January 14, 2019, the defendants filed a motion to dismiss the Timber Hill complaint. Briefing on that motion was completed on February 13, 2019. On August 15, 2019, the Court denied the motion to dismiss the Timber Hill action, holding that this complaint was a legal nullity as a result of the June 11, 2018 consolidation order.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the consolidated putative class action, thirty-seven groups of individual investors in the Company&#8217;s stock and debt securities have chosen to opt out of the consolidated putative class action and filed securities actions in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. These actions were captioned previously in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed on February 23, 2022. Sixteen of the thirty-seven opt-out actions have been dismissed; and the total number of remaining opt-out actions pending in the District of New Jersey is twenty-one actions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These individual shareholder actions assert claims under Sections 10(b), and 20(a) of the Exchange Act. Certain of these individual actions assert additional claims, including claims under Section 18 of the Exchange Act, Sections 11, 12(a)(2), and 15 of the Securities Act, common law fraud, negligent misrepresentation, and claims under the New Jersey Racketeer Influenced and Corrupt Organizations Act. These claims are based on alleged purchases of Company stock, options, and/or debt at various times between January 3, 2013 and August 10, 2016. The allegations in the complaints are similar to those made by plaintiffs in the putative class action. Motions to dismiss have been filed and in most cases decided in many of these individual actions. To date, the Court has dismissed state law claims including New Jersey Racketeer Influenced and Corrupt Organizations Act, common law fraud, and negligent misrepresentation claims in certain cases. On January 7, 2019, the Court entered a stipulation of voluntary dismissal in the Senzar Healthcare Master Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-02286) opt-out action, closing the case. On September 10, 2019, the Court granted defendants&#8217; motion to dismiss all claims in the Bahaa Aly v. Valeant Pharmaceuticals International, Inc. (&#8220;Aly&#8221;) (Case No. 18-cv-17393) opt-out action. On October 9, 2019, the Aly Plaintiffs filed a notice of appeal to the United States Court of Appeals for the Third Circuit. On June 16, 2021, the Court of Appeals granted plaintiffs&#8217; appeal in the Aly action. This action has been remanded to the District Court. On June 19, 2020, the Court entered stipulations of voluntary dismissal in the Catalyst, Mississippi, Connecticut, and Delaware actions. On July 13, 2020, the Court entered a stipulation of voluntary dismissal in the NYCERS action. On December 30, 2020, the Court entered a stipulation of voluntary dismissal in the BlueMountain action. On February 18, 2021, and March 10, 2021, the Court entered stipulations of voluntary dismissal in the T. Rowe, BloombergSen, Principal Funds, Pentwater, Lord Abbett, Equity Trustees, and UC Regents actions. On April 30, 2021, the Court entered a stipulation of voluntary dismissal in the Florida SBA action. On July 20, 2021, the Court entered a stipulation of voluntary dismissal in the Janus action.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disputes the claims against it in the remaining individual opt-out complaints and intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Canadian Securities Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, six putative class actions were filed and served against the Company and certain current or former officers and directors in Canada in the provinces of British Columbia, Ontario and Quebec. The Company is also aware of two additional putative class actions that were filed with the applicable court but which have not been served on the Company and the factual allegations made in these actions are substantially similar to those outlined herein. These actions were captioned previously in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed on February 23, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actions generally allege violations of Canadian provincial securities legislation on behalf of putative classes of persons who purchased or otherwise acquired securities of the Company for periods commencing as early as January 1, 2013 and ending as late as November 16, 2015. The alleged violations relate to the same matters described in the U.S. Securities Litigation description above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these putative class actions, other than the Catucci action in the Quebec Superior Court, was discontinued. In the Catucci action, on August 29, 2017, the judge granted the plaintiffs leave to proceed with their claims under the Quebec Securities Act and authorized the class proceeding. On October 26, 2017, the plaintiffs issued their Judicial Application Originating Class Proceedings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After a hearing on November 11, 2019, the court approved a settlement in the Catucci action between the class members and the Company&#8217;s auditors and the action was dismissed as against them. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 4, 2020, the Company entered into a settlement agreement with the plaintiffs in Catucci, on behalf of the class, pursuant to which it agreed to resolve the Catucci action for the amount of CAD 94,000,000 plus payment of an additional amount to cover notice and settlement administration costs and disbursements. As part of the settlement, the Company and the other defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. Court approval of the settlement was granted after a hearing on November 16, 2020. The Catucci action has now been dismissed against the Company, its current and former directors and officers, its underwriters and its insurers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the class proceedings described above, on April 12, 2018, the Company was served with an application for leave filed in the Quebec Superior Court of Justice to pursue an action under the Quebec Securities Act against the Company and certain current or former officers and directors. This proceeding is captioned BlackRock Asset Management Canada Limited et al. v. Valeant, et al. (Court File No. 500-11-054155-185). The allegations in the proceeding are similar to those made by plaintiffs in the Catucci class action. On June 18, 2018, the same BlackRock entities filed an originating application (Court File No. 500-17-103749-183) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is aware that certain other members of the Catucci class exercised their opt-out rights prior to the June 19, 2018 deadline. On February 15, 2019, one of the entities which exercised its opt-out rights, the California State Teachers&#8217; Retirement System (&#8220;CalSTRS&#8221;), served the Company with an application in the Quebec Superior Court of Justice for leave to pursue an action under the Quebec Securities Act against the Company, certain current or former officers and directors of the Company and its auditor. That proceeding is captioned California State Teachers&#8217; Retirement System v. Bausch Health Companies Inc. et al. (Court File No. 500-11-055722-181). The allegations in the proceeding are similar to those made by the plaintiffs in the Catucci class action and in the BlackRock opt-out proceedings. On that same date, CalSTRS also served the Company with proceedings (Court File No. 500-17-106044-186) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 3, 2020, the Quebec Superior Court granted the applications of CalSTRS and BlackRock for leave to pursue their respective actions asserting claims under the Quebec Securities Act. On June 16, 2020, the Quebec Court of Appeal granted the defendants leave to appeal that decision. The appeal was heard on September 29, 2021 and, by judgment dated October 29, 2021, the appeals were dismissed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 8 and 9, 2020, respectively, CalSTRS amended its proceedings to, among other things, include a new alleged misrepresentation concerning the accounting treatment of &#8220;price appreciation credits&#8221; in respect of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the period covered by the claims. A hearing was held on February 17, 2021 with respect to whether CalSTRS would be permitted to file the proposed amended proceedings.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 9, 2021, the Quebec Superior Court granted the Company&#8217;s application to strike the new allegations from its Quebec Securities Act claim, but permitted the amendments to its claim under the Quebec Civil Code. On December 8, 2021, CalSTRS delivered its amended pleadings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 17, 2021, four additional opt-outs from the Catucci class issued a Statement of Claim in the Ontario Superior Court of Justice. That proceeding is captioned The Bank of Korea et al. v. Valeant Pharmaceuticals International Inc. et al. (Court File No. 21-006589666-0000). In addition, these plaintiffs also served and filed a motion for leave to pursue claims under the Ontario Securities Act. The allegations in this proceeding are similar to those made by the plaintiffs in the Catucci class action and the plaintiffs in the opt-out actions described above. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that it has viable defenses in each of these actions. In each case, the Company intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RICO Class Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between May 27, 2016 and September 16, 2016, three actions were filed in the U.S. District Court for the District of New Jersey against the Company and various third-parties (these actions were subsequently consolidated), alleging claims under </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the federal Racketeer Influenced Corrupt Organizations Act (&#8220;RICO&#8221;) on behalf of a putative class of certain third-party payors that paid claims submitted by Philidor for certain Company-branded drugs between January 2, 2013 and November 9, 2015.&#160; The consolidated complaint alleges, among other things, that the defendants committed predicate acts of mail and wire fraud by submitting or causing to be submitted prescription reimbursement requests that misstated or omitted facts regarding: (1) the identity and licensing status of the dispensing pharmacy; (2) the resubmission of previously denied claims; (3) patient co-pay waivers; (4) the availability of generic alternatives; and (5) the insured&#8217;s consent to renew the prescription.&#160;The complaint further alleges that these acts constitute a pattern of racketeering or a racketeering conspiracy in violation of the RICO statute and caused plaintiffs and the putative class unspecified damages, which may be trebled under the RICO statute.&#160;On August 4, 2021, the Company executed a stipulation of settlement for this action and, on August 17, 2021, the Court preliminarily approved the settlement. On December 6, 2021 the Special Master overseeing this litigation issued a report and recommendation recommending final approval of the settlement, and on February 22, 2022 the settlement was approved by the district court. The time to appeal the district court&#8217;s final approval order expired on March 24, 2022. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Securities and RICO Class Actions and Related Matters</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As referenced above, during the three months ended March 31, 2022, there have been no material updates or developments with respect to certain other proceedings or actions as described under &#8220;Securities and RICO Class Actions and Related Matters&#8221; in Note 20, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC and the CSA on February 23, 2022. Such matters include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Insurance Coverage Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2017, the Company filed a lawsuit against its insurance companies that issued insurance policies covering claims made against the Company, its subsidiaries, and its directors and officers during two distinct policy periods, (i) 2013-14 and (ii) 2015-16. The lawsuit is currently pending in the United States District Court for the District of New Jersey (Valeant Pharmaceuticals International, Inc., et al. v. AIG Insurance Company of Canada, et al.; Case No. 3:18-CV-00493). In the lawsuit, the Company seeks coverage for: (i) the costs of defending and resolving claims brought by former shareholders and debtholders of Allergan, Inc. in In re Allergan, Inc. Proxy Violation Securities Litigation and Timber Hill LLC, individually and on behalf of all others similarly situated v. Pershing Square Capital Management, L.P., et al. (the &#8220;Allergan Securities Litigation&#8221;) (under the 2013-2014 coverage period), and (ii) costs incurred and to be incurred in connection with the securities class actions and opt-out cases described in this section and the SEC Investigation and certain of the other investigations described under &#8220;Complete or Inactive Matters&#8221; in Note 20, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC and the CSA on February 24, 2021 and under &#8220;Governmental and Regulatory Inquiries&#8221; and &#8220;Complete or Inactive Matters&#8221; in Note 21, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC and the CSA on February 19, 2020 (under the 2015-2016 coverage period).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 20, 2021, the Company entered into settlement agreements with the insurers in the 2015-2016 coverage period in which the Company agreed to resolve its claims for insurance coverage in connection with the U.S. Securities Litigation and the Canadian Securities Litigation and related opt-out litigation and related investigations matters described above. On that same day, the Company entered into settlement agreements with two of its insurers in the 2013-2014 coverage period in which the Company agreed to resolve its claims against those two insurers only for insurance coverage in connection with the Allergan Securities Litigation. As a result of all of the settlement agreements entered into with the insurers on July 20, 2021, the Company has received an aggregate sum of $213&#160;million. The Company&#8217;s insurance claims with respect to the Allergan Securities Litigation against the remaining insurers in the 2013-2014 coverage period remain pending.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Hound Partners Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, Hound Partners Offshore Fund, LP, Hound Partners Long Master, LP, and Hound Partners Concentrated Master, LP, filed a lawsuit against the Company in the Superior Court of New Jersey Law Division/Mercer County that asserts claims for common law fraud, negligent misrepresentation, and violations of the New Jersey Racketeer Influenced and Corrupt Organizations Act. The Company disputes the claims and intends to vigorously defend this matter.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Antitrust</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glumetza Antitrust Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between August 2019 and July 2020, eight (8) putative antitrust class actions and four (4) non-class complaints naming the Company, Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc., and Santarus, Inc. (for purposes of this subsection, collectively, the &#8220;Company&#8221;), among other defendants, were filed or transferred to the Northern District of California. Three (3) of the class actions were filed by plaintiffs seeking to represent a class of direct purchasers. The purported classes of </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">direct purchasers filed a consolidated first amended complaint and a motion for class certification in April 2020. The court certified a direct purchaser class in August 2020. The putative class action complaints filed by end payer purchasers have all been voluntarily dismissed. Three (3) of the non-class complaints were filed by direct purchasers. The fourth non-class complaint, asserting claims based on both direct and indirect purchases, was filed by an insurer plaintiff in July 2020 and subsequently amended in September 2020. In December 2020, the court denied the Company&#8217;s motion to dismiss as to the insurer plaintiff&#8217;s direct claims but dismissed the insurer plaintiff&#8217;s indirect claims. On February 2, 2021, the insurer plaintiff&#8217;s motion for leave to amend its complaint was denied.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These actions were consolidated and coordinated in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 3:19-cv-05822-WHA (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The lawsuits alleged that a 2012 settlement of a patent litigation regarding Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or grant any other company a license to do so. The complaints alleged that the settlement agreement resulted in higher prices for Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its generic equivalent both prior to and after generic entry. Both the class and non-class plaintiffs sought damages under federal antitrust laws for claims based on direct purchases.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2021, the insurer plaintiff filed an action asserting its indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others (the &#8220;State Court Action&#8221;) (discussed in further detail below, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">see Glumetza State-Law Insurer Litigations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Defendants&#8217; demurrer in the State Court Action was heard on September 22, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 26, 2021, the Company reached an agreement in principle and, thereafter, on September 14, 2021, executed a final settlement agreement to resolve the class plaintiffs&#8217; claims for $300&#160;million, subject to court approval. On August 1, 2021, the Company also reached an agreement in principle to resolve the non-class direct purchaser plaintiffs&#8217; claims, described above, for additional consideration. A final settlement agreement with the non-class direct purchaser plaintiffs was executed on August 6, 2021. As part of the settlements, the Company admitted no liability as to the claims against it and denied all allegations of wrongdoing. On September 20, 2021, the insurer plaintiff voluntarily dismissed its claims in the consolidated federal action. By stipulation, the insurer plaintiff has asserted its direct opt-out claims in the State Court Action, resulting in the consolidation of all of its opt-out claims in the State Court Action.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 22, 2021, the court granted preliminary approval of the class settlement agreement and vacated the October 2021 trial date and all other pre-trial deadlines in the consolidated actions. On February 3, 2022, the court granted final approval of the class settlement and ordered dismissal of the class plaintiffs&#8217; claims. The deadline to appeal the final approval of the class settlement has now passed, and the settlements have resolved and discharged all asserted class and direct purchaser non-class claims against the Company in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Pricing Antitrust Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s subsidiaries, Oceanside Pharmaceuticals, Inc. (&#8220;Oceanside&#8221;), Bausch Health US, LLC (formerly Valeant Pharmaceuticals North America LLC) (&#8220;Bausch Health US&#8221;), and Bausch Health Americas, Inc. (formerly Valeant Pharmaceuticals International) (&#8220;Bausch Health Americas&#8221;) (for the purposes of this paragraph, collectively, the &#8220;Company&#8221;), are defendants in multidistrict antitrust litigation (&#8220;MDL&#8221;) entitled In re: Generic Pharmaceuticals Pricing Antitrust Litigation, pending in the United States District Court for the Eastern District of Pennsylvania (MDL 2724, 16- MD-2724). The lawsuits seek damages under federal and state antitrust laws, state consumer protection and unjust enrichment laws and allege that the Company&#8217;s subsidiaries entered into a conspiracy to fix, stabilize, and raise prices, rig bids and engage in market and customer allocation for generic pharmaceuticals. The lawsuits, which have been brought as putative class actions by direct purchasers, end payers, and indirect resellers, and as direct actions by direct purchasers, end payers, insurers, States, and various Counties, Cities, and Towns, have been consolidated into the MDL. There are also additional, separate complaints which have been consolidated in the same MDL that do not name the Company or any of its subsidiaries as a defendant. There are cases pending in the Court of Common Pleas of Philadelphia County against the Company and other defendants related to the multidistrict litigation, but no complaint has been filed in the cases. The cases have been placed in deferred status. The Company disputes the claims against it and continues to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, Bausch Health Companies Inc. and certain U.S. and Canadian subsidiaries (for the purposes of this paragraph, collectively the "Company&#8221;) have been named as defendants in a proposed class proceeding entitled Kathryn Eaton v. Teva Canada Limited, et al. in the Federal Court in Toronto, Ontario, Canada (Court File No. T-607-20). The plaintiff seeks to certify a proposed class action on behalf of persons in Canada who purchased generic drugs in the private sector, alleging that the Company and other defendants violated the Competition Act by conspiring to allocate the market, fix prices, and maintain the supply of generic drugs, and seeking damages under federal law. The proposed class action contains similar allegations to the In re: Generic Pharmaceuticals Pricing Antitrust Litigation pending in the United States Court for the Eastern District of Pennsylvania. The Company disputes the claims against it and will defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glumetza State-Law Insurer Litigations</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2021, the insurer plaintiff from the federal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 3:19-cv-05822- WHA (N.D. Cal.) (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) (discussed in further detail above) filed an action asserting its indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others (the &#8220;State Court Action&#8221;). The State Court Action alleges that a 2012 settlement of a patent litigation regarding Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or grant any other company a license to do so. The State Court Action alleges that the settlement agreement resulted in higher prices for Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its generic equivalent both prior to and after generic entry. On September 20, 2021, the parties stipulated that the insurer plaintiff&#8217;s direct opt-out claims from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, discussed above, were deemed asserted in the State Court Action. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defendants&#8217; demurrer in the State Court Action was heard on September 22, 2021. On November 29, 2021, the court denied the motion in part and granted it in part as to certain state law claims, with leave to amend. The insurer plaintiff did not amend the complaint. Defendants&#8217; answers were filed on February 3, 2022. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2022, Health Care Service Corporation filed an action with similar substantive allegations and similar indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disputes the claims and intends to vigorously defend these matters.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Litigation/Paragraph IV Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company (and/or certain of its affiliates) is also party to certain patent infringement proceedings in the United States and Canada, including as arising from claims filed by the Company (or that the Company anticipates filing within the required time periods) in connection with Notices of Paragraph IV Certification (in the United States) and Notices of Allegation (in Canada) received from third-party generic manufacturers respecting their pending applications for generic versions of certain products sold by or on behalf of the Company, including Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 550mg, Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Injection in the United States and Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Canada, or other similar suits.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2020, the Company and Alfasigma S.p.A. (&#8220;Alfasigma&#8221;) received a Notice of Paragraph IV Certification from Norwich Pharmaceuticals Inc. (&#8220;Norwich&#8221;), in which Norwich asserted that the U.S. patents listed in the FDA&#8217;s Orange Book for the Company&#8217;s Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 550 mg, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Norwich&#8217;s generic rifaximin tablets, 550 mg, for which an Abbreviated New Drug Application (&#8220;ANDA&#8221;) has been filed by Norwich. The Company, through its subsidiaries Salix Pharmaceuticals, Inc. and Bausch Health Ireland Limited, holds the New Drug Application for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and owns or exclusively licenses (from Alfasigma) these patents.&#160;On March 26, 2020, certain of the Company&#8217;s subsidiaries and Alfasigma filed suit against Norwich in the U.S. District Court for the District of Delaware (Case No. 20-cv-00430) pursuant to the Hatch-Waxman Act, alleging infringement by Norwich of one or more claims of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a 30-month stay of the approval of Norwich&#8217;s ANDA for rifaximin tablets, 550 mg. Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is protected by 26 patents covering the composition of matter and the use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> listed in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange&#160;Book. Trial in this matter was held in March 2022. A decision is pending. Post-trial briefing is expected to occur in the second quarter of 2022, with a decision expected in the third quarter of 2022. The Company remains confident in the strength of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and will continue to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 23, 2020, the Company received a Notice of Paragraph IV Certification from Perrigo Israel Pharmaceuticals, Ltd. (now Padagis LLC) (&#8220;Padagis&#8221;), in which Padagis asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotine) lotion, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Padagis&#8217; generic lotion, for which an ANDA has been filed by Padagis. On August 28, 2020, the Company filed suit against Padagis pursuant to the Hatch-Waxman Act, alleging infringement by Padagis of one or more claims of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a 30-month stay of the approval of the Padagis ANDA. On September 3, 2020, this action was consolidated with the action between the Company and Padagis described below, regarding Padagis&#8217; ANDA for generic Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate) lotion. A pre-trial conference in the consolidated action has been scheduled for July 20, 2022. The Company remains confident in the strength of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related patents and will vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 20, 2020, the Company received a Notice of Paragraph IV Certification from Padagis, in which Padagis asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate) lotion, 0.01% are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Padagis&#8217; generic halobetasol propionate lotion, for which an ANDA has been filed by Padagis. On May 1, 2020, the Company filed suit against Padagis pursuant to the Hatch-Waxman Act, alleging infringement by Padagis of one or more claims of the </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a 30-month stay of the approval of the Padagis ANDA for halobetasol propionate lotion. On September 3, 2020, this action was consolidated with the action between the Company and Padagis described above, regarding Padagis&#8217; ANDA for generic Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotine) lotion. A pre-trial conference in the consolidated action has been scheduled for July 20, 2022. The Company remains confident in the strength of the Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents and intends to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company commenced litigation against MSN Laboratories Private Ltd. (&#8220;MSN&#8221;) and Mylan Pharmaceuticals Inc., (&#8220;Mylan&#8221;) alleging patent infringement by MSN&#8217;s and Mylan&#8217;s filing of their ANDA for generic Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (plecanatide) 3mg tablets. This suit had been filed following receipt of a Notice of Paragraph IV Certification from each of MSN and Mylan, in which they had each asserted that the U.S. patents listed in the FDA&#8217;s Orange Book for the Company&#8217;s Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 3 mg, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of their respective generic plecanatide tablets, 3 mg. The filing of these suits triggered a 30-month stay of the approval of the MSN and Mylan ANDAs for plecanatide tablets. The Company remains confident in the strength of the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and intends to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2021, the Company received a Notice of Paragraph IV Certification from Slayback Pharma LLC (&#8220;Slayback&#8221;), in which Slayback asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (brimonidine tartrate solution) drops (the &#8220;Lumify Patents&#8221;), are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Slayback&#8217;s generic drops, for which an ANDA has been filed by Slayback. The Company, through its affiliate Bausch + Lomb Ireland Limited, exclusively licenses the Lumify Patents from Eye Therapies, LLC (&#8220;Eye Therapies&#8221;). On September 10, 2021, B&amp;L Inc., Bausch + Lomb Ireland Limited and Eye Therapies filed suit against Slayback pursuant to the Hatch-Waxman Act, alleging infringement by Slayback of one or more claims of the Lumify Patents, thereby triggering a 30-month stay of the approval of the Slayback ANDA.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 20, 2022, B&amp;L Inc. received a Notice of Paragraph IV Certification from Lupin Ltd. (&#8220;Lupin&#8221;), in which Lupin asserted that certain of the Lumify Patents are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Lupin&#8217;s generic brimonidine tartrate solution, for which its ANDA No. 216716 has been filed by Lupin. On February 2, 2022, B&amp;L Inc., Bausch + Lomb Ireland Limited and Eye Therapies filed suit against Lupin pursuant to the Hatch-Waxman Act, alleging patent infringement by Lupin of one or more claims of the Lumify Patents, thereby triggering a 30-month stay of the approval of the Lupin ANDA.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company remains confident in the strength of the Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related patents and intends to vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, patents covering the Company&#8217;s branded pharmaceutical products may be challenged in proceedings other than court proceedings, including inter partes review (&#8220;IPR&#8221;) at the U.S. Patent &amp; Trademark Office. The proceedings operate under different standards from district court proceedings, and are often completed within 18 months of institution.&#160;IPR challenges have been brought against patents covering the Company&#8217;s branded pharmaceutical products.&#160;For example, following Acrux DDS&#8217;s IPR petition, the U.S. Patent and Trial Appeal Board (&#8220;PTAB&#8221;), in May 2017, instituted inter partes review for an Orange Book-listed patent covering Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(U.S. Patent No. 7,214,506 (the &#8220;&#8216;506 Patent&#8221;)) and, on June 6, 2018, issued a written determination invalidating such patent. An appeal of this decision was filed on August 7, 2018. On March 13, 2020, the Court of Appeals for the Federal Circuit reversed this decision and remanded the matter back to the PTAB for further proceedings. As a result of a settlement, a joint motion to terminate the proceedings was filed on November 12, 2020 and, on January 8, 2021, the PTAB granted this motion.  The &#8216;506 Patent, therefore, remains valid and enforceable and expires in 2026. Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is covered by fourteen Orange Book-listed patents owned by the Company or its licensor, which expire in the years 2028 through 2035. In August and September 2018, the Company received notices of the filing of a number of ANDAs with paragraph IV certification, and has timely filed patent infringement suits against these ANDA filers, and, in addition, the Company has also commenced certain patent infringement proceedings in Canada against four separate defendants. All cases in U.S. regarding Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have been settled. In Canada, two lawsuits remain pending against Apotex Inc.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Products Liability Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2016, the Company has been named in a number of product liability lawsuits involving the Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> body powder product acquired in September 2012 from Johnson &amp; Johnson; due to dismissals, twenty-nine (29) of such product liability suits currently remain pending. Potential liability (including its attorneys&#8217; fees and costs) arising out of these remaining suits is subject to full indemnification obligations of Johnson &amp; Johnson owed to the Company and its affiliates, and legal fees and costs will be paid by Johnson &amp; Johnson. Twenty-eight (28) of these lawsuits filed by individual plaintiffs allege that the use of Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> caused the plaintiffs to develop ovarian cancer, mesothelioma or breast cancer. The allegations in these cases include failure to warn, design defect, manufacturing defect, negligence, gross negligence, breach </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of express and implied warranties, civil conspiracy concert in action, negligent misrepresentation, wrongful death, loss of consortium and/or punitive damages. The damages sought include compensatory damages, including medical expenses, lost wages or earning capacity, loss of consortium and/or compensation for pain and suffering, mental anguish anxiety and discomfort, physical impairment and loss of enjoyment of life. Plaintiffs also seek pre- and post-judgment interest, exemplary and punitive damages, and attorneys&#8217; fees. Additionally, two proposed class actions have been filed in Canada against the Company and various Johnson &amp; Johnson entities (one in the Supreme Court of British Columbia and one in the Superior Court of Quebec), on behalf of persons who have purchased or used Johnson &amp; Johnson&#8217;s Baby Powder or Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The class actions allege the use of the product increases certain health risks (British Columbia) or negligence in failing to properly test, failing to warn of health risks, and failing to remove the products from the market in a timely manner (Quebec). The plaintiffs in these actions are seeking awards of general, special, compensatory and punitive damages. On November 17, 2020, the British Columbia court issued a judgment declining to certify a class as to the Company or Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and at this time no appeal of that judgment has been filed. </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2021, the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plaintiff in the British Columbia class action filed a Second Amended Notice of Civil Claim and Application</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for Certification, removing the Company as a defendant; as a result, the British Columbia class action is concluded</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as to the Company.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson, through one or more subsidiaries, has purported to have completed a Texas divisional merger with respect to any talc liabilities at Johnson &amp; Johnson Consumer, Inc. (&#8220;JJCI&#8221;). LTL Management, LLC (&#8220;LTL&#8221;), the resulting entity of the divisional merger, assumed JJCI&#8217;s talc liabilities and thereafter filed for Chapter 11 bankruptcy protection in the United States Bankruptcy Court for the Western District of North Carolina. Pursuant to court orders entered in November 2021, the case was transferred to the United States District Court for the District of New Jersey, and substantially all cases related to Johnson &amp; Johnson&#8217;s talc liability were stayed for a period of sixty (60) days pursuant to a preliminary injunction. Notwithstanding the divisional merger and LTL&#8217;s bankruptcy case, the Company and its affiliates continue to have indemnification claims and rights against Johnson &amp; Johnson and LTL pursuant to the terms of the indemnification agreement entered into between JJCI and its affiliates and the Company and its affiliates, which indemnification agreement remains in effect. As a result, it is the Company&#8217;s current expectation that it will not incur any material impairments with respect to its indemnification claims as a result of the divisional merger or the bankruptcy. In December 2021, certain talc claimants filed motions to dismiss the bankruptcy case. Shortly thereafter, LTL filed a motion in the bankruptcy court to extend the 60-day preliminary injunction. On February 25, 2022, the bankruptcy court entered orders denying the motions to dismiss and extending the preliminary injunction staying substantially all cases subject to the indemnification agreement related to Johnson &amp; Johnson&#8217;s talc liability through at least June 29, 2022. The order denying the motions to dismiss and the order extending the preliminary injunction are subject to appeal and the bankruptcy court certified their appeals directly to the United States Court of Appeals for the Third Circuit. A petition to authorize the direct appeal is currently pending before the Court of Appeals. Further, pursuant to a court order dated March 18, 2022, the bankruptcy court directed certain talc claimants and LTL to mediate the issues related to the case in the hopes of achieving a global resolution. The Bankruptcy Court has also indicated that it intends to order separate mediation with respect to certain consumer protection claims against LTL by various state attorneys general. On May 4, 2022, the Bankruptcy Court extended LTL&#8217;s exclusive period to file a chapter 11 plan until September 9, 2022. To the extent that any cases proceed during the pendency of the bankruptcy case, it is the Company&#8217;s expectation that Johnson &amp; Johnson, in accordance with the indemnification agreement, will continue to vigorously defend the Company in each of the remaining actions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Civil Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Securities Litigation - New Jersey Declaratory Judgment Lawsu</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">it</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 24, 2022, the Company and Bausch + Lomb were named in a declaratory judgment action in the Superior </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Court of New Jersey, Somerset County, Chancery Division, brought by certain individual investors in the Company&#8217;s common shares and debt securities who are also maintaining individual securities fraud claims against the Company and certain current or former officers and directors as part of the U.S. Securities Litigation. This newly filed action seeks a declaratory judgment that the transfer of the Company assets to Bausch + Lomb would constitute a voidable transfer under New Jersey&#8217;s Uniform Voidable Transactions Act and that Bausch + Lomb would become liable for damages awarded against the Company in the individual opt-out actions. The declaratory judgment action alleges that a transfer of assets from the Company to Bausch + Lomb would leave the Company with inadequate financial resources to satisfy these plaintiffs&#8217; alleged securities fraud damages in the underlying individual opt-out actions. None of the plaintiffs in this declaratory judgment action have obtained a judgment against the Company in the underlying individual opt-out actions and the Company disputes the claims against it in those underlying actions. The underlying individual opt-out actions assert claims under Sections 10(b) and 20(a) of the Exchange Act, and certain actions assert claims under Section 18 of the Exchange Act. The allegations in those underlying individual opt out actions are made against the Company and several of its former officers and directors only and relate to, among other things, allegedly false and misleading statements made during the 2013-2016 time period by the Company and/or failures to disclose information about the Company&#8217;s business and prospects including relating to drug pricing and the use of specialty pharmacies. On March 31, 2022, the Company and Bausch + Lomb removed the action to the U.S. District Court for the District of New Jersey.  As a result, the New Jersey Superior Court action is closed and the case is now pending in the </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">District of New Jersey (Case No. 22-cv-01823). On April 29, 2022, Plaintiffs filed a motion to remand. That motion will be fully briefed on June 3, 2022. Other proceedings are in abeyance pending resolution of Plaintiffs&#8217; remand motion. Both the Company and Bausch + Lomb dispute the claims in this declaratory judgment action and intend to vigorously defend this matter. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">California Proposition 65 Related Matter</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2019, plaintiffs filed a proposed class action in California state court against Bausch Health US and Johnson &amp; Johnson (Gutierrez, et al. v. Johnson &amp; Johnson, et al., Case No. 37-2019-00025810-CU-NP-CTL), asserting claims for purported violations of the California Consumer Legal Remedies Act, False Advertising Law and Unfair Competition Law in connection with their sale of talcum powder products that the plaintiffs allege violated Proposition 65 and/or the California Safe Cosmetics Act. This lawsuit was served on Bausch Health US in June 2019 and was subsequently removed to the United States District Court for the Southern District of California, where it is currently pending. Plaintiffs seek damages, disgorgement of profits, injunctive relief, and reimbursement/restitution. The Company filed a motion to dismiss Plaintiffs&#8217; claims, which was granted in April 2020 without prejudice. In May 2020, Plaintiffs filed an amended complaint and in June 2020, filed a motion for leave to amend the complaint further, which was granted. In August 2020, Plaintiffs filed the Fifth Amended Complaint. On January 22, 2021, the Court granted the motion to dismiss with prejudice. On February 19, 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit Court of Appeals. On July 1, 2021, Appellants (Plaintiffs) filed their opening brief; Appellees&#8217; response briefs were filed on October 8, 2021. This matter was stayed by the Ninth Circuit on December 7, 2021, due to the preliminary injunction entered by the bankruptcy court in the LTL bankruptcy proceeding. This stay included Appellants&#8217; reply brief deadline, which was previously due to be filed on or before December 2, 2021. On March 9, 2022, the Ninth Circuit issued an order extending the stay through July 29, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other General Civil Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As referenced above, during the three months ended March 31, 2022, there have been no material updates or developments with respect to certain proceedings or actions as described under &#8220;General Civil Actions&#8221; in Note 20, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC and the CSA on February 24, 2021. These matters include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Mexico Attorney General Consumer Protection Action</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US were named in an action brought by State of New Mexico ex rel. Hector H. Balderas, Attorney General of New Mexico, in the County of Santa Fe New Mexico First Judicial District Court (New Mexico ex rel. Balderas v. Johnson &amp; Johnson, et al., Civil Action No. D-101-CV-2020-00013, filed on January 2, 2020), alleging consumer protection claims against Johnson &amp; Johnson and Johnson &amp; Johnson Consumer Companies, Inc., the Company and Bausch Health US related to Shower to Shower&#174; and its alleged causal link to mesothelioma and other cancers. In April 2020, Bausch Health US filed a motion to dismiss, which in September 2020, the Court granted in part as to the New Mexico Medicaid Fraud Act and New Mexico Fraud Against Taxpayers Act claims and denied as to all other claims. The State of New Mexico brings claims against all defendants under the New Mexico Unfair Practices Act and other common law and equitable causes of action, alleging defendants engaged in wrongful marketing, sale and promotion of talcum powder products. The lawsuit seeks to recover the cost of the talcum powder products as well as the cost of treating asbestos-related cancers allegedly caused by those products. Bausch Health US filed its answer on November 16, 2020. On December 30, 2020 Johnson &amp; Johnson filed a Motion for Partial Judgment on the Pleadings and on January 4, 2021, Bausch Health US filed a joinder to that motion, which was denied on March 8, 2021. Trial is scheduled to begin on March 6, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Doctors Allergy Formula Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, Doctors Allergy Formula, LLC (&#8220;Doctors Allergy&#8221;), filed a lawsuit against Bausch Health Americas in the Supreme Court of the State of New York, County of New York, asserting breach of contract and related claims under a 2015 Asset Purchase Agreement, which purports to include milestone payments that Doctors Allergy alleges should have been paid by Bausch Health Americas.&#160;Doctors Allergy claims its damages are not less than $23 million. Bausch Health Americas has asserted counterclaims against Doctors Allergy. Bausch Health Americas filed a motion seeking an order granting Bausch Health Americas summary judgment on its counterclaims against Plaintiff and dismissing Plaintiff&#8217;s claims against it. The motion was fully briefed as of May 2021. The Court held a hearing on the motion on January 25, 2022. The motion remains pending. Bausch Health Americas disputes the claims against it and will continue to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation with Former Salix CEO</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 28, 2019, former Salix Ltd. CEO and director Carolyn Logan filed a lawsuit in the Delaware Court of Chancery, asserting claims for breach of contract and declaratory relief. On November 19, 2021, Logan amended her complaint to add a claim for breach of the implied covenant of good faith and fair dealing. The lawsuit arises out of the contractual termination of approximately $30 million in unvested equity awards following the determination by the Salix Ltd. Board of Directors that Logan intentionally engaged in wrongdoing that resulted, or would reasonably be expected to result, in material harm to Salix Ltd., or to the business or reputation of Salix Ltd. Logan seeks the restoration of the unvested equity awards and a declaration regarding certain rights related to indemnification. On June 19, 2019, the Court entered an order staying the claim for declaratory relief pending the final resolution of the breach of contract claim. Trial is scheduled to commence on September 6, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disputes the claims against it in each of these matters and intends to vigorously defend the matters.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425357142984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT INFORMATION</a></td>
<td class="text">SEGMENT INFORMATION<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reportable Segments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the planned separation of its Solta business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc., the Company has begun managing its operations in a manner which is consistent with the organizational structure of the two separate entities as proposed by the Solta IPO. As a result, during the first quarter of 2022, the Company&#8217;s Chief Executive Officer (&#8220;CEO&#8221;), who is the Company&#8217;s Chief Operating Decision Maker, commenced managing the business differently through changes in its operating and reportable segments, which necessitated a realignment of the Company&#8217;s historical segment structure. This realignment is consistent with how the Company&#8217;s CEO currently: (i) assesses operating performance on a regular basis, (ii) makes resource allocation decisions and (iii) designates responsibilities of his direct reports. Pursuant to these changes, effective in the first quarter of 2022, the Company operates in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International (formerly International Rx), (iv) Solta Medical and (v) Diversified Products. The new segment structure does not impact the Company&#8217;s reporting units but realigns the two reporting units of the former Ortho Dermatologics segment whereby its medical dermatology reporting unit (Ortho Dermatologics) is now part of the current Diversified Products segment and the Solta reporting unit is now the sole reporting unit of the new Solta Medical segment. Prior period presentation of segment revenues and segment profits has been recast to conform to the current segment reporting structure.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a brief description of the Company&#8217;s segments:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Bausch + Lomb segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Bausch + Lomb Vision Care, Consumer, Surgical and Ophthalmic Pharmaceuticals products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Salix segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of sales in the U.S. of GI products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The International segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of sales, with the exception of sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Solta Medical segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Solta aesthetic medical devices. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;padding-left:14.5pt">The Diversified Products segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products, (iii) Ortho Dermatologics (dermatological) products and (iv) dentistry products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment profit is based on operating income after the elimination of intercompany transactions. Certain costs, such as Amortization of intangible assets, Asset impairments, Acquired in-process research and development costs, Restructuring, integration, separation and IPO costs and Other (income) expense, net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of the Company&#8217;s businesses and incurs certain expenses, gains and losses related to the overall management of the Company, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single&#160;segment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Revenues and Profits</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment revenues and profits were as&#160;follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.471%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,918&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,027&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(194)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(181)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(310)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(357)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments, including loss on assets held for sale</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, integration, separation and IPO costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(362)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(368)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before provision for income taxes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(591)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues by Segment and Product Category </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by segment and product category were as&#160;follows: </span></div><div style="margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.858%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">844&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,918&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">892&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,027&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The top ten products for the three months ended March 31, 2022 and 2021 represented 44% and 40% of total revenues for the three months ended March 31, 2022 and 2021, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Information</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are attributed to a geographic region based on the location of the customer and were as&#160;follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.471%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,115&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,162&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Korea</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,918&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,027&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made and are reflected in the table above.</span></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major Customers</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers that accounted for 10% or more of total revenues were as follows:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation (including McKesson Specialty)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health,&#160;Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425357354008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">SUBSEQUENT EVENTS<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Initial Public Offering </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The registration statement related to the B+L IPO was declared effective on May 5, 2022, and Bausch + Lomb&#8217;s common shares began trading on the New York Stock Exchange and the Toronto Stock Exchange, in each case under the ticker symbol &#8220;BLCO&#8221;, on May 6, 2022. On May 10, 2022, the Selling Shareholder (as previously defined) sold 35,000,000 common shares of Bausch + Lomb at an offering price of $18.00 per share. The net proceeds from the B+L IPO after deducting underwriting commissions and estimated offering expenses were approximately $560 million as of May 10, 2022. In addition, the Selling Shareholder has granted the underwriters an option for a period of 30 days from the date of the B+L IPO to purchase up to an additional 5,250,000 common shares to cover over-allotments at the IPO offering price less underwriting commissions. As of May 10, 2022, the underwriters have not exercised this option. Upon the closing of the B+L IPO (but before exercise of the over-allotment option), the Company directly or indirectly holds 315,000,000 Bausch + Lomb common shares, which represents approximately 90% of Bausch + Lomb&#8217;s common shares.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financing Transactions of Bausch + Lomb</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2022, Bausch + Lomb entered into a credit agreement (the &#8220;B+L Credit Agreement&#8221;, and the credit facilities thereunder, the &#8220;B+L Credit Facilities&#8221;) providing for term loans of approximately $2,500&#160;million with a five-year term to maturity (the &#8220;B+L Term Facility&#8221;) and a five year revolving credit facility of approximately $500&#160;million (the &#8220;B+L Revolving Credit Facility&#8221; or such financing, the &#8220;B+L Debt Financing&#8221;). The B+L Credit Facilities are secured by substantially all of the assets of Bausch + Lomb and its material, wholly-owned Canadian, U.S., Dutch and Irish subsidiaries, subject to certain exceptions. The term loans are denominated in U.S. dollars, and borrowings under the revolving credit facility will be made available in U.S. dollars, euros, pounds sterling and Canadian dollars. As of May 10, 2022, the B+L Revolving Credit Facility remains undrawn.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the B+L Revolving Credit Facility in (i) U.S. dollars bear interest at a rate per annum equal to, at our option, either: (a) a term SOFR-based rate or (b) a U.S. dollar base rate, (ii) Canadian dollars bear interest at a rate per annum equal to, at our option, either: (a) CDOR or (b) a Canadian dollar prime rate, (iii) euros bear interest at a rate per annum equal to EURIBOR and (iv) pounds sterling bear interest at a rate per annum equal to SONIA (provided, however, that the term SOFR-based rate, CDOR, EURIBOR and SONIA shall be no less than 0.00% per annum at any time and the U.S. dollar base rate and the Canadian dollar prime rate shall be no less than 1.00% per annum at any time), in each case, plus an applicable margin. Term SOFR-based loans are subject to a credit spread adjustment of 0.10%.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margins for borrowings under the B+L Revolving Credit Facility are (i) between 0.75% to 1.75% with respect to U.S. dollar base rate or Canadian dollar prime rate borrowings and between 1.75% to 2.75% with respect to SOFR, EURIBOR, SONIA or CDOR borrowings based on the Company&#8217;s total net leverage ratio and (ii) after (x) Bausch + Lomb&#8217;s senior unsecured non-credit-enhanced long term indebtedness for borrowed money receives an investment grade rating from at least two of S&amp;P, Moody&#8217;s and Fitch and (y) the term loan facility has been repaid in full in cash (the &#8220;IG Trigger&#8221;), between 0.015% to 0.475% with respect to U.S. dollar base rate or Canadian dollar prime rate borrowings and between 1.015% to 1.475% with respect to SOFR, EURIBOR, SONIA or CDOR borrowings based on the Company&#8217;s debt rating. In addition, the Company is required to pay commitment fees of 0.25% per annum in respect of the unutilized commitments under the revolving credit facility, payable quarterly in arrears until the IG Trigger and a facility fee between 0.110% to 0.275% of the total revolving commitments, whether used or unused, based on the Company&#8217;s debt rating and payable quarterly in arrears. The Company is also required to pay letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on SOFR borrowings under the revolving credit facility on a per annum basis, payable quarterly in arrears, as well as customary fronting fees for the issuance of letters of credit and agency fees. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the term loan facility bear interest at a rate per annum equal to, at our option, either (i) a term SOFR-based rate, plus an applicable margin of 3.25% or (ii) a U.S. dollar base rate, plus an applicable margin of 2.25% (provided, however, that the term SOFR-based rate shall be no less than 0.50% per annum at any time and the U.S. dollar base rate shall not be lower than 1.50% per annum at any time). Term SOFR-based loans are subject to a credit spread adjustment of 0.10%.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions and customary baskets set forth in the B+L Credit Agreement, the Company is required to make mandatory prepayments of the loans under the B+L Term Facility under certain circumstances, including from: (i) 100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold), (ii) 100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the B+L Credit Agreement), (iii) 50% of Excess Cash Flow (as defined in the B+L Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv) 100% of net cash proceeds from asset sales (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold). These mandatory prepayments may be used to satisfy future amortization.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortization rate for the B+L Term Facility is 1.00% per annum and the first installment shall be payable on September 30, 2022. Bausch + Lomb may direct that prepayments be applied to such amortization payments in order of maturity. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Secured Credit Facilitie</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2022, the Company and certain of its subsidiaries as guarantors entered into that certain Second Amendment to the Fourth Amended and Restated Credit and Guaranty Agreement (the &#8220;Second Amendment&#8221;). The 2022 Restated Credit Agreement provides for a new term facility with an aggregate principal amount of $2,500&#160;million (the &#8220;2027 Term Loan B Facility&#8221; and the loans thereunder the &#8220;2027 Term Loans&#8221;) maturing on February 1, 2027 and a new revolving credit facility of $975&#160;million (the &#8220;2027 Revolving Credit Facility&#8221;) that will mature on the earlier of February 1, 2027 and the date that is 91 calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company and BHA in an aggregate principal amount in excess of $1,000&#160;million. After giving effect to the 2022 Restated Credit Agreement, the 2023 Revolving Credit Facility, June 2025 Term Loan B Facility and November 2025 Term Loan B Facility were refinanced (such refinancing, the &#8220;Credit Agreement Refinancing&#8221;), along with certain of the Company&#8217;s existing senior notes, using proceeds of the Credit Agreement Refinancing, the B+L IPO and the B+L Debt Financing and available cash on hand. As of May 10, 2022, the Company has drawn $350 million on the 2027 Revolving Credit Facility.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2027 Term Loan B Facility bear interest at a rate per annum equal to, at our option, either: (a) a term SOFR-based rate or (b) a U.S. dollar base rate, in each case, plus an applicable margin (provided, however, that the term SOFR-based rate is expected to be no less than 0.50% per annum at any time and the U.S. dollar base rate is expected to be no less than 1.50% per annum at any time). Borrowings under the 2027 Revolving Credit Facility in: (i) U.S. dollars bear interest at a rate per annum equal to, at the Company&#8217;s option, either: (a) a term SOFR-based rate or (b) a U.S. dollar base rate, (ii) Canadian dollars bear interest at a rate per annum equal to, at our option, either: (a) CDOR or (b) a Canadian dollar prime rate and (iii) euros bear interest at a rate per annum equal to EURIBOR (provided, however, that the term SOFR-based rate, CDOR and EURIBOR are expected to be no less than 0.00% per annum at any time and the U.S. dollar base rate and the Canadian dollar prime rate are expected to be no less than 1.00% per annum at any time), in each case, plus an applicable margin. Term SOFR-based loans are subject to a credit spread adjustment ranging from 0.10%-0.25%.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margin for borrowings under the 2027 Term Loan B Facility is 5.25% for term SOFR-based loans and 4.25% for U.S. dollar base rate loans. The applicable interest rate margin for borrowings under the 2027 Revolving Credit Facility ranges from 3.75% to 4.25% for term SOFR-based loans and 2.75% to 3.25% for U.S. dollar base rate loans.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is required to pay commitment fees of 0.25%-0.50% per annum with respect to the unutilized commitments under the 2027 Revolving Credit Facility, payable quarterly in arrears. The Company also is required to pay: (i) letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on term SOFR borrowings under the 2027 Revolving Credit Facility on a per annum basis, payable quarterly in arrears, (ii) customary fronting fees for the issuance of letters of credit and (iii) agency fees.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions and customary baskets set forth in the 2022 Restated Credit Agreement, the Company is required to make mandatory prepayments of the loans under the Senior Secured Credit Facilities under certain circumstances, including from: (i) 100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold), (ii) 100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the 2022 Restated Credit Agreement), (iii) 50% of Excess Cash Flow (as defined in the 2022 Restated Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv) 100% of net cash proceeds from asset sales (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold). These mandatory prepayments may be used to satisfy future amortization. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortization rate for the 2027 Term Loan B Facility is 5.00% per annum and the first installment shall be payable on September 30, 2022. The Company may direct that prepayments be applied to such amortization payments in order of maturity.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Restated Credit Agreement permits the incurrence of incremental credit facility borrowings up to the greater of $1,000&#160;million and 40% of Consolidated Adjusted EBITDA (non-GAAP) (as defined in the 2022 Restated Credit Agreement), subject to customary terms and conditions, as well as the incurrence of additional incremental credit facility borrowings subject to, in the case of secured debt, a secured leverage ratio of not greater than 3.50:1.00, and, in the case of unsecured debt, either a total leverage ratio of not greater than 6.50:1.00 or an interest coverage ratio of not less than 2.00:1.00.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Restated Credit Agreement provides that Bausch + Lomb initially be a &#8220;excluded&#8221; subsidiary subject to the terms of the 2022 Restated Credit Agreement covenants, but does not require Bausch + Lomb to guarantee the obligations under the 2022 Restated Credit Agreement. The 2022 Restated Credit Agreement permits the Company to designate Bausch + Lomb as an &#8220;unrestricted&#8221; subsidiary under the 2022 Restated Credit Agreement and no longer subject to the terms of the covenants thereunder upon achievement of a 7.6x pro forma &#8220;Remainco Total Leverage Ratio&#8221; Such designation could take place at any time after the B+L IPO. The Credit Agreement Refinancing contains provisions designed to facilitate the separation and distribution of Bausch + Lomb.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Redemption of April 2025 Unsecured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 18, 2022, the Company issued conditional notices of redemption to redeem: (i) all April 2025 Unsecured Notes conditioned upon the completion of the Credit Agreement Refinancing and (ii) $370&#160;million in aggregate principal amount of our outstanding 9.000% Senior Unsecured Notes due 2025 (the "December 2025 Unsecured Notes") conditioned upon the receipt of aggregate proceeds from: (i) the B+L IPO, (ii) the B+L Debt Financing, (iii) the Credit Agreement Refinancing and (iv) the issuance of the February 2027 Secured Notes of at least $7,000&#160;million. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the closing of the B+L IPO, the conditions of the Company&#8217;s previously announced redemption of its April 2025 Unsecured Notes were satisfied and the Company discharged the April 2025 Unsecured Notes Indenture using: (i) the proceeds from the issuance of the February 2027 Secured Notes, (ii) the proceeds from the B+L IPO, (iii) the net proceeds from the borrowings under the B+L Debt Financing and (iv) cash on hand. On May 10, 2022, the Company caused sufficient funds for the redemption in full of its April 2025 Unsecured Notes at a redemption price of 101.021% of the principal amount then outstanding to be irrevocably deposited with the Bank of New York Mellon, N.A., as trustee under the April 2025 Unsecured Notes Indenture, and the April 2025 Unsecured Notes Indenture was discharged. The April 2025 Unsecured Notes will be redeemed on May 16, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2022, the Company notified the Trustee and holders of its outstanding December 2025 Unsecured Notes that the conditions to its previously announced redemption would not be satisfied, and the conditional redemption was cancelled.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the closing of the B+L IPO, the discharge of the 6.125% Notes Indenture and the related release in respect of the 2018 Restated Credit Agreement as described above, the guarantees and related security provided by Bausch + Lomb and its subsidiaries in respect of the existing senior notes of the Company and BHA were released.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425357391224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation and Use of Estimates </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Consolidated Financial Statements have been prepared by the Company in U.S. dollars and in accordance with&#160;U.S. generally accepted accounting principles (&#8220;U.S.&#160;GAAP&#8221;) for interim financial reporting, which do not conform in all respects to the requirements of U.S.&#160;GAAP for annual financial statements. Accordingly, these notes to the unaudited Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements prepared in accordance with U.S.&#160;GAAP that are contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the U.S. Securities and Exchange Commission (the&#160;&#8220;SEC&#8221;) and the Canadian Securities Administrators (the&#160;&#8220;CSA&#8221;) on February&#160;23, 2022. The unaudited Consolidated Financial Statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company&#8217;s audited Consolidated Financial Statements for the year ended December&#160;31, 2021, except for the new accounting guidance adopted during the period. The unaudited Consolidated Financial Statements reflect all normal and recurring adjustments necessary for a fair statement of the Company&#8217;s financial position and results of operations for the interim periods. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full&#160;year.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing the unaudited Consolidated Financial Statements, management is required to make estimates and assumptions. This includes estimates and assumptions regarding the nature, timing and extent of the impacts that the COVID-19 pandemic will have on its operations and cash flows.  The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the unaudited Consolidated Financial Statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates and the differences could be material. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company&#8217;s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company&#8217;s results of operations and financial position could be materially impacted.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior year amounts to conform to the current year presentation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">REVENUE RECOGNITION The Company&#8217;s revenues are primarily generated from product sales, principally in the therapeutic areas of eye health, GI and dermatology, that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 19, &#8220;SEGMENT INFORMATION&#8221; for the disaggregation of revenue which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts.<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales Provisions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.&#160; The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers. Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company&#8217;s products. These judgments include the potential impact of the COVID-19 pandemic on, among other things, unemployment and related changes in customer health insurance levels, customer behaviors during the COVID-19 pandemic and government stimulus bills that focus on ensuring availability and access to lifesaving drugs during a public health crisis. This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or require an adjustment related to past sales, or both. If the trend in actual amounts of variable consideration varies from the Company&#8217;s prior estimates, the Company adjusts these estimates when such trend is believed to be sustainable. At that time, the Company would record the necessary adjustments which would affect net product revenue and earnings reported in the current period. The Company applies this method consistently for contracts with similar characteristics.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425358239592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock', window );">Summary of variable consideration provisions</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the activity and ending balances of the Company&#8217;s variable consideration provisions for the three months ended March 31, 2022 and 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.616%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">944&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,863&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provisions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(162)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(599)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(359)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,227)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">926&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,892&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $37 million and $36&#160;million as of March 31, 2022 and January 1, 2022, respectively, which are reflected as a reduction of Trade receivables, net in the Consolidated Balance Sheets. There were no price appreciation credits during the three months ended March 31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.616%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provisions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(160)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(457)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(483)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,222)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">553&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">924&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,891&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Summary of activity in allowance for credit losses</a></td>
<td class="text">The activity in the allowance for credit losses for trade receivables for the three months ended March 31, 2022 and 2021 is as follows.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.447%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.830%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recoveries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Valuation And Qualifying Accounts [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425355068984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of components and classification of financial assets and liabilities measured at fair value</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table presents the components and classification of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.196%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and other settlement deposits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of effect of hedging instruments on financial statements</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of hedging instruments on the Consolidated Statements of Comprehensive Loss and the Consolidated Statements of Operations for the three months ended March 31, 2022 and 2021:</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.792%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.585%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.105%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain recognized in Other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain excluded from assessment of hedge effectiveness</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location of gain of excluded component</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Expense</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Schedule of assets and liabilities associated with derivatives, included in the Consolidated Balance Sheets</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities associated with the Company&#8217;s foreign exchange contracts as included in the Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021 are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.443%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock', window );">Schedule of foreign exchange contracts on the Consolidated Statements of Operations and Consolidated Statements of Cash Flows</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of the Company&#8217;s foreign exchange contracts on the Consolidated Statements of Operations and the Consolidated Statements of Cash Flows for the three months ended March 31, 2022 and 2021:</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.443%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss related to changes in fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) related to settlements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level 3)</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level&#160;3) for the three months ended March 31, 2022 and 2021: </span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:63.132%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.843%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.547%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to Acquisition-related contingent consideration:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion for the time value of money</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments due to changes in estimates of other future payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments/Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of gains and losses on derivative instruments included in an entity's trading activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4F<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624186-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 55<br> -Paragraph 184<br> -URI http://asc.fasb.org/extlink&amp;oid=123421605&amp;loc=SL5634876-113961<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for net investment hedges of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425357210024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of the components of inventories, net</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net consist of:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.740%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,045&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425357424600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of indefinite-lived intangible assets</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of intangible assets consist of:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization<br/>and<br/>Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization<br/>and<br/>Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,452)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(489)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,174)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Technology and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(199)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,419&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,485)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,934&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,180)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bausch + Lomb Trademark</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,117&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,485)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,632&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,128&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,180)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,948&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of finite-lived intangible assets</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of intangible assets consist of:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization<br/>and<br/>Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization<br/>and<br/>Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,452)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(489)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,174)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Technology and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(199)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,419&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,485)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,934&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,180)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bausch + Lomb Trademark</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,117&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,485)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,632&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,128&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,180)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,948&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of estimated aggregate amortization expense for each of the five succeeding years</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense of finite-lived intangible assets for the remainder of 2022 and each of the five succeeding years ending December&#160;31 and thereafter is as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.833%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remainder of 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,023&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">794&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">627&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,934&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of changes in the carrying amount of goodwill</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amounts of goodwill during the three months ended March 31, 2022 and the year ended December&#160;31, 2021 were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.346%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.298%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.447%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.494%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Bausch + Lomb/ International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,044&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Realignment of segment goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,704)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(578)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,357&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,457&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Realignment of segment goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(798)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,292&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">811&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,050&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,427&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425357354008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED AND OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued and other current liabilities</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities consist of:</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.740%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal matters and related fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,530&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rebates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefit costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,303&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,791&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425360714520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of long-term debt</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs consist of the following: </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.849%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Credit Facilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,577&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.50% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.125% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.75% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.875% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,581&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.125%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.00%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.25%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.50%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.00%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.25%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.25%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.25%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,385&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,654&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,168&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of long-term debt maturities</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of debt obligations for the remainder of 2022, the five succeeding years ending December&#160;31 and thereafter are as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:90.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.383%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt obligations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,385&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized premiums, discounts and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,168&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425357270872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Components of net periodic benefit cost</a></td>
<td class="text">Net periodic (benefit) cost for the Company&#8217;s defined benefit pension plans and postretirement benefit plan for the three months ended March 31, 2022 and 2021 consists of: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.971%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.980%"/><td style="width:0.1%"/></tr><tr style="height:20pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Postretirement<br/>Benefit<br/>Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service credit and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic (benefit) cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425360714520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of the components and classification of share-based compensation expense</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components and classification of share-based compensation expenses related to stock options and RSUs for the three months ended March 31, 2022 and 2021: </span></div><div style="margin-bottom:6pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.471%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Summary of share-based awards</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based awards granted for the three months ended March 31, 2022 and 2021 consist of:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,545,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,343,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average exercise price</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time-based RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,662,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,560,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TSR performance-based RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROTC performance-based RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B+L Separation performance-based RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425357366472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of the components of Accumulated other comprehensive loss</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss consists of:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:69.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,961)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,905)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and postretirement benefit plan adjustments, net of income taxes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,974)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,924)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425357282616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND DEVELOPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock', window );">Summary of research and development</a></td>
<td class="text">Research and development costs consist of:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.471%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product related research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality assurance</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Research And Development Expense [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425357250920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER EXPENSE (INCOME), NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of other expense (income), net</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense (income), net consists of:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.471%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and other matters</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of assets, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425358388072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of calculation of net loss per share</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share attributable to Bausch Health Companies Inc. were calculated as follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.066%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.574%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(610)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted weighted-average common shares outstanding</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360.8&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356.8&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per share attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.19)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.71)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425354352072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of segment revenues and profit</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment revenues and profits were as&#160;follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.471%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,918&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,027&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(194)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(181)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(310)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(357)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments, including loss on assets held for sale</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, integration, separation and IPO costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(362)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(368)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before provision for income taxes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(591)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of revenues by segment and product category</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by segment and product category were as&#160;follows: </span></div><div style="margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.858%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">844&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,918&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">892&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,027&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock', window );">Schedule of revenue attributed to a geographic region</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are attributed to a geographic region based on the location of the customer and were as&#160;follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.471%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,115&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,162&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Korea</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,918&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,027&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock', window );">Schedule of customers that accounted for 10% or more of total revenue</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers that accounted for 10% or more of total revenues were as follows:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation (including McKesson Specialty)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health,&#160;Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425357141144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>country</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfCountriesInWhichEntityOperates', window );">Number of countries in which entity operates</a></td>
<td class="nump">100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfCountriesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of countries in which the entity operates as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfCountriesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425355100920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th">
<div>May 10, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 03, 2021 </div>
<div>company</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ProposedBusinessSeparationAndInitialPublicOfferingNumberOfCompaniesEstablished', window );">Proposed business separation and initial public offering, number of companies established | company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">B+L IPO | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares) | shares</a></td>
<td class="nump">35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price of shares sold (in usd per share) | $ / shares</a></td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Shares sold, net proceeds | $</a></td>
<td class="nump">$ 560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ProposedBusinessSeparationAndInitialPublicOfferingNumberOfCompaniesEstablished">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proposed Business Separation And Initial Public Offering, Number Of Companies Established</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ProposedBusinessSeparationAndInitialPublicOfferingNumberOfCompaniesEstablished</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425351193288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Sales return provisions</a></td>
<td class="nump">$ 1,256,000,000<span></span>
</td>
<td class="nump">$ 1,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Cooperative advertising credits included in rebates</a></td>
<td class="nump">1,892,000,000<span></span>
</td>
<td class="nump">1,891,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,863,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,813,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Price appreciation credits</a></td>
<td class="nump">1,918,000,000<span></span>
</td>
<td class="nump">2,027,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_PriceAppreciationCreditMember', window );">Price Appreciation Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Price appreciation credits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Sales return provisions</a></td>
<td class="nump">19,000,000<span></span>
</td>
<td class="nump">34,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Cooperative advertising credits included in rebates</a></td>
<td class="nump">447,000,000<span></span>
</td>
<td class="nump">553,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 482,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 575,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesAdvertisingCreditsPortionMember', window );">Rebates, Advertising Credits Portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Cooperative advertising credits included in rebates</a></td>
<td class="nump">$ 37,000,000<span></span>
</td>
<td class="nump">$ 34,000,000<span></span>
</td>
<td class="nump">$ 36,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_PriceAppreciationCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_PriceAppreciationCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesAdvertisingCreditsPortionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesAdvertisingCreditsPortionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425351004392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION - Variable Consideration Provisions (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve beginning balance</a></td>
<td class="nump">$ 1,863<span></span>
</td>
<td class="nump">$ 1,813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provisions</a></td>
<td class="nump">1,256<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(1,227)<span></span>
</td>
<td class="num">(1,222)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve ending balance</a></td>
<td class="nump">1,892<span></span>
</td>
<td class="nump">1,891<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDiscountsAndAllowancesMember', window );">Discounts and Allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve beginning balance</a></td>
<td class="nump">222<span></span>
</td>
<td class="nump">190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provisions</a></td>
<td class="nump">134<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(162)<span></span>
</td>
<td class="num">(160)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve ending balance</a></td>
<td class="nump">194<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve beginning balance</a></td>
<td class="nump">482<span></span>
</td>
<td class="nump">575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provisions</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(54)<span></span>
</td>
<td class="num">(56)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve ending balance</a></td>
<td class="nump">447<span></span>
</td>
<td class="nump">553<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesMember', window );">Rebates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve beginning balance</a></td>
<td class="nump">944<span></span>
</td>
<td class="nump">779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provisions</a></td>
<td class="nump">581<span></span>
</td>
<td class="nump">602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(599)<span></span>
</td>
<td class="num">(457)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve ending balance</a></td>
<td class="nump">926<span></span>
</td>
<td class="nump">924<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForChargebacksMember', window );">Chargebacks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve beginning balance</a></td>
<td class="nump">170<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provisions</a></td>
<td class="nump">471<span></span>
</td>
<td class="nump">462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(359)<span></span>
</td>
<td class="num">(483)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve ending balance</a></td>
<td class="nump">282<span></span>
</td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDistributionFeesMember', window );">Distribution Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve beginning balance</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provisions</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(53)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve ending balance</a></td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDiscountsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDiscountsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForChargebacksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForChargebacksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDistributionFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDistributionFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425354029720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION - Activity in Allowance for Credit Losses (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Accounts Receivable, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Beginning balance</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Write-offs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries', window );">Recoveries</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther', window );">Foreign exchange and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Ending balance</a></td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Allowance For Foreign Exchange And Other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AccountsReceivableAllowanceForForeignExchangeAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in allowance for credit loss on accounts receivable, from recovery.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425350979656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSING AGREEMENTS AND DIVESTITURE - Narrative (Details) - Disposal Group, Disposed of by Sale, Not Discontinued Operations - Amoun - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Cash proceeds from divestiture</a></td>
<td class="nump">$ 740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Revenue associated with products for disposal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Asset impairments, including loss on assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_AmounPharmaceuticalCompanySAEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_AmounPharmaceuticalCompanySAEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=bhc_AssetImpairmentChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=bhc_AssetImpairmentChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425351059528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Cost-rationalization and integration initiatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Separation and IPO-related costs included in selling, general and administrative expenses</a></td>
<td class="nump">$ 622<span></span>
</td>
<td class="nump">$ 606<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=bhc_RestructuringAndIntegrationCostsMember', window );">Restructuring and Integration Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Cost-rationalization and integration initiatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Liabilities associated with restructuring, integration and separation costs</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Costs incurred</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Restructuring payments</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=bhc_SeparationAndInitialPublicOfferingCostsMember', window );">Separation and IPO Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Cost-rationalization and integration initiatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring, integration, separation, and IPO costs</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Separation and IPO-related costs included in selling, general and administrative expenses</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=bhc_RestructuringAndIntegrationCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=bhc_RestructuringAndIntegrationCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=bhc_SeparationAndInitialPublicOfferingCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=bhc_SeparationAndInitialPublicOfferingCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425355458856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign currency exchange contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Foreign currency exchange contracts</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">766<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure', window );">Restricted cash and other settlement deposits</a></td>
<td class="nump">1,211<span></span>
</td>
<td class="nump">1,537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">236<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Foreign currency exchange contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Foreign currency exchange contracts</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Foreign currency exchange contracts</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">749<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure', window );">Restricted cash and other settlement deposits</a></td>
<td class="nump">1,211<span></span>
</td>
<td class="nump">1,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level 1 | Foreign currency exchange contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Foreign currency exchange contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Foreign currency exchange contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure', window );">Restricted cash and other settlement deposits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level&#160;2 | Foreign currency exchange contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Foreign currency exchange contracts</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Foreign currency exchange contracts</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure', window );">Restricted cash and other settlement deposits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">236<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level&#160;3 | Foreign currency exchange contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Foreign currency exchange contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Foreign currency exchange contracts</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, as of the balance sheet date, of potential payments under the contingent consideration arrangement which may include cash and shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted Cash And Cash Equivalents And Other Settlement Deposits, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425354068856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 16, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>appeal</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_HighlyLiquidInvestmentsMaturityPeriod', window );">Highly liquid investments, maturity period (or less)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember', window );">US Securities Litigation | Settled Litigation | NEW JERSEY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Settlement, escrow fund included in restricted cash and other settlement deposits | $</a></td>
<td class="nump">$ 1,210<span></span>
</td>
<td class="nump">$ 1,210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LitigationSettlementNumberOfObjectorsAppeals', window );">Settlement, escrow fund included in restricted cash, number of objectors' appeals | appeal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_HighlyLiquidInvestmentsMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Highly Liquid Investments, Maturity Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_HighlyLiquidInvestmentsMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LitigationSettlementNumberOfObjectorsAppeals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Number of Objectors' Appeals</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LitigationSettlementNumberOfObjectorsAppeals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NJ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NJ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425354067608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Narrative (Details) - Currency Swap - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities', window );">Payments or receipts in settlement of cross-currency swaps</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Aggregate notional amounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow or inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromHedgeInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425359815096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details) - Net Investment Hedging - Currency Swap - Designated as Hedging Instrument - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Gain recognized in Other comprehensive loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax', window );">Gain excluded from assessment of hedge effectiveness</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425354506888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Currency Exchange Contracts, Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument | Foreign currency exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Aggregate notional amounts</a></td>
<td class="nump">$ 158,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425351191352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included in Consolidated Balance Sheets (Details) - Foreign currency exchange contracts - Not Designated as Hedging Instrument - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Net fair value</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=bhc_AccruedAndOtherCurrentLiabilitiesMember', window );">Accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossLiability', window );">Accrued and other current liabilities</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueGrossLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226003-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueGrossLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=bhc_AccruedAndOtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=bhc_AccruedAndOtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425359625048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included on Consolidated Statements of Operations and Consolidated Statements of Cash Flows (Details) - Foreign currency exchange contracts - Not Designated as Hedging Instrument - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Loss related to changes in fair value</a></td>
<td class="num">$ (7)<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain', window );">Gain related to settlements</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss', window );">Loss related to settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized loss of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425359468648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Narrative (Details) - Recurring basis - Level&#160;3<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>rate</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measurement Input, Discount Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value, contingent consideration obligations, discount rate</a></td>
<td class="nump">0.06<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measurement Input, Discount Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value, contingent consideration obligations, discount rate</a></td>
<td class="nump">0.18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measurement Input, Weighted Average Risk-Adjusted Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value, contingent consideration obligations, discount rate</a></td>
<td class="nump">0.07<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=bhc_MeasurementInputWeightedAverageDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=bhc_MeasurementInputWeightedAverageDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425351058024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Reconciliation of Contingent Consideration Obligations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, beginning of period</a></td>
<td class="nump">$ 241<span></span>
</td>
<td class="nump">$ 328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">3<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments/Settlements</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, end of period</a></td>
<td class="nump">236<span></span>
</td>
<td class="nump">313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion included in Accrued and other current liabilities</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Non-current portion</a></td>
<td class="nump">193<span></span>
</td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=bhc_AccretionForTimeValueOfMoneyMember', window );">Accretion for the time value of money</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember', window );">Fair value adjustments due to changes in estimates of other future payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Acquisition-related contingent consideration</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">$ (14)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=bhc_AccretionForTimeValueOfMoneyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=bhc_AccretionForTimeValueOfMoneyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425440451048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured on a Non-Recurring Basis and Fair Value of Long-term Debt, Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Nonrecurring adjustment | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of long-term debt</a></td>
<td class="nump">$ 21,963<span></span>
</td>
<td class="nump">$ 22,689<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425354026904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES - Components of Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 288<span></span>
</td>
<td class="nump">$ 279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">636<span></span>
</td>
<td class="nump">602<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total Inventories</a></td>
<td class="nump">$ 1,045<span></span>
</td>
<td class="nump">$ 993<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425354967640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL - Major Components of Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 25,419<span></span>
</td>
<td class="nump">$ 25,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(20,485)<span></span>
</td>
<td class="num">(20,180)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">4,934<span></span>
</td>
<td class="nump">5,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Total intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">27,117<span></span>
</td>
<td class="nump">27,128<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Carrying Amount</a></td>
<td class="nump">6,632<span></span>
</td>
<td class="nump">6,948<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Bausch + Lomb Trademark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Carrying Amount</a></td>
<td class="nump">1,698<span></span>
</td>
<td class="nump">1,698<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember', window );">Product brands</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">20,845<span></span>
</td>
<td class="nump">20,842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(16,452)<span></span>
</td>
<td class="num">(16,169)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">4,393<span></span>
</td>
<td class="nump">4,673<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Corporate brands</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">900<span></span>
</td>
<td class="nump">902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(489)<span></span>
</td>
<td class="num">(473)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">411<span></span>
</td>
<td class="nump">429<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember', window );">Product rights/patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">3,321<span></span>
</td>
<td class="nump">3,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(3,191)<span></span>
</td>
<td class="num">(3,174)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_PartnerRelationshipsMember', window );">Partner relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(154)<span></span>
</td>
<td class="num">(158)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_OutLicensedTechnologyMember', window );">Technology and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(199)<span></span>
</td>
<td class="num">(206)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_PartnerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_PartnerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_OutLicensedTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_OutLicensedTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425350237352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>reporting_unit</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="nump">$ 148,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount', window );">Fair value of reporting value, greater than its carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 469,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated goodwill impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,180,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember', window );">Ortho Dermatologics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">469,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units | reporting_unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=bhc_ReportingUnitsExcludingOrthoDermatologicsMember', window );">Reporting Units Excluding Ortho Dermatologics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=bhc_OrthoDermatologicsReportingUnitMember', window );">Ortho Dermatologics Reporting Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestLongTermGrowthRate', window );">Reporting unit, impairment test, long-term growth rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount', window );">Fair value of reporting value, greater than its carrying value</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 469,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestLongTermGrowthRate', window );">Reporting unit, impairment test, long-term growth rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Ortho Dermatologics Reporting Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestLongTermGrowthRate', window );">Reporting unit, impairment test, long-term growth rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">12.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Ortho Dermatologics Reporting Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Amoun</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember', window );">Product brands</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="nump">71,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_DiscontinuedProductLinesMember', window );">Discontinued Product Lines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ReportingUnitImpairmentTestLongTermGrowthRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reporting Unit, Impairment Test, Long-Term Growth Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ReportingUnitImpairmentTestLongTermGrowthRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of fair value of reporting unit in excess of carrying amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=bhc_ReportingUnitsExcludingOrthoDermatologicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=bhc_ReportingUnitsExcludingOrthoDermatologicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=bhc_OrthoDermatologicsReportingUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=bhc_OrthoDermatologicsReportingUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_AmounPharmaceuticalCompanySAEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_AmounPharmaceuticalCompanySAEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_DiscontinuedProductLinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_DiscontinuedProductLinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425350979288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Remainder of 2022</a></td>
<td class="nump">$ 870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">1,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2027</a></td>
<td class="nump">627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 4,934<span></span>
</td>
<td class="nump">$ 5,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425355642168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL - Changes in Carrying Amount of Goodwill (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,457,000,000<span></span>
</td>
<td class="nump">$ 13,044,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(469,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,000,000)<span></span>
</td>
<td class="num">(118,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,427,000,000<span></span>
</td>
<td class="nump">12,457,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombInternationalMember', window );">Bausch + Lomb/ International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,704,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,704,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,318,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,395,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,000,000)<span></span>
</td>
<td class="num">(77,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,292,000,000<span></span>
</td>
<td class="nump">5,318,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,159,000,000<span></span>
</td>
<td class="nump">3,159,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,159,000,000<span></span>
</td>
<td class="nump">3,159,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">825,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">887,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,000,000)<span></span>
</td>
<td class="num">(62,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">811,000,000<span></span>
</td>
<td class="nump">825,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember', window );">Ortho Dermatologics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">798,000,000<span></span>
</td>
<td class="nump">1,267,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(798,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(469,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">798,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,357,000,000<span></span>
</td>
<td class="nump">2,914,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">683,000,000<span></span>
</td>
<td class="num">(578,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">21,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,050,000,000<span></span>
</td>
<td class="nump">$ 2,357,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombInternationalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombInternationalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425355860248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED AND OTHER CURRENT LIABILITIES - Summary of Accrued and Other Current Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_Legalsettlementsandrelatedfees', window );">Legal matters and related fees</a></td>
<td class="nump">$ 1,530<span></span>
</td>
<td class="nump">$ 1,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AccruedProductRebateCurrent', window );">Product rebates</a></td>
<td class="nump">889<span></span>
</td>
<td class="nump">908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AccruedProductReturnCurrent', window );">Product returns</a></td>
<td class="nump">447<span></span>
</td>
<td class="nump">482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest</a></td>
<td class="nump">372<span></span>
</td>
<td class="nump">328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Employee compensation and benefit costs</a></td>
<td class="nump">283<span></span>
</td>
<td class="nump">336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">702<span></span>
</td>
<td class="nump">749<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">$ 4,303<span></span>
</td>
<td class="nump">$ 4,791<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AccruedProductRebateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the current portion of accrued product rebates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AccruedProductRebateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AccruedProductReturnCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for product returns. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AccruedProductReturnCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_Legalsettlementsandrelatedfees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Legal settlements and related fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_Legalsettlementsandrelatedfees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425348822568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Feb. 10, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 08, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 23,385,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,870,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">23,168,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,654,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: Current portion of long-term debt and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-current portion of long-term debt</a></td>
<td class="nump">$ 23,168,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,654,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member', window );">Term Loan B Facility Due June 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">3.21%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 2,629,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,829,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 2,577,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,772,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member', window );">Term Loan B Facility Due November 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">2.96%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 994,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">994,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 985,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">984,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Notes | 5.50% Senior Notes Due November 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 1,740,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,739,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Notes | 6.125% Senior Notes Due February 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">6.125%<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 986,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Notes | 5.75% Senior Notes Due August 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 495,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">495,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Notes | 4.875% Senior Notes Due June 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">4.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.875%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 1,581,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,580,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 6.125% Senior Notes Due April 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 2,650,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,650,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 2,640,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,640,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 9.00% Senior Notes Due December 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 1,483,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,482,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 9.25% Senior Notes Due April 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">9.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 1,490,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,489,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 8.50% Senior Notes Due January 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 1,754,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,754,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 7.00 % Senior Notes Due January 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 743,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">743,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.00% Senior Notes Due January 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 1,238,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,238,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 6.25% Senior Notes Due February 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 1,484,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,483,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.00% Senior Notes Due February 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 990,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">990,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 7.25 % Senior Notes Due May 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">7.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 743,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">742,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.25% Senior Notes Due January 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 1,237,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,237,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.25% Senior Notes Due February 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">990,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">989,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due June 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">2.96%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 285,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.50NotesDueNovember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.50NotesDueNovember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.75NotesDueAugust2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.75NotesDueAugust2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured4875NotesDueJune2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured4875NotesDueJune2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes900DueDecember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes900DueDecember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes925DueApril2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes925DueApril2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes850DueJanuary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes850DueJanuary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueJanuary2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueJanuary2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueJanuary2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueJanuary2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes625DueFebruary2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes625DueFebruary2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueFebruary2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueFebruary2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes725DueMay2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes725DueMay2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueJanuary2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueJanuary2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueFebruary2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueFebruary2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_OtherLongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_OtherLongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425359817528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Covenant Compliance (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=bhc_SeniorSecuredCreditFacilityMember', window );">Senior Secured Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments', window );">Amount available for restricted payments</a></td>
<td class="nump">$ 13,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio', window );">Fixed charge coverage ratio</a></td>
<td class="nump">2.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio', window );">Secured leverage ratio</a></td>
<td class="nump">4.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Amount Available For Restricted Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Compliance, Secured Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Terms, Fixed Charge Coverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=bhc_SeniorSecuredCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=bhc_SeniorSecuredCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425348061304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 01, 2018</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>May 10, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 23,168,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,168,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,654,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member', window );">Revolving Credit Facility Due June 2023 | Eurocurrency rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member', window );">Revolving Credit Facility Due June 2023 | Canada Bankers Acceptance Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member', window );">Revolving Credit Facility Due June 2023 | Canada Bankers Acceptance Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member', window );">Term Loan B Facility Due June 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,565,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">3.21%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.21%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentAnnualAmortizationRatePercentage', window );">Annual amortization rate (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 2,577,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,577,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,772,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member', window );">Term Loan B Facility Due June 2025 | Eurocurrency rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member', window );">Term Loan B Facility Due June 2025 | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member', window );">Term Loan B Facility Due November 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">2.96%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.96%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentAnnualAmortizationRatePercentage', window );">Annual amortization rate (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 985,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 985,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">984,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member', window );">Term Loan B Facility Due November 2025 | Eurocurrency rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member', window );">Term Loan B Facility Due November 2025 | Base Rate or Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredCreditFacilitiesMember', window );">Senior Secured Credit Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet', window );">Debt covenant, mandatory prepayments, percentage net cash proceeds, property and asset losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet', window );">Debt covenant, mandatory prepayments, percentage net cash proceeds, incurrence of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet', window );">Debt covenant, mandatory prepayments, percentage of consolidated excess cash flow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet', window );">Debt covenant, mandatory prepayments, percentage net cash proceeds, asset sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization', window );">Quarterly remaining amortization payments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredCreditFacilitiesMember', window );">Senior Secured Credit Facilities | Federal Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredCreditFacilitiesMember', window );">Senior Secured Credit Facilities | Eurocurrency rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredCreditFacilitiesMember', window );">Senior Secured Credit Facilities | Eurocurrency rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member', window );">6.125% Senior Notes Due April 2025 | Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 2,640,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,640,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,640,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member', window );">6.125% Senior Notes Due April 2025 | Senior Unsecured Notes | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings', window );">Threshold for incremental borrowings</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA', window );">Threshold for incremental borrowings, percentage of adjusted EBITDA</a></td>
<td class="nump">28.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio', window );">Secured leverage ratio</a></td>
<td class="nump">4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum', window );">Interest coverage ratio (not less than)</a></td>
<td class="nump">2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings', window );">Threshold for incremental borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum', window );">Interest coverage ratio (not less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Senior Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio', window );">Secured leverage ratio</a></td>
<td class="nump">3.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum', window );">Total leverage ratio (not greater than)</a></td>
<td class="nump">6.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Senior Unsecured Notes | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum', window );">Total leverage ratio (not greater than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due June 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,225,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold', window );">Alternate term, number of days prior to scheduled maturity in excess of principal amount threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">91 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold', window );">Alternate term, principal amount maturity threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">2.96%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.96%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 285,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Remaining borrowings</a></td>
<td class="nump">1,171,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,171,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due June 2023 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Commitment fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due June 2023 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Commitment fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due June 2023 | Eurocurrency rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due June 2023 | Eurocurrency rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due June 2023 | Base Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due June 2023 | Base Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Revolving Credit Facility Due June 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 54,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Alternate Term, Principal Amount Maturity Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentAnnualAmortizationRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Annual Amortization Rate, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentAnnualAmortizationRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Compliance, Secured Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Mandatory Prepayments, Percentage Net Cash Proceeds, Asset Sales, If Circumstances Met</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Mandatory Prepayments, Percentage Net Cash Proceeds, Incurrence Of Debt, If Circumstances Met</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Mandatory Prepayments, Percentage Net Cash Proceeds, Property And Asset Losses, If Circumstances Met</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Mandatory Prepayments, Percentage Of Consolidated Excess Cash Flow, If Circumstances Met</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Compliance, Total Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Periodic Payment, Quarterly Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Threshold For Incremental Borrowings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Threshold For Incremental Borrowings, Percentage Of Adjusted EBITDA</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_EurodollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=bhc_CanadaBankersAcceptanceRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=bhc_CanadaBankersAcceptanceRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=bhc_BaseRateOrPrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=bhc_BaseRateOrPrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredCreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredCreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425350828696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Senior Secured Notes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 10, 2022</div></th>
<th class="th"><div>Jun. 08, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl', window );">Redemption price percentage to change in control (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 485,000,000<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl', window );">Redemption price percentage to change in control (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured4875NotesDueJune2028Member', window );">4.875% Senior Notes Due June 2028 | Senior Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.875%<span></span>
</td>
<td class="nump">4.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured4875NotesDueJune2028Member', window );">4.875% Senior Notes Due June 2028 | Senior Secured Notes | Debt Instrument, Redemption, Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured4875NotesDueJune2028Member', window );">4.875% Senior Notes Due June 2028 | Senior Secured Notes | Debt Instrument, Redemption, Period Two | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Maximum percentage of principal amount that can be redeemed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueMarch2024Member', window );">7.00% Senior Notes, Due March 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member', window );">6.125% Senior Notes Due February 2027 | Senior Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member', window );">6.125% Senior Notes Due February 2027 | Senior Secured Notes | Debt Instrument, Redemption, Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price (as a percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member', window );">6.125% Senior Notes Due February 2027 | Senior Secured Notes | Debt Instrument, Redemption, Period Two | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Maximum percentage of principal amount that can be redeemed</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Price, Percentage, Change in Control</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentRedemptionPricePercentageChangeinControl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of principal amount of debt redeemed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured4875NotesDueJune2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured4875NotesDueJune2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueMarch2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueMarch2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425360106344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl', window );">Redemption price percentage to change in control (as a percent)</a></td>
<td class="nump">101.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl', window );">Redemption price percentage to change in control (as a percent)</a></td>
<td class="nump">101.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Price, Percentage, Change in Control</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentRedemptionPricePercentageChangeinControl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425357366472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="nump">5.97%<span></span>
</td>
<td class="nump">5.88%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425348799592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Aggregate Maturities of Long-Term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">Remainder of 2022</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">9,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2026</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2027</a></td>
<td class="nump">3,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">9,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt obligations</a></td>
<td class="nump">23,385<span></span>
</td>
<td class="nump">$ 22,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized premiums, discounts and issuance costs</a></td>
<td class="num">(217)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 23,168<span></span>
</td>
<td class="nump">$ 22,654<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425355098520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Maturities, Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>May 10, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Amount drawn under credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,168<span></span>
</td>
<td class="nump">$ 22,654<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member', window );">6.125% Senior Notes Due April 2025 | Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Amount drawn under credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,640<span></span>
</td>
<td class="nump">$ 2,640<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member', window );">6.125% Senior Notes Due April 2025 | Senior Unsecured Notes | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price (as a percent)</a></td>
<td class="nump">101.021%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_A2027RevolvingCreditFacilityMember', window );">2027 Revolving Credit Facility | Subsequent Event | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Amount drawn under credit facility</a></td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A2027RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A2027RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425348039160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefit Plans | U.S. Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service credit and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic (benefit) cost</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefit Plans | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service credit and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic (benefit) cost</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Postretirement Benefit Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service credit and other</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic (benefit) cost</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425355599576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 28, 2020</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>May 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Remaining unrecognized compensation expense related to non-vested awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average service period over which compensation cost is expected to be recognized (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 10 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_OmnibusIncentivePlan2014Member', window );">2014 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common shares available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares available for issuance (in shares)</a></td>
<td class="nump">13,500,000<span></span>
</td>
<td class="nump">11,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,542,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_OmnibusIncentivePlan2014Member', window );">2014 Plan | Non-employee Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant', window );">Aggregate fair market value on awards granted during any calendar year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Plan Modification, Fair Market Value Limit On Annual Grant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bhc_OmnibusIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bhc_OmnibusIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bhc_NonemployeeDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bhc_NonemployeeDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425355645560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Components and classification of share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Components and classification of share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Components and classification of share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Components and classification of share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Components and classification of share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425355738168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Summary of Share-Based Compensation Award Activity (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract', window );"><strong>Stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">2,545<span></span>
</td>
<td class="nump">1,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price (in usd per share)</a></td>
<td class="nump">$ 24.08<span></span>
</td>
<td class="nump">$ 32.56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in usd per share)</a></td>
<td class="nump">$ 6.63<span></span>
</td>
<td class="nump">$ 11.45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bhc_TimeBasedRSUMember', window );">Time-based RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract', window );"><strong>RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">1,662<span></span>
</td>
<td class="nump">2,560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in usd per share)</a></td>
<td class="nump">$ 24.21<span></span>
</td>
<td class="nump">$ 32.45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bhc_TSRPerformanceBasedRestrictedStockUnitsMember', window );">TSR performance-based RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract', window );"><strong>RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in usd per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 56.04<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bhc_ROTCPerformanceBasedRestrictedStockUnitsMember', window );">ROTC performance-based RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract', window );"><strong>RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in usd per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 31.72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bhc_SeparationPerformanceBasedRestrictedStockUnitsMember', window );">B+L Separation performance-based RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract', window );"><strong>RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in usd per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 32.56<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bhc_TimeBasedRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bhc_TimeBasedRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bhc_TSRPerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bhc_TSRPerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bhc_ROTCPerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bhc_ROTCPerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bhc_SeparationPerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bhc_SeparationPerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425354444680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCUMULATED OTHER COMPREHENSIVE LOSS - Summary of Components of Accumulated Other Comprehensive Loss (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Accumulated other comprehensive loss</a></td>
<td class="num">$ (141)<span></span>
</td>
<td class="num">$ (34)<span></span>
</td>
<td class="num">$ (124)<span></span>
</td>
<td class="nump">$ 605<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,961)<span></span>
</td>
<td class="num">(1,905)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Pension and postretirement benefit plan adjustments, net of income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Accumulated other comprehensive loss</a></td>
<td class="num">$ (1,974)<span></span>
</td>
<td class="num">$ (1,924)<span></span>
</td>
<td class="num">$ (2,256)<span></span>
</td>
<td class="num">$ (2,133)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425353919160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND DEVELOPMENT - Summary of Research and Development (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ResearchAndDevelopmentExpenseProductRelated', window );">Product related research and development</a></td>
<td class="nump">$ 121<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ResearchAndDevelopmentExpenseQualityAssurance', window );">Quality assurance</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development costs</a></td>
<td class="nump">$ 127<span></span>
</td>
<td class="nump">$ 112<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ResearchAndDevelopmentExpenseProductRelated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Product Related</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ResearchAndDevelopmentExpenseProductRelated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ResearchAndDevelopmentExpenseQualityAssurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Quality Assurance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ResearchAndDevelopmentExpenseQualityAssurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425355103304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER EXPENSE (INCOME), NET - Summary of Other Expense, Net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Litigation and other matters</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">3<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain on sale of assets, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense (income), net</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="num">$ (30)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425355612744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER EXPENSE (INCOME), NET - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ScheduleOfOtherIncomeAndExpensesLineItems', window );"><strong>Schedule Of Other Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Milestone achievement, included in net (loss) gain on sale of assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bhc_MilestonePaymentRelatedToCertainProductMember', window );">Milestone Payment Related To Certain Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ScheduleOfOtherIncomeAndExpensesLineItems', window );"><strong>Schedule Of Other Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Milestone achievement, included in net (loss) gain on sale of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ScheduleOfOtherIncomeAndExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Schedule Of Other Income And Expenses [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ScheduleOfOtherIncomeAndExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bhc_MilestonePaymentRelatedToCertainProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bhc_MilestonePaymentRelatedToCertainProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425355665720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision (benefit) from income taxes</a></td>
<td class="num">$ (16)<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax expense (benefit) on ordinary loss</a></td>
<td class="nump">14<span></span>
</td>
<td class="num">(33)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount', window );">Income tax provision (benefit) for discrete items</a></td>
<td class="num">(30)<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingencies', window );">Tax provision (benefit) related to changes in uncertain tax positions</a></td>
<td class="num">(36)<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount', window );">Provision related to filing certain tax returns</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount', window );">Provision related to withholding tax, intercompany dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Tax benefit related to filing of certain tax returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Tax provision (benefit) related to stock compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance against deferred tax assets</a></td>
<td class="nump">2,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties', window );">Unrecognized tax benefits including interest and penalties</a></td>
<td class="nump">876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">927<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized tax benefits related to interest and penalties</a></td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Portion of unrecognized tax benefits, if recognized, would reduce the Company's effective tax rate</a></td>
<td class="nump">196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Unrecognized tax benefit, amount possible to decrease in next twelve months</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss', window );">Estimate of possible loss, income tax examination (up to)</a></td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Discrete Items, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Expense Filing Tax Returns, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Withholding Tax, Intercompany Dividends, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross amount of unrecognized tax benefits including interest and penalties pertaining to uncertain tax positions taken in tax returns as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120384911&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated amount of loss resulting from an adverse tax position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32059-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425354063336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE - Schedule of Calculation of Earnings Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Bausch Health Companies Inc.</a></td>
<td class="num">$ (69)<span></span>
</td>
<td class="num">$ (610)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted-average common shares outstanding (in shares)</a></td>
<td class="nump">360.8<span></span>
</td>
<td class="nump">356.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted-average common shares outstanding (in shares)</a></td>
<td class="nump">360.8<span></span>
</td>
<td class="nump">356.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per share attributable to Bausch Health Companies Inc. (in usd per share)</a></td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (1.71)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per share attributable to Bausch Health Companies Inc. (in usd per share)</a></td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (1.71)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425359407656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE - Narrative (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Stock Options and RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive shares not included in the computation of diluted earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive effect of potential common shares (in shares)</a></td>
<td class="nump">3,600<span></span>
</td>
<td class="nump">6,657<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember', window );">Time-based RSUs, Performance-based RSUs and Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive shares not included in the computation of diluted earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive effect of potential common shares (in shares)</a></td>
<td class="nump">9,332<span></span>
</td>
<td class="nump">4,846<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_PerformanceBasedRestrictedStockUnitsMember', window );">Performance-Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive shares not included in the computation of diluted earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount', window );">Excluded from computation of earnings per share, performance conditions not met (in shares)</a></td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities Excluded From Computation Of Earnings Per Share, Performance Conditions Not Met, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_PerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_PerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425357153272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS - Legal Proceeds and Governmental and Regulatory Inquiries (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Current accrued loss contingencies</a></td>
<td class="nump">$ 1,530<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 55<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=116646759&amp;loc=d3e15243-108350<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425348467912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS - Securities and RICO Class Actions and Related Matters (Details)<br> $ in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 20, 2021 </div>
<div>USD ($) </div>
<div>insured</div>
</th>
<th class="th">
<div>Aug. 04, 2020 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 16, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 07, 2017 </div>
<div>insurance_policy_period</div>
</th>
<th class="th">
<div>Oct. 31, 2015 </div>
<div>case</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>case </div>
<div>group </div>
<div>action</div>
</th>
<th class="th">
<div>Sep. 16, 2016 </div>
<div>action</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>case</div>
</th>
<th class="th">
<div>Mar. 17, 2021 </div>
<div>entity</div>
</th>
<th class="th">
<div>Feb. 15, 2019 </div>
<div>entity</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember', window );">US Securities Litigation | New Jersey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors', window );">Number of groups of investors filing action | group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsDismissedNumber', window );">Number of claims dismissed | case</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending', window );">Number of groups of investors filing action, remain pending | group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember', window );">US Securities Litigation | New Jersey | Unfavorable Regulatory Action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of suits filed | case</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember', window );">US Securities Litigation | Settled Litigation | New Jersey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Settlement, agreed to pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember', window );">US Securities Litigation | Settled Litigation | New Jersey | Restricted Cash And Other Settlement Deposits, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Settlement, agreed to pay</a></td>
<td class="nump">$ 1,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_CanadianSecuritiesLitigationMember', window );">Canadian Securities Litigation | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of suits filed | case</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_CanadianSecuritiesLitigationMember', window );">Canadian Securities Litigation | Canada | Violation of Canadian Provincial Securities Legislation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber', window );">Number of suits filed but not yet served | action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction', window );">Number of entities, exercised opt-out right, pursuing action | entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_CanadianSecuritiesLitigationMember', window );">Canadian Securities Litigation | Settled Litigation | Canada | Violation of Canadian Provincial Securities Legislation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Settlement, agreed to pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_RICOClassActionsMember', window );">RICO Class Actions | New Jersey | Unfavorable Regulatory Action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of suits filed | action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_InsuranceCoverageLawsuitMember', window );">Insurance Coverage Lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyNumberOfInsurancePolicyPeriods', window );">Number of distinct insurance policy periods | insurance_policy_period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_InsuranceCoverageLawsuitMember', window );">Insurance Coverage Lawsuit | Settled Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencySettlementAgreementsNumberOfInsurers', window );">Settlement agreements, number of insurers | insured</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty', window );">Aggregate amount to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency New Claims Filed But Not Yet Served Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyNewClaimsFiledButNotYetServedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyNumberOfInsurancePolicyPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Insurance Policy Periods</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyNumberOfInsurancePolicyPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Plaintiffs, Number of Groups of Investors</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Plaintiffs, Number of Groups of Investors, Pending</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencySettlementAgreementsNumberOfInsurers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Settlement Agreements, Number Of Insurers</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencySettlementAgreementsNumberOfInsurers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded from other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedFromOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyClaimsDismissedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of claims dismissed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyClaimsDismissedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NJ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NJ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_UnfavorableRegulatoryActionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_UnfavorableRegulatoryActionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_CanadianSecuritiesLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_CanadianSecuritiesLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=bhc_ViolationofCanadianProvincialSecuritiesLegislationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=bhc_ViolationofCanadianProvincialSecuritiesLegislationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_RICOClassActionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_RICOClassActionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_InsuranceCoverageLawsuitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_InsuranceCoverageLawsuitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425355369368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS - Antitrust (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 26, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 30, 2020 </div>
<div>case</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationMember', window );">Glumetza Antitrust Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of putative antitrust class actions filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationMember', window );">Glumetza Antitrust Litigation | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Settlement, agreed to pay | $</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationMember', window );">Glumetza Antitrust Litigation | Plaintiffs, Direct Purchasers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of putative antitrust class actions filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember', window );">Glumetza Antitrust Litigation, Non-Class Complaints</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of putative antitrust class actions filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember', window );">Glumetza Antitrust Litigation, Non-Class Complaints | Plaintiffs, Direct Purchasers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of putative antitrust class actions filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bhc_PlaintiffsDirectPurchasersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bhc_PlaintiffsDirectPurchasersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425350909768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS - Intellectual Property (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 28, 2020</div></th>
<th class="th"><div>May 01, 2020</div></th>
<th class="th"><div>Mar. 26, 2020</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>defendant </div>
<div>claim</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_NorwichPharmaceuticalsIncLitigationMember', window );">Norwich Pharmaceuticals Inc. Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyStayOfApprovalPeriod', window );">Stay of approval, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember', window );">Perrigo Israel Pharmaceuticals, Ltd. Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyStayOfApprovalPeriod', window );">Stay of approval, period</a></td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_PadagisLitigationMember', window );">Padagis Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyStayOfApprovalPeriod', window );">Stay of approval, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_MSNLaboratoriesPrivateLtdLitigationMember', window );">MSN Laboratories Private Ltd. Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyStayOfApprovalPeriod', window );">Stay of approval, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_PatentInfringementLitigationMember', window );">Patent Infringement Litigation | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyNumberOfSeparateDefendants', window );">Number of separate defendants | defendant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ApotexIncLitigationMember', window );">Apotex Inc. Litigation | Canada | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of lawsuits pending | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyNumberOfSeparateDefendants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Separate Defendants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyNumberOfSeparateDefendants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyStayOfApprovalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Stay Of Approval, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyStayOfApprovalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_NorwichPharmaceuticalsIncLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_NorwichPharmaceuticalsIncLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_PadagisLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_PadagisLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_MSNLaboratoriesPrivateLtdLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_MSNLaboratoriesPrivateLtdLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_PatentInfringementLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_PatentInfringementLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_ApotexIncLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_ApotexIncLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425355821896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS - Product Liability (Details) - case<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationMember', window );">Shower to Shower Product Liability Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyStayOfApprovalPeriod', window );">Stay of approval, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod', window );">Stay of approval, motion to extend, period</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationMember', window );">Shower to Shower Product Liability Litigation | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of lawsuits pending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationMember', window );">Shower to Shower Product Liability Litigation | BRITISH COLUMBIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of lawsuits pending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationMember', window );">Shower to Shower Product Liability Litigation | QUEBEC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of lawsuits pending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationMember', window );">Shower to Shower Product Liability Litigation | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of lawsuits pending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember', window );">Shower to Shower Product Liability Litigation, Alleging Caused Ovarian Cancer, Mesothelioma or Breast Cancer | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of lawsuits pending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_MSNLaboratoriesPrivateLtdLitigationMember', window );">MSN Laboratories Private Ltd. Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyStayOfApprovalPeriod', window );">Stay of approval, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Stay Of Approval, Motion To Extend, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyStayOfApprovalMotionToExtendPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyStayOfApprovalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Stay Of Approval, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyStayOfApprovalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA-BC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA-BC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA-QC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA-QC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_MSNLaboratoriesPrivateLtdLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_MSNLaboratoriesPrivateLtdLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425359641960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS - General Civil Actions (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 28, 2019</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_DoctorsAllergyFormulaLLCLitigationMember', window );">Doctors Allergy Formula, LLC Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages sought</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_LitigationwithFormerSalixCEOMember', window );">Litigation with Former Salix CEO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages sought</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_DoctorsAllergyFormulaLLCLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_DoctorsAllergyFormulaLLCLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_LitigationwithFormerSalixCEOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_LitigationwithFormerSalixCEOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425357133560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>reporting_unit</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember', window );">Ortho Dermatologics</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425355335672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Segment Revenues and Profit (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 08, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,918<span></span>
</td>
<td class="nump">$ 2,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285<span></span>
</td>
<td class="num">(221)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(310)<span></span>
</td>
<td class="num">(357)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges', window );">Goodwill impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(469)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairments, including loss on assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(148)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_RestructuringChargesAndInitialPublicOfferingCosts', window );">Restructuring, integration, separation and IPO costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income (expense), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(362)<span></span>
</td>
<td class="num">(368)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="num">$ (38)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(82)<span></span>
</td>
<td class="num">(591)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">889<span></span>
</td>
<td class="nump">881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">464<span></span>
</td>
<td class="nump">472<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">244<span></span>
</td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">249<span></span>
</td>
<td class="nump">296<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,918<span></span>
</td>
<td class="nump">2,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">812<span></span>
</td>
<td class="nump">916<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segment | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">889<span></span>
</td>
<td class="nump">881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segment | Salix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">464<span></span>
</td>
<td class="nump">472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">322<span></span>
</td>
<td class="nump">327<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segment | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">244<span></span>
</td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segment | Solta Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segment | Diversified Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">249<span></span>
</td>
<td class="nump">296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (194)<span></span>
</td>
<td class="num">$ (181)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible asset amortization expense excluding amortization allocated to alliance and royalty revenue and cost of goods sold during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill, Impairment Loss, Not Included In Asset Impairment Charges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RestructuringChargesAndInitialPublicOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring Charges And Initial Public Offering Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RestructuringChargesAndInitialPublicOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425348466136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Disaggregation of Revenue (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 1,918<span></span>
</td>
<td class="nump">$ 2,027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_PharmaceuticalProductsMember', window );">Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">844<span></span>
</td>
<td class="nump">892<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_DeviceProductsMember', window );">Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">458<span></span>
</td>
<td class="nump">454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_OvertheCounterProductsMember', window );">OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">375<span></span>
</td>
<td class="nump">347<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_BrandedandOtherGenericProductsMember', window );">Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">221<span></span>
</td>
<td class="nump">310<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_OtherRevenuesMember', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">889<span></span>
</td>
<td class="nump">881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb | Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">386<span></span>
</td>
<td class="nump">382<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb | OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">335<span></span>
</td>
<td class="nump">320<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb | Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb | Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">464<span></span>
</td>
<td class="nump">472<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">464<span></span>
</td>
<td class="nump">470<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">244<span></span>
</td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International | Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International | OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International | Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">133<span></span>
</td>
<td class="nump">212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International | Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical | Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical | OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical | Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical | Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">249<span></span>
</td>
<td class="nump">296<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products | Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">205<span></span>
</td>
<td class="nump">242<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products | OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products | Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products | Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_PharmaceuticalProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_PharmaceuticalProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_DeviceProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_DeviceProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_OvertheCounterProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_OvertheCounterProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_BrandedandOtherGenericProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_BrandedandOtherGenericProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_OtherRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_OtherRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425359995288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Narrative (Details) - product<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ConcentrationRiskNumberOfProducts', window );">Number of products represented of total revenue</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember', window );">Product Concentration Risk | Revenues | Customer, Top Ten Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">44.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ConcentrationRiskNumberOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration Risk, Number Of Products</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ConcentrationRiskNumberOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bhc_CustomerTopTenProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bhc_CustomerTopTenProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425355272024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Revenue by Geographic Area (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 1,918<span></span>
</td>
<td class="nump">$ 2,027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=bhc_UnitedStatesandPuertoRicoMember', window );">U.S. and Puerto Rico</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,115<span></span>
</td>
<td class="nump">1,162<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_PL', window );">Poland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_MX', window );">Mexico</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_FR', window );">France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_DE', window );">Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_GB', window );">United Kingdom</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_RU', window );">Russia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_ES', window );">Spain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IT', window );">Italy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_KR', window );">South Korea</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=bhc_OtherCountriesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 219<span></span>
</td>
<td class="nump">$ 280<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bhc_UnitedStatesandPuertoRicoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bhc_UnitedStatesandPuertoRicoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_PL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_PL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_MX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_MX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_RU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_RU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_ES">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_ES</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_KR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_KR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bhc_OtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bhc_OtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425358750504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Major Customers (Details) - Revenues - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember', window );">AmerisourceBergen Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember', window );">McKesson Corporation (including McKesson Specialty)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember', window );">Cardinal Health,&#160;Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bhc_AmerisourceBergenCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bhc_AmerisourceBergenCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bhc_McKessonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bhc_McKessonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bhc_CardinalHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bhc_CardinalHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140425345681512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>May 10, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jan. 18, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">361,331,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359,405,748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,168,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,654,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings', window );">Threshold for incremental borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum', window );">Interest coverage ratio (not less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum', window );">Total leverage ratio (not greater than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_A9.00SeniorNotesdueDecember2025Member', window );">9.00% Senior Notes due December 2025 | Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 370,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet', window );">Debt covenant, redemption and discharge condition, amount, if circumstances met</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member', window );">6.125% Senior Notes Due April 2025 | Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,640,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,640,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings', window );">Threshold for incremental borrowings</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate', window );">Incremental borrowings interest rate</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum', window );">Interest coverage ratio (not less than)</a></td>
<td class="nump">2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Revolving Credit Facility | Senior Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio', window );">Secured leverage ratio (not greater than)</a></td>
<td class="nump">3.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Revolving Credit Facility | Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum', window );">Total leverage ratio (not greater than)</a></td>
<td class="nump">6.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Term Loan Due May 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 2,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentAnnualAmortizationRatePercentage', window );">Annual amortization rate (as a percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Term Loan Due May 2027 | SOFR, CDOR, EURIBOR and SONIA Rates | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="nump">1.015%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Term Loan Due May 2027 | SOFR, CDOR, EURIBOR and SONIA Rates | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="nump">1.475%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Term Loan Due May 2027 | U.S. Dollar Base Rate and Canadian Dollar Prime Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="nump">0.015%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Term Loan Due May 2027 | U.S. Dollar Base Rate and Canadian Dollar Prime Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="nump">0.475%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Term Loan Due May 2027 | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate', window );">Credit spread adjustment (as a percent)</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Term Loan Due May 2027 | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Term Loan Due May 2027 | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Term Loan Due May 2027 | Base Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Revolving Credit Facility Due May 2027 | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Facility fee (as a percent)</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments', window );">Percentage of net cash proceeds of insurance and condemnation proceeds for property or asset losses</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments', window );">Percentage of cash proceeds from incurrence of debt</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments', window );">Percentage of annual excess cash flow</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments', window );">Percentage of cash proceeds from asset sales outside the ordinary course of business payable as mandatory prepayments</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Revolving Credit Facility Due May 2027 | Revolving Credit Facility | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Commitment fee (as a percent)</a></td>
<td class="nump">0.11%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Revolving Credit Facility Due May 2027 | Revolving Credit Facility | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Commitment fee (as a percent)</a></td>
<td class="nump">0.275%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Revolving Credit Facility Due May 2027 | Revolving Credit Facility | SOFR, CDOR, EURIBOR and SONIA Rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Revolving Credit Facility Due May 2027 | Revolving Credit Facility | SOFR, CDOR, EURIBOR and SONIA Rates | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Revolving Credit Facility Due May 2027 | Revolving Credit Facility | SOFR, CDOR, EURIBOR and SONIA Rates | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Revolving Credit Facility Due May 2027 | Revolving Credit Facility | U.S. Dollar Base Rate and Canadian Dollar Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Revolving Credit Facility Due May 2027 | Revolving Credit Facility | U.S. Dollar Base Rate and Canadian Dollar Prime Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Revolving Credit Facility Due May 2027 | Revolving Credit Facility | U.S. Dollar Base Rate and Canadian Dollar Prime Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Revolving Credit Facility Due May 2027 | Revolving Credit Facility | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate', window );">Credit spread adjustment (as a percent)</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | 2027 Term Loan B Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 2,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentAnnualAmortizationRatePercentage', window );">Annual amortization rate (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | 2027 Term Loan B Facility | U.S. Dollar Base Rate and Canadian Dollar Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | 2027 Term Loan B Facility | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | 2027 Term Loan B Facility | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate', window );">Credit spread adjustment (as a percent)</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | 2027 Term Loan B Facility | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate', window );">Credit spread adjustment (as a percent)</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | 2027 Term Loan B Facility | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | 2027 Term Loan B Facility | Base Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | 2027 Term Loan B Facility | SOFR, CDOR and EURIBOR Rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | 2027 Revolving Credit Facility | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 975,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold', window );">Alternate term, number of days prior to scheduled maturity in excess of principal amount threshold</a></td>
<td class="text">91 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold', window );">Alternate term, principal amount maturity threshold</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | 2027 Revolving Credit Facility | Revolving Credit Facility | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Commitment fee (as a percent)</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | 2027 Revolving Credit Facility | Revolving Credit Facility | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Commitment fee (as a percent)</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | 2027 Revolving Credit Facility | Revolving Credit Facility | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | 2027 Revolving Credit Facility | Revolving Credit Facility | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | 2027 Revolving Credit Facility | Revolving Credit Facility | Base Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | 2027 Revolving Credit Facility | Revolving Credit Facility | Base Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Senior Secured Credit Facilities | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments', window );">Percentage of net cash proceeds of insurance and condemnation proceeds for property or asset losses</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments', window );">Percentage of cash proceeds from incurrence of debt</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments', window );">Percentage of annual excess cash flow</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments', window );">Percentage of cash proceeds from asset sales outside the ordinary course of business payable as mandatory prepayments</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | New Restated Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantTotalLeverageRatio', window );">Total leverage ratio</a></td>
<td class="nump">760.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | 6.125% Senior Notes Due April 2025 | Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price (as a percent)</a></td>
<td class="nump">101.021%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | B+L IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="nump">35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price of shares sold (in usd per share)</a></td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Shares sold, net proceeds</a></td>
<td class="nump">$ 560,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Over-Allotment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="nump">5,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_SaleOfStockOverAllotmentTerm', window );">Underwriters option to purchase additional shares, term</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Over-Allotment | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, outstanding (in shares)</a></td>
<td class="nump">315,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction', window );">Percentage of shares held</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Alternate Term, Principal Amount Maturity Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentAnnualAmortizationRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Annual Amortization Rate, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentAnnualAmortizationRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Redemption And Discharge Condition, Amount, If Circumstances Met</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Terms, Secured Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantTotalLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Total Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantTotalLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Compliance, Total Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Credit Spread Adjustment on Variable Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of annual excess cash flow with any excess amounts after the prepayment of the loans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of net cash proceeds from asset sales outside ordinary course of business payable as mandatory prepayments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of net cash proceeds of insurance and condemnation proceeds for property or asset (losses) which is payable as mandatory prepayment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of net cash proceeds from the incurrence of debt payable as mandatory prepayments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Threshold For Incremental Borrowings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility Threshold For Incremental Borrowings Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_SaleOfStockOverAllotmentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Over-Allotment, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_SaleOfStockOverAllotmentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A9.00SeniorNotesdueDecember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A9.00SeniorNotesdueDecember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanDueMay2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanDueMay2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=bhc_SOFRCDOREURIBORAndSONIARatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=bhc_SOFRCDOREURIBORAndSONIARatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueMay2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueMay2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A2027TermLoanBFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A2027TermLoanBFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=bhc_SOFRCDORAndEURIBORRatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=bhc_SOFRCDORAndEURIBORRatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A2027RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A2027RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredCreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredCreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_NewRestatedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_NewRestatedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>bhc-20220331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bhc="http://www.bauschhealth.com/20220331"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2021"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="bhc-20220331.xsd" xlink:type="simple"/>
    <context id="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie4a7b4e0ac9943a9b88f1223220896de_I20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2022-05-05</instant>
        </period>
    </context>
    <context id="i27191b9cf0284661bc72bab06e9a28cc_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idc41203b79724c8b8c35295ae22f1ee5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7062f2c8d3b74170b8ed9d57d942850f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i47ece7f00f6a493a9f2236a26d681928_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i69f7b40936e24b94a92542e01f316976_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib5e530ee58404ccc965b53fc6d73c350_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i13d8ae26fd5b445285277b95f6ab5311_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iba49a57b938b4b89b6c94414674a0509_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i84be42c574674323bfa1ce40efc25a3b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4e97a6c789b1443ba408d058697c5cc2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icdfc8eeec050428bb667d6d8a8100215_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if569d73216764720b3070f4e5764288d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7de19b3349ed480785851723d3e2ec65_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0ae02726ad6f44979a1c380354d1b1ee_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i77808f738d5b47f0b37ad9c848b56f22_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9f4e826d5cae4c6ab418a941d7cc0de2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9c0970c94f194e79b173d2e77e2e293e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icfaddc1e31294937b80e601e88e11ec4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id18917e004004a1cb3c4e185b15bf4f9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3f63b9f26c034375825caac2dc4a720d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib79580d46a03440a901afd4aa7cf0eae_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i38bc8011408047f4b2f92fc815fe79b3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6f1e816041a249bcaedd71a44ddc03c1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0925610a81344f42966f7155678bbe7d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6bc0f97e922441d290fd2952ed4015ca_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2f39cf0ad53f489993087fb8612e9e44_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i580f9e18b59a4b5180b3f4e43139f3fd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7c28220a2c554d82874543d9cef4c95f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7ec67446aa664948b24b2dd151b61e21_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ida777d6fa6784748b45afb0c1b8b936f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2d274a4a3e5a43ae91dfbb2934c4c5d1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i250250ab4d084a8688cdf94e83fcc6ea_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9abb088ab0824fe28335ba83a90707de_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4db7cba132fa4f3593873402ff1be811_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1cf56ffa097d418fbaa7f8cee2095239_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="icf2c42a95b1b488c9bb882abf26775af_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8c96e3e707c44ef29db8e7d1430f0ccf_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ifc469902b8d54318b2dc5e3d6f63767e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1a3043cdb1ec4efba6e8a08d5c15f7d0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8aed8fa227084065a8e36af7e4853547_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if8e74f44512b4b5ba5eadd53d7ab8369_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2671fe8b646f46afb7fa5e65ea5d1e7b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3f5376ee1f8e4cf1a9859fc1a22909f3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i812289a7a0cf44b4b1eed544ad0bec6c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i68726a27c9ca4a3a994459eb340ec3da_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ia0d8e4dd5979420fbef5b45edd961b43_I20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="iae181339de7f48fb8794bf85314efcc0_I20210803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2021-08-03</instant>
        </period>
    </context>
    <context id="i3b5fdcedce07473f95b4d896abcc8dc6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id234e6e6761c4d3fadd602df79c36a18_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3282ac48025c402fb8242346f1697dc3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4f7124918f0c4940946cbc5598b8eb93_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i82cd23474eef475d818ea158ef0a033c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9f025023becd4701b88a21aeb30b1551_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2702eb3989e049ee9ba259ff98e17bd5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iba1bbd977ad949bb8ef314204d0f9031_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i75a4cf7e52aa4b4baa6fd5cc411e8269_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib297e736b3f84933b2038cba50e4d5ed_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia1d87c2977704a1e9e27fa4ce9d6f6ca_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i91537bd044f94fd8a698e842e7d17804_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i445a6442a30f43b594d2d8364e5b4894_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ifcb261aecea64295aab4bf43ac889601_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0bcf6389cdc947f7ae05710631221f68_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i697ad802318444ba908fe6471d84bff7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if292799a4efd4044b18a023be1f10b95_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i5fec8302d4c14f00b65fb0e31f318228_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PriceAppreciationCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia46992a39fd44a9b8ea71a5f0394d386_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4f9959394a574ff69f1d9b58d938d4d3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4e23891f40464cfa8e56cdb7bab0040d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9401e356d1aa4b399cc5adc2cd56f34c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic58ddf3411fb47e0af82f6f1e662bf16_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i54b8dbfb41c7451caad9c7ce92634d2b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3e143ff88d214dff8d83bfb996d04d80_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i038c797945244014ae7afbec7d83111e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie89ad456c68d4bbbbdbaf276e1161261_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i92d2b71d6b3c41538e26137d45cf75e6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5e170c61a34348efbeb9b2757d9d6ff0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5cc8ac7cdffe4470a00c7b19194e2fd9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia71b36fbbd72476aa3d99cbc13954b77_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iacbae26421d743459b9dfa79bcc4f94f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6300cf7309e042b48c456d1a58ee874f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i39945b5b3dde4b2f9bc375faa8ded0c1_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iaa437e0185f6406491796407827b52e0_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="idba10c80ddf84c3cbaffdb663edf3e53_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PriceAppreciationCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3524eadbe1ec47a0a36751409752f55b_D20210331-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i21711d9019c8476f949b23d06ee0e9c1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bhc:AssetImpairmentChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9d5bc364e17040579714c24cebd52ba5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8f59ac9f2ff644c89eb4f65f46c45061_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i956734b907cd48758decdff4f630c6f9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idc39509affcd41d9a58e0cca4fe7e0eb_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i85c368e92b024530907723a0994de3c7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:SeparationAndInitialPublicOfferingCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4fb5f4d139b04ae9b628f854af7fd7ee_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:SeparationAndInitialPublicOfferingCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9bdc5e2685a240ae96ca33df37493045_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i363991f4b7144460a084057864c8034f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ifc1a0b5922ad406796cebf7b0701a0cb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i20f7343e1588476cb8e134ea3252cb58_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if45e89de6ed14de1836e660f70eb9092_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i150d2e94468344d2bba3906c337eef86_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaa7390cf31be44f1986a62d20c407d5b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ica75b10c2fbd403ea21ee75a6cd245bd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie0cbf30c76af4d498983e82d4fdca172_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if05c08af1a034dc7980de8e6d52990be_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0b499ddf7ec0496ba113157683c198d2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i81fe5dde69aa4fa98b7711acbae4387f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i100091396ce9444685173217122765a6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i723c0252bb3e4eb98782b62a2ac15585_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i258050e5f8ba4ce1b2273604ec31e67f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id7cdfcca5d2f4a10b641c8f4d80b31b8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5945a5ff5f34495dab13516392201c16_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5b77eb6463994ae99224a58bba550905_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bhc:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4b4e235324904728b762550f85fa7269_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iee66331a046f4575acc6e455516cc956_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia2c311dd5c6b469480afc3e5392a01db_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1e2fdd6767694d7e97928c8c973cce88_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ieb234a60c94344e9a94bfbc00466a78a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i46cf2f3899da4a21a3b37afd85cde532_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibf2062d283b74ee789d97615ebc112e9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="idf8c5147a31443548f1f01cdff3ee173_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib0fafc41fd0d46f2aafbccde9b40c90f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib1d2d795d550443991566dd2c6bcf53b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8f0e25e6a91b4e2e872255dda15e2d72_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bhc:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i811cc5ac0cc64328ad722d7dad5db8b1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5ec8590d1fe9450a8eb2faa9ceaf5975_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id0b87773b146435a838297c342e6101d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iaf65fa777b444e8b899db7eb8bab459d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5ba0dd91cc574f9abe328ce7f85dc950_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i142e78536e92483bb3067f4b123b35c7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id92289d625924bfcb27511b3c14249c7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">bhc:MeasurementInputWeightedAverageDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib824c124997f479bbc169d1602673e5b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:AccretionForTimeValueOfMoneyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if29face7dd5e4f4f824bb78e8b24bb84_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:AccretionForTimeValueOfMoneyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ifbb2bee16b5a4770b40bde7992c3b661_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7beef5fa81be4f83928de85244de7710_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id1ad1d6d1a0146b0848446f63d1074ab_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idc49a20c1efb4682a698d499e7132490_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i33581fa718c7424d96b4ece6084ce29f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i69ed23fd69344f4bb9c380845d6fda6f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1cfcfb06623f468794d93d4a7a2a0b37_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie2b058cfe7264b67b8928b4f04d339b3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i01425e632a3246ef8376661a776befbe_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i128fe797bfca49acb9c7413882eb5f28_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6778a58f66f24243ab203161f3c6127d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8420c39690874c31bfc4e99fc56813a9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icdae99c37fc148b9b34c052c3f5ee437_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="icc94d751eecd4f2884cec4ffed6f0547_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i184da53a325548e5a9b4d68317c28bf5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7adc09fd30f54c31a00d1b781106171b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i24b3278f312448edbdbbd2e5c8edb4ea_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9aa88c188d514752bb8a235164b310e8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:DiscontinuedProductLinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibd413c64fca1463c942b8ada290af82b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i78352536ea52411880331b5c2102a14b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:DiscontinuedProductLinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i942199177b494651b884505a5348aee8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i12b373f353694a7a92ef13969e363c9c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2f9c2f75c9054ca7be42d333db8aa66a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5a8465040b7746bbbb02d83f214f8936_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9e916e0c53bb4694a37e063fb61adc77_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i56804b7aa6534ed9b555f349c187b56d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7b662e8f657b4e3ab3b79a4cebde04c2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib37696822d2c4572b3c78344c1fd444a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia94fd825df534043ad9a8d3ff85daa7f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1dcff32aa885494dbd4c25e336b285dd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i928ceb331757485bb004adc674715221_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iab3980bb98104da18c9a7bfacb2b814c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icad79738cfa145e4ad3efae80a8f7853_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i883adcdb932a4b7facd79e34969366b7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie485ba4bcfb74a319879f1cc1994ceb1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibc6abfd8107c426d88c7af70640541ed_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i16fa5c63321a4379872d667cd4f09ff7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie3e9f44ea7f04ab4bb12e34a4d9b198f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i03d9858da1a54c6a897587b6b5079ca1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4cc8090790184dbd8e5fef8bc092f80c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id5df5fcbde684e86add3147c9fe2ea1c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i897d561735644b67b640f606386ea273_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i03af4a3fb12d4415985732b5f1713c51_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7c5165be148344bdaf507fcd8cd8faa1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iff8cffb5a07d43829a8ad9375270cefc_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i17fd70111a574d2ca873e85d5d905ac6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i42279724503f49f38806cc3713f1dec9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2c7901af22c14ac2ad3c4144a35ef0c6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i05c0aa9bce2948fe95f19480427221e2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="icb4928a2aeb34ea08a24be593ce24cf0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i05c4425257364b019ef82d6d8127a3d0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i22918d18bb77417eac5d796b8c470056_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i59dd4c241bfe46cab97c7f62aa7998be_D20210331-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i813f53a5817849fa8b332b4429a806c7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:ReportingUnitsExcludingOrthoDermatologicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i352bdc0bdb3746bcab18bb34559bda96_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib3d106cc00bb4068aeaadfb5a27059ab_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3b7487693f3a42968a15d65a005a518a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i579bd73ae67e4680b7518c0d567bd33c_D20210331-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i76fa5b74ac474ce785d33b402a51a48b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0aeee5779e6741b5a846738af963baa7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4bde0da879c447c1bce8cc7c0ff990a9_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i66cd53bf84e745829ac8a76a80274bef_D20210630-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2021-06-30</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i273ea466a0c24f7f9a2bc799a58a59b0_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i84c7e2b9e5eb4b97857089a8cd8efa23_D20211001-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i600f2612b7b641d682431ce561c69ad9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if6561f3b97934eda8c2522f1ea9ce1b7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i76f9207c1db94dfbacf80f2bc2b52b0d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i06779efa67a44834b0f4f24944444a1b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i782e0885b3064787aa9e926150c70157_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibc86294f39b245aebaa7bec35dc0f511_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i54411522c1a245de9350f74e2cd4c3d1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1632bbe90c084a8bbad28b27f64c1f85_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic53f52344dcd464f82fdd9233f9e3fbb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.50NotesDueNovember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i488c2864915b43b0b468383a88a34995_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.50NotesDueNovember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i09bbf996de02471991c5b856e064297d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1ba04ab2a63c40b39e946e401067a3d9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icfa4659d82fd4e9583cb868b85c3feab_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.75NotesDueAugust2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie9b94284819448b1933c562ef7aded08_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.75NotesDueAugust2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2abc875715cb4b1fa661daa27ac2f5af_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic574f713857543fe848f75d40d04e380_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i379ff2b3df7445b5b936e826c3995957_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i247336064728420fafc7c84febff7ebc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib2f961c12b854470a0cc36e07e92006e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes900DueDecember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7146a1406b5149a0897a90ac7344b1bb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes900DueDecember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1b4545d9fb57437bbacc0e55479da783_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes925DueApril2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2f68bb5402fa40aaa3d1e8a5876a1481_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes925DueApril2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6b5e0bf7441145f3a22ac4510e73101b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes850DueJanuary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia02b8e8095664970aeeda0fcc527bb86_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes850DueJanuary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5833ace0facf472a8cf1a49a6becbe8d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4758100c83ee4d7f82d179bcb44516dd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icb63f20c4f224de380f590b991ab70bd_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia6a900b7cea44342b2ebea58f9a1a829_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0a9e5ff5b17847ae8c5b4a20045b80a7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iaa9fb491c6f44e0494c78843ae2d7d07_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic9d48b1e660749f7a7367bb5dc150e1b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3ab99de7a1954ce6996bda7caf7833a8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib88817449df74848a8baeff6c02361f9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes725DueMay2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4341fd255afd4b2f98811eb433952df1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes725DueMay2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i51f3dd4e5a524f1bbf10cd1a0055202c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueJanuary2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5ee2ed402ff54a6f843446ee188a72d8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueJanuary2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if151bdb884d34ff6b871d14b1339db96_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueFebruary2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i504ae7293b234304b31a5f5ef8da3011_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueFebruary2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if31b5959255941138da93ebd548669bb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:OtherLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1cee80bfcbe74e0c8421a1c67604dccd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:OtherLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3baf0d17d1ce4fb09e14886b74b202be_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bhc:SeniorSecuredCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibd8b2b705a834db0850fd8a5ff15144a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6c325805e88f46bb919acf58b5da907e_I20180601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-01</instant>
        </period>
    </context>
    <context id="ic7609d2be3db44f5af9ae6b7c8e642b7_D20180601-20180601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-01</endDate>
        </period>
    </context>
    <context id="i805461905703413cb5837246f45f0ab6_I20180601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-01</instant>
        </period>
    </context>
    <context id="i9f9d786ce6b041f08ba221a702f7956d_I20180601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-01</instant>
        </period>
    </context>
    <context id="i9ec4d9258ade4c988572b72ab0b9bcda_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i50ea92505146474394a150389011b6f2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i87085be380954b8f8d3c8aca38e1f32f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3f1641e5674c4a75b682c9b185796d5c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:CanadaBankersAcceptanceRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9578b054a9c3434d956829eb311cdcd5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:CanadaBankersAcceptanceRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i615747c5edca4f728ff0d5d6e3cdb38d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibb673f79152245ccaaa71c72c83aca5f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if9f46032075146bb974b5459828d0837_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:BaseRateOrPrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iebb71b6e150a4d3583b70be11293ebbb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i88f4e8e6d2a74bb3bbf6df6210d11118_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifce02581a2a24dcf8c3af7034d61d45b_D20220331-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-31</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i20665638c329437cab38c53e8d90d29b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i15c4387da4984e3890700c3445ff56f7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibd749185fb814c7eb0ea4622273efa10_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2b1c2edd6efe487a80e89a2e9dfacbc3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie92612a0f96b4f89b84ac22fb594d512_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i891a2d21f1024827aa29f1df940ffbb3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib8602535e6b14704b3f07b216531b82d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8a1cfa5016e04bb3a7bc13c20a921226_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i730cebd5276140a781d756138d28a05d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3525c40548924586bbd17234ab1c71c3_I20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="iad4d39b309f5434c87cf47a080a1d040_I20210608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-08</instant>
        </period>
    </context>
    <context id="ibcbf9946c1974457a0c4173198dc2413_D20210608-20210608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueMarch2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-08</startDate>
            <endDate>2021-06-08</endDate>
        </period>
    </context>
    <context id="ia2fbd73a42e346bea819f0b583f98618_I20210608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueMarch2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-08</instant>
        </period>
    </context>
    <context id="i95e73196dfe44ca6bb964e033fa104f5_D20210608-20210608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2021-06-08</startDate>
            <endDate>2021-06-08</endDate>
        </period>
    </context>
    <context id="i88e8d3f432e14718a0ba0ed393f9efbf_D20210608-20210608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-08</startDate>
            <endDate>2021-06-08</endDate>
        </period>
    </context>
    <context id="if8673b92629a48189ea708c9a312bfe5_D20210608-20210608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-08</startDate>
            <endDate>2021-06-08</endDate>
        </period>
    </context>
    <context id="if16401eb786046228b3c642b80d44636_I20220210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-10</instant>
        </period>
    </context>
    <context id="ie0fb622b80e1461e88f672d0cba387ac_D20220210-20220210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-10</startDate>
            <endDate>2022-02-10</endDate>
        </period>
    </context>
    <context id="ida33ef4fd5a74725af4144c875055297_D20220210-20220210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-10</startDate>
            <endDate>2022-02-10</endDate>
        </period>
    </context>
    <context id="ice4047eb87914dd280d3a5673cae9b27_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id1e3d8f9146049ff9febeb80d7774565_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="iba4cf152a5ec43589599bfbc8c8881de_I20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A2027RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="iea36229e5f1244b3b1faa248153f8623_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i830e50982f6544d8ac6e50bc7bd7c443_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic655b0478ac14dac9616872cec7db523_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5551d17df34844848847e1383a62e7c3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i74e0245bcf24424487c80b95aed98a9d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i673851b86a634af7b2f89d29c8e7cac4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if2d66b26d13244be9ae6815748b18427_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i28d956fcdc7e473694aec5169b2c17fd_I20140531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-05-31</instant>
        </period>
    </context>
    <context id="i407781f626f341f296f71f5e85d199df_D20180430-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-30</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="i79d17571326d4113a14289e30a432c94_D20180430-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:NonemployeeDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-30</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="ic9d13a041f834d2f9ed315beee256b39_D20200428-20200428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-28</startDate>
            <endDate>2020-04-28</endDate>
        </period>
    </context>
    <context id="i24dd995e79e2480eb8534ebdb9b36ffe_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4c3748cc38b94811b494a048524f18d4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icbcf180e8ee94c498f903101c65055cf_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5189be309deb481aba3dbe709f732ab9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i302c4d997fc44f5f93fd331d80fb1d09_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5c8dba5a632049539392f661e0428449_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i96274aa944bb4685b39b713920d2304f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i16e6e5eeaf9441738f673fb99507f4e5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9aaaf1035cf34c098a5c6e6768c0dbf4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i77c337a40ebb461491bdb6dab1118617_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3fc2981be2ea44a386fb0f04805428f4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibf0b5e90aca84802a2fe6dfc35444ad9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TSRPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ief18d16522574e578066730177201d22_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TSRPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i672f6c3b00ec46e5ae4b3d4816dbc732_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:ROTCPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idbfb63fc6db643aba45a4aa4ec0c1c63_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:ROTCPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i64cc50678b8b42b28c6fffa51684b252_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:SeparationPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3a2ccdb6d9074d6d8d84aba34115a27e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:SeparationPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i46d6cdf39c0344c9997ac487916b5ced_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia421fa8b794e48b48d28fe42bfdcba6b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i27c24a8f9680457fae0e0043ab55f83c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idf07a0520a7f41db853c67b1c28a17a5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib705b8700b7f48e8b664f48c1ff6c694_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bhc:MilestonePaymentRelatedToCertainProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i634a33b4555248bda810d4755ec7944f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5cbb08e41ef540369a6004ec2d016b37_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0765fea13c904226bd504d19d10dcd55_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1b08aef1966547e9bd168396be5172b8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6c234ad885934263b7d0d458906eac06_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ice3d4454e30642078b6d278363d32c89_D20151001-20151031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-10-01</startDate>
            <endDate>2015-10-31</endDate>
        </period>
    </context>
    <context id="i8498207cf8ab47a98694e871b43ed0ac_D20191216-20191216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-16</startDate>
            <endDate>2019-12-16</endDate>
        </period>
    </context>
    <context id="i52b91cd6bf81428da787050c41b56633_D20220331-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bhc:RestrictedCashAndOtherSettlementDepositsCurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-31</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if9003a9e8d5e4cb890f3dca99318e110_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i596e029672034f1ebeeeb10da808b0b3_D20150101-20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="iffef6edab6454226a9a750b828094eab_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i66e66455cad94f43bea051172349e294_D20200804-20200804">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-04</startDate>
            <endDate>2020-08-04</endDate>
        </period>
    </context>
    <context id="ib9363f6177cc4981a294b2f6d18e765d_I20190215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-15</instant>
        </period>
    </context>
    <context id="i3e992c240c2041b78b9cd6b48dde9c97_I20210317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-17</instant>
        </period>
    </context>
    <context id="i70e88a8ce2b644ebb754e35500783f63_D20160527-20160916">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:RICOClassActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-05-27</startDate>
            <endDate>2016-09-16</endDate>
        </period>
    </context>
    <context id="i9c2253862a7e47b3abf3762d16caa354_D20171207-20171207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InsuranceCoverageLawsuitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-07</startDate>
            <endDate>2017-12-07</endDate>
        </period>
    </context>
    <context id="i56f9cd8d429c490aa470859df6ea769c_I20210720">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InsuranceCoverageLawsuitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-20</instant>
        </period>
    </context>
    <context id="i33fa032d820947a1b95a1ffae232ac03_D20210720-20210720">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InsuranceCoverageLawsuitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-20</startDate>
            <endDate>2021-07-20</endDate>
        </period>
    </context>
    <context id="ia47d407ff7c64c98a6e296b58ca6f86d_D20190801-20200730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2020-07-30</endDate>
        </period>
    </context>
    <context id="i7afbeb4c54a7426c95c622c88ede0f55_D20190801-20200730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationNonClassComplaintsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2020-07-30</endDate>
        </period>
    </context>
    <context id="ib6f99e9cc813479883c5c2dc19cb2f6b_D20190801-20200730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:PlaintiffsDirectPurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2020-07-30</endDate>
        </period>
    </context>
    <context id="i3162f07bec9e4a3daa43dcea08a13f2b_D20190801-20200730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:PlaintiffsDirectPurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationNonClassComplaintsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2020-07-30</endDate>
        </period>
    </context>
    <context id="i7cdef9a49476491db7e461eeea893094_D20210726-20210726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-26</startDate>
            <endDate>2021-07-26</endDate>
        </period>
    </context>
    <context id="i3feba39b7c864f9287819ae735b85819_D20200326-20200326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:NorwichPharmaceuticalsIncLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-26</startDate>
            <endDate>2020-03-26</endDate>
        </period>
    </context>
    <context id="i7a34cd34e127459a89499090f4a93cbc_D20200828-20200828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PerrigoIsraelPharmaceuticalsLtdLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-28</startDate>
            <endDate>2020-08-28</endDate>
        </period>
    </context>
    <context id="i7ce85e02604a4aa4b028657df917f434_D20200501-20200501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PadagisLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-01</endDate>
        </period>
    </context>
    <context id="i6770fa9b73a64b54b1f41da09e16bf8f_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:MSNLaboratoriesPrivateLtdLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i484e9a2b823f442e9977dce133acdc8e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PatentInfringementLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i65eb0cafd758435f8136a068d6e0611a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ApotexIncLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if6cd264b4a7249cea5facc5b0e2e6685_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0fb0759d98f74dea9d8da712d3d4ef7b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iadb1f3c2425247b1a17793d33add0cd6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iccdebf1cc8224c95806abf21a3970331_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-BC</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i41ce3780c3a74f4da7f954a056043ef8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-QC</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9980036908434c78bce13e0b3f16a63d_D20211101-20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="id1c54f63619d491e9de1d89624c515eb_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6bbcfb43fc7145b0bb30d7beba40cbb8_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:DoctorsAllergyFormulaLLCLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="idc58c0dcbe644cedb326ae513855b55f_D20190128-20190128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:LitigationwithFormerSalixCEOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-28</startDate>
            <endDate>2019-01-28</endDate>
        </period>
    </context>
    <context id="i0c75337ca1004f2ca22a8acafcee0b80_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i85cfed31dcdb4b5fbdcfd5de90d79e53_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i269760d6627c41d9af67faeb79fcc823_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic7a20cee7c49437a80ead9dc6edc62bf_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1ce8c1f567d4480199ab7c96956ff606_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0baff1dd72ec4f1d9be30dc22385fd78_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i515ccc73a3044997b576a1bf8db45a42_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9fa555eb8f35445291ded844157a0bbf_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i03406ff2404048fa81b2e21abb5623f6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i204e74587c904466ba5b4d9604c5d421_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i78e30f03ea4548deae9a927c4b6a6def_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1d07c8e2cb2b45138d98bfa04aca8095_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i57dad9adbdcb4f9eb8980d1993b5a15e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i956efc9320ef432bad3fbea5c3f1a4fe_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i81a741d98a084635a313bb4bf76f4091_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i64a60b01aba54bed9371ce993d6fcde6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ide4e3d656d794986bc25805dd6eafb35_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i375b53e51f9a46f689b2c28b45772369_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i26543803a914471b91cfff3fec88f408_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i965c5ef9967640559f4a892e2bc019c3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4fb3820e9af24cffa7541b8391ded598_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i33c622ed3818484b99457a5e5ac61b94_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7c9d891249204a23b5a99cff63162625_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i44029f40cbcc4c10b8745e5f1b7f00ea_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i443f3d343d0a48fcb2a083c30d4f80e3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i24ebf624edfd4bdf9d7fdd3ec9d063ec_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i45c1beafb56d472ead9374b62bb12e0d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i93b04924fc4f4e13885891185ac2968f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia9bd671b035e41d69c0e38a6f82fb9cb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iff23cd75a927442b8803bc3729da27ed_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4fc8477c42ba432494cf231b6c0d0bc6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i124b70687528481fa21c28eb1cd32810_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i08499bccbbc4410cb5590fb188cf4b8f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i95c4cba1caca493b898eda95b9d55af7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia38a1019d805412a8c33d8125fa11085_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifb9c9b16f92e4c9ebdac506674e51576_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5ef5e2b06a5642ab9e8f2e182c325773_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if4ad50d4f8264e31a30246a147683d1e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifa28b372582e4ed39b7c1cf546fdc7e2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6242e90d746b4facb737eb995d4cd3a1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibd97f12e125642fcb0965c4f1a9363fc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i59217fa829ff402c854f159e561f67dc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i559671273f154caeb21890281cc0f5d1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6583ef0acc464c159cccb04b0fec1a1b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9b20d7a1afdb4a4880e7ffd0aa66b93d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ica7d291dc2bd424e9fb044bf5d42a71d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5a8e341755db419cb385c32abb37fbf5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2ae1c40162554d5eb82184aadef55683_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i09d760aefc9346f3ba42a8f6e9e5a1c4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id3e109bbefcc46d498195d4ffe5d8600_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ifa0b5f041d2b45cf9d22badd73f64a23_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6786806a071a4586b8fe4628dc8b3a7e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1e5a66dcb11244d9adafcfbfdcfaa3fb_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8ac60a867fe14187a7ad6925c72ddfcb_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i87d31612ba6e4870b08c2e8bbacff14b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6ec570a785a84b3e8b00f4538ffd504c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="icbb358ccd88b4e1582585e87263d2797_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iafde2cd7b3454407911b0fdbcfa6bdd6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i89351cbae84d472fbc3dabeb58d46f5f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iaccd246e128b428da512aad072f4e923_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i365abf392e8246c192b779a84beb07cf_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7aa0024629f24b1e86fc6db4add48d1e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if3a2b93c59aa455cb5ec35f29c61b2af_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i60c320b8b80142589fb80e99cc32f396_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id78c49bd421641d9bc16ae14a49b0f38_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i50631f79a17f4417939599b18339e8ad_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i305ec4b1f3cf485cace07ea69588b9d7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if8080745b5f44e97ae240acceb434c81_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i74bb4d5c955a430c8f54a13eb2e95dbe_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3b0c293a2a6e4e71a0b1622ed24842b9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i63e664ec8ede4265b16d1a42ee684fc0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i54f11fd19e174e98aea8c453c247a13e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i242c0d38400b4e0ebc1e4083d039a5d2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6c17a4613b5a49258f9f5b8c94015244_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i595a156d88824a07951bbc6d45f101aa_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9021db7996494bfb917eaa4217e384e5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib8a36b6287944ab9a444528b83f6e58e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0910908181894cb28f6e71d1b8022f02_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia346b213e50645b0a1038d38fc86c181_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i08f479ec27794028980e1c2521cd237c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2cf35ad54d7f4e3b94b6b600661263c9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CustomerTopTenProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia6c16437fc1645e5bd3f51dbfd6bc45d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CustomerTopTenProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i736938c435c34b8cbf4b9a86a5c1716b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie1c251a743e84e29bcdcb92c1700440f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i29ca60685fd143c4ada8c74045564916_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib389f9ca07bc4c7ca630c86bb01430f2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib632e708eb9e44e5a2c76e757b159704_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id62e8ded86954413866df53834a4022f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id17ace1eafa74b49b1494fa93c34f515_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idfae22764ebc4680bba6944b73990b38_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6d98656df59c417aa61bfd38cf347ab8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i309adbf2ee5c4529ad9d523c886afcbc_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i71f5260404d34943ae2284710ac15bcc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0efa9862b055429eb1653d07596c035a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i038caeba82944fb08a4051fbf6da7b09_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i60f8953bbbe6445eb5947c90b19aab2e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2e0b22a76af3426bae92c761987b0187_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifeb045fdd1fd4540bf7a4106731f2f2c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9e819574885a4427b258852c7217cbb7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ief192120e21c43a1a934405e935223ca_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i02bac5e7352941d58218671cc5ac18ee_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i388557aa2024443c871b4d4a9a886575_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4bd53359a539414b9021c46b47d84743_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iff2ea0b9ea7b4ff2b1dc7c83ee9f0674_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i477436c4d44d4790b5bee0250e92a451_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iee07a351938545e1bc0374c9ee03db58_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3c9cbd283603466d890093b4f1ad2033_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie51fbc2dae9941b8b6e55b6fa231f07c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i704a8bd37aad403db52ecbc7efb33040_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id4b0684914ec4f1b9d774361c28cb7b0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5c455f78b2c24f19ab413825cf24b3b1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:AmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3d795947131641bda6742f32f927ee39_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:AmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i735a4a9dd69c4f20ad6fa633744e4013_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:McKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idc5628f43f5849428205c5a57a1c1fcf_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:McKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iae7d7933e83c4caf870a090351b7a111_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifbf2cc68e33744c4b8947828008ff5d9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib2ffbb57b436490590a2819d68a36061_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i9088830177c14b93899cdc2428206dd1_I20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bhc:BauschLombMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="i9beb6982df2843ba905908dcf5d3e1c9_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bhc:BauschLombMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ie30ec3f614a04d42848dad1250068433_I20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="i9b0e960b1ec848318fdc55394dac24fa_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i07b15b7868704928b2944eba14639156_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ic99afd1f228a44c78581651c6a9579a0_I20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="i969796cd9c2a43459679467ac14382c6_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i1a1c85fad6244e21b4823c99ca9236cb_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i6835eeba06904e7d83cc68aeeb30bc96_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="iaef1fd49551a4a5e99cc5c7286d61d19_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i6062d01783b9476ab5d93d304f908fdb_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i5ed6554f1984485bbe1d859a5cce60e5_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i37d22f117617444f9a62f2666aeaf23e_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="iebf7fa610282462e8a87798c4a0c13b7_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i07c3bdbe9d364f85a235465f6572d30b_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i827cfce6b4184d368806fa2e3eab7b12_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i15b198ca83624b318396f39380edc2ac_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="id2a157fb52da45df95151e9668b651b6_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ic7c0ae85a82c4cb3a319373f684bc55a_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i679d8e8de83d43b8aa7b432b14f90a83_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i8d5a322888ac487b9f4166843a4b2254_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i6a4a857f626f43fcbcdf8083edd3c4b1_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="if0dbac6e5e59470e9e96eab6a439d571_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i4920545cfdfe43ea874d0ca5a349c081_I20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A2027TermLoanBFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="i1a96cf695f3646188214a645c50f0e12_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A2027RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i5263f4eeef0e4a1eb6008213ffca534f_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A2027TermLoanBFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i00ec1ba964804053bf2cebbf5c43f522_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A2027TermLoanBFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i801aca530cc14c9b8be64fb696e6dcf5_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A2027TermLoanBFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDORAndEURIBORRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="id66d7e17675f4184972f0235d07b1e63_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A2027TermLoanBFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i9e33a46b9a8c458e92c2a7533b092615_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A2027TermLoanBFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="iedc6c37d8af5490d993ec3399bc55792_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A2027TermLoanBFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i28d3080b48c44fb2a31f867511fa241f_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A2027TermLoanBFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ib5ba454a7b6c45a3949b8f1985ac313e_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A2027RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i053e8e2380ae405a8cf2ef0d0dac698b_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A2027RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i618e8b101a9e4651a8d45a1516a66fde_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A2027RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ibfc76cd45bc6474988b4e3877373db82_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A2027RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i577466297a53405f9454d33995ecba1e_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A2027RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ib5b37fae66ea41e88fed93726d182d6a_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A2027RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i14ef51bcde474f27be0e9b588872b89a_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i5d6eeadd393b426393e1f0ed889d241d_I20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="ic809285ec99545369921696d670f6b36_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i2fe9c48370994d03935d785c7f1a8b8b_I20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="i49de6c3d04bb472d8b09e6bd0c1887d7_I20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="ia843743426e540ee8c98df5ca73090c9_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:NewRestatedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="iaa22c8251ddf46939526e13e17458660_I20220118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A9.00SeniorNotesdueDecember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-18</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="country">
        <measure>bhc:country</measure>
    </unit>
    <unit id="company">
        <measure>bhc:company</measure>
    </unit>
    <unit id="appeal">
        <measure>bhc:appeal</measure>
    </unit>
    <unit id="rate">
        <measure>bhc:rate</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="reporting_unit">
        <measure>bhc:reporting_unit</measure>
    </unit>
    <unit id="case">
        <measure>bhc:case</measure>
    </unit>
    <unit id="group">
        <measure>bhc:group</measure>
    </unit>
    <unit id="action">
        <measure>bhc:action</measure>
    </unit>
    <unit id="cad">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="entity">
        <measure>bhc:entity</measure>
    </unit>
    <unit id="insurance_policy_period">
        <measure>bhc:insurance_policy_period</measure>
    </unit>
    <unit id="insured">
        <measure>bhc:insured</measure>
    </unit>
    <unit id="defendant">
        <measure>bhc:defendant</measure>
    </unit>
    <unit id="claim">
        <measure>bhc:claim</measure>
    </unit>
    <unit id="product">
        <measure>bhc:product</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180L2ZyYWc6ZGJjN2QwODhkZjdkNDNmZGJmOTU3OTBkMDkyNGQyNjYvdGFibGU6MmE0OTYwMTM5NmVjNDU2M2JmYmYxYTBmOTk3OTAwMGEvdGFibGVyYW5nZToyYTQ5NjAxMzk2ZWM0NTYzYmZiZjFhMGY5OTc5MDAwYV8zLTEtMS0xLTg5MDcy_9fde6d31-8274-4e83-ac65-1863b374a7bb">0000885590</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180L2ZyYWc6ZGJjN2QwODhkZjdkNDNmZGJmOTU3OTBkMDkyNGQyNjYvdGFibGU6MmE0OTYwMTM5NmVjNDU2M2JmYmYxYTBmOTk3OTAwMGEvdGFibGVyYW5nZToyYTQ5NjAxMzk2ZWM0NTYzYmZiZjFhMGY5OTc5MDAwYV80LTEtMS0xLTg5MDcy_b53f797b-c025-4146-bba7-00745dc95964">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180L2ZyYWc6ZGJjN2QwODhkZjdkNDNmZGJmOTU3OTBkMDkyNGQyNjYvdGFibGU6MmE0OTYwMTM5NmVjNDU2M2JmYmYxYTBmOTk3OTAwMGEvdGFibGVyYW5nZToyYTQ5NjAxMzk2ZWM0NTYzYmZiZjFhMGY5OTc5MDAwYV81LTEtMS0xLTg5MDcy_dcfa2248-4453-41c4-9c20-71a3bf79a011">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180L2ZyYWc6ZGJjN2QwODhkZjdkNDNmZGJmOTU3OTBkMDkyNGQyNjYvdGFibGU6MmE0OTYwMTM5NmVjNDU2M2JmYmYxYTBmOTk3OTAwMGEvdGFibGVyYW5nZToyYTQ5NjAxMzk2ZWM0NTYzYmZiZjFhMGY5OTc5MDAwYV82LTEtMS0xLTg5MDcy_0613fda4-f14b-4b67-b529-821575e0a070">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180L2ZyYWc6ZGJjN2QwODhkZjdkNDNmZGJmOTU3OTBkMDkyNGQyNjYvdGFibGU6MmE0OTYwMTM5NmVjNDU2M2JmYmYxYTBmOTk3OTAwMGEvdGFibGVyYW5nZToyYTQ5NjAxMzk2ZWM0NTYzYmZiZjFhMGY5OTc5MDAwYV83LTEtMS0xLTg5MDcy_0a5d6cd0-0ade-4426-a9c2-774515b1cff5">false</dei:AmendmentFlag>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="iea36229e5f1244b3b1faa248153f8623_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183MC9mcmFnOmU0ZTQ5MmIyYjc1ZDRjNDJiYzYyNjQzY2ZkZTViMWVkL3RhYmxlOjYyYWE1YWViNWUyYzQ4YTk4MTVlYzBiYTg1MjM1NjM1L3RhYmxlcmFuZ2U6NjJhYTVhZWI1ZTJjNDhhOTgxNWVjMGJhODUyMzU2MzVfMy0xLTEtMS04OTA3Mg_7c2956ef-0f5f-47fd-9406-5802ec3250d3"
      unitRef="number">0.005</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <dei:DocumentType
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGV4dHJlZ2lvbjphMTM1NTRlMGM4Yzk0ODgwOTc3ZDQyOTMyYzgxOGY2NF8xOTgx_fc850edd-396e-41bb-8549-adcc1867c237">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGFibGU6MDQ2ZTQyMjAyZTA5NGEwODgzZGI4MGYxMWFkZmU5NzQvdGFibGVyYW5nZTowNDZlNDIyMDJlMDk0YTA4ODNkYjgwZjExYWRmZTk3NF8wLTAtMS0xLTg5MDcy_59bd49d1-0a2b-4b0e-89e4-1bd8978efc40">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGFibGU6MDQ2ZTQyMjAyZTA5NGEwODgzZGI4MGYxMWFkZmU5NzQvdGFibGVyYW5nZTowNDZlNDIyMDJlMDk0YTA4ODNkYjgwZjExYWRmZTk3NF8xLTItMS0xLTg5MDcy_9af76d0d-7891-4983-857b-924f99619e92">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGFibGU6MDQ2ZTQyMjAyZTA5NGEwODgzZGI4MGYxMWFkZmU5NzQvdGFibGVyYW5nZTowNDZlNDIyMDJlMDk0YTA4ODNkYjgwZjExYWRmZTk3NF8zLTAtMS0xLTg5MDcy_b251460b-7ab6-4417-a11d-4b1091d88d1c">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGV4dHJlZ2lvbjphMTM1NTRlMGM4Yzk0ODgwOTc3ZDQyOTMyYzgxOGY2NF8xOTc1_4679f6ec-b0f4-4a6e-bd02-b5e3a9240d3a">001-14956</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGV4dHJlZ2lvbjphMTM1NTRlMGM4Yzk0ODgwOTc3ZDQyOTMyYzgxOGY2NF8xOTgy_61dce745-e142-498f-b59f-70bcad273ed2">Bausch Health Companies Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGFibGU6Y2QxZTY5MTM2ZGFhNGM4ZmFkYWIyODkwZWFiN2I1OGQvdGFibGVyYW5nZTpjZDFlNjkxMzZkYWE0YzhmYWRhYjI4OTBlYWI3YjU4ZF8wLTAtMS0xLTg5MDcy_54eb9144-3d04-40eb-872d-4a70a3099c48">A1</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressCountry
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGFibGU6Y2QxZTY5MTM2ZGFhNGM4ZmFkYWIyODkwZWFiN2I1OGQvdGFibGVyYW5nZTpjZDFlNjkxMzZkYWE0YzhmYWRhYjI4OTBlYWI3YjU4ZF8wLTQtMS0xLTg5MDcy_5dc75537-ca9a-4000-bbdf-d1ccf06f81f1">CA</dei:EntityAddressCountry>
    <dei:EntityTaxIdentificationNumber
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGFibGU6Y2QxZTY5MTM2ZGFhNGM4ZmFkYWIyODkwZWFiN2I1OGQvdGFibGVyYW5nZTpjZDFlNjkxMzZkYWE0YzhmYWRhYjI4OTBlYWI3YjU4ZF8wLTctMS0xLTg5MDcy_1c63e76a-636c-4605-a118-15c12012eef0">98-0448205</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGV4dHJlZ2lvbjphMTM1NTRlMGM4Yzk0ODgwOTc3ZDQyOTMyYzgxOGY2NF8xOTg2_71335e5d-2d8e-42d8-ae92-c6a97169264d">2150 St. Elz&#xe9;ar Blvd. West</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGV4dHJlZ2lvbjphMTM1NTRlMGM4Yzk0ODgwOTc3ZDQyOTMyYzgxOGY2NF8xOTgz_62cfcd96-0f76-4e28-beaa-ebfcee0d2c2d">Laval</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGV4dHJlZ2lvbjphMTM1NTRlMGM4Yzk0ODgwOTc3ZDQyOTMyYzgxOGY2NF8xOTg0_79bbbe37-adbc-47a2-931f-eac0d19dade2">QC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCountry
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGV4dHJlZ2lvbjphMTM1NTRlMGM4Yzk0ODgwOTc3ZDQyOTMyYzgxOGY2NF8xOTc2_36f4f928-8afb-42c7-b9c0-985850b4394c">CA</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGV4dHJlZ2lvbjphMTM1NTRlMGM4Yzk0ODgwOTc3ZDQyOTMyYzgxOGY2NF8xOTg1_126ac9c6-719a-461f-8a2b-565a60ef8e9b">H7L 4A8</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGV4dHJlZ2lvbjphMTM1NTRlMGM4Yzk0ODgwOTc3ZDQyOTMyYzgxOGY2NF8xOTg3_f69e7f0b-b230-41e4-8dc2-9e7a02231919">514</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGV4dHJlZ2lvbjphMTM1NTRlMGM4Yzk0ODgwOTc3ZDQyOTMyYzgxOGY2NF8xOTc3_a6c33ecf-a17d-4653-8009-62033c887ab1">744-6792</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGFibGU6MjE3YWFjYzVhNjNjNDE5NmE3Nzc0YzU2MjA2MDRlNTMvdGFibGVyYW5nZToyMTdhYWNjNWE2M2M0MTk2YTc3NzRjNTYyMDYwNGU1M18xLTAtMS0xLTg5MDcy_4ce6cff8-61e2-4f63-b164-ec8094b226bb">Common Shares, No Par Value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGFibGU6MjE3YWFjYzVhNjNjNDE5NmE3Nzc0YzU2MjA2MDRlNTMvdGFibGVyYW5nZToyMTdhYWNjNWE2M2M0MTk2YTc3NzRjNTYyMDYwNGU1M18xLTEtMS0xLTg5MDcy_72f4207e-f526-47cd-9012-8b7feaca84a1">BHC</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGFibGU6MjE3YWFjYzVhNjNjNDE5NmE3Nzc0YzU2MjA2MDRlNTMvdGFibGVyYW5nZToyMTdhYWNjNWE2M2M0MTk2YTc3NzRjNTYyMDYwNGU1M18xLTItMS0xLTg5MDcy_4c5ce663-6f50-4f9f-b460-adccfb561a1e">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGV4dHJlZ2lvbjphMTM1NTRlMGM4Yzk0ODgwOTc3ZDQyOTMyYzgxOGY2NF8xOTc4_e2fe4a05-b930-4e47-85ba-bca1066631a1">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGV4dHJlZ2lvbjphMTM1NTRlMGM4Yzk0ODgwOTc3ZDQyOTMyYzgxOGY2NF8xOTc5_ecedc55d-7973-4c76-80cb-da00cbb91369">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGFibGU6ODRkYzYyMDg2YjUzNDdlMTg2NzM1YjQ2MDJmZjk1M2QvdGFibGVyYW5nZTo4NGRjNjIwODZiNTM0N2UxODY3MzViNDYwMmZmOTUzZF8wLTAtMS0xLTg5MDcy_8332e37a-f9cf-4327-a2da-59558098f8d7">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGFibGU6ODRkYzYyMDg2YjUzNDdlMTg2NzM1YjQ2MDJmZjk1M2QvdGFibGVyYW5nZTo4NGRjNjIwODZiNTM0N2UxODY3MzViNDYwMmZmOTUzZF8wLTctMS0xLTg5MDcy_70ffb8d3-f5a1-4c4a-b930-29e02e0c2065">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGFibGU6ODRkYzYyMDg2YjUzNDdlMTg2NzM1YjQ2MDJmZjk1M2QvdGFibGVyYW5nZTo4NGRjNjIwODZiNTM0N2UxODY3MzViNDYwMmZmOTUzZF8wLTktMS0xLTg5MDcy_5331019e-1656-47dd-b0d8-6bc80c777fb5">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGV4dHJlZ2lvbjphMTM1NTRlMGM4Yzk0ODgwOTc3ZDQyOTMyYzgxOGY2NF8xOTgw_ceddb37f-6c9c-4461-bf94-5fe10686e42e">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ie4a7b4e0ac9943a9b88f1223220896de_I20220505"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xL2ZyYWc6YTEzNTU0ZTBjOGM5NDg4MDk3N2Q0MjkzMmM4MThmNjQvdGV4dHJlZ2lvbjphMTM1NTRlMGM4Yzk0ODgwOTc3ZDQyOTMyYzgxOGY2NF8xOTI5_0a372ed0-037c-4c7c-b3c0-04278cdcb1b4"
      unitRef="shares">361479708</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMy0xLTEtMS04OTA3Mg_c94abbfe-789b-44cc-bfb6-ca88fc3a99d0"
      unitRef="usd">1249000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMy0zLTEtMS04OTA3Mg_e80ff975-8ff1-48f6-a8b9-2840fe534dfa"
      unitRef="usd">582000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <bhc:RestrictedCashAndOtherSettlementDepositsCurrent
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfNC0xLTEtMS04OTA3Mg_c3908cac-5c4c-4452-8477-f3954589612c"
      unitRef="usd">1211000000</bhc:RestrictedCashAndOtherSettlementDepositsCurrent>
    <bhc:RestrictedCashAndOtherSettlementDepositsCurrent
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfNC0zLTEtMS04OTA3Mg_fde993c5-8aa6-4b53-bd06-27743ef5a289"
      unitRef="usd">1537000000</bhc:RestrictedCashAndOtherSettlementDepositsCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfNS0xLTEtMS04OTA3Mg_92bcfc2f-0004-488b-bb22-43ba4e67bbd3"
      unitRef="usd">1566000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfNS0zLTEtMS04OTA3Mg_572e7cc1-74b5-4cfe-8594-628130392ef7"
      unitRef="usd">1775000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfNi0xLTEtMS04OTA3Mg_162f2991-6448-453a-9aae-c6127094abd2"
      unitRef="usd">1045000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfNi0zLTEtMS04OTA3Mg_e8c8c12e-e098-4527-b739-006fe2399342"
      unitRef="usd">993000000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfNy0xLTEtMS04OTA3Mg_fdfb058f-eaa2-41aa-b5a2-d942f363306d"
      unitRef="usd">765000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfNy0zLTEtMS04OTA3Mg_13fc259b-1ded-4710-97f6-c3c3a4c3f593"
      unitRef="usd">720000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfOC0xLTEtMS04OTA3Mg_585f3567-2803-4b18-88eb-9a8721540353"
      unitRef="usd">5836000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfOC0zLTEtMS04OTA3Mg_4938970a-dca5-40a4-87b4-d353d0971ebb"
      unitRef="usd">5607000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfOS0xLTEtMS04OTA3Mg_8a322ad8-af2b-4855-b5a9-12bd837be95f"
      unitRef="usd">1579000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfOS0zLTEtMS04OTA3Mg_4bcef469-a957-484b-aa49-d001ab980f97"
      unitRef="usd">1598000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMTAtMS0xLTEtODkwNzI_7bde9ae0-b3c8-4d1b-97cb-35287f45bfcc"
      unitRef="usd">6632000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMTAtMy0xLTEtODkwNzI_9914db1a-568c-48aa-b139-0a138b76f042"
      unitRef="usd">6948000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMTEtMS0xLTEtODkwNzI_4f2d018d-0ba6-436a-83af-208747fc0258"
      unitRef="usd">12427000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMTEtMy0xLTEtODkwNzI_6928b1ae-151e-42e8-a7df-bff66151fcb4"
      unitRef="usd">12457000000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMTItMS0xLTEtODkwNzI_abb30ddf-5232-4de9-bccd-bc18c1d0a3e5"
      unitRef="usd">2282000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMTItMy0xLTEtODkwNzI_1ea88a75-a9fa-4179-844a-2d5fde1604eb"
      unitRef="usd">2252000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMTMtMS0xLTEtODkwNzI_dc02fa84-bdb3-47c5-a875-3853dd8baadf"
      unitRef="usd">334000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMTMtMy0xLTEtODkwNzI_684f4fe1-ae58-49a0-a42a-7d710d743279"
      unitRef="usd">340000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMTQtMS0xLTEtODkwNzI_c3457ecd-1891-48a1-bde8-57b46f6c3755"
      unitRef="usd">29090000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMTQtMy0xLTEtODkwNzI_57855ce6-02ad-46e1-9ac6-26340679be4e"
      unitRef="usd">29202000000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMTctMS0xLTEtODkwNzI_90cec72d-899c-4ce9-a5ba-6d31e808d39e"
      unitRef="usd">471000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMTctMy0xLTEtODkwNzI_b776fe0c-c08c-4794-88b1-a39a9ab15d45"
      unitRef="usd">407000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMTgtMS0xLTEtODkwNzI_57f029a6-8a4b-4ac4-93a5-2e68264d763e"
      unitRef="usd">4303000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMTgtMy0xLTEtODkwNzI_1b9c42e8-6194-4225-9a54-5cb98e389358"
      unitRef="usd">4791000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMTktMS0xLTEtODkwNzI_88b4d82f-f90a-4746-9230-1c535978749d"
      unitRef="usd">4774000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMTktMy0xLTEtODkwNzI_e5632c36-cacf-4fb5-a51c-054511ce7181"
      unitRef="usd">5198000000</us-gaap:LiabilitiesCurrent>
    <bhc:BusinessCombinationContingentConsiderationNoncurrentLiability
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMjAtMS0xLTEtODkwNzI_597b0325-882e-4944-8d37-485e6c8926f2"
      unitRef="usd">193000000</bhc:BusinessCombinationContingentConsiderationNoncurrentLiability>
    <bhc:BusinessCombinationContingentConsiderationNoncurrentLiability
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMjAtMy0xLTEtODkwNzI_ed698a29-4c20-4f60-ae43-cfeeb4733056"
      unitRef="usd">202000000</bhc:BusinessCombinationContingentConsiderationNoncurrentLiability>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMjEtMS0xLTEtODkwNzI_f4dd3fcb-2755-445b-ba0c-de60613ad7f8"
      unitRef="usd">23168000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMjEtMy0xLTEtODkwNzI_e80c8a06-f7bd-4b16-9b45-12d158fe780e"
      unitRef="usd">22654000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMjItMS0xLTEtODkwNzI_00ffecf8-1aa7-40d4-b9bc-b06d07ea6b1e"
      unitRef="usd">552000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMjItMy0xLTEtODkwNzI_f4561b35-ea15-4880-81f4-0826f74073ae"
      unitRef="usd">529000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMjMtMS0xLTEtODkwNzI_de823fe9-2054-4989-ae6e-6b650a278547"
      unitRef="usd">544000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMjMtMy0xLTEtODkwNzI_c867397d-5d4f-4750-bc5c-5629825d6d9a"
      unitRef="usd">653000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMjQtMS0xLTEtODkwNzI_86f9ca79-0348-452a-857e-cdd8319ec130"
      unitRef="usd">29231000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMjQtMy0xLTEtODkwNzI_629fccf0-f24c-43f3-83db-3f1c870e2938"
      unitRef="usd">29236000000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMjUtMS0xLTEtODkwNzI_66644f4c-dd29-4bae-a55f-1e681358ca9b"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMjUtMy0xLTEtODkwNzI_068cf546-240e-441d-9013-466545604903"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMjctMC0xLTEtODkwNzIvdGV4dHJlZ2lvbjpjYWZiZWVjNjNjYjk0M2RkYTViMDc0ZmFjNDhlNjZlZV82Mg_7555a972-4ef5-4965-a986-b96747406f14"
      unitRef="shares">361331665</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMjctMC0xLTEtODkwNzIvdGV4dHJlZ2lvbjpjYWZiZWVjNjNjYjk0M2RkYTViMDc0ZmFjNDhlNjZlZV82Mg_dc8fc9fb-20a9-4a5b-92e1-0f7344c9e582"
      unitRef="shares">361331665</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMjctMC0xLTEtODkwNzIvdGV4dHJlZ2lvbjpjYWZiZWVjNjNjYjk0M2RkYTViMDc0ZmFjNDhlNjZlZV82OQ_b46feb3d-7289-4d49-8b56-15dada824fb2"
      unitRef="shares">359405748</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMjctMC0xLTEtODkwNzIvdGV4dHJlZ2lvbjpjYWZiZWVjNjNjYjk0M2RkYTViMDc0ZmFjNDhlNjZlZV82OQ_d15dd73c-c2b9-477b-b2c8-d2b0890ce6f3"
      unitRef="shares">359405748</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMjctMS0xLTEtODkwNzI_7ffeb007-e769-41fe-9ac8-62c1ca849174"
      unitRef="usd">10373000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMjctMy0xLTEtODkwNzI_da466f51-1b88-4811-af79-282f657e2e6e"
      unitRef="usd">10317000000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMjgtMS0xLTEtODkwNzI_023cb733-8914-45b3-ba3d-fbfeebb6b7a7"
      unitRef="usd">415000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMjgtMy0xLTEtODkwNzI_9271f5e2-5473-47fe-8914-ca9ca12f7f08"
      unitRef="usd">462000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMjktMS0xLTEtODkwNzI_3d5184b2-d88b-479e-a4c9-033aa0a2b015"
      unitRef="usd">-9030000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMjktMy0xLTEtODkwNzI_c57c6727-7ff3-4dc7-af0c-35fcbf344fd6"
      unitRef="usd">-8961000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMzAtMS0xLTEtODkwNzI_87b07e6d-8c49-436a-90e0-6ca4751fc93c"
      unitRef="usd">-1974000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMzAtMy0xLTEtODkwNzI_2a1e7eb3-257e-4aee-8649-a0948b007f53"
      unitRef="usd">-1924000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMzEtMS0xLTEtODkwNzI_95992186-8f0e-4ac7-bdb6-86b3ec6abd63"
      unitRef="usd">-216000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMzEtMy0xLTEtODkwNzI_00453d6c-e592-4a86-95e3-b752fc7f0815"
      unitRef="usd">-106000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMzItMS0xLTEtODkwNzI_f7ba6ebd-0f7d-4f05-84e0-2938533c4e6d"
      unitRef="usd">75000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMzItMy0xLTEtODkwNzI_250f4153-d8a1-4a63-aafb-ffe5301f8ffd"
      unitRef="usd">72000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMzMtMS0xLTEtODkwNzI_5b992cb2-28bf-4126-b6bd-3e02cfb360e1"
      unitRef="usd">-141000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMzMtMy0xLTEtODkwNzI_3997b385-2e63-4e16-a19e-61b47f7411a6"
      unitRef="usd">-34000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMzQtMS0xLTEtODkwNzI_5da4a518-3d43-48c5-8e56-d13ea3c1a730"
      unitRef="usd">29090000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yMi9mcmFnOmEyYzRkZThlY2MxZjQ0MzBhNjY2MTk3NGY1ODVhMmNhL3RhYmxlOjBlMDJlNzU5Y2QzOTRjY2FhN2U4NzBhYzZkMGRhNTkxL3RhYmxlcmFuZ2U6MGUwMmU3NTljZDM5NGNjYWE3ZTg3MGFjNmQwZGE1OTFfMzQtMy0xLTEtODkwNzI_c9d4aecd-362e-4d16-8abd-1fdfb4054c8f"
      unitRef="usd">29202000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7062f2c8d3b74170b8ed9d57d942850f_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMy01LTEtMS04OTA3Mg_5ba64193-1c0b-4955-9810-dbc858729dd7"
      unitRef="usd">1898000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i47ece7f00f6a493a9f2236a26d681928_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMy03LTEtMS04OTA3Mg_93b1d4d2-f23d-474f-bcaa-0a69777c3a8f"
      unitRef="usd">2003000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i69f7b40936e24b94a92542e01f316976_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfNC01LTEtMS04OTA3Mg_a925b14a-c0bc-4aca-91c0-fc99a76032ab"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib5e530ee58404ccc965b53fc6d73c350_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfNC03LTEtMS04OTA3Mg_30823265-adaa-4311-af08-9c4bd847f63d"
      unitRef="usd">24000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfNS01LTEtMS04OTA3Mg_53c7129b-bbd1-4c88-b8fe-7ffdb0c3751e"
      unitRef="usd">1918000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfNS03LTEtMS04OTA3Mg_4a6a43c9-f68c-444d-a5f1-0486e9d0e91e"
      unitRef="usd">2027000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i7062f2c8d3b74170b8ed9d57d942850f_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfNy01LTEtMS04OTA3Mg_84ab7a50-5d54-4add-a5a4-47403cc7b0c7"
      unitRef="usd">543000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i47ece7f00f6a493a9f2236a26d681928_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfNy03LTEtMS04OTA3Mg_e1e439e4-481b-46dc-b8ee-97afb13173c7"
      unitRef="usd">564000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i69f7b40936e24b94a92542e01f316976_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfOC01LTEtMS04OTA3Mg_04cd5811-e5ab-413e-a84e-ee862d739665"
      unitRef="usd">8000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ib5e530ee58404ccc965b53fc6d73c350_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfOC03LTEtMS04OTA3Mg_7fa0bdad-b93d-493d-a468-2439b7cc382a"
      unitRef="usd">10000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfOS01LTEtMS04OTA3Mg_fd4cbe21-5bea-4413-8c22-a55f8ebae35f"
      unitRef="usd">622000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfOS03LTEtMS04OTA3Mg_0574ea0b-4f92-41a4-a836-ebcb5819317f"
      unitRef="usd">606000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMTAtNS0xLTEtODkwNzI_8fcfe739-6078-492c-9940-fdf96d9f01e5"
      unitRef="usd">127000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMTAtNy0xLTEtODkwNzI_5c61728f-0327-4153-aad2-1c46235aef89"
      unitRef="usd">112000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMTEtNS0xLTEtODkwNzI_c2924bc2-a0c7-4453-879a-b1a9ea8d3202"
      unitRef="usd">310000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMTEtNy0xLTEtODkwNzI_1e816d96-fd2f-45da-b674-729f0798aec7"
      unitRef="usd">357000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMTItNS0xLTEtODkwNzI_2664234f-144f-412d-81cb-1fd4eacfeaf6"
      unitRef="usd">0</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMTItNy0xLTEtODkwNzI_dc1e3780-752c-4543-9cf9-5fc8c8921189"
      unitRef="usd">469000000</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMTMtNS0xLTEtODkwNzI_ba850735-d768-43ab-aa06-29e1af563bae"
      unitRef="usd">8000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMTMtNy0xLTEtODkwNzI_1c16b15d-4e05-4c57-8388-066312c9cdf6"
      unitRef="usd">148000000</us-gaap:AssetImpairmentCharges>
    <bhc:RestructuringChargesAndInitialPublicOfferingCosts
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMTQtNS0xLTEtODkwNzI_8173d398-50c9-41ce-a4cf-c77ff3acd458"
      unitRef="usd">13000000</bhc:RestructuringChargesAndInitialPublicOfferingCosts>
    <bhc:RestructuringChargesAndInitialPublicOfferingCosts
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMTQtNy0xLTEtODkwNzI_246ced12-a029-49fd-afac-48771aaacf41"
      unitRef="usd">12000000</bhc:RestructuringChargesAndInitialPublicOfferingCosts>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMTUtNS0xLTEtODkwNzI_448c1903-57c4-463a-9acb-66e08f7acebe"
      unitRef="usd">-2000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMTUtNy0xLTEtODkwNzI_3a2f2259-059b-4fff-bd9d-81fbc7bf4856"
      unitRef="usd">30000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:CostsAndExpenses
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMTYtNS0xLTEtODkwNzI_a52721b7-5f30-4d6c-8827-11315be207be"
      unitRef="usd">1633000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMTYtNy0xLTEtODkwNzI_764b141a-82e4-4ebd-8206-2768b4b4856f"
      unitRef="usd">2248000000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMTctNS0xLTEtODkwNzI_49aa2090-13fc-4008-baa2-f91aba5c4c57"
      unitRef="usd">285000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMTctNy0xLTEtODkwNzI_3a3183cf-48e6-4789-ab4a-d28eb52714ab"
      unitRef="usd">-221000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMTgtNS0xLTEtODkwNzI_3be73a39-8bb5-4710-a857-1074945e9042"
      unitRef="usd">2000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMTgtNy0xLTEtODkwNzI_057744d0-99d1-4c59-b72c-bdc25fe2ed42"
      unitRef="usd">2000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseDebt
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMTktNS0xLTEtODkwNzI_a560670d-2522-40f3-8da5-ce43908224a9"
      unitRef="usd">362000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMTktNy0xLTEtODkwNzI_0cf92165-ef56-4375-aa52-4597161dff43"
      unitRef="usd">368000000</us-gaap:InterestExpenseDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMjAtNS0xLTEtODkwNzI_606af6d4-5e79-4df6-80a7-13dae65e1d70"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMjAtNy0xLTEtODkwNzI_32aa44c8-938d-4323-9c78-4d43d4212c70"
      unitRef="usd">-5000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMjEtNS0xLTEtODkwNzI_ff05d42d-1b45-4260-be74-ee551bce807b"
      unitRef="usd">-7000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMjEtNy0xLTEtODkwNzI_31d6b299-1bb9-46ab-ab5a-f8555cd06164"
      unitRef="usd">1000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMjItNS0xLTEtODkwNzI_39fa7a89-d0eb-4135-ac9f-b916852e337f"
      unitRef="usd">-82000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMjItNy0xLTEtODkwNzI_b53af802-a1c4-49e5-b0fb-b23b82adb58b"
      unitRef="usd">-591000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMjMtNS0xLTEtODkwNzI_9b5e2a8f-0ce4-4497-b3b1-3bee482dda94"
      unitRef="usd">-16000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMjMtNy0xLTEtODkwNzI_9815a60a-12c3-45e7-bd14-b54a5c6101c6"
      unitRef="usd">16000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMjQtNS0xLTEtODkwNzI_dc6bc22f-ee54-41a3-b991-1daafd9b285b"
      unitRef="usd">-66000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMjQtNy0xLTEtODkwNzI_55ca8b6b-8a11-4ebd-b403-26ad1882e46e"
      unitRef="usd">-607000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMjUtNS0xLTEtODkwNzI_3b52565f-a418-46c3-a051-6f7102e6da9d"
      unitRef="usd">3000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMjUtNy0xLTEtODkwNzI_0ca88355-3ef7-421f-80a5-712d396b10a0"
      unitRef="usd">3000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMjYtNS0xLTEtODkwNzI_326e0352-4fa6-4c3e-af06-15e57a723c72"
      unitRef="usd">-69000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMjYtNy0xLTEtODkwNzI_a1cfe7be-ffcf-43d4-93ab-a08af3e7505e"
      unitRef="usd">-610000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMjktNS0xLTEtODkwNzI_f266d57c-b5a0-476e-a1b5-5001a199c220"
      unitRef="usdPerShare">-0.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMjktNS0xLTEtODkwNzI_f94db0b8-c47c-411f-a96f-5bb5b15b8d0b"
      unitRef="usdPerShare">-0.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMjktNy0xLTEtODkwNzI_3a78cb4a-cd74-4e5a-82bb-785a086facdc"
      unitRef="usdPerShare">-1.71</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMjktNy0xLTEtODkwNzI_ad100ef4-2766-48cf-a11e-b7f8b7476e4d"
      unitRef="usdPerShare">-1.71</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMzMtNS0xLTEtODkwNzI_e6341211-22c5-4e8d-9d08-6e5a2dfd55fc"
      unitRef="shares">360800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMzMtNS0xLTEtODkwNzI_f6333850-e51f-4b8d-b24f-f7cdca664bba"
      unitRef="shares">360800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMzMtNy0xLTEtODkwNzI_4ad30366-a60d-45f8-87e0-3333fbc4dffa"
      unitRef="shares">356800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yNS9mcmFnOjI0OWVhN2QyN2MyMzRjZTNhNGYwZjA4OGY2NTEwMGMyL3RhYmxlOjJjY2Y3MmU2NWQ1ODRmNDJiNWM0Njc0YmNiOWNhZDgzL3RhYmxlcmFuZ2U6MmNjZjcyZTY1ZDU4NGY0MmI1YzQ2NzRiY2I5Y2FkODNfMzMtNy0xLTEtODkwNzI_5d3cff9e-3265-465c-ba1f-047936d2cb35"
      unitRef="shares">356800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yOC9mcmFnOmQ0YjcwMzVlZWI4YjRiODk5MTg4YzlmMjE4YmVlN2M0L3RhYmxlOmU2NTU1ZDYzZTBkOTQ0ODZhZDRiYzQ1ZDg4YzliNTUzL3RhYmxlcmFuZ2U6ZTY1NTVkNjNlMGQ5NDQ4NmFkNGJjNDVkODhjOWI1NTNfMi01LTEtMS04OTA3Mg_e174f489-b8f6-4c39-84dc-e578aa5229b5"
      unitRef="usd">-66000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yOC9mcmFnOmQ0YjcwMzVlZWI4YjRiODk5MTg4YzlmMjE4YmVlN2M0L3RhYmxlOmU2NTU1ZDYzZTBkOTQ0ODZhZDRiYzQ1ZDg4YzliNTUzL3RhYmxlcmFuZ2U6ZTY1NTVkNjNlMGQ5NDQ4NmFkNGJjNDVkODhjOWI1NTNfMi03LTEtMS04OTA3Mg_165bf1c6-9523-4b2c-9e72-e79d95b46384"
      unitRef="usd">-607000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yOC9mcmFnOmQ0YjcwMzVlZWI4YjRiODk5MTg4YzlmMjE4YmVlN2M0L3RhYmxlOmU2NTU1ZDYzZTBkOTQ0ODZhZDRiYzQ1ZDg4YzliNTUzL3RhYmxlcmFuZ2U6ZTY1NTVkNjNlMGQ5NDQ4NmFkNGJjNDVkODhjOWI1NTNfNC01LTEtMS04OTA3Mg_430fdb98-12f5-4b85-9173-4f7565fbdf85"
      unitRef="usd">-56000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yOC9mcmFnOmQ0YjcwMzVlZWI4YjRiODk5MTg4YzlmMjE4YmVlN2M0L3RhYmxlOmU2NTU1ZDYzZTBkOTQ0ODZhZDRiYzQ1ZDg4YzliNTUzL3RhYmxlcmFuZ2U6ZTY1NTVkNjNlMGQ5NDQ4NmFkNGJjNDVkODhjOWI1NTNfNC03LTEtMS04OTA3Mg_d84153cc-c615-4151-9c5a-a2f43f2efdc4"
      unitRef="usd">-124000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yOC9mcmFnOmQ0YjcwMzVlZWI4YjRiODk5MTg4YzlmMjE4YmVlN2M0L3RhYmxlOmU2NTU1ZDYzZTBkOTQ0ODZhZDRiYzQ1ZDg4YzliNTUzL3RhYmxlcmFuZ2U6ZTY1NTVkNjNlMGQ5NDQ4NmFkNGJjNDVkODhjOWI1NTNfNS01LTEtMS04OTA3Mg_f69dba4e-e481-4428-af07-c932dcb4e9c6"
      unitRef="usd">-6000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yOC9mcmFnOmQ0YjcwMzVlZWI4YjRiODk5MTg4YzlmMjE4YmVlN2M0L3RhYmxlOmU2NTU1ZDYzZTBkOTQ0ODZhZDRiYzQ1ZDg4YzliNTUzL3RhYmxlcmFuZ2U6ZTY1NTVkNjNlMGQ5NDQ4NmFkNGJjNDVkODhjOWI1NTNfNS03LTEtMS04OTA3Mg_66f0efbd-c6e7-4187-859f-9474301722ed"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yOC9mcmFnOmQ0YjcwMzVlZWI4YjRiODk5MTg4YzlmMjE4YmVlN2M0L3RhYmxlOmU2NTU1ZDYzZTBkOTQ0ODZhZDRiYzQ1ZDg4YzliNTUzL3RhYmxlcmFuZ2U6ZTY1NTVkNjNlMGQ5NDQ4NmFkNGJjNDVkODhjOWI1NTNfNi01LTEtMS04OTA3Mg_dda1a83d-fd22-49ad-8dfa-dc7bcd33d967"
      unitRef="usd">-50000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yOC9mcmFnOmQ0YjcwMzVlZWI4YjRiODk5MTg4YzlmMjE4YmVlN2M0L3RhYmxlOmU2NTU1ZDYzZTBkOTQ0ODZhZDRiYzQ1ZDg4YzliNTUzL3RhYmxlcmFuZ2U6ZTY1NTVkNjNlMGQ5NDQ4NmFkNGJjNDVkODhjOWI1NTNfNi03LTEtMS04OTA3Mg_d6251661-0b23-480e-b72d-cd793397aa56"
      unitRef="usd">-123000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yOC9mcmFnOmQ0YjcwMzVlZWI4YjRiODk5MTg4YzlmMjE4YmVlN2M0L3RhYmxlOmU2NTU1ZDYzZTBkOTQ0ODZhZDRiYzQ1ZDg4YzliNTUzL3RhYmxlcmFuZ2U6ZTY1NTVkNjNlMGQ5NDQ4NmFkNGJjNDVkODhjOWI1NTNfNy01LTEtMS04OTA3Mg_8ecda77c-9e44-4196-80ec-3d8f74025c48"
      unitRef="usd">-116000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yOC9mcmFnOmQ0YjcwMzVlZWI4YjRiODk5MTg4YzlmMjE4YmVlN2M0L3RhYmxlOmU2NTU1ZDYzZTBkOTQ0ODZhZDRiYzQ1ZDg4YzliNTUzL3RhYmxlcmFuZ2U6ZTY1NTVkNjNlMGQ5NDQ4NmFkNGJjNDVkODhjOWI1NTNfNy03LTEtMS04OTA3Mg_629b8350-65d6-4890-b979-78d991f21720"
      unitRef="usd">-730000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yOC9mcmFnOmQ0YjcwMzVlZWI4YjRiODk5MTg4YzlmMjE4YmVlN2M0L3RhYmxlOmU2NTU1ZDYzZTBkOTQ0ODZhZDRiYzQ1ZDg4YzliNTUzL3RhYmxlcmFuZ2U6ZTY1NTVkNjNlMGQ5NDQ4NmFkNGJjNDVkODhjOWI1NTNfOC01LTEtMS04OTA3Mg_9b28b8dd-b385-4568-a31f-ae6504d85983"
      unitRef="usd">3000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yOC9mcmFnOmQ0YjcwMzVlZWI4YjRiODk5MTg4YzlmMjE4YmVlN2M0L3RhYmxlOmU2NTU1ZDYzZTBkOTQ0ODZhZDRiYzQ1ZDg4YzliNTUzL3RhYmxlcmFuZ2U6ZTY1NTVkNjNlMGQ5NDQ4NmFkNGJjNDVkODhjOWI1NTNfOC03LTEtMS04OTA3Mg_566ded38-aec6-4fca-8e2a-51524fd7b135"
      unitRef="usd">3000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yOC9mcmFnOmQ0YjcwMzVlZWI4YjRiODk5MTg4YzlmMjE4YmVlN2M0L3RhYmxlOmU2NTU1ZDYzZTBkOTQ0ODZhZDRiYzQ1ZDg4YzliNTUzL3RhYmxlcmFuZ2U6ZTY1NTVkNjNlMGQ5NDQ4NmFkNGJjNDVkODhjOWI1NTNfOS01LTEtMS04OTA3Mg_b5f8dde0-64e6-4336-a26f-e69a6772c7d4"
      unitRef="usd">-119000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18yOC9mcmFnOmQ0YjcwMzVlZWI4YjRiODk5MTg4YzlmMjE4YmVlN2M0L3RhYmxlOmU2NTU1ZDYzZTBkOTQ0ODZhZDRiYzQ1ZDg4YzliNTUzL3RhYmxlcmFuZ2U6ZTY1NTVkNjNlMGQ5NDQ4NmFkNGJjNDVkODhjOWI1NTNfOS03LTEtMS04OTA3Mg_14ee18a0-71d9-470e-9712-1738b4424df3"
      unitRef="usd">-733000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="i13d8ae26fd5b445285277b95f6ab5311_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMjUtMi0xLTEtODkwNzI_b0983265-9b7e-4a05-9ee8-658e9aa14fc9"
      unitRef="shares">359400000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i13d8ae26fd5b445285277b95f6ab5311_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMjUtNC0xLTEtODkwNzI_9698fcd9-f06f-4f90-8741-0f2e565c09b1"
      unitRef="usd">10317000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iba49a57b938b4b89b6c94414674a0509_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMjUtNi0xLTEtODkwNzI_449aa583-d253-4802-9d0f-72bbfd4943cc"
      unitRef="usd">462000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i84be42c574674323bfa1ce40efc25a3b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMjUtOC0xLTEtODkwNzI_cec32c7d-9367-406c-8f0d-cdaf3f2a2d11"
      unitRef="usd">-8961000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4e97a6c789b1443ba408d058697c5cc2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMjUtMTAtMS0xLTg5MDcy_622157d1-3e0c-41a7-b165-52a5afe89f18"
      unitRef="usd">-1924000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icdfc8eeec050428bb667d6d8a8100215_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMjUtMTItMS0xLTg5MDcy_f6d5f99a-a06b-4a76-8743-fd6ac3ef9cc6"
      unitRef="usd">-106000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if569d73216764720b3070f4e5764288d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMjUtMTQtMS0xLTg5MDcy_65160cb7-ad20-4e0a-8d7c-dec9cb46d9fe"
      unitRef="usd">72000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMjUtMTYtMS0xLTg5MDcy_01f6d3bb-b658-4eb6-b352-b860cb221346"
      unitRef="usd">-34000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i7de19b3349ed480785851723d3e2ec65_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMjYtMi0xLTEtODkwNzI_57cfc132-ace7-4cb9-b55d-17af55c8cca6"
      unitRef="shares">1900000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7de19b3349ed480785851723d3e2ec65_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMjYtNC0xLTEtODkwNzI_57064e95-52f5-4ff8-9cc1-e9d516433e1d"
      unitRef="usd">56000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0ae02726ad6f44979a1c380354d1b1ee_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMjYtNi0xLTEtODkwNzI_54d36600-f976-4f1b-83f8-ff26acad6e92"
      unitRef="usd">-54000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i77808f738d5b47f0b37ad9c848b56f22_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMjYtMTItMS0xLTg5MDcy_30888e98-a46e-408b-a58f-1ba4bad963cd"
      unitRef="usd">2000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMjYtMTYtMS0xLTg5MDcy_d3b02bd7-3280-4567-afc7-8619dba02bb4"
      unitRef="usd">2000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0ae02726ad6f44979a1c380354d1b1ee_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMjctNi0xLTEtODkwNzI_b20c5e5e-20fc-432a-9027-950989e92bf4"
      unitRef="usd">32000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i77808f738d5b47f0b37ad9c848b56f22_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMjctMTItMS0xLTg5MDcy_47567793-7847-41d3-aa8a-5cb444df0545"
      unitRef="usd">32000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMjctMTYtMS0xLTg5MDcy_b52da956-a337-492c-93f7-ecfda23555c5"
      unitRef="usd">32000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i0ae02726ad6f44979a1c380354d1b1ee_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMjgtNi0xLTEtODkwNzI_ffa47b1c-2127-4ca7-9f52-103cc4d97618"
      unitRef="usd">25000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i77808f738d5b47f0b37ad9c848b56f22_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMjgtMTItMS0xLTg5MDcy_42123ab0-5ddb-49da-b83d-612a77bf5be3"
      unitRef="usd">25000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMjgtMTYtMS0xLTg5MDcy_e0c82ad2-d50c-4c7e-8d00-9986646d9b16"
      unitRef="usd">25000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProfitLoss
      contextRef="i9f4e826d5cae4c6ab418a941d7cc0de2_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzEtOC0xLTEtODkwNzI_db17f732-cb3a-401e-8a00-4897a3a99d38"
      unitRef="usd">-69000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i77808f738d5b47f0b37ad9c848b56f22_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzEtMTItMS0xLTg5MDcy_400cdc28-405d-48f4-b5ad-5cfd0d9c1aba"
      unitRef="usd">-69000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i9c0970c94f194e79b173d2e77e2e293e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzEtMTQtMS0xLTg5MDcy_365ffe23-254b-448a-a573-bc94e2c84b58"
      unitRef="usd">3000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzEtMTYtMS0xLTg5MDcy_3d3b7133-2d73-41d6-8eab-1e1420a33515"
      unitRef="usd">-66000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="icfaddc1e31294937b80e601e88e11ec4_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzItMTAtMS0xLTg5MDcy_fadeba15-8937-4712-ada4-2ac1b2ff2d4d"
      unitRef="usd">-50000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i77808f738d5b47f0b37ad9c848b56f22_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzItMTItMS0xLTg5MDcy_9adfc9ff-4445-47e7-83f1-700b67b77130"
      unitRef="usd">-50000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzItMTYtMS0xLTg5MDcy_bdeaefe3-d9ce-404b-87e1-654ca4a516d9"
      unitRef="usd">-50000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="id18917e004004a1cb3c4e185b15bf4f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzMtMi0xLTEtODkwNzI_14f949ea-f1a9-4675-8dbf-04c9b8819388"
      unitRef="shares">361300000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id18917e004004a1cb3c4e185b15bf4f9_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzMtNC0xLTEtODkwNzI_11c0bbaa-379d-4476-88a3-59d69276b343"
      unitRef="usd">10373000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3f63b9f26c034375825caac2dc4a720d_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzMtNi0xLTEtODkwNzI_7e481303-4cd2-473b-9ece-8bcf0daf8090"
      unitRef="usd">415000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib79580d46a03440a901afd4aa7cf0eae_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzMtOC0xLTEtODkwNzI_badf3bc7-c298-4d7f-9647-e2d972ff07c8"
      unitRef="usd">-9030000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i38bc8011408047f4b2f92fc815fe79b3_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzMtMTAtMS0xLTg5MDcy_8a42ebf0-64df-400d-81cd-86457fee3929"
      unitRef="usd">-1974000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6f1e816041a249bcaedd71a44ddc03c1_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzMtMTItMS0xLTg5MDcy_6dc18650-7e0c-448b-bef4-36d9b5d790d9"
      unitRef="usd">-216000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0925610a81344f42966f7155678bbe7d_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzMtMTQtMS0xLTg5MDcy_d5a1e295-e8ba-4cfa-8d2f-746c351f2cfa"
      unitRef="usd">75000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzMtMTYtMS0xLTg5MDcy_968ec850-e02f-4e1b-94ee-08de2bfa47c3"
      unitRef="usd">-141000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="i6bc0f97e922441d290fd2952ed4015ca_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzYtMi0xLTEtODkwNzI_1a3a8224-395d-4746-bf22-a015cbcca59c"
      unitRef="shares">355400000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6bc0f97e922441d290fd2952ed4015ca_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzYtNC0xLTEtODkwNzI_97c9d4ef-26da-42d8-badf-6af2010a7f3c"
      unitRef="usd">10227000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2f39cf0ad53f489993087fb8612e9e44_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzYtNi0xLTEtODkwNzI_9d3ece54-a881-4fc6-be09-75c92c372a1e"
      unitRef="usd">454000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i580f9e18b59a4b5180b3f4e43139f3fd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzYtOC0xLTEtODkwNzI_81740f2e-f02c-4fc9-9f14-1fb75f6b98ef"
      unitRef="usd">-8013000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7c28220a2c554d82874543d9cef4c95f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzYtMTAtMS0xLTg5MDcy_a350ebb6-68f8-408a-93cc-dd9332f97e8e"
      unitRef="usd">-2133000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7ec67446aa664948b24b2dd151b61e21_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzYtMTItMS0xLTg5MDcy_9a410699-2e76-4de6-b172-1ce83fb399a1"
      unitRef="usd">535000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ida777d6fa6784748b45afb0c1b8b936f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzYtMTQtMS0xLTg5MDcy_d924ff4a-7171-4326-9443-5a535f4ac6e7"
      unitRef="usd">70000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2d274a4a3e5a43ae91dfbb2934c4c5d1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzYtMTYtMS0xLTg5MDcy_eda1a57d-0408-4b58-b270-12a28fb59648"
      unitRef="usd">605000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i250250ab4d084a8688cdf94e83fcc6ea_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzgtMi0xLTEtODkwNzI_eb4a55a8-1947-4132-8741-5e1f0c7a0e27"
      unitRef="shares">2700000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i250250ab4d084a8688cdf94e83fcc6ea_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzgtNC0xLTEtODkwNzI_538e1280-9b61-4651-b8f2-8e78aba82305"
      unitRef="usd">62000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9abb088ab0824fe28335ba83a90707de_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzgtNi0xLTEtODkwNzI_6de43cae-454a-4444-85fb-3805bab4aa63"
      unitRef="usd">-51000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4db7cba132fa4f3593873402ff1be811_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzgtMTItMS0xLTg5MDcy_36a48c24-4bfc-49df-badd-79f0f83170a5"
      unitRef="usd">11000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzgtMTYtMS0xLTg5MDcy_1b254ad8-243b-4e61-83c7-9183f8bab704"
      unitRef="usd">11000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9abb088ab0824fe28335ba83a90707de_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzktNi0xLTEtODkwNzI_985d3d47-cdd3-41a0-97e7-cab892682f8a"
      unitRef="usd">31000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4db7cba132fa4f3593873402ff1be811_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzktMTItMS0xLTg5MDcy_ee5289b2-8ad5-4b11-a2fd-06ab5a62fcea"
      unitRef="usd">31000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzktMTYtMS0xLTg5MDcy_6d82c93f-ea77-47b8-abf5-0c265e5f8e41"
      unitRef="usd">31000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i9abb088ab0824fe28335ba83a90707de_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfNDAtNi0xLTEtODkwNzI_7a4b46ec-0210-4676-9574-76f34db81f91"
      unitRef="usd">41000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i4db7cba132fa4f3593873402ff1be811_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfNDAtMTItMS0xLTg5MDcy_3c364e47-6e7b-499f-aa9d-9619504a55bc"
      unitRef="usd">41000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfNDAtMTYtMS0xLTg5MDcy_334b71d4-37e3-40b4-8de6-c6b692b61942"
      unitRef="usd">41000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProfitLoss
      contextRef="i1cf56ffa097d418fbaa7f8cee2095239_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfNDItOC0xLTEtODkwNzI_d6e835e4-1f14-4ecc-a296-29a57fa52c1b"
      unitRef="usd">-610000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4db7cba132fa4f3593873402ff1be811_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfNDItMTItMS0xLTg5MDcy_9d74eae5-b497-4d3f-a017-319d037cbbfa"
      unitRef="usd">-610000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="icf2c42a95b1b488c9bb882abf26775af_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfMzgtMTQtMS0xLTk5OTIz_d8d7e7e4-f312-4c5e-953b-8def2070c410"
      unitRef="usd">3000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfNDItMTYtMS0xLTg5MDcy_eb04ee6d-956f-46d2-a611-409f17c6a417"
      unitRef="usd">-607000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8c96e3e707c44ef29db8e7d1430f0ccf_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfNDMtMTAtMS0xLTg5MDcy_db5e3a2c-7258-4b2c-a3f8-3d2567241560"
      unitRef="usd">-123000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4db7cba132fa4f3593873402ff1be811_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfNDMtMTItMS0xLTg5MDcy_56005155-f4d1-4e83-addc-f143f97b49c8"
      unitRef="usd">-123000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfNDMtMTYtMS0xLTg5MDcy_e0a3896d-9b1d-4b7c-8a6e-5a895de6b723"
      unitRef="usd">-123000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="ifc469902b8d54318b2dc5e3d6f63767e_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfNDQtMi0xLTEtODkwNzI_f8201394-55ca-401b-95b9-b498c1481cbc"
      unitRef="shares">358100000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifc469902b8d54318b2dc5e3d6f63767e_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfNDQtNC0xLTEtODkwNzI_cf7a6a10-df90-49c8-b6b8-e9ea94c68a50"
      unitRef="usd">10289000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1a3043cdb1ec4efba6e8a08d5c15f7d0_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfNDQtNi0xLTEtODkwNzI_e1a835f1-4fec-4505-8a8a-6d1365649a17"
      unitRef="usd">393000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8aed8fa227084065a8e36af7e4853547_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfNDQtOC0xLTEtODkwNzI_83b27980-ec90-4344-be65-dccb8cf62fbf"
      unitRef="usd">-8623000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if8e74f44512b4b5ba5eadd53d7ab8369_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfNDQtMTAtMS0xLTg5MDcy_a105b798-bf4a-41f6-a69a-24867b518ed2"
      unitRef="usd">-2256000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2671fe8b646f46afb7fa5e65ea5d1e7b_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfNDQtMTItMS0xLTg5MDcy_4d81ddcf-403b-4613-abec-5437cfe1267d"
      unitRef="usd">-197000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3f5376ee1f8e4cf1a9859fc1a22909f3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfNDQtMTQtMS0xLTg5MDcy_c81fd666-a3ac-418d-aaad-ecb6b41a9e0f"
      unitRef="usd">73000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i812289a7a0cf44b4b1eed544ad0bec6c_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zMS9mcmFnOjg4ZmI4MzM4OWY0ZDQ3ZmI4NGQ0YWUwODIyYzMyODI4L3RhYmxlOjFhNGY3ZjQzY2E5ZDQ5YjU4YjUwNmIzYmIzNTI3ZWQzL3RhYmxlcmFuZ2U6MWE0ZjdmNDNjYTlkNDliNThiNTA2YjNiYjM1MjdlZDNfNDQtMTYtMS0xLTg5MDcy_083b724b-d006-422f-9c02-3fdead2ee051"
      unitRef="usd">-124000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMy0xLTEtMS04OTA3Mg_e174f489-b8f6-4c39-84dc-e578aa5229b5"
      unitRef="usd">-66000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMy0zLTEtMS04OTA3Mg_165bf1c6-9523-4b2c-9e72-e79d95b46384"
      unitRef="usd">-607000000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNS0xLTEtMS04OTA3Mg_a4e4f269-50aa-4b61-9616-d5d09e9d5278"
      unitRef="usd">352000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNS0zLTEtMS04OTA3Mg_f7fe1e21-f87c-4c33-af06-86030aa24495"
      unitRef="usd">403000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNi0xLTEtMS04OTA3Mg_a4a951b3-ba40-4e25-a7f0-54f2cfb8ccd7"
      unitRef="usd">14000000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNi0zLTEtMS04OTA3Mg_f4fc9b4d-db09-4af8-b499-656365659458"
      unitRef="usd">13000000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AssetImpairmentCharges
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNy0xLTEtMS04OTA3Mg_ba850735-d768-43ab-aa06-29e1af563bae"
      unitRef="usd">8000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNy0zLTEtMS04OTA3Mg_1c16b15d-4e05-4c57-8388-066312c9cdf6"
      unitRef="usd">148000000</us-gaap:AssetImpairmentCharges>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfOC0xLTEtMS04OTA3Mg_2664234f-144f-412d-81cb-1fd4eacfeaf6"
      unitRef="usd">0</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfOC0zLTEtMS04OTA3Mg_dc1e3780-752c-4543-9cf9-5fc8c8921189"
      unitRef="usd">469000000</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfOS0xLTEtMS04OTA3Mg_1c8ef0c8-e48c-4392-a059-37d8033077ab"
      unitRef="usd">3000000</bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash>
    <bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfOS0zLTEtMS04OTA3Mg_bf249f3a-bd4c-47a4-b23e-7c79be08f7e3"
      unitRef="usd">-9000000</bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash>
    <bhc:AllowancesForLossesOnAccountsReceivableAndInventories
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMTAtMS0xLTEtODkwNzI_8b6b5551-2848-4eb3-bc48-d92dc57637c7"
      unitRef="usd">14000000</bhc:AllowancesForLossesOnAccountsReceivableAndInventories>
    <bhc:AllowancesForLossesOnAccountsReceivableAndInventories
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMTAtMy0xLTEtODkwNzI_b9d22c23-3a57-4e22-8e7a-69d3b2af98de"
      unitRef="usd">17000000</bhc:AllowancesForLossesOnAccountsReceivableAndInventories>
    <bhc:DeferredIncomeTaxNoncashExpenseBenefit
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMTEtMS0xLTEtODkwNzI_9c48af66-19a5-4461-9d95-07416247d98e"
      unitRef="usd">-83000000</bhc:DeferredIncomeTaxNoncashExpenseBenefit>
    <bhc:DeferredIncomeTaxNoncashExpenseBenefit
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMTEtMy0xLTEtODkwNzI_c9317cc9-cc45-4064-b20d-c5f36fdc511b"
      unitRef="usd">-14000000</bhc:DeferredIncomeTaxNoncashExpenseBenefit>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMTItMS0xLTEtODkwNzI_ca64c6c0-e5ad-4388-b02c-a8037479f4ab"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMTItMy0xLTEtODkwNzI_d17ec827-ae5d-4670-9c67-469fb668360a"
      unitRef="usd">23000000</us-gaap:GainLossOnDispositionOfAssets1>
    <bhc:GainLossRelatedToLitigationSettlementGross
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMTMtMS0xLTEtODkwNzI_acc35399-b48a-4966-920c-3a1318c389a0"
      unitRef="usd">1000000</bhc:GainLossRelatedToLitigationSettlementGross>
    <bhc:GainLossRelatedToLitigationSettlementGross
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMTMtMy0xLTEtODkwNzI_3453d565-385c-4b6b-924f-229dae6bae3e"
      unitRef="usd">0</bhc:GainLossRelatedToLitigationSettlementGross>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMTQtMS0xLTEtODkwNzI_88a5f58b-953d-4de4-8024-1c0dbda1c7e3"
      unitRef="usd">360000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMTQtMy0xLTEtODkwNzI_873d18b0-d025-41fb-8430-07c94ab01d8d"
      unitRef="usd">118000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:ShareBasedCompensation
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMTUtMS0xLTEtODkwNzI_106a0a03-d679-43fd-aa38-319c7e827836"
      unitRef="usd">32000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMTUtMy0xLTEtODkwNzI_a851c784-3844-471e-a9f1-f4e99b099550"
      unitRef="usd">31000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMTYtMS0xLTEtODkwNzI_0de0909b-e85b-4a6f-8f7e-3f0835f1ff6b"
      unitRef="usd">2000000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMTYtMy0xLTEtODkwNzI_aa3ef1ed-03ad-4dda-9c16-4461f3ff4f0a"
      unitRef="usd">-12000000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <bhc:DerivativeGainExcludedComponent
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMTctMS0xLTEtODkwNzI_429d6caa-ad6c-478f-a99f-573503ffc94a"
      unitRef="usd">0</bhc:DerivativeGainExcludedComponent>
    <bhc:DerivativeGainExcludedComponent
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMTctMy0xLTEtODkwNzI_73ae7d77-6f36-4e0b-824d-08edba09cd68"
      unitRef="usd">6000000</bhc:DerivativeGainExcludedComponent>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMTgtMS0xLTEtODkwNzI_f47471bc-b8a3-459b-be1b-de57cb4db87a"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMTgtMy0xLTEtODkwNzI_bdc9b56b-bc7f-4992-9209-1d326c608704"
      unitRef="usd">-5000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMjAtMS0xLTEtODkwNzI_4e733726-341a-49f5-86a4-815685b3ddef"
      unitRef="usd">-10000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMjAtMy0xLTEtODkwNzI_d6e22c3b-fd59-4eac-8533-6b6e3d2be675"
      unitRef="usd">18000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMjItMS0xLTEtODkwNzI_759afcf3-9870-41cd-8e1d-b2dd87c2c5ae"
      unitRef="usd">-197000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMjItMy0xLTEtODkwNzI_dc309121-a480-4248-b551-da95ed8189ef"
      unitRef="usd">-60000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMjMtMS0xLTEtODkwNzI_67939ff1-aeaa-4b9f-a3b1-93102e4a2e6c"
      unitRef="usd">73000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMjMtMy0xLTEtODkwNzI_a0b1a867-2dd2-4ae1-b04c-3738006e3385"
      unitRef="usd">35000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMjQtMS0xLTEtODkwNzI_05aaae06-6ed4-4be1-9890-bf65efe1269f"
      unitRef="usd">33000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMjQtMy0xLTEtODkwNzI_d34f3f6b-e0d0-45c7-8535-9fc72be4c035"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMjUtMS0xLTEtODkwNzI_2b941d14-9e77-467b-ae81-bf5c0648d3b1"
      unitRef="usd">-75000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMjUtMy0xLTEtODkwNzI_0bca2c22-b6bb-420e-8d16-bd574023bc1d"
      unitRef="usd">115000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMjYtMS0xLTEtODkwNzI_a0bf3ed9-8cae-472c-8f1b-1eacf5048a11"
      unitRef="usd">-63000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMjYtMy0xLTEtODkwNzI_0b401b13-c968-47d6-af13-3f29aaffbe33"
      unitRef="usd">443000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMjgtMS0xLTEtODkwNzI_2be1069d-3031-4c31-8531-4deb51418487"
      unitRef="usd">46000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMjgtMy0xLTEtODkwNzI_c13d01e1-9954-47c2-82d2-60fc28e156ba"
      unitRef="usd">66000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMjktMS0xLTEtODkwNzI_1c62fc2e-8895-4848-a953-6b258a5f5b96"
      unitRef="usd">11000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMjktMy0xLTEtODkwNzI_9e52085d-89e3-4086-984c-b3807b63e8b6"
      unitRef="usd">2000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMzAtMS0xLTEtODkwNzI_391cd965-107a-43f3-bc4c-acf60e167919"
      unitRef="usd">5000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMzAtMy0xLTEtODkwNzI_d0618f50-ff98-4d38-896e-b02f86e1428d"
      unitRef="usd">5000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMzEtMS0xLTEtODkwNzI_f994e775-14a8-49a6-98cc-d39c429f9004"
      unitRef="usd">6000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMzEtMy0xLTEtODkwNzI_96f84f0d-160d-46e0-b572-977390569e57"
      unitRef="usd">2000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMzItMS0xLTEtODkwNzI_40521685-1e40-4416-9e3e-b39b3f990769"
      unitRef="usd">0</us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested>
    <us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMzItMy0xLTEtODkwNzI_9ad498e7-de0b-4377-b34b-db03aebaee7d"
      unitRef="usd">4000000</us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested>
    <bhc:InterestSettlementOnCrossCurrencySwaps
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMzMtMS0xLTEtODkwNzI_dd0ce51c-f465-4f33-b53f-e701856cc6d5"
      unitRef="usd">0</bhc:InterestSettlementOnCrossCurrencySwaps>
    <bhc:InterestSettlementOnCrossCurrencySwaps
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMzMtMy0xLTEtODkwNzI_ac09f19e-cbd7-4ef0-97cc-9c27757a4659"
      unitRef="usd">11000000</bhc:InterestSettlementOnCrossCurrencySwaps>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMzQtMS0xLTEtODkwNzI_811955b8-e190-47a8-959c-94e5cd91fa3b"
      unitRef="usd">-56000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMzQtMy0xLTEtODkwNzI_bcfed1bd-642c-43b6-9488-dc84f9bd9b60"
      unitRef="usd">-56000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMzYtMS0xLTEtODkwNzI_ebbf3b13-4993-41e4-84ad-57c59bfcd4c1"
      unitRef="usd">986000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMzYtMy0xLTEtODkwNzI_06aa53b4-97d4-458a-ac37-e91749bbf8b1"
      unitRef="usd">-3000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMzctMS0xLTEtODkwNzI_279eff2b-f528-4664-bd4a-1b304a60c5c9"
      unitRef="usd">485000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfMzctMy0xLTEtODkwNzI_58fe3e6a-40a4-4227-bd29-bab3a3ea3a57"
      unitRef="usd">200000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNDAtMS0xLTEtODkwNzI_ef93050b-30cd-458d-bf33-0972185f925c"
      unitRef="usd">25000000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNDAtMy0xLTEtODkwNzI_09523e66-d27b-421b-ad1b-309d4ec46d83"
      unitRef="usd">41000000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNDEtMS0xLTEtODkwNzI_5345ae1c-c833-4301-a71c-41a3bcb5841a"
      unitRef="usd">8000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNDEtMy0xLTEtODkwNzI_a83e0244-5685-40cd-8bcf-f49b0e3dbeaa"
      unitRef="usd">6000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNDItMS0xLTEtODkwNzI_7a81767d-f490-4d0d-8bc2-d1a3228e8942"
      unitRef="usd">1000000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNDItMy0xLTEtODkwNzI_b3821221-2c5a-4e0c-8f40-963938c71627"
      unitRef="usd">4000000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNDMtMS0xLTEtODkwNzI_7cbda6d3-695f-4edf-acaf-44ae3dd00650"
      unitRef="usd">1000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNDMtMy0xLTEtODkwNzI_f3b44eef-ac99-49e1-ae47-f61e07f24cf8"
      unitRef="usd">11000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNDQtMS0xLTEtODkwNzI_5f96b2ba-f9e6-42f4-aaf9-b966c0558f53"
      unitRef="usd">468000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNDQtMy0xLTEtODkwNzI_c0f87495-9a80-4252-b461-0182aafc7b58"
      unitRef="usd">-243000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNDUtMS0xLTEtODkwNzI_9d032266-cc22-413a-9990-9028c11dcbb9"
      unitRef="usd">-8000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNDUtMy0xLTEtODkwNzI_5d67d29a-d399-42b3-af62-9531a8c60455"
      unitRef="usd">-13000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNDYtMS0xLTEtODkwNzI_e5f6e043-466b-4011-b98f-d13054137642"
      unitRef="usd">341000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNDYtMy0xLTEtODkwNzI_8f99fd05-e563-437b-87fd-8386a15f4036"
      unitRef="usd">131000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNDctMS0xLTEtODkwNzI_affc4586-46bf-4391-aff9-ebf77fc084b8"
      unitRef="usd">2119000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2d274a4a3e5a43ae91dfbb2934c4c5d1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNDctMy0xLTEtODkwNzI_2dbd7242-5f27-4b50-87c3-531075b63570"
      unitRef="usd">1816000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNDgtMS0xLTEtODkwNzI_f926a55f-f20d-44b4-944b-afa16f9a1e43"
      unitRef="usd">2460000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i812289a7a0cf44b4b1eed544ad0bec6c_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNDgtMy0xLTEtODkwNzI_339afb1a-546e-4644-9b15-7bf0e1da472a"
      unitRef="usd">1947000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNDktMS0xLTEtODkwNzI_02035ebc-af37-4f96-a32b-a23e58d82f12"
      unitRef="usd">1249000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i812289a7a0cf44b4b1eed544ad0bec6c_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNDktMy0xLTEtODkwNzI_a5685bdb-ffc8-479d-b522-a83714b29083"
      unitRef="usd">679000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <bhc:RestrictedCashAndOtherSettlementDepositsCurrent
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNTAtMS0xLTEtODkwNzI_e41a1083-1478-49c4-9b17-8cbe308961ba"
      unitRef="usd">1211000000</bhc:RestrictedCashAndOtherSettlementDepositsCurrent>
    <bhc:RestrictedCashAndOtherSettlementDepositsCurrent
      contextRef="i812289a7a0cf44b4b1eed544ad0bec6c_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNTAtMy0xLTEtODkwNzI_0ce0fb67-a17a-4fdd-b16a-e2f42d97f7f6"
      unitRef="usd">1214000000</bhc:RestrictedCashAndOtherSettlementDepositsCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNTEtMS0xLTEtOTQ3MDk_a285bd7c-ace7-4bbd-9d39-78c6255a7bb3"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
      contextRef="i812289a7a0cf44b4b1eed544ad0bec6c_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNTEtMy0xLTEtOTQ3MDk_597ace11-d070-4ffd-af4a-91282bc0cc3f"
      unitRef="usd">54000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNTEtMS0xLTEtODkwNzI_0d902b80-dc8d-43dc-a4ad-4d2317f672b9"
      unitRef="usd">2460000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i812289a7a0cf44b4b1eed544ad0bec6c_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18zNC9mcmFnOmM0YTAxMjIxYzhjMjQ0NWE4NDA1ODBhMTAwZjcyY2RlL3RhYmxlOjA5OWVjYTc2YzNiNzQ4ZDlhMzQwM2I5ZjM3OWUzOWE4L3RhYmxlcmFuZ2U6MDk5ZWNhNzZjM2I3NDhkOWEzNDAzYjlmMzc5ZTM5YThfNTEtMy0xLTEtODkwNzI_5229cd8d-c1d4-41e1-a251-69e5ee3d7ac9"
      unitRef="usd">1947000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NatureOfOperations
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180MC9mcmFnOjQ4OTVjZTllODdmMTRiMzVhZjc1M2QyNjVmMzU5NWY4L3RleHRyZWdpb246NDg5NWNlOWU4N2YxNGIzNWFmNzUzZDI2NWYzNTk1ZjhfNTkw_3a641487-a58c-469c-a6c9-a72dd5348083">DESCRIPTION OF BUSINESS Bausch Health Companies Inc. (the&#160;&#x201c;Company&#x201d; or &#x201c;Bausch Health&#x201d;) is a multinational, specialty pharmaceutical and medical device company that develops, manufactures and markets, primarily in the therapeutic areas of eye health, gastroenterology (&#x201c;GI&#x201d;) and dermatology, a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (&#x201c;OTC&#x201d;) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices) which are marketed directly or indirectly in approximately 100 countries.</us-gaap:NatureOfOperations>
    <us-gaap:NumberOfCountriesInWhichEntityOperates
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180MC9mcmFnOjQ4OTVjZTllODdmMTRiMzVhZjc1M2QyNjVmMzU5NWY4L3RleHRyZWdpb246NDg5NWNlOWU4N2YxNGIzNWFmNzUzZDI2NWYzNTk1ZjhfNTc0_7576847f-c059-413a-b79d-766d5ebb16fe"
      unitRef="country">100</us-gaap:NumberOfCountriesInWhichEntityOperates>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180My9mcmFnOjU5YzU0MTc3NGNlOTRhOTM4Y2NhZThmNGEzYzRmMDAwL3RleHRyZWdpb246NTljNTQxNzc0Y2U5NGE5MzhjY2FlOGY0YTNjNGYwMDBfODY0Ng_956cc5e5-536b-4de8-b366-15aa5bddc2af">SIGNIFICANT ACCOUNTING POLICIES &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation and Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Consolidated Financial Statements have been prepared by the Company in U.S. dollars and in accordance with&#160;U.S. generally accepted accounting principles (&#x201c;U.S.&#160;GAAP&#x201d;) for interim financial reporting, which do not conform in all respects to the requirements of U.S.&#160;GAAP for annual financial statements. Accordingly, these notes to the unaudited Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements prepared in accordance with U.S.&#160;GAAP that are contained in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the U.S. Securities and Exchange Commission (the&#160;&#x201c;SEC&#x201d;) and the Canadian Securities Administrators (the&#160;&#x201c;CSA&#x201d;) on February&#160;23, 2022. The unaudited Consolidated Financial Statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company&#x2019;s audited Consolidated Financial Statements for the year ended December&#160;31, 2021, except for the new accounting guidance adopted during the period. The unaudited Consolidated Financial Statements reflect all normal and recurring adjustments necessary for a fair statement of the Company&#x2019;s financial position and results of operations for the interim periods. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full&#160;year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Separation of the Bausch + Lomb Eye Health Business and Initial Public Offering of Solta Medical Business&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 6, 2020, the Company announced its intentions to separate its eye health business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc. (the &#x201c;B+L Separation&#x201d;). On August 3, 2021, the Company announced its intentions to conduct an initial public offering (&#x201c;IPO&#x201d;) of its aesthetic medical device business, Global Solta (the &#x201c;Solta IPO&#x201d;). In January 2022, the Company completed the internal organizational design and structure of the new eye health entity, Bausch + Lomb Corporation (&#x201c;Bausch + Lomb&#x201d;), and the new Global Solta entity, Solta Medical Corporation (&#x201c;Solta&#x201d;), as previously announced. The registration statement related to the B+L IPO of Bausch + Lomb (the &#x201c;B+L IPO&#x201d;) was declared effective on May 5, 2022, and Bausch + Lomb&#x2019;s common stock began trading on the New York Stock Exchange and the Toronto Stock Exchange, in each case under the ticker symbol &#x201c;BLCO&#x201d; on May 6, 2022. Prior to the effectiveness of the registration statement, Bausch + Lomb was an indirect wholly-owned subsidiary of the Company. On May 10, 2022, a wholly owned subsidiary of the Company (the &#x201c;Selling Shareholder&#x201d;) sold 35,000,000 common shares of Bausch + Lomb, at an offering price of $18.00, per share, pursuant to the Bausch + Lomb prospectus. The net proceeds from the B+L IPO after deducting underwriting commissions and estimated offering expenses were approximately $560&#160;million. The Company expects to complete the separation of Bausch + Lomb after the expiry of customary lockups related to the B+L IPO and achievement of targeted debt leverage ratios, subject to the receipt of applicable shareholder and other necessary approvals. The launch of the Solta IPO remains subject to when financial market conditions become favorable (and subject to receipt of regulatory, stock exchange and other approvals and other factors). See Note 20, &#x201c;SUBSEQUENT EVENTS&#x201d; for additional details regarding the B+L IPO.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The B+L Separation and the proposed Solta IPO will establish three separate companies that include: (i) a fully integrated eye health company which will consist of the Company&#x2019;s Bausch + Lomb Global Vision Care, Global Surgical, Global Consumer and Global Ophthalmic Pharmaceuticals businesses, (ii) a global provider of aesthetic medical devices which will consist of the Company&#x2019;s Solta business and (iii) a diversified pharmaceutical company which will include the Company&#x2019;s Salix, International (formerly International Rx), dentistry, neurology, medical dermatology and generics pharmaceutical businesses. These audited Consolidated Financial Statements do not include any adjustments to give effect to either the B+L Separation or the proposed Solta IPO.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Impacts of COVID-19 Pandemic &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unprecedented nature of the COVID-19 pandemic has, and continues to, adversely impact the global economy. The COVID-19 pandemic and the reactions of governments, private sector participants and the public in an effort to contain the spread of the COVID-19 virus and/or address its impacts have had significant direct and indirect effects on businesses and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;commerce. This includes, but is not limited to, disruption to supply chains, employee base and transactional activity, facilities closures and production suspensions.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The extent to which these events may continue to impact the Company&#x2019;s business, financial condition, cash flows and results of operations, in particular, will depend on future developments which are highly uncertain and many of which are outside the Company&#x2019;s control. Such developments include the availability and effectiveness of vaccines for the COVID-19 virus, the ultimate geographic spread and duration of the pandemic, COVID-19 vaccine immunization rates, the extent and duration of a resurgence of the COVID-19 virus and variant strains thereof, such as the delta and omicron variants, new information concerning the severity of the COVID-19 virus, the effectiveness and intensity of measures to contain the COVID-19 virus and the economic impact of the pandemic and the reactions to it. Such developments, among others, depending on their nature, duration and intensity, could have a significant adverse effect on the Company&#x2019;s business, financial condition, cash flows and results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, the Company has been able to continue its operations with limited disruptions in supply and manufacturing.   Although it is difficult to predict the broad macroeconomic effects that the COVID-19 pandemic will have on industries or individual companies, the Company has assessed the possible effects and outcomes of the pandemic on, among other things, its supply chain, customers and distributors, discounts and rebates, employee base, product sustainability, research and development efforts, product pipeline and consumer demand and currently believes that its estimates are reasonable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In preparing the unaudited Consolidated Financial Statements, management is required to make estimates and assumptions. This includes estimates and assumptions regarding the nature, timing and extent of the impacts that the COVID-19 pandemic will have on its operations and cash flows.  The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the unaudited Consolidated Financial Statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates and the differences could be material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company&#x2019;s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company&#x2019;s results of operations and financial position could be materially impacted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made to prior year amounts to conform to the current year presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Changes in Reportable Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commencing in the first quarter of 2022, the Company operates in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International (formerly International Rx), (iv) Solta Medical and (v) Diversified Products. Prior to the first quarter of 2022, the Company operated in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International, (iv) Ortho Dermatologics and (v) Diversified Products. Prior period presentations have been recast to conform to the current segment reporting structure. See Note 19, &#x201c;SEGMENT INFORMATION&#x201d; for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180My9mcmFnOjU5YzU0MTc3NGNlOTRhOTM4Y2NhZThmNGEzYzRmMDAwL3RleHRyZWdpb246NTljNTQxNzc0Y2U5NGE5MzhjY2FlOGY0YTNjNGYwMDBfODY3MQ_a486cfda-8995-494d-8a14-ee5dea96c3ba">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation and Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Consolidated Financial Statements have been prepared by the Company in U.S. dollars and in accordance with&#160;U.S. generally accepted accounting principles (&#x201c;U.S.&#160;GAAP&#x201d;) for interim financial reporting, which do not conform in all respects to the requirements of U.S.&#160;GAAP for annual financial statements. Accordingly, these notes to the unaudited Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements prepared in accordance with U.S.&#160;GAAP that are contained in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the U.S. Securities and Exchange Commission (the&#160;&#x201c;SEC&#x201d;) and the Canadian Securities Administrators (the&#160;&#x201c;CSA&#x201d;) on February&#160;23, 2022. The unaudited Consolidated Financial Statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company&#x2019;s audited Consolidated Financial Statements for the year ended December&#160;31, 2021, except for the new accounting guidance adopted during the period. The unaudited Consolidated Financial Statements reflect all normal and recurring adjustments necessary for a fair statement of the Company&#x2019;s financial position and results of operations for the interim periods. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full&#160;year.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i68726a27c9ca4a3a994459eb340ec3da_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180My9mcmFnOjU5YzU0MTc3NGNlOTRhOTM4Y2NhZThmNGEzYzRmMDAwL3RleHRyZWdpb246NTljNTQxNzc0Y2U5NGE5MzhjY2FlOGY0YTNjNGYwMDBfMTA0NDUzNjA0ODQwMTk_71b8a7b1-cad0-4103-8498-c8eaeea35275"
      unitRef="shares">35000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ia0d8e4dd5979420fbef5b45edd961b43_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180My9mcmFnOjU5YzU0MTc3NGNlOTRhOTM4Y2NhZThmNGEzYzRmMDAwL3RleHRyZWdpb246NTljNTQxNzc0Y2U5NGE5MzhjY2FlOGY0YTNjNGYwMDBfMTA0NDUzNjA0ODQwMzE_8de528df-0d9b-4cba-8aae-7e7a742c3db3"
      unitRef="usdPerShare">18.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i68726a27c9ca4a3a994459eb340ec3da_D20220510-20220510"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180My9mcmFnOjU5YzU0MTc3NGNlOTRhOTM4Y2NhZThmNGEzYzRmMDAwL3RleHRyZWdpb246NTljNTQxNzc0Y2U5NGE5MzhjY2FlOGY0YTNjNGYwMDBfMTA0NDUzNjA0ODQwMzk_7c8693b8-e98f-478f-a657-dc77316843cf"
      unitRef="usd">560000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <bhc:ProposedBusinessSeparationAndInitialPublicOfferingNumberOfCompaniesEstablished
      contextRef="iae181339de7f48fb8794bf85314efcc0_I20210803"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180My9mcmFnOjU5YzU0MTc3NGNlOTRhOTM4Y2NhZThmNGEzYzRmMDAwL3RleHRyZWdpb246NTljNTQxNzc0Y2U5NGE5MzhjY2FlOGY0YTNjNGYwMDBfMjA0Nw_d7afa004-35a8-46cf-98d5-e251d5182d24"
      unitRef="company">3</bhc:ProposedBusinessSeparationAndInitialPublicOfferingNumberOfCompaniesEstablished>
    <us-gaap:UseOfEstimates
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180My9mcmFnOjU5YzU0MTc3NGNlOTRhOTM4Y2NhZThmNGEzYzRmMDAwL3RleHRyZWdpb246NTljNTQxNzc0Y2U5NGE5MzhjY2FlOGY0YTNjNGYwMDBfODYzOA_7b1c164f-a6fb-40e7-ac0c-c2bf6941d0df">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In preparing the unaudited Consolidated Financial Statements, management is required to make estimates and assumptions. This includes estimates and assumptions regarding the nature, timing and extent of the impacts that the COVID-19 pandemic will have on its operations and cash flows.  The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the unaudited Consolidated Financial Statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates and the differences could be material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company&#x2019;s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company&#x2019;s results of operations and financial position could be materially impacted.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180My9mcmFnOjU5YzU0MTc3NGNlOTRhOTM4Y2NhZThmNGEzYzRmMDAwL3RleHRyZWdpb246NTljNTQxNzc0Y2U5NGE5MzhjY2FlOGY0YTNjNGYwMDBfODY0Mw_955753e2-a86c-44d0-a3b7-6443a41340d3">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180My9mcmFnOjU5YzU0MTc3NGNlOTRhOTM4Y2NhZThmNGEzYzRmMDAwL3RleHRyZWdpb246NTljNTQxNzc0Y2U5NGE5MzhjY2FlOGY0YTNjNGYwMDBfODYzNA_5ed66cfe-f568-4d9c-b470-28f4ce610e84">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made to prior year amounts to conform to the current year presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RleHRyZWdpb246OWUyNTVmY2Q2YjIyNDgzMWJmYjkxNDk0ODZhMDBlNWNfNjUyMQ_39e26840-92b6-4e27-986b-d937e35411ab">REVENUE RECOGNITION The Company&#x2019;s revenues are primarily generated from product sales, principally in the therapeutic areas of eye health, GI and dermatology, that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 19, &#x201c;SEGMENT INFORMATION&#x201d; for the disaggregation of revenue which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts.&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Sales Provisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.&#160; The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company&#x2019;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers. Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company&#x2019;s products. These judgments include the potential impact of the COVID-19 pandemic on, among other things, unemployment and related changes in customer health insurance levels, customer behaviors during the COVID-19 pandemic and government stimulus bills that focus on ensuring availability and access to lifesaving drugs during a public health crisis. This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or require an adjustment related to past sales, or both. If the trend in actual amounts of variable consideration varies from the Company&#x2019;s prior estimates, the Company adjusts these estimates when such trend is believed to be sustainable. At that time, the Company would record the necessary adjustments which would affect net product revenue and earnings reported in the current period. The Company applies this method consistently for contracts with similar characteristics.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RleHRyZWdpb246OWUyNTVmY2Q2YjIyNDgzMWJmYjkxNDk0ODZhMDBlNWNfNjUyOA_3c40216f-bdf2-44dd-996f-f9a7d299705f">REVENUE RECOGNITION The Company&#x2019;s revenues are primarily generated from product sales, principally in the therapeutic areas of eye health, GI and dermatology, that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 19, &#x201c;SEGMENT INFORMATION&#x201d; for the disaggregation of revenue which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts.&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Sales Provisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.&#160; The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company&#x2019;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers. Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company&#x2019;s products. These judgments include the potential impact of the COVID-19 pandemic on, among other things, unemployment and related changes in customer health insurance levels, customer behaviors during the COVID-19 pandemic and government stimulus bills that focus on ensuring availability and access to lifesaving drugs during a public health crisis. This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or require an adjustment related to past sales, or both. If the trend in actual amounts of variable consideration varies from the Company&#x2019;s prior estimates, the Company adjusts these estimates when such trend is believed to be sustainable. At that time, the Company would record the necessary adjustments which would affect net product revenue and earnings reported in the current period. The Company applies this method consistently for contracts with similar characteristics.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the activity and ending balances of the Company&#x2019;s variable consideration provisions for the three months ended March 31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;br/&gt;and&lt;br/&gt;Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Distribution&lt;br/&gt;Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balances, January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current period provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(162)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(599)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(359)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,227)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balances, March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $37 million and $36&#160;million as of March 31, 2022 and January 1, 2022, respectively, which are reflected as a reduction of Trade receivables, net in the Consolidated Balance Sheets. There were no price appreciation credits during the three months ended March 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;br/&gt;and&lt;br/&gt;Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Distribution&lt;br/&gt;Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balances, January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current period provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(160)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(457)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(483)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balances, March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $34 million and $32&#160;million as of March 31, 2021 and January 1, 2021, respectively. Included as a reduction of Distribution fees in the table above are price appreciation credits of approximately $1&#160;million during the three months ended March 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Assets and Contract Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are no contract assets for any period presented. Contract liabilities consist of deferred revenue, the balance of which is not material to any period presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Allowance for Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An allowance is maintained for potential credit losses. The Company estimates the current expected credit loss on its receivables based on various factors, including historical credit loss experience, customer credit worthiness, value of collaterals (if any), and any relevant current and reasonably supportable future economic factors.&#160; Additionally, the Company generally estimates the expected credit loss on a pool basis when customers are deemed to have similar risk characteristics. Trade receivable balances are written off against the allowance when it is deemed probable that the trade receivable will not be&#160;collected. Trade receivables, net are stated net of certain sales provisions and the allowance for credit losses. The activity in the allowance for credit losses for trade receivables for the three months ended March 31, 2022 and 2021 is as follows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Write-offs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recoveries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RleHRyZWdpb246OWUyNTVmY2Q2YjIyNDgzMWJmYjkxNDk0ODZhMDBlNWNfNjUxNg_80f56020-f7f6-415c-9817-6bb2b4d3a675">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the activity and ending balances of the Company&#x2019;s variable consideration provisions for the three months ended March 31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;br/&gt;and&lt;br/&gt;Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Distribution&lt;br/&gt;Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balances, January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current period provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(162)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(599)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(359)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,227)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balances, March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $37 million and $36&#160;million as of March 31, 2022 and January 1, 2022, respectively, which are reflected as a reduction of Trade receivables, net in the Consolidated Balance Sheets. There were no price appreciation credits during the three months ended March 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;br/&gt;and&lt;br/&gt;Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Distribution&lt;br/&gt;Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balances, January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current period provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(160)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(457)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(483)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balances, March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i3b5fdcedce07473f95b4d896abcc8dc6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfMi0yLTEtMS04OTA3Mg_f76636c2-a365-47ae-9184-7e93152eb2cb"
      unitRef="usd">222000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="id234e6e6761c4d3fadd602df79c36a18_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfMi00LTEtMS04OTA3Mg_0ed50a89-9a68-4a0d-b931-b9d0a82839d0"
      unitRef="usd">482000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i3282ac48025c402fb8242346f1697dc3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfMi02LTEtMS04OTA3Mg_7b267480-c1cc-47db-bd7c-39d4d68a4e32"
      unitRef="usd">944000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i4f7124918f0c4940946cbc5598b8eb93_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfMi04LTEtMS04OTA3Mg_4d333c50-2223-473e-8d2f-f513e198ae98"
      unitRef="usd">170000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i82cd23474eef475d818ea158ef0a033c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfMi0xMC0xLTEtODkwNzI_a4939e6b-f0d3-4408-b751-f9ecaef7c16c"
      unitRef="usd">45000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfMi0xMi0xLTEtODkwNzI_6d568a51-da5f-49ca-a950-580b65a29d2a"
      unitRef="usd">1863000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i9f025023becd4701b88a21aeb30b1551_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfMy0yLTEtMS04OTA3Mg_97fa42f0-3b65-4e26-b65f-c014a2fa4aff"
      unitRef="usd">134000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i2702eb3989e049ee9ba259ff98e17bd5_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfMy00LTEtMS04OTA3Mg_a6e46a13-3786-4594-ae9e-f9748c3eec1f"
      unitRef="usd">19000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="iba1bbd977ad949bb8ef314204d0f9031_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfMy02LTEtMS04OTA3Mg_28d67997-7009-41dc-a7c5-7df89a283573"
      unitRef="usd">581000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i75a4cf7e52aa4b4baa6fd5cc411e8269_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfMy04LTEtMS04OTA3Mg_57b0bebd-9122-4dc9-9292-7f3d667f1bbc"
      unitRef="usd">471000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="ib297e736b3f84933b2038cba50e4d5ed_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfMy0xMC0xLTEtODkwNzI_85d5c298-143f-4213-8511-67ec0162cb13"
      unitRef="usd">51000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfMy0xMi0xLTEtODkwNzI_a74ee750-487c-4851-8226-ce060cc4b65e"
      unitRef="usd">1256000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i9f025023becd4701b88a21aeb30b1551_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfNC0yLTEtMS04OTA3Mg_997f2cb0-b4c4-4aa2-b798-fb99af457b21"
      unitRef="usd">162000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i2702eb3989e049ee9ba259ff98e17bd5_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfNC00LTEtMS04OTA3Mg_33c66881-2fa7-4eb7-b57a-abaa6ca7b05e"
      unitRef="usd">54000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="iba1bbd977ad949bb8ef314204d0f9031_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfNC02LTEtMS04OTA3Mg_a2a05830-ba6a-45e3-879b-f9c218167c96"
      unitRef="usd">599000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i75a4cf7e52aa4b4baa6fd5cc411e8269_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfNC04LTEtMS04OTA3Mg_98862648-33ce-4cdc-b884-95f2d0673c97"
      unitRef="usd">359000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ib297e736b3f84933b2038cba50e4d5ed_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfNC0xMC0xLTEtODkwNzI_fa92e7a0-370f-45ea-91a1-2951b9e23b68"
      unitRef="usd">53000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfNC0xMi0xLTEtODkwNzI_ca803892-7291-42cf-8ee2-7615c685b5ec"
      unitRef="usd">1227000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ia1d87c2977704a1e9e27fa4ce9d6f6ca_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfNS0yLTEtMS04OTA3Mg_a0cf350d-dc70-4f91-a822-c2a5b241c689"
      unitRef="usd">194000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i91537bd044f94fd8a698e842e7d17804_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfNS00LTEtMS04OTA3Mg_435d1554-253f-4565-95cb-77085ea5f55e"
      unitRef="usd">447000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i445a6442a30f43b594d2d8364e5b4894_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfNS02LTEtMS04OTA3Mg_eea67426-1d9c-4d25-9b00-1991b0d5e164"
      unitRef="usd">926000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ifcb261aecea64295aab4bf43ac889601_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfNS04LTEtMS04OTA3Mg_7d82d0ba-b3e6-4886-b71c-06746109e44a"
      unitRef="usd">282000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i0bcf6389cdc947f7ae05710631221f68_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfNS0xMC0xLTEtODkwNzI_4c09b570-99b0-46a8-b0d6-cf04e84f3844"
      unitRef="usd">43000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjZhMzU1NDA2ZWM4ZDQxMmU4YTQ1MzY3YzJhNzFhNTY5L3RhYmxlcmFuZ2U6NmEzNTU0MDZlYzhkNDEyZThhNDUzNjdjMmE3MWE1NjlfNS0xMi0xLTEtODkwNzI_035d777e-7b9b-437f-843e-d063d20e535a"
      unitRef="usd">1892000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i697ad802318444ba908fe6471d84bff7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RleHRyZWdpb246OWUyNTVmY2Q2YjIyNDgzMWJmYjkxNDk0ODZhMDBlNWNfNDg2MA_5aee83c6-3dcc-4d05-b930-3654c61b36d1"
      unitRef="usd">37000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="if292799a4efd4044b18a023be1f10b95_I20220101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RleHRyZWdpb246OWUyNTVmY2Q2YjIyNDgzMWJmYjkxNDk0ODZhMDBlNWNfNDg2Nw_ed6d4867-60d0-4522-ae86-7b6f91e9c1dd"
      unitRef="usd">36000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5fec8302d4c14f00b65fb0e31f318228_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RleHRyZWdpb246OWUyNTVmY2Q2YjIyNDgzMWJmYjkxNDk0ODZhMDBlNWNfMjc0ODc3OTA3ODA3MQ_974c39e0-50d3-4f2c-9fff-5b2f8db06a02"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ia46992a39fd44a9b8ea71a5f0394d386_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfMi0yLTEtMS04OTA3Mg_3f12321b-92e1-4a46-8385-854574f75bff"
      unitRef="usd">190000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i4f9959394a574ff69f1d9b58d938d4d3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfMi00LTEtMS04OTA3Mg_126fe7ae-59f9-45b5-957c-a1877c4a7765"
      unitRef="usd">575000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i4e23891f40464cfa8e56cdb7bab0040d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfMi02LTEtMS04OTA3Mg_35821c52-6a8c-4a30-aa36-36a852da0e40"
      unitRef="usd">779000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i9401e356d1aa4b399cc5adc2cd56f34c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfMi04LTEtMS04OTA3Mg_3bdb9aeb-29fd-4280-b910-cd82ca48d512"
      unitRef="usd">184000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ic58ddf3411fb47e0af82f6f1e662bf16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfMi0xMC0xLTEtODkwNzI_e51552b4-da76-4722-9c32-21b1cc80dba5"
      unitRef="usd">85000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i2d274a4a3e5a43ae91dfbb2934c4c5d1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfMi0xMi0xLTEtODkwNzI_e08192bc-cba9-43ea-b229-fa243c284530"
      unitRef="usd">1813000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i54b8dbfb41c7451caad9c7ce92634d2b_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfMy0yLTEtMS04OTA3Mg_3183d0d6-751f-47fe-ab9b-667141027bf9"
      unitRef="usd">147000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i3e143ff88d214dff8d83bfb996d04d80_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfMy00LTEtMS04OTA3Mg_901a40b6-ea44-43b2-bdc9-d0683ab86819"
      unitRef="usd">34000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i038c797945244014ae7afbec7d83111e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfMy02LTEtMS04OTA3Mg_e1b52ad4-4c40-4d1a-8ce4-e8244a39cefd"
      unitRef="usd">602000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="ie89ad456c68d4bbbbdbaf276e1161261_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfMy04LTEtMS04OTA3Mg_c5f74f87-fd43-400a-9085-946d1b26697c"
      unitRef="usd">462000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i92d2b71d6b3c41538e26137d45cf75e6_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfMy0xMC0xLTEtODkwNzI_cf3c6d3d-e673-4954-b87e-495b01ae9dc0"
      unitRef="usd">55000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfMy0xMi0xLTEtODkwNzI_5be0f588-b3b5-4360-bb5d-fd30f2f8979a"
      unitRef="usd">1300000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i54b8dbfb41c7451caad9c7ce92634d2b_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfNC0yLTEtMS04OTA3Mg_3191a2d0-e62c-4af0-8384-6b67bdfb45d0"
      unitRef="usd">160000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i3e143ff88d214dff8d83bfb996d04d80_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfNC00LTEtMS04OTA3Mg_282552cf-9679-4797-97cd-56e009d2bc97"
      unitRef="usd">56000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i038c797945244014ae7afbec7d83111e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfNC02LTEtMS04OTA3Mg_3096840c-332d-46ce-9135-4ebc935ca6a2"
      unitRef="usd">457000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ie89ad456c68d4bbbbdbaf276e1161261_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfNC04LTEtMS04OTA3Mg_661fd0b5-0189-4ad1-b2a6-7c7db785b408"
      unitRef="usd">483000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i92d2b71d6b3c41538e26137d45cf75e6_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfNC0xMC0xLTEtODkwNzI_2b25b79c-53f6-475a-89b2-a4420d0543bc"
      unitRef="usd">66000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfNC0xMi0xLTEtODkwNzI_60be33e4-0766-4918-a396-04578341ed93"
      unitRef="usd">1222000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i5e170c61a34348efbeb9b2757d9d6ff0_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfNS0yLTEtMS04OTA3Mg_1279cbd9-4d88-4312-9c78-42f091806b5a"
      unitRef="usd">177000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i5cc8ac7cdffe4470a00c7b19194e2fd9_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfNS00LTEtMS04OTA3Mg_64e783be-91b9-4d25-8040-b860544b91d4"
      unitRef="usd">553000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ia71b36fbbd72476aa3d99cbc13954b77_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfNS02LTEtMS04OTA3Mg_c81a13ac-56ec-45a1-85da-9e4a45cd7922"
      unitRef="usd">924000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="iacbae26421d743459b9dfa79bcc4f94f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfNS04LTEtMS04OTA3Mg_acb5c7ea-2e8f-412a-9d78-0c45c3b1f867"
      unitRef="usd">163000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i6300cf7309e042b48c456d1a58ee874f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfNS0xMC0xLTEtODkwNzI_4152ce0f-e6f6-486c-8074-89afbd261d8f"
      unitRef="usd">74000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i812289a7a0cf44b4b1eed544ad0bec6c_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjI0NWY3MDc3MTM0NDRiODdiZmJiYjRmNGYwYTk3OTAxL3RhYmxlcmFuZ2U6MjQ1ZjcwNzcxMzQ0NGI4N2JmYmJiNGY0ZjBhOTc5MDFfNS0xMi0xLTEtODkwNzI_a33f9a74-dffd-4b2a-8722-baa26dd5349a"
      unitRef="usd">1891000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i39945b5b3dde4b2f9bc375faa8ded0c1_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RleHRyZWdpb246OWUyNTVmY2Q2YjIyNDgzMWJmYjkxNDk0ODZhMDBlNWNfNTI0Ng_6407062c-0579-45dd-8a5f-44b90c3e6a47"
      unitRef="usd">34000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="iaa437e0185f6406491796407827b52e0_I20210101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RleHRyZWdpb246OWUyNTVmY2Q2YjIyNDgzMWJmYjkxNDk0ODZhMDBlNWNfNTI1Mw_bbd83688-e376-4a31-acad-50ac1004c296"
      unitRef="usd">32000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idba10c80ddf84c3cbaffdb663edf3e53_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RleHRyZWdpb246OWUyNTVmY2Q2YjIyNDgzMWJmYjkxNDk0ODZhMDBlNWNfMjc0ODc3OTA3ODA2MA_30e30f03-15b1-4462-9d96-05cb618ab487"
      unitRef="usd">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RleHRyZWdpb246OWUyNTVmY2Q2YjIyNDgzMWJmYjkxNDk0ODZhMDBlNWNfNjUzOQ_d0be902c-d95f-49e1-b7f2-b6cdc156e42f">The activity in the allowance for credit losses for trade receivables for the three months ended March 31, 2022 and 2021 is as follows.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Write-offs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recoveries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjNiZWE0YmIxMDIxZjQ4Nzg4Njc3YTA5ODhiYjJiNGM2L3RhYmxlcmFuZ2U6M2JlYTRiYjEwMjFmNDg3ODg2NzdhMDk4OGJiMmI0YzZfMS0xLTEtMS04OTA3Mg_245518aa-8620-472e-9dd8-e26099adf999"
      unitRef="usd">35000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i2d274a4a3e5a43ae91dfbb2934c4c5d1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjNiZWE0YmIxMDIxZjQ4Nzg4Njc3YTA5ODhiYjJiNGM2L3RhYmxlcmFuZ2U6M2JlYTRiYjEwMjFmNDg3ODg2NzdhMDk4OGJiMmI0YzZfMS0zLTEtMS04OTA3Mg_dae1d455-2f19-4ec8-8843-57ce8831ba13"
      unitRef="usd">39000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjNiZWE0YmIxMDIxZjQ4Nzg4Njc3YTA5ODhiYjJiNGM2L3RhYmxlcmFuZ2U6M2JlYTRiYjEwMjFmNDg3ODg2NzdhMDk4OGJiMmI0YzZfMy0xLTEtMS04OTA3Mg_99b1a915-db60-44cd-96fe-8c88940a5c90"
      unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjNiZWE0YmIxMDIxZjQ4Nzg4Njc3YTA5ODhiYjJiNGM2L3RhYmxlcmFuZ2U6M2JlYTRiYjEwMjFmNDg3ODg2NzdhMDk4OGJiMmI0YzZfMy0zLTEtMS04OTA3Mg_d76f76b8-0537-4dd9-859e-84f744fe862a"
      unitRef="usd">-2000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjNiZWE0YmIxMDIxZjQ4Nzg4Njc3YTA5ODhiYjJiNGM2L3RhYmxlcmFuZ2U6M2JlYTRiYjEwMjFmNDg3ODg2NzdhMDk4OGJiMmI0YzZfNC0xLTEtMS04OTA3Mg_8ec7b04f-5c66-494d-9224-a25616e969d7"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjNiZWE0YmIxMDIxZjQ4Nzg4Njc3YTA5ODhiYjJiNGM2L3RhYmxlcmFuZ2U6M2JlYTRiYjEwMjFmNDg3ODg2NzdhMDk4OGJiMmI0YzZfNC0zLTEtMS04OTA3Mg_9af9bdb5-da52-4003-ae5e-498dd54ad5bd"
      unitRef="usd">1000000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjNiZWE0YmIxMDIxZjQ4Nzg4Njc3YTA5ODhiYjJiNGM2L3RhYmxlcmFuZ2U6M2JlYTRiYjEwMjFmNDg3ODg2NzdhMDk4OGJiMmI0YzZfNS0xLTEtMS04OTA3Mg_ab1ff691-abf7-41a4-98fe-6f12fe8bcfc6"
      unitRef="usd">3000000</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjNiZWE0YmIxMDIxZjQ4Nzg4Njc3YTA5ODhiYjJiNGM2L3RhYmxlcmFuZ2U6M2JlYTRiYjEwMjFmNDg3ODg2NzdhMDk4OGJiMmI0YzZfNS0zLTEtMS04OTA3Mg_6b411684-7bb3-4619-bddd-bd7c779e6fcc"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
    <bhc:AccountsReceivableAllowanceForForeignExchangeAndOther
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjNiZWE0YmIxMDIxZjQ4Nzg4Njc3YTA5ODhiYjJiNGM2L3RhYmxlcmFuZ2U6M2JlYTRiYjEwMjFmNDg3ODg2NzdhMDk4OGJiMmI0YzZfNi0xLTEtMS04OTA3Mg_c1f44d57-e555-4db7-aea1-2215b78ee78f"
      unitRef="usd">0</bhc:AccountsReceivableAllowanceForForeignExchangeAndOther>
    <bhc:AccountsReceivableAllowanceForForeignExchangeAndOther
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjNiZWE0YmIxMDIxZjQ4Nzg4Njc3YTA5ODhiYjJiNGM2L3RhYmxlcmFuZ2U6M2JlYTRiYjEwMjFmNDg3ODg2NzdhMDk4OGJiMmI0YzZfNi0zLTEtMS04OTA3Mg_1e3be402-68b1-415b-9f86-c11418bdfd68"
      unitRef="usd">-1000000</bhc:AccountsReceivableAllowanceForForeignExchangeAndOther>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjNiZWE0YmIxMDIxZjQ4Nzg4Njc3YTA5ODhiYjJiNGM2L3RhYmxlcmFuZ2U6M2JlYTRiYjEwMjFmNDg3ODg2NzdhMDk4OGJiMmI0YzZfNy0xLTEtMS04OTA3Mg_d1e8815c-861b-416f-913c-8bdf0417b0a7"
      unitRef="usd">38000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i812289a7a0cf44b4b1eed544ad0bec6c_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180Ni9mcmFnOjllMjU1ZmNkNmIyMjQ4MzFiZmI5MTQ5NDg2YTAwZTVjL3RhYmxlOjNiZWE0YmIxMDIxZjQ4Nzg4Njc3YTA5ODhiYjJiNGM2L3RhYmxlcmFuZ2U6M2JlYTRiYjEwMjFmNDg3ODg2NzdhMDk4OGJiMmI0YzZfNy0zLTEtMS04OTA3Mg_8a2bb411-64aa-4956-9cc2-6080a2c0492c"
      unitRef="usd">37000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <bhc:AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180OS9mcmFnOjIyNjFkZTZhYWNjOTQ4ZWZhZmE1N2VkODVkM2ZlNzZiL3RleHRyZWdpb246MjI2MWRlNmFhY2M5NDhlZmFmYTU3ZWQ4NWQzZmU3NmJfNDQ4Mw_fb679d36-e8e7-4f39-b0f6-727bfa4f1efd">LICENSING AGREEMENTS AND DIVESTITURE&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Licensing Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company may enter into select licensing and collaborative agreements for the commercialization and/or development of unique products. These products are sometimes investigational treatments in early stage development that target unique conditions. The ultimate outcome, including whether the product will be: (i) fully developed, (ii) approved by regulatory agencies, (iii) covered by third-party payors or (iv) profitable for distribution, is highly uncertain.  The commitment periods under these agreements vary and include customary termination provisions.  Expenses arising from commitments, if any, to fund the development and testing of these products and their promotion are recognized as incurred. Royalties due are recognized when earned and milestone payments are accrued when each milestone has been achieved and payment is probable and can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Divestiture of Amoun Pharmaceutical Company S.A.E. (&#x201c;Amoun&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 31, 2021, the Company announced that it and certain of its affiliates had entered into a definitive agreement to sell all of its equity interests in Amoun for total gross consideration of approximately $740&#160;million (including the assignment to the purchasing entity of an intercompany loan granted by the Company to Amoun), subject to certain adjustments (the &#x201c;Amoun Sale&#x201d;). The Amoun Sale closed on July 26, 2021. As part of the Amoun Sale, cash generated by Amoun during the period from the locked-box date of January 1, 2021 through closing was for the benefit of the purchasing entity, subject to working capital during such period. Amoun manufactures, markets and distributes branded generics of human and animal health products. The Amoun business was part of the International segment (previously included within the former Bausch + Lomb/International segment) and was reclassified as held for sale as of December 31, 2020. As a result of meeting the criteria for held for sale classification, the carrying value of the Amoun business, was adjusted to its estimated fair value, less costs to sell, and the Company recognized an impairment loss of $68&#160;million during the three months ended March 31, 2021, included within Asset impairments, including loss on assets held for sale in the Consolidated Statements of Operations. Revenues associated with Amoun were $60&#160;million for the three months ended March 31, 2021.&lt;/span&gt;&lt;/div&gt;</bhc:AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i3524eadbe1ec47a0a36751409752f55b_D20210331-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180OS9mcmFnOjIyNjFkZTZhYWNjOTQ4ZWZhZmE1N2VkODVkM2ZlNzZiL3RleHRyZWdpb246MjI2MWRlNmFhY2M5NDhlZmFmYTU3ZWQ4NWQzZmU3NmJfMjY2OQ_39377316-b705-481d-9a81-462c8e4b6b3f"
      unitRef="usd">740000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i21711d9019c8476f949b23d06ee0e9c1_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180OS9mcmFnOjIyNjFkZTZhYWNjOTQ4ZWZhZmE1N2VkODVkM2ZlNzZiL3RleHRyZWdpb246MjI2MWRlNmFhY2M5NDhlZmFmYTU3ZWQ4NWQzZmU3NmJfMTY0OTI2NzQ0NjM1NA_b84711ac-12fd-42dd-91cf-47ed2b8f1095"
      unitRef="usd">68000000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i9d5bc364e17040579714c24cebd52ba5_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY180OS9mcmFnOjIyNjFkZTZhYWNjOTQ4ZWZhZmE1N2VkODVkM2ZlNzZiL3RleHRyZWdpb246MjI2MWRlNmFhY2M5NDhlZmFmYTU3ZWQ4NWQzZmU3NmJfODc5NjA5MzAyODI1OA_68d289af-9410-4a64-8377-37adf9c456ab"
      unitRef="usd">60000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <bhc:RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181Mi9mcmFnOmJkYzUzMjQ5NmJmYjRiOTliZWI5NDExNzlkYTU4OWJiL3RleHRyZWdpb246YmRjNTMyNDk2YmZiNGI5OWJlYjk0MTE3OWRhNTg5YmJfMjQ5Mw_c58c0043-d56e-4317-8974-53778b022d92">RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restructuring and Integration Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates opportunities to improve its operating results and implements cost savings programs to streamline its operations and eliminate&#160;redundant processes and expenses. Restructuring and integration costs are expenses associated with the implementation of these cost savings programs and include expenses associated with: (i)&#160;reducing headcount, (ii)&#160;eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives. The liability associated with restructuring and integration costs as of March 31, 2022 was $15 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred $3 million and $3&#160;million of restructuring and integration costs and made payments of $7&#160;million and $5&#160;million during the three months ended March 31, 2022 and 2021, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Separation Costs, Separation-related Costs, IPO Costs and IPO-related Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred, and will incur, costs associated with activities to effectuate the B+L Separation and the Solta IPO. These activities include: (i) separating the Bausch + Lomb and Solta Medical businesses from the remainder of the Company and (ii) registering the Bausch + Lomb and Solta Medical businesses as independent publicly traded entities. Separation and IPO costs are incremental costs directly related to the B+L Separation and Solta IPO and include, but are not limited to: (i) legal, audit and advisory fees, (ii) talent acquisition costs and (iii) costs associated with establishing a new board of directors and related board committees for the Bausch + Lomb and Solta Medical entities. Included in Restructuring, integration, separation and IPO costs for the three months ended March 31, 2022 and 2021 are Separation and IPO costs of $10&#160;million and $9&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has also incurred, and will incur, Separation-related and IPO-related costs which are incremental costs indirectly related to the B+L Separation and Solta IPO. Separation-related and IPO-related costs include, but are not limited to: (i) IT infrastructure and software licensing costs, (ii) rebranding costs and (iii) costs associated with facility relocation and/or modification. Included in Selling, general and administrative for the three months ended March 31, 2022 and 2021 are Separation-related and IPO-related costs of $24&#160;million and $20&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The extent and timing of future charges for these costs cannot be reasonably estimated at this time and could be material.&lt;/span&gt;&lt;/div&gt;</bhc:RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="i8f59ac9f2ff644c89eb4f65f46c45061_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181Mi9mcmFnOmJkYzUzMjQ5NmJmYjRiOTliZWI5NDExNzlkYTU4OWJiL3RleHRyZWdpb246YmRjNTMyNDk2YmZiNGI5OWJlYjk0MTE3OWRhNTg5YmJfNzA5_e594ce7a-5f90-4f08-b884-9db6e1bfef27"
      unitRef="usd">15000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i956734b907cd48758decdff4f630c6f9_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181Mi9mcmFnOmJkYzUzMjQ5NmJmYjRiOTliZWI5NDExNzlkYTU4OWJiL3RleHRyZWdpb246YmRjNTMyNDk2YmZiNGI5OWJlYjk0MTE3OWRhNTg5YmJfNzM0_d5e1e407-d3e7-4e37-80b6-e000555f95c9"
      unitRef="usd">3000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="idc39509affcd41d9a58e0cca4fe7e0eb_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181Mi9mcmFnOmJkYzUzMjQ5NmJmYjRiOTliZWI5NDExNzlkYTU4OWJiL3RleHRyZWdpb246YmRjNTMyNDk2YmZiNGI5OWJlYjk0MTE3OWRhNTg5YmJfNzQx_4e39b9ff-760b-4d95-bfa9-4d8013072190"
      unitRef="usd">3000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:PaymentsForRestructuring
      contextRef="i956734b907cd48758decdff4f630c6f9_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181Mi9mcmFnOmJkYzUzMjQ5NmJmYjRiOTliZWI5NDExNzlkYTU4OWJiL3RleHRyZWdpb246YmRjNTMyNDk2YmZiNGI5OWJlYjk0MTE3OWRhNTg5YmJfODA0_96155526-eac8-4eda-a1ea-f5a091660a27"
      unitRef="usd">7000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="idc39509affcd41d9a58e0cca4fe7e0eb_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181Mi9mcmFnOmJkYzUzMjQ5NmJmYjRiOTliZWI5NDExNzlkYTU4OWJiL3RleHRyZWdpb246YmRjNTMyNDk2YmZiNGI5OWJlYjk0MTE3OWRhNTg5YmJfODEx_1708b59a-f2ea-44aa-81c1-4e0d22e58993"
      unitRef="usd">5000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringCharges
      contextRef="i85c368e92b024530907723a0994de3c7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181Mi9mcmFnOmJkYzUzMjQ5NmJmYjRiOTliZWI5NDExNzlkYTU4OWJiL3RleHRyZWdpb246YmRjNTMyNDk2YmZiNGI5OWJlYjk0MTE3OWRhNTg5YmJfMTY4Nw_821cda46-e3b6-49c9-9163-0000c6ed7ed9"
      unitRef="usd">10000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i4fb5f4d139b04ae9b628f854af7fd7ee_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181Mi9mcmFnOmJkYzUzMjQ5NmJmYjRiOTliZWI5NDExNzlkYTU4OWJiL3RleHRyZWdpb246YmRjNTMyNDk2YmZiNGI5OWJlYjk0MTE3OWRhNTg5YmJfMTY5NA_38005a71-3f6c-4c1f-93b3-8843aa53dc02"
      unitRef="usd">9000000</us-gaap:RestructuringCharges>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i85c368e92b024530907723a0994de3c7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181Mi9mcmFnOmJkYzUzMjQ5NmJmYjRiOTliZWI5NDExNzlkYTU4OWJiL3RleHRyZWdpb246YmRjNTMyNDk2YmZiNGI5OWJlYjk0MTE3OWRhNTg5YmJfMjIyMQ_1526cf19-068a-4f92-af01-88fa884a2f61"
      unitRef="usd">24000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i4fb5f4d139b04ae9b628f854af7fd7ee_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181Mi9mcmFnOmJkYzUzMjQ5NmJmYjRiOTliZWI5NDExNzlkYTU4OWJiL3RleHRyZWdpb246YmRjNTMyNDk2YmZiNGI5OWJlYjk0MTE3OWRhNTg5YmJfMjIyOA_4a749985-02ab-4511-91ab-75c523dc405d"
      unitRef="usd">20000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RleHRyZWdpb246MThlODc5ODM3YTdhNDAwNWE3OTliYjJjNjI2NGIwOTlfNzE2Mw_c543ec53-3962-42e2-9fe0-a77fc1dc2a9f">FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value measurements are estimated based on valuation techniques and inputs categorized as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1&#160;&#x2014;&#160;Quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2&#160;&#x2014;&#160;Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities;&#160;and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3&#160;&#x2014;&#160;Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using discounted cash flow methodologies, pricing models, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or&#160;estimation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the&#160;instrument.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following fair value hierarchy table presents the components and classification of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.196%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash and other settlement deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents consist of highly liquid investments, primarily money market funds, with maturities of three months or less when&#160;purchased, and are reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to their short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, Restricted cash and other settlement deposits includes $1,210&#160;million of payments into an escrow fund under the terms of a settlement agreement regarding certain U.S. securities litigation (which settlement agreement is subject to one objector&#x2019;s appeal of the final court approval of the agreement), and is reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to its short-term nature. These payments will remain in escrow until resolution of the appeal of the final court approval of the settlement agreement, as discussed in Note 18, &#x201c;LEGAL PROCEEDINGS&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers into or out of Level 3 during the three months ended March 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cross-currency Swaps&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2019, the Company entered into cross-currency swaps, with aggregate notional amounts of $1,250 million, to mitigate fluctuation in the value of a portion of its euro-denominated net investment in its consolidated financial statements from fluctuation in exchange rates. The euro-denominated net investment being hedged was the Company&#x2019;s investment in certain euro-denominated subsidiaries. The Company unwound these cross-currency swaps during November 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the unwinding of the cross-currency swaps during November 2021, there were no assets or liabilities associated with the cross-currency swaps included in the Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the effect of hedging instruments on the Consolidated Statements of Comprehensive Loss and the Consolidated Statements of Operations for the three months ended March 31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.585%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain recognized in Other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain excluded from assessment of hedge effectiveness&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Location of gain of excluded component&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No portion of the cross-currency swaps was ineffective for the three months ended March 31, 2021. During the three months ended March 31, 2022 and 2021, the Company received $0 and $11&#160;million, respectively, in interest settlements which are reported as investing activities in the Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Exchange Contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since 2020, the Company has been entering into foreign currency exchange contracts. As of March 31, 2022, these contracts had an aggregate outstanding notional amount of $158&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s foreign currency exchange contracts are remeasured at each reporting date to reflect changes in their fair values determined using forward rates, which are observable market inputs, multiplied by the notional amount. The Company&#x2019;s foreign currency exchange contracts are economically hedging the foreign exchange exposure on certain of the Company&#x2019;s intercompany balances. These contracts have not been designated as an accounting hedge, and therefore the net change in their fair value is reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other. Settlements of the Company&#x2019;s foreign currency exchange contracts are reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other and reported as operating activities in the Consolidated Statements of Cash Flows. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets and liabilities associated with the Company&#x2019;s foreign exchange contracts as included in the Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.072%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the effect of the Company&#x2019;s foreign exchange contracts on the Consolidated Statements of Operations and the Consolidated Statements of Cash Flows for the three months ended March 31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.072%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss related to changes in fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) related to settlements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisition-related Contingent Consideration Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value measurement of contingent consideration obligations arising from business combinations is determined via a probability-weighted discounted cash flow analysis, using unobservable (Level&#160;3) inputs. These inputs may include: (i)&#160;the estimated amount and timing of projected cash flows, (ii)&#160;the probability of the achievement of the factor(s) on which the contingency is based and (iii)&#160;the risk-adjusted discount rate used to present value the probability-weighted cash&#160;flows. Significant increases or decreases in any of those inputs in isolation could result in a significantly higher or lower fair value measurement. At March&#160;31, 2022, the fair value measurements of acquisition-related contingent consideration were determined using risk-adjusted discount rates ranging from 6% to 18%, and a weighted average risk-adjusted discount rate of 7%. The weighted average risk-adjusted discount rate was calculated by weighting each contract&#x2019;s relative fair value at March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level&#160;3) for the three months ended March 31, 2022 and 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.132%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments to Acquisition-related contingent consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accretion for the time value of money&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustments due to changes in estimates of other future payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments/Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion included in Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Long-term Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of long-term debt as of March&#160;31, 2022 and December&#160;31, 2021 was $21,963 million and $22,689 million, respectively, and was estimated using the quoted market prices for the same or similar debt issuances (Level 2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RleHRyZWdpb246MThlODc5ODM3YTdhNDAwNWE3OTliYjJjNjI2NGIwOTlfNzE1Nw_960081d2-c0de-4fba-a440-713f96ab6b88">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following fair value hierarchy table presents the components and classification of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.196%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash and other settlement deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9bdc5e2685a240ae96ca33df37493045_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfMy0yLTEtMS04OTA3Mg_68a5cfa6-a543-4375-82d9-22e4a76d3068"
      unitRef="usd">766000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i363991f4b7144460a084057864c8034f_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfMy00LTEtMS04OTA3Mg_1e839cb2-03a6-4aad-8718-a9da15d2469f"
      unitRef="usd">749000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ifc1a0b5922ad406796cebf7b0701a0cb_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfMy02LTEtMS04OTA3Mg_98e98c15-d4ee-4625-8601-b7e630b19497"
      unitRef="usd">17000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i20f7343e1588476cb8e134ea3252cb58_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfMy04LTEtMS04OTA3Mg_153f2bf2-3c4d-4f3c-9386-cdd0a35e2b31"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if45e89de6ed14de1836e660f70eb9092_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfMy0xMC0xLTEtODkwNzI_533714de-eef5-40b3-b62b-7ab0fcdc9f1a"
      unitRef="usd">76000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i150d2e94468344d2bba3906c337eef86_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfMy0xMi0xLTEtODkwNzI_e0f7f5a4-db3e-4702-bab4-c83be6dafd9a"
      unitRef="usd">58000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iaa7390cf31be44f1986a62d20c407d5b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfMy0xNC0xLTEtODkwNzI_730897ee-c49e-4a2e-945b-c0819cfb2540"
      unitRef="usd">18000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ica75b10c2fbd403ea21ee75a6cd245bd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfMy0xNi0xLTEtODkwNzI_0910e073-606b-4809-a19f-4cb590e8fa23"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="i9bdc5e2685a240ae96ca33df37493045_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNC0yLTEtMS04OTA3Mg_d7173a81-beca-4746-9c20-3afd33ea1680"
      unitRef="usd">1211000000</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="i363991f4b7144460a084057864c8034f_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNC00LTEtMS04OTA3Mg_da5daf34-cd75-43f9-a1df-d6fbc8d6ad18"
      unitRef="usd">1211000000</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="ifc1a0b5922ad406796cebf7b0701a0cb_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNC02LTEtMS04OTA3Mg_6ddd6520-9786-43df-816f-e7be47ae0f7e"
      unitRef="usd">0</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="i20f7343e1588476cb8e134ea3252cb58_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNC04LTEtMS04OTA3Mg_31f5a0c1-abfa-490f-8936-76d2e45ed173"
      unitRef="usd">0</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="if45e89de6ed14de1836e660f70eb9092_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNC0xMC0xLTEtODkwNzI_29c93337-eff1-417f-8070-efb92bb0794c"
      unitRef="usd">1537000000</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="i150d2e94468344d2bba3906c337eef86_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNC0xMi0xLTEtODkwNzI_df9e7cc3-64e5-4849-a0ee-536daf9245d5"
      unitRef="usd">1537000000</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="iaa7390cf31be44f1986a62d20c407d5b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNC0xNC0xLTEtODkwNzI_61e33630-ef22-4894-ab9a-cf39eeb86c25"
      unitRef="usd">0</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="ica75b10c2fbd403ea21ee75a6cd245bd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNC0xNi0xLTEtODkwNzI_beda486f-8e50-44be-9fa6-bc51a7a842fb"
      unitRef="usd">0</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <us-gaap:DerivativeAssets
      contextRef="ie0cbf30c76af4d498983e82d4fdca172_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNS0yLTEtMS04OTA3Mg_1bb7f1d6-dc49-4371-8cf2-4588a5e68c95"
      unitRef="usd">1000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="if05c08af1a034dc7980de8e6d52990be_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNS00LTEtMS04OTA3Mg_1f8c830b-2967-4efc-9c85-c01b7e9c22e9"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i0b499ddf7ec0496ba113157683c198d2_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNS02LTEtMS04OTA3Mg_866ab892-b588-4b91-8afa-54cea9fe1f08"
      unitRef="usd">1000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i81fe5dde69aa4fa98b7711acbae4387f_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNS02LTEtMS04OTA3Mg_cb0add76-303f-47a6-96dd-8a3a6382b373"
      unitRef="usd">1000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeAssets
      contextRef="i100091396ce9444685173217122765a6_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNS04LTEtMS04OTA3Mg_1a6d6974-54d2-44e9-b1e3-64129de0a53e"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i723c0252bb3e4eb98782b62a2ac15585_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNS0xMC0xLTEtODkwNzI_730ee82e-2a71-45a9-aba7-a0b26dd926bf"
      unitRef="usd">1000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i258050e5f8ba4ce1b2273604ec31e67f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNS0xMi0xLTEtODkwNzI_fda77e76-db1e-462a-915b-48d75383fafe"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="id7cdfcca5d2f4a10b641c8f4d80b31b8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNS0xNC0xLTEtODkwNzI_d3442b5e-4d51-4d85-aa59-b5fbadb3b1e3"
      unitRef="usd">1000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i5945a5ff5f34495dab13516392201c16_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNS0xNi0xLTEtODkwNzI_9ea71d55-92ca-4d29-bf92-cf9ee5699679"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="i9bdc5e2685a240ae96ca33df37493045_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNy0yLTEtMS04OTA3Mg_ecf2d9d6-d475-4f31-b525-4a8256648282"
      unitRef="usd">236000000</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="i363991f4b7144460a084057864c8034f_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNy00LTEtMS04OTA3Mg_d9e0c328-25cf-4530-8a17-b460862e74f6"
      unitRef="usd">0</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="ifc1a0b5922ad406796cebf7b0701a0cb_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNy02LTEtMS04OTA3Mg_334853e9-c17a-4cdd-9387-d5bbf2715933"
      unitRef="usd">0</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="i20f7343e1588476cb8e134ea3252cb58_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNy04LTEtMS04OTA3Mg_b9ea3d03-5790-4dee-877a-f3e7cd5a427a"
      unitRef="usd">236000000</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="if45e89de6ed14de1836e660f70eb9092_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNy0xMC0xLTEtODkwNzI_3b962e62-f4e2-4165-868e-1ea2dc364a88"
      unitRef="usd">241000000</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="i150d2e94468344d2bba3906c337eef86_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNy0xMi0xLTEtODkwNzI_1d058e20-5ac3-4807-817b-13c7ce4d4415"
      unitRef="usd">0</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="iaa7390cf31be44f1986a62d20c407d5b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNy0xNC0xLTEtODkwNzI_1f5dc323-2e3b-4841-b634-ecc9a7f5efd9"
      unitRef="usd">0</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="ica75b10c2fbd403ea21ee75a6cd245bd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfNy0xNi0xLTEtODkwNzI_e04b01e3-f7a2-499b-8d48-4da3100c85a7"
      unitRef="usd">241000000</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="ie0cbf30c76af4d498983e82d4fdca172_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfOS0yLTEtMS04OTA3Mg_55afe13c-4cd0-4c1c-b8b9-98d25d8494ea"
      unitRef="usd">8000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="if05c08af1a034dc7980de8e6d52990be_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfOS00LTEtMS04OTA3Mg_b9ca63bf-70e5-4afc-aff2-92237513f2a5"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssetFairValueGrossLiability
      contextRef="i5b77eb6463994ae99224a58bba550905_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfOS02LTEtMS04OTA3Mg_41a3d573-ec67-46fc-8482-2505ce0aad6f"
      unitRef="usd">8000000</us-gaap:DerivativeAssetFairValueGrossLiability>
    <us-gaap:DerivativeLiabilities
      contextRef="i0b499ddf7ec0496ba113157683c198d2_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfOS02LTEtMS04OTA3Mg_7a694287-5200-4576-b5bc-6c1a3d61dc2d"
      unitRef="usd">8000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i100091396ce9444685173217122765a6_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfOS04LTEtMS04OTA3Mg_1defc974-5f70-40fd-bcb4-34c9dd884262"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i723c0252bb3e4eb98782b62a2ac15585_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfOS0xMC0xLTEtODkwNzI_a4982000-f151-433f-b23d-4eace0dd63bb"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i258050e5f8ba4ce1b2273604ec31e67f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfOS0xMi0xLTEtODkwNzI_9d7d09e6-c0ab-4b19-abed-103382724222"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="id7cdfcca5d2f4a10b641c8f4d80b31b8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfOS0xNC0xLTEtODkwNzI_559e5cb8-d8b9-421d-b92e-c2e4c1662e41"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i5945a5ff5f34495dab13516392201c16_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjg3OTg1Y2MyNGI1MDQ5OTg5NTEwYmNlOWMzYWQwMTk2L3RhYmxlcmFuZ2U6ODc5ODVjYzI0YjUwNDk5ODk1MTBiY2U5YzNhZDAxOTZfOS0xNi0xLTEtODkwNzI_d75ef04e-b977-4af3-ac38-c28f06ec20bf"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <bhc:HighlyLiquidInvestmentsMaturityPeriod
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RleHRyZWdpb246MThlODc5ODM3YTdhNDAwNWE3OTliYjJjNjI2NGIwOTlfMTQyOA_79f465a7-13c1-482c-b93d-8b7b6ff3e53d">P3M</bhc:HighlyLiquidInvestmentsMaturityPeriod>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i4b4e235324904728b762550f85fa7269_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RleHRyZWdpb246MThlODc5ODM3YTdhNDAwNWE3OTliYjJjNjI2NGIwOTlfMTYyNA_897801c3-4b52-413e-9118-979b56455b05"
      unitRef="usd">1210000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <bhc:LitigationSettlementNumberOfObjectorsAppeals
      contextRef="iee66331a046f4575acc6e455516cc956_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RleHRyZWdpb246MThlODc5ODM3YTdhNDAwNWE3OTliYjJjNjI2NGIwOTlfMTc4OA_0dc84ce6-be01-455f-9f23-02f32325c7af"
      unitRef="appeal">1</bhc:LitigationSettlementNumberOfObjectorsAppeals>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ia2c311dd5c6b469480afc3e5392a01db_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RleHRyZWdpb246MThlODc5ODM3YTdhNDAwNWE3OTliYjJjNjI2NGIwOTlfMjMxMg_5ae28055-7487-4e17-9b60-be54c1efa19c"
      unitRef="usd">1250000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RleHRyZWdpb246MThlODc5ODM3YTdhNDAwNWE3OTliYjJjNjI2NGIwOTlfNzE3MA_6fda01f8-3292-4632-b241-c066d2dd5a05">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the effect of hedging instruments on the Consolidated Statements of Comprehensive Loss and the Consolidated Statements of Operations for the three months ended March 31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.585%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain recognized in Other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain excluded from assessment of hedge effectiveness&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Location of gain of excluded component&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i1e2fdd6767694d7e97928c8c973cce88_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjJiNTcyOTExMTFiOTRkMWE5YWQyZDdiMDY5ZjkxZjBlL3RhYmxlcmFuZ2U6MmI1NzI5MTExMWI5NGQxYTlhZDJkN2IwNjlmOTFmMGVfMi01LTEtMS04OTA3Mg_ab9e21cd-9749-4218-b98a-d63ccb26ca4f"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ieb234a60c94344e9a94bfbc00466a78a_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjJiNTcyOTExMTFiOTRkMWE5YWQyZDdiMDY5ZjkxZjBlL3RhYmxlcmFuZ2U6MmI1NzI5MTExMWI5NGQxYTlhZDJkN2IwNjlmOTFmMGVfMi03LTEtMS04OTA3Mg_fcbe1507-f141-4720-8113-520d0fd98c18"
      unitRef="usd">41000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i46cf2f3899da4a21a3b37afd85cde532_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjJiNTcyOTExMTFiOTRkMWE5YWQyZDdiMDY5ZjkxZjBlL3RhYmxlcmFuZ2U6MmI1NzI5MTExMWI5NGQxYTlhZDJkN2IwNjlmOTFmMGVfMy01LTEtMS04OTA3Mg_67b203f8-1070-4bd3-9cbe-b4f6b3d5d1a7"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="ibf2062d283b74ee789d97615ebc112e9_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjJiNTcyOTExMTFiOTRkMWE5YWQyZDdiMDY5ZjkxZjBlL3RhYmxlcmFuZ2U6MmI1NzI5MTExMWI5NGQxYTlhZDJkN2IwNjlmOTFmMGVfMy03LTEtMS04OTA3Mg_5e939c60-4f90-4744-99b0-da0e15f95fc0"
      unitRef="usd">6000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:PaymentsForProceedsFromHedgeInvestingActivities
      contextRef="idf8c5147a31443548f1f01cdff3ee173_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RleHRyZWdpb246MThlODc5ODM3YTdhNDAwNWE3OTliYjJjNjI2NGIwOTlfMzczMg_1a0b6d85-453f-4837-82f4-ae54f255e070"
      unitRef="usd">0</us-gaap:PaymentsForProceedsFromHedgeInvestingActivities>
    <us-gaap:PaymentsForProceedsFromHedgeInvestingActivities
      contextRef="ib0fafc41fd0d46f2aafbccde9b40c90f_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RleHRyZWdpb246MThlODc5ODM3YTdhNDAwNWE3OTliYjJjNjI2NGIwOTlfMzczOQ_be7226df-dc49-4f50-a6d2-47ba7834a390"
      unitRef="usd">11000000</us-gaap:PaymentsForProceedsFromHedgeInvestingActivities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ib1d2d795d550443991566dd2c6bcf53b_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RleHRyZWdpb246MThlODc5ODM3YTdhNDAwNWE3OTliYjJjNjI2NGIwOTlfNDA1NA_d9b1f054-530f-4f8a-b1e3-bf2c380c28f3"
      unitRef="usd">158000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RleHRyZWdpb246MThlODc5ODM3YTdhNDAwNWE3OTliYjJjNjI2NGIwOTlfNzE3MQ_454d4432-7f33-4044-ae5b-62c174f7691e">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets and liabilities associated with the Company&#x2019;s foreign exchange contracts as included in the Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.072%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeAssetFairValueGrossLiability
      contextRef="i5b77eb6463994ae99224a58bba550905_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjJkYTExNTMzNGE0ZjRmMGNiZDQ0NzRlODRlNzc5MDc0L3RhYmxlcmFuZ2U6MmRhMTE1MzM0YTRmNGYwY2JkNDQ3NGU4NGU3NzkwNzRfMS0xLTEtMS04OTA3Mg_41a3d573-ec67-46fc-8482-2505ce0aad6f"
      unitRef="usd">8000000</us-gaap:DerivativeAssetFairValueGrossLiability>
    <us-gaap:DerivativeLiabilities
      contextRef="i0b499ddf7ec0496ba113157683c198d2_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjJkYTExNTMzNGE0ZjRmMGNiZDQ0NzRlODRlNzc5MDc0L3RhYmxlcmFuZ2U6MmRhMTE1MzM0YTRmNGYwY2JkNDQ3NGU4NGU3NzkwNzRfMS0xLTEtMS04OTA3Mg_7a694287-5200-4576-b5bc-6c1a3d61dc2d"
      unitRef="usd">8000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssetFairValueGrossLiability
      contextRef="i8f0e25e6a91b4e2e872255dda15e2d72_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjJkYTExNTMzNGE0ZjRmMGNiZDQ0NzRlODRlNzc5MDc0L3RhYmxlcmFuZ2U6MmRhMTE1MzM0YTRmNGYwY2JkNDQ3NGU4NGU3NzkwNzRfMS0zLTEtMS04OTA3Mg_e151d3a4-f30b-4690-adbd-031ab6121b8d"
      unitRef="usd">0</us-gaap:DerivativeAssetFairValueGrossLiability>
    <us-gaap:DerivativeAssets
      contextRef="i0b499ddf7ec0496ba113157683c198d2_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjJkYTExNTMzNGE0ZjRmMGNiZDQ0NzRlODRlNzc5MDc0L3RhYmxlcmFuZ2U6MmRhMTE1MzM0YTRmNGYwY2JkNDQ3NGU4NGU3NzkwNzRfMi0xLTEtMS04OTA3Mg_866ab892-b588-4b91-8afa-54cea9fe1f08"
      unitRef="usd">1000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i81fe5dde69aa4fa98b7711acbae4387f_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjJkYTExNTMzNGE0ZjRmMGNiZDQ0NzRlODRlNzc5MDc0L3RhYmxlcmFuZ2U6MmRhMTE1MzM0YTRmNGYwY2JkNDQ3NGU4NGU3NzkwNzRfMi0xLTEtMS04OTA3Mg_cb0add76-303f-47a6-96dd-8a3a6382b373"
      unitRef="usd">1000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i811cc5ac0cc64328ad722d7dad5db8b1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjJkYTExNTMzNGE0ZjRmMGNiZDQ0NzRlODRlNzc5MDc0L3RhYmxlcmFuZ2U6MmRhMTE1MzM0YTRmNGYwY2JkNDQ3NGU4NGU3NzkwNzRfMi0zLTEtMS04OTA3Mg_4358cbfe-50c6-40e7-a44d-4f2d7ebdff7d"
      unitRef="usd">1000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeLiabilities
      contextRef="ib1d2d795d550443991566dd2c6bcf53b_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjJkYTExNTMzNGE0ZjRmMGNiZDQ0NzRlODRlNzc5MDc0L3RhYmxlcmFuZ2U6MmRhMTE1MzM0YTRmNGYwY2JkNDQ3NGU4NGU3NzkwNzRfMy0xLTEtMS04OTA3Mg_883d8aac-6a1a-4bc1-bbaa-5ed82e287a93"
      unitRef="usd">7000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i5ec8590d1fe9450a8eb2faa9ceaf5975_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjJkYTExNTMzNGE0ZjRmMGNiZDQ0NzRlODRlNzc5MDc0L3RhYmxlcmFuZ2U6MmRhMTE1MzM0YTRmNGYwY2JkNDQ3NGU4NGU3NzkwNzRfMy0zLTEtMS04OTA3Mg_5d796236-1ddd-4f81-b47e-b1cf17874e26"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilities>
    <us-gaap:ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RleHRyZWdpb246MThlODc5ODM3YTdhNDAwNWE3OTliYjJjNjI2NGIwOTlfNzE2Ng_686db161-8775-4bf2-801a-4f7f4bcc5e4f">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the effect of the Company&#x2019;s foreign exchange contracts on the Consolidated Statements of Operations and the Consolidated Statements of Cash Flows for the three months ended March 31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.072%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss related to changes in fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) related to settlements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="id0b87773b146435a838297c342e6101d_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjcyMWQ3MjE3MmM5ZTQ5OTliMzNkYjRkZGQwZDI1NDQxL3RhYmxlcmFuZ2U6NzIxZDcyMTcyYzllNDk5OWIzM2RiNGRkZDBkMjU0NDFfMi01LTEtMS04OTA3Mg_069ebd5f-6380-4819-9626-0d04b716f4be"
      unitRef="usd">-7000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="iaf65fa777b444e8b899db7eb8bab459d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjcyMWQ3MjE3MmM5ZTQ5OTliMzNkYjRkZGQwZDI1NDQxL3RhYmxlcmFuZ2U6NzIxZDcyMTcyYzllNDk5OWIzM2RiNGRkZDBkMjU0NDFfMi03LTEtMS04OTA3Mg_bd2819b8-8125-4413-b11d-3be98eb48692"
      unitRef="usd">-2000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain
      contextRef="id0b87773b146435a838297c342e6101d_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjcyMWQ3MjE3MmM5ZTQ5OTliMzNkYjRkZGQwZDI1NDQxL3RhYmxlcmFuZ2U6NzIxZDcyMTcyYzllNDk5OWIzM2RiNGRkZDBkMjU0NDFfMy01LTEtMS04OTA3Mg_de74c0bc-a8ac-40fc-915b-ae321d0fe2a4"
      unitRef="usd">7000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss
      contextRef="iaf65fa777b444e8b899db7eb8bab459d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjcyMWQ3MjE3MmM5ZTQ5OTliMzNkYjRkZGQwZDI1NDQxL3RhYmxlcmFuZ2U6NzIxZDcyMTcyYzllNDk5OWIzM2RiNGRkZDBkMjU0NDFfMy03LTEtMS04OTA3Mg_cd348d7a-3af4-4120-8753-cbcac2b2e30b"
      unitRef="usd">9000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i5ba0dd91cc574f9abe328ce7f85dc950_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RleHRyZWdpb246MThlODc5ODM3YTdhNDAwNWE3OTliYjJjNjI2NGIwOTlfNjEyMw_b8a4bc3f-365a-4bb0-bf43-6e95322fd392"
      unitRef="rate">0.06</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i142e78536e92483bb3067f4b123b35c7_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RleHRyZWdpb246MThlODc5ODM3YTdhNDAwNWE3OTliYjJjNjI2NGIwOTlfNjEyOQ_4d9ec85a-361c-481d-aa91-26fa87fe1b0b"
      unitRef="rate">0.18</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="id92289d625924bfcb27511b3c14249c7_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RleHRyZWdpb246MThlODc5ODM3YTdhNDAwNWE3OTliYjJjNjI2NGIwOTlfNjE4Nw_5b536b38-8803-4feb-a103-c79a545e96c6"
      unitRef="rate">0.07</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RleHRyZWdpb246MThlODc5ODM3YTdhNDAwNWE3OTliYjJjNjI2NGIwOTlfNzE1MQ_b244da51-80cf-4b1e-8009-42e59f172f23">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level&#160;3) for the three months ended March 31, 2022 and 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.132%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments to Acquisition-related contingent consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accretion for the time value of money&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustments due to changes in estimates of other future payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments/Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion included in Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjlkN2Y5ZGE5NmNhNjQ4YzZiNTJiNzkwNTc1MDU1MTA1L3RhYmxlcmFuZ2U6OWQ3ZjlkYTk2Y2E2NDhjNmI1MmI3OTA1NzUwNTUxMDVfMi00LTEtMS04OTA3Mg_5baac17b-3328-464e-a93b-e8ad634d290c"
      unitRef="usd">241000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i2d274a4a3e5a43ae91dfbb2934c4c5d1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjlkN2Y5ZGE5NmNhNjQ4YzZiNTJiNzkwNTc1MDU1MTA1L3RhYmxlcmFuZ2U6OWQ3ZjlkYTk2Y2E2NDhjNmI1MmI3OTA1NzUwNTUxMDVfMi04LTEtMS04OTA3Mg_6b90cff4-2516-4406-b210-c932edaf76b5"
      unitRef="usd">328000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ib824c124997f479bbc169d1602673e5b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjlkN2Y5ZGE5NmNhNjQ4YzZiNTJiNzkwNTc1MDU1MTA1L3RhYmxlcmFuZ2U6OWQ3ZjlkYTk2Y2E2NDhjNmI1MmI3OTA1NzUwNTUxMDVfNC0yLTEtMS04OTA3Mg_bd12fa99-54ec-4a29-a3df-8812a8446dd6"
      unitRef="usd">4000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="if29face7dd5e4f4f824bb78e8b24bb84_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjlkN2Y5ZGE5NmNhNjQ4YzZiNTJiNzkwNTc1MDU1MTA1L3RhYmxlcmFuZ2U6OWQ3ZjlkYTk2Y2E2NDhjNmI1MmI3OTA1NzUwNTUxMDVfNC02LTEtMS04OTA3Mg_4ea748d2-be20-4d94-84ca-9c093a3f718e"
      unitRef="usd">5000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ifbb2bee16b5a4770b40bde7992c3b661_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjlkN2Y5ZGE5NmNhNjQ4YzZiNTJiNzkwNTc1MDU1MTA1L3RhYmxlcmFuZ2U6OWQ3ZjlkYTk2Y2E2NDhjNmI1MmI3OTA1NzUwNTUxMDVfNS0yLTEtMS04OTA3Mg_7458dc89-be33-4350-9b36-3828c14f6484"
      unitRef="usd">-1000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i7beef5fa81be4f83928de85244de7710_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjlkN2Y5ZGE5NmNhNjQ4YzZiNTJiNzkwNTc1MDU1MTA1L3RhYmxlcmFuZ2U6OWQ3ZjlkYTk2Y2E2NDhjNmI1MmI3OTA1NzUwNTUxMDVfNS02LTEtMS04OTA3Mg_64a27ae0-119a-4049-bea9-738a1fa946c9"
      unitRef="usd">-14000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjlkN2Y5ZGE5NmNhNjQ4YzZiNTJiNzkwNTc1MDU1MTA1L3RhYmxlcmFuZ2U6OWQ3ZjlkYTk2Y2E2NDhjNmI1MmI3OTA1NzUwNTUxMDVfNi00LTEtMS04OTA3Mg_abe0cebf-3250-45e1-be3a-4fcbd7700994"
      unitRef="usd">3000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjlkN2Y5ZGE5NmNhNjQ4YzZiNTJiNzkwNTc1MDU1MTA1L3RhYmxlcmFuZ2U6OWQ3ZjlkYTk2Y2E2NDhjNmI1MmI3OTA1NzUwNTUxMDVfNi04LTEtMS04OTA3Mg_871bb1b0-3fa6-44ce-88e6-518f17e00d96"
      unitRef="usd">-9000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjlkN2Y5ZGE5NmNhNjQ4YzZiNTJiNzkwNTc1MDU1MTA1L3RhYmxlcmFuZ2U6OWQ3ZjlkYTk2Y2E2NDhjNmI1MmI3OTA1NzUwNTUxMDVfNy00LTEtMS04OTA3Mg_85348f65-9922-4bb9-adeb-d8615a6f5264"
      unitRef="usd">8000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjlkN2Y5ZGE5NmNhNjQ4YzZiNTJiNzkwNTc1MDU1MTA1L3RhYmxlcmFuZ2U6OWQ3ZjlkYTk2Y2E2NDhjNmI1MmI3OTA1NzUwNTUxMDVfNy04LTEtMS04OTA3Mg_c3384ad8-b550-424b-9086-97f42eb41581"
      unitRef="usd">6000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjlkN2Y5ZGE5NmNhNjQ4YzZiNTJiNzkwNTc1MDU1MTA1L3RhYmxlcmFuZ2U6OWQ3ZjlkYTk2Y2E2NDhjNmI1MmI3OTA1NzUwNTUxMDVfOS00LTEtMS04OTA3Mg_adddb46f-5057-49f4-88f5-10aebd6db145"
      unitRef="usd">236000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i812289a7a0cf44b4b1eed544ad0bec6c_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjlkN2Y5ZGE5NmNhNjQ4YzZiNTJiNzkwNTc1MDU1MTA1L3RhYmxlcmFuZ2U6OWQ3ZjlkYTk2Y2E2NDhjNmI1MmI3OTA1NzUwNTUxMDVfOS04LTEtMS04OTA3Mg_da9369ea-173c-4224-9f58-9cafcdeb332d"
      unitRef="usd">313000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjlkN2Y5ZGE5NmNhNjQ4YzZiNTJiNzkwNTc1MDU1MTA1L3RhYmxlcmFuZ2U6OWQ3ZjlkYTk2Y2E2NDhjNmI1MmI3OTA1NzUwNTUxMDVfMTAtNC0xLTEtODkwNzI_2914f8c6-eff8-48c6-be9b-5fbb5ae53e0f"
      unitRef="usd">43000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i812289a7a0cf44b4b1eed544ad0bec6c_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjlkN2Y5ZGE5NmNhNjQ4YzZiNTJiNzkwNTc1MDU1MTA1L3RhYmxlcmFuZ2U6OWQ3ZjlkYTk2Y2E2NDhjNmI1MmI3OTA1NzUwNTUxMDVfMTAtOC0xLTEtODkwNzI_3c535b38-948a-48f8-91ed-5b5aa6e4ea5c"
      unitRef="usd">111000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjlkN2Y5ZGE5NmNhNjQ4YzZiNTJiNzkwNTc1MDU1MTA1L3RhYmxlcmFuZ2U6OWQ3ZjlkYTk2Y2E2NDhjNmI1MmI3OTA1NzUwNTUxMDVfMTEtNC0xLTEtODkwNzI_a1693f95-aeb3-4563-adbb-52841c59c1d1"
      unitRef="usd">193000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i812289a7a0cf44b4b1eed544ad0bec6c_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RhYmxlOjlkN2Y5ZGE5NmNhNjQ4YzZiNTJiNzkwNTc1MDU1MTA1L3RhYmxlcmFuZ2U6OWQ3ZjlkYTk2Y2E2NDhjNmI1MmI3OTA1NzUwNTUxMDVfMTEtOC0xLTEtODkwNzI_c92b80df-5468-4fa6-9427-f9d42f2964dc"
      unitRef="usd">202000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:DebtInstrumentFairValue
      contextRef="id1ad1d6d1a0146b0848446f63d1074ab_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RleHRyZWdpb246MThlODc5ODM3YTdhNDAwNWE3OTliYjJjNjI2NGIwOTlfNzAyNg_c1ffe3d6-cebe-4bfd-9ce4-b71b76e9549c"
      unitRef="usd">21963000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="idc49a20c1efb4682a698d499e7132490_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181NS9mcmFnOjE4ZTg3OTgzN2E3YTQwMDVhNzk5YmIyYzYyNjRiMDk5L3RleHRyZWdpb246MThlODc5ODM3YTdhNDAwNWE3OTliYjJjNjI2NGIwOTlfNzAzMw_ea6faa23-4339-440c-85d9-4185582a3e4f"
      unitRef="usd">22689000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181OC9mcmFnOmY4YjczNTUyMjJjYzRkZWU4MDIwMGEwYTg0YmEwODcyL3RleHRyZWdpb246ZjhiNzM1NTIyMmNjNGRlZTgwMjAwYTBhODRiYTA4NzJfNTc_431e7c10-3773-493b-94a8-bb7791c2168a">INVENTORIES&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories, net consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181OC9mcmFnOmY4YjczNTUyMjJjYzRkZWU4MDIwMGEwYTg0YmEwODcyL3RleHRyZWdpb246ZjhiNzM1NTIyMmNjNGRlZTgwMjAwYTBhODRiYTA4NzJfNDg_7dff0b6a-187b-4875-ae89-fc7225f7cfe8">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories, net consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181OC9mcmFnOmY4YjczNTUyMjJjYzRkZWU4MDIwMGEwYTg0YmEwODcyL3RhYmxlOjBkNTIwNTY5ZDc5MDQwNzI5OWEyN2FlODI3Zjc5MzBlL3RhYmxlcmFuZ2U6MGQ1MjA1NjlkNzkwNDA3Mjk5YTI3YWU4MjdmNzkzMGVfMS0yLTEtMS04OTA3Mg_a57adedd-7c28-4ef5-a833-741dd3d43c07"
      unitRef="usd">288000000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181OC9mcmFnOmY4YjczNTUyMjJjYzRkZWU4MDIwMGEwYTg0YmEwODcyL3RhYmxlOjBkNTIwNTY5ZDc5MDQwNzI5OWEyN2FlODI3Zjc5MzBlL3RhYmxlcmFuZ2U6MGQ1MjA1NjlkNzkwNDA3Mjk5YTI3YWU4MjdmNzkzMGVfMS00LTEtMS04OTA3Mg_cc49aa04-9715-444c-ac5b-658e94c6f5fb"
      unitRef="usd">279000000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181OC9mcmFnOmY4YjczNTUyMjJjYzRkZWU4MDIwMGEwYTg0YmEwODcyL3RhYmxlOjBkNTIwNTY5ZDc5MDQwNzI5OWEyN2FlODI3Zjc5MzBlL3RhYmxlcmFuZ2U6MGQ1MjA1NjlkNzkwNDA3Mjk5YTI3YWU4MjdmNzkzMGVfMi0yLTEtMS04OTA3Mg_ff19a958-ec73-4d5b-ac66-8631f804c3a1"
      unitRef="usd">121000000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181OC9mcmFnOmY4YjczNTUyMjJjYzRkZWU4MDIwMGEwYTg0YmEwODcyL3RhYmxlOjBkNTIwNTY5ZDc5MDQwNzI5OWEyN2FlODI3Zjc5MzBlL3RhYmxlcmFuZ2U6MGQ1MjA1NjlkNzkwNDA3Mjk5YTI3YWU4MjdmNzkzMGVfMi00LTEtMS04OTA3Mg_8ba99d84-e063-47ad-aa1d-f9fc16017ed5"
      unitRef="usd">112000000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181OC9mcmFnOmY4YjczNTUyMjJjYzRkZWU4MDIwMGEwYTg0YmEwODcyL3RhYmxlOjBkNTIwNTY5ZDc5MDQwNzI5OWEyN2FlODI3Zjc5MzBlL3RhYmxlcmFuZ2U6MGQ1MjA1NjlkNzkwNDA3Mjk5YTI3YWU4MjdmNzkzMGVfMy0yLTEtMS04OTA3Mg_802a470b-0b93-4f5e-bc87-d86169ce4904"
      unitRef="usd">636000000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181OC9mcmFnOmY4YjczNTUyMjJjYzRkZWU4MDIwMGEwYTg0YmEwODcyL3RhYmxlOjBkNTIwNTY5ZDc5MDQwNzI5OWEyN2FlODI3Zjc5MzBlL3RhYmxlcmFuZ2U6MGQ1MjA1NjlkNzkwNDA3Mjk5YTI3YWU4MjdmNzkzMGVfMy00LTEtMS04OTA3Mg_06bcddbf-25d2-44de-9b48-acb91a904e24"
      unitRef="usd">602000000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181OC9mcmFnOmY4YjczNTUyMjJjYzRkZWU4MDIwMGEwYTg0YmEwODcyL3RhYmxlOjBkNTIwNTY5ZDc5MDQwNzI5OWEyN2FlODI3Zjc5MzBlL3RhYmxlcmFuZ2U6MGQ1MjA1NjlkNzkwNDA3Mjk5YTI3YWU4MjdmNzkzMGVfNC0yLTEtMS04OTA3Mg_5a90bf87-0932-43a2-bf0b-4b38d1af2ffa"
      unitRef="usd">1045000000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY181OC9mcmFnOmY4YjczNTUyMjJjYzRkZWU4MDIwMGEwYTg0YmEwODcyL3RhYmxlOjBkNTIwNTY5ZDc5MDQwNzI5OWEyN2FlODI3Zjc5MzBlL3RhYmxlcmFuZ2U6MGQ1MjA1NjlkNzkwNDA3Mjk5YTI3YWU4MjdmNzkzMGVfNC00LTEtMS04OTA3Mg_bae9882f-7004-4894-bb92-ba133bdf50ee"
      unitRef="usd">993000000</us-gaap:InventoryGross>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMjI0MjM_a5986c73-99ec-4a9d-9ebf-a7b030a79ebd">INTANGIBLE ASSETS AND GOODWILL &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The major components of intangible assets consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;br/&gt;and&lt;br/&gt;Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;br/&gt;and&lt;br/&gt;Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,452)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(489)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product rights/patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,191)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Partner relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(199)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,485)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb Trademark&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,485)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Impairment charges associated with these assets are included in Asset impairments in the Consolidated Statement of Operations. The Company continues to monitor the recoverability of its finite-lived intangible assets and tests the intangible assets for impairment if indicators of impairment are present. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Asset impairments, including loss on assets held for sale for the three months ended March 31, 2022 were $8&#160;million and include: (i) impairments of $4&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines, and (ii) impairments of $4&#160;million, in aggregate, related to the discontinuance of certain product lines.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Asset impairments, including loss on assets held for sale for the three months ended March 31, 2021 were $148&#160;million and include: (i) $71&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines in the Ortho Dermatologics business, (ii) an adjustment of $68&#160;million due to the loss on assets held for sale in connection with the Amoun Sale and (iii) impairments of $9&#160;million, in aggregate, related to the discontinuance of certain product lines. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated amortization expense of finite-lived intangible assets for the remainder of 2022 and each of the five succeeding years ending December&#160;31 and thereafter is as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remainder of 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in the carrying amounts of goodwill during the three months ended March 31, 2022 and the year ended December&#160;31, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.298%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb/ International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Ortho Dermatologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance, January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Realignment of segment goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,704)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(578)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Realignment of segment goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(798)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance, March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is not amortized but is tested for impairment at least annually on October 1st at the reporting unit level. A reporting unit is the same as, or one level below, an operating segment. The Company performs its annual impairment test by first assessing qualitative factors. Where the qualitative assessment suggests that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed for that reporting unit (Step 1).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of a reporting unit refers to the price that would be received to sell the unit as a whole in an orderly transaction between market participants. The Company estimates the fair value of a reporting unit using a discounted cash flow model which utilizes Level 3 unobservable inputs. The discounted cash flow model relies on assumptions regarding revenue growth rates, gross profit, projected working capital needs, selling, general and administrative expenses, research and development expenses, capital expenditures, income tax rates, discount rates and terminal growth rates. To estimate fair value, the Company discounts the forecasted cash flows of each reporting unit. The discount rate the Company uses represents the estimated weighted average cost of capital, which reflects the overall level of inherent risk involved in its reporting unit operations and the rate of return a market participant would expect to earn. The quantitative fair value test is performed utilizing long-term growth rates and discount rates applied to the estimated cash flows in estimation of fair value. To estimate cash flows beyond the final year of its model, the Company estimates a terminal value by applying an in-perpetuity growth assumption and discount factor to determine the reporting unit&#x2019;s terminal value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To forecast a reporting unit&#x2019;s cash flows the Company takes into consideration economic conditions and trends, estimated future operating results, management&#x2019;s and a market participant&#x2019;s view of growth rates and product lives, and anticipates future economic conditions. Revenue growth rates inherent in these forecasts are based on input from internal and external market research that compare factors such as growth in global economies, recent industry trends and product life-cycles. Macroeconomic factors such as changes in economies, changes in the competitive landscape including the unexpected loss of exclusivity to the Company&#x2019;s product portfolio, changes in government legislation, product life-cycles, industry consolidations and other changes beyond the Company&#x2019;s control could have a positive or negative impact on achieving its targets. Accordingly, if market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future and such change could be material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;First Quarter 2021 - Realignment of Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commencing in the first quarter of 2021, the Company began operating in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International, (iv) Ortho Dermatologics and (v) Diversified Products. The Bausch + Lomb segment consisted of the: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units. The Salix segment consisted of the Salix reporting unit. The International segment consisted of the International (formerly International Rx) reporting unit. The Ortho Dermatologics segment consisted of the: (i) Ortho Dermatologics and (ii) Global Solta reporting units. The Diversified Products segment consisted of the: (i) Neurology and Other, (ii) Generics and (iii) Dentistry reporting units. This realignment in segment structure resulted in a change in the Company&#x2019;s former International reporting unit, which was divided between the International Bausch + Lomb reporting unit and International reporting unit. In addition, as part of the realignment of segment structure, certain products historically included in the Generics reporting unit were included in the U.S. Bausch + Lomb reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of this realignment, goodwill was reassigned to each of the aforementioned reporting units using a relative fair value approach. Goodwill previously reported in the former International reporting unit was reassigned to the International Bausch + Lomb and International reporting units, and a portion of goodwill previously reported in the former Generics reporting unit was reassigned to the U.S. Bausch + Lomb reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immediately prior to the change in reporting units, the Company performed a qualitative fair value assessment for its former: (i) International and (ii) Generics reporting units. Based on the qualitative fair value assessment performed, Management believed that it was more likely than not that the carrying values of its former: (i) International and (ii) Generics reporting units were less than their respective fair values and therefore, concluded a quantitative assessment was not required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immediately following the change in reporting units, as a result of the change in composition of the net assets for its: (i) International Bausch + Lomb, (ii) International and (iii) Generics reporting units, the Company performed a quantitative fair value test. The quantitative fair value test utilized a range of long-term growth rates of 1.0% to 3.0% and a range of discount rates between 11.0% and 12.25%, in estimation of the fair value of the reporting units. After completing the testing, the fair value of each of these reporting units exceeded its carrying value by more than 40%, and, therefore, there was no impairment to goodwill. In addition, as the U.S. Bausch + Lomb reporting unit had a change in composition of its net assets related to certain products historically included in the Generics reporting unit now being included in the U.S. Bausch + Lomb reporting unit, the Company performed a qualitative assessment of this reporting unit. Based on the qualitative fair value assessment performed, Management believed that it was more likely than not that the carrying value of its current U.S. Bausch + Lomb reporting unit was less than its fair value and therefore, concluded a quantitative assessment was not required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2021 Interim Goodwill Impairment Testing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the interim periods of 2021, with the exception of the Ortho Dermatologics reporting unit, no events occurred, or circumstances changed that would indicate that the fair value of any other reporting unit might be below its carrying value and therefore, no impairments were recorded.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2021, management identified launches of certain Ortho Dermatologics products which were not going to achieve their trajectories as forecasted once the social restrictions associated with the COVID-19 pandemic began to ease in the U.S. and offices of health care professionals could reopen. In addition, insurance coverage pressures within the U.S. continued to persist limiting patient access to topical acne and psoriasis products. In light of these developments, during the first quarter of 2021, the Company began taking steps to: (i) redirect its R&amp;amp;D spend to eliminate projects it had identified as high cost and high risk, (ii) redirect a portion of its marketing and product development outside the U.S. to geographies where there is better patient access and (iii) reduce its cost structure to be more competitive. As a result, during the three months ended March 31, 2021, the Company revised its long-term forecasts for the Ortho Dermatologics reporting unit. Management believed that these events were indicators that there was less headroom as of March 31, 2021 as compared to the headroom calculated on the date goodwill was last tested for impairment (October 1, 2020). Therefore, a quantitative fair value test for the Ortho Dermatologics reporting unit was performed. The quantitative fair value test utilized the Company&#x2019;s most recent cash flow projections as revised in the first quarter of 2021 to reflect the business changes previously discussed, including a range of potential outcomes, along with a long-term growth rate of 1.0% and a range of discount rates between 9.0% and 10.0%. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at March 31, 2021, and the Company recognized a goodwill impairment of $469&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Second Quarter 2021 - Realignment of Bausch + Lomb Reporting Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commencing in the second quarter of 2021, the Company changed the way it reviews the financial information of its Bausch + Lomb segment. Beginning in the second quarter of 2021, management no longer reviews the financial information of its Bausch + Lomb segment on a geographic basis, but instead reviews this financial information on a business line basis. This change created a change in the reporting units of the Bausch + Lomb segment. After the change, under its business line view, the Bausch + Lomb segment consisted of the global: (i) Vision Care / Consumer Products, (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units. Prior to the second quarter of 2021, under the geographic view, the Bausch + Lomb segment consisted of the former: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units. As a result of the realignment, goodwill was reassigned to each of the aforementioned reporting units using a relative fair value approach. The change in Bausch + Lomb reporting units did not impact the reported revenues and segment profits of the Bausch + Lomb segment for any prior periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immediately prior to the change in its Bausch + Lomb reporting units, the Company performed a qualitative fair value assessment for its former reporting units. Based on the qualitative fair value assessment, management believed that it was more likely than not that the carrying values of its former: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units were less than their respective fair values and, therefore, concluded a quantitative assessment was not required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the change in composition of net assets, the Company performed a quantitative fair value test of its new: (i) Vision Care / Consumer Products, (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units immediately following the change in the Bausch + Lomb segment. The quantitative fair value test utilized long-term growth rates of 2.0% and 3.0% and a range of discount rates between 7.0% and 10.0%, in estimation of the fair value of the reporting units. After completing &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the testing, the fair value of each of these reporting units exceeded its carrying value by more than 45%, and, therefore, there was no impairment to goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2021 Annual Goodwill Impairment Test&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company conducted its annual goodwill impairment test as of October 1, 2021 by first assessing qualitative factors. Based on its qualitative assessment as of October 1, 2021, management believed that, with the exception of the Ortho Dermatologics reporting unit, it was more likely than not that the carrying amounts of its reporting units were less than their respective fair values and therefore concluded that a quantitative fair value test for those reporting units was not required. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of its qualitative assessment of the Ortho Dermatologics reporting unit as of October 1, 2021, the Company considered, among other matters, the limited headroom as a result of the impairment to the goodwill of the Ortho Dermatologics reporting unit when last tested (March 31, 2021) and macroeconomic factors such as higher than expected inflation for many commodities, volatility in many of the equity markets and pressures on market interest rates. The Company believed that these facts and circumstances may suggest that it was more likely than not that the fair value of the Ortho Dermatologics reporting unit was less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performed a quantitative fair value test for the Ortho Dermatologics reporting unit as of October 1, 2021, utilizing a long-term growth rate of 1.0% and a discount rate of 9.0%, in estimation of the fair value of this reporting unit. Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was approximately 10% greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;First Quarter 2022 - Realignment of Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commencing in the first quarter of 2022, the Company began operating in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International, (iv) Solta Medical and (v) Diversified Products. The Bausch + Lomb segment consists of the: (i) Vision Care / Consumer Products, (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units. The Salix segment consists of the Salix reporting unit. The International segment consists of the International reporting unit. The Solta Medical segment consists of the Global Solta reporting unit. The Diversified Products segment consists of the: (i) Neurology and Other, (ii) Generics, (iii) Ortho Dermatologics and (iv) Dentistry reporting units. As such, the new segment structure does not impact the Company&#x2019;s reporting units but realigns the two reporting units of the former Ortho Dermatologics segment whereby the Ortho Dermatologics reporting unit is now part of the current Diversified Products segment and the Solta reporting unit is now its own operating and reportable segment, and therefore management concluded that a quantitative fair value test was not required. See Note 19, &#x201c;SEGMENT INFORMATION&#x201d; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;March 31, 2022 Interim Assessment of Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to monitor market conditions which could impact the previous valuation of Ortho Dermatologics reporting unit. During the three months ended March 31, 2022, macroeconomic factors have impacted interest rates and the U.S. inflation rate is higher than previously expected.  Given the limited headroom calculated on October 1, 2021, the Company believed that these facts and circumstances suggest the fair value of the Ortho Dermatologics reporting unit could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The quantitative fair value test utilized the Company&#x2019;s most recent cash flow projections as revised in the first quarter of 2022 and utilized a long-term growth rate of 1% and a discount rate of 9%.  The discount rate contemplates changes in the current macroeconomic conditions noting certain inputs such as the risk free rate increased over the three months ended March 31, 2022, and was offset by decreases in other reporting unit specific risks during the same period. Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was less than 2% greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit. If market conditions deteriorate requiring management to revise its assumptions such as its long-term growth or discount rates, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future and those charges could be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No other events occurred or circumstances changed during the period October 1, 2021 (the last time goodwill was tested for all other reporting units) through March 31, 2022 that would indicate that the fair value of any reporting unit, other than the Ortho Dermatologics reporting unit, might be below its carrying value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated goodwill impairment charges through March&#160;31, 2022 were $4,180 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMjI0MjQ_5bd8549f-66a3-4fed-a463-8d9e17ceec83">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The major components of intangible assets consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;br/&gt;and&lt;br/&gt;Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;br/&gt;and&lt;br/&gt;Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,452)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(489)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product rights/patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,191)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Partner relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(199)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,485)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb Trademark&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,485)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMjI0NjM_734ede77-0685-4804-b290-897d2677215c">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The major components of intangible assets consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;br/&gt;and&lt;br/&gt;Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;br/&gt;and&lt;br/&gt;Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,452)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(489)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product rights/patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,191)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Partner relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(199)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,485)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb Trademark&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,485)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i33581fa718c7424d96b4ece6084ce29f_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfMy0yLTEtMS04OTA3Mg_da4e8d8c-4c83-4e86-bb3b-abfa5d17541e"
      unitRef="usd">20845000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i33581fa718c7424d96b4ece6084ce29f_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfMy00LTEtMS04OTA3Mg_368f77a3-ca92-472a-99bc-8f7ddb45ebfc"
      unitRef="usd">16452000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i33581fa718c7424d96b4ece6084ce29f_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfMy02LTEtMS04OTA3Mg_0dd6f281-69f9-456f-9ddb-57331e1ef1dd"
      unitRef="usd">4393000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i69ed23fd69344f4bb9c380845d6fda6f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfMy04LTEtMS04OTA3Mg_3c1f4b81-aef0-472e-be87-9797e15d19c1"
      unitRef="usd">20842000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i69ed23fd69344f4bb9c380845d6fda6f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfMy0xMC0xLTEtODkwNzI_8726de84-36f0-4481-b821-15c7bbada4e1"
      unitRef="usd">16169000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i69ed23fd69344f4bb9c380845d6fda6f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfMy0xMi0xLTEtODkwNzI_89282ddb-121d-4eed-a3f8-81e48bd1871b"
      unitRef="usd">4673000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i1cfcfb06623f468794d93d4a7a2a0b37_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNC0yLTEtMS04OTA3Mg_f970c382-38a9-4d7d-8547-d331714dd92d"
      unitRef="usd">900000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i1cfcfb06623f468794d93d4a7a2a0b37_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNC00LTEtMS04OTA3Mg_5ead1493-635e-4896-9471-3d73f12355cf"
      unitRef="usd">489000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i1cfcfb06623f468794d93d4a7a2a0b37_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNC02LTEtMS04OTA3Mg_aa1041c4-8d58-43b1-a0d7-31d89a3bce0f"
      unitRef="usd">411000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie2b058cfe7264b67b8928b4f04d339b3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNC04LTEtMS04OTA3Mg_4632468f-ea3a-4ec1-8cef-885b4c193d3f"
      unitRef="usd">902000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie2b058cfe7264b67b8928b4f04d339b3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNC0xMC0xLTEtODkwNzI_be46a53b-1386-4b82-9f71-255a18b2e6b7"
      unitRef="usd">473000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie2b058cfe7264b67b8928b4f04d339b3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNC0xMi0xLTEtODkwNzI_98a361b5-57d5-456c-a04e-e1a4aac18bd9"
      unitRef="usd">429000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i01425e632a3246ef8376661a776befbe_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNS0yLTEtMS04OTA3Mg_e88dc25e-5a64-45d9-832b-cc20ccf211fc"
      unitRef="usd">3321000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i01425e632a3246ef8376661a776befbe_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNS00LTEtMS04OTA3Mg_cf66fec2-5210-4dd2-8868-eb9b26768ee6"
      unitRef="usd">3191000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i01425e632a3246ef8376661a776befbe_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNS02LTEtMS04OTA3Mg_9b46a088-fa27-494f-b23c-292ec2684509"
      unitRef="usd">130000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i128fe797bfca49acb9c7413882eb5f28_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNS04LTEtMS04OTA3Mg_af2f1e01-83f8-45ad-b663-458cd802b2c2"
      unitRef="usd">3321000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i128fe797bfca49acb9c7413882eb5f28_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNS0xMC0xLTEtODkwNzI_6fe9d77c-605d-435b-b391-2b27b02613c9"
      unitRef="usd">3174000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i128fe797bfca49acb9c7413882eb5f28_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNS0xMi0xLTEtODkwNzI_c2e8a018-e915-4c33-a898-49d95e88a138"
      unitRef="usd">147000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6778a58f66f24243ab203161f3c6127d_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNi0yLTEtMS04OTA3Mg_7372a158-92e3-4aa3-9d2b-f32c34ad0483"
      unitRef="usd">154000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6778a58f66f24243ab203161f3c6127d_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNi00LTEtMS04OTA3Mg_05a38d30-13e9-45a1-8bf1-63aaae7f1360"
      unitRef="usd">154000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6778a58f66f24243ab203161f3c6127d_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNi02LTEtMS04OTA3Mg_941af8b7-6308-4579-bbcf-2399d77499ed"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i8420c39690874c31bfc4e99fc56813a9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNi04LTEtMS04OTA3Mg_9b731554-3725-4b61-841a-cc61b54b9a3d"
      unitRef="usd">158000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i8420c39690874c31bfc4e99fc56813a9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNi0xMC0xLTEtODkwNzI_783fe39d-4d10-4f0f-88e9-43cb59f5cb1d"
      unitRef="usd">158000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8420c39690874c31bfc4e99fc56813a9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNi0xMi0xLTEtODkwNzI_37c96d57-6503-4367-8a22-d3dc8e33bd3e"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="icdae99c37fc148b9b34c052c3f5ee437_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNy0yLTEtMS04OTA3Mg_b4cd772d-bd5f-4dad-827e-c68246b9e2a6"
      unitRef="usd">199000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="icdae99c37fc148b9b34c052c3f5ee437_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNy00LTEtMS04OTA3Mg_421901fd-75f0-4127-b7af-9ef25c2ab85b"
      unitRef="usd">199000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="icdae99c37fc148b9b34c052c3f5ee437_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNy02LTEtMS04OTA3Mg_06a22ca2-d547-4309-aab9-160694f0242c"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="icc94d751eecd4f2884cec4ffed6f0547_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNy04LTEtMS04OTA3Mg_fe0d572f-78db-406a-9d3e-1e7908549175"
      unitRef="usd">207000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="icc94d751eecd4f2884cec4ffed6f0547_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNy0xMC0xLTEtODkwNzI_112c5796-9150-4764-8d72-b94b57678077"
      unitRef="usd">206000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="icc94d751eecd4f2884cec4ffed6f0547_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfNy0xMi0xLTEtODkwNzI_bc9d8173-1e4e-41f4-b123-28def67821da"
      unitRef="usd">1000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfOC0yLTEtMS04OTA3Mg_548288b0-1e77-43e9-892d-007aee9437bd"
      unitRef="usd">25419000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfOC00LTEtMS04OTA3Mg_124c6edc-7599-4fc8-9eaa-21b8fe2e3476"
      unitRef="usd">20485000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfOC02LTEtMS04OTA3Mg_55df365c-fa97-43eb-9db4-05d2bb05fb9b"
      unitRef="usd">4934000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfOC04LTEtMS04OTA3Mg_bfcf558d-3b5d-43e9-b077-9373d020f7a3"
      unitRef="usd">25430000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfOC0xMC0xLTEtODkwNzI_aadc8270-dde8-4258-b4a2-d968dfc23452"
      unitRef="usd">20180000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfOC0xMi0xLTEtODkwNzI_eb8781b7-a0e5-4f6c-9955-4525c39d5eeb"
      unitRef="usd">5250000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i184da53a325548e5a9b4d68317c28bf5_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfMTAtMi0xLTEtODkwNzI_a4d9dcd8-446d-4b4b-8678-78694bf320be"
      unitRef="usd">1698000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i184da53a325548e5a9b4d68317c28bf5_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfMTAtNi0xLTEtODkwNzI_7157f9c7-c1b2-4e00-ab9b-57968075ca25"
      unitRef="usd">1698000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i7adc09fd30f54c31a00d1b781106171b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfMTAtOC0xLTEtODkwNzI_df33da77-3c58-4031-86cf-1d0fe95e5b46"
      unitRef="usd">1698000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i7adc09fd30f54c31a00d1b781106171b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfMTAtMTItMS0xLTg5MDcy_aa6f09a3-a6a3-44e4-84f0-56f7c1ea4ae3"
      unitRef="usd">1698000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfMTEtMi0xLTEtODkwNzI_68255282-af26-43b1-abe2-baaded50d2da"
      unitRef="usd">27117000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfMTEtNC0xLTEtODkwNzI_e579e603-46dd-477c-8017-fc43c77325d9"
      unitRef="usd">20485000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfMTEtNi0xLTEtODkwNzI_c64c37bf-013c-446c-a44d-4da980c7cb1e"
      unitRef="usd">6632000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfMTEtOC0xLTEtODkwNzI_4c2e1ef7-219c-46e7-ad17-41bd8dab96e8"
      unitRef="usd">27128000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfMTEtMTAtMS0xLTg5MDcy_dbc9fcc3-9d95-4030-a637-14daf974daa8"
      unitRef="usd">20180000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOmE2ZGQ1OWM2M2I2MzQ3ZTc4NzE4YWUzMGY5OWM2NTczL3RhYmxlcmFuZ2U6YTZkZDU5YzYzYjYzNDdlNzg3MThhZTMwZjk5YzY1NzNfMTEtMTItMS0xLTg5MDcy_b4db95ce-80bf-4340-a5a7-80b5a9ee08cf"
      unitRef="usd">6948000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfNjY3_8caa150a-eca6-461c-89c3-65548f828eda"
      unitRef="usd">8000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i24b3278f312448edbdbbd2e5c8edb4ea_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfNzAy_06fc97db-aa35-42ca-b507-eb3964110f74"
      unitRef="usd">4000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i9aa88c188d514752bb8a235164b310e8_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfOTAz_eb29eae1-cf76-479e-b515-94f440dcc34a"
      unitRef="usd">4000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMTA1MQ_2049f20d-e45d-4beb-8759-aa8faac9a3db"
      unitRef="usd">148000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="ibd413c64fca1463c942b8ada290af82b_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMTA4Ng_04d6538f-939d-4756-a3af-2f3fc2dab5dd"
      unitRef="usd">71000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i9d5bc364e17040579714c24cebd52ba5_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMTY0OTI2NzQ4NDgwNA_eb05ff62-29e1-42f3-9f14-4b75f61f1639"
      unitRef="usd">68000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i78352536ea52411880331b5c2102a14b_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMTE3NQ_419baeeb-5755-4466-bcea-e268ef8dcf67"
      unitRef="usd">9000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMjI0NTI_e1554673-252b-4722-a705-f6c3a24393ce">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated amortization expense of finite-lived intangible assets for the remainder of 2022 and each of the five succeeding years ending December&#160;31 and thereafter is as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remainder of 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE5NWZjZmQ3OGNjMzQ5MWFhYjgzY2VmYjE1YmNjM2ZiL3RhYmxlcmFuZ2U6MTk1ZmNmZDc4Y2MzNDkxYWFiODNjZWZiMTViY2MzZmJfMS0yLTEtMS04OTA3Mg_54f36e78-3dfa-429a-9f2a-52640c9686e2"
      unitRef="usd">870000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE5NWZjZmQ3OGNjMzQ5MWFhYjgzY2VmYjE1YmNjM2ZiL3RhYmxlcmFuZ2U6MTk1ZmNmZDc4Y2MzNDkxYWFiODNjZWZiMTViY2MzZmJfMS00LTEtMS04OTA3Mg_3dd28d59-aeef-4ca5-8b37-93c3169e5717"
      unitRef="usd">1023000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE5NWZjZmQ3OGNjMzQ5MWFhYjgzY2VmYjE1YmNjM2ZiL3RhYmxlcmFuZ2U6MTk1ZmNmZDc4Y2MzNDkxYWFiODNjZWZiMTViY2MzZmJfMS02LTEtMS04OTA3Mg_9b5d99bb-b7d5-4fd8-999f-534c2d48b1f4"
      unitRef="usd">901000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE5NWZjZmQ3OGNjMzQ5MWFhYjgzY2VmYjE1YmNjM2ZiL3RhYmxlcmFuZ2U6MTk1ZmNmZDc4Y2MzNDkxYWFiODNjZWZiMTViY2MzZmJfMS04LTEtMS04OTA3Mg_aa55363d-8438-4978-a009-06f099ecda7c"
      unitRef="usd">794000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE5NWZjZmQ3OGNjMzQ5MWFhYjgzY2VmYjE1YmNjM2ZiL3RhYmxlcmFuZ2U6MTk1ZmNmZDc4Y2MzNDkxYWFiODNjZWZiMTViY2MzZmJfMS0xMC0xLTEtODkwNzI_8ee539f4-0f0d-48f7-9f3c-a46510ece2c9"
      unitRef="usd">664000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE5NWZjZmQ3OGNjMzQ5MWFhYjgzY2VmYjE1YmNjM2ZiL3RhYmxlcmFuZ2U6MTk1ZmNmZDc4Y2MzNDkxYWFiODNjZWZiMTViY2MzZmJfMS0xMi0xLTEtODkwNzI_bb438c09-aac7-4b2a-9516-75205024d44f"
      unitRef="usd">627000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE5NWZjZmQ3OGNjMzQ5MWFhYjgzY2VmYjE1YmNjM2ZiL3RhYmxlcmFuZ2U6MTk1ZmNmZDc4Y2MzNDkxYWFiODNjZWZiMTViY2MzZmJfMS0xNC0xLTEtODkwNzI_47101932-1643-4931-895d-41589f83c5c0"
      unitRef="usd">55000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE5NWZjZmQ3OGNjMzQ5MWFhYjgzY2VmYjE1YmNjM2ZiL3RhYmxlcmFuZ2U6MTk1ZmNmZDc4Y2MzNDkxYWFiODNjZWZiMTViY2MzZmJfMS0xNi0xLTEtODkwNzI_68417954-0cab-43d3-b5b1-1d6c0d26e99b"
      unitRef="usd">4934000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMjI0Njg_482767cf-1afd-447d-b8d3-fc1a23ba3654">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in the carrying amounts of goodwill during the three months ended March 31, 2022 and the year ended December&#160;31, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.298%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb/ International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Ortho Dermatologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance, January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Realignment of segment goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,704)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(578)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Realignment of segment goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(798)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance, March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i942199177b494651b884505a5348aee8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfMS0yLTEtMS04OTA3Mg_376d1f9f-fdd9-41f7-a013-3402dd5ccf5b"
      unitRef="usd">5704000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i12b373f353694a7a92ef13969e363c9c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfMS02LTEtMS04OTA3Mg_874e9ae9-3022-4c3b-aafe-5e26b23e1a8c"
      unitRef="usd">3159000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i2f9c2f75c9054ca7be42d333db8aa66a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfMS0xMC0xLTEtODkwNzI_e83b06f7-3487-4492-addc-39d7e5343e59"
      unitRef="usd">1267000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i5a8465040b7746bbbb02d83f214f8936_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfMS0xMi0xLTEtODkwNzI_18a24ef0-bcff-4802-bcc1-a4ea081c2796"
      unitRef="usd">2914000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i2d274a4a3e5a43ae91dfbb2934c4c5d1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfMS0xNC0xLTEtODkwNzI_2ce1595e-db00-4727-8213-76ea36db61cc"
      unitRef="usd">13044000000</us-gaap:Goodwill>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i9e916e0c53bb4694a37e063fb61adc77_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfMi0yLTEtMS04OTA3Mg_b3e25ae5-cc10-4138-8cbc-67a21cc98099"
      unitRef="usd">-5704000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i56804b7aa6534ed9b555f349c187b56d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfMi00LTEtMS05NDc3MQ_88b1bfca-004e-4646-8de1-ff0d1a840071"
      unitRef="usd">5395000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i7b662e8f657b4e3ab3b79a4cebde04c2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfMi04LTEtMS05NDc3MQ_ff8c09e0-495e-4cfb-86dd-7c96d95ddc14"
      unitRef="usd">887000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="ib37696822d2c4572b3c78344c1fd444a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfMi0xNC0xLTEtOTQ3NzE_48d62aea-7a9c-4442-a695-ac946a0be89e"
      unitRef="usd">-578000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="ia94fd825df534043ad9a8d3ff85daa7f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfMi0xNC0xLTEtODkwNzI_fc64e22b-cc79-4e75-95d2-33218a9994a7"
      unitRef="usd">0</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i9e916e0c53bb4694a37e063fb61adc77_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfMy0yLTEtMS04OTA3Mg_e23abf98-1bae-4a47-a453-4bbb6412170a"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i1dcff32aa885494dbd4c25e336b285dd_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfMy0xMC0xLTEtOTQ3Nzc_f3d04935-780e-439c-94b2-a040717a5274"
      unitRef="usd">469000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ia94fd825df534043ad9a8d3ff85daa7f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfMy0xNC0xLTEtODkwNzI_a69ed944-8172-4285-9515-b31556f17733"
      unitRef="usd">469000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i9e916e0c53bb4694a37e063fb61adc77_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfNC0yLTEtMS04OTA3Mg_920a5063-116b-406c-bbdc-c397fd8ffdde"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i56804b7aa6534ed9b555f349c187b56d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfNC00LTEtMS05NDc3OQ_c73a7c53-ef91-463f-8625-bfe035f5217a"
      unitRef="usd">77000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i7b662e8f657b4e3ab3b79a4cebde04c2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfNC04LTEtMS05NDc4MQ_ed9dec3c-690a-4925-bb83-9c4e8e4ece5e"
      unitRef="usd">62000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ib37696822d2c4572b3c78344c1fd444a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfNC0xNC0xLTEtOTQ3ODM_c18613aa-fc8f-4407-bde1-9e11105146fd"
      unitRef="usd">-21000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ia94fd825df534043ad9a8d3ff85daa7f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfNC0xNC0xLTEtODkwNzI_7c6762f0-7ec3-41e0-a8ca-f2d3f1da2867"
      unitRef="usd">118000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i928ceb331757485bb004adc674715221_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfNS0yLTEtMS04OTA3Mg_a561b6a1-8cea-49ba-bb0e-bd1d0d5b47ca"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="iab3980bb98104da18c9a7bfacb2b814c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfNS00LTEtMS04OTA3Mg_e107eaa7-850d-4f3e-93cc-55d34dc15389"
      unitRef="usd">5318000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="icad79738cfa145e4ad3efae80a8f7853_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfNS02LTEtMS04OTA3Mg_3a27ec61-cbad-42c4-9219-58f3617a31f8"
      unitRef="usd">3159000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i883adcdb932a4b7facd79e34969366b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfNS04LTEtMS04OTA3Mg_7025f5e6-474d-4a6c-b953-59506822ac67"
      unitRef="usd">825000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ie485ba4bcfb74a319879f1cc1994ceb1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfNS0xMC0xLTEtODkwNzI_2d293676-7360-4ae0-b033-4257f37a40c1"
      unitRef="usd">798000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ibc6abfd8107c426d88c7af70640541ed_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfNS0xMi0xLTEtOTQ3OTA_50ad45fe-f2cb-4b1a-8727-2a61e549e4b2"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i16fa5c63321a4379872d667cd4f09ff7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfNS0xMi0xLTEtODkwNzI_46b940e0-26c9-4647-9086-b157116101bc"
      unitRef="usd">2357000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfNS0xNC0xLTEtODkwNzI_17d1ac96-2afa-4753-9faf-ad70b3e22de9"
      unitRef="usd">12457000000</us-gaap:Goodwill>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="ie3e9f44ea7f04ab4bb12e34a4d9b198f_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfNi0yLTEtMS04OTA3Mg_4e1b1e70-6091-4457-ab6e-a2180c0460f2"
      unitRef="usd">0</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i03d9858da1a54c6a897587b6b5079ca1_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfNi0xMC0xLTEtOTQ3OTk_9cbe4b72-816f-4bbf-a842-5d0c762bf629"
      unitRef="usd">-798000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i4cc8090790184dbd8e5fef8bc092f80c_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfNi0xMi0xLTEtOTQ4MDM_785923d3-5eeb-4709-9b02-2afd7eea92af"
      unitRef="usd">115000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="id5df5fcbde684e86add3147c9fe2ea1c_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfNi0xMi0xLTEtODkwNzI_d7160b1c-4909-4064-bb90-5569ede4f672"
      unitRef="usd">683000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfNi0xNC0xLTEtODkwNzI_04cbac96-c05a-4037-872b-287af0b374cf"
      unitRef="usd">0</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ie3e9f44ea7f04ab4bb12e34a4d9b198f_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfNy0yLTEtMS0xMDE2ODY_e187fbc3-04ea-42e9-81ff-39a2b9adb889"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i897d561735644b67b640f606386ea273_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfOC00LTEtMS04OTA3Mg_02edff88-706a-4720-bc6b-7fec5c527fd9"
      unitRef="usd">26000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i03af4a3fb12d4415985732b5f1713c51_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfOC04LTEtMS04OTA3Mg_c13cfeff-368f-42b1-b353-c0a373a7ce51"
      unitRef="usd">14000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="id5df5fcbde684e86add3147c9fe2ea1c_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfOC0xMi0xLTEtODkwNzI_843a7255-37b6-49cf-8da6-c7e9d3f0142d"
      unitRef="usd">-10000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfOC0xNC0xLTEtODkwNzI_a3c31bb2-502d-47bb-81c5-71679cca1646"
      unitRef="usd">30000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i7c5165be148344bdaf507fcd8cd8faa1_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfOS0yLTEtMS04OTA3Mg_6fb0fcdd-593e-4bd3-be35-25494c829169"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="iff8cffb5a07d43829a8ad9375270cefc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfOS00LTEtMS04OTA3Mg_15979faf-d065-4ddc-a42d-0eb0d9297e8f"
      unitRef="usd">5292000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i17fd70111a574d2ca873e85d5d905ac6_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfOS02LTEtMS04OTA3Mg_b0e8b958-5567-461f-be60-6012b75995c7"
      unitRef="usd">3159000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i42279724503f49f38806cc3713f1dec9_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfOS04LTEtMS04OTA3Mg_4f04a910-a4d3-4ce5-85d8-5efba0a2994b"
      unitRef="usd">811000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i2c7901af22c14ac2ad3c4144a35ef0c6_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfOS0xMC0xLTEtODkwNzI_56c0275b-5ce2-42a1-af87-02e2dd8fad49"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i05c0aa9bce2948fe95f19480427221e2_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfOC0xMi0xLTEtOTQ3OTI_f8b64629-b999-42da-b3c6-d87f94111738"
      unitRef="usd">115000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="icb4928a2aeb34ea08a24be593ce24cf0_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfOS0xMi0xLTEtODkwNzI_fd9bb101-a3a3-4bcc-bdbc-c46e269052b5"
      unitRef="usd">3050000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RhYmxlOjE1MDllMDMyNWExNTQwNjdiOWUxMDJkNDNmZGMzZGJlL3RhYmxlcmFuZ2U6MTUwOWUwMzI1YTE1NDA2N2I5ZTEwMmQ0M2ZkYzNkYmVfOS0xNC0xLTEtODkwNzI_9f1168ef-9f8a-47c6-98e4-41f11c98c624"
      unitRef="usd">12427000000</us-gaap:Goodwill>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i05c4425257364b019ef82d6d8127a3d0_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMTU0NTc_56612e34-23b1-493c-b38b-0524910b23c9"
      unitRef="number">0.010</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i22918d18bb77417eac5d796b8c470056_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMTU0NjM_0feed543-5287-4a77-a36b-dc440d8ac54b"
      unitRef="number">0.030</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i05c4425257364b019ef82d6d8127a3d0_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMTU1MDQ_e2cc3e29-4c43-499f-876d-5fec8f2e1cc5"
      unitRef="number">0.110</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i22918d18bb77417eac5d796b8c470056_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMTU1MTE_f4c720d6-b6df-4e9f-a082-b9e608fa1d7b"
      unitRef="number">0.1225</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="i812289a7a0cf44b4b1eed544ad0bec6c_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMTU2OTA_6e004799-2777-4f4f-b149-635ff6b1694c"
      unitRef="number">0.40</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i59dd4c241bfe46cab97c7f62aa7998be_D20210331-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMTU3MjA_ed520cbf-ab9a-4cc8-9316-6252aa4637ff"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i813f53a5817849fa8b332b4429a806c7_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMjc0ODc3OTExMjU5NA_bb8c6f3b-a6fa-45f0-b2ab-8f4950c3e211"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i352bdc0bdb3746bcab18bb34559bda96_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMTc5Njg_5f247fd5-cfcf-4e7d-8a1e-03074df45e57"
      unitRef="number">0.010</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="ib3d106cc00bb4068aeaadfb5a27059ab_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMTgwMDk_eda86c98-447f-4d9f-9922-907a9a9665d5"
      unitRef="number">0.090</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i3b7487693f3a42968a15d65a005a518a_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMTgwMTY_7c7b6879-1705-472e-b06c-5c3ca66dfb6c"
      unitRef="number">0.100</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i579bd73ae67e4680b7518c0d567bd33c_D20210331-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMTgyMTk_a2bb4b41-d341-4793-a4f0-34d5572e4c04"
      unitRef="usd">469000000</us-gaap:GoodwillImpairmentLoss>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i76fa5b74ac474ce785d33b402a51a48b_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMjAyNzA_f7f8720c-2cc1-4233-9a1b-4171688f5761"
      unitRef="number">0.020</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i0aeee5779e6741b5a846738af963baa7_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMjAyNzc_7b7186a0-fda0-4ee1-93ab-d5997a1d7e8d"
      unitRef="number">0.030</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i76fa5b74ac474ce785d33b402a51a48b_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMjAzMTg_1c64298f-7401-4f21-b307-13eb9b76c199"
      unitRef="number">0.070</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i76fa5b74ac474ce785d33b402a51a48b_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMjAzMTg_3e1a7d77-2e15-4a20-84f5-96cf8f9e087e"
      unitRef="number">0.070</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i0aeee5779e6741b5a846738af963baa7_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMjAzMjU_56b95725-45a4-4833-806e-5bd1f6650b0f"
      unitRef="number">0.100</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i0aeee5779e6741b5a846738af963baa7_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMjAzMjU_a475e520-0dfd-41d9-b634-93400caae45a"
      unitRef="number">0.100</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="i4bde0da879c447c1bce8cc7c0ff990a9_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMjA1MDQ_8997ecc3-e249-49e0-b07d-34a739c61b2f"
      unitRef="number">0.45</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="i4bde0da879c447c1bce8cc7c0ff990a9_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMjA1MDQ_ee3cc7ba-ef47-4009-86fc-fe6141c2e168"
      unitRef="number">0.45</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i66cd53bf84e745829ac8a76a80274bef_D20210630-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMjA1MzQ_7ec7775a-d7fd-4ca3-a9d2-d3682b776851"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i273ea466a0c24f7f9a2bc799a58a59b0_I20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMTY0OTI2NzQ2ODIwMg_a96f342d-8e3c-4253-a440-5fde658ec162"
      unitRef="number">0.010</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i273ea466a0c24f7f9a2bc799a58a59b0_I20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMTY0OTI2NzQ2ODIwOA_247057dc-fb07-4b95-a7c1-f317547a5c53"
      unitRef="number">0.090</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="i273ea466a0c24f7f9a2bc799a58a59b0_I20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMTY0OTI2NzQ2ODIxNA_aec26595-6623-4305-b251-14165e39c499"
      unitRef="number">0.10</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i84c7e2b9e5eb4b97857089a8cd8efa23_D20211001-20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMTY0OTI2NzQ2ODIxOA_4a3691e3-0997-4e31-b467-ffeffdda5ac4"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:NumberOfReportingUnits
      contextRef="i03d9858da1a54c6a897587b6b5079ca1_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMjc0ODc3OTExMjYwOQ_64475b6c-e5c5-4911-a540-07a779b7fd34"
      unitRef="reporting_unit">2</us-gaap:NumberOfReportingUnits>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i600f2612b7b641d682431ce561c69ad9_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMjc0ODc3OTEzMDEyMQ_6b32980f-5024-41a6-baec-b89628cbfc8a"
      unitRef="number">0.01</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i600f2612b7b641d682431ce561c69ad9_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMjc0ODc3OTEzMDEyNQ_9791a21d-54bb-4616-909c-95756fa19a5d"
      unitRef="number">0.09</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="i600f2612b7b641d682431ce561c69ad9_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMjc0ODc3OTEzMDEyOQ_a3aedd68-b811-412f-b875-c0ea735a5efd"
      unitRef="number">0.02</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="if6561f3b97934eda8c2522f1ea9ce1b7_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMjc0ODc3OTEzMDEzMg_07fd2a49-3c5d-40d0-8cad-cfc181a90dfa"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182MS9mcmFnOjU4ODc1NjIwMTBjNDQ2ODBiNDEzYTVkN2M5MjExOGIzL3RleHRyZWdpb246NTg4NzU2MjAxMGM0NDY4MGI0MTNhNWQ3YzkyMTE4YjNfMjI0MjA_2b9dd7f4-c514-4b87-9903-67bd9461f03a"
      unitRef="usd">4180000000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182NC9mcmFnOjU5NGZhYjcyMTcwZTQ1NjdiMDFiYTBmNjAxYmM3ZjUwL3RleHRyZWdpb246NTk0ZmFiNzIxNzBlNDU2N2IwMWJhMGY2MDFiYzdmNTBfOTc_e36297a1-d83a-4b7c-82a2-ef5f6872e875">ACCRUED AND OTHER CURRENT LIABILITIES&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal matters and related fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182NC9mcmFnOjU5NGZhYjcyMTcwZTQ1NjdiMDFiYTBmNjAxYmM3ZjUwL3RleHRyZWdpb246NTk0ZmFiNzIxNzBlNDU2N2IwMWJhMGY2MDFiYzdmNTBfOTQ_6ae97a61-e5ee-4704-829a-1d9cb3a1f252">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal matters and related fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <bhc:Legalsettlementsandrelatedfees
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182NC9mcmFnOjU5NGZhYjcyMTcwZTQ1NjdiMDFiYTBmNjAxYmM3ZjUwL3RhYmxlOmE2YTUyNDdiYmRmZTQ1OGRiNTU4OTAyZDQ5ZGFjYzViL3RhYmxlcmFuZ2U6YTZhNTI0N2JiZGZlNDU4ZGI1NTg5MDJkNDlkYWNjNWJfMS0yLTEtMS04OTA3Mg_c24287d0-6e4e-40b5-afa2-666a3435c2cb"
      unitRef="usd">1530000000</bhc:Legalsettlementsandrelatedfees>
    <bhc:Legalsettlementsandrelatedfees
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182NC9mcmFnOjU5NGZhYjcyMTcwZTQ1NjdiMDFiYTBmNjAxYmM3ZjUwL3RhYmxlOmE2YTUyNDdiYmRmZTQ1OGRiNTU4OTAyZDQ5ZGFjYzViL3RhYmxlcmFuZ2U6YTZhNTI0N2JiZGZlNDU4ZGI1NTg5MDJkNDlkYWNjNWJfMS00LTEtMS04OTA3Mg_b0048e69-c094-462a-904a-646a07a90da5"
      unitRef="usd">1890000000</bhc:Legalsettlementsandrelatedfees>
    <bhc:AccruedProductRebateCurrent
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182NC9mcmFnOjU5NGZhYjcyMTcwZTQ1NjdiMDFiYTBmNjAxYmM3ZjUwL3RhYmxlOmE2YTUyNDdiYmRmZTQ1OGRiNTU4OTAyZDQ5ZGFjYzViL3RhYmxlcmFuZ2U6YTZhNTI0N2JiZGZlNDU4ZGI1NTg5MDJkNDlkYWNjNWJfMi0yLTEtMS04OTA3Mg_67640732-f4b8-456e-bc03-ba53550e01cf"
      unitRef="usd">889000000</bhc:AccruedProductRebateCurrent>
    <bhc:AccruedProductRebateCurrent
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182NC9mcmFnOjU5NGZhYjcyMTcwZTQ1NjdiMDFiYTBmNjAxYmM3ZjUwL3RhYmxlOmE2YTUyNDdiYmRmZTQ1OGRiNTU4OTAyZDQ5ZGFjYzViL3RhYmxlcmFuZ2U6YTZhNTI0N2JiZGZlNDU4ZGI1NTg5MDJkNDlkYWNjNWJfMi00LTEtMS04OTA3Mg_729a1416-0d0b-4c19-aeef-2f269242c8a6"
      unitRef="usd">908000000</bhc:AccruedProductRebateCurrent>
    <bhc:AccruedProductReturnCurrent
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182NC9mcmFnOjU5NGZhYjcyMTcwZTQ1NjdiMDFiYTBmNjAxYmM3ZjUwL3RhYmxlOmE2YTUyNDdiYmRmZTQ1OGRiNTU4OTAyZDQ5ZGFjYzViL3RhYmxlcmFuZ2U6YTZhNTI0N2JiZGZlNDU4ZGI1NTg5MDJkNDlkYWNjNWJfMy0yLTEtMS04OTA3Mg_9045b0ed-a73a-4ddb-af7f-674a8e9ba7ad"
      unitRef="usd">447000000</bhc:AccruedProductReturnCurrent>
    <bhc:AccruedProductReturnCurrent
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182NC9mcmFnOjU5NGZhYjcyMTcwZTQ1NjdiMDFiYTBmNjAxYmM3ZjUwL3RhYmxlOmE2YTUyNDdiYmRmZTQ1OGRiNTU4OTAyZDQ5ZGFjYzViL3RhYmxlcmFuZ2U6YTZhNTI0N2JiZGZlNDU4ZGI1NTg5MDJkNDlkYWNjNWJfMy00LTEtMS04OTA3Mg_472b1712-b570-4966-94f7-29492d6b2802"
      unitRef="usd">482000000</bhc:AccruedProductReturnCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182NC9mcmFnOjU5NGZhYjcyMTcwZTQ1NjdiMDFiYTBmNjAxYmM3ZjUwL3RhYmxlOmE2YTUyNDdiYmRmZTQ1OGRiNTU4OTAyZDQ5ZGFjYzViL3RhYmxlcmFuZ2U6YTZhNTI0N2JiZGZlNDU4ZGI1NTg5MDJkNDlkYWNjNWJfNC0yLTEtMS04OTA3Mg_2b58c563-89d1-4a51-aef4-bafeb9451add"
      unitRef="usd">372000000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182NC9mcmFnOjU5NGZhYjcyMTcwZTQ1NjdiMDFiYTBmNjAxYmM3ZjUwL3RhYmxlOmE2YTUyNDdiYmRmZTQ1OGRiNTU4OTAyZDQ5ZGFjYzViL3RhYmxlcmFuZ2U6YTZhNTI0N2JiZGZlNDU4ZGI1NTg5MDJkNDlkYWNjNWJfNC00LTEtMS04OTA3Mg_810a6679-aef2-470a-9975-2b8d563252c5"
      unitRef="usd">328000000</us-gaap:InterestPayableCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182NC9mcmFnOjU5NGZhYjcyMTcwZTQ1NjdiMDFiYTBmNjAxYmM3ZjUwL3RhYmxlOmE2YTUyNDdiYmRmZTQ1OGRiNTU4OTAyZDQ5ZGFjYzViL3RhYmxlcmFuZ2U6YTZhNTI0N2JiZGZlNDU4ZGI1NTg5MDJkNDlkYWNjNWJfNS0yLTEtMS04OTA3Mg_9c65225f-f57c-4ca6-9e16-beaca42367b3"
      unitRef="usd">283000000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182NC9mcmFnOjU5NGZhYjcyMTcwZTQ1NjdiMDFiYTBmNjAxYmM3ZjUwL3RhYmxlOmE2YTUyNDdiYmRmZTQ1OGRiNTU4OTAyZDQ5ZGFjYzViL3RhYmxlcmFuZ2U6YTZhNTI0N2JiZGZlNDU4ZGI1NTg5MDJkNDlkYWNjNWJfNS00LTEtMS04OTA3Mg_2a116e60-a25c-4b8f-bd8b-d9d7ef3ab9fe"
      unitRef="usd">336000000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182NC9mcmFnOjU5NGZhYjcyMTcwZTQ1NjdiMDFiYTBmNjAxYmM3ZjUwL3RhYmxlOmE2YTUyNDdiYmRmZTQ1OGRiNTU4OTAyZDQ5ZGFjYzViL3RhYmxlcmFuZ2U6YTZhNTI0N2JiZGZlNDU4ZGI1NTg5MDJkNDlkYWNjNWJfNi0yLTEtMS04OTA3Mg_7f9f6761-42c4-444d-806f-d88504988201"
      unitRef="usd">80000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182NC9mcmFnOjU5NGZhYjcyMTcwZTQ1NjdiMDFiYTBmNjAxYmM3ZjUwL3RhYmxlOmE2YTUyNDdiYmRmZTQ1OGRiNTU4OTAyZDQ5ZGFjYzViL3RhYmxlcmFuZ2U6YTZhNTI0N2JiZGZlNDU4ZGI1NTg5MDJkNDlkYWNjNWJfNi00LTEtMS04OTA3Mg_cc1353be-e9e7-4e10-a964-a1da5a2ac168"
      unitRef="usd">98000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182NC9mcmFnOjU5NGZhYjcyMTcwZTQ1NjdiMDFiYTBmNjAxYmM3ZjUwL3RhYmxlOmE2YTUyNDdiYmRmZTQ1OGRiNTU4OTAyZDQ5ZGFjYzViL3RhYmxlcmFuZ2U6YTZhNTI0N2JiZGZlNDU4ZGI1NTg5MDJkNDlkYWNjNWJfNy0yLTEtMS04OTA3Mg_f1f39691-c4b4-4779-a826-d508a52d9151"
      unitRef="usd">702000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182NC9mcmFnOjU5NGZhYjcyMTcwZTQ1NjdiMDFiYTBmNjAxYmM3ZjUwL3RhYmxlOmE2YTUyNDdiYmRmZTQ1OGRiNTU4OTAyZDQ5ZGFjYzViL3RhYmxlcmFuZ2U6YTZhNTI0N2JiZGZlNDU4ZGI1NTg5MDJkNDlkYWNjNWJfNy00LTEtMS04OTA3Mg_dd6f7ad1-0c99-4464-b611-eb513df40a6b"
      unitRef="usd">749000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182NC9mcmFnOjU5NGZhYjcyMTcwZTQ1NjdiMDFiYTBmNjAxYmM3ZjUwL3RhYmxlOmE2YTUyNDdiYmRmZTQ1OGRiNTU4OTAyZDQ5ZGFjYzViL3RhYmxlcmFuZ2U6YTZhNTI0N2JiZGZlNDU4ZGI1NTg5MDJkNDlkYWNjNWJfOC0yLTEtMS04OTA3Mg_a285d8d3-37a2-43de-a664-ba0e351fb3fb"
      unitRef="usd">4303000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182NC9mcmFnOjU5NGZhYjcyMTcwZTQ1NjdiMDFiYTBmNjAxYmM3ZjUwL3RhYmxlOmE2YTUyNDdiYmRmZTQ1OGRiNTU4OTAyZDQ5ZGFjYzViL3RhYmxlcmFuZ2U6YTZhNTI0N2JiZGZlNDU4ZGI1NTg5MDJkNDlkYWNjNWJfOC00LTEtMS04OTA3Mg_a811e871-8e8d-468f-bdc0-ba4adfbdaa02"
      unitRef="usd">4791000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTk1NjY_55aa3025-0a10-4d0d-a069-31e6e7ffad0e">FINANCING ARRANGEMENTS&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net of Premiums, Discounts and Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net of Premiums, Discounts and Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Secured Credit Facilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023 Revolving Credit Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2025 Term Loan B Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2025 Term Loan B Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Secured Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.50% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.125% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.75% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;August 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.875% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Unsecured Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.125%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.00%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.00%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.00%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total long-term debt and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Current portion of long-term debt and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Covenant Compliance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Secured Credit Facilities (as defined below) and the indentures governing the Senior Secured Notes and Senior Unsecured Notes contain customary affirmative and negative covenants and specified events of default. These affirmative &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and negative covenants include, among other things, and subject to certain qualifications and exceptions, covenants that restrict the Company&#x2019;s ability and the ability of its subsidiaries to: incur or guarantee additional indebtedness; create or permit liens on assets; pay dividends on capital stock or redeem, repurchase or retire capital stock or subordinated indebtedness; make certain investments and other restricted payments; engage in mergers, acquisitions, consolidations and amalgamations; transfer and sell certain assets; and engage in transactions with affiliates. As of March&#160;31, 2022, the amount available for restricted payments under the &#x201c;builder basket&#x201d; in the Company&#x2019;s most restrictive indentures (as defined by those indentures) was approximately $13,900&#160;million (although such availability is subject to the Company&#x2019;s compliance with a 2.00:1.00 fixed charge coverage ratio). The 2023 Revolving Credit Facility (as defined below) also contains a financial maintenance covenant that, prior to giving effect to the Second Amendment (as defined below), required the Company to maintain a first lien net leverage ratio of not greater than 4.00:1.00. The financial maintenance covenant may be waived or amended without the consent of the term loan facility lenders and contains a customary term loan facility standstill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2022, the Company was in compliance with its financial maintenance covenant related to its debt obligations. The Company, based on its current forecast for the next twelve months from the date of issuance of these financial statements, expects to remain in compliance with its financial maintenance covenant and meet its debt service obligations over that same period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to take steps to improve its operating results to ensure continual compliance with its financial maintenance covenant and may take other actions to reduce its debt levels to align with the Company&#x2019;s long-term strategy, including divesting other businesses, refinancing debt and issuing equity or equity-linked securities as deemed appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Senior Secured Credit Facilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 1, 2018, the Company and certain of its subsidiaries as guarantors entered into the &#x201c;Senior Secured Credit Facilities&#x201d; under the Company&#x2019;s Fourth Amended and Restated Credit and Guaranty Agreement, as amended by the First Incremental Amendment to the Restated Credit Agreement, dated as of November 27, 2018 (the &#x201c;2018 Restated Credit Agreement&#x201d;) with a syndicate of financial institutions and investors as lenders. Prior to the Second Amendment (as defined below), the 2018 Restated Credit Agreement provided for a revolving credit facility of $1,225 million, maturing on the earlier of June 1, 2023 and the date that is 91 calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company and Bausch Health Americas, Inc. (&#x201c;BHA&#x201d;) in an aggregate principal amount in excess of $1,000 million (the &#x201c;2023 Revolving Credit Facility&#x201d;) and term loan facilities of original principal amounts of $4,565 million and $1,500 million, maturing in June 2025 (the &#x201c;June 2025 Term Loan B Facility&#x201d;) and November 2025 (the &#x201c;November 2025 Term Loan B Facility"), respectively. Both the Company and BHA were borrowers with respect to the 2023 Revolving Credit Facility. Borrowings under the 2023 Revolving Credit Facility could be made in U.S. dollars or Canadian dollars (or if an amendment to the 2018 Restated Credit Agreement was made to replace LIBOR with an alternative benchmark rate with respect to borrowings under the Revolving Credit Facility denominated in euros, euros). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Description of Senior Secured Credit Facilities as of March 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following description describes the 2018 Restated Credit Agreement as in effect on March 31, 2022, prior to giving effect to the Second Amendment (as defined below). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the Senior Secured Credit Facilities in U.S. dollars bear interest at a rate per annum equal to, at the Company&#x2019;s option, either: (i) a base rate determined by reference to the highest of: (a) the prime rate (as defined in the 2018 Restated Credit Agreement), (b) the federal funds effective rate plus 1/2 of 1.00% or (c) the eurocurrency rate (as defined in the 2018 Restated Credit Agreement) for a period of one month plus 1.00% (or if such eurocurrency rate shall not be ascertainable, 1.00%) or (ii) a eurocurrency rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing adjusted for certain additional costs (provided, however, that the eurocurrency rate shall at no time be less than 0.00% per annum), in each case plus an applicable margin. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the 2023 Revolving Credit Facility in euros, when available, are expected to bear interest at a term benchmark rate determined by reference to the costs of funds for euro deposits for the interest period relevant to such borrowing (provided, however, that the eurocurrency rate is at no time expected to be less than 0.00% per annum), plus an applicable margin. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the 2023 Revolving Credit Facility in Canadian dollars bear interest at a rate per annum equal to, at the Company&#x2019;s option, either: (i) a prime rate determined by reference to the higher of: (a) the rate of interest last quoted by The Wall Street Journal as the &#x201c;Canadian Prime Rate&#x201d; or, if The Wall Street Journal ceases to quote such rate, the highest per annum interest rate published by the Bank of Canada as its prime rate and (b) the 1 month BA rate (as defined below) calculated daily plus 1.00% (provided, however, that the prime rate shall at no time be less than 0.00%) or (ii) the bankers&#x2019; acceptance rate for Canadian dollar deposits in the Toronto interbank market (the &#x201c;BA rate&#x201d;) for the interest period relevant to such borrowing (provided, however, that the BA rate shall at no time be less than 0.00% per annum), in each case plus an applicable margin.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to certain exceptions and customary baskets set forth in the 2018 Restated Credit Agreement, the Company is required to make mandatory prepayments of the loans under the Senior Secured Credit Facilities under certain circumstances, including from: (i)&#160;100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold), (ii)&#160;100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the 2018 Restated Credit Agreement), (iii)&#160;50% of Excess Cash Flow (as&#160;defined in the 2018 Restated Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv)&#160;100% of net cash proceeds from asset sales (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold). These mandatory prepayments may be used to satisfy future amortization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The applicable interest rate margins for the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility are 2.00% and 1.75%, respectively, with respect to base rate and prime rate borrowings and 3.00% and 2.75%, respectively, with respect to eurocurrency rate and BA rate borrowings. As of March 31, 2022, the stated rates of interest on the Company&#x2019;s borrowings under the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility were 3.21% and 2.96% per annum, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortization rate for both the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility is 5.00% per annum. The Company may direct that prepayments be applied to such amortization payments in order of maturity. As of March 31, 2022, there were no remaining mandatory quarterly amortization payments for the Senior Secured Credit Facilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The applicable interest rate margins for borrowings under the 2023 Revolving Credit Facility are 1.50%-2.00% with respect to base rate or prime rate borrowings and 2.50%-3.00% with respect to eurocurrency rate or BA rate borrowings. As of March 31, 2022, the stated rate of interest on the 2023 Revolving Credit Facility was 2.96% per annum. As of March&#160;31, 2022, the Company had no outstanding borrowings, $54 million of issued and outstanding letters of credit and remaining availability of $1,171 million under its 2023 Revolving Credit Facility. In addition, the Company is required to pay commitment fees of 0.25%-0.50% per annum with respect to the unutilized commitments under the 2023 Revolving Credit Facility, payable quarterly in arrears. The Company also is required to pay: (i) letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on eurocurrency rate borrowings under the 2023 Revolving Credit Facility on a per annum basis, payable quarterly in arrears, (ii) customary fronting fees for the issuance of letters of credit and (iii) agency&#160;fees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2018 Restated Credit Agreement permits the incurrence of incremental credit facility borrowings up to the greater of $1,000 million and 28.5% of Consolidated Adjusted EBITDA (non-GAAP) (as defined in the 2018 Restated Credit Agreement), subject to customary terms and conditions, as well as the incurrence of additional incremental credit facility borrowings subject to, in the case of secured debt, a secured leverage ratio of not greater than 3.50:1.00, and, in the case of unsecured debt, either a total leverage ratio of not greater than 6.50:1.00 or an interest coverage ratio of not less than 2.00:1.00.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As more fully discussed in Note 20, &#x201c;SUBSEQUENT EVENTS&#x201d;, on May 10, 2022 in connection with the B+L IPO, the Company completed a series of transactions in which among other things: (i) Bausch + Lomb entered into a new credit facility, (ii) the Company repaid certain amounts outstanding under its existing term B loans, (iii) the Company refinanced the remaining amounts outstanding under its credit facilities and (iv) the Company discharged the indenture governing the 6.125% Senior Unsecured Notes due 2025 (the &#x201c;April 2025 Unsecured Notes&#x201d; and the related indenture the &#x201c;April 2025 Unsecured Notes Indenture&#x201d;) with, among other sources, the net proceeds from the February 2027 Secured Notes (defined below). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Senior Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Secured Notes are guaranteed by each of the Company&#x2019;s subsidiaries that is a guarantor under the 2018 Restated Credit Agreement and existing Senior Unsecured Notes (together, the &#x201c;Note Guarantors&#x201d;). In connection with the closing of the B+L IPO, the discharge of the 6.125% Notes Indenture and the related release in respect of the 2018 Restated Credit Agreement, the guarantees and related security provided by Bausch + Lomb and its subsidiaries in respect of the existing senior notes of the Company and BHA were released.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Secured Notes and the guarantees related thereto are senior obligations and are secured, subject to permitted liens and certain other exceptions, by the same first priority liens that secure the Company&#x2019;s obligations under the 2022 Restated Credit Agreement (as defined below) under the terms of the indentures governing the Senior Secured Notes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Secured Notes and the guarantees rank equally in right of repayment with all of the Company&#x2019;s and Note Guarantors&#x2019; respective existing and future unsubordinated indebtedness and senior to the Company&#x2019;s and Note Guarantors&#x2019; respective future subordinated indebtedness. The Senior Secured Notes and the guarantees related thereto are effectively &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;pari passu&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; with the Company&#x2019;s and the Note Guarantors&#x2019; respective existing and future indebtedness secured by a first priority &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;lien on the collateral securing the Senior Secured Notes and effectively senior to the Company&#x2019;s and the Note Guarantors&#x2019; respective existing and future indebtedness that is unsecured, including the existing Senior Unsecured Notes, or that is secured by junior liens, in each case to the extent of the value of the collateral. In addition, the Senior Secured Notes are structurally subordinated to: (i) all liabilities of any of the Company&#x2019;s subsidiaries that do not guarantee the Senior Secured Notes and (ii) any of the Company&#x2019;s debt that is secured by assets that are not collateral.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the occurrence of a change in control (as defined in the indentures governing the Senior Secured Notes), unless the Company has exercised its right to redeem all of the notes of a series, holders of the Senior Secured Notes may require the Company to repurchase such holder&#x2019;s notes, in whole or in part, at a purchase price equal to 101% of the principal amount thereof plus accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;4.875% Senior Secured Notes due 2028 - June 2021 Refinancing Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 8, 2021, the Company issued $1,600&#160;million aggregate principal amount of 4.875% Senior Secured Notes due June 2028 (the &#x201c;June 2028 Secured Notes&#x201d;) in a private placement. The proceeds and cash on hand were used to: (i) repurchase a portion and redeem the remainder of $1,600&#160;million of 7.00% Senior Secured Notes due 2024 (the &#x201c;March 2024 Secured Notes&#x201d;), representing the remaining outstanding principal balance of the March 2024 Secured Notes and (ii) pay all fees and expenses associated with these transactions (collectively, the &#x201c;June 2021 Refinancing Transactions&#x201d;). The June 2021 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $38&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#x2019;s carrying value. Interest on the June 2028 Secured Notes is payable semi-annually in arrears on each June 1 and December 1.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The June 2028 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after June 1, 2024, at the redemption prices set forth in the June 2028 Secured Notes indenture. The Company may redeem some or all of the June 2028 Secured Notes prior to June 1, 2024 at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest to, but not including, the date of the redemption plus a &#x201c;make-whole&#x201d; premium. In addition, at any time prior to June 1, 2024, the Company may redeem up to 40% of the aggregate principal amount of the June 2028 Secured Notes using the net proceeds of certain equity offerings at the redemption price set forth in the June 2028 Secured Notes indenture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;6.125% Senior Secured Notes due 2027 - February 2022 Financing&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 10, 2022, the Company issued $1,000&#160;million aggregate principal amount of 6.125% senior secured notes due February 2027 (the &#x201c;February 2027 Secured Notes&#x201d;). As discussed in further detail below, the proceeds from the February 2027 Secured Notes, along with proceeds from the B+L IPO, the 2027 Term Loans and the B+L Debt Financing (each as defined below) and cash on hand, were used to deposit funds sufficient to redeem in full all outstanding April 2025 Unsecured Notes and for the Credit Agreement Refinancing. The February 2027 Secured Notes accrue interest at a rate of 6.125% per year, payable semi-annually in arrears on each February and August. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The February 2027 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after February 2024, at the redemption prices set forth in the indenture. The Company may redeem some or all of the February 2027 Secured Notes prior to February 2024 at a price equal to 100% of the principal amount thereof plus a &#x201c;make-whole&#x201d; premium. Prior to February 2024, the Company may redeem up to 40% of the aggregate principal amount of the February 2027 Secured Notes using the proceeds of certain equity offerings at the redemption price set forth in the indenture.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Senior Unsecured Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Unsecured Notes issued by the Company are the Company&#x2019;s senior unsecured obligations and are jointly and severally guaranteed on a senior unsecured basis by each of its subsidiaries that is a guarantor under the Senior Secured Credit Facilities. The Senior Unsecured Notes issued by BHA are senior unsecured obligations of BHA and are jointly and severally guaranteed on a senior unsecured basis by the Company and each of its subsidiaries (other than BHA) that is a guarantor under the Senior Secured Credit Facilities. Future subsidiaries of the Company and BHA, if any, may be required to guarantee the Senior Unsecured Notes. In connection with the closing of the B+L IPO, the discharge of the April 2025 Unsecured Notes Indenture and the related release in respect of the 2018 Restated Credit Agreement, the guarantees and related security provided by Bausch + Lomb and its subsidiaries in respect of the existing senior notes of the Company and BHA were released.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company experiences a change in control, the Company may be required to make an offer to repurchase each series of Senior Unsecured Notes, in whole or in part, at a purchase price equal to 101% of the aggregate principal amount of the Senior Unsecured Notes repurchased, plus accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average Stated Rate of Interest&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average stated rate of interest for the Company&#x2019;s outstanding debt obligations as of March&#160;31, 2022 and December&#160;31, 2021 was 5.97% and 5.88%, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Maturities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of debt obligations for the remainder of 2022, the five succeeding years ending December&#160;31 and thereafter are as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized premiums, discounts and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt and other&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the closing of the B+L IPO, the conditions to the Company&#x2019;s previously announced redemption of its April 2025 Unsecured Notes were satisfied. On May 10, 2022, the Company caused sufficient funds for the redemption in full of the April 2025 Unsecured Notes at a redemption price of 101.021% of the principal amount thereof to be irrevocably deposited with the Bank of New York Mellon, N.A., as trustee under the April 2025 Unsecured Notes Indenture and the April 2025 Unsecured Notes was discharged. The April 2025 Unsecured Notes will be redeemed on May 16, 2022. In addition, as of May 10, 2022, the Company has drawn $350 million on the 2027 Revolving Credit Facility (defined below).&lt;/span&gt;&lt;/div&gt;This satisfaction and discharge, as well as the B+L Debt Financing, the Credit Agreement Refinancing and the borrowings under the 2027 Revolving Credit Facility (each as defined in Note 20, &#x201c;SUBSEQUENT EVENTS&#x201d;), are not reflected in the maturities table above.  See Note 20, &#x201c;SUBSEQUENT EVENTS&#x201d; for further details regarding these transactions.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTk1Njg_56b5e9b3-9869-4929-aea4-3f32010a437e">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net of Premiums, Discounts and Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net of Premiums, Discounts and Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Secured Credit Facilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023 Revolving Credit Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2025 Term Loan B Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2025 Term Loan B Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Secured Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.50% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.125% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.75% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;August 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.875% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Unsecured Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.125%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.00%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.00%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.00%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total long-term debt and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Current portion of long-term debt and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i76f9207c1db94dfbacf80f2bc2b52b0d_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMy00LTEtMS04OTA3Mg_fe888f9c-a59f-4e58-b338-7ff63cfcda85"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i76f9207c1db94dfbacf80f2bc2b52b0d_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMy02LTEtMS04OTA3Mg_12eba395-1ea3-4687-acee-018dae0612b2"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i06779efa67a44834b0f4f24944444a1b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMy04LTEtMS04OTA3Mg_8c46ac14-5d1e-431a-9c0d-12094e427e27"
      unitRef="usd">285000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i06779efa67a44834b0f4f24944444a1b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMy0xMC0xLTEtODkwNzI_466b4d54-4e2f-44cb-b422-467823ba4f02"
      unitRef="usd">285000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i782e0885b3064787aa9e926150c70157_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfNC00LTEtMS04OTA3Mg_3381560e-c59a-4296-b8b0-8e7527937bcb"
      unitRef="usd">2629000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i782e0885b3064787aa9e926150c70157_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfNC02LTEtMS04OTA3Mg_d261d49b-b2d1-48af-8d1c-8ee69c7e0fc7"
      unitRef="usd">2577000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ibc86294f39b245aebaa7bec35dc0f511_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfNC04LTEtMS04OTA3Mg_f81b18e0-ea65-484e-8cf2-3685d6a2ff75"
      unitRef="usd">2829000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ibc86294f39b245aebaa7bec35dc0f511_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfNC0xMC0xLTEtODkwNzI_4b282a0e-9948-4418-90f5-57cb43e98ee5"
      unitRef="usd">2772000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i54411522c1a245de9350f74e2cd4c3d1_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfNS00LTEtMS04OTA3Mg_99a2ec0c-0eae-4027-a94f-bb763cf9f8e8"
      unitRef="usd">994000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i54411522c1a245de9350f74e2cd4c3d1_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfNS02LTEtMS04OTA3Mg_3ae0111e-0da9-4d3f-ba23-d293060dc54f"
      unitRef="usd">985000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1632bbe90c084a8bbad28b27f64c1f85_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfNS04LTEtMS04OTA3Mg_4d324e1a-9cdf-4af2-9318-2133aaacd748"
      unitRef="usd">994000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i1632bbe90c084a8bbad28b27f64c1f85_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfNS0xMC0xLTEtODkwNzI_fd07aa38-51e0-4150-9b71-d92ffb8d9536"
      unitRef="usd">984000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic53f52344dcd464f82fdd9233f9e3fbb_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfOC0wLTEtMS04OTA3Mi90ZXh0cmVnaW9uOjkxNTc1ZGNmMmZjODRkOWE4YWUyNmI4YzA2OTg1NmU4XzQ_288a7759-a31b-4e05-9bb0-1e0206e9f449"
      unitRef="number">0.0550</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic53f52344dcd464f82fdd9233f9e3fbb_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfOC00LTEtMS04OTA3Mg_22564be4-84e4-4efc-9665-ed8bed40b965"
      unitRef="usd">1750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ic53f52344dcd464f82fdd9233f9e3fbb_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfOC02LTEtMS04OTA3Mg_0eeed0b4-3f2a-45ef-9063-54b3fc65525f"
      unitRef="usd">1740000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i488c2864915b43b0b468383a88a34995_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfOC04LTEtMS04OTA3Mg_a8cfffbd-c2f3-4126-853d-6b27e8595f07"
      unitRef="usd">1750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i488c2864915b43b0b468383a88a34995_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfOC0xMC0xLTEtODkwNzI_463ad2f6-ab66-4ff1-9aec-a1205be46889"
      unitRef="usd">1739000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i09bbf996de02471991c5b856e064297d_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfOS0wLTEtMS05MzQxMy90ZXh0cmVnaW9uOjVjZTk2ZmFjMjg4MzRkNzNiOTU2YzRkZWY2OWRkZTc4XzE2NDkyNjc0NDE2OTQ_15d04dec-ea40-41ab-b696-e9fc56febb54"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i09bbf996de02471991c5b856e064297d_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfOS00LTEtMS05MzQwMw_08d7265b-76f8-4d97-b4d9-bd7578a6fd74"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i09bbf996de02471991c5b856e064297d_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfOS02LTEtMS05MzQwMw_540c58ed-94b8-48bb-91ce-0cbe3c226b93"
      unitRef="usd">986000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1ba04ab2a63c40b39e946e401067a3d9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfOS04LTEtMS05MzQwMw_70acc2e7-6981-4125-8486-d8fe1b2a6a91"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i1ba04ab2a63c40b39e946e401067a3d9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfOS0xMC0xLTEtOTM0MDM_23400e97-94cb-40aa-b248-f538942df38f"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="icfa4659d82fd4e9583cb868b85c3feab_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfOS0wLTEtMS04OTA3Mi90ZXh0cmVnaW9uOjRlMmQ0MGRiMjBiMDRjOGFhODIyNTU2M2Q4OTU5MmJjXzQ_6901e661-c1ac-4ae7-80ef-1bb67d1f9296"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="icfa4659d82fd4e9583cb868b85c3feab_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfOS00LTEtMS04OTA3Mg_3d29c69c-9c7c-4610-9b07-6d73eda3292d"
      unitRef="usd">500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="icfa4659d82fd4e9583cb868b85c3feab_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfOS02LTEtMS04OTA3Mg_7eb4757b-f5a7-48e1-92fe-275040868b29"
      unitRef="usd">495000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ie9b94284819448b1933c562ef7aded08_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfOS04LTEtMS04OTA3Mg_db2c6c76-e89e-454f-87ce-2cf53911e708"
      unitRef="usd">500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ie9b94284819448b1933c562ef7aded08_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfOS0xMC0xLTEtODkwNzI_c2457a1c-fdc3-4973-9a9a-d29ba53a4bf1"
      unitRef="usd">495000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2abc875715cb4b1fa661daa27ac2f5af_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTAtMC0xLTEtODkwNzIvdGV4dHJlZ2lvbjo5YWQ1YzQ4NGQzNjc0ZjBjYmI0ZWFhNjg2MTBkYzQ1ZF80_c1f56975-77cd-434b-882b-d3b0afd97f4d"
      unitRef="number">0.04875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2abc875715cb4b1fa661daa27ac2f5af_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTAtNC0xLTEtODkwNzI_a2438bd5-b52f-4d4e-9005-b325d9a78f27"
      unitRef="usd">1600000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i2abc875715cb4b1fa661daa27ac2f5af_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTAtNi0xLTEtODkwNzI_1efd8306-0d5b-456b-8425-948959805433"
      unitRef="usd">1581000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic574f713857543fe848f75d40d04e380_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTAtOC0xLTEtODkwNzI_2f04d12c-0bc8-47b3-8853-8ea273d31d82"
      unitRef="usd">1600000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ic574f713857543fe848f75d40d04e380_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTAtMTAtMS0xLTg5MDcy_0d35d2b4-0e34-41fc-af39-8dff642c6e04"
      unitRef="usd">1580000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i379ff2b3df7445b5b936e826c3995957_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTItMC0xLTEtODkwNzIvdGV4dHJlZ2lvbjplYjY1NDNkMjY1OTk0MWYzYWNmNjRhNWRjMjllMzUwYV80_472c0a85-35c6-46dc-b060-4e8397c0f00e"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i379ff2b3df7445b5b936e826c3995957_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTItNC0xLTEtODkwNzI_82dd316d-1315-48db-aefe-6bfbfab6db82"
      unitRef="usd">2650000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i379ff2b3df7445b5b936e826c3995957_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTItNi0xLTEtODkwNzI_457e08d5-f170-468b-95f2-19e9d88162a2"
      unitRef="usd">2640000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i247336064728420fafc7c84febff7ebc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTItOC0xLTEtODkwNzI_df3e7d2e-1b93-48d0-8121-1e8175dbee9e"
      unitRef="usd">2650000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i247336064728420fafc7c84febff7ebc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTItMTAtMS0xLTg5MDcy_70d26337-7132-4d23-b2c7-4ebfd7f1e0b1"
      unitRef="usd">2640000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib2f961c12b854470a0cc36e07e92006e_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTMtMC0xLTEtODkwNzIvdGV4dHJlZ2lvbjphZmU0YTZkYmJmYjI0Nzc5OTI1MDUwYWZlZWRhZjEwN180_9af6e74c-c446-46bb-b278-e8a9a54c7899"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib2f961c12b854470a0cc36e07e92006e_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTMtNC0xLTEtODkwNzI_b0b679ce-70f1-412a-959c-ccc18b54ded2"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ib2f961c12b854470a0cc36e07e92006e_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTMtNi0xLTEtODkwNzI_ceea6daf-2622-441a-9ade-a3e141d159e0"
      unitRef="usd">1483000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i7146a1406b5149a0897a90ac7344b1bb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTMtOC0xLTEtODkwNzI_22a0a136-5de9-437f-a520-5222d7c76e5e"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i7146a1406b5149a0897a90ac7344b1bb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTMtMTAtMS0xLTg5MDcy_a78dbe6d-9477-4ae8-82f0-a286e766acfc"
      unitRef="usd">1482000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1b4545d9fb57437bbacc0e55479da783_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTQtMC0xLTEtODkwNzIvdGV4dHJlZ2lvbjpkNGYzNjA1MzRlODc0OWQ1OTdmYTg4NmU0ZWUxZGMyMl80_931d978d-ed36-4b0f-b5ee-6efdf4acf3fe"
      unitRef="number">0.0925</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1b4545d9fb57437bbacc0e55479da783_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTQtNC0xLTEtODkwNzI_1416fef8-fe1f-464f-86b4-9d7941994925"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i1b4545d9fb57437bbacc0e55479da783_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTQtNi0xLTEtODkwNzI_dd83b562-94cf-43b7-b1b6-b0bdb25f5ae3"
      unitRef="usd">1490000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2f68bb5402fa40aaa3d1e8a5876a1481_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTQtOC0xLTEtODkwNzI_693c00f9-b02d-4067-a406-6e3da7df2e0f"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i2f68bb5402fa40aaa3d1e8a5876a1481_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTQtMTAtMS0xLTg5MDcy_735fcde5-6839-4903-9f04-42afb7ddeb0a"
      unitRef="usd">1489000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6b5e0bf7441145f3a22ac4510e73101b_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTUtMC0xLTEtODkwNzIvdGV4dHJlZ2lvbjplMDE4YjZhZDgxZTE0YzA5YjZjYmJkZTVmYjJiNWY1MV80_7ee06571-bdad-420c-b27d-4820a1ffe2ac"
      unitRef="number">0.0850</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i6b5e0bf7441145f3a22ac4510e73101b_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTUtNC0xLTEtODkwNzI_c00621f0-70a9-454b-9c17-5908ea02a3b8"
      unitRef="usd">1750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i6b5e0bf7441145f3a22ac4510e73101b_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTUtNi0xLTEtODkwNzI_35224b34-d725-46cd-965b-21be94491e99"
      unitRef="usd">1754000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia02b8e8095664970aeeda0fcc527bb86_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTUtOC0xLTEtODkwNzI_2afc085d-e85e-4167-bb77-875b9a3d9e14"
      unitRef="usd">1750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ia02b8e8095664970aeeda0fcc527bb86_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTUtMTAtMS0xLTg5MDcy_433b673f-5868-4426-91da-f72eb94f003b"
      unitRef="usd">1754000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5833ace0facf472a8cf1a49a6becbe8d_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTYtMC0xLTEtODkwNzIvdGV4dHJlZ2lvbjpkODhhZGE3OGMzMWY0YzM1YmI0NGZiYTE5Zjk4ZjZiOF80_d2abc2d7-cdfc-49b0-829d-a1f6f655b3f8"
      unitRef="number">0.0700</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5833ace0facf472a8cf1a49a6becbe8d_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTYtNC0xLTEtODkwNzI_a27f1d66-b6bd-45b4-9921-0ec4c4779a2e"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i5833ace0facf472a8cf1a49a6becbe8d_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTYtNi0xLTEtODkwNzI_838e475f-7812-4fea-8045-6dccddff3878"
      unitRef="usd">743000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i4758100c83ee4d7f82d179bcb44516dd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTYtOC0xLTEtODkwNzI_1260d079-b593-4ac6-910f-b4ebadd54ec6"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i4758100c83ee4d7f82d179bcb44516dd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTYtMTAtMS0xLTg5MDcy_11338064-18ee-49bc-8a0e-4162acf2aa4e"
      unitRef="usd">743000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="icb63f20c4f224de380f590b991ab70bd_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTctMC0xLTEtODkwNzIvdGV4dHJlZ2lvbjo4OTJmNTIxYjZlYmQ0YmE5YjM5YmVlODJmOTFiYzc5MV80_90a017a9-263e-496d-8eaf-1a11eddc1dc8"
      unitRef="number">0.0500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="icb63f20c4f224de380f590b991ab70bd_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTctNC0xLTEtODkwNzI_c27b60cb-f219-4496-903a-6a32de2d515f"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="icb63f20c4f224de380f590b991ab70bd_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTctNi0xLTEtODkwNzI_2224737f-058c-412b-81f1-08f8a2aa299b"
      unitRef="usd">1238000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia6a900b7cea44342b2ebea58f9a1a829_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTctOC0xLTEtODkwNzI_a4b62ea0-8b2c-4bee-a62f-cd701fef4644"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ia6a900b7cea44342b2ebea58f9a1a829_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTctMTAtMS0xLTg5MDcy_4b7625cd-3c84-4ace-94f9-bce44cea4afb"
      unitRef="usd">1238000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0a9e5ff5b17847ae8c5b4a20045b80a7_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTgtMC0xLTEtODkwNzIvdGV4dHJlZ2lvbjplNWEyMGZmZTFhMmQ0Y2VkYTZiZGE0YWU3Mjg1MTVmNV80_cb2775a0-d07e-4095-99c2-ce98b6dbb168"
      unitRef="number">0.0625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0a9e5ff5b17847ae8c5b4a20045b80a7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTgtNC0xLTEtODkwNzI_7c52ef51-c087-466c-8c92-a279a3ea329e"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i0a9e5ff5b17847ae8c5b4a20045b80a7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTgtNi0xLTEtODkwNzI_aaa6d7fb-e5cf-4ebf-8dee-e969de2fde31"
      unitRef="usd">1484000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iaa9fb491c6f44e0494c78843ae2d7d07_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTgtOC0xLTEtODkwNzI_32bb3e2d-c836-4242-ac93-c7339da58e12"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="iaa9fb491c6f44e0494c78843ae2d7d07_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTgtMTAtMS0xLTg5MDcy_0c90b3c4-fc8b-42d9-b805-c4006b36923f"
      unitRef="usd">1483000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic9d48b1e660749f7a7367bb5dc150e1b_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTktMC0xLTEtODkwNzI_70ce870a-f4fa-4e1e-998f-038df23d8bfc"
      unitRef="number">0.0500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic9d48b1e660749f7a7367bb5dc150e1b_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTktNC0xLTEtODkwNzI_2bb64a4a-cc87-4368-95f2-80b16b3a2108"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ic9d48b1e660749f7a7367bb5dc150e1b_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTktNi0xLTEtODkwNzI_7094bf2d-e9eb-4485-a631-a6e797660d2c"
      unitRef="usd">990000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i3ab99de7a1954ce6996bda7caf7833a8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTktOC0xLTEtODkwNzI_86e75585-d0eb-4670-8472-9d88e34d99bc"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i3ab99de7a1954ce6996bda7caf7833a8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMTktMTAtMS0xLTg5MDcy_b7f83aef-de8d-42f7-bcb6-185000c3f208"
      unitRef="usd">990000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib88817449df74848a8baeff6c02361f9_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjAtMC0xLTEtODkwNzIvdGV4dHJlZ2lvbjo3NjA5M2MwMjEyZWI0ZmUyOTcyMDk4ZDljYTBkMjNkZl80_2fe58e5e-19db-42b5-b100-14974d1356fe"
      unitRef="number">0.0725</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib88817449df74848a8baeff6c02361f9_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjAtNC0xLTEtODkwNzI_6fbb7bd4-5297-4638-9466-2e5dd6e5dee6"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ib88817449df74848a8baeff6c02361f9_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjAtNi0xLTEtODkwNzI_6c6c9b23-a3bf-4821-864e-1abfa8de1fb4"
      unitRef="usd">743000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i4341fd255afd4b2f98811eb433952df1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjAtOC0xLTEtODkwNzI_bf095778-aaf9-481b-8e9b-21193c55762f"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i4341fd255afd4b2f98811eb433952df1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjAtMTAtMS0xLTg5MDcy_b863272a-60f7-45d1-9893-d7019f48dbb6"
      unitRef="usd">742000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i51f3dd4e5a524f1bbf10cd1a0055202c_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjEtMC0xLTEtODkwNzIvdGV4dHJlZ2lvbjpkMTM4MzZkNTNhMzI0NTBlYmEyODJkYzNhMGY3YTI4OF80_5497538c-5819-489d-8a26-5832d8ab6525"
      unitRef="number">0.0525</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i51f3dd4e5a524f1bbf10cd1a0055202c_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjEtNC0xLTEtODkwNzI_5ff71bdd-b141-473c-a390-795fea864330"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i51f3dd4e5a524f1bbf10cd1a0055202c_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjEtNi0xLTEtODkwNzI_1ad3cd5b-8609-4581-a423-16197760dd95"
      unitRef="usd">1237000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5ee2ed402ff54a6f843446ee188a72d8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjEtOC0xLTEtODkwNzI_bca4165a-e2de-4b9b-8b0d-42ccda86ba09"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i5ee2ed402ff54a6f843446ee188a72d8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjEtMTAtMS0xLTg5MDcy_d64b5077-b52c-4eed-9db9-baa8b4f3380e"
      unitRef="usd">1237000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if151bdb884d34ff6b871d14b1339db96_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjItMC0xLTEtODkwNzI_11e715de-e8a1-4b2b-b6f4-2d2bec164e2f"
      unitRef="number">0.0525</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if151bdb884d34ff6b871d14b1339db96_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjItNC0xLTEtODkwNzI_0d5b9232-f5c5-4c71-9ff8-5f7816517b97"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="if151bdb884d34ff6b871d14b1339db96_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjItNi0xLTEtODkwNzI_1d5ca0d5-f947-4720-9592-537eac69e906"
      unitRef="usd">990000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i504ae7293b234304b31a5f5ef8da3011_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjItOC0xLTEtODkwNzI_b2a01c9b-b8a2-4312-93a7-84e6318f6646"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i504ae7293b234304b31a5f5ef8da3011_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjItMTAtMS0xLTg5MDcy_1f84a327-be92-44aa-9a1f-de033d7bee95"
      unitRef="usd">989000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if31b5959255941138da93ebd548669bb_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjMtNC0xLTEtODkwNzI_87abbdf4-681a-4fe3-8ab4-ab7c6222c1ef"
      unitRef="usd">12000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="if31b5959255941138da93ebd548669bb_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjMtNi0xLTEtODkwNzI_27768a34-6f3a-4884-a70f-62b0b862132d"
      unitRef="usd">12000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1cee80bfcbe74e0c8421a1c67604dccd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjMtOC0xLTEtODkwNzI_a555f3e4-2f30-4fa4-9b60-22f04d0def04"
      unitRef="usd">12000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i1cee80bfcbe74e0c8421a1c67604dccd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjMtMTAtMS0xLTg5MDcy_79aa8c1a-2844-4cd7-8eb9-e2bb6ff0d806"
      unitRef="usd">12000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjQtNC0xLTEtODkwNzI_3073f3f4-f28e-4b01-bdbd-501a556d1ecb"
      unitRef="usd">23385000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjQtNi0xLTEtODkwNzI_990b78f3-7cf0-4fee-81a9-967768f87697"
      unitRef="usd">23168000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjQtOC0xLTEtODkwNzI_45471997-fae5-4118-a106-4b7d250597d5"
      unitRef="usd">22870000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjQtMTAtMS0xLTg5MDcy_91885a60-bc2a-44fc-9714-53c05b2fa8bd"
      unitRef="usd">22654000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjUtNi0xLTEtODkwNzI_18eefa7b-afc6-430a-8575-54552d86e1c5"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjUtMTAtMS0xLTg5MDcy_a9782ead-8094-4703-b319-4abd7cb1b0e6"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjYtNi0xLTEtODkwNzI_fe25b7e2-2614-40a9-b569-b866bcf656f9"
      unitRef="usd">23168000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmNmOWM2MDdjNTAxMTQ4ZDc4NjI5OWEzMzg2NzE2ZDRmL3RhYmxlcmFuZ2U6Y2Y5YzYwN2M1MDExNDhkNzg2Mjk5YTMzODY3MTZkNGZfMjYtMTAtMS0xLTg5MDcy_61cd208e-ecb5-430a-b67e-e0378871a03a"
      unitRef="usd">22654000000</us-gaap:LongTermDebtNoncurrent>
    <bhc:DebtInstrumentCovenantAmountAvailableForRestrictedPayments
      contextRef="i3baf0d17d1ce4fb09e14886b74b202be_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTIwMQ_58c19394-416c-4c68-9ab4-e801d9965526"
      unitRef="usd">13900000000</bhc:DebtInstrumentCovenantAmountAvailableForRestrictedPayments>
    <bhc:DebtInstrumentCovenantTermsFixedChargeCoverageRatio
      contextRef="ibd8b2b705a834db0850fd8a5ff15144a_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTI3OA_6c9d0336-4fc9-4a81-ac26-09326bf43ce9"
      unitRef="number">2.00</bhc:DebtInstrumentCovenantTermsFixedChargeCoverageRatio>
    <bhc:DebtInstrumentCovenantComplianceSecuredLeverageRatio
      contextRef="ibd8b2b705a834db0850fd8a5ff15144a_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTUwNw_c73c5d33-79f1-44df-831c-a939fdaef05d"
      unitRef="number">4.00</bhc:DebtInstrumentCovenantComplianceSecuredLeverageRatio>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i6c325805e88f46bb919acf58b5da907e_I20180601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMjk0Ng_1525bb68-ad51-451f-b1ca-1cd4ab1ea7a4"
      unitRef="usd">1225000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <bhc:DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold
      contextRef="ic7609d2be3db44f5af9ae6b7c8e642b7_D20180601-20180601"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMzAxNg_76965e29-82c5-4099-bf87-c4afc3fcc0c7">P91D</bhc:DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold>
    <bhc:DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold
      contextRef="i6c325805e88f46bb919acf58b5da907e_I20180601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMzIwMg_acdddc1b-1287-4332-ad63-d04f89d320d6"
      unitRef="usd">1000000000</bhc:DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i805461905703413cb5837246f45f0ab6_I20180601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMzMwMg_03b0b056-f70e-46d4-a8b5-aad7ab573602"
      unitRef="usd">4565000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i9f9d786ce6b041f08ba221a702f7956d_I20180601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMzMwOQ_162563f5-2a9e-4280-a414-e4455821061b"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i9ec4d9258ade4c988572b72ab0b9bcda_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNDA5Ng_e8dcf7af-697c-40b6-a314-341f6a8111bf"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i9ec4d9258ade4c988572b72ab0b9bcda_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNDE1Nw_bcd56faa-481d-4cfe-aa50-40c5d83c88c2"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i50ea92505146474394a150389011b6f2_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNDQyNg_382719af-f27b-47c3-8a17-81c6f39b80dd"
      unitRef="number">0.0000</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i87085be380954b8f8d3c8aca38e1f32f_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNDc3Mg_506dfa18-d17b-4b79-a349-07354cd6e5d1"
      unitRef="number">0.0000</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i3f1641e5674c4a75b682c9b185796d5c_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNTMyOQ_56422655-09d9-4232-aafc-a83ed2cff1d5"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i9578b054a9c3434d956829eb311cdcd5_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNTQwMg_bf8c8cad-55dc-4a4f-8a0d-416f3252dd13"
      unitRef="number">0.0000</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i9578b054a9c3434d956829eb311cdcd5_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNTYzOA_446a3bb7-cff1-4a3e-8c3d-7cb57bb19118"
      unitRef="number">0.0000</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <bhc:DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet
      contextRef="i615747c5edca4f728ff0d5d6e3cdb38d_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNTk0OA_8024e04d-858b-4898-9f64-517c304a16ea"
      unitRef="number">1</bhc:DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet>
    <bhc:DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet
      contextRef="i615747c5edca4f728ff0d5d6e3cdb38d_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNjExMA_c8f3d6c2-66cb-4f40-8c85-b4598611d399"
      unitRef="number">1</bhc:DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet>
    <bhc:DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet
      contextRef="i615747c5edca4f728ff0d5d6e3cdb38d_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNjI0Nw_b9648f0b-bfe4-4bd3-b956-ff609b3a3967"
      unitRef="number">0.50</bhc:DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet>
    <bhc:DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet
      contextRef="i615747c5edca4f728ff0d5d6e3cdb38d_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNjQwNA_86d34293-ab6d-4d5a-a942-e394b998d83e"
      unitRef="number">1</bhc:DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ibb673f79152245ccaaa71c72c83aca5f_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNjYxNA_3b63623e-d6d7-4256-9a36-1e2e74cb0d33"
      unitRef="number">0.0200</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="if9f46032075146bb974b5459828d0837_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNjYyMQ_b5b73469-3dde-4c90-9204-bd524d2cd477"
      unitRef="number">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="iebb71b6e150a4d3583b70be11293ebbb_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNjY5NQ_a1ea0d0d-b6e1-4b76-bb9c-c01857b834c6"
      unitRef="number">0.0300</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i88f4e8e6d2a74bb3bbf6df6210d11118_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNjcwMg_559fd51a-1b4b-44b2-af05-913ba5618eeb"
      unitRef="number">0.0275</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i782e0885b3064787aa9e926150c70157_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNjg2OA_add41a76-fd12-4f0e-8d8a-1f3a11e16102"
      unitRef="number">0.0321</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i54411522c1a245de9350f74e2cd4c3d1_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNjg3NQ_ba860b99-5278-4b00-adf8-c86455ad8af2"
      unitRef="number">0.0296</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <bhc:DebtInstrumentAnnualAmortizationRatePercentage
      contextRef="i54411522c1a245de9350f74e2cd4c3d1_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNjk1NQ_468e20f9-f22f-4847-91fc-ae236e94726b"
      unitRef="number">0.0500</bhc:DebtInstrumentAnnualAmortizationRatePercentage>
    <bhc:DebtInstrumentAnnualAmortizationRatePercentage
      contextRef="i782e0885b3064787aa9e926150c70157_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNjk1NQ_d1f1b011-dd1c-47ac-9318-8ead563ca266"
      unitRef="number">0.0500</bhc:DebtInstrumentAnnualAmortizationRatePercentage>
    <bhc:DebtInstrumentPeriodicPaymentQuarterlyAmortization
      contextRef="ifce02581a2a24dcf8c3af7034d61d45b_D20220331-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNzA4Nw_b11f2d71-44c6-4537-b58f-2f7b361bbe1e"
      unitRef="usd">0</bhc:DebtInstrumentPeriodicPaymentQuarterlyAmortization>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i20665638c329437cab38c53e8d90d29b_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNzI4MQ_b3526a1a-4451-495f-aea6-c6ab0dd3ad30"
      unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i15c4387da4984e3890700c3445ff56f7_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNzI4NA_13fb0a9e-aa06-4241-a204-79638690aa1f"
      unitRef="number">0.0200</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ibd749185fb814c7eb0ea4622273efa10_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNzM0Mg_ca0ff2f1-9a64-410c-85e1-c6d285b77839"
      unitRef="number">0.0250</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i2b1c2edd6efe487a80e89a2e9dfacbc3_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNzM0NQ_2cf8d677-c1f4-4b20-b585-e641795bdce6"
      unitRef="number">0.0300</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i76f9207c1db94dfbacf80f2bc2b52b0d_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNzQ4MA_ebfc81d0-9400-49ce-a49d-4e136dd7be98"
      unitRef="number">0.0296</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i76f9207c1db94dfbacf80f2bc2b52b0d_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNzUyMA_1a992a18-b0f4-455f-9e5b-1e1befad0a00"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ie92612a0f96b4f89b84ac22fb594d512_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNzU0Nw_37b7c9fa-cfa1-4a8e-b4c7-d174365fd09b"
      unitRef="usd">54000000</us-gaap:LongTermDebt>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="i76f9207c1db94dfbacf80f2bc2b52b0d_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNzYyNA_aa119e01-55a6-4396-a41e-c41c92e5296d"
      unitRef="usd">1171000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i891a2d21f1024827aa29f1df940ffbb3_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNzczMg_8dc705e2-b071-4bb4-890c-a6ebc0a83bf3"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="ib8602535e6b14704b3f07b216531b82d_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfNzczNQ_2844464e-ee65-4884-a63a-9f90551b70c1"
      unitRef="number">0.0050</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <bhc:LineOfCreditFacilityThresholdForIncrementalBorrowings
      contextRef="ibd8b2b705a834db0850fd8a5ff15144a_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfODM4NQ_361ba02e-c35a-4a6f-94c0-088fae091a1b"
      unitRef="usd">1000000000</bhc:LineOfCreditFacilityThresholdForIncrementalBorrowings>
    <bhc:LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA
      contextRef="ibd8b2b705a834db0850fd8a5ff15144a_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfODM5Mg_341fad45-d3dd-4fd2-8bc4-4f209389eacb"
      unitRef="number">0.285</bhc:LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA>
    <bhc:DebtInstrumentCovenantComplianceSecuredLeverageRatio
      contextRef="i8a1cfa5016e04bb3a7bc13c20a921226_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfODY2Mw_062b7c56-48b4-44eb-850a-4dfef41e5a6d"
      unitRef="number">3.50</bhc:DebtInstrumentCovenantComplianceSecuredLeverageRatio>
    <bhc:DebtInstrumentCovenantTotalLeverageRatioMaximum
      contextRef="i730cebd5276140a781d756138d28a05d_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfODc0OQ_41bf1a75-8163-4483-b66c-e9afd0e4b4ba"
      unitRef="number">6.50</bhc:DebtInstrumentCovenantTotalLeverageRatioMaximum>
    <bhc:DebtInstrumentCovenantInterestCoverageRatioMinimum
      contextRef="ibd8b2b705a834db0850fd8a5ff15144a_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfODgwMg_3c676794-b448-4bd5-9fe7-fd854efb351f"
      unitRef="number">2.00</bhc:DebtInstrumentCovenantInterestCoverageRatioMinimum>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3525c40548924586bbd17234ab1c71c3_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTY0OTI2NzQ0NzY1Mjc_8d665c34-d4ef-4214-8095-73452d08f215"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <bhc:DebtInstrumentRedemptionPricePercentageChangeinControl
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTA3Nzk_ccade392-161d-47ca-85c7-1a3ca52b6f8e"
      unitRef="number">1.01</bhc:DebtInstrumentRedemptionPricePercentageChangeinControl>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iad4d39b309f5434c87cf47a080a1d040_I20210608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTA4NDg_91340a77-1ad3-4aaf-8f45-18d5985800c3"
      unitRef="number">0.04875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iad4d39b309f5434c87cf47a080a1d040_I20210608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTA5NTQ_424d0248-d98d-4748-be20-f69396f4be4e"
      unitRef="usd">1600000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iad4d39b309f5434c87cf47a080a1d040_I20210608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTA5ODc_91340a77-1ad3-4aaf-8f45-18d5985800c3"
      unitRef="number">0.04875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ibcbf9946c1974457a0c4173198dc2413_D20210608-20210608"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTExNzg_ab981e7a-a2e4-46ab-9e99-0ea2162b4a18"
      unitRef="usd">1600000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia2fbd73a42e346bea819f0b583f98618_I20210608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTExODQ_a0a48210-f14b-4c60-9d8d-6e34aabfe4bd"
      unitRef="number">0.0700</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i95e73196dfe44ca6bb964e033fa104f5_D20210608-20210608"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTE2MTY_44e3695c-02f1-47a7-9c0d-8efbbfd58f51"
      unitRef="usd">-38000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i88e8d3f432e14718a0ba0ed393f9efbf_D20210608-20210608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTIxNzE_46a57b00-7b3f-42fc-b415-59d558c432a5"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="if8673b92629a48189ea708c9a312bfe5_D20210608-20210608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTIzOTY_a4284ee9-b487-428d-9854-e00f5c170ca0"
      unitRef="number">0.40</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if16401eb786046228b3c642b80d44636_I20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTY0OTI2NzQ2OTEwNg_80a190a5-0e66-4d95-8cca-08348a690ac6"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="if16401eb786046228b3c642b80d44636_I20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTY0OTI2NzQ3MDA2Nw_c47df40f-d8aa-4300-9bff-d813cd303ec3"
      unitRef="usd">1000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if16401eb786046228b3c642b80d44636_I20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTA5OTUxMTY4MjExNQ_e46f2da0-472e-4620-9a97-43f4e9cede50"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if16401eb786046228b3c642b80d44636_I20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTA5OTUxMTY4MjEyNA_e46f2da0-472e-4620-9a97-43f4e9cede50"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="ie0fb622b80e1461e88f672d0cba387ac_D20220210-20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTA0NDUzNjA1MTIzMTk_114c7f69-30c6-484f-8fad-a38cce263bfc"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="ida33ef4fd5a74725af4144c875055297_D20220210-20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTA0NDUzNjA1MTIzMjU_c9d5b81c-c785-480a-ae71-14f6e7ebf48a"
      unitRef="number">0.40</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <bhc:DebtInstrumentRedemptionPricePercentageChangeinControl
      contextRef="ice4047eb87914dd280d3a5673cae9b27_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTM0NTE_1247d314-4881-46bc-b277-515b598f1387"
      unitRef="number">1.01</bhc:DebtInstrumentRedemptionPricePercentageChangeinControl>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTg3NzA_9c82a978-0810-4a9c-ae7f-bb126d350215"
      unitRef="number">0.0597</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTg3Nzc_a446f902-9e73-45e3-a8c6-5a5316babcce"
      unitRef="number">0.0588</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTk1ODE_1221231d-bd27-43b7-8ce9-e5b05f31733a">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of debt obligations for the remainder of 2022, the five succeeding years ending December&#160;31 and thereafter are as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized premiums, discounts and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt and other&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmEyOTRjZTNjMDI1MzRkYTc5MDEyYzE1NGViYjAxNWI2L3RhYmxlcmFuZ2U6YTI5NGNlM2MwMjUzNGRhNzkwMTJjMTU0ZWJiMDE1YjZfMS0xLTEtMS04OTA3Mg_c054e93f-465a-4cd3-98db-4d5a6c9f6b0f"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmEyOTRjZTNjMDI1MzRkYTc5MDEyYzE1NGViYjAxNWI2L3RhYmxlcmFuZ2U6YTI5NGNlM2MwMjUzNGRhNzkwMTJjMTU0ZWJiMDE1YjZfMi0xLTEtMS04OTA3Mg_fb13e426-e2bc-4456-8c29-89763bf50d0f"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmEyOTRjZTNjMDI1MzRkYTc5MDEyYzE1NGViYjAxNWI2L3RhYmxlcmFuZ2U6YTI5NGNlM2MwMjUzNGRhNzkwMTJjMTU0ZWJiMDE1YjZfMy0xLTEtMS04OTA3Mg_fd233b9b-c50c-49e6-b437-84a7ba4601a2"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmEyOTRjZTNjMDI1MzRkYTc5MDEyYzE1NGViYjAxNWI2L3RhYmxlcmFuZ2U6YTI5NGNlM2MwMjUzNGRhNzkwMTJjMTU0ZWJiMDE1YjZfNC0xLTEtMS04OTA3Mg_16b1a4b5-824c-49c5-9d83-ec38dd0ff7b4"
      unitRef="usd">9523000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmEyOTRjZTNjMDI1MzRkYTc5MDEyYzE1NGViYjAxNWI2L3RhYmxlcmFuZ2U6YTI5NGNlM2MwMjUzNGRhNzkwMTJjMTU0ZWJiMDE1YjZfNS0xLTEtMS04OTA3Mg_cb71bd2e-be07-4fff-be41-22004dd2c41a"
      unitRef="usd">1500000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmEyOTRjZTNjMDI1MzRkYTc5MDEyYzE1NGViYjAxNWI2L3RhYmxlcmFuZ2U6YTI5NGNlM2MwMjUzNGRhNzkwMTJjMTU0ZWJiMDE1YjZfNi0xLTEtMS04OTA3Mg_cfcd2bd9-cd8d-499e-b1dc-717022629fa7"
      unitRef="usd">3250000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmEyOTRjZTNjMDI1MzRkYTc5MDEyYzE1NGViYjAxNWI2L3RhYmxlcmFuZ2U6YTI5NGNlM2MwMjUzNGRhNzkwMTJjMTU0ZWJiMDE1YjZfNy0xLTEtMS04OTA3Mg_935af95a-23c6-4e46-bb0a-f1526284e0c5"
      unitRef="usd">9112000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmEyOTRjZTNjMDI1MzRkYTc5MDEyYzE1NGViYjAxNWI2L3RhYmxlcmFuZ2U6YTI5NGNlM2MwMjUzNGRhNzkwMTJjMTU0ZWJiMDE1YjZfOC0xLTEtMS04OTA3Mg_594d2249-1e65-418c-8d3c-469e3e2b0d59"
      unitRef="usd">23385000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmEyOTRjZTNjMDI1MzRkYTc5MDEyYzE1NGViYjAxNWI2L3RhYmxlcmFuZ2U6YTI5NGNlM2MwMjUzNGRhNzkwMTJjMTU0ZWJiMDE1YjZfOS0xLTEtMS04OTA3Mg_17724e15-66a2-4a69-ba13-b712cc227310"
      unitRef="usd">217000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RhYmxlOmEyOTRjZTNjMDI1MzRkYTc5MDEyYzE1NGViYjAxNWI2L3RhYmxlcmFuZ2U6YTI5NGNlM2MwMjUzNGRhNzkwMTJjMTU0ZWJiMDE1YjZfMTAtMS0xLTEtODkwNzI_990b78f3-7cf0-4fee-81a9-967768f87697"
      unitRef="usd">23168000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="id1e3d8f9146049ff9febeb80d7774565_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTY0OTI2NzQ0NzUwMjM_b61362b9-439c-4dd7-bf8e-fdfcc47929cd"
      unitRef="number">1.01021</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:LongTermDebt
      contextRef="iba4cf152a5ec43589599bfbc8c8881de_I20220510"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY182Ny9mcmFnOmIyMWIyNThkMGU4NzRlMWY4NTA2NDdiMWQwZjEyYmZiL3RleHRyZWdpb246YjIxYjI1OGQwZTg3NGUxZjg1MDY0N2IxZDBmMTJiZmJfMTA5OTUxMTY4NjM1OA_56c0fdb2-8a62-410f-9f4b-571bc707b6e5"
      unitRef="usd">350000000</us-gaap:LongTermDebt>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RleHRyZWdpb246NjljNThhNjhjNjYyNDEwMGEzOTJmYTRjODI4N2VhZjJfNDAx_03f176de-4bd0-4095-976e-fa2c9ef6cb5c">PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sponsors defined benefit plans and a participatory defined benefit postretirement medical and life insurance plan, which covers certain U.S. employees and employees in certain other countries. Net periodic (benefit) cost for the Company&#x2019;s defined benefit pension plans and postretirement benefit plan for the three months ended March 31, 2022 and 2021 consists of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Postretirement&lt;br/&gt;Benefit&lt;br/&gt;Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service credit and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic (benefit) cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RleHRyZWdpb246NjljNThhNjhjNjYyNDEwMGEzOTJmYTRjODI4N2VhZjJfMzk4_04fe13cf-8d85-4a44-8d28-86596874e099">Net periodic (benefit) cost for the Company&#x2019;s defined benefit pension plans and postretirement benefit plan for the three months ended March 31, 2022 and 2021 consists of: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Postretirement&lt;br/&gt;Benefit&lt;br/&gt;Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service credit and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic (benefit) cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i830e50982f6544d8ac6e50bc7bd7c443_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfMy0yLTEtMS04OTA3Mg_50e4b20d-4a2c-4ea1-a2fc-88bb50fb9efe"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ic655b0478ac14dac9616872cec7db523_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfMy00LTEtMS04OTA3Mg_8c36b4c7-712e-4160-a263-61456b99dd45"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i5551d17df34844848847e1383a62e7c3_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfMy02LTEtMS04OTA3Mg_03113176-6a9c-47ed-96fa-53e56b16399c"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i74e0245bcf24424487c80b95aed98a9d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfMy04LTEtMS04OTA3Mg_d87ca5c2-6209-418d-832f-fd779b5e3102"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i673851b86a634af7b2f89d29c8e7cac4_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfMy0xMC0xLTEtODkwNzI_ad1ae374-18f2-4f62-ad97-3b2bae0a6166"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="if2d66b26d13244be9ae6815748b18427_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfMy0xMi0xLTEtODkwNzI_737ff188-9e3b-4bc8-97e3-c5dce6bcee73"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i830e50982f6544d8ac6e50bc7bd7c443_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfNC0yLTEtMS04OTA3Mg_50922abd-6339-4f9e-a8fa-69f04078e328"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ic655b0478ac14dac9616872cec7db523_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfNC00LTEtMS04OTA3Mg_a312cf7e-6063-46da-9d5c-43276ab9980a"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i5551d17df34844848847e1383a62e7c3_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfNC02LTEtMS04OTA3Mg_0d118578-959a-4205-8b16-906521ed4a64"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i74e0245bcf24424487c80b95aed98a9d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfNC04LTEtMS04OTA3Mg_d2541c4a-03b3-4630-8d09-064eb2a5aa12"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i673851b86a634af7b2f89d29c8e7cac4_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfNC0xMC0xLTEtODkwNzI_635b630e-66e7-4d85-8b99-e41ddf7ac52e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="if2d66b26d13244be9ae6815748b18427_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfNC0xMi0xLTEtODkwNzI_d94cae6a-686e-4fb8-9081-72d72629b5c0"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i830e50982f6544d8ac6e50bc7bd7c443_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfNS0yLTEtMS04OTA3Mg_28295b3f-ca72-4576-9519-4521fd59113e"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ic655b0478ac14dac9616872cec7db523_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfNS00LTEtMS04OTA3Mg_590a1e75-3e71-4e1b-8c59-a684bc157b42"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i5551d17df34844848847e1383a62e7c3_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfNS02LTEtMS04OTA3Mg_7e0df1bb-adb9-4e0c-8586-5a67d76b6387"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i74e0245bcf24424487c80b95aed98a9d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfNS04LTEtMS04OTA3Mg_d661e4e3-12d3-46b3-bc63-187b5e1f771b"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i673851b86a634af7b2f89d29c8e7cac4_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfNS0xMC0xLTEtODkwNzI_3ff493e2-0541-450b-8591-3646705cc84d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="if2d66b26d13244be9ae6815748b18427_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfNS0xMi0xLTEtODkwNzI_48df1b5e-e232-46d9-9994-1472c8a380ab"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i830e50982f6544d8ac6e50bc7bd7c443_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfNi0yLTEtMS04OTA3Mg_a62461af-e802-4bad-8b84-b147f41b439f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ic655b0478ac14dac9616872cec7db523_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfNi00LTEtMS04OTA3Mg_dda8221f-cd14-45c4-8bfa-c90971c9b867"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i5551d17df34844848847e1383a62e7c3_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfNi02LTEtMS04OTA3Mg_65b32369-b973-4fd7-b10e-927f81403562"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i74e0245bcf24424487c80b95aed98a9d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfNi04LTEtMS04OTA3Mg_a37b9ea4-009c-4b49-8164-644dcfffb01b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i673851b86a634af7b2f89d29c8e7cac4_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfNi0xMC0xLTEtODkwNzI_cf9bbfbe-9f7c-4439-9fb3-45e188fe69db"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="if2d66b26d13244be9ae6815748b18427_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfNi0xMi0xLTEtODkwNzI_edf87c5c-e2f6-4e6d-a3c9-7065755f9a69"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i830e50982f6544d8ac6e50bc7bd7c443_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfOC0yLTEtMS04OTA3Mg_f4ecc7bd-73f4-44b1-8e02-1a717cf5217c"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ic655b0478ac14dac9616872cec7db523_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfOC00LTEtMS04OTA3Mg_4a3a6a7e-77a0-4f5f-bfc3-5cf04355b3df"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i5551d17df34844848847e1383a62e7c3_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfOC02LTEtMS04OTA3Mg_4654f78a-0459-4c7d-8aef-c135f2ebff09"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i74e0245bcf24424487c80b95aed98a9d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfOC04LTEtMS04OTA3Mg_1af9dc21-c6da-467d-a441-0f62b02a06cb"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i673851b86a634af7b2f89d29c8e7cac4_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfOC0xMC0xLTEtODkwNzI_0d6707ac-8303-4dc8-94c2-f4a02bb21c47"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="if2d66b26d13244be9ae6815748b18427_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183My9mcmFnOjY5YzU4YTY4YzY2MjQxMDBhMzkyZmE0YzgyODdlYWYyL3RhYmxlOmViNDM0MTcyNDlmMjRiZDk5MWRmOWEzYmU5NDQzNDYxL3RhYmxlcmFuZ2U6ZWI0MzQxNzI0OWYyNGJkOTkxZGY5YTNiZTk0NDM0NjFfOC0xMi0xLTEtODkwNzI_4e8db2ea-c7a7-4a32-a120-7caedfc4086e"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RleHRyZWdpb246NTc4NWQ3MGNhMjAzNDc2MWI3MzI3ZThlZmVlYjYxYjFfNDU0Mg_c5f386bf-804e-43f9-aaa7-792fd171612e">SHARE-BASED COMPENSATIONIn May 2014, shareholders approved the Company&#x2019;s 2014 Omnibus Incentive Plan (the &#x201c;2014 Plan&#x201d;) which replaced the Company&#x2019;s 2011 Omnibus Incentive Plan (the &#x201c;2011 Plan&#x201d;) for future equity awards granted by the Company. The Company transferred the common shares available under the 2011 Plan to the 2014 Plan. The maximum number of common shares that may be issued to participants under the 2014 Plan was equal to 18,000,000 common shares, plus the number of common shares under the 2011 Plan reserved but unissued and not underlying outstanding awards and the number of common shares becoming available for reuse after awards are terminated, forfeited, cancelled, exchanged or surrendered under the 2011 Plan &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and the Company&#x2019;s 2007 Equity Compensation Plan. The Company registered 20,000,000 common shares for issuance under the 2014 Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective April 30, 2018, the Company amended and restated the 2014 Plan (the &#x201c;Amended and Restated 2014 Plan&#x201d;). The Amended and Restated 2014 Plan includes the following amendments: (i) the number of common shares authorized for issuance under the Amended and Restated 2014 Plan has been increased by an additional 11,900,000 common shares, as approved by the requisite number of shareholders at the Company&#x2019;s annual general meeting held on April 30, 2018, (ii) introduction of a $750,000 aggregate fair market value limit on awards (in either equity, cash or other compensation) that can be granted in any calendar year to a participant who is a non-employee director, (iii) housekeeping changes to address changes to Section 162(m) of the Internal Revenue Code, (iv) awards are expressly subject to the Company&#x2019;s clawback policy and (v) awards not assumed or substituted in connection with a Change of Control (as defined in the Amended and Restated 2014 Plan) will only vest on a pro rata basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective April 28, 2020, the Company further amended and restated the Amended and Restated 2014 Plan (the &#x201c;Further Amended and Restated 2014 Plan&#x201d;). The Further Amended and Restated 2014 Plan includes the following amendments: (i) the number of common shares authorized for issuance under the Further Amended and Restated 2014 Plan has been increased by an additional 13,500,000 common shares, as approved by the requisite number of shareholders at the Company&#x2019;s annual general meeting held on April 28, 2020, (ii) the exercise price of stock options and share appreciation rights (&#x201c;SARs&#x201d;) will be based on the closing price of the underlying common shares on the date such stock options or SARs are granted (rather than on the last preceding trading date), (iii)&#160;additional provisions clarifying that: (a)&#160;stock options and SARs will not be eligible for the payment of dividend or dividend equivalents and (b)&#160;the Talent and Compensation Committee of the Board of Directors of the Company cannot, without shareholder approval, seek to effect any repricing of any previously granted &#x201c;underwater&#x201d; stock option or SAR and (iv) other housekeeping and/or clerical changes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Approximately 8,542,000 common shares were available for future grants as of March&#160;31, 2022. The Company uses reserved and unissued common shares to satisfy its obligations under its share-based compensation plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a long-term incentive program with the objective of aligning the share-based awards granted to senior management with the Company&#x2019;s focus on improving its tangible capital usage and allocation while maintaining focus on improving total shareholder return over the long-term. The share-based awards granted under this long-term incentive program consist of time-based stock options, time-based restricted share units (&#x201c;RSUs&#x201d;) and performance-based RSUs. Performance-based RSUs are comprised of awards that: (i) vest upon achievement of certain share price appreciation conditions that are based on total shareholder return (&#x201c;TSR&#x201d;), (ii) vest upon attainment of certain performance targets that are based on the Company&#x2019;s return on tangible capital (&#x201c;ROTC&#x201d;) and (iii) vest fully or partially upon attainment of certain goals that are linked to the B+L Separation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components and classification of share-based compensation expenses related to stock options and RSUs for the three months ended March 31, 2022 and 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based awards granted for the three months ended March 31, 2022 and 2021 consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,545,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,343,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,662,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,560,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;TSR performance-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROTC performance-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;B+L Separation performance-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, the remaining unrecognized compensation expenses related to all outstanding non-vested stock options, time-based RSUs and performance-based RSUs amounted to $134 million, which will be amortized over a weighted-average period of 1.84 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i28d956fcdc7e473694aec5169b2c17fd_I20140531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RleHRyZWdpb246NTc4NWQ3MGNhMjAzNDc2MWI3MzI3ZThlZmVlYjYxYjFfNDQ0_c345faf2-6b0d-4211-b34b-897b83620c11"
      unitRef="shares">18000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i28d956fcdc7e473694aec5169b2c17fd_I20140531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RleHRyZWdpb246NTc4NWQ3MGNhMjAzNDc2MWI3MzI3ZThlZmVlYjYxYjFfODA0_c3daf8e4-771d-4057-978a-5796db9edf10"
      unitRef="shares">20000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i407781f626f341f296f71f5e85d199df_D20180430-20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RleHRyZWdpb246NTc4NWQ3MGNhMjAzNDc2MWI3MzI3ZThlZmVlYjYxYjFfMTE3Mg_76d00012-0179-4c3d-ba09-502684c6015f"
      unitRef="shares">11900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant
      contextRef="i79d17571326d4113a14289e30a432c94_D20180430-20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RleHRyZWdpb246NTc4NWQ3MGNhMjAzNDc2MWI3MzI3ZThlZmVlYjYxYjFfMTMyOQ_30a97619-edbe-4780-9cc5-6828e1182a2c"
      unitRef="usd">750000</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="ic9d13a041f834d2f9ed315beee256b39_D20200428-20200428"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RleHRyZWdpb246NTc4NWQ3MGNhMjAzNDc2MWI3MzI3ZThlZmVlYjYxYjFfMjIxOA_c7c3fdf4-f2bb-4a73-943e-de5df066797b"
      unitRef="shares">13500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i24dd995e79e2480eb8534ebdb9b36ffe_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RleHRyZWdpb246NTc4NWQ3MGNhMjAzNDc2MWI3MzI3ZThlZmVlYjYxYjFfMzAyNQ_cc463b1c-6eaf-4238-8736-9a0c8a00e004"
      unitRef="shares">8542000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RleHRyZWdpb246NTc4NWQ3MGNhMjAzNDc2MWI3MzI3ZThlZmVlYjYxYjFfNDUzNw_408fe0ed-6b3b-4456-af4a-6929c56ded5d">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components and classification of share-based compensation expenses related to stock options and RSUs for the three months ended March 31, 2022 and 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4c3748cc38b94811b494a048524f18d4_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmNiODY2ZWQyYjQxZTRkNmViZTNkY2UyZjg1MGRhMDc5L3RhYmxlcmFuZ2U6Y2I4NjZlZDJiNDFlNGQ2ZWJlM2RjZTJmODUwZGEwNzlfMi01LTEtMS04OTA3Mg_ac1fda45-7bed-4d23-8de4-c87e9d4ca963"
      unitRef="usd">4000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icbcf180e8ee94c498f903101c65055cf_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmNiODY2ZWQyYjQxZTRkNmViZTNkY2UyZjg1MGRhMDc5L3RhYmxlcmFuZ2U6Y2I4NjZlZDJiNDFlNGQ2ZWJlM2RjZTJmODUwZGEwNzlfMi03LTEtMS04OTA3Mg_095c84f9-b5e3-4c35-96fe-3dd2463cb2ae"
      unitRef="usd">4000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5189be309deb481aba3dbe709f732ab9_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmNiODY2ZWQyYjQxZTRkNmViZTNkY2UyZjg1MGRhMDc5L3RhYmxlcmFuZ2U6Y2I4NjZlZDJiNDFlNGQ2ZWJlM2RjZTJmODUwZGEwNzlfMy01LTEtMS04OTA3Mg_53fd21e1-c39b-48fe-921d-ddce186018a8"
      unitRef="usd">28000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i302c4d997fc44f5f93fd331d80fb1d09_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmNiODY2ZWQyYjQxZTRkNmViZTNkY2UyZjg1MGRhMDc5L3RhYmxlcmFuZ2U6Y2I4NjZlZDJiNDFlNGQ2ZWJlM2RjZTJmODUwZGEwNzlfMy03LTEtMS04OTA3Mg_8663ac0e-e642-4b5c-ac20-ef4d51f430c4"
      unitRef="usd">27000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmNiODY2ZWQyYjQxZTRkNmViZTNkY2UyZjg1MGRhMDc5L3RhYmxlcmFuZ2U6Y2I4NjZlZDJiNDFlNGQ2ZWJlM2RjZTJmODUwZGEwNzlfNC01LTEtMS04OTA3Mg_1c0d6e34-9a74-46c4-b964-676a5fcd56cd"
      unitRef="usd">32000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmNiODY2ZWQyYjQxZTRkNmViZTNkY2UyZjg1MGRhMDc5L3RhYmxlcmFuZ2U6Y2I4NjZlZDJiNDFlNGQ2ZWJlM2RjZTJmODUwZGEwNzlfNC03LTEtMS04OTA3Mg_160ef1fb-f629-479b-af6b-c5ef1dc7feb4"
      unitRef="usd">31000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5c8dba5a632049539392f661e0428449_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmNiODY2ZWQyYjQxZTRkNmViZTNkY2UyZjg1MGRhMDc5L3RhYmxlcmFuZ2U6Y2I4NjZlZDJiNDFlNGQ2ZWJlM2RjZTJmODUwZGEwNzlfNi01LTEtMS04OTA3Mg_10a99658-c916-4b23-a9c5-a973569b317e"
      unitRef="usd">3000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i96274aa944bb4685b39b713920d2304f_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmNiODY2ZWQyYjQxZTRkNmViZTNkY2UyZjg1MGRhMDc5L3RhYmxlcmFuZ2U6Y2I4NjZlZDJiNDFlNGQ2ZWJlM2RjZTJmODUwZGEwNzlfNi03LTEtMS04OTA3Mg_8bb09638-1075-4b01-83b7-b33c27e680d2"
      unitRef="usd">3000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i16e6e5eeaf9441738f673fb99507f4e5_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmNiODY2ZWQyYjQxZTRkNmViZTNkY2UyZjg1MGRhMDc5L3RhYmxlcmFuZ2U6Y2I4NjZlZDJiNDFlNGQ2ZWJlM2RjZTJmODUwZGEwNzlfNy01LTEtMS04OTA3Mg_4340a066-2c41-4a1c-a67d-b305624f8d2c"
      unitRef="usd">29000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9aaaf1035cf34c098a5c6e6768c0dbf4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmNiODY2ZWQyYjQxZTRkNmViZTNkY2UyZjg1MGRhMDc5L3RhYmxlcmFuZ2U6Y2I4NjZlZDJiNDFlNGQ2ZWJlM2RjZTJmODUwZGEwNzlfNy03LTEtMS04OTA3Mg_7a8f4af0-6767-417c-9900-faaff12ec366"
      unitRef="usd">28000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmNiODY2ZWQyYjQxZTRkNmViZTNkY2UyZjg1MGRhMDc5L3RhYmxlcmFuZ2U6Y2I4NjZlZDJiNDFlNGQ2ZWJlM2RjZTJmODUwZGEwNzlfOC01LTEtMS04OTA3Mg_42d93029-d404-4ffb-889f-6e497e07f488"
      unitRef="usd">32000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmNiODY2ZWQyYjQxZTRkNmViZTNkY2UyZjg1MGRhMDc5L3RhYmxlcmFuZ2U6Y2I4NjZlZDJiNDFlNGQ2ZWJlM2RjZTJmODUwZGEwNzlfOC03LTEtMS04OTA3Mg_09eb0229-1b32-4240-a9d6-dee36ceb526d"
      unitRef="usd">31000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RleHRyZWdpb246NTc4NWQ3MGNhMjAzNDc2MWI3MzI3ZThlZmVlYjYxYjFfNDUyOQ_e720366f-a229-4af2-b212-ecb0ef06e6cd">&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based awards granted for the three months ended March 31, 2022 and 2021 consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,545,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,343,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,662,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,560,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;TSR performance-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROTC performance-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;B+L Separation performance-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i4c3748cc38b94811b494a048524f18d4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmZjYzc3MzUyZWEwNjRkODQ5YzM3NDNmYTNkY2NlYmU1L3RhYmxlcmFuZ2U6ZmNjNzczNTJlYTA2NGQ4NDljMzc0M2ZhM2RjY2ViZTVfMi0xLTEtMS04OTA3Mg_429efa6f-39af-45ae-9e42-f0d06bf5c9d3"
      unitRef="shares">2545000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="icbcf180e8ee94c498f903101c65055cf_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmZjYzc3MzUyZWEwNjRkODQ5YzM3NDNmYTNkY2NlYmU1L3RhYmxlcmFuZ2U6ZmNjNzczNTJlYTA2NGQ4NDljMzc0M2ZhM2RjY2ViZTVfMi0zLTEtMS04OTA3Mg_d54010ce-64d6-4f38-8e62-da114e10b903"
      unitRef="shares">1343000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i4c3748cc38b94811b494a048524f18d4_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmZjYzc3MzUyZWEwNjRkODQ5YzM3NDNmYTNkY2NlYmU1L3RhYmxlcmFuZ2U6ZmNjNzczNTJlYTA2NGQ4NDljMzc0M2ZhM2RjY2ViZTVfMy0xLTEtMS04OTA3Mg_ec298887-f573-4762-92d3-7ada76b3e9ab"
      unitRef="usdPerShare">24.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="icbcf180e8ee94c498f903101c65055cf_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmZjYzc3MzUyZWEwNjRkODQ5YzM3NDNmYTNkY2NlYmU1L3RhYmxlcmFuZ2U6ZmNjNzczNTJlYTA2NGQ4NDljMzc0M2ZhM2RjY2ViZTVfMy0zLTEtMS04OTA3Mg_1933ee78-67c5-4b45-813b-2f054d47e855"
      unitRef="usdPerShare">32.56</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4c3748cc38b94811b494a048524f18d4_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmZjYzc3MzUyZWEwNjRkODQ5YzM3NDNmYTNkY2NlYmU1L3RhYmxlcmFuZ2U6ZmNjNzczNTJlYTA2NGQ4NDljMzc0M2ZhM2RjY2ViZTVfNC0xLTEtMS04OTA3Mg_019ec593-7518-4153-9748-e25e8c12dafd"
      unitRef="usdPerShare">6.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="icbcf180e8ee94c498f903101c65055cf_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmZjYzc3MzUyZWEwNjRkODQ5YzM3NDNmYTNkY2NlYmU1L3RhYmxlcmFuZ2U6ZmNjNzczNTJlYTA2NGQ4NDljMzc0M2ZhM2RjY2ViZTVfNC0zLTEtMS04OTA3Mg_2a9171d6-e3d4-446c-a152-db0cbd85e46f"
      unitRef="usdPerShare">11.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i77c337a40ebb461491bdb6dab1118617_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmZjYzc3MzUyZWEwNjRkODQ5YzM3NDNmYTNkY2NlYmU1L3RhYmxlcmFuZ2U6ZmNjNzczNTJlYTA2NGQ4NDljMzc0M2ZhM2RjY2ViZTVfNi0xLTEtMS04OTA3Mg_9c11e6d6-9e24-4a8e-8155-8b823727cb53"
      unitRef="shares">1662000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i3fc2981be2ea44a386fb0f04805428f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmZjYzc3MzUyZWEwNjRkODQ5YzM3NDNmYTNkY2NlYmU1L3RhYmxlcmFuZ2U6ZmNjNzczNTJlYTA2NGQ4NDljMzc0M2ZhM2RjY2ViZTVfNi0zLTEtMS04OTA3Mg_ca38e798-9245-4982-82d1-c02a02fdcdba"
      unitRef="shares">2560000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i77c337a40ebb461491bdb6dab1118617_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmZjYzc3MzUyZWEwNjRkODQ5YzM3NDNmYTNkY2NlYmU1L3RhYmxlcmFuZ2U6ZmNjNzczNTJlYTA2NGQ4NDljMzc0M2ZhM2RjY2ViZTVfNy0xLTEtMS04OTA3Mg_47d04d5c-5733-4f5e-9e4e-3c802dd6bd10"
      unitRef="usdPerShare">24.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3fc2981be2ea44a386fb0f04805428f4_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmZjYzc3MzUyZWEwNjRkODQ5YzM3NDNmYTNkY2NlYmU1L3RhYmxlcmFuZ2U6ZmNjNzczNTJlYTA2NGQ4NDljMzc0M2ZhM2RjY2ViZTVfNy0zLTEtMS04OTA3Mg_e60b9bbc-b195-4e51-a6a6-26d6ed92fc11"
      unitRef="usdPerShare">32.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ibf0b5e90aca84802a2fe6dfc35444ad9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmZjYzc3MzUyZWEwNjRkODQ5YzM3NDNmYTNkY2NlYmU1L3RhYmxlcmFuZ2U6ZmNjNzczNTJlYTA2NGQ4NDljMzc0M2ZhM2RjY2ViZTVfOS0xLTEtMS04OTA3Mg_04d3f3ab-a566-4c11-a28b-d9fb46c9287f"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ief18d16522574e578066730177201d22_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmZjYzc3MzUyZWEwNjRkODQ5YzM3NDNmYTNkY2NlYmU1L3RhYmxlcmFuZ2U6ZmNjNzczNTJlYTA2NGQ4NDljMzc0M2ZhM2RjY2ViZTVfOS0zLTEtMS04OTA3Mg_cb275227-3292-4e5d-962d-067a124ce199"
      unitRef="shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ibf0b5e90aca84802a2fe6dfc35444ad9_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmZjYzc3MzUyZWEwNjRkODQ5YzM3NDNmYTNkY2NlYmU1L3RhYmxlcmFuZ2U6ZmNjNzczNTJlYTA2NGQ4NDljMzc0M2ZhM2RjY2ViZTVfMTAtMS0xLTEtODkwNzI_18aba2fd-0aa6-4a55-b3c1-78ea9c5c320c"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ief18d16522574e578066730177201d22_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmZjYzc3MzUyZWEwNjRkODQ5YzM3NDNmYTNkY2NlYmU1L3RhYmxlcmFuZ2U6ZmNjNzczNTJlYTA2NGQ4NDljMzc0M2ZhM2RjY2ViZTVfMTAtMy0xLTEtODkwNzI_f0ae4d7d-da7d-461e-8e8b-d9c2b58d1ada"
      unitRef="usdPerShare">56.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i672f6c3b00ec46e5ae4b3d4816dbc732_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmZjYzc3MzUyZWEwNjRkODQ5YzM3NDNmYTNkY2NlYmU1L3RhYmxlcmFuZ2U6ZmNjNzczNTJlYTA2NGQ4NDljMzc0M2ZhM2RjY2ViZTVfMTItMS0xLTEtODkwNzI_83729d98-5f97-4acb-8e1e-d90138203fa8"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="idbfb63fc6db643aba45a4aa4ec0c1c63_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmZjYzc3MzUyZWEwNjRkODQ5YzM3NDNmYTNkY2NlYmU1L3RhYmxlcmFuZ2U6ZmNjNzczNTJlYTA2NGQ4NDljMzc0M2ZhM2RjY2ViZTVfMTItMy0xLTEtODkwNzI_5f3df5dd-b55f-456e-ac84-fec075ee9b77"
      unitRef="shares">413000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i672f6c3b00ec46e5ae4b3d4816dbc732_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmZjYzc3MzUyZWEwNjRkODQ5YzM3NDNmYTNkY2NlYmU1L3RhYmxlcmFuZ2U6ZmNjNzczNTJlYTA2NGQ4NDljMzc0M2ZhM2RjY2ViZTVfMTMtMS0xLTEtODkwNzI_2a1f297a-c726-4001-ad56-a6125561242d"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="idbfb63fc6db643aba45a4aa4ec0c1c63_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmZjYzc3MzUyZWEwNjRkODQ5YzM3NDNmYTNkY2NlYmU1L3RhYmxlcmFuZ2U6ZmNjNzczNTJlYTA2NGQ4NDljMzc0M2ZhM2RjY2ViZTVfMTMtMy0xLTEtODkwNzI_0c2fed7a-02c5-46ba-b3af-41ee6e7bec4f"
      unitRef="usdPerShare">31.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i64cc50678b8b42b28c6fffa51684b252_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmZjYzc3MzUyZWEwNjRkODQ5YzM3NDNmYTNkY2NlYmU1L3RhYmxlcmFuZ2U6ZmNjNzczNTJlYTA2NGQ4NDljMzc0M2ZhM2RjY2ViZTVfMTUtMS0xLTEtODkwNzI_50e61d9a-1477-4d4d-8737-110f3ecead7f"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i3a2ccdb6d9074d6d8d84aba34115a27e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmZjYzc3MzUyZWEwNjRkODQ5YzM3NDNmYTNkY2NlYmU1L3RhYmxlcmFuZ2U6ZmNjNzczNTJlYTA2NGQ4NDljMzc0M2ZhM2RjY2ViZTVfMTUtMy0xLTEtODkwNzI_dadb9747-d8b3-4bd8-973b-d84165c83599"
      unitRef="shares">132000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i64cc50678b8b42b28c6fffa51684b252_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmZjYzc3MzUyZWEwNjRkODQ5YzM3NDNmYTNkY2NlYmU1L3RhYmxlcmFuZ2U6ZmNjNzczNTJlYTA2NGQ4NDljMzc0M2ZhM2RjY2ViZTVfMTYtMS0xLTEtODkwNzI_bc68ae3f-e10e-44d2-a26a-86f38ab4ddce"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3a2ccdb6d9074d6d8d84aba34115a27e_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RhYmxlOmZjYzc3MzUyZWEwNjRkODQ5YzM3NDNmYTNkY2NlYmU1L3RhYmxlcmFuZ2U6ZmNjNzczNTJlYTA2NGQ4NDljMzc0M2ZhM2RjY2ViZTVfMTYtMy0xLTEtODkwNzI_7141c25d-42ba-417f-941b-29b70b88f0b5"
      unitRef="usdPerShare">32.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RleHRyZWdpb246NTc4NWQ3MGNhMjAzNDc2MWI3MzI3ZThlZmVlYjYxYjFfNDQ1OQ_6b9cf86e-361c-4868-bb90-af845b33aefa"
      unitRef="usd">134000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183Ni9mcmFnOjU3ODVkNzBjYTIwMzQ3NjFiNzMyN2U4ZWZlZWI2MWIxL3RleHRyZWdpb246NTc4NWQ3MGNhMjAzNDc2MWI3MzI3ZThlZmVlYjYxYjFfNDUyMQ_7a2d6c9b-138f-4b47-a9a8-e7dd7bea8478">P1Y10M2D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183OS9mcmFnOjA1ODA3YThkOTdkYTRlMjBhYjI1M2ExNGMyNzc2MTNjL3RleHRyZWdpb246MDU4MDdhOGQ5N2RhNGUyMGFiMjUzYTE0YzI3NzYxM2NfNDc2_2fa77d9a-6caa-478c-a522-f310f5e138ba">ACCUMULATED OTHER COMPREHENSIVE LOSS&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive loss consists of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,961)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,905)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pension and postretirement benefit plan adjustments, net of income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,974)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,924)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are not provided for foreign currency translation adjustments arising on the translation of the Company&#x2019;s operations having a functional currency other than the U.S. dollar, except to the extent of translation adjustments related to the Company&#x2019;s retained earnings for foreign jurisdictions in which the Company is not considered to be permanently reinvested.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183OS9mcmFnOjA1ODA3YThkOTdkYTRlMjBhYjI1M2ExNGMyNzc2MTNjL3RleHRyZWdpb246MDU4MDdhOGQ5N2RhNGUyMGFiMjUzYTE0YzI3NzYxM2NfNDcy_800913d3-9930-4e38-8270-9f54ce3bf2dc">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive loss consists of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,961)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,905)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pension and postretirement benefit plan adjustments, net of income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,974)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,924)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i46d6cdf39c0344c9997ac487916b5ced_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183OS9mcmFnOjA1ODA3YThkOTdkYTRlMjBhYjI1M2ExNGMyNzc2MTNjL3RhYmxlOjBhMDZmYmExMDU0OTQxNTViYmI1YTA2ZjczZWVmNTE5L3RhYmxlcmFuZ2U6MGEwNmZiYTEwNTQ5NDE1NWJiYjVhMDZmNzNlZWY1MTlfMS0yLTEtMS04OTA3Mg_5ab5021a-68c9-4b29-be27-29f8199ba1ba"
      unitRef="usd">-1961000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia421fa8b794e48b48d28fe42bfdcba6b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183OS9mcmFnOjA1ODA3YThkOTdkYTRlMjBhYjI1M2ExNGMyNzc2MTNjL3RhYmxlOjBhMDZmYmExMDU0OTQxNTViYmI1YTA2ZjczZWVmNTE5L3RhYmxlcmFuZ2U6MGEwNmZiYTEwNTQ5NDE1NWJiYjVhMDZmNzNlZWY1MTlfMS00LTEtMS04OTA3Mg_13a23286-0cf9-42b8-b929-dbbb6c31b00d"
      unitRef="usd">-1905000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i27c24a8f9680457fae0e0043ab55f83c_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183OS9mcmFnOjA1ODA3YThkOTdkYTRlMjBhYjI1M2ExNGMyNzc2MTNjL3RhYmxlOjBhMDZmYmExMDU0OTQxNTViYmI1YTA2ZjczZWVmNTE5L3RhYmxlcmFuZ2U6MGEwNmZiYTEwNTQ5NDE1NWJiYjVhMDZmNzNlZWY1MTlfMi0yLTEtMS04OTA3Mg_17144cdc-4e3c-47dd-822d-98ff8ab36faa"
      unitRef="usd">-13000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idf07a0520a7f41db853c67b1c28a17a5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183OS9mcmFnOjA1ODA3YThkOTdkYTRlMjBhYjI1M2ExNGMyNzc2MTNjL3RhYmxlOjBhMDZmYmExMDU0OTQxNTViYmI1YTA2ZjczZWVmNTE5L3RhYmxlcmFuZ2U6MGEwNmZiYTEwNTQ5NDE1NWJiYjVhMDZmNzNlZWY1MTlfMi00LTEtMS04OTA3Mg_6370b943-8917-4a3c-b544-ad858c62c485"
      unitRef="usd">-19000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i38bc8011408047f4b2f92fc815fe79b3_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183OS9mcmFnOjA1ODA3YThkOTdkYTRlMjBhYjI1M2ExNGMyNzc2MTNjL3RhYmxlOjBhMDZmYmExMDU0OTQxNTViYmI1YTA2ZjczZWVmNTE5L3RhYmxlcmFuZ2U6MGEwNmZiYTEwNTQ5NDE1NWJiYjVhMDZmNzNlZWY1MTlfMy0yLTEtMS04OTA3Mg_038ecc78-b97a-4ed4-a134-94051a310343"
      unitRef="usd">-1974000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4e97a6c789b1443ba408d058697c5cc2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY183OS9mcmFnOjA1ODA3YThkOTdkYTRlMjBhYjI1M2ExNGMyNzc2MTNjL3RhYmxlOjBhMDZmYmExMDU0OTQxNTViYmI1YTA2ZjczZWVmNTE5L3RhYmxlcmFuZ2U6MGEwNmZiYTEwNTQ5NDE1NWJiYjVhMDZmNzNlZWY1MTlfMy00LTEtMS04OTA3Mg_14cf31a7-1f5e-4b58-9e3e-1d8ceeb9a910"
      unitRef="usd">-1924000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184Mi9mcmFnOjU0ZGUyZTQ1MWUwYzRjNjZhOWQ1ODFhZDYyZTVlMDBlL3RleHRyZWdpb246NTRkZTJlNDUxZTBjNGM2NmE5ZDU4MWFkNjJlNWUwMGVfMjMz_979887fc-95f0-4f23-897b-8b73ce3eafa9">RESEARCH AND DEVELOPMENT&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in Research and development are costs related to product development and quality assurance programs. Quality assurance are the costs incurred to meet evolving customer and regulatory standards. Research and development costs consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product related research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Quality assurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <bhc:SummaryOfResearchAndDevelopmentExpenseTableTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184Mi9mcmFnOjU0ZGUyZTQ1MWUwYzRjNjZhOWQ1ODFhZDYyZTVlMDBlL3RleHRyZWdpb246NTRkZTJlNDUxZTBjNGM2NmE5ZDU4MWFkNjJlNWUwMGVfMjM2_53279af7-348c-407c-848c-826bc570a7bc">Research and development costs consist of:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product related research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Quality assurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</bhc:SummaryOfResearchAndDevelopmentExpenseTableTextBlock>
    <bhc:ResearchAndDevelopmentExpenseProductRelated
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184Mi9mcmFnOjU0ZGUyZTQ1MWUwYzRjNjZhOWQ1ODFhZDYyZTVlMDBlL3RhYmxlOjIwNTllY2VjYThjODQ2YmNhYmRhMDNiOGYwMWYyNTBiL3RhYmxlcmFuZ2U6MjA1OWVjZWNhOGM4NDZiY2FiZGEwM2I4ZjAxZjI1MGJfMi02LTEtMS04OTA3Mg_8a7ab1f8-1f26-457f-91fa-1d1fffaf8b53"
      unitRef="usd">121000000</bhc:ResearchAndDevelopmentExpenseProductRelated>
    <bhc:ResearchAndDevelopmentExpenseProductRelated
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184Mi9mcmFnOjU0ZGUyZTQ1MWUwYzRjNjZhOWQ1ODFhZDYyZTVlMDBlL3RhYmxlOjIwNTllY2VjYThjODQ2YmNhYmRhMDNiOGYwMWYyNTBiL3RhYmxlcmFuZ2U6MjA1OWVjZWNhOGM4NDZiY2FiZGEwM2I4ZjAxZjI1MGJfMi04LTEtMS04OTA3Mg_bcc15aa2-a824-498f-ad97-fd9bf986701b"
      unitRef="usd">105000000</bhc:ResearchAndDevelopmentExpenseProductRelated>
    <bhc:ResearchAndDevelopmentExpenseQualityAssurance
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184Mi9mcmFnOjU0ZGUyZTQ1MWUwYzRjNjZhOWQ1ODFhZDYyZTVlMDBlL3RhYmxlOjIwNTllY2VjYThjODQ2YmNhYmRhMDNiOGYwMWYyNTBiL3RhYmxlcmFuZ2U6MjA1OWVjZWNhOGM4NDZiY2FiZGEwM2I4ZjAxZjI1MGJfMy02LTEtMS04OTA3Mg_8a99d0c5-f00f-48f5-acf3-0095c9b755db"
      unitRef="usd">6000000</bhc:ResearchAndDevelopmentExpenseQualityAssurance>
    <bhc:ResearchAndDevelopmentExpenseQualityAssurance
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184Mi9mcmFnOjU0ZGUyZTQ1MWUwYzRjNjZhOWQ1ODFhZDYyZTVlMDBlL3RhYmxlOjIwNTllY2VjYThjODQ2YmNhYmRhMDNiOGYwMWYyNTBiL3RhYmxlcmFuZ2U6MjA1OWVjZWNhOGM4NDZiY2FiZGEwM2I4ZjAxZjI1MGJfMy04LTEtMS04OTA3Mg_fe460784-0190-4747-ac31-ca7042f05233"
      unitRef="usd">7000000</bhc:ResearchAndDevelopmentExpenseQualityAssurance>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184Mi9mcmFnOjU0ZGUyZTQ1MWUwYzRjNjZhOWQ1ODFhZDYyZTVlMDBlL3RhYmxlOjIwNTllY2VjYThjODQ2YmNhYmRhMDNiOGYwMWYyNTBiL3RhYmxlcmFuZ2U6MjA1OWVjZWNhOGM4NDZiY2FiZGEwM2I4ZjAxZjI1MGJfNC02LTEtMS04OTA3Mg_3e8fd65f-4ad0-46da-bfd4-188867175987"
      unitRef="usd">127000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184Mi9mcmFnOjU0ZGUyZTQ1MWUwYzRjNjZhOWQ1ODFhZDYyZTVlMDBlL3RhYmxlOjIwNTllY2VjYThjODQ2YmNhYmRhMDNiOGYwMWYyNTBiL3RhYmxlcmFuZ2U6MjA1OWVjZWNhOGM4NDZiY2FiZGEwM2I4ZjAxZjI1MGJfNC04LTEtMS04OTA3Mg_dc078dd2-be31-450b-bacf-efc58e30c790"
      unitRef="usd">112000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184NS9mcmFnOjY0ZmUxN2U3ZDJiYzQxMjFhYThiYjc5MzNhN2FhNDQxL3RleHRyZWdpb246NjRmZTE3ZTdkMmJjNDEyMWFhOGJiNzkzM2E3YWE0NDFfMTI2Mw_6f4db32e-91cc-40cb-b1b2-f0ec74e12572">OTHER EXPENSE (INCOME), NET&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other expense (income), net consists of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Litigation and other matters&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on sale of assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired in-process research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain on sale of assets, net for the three months ended March 31, 2021, includes $25&#160;million related to the achievement of a milestone related to a certain product.&lt;/span&gt;&lt;/div&gt;</us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184NS9mcmFnOjY0ZmUxN2U3ZDJiYzQxMjFhYThiYjc5MzNhN2FhNDQxL3RleHRyZWdpb246NjRmZTE3ZTdkMmJjNDEyMWFhOGJiNzkzM2E3YWE0NDFfMTI1NQ_707a9f31-9b25-4def-8b40-c3b0f67549a7">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other expense (income), net consists of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Litigation and other matters&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on sale of assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired in-process research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184NS9mcmFnOjY0ZmUxN2U3ZDJiYzQxMjFhYThiYjc5MzNhN2FhNDQxL3RhYmxlOjVhMzRlOTNkM2NmMjQxMmJiZjVlZDhmMDUzOTQ5M2I1L3RhYmxlcmFuZ2U6NWEzNGU5M2QzY2YyNDEyYmJmNWVkOGYwNTM5NDkzYjVfMi02LTEtMS04OTA3Mg_66af668a-788c-4a52-84ba-82424749e4de"
      unitRef="usd">1000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184NS9mcmFnOjY0ZmUxN2U3ZDJiYzQxMjFhYThiYjc5MzNhN2FhNDQxL3RhYmxlOjVhMzRlOTNkM2NmMjQxMmJiZjVlZDhmMDUzOTQ5M2I1L3RhYmxlcmFuZ2U6NWEzNGU5M2QzY2YyNDEyYmJmNWVkOGYwNTM5NDkzYjVfMi04LTEtMS04OTA3Mg_2c1ef53f-4f35-46f3-bc91-256785e46a54"
      unitRef="usd">0</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184NS9mcmFnOjY0ZmUxN2U3ZDJiYzQxMjFhYThiYjc5MzNhN2FhNDQxL3RhYmxlOjVhMzRlOTNkM2NmMjQxMmJiZjVlZDhmMDUzOTQ5M2I1L3RhYmxlcmFuZ2U6NWEzNGU5M2QzY2YyNDEyYmJmNWVkOGYwNTM5NDkzYjVfMy02LTEtMS04OTA3Mg_0f7492ad-d6f0-4ec3-92ff-7efb7443b655"
      unitRef="usd">3000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184NS9mcmFnOjY0ZmUxN2U3ZDJiYzQxMjFhYThiYjc5MzNhN2FhNDQxL3RhYmxlOjVhMzRlOTNkM2NmMjQxMmJiZjVlZDhmMDUzOTQ5M2I1L3RhYmxlcmFuZ2U6NWEzNGU5M2QzY2YyNDEyYmJmNWVkOGYwNTM5NDkzYjVfMy04LTEtMS04OTA3Mg_a354ee90-99f2-45f5-a6c8-e2288ab49451"
      unitRef="usd">-9000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184NS9mcmFnOjY0ZmUxN2U3ZDJiYzQxMjFhYThiYjc5MzNhN2FhNDQxL3RhYmxlOjVhMzRlOTNkM2NmMjQxMmJiZjVlZDhmMDUzOTQ5M2I1L3RhYmxlcmFuZ2U6NWEzNGU5M2QzY2YyNDEyYmJmNWVkOGYwNTM5NDkzYjVfNC02LTEtMS04OTA3Mg_886c4edc-e6e5-4b39-9e46-bd6f596568e1"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184NS9mcmFnOjY0ZmUxN2U3ZDJiYzQxMjFhYThiYjc5MzNhN2FhNDQxL3RhYmxlOjVhMzRlOTNkM2NmMjQxMmJiZjVlZDhmMDUzOTQ5M2I1L3RhYmxlcmFuZ2U6NWEzNGU5M2QzY2YyNDEyYmJmNWVkOGYwNTM5NDkzYjVfNC04LTEtMS04OTA3Mg_3113236b-2643-4342-ad83-13ec5e42f285"
      unitRef="usd">23000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184NS9mcmFnOjY0ZmUxN2U3ZDJiYzQxMjFhYThiYjc5MzNhN2FhNDQxL3RhYmxlOjVhMzRlOTNkM2NmMjQxMmJiZjVlZDhmMDUzOTQ5M2I1L3RhYmxlcmFuZ2U6NWEzNGU5M2QzY2YyNDEyYmJmNWVkOGYwNTM5NDkzYjVfNS02LTEtMS04OTA3Mg_5ef87e4f-d53f-40c6-8310-a055d64f54b5"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184NS9mcmFnOjY0ZmUxN2U3ZDJiYzQxMjFhYThiYjc5MzNhN2FhNDQxL3RhYmxlOjVhMzRlOTNkM2NmMjQxMmJiZjVlZDhmMDUzOTQ5M2I1L3RhYmxlcmFuZ2U6NWEzNGU5M2QzY2YyNDEyYmJmNWVkOGYwNTM5NDkzYjVfNS04LTEtMS04OTA3Mg_1a59153d-881a-4beb-a954-a211e7a6efab"
      unitRef="usd">2000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184NS9mcmFnOjY0ZmUxN2U3ZDJiYzQxMjFhYThiYjc5MzNhN2FhNDQxL3RhYmxlOjVhMzRlOTNkM2NmMjQxMmJiZjVlZDhmMDUzOTQ5M2I1L3RhYmxlcmFuZ2U6NWEzNGU5M2QzY2YyNDEyYmJmNWVkOGYwNTM5NDkzYjVfNi02LTEtMS04OTA3Mg_c40dd8ca-2631-4876-a5a0-9a9eba1c6356"
      unitRef="usd">-2000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184NS9mcmFnOjY0ZmUxN2U3ZDJiYzQxMjFhYThiYjc5MzNhN2FhNDQxL3RhYmxlOjVhMzRlOTNkM2NmMjQxMmJiZjVlZDhmMDUzOTQ5M2I1L3RhYmxlcmFuZ2U6NWEzNGU5M2QzY2YyNDEyYmJmNWVkOGYwNTM5NDkzYjVfNi04LTEtMS04OTA3Mg_0f26368b-dfc9-43be-8ca1-e49f8a5e9e56"
      unitRef="usd">30000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="ib705b8700b7f48e8b664f48c1ff6c694_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184NS9mcmFnOjY0ZmUxN2U3ZDJiYzQxMjFhYThiYjc5MzNhN2FhNDQxL3RleHRyZWdpb246NjRmZTE3ZTdkMmJjNDEyMWFhOGJiNzkzM2E3YWE0NDFfMTAyNw_1be29b36-ddc4-452b-a091-419557c1b57d"
      unitRef="usd">25000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184OC9mcmFnOjgyZWIxNTk5NmI2ZjQ5MDFhMjY0NzI0NTFiMmIyNjhlL3RleHRyZWdpb246ODJlYjE1OTk2YjZmNDkwMWEyNjQ3MjQ1MWIyYjI2OGVfNzg1MQ_f51e3c65-6489-476f-b822-e59cc90fd5e8">INCOME TAXES&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For interim financial statement purposes, U.S. GAAP income tax expense/benefit related to ordinary income is determined by applying an estimated annual effective income tax rate against a company&#x2019;s ordinary income. Income tax expense/benefit related to items not characterized as ordinary income is recognized as a discrete item when incurred. The estimation of the Company&#x2019;s income tax provision requires the use of management forecasts and other estimates, application of statutory income tax rates, and an evaluation of valuation allowances. The Company&#x2019;s estimated annual effective income tax rate may be revised, if necessary, in each interim period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Benefit from income taxes for the three months ended March 31, 2022 was $16 million and included: (i) $14&#160;million of income tax expense for the Company&#x2019;s ordinary loss for the three months ended March 31, 2022 and (ii) $30 million of net income tax benefit for discrete items, which includes: (a) $36&#160;million of net income tax benefit tax provision recognized for changes in uncertain tax positions, and (b) a $6&#160;million tax provision associated with filing certain tax returns.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provision for income taxes for the three months ended March 31, 2021 was $16 million and included: (i) $49 million of net income tax provision for discrete items, which includes: (a) a $46&#160;million tax provision related to potential and recognized withholding tax on intercompany dividends, (b) a $6&#160;million tax benefit associated with the filing of certain tax returns, (c) a $6 million tax benefit related to a deduction for stock compensation (d) a $3 million tax provision recognized for changes in uncertain tax positions and (ii) $33&#160;million of income tax benefit for the Company&#x2019;s ordinary loss for the three months ended March 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, the provision for income taxes will increase or decrease, respectively, in the period such determination is made except that, as a result of the 2018 adoption of guidance regarding intra-entity transfers, any change in valuation allowance surrounding the adoption of the intra-entity transfer resulting from this adoption was recorded within equity. The valuation allowance against deferred tax assets was $2,252 million and $2,222 million as of March&#160;31, 2022 and December&#160;31, 2021, respectively. The decrease was primarily due to loss in Canada. The Company will continue to assess the need for a valuation allowance on a go-forward basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 8, 2021, the Organisation for Economic Co-operation and Development (&#x201c;OECD&#x201d;)/G20 inclusive framework on Base Erosion and Profit Shifting (the &#x201c;Inclusive Framework&#x201d;) published a statement updating and finalizing the key components of a two-pillar plan on global tax reform originally agreed on July 1, 2021, and a timetable for implementation by 2023. The Inclusive Framework plan has now been agreed to by 141 OECD members, including several countries which did not agree to the initial plan. Under pillar one, taxing rights over multinational businesses with global turnover above &#x20ac;20 billion and a profit margin above 10% will generally be re-allocated to market jurisdictions. Under pillar two, the Inclusive Framework has agreed on a global minimum corporate tax rate of 15% for companies with revenue above &#x20ac;750 million, calculated on a country-by-country basis. On October 30, 2021, the G20 formally endorsed the new global minimum corporate tax rate rules. The Inclusive Framework agreement must now be implemented by the OECD Members who have agreed to the plan, effective in 2023. On December 20, 2021, the OECD published model rules to implement the pillar two rules, which are generally consistent with agreements reached by the Inclusive Framework in October 2021. Additional guidance is expected to be published in 2022. The Company will continue to monitor the implementation of the Inclusive Framework agreement by the countries in which we operate. While the Company is unable to predict when and how the Inclusive Framework agreement will be enacted into law in these countries, it is possible that the implementation of the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inclusive Framework agreement, including the global minimum corporate tax rate could have a material effect on the Company&#x2019;s liability for corporate taxes and the Company&#x2019;s consolidated effective tax rate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2022 and December&#160;31, 2021, the Company had $876 million and $927 million of unrecognized tax benefits, which included $43 million and $41 million of interest and penalties, respectively. Of the total unrecognized tax benefits as of March&#160;31, 2022, $196 million would reduce the Company&#x2019;s effective tax rate, if recognized. The Company believes that it is reasonably possible that the total amount of unrecognized tax benefits at March&#160;31, 2022 could decrease by approximately $21 million in the next 12 months as a result of the resolution of certain tax audits and other events.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to be under examination by the Canada Revenue Agency. The Company&#x2019;s position as of March&#160;31, 2022 with regard to proposed audit adjustments was updated to reflect an updated assessment received for 2015 which would primarily result in a loss of tax attributes that are subject to a full valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, the Company undertook an internal restructuring in the form of what is commonly known as a Granite Trust transaction, which resulted in a recorded capital loss (the &#x201c;2017 capital loss&#x201d;). In the U.S., the 2014 tax year remains open to the extent of the portion of the 2017 capital loss carried back to that year. The Internal Revenue Service (&#x201c;IRS&#x201d;) is continuing its examination of the Company&#x2019;s annual tax filings for 2015 and 2016 and the Company&#x2019;s short period tax return for the period ended September 8, 2017, which was filed as a result of the Company&#x2019;s internal restructuring efforts during 2017. Recently, the Company has received a notice of proposed adjustment from the IRS that would disallow the 2017 capital loss. To date, the Company has not received an assessment from the IRS but expects to receive a notice of proposed tax deficiency. The Company intends to contest any proposed tax deficiency through the IRS administrative appeals process, and if necessary, appropriate litigation. If the Company were ultimately unsuccessful in defending its position, and all or a substantial portion of the 2017 capital loss deduction were disallowed, the Company estimates, in a worst case scenario, that it could be liable for additional income taxes (excluding penalties and interest) of up to $2,100&#160;million, which could have an adverse effect on the Company&#x2019;s financial condition and results of operations. The Company intends to vigorously defend its position, including through appropriate litigation, if necessary, and ultimately believes it will sustain its deduction of the 2017 capital loss, and, accordingly, no income tax provision has been recorded. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s U.S. affiliates remain under examination for various state tax audits in the U.S. for years 2015 through 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s subsidiaries in Germany are under audit for tax years 2014 through 2016. At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company&#x2019;s Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s subsidiaries in Australia are under audit by the Australian Taxation Office for various years beginning in 2011 through 2017. At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company&#x2019;s Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain affiliates of the Company in regions outside of Canada, the U.S., Germany and Australia are currently under examination by relevant taxing authorities, and all necessary accruals have been recorded, including uncertain tax benefits.  At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company&#x2019;s Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184OC9mcmFnOjgyZWIxNTk5NmI2ZjQ5MDFhMjY0NzI0NTFiMmIyNjhlL3RleHRyZWdpb246ODJlYjE1OTk2YjZmNDkwMWEyNjQ3MjQ1MWIyYjI2OGVfNzA3_9b5e2a8f-0ce4-4497-b3b1-3bee482dda94"
      unitRef="usd">-16000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184OC9mcmFnOjgyZWIxNTk5NmI2ZjQ5MDFhMjY0NzI0NTFiMmIyNjhlL3RleHRyZWdpb246ODJlYjE1OTk2YjZmNDkwMWEyNjQ3MjQ1MWIyYjI2OGVfNzI4_e5324ef9-1c49-421e-bf50-c0ede4ec60a0"
      unitRef="usd">14000000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <bhc:EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184OC9mcmFnOjgyZWIxNTk5NmI2ZjQ5MDFhMjY0NzI0NTFiMmIyNjhlL3RleHRyZWdpb246ODJlYjE1OTk2YjZmNDkwMWEyNjQ3MjQ1MWIyYjI2OGVfODA1_326a4b88-4a46-4194-a0f9-ce5d961546a8"
      unitRef="usd">-30000000</bhc:EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184OC9mcmFnOjgyZWIxNTk5NmI2ZjQ5MDFhMjY0NzI0NTFiMmIyNjhlL3RleHRyZWdpb246ODJlYjE1OTk2YjZmNDkwMWEyNjQ3MjQ1MWIyYjI2OGVfODc0_0ca882a1-66af-40f7-a182-9f21cc909e7e"
      unitRef="usd">-36000000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <bhc:EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184OC9mcmFnOjgyZWIxNTk5NmI2ZjQ5MDFhMjY0NzI0NTFiMmIyNjhlL3RleHRyZWdpb246ODJlYjE1OTk2YjZmNDkwMWEyNjQ3MjQ1MWIyYjI2OGVfMTIwMQ_daf72e3a-3fd7-46a2-bf09-2069667f7bec"
      unitRef="usd">6000000</bhc:EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184OC9mcmFnOjgyZWIxNTk5NmI2ZjQ5MDFhMjY0NzI0NTFiMmIyNjhlL3RleHRyZWdpb246ODJlYjE1OTk2YjZmNDkwMWEyNjQ3MjQ1MWIyYjI2OGVfMTI5Mw_9815a60a-12c3-45e7-bd14-b54a5c6101c6"
      unitRef="usd">16000000</us-gaap:IncomeTaxExpenseBenefit>
    <bhc:EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184OC9mcmFnOjgyZWIxNTk5NmI2ZjQ5MDFhMjY0NzI0NTFiMmIyNjhlL3RleHRyZWdpb246ODJlYjE1OTk2YjZmNDkwMWEyNjQ3MjQ1MWIyYjI2OGVfMTMxNA_d6ee057c-398d-42fd-80e7-c756ed98a55d"
      unitRef="usd">49000000</bhc:EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount>
    <bhc:EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184OC9mcmFnOjgyZWIxNTk5NmI2ZjQ5MDFhMjY0NzI0NTFiMmIyNjhlL3RleHRyZWdpb246ODJlYjE1OTk2YjZmNDkwMWEyNjQ3MjQ1MWIyYjI2OGVfMTM4Mw_42fce428-cc73-483b-a54d-85a433aa9a26"
      unitRef="usd">46000000</bhc:EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184OC9mcmFnOjgyZWIxNTk5NmI2ZjQ5MDFhMjY0NzI0NTFiMmIyNjhlL3RleHRyZWdpb246ODJlYjE1OTk2YjZmNDkwMWEyNjQ3MjQ1MWIyYjI2OGVfMTQ1OQ_18488f30-01b2-431a-a445-6cd374c7d36a"
      unitRef="usd">-6000000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184OC9mcmFnOjgyZWIxNTk5NmI2ZjQ5MDFhMjY0NzI0NTFiMmIyNjhlL3RleHRyZWdpb246ODJlYjE1OTk2YjZmNDkwMWEyNjQ3MjQ1MWIyYjI2OGVfMTUzMg_4cd30574-9948-4e80-b3fd-605494c91c05"
      unitRef="usd">-6000000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184OC9mcmFnOjgyZWIxNTk5NmI2ZjQ5MDFhMjY0NzI0NTFiMmIyNjhlL3RleHRyZWdpb246ODJlYjE1OTk2YjZmNDkwMWEyNjQ3MjQ1MWIyYjI2OGVfMTYwOA_8bd3d62d-addb-4cfd-963c-f8fc4ddc9fcf"
      unitRef="usd">3000000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184OC9mcmFnOjgyZWIxNTk5NmI2ZjQ5MDFhMjY0NzI0NTFiMmIyNjhlL3RleHRyZWdpb246ODJlYjE1OTk2YjZmNDkwMWEyNjQ3MjQ1MWIyYjI2OGVfMTc1MQ_5e78c59f-4b49-4a34-bf04-e0ec06f2b6a8"
      unitRef="usd">-33000000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184OC9mcmFnOjgyZWIxNTk5NmI2ZjQ5MDFhMjY0NzI0NTFiMmIyNjhlL3RleHRyZWdpb246ODJlYjE1OTk2YjZmNDkwMWEyNjQ3MjQ1MWIyYjI2OGVfMjUwMA_b8dd3a60-61c9-451f-904f-b7017cbbb614"
      unitRef="usd">2252000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184OC9mcmFnOjgyZWIxNTk5NmI2ZjQ5MDFhMjY0NzI0NTFiMmIyNjhlL3RleHRyZWdpb246ODJlYjE1OTk2YjZmNDkwMWEyNjQ3MjQ1MWIyYjI2OGVfMjUwNw_6a1e609c-8158-4a2e-b70d-9476d3935380"
      unitRef="usd">2222000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184OC9mcmFnOjgyZWIxNTk5NmI2ZjQ5MDFhMjY0NzI0NTFiMmIyNjhlL3RleHRyZWdpb246ODJlYjE1OTk2YjZmNDkwMWEyNjQ3MjQ1MWIyYjI2OGVfNDM4MA_724eb3a5-2768-4c24-ac91-6144c797e8b7"
      unitRef="usd">876000000</bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties>
    <bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184OC9mcmFnOjgyZWIxNTk5NmI2ZjQ5MDFhMjY0NzI0NTFiMmIyNjhlL3RleHRyZWdpb246ODJlYjE1OTk2YjZmNDkwMWEyNjQ3MjQ1MWIyYjI2OGVfNDM4Nw_a94816db-d2c7-4b7c-8003-79f2e1a055bb"
      unitRef="usd">927000000</bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184OC9mcmFnOjgyZWIxNTk5NmI2ZjQ5MDFhMjY0NzI0NTFiMmIyNjhlL3RleHRyZWdpb246ODJlYjE1OTk2YjZmNDkwMWEyNjQ3MjQ1MWIyYjI2OGVfNDQzNQ_3db16d0f-c705-4729-9621-6298d91cb136"
      unitRef="usd">43000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="idc41203b79724c8b8c35295ae22f1ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184OC9mcmFnOjgyZWIxNTk5NmI2ZjQ5MDFhMjY0NzI0NTFiMmIyNjhlL3RleHRyZWdpb246ODJlYjE1OTk2YjZmNDkwMWEyNjQ3MjQ1MWIyYjI2OGVfNDQ0Mg_350a407c-b6b8-4993-a6ad-a627a80bc84f"
      unitRef="usd">41000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184OC9mcmFnOjgyZWIxNTk5NmI2ZjQ5MDFhMjY0NzI0NTFiMmIyNjhlL3RleHRyZWdpb246ODJlYjE1OTk2YjZmNDkwMWEyNjQ3MjQ1MWIyYjI2OGVfNDUzNQ_86816eb3-9da4-44cf-b619-604b175b803d"
      unitRef="usd">196000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184OC9mcmFnOjgyZWIxNTk5NmI2ZjQ5MDFhMjY0NzI0NTFiMmIyNjhlL3RleHRyZWdpb246ODJlYjE1OTk2YjZmNDkwMWEyNjQ3MjQ1MWIyYjI2OGVfNDc0MQ_bd27c767-0664-48de-9e6b-bed935d5826f"
      unitRef="usd">21000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY184OC9mcmFnOjgyZWIxNTk5NmI2ZjQ5MDFhMjY0NzI0NTFiMmIyNjhlL3RleHRyZWdpb246ODJlYjE1OTk2YjZmNDkwMWEyNjQ3MjQ1MWIyYjI2OGVfNjQ2NQ_e5e440b6-6ddb-42f0-bee4-ddb5772e2f10"
      unitRef="usd">2100000000</us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185MS9mcmFnOmIyN2I0MDRkZDY5YzQwMjFiNmVhNjg3NGE0ZjI5NGQyL3RleHRyZWdpb246YjI3YjQwNGRkNjljNDAyMWI2ZWE2ODc0YTRmMjk0ZDJfMTI1MA_7cd7165a-c6a6-4917-be55-7f716460dec0">LOSS PER SHARE&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss per share attributable to Bausch Health Companies Inc. were calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Bausch Health Companies Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(610)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted weighted-average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted loss per share attributable to Bausch Health Companies Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2022 and 2021, all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive. The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been approximately 3,600,000 and 6,657,000 common shares for the three months ended March 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2022 and 2021, time-based RSUs, performance-based RSUs and stock options to purchase approximately 9,332,000 and 4,846,000 common shares, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method. During the three &lt;/span&gt;&lt;/div&gt;months ended March 31, 2022, an additional 156,000 performance-based RSUs were not included in the computation of diluted earnings per share as the required performance conditions had not been met.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185MS9mcmFnOmIyN2I0MDRkZDY5YzQwMjFiNmVhNjg3NGE0ZjI5NGQyL3RleHRyZWdpb246YjI3YjQwNGRkNjljNDAyMWI2ZWE2ODc0YTRmMjk0ZDJfMTI2MA_64eb8a11-5ddb-4f0d-a9ea-473e70c5a4be">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss per share attributable to Bausch Health Companies Inc. were calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Bausch Health Companies Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(610)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted weighted-average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted loss per share attributable to Bausch Health Companies Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185MS9mcmFnOmIyN2I0MDRkZDY5YzQwMjFiNmVhNjg3NGE0ZjI5NGQyL3RhYmxlOjBhMDg4ZDNlYjBlZTQ5OTBiY2Q1YWFhNDhjN2E0M2ZhL3RhYmxlcmFuZ2U6MGEwODhkM2ViMGVlNDk5MGJjZDVhYWE0OGM3YTQzZmFfMi01LTEtMS04OTA3Mg_659f2e29-9a97-4ab5-8542-86eae9db9df8"
      unitRef="usd">-69000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185MS9mcmFnOmIyN2I0MDRkZDY5YzQwMjFiNmVhNjg3NGE0ZjI5NGQyL3RhYmxlOjBhMDg4ZDNlYjBlZTQ5OTBiY2Q1YWFhNDhjN2E0M2ZhL3RhYmxlcmFuZ2U6MGEwODhkM2ViMGVlNDk5MGJjZDVhYWE0OGM3YTQzZmFfMi03LTEtMS04OTA3Mg_369c0376-acd7-4221-b1b9-a80a0d5253dd"
      unitRef="usd">-610000000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185MS9mcmFnOmIyN2I0MDRkZDY5YzQwMjFiNmVhNjg3NGE0ZjI5NGQyL3RhYmxlOjBhMDg4ZDNlYjBlZTQ5OTBiY2Q1YWFhNDhjN2E0M2ZhL3RhYmxlcmFuZ2U6MGEwODhkM2ViMGVlNDk5MGJjZDVhYWE0OGM3YTQzZmFfMy01LTEtMS04OTA3Mg_e6341211-22c5-4e8d-9d08-6e5a2dfd55fc"
      unitRef="shares">360800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185MS9mcmFnOmIyN2I0MDRkZDY5YzQwMjFiNmVhNjg3NGE0ZjI5NGQyL3RhYmxlOjBhMDg4ZDNlYjBlZTQ5OTBiY2Q1YWFhNDhjN2E0M2ZhL3RhYmxlcmFuZ2U6MGEwODhkM2ViMGVlNDk5MGJjZDVhYWE0OGM3YTQzZmFfMy01LTEtMS04OTA3Mg_f6333850-e51f-4b8d-b24f-f7cdca664bba"
      unitRef="shares">360800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185MS9mcmFnOmIyN2I0MDRkZDY5YzQwMjFiNmVhNjg3NGE0ZjI5NGQyL3RhYmxlOjBhMDg4ZDNlYjBlZTQ5OTBiY2Q1YWFhNDhjN2E0M2ZhL3RhYmxlcmFuZ2U6MGEwODhkM2ViMGVlNDk5MGJjZDVhYWE0OGM3YTQzZmFfMy03LTEtMS04OTA3Mg_4ad30366-a60d-45f8-87e0-3333fbc4dffa"
      unitRef="shares">356800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185MS9mcmFnOmIyN2I0MDRkZDY5YzQwMjFiNmVhNjg3NGE0ZjI5NGQyL3RhYmxlOjBhMDg4ZDNlYjBlZTQ5OTBiY2Q1YWFhNDhjN2E0M2ZhL3RhYmxlcmFuZ2U6MGEwODhkM2ViMGVlNDk5MGJjZDVhYWE0OGM3YTQzZmFfMy03LTEtMS04OTA3Mg_5d3cff9e-3265-465c-ba1f-047936d2cb35"
      unitRef="shares">356800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185MS9mcmFnOmIyN2I0MDRkZDY5YzQwMjFiNmVhNjg3NGE0ZjI5NGQyL3RhYmxlOjBhMDg4ZDNlYjBlZTQ5OTBiY2Q1YWFhNDhjN2E0M2ZhL3RhYmxlcmFuZ2U6MGEwODhkM2ViMGVlNDk5MGJjZDVhYWE0OGM3YTQzZmFfNy01LTEtMS04OTA3Mg_f266d57c-b5a0-476e-a1b5-5001a199c220"
      unitRef="usdPerShare">-0.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185MS9mcmFnOmIyN2I0MDRkZDY5YzQwMjFiNmVhNjg3NGE0ZjI5NGQyL3RhYmxlOjBhMDg4ZDNlYjBlZTQ5OTBiY2Q1YWFhNDhjN2E0M2ZhL3RhYmxlcmFuZ2U6MGEwODhkM2ViMGVlNDk5MGJjZDVhYWE0OGM3YTQzZmFfNy01LTEtMS04OTA3Mg_f94db0b8-c47c-411f-a96f-5bb5b15b8d0b"
      unitRef="usdPerShare">-0.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185MS9mcmFnOmIyN2I0MDRkZDY5YzQwMjFiNmVhNjg3NGE0ZjI5NGQyL3RhYmxlOjBhMDg4ZDNlYjBlZTQ5OTBiY2Q1YWFhNDhjN2E0M2ZhL3RhYmxlcmFuZ2U6MGEwODhkM2ViMGVlNDk5MGJjZDVhYWE0OGM3YTQzZmFfNy03LTEtMS04OTA3Mg_3a78cb4a-cd74-4e5a-82bb-785a086facdc"
      unitRef="usdPerShare">-1.71</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185MS9mcmFnOmIyN2I0MDRkZDY5YzQwMjFiNmVhNjg3NGE0ZjI5NGQyL3RhYmxlOjBhMDg4ZDNlYjBlZTQ5OTBiY2Q1YWFhNDhjN2E0M2ZhL3RhYmxlcmFuZ2U6MGEwODhkM2ViMGVlNDk5MGJjZDVhYWE0OGM3YTQzZmFfNy03LTEtMS04OTA3Mg_ad100ef4-2766-48cf-a11e-b7f8b7476e4d"
      unitRef="usdPerShare">-1.71</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i634a33b4555248bda810d4755ec7944f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185MS9mcmFnOmIyN2I0MDRkZDY5YzQwMjFiNmVhNjg3NGE0ZjI5NGQyL3RleHRyZWdpb246YjI3YjQwNGRkNjljNDAyMWI2ZWE2ODc0YTRmMjk0ZDJfNDQz_9c613763-c2a1-4899-936a-f1105035d027"
      unitRef="shares">3600000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5cbb08e41ef540369a6004ec2d016b37_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185MS9mcmFnOmIyN2I0MDRkZDY5YzQwMjFiNmVhNjg3NGE0ZjI5NGQyL3RleHRyZWdpb246YjI3YjQwNGRkNjljNDAyMWI2ZWE2ODc0YTRmMjk0ZDJfNDUw_397831e2-9af3-4b23-8e97-e05f73f0087e"
      unitRef="shares">6657000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0765fea13c904226bd504d19d10dcd55_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185MS9mcmFnOmIyN2I0MDRkZDY5YzQwMjFiNmVhNjg3NGE0ZjI5NGQyL3RleHRyZWdpb246YjI3YjQwNGRkNjljNDAyMWI2ZWE2ODc0YTRmMjk0ZDJfNTky_906cd794-d875-4aa6-aed1-394408fe3412"
      unitRef="shares">9332000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1b08aef1966547e9bd168396be5172b8_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185MS9mcmFnOmIyN2I0MDRkZDY5YzQwMjFiNmVhNjg3NGE0ZjI5NGQyL3RleHRyZWdpb246YjI3YjQwNGRkNjljNDAyMWI2ZWE2ODc0YTRmMjk0ZDJfNTk5_6d1eb00a-de8b-4f32-819b-7b9f29b0a51b"
      unitRef="shares">4846000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <bhc:SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount
      contextRef="i6c234ad885934263b7d0d458906eac06_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185MS9mcmFnOmIyN2I0MDRkZDY5YzQwMjFiNmVhNjg3NGE0ZjI5NGQyL3RleHRyZWdpb246YjI3YjQwNGRkNjljNDAyMWI2ZWE2ODc0YTRmMjk0ZDJfODA5_49da0c0b-5659-4da2-93aa-54bcf6100f1a"
      unitRef="shares">156000</bhc:SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount>
    <bhc:SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount
      contextRef="i6c234ad885934263b7d0d458906eac06_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185MS9mcmFnOmIyN2I0MDRkZDY5YzQwMjFiNmVhNjg3NGE0ZjI5NGQyL3RleHRyZWdpb246YjI3YjQwNGRkNjljNDAyMWI2ZWE2ODc0YTRmMjk0ZDJfODA5_5f5fa1c1-662c-48e2-9bf9-603878807fe7"
      unitRef="shares">156000</bhc:SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfNDYwMjI_969d8b27-43eb-41b9-9a97-6710d08f2bab">LEGAL PROCEEDINGS&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company becomes involved in various legal and administrative proceedings, which include product liability, intellectual property, commercial, tax, antitrust, governmental and regulatory investigations, related private litigation and ordinary course employment-related issues. From time to time, the Company also initiates actions or files counterclaims. The Company could be subject to counterclaims or other suits in response to actions it may initiate. The Company believes that the prosecution of these actions and counterclaims is important to preserve and protect the Company, its reputation and its assets. Certain of these proceedings and actions are described in Note 20, &#x201c;LEGAL PROCEEDINGS,&#x201d; to the Company&#x2019;s Consolidated Financial Statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC and the CSA on February 23, 2022. Except as described below, there have been no material updates or developments with respect to any such proceedings or actions during the three months ended March 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On a quarterly basis, the Company evaluates developments in legal proceedings, potential settlements and other matters that could increase or decrease the amount of the liability accrued. As of March 31, 2022, the Company&#x2019;s Consolidated Balance Sheets includes accrued current loss contingencies of $1,530 million related to matters which are both probable and reasonably estimable. For all other matters, unless otherwise indicated, the Company cannot reasonably predict the outcome of these legal proceedings, nor can it estimate the amount of loss, or range of loss, if any, that may result from these proceedings. An adverse outcome in certain of these proceedings could have a material adverse effect on the Company&#x2019;s business, financial condition and results of operations, and could cause the market value of its common shares and/or debt securities to decline.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Governmental and Regulatory Inquiries&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As referenced above, during the three months ended March 31, 2022, there have been no material updates or developments with respect to certain other proceedings or actions as described under &#x201c;Governmental and Regulatory Inquiries&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Note 20, &#x201c;LEGAL PROCEEDINGS,&#x201d; to the Company&#x2019;s Consolidated Financial Statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC and the CSA on February 23, 2022. These matters include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investigation by the U.S. Attorney&#x2019;s Office for the District of Massachusetts - re OraPharma&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, the Company received a subpoena from the U.S. Attorney&#x2019;s Office for the District of Massachusetts, requesting materials including documents concerning the sales, marketing, coverage and reimbursement of Arestin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, including related support services, and other matters. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is cooperating with this investigation. The Company cannot predict the outcome or the duration of this investigation or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of this investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Securities and RICO Class Actions and Related Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. Securities Litigation - Opt-Out Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 16, 2019, the Company announced that it had agreed to settle, subject to final court approval, the consolidated securities class action filed in the U.S. District Court for the District of New Jersey (In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658). On January 31, 2021, the District Court issued an order granting final approval of this settlement. On February 4, 2021, Timber Hill LLC filed a notice of appeal of the Court&#x2019;s final approval order, which overruled its objections to the allocation of settlement proceeds as between common stock and options. On March 1, 2021, Cathy Lochridge filed a notice of appeal of the Court&#x2019;s final approval order, which overruled her objections as to the attorneys&#x2019; fees awarded to class counsel. On October 14, 2021, Timber Hill LLC dismissed its appeal of the final approval order. On December 20, 2021, the Third Circuit denied Lochridge&#x2019;s appeal. On January 3, 2022, Lochridge filed a petition for rehearing of the appeal en banc which remains pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2015, four putative securities class actions were filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. The allegations related to, among other things, allegedly false and misleading statements and/or failures to disclose information about the Company&#x2019;s business and prospects, including relating to drug pricing, the Company&#x2019;s use of specialty pharmacies, and the Company&#x2019;s relationship with Philidor. On May 31, 2016, the court entered an order consolidating the four actions under the caption In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658. On December 16, 2019, the Company, the current or former officers and directors, ValueAct, and the underwriters announced that they agreed to resolve the securities action for $1,210 million, subject to final court approval. This settlement received final approval from the court on January &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31, 2021 and will resolve and discharge all claims against the Company in the class action. As part of the settlement, the Company and the other settling defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. The settlement remains subject to appeal of the final court approval (as such appeal is further described above). In order to qualify for a settlement payment all persons and entities that purchased or otherwise acquired the Company securities during the class period must have submitted a proof of claim and release form by May 6, 2020. The settlement payments have been paid into an escrow account in accordance with the payment schedule outlined in the settlement agreement. These payments, less certain settlement expenses and attorneys&#x2019; fees, will remain in escrow until resolution of the appeal of the final court approval of the settlement agreement. The opt-out litigations discussed below remain ongoing. As of March 31, 2022, Restricted cash and other settlement deposits includes an aggregate $1,210&#160;million of: (i) payments in the escrow fund and (ii) certain disbursements for settlement expenses and attorney&#x2019;s fees. Disbursements for attorney&#x2019;s fees remain refundable until resolution of the appeal of the final court approval of the settlement agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 6, 2018, a putative class action was filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. This action, captioned Timber Hill LLC, v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 18-cv-10246) (&#x201c;Timber Hill&#x201d;), asserts securities fraud claims under Sections 10(b) and 20(a) of the Exchange Act on behalf of a putative class of persons who purchased call options or sold put options on the Company&#x2019;s common stock during the period January 4, 2013 through August 11, 2016. On June 11, 2018, this action was consolidated with In re Valeant Pharmaceuticals International, Inc. Securities Litigation, (Case No. 15-cv-07658). On January 14, 2019, the defendants filed a motion to dismiss the Timber Hill complaint. Briefing on that motion was completed on February 13, 2019. On August 15, 2019, the Court denied the motion to dismiss the Timber Hill action, holding that this complaint was a legal nullity as a result of the June 11, 2018 consolidation order.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the consolidated putative class action, thirty-seven groups of individual investors in the Company&#x2019;s stock and debt securities have chosen to opt out of the consolidated putative class action and filed securities actions in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. These actions were captioned previously in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2021, filed on February 23, 2022. Sixteen of the thirty-seven opt-out actions have been dismissed; and the total number of remaining opt-out actions pending in the District of New Jersey is twenty-one actions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These individual shareholder actions assert claims under Sections 10(b), and 20(a) of the Exchange Act. Certain of these individual actions assert additional claims, including claims under Section 18 of the Exchange Act, Sections 11, 12(a)(2), and 15 of the Securities Act, common law fraud, negligent misrepresentation, and claims under the New Jersey Racketeer Influenced and Corrupt Organizations Act. These claims are based on alleged purchases of Company stock, options, and/or debt at various times between January 3, 2013 and August 10, 2016. The allegations in the complaints are similar to those made by plaintiffs in the putative class action. Motions to dismiss have been filed and in most cases decided in many of these individual actions. To date, the Court has dismissed state law claims including New Jersey Racketeer Influenced and Corrupt Organizations Act, common law fraud, and negligent misrepresentation claims in certain cases. On January 7, 2019, the Court entered a stipulation of voluntary dismissal in the Senzar Healthcare Master Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-02286) opt-out action, closing the case. On September 10, 2019, the Court granted defendants&#x2019; motion to dismiss all claims in the Bahaa Aly v. Valeant Pharmaceuticals International, Inc. (&#x201c;Aly&#x201d;) (Case No. 18-cv-17393) opt-out action. On October 9, 2019, the Aly Plaintiffs filed a notice of appeal to the United States Court of Appeals for the Third Circuit. On June 16, 2021, the Court of Appeals granted plaintiffs&#x2019; appeal in the Aly action. This action has been remanded to the District Court. On June 19, 2020, the Court entered stipulations of voluntary dismissal in the Catalyst, Mississippi, Connecticut, and Delaware actions. On July 13, 2020, the Court entered a stipulation of voluntary dismissal in the NYCERS action. On December 30, 2020, the Court entered a stipulation of voluntary dismissal in the BlueMountain action. On February 18, 2021, and March 10, 2021, the Court entered stipulations of voluntary dismissal in the T. Rowe, BloombergSen, Principal Funds, Pentwater, Lord Abbett, Equity Trustees, and UC Regents actions. On April 30, 2021, the Court entered a stipulation of voluntary dismissal in the Florida SBA action. On July 20, 2021, the Court entered a stipulation of voluntary dismissal in the Janus action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company disputes the claims against it in the remaining individual opt-out complaints and intends to defend itself vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Canadian Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2015, six putative class actions were filed and served against the Company and certain current or former officers and directors in Canada in the provinces of British Columbia, Ontario and Quebec. The Company is also aware of two additional putative class actions that were filed with the applicable court but which have not been served on the Company and the factual allegations made in these actions are substantially similar to those outlined herein. These actions were captioned previously in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2021, filed on February 23, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The actions generally allege violations of Canadian provincial securities legislation on behalf of putative classes of persons who purchased or otherwise acquired securities of the Company for periods commencing as early as January 1, 2013 and ending as late as November 16, 2015. The alleged violations relate to the same matters described in the U.S. Securities Litigation description above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each of these putative class actions, other than the Catucci action in the Quebec Superior Court, was discontinued. In the Catucci action, on August 29, 2017, the judge granted the plaintiffs leave to proceed with their claims under the Quebec Securities Act and authorized the class proceeding. On October 26, 2017, the plaintiffs issued their Judicial Application Originating Class Proceedings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;After a hearing on November 11, 2019, the court approved a settlement in the Catucci action between the class members and the Company&#x2019;s auditors and the action was dismissed as against them. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 4, 2020, the Company entered into a settlement agreement with the plaintiffs in Catucci, on behalf of the class, pursuant to which it agreed to resolve the Catucci action for the amount of CAD 94,000,000 plus payment of an additional amount to cover notice and settlement administration costs and disbursements. As part of the settlement, the Company and the other defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. Court approval of the settlement was granted after a hearing on November 16, 2020. The Catucci action has now been dismissed against the Company, its current and former directors and officers, its underwriters and its insurers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the class proceedings described above, on April 12, 2018, the Company was served with an application for leave filed in the Quebec Superior Court of Justice to pursue an action under the Quebec Securities Act against the Company and certain current or former officers and directors. This proceeding is captioned BlackRock Asset Management Canada Limited et al. v. Valeant, et al. (Court File No. 500-11-054155-185). The allegations in the proceeding are similar to those made by plaintiffs in the Catucci class action. On June 18, 2018, the same BlackRock entities filed an originating application (Court File No. 500-17-103749-183) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is aware that certain other members of the Catucci class exercised their opt-out rights prior to the June 19, 2018 deadline. On February 15, 2019, one of the entities which exercised its opt-out rights, the California State Teachers&#x2019; Retirement System (&#x201c;CalSTRS&#x201d;), served the Company with an application in the Quebec Superior Court of Justice for leave to pursue an action under the Quebec Securities Act against the Company, certain current or former officers and directors of the Company and its auditor. That proceeding is captioned California State Teachers&#x2019; Retirement System v. Bausch Health Companies Inc. et al. (Court File No. 500-11-055722-181). The allegations in the proceeding are similar to those made by the plaintiffs in the Catucci class action and in the BlackRock opt-out proceedings. On that same date, CalSTRS also served the Company with proceedings (Court File No. 500-17-106044-186) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 3, 2020, the Quebec Superior Court granted the applications of CalSTRS and BlackRock for leave to pursue their respective actions asserting claims under the Quebec Securities Act. On June 16, 2020, the Quebec Court of Appeal granted the defendants leave to appeal that decision. The appeal was heard on September 29, 2021 and, by judgment dated October 29, 2021, the appeals were dismissed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 8 and 9, 2020, respectively, CalSTRS amended its proceedings to, among other things, include a new alleged misrepresentation concerning the accounting treatment of &#x201c;price appreciation credits&#x201d; in respect of Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; during the period covered by the claims. A hearing was held on February 17, 2021 with respect to whether CalSTRS would be permitted to file the proposed amended proceedings.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 9, 2021, the Quebec Superior Court granted the Company&#x2019;s application to strike the new allegations from its Quebec Securities Act claim, but permitted the amendments to its claim under the Quebec Civil Code. On December 8, 2021, CalSTRS delivered its amended pleadings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 17, 2021, four additional opt-outs from the Catucci class issued a Statement of Claim in the Ontario Superior Court of Justice. That proceeding is captioned The Bank of Korea et al. v. Valeant Pharmaceuticals International Inc. et al. (Court File No. 21-006589666-0000). In addition, these plaintiffs also served and filed a motion for leave to pursue claims under the Ontario Securities Act. The allegations in this proceeding are similar to those made by the plaintiffs in the Catucci class action and the plaintiffs in the opt-out actions described above. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that it has viable defenses in each of these actions. In each case, the Company intends to defend itself vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;RICO Class Actions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Between May 27, 2016 and September 16, 2016, three actions were filed in the U.S. District Court for the District of New Jersey against the Company and various third-parties (these actions were subsequently consolidated), alleging claims under &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the federal Racketeer Influenced Corrupt Organizations Act (&#x201c;RICO&#x201d;) on behalf of a putative class of certain third-party payors that paid claims submitted by Philidor for certain Company-branded drugs between January 2, 2013 and November 9, 2015.&#160; The consolidated complaint alleges, among other things, that the defendants committed predicate acts of mail and wire fraud by submitting or causing to be submitted prescription reimbursement requests that misstated or omitted facts regarding: (1) the identity and licensing status of the dispensing pharmacy; (2) the resubmission of previously denied claims; (3) patient co-pay waivers; (4) the availability of generic alternatives; and (5) the insured&#x2019;s consent to renew the prescription.&#160;The complaint further alleges that these acts constitute a pattern of racketeering or a racketeering conspiracy in violation of the RICO statute and caused plaintiffs and the putative class unspecified damages, which may be trebled under the RICO statute.&#160;On August 4, 2021, the Company executed a stipulation of settlement for this action and, on August 17, 2021, the Court preliminarily approved the settlement. On December 6, 2021 the Special Master overseeing this litigation issued a report and recommendation recommending final approval of the settlement, and on February 22, 2022 the settlement was approved by the district court. The time to appeal the district court&#x2019;s final approval order expired on March 24, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Securities and RICO Class Actions and Related Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As referenced above, during the three months ended March 31, 2022, there have been no material updates or developments with respect to certain other proceedings or actions as described under &#x201c;Securities and RICO Class Actions and Related Matters&#x201d; in Note 20, &#x201c;LEGAL PROCEEDINGS,&#x201d; to the Company&#x2019;s Consolidated Financial Statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC and the CSA on February 23, 2022. Such matters include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Insurance Coverage Lawsuit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 7, 2017, the Company filed a lawsuit against its insurance companies that issued insurance policies covering claims made against the Company, its subsidiaries, and its directors and officers during two distinct policy periods, (i) 2013-14 and (ii) 2015-16. The lawsuit is currently pending in the United States District Court for the District of New Jersey (Valeant Pharmaceuticals International, Inc., et al. v. AIG Insurance Company of Canada, et al.; Case No. 3:18-CV-00493). In the lawsuit, the Company seeks coverage for: (i) the costs of defending and resolving claims brought by former shareholders and debtholders of Allergan, Inc. in In re Allergan, Inc. Proxy Violation Securities Litigation and Timber Hill LLC, individually and on behalf of all others similarly situated v. Pershing Square Capital Management, L.P., et al. (the &#x201c;Allergan Securities Litigation&#x201d;) (under the 2013-2014 coverage period), and (ii) costs incurred and to be incurred in connection with the securities class actions and opt-out cases described in this section and the SEC Investigation and certain of the other investigations described under &#x201c;Complete or Inactive Matters&#x201d; in Note 20, &#x201c;LEGAL PROCEEDINGS,&#x201d; to the Company&#x2019;s Consolidated Financial Statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC and the CSA on February 24, 2021 and under &#x201c;Governmental and Regulatory Inquiries&#x201d; and &#x201c;Complete or Inactive Matters&#x201d; in Note 21, &#x201c;LEGAL PROCEEDINGS,&#x201d; to the Company&#x2019;s Consolidated Financial Statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC and the CSA on February 19, 2020 (under the 2015-2016 coverage period).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 20, 2021, the Company entered into settlement agreements with the insurers in the 2015-2016 coverage period in which the Company agreed to resolve its claims for insurance coverage in connection with the U.S. Securities Litigation and the Canadian Securities Litigation and related opt-out litigation and related investigations matters described above. On that same day, the Company entered into settlement agreements with two of its insurers in the 2013-2014 coverage period in which the Company agreed to resolve its claims against those two insurers only for insurance coverage in connection with the Allergan Securities Litigation. As a result of all of the settlement agreements entered into with the insurers on July 20, 2021, the Company has received an aggregate sum of $213&#160;million. The Company&#x2019;s insurance claims with respect to the Allergan Securities Litigation against the remaining insurers in the 2013-2014 coverage period remain pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Hound Partners Lawsuit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, Hound Partners Offshore Fund, LP, Hound Partners Long Master, LP, and Hound Partners Concentrated Master, LP, filed a lawsuit against the Company in the Superior Court of New Jersey Law Division/Mercer County that asserts claims for common law fraud, negligent misrepresentation, and violations of the New Jersey Racketeer Influenced and Corrupt Organizations Act. The Company disputes the claims and intends to vigorously defend this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Antitrust&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Glumetza Antitrust Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Between August 2019 and July 2020, eight (8) putative antitrust class actions and four (4) non-class complaints naming the Company, Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc., and Santarus, Inc. (for purposes of this subsection, collectively, the &#x201c;Company&#x201d;), among other defendants, were filed or transferred to the Northern District of California. Three (3) of the class actions were filed by plaintiffs seeking to represent a class of direct purchasers. The purported classes of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;direct purchasers filed a consolidated first amended complaint and a motion for class certification in April 2020. The court certified a direct purchaser class in August 2020. The putative class action complaints filed by end payer purchasers have all been voluntarily dismissed. Three (3) of the non-class complaints were filed by direct purchasers. The fourth non-class complaint, asserting claims based on both direct and indirect purchases, was filed by an insurer plaintiff in July 2020 and subsequently amended in September 2020. In December 2020, the court denied the Company&#x2019;s motion to dismiss as to the insurer plaintiff&#x2019;s direct claims but dismissed the insurer plaintiff&#x2019;s indirect claims. On February 2, 2021, the insurer plaintiff&#x2019;s motion for leave to amend its complaint was denied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These actions were consolidated and coordinated in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Glumetza Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Case No. 3:19-cv-05822-WHA (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Glumetza Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;). The lawsuits alleged that a 2012 settlement of a patent litigation regarding Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; or grant any other company a license to do so. The complaints alleged that the settlement agreement resulted in higher prices for Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and its generic equivalent both prior to and after generic entry. Both the class and non-class plaintiffs sought damages under federal antitrust laws for claims based on direct purchases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 8, 2021, the insurer plaintiff filed an action asserting its indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others (the &#x201c;State Court Action&#x201d;) (discussed in further detail below, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;see Glumetza State-Law Insurer Litigations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). Defendants&#x2019; demurrer in the State Court Action was heard on September 22, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 26, 2021, the Company reached an agreement in principle and, thereafter, on September 14, 2021, executed a final settlement agreement to resolve the class plaintiffs&#x2019; claims for $300&#160;million, subject to court approval. On August 1, 2021, the Company also reached an agreement in principle to resolve the non-class direct purchaser plaintiffs&#x2019; claims, described above, for additional consideration. A final settlement agreement with the non-class direct purchaser plaintiffs was executed on August 6, 2021. As part of the settlements, the Company admitted no liability as to the claims against it and denied all allegations of wrongdoing. On September 20, 2021, the insurer plaintiff voluntarily dismissed its claims in the consolidated federal action. By stipulation, the insurer plaintiff has asserted its direct opt-out claims in the State Court Action, resulting in the consolidation of all of its opt-out claims in the State Court Action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 22, 2021, the court granted preliminary approval of the class settlement agreement and vacated the October 2021 trial date and all other pre-trial deadlines in the consolidated actions. On February 3, 2022, the court granted final approval of the class settlement and ordered dismissal of the class plaintiffs&#x2019; claims. The deadline to appeal the final approval of the class settlement has now passed, and the settlements have resolved and discharged all asserted class and direct purchaser non-class claims against the Company in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Glumetza Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Generic Pricing Antitrust Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s subsidiaries, Oceanside Pharmaceuticals, Inc. (&#x201c;Oceanside&#x201d;), Bausch Health US, LLC (formerly Valeant Pharmaceuticals North America LLC) (&#x201c;Bausch Health US&#x201d;), and Bausch Health Americas, Inc. (formerly Valeant Pharmaceuticals International) (&#x201c;Bausch Health Americas&#x201d;) (for the purposes of this paragraph, collectively, the &#x201c;Company&#x201d;), are defendants in multidistrict antitrust litigation (&#x201c;MDL&#x201d;) entitled In re: Generic Pharmaceuticals Pricing Antitrust Litigation, pending in the United States District Court for the Eastern District of Pennsylvania (MDL 2724, 16- MD-2724). The lawsuits seek damages under federal and state antitrust laws, state consumer protection and unjust enrichment laws and allege that the Company&#x2019;s subsidiaries entered into a conspiracy to fix, stabilize, and raise prices, rig bids and engage in market and customer allocation for generic pharmaceuticals. The lawsuits, which have been brought as putative class actions by direct purchasers, end payers, and indirect resellers, and as direct actions by direct purchasers, end payers, insurers, States, and various Counties, Cities, and Towns, have been consolidated into the MDL. There are also additional, separate complaints which have been consolidated in the same MDL that do not name the Company or any of its subsidiaries as a defendant. There are cases pending in the Court of Common Pleas of Philadelphia County against the Company and other defendants related to the multidistrict litigation, but no complaint has been filed in the cases. The cases have been placed in deferred status. The Company disputes the claims against it and continues to defend itself vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, Bausch Health Companies Inc. and certain U.S. and Canadian subsidiaries (for the purposes of this paragraph, collectively the "Company&#x201d;) have been named as defendants in a proposed class proceeding entitled Kathryn Eaton v. Teva Canada Limited, et al. in the Federal Court in Toronto, Ontario, Canada (Court File No. T-607-20). The plaintiff seeks to certify a proposed class action on behalf of persons in Canada who purchased generic drugs in the private sector, alleging that the Company and other defendants violated the Competition Act by conspiring to allocate the market, fix prices, and maintain the supply of generic drugs, and seeking damages under federal law. The proposed class action contains similar allegations to the In re: Generic Pharmaceuticals Pricing Antitrust Litigation pending in the United States Court for the Eastern District of Pennsylvania. The Company disputes the claims against it and will defend itself vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Glumetza State-Law Insurer Litigations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 8, 2021, the insurer plaintiff from the federal &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Glumetza Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Case No. 3:19-cv-05822- WHA (N.D. Cal.) (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Glumetza Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) (discussed in further detail above) filed an action asserting its indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others (the &#x201c;State Court Action&#x201d;). The State Court Action alleges that a 2012 settlement of a patent litigation regarding Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or grant any other company a license to do so. The State Court Action alleges that the settlement agreement resulted in higher prices for Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and its generic equivalent both prior to and after generic entry. On September 20, 2021, the parties stipulated that the insurer plaintiff&#x2019;s direct opt-out claims from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Glumetza Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, discussed above, were deemed asserted in the State Court Action. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Defendants&#x2019; demurrer in the State Court Action was heard on September 22, 2021. On November 29, 2021, the court denied the motion in part and granted it in part as to certain state law claims, with leave to amend. The insurer plaintiff did not amend the complaint. Defendants&#x2019; answers were filed on February 3, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 5, 2022, Health Care Service Corporation filed an action with similar substantive allegations and similar indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company disputes the claims and intends to vigorously defend these matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intellectual Property&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Patent Litigation/Paragraph IV Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company (and/or certain of its affiliates) is also party to certain patent infringement proceedings in the United States and Canada, including as arising from claims filed by the Company (or that the Company anticipates filing within the required time periods) in connection with Notices of Paragraph IV Certification (in the United States) and Notices of Allegation (in Canada) received from third-party generic manufacturers respecting their pending applications for generic versions of certain products sold by or on behalf of the Company, including Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 550mg, Bryhali&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Trulance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lumify&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Relistor&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Injection in the United States and Jublia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in Canada, or other similar suits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 17, 2020, the Company and Alfasigma S.p.A. (&#x201c;Alfasigma&#x201d;) received a Notice of Paragraph IV Certification from Norwich Pharmaceuticals Inc. (&#x201c;Norwich&#x201d;), in which Norwich asserted that the U.S. patents listed in the FDA&#x2019;s Orange Book for the Company&#x2019;s Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; tablets, 550 mg, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Norwich&#x2019;s generic rifaximin tablets, 550 mg, for which an Abbreviated New Drug Application (&#x201c;ANDA&#x201d;) has been filed by Norwich. The Company, through its subsidiaries Salix Pharmaceuticals, Inc. and Bausch Health Ireland Limited, holds the New Drug Application for Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and owns or exclusively licenses (from Alfasigma) these patents.&#160;On March 26, 2020, certain of the Company&#x2019;s subsidiaries and Alfasigma filed suit against Norwich in the U.S. District Court for the District of Delaware (Case No. 20-cv-00430) pursuant to the Hatch-Waxman Act, alleging infringement by Norwich of one or more claims of the Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Patents, thereby triggering a 30-month stay of the approval of Norwich&#x2019;s ANDA for rifaximin tablets, 550 mg. Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is protected by 26 patents covering the composition of matter and the use of Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; listed in the FDA&#x2019;s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange&#160;Book. Trial in this matter was held in March 2022. A decision is pending. Post-trial briefing is expected to occur in the second quarter of 2022, with a decision expected in the third quarter of 2022. The Company remains confident in the strength of the Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; patents and will continue to vigorously pursue this matter and defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 23, 2020, the Company received a Notice of Paragraph IV Certification from Perrigo Israel Pharmaceuticals, Ltd. (now Padagis LLC) (&#x201c;Padagis&#x201d;), in which Padagis asserted that certain U.S. patents, each of which is listed in the FDA&#x2019;s Orange Book for Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (halobetasol propionate and tazarotine) lotion, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Padagis&#x2019; generic lotion, for which an ANDA has been filed by Padagis. On August 28, 2020, the Company filed suit against Padagis pursuant to the Hatch-Waxman Act, alleging infringement by Padagis of one or more claims of the Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Patents, thereby triggering a 30-month stay of the approval of the Padagis ANDA. On September 3, 2020, this action was consolidated with the action between the Company and Padagis described below, regarding Padagis&#x2019; ANDA for generic Bryhali&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (halobetasol propionate) lotion. A pre-trial conference in the consolidated action has been scheduled for July 20, 2022. The Company remains confident in the strength of the Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; related patents and will vigorously defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 20, 2020, the Company received a Notice of Paragraph IV Certification from Padagis, in which Padagis asserted that certain U.S. patents, each of which is listed in the FDA&#x2019;s Orange Book for Bryhali&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (halobetasol propionate) lotion, 0.01% are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Padagis&#x2019; generic halobetasol propionate lotion, for which an ANDA has been filed by Padagis. On May 1, 2020, the Company filed suit against Padagis pursuant to the Hatch-Waxman Act, alleging infringement by Padagis of one or more claims of the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bryhali&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Patents, thereby triggering a 30-month stay of the approval of the Padagis ANDA for halobetasol propionate lotion. On September 3, 2020, this action was consolidated with the action between the Company and Padagis described above, regarding Padagis&#x2019; ANDA for generic Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (halobetasol propionate and tazarotine) lotion. A pre-trial conference in the consolidated action has been scheduled for July 20, 2022. The Company remains confident in the strength of the Bryhali&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Patents and intends to vigorously pursue this matter and defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, the Company commenced litigation against MSN Laboratories Private Ltd. (&#x201c;MSN&#x201d;) and Mylan Pharmaceuticals Inc., (&#x201c;Mylan&#x201d;) alleging patent infringement by MSN&#x2019;s and Mylan&#x2019;s filing of their ANDA for generic Trulance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (plecanatide) 3mg tablets. This suit had been filed following receipt of a Notice of Paragraph IV Certification from each of MSN and Mylan, in which they had each asserted that the U.S. patents listed in the FDA&#x2019;s Orange Book for the Company&#x2019;s Trulance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; tablets, 3 mg, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of their respective generic plecanatide tablets, 3 mg. The filing of these suits triggered a 30-month stay of the approval of the MSN and Mylan ANDAs for plecanatide tablets. The Company remains confident in the strength of the Trulance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; patents and intends to vigorously pursue this matter and defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 16, 2021, the Company received a Notice of Paragraph IV Certification from Slayback Pharma LLC (&#x201c;Slayback&#x201d;), in which Slayback asserted that certain U.S. patents, each of which is listed in the FDA&#x2019;s Orange Book for Lumify&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (brimonidine tartrate solution) drops (the &#x201c;Lumify Patents&#x201d;), are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Slayback&#x2019;s generic drops, for which an ANDA has been filed by Slayback. The Company, through its affiliate Bausch + Lomb Ireland Limited, exclusively licenses the Lumify Patents from Eye Therapies, LLC (&#x201c;Eye Therapies&#x201d;). On September 10, 2021, B&amp;amp;L Inc., Bausch + Lomb Ireland Limited and Eye Therapies filed suit against Slayback pursuant to the Hatch-Waxman Act, alleging infringement by Slayback of one or more claims of the Lumify Patents, thereby triggering a 30-month stay of the approval of the Slayback ANDA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 20, 2022, B&amp;amp;L Inc. received a Notice of Paragraph IV Certification from Lupin Ltd. (&#x201c;Lupin&#x201d;), in which Lupin asserted that certain of the Lumify Patents are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Lupin&#x2019;s generic brimonidine tartrate solution, for which its ANDA No. 216716 has been filed by Lupin. On February 2, 2022, B&amp;amp;L Inc., Bausch + Lomb Ireland Limited and Eye Therapies filed suit against Lupin pursuant to the Hatch-Waxman Act, alleging patent infringement by Lupin of one or more claims of the Lumify Patents, thereby triggering a 30-month stay of the approval of the Lupin ANDA.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company remains confident in the strength of the Lumify&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; related patents and intends to vigorously defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, patents covering the Company&#x2019;s branded pharmaceutical products may be challenged in proceedings other than court proceedings, including inter partes review (&#x201c;IPR&#x201d;) at the U.S. Patent &amp;amp; Trademark Office. The proceedings operate under different standards from district court proceedings, and are often completed within 18 months of institution.&#160;IPR challenges have been brought against patents covering the Company&#x2019;s branded pharmaceutical products.&#160;For example, following Acrux DDS&#x2019;s IPR petition, the U.S. Patent and Trial Appeal Board (&#x201c;PTAB&#x201d;), in May 2017, instituted inter partes review for an Orange Book-listed patent covering Jublia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(U.S. Patent No. 7,214,506 (the &#x201c;&#x2018;506 Patent&#x201d;)) and, on June 6, 2018, issued a written determination invalidating such patent. An appeal of this decision was filed on August 7, 2018. On March 13, 2020, the Court of Appeals for the Federal Circuit reversed this decision and remanded the matter back to the PTAB for further proceedings. As a result of a settlement, a joint motion to terminate the proceedings was filed on November 12, 2020 and, on January 8, 2021, the PTAB granted this motion.  The &#x2018;506 Patent, therefore, remains valid and enforceable and expires in 2026. Jublia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;is covered by fourteen Orange Book-listed patents owned by the Company or its licensor, which expire in the years 2028 through 2035. In August and September 2018, the Company received notices of the filing of a number of ANDAs with paragraph IV certification, and has timely filed patent infringement suits against these ANDA filers, and, in addition, the Company has also commenced certain patent infringement proceedings in Canada against four separate defendants. All cases in U.S. regarding Jublia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; have been settled. In Canada, two lawsuits remain pending against Apotex Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Liability &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Shower to Shower&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Products Liability Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since 2016, the Company has been named in a number of product liability lawsuits involving the Shower to Shower&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; body powder product acquired in September 2012 from Johnson &amp;amp; Johnson; due to dismissals, twenty-nine (29) of such product liability suits currently remain pending. Potential liability (including its attorneys&#x2019; fees and costs) arising out of these remaining suits is subject to full indemnification obligations of Johnson &amp;amp; Johnson owed to the Company and its affiliates, and legal fees and costs will be paid by Johnson &amp;amp; Johnson. Twenty-eight (28) of these lawsuits filed by individual plaintiffs allege that the use of Shower to Shower&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; caused the plaintiffs to develop ovarian cancer, mesothelioma or breast cancer. The allegations in these cases include failure to warn, design defect, manufacturing defect, negligence, gross negligence, breach &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of express and implied warranties, civil conspiracy concert in action, negligent misrepresentation, wrongful death, loss of consortium and/or punitive damages. The damages sought include compensatory damages, including medical expenses, lost wages or earning capacity, loss of consortium and/or compensation for pain and suffering, mental anguish anxiety and discomfort, physical impairment and loss of enjoyment of life. Plaintiffs also seek pre- and post-judgment interest, exemplary and punitive damages, and attorneys&#x2019; fees. Additionally, two proposed class actions have been filed in Canada against the Company and various Johnson &amp;amp; Johnson entities (one in the Supreme Court of British Columbia and one in the Superior Court of Quebec), on behalf of persons who have purchased or used Johnson &amp;amp; Johnson&#x2019;s Baby Powder or Shower to Shower&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  The class actions allege the use of the product increases certain health risks (British Columbia) or negligence in failing to properly test, failing to warn of health risks, and failing to remove the products from the market in a timely manner (Quebec). The plaintiffs in these actions are seeking awards of general, special, compensatory and punitive damages. On November 17, 2020, the British Columbia court issued a judgment declining to certify a class as to the Company or Shower to Shower&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and at this time no appeal of that judgment has been filed. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 16, 2021, the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;plaintiff in the British Columbia class action filed a Second Amended Notice of Civil Claim and Application&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for Certification, removing the Company as a defendant; as a result, the British Columbia class action is concluded&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Johnson &amp;amp; Johnson, through one or more subsidiaries, has purported to have completed a Texas divisional merger with respect to any talc liabilities at Johnson &amp;amp; Johnson Consumer, Inc. (&#x201c;JJCI&#x201d;). LTL Management, LLC (&#x201c;LTL&#x201d;), the resulting entity of the divisional merger, assumed JJCI&#x2019;s talc liabilities and thereafter filed for Chapter 11 bankruptcy protection in the United States Bankruptcy Court for the Western District of North Carolina. Pursuant to court orders entered in November 2021, the case was transferred to the United States District Court for the District of New Jersey, and substantially all cases related to Johnson &amp;amp; Johnson&#x2019;s talc liability were stayed for a period of sixty (60) days pursuant to a preliminary injunction. Notwithstanding the divisional merger and LTL&#x2019;s bankruptcy case, the Company and its affiliates continue to have indemnification claims and rights against Johnson &amp;amp; Johnson and LTL pursuant to the terms of the indemnification agreement entered into between JJCI and its affiliates and the Company and its affiliates, which indemnification agreement remains in effect. As a result, it is the Company&#x2019;s current expectation that it will not incur any material impairments with respect to its indemnification claims as a result of the divisional merger or the bankruptcy. In December 2021, certain talc claimants filed motions to dismiss the bankruptcy case. Shortly thereafter, LTL filed a motion in the bankruptcy court to extend the 60-day preliminary injunction. On February 25, 2022, the bankruptcy court entered orders denying the motions to dismiss and extending the preliminary injunction staying substantially all cases subject to the indemnification agreement related to Johnson &amp;amp; Johnson&#x2019;s talc liability through at least June 29, 2022. The order denying the motions to dismiss and the order extending the preliminary injunction are subject to appeal and the bankruptcy court certified their appeals directly to the United States Court of Appeals for the Third Circuit. A petition to authorize the direct appeal is currently pending before the Court of Appeals. Further, pursuant to a court order dated March 18, 2022, the bankruptcy court directed certain talc claimants and LTL to mediate the issues related to the case in the hopes of achieving a global resolution. The Bankruptcy Court has also indicated that it intends to order separate mediation with respect to certain consumer protection claims against LTL by various state attorneys general. On May 4, 2022, the Bankruptcy Court extended LTL&#x2019;s exclusive period to file a chapter 11 plan until September 9, 2022. To the extent that any cases proceed during the pendency of the bankruptcy case, it is the Company&#x2019;s expectation that Johnson &amp;amp; Johnson, in accordance with the indemnification agreement, will continue to vigorously defend the Company in each of the remaining actions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;General Civil Actions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. Securities Litigation - New Jersey Declaratory Judgment Lawsu&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;it&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 24, 2022, the Company and Bausch + Lomb were named in a declaratory judgment action in the Superior &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Court of New Jersey, Somerset County, Chancery Division, brought by certain individual investors in the Company&#x2019;s common shares and debt securities who are also maintaining individual securities fraud claims against the Company and certain current or former officers and directors as part of the U.S. Securities Litigation. This newly filed action seeks a declaratory judgment that the transfer of the Company assets to Bausch + Lomb would constitute a voidable transfer under New Jersey&#x2019;s Uniform Voidable Transactions Act and that Bausch + Lomb would become liable for damages awarded against the Company in the individual opt-out actions. The declaratory judgment action alleges that a transfer of assets from the Company to Bausch + Lomb would leave the Company with inadequate financial resources to satisfy these plaintiffs&#x2019; alleged securities fraud damages in the underlying individual opt-out actions. None of the plaintiffs in this declaratory judgment action have obtained a judgment against the Company in the underlying individual opt-out actions and the Company disputes the claims against it in those underlying actions. The underlying individual opt-out actions assert claims under Sections 10(b) and 20(a) of the Exchange Act, and certain actions assert claims under Section 18 of the Exchange Act. The allegations in those underlying individual opt out actions are made against the Company and several of its former officers and directors only and relate to, among other things, allegedly false and misleading statements made during the 2013-2016 time period by the Company and/or failures to disclose information about the Company&#x2019;s business and prospects including relating to drug pricing and the use of specialty pharmacies. On March 31, 2022, the Company and Bausch + Lomb removed the action to the U.S. District Court for the District of New Jersey.  As a result, the New Jersey Superior Court action is closed and the case is now pending in the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;District of New Jersey (Case No. 22-cv-01823). On April 29, 2022, Plaintiffs filed a motion to remand. That motion will be fully briefed on June 3, 2022. Other proceedings are in abeyance pending resolution of Plaintiffs&#x2019; remand motion. Both the Company and Bausch + Lomb dispute the claims in this declaratory judgment action and intend to vigorously defend this matter. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;California Proposition 65 Related Matter&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 19, 2019, plaintiffs filed a proposed class action in California state court against Bausch Health US and Johnson &amp;amp; Johnson (Gutierrez, et al. v. Johnson &amp;amp; Johnson, et al., Case No. 37-2019-00025810-CU-NP-CTL), asserting claims for purported violations of the California Consumer Legal Remedies Act, False Advertising Law and Unfair Competition Law in connection with their sale of talcum powder products that the plaintiffs allege violated Proposition 65 and/or the California Safe Cosmetics Act. This lawsuit was served on Bausch Health US in June 2019 and was subsequently removed to the United States District Court for the Southern District of California, where it is currently pending. Plaintiffs seek damages, disgorgement of profits, injunctive relief, and reimbursement/restitution. The Company filed a motion to dismiss Plaintiffs&#x2019; claims, which was granted in April 2020 without prejudice. In May 2020, Plaintiffs filed an amended complaint and in June 2020, filed a motion for leave to amend the complaint further, which was granted. In August 2020, Plaintiffs filed the Fifth Amended Complaint. On January 22, 2021, the Court granted the motion to dismiss with prejudice. On February 19, 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit Court of Appeals. On July 1, 2021, Appellants (Plaintiffs) filed their opening brief; Appellees&#x2019; response briefs were filed on October 8, 2021. This matter was stayed by the Ninth Circuit on December 7, 2021, due to the preliminary injunction entered by the bankruptcy court in the LTL bankruptcy proceeding. This stay included Appellants&#x2019; reply brief deadline, which was previously due to be filed on or before December 2, 2021. On March 9, 2022, the Ninth Circuit issued an order extending the stay through July 29, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other General Civil Actions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As referenced above, during the three months ended March 31, 2022, there have been no material updates or developments with respect to certain proceedings or actions as described under &#x201c;General Civil Actions&#x201d; in Note 20, &#x201c;LEGAL PROCEEDINGS,&#x201d; to the Company&#x2019;s Consolidated Financial Statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC and the CSA on February 24, 2021. These matters include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New Mexico Attorney General Consumer Protection Action&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and Bausch Health US were named in an action brought by State of New Mexico ex rel. Hector H. Balderas, Attorney General of New Mexico, in the County of Santa Fe New Mexico First Judicial District Court (New Mexico ex rel. Balderas v. Johnson &amp;amp; Johnson, et al., Civil Action No. D-101-CV-2020-00013, filed on January 2, 2020), alleging consumer protection claims against Johnson &amp;amp; Johnson and Johnson &amp;amp; Johnson Consumer Companies, Inc., the Company and Bausch Health US related to Shower to Shower&#xae; and its alleged causal link to mesothelioma and other cancers. In April 2020, Bausch Health US filed a motion to dismiss, which in September 2020, the Court granted in part as to the New Mexico Medicaid Fraud Act and New Mexico Fraud Against Taxpayers Act claims and denied as to all other claims. The State of New Mexico brings claims against all defendants under the New Mexico Unfair Practices Act and other common law and equitable causes of action, alleging defendants engaged in wrongful marketing, sale and promotion of talcum powder products. The lawsuit seeks to recover the cost of the talcum powder products as well as the cost of treating asbestos-related cancers allegedly caused by those products. Bausch Health US filed its answer on November 16, 2020. On December 30, 2020 Johnson &amp;amp; Johnson filed a Motion for Partial Judgment on the Pleadings and on January 4, 2021, Bausch Health US filed a joinder to that motion, which was denied on March 8, 2021. Trial is scheduled to begin on March 6, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Doctors Allergy Formula Lawsuit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2018, Doctors Allergy Formula, LLC (&#x201c;Doctors Allergy&#x201d;), filed a lawsuit against Bausch Health Americas in the Supreme Court of the State of New York, County of New York, asserting breach of contract and related claims under a 2015 Asset Purchase Agreement, which purports to include milestone payments that Doctors Allergy alleges should have been paid by Bausch Health Americas.&#160;Doctors Allergy claims its damages are not less than $23 million. Bausch Health Americas has asserted counterclaims against Doctors Allergy. Bausch Health Americas filed a motion seeking an order granting Bausch Health Americas summary judgment on its counterclaims against Plaintiff and dismissing Plaintiff&#x2019;s claims against it. The motion was fully briefed as of May 2021. The Court held a hearing on the motion on January 25, 2022. The motion remains pending. Bausch Health Americas disputes the claims against it and will continue to defend itself vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation with Former Salix CEO&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 28, 2019, former Salix Ltd. CEO and director Carolyn Logan filed a lawsuit in the Delaware Court of Chancery, asserting claims for breach of contract and declaratory relief. On November 19, 2021, Logan amended her complaint to add a claim for breach of the implied covenant of good faith and fair dealing. The lawsuit arises out of the contractual termination of approximately $30 million in unvested equity awards following the determination by the Salix Ltd. Board of Directors that Logan intentionally engaged in wrongdoing that resulted, or would reasonably be expected to result, in material harm to Salix Ltd., or to the business or reputation of Salix Ltd. Logan seeks the restoration of the unvested equity awards and a declaration regarding certain rights related to indemnification. On June 19, 2019, the Court entered an order staying the claim for declaratory relief pending the final resolution of the breach of contract claim. Trial is scheduled to commence on September 6, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company disputes the claims against it in each of these matters and intends to vigorously defend the matters.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:LitigationReserveCurrent
      contextRef="i27191b9cf0284661bc72bab06e9a28cc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMTM2Nw_b5f3d4e1-a83c-474c-b641-01e4962498fa"
      unitRef="usd">1530000000</us-gaap:LitigationReserveCurrent>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="ice3d4454e30642078b6d278363d32c89_D20151001-20151031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfNDA2OA_131b84c7-8851-42f2-b061-6c490ee8c6a5"
      unitRef="case">4</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="ice3d4454e30642078b6d278363d32c89_D20151001-20151031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfNDYwOQ_ee414666-abe6-4e18-89f6-67f6736bf914"
      unitRef="case">4</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i8498207cf8ab47a98694e871b43ed0ac_D20191216-20191216"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfNDkwOQ_fde975e5-a86d-43ad-aeff-442f77f13538"
      unitRef="usd">1210000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i52b91cd6bf81428da787050c41b56633_D20220331-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMjc0ODc3OTE3MzA4NA_cfdf29c4-f545-4294-931e-d63339fc8047"
      unitRef="usd">1210000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors
      contextRef="if9003a9e8d5e4cb890f3dca99318e110_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfNzA1MA_1100b259-6240-44e5-837e-3fe75ed216ab"
      unitRef="group">37</bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors>
    <us-gaap:LossContingencyClaimsDismissedNumber
      contextRef="if9003a9e8d5e4cb890f3dca99318e110_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfNzUwMw_f3c037d8-d3a1-475f-b113-bc0765481aa0"
      unitRef="case">16</us-gaap:LossContingencyClaimsDismissedNumber>
    <bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors
      contextRef="if9003a9e8d5e4cb890f3dca99318e110_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfNzUxMw_1100b259-6240-44e5-837e-3fe75ed216ab"
      unitRef="group">37</bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors>
    <bhc:LossContingencyPlaintiffsNumberofGroupsofInvestorsPending
      contextRef="if9003a9e8d5e4cb890f3dca99318e110_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfNzY0NA_25695cb8-37d8-4cf7-9f70-8ef7adda6c2b"
      unitRef="group">21</bhc:LossContingencyPlaintiffsNumberofGroupsofInvestorsPending>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i596e029672034f1ebeeeb10da808b0b3_D20150101-20151231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMTAxOTU_f7e66203-70a7-49f9-b589-41715d19af4c"
      unitRef="case">6</us-gaap:LossContingencyNewClaimsFiledNumber>
    <bhc:LossContingencyNewClaimsFiledButNotYetServedNumber
      contextRef="iffef6edab6454226a9a750b828094eab_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMTA0MTM_b34b4600-e04a-486f-873a-9f41007c3bb2"
      unitRef="action">2</bhc:LossContingencyNewClaimsFiledButNotYetServedNumber>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i66e66455cad94f43bea051172349e294_D20200804-20200804"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMTE4Mjc_481628f0-7d19-4ede-a37f-7f58ffb6e257"
      unitRef="cad">94000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction
      contextRef="ib9363f6177cc4981a294b2f6d18e765d_I20190215"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMTMyNTM_fd1ec1f8-4429-4303-bb3f-b561c6d58077"
      unitRef="entity">1</bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction>
    <bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction
      contextRef="i3e992c240c2041b78b9cd6b48dde9c97_I20210317"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMTUxNzg_6448a0cc-e337-46d7-8221-be18a29e523a"
      unitRef="entity">4</bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i70e88a8ce2b644ebb754e35500783f63_D20160527-20160916"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMTU5Mjg_f4477fc8-129b-4987-bce7-7b382b5b7a01"
      unitRef="action">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <bhc:LossContingencyNumberOfInsurancePolicyPeriods
      contextRef="i9c2253862a7e47b3abf3762d16caa354_D20171207-20171207"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMTc1Nzc_c6f43704-84e8-441e-8c5d-bf91a25dd7a7"
      unitRef="insurance_policy_period">2</bhc:LossContingencyNumberOfInsurancePolicyPeriods>
    <bhc:LossContingencySettlementAgreementsNumberOfInsurers
      contextRef="i56f9cd8d429c490aa470859df6ea769c_I20210720"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMTk1NDI_ec52029c-4a57-4d9c-89ff-3e35ff13d2a2"
      unitRef="insured">2</bhc:LossContingencySettlementAgreementsNumberOfInsurers>
    <bhc:LossContingencySettlementAgreementsNumberOfInsurers
      contextRef="i56f9cd8d429c490aa470859df6ea769c_I20210720"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMTk2NTg_06005d09-6667-4d49-be1e-2ce84ed98b02"
      unitRef="insured">2</bhc:LossContingencySettlementAgreementsNumberOfInsurers>
    <us-gaap:LitigationSettlementAmountAwardedFromOtherParty
      contextRef="i33fa032d820947a1b95a1ffae232ac03_D20210720-20210720"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMTk4OTU_6d8a89c8-de9a-4ba1-976e-27950d33e70c"
      unitRef="usd">213000000</us-gaap:LitigationSettlementAmountAwardedFromOtherParty>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="ia47d407ff7c64c98a6e296b58ca6f86d_D20190801-20200730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMjI3OTc_f8272f83-2917-48d5-b200-4ade02e534b8"
      unitRef="case">8</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i7afbeb4c54a7426c95c622c88ede0f55_D20190801-20200730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMjI4NDE_15c65db4-330a-4019-a489-b887c74f9905"
      unitRef="case">4</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="ib6f99e9cc813479883c5c2dc19cb2f6b_D20190801-20200730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMjMxMjA_50336fa9-f5d8-4800-bbaa-da28f941d542"
      unitRef="case">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i3162f07bec9e4a3daa43dcea08a13f2b_D20190801-20200730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMjM1MzA_0dde5229-e6b6-437c-b61c-c4c5ee9a60ac"
      unitRef="case">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i7cdef9a49476491db7e461eeea893094_D20210726-20210726"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMjUyMDE_3d853262-f6f2-4395-bbe7-a14cb5337894"
      unitRef="usd">300000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <bhc:LossContingencyStayOfApprovalPeriod
      contextRef="i3feba39b7c864f9287819ae735b85819_D20200326-20200326"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMzA5NTM_0813a895-a615-4575-bf33-e1f40eb7e478">P30M</bhc:LossContingencyStayOfApprovalPeriod>
    <bhc:LossContingencyStayOfApprovalPeriod
      contextRef="i7a34cd34e127459a89499090f4a93cbc_D20200828-20200828"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMzIxMzc_3d3f921a-d51f-4e28-882b-707a8b2b53de">P30M</bhc:LossContingencyStayOfApprovalPeriod>
    <bhc:LossContingencyStayOfApprovalPeriod
      contextRef="i7ce85e02604a4aa4b028657df917f434_D20200501-20200501"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMzMxNTU_4a85a2a5-a6b8-4263-a238-9587045ada6c">P30M</bhc:LossContingencyStayOfApprovalPeriod>
    <bhc:LossContingencyStayOfApprovalPeriod
      contextRef="i6770fa9b73a64b54b1f41da09e16bf8f_D20210401-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMzQzMDI_589b2668-18c0-42e7-afa7-da70340ff904">P30M</bhc:LossContingencyStayOfApprovalPeriod>
    <bhc:LossContingencyNumberOfSeparateDefendants
      contextRef="i484e9a2b823f442e9977dce133acdc8e_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMjc0ODc3OTE2NDgyNw_b8ee92dd-77fc-49d7-8734-ea058bd25d9e"
      unitRef="defendant">4</bhc:LossContingencyNumberOfSeparateDefendants>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i65eb0cafd758435f8136a068d6e0611a_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMjc0ODc3OTE2NDgzNg_567f1a7f-4338-49d7-970b-2c1c6a5e1ca6"
      unitRef="claim">2</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="if6cd264b4a7249cea5facc5b0e2e6685_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMzc1NjE_f3a8fda5-ccb9-45b5-8a1c-90472d897004"
      unitRef="case">29</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i0fb0759d98f74dea9d8da712d3d4ef7b_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMzc4ODU_b4da49b0-b43f-45b7-ab87-a9518bb549b7"
      unitRef="case">28</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="iadb1f3c2425247b1a17793d33add0cd6_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMzg3MzM_4bfe3ec0-e4cc-49c0-ac2e-c11adce8b549"
      unitRef="case">2</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="iccdebf1cc8224c95806abf21a3970331_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMzg4NDU_eff7c54c-20fe-4b7b-8160-db721c5eddd4"
      unitRef="case">1</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i41ce3780c3a74f4da7f954a056043ef8_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMzg4OTM_a6e19d6a-c878-4aa1-a8f5-37982038a66a"
      unitRef="case">1</us-gaap:LossContingencyPendingClaimsNumber>
    <bhc:LossContingencyStayOfApprovalPeriod
      contextRef="i9980036908434c78bce13e0b3f16a63d_D20211101-20211130"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMjc0ODc3OTE2NDg0NQ_305f2ead-3e5c-4b65-8ff4-a335c7ee5194">P60D</bhc:LossContingencyStayOfApprovalPeriod>
    <bhc:LossContingencyStayOfApprovalMotionToExtendPeriod
      contextRef="id1c54f63619d491e9de1d89624c515eb_D20211201-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfMjc0ODc3OTE2NDg1Mw_ec581cc6-dc93-449b-a46e-9308b79fa907">P60D</bhc:LossContingencyStayOfApprovalMotionToExtendPeriod>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="i6bbcfb43fc7145b0bb30d7beba40cbb8_D20180401-20180430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfNDQ3NzU_b2c2bb17-737b-4970-a55d-52690a790bd2"
      unitRef="usd">23000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="idc58c0dcbe644cedb326ae513855b55f_D20190128-20190128"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185NC9mcmFnOjEwMjgyM2YxYzJmMDQ4OWU4YzJiZDgyYjcxZDRjN2Q0L3RleHRyZWdpb246MTAyODIzZjFjMmYwNDg5ZThjMmJkODJiNzFkNGM3ZDRfNDU0OTk_47d93c61-23bc-4583-a6d4-0df15975da03"
      unitRef="usd">30000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RleHRyZWdpb246MmM4ZjBlMDNkMmMyNGY4OTllNTViNDcwMjNiMmQ3YzdfNDExNg_730f7d5e-ff90-4492-b139-7fc732ad3bc4">SEGMENT INFORMATION&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reportable Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the planned separation of its Solta business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc., the Company has begun managing its operations in a manner which is consistent with the organizational structure of the two separate entities as proposed by the Solta IPO. As a result, during the first quarter of 2022, the Company&#x2019;s Chief Executive Officer (&#x201c;CEO&#x201d;), who is the Company&#x2019;s Chief Operating Decision Maker, commenced managing the business differently through changes in its operating and reportable segments, which necessitated a realignment of the Company&#x2019;s historical segment structure. This realignment is consistent with how the Company&#x2019;s CEO currently: (i) assesses operating performance on a regular basis, (ii) makes resource allocation decisions and (iii) designates responsibilities of his direct reports. Pursuant to these changes, effective in the first quarter of 2022, the Company operates in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International (formerly International Rx), (iv) Solta Medical and (v) Diversified Products. The new segment structure does not impact the Company&#x2019;s reporting units but realigns the two reporting units of the former Ortho Dermatologics segment whereby its medical dermatology reporting unit (Ortho Dermatologics) is now part of the current Diversified Products segment and the Solta reporting unit is now the sole reporting unit of the new Solta Medical segment. Prior period presentation of segment revenues and segment profits has been recast to conform to the current segment reporting structure.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a brief description of the Company&#x2019;s segments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;The Bausch + Lomb segment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consists of global sales of Bausch + Lomb Vision Care, Consumer, Surgical and Ophthalmic Pharmaceuticals products.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;The Salix segment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; consists of sales in the U.S. of GI products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;The International segment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; consists of sales, with the exception of sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;The Solta Medical segment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consists of global sales of Solta aesthetic medical devices. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;padding-left:14.5pt"&gt;The Diversified Products segment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products, (iii) Ortho Dermatologics (dermatological) products and (iv) dentistry products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment profit is based on operating income after the elimination of intercompany transactions. Certain costs, such as Amortization of intangible assets, Asset impairments, Acquired in-process research and development costs, Restructuring, integration, separation and IPO costs and Other (income) expense, net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of the Company&#x2019;s businesses and incurs certain expenses, gains and losses related to the overall management of the Company, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single&#160;segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Revenues and Profits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment revenues and profits were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment profits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(310)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(357)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset impairments, including loss on assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring, integration, separation and IPO costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(221)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(362)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(368)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(591)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenues by Segment and Product Category &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues by segment and product category were as&#160;follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.858%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The top ten products for the three months ended March 31, 2022 and 2021 represented 44% and 40% of total revenues for the three months ended March 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Geographic Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are attributed to a geographic region based on the location of the customer and were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. and Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Poland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mexico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Russia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Spain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Italy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;South Korea&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made and are reflected in the table above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Major Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customers that accounted for 10% or more of total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Corporation (including McKesson Specialty)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health,&#160;Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportingUnits
      contextRef="i03d9858da1a54c6a897587b6b5079ca1_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RleHRyZWdpb246MmM4ZjBlMDNkMmMyNGY4OTllNTViNDcwMjNiMmQ3YzdfMTY0OTI2NzQ0ODkzOA_d9e5c898-70c9-4bad-be6f-127b70715657"
      unitRef="reporting_unit">2</us-gaap:NumberOfReportingUnits>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RleHRyZWdpb246MmM4ZjBlMDNkMmMyNGY4OTllNTViNDcwMjNiMmQ3YzdfNDEyNw_679295de-f258-41e2-a692-46374402e85c">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment revenues and profits were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment profits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(310)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(357)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset impairments, including loss on assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring, integration, separation and IPO costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(221)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(362)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(368)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(591)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c75337ca1004f2ca22a8acafcee0b80_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMy01LTEtMS04OTA3Mg_28c81470-a8c6-499f-aeed-375832832629"
      unitRef="usd">889000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i85cfed31dcdb4b5fbdcfd5de90d79e53_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMy03LTEtMS04OTA3Mg_ea7612d6-08a3-4348-9d61-f86b7eaa3ecd"
      unitRef="usd">881000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i269760d6627c41d9af67faeb79fcc823_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfNC01LTEtMS04OTA3Mg_1b3b7729-fd6f-44b2-a433-ca86fdb61cfc"
      unitRef="usd">464000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic7a20cee7c49437a80ead9dc6edc62bf_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfNC03LTEtMS04OTA3Mg_16f510bf-5434-411e-99e0-4885582e1684"
      unitRef="usd">472000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ce8c1f567d4480199ab7c96956ff606_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfNS01LTEtMS04OTA3Mg_f2092f50-110c-471d-a655-0d3bbc6c1411"
      unitRef="usd">244000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0baff1dd72ec4f1d9be30dc22385fd78_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfNS03LTEtMS04OTA3Mg_92b64085-c671-4899-b07a-3c44c3a8ae91"
      unitRef="usd">306000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i515ccc73a3044997b576a1bf8db45a42_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfNi01LTEtMS04OTA3Mg_99aff6ba-50f1-4039-b571-89cce548ec51"
      unitRef="usd">72000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9fa555eb8f35445291ded844157a0bbf_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfNi03LTEtMS04OTA3Mg_c22ad469-96b7-43a9-9986-b9e78342adea"
      unitRef="usd">72000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i03406ff2404048fa81b2e21abb5623f6_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfNy01LTEtMS04OTA3Mg_45a238d5-4192-4024-b3b5-893da43f6024"
      unitRef="usd">249000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i204e74587c904466ba5b4d9604c5d421_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfNy03LTEtMS04OTA3Mg_279f60a8-5f63-471d-b9fb-922281511b77"
      unitRef="usd">296000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i78e30f03ea4548deae9a927c4b6a6def_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfOC01LTEtMS04OTA3Mg_2e67e49d-d904-4d54-a2be-a5a6c0ab85b5"
      unitRef="usd">1918000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d07c8e2cb2b45138d98bfa04aca8095_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfOC03LTEtMS04OTA3Mg_9b17e83d-2cea-4446-af28-7e9e4710b900"
      unitRef="usd">2027000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0c75337ca1004f2ca22a8acafcee0b80_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMTAtNS0xLTEtODkwNzI_6468c856-36ac-4c01-abab-3190f8753452"
      unitRef="usd">206000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i85cfed31dcdb4b5fbdcfd5de90d79e53_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMTAtNy0xLTEtODkwNzI_3bc09308-0b36-4455-8b47-94de44bbf69d"
      unitRef="usd">239000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i269760d6627c41d9af67faeb79fcc823_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMTEtNS0xLTEtODkwNzI_0414dcd3-02cf-4a4e-9215-a3b793a7a6cd"
      unitRef="usd">322000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic7a20cee7c49437a80ead9dc6edc62bf_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMTEtNy0xLTEtODkwNzI_d377441e-487f-4158-b8cb-7269fcc918ea"
      unitRef="usd">327000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1ce8c1f567d4480199ab7c96956ff606_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMTItNS0xLTEtODkwNzI_bc26880d-523d-4a40-a2a1-aa7f659f264c"
      unitRef="usd">91000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0baff1dd72ec4f1d9be30dc22385fd78_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMTItNy0xLTEtODkwNzI_6976b04a-6931-4037-9b39-5eb482eabf4a"
      unitRef="usd">109000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i515ccc73a3044997b576a1bf8db45a42_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMTMtNS0xLTEtODkwNzI_b7c6381a-ce7d-4779-920e-330c05026456"
      unitRef="usd">35000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9fa555eb8f35445291ded844157a0bbf_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMTMtNy0xLTEtODkwNzI_d97f25c8-103a-4bc7-a422-fd3687c95807"
      unitRef="usd">41000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i03406ff2404048fa81b2e21abb5623f6_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMTQtNS0xLTEtODkwNzI_e33b8cfe-8f23-4ddd-95e6-66652f177d07"
      unitRef="usd">158000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i204e74587c904466ba5b4d9604c5d421_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMTQtNy0xLTEtODkwNzI_7f490ec2-533c-475f-a953-6ff2d5f3c6d9"
      unitRef="usd">200000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i78e30f03ea4548deae9a927c4b6a6def_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMTUtNS0xLTEtODkwNzI_ab612d30-ca6a-4602-bb3c-467b37a574dd"
      unitRef="usd">812000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1d07c8e2cb2b45138d98bfa04aca8095_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMTUtNy0xLTEtODkwNzI_97fbbbd2-5e9b-4496-8167-b532e89d314e"
      unitRef="usd">916000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i57dad9adbdcb4f9eb8980d1993b5a15e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMTYtNS0xLTEtODkwNzI_fb218582-cac2-45ed-ae8d-e68fa5cba6ee"
      unitRef="usd">-194000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i956efc9320ef432bad3fbea5c3f1a4fe_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMTYtNy0xLTEtODkwNzI_899972c4-3707-45fb-9d63-dc7ff701c650"
      unitRef="usd">-181000000</us-gaap:OperatingIncomeLoss>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMTctNS0xLTEtODkwNzI_4eca1266-7a69-4f34-bece-a8eabced0181"
      unitRef="usd">310000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMTctNy0xLTEtODkwNzI_61c69000-a645-48e7-a7cf-610da29e8a4a"
      unitRef="usd">357000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMTgtNS0xLTEtODkwNzI_602dbbcf-87b1-4660-87ab-b672ebdd7277"
      unitRef="usd">0</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMTgtNy0xLTEtODkwNzI_27da2c62-10c1-4c4e-ba9f-84173dd35cfe"
      unitRef="usd">469000000</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMTktNS0xLTEtODkwNzI_0214e145-949d-4520-8425-2ddc875f4931"
      unitRef="usd">8000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMTktNy0xLTEtODkwNzI_ec59572e-8ddc-449b-8656-a6d35de5038d"
      unitRef="usd">148000000</us-gaap:AssetImpairmentCharges>
    <bhc:RestructuringChargesAndInitialPublicOfferingCosts
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMjAtNS0xLTEtODkwNzI_faf65571-a028-4a17-9577-1b052247daeb"
      unitRef="usd">13000000</bhc:RestructuringChargesAndInitialPublicOfferingCosts>
    <bhc:RestructuringChargesAndInitialPublicOfferingCosts
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMjAtNy0xLTEtODkwNzI_d26b8bbc-9fd5-4027-9d25-568c56e33e33"
      unitRef="usd">12000000</bhc:RestructuringChargesAndInitialPublicOfferingCosts>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMjEtNS0xLTEtODkwNzI_05f7a39d-2744-45a8-b6e1-74b9ccc66877"
      unitRef="usd">-2000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMjEtNy0xLTEtODkwNzI_cb7f20be-0d13-46fb-b6eb-de6eca1604ea"
      unitRef="usd">30000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMjItNS0xLTEtODkwNzI_cd33ffa4-cded-4037-8e6d-7aa5e3b4982b"
      unitRef="usd">285000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMjItNy0xLTEtODkwNzI_e7d934c9-3687-48e1-bd84-0e2b85c189ed"
      unitRef="usd">-221000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMjMtNS0xLTEtODkwNzI_67cd5e54-507e-4969-b27e-9c6317b7b607"
      unitRef="usd">2000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMjMtNy0xLTEtODkwNzI_71b9777f-b5dc-4785-bb7a-679d62a02948"
      unitRef="usd">2000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseDebt
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMjQtNS0xLTEtODkwNzI_117d1301-b7e2-49c4-96c6-1750ba495011"
      unitRef="usd">362000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMjQtNy0xLTEtODkwNzI_d5e232ec-a3a6-4ff3-94f8-871648d7a13a"
      unitRef="usd">368000000</us-gaap:InterestExpenseDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMjUtNS0xLTEtODkwNzI_7cf72887-35fe-4ff0-8da4-4add938d166f"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMjUtNy0xLTEtODkwNzI_99e3412d-7e76-48b3-90c4-d60e8ec16b80"
      unitRef="usd">-5000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMjYtNS0xLTEtODkwNzI_e9c32773-2ebe-41b5-bbc5-240a70cd1fdb"
      unitRef="usd">-7000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMjYtNy0xLTEtODkwNzI_a44a5c86-65ea-4c49-ad12-8286a80134e9"
      unitRef="usd">1000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMjctNS0xLTEtODkwNzI_b266040d-4956-4110-9b24-def10abcd19d"
      unitRef="usd">-82000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjc0MTFmNmJkOGYzMjRlY2FiNDk2OWJjYzY3NTYxOTBkL3RhYmxlcmFuZ2U6NzQxMWY2YmQ4ZjMyNGVjYWI0OTY5YmNjNjc1NjE5MGRfMjctNy0xLTEtODkwNzI_6a724f17-00d4-404e-98b4-021928dd9f72"
      unitRef="usd">-591000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RleHRyZWdpb246MmM4ZjBlMDNkMmMyNGY4OTllNTViNDcwMjNiMmQ3YzdfNDE1Nw_e2e45ff4-4a5d-4118-b271-d95152d13e6b">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues by segment and product category were as&#160;follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.858%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i81a741d98a084635a313bb4bf76f4091_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMi0xLTEtMS04OTA3Mg_077db12a-8246-4e19-863d-8d883b953389"
      unitRef="usd">110000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i64a60b01aba54bed9371ce993d6fcde6_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMi0zLTEtMS04OTA3Mg_777882ed-d374-4508-a976-94cc68373faf"
      unitRef="usd">464000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide4e3d656d794986bc25805dd6eafb35_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMi01LTEtMS04OTA3Mg_5b5c232c-41d3-4f49-a2b4-06ad6d1e0de6"
      unitRef="usd">65000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i375b53e51f9a46f689b2c28b45772369_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMi03LTEtMS04OTA3Mg_e5f65ce1-bdc0-4858-b705-4fae018be475"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i26543803a914471b91cfff3fec88f408_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMi05LTEtMS04OTA3Mg_72145d45-3841-492f-92f9-edd257dce5e8"
      unitRef="usd">205000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i965c5ef9967640559f4a892e2bc019c3_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMi0xMS0xLTEtODkwNzI_06c80ad4-4e02-429b-8df3-a9a78eada263"
      unitRef="usd">844000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4fb3820e9af24cffa7541b8391ded598_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMy0xLTEtMS04OTA3Mg_e6916c58-702e-43de-b584-219e86a1ceb4"
      unitRef="usd">386000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i33c622ed3818484b99457a5e5ac61b94_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMy0zLTEtMS04OTA3Mg_216a6dc0-24c9-452b-97f1-564865bad0d2"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c9d891249204a23b5a99cff63162625_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMy01LTEtMS04OTA3Mg_7c0878c1-cec8-441f-ba09-e0d5bbe47435"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i44029f40cbcc4c10b8745e5f1b7f00ea_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMy03LTEtMS04OTA3Mg_06f802e2-9f13-41f7-a92a-0ee9ce831998"
      unitRef="usd">72000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i443f3d343d0a48fcb2a083c30d4f80e3_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMy05LTEtMS04OTA3Mg_20b6a014-d4ee-4a38-876b-9b2b216a55dd"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i24ebf624edfd4bdf9d7fdd3ec9d063ec_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMy0xMS0xLTEtODkwNzI_da48d07b-53db-438d-ac4c-1fabdcda2d4e"
      unitRef="usd">458000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i45c1beafb56d472ead9374b62bb12e0d_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNC0xLTEtMS04OTA3Mg_efbdc15a-4f03-4ec0-85a6-8c4ab3cf28d4"
      unitRef="usd">335000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i93b04924fc4f4e13885891185ac2968f_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNC0zLTEtMS04OTA3Mg_cc27986a-b08c-4d1f-a7c7-3665db491562"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia9bd671b035e41d69c0e38a6f82fb9cb_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNC01LTEtMS04OTA3Mg_151a7d5d-42ec-4c7c-992b-d5da81b1801f"
      unitRef="usd">38000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff23cd75a927442b8803bc3729da27ed_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNC03LTEtMS04OTA3Mg_6042c55f-5526-4fd4-afc7-7bbf3fe90fbe"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4fc8477c42ba432494cf231b6c0d0bc6_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNC05LTEtMS04OTA3Mg_7a57af37-4d15-424f-994d-fa8a15eae8fc"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i124b70687528481fa21c28eb1cd32810_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNC0xMS0xLTEtODkwNzI_b40b5193-2149-4bbb-99c2-bbfa13471689"
      unitRef="usd">375000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i08499bccbbc4410cb5590fb188cf4b8f_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNS0xLTEtMS04OTA3Mg_07ca5090-130f-460f-a870-a105d1d0e2c7"
      unitRef="usd">52000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i95c4cba1caca493b898eda95b9d55af7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNS0zLTEtMS04OTA3Mg_c90c7b09-fc7a-44ca-a933-73c693c13c93"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia38a1019d805412a8c33d8125fa11085_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNS01LTEtMS04OTA3Mg_4d66e7f8-2e37-4f7b-a281-4d19a0a56977"
      unitRef="usd">133000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb9c9b16f92e4c9ebdac506674e51576_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNS03LTEtMS04OTA3Mg_d11fcab6-edce-421e-acd5-a925ecff195d"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5ef5e2b06a5642ab9e8f2e182c325773_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNS05LTEtMS04OTA3Mg_96bf8733-5136-43ca-b425-91a0ad803a3a"
      unitRef="usd">36000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if4ad50d4f8264e31a30246a147683d1e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNS0xMS0xLTEtODkwNzI_dbd80ea4-e7b2-4035-9db2-cc85d04c903a"
      unitRef="usd">221000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifa28b372582e4ed39b7c1cf546fdc7e2_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNi0xLTEtMS04OTA3Mg_2febece8-c3db-4012-aca8-a4b02b3acc51"
      unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6242e90d746b4facb737eb995d4cd3a1_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNi0zLTEtMS04OTA3Mg_5c134b97-0ff7-4e76-8147-ed2bd3804960"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibd97f12e125642fcb0965c4f1a9363fc_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNi01LTEtMS04OTA3Mg_3f73dee3-5e74-45ca-a34d-14b640160fd0"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i59217fa829ff402c854f159e561f67dc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNi03LTEtMS04OTA3Mg_7c2e8d29-c85c-46e0-9816-9dc615a846ba"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i559671273f154caeb21890281cc0f5d1_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNi05LTEtMS04OTA3Mg_68b88113-6342-47a8-a1ef-407efb6d14a8"
      unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6583ef0acc464c159cccb04b0fec1a1b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNi0xMS0xLTEtODkwNzI_2536d9a7-5faf-49c6-a87c-078b0e51c645"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i897d561735644b67b640f606386ea273_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNy0xLTEtMS04OTA3Mg_9a803344-53bd-4cb0-9334-8377f40a7455"
      unitRef="usd">889000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b20d7a1afdb4a4880e7ffd0aa66b93d_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNy0zLTEtMS04OTA3Mg_952f4116-7c02-47c6-b19d-4cac0cc6096d"
      unitRef="usd">464000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i03af4a3fb12d4415985732b5f1713c51_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNy01LTEtMS04OTA3Mg_44ab95b9-8844-4dd0-aeb0-f7d860e534e3"
      unitRef="usd">244000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4cc8090790184dbd8e5fef8bc092f80c_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNy03LTEtMS04OTA3Mg_eccf966c-2177-4ecf-8e68-7fde560493d2"
      unitRef="usd">72000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id5df5fcbde684e86add3147c9fe2ea1c_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNy05LTEtMS04OTA3Mg_b39fc3c4-4302-4610-802b-5dfff86bcf1d"
      unitRef="usd">249000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfNy0xMS0xLTEtODkwNzI_6a0840bb-e036-45f4-9f37-b25b5d0c242d"
      unitRef="usd">1918000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ica7d291dc2bd424e9fb044bf5d42a71d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTAtMS0xLTEtODkwNzI_a0360def-68ba-4d0a-83a4-8b8d0a1e141b"
      unitRef="usd">121000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5a8e341755db419cb385c32abb37fbf5_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTAtMy0xLTEtODkwNzI_88a725c8-fa9f-406a-8c83-0f4fee4e0313"
      unitRef="usd">470000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2ae1c40162554d5eb82184aadef55683_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTAtNS0xLTEtODkwNzI_cdc9b809-7c92-49f4-8a47-580b90f68340"
      unitRef="usd">59000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i09d760aefc9346f3ba42a8f6e9e5a1c4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTAtNy0xLTEtODkwNzI_b2171481-6b39-4187-8e34-dc97a77995ed"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id3e109bbefcc46d498195d4ffe5d8600_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTAtOS0xLTEtODkwNzI_f4a9bc4a-5545-4af0-8a6f-1742ac3d0923"
      unitRef="usd">242000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifa0b5f041d2b45cf9d22badd73f64a23_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTAtMTEtMS0xLTg5MDcy_4215311f-dd5a-413c-9399-4fad304ebc66"
      unitRef="usd">892000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6786806a071a4586b8fe4628dc8b3a7e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTEtMS0xLTEtODkwNzI_a3805cd3-d37b-4d10-98ad-ef70f40c3844"
      unitRef="usd">382000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e5a66dcb11244d9adafcfbfdcfaa3fb_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTEtMy0xLTEtODkwNzI_98595771-2c99-4ea7-be86-57d2e80ed3f1"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8ac60a867fe14187a7ad6925c72ddfcb_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTEtNS0xLTEtODkwNzI_e090b0da-3bd7-4867-a912-c4243c74cdcf"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i87d31612ba6e4870b08c2e8bbacff14b_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTEtNy0xLTEtODkwNzI_63ebc88f-9ec1-4c1b-8564-19c108043e88"
      unitRef="usd">72000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6ec570a785a84b3e8b00f4538ffd504c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTEtOS0xLTEtODkwNzI_9b102b30-c6ef-4e2c-8030-65629026cbf9"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icbb358ccd88b4e1582585e87263d2797_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTEtMTEtMS0xLTg5MDcy_8ef890df-a648-43e3-8686-47525f1e6652"
      unitRef="usd">454000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iafde2cd7b3454407911b0fdbcfa6bdd6_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTItMS0xLTEtODkwNzI_2909f478-4280-4519-aa8f-fa720082ce86"
      unitRef="usd">320000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i89351cbae84d472fbc3dabeb58d46f5f_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTItMy0xLTEtODkwNzI_12eed38a-b915-4b24-a7de-3f38064b843f"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaccd246e128b428da512aad072f4e923_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTItNS0xLTEtODkwNzI_4b33c095-553d-4df7-9f41-a91feb77605a"
      unitRef="usd">25000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i365abf392e8246c192b779a84beb07cf_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTItNy0xLTEtODkwNzI_95b1b5bd-4056-4697-8a3d-5ddfd366bb64"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7aa0024629f24b1e86fc6db4add48d1e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTItOS0xLTEtODkwNzI_0e02dc33-0aa8-4668-a191-6b657f41d045"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if3a2b93c59aa455cb5ec35f29c61b2af_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTItMTEtMS0xLTg5MDcy_75774a91-fd26-4cba-8fbc-969502f2bdfb"
      unitRef="usd">347000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i60c320b8b80142589fb80e99cc32f396_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTMtMS0xLTEtODkwNzI_104c227b-cee9-430b-9763-5b47ec7fa2cf"
      unitRef="usd">51000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id78c49bd421641d9bc16ae14a49b0f38_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTMtMy0xLTEtODkwNzI_6d3ab044-f5fe-48f0-9535-e355869b1274"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i50631f79a17f4417939599b18339e8ad_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTMtNS0xLTEtODkwNzI_6856292d-a8ca-48f9-beef-46de742ccc32"
      unitRef="usd">212000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i305ec4b1f3cf485cace07ea69588b9d7_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTMtNy0xLTEtODkwNzI_d480eb25-b3bf-4b97-8480-d914034bdc93"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if8080745b5f44e97ae240acceb434c81_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTMtOS0xLTEtODkwNzI_030dc9b2-e708-4fd5-99fa-350483560701"
      unitRef="usd">47000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i74bb4d5c955a430c8f54a13eb2e95dbe_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTMtMTEtMS0xLTg5MDcy_54900a84-45d2-4dcb-ab3e-276ef2357e39"
      unitRef="usd">310000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b0c293a2a6e4e71a0b1622ed24842b9_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTQtMS0xLTEtODkwNzI_11e7f9b2-3544-490b-ad33-59caa37114e9"
      unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i63e664ec8ede4265b16d1a42ee684fc0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTQtMy0xLTEtODkwNzI_ca5190fe-b843-429b-b76d-4e1407728785"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i54f11fd19e174e98aea8c453c247a13e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTQtNS0xLTEtODkwNzI_6c217da1-5a7e-42b9-9e6f-d438a5097ff6"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i242c0d38400b4e0ebc1e4083d039a5d2_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTQtNy0xLTEtODkwNzI_80dd3256-e916-4ef8-a60b-e65d28a55453"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c17a4613b5a49258f9f5b8c94015244_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTQtOS0xLTEtODkwNzI_1c6f9a34-4e56-4a89-b2fa-da2f8351806f"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i595a156d88824a07951bbc6d45f101aa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTQtMTEtMS0xLTg5MDcy_2da99fa2-a3e7-4cac-b6d5-425fdb33cfd6"
      unitRef="usd">24000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9021db7996494bfb917eaa4217e384e5_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTUtMS0xLTEtODkwNzI_78d1b886-b228-4478-8d7a-7a67a2422d1d"
      unitRef="usd">881000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib8a36b6287944ab9a444528b83f6e58e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTUtMy0xLTEtODkwNzI_3556d09a-7d0b-4bf7-99e6-8f538748ddc9"
      unitRef="usd">472000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0910908181894cb28f6e71d1b8022f02_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTUtNS0xLTEtODkwNzI_dd6516be-f2bb-46c6-b91f-cab1f10593f4"
      unitRef="usd">306000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia346b213e50645b0a1038d38fc86c181_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTUtNy0xLTEtODkwNzI_c34ed5ff-6143-4755-b1f9-29c07b12d521"
      unitRef="usd">72000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i08f479ec27794028980e1c2521cd237c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTUtOS0xLTEtODkwNzI_019e4ed7-c7ee-48e3-be82-9b7a174f3261"
      unitRef="usd">296000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjU0NTY2OWM3OWU0YjQzNjZhYmQ3YjQ0NWFkYWYwYTBlL3RhYmxlcmFuZ2U6NTQ1NjY5Yzc5ZTRiNDM2NmFiZDdiNDQ1YWRhZjBhMGVfMTUtMTEtMS0xLTg5MDcy_42ce6560-711a-4a23-a91d-1d1fa3969756"
      unitRef="usd">2027000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <bhc:ConcentrationRiskNumberOfProducts
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RleHRyZWdpb246MmM4ZjBlMDNkMmMyNGY4OTllNTViNDcwMjNiMmQ3YzdfMzcyNA_93600559-7a85-4618-aa08-c6c45b65ff6d"
      unitRef="product">10</bhc:ConcentrationRiskNumberOfProducts>
    <bhc:ConcentrationRiskNumberOfProducts
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RleHRyZWdpb246MmM4ZjBlMDNkMmMyNGY4OTllNTViNDcwMjNiMmQ3YzdfMzcyNA_cfbaff55-e768-4ab4-9341-f58d4ae6bbb5"
      unitRef="product">10</bhc:ConcentrationRiskNumberOfProducts>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2cf35ad54d7f4e3b94b6b600661263c9_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RleHRyZWdpb246MmM4ZjBlMDNkMmMyNGY4OTllNTViNDcwMjNiMmQ3YzdfMzc1OQ_11a0f893-958d-44fd-ba00-d277d88b30e4"
      unitRef="number">0.44</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia6c16437fc1645e5bd3f51dbfd6bc45d_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RleHRyZWdpb246MmM4ZjBlMDNkMmMyNGY4OTllNTViNDcwMjNiMmQ3YzdfMzc2Ng_f3896a56-d7ea-46da-a202-ec25770b14ee"
      unitRef="number">0.40</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RleHRyZWdpb246MmM4ZjBlMDNkMmMyNGY4OTllNTViNDcwMjNiMmQ3YzdfNDE1MA_ee00ada9-183e-4b65-9ecb-7a8fe2f65f3e">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are attributed to a geographic region based on the location of the customer and were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. and Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Poland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mexico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Russia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Spain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Italy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;South Korea&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i736938c435c34b8cbf4b9a86a5c1716b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfMi01LTEtMS04OTA3Mg_3e9fed06-24a1-4545-af63-8f4ac47e865d"
      unitRef="usd">1115000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie1c251a743e84e29bcdcb92c1700440f_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfMi03LTEtMS04OTA3Mg_30eddfdf-e1f7-418f-b4aa-a52207273bd7"
      unitRef="usd">1162000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i29ca60685fd143c4ada8c74045564916_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfMy01LTEtMS04OTA3Mg_a1a095b2-6c51-45ed-a9c8-6c6c730083aa"
      unitRef="usd">103000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib389f9ca07bc4c7ca630c86bb01430f2_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfMy03LTEtMS04OTA3Mg_62723939-932c-4173-97d9-a9a52c98e737"
      unitRef="usd">110000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib632e708eb9e44e5a2c76e757b159704_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfNC01LTEtMS04OTA3Mg_f607b134-8587-42a9-8cd9-9f3e8fe94bd6"
      unitRef="usd">78000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id62e8ded86954413866df53834a4022f_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfNC03LTEtMS04OTA3Mg_ccfe9005-6b03-4b45-8414-ca7ab2efdabd"
      unitRef="usd">76000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id17ace1eafa74b49b1494fa93c34f515_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfNS01LTEtMS04OTA3Mg_07b9070c-06e0-497b-b535-a544a3cd5dc6"
      unitRef="usd">76000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idfae22764ebc4680bba6944b73990b38_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfNS03LTEtMS04OTA3Mg_21845dd5-31b8-4aa4-9135-535ebb98207f"
      unitRef="usd">62000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d98656df59c417aa61bfd38cf347ab8_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfNi01LTEtMS04OTA3Mg_10232be6-da44-46f8-9b57-f6680be3d861"
      unitRef="usd">61000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i309adbf2ee5c4529ad9d523c886afcbc_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfNi03LTEtMS04OTA3Mg_a80d036f-8014-4182-b009-3b8e2f22ddb7"
      unitRef="usd">69000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i71f5260404d34943ae2284710ac15bcc_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfNy01LTEtMS0xMDIyODE_bed595fc-068c-4207-a4eb-710d1af43cbb"
      unitRef="usd">57000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0efa9862b055429eb1653d07596c035a_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfNy03LTEtMS0xMDIyODg_af18ab54-cb95-4f29-afcf-5e99cf5572d4"
      unitRef="usd">54000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i038caeba82944fb08a4051fbf6da7b09_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfNy01LTEtMS04OTA3Mg_2f36c00f-cc73-4102-b679-d202334ab719"
      unitRef="usd">51000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i60f8953bbbe6445eb5947c90b19aab2e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfNy03LTEtMS04OTA3Mg_5cd270a0-7d00-4231-8607-cb92d69ad9d4"
      unitRef="usd">60000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2e0b22a76af3426bae92c761987b0187_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfOC01LTEtMS04OTA3Mg_d4cfd68f-ced9-42bd-949c-1f9b35f22f80"
      unitRef="usd">45000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifeb045fdd1fd4540bf7a4106731f2f2c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfOC03LTEtMS04OTA3Mg_a08bed21-1876-4ced-90a3-c8a8aa250378"
      unitRef="usd">42000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9e819574885a4427b258852c7217cbb7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfMTAtNS0xLTEtODkwNzI_5092b72d-e56c-43f8-8c87-dde11469d67f"
      unitRef="usd">28000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief192120e21c43a1a934405e935223ca_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfMTAtNy0xLTEtODkwNzI_ef3b2fd2-26dd-42c4-b10b-f6f446fd0cc1"
      unitRef="usd">25000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i02bac5e7352941d58218671cc5ac18ee_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfMTEtNS0xLTEtODkwNzI_f1f7e57a-94a1-44e3-adb1-72d959d238c0"
      unitRef="usd">25000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i388557aa2024443c871b4d4a9a886575_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfMTEtNy0xLTEtODkwNzI_22c4bfce-b8a8-4b80-b5be-7fd13007844c"
      unitRef="usd">31000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4bd53359a539414b9021c46b47d84743_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfMTItNS0xLTEtODkwNzI_f5f0b262-a044-4731-b319-628f0221e15b"
      unitRef="usd">21000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff2ea0b9ea7b4ff2b1dc7c83ee9f0674_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfMTItNy0xLTEtODkwNzI_d5b3c7d0-92f5-4bf3-b3c3-40689131977d"
      unitRef="usd">19000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i477436c4d44d4790b5bee0250e92a451_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfMTMtNS0xLTEtODkwNzI_98b9a7f0-4fc1-44fd-83d8-05c1939859e9"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee07a351938545e1bc0374c9ee03db58_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfMTMtNy0xLTEtODkwNzI_7ccafa6b-89af-496d-95a8-bccf3a2de16d"
      unitRef="usd">17000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3c9cbd283603466d890093b4f1ad2033_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfMTQtNS0xLTEtMTAyMjkw_bd464926-04bc-40ec-a7d8-ed540d788faf"
      unitRef="usd">19000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie51fbc2dae9941b8b6e55b6fa231f07c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfMTQtNy0xLTEtMTAyMjky_4448be82-3f62-4532-9eea-d4a4f1295977"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i704a8bd37aad403db52ecbc7efb33040_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfMTQtNS0xLTEtODkwNzI_816d2731-9f6e-47c4-994d-cf1fed71bd95"
      unitRef="usd">219000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id4b0684914ec4f1b9d774361c28cb7b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfMTQtNy0xLTEtODkwNzI_4470e357-f770-4424-9884-29bdc1379d1f"
      unitRef="usd">280000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfMTUtNS0xLTEtODkwNzI_88e1a289-9d0e-4875-b397-5b7b17e56c6b"
      unitRef="usd">1918000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb2f9676f0764189975e7267a9f7b9b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjdhNzViYzRjZWVlYjRiMDg4N2ZiZjVjYjZmNDUwMzE2L3RhYmxlcmFuZ2U6N2E3NWJjNGNlZWViNGIwODg3ZmJmNWNiNmY0NTAzMTZfMTUtNy0xLTEtODkwNzI_704e9155-5778-49e1-8472-2501314fda0d"
      unitRef="usd">2027000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RleHRyZWdpb246MmM4ZjBlMDNkMmMyNGY4OTllNTViNDcwMjNiMmQ3YzdfNDE0Mw_6065637b-7b2a-4c7e-88c0-8eb60cfa803d">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customers that accounted for 10% or more of total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Corporation (including McKesson Specialty)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health,&#160;Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5c455f78b2c24f19ab413825cf24b3b1_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjljOTNjZTc4NzgzZTQ1MDI5ZGYzOTJmZjU0N2MyNzIwL3RhYmxlcmFuZ2U6OWM5M2NlNzg3ODNlNDUwMjlkZjM5MmZmNTQ3YzI3MjBfMi0xLTEtMS04OTA3Mg_dc001075-f30f-446c-b5d9-3235d89eeae4"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3d795947131641bda6742f32f927ee39_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjljOTNjZTc4NzgzZTQ1MDI5ZGYzOTJmZjU0N2MyNzIwL3RhYmxlcmFuZ2U6OWM5M2NlNzg3ODNlNDUwMjlkZjM5MmZmNTQ3YzI3MjBfMi0zLTEtMS04OTA3Mg_78a33fa8-71f0-470a-871b-65db349648a5"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i735a4a9dd69c4f20ad6fa633744e4013_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjljOTNjZTc4NzgzZTQ1MDI5ZGYzOTJmZjU0N2MyNzIwL3RhYmxlcmFuZ2U6OWM5M2NlNzg3ODNlNDUwMjlkZjM5MmZmNTQ3YzI3MjBfMy0xLTEtMS04OTA3Mg_a4f7e4f6-9784-47d2-8def-2a904369882d"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="idc5628f43f5849428205c5a57a1c1fcf_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjljOTNjZTc4NzgzZTQ1MDI5ZGYzOTJmZjU0N2MyNzIwL3RhYmxlcmFuZ2U6OWM5M2NlNzg3ODNlNDUwMjlkZjM5MmZmNTQ3YzI3MjBfMy0zLTEtMS04OTA3Mg_d9b5e8ef-d89a-4461-9d04-2d6cdb96d4e4"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iae7d7933e83c4caf870a090351b7a111_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjljOTNjZTc4NzgzZTQ1MDI5ZGYzOTJmZjU0N2MyNzIwL3RhYmxlcmFuZ2U6OWM5M2NlNzg3ODNlNDUwMjlkZjM5MmZmNTQ3YzI3MjBfNC0xLTEtMS04OTA3Mg_639c6239-cefc-4f5f-bb84-a220b352e6e8"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ifbf2cc68e33744c4b8947828008ff5d9_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY185Ny9mcmFnOjJjOGYwZTAzZDJjMjRmODk5ZTU1YjQ3MDIzYjJkN2M3L3RhYmxlOjljOTNjZTc4NzgzZTQ1MDI5ZGYzOTJmZjU0N2MyNzIwL3RhYmxlcmFuZ2U6OWM5M2NlNzg3ODNlNDUwMjlkZjM5MmZmNTQ3YzI3MjBfNC0zLTEtMS04OTA3Mg_ad2ceae3-db1d-43a0-9344-d36ed95a9ef7"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMTk0OTc_a7f1b217-5ef5-44c3-9d5f-4feac49a851f">SUBSEQUENT EVENTS&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Initial Public Offering &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The registration statement related to the B+L IPO was declared effective on May 5, 2022, and Bausch + Lomb&#x2019;s common shares began trading on the New York Stock Exchange and the Toronto Stock Exchange, in each case under the ticker symbol &#x201c;BLCO&#x201d;, on May 6, 2022. On May 10, 2022, the Selling Shareholder (as previously defined) sold 35,000,000 common shares of Bausch + Lomb at an offering price of $18.00 per share. The net proceeds from the B+L IPO after deducting underwriting commissions and estimated offering expenses were approximately $560 million as of May 10, 2022. In addition, the Selling Shareholder has granted the underwriters an option for a period of 30 days from the date of the B+L IPO to purchase up to an additional 5,250,000 common shares to cover over-allotments at the IPO offering price less underwriting commissions. As of May 10, 2022, the underwriters have not exercised this option. Upon the closing of the B+L IPO (but before exercise of the over-allotment option), the Company directly or indirectly holds 315,000,000 Bausch + Lomb common shares, which represents approximately 90% of Bausch + Lomb&#x2019;s common shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financing Transactions of Bausch + Lomb&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 10, 2022, Bausch + Lomb entered into a credit agreement (the &#x201c;B+L Credit Agreement&#x201d;, and the credit facilities thereunder, the &#x201c;B+L Credit Facilities&#x201d;) providing for term loans of approximately $2,500&#160;million with a five-year term to maturity (the &#x201c;B+L Term Facility&#x201d;) and a five year revolving credit facility of approximately $500&#160;million (the &#x201c;B+L Revolving Credit Facility&#x201d; or such financing, the &#x201c;B+L Debt Financing&#x201d;). The B+L Credit Facilities are secured by substantially all of the assets of Bausch + Lomb and its material, wholly-owned Canadian, U.S., Dutch and Irish subsidiaries, subject to certain exceptions. The term loans are denominated in U.S. dollars, and borrowings under the revolving credit facility will be made available in U.S. dollars, euros, pounds sterling and Canadian dollars. As of May 10, 2022, the B+L Revolving Credit Facility remains undrawn.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the B+L Revolving Credit Facility in (i) U.S. dollars bear interest at a rate per annum equal to, at our option, either: (a) a term SOFR-based rate or (b) a U.S. dollar base rate, (ii) Canadian dollars bear interest at a rate per annum equal to, at our option, either: (a) CDOR or (b) a Canadian dollar prime rate, (iii) euros bear interest at a rate per annum equal to EURIBOR and (iv) pounds sterling bear interest at a rate per annum equal to SONIA (provided, however, that the term SOFR-based rate, CDOR, EURIBOR and SONIA shall be no less than 0.00% per annum at any time and the U.S. dollar base rate and the Canadian dollar prime rate shall be no less than 1.00% per annum at any time), in each case, plus an applicable margin. Term SOFR-based loans are subject to a credit spread adjustment of 0.10%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The applicable interest rate margins for borrowings under the B+L Revolving Credit Facility are (i) between 0.75% to 1.75% with respect to U.S. dollar base rate or Canadian dollar prime rate borrowings and between 1.75% to 2.75% with respect to SOFR, EURIBOR, SONIA or CDOR borrowings based on the Company&#x2019;s total net leverage ratio and (ii) after (x) Bausch + Lomb&#x2019;s senior unsecured non-credit-enhanced long term indebtedness for borrowed money receives an investment grade rating from at least two of S&amp;amp;P, Moody&#x2019;s and Fitch and (y) the term loan facility has been repaid in full in cash (the &#x201c;IG Trigger&#x201d;), between 0.015% to 0.475% with respect to U.S. dollar base rate or Canadian dollar prime rate borrowings and between 1.015% to 1.475% with respect to SOFR, EURIBOR, SONIA or CDOR borrowings based on the Company&#x2019;s debt rating. In addition, the Company is required to pay commitment fees of 0.25% per annum in respect of the unutilized commitments under the revolving credit facility, payable quarterly in arrears until the IG Trigger and a facility fee between 0.110% to 0.275% of the total revolving commitments, whether used or unused, based on the Company&#x2019;s debt rating and payable quarterly in arrears. The Company is also required to pay letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on SOFR borrowings under the revolving credit facility on a per annum basis, payable quarterly in arrears, as well as customary fronting fees for the issuance of letters of credit and agency fees. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the term loan facility bear interest at a rate per annum equal to, at our option, either (i) a term SOFR-based rate, plus an applicable margin of 3.25% or (ii) a U.S. dollar base rate, plus an applicable margin of 2.25% (provided, however, that the term SOFR-based rate shall be no less than 0.50% per annum at any time and the U.S. dollar base rate shall not be lower than 1.50% per annum at any time). Term SOFR-based loans are subject to a credit spread adjustment of 0.10%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to certain exceptions and customary baskets set forth in the B+L Credit Agreement, the Company is required to make mandatory prepayments of the loans under the B+L Term Facility under certain circumstances, including from: (i) 100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold), (ii) 100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the B+L Credit Agreement), (iii) 50% of Excess Cash Flow (as defined in the B+L Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv) 100% of net cash proceeds from asset sales (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold). These mandatory prepayments may be used to satisfy future amortization.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortization rate for the B+L Term Facility is 1.00% per annum and the first installment shall be payable on September 30, 2022. Bausch + Lomb may direct that prepayments be applied to such amortization payments in order of maturity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Senior Secured Credit Facilitie&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 10, 2022, the Company and certain of its subsidiaries as guarantors entered into that certain Second Amendment to the Fourth Amended and Restated Credit and Guaranty Agreement (the &#x201c;Second Amendment&#x201d;). The 2022 Restated Credit Agreement provides for a new term facility with an aggregate principal amount of $2,500&#160;million (the &#x201c;2027 Term Loan B Facility&#x201d; and the loans thereunder the &#x201c;2027 Term Loans&#x201d;) maturing on February 1, 2027 and a new revolving credit facility of $975&#160;million (the &#x201c;2027 Revolving Credit Facility&#x201d;) that will mature on the earlier of February 1, 2027 and the date that is 91 calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company and BHA in an aggregate principal amount in excess of $1,000&#160;million. After giving effect to the 2022 Restated Credit Agreement, the 2023 Revolving Credit Facility, June 2025 Term Loan B Facility and November 2025 Term Loan B Facility were refinanced (such refinancing, the &#x201c;Credit Agreement Refinancing&#x201d;), along with certain of the Company&#x2019;s existing senior notes, using proceeds of the Credit Agreement Refinancing, the B+L IPO and the B+L Debt Financing and available cash on hand. As of May 10, 2022, the Company has drawn $350 million on the 2027 Revolving Credit Facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the 2027 Term Loan B Facility bear interest at a rate per annum equal to, at our option, either: (a) a term SOFR-based rate or (b) a U.S. dollar base rate, in each case, plus an applicable margin (provided, however, that the term SOFR-based rate is expected to be no less than 0.50% per annum at any time and the U.S. dollar base rate is expected to be no less than 1.50% per annum at any time). Borrowings under the 2027 Revolving Credit Facility in: (i) U.S. dollars bear interest at a rate per annum equal to, at the Company&#x2019;s option, either: (a) a term SOFR-based rate or (b) a U.S. dollar base rate, (ii) Canadian dollars bear interest at a rate per annum equal to, at our option, either: (a) CDOR or (b) a Canadian dollar prime rate and (iii) euros bear interest at a rate per annum equal to EURIBOR (provided, however, that the term SOFR-based rate, CDOR and EURIBOR are expected to be no less than 0.00% per annum at any time and the U.S. dollar base rate and the Canadian dollar prime rate are expected to be no less than 1.00% per annum at any time), in each case, plus an applicable margin. Term SOFR-based loans are subject to a credit spread adjustment ranging from 0.10%-0.25%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The applicable interest rate margin for borrowings under the 2027 Term Loan B Facility is 5.25% for term SOFR-based loans and 4.25% for U.S. dollar base rate loans. The applicable interest rate margin for borrowings under the 2027 Revolving Credit Facility ranges from 3.75% to 4.25% for term SOFR-based loans and 2.75% to 3.25% for U.S. dollar base rate loans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company is required to pay commitment fees of 0.25%-0.50% per annum with respect to the unutilized commitments under the 2027 Revolving Credit Facility, payable quarterly in arrears. The Company also is required to pay: (i) letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on term SOFR borrowings under the 2027 Revolving Credit Facility on a per annum basis, payable quarterly in arrears, (ii) customary fronting fees for the issuance of letters of credit and (iii) agency fees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to certain exceptions and customary baskets set forth in the 2022 Restated Credit Agreement, the Company is required to make mandatory prepayments of the loans under the Senior Secured Credit Facilities under certain circumstances, including from: (i) 100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold), (ii) 100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the 2022 Restated Credit Agreement), (iii) 50% of Excess Cash Flow (as defined in the 2022 Restated Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv) 100% of net cash proceeds from asset sales (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold). These mandatory prepayments may be used to satisfy future amortization. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortization rate for the 2027 Term Loan B Facility is 5.00% per annum and the first installment shall be payable on September 30, 2022. The Company may direct that prepayments be applied to such amortization payments in order of maturity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2022 Restated Credit Agreement permits the incurrence of incremental credit facility borrowings up to the greater of $1,000&#160;million and 40% of Consolidated Adjusted EBITDA (non-GAAP) (as defined in the 2022 Restated Credit Agreement), subject to customary terms and conditions, as well as the incurrence of additional incremental credit facility borrowings subject to, in the case of secured debt, a secured leverage ratio of not greater than 3.50:1.00, and, in the case of unsecured debt, either a total leverage ratio of not greater than 6.50:1.00 or an interest coverage ratio of not less than 2.00:1.00.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2022 Restated Credit Agreement provides that Bausch + Lomb initially be a &#x201c;excluded&#x201d; subsidiary subject to the terms of the 2022 Restated Credit Agreement covenants, but does not require Bausch + Lomb to guarantee the obligations under the 2022 Restated Credit Agreement. The 2022 Restated Credit Agreement permits the Company to designate Bausch + Lomb as an &#x201c;unrestricted&#x201d; subsidiary under the 2022 Restated Credit Agreement and no longer subject to the terms of the covenants thereunder upon achievement of a 7.6x pro forma &#x201c;Remainco Total Leverage Ratio&#x201d; Such designation could take place at any time after the B+L IPO. The Credit Agreement Refinancing contains provisions designed to facilitate the separation and distribution of Bausch + Lomb.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Redemption of April 2025 Unsecured Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 18, 2022, the Company issued conditional notices of redemption to redeem: (i) all April 2025 Unsecured Notes conditioned upon the completion of the Credit Agreement Refinancing and (ii) $370&#160;million in aggregate principal amount of our outstanding 9.000% Senior Unsecured Notes due 2025 (the "December 2025 Unsecured Notes") conditioned upon the receipt of aggregate proceeds from: (i) the B+L IPO, (ii) the B+L Debt Financing, (iii) the Credit Agreement Refinancing and (iv) the issuance of the February 2027 Secured Notes of at least $7,000&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In connection with the closing of the B+L IPO, the conditions of the Company&#x2019;s previously announced redemption of its April 2025 Unsecured Notes were satisfied and the Company discharged the April 2025 Unsecured Notes Indenture using: (i) the proceeds from the issuance of the February 2027 Secured Notes, (ii) the proceeds from the B+L IPO, (iii) the net proceeds from the borrowings under the B+L Debt Financing and (iv) cash on hand. On May 10, 2022, the Company caused sufficient funds for the redemption in full of its April 2025 Unsecured Notes at a redemption price of 101.021% of the principal amount then outstanding to be irrevocably deposited with the Bank of New York Mellon, N.A., as trustee under the April 2025 Unsecured Notes Indenture, and the April 2025 Unsecured Notes Indenture was discharged. The April 2025 Unsecured Notes will be redeemed on May 16, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 10, 2022, the Company notified the Trustee and holders of its outstanding December 2025 Unsecured Notes that the conditions to its previously announced redemption would not be satisfied, and the conditional redemption was cancelled.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the closing of the B+L IPO, the discharge of the 6.125% Notes Indenture and the related release in respect of the 2018 Restated Credit Agreement as described above, the guarantees and related security provided by Bausch + Lomb and its subsidiaries in respect of the existing senior notes of the Company and BHA were released.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i68726a27c9ca4a3a994459eb340ec3da_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMTk0ODA_94ed8ab3-4833-4ca9-a349-3d7f5edd36a1"
      unitRef="shares">35000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ia0d8e4dd5979420fbef5b45edd961b43_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzEwNDQ1MzYwNTEzOTUw_7fae6b81-bf1e-45dd-a296-c39fc01268b6"
      unitRef="usdPerShare">18.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i68726a27c9ca4a3a994459eb340ec3da_D20220510-20220510"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzEwNDQ1MzYwNTEzOTY2_28c4f7d7-f44f-4c77-bf30-81424d01a72d"
      unitRef="usd">560000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <bhc:SaleOfStockOverAllotmentTerm
      contextRef="ib2ffbb57b436490590a2819d68a36061_D20220510-20220510"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg3MzE_4086f145-fa5f-49b5-92f4-9565b9c27a6e">P30D</bhc:SaleOfStockOverAllotmentTerm>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ib2ffbb57b436490590a2819d68a36061_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg3MjA_9a7d0839-8472-4c99-b119-e6f9e622ca68"
      unitRef="shares">5250000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9088830177c14b93899cdc2428206dd1_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzEwOTk1MTE2ODE3MTc_06530d08-adf8-43ad-94dd-87a8213424cd"
      unitRef="shares">315000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction
      contextRef="i9beb6982df2843ba905908dcf5d3e1c9_D20220510-20220510"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzEwOTk1MTE2ODE3MzA_cb9f7b43-198d-4809-816e-6428e824f9f5"
      unitRef="number">0.90</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ie30ec3f614a04d42848dad1250068433_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg3Mzk_8c912cfd-cdf6-4ff2-9073-4b87cdab60e2"
      unitRef="usd">2500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="i9b0e960b1ec848318fdc55394dac24fa_D20220510-20220510"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg3NjM_36877417-c208-46ad-8cf4-1544ecad1554">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="i07b15b7868704928b2944eba14639156_D20220510-20220510"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg3NzM_44a79dc3-4f46-409a-9f53-bfa3ee4f8ad6">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ic99afd1f228a44c78581651c6a9579a0_I20220510"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg3NzU_be041775-012d-434f-9a96-ba06ecd15560"
      unitRef="usd">500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i969796cd9c2a43459679467ac14382c6_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg3ODk_979a04e8-1b6c-4370-a77c-449f99440d30"
      unitRef="number">0.0000</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i1a1c85fad6244e21b4823c99ca9236cb_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg3OTc_d72b6c22-ae73-4fe2-8917-7f24a5172a19"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate
      contextRef="i6835eeba06904e7d83cc68aeeb30bc96_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzE2NDkyNjc0NDg1NzQw_4278d38b-318b-4e77-b789-84fc06675e0d"
      unitRef="number">0.0010</bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="iaef1fd49551a4a5e99cc5c7286d61d19_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg4MDQ_cc9958e7-7d7b-4efc-b3c8-ef9f05b5d870"
      unitRef="number">0.0075</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i6062d01783b9476ab5d93d304f908fdb_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg4MTE_fcf5d492-a087-4fbe-84d6-231226a5a129"
      unitRef="number">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i5ed6554f1984485bbe1d859a5cce60e5_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg4MTg_27f75ac4-6662-4372-a1bf-6eed03042059"
      unitRef="number">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i37d22f117617444f9a62f2666aeaf23e_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg4MjU_9d703785-3819-425b-b06b-a3dfafae7023"
      unitRef="number">0.0275</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="iebf7fa610282462e8a87798c4a0c13b7_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg4MzI_93553db0-fed0-4f04-ac98-a6d2f3104ce8"
      unitRef="number">0.00015</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i07c3bdbe9d364f85a235465f6572d30b_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg4NDA_3cbfa130-6bed-4119-a80d-a4fd88aa4686"
      unitRef="number">0.00475</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i827cfce6b4184d368806fa2e3eab7b12_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg4NDg_7448b5ee-e522-4a13-9cec-d5e952c4dd6b"
      unitRef="number">0.01015</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i15b198ca83624b318396f39380edc2ac_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg4NTY_ae0b843a-dbc0-4c22-806d-8979fe1c72b4"
      unitRef="number">0.01475</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i07b15b7868704928b2944eba14639156_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg4NjQ_f4eac893-638a-4a5e-9803-cfb760e484ea"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="id2a157fb52da45df95151e9668b651b6_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg4NzE_b667729a-58a2-4aee-8365-8bc17844c1c9"
      unitRef="number">0.00110</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="ic7c0ae85a82c4cb3a319373f684bc55a_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg4Nzk_d5cf685a-84b8-416d-a647-d6e421eb91ae"
      unitRef="number">0.00275</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i679d8e8de83d43b8aa7b432b14f90a83_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg4ODc_d81264f3-07fc-4c5e-8940-08ff5181cab5"
      unitRef="number">0.0325</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i8d5a322888ac487b9f4166843a4b2254_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg4OTU_01a4282c-2f32-4718-abb8-14bc628a4bce"
      unitRef="number">0.0225</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i6a4a857f626f43fcbcdf8083edd3c4b1_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzE2NDkyNjc0NDg1NzQ3_3f96f077-6a81-4b86-bb7d-9cd3e3bb0a6a"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="if0dbac6e5e59470e9e96eab6a439d571_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzE2NDkyNjc0NDg1NzU0_7dc9b8d7-4c02-402d-b2ad-c7c0ad3f2e37"
      unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate
      contextRef="i679d8e8de83d43b8aa7b432b14f90a83_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzE2NDkyNjc0NDg1NzYx_a9ee8d97-0eb9-449b-a143-683dc4beffff"
      unitRef="number">0.0010</bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate>
    <bhc:LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments
      contextRef="i07b15b7868704928b2944eba14639156_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg5MDI_6667054a-ba7c-4ff2-af22-737b97cf9494"
      unitRef="number">1</bhc:LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments>
    <bhc:LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments
      contextRef="i07b15b7868704928b2944eba14639156_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg5MDg_905e6787-dad7-40b9-9baf-6572a2ed1459"
      unitRef="number">1</bhc:LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments>
    <bhc:LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments
      contextRef="i07b15b7868704928b2944eba14639156_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg5MTQ_31071885-bd1c-440d-8658-edd34e02fd0b"
      unitRef="number">0.50</bhc:LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments>
    <bhc:LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments
      contextRef="i07b15b7868704928b2944eba14639156_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg5MTk_76d5e468-ae08-4e15-832c-aaa652008ee3"
      unitRef="number">1</bhc:LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments>
    <bhc:DebtInstrumentAnnualAmortizationRatePercentage
      contextRef="ie30ec3f614a04d42848dad1250068433_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg5MjU_28f9b26d-729f-4814-a659-ee690286d4d6"
      unitRef="number">0.0100</bhc:DebtInstrumentAnnualAmortizationRatePercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i4920545cfdfe43ea874d0ca5a349c081_I20220510"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg5MzI_5d4ac766-14c9-4d08-a278-7d5c90cb7e95"
      unitRef="usd">2500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="iba4cf152a5ec43589599bfbc8c8881de_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg5NDg_0792b5b8-5340-45bd-9293-a43c8d82303c"
      unitRef="usd">975000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <bhc:DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold
      contextRef="i1a96cf695f3646188214a645c50f0e12_D20220510-20220510"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzE2NDkyNjc0NDg1NzY4_058c2c9c-71c5-4c7e-8b1f-86d60d169a3b">P91D</bhc:DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold>
    <bhc:DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold
      contextRef="iba4cf152a5ec43589599bfbc8c8881de_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg5NjI_cb4de2d1-189c-479b-9670-a44178f02e69"
      unitRef="usd">1000000000</bhc:DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold>
    <us-gaap:LongTermDebt
      contextRef="iba4cf152a5ec43589599bfbc8c8881de_I20220510"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzE2NDkyNjc0NDg1Nzc2_56c0fdb2-8a62-410f-9f4b-571bc707b6e5"
      unitRef="usd">350000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i5263f4eeef0e4a1eb6008213ffca534f_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg5Nzg_db8081a5-e3c1-421e-b441-3a46fabee19a"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i00ec1ba964804053bf2cebbf5c43f522_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg5ODU_85650845-55b0-4633-84df-0329fd0a83fb"
      unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i801aca530cc14c9b8be64fb696e6dcf5_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjg5OTI_268dfd74-00cb-43db-b2d1-4285d89f0777"
      unitRef="number">0.0000</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="id66d7e17675f4184972f0235d07b1e63_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkwMDA_77524024-2006-494e-96cf-30e0bd994a27"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate
      contextRef="i5263f4eeef0e4a1eb6008213ffca534f_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzE2NDkyNjc0NDg1Nzg1_3a9139d2-2d3f-4478-8da0-859386214f90"
      unitRef="number">0.0010</bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate>
    <bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate
      contextRef="i9e33a46b9a8c458e92c2a7533b092615_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzE2NDkyNjc0NDg1Nzky_006f532e-18b8-46de-8d90-4e0de34c4ce4"
      unitRef="number">0.0025</bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="iedc6c37d8af5490d993ec3399bc55792_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkwMDc_4e447bf0-01b2-460e-89a2-6971f4943066"
      unitRef="number">0.0525</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i28d3080b48c44fb2a31f867511fa241f_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkwMTQ_fcef0ca5-f9ee-4a4d-b16f-52273c5b9bbe"
      unitRef="number">0.0425</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ib5ba454a7b6c45a3949b8f1985ac313e_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkwMjE_f5f4bd7c-fe64-420d-ac0f-25b036edccf1"
      unitRef="number">0.0375</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i053e8e2380ae405a8cf2ef0d0dac698b_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkwMjg_a555f2f6-71f7-4010-8285-8dbe479203fd"
      unitRef="number">0.0425</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i618e8b101a9e4651a8d45a1516a66fde_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkwMzU_db298e49-7340-463d-a9ad-ea38728ad7a5"
      unitRef="number">0.0275</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ibfc76cd45bc6474988b4e3877373db82_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkwNDI_f343642d-2d32-4aac-8bf4-a7d53a894bb5"
      unitRef="number">0.0325</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i577466297a53405f9454d33995ecba1e_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkwNDk_b4e82447-bf60-4b2f-92cd-53255abefd1c"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="ib5b37fae66ea41e88fed93726d182d6a_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkwNTY_00270621-96b0-4960-b6d9-0e3250900a3d"
      unitRef="number">0.0050</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <bhc:LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments
      contextRef="i14ef51bcde474f27be0e9b588872b89a_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkwNjM_b8dc0d92-1e53-40be-ab58-a38996b6d714"
      unitRef="number">1</bhc:LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments>
    <bhc:LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments
      contextRef="i14ef51bcde474f27be0e9b588872b89a_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkwNjk_8a604c67-781a-4a8e-a268-24e41060d7f3"
      unitRef="number">1</bhc:LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments>
    <bhc:LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments
      contextRef="i14ef51bcde474f27be0e9b588872b89a_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkwNzU_e3f3d17b-2ad2-4127-ae9d-85746eb46103"
      unitRef="number">0.50</bhc:LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments>
    <bhc:LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments
      contextRef="i14ef51bcde474f27be0e9b588872b89a_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkwODA_ecd4c961-835a-41c2-bb32-b67f10e57e97"
      unitRef="number">1</bhc:LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments>
    <bhc:DebtInstrumentAnnualAmortizationRatePercentage
      contextRef="i4920545cfdfe43ea874d0ca5a349c081_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkwODY_78212e57-c4d9-466d-8012-ec6fd65f7102"
      unitRef="number">0.0500</bhc:DebtInstrumentAnnualAmortizationRatePercentage>
    <bhc:LineOfCreditFacilityThresholdForIncrementalBorrowings
      contextRef="i5d6eeadd393b426393e1f0ed889d241d_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkwOTM_2ebad52b-52e8-46bd-a046-775c57bbc05d"
      unitRef="usd">1000000000</bhc:LineOfCreditFacilityThresholdForIncrementalBorrowings>
    <bhc:LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate
      contextRef="ic809285ec99545369921696d670f6b36_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkxMDk_fb6bcce3-0ef3-4470-b69e-8f334ae67ce0"
      unitRef="number">0.40</bhc:LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate>
    <bhc:DebtInstrumentCovenantTermsSecuredLeverageRatio
      contextRef="i2fe9c48370994d03935d785c7f1a8b8b_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkxMTQ_065eb5e8-e4cc-4d96-be82-891b577d69ef"
      unitRef="number">3.50</bhc:DebtInstrumentCovenantTermsSecuredLeverageRatio>
    <bhc:DebtInstrumentCovenantTotalLeverageRatioMaximum
      contextRef="i49de6c3d04bb472d8b09e6bd0c1887d7_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkxMjA_74a0ec1e-49c2-4944-bc11-71cfeef63067"
      unitRef="number">6.50</bhc:DebtInstrumentCovenantTotalLeverageRatioMaximum>
    <bhc:DebtInstrumentCovenantInterestCoverageRatioMinimum
      contextRef="i5d6eeadd393b426393e1f0ed889d241d_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkxMjY_76e592a1-4b45-4f55-ad75-d2a5833e935f"
      unitRef="number">2.00</bhc:DebtInstrumentCovenantInterestCoverageRatioMinimum>
    <bhc:DebtInstrumentCovenantTotalLeverageRatio
      contextRef="ia843743426e540ee8c98df5ca73090c9_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkxMzI_aeea666f-8f80-497e-b012-abfbf2a4ee52"
      unitRef="number">7.6</bhc:DebtInstrumentCovenantTotalLeverageRatio>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="iaa22c8251ddf46939526e13e17458660_I20220118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkxMzc_b350c47a-2ed4-4b57-9b54-9ffb2b6987c9"
      unitRef="usd">370000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iaa22c8251ddf46939526e13e17458660_I20220118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkxNTE_c7697313-37d8-4591-8a8c-822820e775c6"
      unitRef="number">0.09000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <bhc:DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet
      contextRef="iaa22c8251ddf46939526e13e17458660_I20220118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkxNTk_f77e5db9-35be-4707-95ba-218de6a32fc1"
      unitRef="usd">7000000000</bhc:DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="id1e3d8f9146049ff9febeb80d7774565_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzI3NDg3NzkxMjkxNzU_5dce3528-39a4-45a8-937e-8bb7d87e29e3"
      unitRef="number">1.01021</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3525c40548924586bbd17234ab1c71c3_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwMWM0NjFjYmQzMzQ5MmE4OTNjODQzNzNhOGU3Y2JjL3NlYzo4MDFjNDYxY2JkMzM0OTJhODkzYzg0MzczYThlN2NiY18xMDAvZnJhZzplYzA5M2E2NDFhNWU0ZjBmOTBkNGJlNjQyNWQ0MjgzNS90ZXh0cmVnaW9uOmVjMDkzYTY0MWE1ZTRmMGY5MGQ0YmU2NDI1ZDQyODM1XzE2NDkyNjc0NDg1Nzk5_8d665c34-d4ef-4214-8095-73452d08f215"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>110
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( #"*JE0'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  PBJI4)1$%2>X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2@,Q$(9?17+?G62+"F&;B^*I!<&"XBTDTS:XR89D9+=O;W9MMX@^@)!+9OY\
M\PVD-5&:/N%SZB,F<IAO1M^%+$U<LR-1E #9'-'K7)=$*,U]G[RF<DT'B-I\
MZ -"P_D=>"1M-6F8@%5<B$RUUDB34%.?SGAK%GS\3-T,LP:P0X^!,HA: %/3
MQ'@:NQ:N@ E&F'S^+J!=B'/U3^S< 79.CMDMJ6$8ZF$UY\H. MZVFY=YW<J%
M3#H8+*^RDW2*N&:7R:^KA\?=$U,-;YJ*WU:"[QHAQ7TY[Y/K#[^KL.^MV[M_
M;'P15"W\^A?J"U!+ P04    "  PBJI4F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M #"*JE1]22)L5P4  !86   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MI9A=<^(V%(:OM[]"0V<ZNS,!VS*?6\(,89,FTR1+0KH[::<7PA;@B6Q168;0
M7]\CV]@D-<=TFHO@K_/Z\9'T'DG#K50O\8IS35Y#$<7GC976Z\^6%7LK'K*X
M)=<\@CL+J4*FX50MK7BM.//3H%!8U+:[5LB"J#$:IM>F:C24B19!Q*>*Q$D8
M,K6[X$)NSQM.8W_A,5BNM+E@C89KMN0SKG];3Q6<686*'X0\B@,9$<47YXVQ
M\WGBNB8@?>);P+?QP3$QGS*7\L6<W/CG#=L0<<$];208_&SXA MAE(#CKURT
M4;S3!!X>[]6OTH^'CYFSF$^D^![X>G7>Z#>(SQ<L$?I1;J]Y_D$=H^=)$:?_
MR39[MD,;Q$MB+<,\& C"(,I^V6N>B(, .C@20/, ^B[ <8\$N'E FCDK(TL_
MZPO3;#14<DN4>1K4S$&:FS0:OB:(3#/.M(*[ <3IT1?I)= JFK#()Y>1#O2.
MW$19]S!I;I)XQ12/AY:&MYD8R\N5+S)E>D39)7<RTJL85'WNOXVW@+) I7O4
M"XH*WC'5(JYS1JA-:07/I"Y\1^Q.5?0;&K=(G)O*N4?D)G+#%?EC/(^U@K[X
M)R+9+B3;J62[KBV>=FM>E7 \W+&;#PA%IZ#HG$;QD#"EN1([\LC74NDJ(EQ*
MJX0C1-V"J'L:T92K0)INZA/H[)4IPI7V7>B'#Q]JND&O8.N=V&:*@;>E8^9X
MNG"M!1,QEJ]^P=1'=?)A?!4(3NZ3<,Y5%0NN8=M.TVD/.EV$9U#P#$[A>>3+
MP P62-8]"RM;#]>Y8 F4,7+-F= K,I'AFD4!C\&OO!:"Z=BE%]JG@(*>5-"$
MJ0.>D9F&OD:D@C<FD58[^/4KZ6O4QPX&>6#8SBF08]\'6X[/]E250+C29(P!
MT1*(G@+TQ%[)C0]#(5@$7E8\CG>^&LE!OVFWVWUJ=S#"TJH=]S^E+#\@M_ <
M^1I5-R8N29V.#3VC12[%WS_]2%WW9Z;(A=CX+?*=QQK#+LN!@QOZOUK:G$$_
M?)+;J!(9E[ME&R8PL+)".+BOOP<K1LA4R4T0>=4)Q34?)AA:62H<W.'?HTUE
MK)D@OP?KX\,65[SNW9+VN(_1E<7"P1T^;<$Q3+>/P^ "':>-@905PL'M_59Z
MD)7I2D98B:@1Z;7;S6YO@)51IZP1#F[N3X&&<B47Q*$?YY_(C'N)@FQ58N%*
M4!A",)]9.F\](_>23&%L?F,"G8S0LDI0W,>ATOM!M"2S73B7H@JP1N#B&NOK
MM*P$%/?O?8[(Y:NW8M&2'ZVK-4+WS[-+C*@L!?2D4C!)E#)SHFPBE.8*'"*I
M7$34*#Z_7WJ\)2M+ #VI!-Q$,*/-EHYF"LGVJ)5DN&(-6>GR]"27-[,UF&*
MD2YE=36OT;EE"GK V/-@B0Q3%^YGDAAC:?@4-^=9R(3!*QLTFWU5<^):=;-<
M6GH]K?'ZD*NE@?D%0HL98343KE3+5#H\Q0TZ;\W9B@N! OV_I0 MG9Z>M!C8
MFZ*6WLM9[HWD:Z*A.D:IFWT,HGRI_ZER;9V]I9.^Q>P-;49NUVGW!CT;2N.F
M"K&T?GK2^F "XU!!5;J)?/Y*?N75><.E;/CK]SN=@8TM\4NK=W&GWAO951";
M>OG,H9!@J\\:N6;3H4T76P:XI?F[N&<7"\]#MBNX6.FR-6)U>R)E 7!QNWY/
ME:_8CW/A<@]HK@ZV:G"K'@.2GV$)MJSDP 6.#D?K8.?-N%&Z(1D3SZS)LDVX
MXFJQZ3E.M_JL\O%LQ_2.&3.+B> +"+5;/1AK*MN$S$ZT7*?[>'.IM0S3PQ5G
M/E?F ;B_D%+O3\P+BJW@T3]02P,$%     @ ,(JJ5'$FO=4T!@  EQ@  !@
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M\:R23#'YP&9K9#O?_@^.7HZ^AQAQ0PQ6/D^Y=OGJN47<W#*1A(17&RJ;U!$
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M,%S9WH*W+UI4S47RK=!:%,WCAE%8JL8 ?K\3P-+MB[F;[OX7L?X/4$L#!!0
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MTI"HYLHV <JUF_JE1'.'W+(RKQPHFV#.2REQ']B+U+V;Z5]02P,$%     @
M,(JJ5(V)!OXI!@  P1D  !@   !X;"]W;W)K<VAE971S+W-H965T-"YX;6S%
M65%OHS@0_BM6M ^MU"1@$I*LTDAMVKVKM-U43??NV0E.0 LX9YNF=[_^QH8
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MOT : ?R_%D*_+(R#>J ;_0502P,$%     @ ,(JJ5'6D-T:R!0  HQD  !@
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M/"W ]TL',^,'.J#[1=NK_P!02P,$%     @ ,(JJ5,KVRZ2U"P  (!\  !D
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MZ F7/E+22[#S^&&0V8 3/3X"4N!?%L!^:6WH7MC!^DOQ[&]02P,$%     @
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M.@]9,_*N>/MLSJ\ \6AE:UNBM-PZC=+C:U:3]N*WPMEQ.]2G-JF')G,I;]O
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MNDR7/#):JJ),_\W>+^07X'#- ^_QY5D5" B4)PB/&,.>0ES("$K&!7IBAAD
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MR1^MV34:IZH*<MM9[J!(A6(@:>3SEMT1N9[=>7MXWR<MYFH#W1EX_,#<>%C
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M!3V ^S,%;&._T +5+^8]_U]02P,$%     @ ,(JJ5.1\.$3+ @  U@4  !D
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MT7#4J-2E2AHTH .4>47&@I6H<G4IUO1+9B#UJ"W04L)<  JL#TH!["4- -N
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M,)S-[7AH*E)2X]R"JXI"V.=+5&8[BGK1_N!!KG/R!_%X6(HU+I">RKGE77Q
MR62!VDFCP>)J%$UZ%Y<#+Q\$/DO<NJ,U>$^6QGSUFYML%'4](528DD<0_+?!
M*2KE@9C&?PUF=##I%8_7>_2/P7?V92D<3HWZ6V:4CZ+S"#)<B4K1@]E>8^//
MJ<=+C7+A"]M:]NPT@K1R9(I&F1D44M?_8M?$X4CAO/N*0M(H)(%W;2BPO!(D
MQD-KMF"]-*/Y17 U:#,YJ7U2%F3Y5K(>C2?3Z=/=T^WD<78%]X_7LP>8WM_-
M'V;7LT^+F\\SN+U?+(8QL24O'Z<-ZF6-FKR"VH<[HREW,-,99B_U8V9XH)GL
M:5XF;P+>"=N!?J\-23=)WL#K']SN![S^*WA34W -Y[ZX-@@W.C4%PLFM<:[5
MAD_<"V8%CV+7A@F1E<N*Q%(AD(&YL*@)_IDL'5DNJ7_?(#,XD!D$,H/?G(-?
M1X5)FE9%I01A!H9RM)"^B(SBB/ 1;QPY#LH%G$C-=:@4MY1K ><ES4-BKC#%
M8LD ?L,-P^V@N8 MARM]!HZ5=FPF-&+VA>NZ\&'\ TYZ[0_O>ZUFU3UMP;SI
M>*$S* U'&4E:#.)+U+B2!*42QS"N#;I.F:P326*'C@'[+?Y\V(.?#?:KA%<W
MQZ*<5-"&@:W92*Y8X&GG?S_CA->63NHU\#&'\(48<_)'OMR$?O[SW7G2._N+
M UFB#0(.<K'QN@)6E0Z#2JCO%NN44"YJY*?.H@.944K8-N NQ9)\3?HKW)&/
MD+?W"DN+=9H;A?]3XC#S".=[%%8S(_<B!E\J]C&3:<V92V";2T[\$1!(%T(8
MBB5#6UM:(K"KA=!,03VS$:DWZ)A&YT=]$Q_-L0+M.DQK7W^5IGJD'4X/#\*D
MGH/?Q>O7A MS+9FJPA6K=CM^_MIZ0M<;,F68BDM#/&/#,N='#:T7X/N5,;3?
M> .'9W+\#5!+ P04    "  PBJI4#]=&()X"  #Z!0  &0   'AL+W=O<FMS
M:&5E=',O<VAE970R,2YX;6RM5-]OVC 0_E=.T1XV:2(AT!]"@ 2%J976CM&N
M>YCV8)(CL>K8J>U ^>]W=D(&6N%I+X[/_NZ[^YR[&VZ5?C$YHH6W0D@S"G)K
MRT$8FB3'@IF.*E'2S5KI@EDR=1::4B-+O5,APCB*+L."<1F,A_YLH<=#55G!
M)2XTF*HHF-Y-4:CM*.@&^X,ESW+K#L+QL&09/J+]42XT66'+DO("I>%*@L;U
M*)AT!].^PWO ,\>M.=B#4[)2ZL49=^DHB%Q"*#"QCH'19X,W*(0CHC1>&\Z@
M#>D<#_=[]B]>.VE9,8,W2OSDJ<U'P74 *:Y9)>Q2;6^QT7/A^!(EC%]A6V-[
MEP$DE;&J:)PI@X++^LO>FG<X<+B.3CC$C4/L\ZX#^2QGS++Q4*LM:(<F-K?Q
M4KTW)<>E^RF/5M,M)S\[7LX?YY/ES2U,'F8PFS_/OWY;W,\?GH:A)7:'"9.&
M:5HSQ2>8>G"OI,T-S&6*Z;%_2%FUJ<7[U*;Q6<)[ICO0ZWZ&.(KC,WR]5FK/
M\_5.246#3"<Y,)G"##=4D"65EX5?DY6QFNKC]YDH_39*WT?I_X<'/<ODVG%@
M2I;@**!^,Z@W&)RDASN9B(H>'KB$(Z7I@5*F$1)EK*%^$LP2VBHHM4JKQ!X#
MR?&U8H+;'3!C*LUD@@Z9:5:8#GS_Y\Y1VWQ/SV52:5WS%VZVX$:)#9=94].H
M?0B-645Y*+T#8^F Z93(3Z9?<R>*1H*QH-8#>,HUXE'AP4=Z@((+03UO/OG:
M<4L7%HW,O7)]*LH'Z!*<UNCB'9V7<.41?NW&\%[)A ?]2%(S/W5<XI6T=6NV
MI^U@F]3]_!=>3T5J@HQ+ P+7Y!IUKBX"T/6DJ0VK2M_=*V7I7?TVI^&,V@'H
M?JV4W1LN0#ONQW\ 4$L#!!0    ( #"*JE0H9K[4V0(  #\&   9    >&PO
M=V]R:W-H965T<R]S:&5E=#(R+GAM;*U5;4_;,!#^*Z<,3:T$39N4P5A;J679
M0%JA O8B3?O@)M?&6F('VZ'LW^]L)UF1!A^F?8CCE[OGGN?BNTQV4OW4.:*!
MQ[(0>AKDQE1G8:C3'$NF![)"02<;J4IF:*FVH:X4LLPYE448#8=OPI)Q$<PF
M;F^E9A-9FX(+7"G0=5DR]6N!A=Q-@U'0;MSP;6[L1CB;5&R+MV@^5RM%J[!#
MR7B)0G,I0.%F&LQ'9XNQM7<&7SCN]-X<K)*UE#_MXC*;!D-+" M,C45@]'K
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M )(F2*/O( _=@*TE>,BS\_X0]NCGV7F7Q]=59R;HL/G]*0L[S^9]26@HO8$
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MYT^.PI5B>O!FP[]K61CO3<DOUTHB7+0 GR^-\>F!#FA^Z/3J?U!+ P04
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M O2_TE0$_<(?L+M0S?X'4$L#!!0    ( #"*JE1>@;1+?B4  &N'   9
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;.T]:7/;1I9_!>6=VI*J((FD#LN.
MXRH=3J*,#ZWE9'9K:S\T@2;98Q!@T(!HYM?O._H$0,JRG=GL[%;YD'!TOW[W
MU8T7ZZK^J!=2-LFG95'J[Y\LFF;U_.A(9PNY%/JP6LD2[LRJ>BD:^+6>'^E5
M+45.+RV+H\EH=':T%*I\\O(%7;NM7[ZHVJ90I;RM$]TNEZ+>7,JB6G__9/S$
M7GBOYHL&+QR]?+$2<WDGFU]6MS7\=N1&R=52EEI595++V?=/+L;/+T_P>7K@
M5R77.O@YP95,J^HC_G*3?_]DA #)0F8-CB#@OWMY)8L"!P(P?C-C/G%3XHOA
MSW;T'VCML):IT/*J*OZF\F;Q_9/S)TDN9Z(MFO?5^B=IUG.*XV55H>G?9,W/
MGDZ>)%FKFVII7@8(EJKD_\4G@X?@A?/1EA<FYH4)P<T3$937HA$O7]35.JGQ
M:1@-?Z"ETML G"J1*'=-#7<5O->\?/WJQXO7R>W[=U>O7EW?O/WQ[L51 \/B
MS:/,#'')0TRV#'&<O*G*9J&35V4N\_C](P#'P32Q,%U.=@[X1M2'R?$X32:C
MR63'>,=NC<<TWO&6\:ZJY5(UP$F-3D29)U< KBKGLLR4U,FUTEE1Z;:6R7]>
M3'53 Z/\UXY93]RL)S3KR==@]I%#)#_4U3)I0"J2IJ+_TZ192%C1<B7*33*5
M6;6$-:GROBKN90X_)/>B5E6KDT+.14'K%SDPDL*5HD0DJ[K*I,P!(SI-U@N5
M+>"UK&ASNI6W69,42DQ5H9I-"K<:$"&0J19&@_LK6>-EF'<IZTR) B 2GU*8
MJ%%-#0R<)O/J7M8EXM\ 4,MY6XBFJC<(J=2-F@N449B_EG # %_5ZAY^@)GM
M37JSJ@%.4!XP7UMKF<CEJJ@V./2!?5-IW4I]^!"J1*$KF!V&A[<T:0<  "9(
M9JJ "S !K+3."J&6,-J'X%6X5>2 :]!DT[\#)G""Z'$<I8+)4/FI!LD!Z](K
M&)^ L7.I!B1YXX"()YG*0DG #0 M&H(<D*UEUA(NJAE>@N'L6(B<& 8%?Y:K
MJFZ $C@KZ&PM:Z W/@IC-02YGQ%("Z#6<M4V'M]X26@M0?$G5T!IT/)^[H!Q
MF*\L+"!*N=19K:;,@F]A,A#F-/G7?SF?3$;?]?@ZI1OC[XA4'B2\.G[ZG4:)
MU56A<B+P#\ !)7):<@>02I9KP[$TW= (%V6)#/M>(D826!WJ]&0\.OAK I:-
M7ME(42<2=5AR+3.YG +]C!:"?Y$K<E#.S8(>OGMU16NFN>XN:$0YK5ODS<DQ
MJZ[#Y-6G3*X:P&" CRD:0N)%0--" $&F4I9)60$S /5P7>TJ)Z8$P'+@@:):
M\2)I=N0DPW3()[H%>0TI 2]90N1M#9<(QF912YDL65'S(D'-PJM6SQXF[X#D
MR6^P H"BV*"M4SJ6&7DOBI8@B\ "E+-RB33)"H@..@ N _LTA?3ZET4#5@L3
M&?YFD0(B@F,!G$4+-S\C &*)K&TXSVLC6&A6MS(_3"XTWHQ7E#[,2I>B %8"
M:J+]=$RD[;A@@.L:P$[ /J!&",T&3/>7<7IZ/ *K7!3LHK ":BJW-M:F* ]3
M6#3B9RJFA31*4.BJA%\!KZ !EWCC$-D25%,1XRA-VA)TDN:K:P58466N,IPN
MIE FRK)JPK%![.%)EG1PRM ^> D>(%L) , HJ)P8K*9+ D1&BB2J!6##7U&S
MA-0($105&W J^$;)C!1Q5V, S8#?<K ,V@,&G)3MTC+,)B0TPHN+'47.9B@8
MU; &F+8:S"L".G,*!$B:*Z?L&%XB+9HU:Y*,:H6),]$:A@0']B-XS"@/A '4
MDV@"822] 'H3HQ\1&T^;!-5V#?.@-J^0L]'0'R8_=NWB>V\7;\K?6E7C&Q>H
ME&>@+(!10<=.X:7T49+];72-HPLQYA:%$RFZ%F"IK<K_K+5:*_!_V61\(*:W
M"L3 ^!QP%/A)R71#H_QR> =BU  22^GA?C>;*=!I%L9K]/10 Y""U%IDBQ8U
MLDX.@+[)NUK< L<N!4R17+1S\-@ DO&S6*_4L#J%#J5 IV=5R5(XN?Y*,-#G
M^ZW%Q0%#6[:T*\=K>96U3#$05V##TG*^%J 44R.+<!&]4. RB"6-.*OE%+U$
M?!FGO:AI%F"I\=.3[Y(TF,/J;MVNB-KH*0'T1OHC91R[:0JA,MH"QC'$5CIV
M;#O^(ROI0<W,R +Q%M[/ZXY&$@?C,%@]'6YORQ)PG_'J _>6WZKA>JZL>XG:
M&OQ9]!<U8"'6H&"_E,;% 9## !TF=U[#D7#?7+U+K@H@<W(1.*CO#9;?&.XF
MQ@E>?>V=_8/DW:HY> <S!A?!0W%B-CY+!_@4,=N2HJ1U@1%;"&#:.:A(,LSL
MBJ2AYX[6H*!X M"T CS>4PP#@V:A"@ET>$8+8Y0:(3<JA!;D./V*QAP2@+=R
MG?R,-FN3[-V@YY#\"KR,CCK+8B;!S<]0#&[0HR]I^0C639EMP5B:7*&W]+8Z
M3,:G!]G]P>CIV>GY/KEU/XN2M(Q731% #"?%38 K9"]4W/-:D+]C$&11XSC
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MB>O> (,/6K34$N&@S.$?12ATQMI2,O^/SU.4&.L?1?'.6N@_E4ND+&2IM<8
M6L?+39/[P\=8YS21J+/@_SUOD,_1((]'DY.S_63/9*6">4PZ:C^E>DG=Z%!5
MS6K1YE:]L_MP9QW\\6AOND_KFHSVQ+XETZM/H!,QOWK!*<VI7(B"%%B/,G#-
M*M?UH@K4:4:9Y)4+_8%I<GS97QO.?$4A4:!FC8*U-I>"BO$Q9B"K=KZPV:.Q
M<;$\4YDKYRE'C@$G12$VJ<EOYDKM/1P/<UAD?:G 4-O@8UD1I.P.8YS$<4[
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M%J2H5K^;"4S9Q+4.18[:Y"R$+@Q@N%&$)_\9 @-BU@M6%MRG4ZNY*KEZREU
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M_Q(\C__7XAD+6(_ LVV&[4CCZ0'E#[K2N+U]<:#[8JCW0GNH;$G<8F'KK/@
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M^& M^TM3K7!(C(N::DD_@K^?RQH?@/NS"BAF?L$)UE7]D<![^=]02P,$%
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MAH.A>*,SF44,3? 0*SG9=D3,1H2V'X,+10"E"2:DB/!9(\;F1CEPVR<E!"2
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M 2V[WBLPM6X86UBLOG4C[&A ARL#)2F#Z?+WV:\_'/\D *E:-;I"KB(BG/$
MDB8 #>@A@94,*[% 3YM LULWSO%[=50N%I0.$1/$LP2AAC*0D8KMJHN2C)9S
M;9CMN/2(6H?*N  #:26Q.6PDV[9O$LE"BD\V_TG!R_2[34^OULKV*GD8@T+
M@2.Z*)5Z2+!IU?5<PV,F5%P,:PU_>+'PKDGE==.=T6Y:HT!,>1=**"WQT/A
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M$3YJ)TH2\\EIP^S"7T(MN3!;1T<0^C$>\CB*8QJ#M,\["4^[PT%$'#&&L[A
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M>K)0NP ZWRAE=X8CZ!_!^5]02P,$%     @ ,(JJ5#C;L=F<!0  $1$  !D
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M<82VVYSCYU@:!+R?"Z&W!R.@_1=D^ ]02P,$%     @ ,(JJ5-@(0(O: @
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M<VAE971S+W-H965T,S4N>&UL?55M;]HP$/XKIZR:0-H(!+IV+2!!EVI(+8V
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M!J3RA]7MB\'",QO][V!1V+UF,/OI=^J+BJOZ!'@A;!BQ_PSK"GVJF_RCV[!
ME;H[7Y,&MZ6I+\;V;?M9,:UOTV?S^IN$])P*TF:.&W(-NM?42:J^Y^N)D96[
M6]?2T$WMAAE]&J&R!K2^D=(<)A:@_=B:_ -02P,$%     @ ,(JJ5&]*X@&[
M @  LP4  !D   !X;"]W;W)K<VAE971S+W-H965T,S<N>&ULC53?;^(P#/Y7
MK.H>0$(K%/93@,08ITT:&P*V>SC=0V@-S2U->DDZV']_3EHZ3AKH7MK8L3]_
MMF/WMTJ_F131PBX3T@R"U-K\)@Q-G&+&S)G*4=+-6NF,61+U)C2Y1I9XITR$
M4;M]$6:,RV#8][J9'O958067.--@BBQC^N,6A=H.@DZP5\SY)K5.$0[[.=O@
M NU+/M,DA35*PC.4ABL)&M>#8-2YN>TY>V_PRG%K#L[@,EDI]>:$AV00M!TA
M%!A;A\#H]XYC%,(!$8T_%690AW2.A^<]^G>?.^6R8@;'2OS@B4T'P54 ":Y9
M(>Q<;>^QRN?<X<5*&/^%;6E[>1Y 7!BKLLJ9&&1<EG^VJ^IPX'#5/N(050Z1
MYUT&\BSOF&7#OE9;T,Z:T-S!I^J]B1R7KBD+J^F6DY\=CL;CE^G+XV@YN8/G
MY?UD#N/GZ6P^N9\\+1Y>)_#XO%A 8\E6 DVS'UH*Z1S#N(*_+>&C(_!=F"II
M4P,3F6#RKW](5&N^T9[O;702<,KT&70[+8C:470"KUOGW_5XW2-X8Y718T[=
M*WM'>)"QRA :C\J89@N>:"C4&I9LUX*1M9JO"NLJ 5;!C&F4%GZ.5L9J>EN_
M3I#IU61ZGDSO")D%C5Q2$#X%M2D"D<F5I##&:49Q7&2%8!834'2M_?TG>4&D
MO^K0Z9C_@THJ$HRG<0,-+NDE"D%#99I #8E3WY$[C#%;$8 3:&1H("0]84UU
MBC^ BB0-A?&CF/RFEYVY^GV#1J=U?=%I5J?V>1-FU<PSF4"NJ+QHN49OOD*)
M:VXA%^P0QK1 EKWB90<MVZ$AP&Z3/M=[\,O>_A3UFE_U*SP8I SUQJ\+EWXA
M;3E3M;;>2*-R$#_-RW5&==EP:4#@FES;9VX!Z')%E()5N1_+E;(TY/Z8TE9%
M[0SH?JV4W0LN0+VGAW\!4$L#!!0    ( #"*JE1*L'\N8P(  "H%   9
M>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;'U4WV_:,!#^5T[1'EII:D*@/X0
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M]R*?H>>\X06G24:3E*Y5Y:0QPKI+\>C$4T;IE-Z#.+F@9$*@V<]\R1M'F#0
M?\#IY@GT(S#V2R-=.#ZA[!>J1@]Q%+QIC9'<C2)\9Z ;-F 8L2E=H+0\N01C
M^#3 L:*D3RCSW$V%:\J%[B$+OOJ4V$&D24^DR7<3:;T9!EO#46[S7+6-<\5U
M&A:\(=QJUX/<YOF2N*+>2\3:K?;\GZKZNY^#&UZ<0ITTJM6Y.!-Z(9K^$\CQ
MD65O_/\R_R2,4=N3P\TG2S]_NQ2YY)5]0H..(9N^ 8TTUL#6CP(3Y3X:37Z
M6HO9\,U+>S5^=K"IG4WN^&;(QZ([X_1O^Q/B:7<PVBSOCI?P>"$;0Y680S0X
MF*#GZN[(UCU8M?3'I)FRB+P?ECCE"NT68'ZNE%T_. 7]N?GD_U!+ P04
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ML-4T^!1 @25KA-VI]C/V]=P[OEP)XW^A[6.C /+&6%7W8%)0<]E]V6O?ARM
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M3)/*IE2V,7+E&OU<&AP;;IG@8 =E!?#]0DJSVU@'Q5^%P5]02P,$%     @
M,(JJ5$)YUG/* @  JP8  !D   !X;"]W;W)K<VAE971S+W-H965T-#<N>&UL
MM55=;^(P$/PKJZ@/K40;"!2J"I H<#VDEJN@[3V<[L$D"['JV*GM0/OONS9I
MA*Z 3B?=2^*OF9W9C3?=C=(O)D6T\)8):7I!:FU^'88F3C%CYD+E*&EGJ73&
M+$WU*C2Y1I9X4";"J%YOAQGC,NAW_=J#[G=58067^*#!%%G&]/L-"K7I!8W@
M<V'&5ZEU"V&_F[,5SM$^Y0^:9F'%DO ,I>%*@L9E+Q@TKH<==]X?>.:X,3MC
M<$X62KVXR23I!74G" 7&UC$P>JUQB$(X(I+Q6G(&54@'W!U_LG_SWLG+@AD<
M*O&3)S;M!5<!)+ADA; SM?F.I9]+QQ<K8?P3-N79>@!Q8:S*2C IR+C<OME;
MF8<=0*-U !"5@.AO <T2T/1&M\J\K1&SK-_5:@/:G28V-_"Y\6ARPZ6KXMQJ
MVN6$L_V[R7 \G4^FMS"XG8W']^/IXQP&TQ&,)L_C^>/D\6DVAG.8,JV92SB<
MCM R+LP9K8ZXR95A FZU*O):.<<$U!(6[S!G FLP5=9MQ$I:+@O:_)&CXU+2
M$,4@4X6D]]-\!*<G9W "7,(]%\+M=T-+%IW0,"[MW&SM1 ?LW#-] <U&#:)Z
MU-@#'_XS/*3$5MF-JNQ&GJ]Y@.^F,+1B# SBUX(;[K_<7W>T!A.+F?E])$:S
MBM'T,5H'8@R922'7*D9,#"RURB"A0AG+;:%Q7PJW?&W/YV[YNM]IU;OA>H^(
M5B6B=53$#-=(Q05FC(HYLU3F#;=>5U+$EG0I3;*VG\N^NK2^:&H?D'192;H\
M*FE@##5!GN6,:VH[UM3HTXI%D7"Y J&H**Z+N$,&4A2)ETCJ\$A-VE7L]G^K
M>Z>*T3GJ;U(Y<]=-*+DZ%U3WI/2T+\F=KTF^^B/)X4XK<6V<;L2*TTT5N"10
M_:)#2=?;UKB=6)7[[K)0EGJ5'Z;T-T'M#M#^4BG[.7$-J_H_]3\ 4$L#!!0
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M=YDS:7&(W!TR0)-MM8ZQ%#ZK']JQ#H,4QN!KTR\>T7?'[!*3JD9U1*7[CO%
MHU*H( ZT%#YO[^^MP'$Q@+EX"+2#_>@#3;:E.?0%^X[21R([V#]:@B;;NAUA
M _B$?>AS/\>^ &;?L<@.BH?IXN.0,J.JQR'!QC-+>-Z$=\-'83MPJ W@B?.
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MRS;56)=3O12L6OG!^* LC5F_S.DA1.T4Z#Q3RKX(SD#UM/9^ 5!+ P04
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M):1<:=F82Z?A7Z\S/^G$D\[\I/,+,L.>S-"1&5ZJ *$27@EK\!H2I5 K(+R
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M]%N!V@70_%(IN^NXFZOZ4>G_ E!+ P04    "  PBJI4)&MXPPL#   X!P
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MAEO\.@%E!7!_+:5YG=@#RN^=X?]02P,$%     @ ,(JJ5$H13DJ1 @  F@4
M !D   !X;"]W;W)K<VAE971S+W-H965T-3@N>&ULC51;;]HP%/XK1UDUM5+;
MA(2RM@N14BX:$D05E.YAVH-)#N#5B9GM0"?MQ\]V0D:E@OJ2^'*^[YSO7!SN
MN'B1:T0%KSDK9-=9*[6Y=UV9KC$G\IIOL- W2RYRHO16K%RY$4@R"\J9ZWM>
MQ\T)+9PHM&>/(@IYJ1@M\%& +/.<B#\/R/BNZ[2<_<&4KM;*'+A1N"$KG*&:
M;QZ%WKD-2T9S+"3E!0A<=IVX==]K&WMK\$QQ)P_68)0L.'\QFU'6=3P3$#),
ME6$@^K?%'C)FB'08OVM.IW%I@(?K/?O0:M=:%D1BC[/O-%/KKG/K0(9+4C(U
MY;MO6.NY,7PI9])^85?;>@ZDI50\K\$Z@IP6U9^\UGDX +3:1P!^#? _"@AJ
M0&"%5I%967VB2!0*O@-AK#6;6=C<6+160PM3Q9D2^I9JG(J&\6@*S_%X/H#)
M()[-IX/)('F:09ST83A*XJ0WBL<P2F9/TWEU<P6QE*@DD"*#,24+RJBB*&&"
M1)8",S#5@8075U-,2R%HL8('(FF%&!(JX)FP$H$O8<R+U95"D4,?%^H2$B($
M,86%\SXJ0IF\T [GLSZ<GUW &= ")I0QW0 R=)76;U2X::WUH=+J']$Z(>(:
M@M8E^)[OOP/OG8;W,6W@K;=P5V>]2;W?I-ZW?.TC?#I#HDD0R7[I8NOQ4/ 7
MQKA%]OE3J^-]]4\X"AI'@744'*MQD_++C]3N?]6,U9LHJS+^&&L',%*8RY\G
MPFLWX;5/YL&&M]UW!&LZ(M,=\5Z1*[:.93./U#;R6W>=('2WA[5\Q\KOW-XU
M5E6H[L'DF%=+M\B*%A(8+C7.N_YRXX"H7H)JH_C&#M."*SV:=KG6CR<*8Z#O
MEYRK_<;,9_,<1_\ 4$L#!!0    ( #"*JE33XO73= (  $ &   9    >&PO
M=V]R:W-H965T<R]S:&5E=#4Y+GAM;(U5VV[;, S]%<'80PML]2UQ+W "M$F+
MY:%=D?3R,.Q!L9E$J"QYDA*W?S]*=@VW=8*]V)1T#GE(FG):2?6B-P"&O!9<
MZ)&W,::\\'V=;:"@^D26(/!D)55!#2[5VM>E IH[4L']* @2OZ!,>./4[=VK
M<2JWAC,!]XKH;5%0]78%7%8C+_3>-^9LO3%VPQ^G)5W# LQC>:]PY;=><E:
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MN<$K'I0%X/E*2O.^L+=(^],8_P-02P,$%     @ ,(JJ5,[9&;"@!   I!8
M !D   !X;"]W;W)K<VAE971S+W-H965T-C N>&ULM9CO<Z(X&,?_E8RS+W;G
MKH4D@-"QSEC=[3G3=IVU>_LZ:E2N0+@0Z_;^^@M(B9+ .G?X1OGQ?9Y\\_#P
M 3+8,_Z2;2D5X&<<)=EM;RM$>F-9V7)+8Y)=LY0F\LR:\9@(N<LW5I9R2E9%
M4!Q9R+8]*R9ATAL.BF,S/ARPG8C"A,XXR'9Q3/C;'8W8_K8'>^\'OH6;K<@/
M6,-!2C9T3L7W=,;EGE5E684Q3;*0)8#3]6UO!&_&V,L#"L6?(=UG1]L@G\J"
ML9=\9[JZ[=FY(QK1I<A3$/GW2L<TBO),TL??9=)>-68>>+S]GOU+,7DYF07)
MZ)A%/\*5V-[V_!Y8T3791>(;V_]!RPFY>;XEB[+B%^Q+K=T#RUTF6%P&2P=Q
MF!S^R<^R$$<!T&D(0&4 .C< EP&XF.C!63&M"1%D..!L#WBNEMGRC:(V1;2<
M39CDEW$NN#P;RC@QG#X]CY[NIW</G\%H/O_\/ >CIPFX__IU\F/Z\ "NP"/Y
MBW$P9G'*$IJ(#+ UF":"))MP$5$PRC(J#WZ<4$'"*/LD([[/)^#CAT_@ P@3
M\!A&D;Q<V< 2TFT^IK4LG=T=G*$&9X^$7P,,?P?(1L@0/FX/G]!E%0Y/PRU9
MHZI0J"H4*O+AAGQ?PB04]"J23;>2$ZL*0(H"W+2,@*L1<#&"TS#"/6=9!L:$
M\[<PV8!1S':),-7MD,8KTN2WZ>L0N0X,!M;K<7F,*FQ7JA./3N71:?4X6BYW
M\2XB0A9!&N0B_(<<;L=D!:9Q2D(>YUUBLGW([!X9ND*VX[LUWT89]!N,NY5Q
MM]7XDR3B&:5UM<&= #LUA[K(16Z#/Z_RY[6VUS,3)-+[JJ6M^E7F?C=MU=>F
MA?H0]FN3-ZJ0;YZ]7WGTN[@ZOC:VYV%4,V@0!4Z#OZ#R%[3ZNR,[^0 %OX$'
M%B_ ,R<K^3#E+RU7!]H*P';KE9\F\JGSG^$"CT /NZAQF>6X?M +_%J1?Z4Z
M]:@8"U&KQQEGJ]U2@ 67/&EK?JB@"O&%N T5%&$[%<^^Q: .-V3[3AV!#3+4
M4%[%0-@.P?]#;ZA3[PIZCEN__<PZV1P-YA4@H==)_WHZPG& ZRX-*J^/&SPJ
MU,)VUHX93QF7]3VC@Q4;H7^I#E9\@^V .[^# ZUP@6W7JVL2-70O4J!$]L6Z
MMTQ]TI6.7W]E,JJ:N@(I\J).R(MTICH0UBT:1*CAWD)'[[;G<9?G'SV9E<H:
M:X4\3:WXBR[%7Z3XBSKB+]+!BC'2:OP+U:E+15]T.?HB U4Q##3G1EG?:;"N
MV(LZ82_2J0IQ'0XFD=-O<*C(B]K).R-<))0#3J.BJ-DV3%L;6.$770J_2.$7
M=81?I),5NO7O$Z.HX=T,*_SBR^$7&\"J^S:KFHPK_.).\(MULM9;MU5RZDZA
M%[>C]YDNMPF+V.:M*"036\K;%A..5A,N!5ZLP(L[ B_6D0H#;<7"]-K;0 :L
ML(LOAUUL>IG5?1M4R/8:C"OHXDZ@6V;QVOI6E]2?9M;1$F*^?OM(^"9,,A#1
MM8RQK_MR=ORP)'K8$2PM5A473 @6%YM;*K^+>2Z0Y]>,B?>=?*&R6I@>_@M0
M2P,$%     @ ,(JJ5/4JL&)W!0  C!X  !D   !X;"]W;W)K<VAE971S+W-H
M965T-C$N>&ULQ5EM;^(X$/XK%KJ3]J1NB9T [8HBM0UP/?5-9??VP^ET,L&
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M;/T[R2;4T?8"%HKT%ZPW8WMN"P2)D"S*P"J"B,:;__@E2\06 ,$* ,H :%^
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M#3!F$[J(Y0M?_L7*"05YO!&/L^(W6):V?@.,%IGD2>FL%"11NOI+W\M$K#E
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ML+VDV[;% C_(T/P@ANTEUE%M$,/VDF[;E@X$(7L11)\%X=0S%=W7<KY7T4T
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M:GNE9KP4I+CK,,LC->EC)O.T<'R8K)K/BGJQ\1Q=S9TJZ[::A"L5T')TS-<
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ML1K#HF>4+N^@+S](L2CO3#\)*45<OIUS-N-I0:!^?Q9"KCX4U[#7_Q7 Q?\
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MC5M<.)4WMOG R"3K#5^DP4XS>UQ#$()*#?#]4DJS&Z0!RG\O]/\%4$L#!!0
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ME&9I5/8"?=](:9XV=I:JI_/Q?U!+ P04    "  PBJI4#G:4LQ@#  "5"P
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M=(67\Q/Z5^^=O.R8P:D2OWANRU'P)8 <]ZP6=J.:;]CY&3J\3 GCO]!TN5$
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MQ*A&?R_A#%H8FNE_6BST:@N]UEA6!M(L-XCDN9);PJ\0U!V3\:F,MS,%'LK
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M2ZG=]"@\ZJ@V)SM=,) XKZ+Y@4Z,"I7,H]]D]H]D=@_F0ON= ,-(PH1&G&X
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M96'>9)0VP9ROA-"[P(Y]^\HG/P!02P,$%     @ ,(JJ5-U;&NLB @  M 0
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M"[#G/+N)SHTX([VA'UV_0M</<VD(JT,[->.>;N9F!IB1!T;3"U;!BJ5SH!<
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M/2"(YSL6&-#B!?8"!YIVK#U!# 76@[A'1P0&$'DXB3:BEL;DAE,"2+S(L:A
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MY(GL/5JD&S#MZ,5CADD!HZ(]+DW1%B\=(N!,Y-BB10"@R-ZB1?LM&AHR3 E
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M-& R-3#7-T+H]T7Z <7?'O/_ %!+ P04    "  PBJI4@Z/VH<X"   ("0
M&0   'AL+W=O<FMS:&5E=',O<VAE970Y-2YX;6RU5EUOVC 4_2M6IDVMU)$O
M2FD'2$#;%6VT%73;P[0'-[D0#\?.;*>T_WZV$U*H(&Q2^Y+8US[GWN.C^*:S
MY&(A$P"%'E/*9-=)E,K.7%=&":18-G@&3*_,N$BQTE,Q=V4F ,<6E%(W\+R6
MFV+"G%['QFY%K\-S10F#6X%DGJ98/ V \F77\9U58$+FB3(!M]?)\!RFH+YE
MMT+/W(HE)BDP23A# F9=I^^?#7T+L#N^$UC*M3$R4NXY7YC)*.XZGJD(*$3*
M4&#]>H A4&J8=!U_2E*GRFF Z^,5^Z45K\7<8PE#3G^06"5=I^V@&&8XIVK"
MEU=0"CHV?!&GTC[1LMSK.2C*I>)I"=85I(05;_Q8'L0:0/-L!P0E('@):.X
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M GI[ZNT%]/:3S6X!O3WU]@)Z>^KM!?3VU-L+Z.VIMQ?0VU-O+Z!WH-Y!0.]
MO8. WH%Z!P&] _4. GH'ZAT$] Z3/RL%] [4.PCH':AW$- [4.\@H'>@WD%
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MMO?)ZN-IXS%KD]3SW'=-'>)Z]CBVOZ6LGQ/2>'+9XW?=[*_BAB1[,^&X\N>
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M7_*SY6]IMS\!4$L! A0#%     @ ,(JJ5 =!36*!    L0   !
M     ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  PBJI4)1$%
M2>X    K @  $0              @ &O    9&]C4')O<',O8V]R92YX;6Q0
M2P$"% ,4    "  PBJI4F5R<(Q &  "<)P  $P              @ ', 0
M>&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( #"*JE1]22)L5P4  !86
M   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q0
M2P$"% ,4    "  PBJI4<2:]U30&  "7&   &               @(&:#0
M>&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ ,(JJ5!&O.!T\
M @  0P4  !@              ("!!!0  'AL+W=O<FMS:&5E=',O<VAE970S
M+GAM;%!+ 0(4 Q0    ( #"*JE2-B0;^*08  ,$9   8              "
M@786  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    "  PBJI4
MMAR#]5X#  #<"0  &               @('5'   >&PO=V]R:W-H965T<R]S
M:&5E=#4N>&UL4$L! A0#%     @ ,(JJ5'6D-T:R!0  HQD  !@
M     ("!:2   'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    (
M #"*JE1I'ADP8P@  ,@D   8              " @5$F  !X;"]W;W)K<VAE
M971S+W-H965T-RYX;6Q02P$"% ,4    "  PBJI4(I50#40#  #X!@  &
M            @('J+@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#
M%     @ ,(JJ5&ZHQ1PG#@  W28  !@              ("!9#(  'AL+W=O
M<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( #"*JE3*]LNDM0L  " ?
M   9              " @<%   !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL
M4$L! A0#%     @ ,(JJ5*."7RID!@  -0X  !D              ("!K4P
M 'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    "  PBJI4('$M
MM&$%  #0#@  &0              @(%(4P  >&PO=V]R:W-H965T<R]S:&5E
M=#$R+GAM;%!+ 0(4 Q0    ( #"*JE2HAY8)' P  "XE   9
M  " @>!8  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @
M,(JJ5/H6>=99 @  \ 0  !D              ("!,V4  'AL+W=O<FMS:&5E
M=',O<VAE970Q-"YX;6Q02P$"% ,4    "  PBJI4?UK%8#\5   ]3P  &0
M            @('#9P  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4
M Q0    ( #"*JE3D?#A$RP(  -8%   9              " @3E]  !X;"]W
M;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ ,(JJ5&?Q/LQV%P
MLE0  !D              ("!.X   'AL+W=O<FMS:&5E=',O<VAE970Q-RYX
M;6Q02P$"% ,4    "  PBJI4^9PUOD@#  #0!P  &0              @('H
MEP  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( #"*JE2U
MA@F[40D  #P:   9              " @6>;  !X;"]W;W)K<VAE971S+W-H
M965T,3DN>&UL4$L! A0#%     @ ,(JJ5/\#5-9' P  ,@<  !D
M     ("![Z0  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #"*JE1>@;1+?B4  &N'   9              "
M@4^_  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ ,(JJ
M5&9_*W<F"P  W1P  !D              ("!!.4  'AL+W=O<FMS:&5E=',O
M<VAE970R-BYX;6Q02P$"% ,4    "  PBJI486=TM3<0   V/0  &0
M        @(%A\   >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0
M   ( #"*JE3 "(P9( P  *XA   9              " @<\  0!X;"]W;W)K
M<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ ,(JJ5+1]S.ZN!   ?0L
M !D              ("!)@T! 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q0
M2P$"% ,4    "  PBJI4#SS.M?D%   *$P  &0              @($+$@$
M>&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( #"*JE1'=M"G
M= (  ! %   9              " @3L8 0!X;"]W;W)K<VAE971S+W-H965T
M,S$N>&UL4$L! A0#%     @ ,(JJ5#C;L=F<!0  $1$  !D
M ("!YAH! 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    "  P
MBJI4V A B]H"  #%!0  &0              @(&Y( $ >&PO=V]R:W-H965T
M<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( #"*JE0AUY35OP0  &L,   9
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M970S."YX;6Q02P$"% ,4    "  PBJI4L7_*!J4"  "4!0  &0
M    @(%F-0$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    (
M #"*JE1PU0Q0J (  / %   9              " @4(X 0!X;"]W;W)K<VAE
M971S+W-H965T-# N>&UL4$L! A0#%     @ ,(JJ5)%;9,\A!@  0P\  !D
M             ("!(3L! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"
M% ,4    "  PBJI4Y8R]41H"   6!   &0              @(%Y00$ >&PO
M=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( #"*JE0;*!#][@(
M $,'   9              " @<I# 0!X;"]W;W)K<VAE971S+W-H965T-#,N
M>&UL4$L! A0#%     @ ,(JJ5$W8.>W. P  .@\  !D              ("!
M[T8! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    "  PBJI4
M*09"O?$$  #,&   &0              @('T2@$ >&PO=V]R:W-H965T<R]S
M:&5E=#0U+GAM;%!+ 0(4 Q0    ( #"*JE3*6DL>Y0(  #8(   9
M      " @1Q0 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%
M  @ ,(JJ5$)YUG/* @  JP8  !D              ("!.%,! 'AL+W=O<FMS
M:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    "  PBJI44K^5HUH#  # "@
M&0              @($Y5@$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+
M 0(4 Q0    ( #"*JE0>83U2$04  /X;   9              " @<I9 0!X
M;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ ,(JJ5.MU%C(<
M P  YP<  !D              ("!$E\! 'AL+W=O<FMS:&5E=',O<VAE970U
M,"YX;6Q02P$"% ,4    "  PBJI49^)*2 0#  #"!P  &0
M@(%E8@$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( #"*
MJE2\F= 7 @,  &8'   9              " @:!E 0!X;"]W;W)K<VAE971S
M+W-H965T-3(N>&UL4$L! A0#%     @ ,(JJ5%ACU5AW @  XP0  !D
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M 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    "  PBJI4@/"
M.^L#  #[#   &0              @($L=0$ >&PO=V]R:W-H965T<R]S:&5E
M=#4W+GAM;%!+ 0(4 Q0    ( #"*JE1*$4Y*D0(  )H%   9
M  " @4YY 0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @
M,(JJ5-/B]=-T @  0 8  !D              ("!%GP! 'AL+W=O<FMS:&5E
M=',O<VAE970U.2YX;6Q02P$"% ,4    "  PBJI4SMD9L* $  "D%@  &0
M            @('!?@$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4
M Q0    ( #"*JE3U*K!B=P4  (P>   9              " @9B# 0!X;"]W
M;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ ,(JJ5/[D+TS  @
MH <  !D              ("!1HD! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX
M;6Q02P$"% ,4    "  PBJI4LC5)DF %  #1'@  &0              @($]
MC $ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( #"*JE2$
MQ3 ])P,  !()   9              " @=21 0!X;"]W;W)K<VAE971S+W-H
M965T-C0N>&UL4$L! A0#%     @ ,(JJ5"(G]QM_"   6D   !D
M     ("!,I4! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #"*JE3]I_1$#@(  *0$   9              "
M@:JQ 0!X;"]W;W)K<VAE971S+W-H965T-S N>&UL4$L! A0#%     @ ,(JJ
M5(#SVWH* P  X0@  !D              ("![[,! 'AL+W=O<FMS:&5E=',O
M<VAE970W,2YX;6Q02P$"% ,4    "  PBJI41,[%!P<#  "4"0  &0
M        @($PMP$ >&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4 Q0
M   ( #"*JE2N*UZU_@,  &H0   9              " @6ZZ 0!X;"]W;W)K
M<VAE971S+W-H965T-S,N>&UL4$L! A0#%     @ ,(JJ5/6DV$'  P  J0L
M !D              ("!H[X! 'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6Q0
M2P$"% ,4    "  PBJI4#G:4LQ@#  "5"P  &0              @(&:P@$
M>&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+ 0(4 Q0    ( #"*JE1/"@UQ
MT0,  %</   9              " @>G% 0!X;"]W;W)K<VAE971S+W-H965T
M-S8N>&UL4$L! A0#%     @ ,(JJ5.,&L/D< P  ^ H  !D
M ("!\<D! 'AL+W=O<FMS:&5E=',O<VAE970W-RYX;6Q02P$"% ,4    "  P
MBJI4% 9(7)$"  "+!@  &0              @(%$S0$ >&PO=V]R:W-H965T
M<R]S:&5E=#<X+GAM;%!+ 0(4 Q0    ( #"*JE25,I><_P(  .X'   9
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M970X,RYX;6Q02P$"% ,4    "  PBJI4C?;H%B8"   H!   &0
M    @(%3X0$ >&PO=V]R:W-H965T<R]S:&5E=#@T+GAM;%!+ 0(4 Q0    (
M #"*JE0,:B)?I@4  &L9   9              " @;#C 0!X;"]W;W)K<VAE
M971S+W-H965T.#4N>&UL4$L! A0#%     @ ,(JJ5!Z<?J/V @  H@H  !D
M             ("!C>D! 'AL+W=O<FMS:&5E=',O<VAE970X-BYX;6Q02P$"
M% ,4    "  PBJI4 (G8,W,#   ,#0  &0              @(&Z[ $ >&PO
M=V]R:W-H965T<R]S:&5E=#@W+GAM;%!+ 0(4 Q0    ( #"*JE32U4</Q0,
M )\/   9              " @63P 0!X;"]W;W)K<VAE971S+W-H965T.#@N
M>&UL4$L! A0#%     @ ,(JJ5&*8JT%F @  \04  !D              ("!
M8/0! 'AL+W=O<FMS:&5E=',O<VAE970X.2YX;6Q02P$"% ,4    "  PBJI4
MW5L:ZR("  "T!   &0              @(']]@$ >&PO=V]R:W-H965T<R]S
M:&5E=#DP+GAM;%!+ 0(4 Q0    ( #"*JE03F73^*@8  #@@   9
M      " @5;Y 0!X;"]W;W)K<VAE971S+W-H965T.3$N>&UL4$L! A0#%
M  @ ,(JJ5/;&>YV !P  &34  !D              ("!M_\! 'AL+W=O<FMS
M:&5E=',O<VAE970Y,BYX;6Q02P$"% ,4    "  PBJI4,T+IQZ$"  #C!@
M&0              @(%N!P( >&PO=V]R:W-H965T<R]S:&5E=#DS+GAM;%!+
M 0(4 Q0    ( #"*JE2BN(B.E 0   (9   9              " @48* @!X
M;"]W;W)K<VAE971S+W-H965T.30N>&UL4$L! A0#%     @ ,(JJ5(.C]J'.
M @  " D  !D              ("!$0\" 'AL+W=O<FMS:&5E=',O<VAE970Y
M-2YX;6Q02P$"% ,4    "  PBJI4ZA'+=D0-   :9   &0
M@($6$@( >&PO=V]R:W-H965T<R]S:&5E=#DV+GAM;%!+ 0(4 Q0    ( #"*
MJE1)CH5O$@,   P1   -              "  9$? @!X;"]S='EL97,N>&UL
M4$L! A0#%     @ ,(JJ5)>*NQS     $P(   L              ( !SB("
M %]R96QS+RYR96QS4$L! A0#%     @ ,(JJ5/(&?+H6!P  >#\   \
M         ( !MR," 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( #"*JE04
M-@ <O@(  '<X   :              "  ?HJ @!X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( #"*JE1&_2!Z3 (  )XV   3
M      "  ? M @!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !H &@ CQP
' &TP @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>508</ContextCount>
  <ElementCount>363</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>175</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>19</UnitCount>
  <MyReports>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' DEFICIT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF SHAREHOLDERS' DEFICIT</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - DESCRIPTION OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS</Role>
      <ShortName>DESCRIPTION OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - REVENUE RECOGNITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/REVENUERECOGNITION</Role>
      <ShortName>REVENUE RECOGNITION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2111104 - Disclosure - LICENSING AGREEMENTS AND DIVESTITURE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURE</Role>
      <ShortName>LICENSING AGREEMENTS AND DIVESTITURE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2113105 - Disclosure - RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS</Role>
      <ShortName>RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2115106 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2127107 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INVENTORIES</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2130108 - Disclosure - INTANGIBLE ASSETS AND GOODWILL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2136109 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES</Role>
      <ShortName>ACCRUED AND OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2139110 - Disclosure - FINANCING ARRANGEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS</Role>
      <ShortName>FINANCING ARRANGEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2149111 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2152112 - Disclosure - SHARE-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION</Role>
      <ShortName>SHARE-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2157113 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS</Role>
      <ShortName>ACCUMULATED OTHER COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2160114 - Disclosure - RESEARCH AND DEVELOPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT</Role>
      <ShortName>RESEARCH AND DEVELOPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2163115 - Disclosure - OTHER EXPENSE (INCOME), NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENET</Role>
      <ShortName>OTHER EXPENSE (INCOME), NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2167116 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2169117 - Disclosure - LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LOSSPERSHARE</Role>
      <ShortName>LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2173118 - Disclosure - LEGAL PROCEEDINGS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEGALPROCEEDINGS</Role>
      <ShortName>LEGAL PROCEEDINGS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2180119 - Disclosure - SEGMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATION</Role>
      <ShortName>SEGMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2188120 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - REVENUE RECOGNITION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/REVENUERECOGNITIONTables</Role>
      <ShortName>REVENUE RECOGNITION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/REVENUERECOGNITION</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2316302 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2328303 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INVENTORIESTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/INVENTORIES</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2331304 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2337305 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables</Role>
      <ShortName>ACCRUED AND OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2340306 - Disclosure - FINANCING ARRANGEMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables</Role>
      <ShortName>FINANCING ARRANGEMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2350307 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2353308 - Disclosure - SHARE-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables</Role>
      <ShortName>SHARE-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2358309 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables</Role>
      <ShortName>ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2361310 - Disclosure - RESEARCH AND DEVELOPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables</Role>
      <ShortName>RESEARCH AND DEVELOPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2364311 - Disclosure - OTHER EXPENSE (INCOME), NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETTables</Role>
      <ShortName>OTHER EXPENSE (INCOME), NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENET</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2370312 - Disclosure - LOSS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LOSSPERSHARETables</Role>
      <ShortName>LOSS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/LOSSPERSHARE</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2381313 - Disclosure - SEGMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables</Role>
      <ShortName>SEGMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/SEGMENTINFORMATION</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - DESCRIPTION OF BUSINESS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails</Role>
      <ShortName>DESCRIPTION OF BUSINESS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - REVENUE RECOGNITION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails</Role>
      <ShortName>REVENUE RECOGNITION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - REVENUE RECOGNITION - Variable Consideration Provisions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails</Role>
      <ShortName>REVENUE RECOGNITION - Variable Consideration Provisions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - REVENUE RECOGNITION - Activity in Allowance for Credit Losses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails</Role>
      <ShortName>REVENUE RECOGNITION - Activity in Allowance for Credit Losses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - LICENSING AGREEMENTS AND DIVESTITURE - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails</Role>
      <ShortName>LICENSING AGREEMENTS AND DIVESTITURE - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails</Role>
      <ShortName>RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2417408 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2419410 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2420411 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2421412 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Currency Exchange Contracts, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Currency Exchange Contracts, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2422413 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included in Consolidated Balance Sheets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included in Consolidated Balance Sheets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2423414 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included on Consolidated Statements of Operations and Consolidated Statements of Cash Flows (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included on Consolidated Statements of Operations and Consolidated Statements of Cash Flows (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2424415 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2425416 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Reconciliation of Contingent Consideration Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Reconciliation of Contingent Consideration Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2426417 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured on a Non-Recurring Basis and Fair Value of Long-term Debt, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured on a Non-Recurring Basis and Fair Value of Long-term Debt, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2429418 - Disclosure - INVENTORIES - Components of Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails</Role>
      <ShortName>INVENTORIES - Components of Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2432419 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Major Components of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL - Major Components of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2433420 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2434421 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2435422 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Changes in Carrying Amount of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL - Changes in Carrying Amount of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2438423 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES - Summary of Accrued and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>ACCRUED AND OTHER CURRENT LIABILITIES - Summary of Accrued and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2441424 - Disclosure - FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2442425 - Disclosure - FINANCING ARRANGEMENTS - Covenant Compliance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Covenant Compliance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2443426 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2444427 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Senior Secured Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2445428 - Disclosure - FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2446429 - Disclosure - FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2447430 - Disclosure - FINANCING ARRANGEMENTS - Aggregate Maturities of Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Aggregate Maturities of Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2448431 - Disclosure - FINANCING ARRANGEMENTS - Maturities, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesNarrativeDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Maturities, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2451432 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2454433 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2455434 - Disclosure - SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2456435 - Disclosure - SHARE-BASED COMPENSATION - Summary of Share-Based Compensation Award Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Summary of Share-Based Compensation Award Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2459436 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS - Summary of Components of Accumulated Other Comprehensive Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails</Role>
      <ShortName>ACCUMULATED OTHER COMPREHENSIVE LOSS - Summary of Components of Accumulated Other Comprehensive Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2462437 - Disclosure - RESEARCH AND DEVELOPMENT - Summary of Research and Development (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails</Role>
      <ShortName>RESEARCH AND DEVELOPMENT - Summary of Research and Development (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2465438 - Disclosure - OTHER EXPENSE (INCOME), NET - Summary of Other Expense, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETSummaryofOtherExpenseNetDetails</Role>
      <ShortName>OTHER EXPENSE (INCOME), NET - Summary of Other Expense, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2466439 - Disclosure - OTHER EXPENSE (INCOME), NET - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails</Role>
      <ShortName>OTHER EXPENSE (INCOME), NET - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2468440 - Disclosure - INCOME TAXES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails</Role>
      <ShortName>INCOME TAXES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2471441 - Disclosure - LOSS PER SHARE - Schedule of Calculation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails</Role>
      <ShortName>LOSS PER SHARE - Schedule of Calculation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>2472442 - Disclosure - LOSS PER SHARE - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails</Role>
      <ShortName>LOSS PER SHARE - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>2474443 - Disclosure - LEGAL PROCEEDINGS - Legal Proceeds and Governmental and Regulatory Inquiries (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEGALPROCEEDINGSLegalProceedsandGovernmentalandRegulatoryInquiriesDetails</Role>
      <ShortName>LEGAL PROCEEDINGS - Legal Proceeds and Governmental and Regulatory Inquiries (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>2475444 - Disclosure - LEGAL PROCEEDINGS - Securities and RICO Class Actions and Related Matters (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails</Role>
      <ShortName>LEGAL PROCEEDINGS - Securities and RICO Class Actions and Related Matters (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>2476445 - Disclosure - LEGAL PROCEEDINGS - Antitrust (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails</Role>
      <ShortName>LEGAL PROCEEDINGS - Antitrust (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>2477446 - Disclosure - LEGAL PROCEEDINGS - Intellectual Property (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails</Role>
      <ShortName>LEGAL PROCEEDINGS - Intellectual Property (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>2478447 - Disclosure - LEGAL PROCEEDINGS - Product Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails</Role>
      <ShortName>LEGAL PROCEEDINGS - Product Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>2479448 - Disclosure - LEGAL PROCEEDINGS - General Civil Actions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails</Role>
      <ShortName>LEGAL PROCEEDINGS - General Civil Actions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>2482449 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails</Role>
      <ShortName>SEGMENT INFORMATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>2483450 - Disclosure - SEGMENT INFORMATION - Segment Revenues and Profit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails</Role>
      <ShortName>SEGMENT INFORMATION - Segment Revenues and Profit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>2484451 - Disclosure - SEGMENT INFORMATION - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails</Role>
      <ShortName>SEGMENT INFORMATION - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>2485452 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1</Role>
      <ShortName>SEGMENT INFORMATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>2486453 - Disclosure - SEGMENT INFORMATION - Revenue by Geographic Area (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails</Role>
      <ShortName>SEGMENT INFORMATION - Revenue by Geographic Area (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>2487454 - Disclosure - SEGMENT INFORMATION - Major Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails</Role>
      <ShortName>SEGMENT INFORMATION - Major Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="bhc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>2489455 - Disclosure - SUBSEQUENT EVENTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails</Role>
      <ShortName>SUBSEQUENT EVENTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="bhc-20220331.htm">bhc-20220331.htm</File>
    <File>bhc-20220331.xsd</File>
    <File>bhc-20220331_cal.xml</File>
    <File>bhc-20220331_def.xml</File>
    <File>bhc-20220331_lab.xml</File>
    <File>bhc-20220331_pre.xml</File>
    <File>exhibit1013formofrsugranta.htm</File>
    <File>exhibit1014formofoptiongra.htm</File>
    <File>exhibit311q12022.htm</File>
    <File>exhibit312q12022.htm</File>
    <File>exhibit321q12022.htm</File>
    <File>exhibit322q12022.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="1085">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>116
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "bhc-20220331.htm": {
   "axisCustom": 0,
   "axisStandard": 44,
   "contextCount": 508,
   "dts": {
    "calculationLink": {
     "local": [
      "bhc-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bhc-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "bhc-20220331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bhc-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bhc-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "bhc-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 724,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 1,
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 6
   },
   "keyCustom": 70,
   "keyStandard": 293,
   "memberCustom": 101,
   "memberStandard": 73,
   "nsprefix": "bhc",
   "nsuri": "http://www.bauschhealth.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Document and Entity Information",
     "role": "http://www.bauschhealth.com/role/DocumentandEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - REVENUE RECOGNITION",
     "role": "http://www.bauschhealth.com/role/REVENUERECOGNITION",
     "shortName": "REVENUE RECOGNITION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111104 - Disclosure - LICENSING AGREEMENTS AND DIVESTITURE",
     "role": "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURE",
     "shortName": "LICENSING AGREEMENTS AND DIVESTITURE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113105 - Disclosure - RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS",
     "role": "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS",
     "shortName": "RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115106 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127107 - Disclosure - INVENTORIES",
     "role": "http://www.bauschhealth.com/role/INVENTORIES",
     "shortName": "INVENTORIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130108 - Disclosure - INTANGIBLE ASSETS AND GOODWILL",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136109 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES",
     "role": "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES",
     "shortName": "ACCRUED AND OTHER CURRENT LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139110 - Disclosure - FINANCING ARRANGEMENTS",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS",
     "shortName": "FINANCING ARRANGEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2149111 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2152112 - Disclosure - SHARE-BASED COMPENSATION",
     "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION",
     "shortName": "SHARE-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i27191b9cf0284661bc72bab06e9a28cc_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i27191b9cf0284661bc72bab06e9a28cc_I20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ReceivablesNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2157113 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS",
     "role": "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS",
     "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2160114 - Disclosure - RESEARCH AND DEVELOPMENT",
     "role": "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT",
     "shortName": "RESEARCH AND DEVELOPMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2163115 - Disclosure - OTHER EXPENSE (INCOME), NET",
     "role": "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENET",
     "shortName": "OTHER EXPENSE (INCOME), NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2167116 - Disclosure - INCOME TAXES",
     "role": "http://www.bauschhealth.com/role/INCOMETAXES",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2169117 - Disclosure - LOSS PER SHARE",
     "role": "http://www.bauschhealth.com/role/LOSSPERSHARE",
     "shortName": "LOSS PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2173118 - Disclosure - LEGAL PROCEEDINGS",
     "role": "http://www.bauschhealth.com/role/LEGALPROCEEDINGS",
     "shortName": "LEGAL PROCEEDINGS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2180119 - Disclosure - SEGMENT INFORMATION",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATION",
     "shortName": "SEGMENT INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2188120 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://www.bauschhealth.com/role/SUBSEQUENTEVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - REVENUE RECOGNITION (Tables)",
     "role": "http://www.bauschhealth.com/role/REVENUERECOGNITIONTables",
     "shortName": "REVENUE RECOGNITION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i27191b9cf0284661bc72bab06e9a28cc_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316302 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS (Tables)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328303 - Disclosure - INVENTORIES (Tables)",
     "role": "http://www.bauschhealth.com/role/INVENTORIESTables",
     "shortName": "INVENTORIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331304 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2337305 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES (Tables)",
     "role": "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables",
     "shortName": "ACCRUED AND OTHER CURRENT LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2340306 - Disclosure - FINANCING ARRANGEMENTS (Tables)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables",
     "shortName": "FINANCING ARRANGEMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2350307 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2353308 - Disclosure - SHARE-BASED COMPENSATION (Tables)",
     "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables",
     "shortName": "SHARE-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2358309 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)",
     "role": "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables",
     "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:SummaryOfResearchAndDevelopmentExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2361310 - Disclosure - RESEARCH AND DEVELOPMENT (Tables)",
     "role": "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables",
     "shortName": "RESEARCH AND DEVELOPMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:SummaryOfResearchAndDevelopmentExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2364311 - Disclosure - OTHER EXPENSE (INCOME), NET (Tables)",
     "role": "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETTables",
     "shortName": "OTHER EXPENSE (INCOME), NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CostsAndExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2370312 - Disclosure - LOSS PER SHARE (Tables)",
     "role": "http://www.bauschhealth.com/role/LOSSPERSHARETables",
     "shortName": "LOSS PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2381313 - Disclosure - SEGMENT INFORMATION (Tables)",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables",
     "shortName": "SEGMENT INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i27191b9cf0284661bc72bab06e9a28cc_I20220331",
      "decimals": "-2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfCountriesInWhichEntityOperates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "country",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - DESCRIPTION OF BUSINESS - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails",
     "shortName": "DESCRIPTION OF BUSINESS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i27191b9cf0284661bc72bab06e9a28cc_I20220331",
      "decimals": "-2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfCountriesInWhichEntityOperates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "country",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "iae181339de7f48fb8794bf85314efcc0_I20210803",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:ProposedBusinessSeparationAndInitialPublicOfferingNumberOfCompaniesEstablished",
      "reportCount": 1,
      "unique": true,
      "unitRef": "company",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "iae181339de7f48fb8794bf85314efcc0_I20210803",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:ProposedBusinessSeparationAndInitialPublicOfferingNumberOfCompaniesEstablished",
      "reportCount": 1,
      "unique": true,
      "unitRef": "company",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - REVENUE RECOGNITION - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
     "shortName": "REVENUE RECOGNITION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i5fec8302d4c14f00b65fb0e31f318228_D20220101-20220331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "idc41203b79724c8b8c35295ae22f1ee5_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - REVENUE RECOGNITION - Variable Consideration Provisions (Details)",
     "role": "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails",
     "shortName": "REVENUE RECOGNITION - Variable Consideration Provisions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesDeductions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "idc41203b79724c8b8c35295ae22f1ee5_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - REVENUE RECOGNITION - Activity in Allowance for Credit Losses (Details)",
     "role": "http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails",
     "shortName": "REVENUE RECOGNITION - Activity in Allowance for Credit Losses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "idc41203b79724c8b8c35295ae22f1ee5_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i3524eadbe1ec47a0a36751409752f55b_D20210331-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromDivestitureOfBusinesses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - LICENSING AGREEMENTS AND DIVESTITURE - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
     "shortName": "LICENSING AGREEMENTS AND DIVESTITURE - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i3524eadbe1ec47a0a36751409752f55b_D20210331-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromDivestitureOfBusinesses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414407 - Disclosure - RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails",
     "shortName": "RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i8f59ac9f2ff644c89eb4f65f46c45061_I20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib1d2d795d550443991566dd2c6bcf53b_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417408 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i9bdc5e2685a240ae96ca33df37493045_I20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "role": "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:HighlyLiquidInvestmentsMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:HighlyLiquidInvestmentsMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "idf8c5147a31443548f1f01cdff3ee173_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForProceedsFromHedgeInvestingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419410 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "idf8c5147a31443548f1f01cdff3ee173_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForProceedsFromHedgeInvestingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i1e2fdd6767694d7e97928c8c973cce88_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420411 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i1e2fdd6767694d7e97928c8c973cce88_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib1d2d795d550443991566dd2c6bcf53b_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421412 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Currency Exchange Contracts, Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Currency Exchange Contracts, Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib1d2d795d550443991566dd2c6bcf53b_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib1d2d795d550443991566dd2c6bcf53b_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422413 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included in Consolidated Balance Sheets (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included in Consolidated Balance Sheets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i5b77eb6463994ae99224a58bba550905_I20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssetFairValueGrossLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "id0b87773b146435a838297c342e6101d_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423414 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included on Consolidated Statements of Operations and Consolidated Statements of Cash Flows (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included on Consolidated Statements of Operations and Consolidated Statements of Cash Flows (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "id0b87773b146435a838297c342e6101d_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i5ba0dd91cc574f9abe328ce7f85dc950_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "rate",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424415 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i5ba0dd91cc574f9abe328ce7f85dc950_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "rate",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "idc41203b79724c8b8c35295ae22f1ee5_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425416 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Reconciliation of Contingent Consideration Obligations (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Reconciliation of Contingent Consideration Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "idc41203b79724c8b8c35295ae22f1ee5_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "id1ad1d6d1a0146b0848446f63d1074ab_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426417 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured on a Non-Recurring Basis and Fair Value of Long-term Debt, Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured on a Non-Recurring Basis and Fair Value of Long-term Debt, Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "id1ad1d6d1a0146b0848446f63d1074ab_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i27191b9cf0284661bc72bab06e9a28cc_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429418 - Disclosure - INVENTORIES - Components of Inventories (Details)",
     "role": "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails",
     "shortName": "INVENTORIES - Components of Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i27191b9cf0284661bc72bab06e9a28cc_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i6bc0f97e922441d290fd2952ed4015ca_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' DEFICIT",
     "role": "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT",
     "shortName": "CONSOLIDATED STATEMENTS OF SHAREHOLDERS' DEFICIT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i6bc0f97e922441d290fd2952ed4015ca_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i27191b9cf0284661bc72bab06e9a28cc_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432419 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Major Components of Intangible Assets (Details)",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL - Major Components of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i27191b9cf0284661bc72bab06e9a28cc_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433420 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i27191b9cf0284661bc72bab06e9a28cc_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434421 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details)",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i27191b9cf0284661bc72bab06e9a28cc_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "idc41203b79724c8b8c35295ae22f1ee5_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435422 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Changes in Carrying Amount of Goodwill (Details)",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL - Changes in Carrying Amount of Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i2d274a4a3e5a43ae91dfbb2934c4c5d1_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i27191b9cf0284661bc72bab06e9a28cc_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:Legalsettlementsandrelatedfees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438423 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES - Summary of Accrued and Other Current Liabilities (Details)",
     "role": "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails",
     "shortName": "ACCRUED AND OTHER CURRENT LIABILITIES - Summary of Accrued and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i27191b9cf0284661bc72bab06e9a28cc_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:Legalsettlementsandrelatedfees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i27191b9cf0284661bc72bab06e9a28cc_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441424 - Disclosure - FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
     "shortName": "FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i27191b9cf0284661bc72bab06e9a28cc_I20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i3baf0d17d1ce4fb09e14886b74b202be_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:DebtInstrumentCovenantAmountAvailableForRestrictedPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442425 - Disclosure - FINANCING ARRANGEMENTS - Covenant Compliance (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
     "shortName": "FINANCING ARRANGEMENTS - Covenant Compliance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i3baf0d17d1ce4fb09e14886b74b202be_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:DebtInstrumentCovenantAmountAvailableForRestrictedPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i27191b9cf0284661bc72bab06e9a28cc_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443426 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
     "shortName": "FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i87085be380954b8f8d3c8aca38e1f32f_D20220101-20220331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentBasisSpreadOnVariableRate1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:DebtInstrumentRedemptionPricePercentageChangeinControl",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444427 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Notes (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
     "shortName": "FINANCING ARRANGEMENTS - Senior Secured Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "iad4d39b309f5434c87cf47a080a1d040_I20210608",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:DebtInstrumentRedemptionPricePercentageChangeinControl",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445428 - Disclosure - FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
     "shortName": "FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i27191b9cf0284661bc72bab06e9a28cc_I20220331",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtWeightedAverageInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446429 - Disclosure - FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails",
     "shortName": "FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i27191b9cf0284661bc72bab06e9a28cc_I20220331",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtWeightedAverageInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i27191b9cf0284661bc72bab06e9a28cc_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447430 - Disclosure - FINANCING ARRANGEMENTS - Aggregate Maturities of Long-Term Debt (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails",
     "shortName": "FINANCING ARRANGEMENTS - Aggregate Maturities of Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i27191b9cf0284661bc72bab06e9a28cc_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i27191b9cf0284661bc72bab06e9a28cc_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448431 - Disclosure - FINANCING ARRANGEMENTS - Maturities, Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesNarrativeDetails",
     "shortName": "FINANCING ARRANGEMENTS - Maturities, Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i830e50982f6544d8ac6e50bc7bd7c443_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451432 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details)",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i830e50982f6544d8ac6e50bc7bd7c443_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i27191b9cf0284661bc72bab06e9a28cc_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454433 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
     "shortName": "SHARE-BASED COMPENSATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i27191b9cf0284661bc72bab06e9a28cc_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455434 - Disclosure - SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details)",
     "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails",
     "shortName": "SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i4c3748cc38b94811b494a048524f18d4_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456435 - Disclosure - SHARE-BASED COMPENSATION - Summary of Share-Based Compensation Award Activity (Details)",
     "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails",
     "shortName": "SHARE-BASED COMPENSATION - Summary of Share-Based Compensation Award Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i4c3748cc38b94811b494a048524f18d4_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i27191b9cf0284661bc72bab06e9a28cc_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459436 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS - Summary of Components of Accumulated Other Comprehensive Loss (Details)",
     "role": "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails",
     "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS - Summary of Components of Accumulated Other Comprehensive Loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i46d6cdf39c0344c9997ac487916b5ced_I20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:ResearchAndDevelopmentExpenseProductRelated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2462437 - Disclosure - RESEARCH AND DEVELOPMENT - Summary of Research and Development (Details)",
     "role": "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails",
     "shortName": "RESEARCH AND DEVELOPMENT - Summary of Research and Development (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:ResearchAndDevelopmentExpenseProductRelated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossRelatedToLitigationSettlement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2465438 - Disclosure - OTHER EXPENSE (INCOME), NET - Summary of Other Expense, Net (Details)",
     "role": "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETSummaryofOtherExpenseNetDetails",
     "shortName": "OTHER EXPENSE (INCOME), NET - Summary of Other Expense, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossRelatedToLitigationSettlement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - DESCRIPTION OF BUSINESS",
     "role": "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS",
     "shortName": "DESCRIPTION OF BUSINESS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossOnDispositionOfAssets1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2466439 - Disclosure - OTHER EXPENSE (INCOME), NET - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails",
     "shortName": "OTHER EXPENSE (INCOME), NET - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib705b8700b7f48e8b664f48c1ff6c694_D20210101-20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GainLossOnDispositionOfAssets1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2468440 - Disclosure - INCOME TAXES - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails",
     "shortName": "INCOME TAXES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2471441 - Disclosure - LOSS PER SHARE - Schedule of Calculation of Earnings Per Share (Details)",
     "role": "http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails",
     "shortName": "LOSS PER SHARE - Schedule of Calculation of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i634a33b4555248bda810d4755ec7944f_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2472442 - Disclosure - LOSS PER SHARE - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails",
     "shortName": "LOSS PER SHARE - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i634a33b4555248bda810d4755ec7944f_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i27191b9cf0284661bc72bab06e9a28cc_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationReserveCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2474443 - Disclosure - LEGAL PROCEEDINGS - Legal Proceeds and Governmental and Regulatory Inquiries (Details)",
     "role": "http://www.bauschhealth.com/role/LEGALPROCEEDINGSLegalProceedsandGovernmentalandRegulatoryInquiriesDetails",
     "shortName": "LEGAL PROCEEDINGS - Legal Proceeds and Governmental and Regulatory Inquiries (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i27191b9cf0284661bc72bab06e9a28cc_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationReserveCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "if9003a9e8d5e4cb890f3dca99318e110_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors",
      "reportCount": 1,
      "unique": true,
      "unitRef": "group",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2475444 - Disclosure - LEGAL PROCEEDINGS - Securities and RICO Class Actions and Related Matters (Details)",
     "role": "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails",
     "shortName": "LEGAL PROCEEDINGS - Securities and RICO Class Actions and Related Matters (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "if9003a9e8d5e4cb890f3dca99318e110_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors",
      "reportCount": 1,
      "unique": true,
      "unitRef": "group",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ia47d407ff7c64c98a6e296b58ca6f86d_D20190801-20200730",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyNewClaimsFiledNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "case",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2476445 - Disclosure - LEGAL PROCEEDINGS - Antitrust (Details)",
     "role": "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
     "shortName": "LEGAL PROCEEDINGS - Antitrust (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ia47d407ff7c64c98a6e296b58ca6f86d_D20190801-20200730",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyNewClaimsFiledNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "case",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i3feba39b7c864f9287819ae735b85819_D20200326-20200326",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:LossContingencyStayOfApprovalPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2477446 - Disclosure - LEGAL PROCEEDINGS - Intellectual Property (Details)",
     "role": "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
     "shortName": "LEGAL PROCEEDINGS - Intellectual Property (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i3feba39b7c864f9287819ae735b85819_D20200326-20200326",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:LossContingencyStayOfApprovalPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i9980036908434c78bce13e0b3f16a63d_D20211101-20211130",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:LossContingencyStayOfApprovalPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2478447 - Disclosure - LEGAL PROCEEDINGS - Product Liability (Details)",
     "role": "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
     "shortName": "LEGAL PROCEEDINGS - Product Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i9980036908434c78bce13e0b3f16a63d_D20211101-20211130",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:LossContingencyStayOfApprovalPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i6bbcfb43fc7145b0bb30d7beba40cbb8_D20180401-20180430",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyDamagesSoughtValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2479448 - Disclosure - LEGAL PROCEEDINGS - General Civil Actions (Details)",
     "role": "http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails",
     "shortName": "LEGAL PROCEEDINGS - General Civil Actions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i6bbcfb43fc7145b0bb30d7beba40cbb8_D20180401-20180430",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyDamagesSoughtValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i03d9858da1a54c6a897587b6b5079ca1_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportingUnits",
      "reportCount": 1,
      "unitRef": "reporting_unit",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2482449 - Disclosure - SEGMENT INFORMATION - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
     "shortName": "SEGMENT INFORMATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2483450 - Disclosure - SEGMENT INFORMATION - Segment Revenues and Profit (Details)",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails",
     "shortName": "SEGMENT INFORMATION - Segment Revenues and Profit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i78e30f03ea4548deae9a927c4b6a6def_D20220101-20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2484451 - Disclosure - SEGMENT INFORMATION - Disaggregation of Revenue (Details)",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
     "shortName": "SEGMENT INFORMATION - Disaggregation of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i965c5ef9967640559f4a892e2bc019c3_D20220101-20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:ConcentrationRiskNumberOfProducts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2485452 - Disclosure - SEGMENT INFORMATION - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1",
     "shortName": "SEGMENT INFORMATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:ConcentrationRiskNumberOfProducts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "ib9040b933e1341ce9ef4653a321a13de_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2486453 - Disclosure - SEGMENT INFORMATION - Revenue by Geographic Area (Details)",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails",
     "shortName": "SEGMENT INFORMATION - Revenue by Geographic Area (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i736938c435c34b8cbf4b9a86a5c1716b_D20220101-20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i5c455f78b2c24f19ab413825cf24b3b1_D20220101-20220331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2487454 - Disclosure - SEGMENT INFORMATION - Major Customers (Details)",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
     "shortName": "SEGMENT INFORMATION - Major Customers (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i5c455f78b2c24f19ab413825cf24b3b1_D20220101-20220331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "i27191b9cf0284661bc72bab06e9a28cc_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2489455 - Disclosure - SUBSEQUENT EVENTS - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails",
     "shortName": "SUBSEQUENT EVENTS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220331.htm",
      "contextRef": "iaa22c8251ddf46939526e13e17458660_I20220118",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentRepurchasedFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 175,
   "tag": {
    "bhc_A2027RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2027 Revolving Credit Facility",
        "label": "2027 Revolving Credit Facility [Member]",
        "terseLabel": "2027 Revolving Credit Facility"
       }
      }
     },
     "localname": "A2027RevolvingCreditFacilityMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesNarrativeDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A2027TermLoanBFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2027 Term Loan B Facility",
        "label": "2027 Term Loan B Facility [Member]",
        "terseLabel": "2027 Term Loan B Facility"
       }
      }
     },
     "localname": "A2027TermLoanBFacilityMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A9.00SeniorNotesdueDecember2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "9.00% Senior Notes due December 2025 [Member]",
        "label": "9.00% Senior Notes due December 2025 [Member]",
        "terseLabel": "9.00% Senior Notes due December 2025"
       }
      }
     },
     "localname": "A9.00SeniorNotesdueDecember2025Member",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AccountsReceivableAllowanceForForeignExchangeAndOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Allowance For Foreign Exchange And Other",
        "label": "Accounts Receivable, Allowance For Foreign Exchange And Other",
        "negatedTerseLabel": "Foreign exchange and other"
       }
      }
     },
     "localname": "AccountsReceivableAllowanceForForeignExchangeAndOther",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AccretionForTimeValueOfMoneyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accretion For Time Value Of Money [Member]",
        "label": "Accretion For Time Value Of Money [Member]",
        "terseLabel": "Accretion for the time value of money"
       }
      }
     },
     "localname": "AccretionForTimeValueOfMoneyMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AccruedAndOtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued And Other Current Liabilities",
        "label": "Accrued And Other Current Liabilities [Member]",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "AccruedAndOtherCurrentLiabilitiesMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AccruedProductRebateCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the current portion of accrued product rebates.",
        "label": "Accrued Product Rebate Current",
        "terseLabel": "Product rebates"
       }
      }
     },
     "localname": "AccruedProductRebateCurrent",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AccruedProductReturnCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for product returns. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Product Return Current",
        "terseLabel": "Product returns"
       }
      }
     },
     "localname": "AccruedProductReturnCurrent",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisitions, Licensing Agreements, And Assets Held For Sale Disclosures [Text Block]",
        "label": "Acquisitions, Licensing Agreements, And Assets Held For Sale Disclosures [Text Block]",
        "terseLabel": "LICENSING AGREEMENTS AND DIVESTITURE"
       }
      }
     },
     "localname": "AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_AllowancesForLossesOnAccountsReceivableAndInventories": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the current period expense charged against operations (1) for the purpose of reducing receivables to an amount that approximates their net realizable value and (2) the charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.",
        "label": "Allowances for Losses on Accounts Receivable and Inventories",
        "terseLabel": "Allowances for losses on trade receivable and inventories"
       }
      }
     },
     "localname": "AllowancesForLossesOnAccountsReceivableAndInventories",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AmerisourceBergenCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the major customer of the entity, AmerisourceBergen Corporation.",
        "label": "Amerisource Bergen Corporation [Member]",
        "terseLabel": "AmerisourceBergen Corporation"
       }
      }
     },
     "localname": "AmerisourceBergenCorporationMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible asset amortization expense excluding amortization allocated to alliance and royalty revenue and cost of goods sold during the period.",
        "label": "Amortization of Intangible Assets Excluding Amortization Allocated to Revenues Cost of Good Sold",
        "negatedLabel": "Amortization of intangible assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AmounPharmaceuticalCompanySAEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amoun Pharmaceutical Company S.A.E",
        "label": "Amoun Pharmaceutical Company S.A.E [Member]",
        "terseLabel": "Amoun"
       }
      }
     },
     "localname": "AmounPharmaceuticalCompanySAEMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ApotexIncLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Apotex Inc. Litigation",
        "label": "Apotex Inc. Litigation [Member]",
        "terseLabel": "Apotex Inc. Litigation"
       }
      }
     },
     "localname": "ApotexIncLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AssetImpairmentChargesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Impairment Charges",
        "label": "Asset Impairment Charges [Member]",
        "terseLabel": "Asset impairments, including loss on assets held for sale"
       }
      }
     },
     "localname": "AssetImpairmentChargesMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_BaseRateOrPrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Base Rate Or Prime Rate [Member]",
        "label": "Base Rate Or Prime Rate [Member]",
        "terseLabel": "Base Rate or Prime Rate"
       }
      }
     },
     "localname": "BaseRateOrPrimeRateMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_BauschLombInternationalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bausch Lomb/International [Member]",
        "label": "Bausch + Lomb/International [Member]",
        "terseLabel": "Bausch + Lomb/ International"
       }
      }
     },
     "localname": "BauschLombInternationalMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_BauschLombMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bausch + Lomb",
        "label": "Bausch + Lomb [Member]",
        "terseLabel": "Bausch + Lomb",
        "verboseLabel": "Bausch + Lomb"
       }
      }
     },
     "localname": "BauschLombMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_BrandedandOtherGenericProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Branded and Other Generic Products [Member]",
        "label": "Branded and Other Generic Products [Member]",
        "terseLabel": "Branded and Other Generics"
       }
      }
     },
     "localname": "BrandedandOtherGenericProductsMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, as of the balance sheet date, of potential payments under the contingent consideration arrangement which may include cash and shares.",
        "label": "Business Acquisition, Contingent Consideration Fair Value Disclosure",
        "terseLabel": "Acquisition-related contingent consideration"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationFairValueDisclosure",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the cash-flow impact of any change, including any differences arising upon settlement, recognized during the reporting period in the value of an asset or assets, arising from an item of contingent consideration, recognized in a business combination.",
        "label": "Business Combination, Contingent Consideration Arrangements Change in Amount of Contingent Consideration Asset Cash",
        "terseLabel": "Acquisition-related contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_BusinessCombinationContingentConsiderationNoncurrentLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Noncurrent Liability",
        "label": "Business Combination, Contingent Consideration, Noncurrent Liability",
        "terseLabel": "Acquisition-related contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationNoncurrentLiability",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_CanadaBankersAcceptanceRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Canada Bankers Acceptance Rate [Member]",
        "label": "Canada Bankers Acceptance Rate [Member]",
        "terseLabel": "Canada Bankers Acceptance Rate"
       }
      }
     },
     "localname": "CanadaBankersAcceptanceRateMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_CanadianSecuritiesLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Canadian Securities Litigation",
        "label": "Canadian Securities Litigation [Member]",
        "terseLabel": "Canadian Securities Litigation"
       }
      }
     },
     "localname": "CanadianSecuritiesLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_CardinalHealthIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the major customer of the entity, Cardinal Health, Inc.",
        "label": "Cardinal Health Inc [Member]",
        "terseLabel": "Cardinal Health,\u00a0Inc."
       }
      }
     },
     "localname": "CardinalHealthIncMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ConcentrationRiskNumberOfProducts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration Risk, Number Of Products",
        "label": "Concentration Risk, Number Of Products",
        "terseLabel": "Number of products represented of total revenue"
       }
      }
     },
     "localname": "ConcentrationRiskNumberOfProducts",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_CustomerTopTenProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer, Top Ten Products",
        "label": "Customer, Top Ten Products [Member]",
        "terseLabel": "Customer, Top Ten Products"
       }
      }
     },
     "localname": "CustomerTopTenProductsMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold",
        "label": "Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold",
        "terseLabel": "Alternate term, number of days prior to scheduled maturity in excess of principal amount threshold"
       }
      }
     },
     "localname": "DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Alternate Term, Principal Amount Maturity Threshold",
        "label": "Debt Instrument, Alternate Term, Principal Amount Maturity Threshold",
        "terseLabel": "Alternate term, principal amount maturity threshold"
       }
      }
     },
     "localname": "DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DebtInstrumentAnnualAmortizationRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Annual Amortization Rate, Percentage",
        "label": "Debt Instrument, Annual Amortization Rate, Percentage",
        "terseLabel": "Annual amortization rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentAnnualAmortizationRatePercentage",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Amount Available For Restricted Payments",
        "label": "Debt Instrument, Covenant, Amount Available For Restricted Payments",
        "terseLabel": "Amount available for restricted payments"
       }
      }
     },
     "localname": "DebtInstrumentCovenantAmountAvailableForRestrictedPayments",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Compliance, Secured Leverage Ratio",
        "label": "Debt Instrument, Covenant Compliance, Secured Leverage Ratio",
        "terseLabel": "Secured leverage ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantComplianceSecuredLeverageRatio",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Interest Coverage Ratio, Minimum",
        "label": "Debt Instrument, Covenant, Interest Coverage Ratio, Minimum",
        "terseLabel": "Interest coverage ratio (not less than)"
       }
      }
     },
     "localname": "DebtInstrumentCovenantInterestCoverageRatioMinimum",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Mandatory Prepayments, Percentage Net Cash Proceeds, Asset Sales, If Circumstances Met",
        "label": "Debt Instrument, Covenant, Mandatory Prepayments, Percentage Net Cash Proceeds, Asset Sales, If Circumstances Met",
        "terseLabel": "Debt covenant, mandatory prepayments, percentage net cash proceeds, asset sales"
       }
      }
     },
     "localname": "DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Mandatory Prepayments, Percentage Net Cash Proceeds, Incurrence Of Debt, If Circumstances Met",
        "label": "Debt Instrument, Covenant, Mandatory Prepayments, Percentage Net Cash Proceeds, Incurrence Of Debt, If Circumstances Met",
        "terseLabel": "Debt covenant, mandatory prepayments, percentage net cash proceeds, incurrence of debt"
       }
      }
     },
     "localname": "DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Mandatory Prepayments, Percentage Net Cash Proceeds, Property And Asset Losses, If Circumstances Met",
        "label": "Debt Instrument, Covenant, Mandatory Prepayments, Percentage Net Cash Proceeds, Property And Asset Losses, If Circumstances Met",
        "terseLabel": "Debt covenant, mandatory prepayments, percentage net cash proceeds, property and asset losses"
       }
      }
     },
     "localname": "DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Mandatory Prepayments, Percentage Of Consolidated Excess Cash Flow, If Circumstances Met",
        "label": "Debt Instrument, Covenant, Mandatory Prepayments, Percentage Of Consolidated Excess Cash Flow, If Circumstances Met",
        "terseLabel": "Debt covenant, mandatory prepayments, percentage of consolidated excess cash flow"
       }
      }
     },
     "localname": "DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Redemption And Discharge Condition, Amount, If Circumstances Met",
        "label": "Debt Instrument, Covenant, Redemption And Discharge Condition, Amount, If Circumstances Met",
        "terseLabel": "Debt covenant, redemption and discharge condition, amount, if circumstances met"
       }
      }
     },
     "localname": "DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Terms, Fixed Charge Coverage Ratio",
        "label": "Debt Instrument, Covenant Terms, Fixed Charge Coverage Ratio",
        "terseLabel": "Fixed charge coverage ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTermsFixedChargeCoverageRatio",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Terms, Secured Leverage Ratio",
        "label": "Debt Instrument, Covenant Terms, Secured Leverage Ratio",
        "terseLabel": "Secured leverage ratio (not greater than)"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTermsSecuredLeverageRatio",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bhc_DebtInstrumentCovenantTotalLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Total Leverage Ratio",
        "label": "Debt Instrument, Covenant, Total Leverage Ratio",
        "terseLabel": "Total leverage ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTotalLeverageRatio",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Compliance, Total Leverage Ratio",
        "label": "Debt Instrument, Covenant, Total Leverage Ratio, Maximum",
        "terseLabel": "Total leverage ratio (not greater than)"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTotalLeverageRatioMaximum",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Credit Spread Adjustment on Variable Rate",
        "label": "Debt Instrument, Credit Spread Adjustment on Variable Rate",
        "terseLabel": "Credit spread adjustment (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentCreditSpreadAdjustmentOnVariableRate",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Periodic Payment, Quarterly Amortization",
        "label": "Debt Instrument, Periodic Payment, Quarterly Amortization",
        "terseLabel": "Quarterly remaining amortization payments"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentQuarterlyAmortization",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DebtInstrumentRedemptionPricePercentageChangeinControl": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Redemption Price, Percentage, Change in Control",
        "label": "Debt Instrument, Redemption Price, Percentage, Change in Control",
        "terseLabel": "Redemption price percentage to change in control (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentageChangeinControl",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DeferredIncomeTaxNoncashExpenseBenefit": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The noncash component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations.",
        "label": "Deferred Income Tax Noncash Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxNoncashExpenseBenefit",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DerivativeGainExcludedComponent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative, Gain, Excluded Component",
        "label": "Derivative, Gain, Excluded Component",
        "negatedTerseLabel": "Gain excluded from hedge effectiveness"
       }
      }
     },
     "localname": "DerivativeGainExcludedComponent",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DeviceProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Device Products [Member]",
        "label": "Device Products [Member]",
        "terseLabel": "Devices"
       }
      }
     },
     "localname": "DeviceProductsMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_DiscontinuedProductLinesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discontinued Product Lines",
        "label": "Discontinued Product Lines [Member]",
        "terseLabel": "Discontinued Product Lines"
       }
      }
     },
     "localname": "DiscontinuedProductLinesMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_DiversifiedProductsSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Diversified Products Segment [Member]",
        "label": "Diversified Products Segment [Member]",
        "terseLabel": "Diversified Products"
       }
      }
     },
     "localname": "DiversifiedProductsSegmentMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_DoctorsAllergyFormulaLLCLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Doctors Allergy Formula, LLC Litigation [Member]",
        "label": "Doctors Allergy Formula, LLC Litigation [Member]",
        "terseLabel": "Doctors Allergy Formula, LLC Litigation"
       }
      }
     },
     "localname": "DoctorsAllergyFormulaLLCLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Discrete Items, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Discrete Items, Amount",
        "terseLabel": "Income tax provision (benefit) for discrete items"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Expense Filing Tax Returns, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Expense Filing Tax Returns, Amount",
        "terseLabel": "Provision related to filing certain tax returns"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Withholding Tax, Intercompany Dividends, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Withholding Tax, Intercompany Dividends, Amount",
        "terseLabel": "Provision related to withholding tax, intercompany dividends"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Options, Time-Based Restricted Stock Units, and Performance-Based Restricted Stock Units [Member]",
        "label": "Employee Stock Options, Time-Based Restricted Stock Units, and Performance-Based Restricted Stock Units [Member]",
        "terseLabel": "Time-based RSUs, Performance-based RSUs and Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Adjustments, Changes In Estimates Of Other Future Payments [Member]",
        "label": "Fair Value Adjustments, Changes In Estimates Of Other Future Payments [Member]",
        "terseLabel": "Fair value adjustments due to changes in estimates of other future payments"
       }
      }
     },
     "localname": "FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Finite Lived and Indefinite Lived Intangible Assets [Line Items]",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_GainLossRelatedToLitigationSettlementGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) Related to Litigation Settlement, Gross payments not offset by insurance proceeds.",
        "label": "Gain (Loss) Related To Litigation Settlement, Gross",
        "negatedLabel": "Reductions to accrued legal settlements"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlementGross",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_GlumetzaAntitrustLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Glumetza Antitrust Class Actions Litigation [Member]",
        "label": "Glumetza Antitrust Litigation [Member]",
        "terseLabel": "Glumetza Antitrust Litigation"
       }
      }
     },
     "localname": "GlumetzaAntitrustLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Glumetza Antitrust Litigation, Non-Class Complaints [Member]",
        "label": "Glumetza Antitrust Litigation, Non-Class Complaints [Member]",
        "terseLabel": "Glumetza Antitrust Litigation, Non-Class Complaints"
       }
      }
     },
     "localname": "GlumetzaAntitrustLitigationNonClassComplaintsMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill, Impairment Loss, Not Included In Asset Impairment Charges",
        "label": "Goodwill, Impairment Loss, Not Included In Asset Impairment Charges",
        "negatedTerseLabel": "Goodwill impairments",
        "terseLabel": "Goodwill impairments",
        "verboseLabel": "Goodwill impairments"
       }
      }
     },
     "localname": "GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_HighlyLiquidInvestmentsMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Highly Liquid Investments, Maturity Period",
        "label": "Highly Liquid Investments, Maturity Period",
        "terseLabel": "Highly liquid investments, maturity period (or less)"
       }
      }
     },
     "localname": "HighlyLiquidInvestmentsMaturityPeriod",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_InsuranceCoverageLawsuitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Insurance Coverage Lawsuit [Member]",
        "label": "Insurance Coverage Lawsuit [Member]",
        "terseLabel": "Insurance Coverage Lawsuit"
       }
      }
     },
     "localname": "InsuranceCoverageLawsuitMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_InterestSettlementOnCrossCurrencySwaps": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Settlement On Cross-Currency Swaps",
        "label": "Interest Settlement On Cross-Currency Swaps",
        "terseLabel": "Interest settlements from cross-currency swaps"
       }
      }
     },
     "localname": "InterestSettlementOnCrossCurrencySwaps",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_InternationalRxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "International Rx",
        "label": "International Rx [Member]",
        "terseLabel": "International",
        "verboseLabel": "International"
       }
      }
     },
     "localname": "InternationalRxMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_Legalsettlementsandrelatedfees": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal settlements and related fees",
        "label": "Legal settlements and related fees",
        "terseLabel": "Legal matters and related fees"
       }
      }
     },
     "localname": "Legalsettlementsandrelatedfees",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of annual excess cash flow with any excess amounts after the prepayment of the loans.",
        "label": "Line of Credit Facility, Percentage of Consolidated Excess Cash Flow Payable as Mandatory Prepayments",
        "terseLabel": "Percentage of annual excess cash flow"
       }
      }
     },
     "localname": "LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of net cash proceeds from asset sales outside ordinary course of business payable as mandatory prepayments.",
        "label": "Line of Credit Facility, Percentage of Net Cash Proceeds from Asset Sales Outside Ordinary Course of Business Payable as Mandatory Prepayments",
        "terseLabel": "Percentage of cash proceeds from asset sales outside the ordinary course of business payable as mandatory prepayments"
       }
      }
     },
     "localname": "LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of net cash proceeds of insurance and condemnation proceeds for property or asset (losses) which is payable as mandatory prepayment.",
        "label": "Line of Credit Facility, Percentage of Net Cash Proceeds of Insurance and Condemnation Proceeds from Property or Asset Losses Payable as Mandatory Prepayments",
        "terseLabel": "Percentage of net cash proceeds of insurance and condemnation proceeds for property or asset losses"
       }
      }
     },
     "localname": "LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of net cash proceeds from the incurrence of debt payable as mandatory prepayments.",
        "label": "Line of Credit Facility, Percentage of Net Proceeds from Incurrence of Debt Payable as Mandatory Pre-payments",
        "terseLabel": "Percentage of cash proceeds from incurrence of debt"
       }
      }
     },
     "localname": "LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility, Threshold For Incremental Borrowings",
        "label": "Line Of Credit Facility, Threshold For Incremental Borrowings",
        "terseLabel": "Threshold for incremental borrowings"
       }
      }
     },
     "localname": "LineOfCreditFacilityThresholdForIncrementalBorrowings",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility Threshold For Incremental Borrowings Interest Rate",
        "label": "Line Of Credit Facility Threshold For Incremental Borrowings Interest Rate",
        "terseLabel": "Incremental borrowings interest rate"
       }
      }
     },
     "localname": "LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility, Threshold For Incremental Borrowings, Percentage Of Adjusted EBITDA",
        "label": "Line Of Credit Facility, Threshold For Incremental Borrowings, Percentage Of Adjusted EBITDA",
        "terseLabel": "Threshold for incremental borrowings, percentage of adjusted EBITDA"
       }
      }
     },
     "localname": "LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_LitigationSettlementNumberOfObjectorsAppeals": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation Settlement, Number of Objectors' Appeals",
        "label": "Litigation Settlement, Number of Objectors' Appeals",
        "terseLabel": "Settlement, escrow fund included in restricted cash, number of objectors' appeals"
       }
      }
     },
     "localname": "LitigationSettlementNumberOfObjectorsAppeals",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LitigationwithFormerSalixCEOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation with Former Salix CEO [Member]",
        "label": "Litigation with Former Salix CEO [Member]",
        "terseLabel": "Litigation with Former Salix CEO"
       }
      }
     },
     "localname": "LitigationwithFormerSalixCEOMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_LossContingencyNewClaimsFiledButNotYetServedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency New Claims Filed But Not Yet Served Number",
        "label": "Loss Contingency New Claims Filed But Not Yet Served Number",
        "terseLabel": "Number of suits filed but not yet served"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledButNotYetServedNumber",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action",
        "label": "Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action",
        "terseLabel": "Number of entities, exercised opt-out right, pursuing action"
       }
      }
     },
     "localname": "LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencyNumberOfInsurancePolicyPeriods": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Insurance Policy Periods",
        "label": "Loss Contingency, Number Of Insurance Policy Periods",
        "terseLabel": "Number of distinct insurance policy periods"
       }
      }
     },
     "localname": "LossContingencyNumberOfInsurancePolicyPeriods",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencyNumberOfSeparateDefendants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Separate Defendants",
        "label": "Loss Contingency, Number Of Separate Defendants",
        "terseLabel": "Number of separate defendants"
       }
      }
     },
     "localname": "LossContingencyNumberOfSeparateDefendants",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Plaintiffs, Number of Groups of Investors",
        "label": "Loss Contingency, Plaintiffs, Number of Groups of Investors",
        "terseLabel": "Number of groups of investors filing action"
       }
      }
     },
     "localname": "LossContingencyPlaintiffsNumberofGroupsofInvestors",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Plaintiffs, Number of Groups of Investors, Pending",
        "label": "Loss Contingency, Plaintiffs, Number of Groups of Investors, Pending",
        "terseLabel": "Number of groups of investors filing action, remain pending"
       }
      }
     },
     "localname": "LossContingencyPlaintiffsNumberofGroupsofInvestorsPending",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencySettlementAgreementsNumberOfInsurers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Settlement Agreements, Number Of Insurers",
        "label": "Loss Contingency, Settlement Agreements, Number Of Insurers",
        "terseLabel": "Settlement agreements, number of insurers"
       }
      }
     },
     "localname": "LossContingencySettlementAgreementsNumberOfInsurers",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencyStayOfApprovalMotionToExtendPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Stay Of Approval, Motion To Extend, Period",
        "label": "Loss Contingency, Stay Of Approval, Motion To Extend, Period",
        "terseLabel": "Stay of approval, motion to extend, period"
       }
      }
     },
     "localname": "LossContingencyStayOfApprovalMotionToExtendPeriod",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_LossContingencyStayOfApprovalPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Stay Of Approval, Period",
        "label": "Loss Contingency, Stay Of Approval, Period",
        "terseLabel": "Stay of approval, period"
       }
      }
     },
     "localname": "LossContingencyStayOfApprovalPeriod",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_MSNLaboratoriesPrivateLtdLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MSN Laboratories Private Ltd. Litigation",
        "label": "MSN Laboratories Private Ltd. Litigation [Member]",
        "terseLabel": "MSN Laboratories Private Ltd. Litigation"
       }
      }
     },
     "localname": "MSNLaboratoriesPrivateLtdLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_McKessonCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the major customer of the entity, McKesson Corporation.",
        "label": "Mc Kesson Corporation [Member]",
        "terseLabel": "McKesson Corporation (including McKesson Specialty)"
       }
      }
     },
     "localname": "McKessonCorporationMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_MeasurementInputWeightedAverageDiscountRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Weighted-Average Discount Rate [Member]",
        "label": "Measurement Input, Weighted-Average Discount Rate [Member]",
        "terseLabel": "Measurement Input, Weighted Average Risk-Adjusted Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputWeightedAverageDiscountRateMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_MilestonePaymentRelatedToCertainProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment Related To Certain Product [Member]",
        "label": "Milestone Payment Related To Certain Product [Member]",
        "terseLabel": "Milestone Payment Related To Certain Product"
       }
      }
     },
     "localname": "MilestonePaymentRelatedToCertainProductMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_NewRestatedCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Restated Credit Agreement",
        "label": "New Restated Credit Agreement [Member]",
        "terseLabel": "New Restated Credit Agreement"
       }
      }
     },
     "localname": "NewRestatedCreditAgreementMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_NonemployeeDirectorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonemployee Director [Member]",
        "label": "Nonemployee Director [Member]",
        "terseLabel": "Non-employee Director"
       }
      }
     },
     "localname": "NonemployeeDirectorMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_NorwichPharmaceuticalsIncLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Norwich Pharmaceuticals Inc. Litigation",
        "label": "Norwich Pharmaceuticals Inc. Litigation [Member]",
        "terseLabel": "Norwich Pharmaceuticals Inc. Litigation"
       }
      }
     },
     "localname": "NorwichPharmaceuticalsIncLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OmnibusIncentivePlan2014Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Omnibus Incentive Plan 2014 [Member]",
        "label": "Omnibus Incentive Plan 2014 [Member]",
        "terseLabel": "2014 Plan"
       }
      }
     },
     "localname": "OmnibusIncentivePlan2014Member",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OrthoDermatologicsReportingUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ortho Dermatologics Reporting Unit [Member]",
        "label": "Ortho Dermatologics Reporting Unit [Member]",
        "terseLabel": "Ortho Dermatologics Reporting Unit"
       }
      }
     },
     "localname": "OrthoDermatologicsReportingUnitMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OrthoDermatologicsSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ortho Dermatologics Segment [Member]",
        "label": "Ortho Dermatologics Segment [Member]",
        "verboseLabel": "Ortho Dermatologics"
       }
      }
     },
     "localname": "OrthoDermatologicsSegmentMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OtherCountriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Countries [Member]",
        "label": "Other Countries [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherCountriesMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OtherLongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents long-term debt obligations not elsewhere enumerated.",
        "label": "Other Long Term Debt [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherLongTermDebtMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OtherRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Revenues [Member]",
        "label": "Other Revenues [Member]",
        "terseLabel": "Other revenues"
       }
      }
     },
     "localname": "OtherRevenuesMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OutLicensedTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the rights to receive cash flows under an out-license arrangement (for example, license fees, milestone payments and royalties).",
        "label": "Out Licensed Technology [Member]",
        "terseLabel": "Technology and other"
       }
      }
     },
     "localname": "OutLicensedTechnologyMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OvertheCounterProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Over the Counter Products [Member]",
        "label": "Over the Counter Products [Member]",
        "terseLabel": "OTC"
       }
      }
     },
     "localname": "OvertheCounterProductsMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PadagisLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Padagis Litigation",
        "label": "Padagis Litigation [Member]",
        "terseLabel": "Padagis Litigation"
       }
      }
     },
     "localname": "PadagisLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PartnerRelationshipsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to existing arrangements with various other entities, for which the entity provides regulatory, compliance, sales, marketing and distribution functions.",
        "label": "Partner Relationships [Member]",
        "terseLabel": "Partner relationships"
       }
      }
     },
     "localname": "PartnerRelationshipsMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PatentInfringementLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent Infringement Litigation",
        "label": "Patent Infringement Litigation [Member]",
        "terseLabel": "Patent Infringement Litigation"
       }
      }
     },
     "localname": "PatentInfringementLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance-Based Restricted Stock Units",
        "label": "Performance-Based Restricted Stock Units [Member]",
        "terseLabel": "Performance-Based Restricted Stock Units"
       }
      }
     },
     "localname": "PerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Perrigo Israel Pharmaceuticals, Ltd. Litigation",
        "label": "Perrigo Israel Pharmaceuticals, Ltd. Litigation [Member]",
        "terseLabel": "Perrigo Israel Pharmaceuticals, Ltd. Litigation"
       }
      }
     },
     "localname": "PerrigoIsraelPharmaceuticalsLtdLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PharmaceuticalProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical Products [Member]",
        "label": "Pharmaceutical Products [Member]",
        "terseLabel": "Pharmaceuticals"
       }
      }
     },
     "localname": "PharmaceuticalProductsMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PlaintiffsDirectPurchasersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plaintiffs, Direct Purchasers [Member]",
        "label": "Plaintiffs, Direct Purchasers [Member]",
        "terseLabel": "Plaintiffs, Direct Purchasers"
       }
      }
     },
     "localname": "PlaintiffsDirectPurchasersMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PriceAppreciationCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price Appreciation Credit [Member]",
        "label": "Price Appreciation Credit [Member]",
        "terseLabel": "Price Appreciation Credit"
       }
      }
     },
     "localname": "PriceAppreciationCreditMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ProductBrandsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the rights to non-patented product brands.",
        "label": "Product Brands [Member]",
        "terseLabel": "Product brands"
       }
      }
     },
     "localname": "ProductBrandsMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ProposedBusinessSeparationAndInitialPublicOfferingNumberOfCompaniesEstablished": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proposed Business Separation And Initial Public Offering, Number Of Companies Established",
        "label": "Proposed Business Separation And Initial Public Offering, Number Of Companies Established",
        "terseLabel": "Proposed business separation and initial public offering, number of companies established"
       }
      }
     },
     "localname": "ProposedBusinessSeparationAndInitialPublicOfferingNumberOfCompaniesEstablished",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_RICOClassActionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RICO Class Actions",
        "label": "RICO Class Actions [Member]",
        "terseLabel": "RICO Class Actions"
       }
      }
     },
     "localname": "RICOClassActionsMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ROTCPerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ROTC Performance-Based Restricted Stock Units [Member]",
        "label": "ROTC Performance-Based Restricted Stock Units [Member]",
        "terseLabel": "ROTC performance-based RSUs"
       }
      }
     },
     "localname": "ROTCPerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate",
        "label": "Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate",
        "terseLabel": "Reporting unit, impairment test, estimated cash flows, discount rate"
       }
      }
     },
     "localname": "ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_ReportingUnitImpairmentTestLongTermGrowthRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reporting Unit, Impairment Test, Long-Term Growth Rate",
        "label": "Reporting Unit, Impairment Test, Long-Term Growth Rate",
        "terseLabel": "Reporting unit, impairment test, long-term growth rate"
       }
      }
     },
     "localname": "ReportingUnitImpairmentTestLongTermGrowthRate",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_ReportingUnitsExcludingOrthoDermatologicsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reporting Units Excluding Ortho Dermatologics",
        "label": "Reporting Units Excluding Ortho Dermatologics [Member]",
        "terseLabel": "Reporting Units Excluding Ortho Dermatologics"
       }
      }
     },
     "localname": "ReportingUnitsExcludingOrthoDermatologicsMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ResearchAndDevelopmentExpenseProductRelated": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Expense, Product Related",
        "label": "Research And Development Expense, Product Related",
        "terseLabel": "Product related research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseProductRelated",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_ResearchAndDevelopmentExpenseQualityAssurance": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Expense, Quality Assurance",
        "label": "Research And Development Expense, Quality Assurance",
        "terseLabel": "Quality assurance"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseQualityAssurance",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_ReserveForChargebacksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve For Chargebacks [Member]",
        "label": "Reserve For Chargebacks [Member]",
        "terseLabel": "Chargebacks"
       }
      }
     },
     "localname": "ReserveForChargebacksMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReserveForCustomerReturnsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve For Customer Returns [Member]",
        "label": "Reserve For Customer Returns [Member]",
        "terseLabel": "Returns"
       }
      }
     },
     "localname": "ReserveForCustomerReturnsMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReserveForDiscountsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve For Discounts And Allowances [Member]",
        "label": "Reserve For Discounts And Allowances [Member]",
        "terseLabel": "Discounts and Allowances"
       }
      }
     },
     "localname": "ReserveForDiscountsAndAllowancesMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReserveForDistributionFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve For Distribution Fees [Member]",
        "label": "Reserve For Distribution Fees [Member]",
        "terseLabel": "Distribution Fees"
       }
      }
     },
     "localname": "ReserveForDistributionFeesMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReserveForRebatesAdvertisingCreditsPortionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve For Rebates, Advertising Credits Portion [Member]",
        "label": "Reserve For Rebates, Advertising Credits Portion [Member]",
        "terseLabel": "Rebates, Advertising Credits Portion"
       }
      }
     },
     "localname": "ReserveForRebatesAdvertisingCreditsPortionMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReserveForRebatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve For Rebates [Member]",
        "label": "Reserve For Rebates [Member]",
        "terseLabel": "Rebates"
       }
      }
     },
     "localname": "ReserveForRebatesMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash And Cash Equivalents And Other Settlement Deposits, Fair Value Disclosure",
        "label": "Restricted Cash And Cash Equivalents And Other Settlement Deposits, Fair Value Disclosure",
        "terseLabel": "Restricted cash and other settlement deposits"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_RestrictedCashAndOtherSettlementDepositsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash And Other Settlement Deposits, Current",
        "label": "Restricted Cash And Other Settlement Deposits, Current",
        "terseLabel": "Restricted cash and other settlement deposits",
        "verboseLabel": "Restricted cash and other settlement deposits"
       }
      }
     },
     "localname": "RestrictedCashAndOtherSettlementDepositsCurrent",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash And Other Settlement Deposits, Current",
        "label": "Restricted Cash And Other Settlement Deposits, Current [Member]",
        "terseLabel": "Restricted Cash And Other Settlement Deposits, Current"
       }
      }
     },
     "localname": "RestrictedCashAndOtherSettlementDepositsCurrentMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RestructuringAndIntegrationCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring And Integration Costs",
        "label": "Restructuring And Integration Costs [Member]",
        "terseLabel": "Restructuring and Integration Costs"
       }
      }
     },
     "localname": "RestructuringAndIntegrationCostsMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring And Related Activities And Initial Public Offering Costs Disclosure",
        "label": "Restructuring And Related Activities And Initial Public Offering Costs Disclosure [Text Block]",
        "terseLabel": "RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_RestructuringChargesAndInitialPublicOfferingCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 7.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring Charges And Initial Public Offering Costs",
        "label": "Restructuring Charges And Initial Public Offering Costs",
        "negatedTerseLabel": "Restructuring, integration, separation and IPO costs",
        "terseLabel": "Restructuring, integration, separation and IPO costs"
       }
      }
     },
     "localname": "RestructuringChargesAndInitialPublicOfferingCosts",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_RevenuesNetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate net revenues during the period in the normal course of business.",
        "label": "Revenues Net [Member]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenuesNetMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RevolvingCreditFacilityDueJune2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revolving Credit Facility Due June 2023 [Member]",
        "label": "Revolving Credit Facility Due June 2023 [Member]",
        "terseLabel": "Revolving Credit Facility Due June 2023"
       }
      }
     },
     "localname": "RevolvingCreditFacilityDueJune2023Member",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RevolvingCreditFacilityDueMay2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revolving Credit Facility Due May 2027",
        "label": "Revolving Credit Facility Due May 2027 [Member]",
        "terseLabel": "Revolving Credit Facility Due May 2027"
       }
      }
     },
     "localname": "RevolvingCreditFacilityDueMay2027Member",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SOFRCDORAndEURIBORRatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SOFR, CDOR and EURIBOR Rates",
        "label": "SOFR, CDOR and EURIBOR Rates [Member]",
        "terseLabel": "SOFR, CDOR and EURIBOR Rates"
       }
      }
     },
     "localname": "SOFRCDORAndEURIBORRatesMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SOFRCDOREURIBORAndSONIARatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SOFR, CDOR, EURIBOR and SONIA Rates",
        "label": "SOFR, CDOR, EURIBOR and SONIA Rates [Member]",
        "terseLabel": "SOFR, CDOR, EURIBOR and SONIA Rates"
       }
      }
     },
     "localname": "SOFRCDOREURIBORAndSONIARatesMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SaleOfStockOverAllotmentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Over-Allotment, Term",
        "label": "Sale of Stock, Over-Allotment, Term",
        "terseLabel": "Underwriters option to purchase additional shares, term"
       }
      }
     },
     "localname": "SaleOfStockOverAllotmentTerm",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_SalixSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Salix Segment [Member]",
        "label": "Salix Segment [Member]",
        "terseLabel": "Salix"
       }
      }
     },
     "localname": "SalixSegmentMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the carrying value of amortizable and nonamortizable intangibles assets, in total and by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Schedule of Finite Lived and Indefinite Lived Intangible Asset by Major Class [Table]",
        "terseLabel": "Schedule of Finite Lived and Indefinite Lived Intangible Asset by Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_ScheduleOfOtherIncomeAndExpensesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Schedule Of Other Income And Expenses [Table]",
        "label": "Schedule Of Other Income And Expenses [Line Items]",
        "terseLabel": "Schedule Of Other Income And Expenses [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfOtherIncomeAndExpensesLineItems",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_ScheduleOfOtherIncomeAndExpensesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Other Income And Expenses [Table]",
        "label": "Schedule Of Other Income And Expenses [Table]",
        "terseLabel": "Schedule Of Other Income And Expenses [Table]"
       }
      }
     },
     "localname": "ScheduleOfOtherIncomeAndExpensesTable",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities Excluded From Computation Of Earnings Per Share, Performance Conditions Not Met, Amount",
        "label": "Securities Excluded From Computation Of Earnings Per Share, Performance Conditions Not Met, Amount",
        "terseLabel": "Excluded from computation of earnings per share, performance conditions not met (in shares)"
       }
      }
     },
     "localname": "SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bhc_SeniorNotes500DueFebruary2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 5.00%, Due February 2029",
        "label": "Senior Notes, 5.00%, Due February 2029 [Member]",
        "terseLabel": "5.00% Senior Notes Due February 2029"
       }
      }
     },
     "localname": "SeniorNotes500DueFebruary2029Member",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes500DueJanuary2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.00% Senior Notes Due January 2028 [Member]",
        "label": "Senior Notes, 5.00%, Due January 2028 [Member]",
        "terseLabel": "5.00% Senior Notes Due January 2028"
       }
      }
     },
     "localname": "SeniorNotes500DueJanuary2028Member",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes525DueFebruary2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 5.25%, Due February 2031",
        "label": "Senior Notes, 5.25%, Due February 2031 [Member]",
        "terseLabel": "5.25% Senior Notes Due February 2031"
       }
      }
     },
     "localname": "SeniorNotes525DueFebruary2031Member",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes525DueJanuary2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.25% Senior Notes Due January 2030 [Member]",
        "label": "Senior Notes, 5.25%, Due January 2030 [Member]",
        "terseLabel": "5.25% Senior Notes Due January 2030"
       }
      }
     },
     "localname": "SeniorNotes525DueJanuary2030Member",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes6125DueApril2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.125% Senior Notes due April 2025 [Member]",
        "label": "Senior Notes, 6.125%, Due April 2025 [Member]",
        "terseLabel": "6.125% Senior Notes Due April 2025"
       }
      }
     },
     "localname": "SeniorNotes6125DueApril2025Member",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes625DueFebruary2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 6.25%, Due February 2029",
        "label": "Senior Notes, 6.25%, Due February 2029 [Member]",
        "terseLabel": "6.25% Senior Notes Due February 2029"
       }
      }
     },
     "localname": "SeniorNotes625DueFebruary2029Member",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes700DueJanuary2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes 7.00 Percent Due January 2028 [Member]",
        "label": "Senior Notes, 7.00%, Due January 2028 [Member]",
        "terseLabel": "7.00 % Senior Notes Due January 2028"
       }
      }
     },
     "localname": "SeniorNotes700DueJanuary2028Member",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes700DueMarch2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 7.00%, Due March 2024",
        "label": "Senior Notes, 7.00%, Due March 2024 [Member]",
        "terseLabel": "7.00% Senior Notes, Due March 2024"
       }
      }
     },
     "localname": "SeniorNotes700DueMarch2024Member",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes725DueMay2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes 7.25 Percent Due May 2029 [Member]",
        "label": "Senior Notes, 7.25%, Due May 2029 [Member]",
        "terseLabel": "7.25 % Senior Notes Due May 2029"
       }
      }
     },
     "localname": "SeniorNotes725DueMay2029Member",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes850DueJanuary2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "8.50% Senior Notes Due January 2027 [Member]",
        "label": "Senior Notes, 8.50%, Due January 2027 [Member]",
        "terseLabel": "8.50% Senior Notes Due January 2027"
       }
      }
     },
     "localname": "SeniorNotes850DueJanuary2027Member",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes900DueDecember2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "9.00% Senior Notes due December 2025 [Member]",
        "label": "Senior Notes, 9.00%, Due December 2025 [Member]",
        "terseLabel": "9.00% Senior Notes Due December 2025"
       }
      }
     },
     "localname": "SeniorNotes900DueDecember2025Member",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes925DueApril2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "9.25% Senior Notes Due April 2026 [Member]",
        "label": "Senior Notes, 9.25%, Due April 2026 [Member]",
        "verboseLabel": "9.25% Senior Notes Due April 2026"
       }
      }
     },
     "localname": "SeniorNotes925DueApril2026Member",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecured4875NotesDueJune2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured 4.875% Notes Due June 2028",
        "label": "Senior Secured 4.875% Notes Due June 2028 [Member]",
        "terseLabel": "4.875% Senior Notes Due June 2028"
       }
      }
     },
     "localname": "SeniorSecured4875NotesDueJune2028Member",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecured5.50NotesDueNovember2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured 5.50% Notes Due November 2025 [Member]",
        "label": "Senior Secured 5.50% Notes Due November 2025 [Member]",
        "terseLabel": "5.50% Senior Notes Due November 2025"
       }
      }
     },
     "localname": "SeniorSecured5.50NotesDueNovember2025Member",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecured5.75NotesDueAugust2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured 5.75% Notes Due August 2027 [Member]",
        "label": "Senior Secured 5.75% Notes Due August 2027 [Member]",
        "verboseLabel": "5.75% Senior Notes Due August 2027"
       }
      }
     },
     "localname": "SeniorSecured5.75NotesDueAugust2027Member",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecured6125NotesDueFebruary2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured 6.125% Notes Due February 2027",
        "label": "Senior Secured 6.125% Notes Due February 2027 [Member]",
        "terseLabel": "6.125% Senior Notes Due February 2027"
       }
      }
     },
     "localname": "SeniorSecured6125NotesDueFebruary2027Member",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecuredCreditFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured Credit Facilities [Member]",
        "label": "Senior Secured Credit Facilities [Member]",
        "terseLabel": "Senior Secured Credit Facilities"
       }
      }
     },
     "localname": "SeniorSecuredCreditFacilitiesMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecuredCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured Credit Facility",
        "label": "Senior Secured Credit Facility [Member]",
        "terseLabel": "Senior Secured Credit Facility"
       }
      }
     },
     "localname": "SeniorSecuredCreditFacilityMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeparationAndInitialPublicOfferingCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Separation And Initial Public Offering Costs",
        "label": "Separation And Initial Public Offering Costs [Member]",
        "terseLabel": "Separation and IPO Costs"
       }
      }
     },
     "localname": "SeparationAndInitialPublicOfferingCostsMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeparationPerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Separation Performance-Based Restricted Stock Units",
        "label": "Separation Performance-Based Restricted Stock Units [Member]",
        "terseLabel": "B+L Separation performance-based RSUs"
       }
      }
     },
     "localname": "SeparationPerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Plan Modification, Fair Market Value Limit On Annual Grant",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Plan Modification, Fair Market Value Limit On Annual Grant",
        "terseLabel": "Aggregate fair market value on awards granted during any calendar year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shower To Shower Product Liability Litigation, Alleging Caused Ovarian Cancer, Mesothelioma Or Breast Cancer",
        "label": "Shower To Shower Product Liability Litigation, Alleging Caused Ovarian Cancer, Mesothelioma Or Breast Cancer [Member]",
        "terseLabel": "Shower to Shower Product Liability Litigation, Alleging Caused Ovarian Cancer, Mesothelioma or Breast Cancer"
       }
      }
     },
     "localname": "ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ShowerToShowerProductLiabilityLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shower to Shower Product Liability Litigation [Member]",
        "label": "Shower To Shower Product Liability Litigation [Member]",
        "terseLabel": "Shower to Shower Product Liability Litigation"
       }
      }
     },
     "localname": "ShowerToShowerProductLiabilityLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SoltaMedicalSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Solta Medical Segment",
        "label": "Solta Medical Segment [Member]",
        "terseLabel": "Solta Medical"
       }
      }
     },
     "localname": "SoltaMedicalSegmentMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Research And Development Expense [Table Text Block]",
        "label": "Summary Of Research And Development Expense [Table Text Block]",
        "terseLabel": "Summary of research and development"
       }
      }
     },
     "localname": "SummaryOfResearchAndDevelopmentExpenseTableTextBlock",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Valuation And Qualifying Accounts [Table Text Block]",
        "label": "Summary Of Valuation And Qualifying Accounts [Table Text Block]",
        "terseLabel": "Summary of variable consideration provisions"
       }
      }
     },
     "localname": "SummaryOfValuationAndQualifyingAccountsTableTextBlock",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_TSRPerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TSR Performance-Based Restricted Stock Units [Member]",
        "label": "TSR Performance-Based Restricted Stock Units [Member]",
        "terseLabel": "TSR performance-based RSUs"
       }
      }
     },
     "localname": "TSRPerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TermLoanBFacilityDueJune2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan B Facility Due June 2025 [Member]",
        "label": "Term Loan B Facility Due June 2025 [Member]",
        "verboseLabel": "Term Loan B Facility Due June 2025"
       }
      }
     },
     "localname": "TermLoanBFacilityDueJune2025Member",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TermLoanBFacilityDueNovember2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan B Facility Due November 2025 [Member]",
        "label": "Term Loan B Facility Due November 2025 [Member]",
        "terseLabel": "Term Loan B Facility Due November 2025"
       }
      }
     },
     "localname": "TermLoanBFacilityDueNovember2025Member",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TermLoanDueMay2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan Due May 2027",
        "label": "Term Loan Due May 2027 [Member]",
        "terseLabel": "Term Loan Due May 2027"
       }
      }
     },
     "localname": "TermLoanDueMay2027Member",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TimeBasedRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents stock awards in the form of time-based restricted stock units (RSUs) to certain directors, officers and other eligible employees pursuant to the company's incentive compensation plan.",
        "label": "Time Based RSU [Member]",
        "terseLabel": "Time-based RSUs"
       }
      }
     },
     "localname": "TimeBasedRSUMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "U.S. Dollar Base Rate and Canadian Dollar Prime Rate",
        "label": "U.S. Dollar Base Rate and Canadian Dollar Prime Rate [Member]",
        "terseLabel": "U.S. Dollar Base Rate and Canadian Dollar Prime Rate"
       }
      }
     },
     "localname": "USDollarBaseRateAndCanadianDollarPrimeRateMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_UnitedStatesandPuertoRicoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "United States and Puerto Rico [Member]",
        "label": "United States and Puerto Rico [Member]",
        "terseLabel": "U.S. and Puerto Rico"
       }
      }
     },
     "localname": "UnitedStatesandPuertoRicoMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross amount of unrecognized tax benefits including interest and penalties pertaining to uncertain tax positions taken in tax returns as of the balance sheet date.",
        "label": "Unrecognized Tax Benefits, Including Interest and Penalties",
        "terseLabel": "Unrecognized tax benefits including interest and penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncludingInterestAndPenalties",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_ValeantUSSecuritiesLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valeant US Securities Litigation [Member]",
        "label": "Valeant US Securities Litigation [Member]",
        "terseLabel": "US Securities Litigation"
       }
      }
     },
     "localname": "ValeantUSSecuritiesLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ViolationofCanadianProvincialSecuritiesLegislationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Violation of Canadian Provincial Securities Legislation [Member]",
        "label": "Violation of Canadian Provincial Securities Legislation [Member]",
        "terseLabel": "Violation of Canadian Provincial Securities Legislation"
       }
      }
     },
     "localname": "ViolationofCanadianProvincialSecuritiesLegislationMember",
     "nsuri": "http://www.bauschhealth.com/20220331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CANADA",
        "terseLabel": "Canada"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA",
        "terseLabel": "China"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_DE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GERMANY",
        "terseLabel": "Germany"
       }
      }
     },
     "localname": "DE",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_ES": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SPAIN",
        "terseLabel": "Spain"
       }
      }
     },
     "localname": "ES",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_FR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FRANCE",
        "terseLabel": "France"
       }
      }
     },
     "localname": "FR",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_GB": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED KINGDOM",
        "terseLabel": "United Kingdom"
       }
      }
     },
     "localname": "GB",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_IT": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ITALY",
        "terseLabel": "Italy"
       }
      }
     },
     "localname": "IT",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_KR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "KOREA, REPUBLIC OF",
        "terseLabel": "South Korea"
       }
      }
     },
     "localname": "KR",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_MX": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MEXICO",
        "terseLabel": "Mexico"
       }
      }
     },
     "localname": "MX",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_PL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "POLAND",
        "terseLabel": "Poland"
       }
      }
     },
     "localname": "PL",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_RU": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RUSSIAN FEDERATION",
        "terseLabel": "Russia"
       }
      }
     },
     "localname": "RU",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S. Plan"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Smaller Reporting Company"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r133",
      "r185",
      "r198",
      "r199",
      "r200",
      "r201",
      "r203",
      "r205",
      "r209",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r300",
      "r302",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r133",
      "r185",
      "r198",
      "r199",
      "r200",
      "r201",
      "r203",
      "r205",
      "r209",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r300",
      "r302",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r63",
      "r65",
      "r131",
      "r132",
      "r309",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r216",
      "r369",
      "r373",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r308",
      "r344",
      "r465",
      "r470",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r630",
      "r674",
      "r678",
      "r698",
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r308",
      "r344",
      "r465",
      "r470",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r630",
      "r674",
      "r678",
      "r698",
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r216",
      "r369",
      "r373",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r212",
      "r369",
      "r371",
      "r631",
      "r673",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r212",
      "r369",
      "r371",
      "r631",
      "r673",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r308",
      "r344",
      "r406",
      "r465",
      "r470",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r630",
      "r674",
      "r678",
      "r698",
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r308",
      "r344",
      "r406",
      "r465",
      "r470",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r630",
      "r674",
      "r678",
      "r698",
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r64",
      "r65",
      "r131",
      "r132",
      "r309",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r213",
      "r214",
      "r369",
      "r372",
      "r676",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r213",
      "r214",
      "r369",
      "r372",
      "r676",
      "r687",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r218",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r134",
      "r135",
      "r136",
      "r138",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_CA-BC": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BRITISH COLUMBIA",
        "terseLabel": "BRITISH COLUMBIA"
       }
      }
     },
     "localname": "CA-BC",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_CA-QC": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "QUEBEC",
        "terseLabel": "QUEBEC"
       }
      }
     },
     "localname": "CA-QC",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_NJ": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW JERSEY",
        "terseLabel": "NEW JERSEY",
        "verboseLabel": "New Jersey"
       }
      }
     },
     "localname": "NJ",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "ACCRUED AND OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r40",
      "r616"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r14",
      "r15",
      "r44"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Employee compensation and benefit costs"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r21",
      "r638",
      "r656"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued and other current liabilities",
        "totalLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r71",
      "r76",
      "r83",
      "r84",
      "r85",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Pension and postretirement benefit plan adjustments, net of income taxes"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r28",
      "r74",
      "r75",
      "r76",
      "r658",
      "r683",
      "r684"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r83",
      "r84",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income Loss [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r73",
      "r76",
      "r83",
      "r84",
      "r85",
      "r141",
      "r142",
      "r143",
      "r542",
      "r679",
      "r680",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r69",
      "r76",
      "r83",
      "r84",
      "r85",
      "r542",
      "r601",
      "r602",
      "r603",
      "r604",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r490",
      "r491",
      "r492",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Employee withholding taxes related to share-based awards"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r472",
      "r474",
      "r495",
      "r496"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash (used in) provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r474",
      "r487",
      "r494"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r219",
      "r224",
      "r225",
      "r229"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries": {
     "auth_ref": [
      "r228"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in allowance for credit loss on accounts receivable, from recovery.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Recovery",
        "terseLabel": "Recoveries"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableRecoveries",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]",
        "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "auth_ref": [
      "r227"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff",
        "negatedTerseLabel": "Write-offs"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r119",
      "r328",
      "r339",
      "r340",
      "r610"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization and write-off of debt premiums, discounts and issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Dilutive effect of potential common shares (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Anti-dilutive shares not included in the computation of diluted earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r119",
      "r257"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 6.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "negatedLabel": "Asset impairments, including loss on assets held for sale",
        "terseLabel": "Asset impairments, including loss on assets held for sale",
        "verboseLabel": "Asset impairments, including loss on assets held for sale"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r128",
      "r193",
      "r200",
      "r207",
      "r222",
      "r290",
      "r291",
      "r292",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r301",
      "r303",
      "r304",
      "r535",
      "r543",
      "r594",
      "r614",
      "r616",
      "r636",
      "r655"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r12",
      "r13",
      "r58",
      "r128",
      "r222",
      "r290",
      "r291",
      "r292",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r301",
      "r303",
      "r304",
      "r535",
      "r543",
      "r594",
      "r614",
      "r616"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r476",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r552",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]",
        "terseLabel": "Base Rate"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r522"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETSummaryofOtherExpenseNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Acquisition-related contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETSummaryofOtherExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r527",
      "r528"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Current portion included in Accrued and other current liabilities"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Fair value, contingent consideration obligations, discount rate"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r527",
      "r528"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Non-current portion"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r10",
      "r38",
      "r121"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r115",
      "r121",
      "r122"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "totalLabel": "Cash, cash equivalents and restricted cash, end of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r115",
      "r599"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r49",
      "r275",
      "r642",
      "r664"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 18)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common shares available for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r141",
      "r142",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Shares"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)",
        "terseLabel": "Common shares, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r24",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common shares, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r24",
      "r616"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common shares, no par value, unlimited shares authorized, 361,331,665 and 359,405,748 issued and outstanding at March 31, 2022 and December\u00a031, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r79",
      "r81",
      "r82",
      "r93",
      "r648",
      "r669"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss attributable to Bausch Health Companies Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r79",
      "r81",
      "r92",
      "r533",
      "r534",
      "r547",
      "r647",
      "r668"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Comprehensive income attributable to noncontrolling interest"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r79",
      "r81",
      "r91",
      "r532",
      "r547",
      "r646",
      "r667"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r90",
      "r103",
      "r645",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "ACCUMULATED OTHER COMPREHENSIVE LOSS"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r175",
      "r176",
      "r216",
      "r592",
      "r593",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r175",
      "r176",
      "r216",
      "r592",
      "r593",
      "r685",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r175",
      "r176",
      "r216",
      "r592",
      "r593",
      "r685",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r175",
      "r176",
      "r216",
      "r592",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r175",
      "r176",
      "r216",
      "r592",
      "r593",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r124",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractualRightsMember": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights that arise from a contractual arrangement with a third party (not including franchise rights and license agreements).",
        "label": "Contractual Rights [Member]",
        "terseLabel": "Product rights/patents"
       }
      }
     },
     "localname": "ContractualRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r201",
      "r203",
      "r209",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r98",
      "r631"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Expenses"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrencySwapMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Swap involving the exchange of principal and interest in one currency for another currency.",
        "label": "Currency Swap [Member]",
        "terseLabel": "Currency Swap"
       }
      }
     },
     "localname": "CurrencySwapMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r173",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r126",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r322",
      "r329",
      "r330",
      "r332",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "FINANCING ARRANGEMENTS"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r127",
      "r133",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r312",
      "r318",
      "r319",
      "r320",
      "r321",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r337",
      "r338",
      "r339",
      "r340",
      "r611",
      "r637",
      "r639",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Variable rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r22",
      "r333",
      "r639",
      "r654"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Principal Amount",
        "totalLabel": "Total debt obligations"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r305",
      "r337",
      "r338",
      "r609",
      "r611",
      "r612"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r320",
      "r337",
      "r338",
      "r591"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Fair value of long-term debt"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r46",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Stated interest rate on debt (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]",
        "verboseLabel": "Long-term debt, net of unamortized debt discount"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r47",
      "r127",
      "r133",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r312",
      "r318",
      "r319",
      "r320",
      "r321",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r337",
      "r338",
      "r339",
      "r340",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Debt Instrument, Redemption, Period One"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "Debt Instrument, Redemption, Period Two"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Redemption price (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of principal amount of debt redeemed.",
        "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed",
        "terseLabel": "Maximum percentage of principal amount that can be redeemed"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentRepurchasedFaceAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of the original debt instrument that was repurchased.",
        "label": "Debt Instrument, Repurchased Face Amount",
        "terseLabel": "Repurchased principal amount"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasedFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r47",
      "r127",
      "r133",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r312",
      "r318",
      "r319",
      "r320",
      "r321",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r331",
      "r337",
      "r338",
      "r339",
      "r340",
      "r347",
      "r348",
      "r349",
      "r350",
      "r608",
      "r609",
      "r611",
      "r612",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r318",
      "r334",
      "r337",
      "r338",
      "r610"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedTerseLabel": "Unamortized premiums, discounts and issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtWeightedAverageInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of debt outstanding.",
        "label": "Debt, Weighted Average Interest Rate",
        "terseLabel": "Weighted average interest rate"
       }
      }
     },
     "localname": "DebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "auth_ref": [
      "r508"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "terseLabel": "Unrecognized tax benefit, amount possible to decrease in next twelve months"
       }
      }
     },
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r502",
      "r503"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "verboseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r502",
      "r503"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liabilities, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r511"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "terseLabel": "Valuation allowance against deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "auth_ref": [
      "r384",
      "r423",
      "r450",
      "r455",
      "r456"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "terseLabel": "Amortization of prior service credit and other"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r384",
      "r421",
      "r448",
      "r455",
      "r456"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedTerseLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r384",
      "r388",
      "r420",
      "r447",
      "r455",
      "r456"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "terseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r418",
      "r445",
      "r455",
      "r456"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "totalLabel": "Net periodic (benefit) cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r386",
      "r419",
      "r446",
      "r455",
      "r456"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "terseLabel": "Service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r119",
      "r259"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization of intangible assets"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetFairValueGrossLiability": {
     "auth_ref": [
      "r60",
      "r67",
      "r554"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Asset, Fair Value, Gross Liability",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "DerivativeAssetFairValueGrossLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r61",
      "r62",
      "r65",
      "r591"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "terseLabel": "Foreign currency exchange contracts"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r59",
      "r65",
      "r66",
      "r554",
      "r629"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Fair Value, Gross Asset",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r65",
      "r553",
      "r555",
      "r561",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r551",
      "r553",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r551",
      "r553",
      "r561",
      "r567",
      "r568",
      "r570",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain": {
     "auth_ref": [
      "r560",
      "r562"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain",
        "terseLabel": "Gain related to settlements"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "auth_ref": [
      "r560",
      "r562"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "terseLabel": "Loss related to changes in fair value"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss": {
     "auth_ref": [
      "r560",
      "r562"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized loss of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Loss",
        "negatedTerseLabel": "Loss related to settlements"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r61",
      "r62",
      "r65",
      "r591"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Foreign currency exchange contracts",
        "totalLabel": "Net fair value"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r548",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Aggregate notional amounts"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r369",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "SHARE-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r258",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]",
        "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": {
     "auth_ref": [
      "r3",
      "r4",
      "r7",
      "r262"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents",
        "terseLabel": "Cash and cash equivalents, held for sale"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "auth_ref": [
      "r6",
      "r9"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "terseLabel": "Revenue associated with products for disposal"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r461",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r94",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r154",
      "r156",
      "r158",
      "r159",
      "r160",
      "r164",
      "r165",
      "r576",
      "r577",
      "r649",
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic loss per share attributable to Bausch Health Companies Inc. (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r94",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r156",
      "r158",
      "r159",
      "r160",
      "r164",
      "r165",
      "r576",
      "r577",
      "r649",
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted loss per share attributable to Bausch Health Companies Inc. (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r599"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "auth_ref": [
      "r497",
      "r505"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount",
        "terseLabel": "Tax provision (benefit) related to stock compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Components and classification of share-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r488"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Remaining unrecognized compensation expense related to non-vested awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average service period over which compensation cost is expected to be recognized (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Major Customer [Line Items]",
        "terseLabel": "Revenue, Major Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r83",
      "r84",
      "r85",
      "r141",
      "r142",
      "r143",
      "r145",
      "r151",
      "r153",
      "r167",
      "r223",
      "r346",
      "r351",
      "r490",
      "r491",
      "r492",
      "r513",
      "r514",
      "r575",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r606",
      "r679",
      "r680",
      "r681",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EurodollarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate based on U.S. dollar denominated deposits at foreign banks or foreign branches of U.S. banks.",
        "label": "Eurodollar [Member]",
        "terseLabel": "Eurocurrency rate"
       }
      }
     },
     "localname": "EurodollarMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "verboseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r578",
      "r579",
      "r580",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r320",
      "r337",
      "r338",
      "r407",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r455",
      "r579",
      "r620",
      "r621",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r578",
      "r579",
      "r582",
      "r583",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r320",
      "r407",
      "r409",
      "r414",
      "r455",
      "r579",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r320",
      "r337",
      "r338",
      "r407",
      "r409",
      "r414",
      "r455",
      "r579",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r320",
      "r337",
      "r338",
      "r407",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r455",
      "r579",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "verboseLabel": "Reconciliation of contingent payment obligations measured on a recurring basis"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r584",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r584",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r585"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Acquisition-related contingent consideration"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r586"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedTerseLabel": "Payments/Settlements"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r584"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance, end of period",
        "periodStartLabel": "Balance, beginning of period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r320",
      "r337",
      "r338",
      "r407",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r455",
      "r620",
      "r621",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsNonrecurringMember": {
     "auth_ref": [
      "r578",
      "r579",
      "r582",
      "r583",
      "r587",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value.",
        "label": "Fair Value, Nonrecurring [Member]",
        "terseLabel": "Nonrecurring adjustment"
       }
      }
     },
     "localname": "FairValueMeasurementsNonrecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r588",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FederalFundsEffectiveSwapRateMember": {
     "auth_ref": [
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg.",
        "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]",
        "terseLabel": "Federal Funds"
       }
      }
     },
     "localname": "FederalFundsEffectiveSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r249"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization and Impairments"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r250"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r250"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r250"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r250"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r250"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r244",
      "r246",
      "r249",
      "r252",
      "r632",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r249",
      "r633"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r244",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r249",
      "r632"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "terseLabel": "Finite-lived intangible assets:"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r595",
      "r596",
      "r597",
      "r598"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Foreign exchange and other"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r120",
      "r597",
      "r598"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "negatedLabel": "Foreign exchange loss"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r65",
      "r407",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign currency exchange contracts"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignPlanMember": {
     "auth_ref": [
      "r460",
      "r464",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Foreign Plan [Member]",
        "terseLabel": "Non-U.S. Plans"
       }
      }
     },
     "localname": "ForeignPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r119"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETSummaryofOtherExpenseNetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedLabel": "Net gain on sale of assets",
        "negatedTerseLabel": "Gain on sale of assets, net",
        "verboseLabel": "Milestone achievement, included in net (loss) gain on sale of assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails",
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETSummaryofOtherExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r275"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETSummaryofOtherExpenseNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "negatedTerseLabel": "Litigation and other matters"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETSummaryofOtherExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r119",
      "r341",
      "r342"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on extinguishment of debt",
        "terseLabel": "Loss on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r231",
      "r233",
      "r616",
      "r635"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Balance at the end of the period",
        "periodStartLabel": "Balance at the beginning of the period",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "INTANGIBLE ASSETS AND GOODWILL"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r236"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "negatedTerseLabel": "Foreign exchange and other"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r234",
      "r238"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Accumulated goodwill impairment charges"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r119",
      "r232",
      "r235",
      "r241"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "negatedLabel": "Impairment",
        "verboseLabel": "Goodwill impairment"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r237"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "terseLabel": "Realignment of segment goodwill"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Change in the carrying amount of goodwill"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r551",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "B+L IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r119",
      "r253"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-lived",
        "terseLabel": "Impairment of intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "auth_ref": [
      "r119",
      "r256"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.",
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "verboseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r88",
      "r193",
      "r199",
      "r203",
      "r206",
      "r209",
      "r634",
      "r643",
      "r650",
      "r671"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r461",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r261",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r129",
      "r506",
      "r510",
      "r512",
      "r515",
      "r517",
      "r519",
      "r520",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss": {
     "auth_ref": [
      "r508"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated amount of loss resulting from an adverse tax position.",
        "label": "Income Tax Examination, Estimate of Possible Loss",
        "terseLabel": "Estimate of possible loss, income tax examination (up to)"
       }
      }
     },
     "localname": "IncomeTaxExaminationEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r130",
      "r152",
      "r153",
      "r191",
      "r504",
      "r516",
      "r518",
      "r672"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Benefit from (provision for) income taxes",
        "terseLabel": "Provision (benefit) from income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r501",
      "r505"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "negatedTerseLabel": "Tax benefit related to filing of certain tax returns"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r505"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Income tax expense (benefit) on ordinary loss"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxContingencies": {
     "auth_ref": [
      "r505"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount",
        "verboseLabel": "Tax provision (benefit) related to changes in uncertain tax positions"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable, accrued and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Trade receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Shareholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r245",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r251"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]",
        "terseLabel": "Indefinite-lived intangible assets:"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r245",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "totalLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r243",
      "r247"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "terseLabel": "Total intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r101",
      "r326",
      "r336",
      "r339",
      "r340"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "negatedLabel": "Interest expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseMember": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing interest expense.",
        "label": "Interest Expense [Member]",
        "terseLabel": "Interest Expense"
       }
      }
     },
     "localname": "InterestExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r15",
      "r16",
      "r44"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Total Inventories"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r11",
      "r57",
      "r616"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r100",
      "r186"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "terseLabel": "LEGAL PROCEEDINGS"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r43",
      "r128",
      "r201",
      "r222",
      "r290",
      "r291",
      "r292",
      "r295",
      "r296",
      "r297",
      "r299",
      "r301",
      "r303",
      "r304",
      "r536",
      "r543",
      "r544",
      "r594",
      "r614",
      "r615"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r31",
      "r128",
      "r222",
      "r594",
      "r616",
      "r641",
      "r661"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and deficit"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r45",
      "r128",
      "r222",
      "r290",
      "r291",
      "r292",
      "r295",
      "r296",
      "r297",
      "r299",
      "r301",
      "r303",
      "r304",
      "r536",
      "r543",
      "r544",
      "r594",
      "r614",
      "r615",
      "r616"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Facility fee (as a percent)"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Remaining borrowings"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.",
        "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "terseLabel": "Commitment fee (as a percent)"
       }
      }
     },
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LitigationReserveCurrent": {
     "auth_ref": [
      "r49",
      "r275",
      "r284"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.",
        "label": "Estimated Litigation Liability, Current",
        "terseLabel": "Current accrued loss contingencies"
       }
      }
     },
     "localname": "LitigationReserveCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSLegalProceedsandGovernmentalandRegulatoryInquiriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded from other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded from Other Party",
        "terseLabel": "Aggregate amount to be received"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedFromOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Settlement, agreed to pay",
        "verboseLabel": "Settlement, escrow fund included in restricted cash and other settlement deposits"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r22",
      "r319",
      "r335",
      "r337",
      "r338",
      "r639",
      "r657"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Long-term debt",
        "totalLabel": "Total long-term debt and other",
        "verboseLabel": "Amount drawn under credit facility"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "verboseLabel": "Less: Current portion of long-term debt and other"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r133",
      "r288",
      "r324"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r133",
      "r288",
      "r324"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r133",
      "r288",
      "r324"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r133",
      "r288",
      "r324"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r133",
      "r288",
      "r324"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r133",
      "r288",
      "r324"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r133"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Non-current portion of long-term debt",
        "verboseLabel": "Non-current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r47",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r275",
      "r276",
      "r277",
      "r279",
      "r280",
      "r281",
      "r283",
      "r286",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r275",
      "r276",
      "r277",
      "r279",
      "r280",
      "r281",
      "r283",
      "r286",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyClaimsDismissedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of claims dismissed.",
        "label": "Loss Contingency, Claims Dismissed, Number",
        "terseLabel": "Number of claims dismissed"
       }
      }
     },
     "localname": "LossContingencyClaimsDismissedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r275",
      "r278",
      "r282"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Damages sought"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r275",
      "r276",
      "r277",
      "r279",
      "r280",
      "r281",
      "r283",
      "r286",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "Number of suits filed",
        "verboseLabel": "Number of putative antitrust class actions filed"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Number of lawsuits pending"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Measurement Input, Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r53",
      "r128",
      "r222",
      "r290",
      "r295",
      "r296",
      "r297",
      "r303",
      "r304",
      "r594",
      "r640",
      "r660"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r168",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "DESCRIPTION OF BUSINESS"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows From Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows From Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r115",
      "r117",
      "r120"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash (used in) provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows From Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r9",
      "r77",
      "r80",
      "r85",
      "r89",
      "r120",
      "r128",
      "r144",
      "r146",
      "r147",
      "r148",
      "r149",
      "r152",
      "r153",
      "r157",
      "r193",
      "r199",
      "r203",
      "r206",
      "r209",
      "r222",
      "r290",
      "r291",
      "r292",
      "r295",
      "r296",
      "r297",
      "r299",
      "r301",
      "r303",
      "r304",
      "r577",
      "r594",
      "r644",
      "r665"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss attributable to Bausch Health Companies Inc.",
        "totalLabel": "Net loss attributable to Bausch Health Companies Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r77",
      "r80",
      "r85",
      "r152",
      "r153",
      "r539",
      "r546"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Net income attributable to noncontrolling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net Investment Hedging"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r351",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non- controlling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfCountriesInWhichEntityOperates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of countries in which the entity operates as of balance sheet date.",
        "label": "Number of Countries in which Entity Operates",
        "terseLabel": "Number of countries in which entity operates"
       }
      }
     },
     "localname": "NumberOfCountriesInWhichEntityOperates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportingUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.",
        "label": "Number of Reporting Units",
        "terseLabel": "Number of reporting units"
       }
      }
     },
     "localname": "NumberOfReportingUnits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r193",
      "r199",
      "r203",
      "r206",
      "r209"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Operating income (loss)",
        "totalLabel": "Operating income (loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r201",
      "r203",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segment"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r44"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r72",
      "r74",
      "r532",
      "r541"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent",
        "negatedLabel": "Pension and postretirement benefit plan adjustments, net of income taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax": {
     "auth_ref": [
      "r70",
      "r74",
      "r559",
      "r564",
      "r573"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax",
        "terseLabel": "Gain excluded from assessment of hedge effectiveness"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r563"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Gain recognized in Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r78",
      "r81",
      "r83",
      "r84",
      "r86",
      "r90",
      "r346",
      "r600",
      "r605",
      "r606",
      "r645",
      "r666"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive loss",
        "totalLabel": "Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive (loss) income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": {
     "auth_ref": [
      "r380",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.",
        "label": "Other Income and Other Expense Disclosure [Text Block]",
        "terseLabel": "OTHER EXPENSE (INCOME), NET"
       }
      }
     },
     "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENET"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETSummaryofOtherExpenseNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedTotalLabel": "Other expense (income), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETSummaryofOtherExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 8.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "negatedTerseLabel": "Other expense (income), net",
        "verboseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
     "auth_ref": [
      "r382",
      "r383",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r430",
      "r431",
      "r433",
      "r436",
      "r440",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.",
        "label": "Other Postretirement Benefits Plan [Member]",
        "terseLabel": "Postretirement Benefit Plan"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Bausch Health Companies\u00a0Inc. Shareholders\u2019 (Deficit) Equity"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedLabel": "Payments of acquisition-related contingent consideration"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for Legal Settlements",
        "negatedTerseLabel": "Payments of accrued legal settlements"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromHedgeInvestingActivities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow or inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.",
        "label": "Payments for (Proceeds from) Hedge, Investing Activities",
        "terseLabel": "Payments or receipts in settlement of cross-currency swaps"
       }
      }
     },
     "localname": "PaymentsForProceedsFromHedgeInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r113",
      "r267"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "terseLabel": "Restructuring payments"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Payments of financing costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedLabel": "Payments of employee withholding taxes related to share-based awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedTerseLabel": "Payments for intangible and other assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r221"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PendingLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.",
        "label": "Pending Litigation [Member]",
        "terseLabel": "Pending Litigation"
       }
      }
     },
     "localname": "PendingLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r406",
      "r408",
      "r414",
      "r432",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r455",
      "r457",
      "r458",
      "r459",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r381",
      "r383",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r430",
      "r431",
      "r433",
      "r436",
      "r440",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r459",
      "r460",
      "r466",
      "r467",
      "r468",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "terseLabel": "Pension Benefit Plans"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r476",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r12",
      "r36",
      "r37"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r104"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "terseLabel": "Cash proceeds from divestiture"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the cash inflow during the period from the sale of a component of the entity.",
        "label": "Proceeds from Divestiture of Businesses, Net of Cash Divested",
        "terseLabel": "Proceeds from sale of assets and businesses, net of costs to sell"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinessesNetOfCashDivested",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Issuance of long-term debt, net of discounts"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r107",
      "r112"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from sale of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Other revenues"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.",
        "label": "Product Concentration Risk [Member]",
        "terseLabel": "Product Concentration Risk"
       }
      }
     },
     "localname": "ProductConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r9",
      "r77",
      "r80",
      "r85",
      "r114",
      "r128",
      "r144",
      "r152",
      "r153",
      "r193",
      "r199",
      "r203",
      "r206",
      "r209",
      "r222",
      "r290",
      "r291",
      "r292",
      "r295",
      "r296",
      "r297",
      "r299",
      "r301",
      "r303",
      "r304",
      "r532",
      "r538",
      "r540",
      "r546",
      "r547",
      "r577",
      "r594",
      "r650"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "netLabel": "Net (loss) income",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r18",
      "r19",
      "r260",
      "r616",
      "r651",
      "r663"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r95",
      "r226"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Provision"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r25",
      "r32",
      "r616",
      "r662",
      "r686"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Repayments of long-term debt",
        "terseLabel": "Repayments of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReportingUnitAxis": {
     "auth_ref": [
      "r240",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by reporting unit.",
        "label": "Reporting Unit [Axis]",
        "terseLabel": "Reporting Unit [Axis]"
       }
      }
     },
     "localname": "ReportingUnitAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReportingUnitDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Level of reporting at which goodwill is tested for impairment.",
        "label": "Reporting Unit [Domain]",
        "terseLabel": "Reporting Unit [Domain]"
       }
      }
     },
     "localname": "ReportingUnitDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of fair value of reporting unit in excess of carrying amount.",
        "label": "Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount",
        "terseLabel": "Fair value of reporting value, greater than its carrying value"
       }
      }
     },
     "localname": "ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]",
        "terseLabel": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r500"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development",
        "totalLabel": "Research and development costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "verboseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETSummaryofOtherExpenseNetDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Acquired in-process research and development costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETSummaryofOtherExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "auth_ref": [
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.",
        "label": "Research, Development, and Computer Software Disclosure [Text Block]",
        "terseLabel": "RESEARCH AND DEVELOPMENT"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedCostIncurredCost": {
     "auth_ref": [
      "r266",
      "r269",
      "r272",
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.",
        "label": "Restructuring and Related Cost, Incurred Cost",
        "terseLabel": "Costs incurred"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostIncurredCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r119",
      "r265",
      "r270",
      "r272"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring, integration, separation, and IPO costs"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r266",
      "r267",
      "r272",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Cost-rationalization and integration initiatives"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r267",
      "r271"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "terseLabel": "Liabilities associated with restructuring, integration and separation costs"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r27",
      "r351",
      "r493",
      "r616",
      "r659",
      "r682",
      "r684"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r141",
      "r142",
      "r143",
      "r145",
      "r151",
      "r153",
      "r223",
      "r490",
      "r491",
      "r492",
      "r513",
      "r514",
      "r575",
      "r679",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "auth_ref": [
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r433",
      "r436",
      "r441",
      "r442",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r460",
      "r464",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "terseLabel": "Retirement Plan Sponsor Location [Axis]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "auth_ref": [
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r433",
      "r436",
      "r441",
      "r442",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r460",
      "r464",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "terseLabel": "Retirement Plan Sponsor Location [Domain]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r381",
      "r382",
      "r383",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r430",
      "r431",
      "r433",
      "r436",
      "r440",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r466",
      "r467",
      "r468",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r381",
      "r382",
      "r383",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r430",
      "r431",
      "r433",
      "r436",
      "r440",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r466",
      "r467",
      "r468",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r184",
      "r185",
      "r198",
      "r204",
      "r205",
      "r212",
      "r213",
      "r216",
      "r368",
      "r369",
      "r631"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues",
        "verboseLabel": "Price appreciation credits"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r125",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r370",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "REVENUE RECOGNITION"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]",
        "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]"
       }
      }
     },
     "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information when using transition method for cumulative effect in initial period of application for revenue from contract with customer.",
        "label": "Revenue, Initial Application Period Cumulative Effect Transition [Table]",
        "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Table]"
       }
      }
     },
     "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]"
       }
      }
     },
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Shares sold, net proceeds"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Shares sold (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.",
        "label": "Sale of Stock, Percentage of Ownership after Transaction",
        "terseLabel": "Percentage of shares held"
       }
      }
     },
     "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Price of shares sold (in usd per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Summary of activity in allowance for credit losses"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued and other current liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r76",
      "r605",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of the components of Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r523",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Summary of the components and classification of share-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of long-term debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r439",
      "r440",
      "r443",
      "r444",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans.  Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "terseLabel": "Schedule of assets and liabilities associated with derivatives, included in the Consolidated Balance Sheets"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock": {
     "auth_ref": [
      "r569",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of gains and losses on derivative instruments included in an entity's trading activities.",
        "label": "Schedule of Derivative Instruments Included in Trading Activities [Table Text Block]",
        "terseLabel": "Schedule of foreign exchange contracts on the Consolidated Statements of Operations and Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of calculation of net loss per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r474",
      "r486",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Schedule of revenues by segment and product category"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.",
        "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "terseLabel": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r578",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of components and classification of financial assets and liabilities measured at fair value"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r244",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of finite-lived intangible assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r239",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r239",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of changes in the carrying amount of goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r251",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of indefinite-lived intangible assets"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r17",
      "r33",
      "r34",
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of the components of inventories, net"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of long-term debt maturities"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "terseLabel": "Components of net periodic benefit cost"
       }
      }
     },
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for net investment hedges of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Net Investment Hedges, Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Schedule of effect of hedging instruments on financial statements"
       }
      }
     },
     "localname": "ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "terseLabel": "Schedule of other expense (income), net"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r266",
      "r267",
      "r268",
      "r269",
      "r272",
      "r273",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.",
        "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]",
        "terseLabel": "Schedule of customers that accounted for 10% or more of total revenue"
       }
      }
     },
     "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": {
     "auth_ref": [
      "r97",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]",
        "terseLabel": "Schedule of revenue attributed to a geographic region"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "auth_ref": [
      "r87",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r193",
      "r196",
      "r202",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r193",
      "r196",
      "r202",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of segment revenues and profit"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r480",
      "r482",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Activity [Table Text Block]",
        "terseLabel": "Summary of share-based awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r476",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of estimated aggregate amortization expense for each of the five succeeding years"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Senior Secured Notes"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": {
     "auth_ref": [
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg.",
        "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]",
        "terseLabel": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate"
       }
      }
     },
     "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r181",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r198",
      "r199",
      "r200",
      "r201",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r209",
      "r216",
      "r269",
      "r274",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r181",
      "r182",
      "r183",
      "r193",
      "r197",
      "r203",
      "r207",
      "r208",
      "r209",
      "r210",
      "r212",
      "r215",
      "r216",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "SEGMENT INFORMATION"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment reporting information"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative",
        "verboseLabel": "Separation and IPO-related costs included in selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "verboseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SettledLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.",
        "label": "Settled Litigation [Member]",
        "terseLabel": "Settled Litigation"
       }
      }
     },
     "localname": "SettledLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares available for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Maximum shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for future grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures [Abstract]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r473",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r123",
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r5",
      "r181",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r198",
      "r199",
      "r200",
      "r201",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r209",
      "r216",
      "r239",
      "r263",
      "r269",
      "r274",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r51",
      "r83",
      "r84",
      "r85",
      "r141",
      "r142",
      "r143",
      "r145",
      "r151",
      "r153",
      "r167",
      "r223",
      "r346",
      "r351",
      "r490",
      "r491",
      "r492",
      "r513",
      "r514",
      "r575",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r606",
      "r679",
      "r680",
      "r681",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r167",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-based Payment Arrangement [Member]",
        "terseLabel": "Stock Options and RSUs"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures [Abstract]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r23",
      "r24",
      "r346",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Common shares issued under share-based compensation plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r23",
      "r24",
      "r351",
      "r475",
      "r483"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Common shares issued under share-based compensation plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r24",
      "r29",
      "r30",
      "r128",
      "r220",
      "r222",
      "r594",
      "r616"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Bausch Health Companies Inc. shareholders\u2019 deficit"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Deficit"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r84",
      "r128",
      "r141",
      "r142",
      "r143",
      "r145",
      "r151",
      "r222",
      "r223",
      "r351",
      "r490",
      "r491",
      "r492",
      "r513",
      "r514",
      "r530",
      "r531",
      "r545",
      "r575",
      "r594",
      "r600",
      "r601",
      "r606",
      "r680",
      "r681",
      "r707"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total deficit",
        "verboseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r607",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r607",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r607",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r607",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r617",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "terseLabel": "Corporate brands"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TrademarksMember": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "Trademarks [Member]",
        "terseLabel": "Bausch + Lomb Trademark"
       }
      }
     },
     "localname": "TrademarksMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r266",
      "r267",
      "r272",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnfavorableRegulatoryActionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A enacted or proposed action, ruling or regulation that is likely to or possibly will have an adverse effect on the entity's financial position or results of operations, excluding tax matters.",
        "label": "Unfavorable Regulatory Action [Member]",
        "terseLabel": "Unfavorable Regulatory Action"
       }
      }
     },
     "localname": "UnfavorableRegulatoryActionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r507"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Unrecognized tax benefits related to interest and penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r509"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Portion of unrecognized tax benefits, if recognized, would reduce the Company's effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnsecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.",
        "label": "Unsecured Debt [Member]",
        "terseLabel": "Senior Unsecured Notes",
        "verboseLabel": "Unsecured Debt"
       }
      }
     },
     "localname": "UnsecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r172",
      "r177",
      "r178",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r134",
      "r139"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Reserve ending balance",
        "periodStartLabel": "Reserve beginning balance",
        "terseLabel": "Cooperative advertising credits included in rebates"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts": {
     "auth_ref": [
      "r137"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account",
        "terseLabel": "Current period provisions",
        "verboseLabel": "Sales return provisions"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToOtherAccounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r138"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "negatedTerseLabel": "Payments and credits"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r134",
      "r135",
      "r136",
      "r138",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r134",
      "r135",
      "r136",
      "r138",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r155",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted weighted-average common shares outstanding (in shares)",
        "verboseLabel": "Diluted weighted-average common shares (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r154",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic weighted-average common shares outstanding (in shares)",
        "verboseLabel": "Basic weighted-average common shares (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 19
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "http://asc.fasb.org/topic&trid=2134417"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8475-108599"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2611-110228"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2443-110228"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=116646759&loc=d3e15243-108350"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "610",
   "URI": "http://asc.fasb.org/topic&trid=49130413"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120384911&loc=d3e23163-113944"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "720",
   "URI": "http://asc.fasb.org/topic&trid=2122503"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32059-109318"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613674-111683"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624186-113959"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "184",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5634876-113961"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226003-175313"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(dd)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "730",
   "Topic": "985",
   "URI": "http://asc.fasb.org/subtopic&trid=2197926"
  },
  "r701": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r702": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r703": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r704": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r705": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r706": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>117
<FILENAME>0000885590-22-000025-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000885590-22-000025-xbrl.zip
M4$L#!!0    ( #&*JE0.1F:*&D($ *4U*P 0    8FAC+3(P,C(P,S,Q+FAT
M;>R]67>;1\XM?/_^BGRY/NK4@)JRNG.6QQSWL2VW[:2/<],+0*$L)A*I)BG'
MSJ__4)0H6XH'.:9$/C3=;H?#,['V!FJC!N#O__OUT>$WKV0Z&TW&__C6_LU\
M^\W__N'O_]_>WO^[_?3A-W<G?'(DX_DW=Z:"<ZG?_#Z:'WSS[RJSW[YIT\G1
M-_^>3'\;O<*]O<4Y=R;';Z:CEP?S;YQQ[M*7T^\+FU*\F#W/,>R!.+]'D/(>
M$I90BP=OR_]Z^;WQ47P(8:\V<'O0K-M#%-FS.45!ABP-_E?]/AO+$"U3]1Z*
MPUP\9_#)8Y;$Q/VV!W/]=?H+Q[/OJXS^\>W!?'[\_7??O:;IX=]FPG][.7GU
MG7[QG3ZN_2]\>W;H:#8!9]/YX;___OO?%J=,IB_U4.._.SMB>4+_LEZZ_-FQ
M\;O3+\\/G8TN7/=WOSS2?O?_'CU\Q@=RA'NC\6R.8Y;E6;/Y\?3]3]^_63S^
M\E">G(SGTS?O/_KLRPLGT %?>"+"DQD?' @>S@_^QI.C?K SWI^?<#+;>XEX
M?'Y2PQDM?L39%XNK[QF[]_:4UX>C\6_O^]VVE/+=XMOSQG\]?W_#C\9ZF'1:
M?C>?XGC6)M,CG"MM^_W,GG%[UKUSD3W]S1<NM&R#CUW'ACV3WWUNO?GH8SRX
MB-.'?V$GXO*B?VJ+B]?L7Q/.Y.UO^=#!UK_S8\ZI,IW_&1G]\#(JWQ_B^.4_
MOI7QWD_/OE5+$:P__/U(YOA-/WE/_GLR>O6/;^],QG.U_[WG;X[U@?CTW3^^
MG<OK^7>+W_3=#__S/__S]_EH?B@_*)/VEF3Y^W>GG_W]N],KTZ2^^>'O=?3J
MF]G\S:'\X]LZFAT?XIOOQY.QZ/U'K[_O!\KT].6H5ADO7NKWC]4'34=\>OO7
M\Z?2_O'MB(H!0\5[L1XL2U&O$(-'[RQ:7^4_=Q>/8O47OR7P&(_ZK67T_;VQ
M/M^;._IKIGCX8%SE]?^5-]]^,ZIZZ>I_?D-W)Z\>NJ>O7OA')_77>Z]^^;'\
MNO_KR]\?_?N1>?SK_5]?'/WKCT=__"L\.KH'^\\?_[I_]U]_//[C\<'^CS_Y
M%^Z?OS[TCP]?_#&!1W?O__KX[HO7^MEOC_YX9/:?__-@_^YO?[SXXZ5Y] ?_
M\>+YP>%C]WCTPF;ST/WRYL6_.?[RXS]_?>S^]?O^W8/??OFU_O;X[N,C_>QH
M__E/?O_Y[=\>W?WMS>,?__7F\:\O7M4?[X_HQY^B/H=>^\7OCYX_"H^/?M9[
M_N0>N7\>O3C2>S^_K>?^IN?>^OW1C_?.SOE9[Q7&OSR?O'GQ_%_A\:^W7C_Z
MXS?W2_]]SU_\\>+HE]$OO]X_>/3CB[#_G,.CN[=^?_%S_N/A\WOS1\_,ZX?/
M7^IG_.8_I56)U=N][!*H4\]^#[M[MSEZ\@DP$7W[@]$_.8=0S-^_NP#J=6)\
MYV0Z58#OCV:,AR\$I_?&]:YV8]]^<VKS>H?7\^^K?K)WI+<]V*NXH\ G*6#^
M1 $*OJ62:(^-TW[=0MPCPK1G3()0N802X=L?K/NNNX4;0W^I7=["?U\_F>T
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M,OQB:=I#FN*C.* "6%P )\8V;V-)<9OL[]:XGGV]/S^0Z3::(P4)WFC/D<$
M,Y<8^M 7QYJ\]BUFF\SQ9N%<BW4RN59BBLVD"#:7DH(D%Q-VJRVT#C@WM=W>
MU6A/9/JLR]OSMJBC5_H;WCUT,5J \\DY03]3SOWI_/[A71E/CD;C]UWVJJ+[
MPB6^N_CTGU*3&@EFE8ZQU4  0?632TJ3H%VS.@%K;TY-?J[-+RW[V5P![^?<
M^^])G_N:'!U/QOIV=M$!Z.='D_&S^81_6[W57XO,)15'&!0,GPDH%XI<H$]#
M)$ -/\O60'.KUE$?8\'#)SBJ#\9W\'@TQ\.!P)2!!!R'U('QSE-#RP)&&KN
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M&PI\24*$)IR]<1780C.&8FADQ/>J1MF=5:7:["#NPV5P.F)/IOWM\?%4>+1
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MJGW]N)H,8,A$&((I9@"+BC>"&A\>QUKL3F2>GDB]-';U<(0T.AS-1Y_<R3I
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M5&YL &J%60:S=NM<J6A_I4&6FHGB)!I=Q>)CI $L)MD$'7XMT$CO8!04;I0
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MV7;QB&,(I)I=":2*';E$&W-R+)PJ!;><H#[CD=WQ:/-Y9*_.([NZS*(AV%Z
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M_%#VVX-Q';T:U1,\?(OFX\E8CHX/)V]$[JK[Y/ED99OGOV[JL%+'8R\ITTO
MN5:D>AM(1%R(Y,NB"S9&^;2W?+%IU-DT()WIZ+@K+0J[=.B7]*]0:^GKK(LX
MR$8H!P]"E0KYV-H ZBQN1O^ZPKUOP%ZE++//5"!;2Z"BQT .#IK-=4BAS*W?
M<5K_K&KOG?GD9_,)_[:_6+6QC7$*$RM@1K)( 8:26S%>8>/8%QYQ&U"<LC%
MKF<HU.9"JHM*%5*+1$)?29(I+7F'5(9OD4]%0\P1SZ4NH/QI/)K/GC[[:1NM
MTAO72ZZ5U+B7P&S%MZJ U6P:V6K*\*UR/6"NQS(Y5\* T3L#)?CBBVLQ6NF*
M$V!(EJER97*DGE1;HI_Y_G%DA5;Z)KY;VF3R2@XGQ_W8>Z^/]6I;F<FQ1)<
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MGGL1OW56]Y>9I2\(^)+8NE,%?]B5=SO>)YU/MK-"CN#=K-=+"XRJ&1_2KC"
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MP)3'H$8$U#$CUTY,09G%[8A3+IRM=U]&BO9BP9Z1XC;7#GI0[,CYV_43DD1
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M2Z<7&+;[BKZ>[^PT?M%GOS0FXLS3UWYI*-9\?_[ZN.^+2]'MEEAFO**%3H%
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M2-:SY^("]HU;3O01=/41I+7?5J)<47=&PX\:N3%69?Y)<]"H2B1O7"@U>(G
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M%_+\FGS0B,?RW1_2O!B"6LT4L& -\KGRN'5SK^F'-YZG&GXI+?((H13#TIT
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M)8[@T8^?&CC5> N305GI%Y]]TD2SH0L)A;)NIM8*RJ7WA:Y4:;2[:- :!KE
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M#98+XQ8K%2L]_[HXS[AJ61?GO"[60Z8)G=18!-Q[F]QR;\ JZD%@8J2TD=M
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M7.3U5/+ZH-Z4-)DO6(,Y*)V/HTE,P'C#@!B'+8F1>)9+AZ-F)&$4^"Y-'+G
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MD)8^Z;=HC9%1I2<G2'-"]>.+#;SN]V)[^'M:NXHNFTJ7'=0:-'@1%.4A=V3
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M]VXERY0^KR*^O2[=M,U.U^_<L$Q9J*98J(Y.:LK8L, B$1HX,B8M5 *#%EB
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MS&*F2F,MW)Z9QS&N[)$W:;,9OK%5D1?3,=(?]90*97CD*O%08B9@/C!0B##
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MV&I1C3W!S=A_S[%OGWX(7GJN9($D]D"8!:7(!"4!Z674)&A'O(>QORQ$.U.
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M64F4 4<^A="N4&,_':4)+VM9/M:^/\S'VH<+CK7?G'&<&5E(ZM,=E(A4?[]
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ME3L^7MN.>+/.EK[OC^GNU30S]RYAR TZ=>GFY4?<_^7-CH^ZZN(U.UW%H3>
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M:'DU/W:_!(_.PVC88---L.ELC7-I;8G11"!O)7 N[CS2,@:DG%*:8R.<QD\
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M%! 9Q(I4^2@=I6<L*/I5K.6Z]3BO+L)__<"VH(\ZL"U^I<#V:YAZ1]/$CE)
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MVFO2'_I9=M[RU/8F@+:E2:TZ6;F:O?O=04J'+'>U?/-,=H4,[WMFJV3PHI1
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M,/ZS&> ',L#T@@$^L"DG+V\JKVQU6%4C@.8O*D>E QOE]C\S;OW?DFKDW3=
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M^V,[B&&S8;NA8?NQT8^I$WU.=MGN-H;'L9$]^'N==J@28/YF.[;K8^/]<8Q
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MQTH67N[L0_.CPS0P\D]ZW7AQ'S;^,O/Y3%6JYZDX.0VF+J'<&)6X,LYY(DT
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M];TD]TRYA#!A/A]Y>V0YSVF$K='8*^](W-B6FY+1HJ@6."UPNLYND\7T?WA
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MB[:Z&K>,M<C8J\<J0]7@J_807N87\6\&A7>D, ]F/%57FMGH;KF//1A4L?_
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M2B(M2N5#N>A4>3[V/B7M))?4(&>, 8 ,%CGF)0I:)<,)(8KI568.*.!8P+&
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MC9VMQL[T]?P>N'L W-RP@\T&O*S7C?7M#1<[O?-->%.C=QK[MGIJE,=\JW$
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MO.QA3EXRWNS(!S-@-F9(&QV!9*3[\1G(Y9E&]8K!>!OM#F.IQ?K5R0F\!48
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MG-/*SS:=4+NVHK&%,I*9VIT?6T6R/Y-^>NW"P0T)!6@X+'B=$&%Q]Z)FNCS
MT7:632VN)\T"$"ABD,6I#D,L3T2#W#>=?5'"/%B"^WUSUV<$Z<-DK*^)P5;-
M9)_)!WG&H=[52MNNR4J?I#3<+6-\DAIQ\<.T!@BMFW/UK]&?MP<?UY78KF2R
M KQXZ[GB/BHMP UR'%/PWRW7([Q&,EQA=O>/H6Y?-KYO'R65M*+8(^H]^#^4
M,60L<8@31:3622A)7KRB:\)HL(TQ"J4,^+R<.&$UEXIIFXQDSEI5G?"Z3]@?
M*:>(EA:C%. 'CY$@PZQ#01BC<F)KU.%'9K8_-)=7.-V5]/"]OG]\1+SDU.B$
M%,? \8D2Y!A6B+#HC%/2$V.NZ<%:G>D&GBF+Q*J@%**1",0MQ4CS))"1/NED
M(M8JOGBEEO#XDQ#KU?%?<_RGGX^$=$8H"B<O+$=<@Q+76$8D7"!)2H$=3JNR
M='6FCWNFEBL1!3 R#BF .18,<I)QT-W@SGAK(YSU%>&4!ZU0J7I+W-A;0E2]
M)1ZQM\1S[16QB:5AW(6(@]7*>,Z5)\Y'[;WR."5CL#7+E415&K8>/5$4JFKP
MXJ+W#$7*#>)@ZR&'54",6\6,E\31E75_=:R/?JPQ,MAQ9U%,7"&0" 9IF3Q*
M41)./-CY4K]XQ1>K41^L!%!*'P1S2?.HN-#46*^MDE9CJD#.IF&Z A %NL$R
MK,H=5B>)[Q^.@,V54L*BH+)%Z"U#U@2* I.:.J6D%C?6.,R4 #X-$/\N]5K;
MY0B'J\JUGL:#WSC!8)QKT.WDJ,%0NP_'5RQ+4"I@^S)W>C:AF=QZNL4XA)9O
M=47AY-([7!U-NV]1V6K!N'(DQC@:M[:>4%-QM.*FMTH*[RXQU19B;<^A\F=[
MTKCS&L*Y?1K?%20VF.6*HEM[3D6'0X=OEA6"<%%PMX:!O*+P!8YLNK)@/BHX
M*SV+_(H1;]U^P1<GL3-38?#+;+KAKP4UM:_M5YX+58H,#SB_<</Q9B>5K<$+
MDFJ73]YN=W-Q4$ZN_Z>;WV[E/N3-3OG^<-69ON#5LJAEU$1]5#;4'0\F*4I!
M,\F.9EW,5.HLUG/D59=7FRWKS*VZAZ-O5@BB+T(4MRRCN&DBS@SOWL"L,V49
MXWJ.^3J79\"F^W>);:]0WW(%VTZ&=JRM_H,J%BV7TF)/>5+)6.J\,L8*;85Q
MP_Y)!..J_F,-N;0'L)Y=VOB>KP_W.CZR1B;&:4 :_!C$J<AIM1PCD4*40D=/
M)+V^%&1VW,W&G7\%7]^.%O:VCRA76*@ OJO#X,HZ(Y!5GJ#$B!)<6>$%NZ(,
MY):X]2V:=-Q03W!G-5/D%7XK2 'TUX^@T0IF63^9?FML']GHJ11 G%)2ACC#
M CDJ""*<2!&9\3S'Q<DRB75<)"SWEI@;DQX3TX;EG? 7S;V*U)DHH@,F4EHH
MK(W5/NB8+&4E_I*I!=T@VBK\Y5ZT B*-6R8-B0QA8T"D14:0XU*AE&)*(5AA
M/;\-%+/,F7B20P3N.X*&5B-H*'W4$33E?)-Z#&6WA_L-GQDEP/_ $HG]J^;2
MC)/Q[SB69OS]Z^>4%/>?V<.KKG/-0)G;SY.9W>&;Q\F,CO[J43?_7#MH9KN$
M(4H2[0!;+$Z9"=W8GZ^6F.]), ]VY?JA825(69ITI4(<?_,HOS2?K,*"T4('
M2ZS@7EIME-#*22>P,MZ20C?242NFA7G@2W1CHS#8]M*,<36K&T$:^%Q/>='M
MA7[L_+SZ<:8=T\'%WH<CR;D23GH4P;A'W!""X& PPLHJ99Q*@8%^'%PL49!7
M%'D-2SJNF^U4]%9QE[>UWHNQU1<S\X1&O?2N9<!16? R_AU=M%CXQ;3TSM]:
M%-CS.-041+X:G+P(&G^*L=;H@NM,S%8M\Q_%OW]Z^[[^MK%? WK?^UC?WM_=
M:Q3OD-_+FJ1A1Z'9HKWG:8',H*]TW.!O>P:,'AG(3V,'5HD7%2V@BOY.[2[0
M;8$<SX]H+!MGE7VGID3ZJ-E+07YCM_PVC8!6:/]%MZ[ PHNQE.5J"O![&IL>
MLV915C4!Q@L$J3F+GT^UK!E!Z2]KM?? 6YWE@8'9#D+71AY60<4GB/@=08CQ
MU,H*\+XC6SQ^AR5:G,[4S) U@> 2XT0EH0Y,(4Z"U)0SXJ.0Q$MC0YG'<YTU
M5('@=[&"OM=WWE[6P0IRC!J-$Q*8<L2)E<C9Z)'31E+M7?(ZI_ ^% 3^T*=?
M0>"WHX3&AR.C#+&4!"2X<XA+(I'!QB,CE)#)$F-%>/%JL<?(OT G91$U2PG%
M*;?/6H7.FQ]7/31A9[7GE%8'*S%+\%'KS&)V]R3$7(CY9O]K+67]7"K.3N['
M4*#I_PS["]Q">V<*OBC"?:D/9@68Y4!BQ76*I2YMUIN3+,#H]L4*^M/="_M
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MMH($PE(I$Y.5RG*N&7<X\42YX?E_EKC;IF5>;Q-5DF<5R</GVZ5Y+JTG'(E
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MQBF"@J$I.1V,8#(KT$UBS)^O6K71'6Q A6IUC>H:*U_C1P^^FVIL-M-34A8
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M5#FG9076;1H?+^35V>2Q%@%%+2+B1"KDG%)(*^%,'OH;":_T;\7'%5CWR'#
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M#IB'ZH+D3F"ED!.YKV*, 9G@#'+6:L=3'K,0-T\!KRFS[5D6?"8BP!-R6O/
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MA7ZPX#*D2(53D2(J">AS; UR0L(/+:7S20J9S,,$U^[%.YN"1%<"?#.D527
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MZ,N4G+N#/;R,\#YW<I+BB-C>C!?]+E:(>$%G_CNX03IXA46DH*$RY.@<1]J
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M871*QDJ.WFX[U<2T8H%Q;[!1GFPUOALT!%BZ<8+4/>,L*F>Y491Z3!FV7OG
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M;:AU[^ZC#GOJ9%"8B9RI$%3PQL?>HT51,"YX5=+'1XW>>-U7<(7]I_/F]X\
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M8:)Y:%GSTP?:>-<\;9QM <+8>!UM?-^EQ_"NX_-_VD=G,)Z8O[3],0=;UO)
MI3 !R9QYQ&A02&N CD*1X'"!!2:^%!/ 0MYMQ?1N&81CA08KV'!&9&X\R6.
M&SN'E</F1>8!QB]@:P:](<#-P;^W]G?07UL'.]O9F[W&^YWFP=;A[EYSA$(5
M0;P>8]"/\5P)$F?#_J 5KAY>W)*1^V<2;RJHN77!IA<XR-QIZV1>*& &QQ7H
MQYJPG$H7!*4Z'BZ6-?15!@S!-K)^).K3;AOPMI_IBXM>]ZMWV>#49Y$-=.<J
M)8<7?_;3]=G>>:=EAOULMV.! 5I??18%<O8RWA"O)/F?Z;KX;?J,__PCNSQM
MV=.LYR_:VBY_.+[CP_'TPT.WEX7A #@W\_\[; VN,GVI>ZZ??>[I3FSM:JXF
MW[B9'5Y_R 9P33_X7J\:ENV>G\/"IT6!Y?BJ6^TH(T#Q@?5)5XP'D VZHR_*
MZ99//M??6N?#\ZPS/#=P2S?,/'-PJ@=PT55F?-;J]X?QQ=WL0D=AU8(Q#?K3
M+RN?G5WJ?IR>;L>KEZIEY3MF-#,BG>(B6&<+SPHJ%-/><BR4(187P9WLQM?D
M?%HAVVV^G<7(:_R;1,BM'JSA9Q_Q\*^K.8C<BGO13&NQ%]*O_:WAX+3; [YP
MTU4?L&+(=0>H&L-8G<N?';A^R$\L93SH0) PN4.,8(P,909)51A)!<DMQB"F
MY09 4OS?G%(V378;V45[V$\TM8PP%Y$X?.][$0_,<!"IK*37V%*ATQV4=[2O
M0%)GW>&@/X#OX]\5^\6K;GJ?\? Y73_FLLC*/3_L^TR' =PS>A*P-GR$BZ,H
MWHB7!=]*?UH-4-%NQS_]-WL:"=%EL0G$$%@Z#@\^+IK8(IUO4G[,29$*J*D
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M&L \8I\65I=UIVN2Z&C'Z_;$@M (]=C2A4W&&#; ;"0EK>F3>"%L"K%#A5(
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MMQA%?O_AEC&\I= =G'5Q^*IS",.<C":U3HO!+^C5COET)D$^]O+;$7*<YT;
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M!8NLG$6VY]M%D=C^'9V+E@:BPT74K_>(T!WMOHV"N2=,UL;PZZ'VD4WA5K1
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ML6GO6\]%Q<F"HQSE%:%-84Q4-L!&PP$6"I?X1\O [3/A" 37 ,-:3=B6E*F
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M32<'M%0EC 4MNBJ@^Q!V5G&!K6\V./Q.45FBXNH;O&ITMP[S((NI5SY05;6
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MED_$4]A,PHTYM@JM9.$#4NW!#],1]6L6]8LBUJ*I$,9-/@OQTQ1VU4.C6\E
MID9LPT<5!ZM)[PGC5<209=R-2A.Q,$A?*:H.>J>,2-*TOA VG&JEIQ)HDJS"
MB!5W:BHEMJ&%^FJ"M H0H*UD526NC3]1WK*DLS04$B_$4I%1!Q1)\[.L >F>
MJZ)=JB\EVK)-8#E\GNGYZXM&#'5NI/:N[=Q./H&X^%K[&V>15%UL.YD?.EF:
M>YZ?N"P&11#[7N2QF$=9FITFT8L[3SV*Y'CVF^7$9(@]1.VLDVS]'/1HW^.5
MD6J->#'[+4!Z1F&/KB(# </3M]/$\[CC(:]OP@L_##SFN0YSO)P3&0CL94$&
M(DE]VT?A,2<O5F2AX=F[HAAE7O$3>,R;T23[\M"GW$*=<G]\/GKWZ>J?D^UO
M_^S^\?G@\\<+^ V<5G\YGS[_Z1W *?;I\Q]?#MT#;^F4NSCP__G\9G2P>_@%
M_EX<OOL$XQN-#D_^+@]W,S@]#\N#BS^]3]]R..7VOAZ>G4:>741YP*VB2&RD
M]W"MU/$2*RJRR'-9#D>?OX3%]UTW3KF;QJSP<]=GF6-GJ9>E/C9/]8(7 PZF
MPQ3=R@J,C-?'>^\.]@Y/!ON';X\^'FR?[!\==ME"VCNSWS>Y]JGM4=J>P[."
MIT&8,#\(BY0%41+[S"W@#IGC/&)?9NW>%3),V3,IU<\!B;/?BP\F:H<QU4].
M66,E8"#J>#*:L<;F(.HH,H9R+A@<9H,I-MC-D)^D8N@S2,X\710J8D"YJ!AM
MQW]T?KHG/2T86,_F:!B-V9GJ#H9$PTT%(%-<P#(W3*1;-?;N'L^:UYM48 V5
MWYBPWF#.JSGVV-$UGK.K2</9H4GR"3,H8>G*6*39V/]PU"&R,K!,!:$._@O^
MX$R\\5+56X/Z.4>;9N\KS^8$%#X2M88ZJ0 N8Y-(P,KL%7P8XCY'8F)@&+O@
M66"]^." ?4&@;=-Y6\]DRY#,RX+ 68)R2H 41>4ES;$QZ[+LKVKV1BWWADH0
M@&C!+<L9$XR/%2>I5_#HOM&?EVB:4GL.>;-F@23TT[Q+SQ*?3Z[ZYP5<;@WF
M_FWPLGQ%/G--7J9^(?B#W#-I N*8S^9@> Y2!D\9PL_@=Q<PD[6N2<94QD2R
MA^1RLH6-!!?#U:*K$V'2)!RWU%20R(5=*E(?.9-UFY51F%YR!8:2.JV\U#PV
MUXN8?+VF\+EQA'K63DQ-JS1(OC9Y%$/Y5OMHMH_5)GHI0AP@,NW//WY]A3^X
M?"4WRX'L"4.S Y_NPHM4M> Y^M!""XQ!Q2U)P""?\%JPO<&;9?U%K)6R-\CO
MQZ+6F9(9L6-6A@?T+T_QHVYC/2]/XB#.F<,"/PO!/(V".$K#-+"C)&-.KT&T
MMLN!:AVO#22L7G@B;>-_LN%T</()QK/O'G[[T\8Q'6V?Y@D/LCB)K<C.$LM/
M66ZE/"PLQXW2R(Z<( RB%0U6NA(B=9$,TQU5,]"NNQP7 0[B,ZQ<49)(E2'8
MHP]KM*4LY_K*1>?.@Y<]]WJEJX<-5@O%AM&W'_3#%0)3;*7.H^1-"5\^&?'N
MU_(YN*O:.U'>''0.53_+RG*S@135<\LA5/R2C^>2+D1]*,M<&I9T4&9(KD;N
M--6=:_XM^9K-[=0@&R7_#.RJDY:.+=$V4)4(B"B>F@&*KO;2:OCN\]!R]9S^
MF?F97O'*+$&_K4U63OA@;;JO]YX=7[C/N,SM$EHEUP]))R3M(='30M#9(5:O
M-NQM.=J_A5VXPRH^-'BSC^<@3>J0/IJ>S\[9Z*+,!A\$DP.?4T^'N@'//::5
M^JXJV<W&^7D;1X2GY89YV.ZOQH81.T71K"/'"'SX;G]9UC?"]?"#6BU<;2?D
M40K9L E(\*\9US;!"EW=H*!!*0L+CO$:?@W*V+!$+Q$'/L2L:5WFO)%B_-6'
M.:_ #ON(T'&X?UHQ2NI.6VI=/VBH+R!*47C*B@O%,7&R8X"I-YOD*6R27C_@
MT9HNU\C\&J%;(5,_-2/43^CQV,0%!K5:7-:ZI@])BW+=^2T"6JNTE[R685(>
M[S#F\TKX\B95G>)QXQ6;TBT$-0E7$4&M([7V%%&ROEC"R]SX)QN]:FM2"I:A
M9&*!VN(^#(]'XQ8?M^(%Z!>GHE/DV C EF,BMA2M<>AT%"P".@U!2%C%+&EP
M9FY1]RK!HEWC"M1S.#YA4;<O,,;PS;P#&Y^5&/,4C)5#"70WVD7 1]E_YZ7H
MCV%1B7!-X5M.13 "1*6+B]43/W(5QJ 2*1SJ625[:1G)%/SU_H<C\2MQ?))X
MO13O_DIUS,:VWDB9*('LW:+?"Y!8F;9H1V(0#":"^[+3QU?Z82U#R>6,"VHG
M$?ZFZ(O\?4.X:<3!O^<\?S2RMS/!4@7,Z,AIK#5L!%YQ2%5D,)N+IF?'RL6&
M289519*5&?LJ.H<368^1BUH1VU$Y%JX@%-F\:EIN-GW2"8*A>Y(OT]A/B)MR
M9*YQ^XDJ_Z)$1V8HC#N0P.F<CPHZ44'FLEB821$B%5.)H^:5A^9@=)0>23:,
M.+[8;KI# '8-&R+=$^Y/:?TB&;$EU$*KY[M*].0"*P3_4.N)NPBV5XF#(TU^
M@6AYNADJ #FK Y&A1*[.@=0>".+EK7>#^PDUS\0.6Y$6*HC+'F=HQ$4YB@JB
M;K#FUV+-@PW6_ &QYM?B,SIXCL2.LB*T_31+?-\)D]B->.C8F1M$OF=[P5/%
M<RA3Y*.9S_@@\AA+L)@?"9&2V,.CH@N6VF\(>]\LY)>_,&QJ<7AU&D:)FP0Y
MMPHWB"W?X:[%PL2U_-"+?-]V>1QD71C48Q?/]99R*]VFTFS$L,%J<?*(--/U
MV2)\Q6#5*TH 0%<[C=BTYK^I/WY'M.B(+7XKQS1@^M'O[3GM:?I,#Q1?-PH:
M=!0IZ5D%_Y^K)\NOM^BK?\WRY>^B:,N/G)5?VUNM[V#D."G_YX7W0EVGW@&V
M-/_!5ZX;6>>[P/=O^DXWGJIX*XY6?[M^/ \QUIN-YU\D,=6JI5"GHSUPZ R\
ME_6]]J;)TJ7N]"M>_/N2U;74$ITVQL\_!&V1ID:BK8,)$6WMM8FVM#ZYQ:SW
MO#5&D7[..\>WKTFC27B)M1:B=*1^U7KK!]<@WR?@4H^CXH=K!V12#M0$/RU!
M1>OI!DMSHS?^Y6;.N<U63EGVY:P"!SI7[DF6<5X4ZU[[Y^WQZZTG6X"UA=7T
MVZ/?SM=.]TVD==4][FT[/*Y!WEJ""_J?K@0/\+^CK2AXY,+<2@,_08'NS'Y7
M5FZS:O;@*6B?_]5=I%N]HOEJ5%CYJ-[M%H75=A8%GA=E#'[I%V[&7)?%+&,%
M['L[C>UKX-++A=52J[^M)A=87XU#^$\Y.]\!+Q9[Y>U]E3V*M@6H/S]A7Q]/
M-?7= B;GGRZ^CHX^9_;!R=N+0ZR:?O?I&_QF],E]6Q[N?G&/_O/'YT_?/GF'
M)Y^^'IV\^:)^ \^:_^/^%1Y^^_/KP7\^N?!._C^?,<CR]^=/_]F'L7X*/ET<
M?C[\G#F'G_>"@W<?BX.%[;P_V9L='-OPWMO>P=FI&V>QXR/53IR%EI\DA<4X
MSRTO"F+/A?\+W>3%ZSA.EB#6(CCQ/3M!J>A;[(B-7MKHI6OU4AQD!<\])\_R
MU$^#(LVS(@]RGMAYE/# $TWNE5YR-GKI$>@EKZ.7.(M"Q\U#RXZ99_F>'UM)
M'CI6$8=IQ!GS>):C7G(>D5ZZ)\?KJ9BM!.]]@N;J35T;]W8KUWM$/&D]ZH9)
M%-IY&+I1YCMYPHHP*AA/HZ3(LMCU-O;=(].CASM+]IV3>FD4N8E5Y&%A^7[J
M6LSW/"MC<5CD:>AD1?;BM1_ZWZM'U^BR'V7?;3;R#3=R%C'7AA>%;9SX7L1B
MF[,\R;.0P_^[:;$QB![?1NX:1$Y8!(Z=%E8 QI#E.PZWDH3;EA_'01"[W EC
M'S9RY#ZBC?SSXW@799Z/^ /MR%9)RA,TC*[QEV^D3V_J.S]I?>ID/,Z<(@BC
MW/=CVTD2ED99$B9!6!2A'6X,H\>F3X^7#*/"M1.W"&S+<>S,\B,GMU@8!):=
M>VF:A9GC(Y61ZW^W8?3X E^;C:PCV"DK"B?/(Y=G/OR1I-RS\\QUO3@H\BC>
M&$:/;R-W#:/$34/?C@,K"R,'S*$DL5([8I:7^7[FL9CQQ$$ZT? 1;>2?'REZ
M4,.H58;X! VCC:-Y0WT:.$&699''/-OWDR1*@RAD3EK$>>H'S'<WAM%CTZ?E
MDF$$QBP8L2FS KL ?6I[H$\#T*QQ B(<^#'/ M"GC\K/W.SC>]['2<&"(.!I
M7'B![P=NXN0\CWW?"2)FIYN T6/<QUV["*Q8EOMA8B5A&EF^Q^"O) ZM-.%1
M[/GP)6>/;!__8O&BOG+[)V@=;;S-FWJ;GF^'1>'Z-OQO7+#825WN.BQ-@]#U
MBDW8Z-%IU66\%)BQKA?G@>4[6)9FN[Z5>FD UI&7,Q\6$3[!L-$SQ$MM-K).
MC-L^C_P@CK($_)P0C.4@]?,DM/TLR'W7V9A'CV\C=\TC-TI@L[+8"HK0$_'?
M-"E2*W%=-W8"QTFC"#9R\IS"1O=:,_<H0B_W4GOP' &>MW[_9Z.<HYA[=F%[
MG/F!'X.3PQ.6(((I#5F8\^+G6%E/H@'8$]#<1\N0)I>'$?>3W,KA]+7\// M
MYJ;<8@$+,YNE<9 &+UX[P\2)[\FWO4VUX$,&L#;:<*,-NU"%W(ZRF+M9ZJ8^
M]CS,DS@MF.VSC,5V$OP<4W6C#>]-&RZE/U,GXK&76V[&F>6#.V*QPHVMB"<<
MK%H[36P;[-BA[49/11O>4QCP4>NN-E'BDZQCOFFXX ;W,$3*FR*YW!S9:NZE
MD/EA1_F+E80\]4KF[[2O?@$3ZGE:2?=>R:Q[L^T3WRMVC-X8.K>I"#S9GAT>
MVU_1V($Q71U^VS\-_3#.XB"TO)!EEI_!8K"4I9;G)'81PP+Z@8MT*-\=L7M\
MR(2-XGFFBN?>2Y4WBN<>%,^BK7B\-+,3SXXM._5"<+&"P(I3/[(2/^>^GZ9%
MF.2@>+SOSOEMH!2_6BWR)N7Z4+7(&T7YO8IR[_^R]ZY-;25+UO!?4? \9Z([
MQN6I2];-_081OG6/SQR@NXU//_87(NL&LH7$2& W_O5OUI:$00(;V1@+N\X%
M Q+:M7?E6KDR*RMK2:%Q$$">3#$N8V& D)F70C-4-$\*+9K:M$')+ZXY:\41
MZXO4&]]LW)!Z TA=D#1)60L@,@-G":E".Q9<#,P2SQ*A>N%J<:CZ\ISQ&E4_
MW#%)<]=W$[=B^V^UF[@1YI<2YK,E:1.B-,[QQ+14J4H;SE"B8(BV&.V+-! W
M-OT7MZ-:O]Q3 ^I7VRW<@'H#0%U0-C5.#!R0&:^Z[6N6^: \TSF DQE# 5(V
M@K=D3=L.W)(V=VP[<"/,+R7,K65E8Z-13B"+V9*RL=8S+WEF2O'(-2=AH\WT
M4+>UB00;4-=]OV\#Z@T =3%GXVV1.CI&SQ\9A&@9<:AD)2E3MR)IQ^W&)OS8
M'7';AMZ6N;F[&WH;;7XI;?ZQI&^R4L'%DIDK4C%(*3&OLV'&&"V+L#95VA3Z
MIC:+M-3-&B+UQG?L-J3> %(7!(XMX'F.DFFE:DM&71AZK5BEV*2+BB;Y6N#'
MUPBI7YJZN8-;<F\PJOJR#6EWFI%N?)MJ8Z0O9:072]H!0SV$1'$6T5#(9;AD
M(51N,C8HB]J2G-C8=.*F"EK69J-IP_A:;KYL&+\!C"^H#F]+""&1ZL@^, !O
MF!/&LJ"5S,XG)2#7E=V;:@2R?MLG[^#YKX]'XZ,102&W],H=H\^?5ED_L@F3
MQQ12#%!\#LX[GH3W*F@4.E]#(TWHANF[1J0W3:0OE\12"9)&[R2))8KA0.?$
M,+O$LG$%=0QH,F%%^.6.^DN'LK<<RUV$J]<FE^B5Y+F D@&3*B'3U*LB$$J^
MAMQI</UZ<%W0/<Y[;V4$IBRW!-?:^RP9Q5*TI5@NHM&<X'K)"8O?!*X_0E.(
MAX<C&LS[KN:W-RJ]_O 8A_O]VF4 )Y-\)Q>3?NPU^%7H,W@./'BELE @8O;$
MHD8K5%*@4.DZ:F?*FN$@/CAO2COEV9DA/>SLZ$.7GG-O>S@8C"))ZK0[FC7Y
MF3P>38YWRF^C47H^&J1&N2M1;EQ22) C"FD,LV@\@Z* A1PS0Y<QQ)PXL>W&
MIA++">[K4VXKLUECB,<@BS?6%&X-"/+ 5F<KC45?;/"!7SLAU""^+A!?+#\F
MW>3)X!@:T Q<M@QM+,P(GE#Z[+"6'RN]O+'JFT#\1\@55=M^UQ\,>OW#(^R/
M:]NMNRBD?NPX]%OIJ+GQ/#NSG1I\;H^.*1(E?LWIV;#CVP^O/S[ \7Z>7&QZ
M6/I_Y\3>Y_&H,>Q*#+N_W :(RQ0"4:JS03 PAM-W&%@P5N90=^?4QMW_\7^<
M%/*7-:H4:#A?:S7U!4!O@%X-T N225I21M%()G@D0$?(+- 4,@?"JI14;9%4
MCZA?WK'5$E%?*Q%5+?V\7KK7ZP]G\41O0+CH$3*G*:G>01ZDZNMZ$T+!'=15
M+7J]=6$U3^LW0KT!0GVSW(9'"LB"PD]?N^2#EJ200&HF4XK.Z@*>)F9SN=ZY
M)9F^"YC>F"QJ,+U9F"[HGARUUQ2S,$>XK(5'@3FC#4-#FB=ES95+&YL"U@2H
M/T*JZ,\\.1Z?Q..3,8VX:I[CO#_N,J?W>I-\A-/O>SA,O6>_[]!CF+14TG?-
MI3>:2[I@73,6?3BDP+)_W,?![R=AT(\[I>3NY6I:C6)7H=C7RRVC"Q:CZ^'5
MR*5C@,(RHES+1.!:2J# ,P>B6+4>D66#[]I*H0;?6X'OXHYW:8(+(3)?ZHFK
M7!)\$P4RVKBH32965HK@N[S[HB6&OA+X=HX/\KCF@D:'N?=3_OLH#R?YYWN]
M83Z^@SJHQ92WJ(.N*NVL%K50W_ET:E?;^;A1Z$H4>DE+9ETL*I^8M  ,-#H6
M3!;,0O Q1F-<=\SM>H28#;<WW8OYIE-!#:TWB]8%P1.#+9*'S'@2BH$I=5D[
M!Y:RJ:6#AD/7EOF+-\"WM-!JJF=N\&?*IZZ!+5'D'5 \-Q@Z_L#[>F]\(:SM
M;_E2+EWNV!R34J4@L)ARFC:"==DD9A%U5@&\DX&4C_OBQH9W[)#H'QGCMYP[
M:KO9OA[:%Q?3;/(*HF>U%V*MNQ8L) >,9QF<CC1_N9[1)6]@-]OZ;>"_@XFD
M[G2+/#F>*:H[**5:$/JMU-*SX5NRG%J*,"70N2TU$EV)1)=;01L;D\X:F.8V
M,_#&LR#I.Q^-$C;88/BER:+6"?J[ >N-9XP:6&\*K(O=$D7PUMK"@J[E0]9I
M%H)%9JQ/1B*7'MQZ@?5'2!6=Z9K9VM@=%#:MO. ;*INI]<Q2ZD]R:#RY&D\N
M]W\6PB:A: J"S9)$303F331,6,T#@M=<U$WW9DVJ"!I*US"1TU!ZXRA=+/71
M62J9(T.%AD$IBGDHCCDK#+ADB4_KRI?YDF+H5NNS$L;^-=OG14.D(9_T)P=5
MQ=>^1(DL_@X*FQ8$?BM=\QOVAY-J3WFR,WQZP9YVRI0_VV[Y&^#5Y0[6-A8K
MG;-,Z9(KKW+F$@(#,F"O7!+&E!O;+=\2.]^W#+IB/>L:Z&XH7@W%BSVJ?28B
MEHG9;$D=N4#JB%,@DPS/+D=A@N,;F\LKV6VCV%<"WJ^C,?U8M5$\P.%^[K:$
MC6IQW!W412V4_/9ET#.#>GPR'N=A/-T=TQU-QU/9M9+KHTP2*>_BWXU-5V+3
MY4;5V4<EK55,YD":2(2:.8^:2>!H>4RBI+"Q^24=VEH^:'V#FQM/!S7H?D7H
M+@@A!$ =G6%&9ZR]@CS#)"1STAETG%@Y^XW-+SX"M66*5L\4A<[(>T?CT=O^
MI&*P]@2:U4L?X]_Y+FZ4_T1T^:F_FU6*3>?F@2(+2J.3VLU[/B5?5E^Y=G;P
M?S_S+)R;>$#K[9_60V1^J#?]=3PZ?$P7[0]/Z G."E)'PYFGFKYOMX*6PODQ
MTB3TAS@^?7:<#R?;HV$=[G@T&'0EK*V<XS,\VW)O\""-H7E/#+RF$%\(SGR0
M%.+G(C@&4J6^'C5W SOU;@YTWSBYU^BWT>]=RI,V^ETC^EWLVXY60A&6<9Z
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M&N8B8%"Q2)=JIEC=U'I\Z^:^AD#V*G#P$DJ$ EDHY[3S@HP:H_3&E:;A[P[
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MCF&>+>6+R9/[ I:X13K.0 O/$$F)%[22<R=C=F9C4ZU5=^'6)OS&F_,J+6+
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M ]WAR?'5?W+NYF(F<(YOGS=D'9.R9U,]?6;GOAZ,YZ,YPOW,PCCC&X:%!OL
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M1O<!'T3RI0U.!7H3B_&Z* .&8G])XM@0>6I>>+YB_]658GA U%[[_E5<S4_
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M99CH\,"KQ2FN605G=#=];-8ZO\.Y;#,H>^A)#7K2^7X=U/]\&))'P'4ZK22
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M!RQ2D\97W/7.LSC<&V/DE\R'4K>Z!2\]H6H [$@=SE63P&@)-_ITDHR<,Y6
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MJ^D5%RG899.<89[+C;- EI4_$587<'=%PP>%;2+)\$).&=,7'%^_G@HSKWT
M!J7FG>2[8UK%\L \>W=RW#QZSE-I82NZ9Q[7MN-\F&ZR!=:0Z*I)6^FN%DF9
MQV2$_B:K=>*MUE/4,YO;0?Z03JV['^W_%Q2Y2%<6L)(7L&09> '5I;@.NA]-
M :(>?4+21@7R*0$GE*\,-BE\D)?81<C=B%Q;G8GS,6':A@3^VKC5-]R=ZW0-
M1U%"3:#5)0)?C&""/L_E9K@;0F[:H+)8$U0_1<%[1-$45_"._2Y&(<5#*3T@
MP Y1Q)B< W\4).6,^_EA\#1G$%8Y![4;V%,\F("V(ON4#@ON==@ .=:-<<]/
M7YP).*3!-=G4B4NP^GNRW1]*0C0/A(ZGTNY&%*7N:\8GU9&*D?7P' 0@"711
MTQ']"%6-PJ:.F 5>-PX\FV"C'CI]<=X\QKCY-2(^U1I;LVV;::K[X>I#K(#(
MB>SE*,>#;\GG;4/Z/5/'^:K<P2@0:$8!Q!KEV%4:CVH8@$/:%J, 8QFM/IKQ
MV2^X7:W6Y@R4H1_!42ZMG-6DH'Q;NZ5[4?%AGE\6X9Q"2HIX$;";9RF/TN-9
MPO*G5  "9W^BP C:;YB'9<;(KO9E-O>.L)[Z+"]>]KF!VR@$,WU.;=%AZ G"
M 7&C3)(<C5JGTZ'9V)9[WHFQ7M:\3;1IEE4Q0?2+], Y7!1):H&]X,1S'Q,F
MP,(1R0TU4 346Y%@S8HR?1*13&J_&Q]R-Q[.$Q3P>0[>U'G[;0#_PY"EYWR>
M.?J[YNCMH@MK>^?8CF=L/,/@Q4D8X3KN7%RE$;4NOL+Q8*O&+XG[/*[.?>=Y
MN@RUD?"4MLH=Y^&'W#Q$2QK\5_ "-&&:A+8!\&,ZU1X\0O^-'WY'0;O(JVCV
MP(?\&]B(NF\[FOU[.?MJ-;,IC*@PJ6@WO:R9],,@ GV8S^'6[$G,$7>-WE*A
M9M@JY\H]KA"6G\,K!).59#F(1UO'(C%.@,BJ2\%9E9_0\EDMI!Y=8KATW1(\
MMFOPSC#-L9Q1XQ G;5T'&_O-?C2S\I_F6#Q6Q1PL"+?+QU,X%!_?$7A8A'^D
M^5X?W5<?/5N&?X18VI.IY\&KW#0*Z_7_$CS#T(_"MO6GNF6V&X-\RVVS31G9
MZ?%;74;6;'>ZSP6K+%3>K0U Y3#*E,/82'5GJ+Y20OM%& G*-+D.:B@S5"H!
M@,MT<'UN^/\+!3=3B !-E@)BF"6I,E1KE.^=8L8I0I[__>9]R,T+$@.2TF+&
M;$\8)#DY33Y3[;>%I*![5BTK2AXBC'2.1QW"VN'6L/9TZOT5S[4_\E6*;6OR
MSY3X1_QOH99)EF-:;WLWN0WQ23Z$U5*"?LD<0X$JBQ<8GR@)ZH6(@\C0J(KC
MB:*6H255+M6B]#B\<=^L2=^>.J,WV%-G[)7/=U4^@SLJG[IF:9 *B</Y*H(S
M:3'+R\6,<B>@,\(X7(1@3JN#[?K&$O?7.EZ-X;A$'--=TQZ3:DD8B;G?$ 5;
M6B%5E0MGV*7OZ'-1>HB&6E=[E"9AQ ;>HDAB0D>5X51)%S!]SFIDAD,,765+
M"=[67XWA'O9VW*L /)3L$AY\>5"K5)PF*7<%0CDYQKS[X6*1:CY.;9J\.3XT
M%>[BO&SM?; IH9G$_^^G9-1J1[U!.YK$W6YOW E'XVXTZG6'W7"DAM$D^MCN
M#G[:;DH\1D>'1Q:K*&<K[*_$$,X6[#EUFKT$&7R51.B7PC(<ZD1C^6@=P1N"
M,VX* Y&QB;:,W_U'.%_\<JPW-.R)4C>FFE1)&C?S:BF)P2GL3\;5:HV#^?HI
MG"$Y$YMCDS0!*Z'5D"_P^PIO3+G\(*PNS0 6R8)<"M._+BR(Q(03F!1HX+JJ
MBGZ*E<&@[:BC%OPI-'0+S6C)O41,1Q+.F^A@ VH7W,RR[F2#T4+ATB-Y@TJO
ME  F<\)<.5U0]*OJ=L2/.(2^4T2$ESD#IP3F+J)IH8.C*C$+7#9<(D!&JW'F
MG9+U,(7H4J5F1S'7?IJ&DUPTK4GFET['L3GX:5$"4_*'$!%G\7_G?B]E&$-]
MM5FK)^G*B^C8UA"DBTM7/(CD 8X%FK'M@L)M%M%S+)>(:W+'P5S]L*!PN,B
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M\OT<%JI];42M-F*TKXWXX9)*.U<,N[/G<?#W,&.SOD%A*A-ZX/8CW;98=IR
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M>25ZYMS<N?7C/7_O NS4]MMF-*?T@C%-R=F<6FL'4((;E\);TET\OX0#^%O
MHHW@,KD2XZGF5DFU]53[WQNXG=COP6@DI;AHV>M(BN P1<_!/Q#08"QLQSM5
MKMN>#3HL4J-7-0,:/O(J+)(<GV<-[93:Z7#[G(V];U0VHV.<DN'U:: 2 B\/
MKG!G</4=HURVV<3NK[#]ACGML$D&3 V<$U2)9U0DQ5GA.SJ(77\8OV@$V+H#
MU74A_]<$^?F$A-8F)/T-=\6#.E3;2ZH<TQPTA*\:.54LI3Q)00<=-T)&@R4%
M=Z1:U+,T@0M[J;4_,;X"K9-QN>GQI><"Z>(2<8-"[A]&Y,-.#MVZ0)G"( B.
MRCA#W"*R+OH/YN$%S[Z&A^=\)MWEGA\$OX'Y %-)^P6;7H)X3;#;$888JH(-
M;-JG-.)K]NR<YAG)4O?NJ<6Z!/SEA+LPG$3-J[!K#K:+([H'@QOT*>C(UUF#
M@SEV$&'?L<$V]C-R8R.7R$R7T\E,K%2-8 :C6LK_Q[;1<P-6ON)KG*G!?X4+
M52V3J&S81^G1Q;4<+KNXU O,:@P.WNB2-4?J0(3 PIEQ"Q0.);S$;K?M5O,?
M>!U-;4;!;.HYR,B)@!M)I7I.,7$0Z7:XW*;%7#>I\&56CEK2SK2_/>%6O#2/
MWZ?>#>97BE/0;9N"?GGZYO#-T>F;7[U,WU?(0Z,4Z5X.)BU@,+3'[.IHI^ 0
M)&6%=&[-F[R9OVY)KY,UYYQ3]OXF$ FROB2Q.T*W0?I/N4ESLF7J\%+;G(O>
MG2K$63%,B=<59'?M-?]SUPN>3:?-%V%*ZN1\AC6>AVY7.WKK'%M#1]@*.#B;
MI)+;+0_D9?=9SUK6<[P]ZWF7^K3^3_M<Z>,JP#L5O^$MR#8>0H>4PWF:VOO4
M@)P6\K8V8^7TVRPIK$09L+"T*'@U!PL-734LZ(W9+4AT\D6EQK3T7#,A=ZMS
M4#ZB&;VC//ER1+KX;9&0]W8D!2+?IMS^]K@A4\ARS7TI!.%YFY';SG.8*,3
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MP8&4GJ-;UD7B20S_"KV:!XDY4=5%..?F3<*!:.NA'(0 ?B$6'SATI.\QFHX
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M"@O-7TA!G.$ +I+RD^#>:$TN88I!\. &NI5WK!S=S8<(2 OM)-A],X9RUQ"
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M@S)X/U3I1+R@J[>G:3B?4Z,6,:KD(GJ#*HVHT.\*S70,_3+Q<U(:Y*@< /A
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MU UN-)_Y#0K2ZFZ-(C5$PV3N;( N['7,MP4SM/L]&-2@]8L':6CW.OZG&MC
MU :&Q(0K%_WX].^6Z,<]U*D^5I+C;.6 *<2.#A*24-(*W*5L6:R:>#LLH'>L
M);J:ZHFXL\>1!4H;>V2-.+_>P*-:Q+K7C=9E^#M+TM2P,7CGL&OX.W#3T7>4
MPL0$_Q6\*'#"P"C9R^8]9/,;/_R.#N5%#L;Q@\X'-[VP#%#NP1TKS@F'002:
M.I]3,V?#:8\. !C8&.#R+ 2DWLMA_'[,RE1M(&<)!AUT'^GR$TK^:B%,0J;[
M+T(JK\'G *6-3:>6,^F+*(Z3G ;[3;+?)-]MDWBE]:5E3J"*E.**3!4RI;/8
M!-LT6L%I=Q <EF+RL(7S>'VZ.R[D.V4*9G$>-W5\?>$$G'[5G20.K8O_@5S\
MAT4P8-QOT]B-;:!M$@Z:,+<+1LU*,0ETKX^Z5U762$.<%JU:>R):C6/V"[HH
MC#(V-A9E7B3@K-FFN6LQ#Y#7E+J2V.FTY$-.(UJZ'5C<,/M84>C0CFRJ=\)P
MD<J$(\Z $,B^UHV?/7Y<J9AU!Y9X/:W [Y3 EY?:4!C=8; /^PG^8'3\!'W,
MC3.HFY39Z7FTV^ZF4 KVI\K98Q)>28[4>?-ARX1KJ['$T%CHH.V9/*\TS?A,
M(S@, Q(/&"4TL <Q%R]ABRX+_'*?JK>(]LWTK:4'#--8VB!;)NR=U"&,F"JX
MX:(8UF2*$(U5'H=4:-4>_E+:<E<LC 6QT675;,3 .Z&R3C!41Y24X8((?'1O
M.>ZMB(+?$-;!>?@)OT3)VA QI(Z"OA,JO)U6-[C=CLW$EWC_J^<Z/*)K$R]S
MV]7.>AF3U=JT;*SZE<K#PG3B=(NV)R%!]#DZ2B%+&^@T 7V]1#*=IC,E;648
M,HRX4-,\JDP5N^F&B/J(^RG.<_D;!@271&+K/;N"Z;0ZL-8=5_*0.QN!ZX).
MFGG;(=OO=\]X@ V0Z@,7>&![_[ID:K7>GLQPIZ.]5LER_RA4)V8Y ^IF1@5&
M?_U30Q'?ZEEZ^.;4&#;(,TYF,L^!X5^P^JU0N(B88B#@*]+;FG7VO'(W.'U<
MY9,B2?;NQ3V6ACIP9T1[-O:):E\4JQD,>#^K]YO5-W J.CQK;*#14)G:VX2Q
MM/GH,75:J;>LH ?!80KJ&%5NS4S01D8HK7:5?S-CH%) #K.47#.;B$IO>(1T
MMKNMOEDTR_$DW3(LBD[DW 20S56V+ANN?5)B5:ZQ.^$\F"KGS8UM20T4PY2(
MSC7V9M.(_]SX\D,X[!Y>GSN6+=F<3C-8/HWK!#T6Y^#7,1B-4Q(HQ\J#(4.7
MKH2'1?A'FC]6A?2@?O*S9?A'B'TX,O4\>)5SG\Q-&2?G0.BTGC=0Y10JVT_Z
MO29]VP1;=OCVZ'G#H3-*967 AI\1*2"JP^!2I4A?@.;2_+E3:Y]A(1Q%(*C]
M*WA.MB+5AC.FM!V9[/ =7M<\#%YC;X+'NJ8/JOI:!ZW!7W9L'8/K@I6U;//2
MI%TJ(K5Z)+R0N*Y>X_8=_-\UEU\C 9,LRZ]TLBN,V='>* BUHW-?.-GO;"^<
MQ.$F\?_[*1FUVE%OT(XF<;?;&W?"T;@;C7K=83<<J6$TB3ZV^^V?]N66/T9'
MV.'&=3;A[ MJJOQD(XY^,8>-ZSE!F+Q:XD]C/GH0(<"=="A>%3-5EN@LPDSK
M5&.XD@_\_#MWJ>:4X#Q$QC@75D\:,L%&1MSX0\XMK(/$0'SS59Y33.]\"?I+
M')VW*96<(V.H,#AMOUI(G81(R(33DXRZD6VI>KCEIAX-1C]M%Y&'$/&[IGE@
M#9*P^?X3<1\&OX?%DY5[MR]+IQ'PFV,,D3J;R0Q0:ZPYQD_Q2FE"3[GQB+@'
M&/*?11;BF\SA2,,-< F_!Q.-[]L(7L"16%3R"PU@"3&BA2>M/(XW& AN0/$K
M'?!*]3ZBUH6P(?(Y5;D9XO<Z[EC2+I_#2!63<,F1Y\O<^WDT"[&AR66-Y;0L
M,?FE^1V*I)1"A]2VM9*'HD.7KIIP'R0A3,JBHBCND^WI=D:!>X%'@=JB=@$4
M9P#-*>)S=X87S1K3]UECNH8UI@Z@VCD,O7'O/XX:><V]1J%E_9N/XE#PV"I?
M$+T(1H? GJQ85A' C<U1"@WD]K.[V-TF*T'$&H']M1QNZ_O:!8H1(C]!C.6&
MC"A2#0I.''1!2(TLI<:LIEUQGW,B#H].20WI4U*91!O?I:3C5(<V)A57A&4Y
M.(')/&$H ^?@\+T*V8S49;"$W;4@M/Y4>X,TEY1"B\,Y4\> ,UD*F0K.05Y0
MB1*GT;RM+GDB[BGHMLVP.J!<GWO)F%WEJ$AT6P[,6^<Q:]1$9YJBJ@ #(>+'
MPT_L;?$GDS#[Q-2UB.N07S!#LE9^#4Y6F:YW-!I.FI%:# OT@NE=C4V"[V5L
M%U2[=!.:39T8C_)R:7)A^%6TFF#V;!E&GYXJN/\BQ_9H?"Y19%>?&1J1>UEE
MDM8-D?T-Y9*^0<%<*?P#&T<BHT&!QY/L")%UDWTL?PEFNI(%*39MU8;9._K\
M@JTV!5MF:>Q$QHD::GIGU]J"&?E$/&,YOU#XF%@H<;)-4B!C]_,LH88+.%[)
MI INE#: 7_:BT]3\<-A&,4:Y_9$>H"6+9S-F]AN:X9<K@2S7K_'4'>GGU#31
M,^D>$;0O-^6+*<EJ1@.7;[)#C)'SNV)C'6,/F\:@]!ZH5;R8)YHF98S1150'
M :J8!MBB&63MI-XU+&D^ZHG=C?,1)],IEN;HAC@1MF-CBXCJIZ[P\!%F$K)>
MS-O# Z;KM-8@F?.%$'+=;G$189 [U9^W6>R&I]/YO+!2[QI>N7.@-OS,O>BX
M<A9,,4--=:-I3$7',65<L%B)-A:FR5_RHLT)U9],MVZ*0J%3P.CI.:QN5:C2
M6*_;=@K7HDGZ'6GV ZP?83I<F#?RPO#$J>"4%AH@^[I::F7'YK#9RQF]BB<<
MUS"-*C//@!,#1"HLD .6NNAR BDH<T9)A1GJ&I.%,G5OI#GX+%DZ$X!X)M-E
M0@!^_%:.%'N7\W29*2(%@8^4(-V-NNW&W8=^L+/-<??J*=0M:3W_V1>B&VY/
M<U@?JLA-;<A63*T_80H8&XX$,AF','SCZ,Q@:$G65*BNJK0V4:E5P@:3"$8S
M#Z,BMYZ*7X7I6F*.L<7EVK* .JQ@7GZ#=75O+[_3WN'D_QB1K;L61]M%.3K[
M<'K<;(^#M]A<"*?_B5HV(#)5ML"S(^:^'\2M8-IJF'E8Z'F8A:+ 72^BL::#
M7<7)(KSB+;Y^1VVS8(<$0Q)TF</],NGK"68QA>E+Z:I.]:E@&;G->!;5)*46
ME)@,9RB?KFP)M9T [QG&:Z]VE8BR^&^.A5&!*P+X]2:EK8,FG NS8N(C.</E
M#]Y\)6XSN\5<$DM2<XE!"Y9L*L('O@?3J"E",7#(\8#?*+"9\A7XDA/-,+D$
M95^&NBQ1!V@:;J^A"!P;TMR.XX*WMQJVK/FSY(12K\Y,789" :%/V""N"GU@
M;^S1U:):):&=I#[%A*7#EMOU,QC%+R3G*71/881Q9IY5*K'9-1%R*L#!WG)$
M1]H1ILF4B?O6A^'P7>1H6C%\2H];FAQQ#Q(^6[FC20&^MF);U+QC55PJMOG0
MO3*=[@582<&RF%\LUZ$SCG3IZ>60L+4/;+L)_0Q'JOC-L X?80$X>';7#7(5
M-DU>:",8C+%B;84.@D-,K]#3;%&*(?P(KL(HPL?AB(Y!0P@P!ZO9DFPJ@6F$
M=SJC 2,YI1 >[A50>@(4A^^3+.-9)H,XPD5:L:&Z>4V?IL+U=MAE$<9\@H,9
M6A52M 3;H6F4(ZVNP.K#;%6W@D3:+A5"1A>S1-6ZG73:SMZ@C3C7EJ=G=U.)
M:_ , :#&V_$2&\_74-:.5V($N&;6K.OZF@'"LIZ79DQ\1K!,$;!1RPFZ'-A
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MD=30_(#:M)N.0.H+T(&X72\]C<_H#FRO04L=Q3Q7^)[>4H5[J:XM4O6&=>/
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M/>.[^W@6$)_L^4T7)T.?2X8VML)BJ3=-4+.:;VEX:&2<YR-@Q%[G=,L,#8?
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M(Q;' +2S(,JE*Y1W=O<6V=V=%BIHB'+S8_MYM&GK^S("!24)PMJP_@++>W$
M/X\J]C>\9Y"CQPWV7FHX#(_66.%U\7N,V//#SC)\>LL0L+=D&7Y'-DJ.%A.
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M-2/LS<^>6/]['@K847R_1_OK)\$DCH(!? 6*5I(E:!6D"M%?>P/@IFDIL,W
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M:Z*0J'.CYMV #<@?>)#:5:SN[?KB.>PK\"Q@.>&ES< $(54#0/XI!;.5(3I
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M!) $*6:C&QF% E#6RT=8''.FO4F,L,TG>ZHH5.\>Y#$)0D$J\6$):E4)S[_
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M@P/"$,P6C;GYEAHBBMGB<+O<ILNJ]^Q+G/BDU,2QY!<39=PIQP8&2$BML[>
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M41')@W2LF?E[).\]Q25]:CES:F)JB51-@%+540,D&DH.JUFR$I/$[Z8B()8
MRG(62FM1&M'6MV9 UO=(UKKNS ^;WCT;)=:NYDL</6*' &N44J6.2L-'JRP3
M,9 K]4O?5['KV--3L*</:J3]Q4]NCD88R[40>XI'^L32/C$G9Q94J2UL-8@9
M]5[5%WH$=G+Z&W8BDLH* )SR57%I&(M(,Z-B[G<8<+\UJY\ #W?&M6@IW>1H
MJ/9F%&FS26HX(&BBQ8(#W%(S6&Z3!'K@R6SYHZ"7LI98_O91VI[DT5#<Q-00
MCYP::H?XNG);IQVAIGNL;7(J?!<_9T;Q[@VU_ Y&YA#-631(N2C*R^C )!K;
MQUX9N[ %1I JL];^^C%ZUQ6X9>%5MU-&K/DWL=6 O@))90Q["])LQ*Q@8I$N
M957"HRV49UCF_4Y$8A!P<Z+2ZHO&SV,/95747/3N%UC,QMW/(E..39OD1A)1
M3(OW%?+0]'IBF$%J.N<W"CYH/\LC23/M Z&YNS3MC3JS3(*?N)H4241--_IW
MWA^@&Z4#GEYD5:GK3FV)Q*8$V$=;*W;:V8EO5>GXMD)6.$8!#.*UW30TC^S?
MZK)<+)WOO[;:V#$D^G'\@QK]6,"669Y$!8TH<>"_1M\*?#\P;6*HJUT6^S]X
MA$Z4$MQ=H?%,H?&)*S3>?2'S.+RO_<B\[]&XDL7IGI"?/@7O*\8B<>,.,PP(
M3=5Q''(O!%('JJHP("=V,!H\@#LVB#4NPQCY[(-EF/43FL>;#(D4UO&QU9;S
MW=7G"^_[^;\NGL\F#@;__4MPVFK[O>.VWQ]TN[VSCC@]Z_JGO>Y)5YS*$[_O
M_V_[M/W+3NO^WVAT!NFBUSRNUON&C<9S9>-]36*@U'WN'F4Z&B 3$EX_"20Z
MS8#K!%.K\=],*$I-]P73>GW@*!EYB/DG+*SO ==A^W0CO<;JD8>(\=AD*FW#
MILH@;?>8E7V?Z<:D;L][XKTOQ#X[QLM=]XI^U.7=_H--T7<"&]XAA\LG,FEX
MUSE@DZ^DVM5TG(U%B .+OHY%,A&^S"DYQ9HBNDTW]<M?'.%LT77,)YQK^/U/
M33";I)=24@13BCUV%S[\>#F+ZPZY-K^I^<A%0?A(]?W<3B1K%"V!<0*I40KF
M\&J-@%;#/R%3^#4P8V^B6O\-Y U.N6[,3C,FI2L'C3_VO@5^C.OW$T%6XK3$
MULV+&N8!LNZP26O]@RPFOK^SIDH[(MD%(BFWC=QVU>4>G'>,>2=P[GUP@Y/K
M:9[[5\U M@WUZI0 =GS-8X'J68'I6[A")/,$1[IP0UWM:>$H)/Z/F-(2GA]2
M!J-R@1E&:U@P.ZSJ!L4<#*P_1?BZS(X/@IO7'G7(3K/D[C&TEZTVN+6/84IN
M!;2X^WH>:3$\0/G2R,7-8E>WPS=S] K_G)7+"?+LG;I RB%LF,&=]T[B:]0-
M-5J]@K/AS9_DT9@_RJ/(5=#]&G5.(J74-TPK9'O,&@)F EB,_7F1%$J0I2Q$
M:[:I2LA-5</7(),3H@5.RT6@Z]\/C<M,S4!&=RYV*-9^N3/CE[N^^(AY*M[E
MEP]7WSY3^]I'<L\)\M%&F'EL[JQ\0'P#Y3SU>:9S$:^E*6Y6@'=?2:GLNV(7
MGLE&T\!*E"^O,?,)S]N%.\:XE^ 8=!9C#^_B-SH;C6<''V*&]B'_VW90SZR\
M>HA<#6JN'D>$:3Q[)D8 ZTCJ@[H3S9YZI2/IE=<XT3+M48_F>8)WIC]JK]L\
MZG5VI.?H2;-UNMZJ^[+7=K/7/=Z1O3JX[AA<SY;K/?R,_7R[,TU(%5O<]3ZD
MLPU_"SFT3K/?QVV>O%\-7Y^^5>Z^0J[M(+<.Y-Z1'NIZ=KN>W78W*2HA<EV[
MUX'=5[L3@$,LAU@.L1QB;37L9A!KOSJPUA^ZFG_XI&U7EUCCT?#2;=)MTFUR
MT28?J1\LM>DZH:#,EG"Z>I.GE##T%%U?5X';OC7$JSOB=C>V.ST]<PULM_N*
M>L<;N:%-'/57QY <0VH[AK3=5]3;S*P6QY <0]H$0W+L:+LO:#/R8O/<Z)'\
M<KMBN%(IF!N'M(;YT'.CD+;[BCJ;N:'-LS"''DM1\,F:8SD<!3\;!:]J$CD*
M?DGH<7"ZD5%W[G*6&T3XW)>S>;)]84&O4J6_&W6XAH*ZJH;JO"#/[05Q3EF'
M'O-AUFUM)HKHKFAY"CYR%.S08[Z:>KR"GNJ(]]F-B!4&1.X+X;ZT"(3="LEY
M05:&GW-C;OL-N3B$PPY'O[M[0XY^'7;,AQFU#^^\=43LKFF;SONB(Q-UK2Z=
M<V2- (4K8]GR*W(!"H<>BRCXS 4HMOR*7(#"H<<B%WCOQ 4HMO=VVL<N0+'G
M 8KOI1[*3^$AN>]W2_?!V;>ZMI7/O]UDU&Z<M5<M?%L5!#OD17H86F_A];9:
MVW>YFQ<7CDDZ)KF*R=IH=4ZVCXX<DW1,TC%)QR2WX^ '[=;9RO4U^\@>=Y #
M'AR]V,HHO0G]),]:>FQ7TS.M89%3%^YD$.<XXN=16C>Z7;I=[ODN:]=X24V1
MOZI)9+]YY4]P[LLHB#;>+-FMX=;8V35>6+Z3:S_\A*9CW1&W6_?NN++4;3<"
M5VYMLR_!8\>07B)#ZKI$TFUG2*O&7!Q#<@QI9QG20;?KLNJV]W;:/9=5M^=9
M=:[Q\)HMASJN7GC+K^AX565W7Z)\#CV6H^ UTYL<!3L*=A2\!3![_@P.=SFN
M\; K[W>-AQ\'?F=N&-R6WU#7>6,=>BQ*HG?QE"V_HJZ;+^O08Y&+>X7A)8YX
MG_UVGKWIPN8)]Z4%(%S?X8<)N%7[UCA/R#/?T,K=V_;%'>+08RGT6-4+X CX
MF6_H:#.!(D? NX$>!ROTGG*T^^PFQ,LM\WTI<0C79OB1.F"NVA3+.42>.R'"
ME:LX]%A0/+!R4Q]'P<]-P9OAL8Z"=P,]#GIN#N(6WTZG[>(1>QZ/X#;#J>H%
M,N7N(!OL$<? J&LAXYK(/1J MIL>3]MKUIH\'H2<D^I)0P";J27:O&QQK-2Q
MTF=.N5TU'\RQTMUBI9M)AW"LU+'2%\9*#]JM%=H#.#:Z4VSTH+V"IV-?6"AY
M.G[+!. C_'<0W.C_A?_1.U,_[Q[#^M,X#;#XZ4TB0Y$%-_+M;3#(QFIM^U<*
MWUO%3T0?4#O/YO_$@ILOL=#J^4'488>U@9$%$?[?L>DD/14C>=A/I/AQ*(:P
MV3<BO!5WZ2^_E<XT":)#&X#5L_,)__)?_01^5_/6$D2)3Y2AH#ZD1]X0Z] ?
M\9M:S18>6B-J]YC^]HYZ_-_*W^7[F% [6,VY3F$9]8EJ\&LC^A]YF@7#._XH
MB 9P?V\Z/?)]/=TM\JF##+;@+W&O5\E(1('O?5,#M3P1#3S]X<<DOLW&WC>1
MP1<'41P=?CP___JZ?"?+ N=T"X"S%"A&=.J&)SQ]8F\B19HGLN$%J3>00_CI
MP!, *\\?BV@DO3B"?T_AM?'@, ;.=LC_]OHBA5\$D9E7QD_Z<91F(LH\/T\2
M&?EWZL&#8.B)Z11N#IG/:T_^],,<<=3+QM(+)E/A9UX\A-60%WC"_W<>,"-)
M&Q[<@P209K!/OL5!D,*+LB#*J38S;9I[5;M1)[5N%L^G/H1-T]$58L#>LM2;
MQ"F(Z@#>GX5W< S848);Y4<!+B+R Q%J>+T&( [PH@%<PSCQ?.#Y A8.,CF!
M'<-)^GD*P$Q3V'(V%IDW%C?2ZTL9>?%MI'X51P#@!-Z=2.].BJ3F(.43,*#@
MU_T[=4%T!U/."?%N@.-.%(RF2>#+IO<=P$O_I#/!"P&ZL-!$#*273W&CV6WL
M_9!WWB"A+),W (_7=8L#]-+42V48XK7QFOBB@Z#\?"I"B;B$/^++P3V\0XA&
M=UZ. (GG'Q)7K'X]>YE9#$@**Z6(F@!)H!#8#1P&KS*1TS@A(:>]W' CN&YF
M[0,VFJ$CO.'=!MDXSK,*(L*B0$%1@<> L4P1PQ .IA"/EET.9S489W'7!D]?
MA@&<6N%,FOMCC7&P"F )@&^8AWC^(,(7Q$F*Y I[O\,WW 1PK0)^!Z0F\>2
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MJR("ML_L"@332>_MD^Q[2?)I>+\'<984[,$!;WG@$25^14:1_"-(X0 .B&L
M$1DQ$/_?F]=-[UT<I< C$H+L05!'[\"%?'H*>1;/$ ZB+!&QGX?B_[/WILUM
M(TNZ\%]!]-M]PXZ!9)':VW<F0I9E'YUQ6Q[)/7WGTP0$%B4<@P /%LD\O_[-
MK38 I*C%%B7AWIB9MD@"M61EY?+DDT60J@S5ESST8YJ?1VEP5L.%!M,/@VD$
M"Q&EH%3R\;A457 ^8[T"-X42Q6A4G]')'H]:P'L='$9P'YS7<'^HL@Q==57
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M7>;!>W1_*OQU$I?F5TTPAUF))=[87%\N>DCS:_B.K<KZHJ9Q,NI3QW?)\A_
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ML3=S3!M*T"*HIY19REQ3:SL<;G=M''PQ!ENJ"/!_@<I+<VEZ$E7>\QL[F:*
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M)%YNR4\J/EL0S$G&Z4[:[L&>;SQ0S%H55928W*B),Y'=4087=83A#G . KJ
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M<?.44+])1KSW(:/CS*^9(-$ + <; P,M: 6UR;3 %A.$99.N1:BYZDR@S S
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M!8L@;4-%<5WD^8A<Z,X5L%B@X\]@X7\\?O?I*#@X.SN2$-G'DY/W?QU_^O0
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M>)ED4;][*[A[?E\_S4+7VLW3NBR3B/;RSV\%IDO-E:"^8RF;81\,'57?II!
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MWIB$G)>J#G7;C4K@F1&2U8XL :0FC;3)*P_K*J"G*8R";GR-?0T=Q(Q&%3:
MLZUH69*-T<^0!&MA#%+_[V,#S6H#;O,QVX4TT+X?1*N(8[,OXN@U\L]T/FU+
M=HDO$2]?-%92$*I08R.-85F!3E6D.0VUE1^V,OJOOVD??5^=R"A<LS'\T/ 9
MFW]4#*?0A.K$=N8$EVQ3!J),1#@#%0HT?L[$RAQS2'536=.]C+&8@K1,_N53
MJS>;/G3P*;=)XQL=SAHA8/NHE]M]['DX#XVV?. )2M3!,5M@&\&>LUW4)SE8
MF+JH1B1"?4]*CZA?X#E6SEO=\5SOA #E8.%=9/1D[);SG2"2E@Q8N@<\(PEZ
MBO+2N,V8;7?"W!F,(35=/3F2WI(#K) >@QV3NSD=^$-*"7[Q.V.53!E<J/6@
M>2EH*[#ESZ/XFXV8@8-A$=4>VM7P-[T.Y_0M91(F39P]1E[:&(40)?4?&-KE
MWW%W@KK(PE[;/6GI+;D*03,+&DK9.5UEG]$>/L4=&Y%5I4Q39)>%F[<.H^P,
M.IW7%]@TI; 0E9'-/#M@UD!PK*&+=KM67&.7Y?@;W5)6 &^]=#QNQVR;HM<L
MXH)+%&N[DX>-0T!-(K97LN=PI0A/'VV[WG##=/::\H14MAPE*0;B1=Z<5\.G
M%$)U9,HR184<,&,VVX#H;"7B-2ZBFOM-1.=UJ23Z95FBA,.#>[Q>*8<U2H_!
M(8ES.R^YO9(=VOI7\V-X<L[PULR+='2-O9(]1BL:5(-FBSAN/@BB\S GJ';P
MQ;SN(+9)+</V+E^3.>@??ZG/X:()3JAR'?T?^*TWE@XR+<F:" <+CL_[@8U=
M2EZV0;PE(;SD"MUP%I&X+JB$UI)S]>?]T>_O1F^/+PS[02)7$[J%S3N@\"WA
M<@[QA('\D-\;@0",+)^."4H+*.0(;@R6AE.4L#@![4+_/&#H\7!CL,&"8E+\
M]$2R^B24[!S55%TD)<=1FS%I]_@7"AGQS1VWD$IV4>"=VT&ZL:(D0\\JX0I)
M.=.]#*^(#.OR30<I3RDX%@;83^J\H44(T?.LU(HZ552TYZFNBSH9T4W(Y@Z5
MS\@S],U$R86JG%>LK>\UE<'@M,^NFWOD9% Q&=4R8Z*G^6.BPE<]]:)[B)C>
M]D>8][;X2DJN([6Z8XNY5:?@W\<SWG7)#Q/M>Q5]4YEF@,>V4,B$$$0C9$$N
MI;"UW^3'K=)(.87:Y!A&9XOS%P0%&*ND"C :[;(>]^=T-;;0+9,, TIACO)K
M5LGXK_A2;AM"CN!U(V@0W3EQ%I2SLE(3[@ U=S=_]&8=8%QMWOH,;UJ?P?:C
M;Q$,H;%%F^NT ES]!%MP#*L<# [6M0MXBC#5#YR.T?Z?[-1!EF&2_U21?P/;
M!<X2_'9C[3]-8?9,1<CQB ;N>[ %)^"I,1!@<Q!BG[Y!*-14^&MU7M0(51AN
MTF?#,.A:)0RT7E!:0">FQ_3_WOZ<Y=-+Q7?&,JL%NN@+N-S!\3&["$EI%NJ_
M.F?XLR9"#@!-9D2-CV ;.("-)#QH!N'_E;V6M!SQHI66B(<<[#/V2S45]9$F
M&083:I)03QP#H3D[.O0@-)[G[3SGP-[ F 9\98#%\IS#,P/%\;.'C4Y?IJ6T
M@!TQ.1 LI!;GUV 5*+&MKM_]YKA!]0RWUG>W'^VF.!@Q=S1AR*W"C<[SNI)H
MD<[!<OA'_FZS"Z;>M?#Z2M"Y2&>);O,'S[Z.BM%:FN??Z(_($,E()S'$QI3B
M^VDZQ1Y<_M7BTQL^U$%G'%4G6=^<LP5GQ9Z1,WCU7\A#7RA>7"$86K"\E KZ
MYO9^;+KGSF T>8O>< 9J!>6EE". $R@,2UF9:&O9G!)/5G@ZC3RN%Z' \NBJ
M7 ^^LIS-GP*,-,(V.<@H9@(LV(\$9C92L"*.&4_Q< ](6D_IJ^3"7B4ELT+Q
M0Q:_EB(78P2QR5#Q&7%2Q/6DK*1Y,P*P['#<_1:QPDW/13*=!T:,C--=6[!$
M' O0<'Z2=:98$'@N-+TXJH6<,>)X$5BY24E$>^#ZE@EQ5^4:4TG>JG"Y(4K/
M F;U!AD/2/RF^:L0-K8X34IRLY  NJ@ZGQEQ1;SP!^D$J0Q7?;^,4 U*Y$DD
M"S\Y5T:LD$[*LGB9P9#?#].Q(B3Z&Q[D"5J'NDY&__Y+LK<QB+=V!O'Y:'-S
M:W\8[>UOQGM;F[N;T9[:C<_C_QUN[/WR,$K^AROTW4Z%;A7:YCK_W_^J\?JK
M3+#/_#75?WR?E,CN1XB& ]+P?W"E!VJW9WKQG4B) ;R9^%]'B!O!,Z>0^8.5
MO>AX4M##M\&QY@DXQ:..:Z,U/LI?Z\M"+>%^,>10K$.HGCEY>I?MN.9\ >\)
M:7 N1A5S!;U@(F0<&5M]U]Q)?QCL@[E:<(?KTC07.X#[?H9,C)C9T(WOX0J0
M1A+TG5,+IC@QK50"/;VF4 5+RY/C/6"X6/V0*W_>Y>G: OQ+;1"LWX"!?7E8
MY*T>B[QRJO^6:)>VQGJFVOR ]-0?A.L270 F/B$D1L&O@_UP=V<H%:E)FFH5
M]^MFN#/<]/\^+4 O@:OH%JV!\XIU]^/D._QO2_Y"#7,B4-UH?)D_A]JR)MX)
M,FY-^[T1IN8+^%%:F^S\O(?;&7DJ;AA<PT>_#O9"L%J\H:\'Q^,&C1&L0*&X
ME@K;2Y6$1H!CQX2F:U,PZ(R!M^S KLE> V?"/)#*:K[3!,% _W5G<VOI<;F/
M>9!QN1-MC&M[?[\Q+K"K,<M9UN?_$$^H306D':SV1N,6>5Q2W@P9BV>!T6(3
MPP66F7*?."HOB6D,?*"#UOSM7-I/Y\F2&8$&#-V<<%PP9:;6D&/3DE(U5F%S
MQY?W1!/4.CT>SZP+Y-_^U"8(!_T!!QWB<-F_9I8L+&&OT#-B.@S#C:1ALM(E
MMS&7N0N,GFZ2*N_3-;O\CO<R9U79LO.WA38L=-PG9_?=S)$1N_5[M$A=Z:O!
MM4^?Z;70/N (-5"F4:3I>.0T@IQZ'1YL#AI+5(.L1IO3I)OF82'@.%LRY+ 9
MC2PB#$+02.2Q4BHQ!LF5,VDBEH(_,DQU.EIFX5\!<5M*O[>[.[Z#P7-Q?+?$
M\3WD72ZMT_L%ZRU'Z)<\C3.]<,+6RPK<F08_9I(K=*I/"$^H?=S0.GN$:'1/
M#=ULEXD:!T??55S3[4/0/3C#.A5Q>'3BI2+X^]8K;GW_PXE-.2#+I,)K0O-?
M--CD+(.<WJK8W:JIV:KY]MXZ]0:G6Y9"B_(Z@KC0_(Y.>-P?3O#AXE,;0IDE
M7DW&F+V>%XSD[LIEZVDKET-K&1QSR]E4'[K@!.&Y5EXX?@'6R#,]?5\I@D4R
MDWDF4U=*(]&+962/P,QCLUJ%7BV1V)@L2? OF'F9Z@@O"P7W&SS@LI3@C^_H
M.4T*=2S-&-QJQ!T,* XM71YF<'E^4PSQ:OT@%/#!LN/NXT;-N-'V_+C1;33&
M[B]]M&FQ;OA)V]RM$;\<G'X-CH_7@Y.O?SLZ#8X_?S@Y_>/@Z_')YSM?$L.-
MIWU).+EDL4 _$6+MBV7Y>*9WPH?<QVNA':+()1?>$Z]92*&HJSDV8"\I@8N*
M^#.2LP[V0IW$^'3T\>!3\.7TY/#HZ/WQYX]G3G8=W';*BDA2]1*SO]0_1'%S
MJB*9^ $->SL[H0V3?U!IJ:[I5DNRKO3MW7VJX>:SD>@#$6D7\/#\I'EC'V9]
M9#+QI:+,.+@7E!9<.GUG>!T-'J(K8W<CNFZE\F,4R+;ET,[T NK0Q>M$]2H6
M4R3Y2O8MQ)[3B'HIDB;FY2(!Z2 K;(KUV9E$-KB.!J$TH5XR[5(ML1IC6''X
M2L>B:--Q\/O3B /,C>VUCNU@R-D0MQ,7E>Y(@':)IN'M)F4Q5^Q<1:7XU;J]
M^/G,-.MV7Z(;^5H R#2G[@=2W'21YN=D6T\F=6;[MUW:T>DG"*B[_0A^;>:6
M%)DZ>]-+G&XEV--D!*+2W;OA.VR8GI6P+/,(3,MAA\/KVAS]BYJ01<@% 1]E
ML<85S@Q-<^MC0\RJ*Q4RO[D;0:9LJ%U?186Z(%??!3<N_B61>>%9\HD%.%E@
MU97/$]M\:.CX.K'&!81>;-UTLN PAY\E<.AK7>I0+Y&#^X]]ZK"772G9(!3F
MYXJU/'%QB%LZ22D',(WJ++XDW-,$(\7XI8XCQVHXSQB+9;[9.M;ZA!*2@]^
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MO-5<Q%E5>.(D(2+ZUEW=BMLBA43NBX$:C*\+"AR^@G@;)&R[R@LB#4 E5NL
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M=/YD##$%'-J91MS%)6QOF?H_*, =VPD<<H35B[O1Q"U2M,\,ZL/R#=,&L^[
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M>ET7X98RU?KW6LKVA-A]N_\X&)I?S=ZH\\WL]D<' 2[/5(R?SK8[\OBM<=>
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M'=</*"_J]SWWGKC(M0AR,I_^<$W;M8%"A;RHZXU<?NMP"AFU6?,F6MQJ+=-
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M9#)Y<Q0'$^^9OOJ)!@OK&_;@J$#^B5=.H5OD?L?4-RP++_B&$-HG48XH)E0
M[O7*(;E@F9A&@4[!!KX_B;8%S+" ;0TBE:/;+928Z,-#MNFR,63[6[;],VS6
MRH#X*Q_''\ T*S-)U?DH .CZZI&\;3R(HCG_"!%ERXBSS&:R)1<B.5:*YD![
M'GTEUFRC^*_".:0*#!10@GLX[X:[Y 7;O,(W/@$7?<(\">1."6LA#^'Y4/4)
M+/UM?=^5VSL9 HA"N-.*B>$JNR()0@4P7FNE?IVFK?\>NICMZZXK=%)$KD)7
MDRQU\H*2L?9N4_Q"2-64=R5F:F2\-PZ C@+$^F$L%M1[0<ZC!P+'GOG&MH9V
M9*YECY+*</KP=?T;<SN8 _LTJG[@18I4 4U_8+\":.*#&F.O* _)Y/F" J8*
M+/98K=\UH@7;'P@S@],%D>B0N5W>D%B>&.52,@403M%X)<&,^99S3)D_3=[:
M9E_<.QE*!3J8+7S@&>6H.E8^#UU(I4#'>&W*N@,8':]>C@RS),XJ0ZI %Y]&
M=QYK!(5\#^R^V=*8'(>*OAA0,I?8T%?GHT#G#<MBHNVD]*N]'OXG9<%*:7(%
MN@J[=M;(-H2/5L&VDOZ):13H%']3A&<JL^_1&Y2B.$)^NTQ_$N]B^6/U [:D
M/;*M[83-2R"Y1X0^(OH=!U 5R;8Y<Q+TW:@$_('R$-HVW_('-D'1G7;&D-_P
MNK<[;%4J/B\A54#1-D_50FA^2N-LHE\VCV2I%>AHDG-(_<:^VP;/,3)N;-OP
MBA;;/5%9<O4UN55?+P*2VEN+*16 -U?R#/]G_A42M@7$4:YM2Q$TF"=NF-(C
MXN(SZ(>3LGL._CUUY1$C:-Z<YV078? [ALN7F#<0)>NRJ1JQZNS 2 %-&B :
MN'"H,SH;[\_(HBPQ(J!0H$.;-VWAU[:#"%P$XL U3 &;V__$S+#1%VQ'9<'2
MEW;)L'JG4(MT0?&6DI T.M@L6^-DZ17 >L"+G\ADXD<7W Q">!G>Q[1,A4OI
M%.B<,6?2?(\U#=]BRC2P[=&%1R5"9C*4"G1P,Y"Y6D6,*<7\#S^IV^<%00P>
MZ:"H%*\/KOU/MMA]V;VY@$ !.-GP0[%!)&5(_._)@"<;SJW@25!^M%F]93LW
M&]LH]GCX\R/$DMM^R]$J@&!:5CQZ*CE!7_!+!3H0A6_ RZ*E09_BWRK0B>2P
M77_"F]AQ+6\.8;@XO16=Z-RZ?Y$C/D W[>#S; D%1N$SSQKOENGE9:S)?0RW
M%4I?M](H@* P/<F/Z 9+PX]+7$6[KRI<%-V*)^>0A]C";-\(Q09)$>B]1]E_
MV2X)#I/RRU22#>76,=F1FZ)CDV8TH_LYL'U/O3G$'\/HGN)^[L'GS,D.MFK:
M_&IDN.+@$0?1 =SM <YW$?9>A2(@WJ]RME#V.*%"9B)GPM)-5DFX5892@0Z:
MDPF&^PIQM R-T1NXK&SN,G^/-9L+C^T9VU(SS8-?1+=+E2CS 3@K:A/X\\'^
M:OL"R7 :E0-,L.#NDS(R1<^_W+$&O"  $FH?$L,$1HFQ$.!?2J=J>034V/4G
MZ[&5])PNW/KM^IY#;$ NNF(A*1H?H"5?[_RBH[Z"P_#O)$^%4\('. K=B<^*
M66PL.+L?>A!;1KH* [WE]8+X,GM\AR>8]5JHA_(</C@J\VC]+YL%GGRT34"@
MP!J\EK.,[[L27ATL=R.Q'"=%U]C]#V7_AQVPANG%[(R]\I;@C"SD\B(7Z1:[
M>$)$EDZ.7%&XQZ/A_HA79*($Z$7K4WJ=*<05"-L515?CQ]N[R#O>>Q7<68J:
M.>(>?@6P^1D^[DJML@HE1T]*Z130D^1DO6']%1*?1-4LA2?KJ]0.[,E5T?U*
MF3N]X=_%R29H&%1/,/7'\^CN@N07$(-)GB'IT\PK)._C[O^P]JG@M0H#J''Z
M)2ZUWRT(N\E#T?7OR:78\J8N^3>VV>(=+]=^="LJ1.GC8B\##HRXR($8X=8!
MV8V9HM,Y!I GZ,H\OJ*?*F"]'T>]+GJ&?8<'>:P!CXO@"D\L5&"@0'>WEZ=(
MW?PM3:Y 5[>?92S-;4J1*M'%LM?P)*IR*S)1H-NYT^D5#[,KU!5^BBE^W;X$
MIH)?*M !P=-A\?Q9>^]@ER?(BOE\Y+TO_;E+GD-8M-FGY 7#&8:+>J/D7MPR
M*@70E,D+_4Z"&=Q0'&6%N+]B12>Z[L@+VY6P]?T V:<*4A1U&XV;3_5ZIA[>
MKG(@1)+X/T1E8&=*<1#=CG  Y2CDIZ@:[)+F$.65WCG#4E6T"AO5W(7CNQQ7
MV4JIP!R[\Z)+MQT'T^D2SC^'#NIVV[)[%'EZ!3J;O54' BSKEZRL7N+)_@R*
MF*SHR#_;H6 WQ#[XK/T)/&DR$MWC_S["%#5%V5.&:X^:7,J?3BRF4T!MA-=Z
M[',EB#*7@!2;<WZ'+0'E.8"_7<;L(YWN._P"[\=)E8P7_U8!+5V++,#30LG=
M0YG'!ZH\VE/&0H$NRSZ%M_=;>FHX(X_$P7[ ;')\R'UU&4T;TX -6*R4)4'%
M:DP40+DH<[)ZS(9Y',R;C\YV(N?6H]1[A4+92GD8"6Z*ALDWEI?T]%Q4QN--
MN"3?8_['"\ N?TY+BM5'G_U)O*0>+GV(*O=#!31[[2KF@))G+N >5[K"N9!.
M@<[)WCT,6X<IA()1Z&.[_P+O#+MMF#OT$?M>,,,.82+[])9BY ?)-X>X]G@O
MT0H,,7_V%IQ);$71B\BLE:7+A$0*=*NZ)1I@%_92![1M*XX?;>+8MB] CPPA
M"SERT?SM! I@6W0^0OXE55EJ!3J:O:Z$[VQ7\9]F7?ZBDVV4"G2P^,'6DMBS
MD$:!3N4?85Z[/;XD"R-'K&0WI4Q+*9D"72O>TD61?.,%$=X^GK!-2D0'9:5;
M^[!4=-\@>!.AZ[E3L+-,UFLP&^[XLD(1%P5>4ZCX(*W\_4ME?-2LGET5>!KV
MGZ'/GQOPV_R$KM]QD\<Q_/C$^GT8A#0)&Y08^@,P5L"6Y*X<V^D)T.VD"G11
M_O&NS(6+,92=N%J<)_8*26"YAPER@+?#]A.O:-IDR]FK5>GOP'.(M8S2!)5/
M<&WC\N$[FDW_-IT:S49%U[B(5(%9Q<U:L@2"^R!QX4G1SU7I2A(^D^C&YD\5
MZ$)\B?"J)AP.FY<M\$(:19TZB2,&V<,#FT=<W^U<PQY"54B[],.@2RPX56"/
ML35S8>M3<@^.D$2)&;$Z^N-'#85*A-5];/ >(*]2^(IY3@2>IDJ/ /GESX$<
MC+\:+X247=U4^MA/!08?_;[/JJ55'BBZ73ZB/SW*7[Z5O 1K3_;*7)/UE4QG
MSK)+F,+;4?0XVL4@.(T=+$O*0R2I/[Q 9-@?M_<_J5N5BP*6<J=T<7+22A@\
M.0!G%5;'BN<:P0?@<QILOL_62=BN]:G--G]TV?9"ZC.:9%?X0TY:'K)%*@#"
M523:2B-G^":>D5M^K,#$VW3 X7A-5:=]C491ISU]>)G-^>@ ;]\MN$S/Y>N#
M&QT%W#X"NW%3-3RRBXG,3O4H^HAM\[8SOC,.:XI%<A2(=*=G[_9?MW?CI8@1
MP;PVQJ-P,2X/2?<GCTP#RVXRE:!4H(-WS%NF/IF0E=63R^25T_W0SOUZSOKF
ML[W!'/WVT_\!4$L#!!0    ( #&*JE1UW[+*$2<  %5\ 0 4    8FAC+3(P
M,C(P,S,Q7V-A;"YX;6S=?5ES6SF2[GO_"M^:UXLV]J6CNR=D6ZY6A"SY2JJJ
MGB<&EH3-*8K4D)1=GE]_$X?4OI@B ?*XIB=<UF*>#\CO(!?D\O?__.-\].H+
M3&?#R?@?/[&_TI]>P3A.TG#\Z1\__7+VGMB?_O.??_G+W_\/(?]^<W+XZMTD
M7I[#>/[J[13\'-*KK\/YYU>_)9C]_BI/)^>O?IM,?Q]^\83\L_M';R<7WZ;#
M3Y_GKSCE_/Y/IW]SD3HG@!(1M2(2N"!!&DM\\$XE)Z1@[O]^^AL5&H12BJ0L
M.9&9<>(] &'6:/!16LBR^]#1</S[W\H?P<_@%2YN/.N^_,=/G^?SB[^]?OWU
MZ]>__A&FH[].II]><TK%ZZO?_FGYZW\\^/VOHOMMYIQ[W?WT^E=GP\=^$3^6
MO?[WA\/3^!G./1F.9W,_CN4!L^'?9MTW#R?1S[L]_RZN5T_^1OF*7/T:*=\B
MN#&"_?6/6?KIGW]Y]6JQ'=/)"$X@ORK__>7DX,XC@[]$0)_!C^:?_QHGYZ_+
M+[U^>WQT>GQX\&[O;/_=F[W#O:.W^Z?_VM\_.\4E=!\Y_W8!__AI-CR_&,'5
M]SY/(?_CI_ YDB)J*A8X_N/ISWI] S'Z4;P<=3MRB%\O/[%@J8<6_IC#.,%B
M9ZX>/)K$.[\T*G*93*_^Y<@'&'7?'5S.R"?O+P:G\TG\_?-DE/"EV?^?R^'\
MVT!&19U7CF1F#++3,N(A*)*#=CK)R'(4=W>IK&F&B^KDF?TL=$)=/@*%R]EK
M&,UG5]\I.\H(94O9_L?36!:;NO[JWD[.SR?C[G-_]:-+&'!'8PA2$AMS)C+(
M3"P+GL3$. W2*BYMD[7=1W)W9;<(LS>-KR93W (\OWYZ]17*:;,\RA:P_#0^
M8-+=%VGY&Z]GE^?GW6>2X1S.K_Y].=>J<F ^J;CI"\GB"C85_5Y*P[)V/_KH
MA^E@_-9?#.=^= O<P%N3';.(*X6$BU2)."Z!"/Q;DCKZZ%03,GP?VRKTX#\F
M/2H+IAIA3F#NAV-(^WXZ1GMAMA?1-BB[#ND=Y&$<S@?14*XSBE1F#D1:DXBU
M"(Y'S9(2,>D0FQ#F^]A6(8SX,0E363#U3I@;',?SSS!%!E],X3.,9\,O<(!F
MYSD<3F:S(Y@?YS/_QR#1S()0@5 -FD@T HF+!7-R/,<0J0+=YKAY&=!5J"1_
M3"JU%%D]7LUF,)\- O.90I D"D"MR9,DCF5/..!1B-X#9\FTH4OW_#JK>'LY
MG:)_-6!:9"VU)I"=)Y(%W$C:K4@IIK54'EHN9@FC3T;7&E)^P.:UM[@:5S].
M)Q<PG7_[./+C^=XXE7?THGC4^ H-E S!4ID(=0'=7,D1D0)%J)<Q S6.AC;V
MU7.H^F195>! -0%4H\3!>.['GX9A!(OE(9#]/^+HL@1A?IY,TM?A:#1@G('F
M+A/&7$"%K2VQD#0Q-+N@C3$I^";46 5=GVRI"A2I+I!J5+E^NA&:.JUX.;M0
MNP:FB'<!A2<U!8=J5J@V;OE+1+XMFZ>"R-?:V&IB1:L<4">EA4&%=M0U[P;"
MH>UF-2<F"334(6=BC?+$RZ"\$#D%V48E/(UI%=&K'T?TE3:_&ADZ.WN)83*.
M2V,%M0^W"4UWT%(0Z4(@5@A'C&4B4LC)RC;VX*-P5J& _G$HL/F65Y/^X="'
MX6@X'\(,C9-'O#DMF*-69A)41KT372+.H*_EM=4B1O2X1)M@\_>055SY@ &U
M$%,B7EB*SB,-Q F*0DB,<\Y<SLZU7F2??)^JK+C/_G4WOAKG'ZX'S^*%N?5Q
M,NVV?#Z?#L/EW*--=C8I[^AD/,<=Q$_\A-8:3&$V'W#%\+7TB9@<;3D!\+3V
MF1-NH_364Z=B&YNH#OX^^5E-^;8#<5>C:@FZ#^?%72P;\Q9A(208Q_+N^$BM
M=EF1HAF(U R(34*1)+/V3DG'E6QV5?8$J#YY9DU)54LP+13Y@&;AC+*:4,M"
ML2,9\2FB>R&9 &99Q/]M5YUMM)ZK )K-Z UYC2ZPD45>^!I:9RSN:^(J6.64
MHZV7U<- Y;J2?T8OK[/C&S,Y?(Z#-Y>SX1AF,WR]PG#<K?[ZW9KCWV9#W-KN
MVS>&\Q7N;P.5M+3H*Q4YFA(CP1?:*4%,E,*! B?LO:#5@_21C4'T5*VNQ8SM
M2J3>43@9?SJ#Z?D["/-;_I5-/B5G*(FZ>&S!.Q(DEX12#Q(8#X*VT9>/X^FI
MJMSL"-E\Y]L%N6XML@1;@O<\,R2D=AK7:;PA+B)3F3?,)>4=8VUN>[\#K$^1
MSEJ\J"F+NH&OVT!N"!NUI9T?ZD-"6]]F20+S0"#DR 4/6>@VKMW3F/H4!:U%
MBTH2J'RQ?V7\9,6226B\1UXNYY2P)- 4B6::6Z.RY;E-,M$S5^)K>)!^]KEX
M*/B?XO9\\:/.9YF_]=/I-]3BBPQ %6CVTN R&=4$=;,G ?4SR3PYJ< &IG(;
M7W(5>'VRMM?GR ,7LKIDJIC@)S";3X=Q#FD)L'M+3V$^'T'Q=]_!Q60VO-F"
MJ).D/#ABP4<BO4@D1(G&7N(V6B%IN']6/FITO_"Q?3*S-Z=$ZWVOF(,9 9D:
M1IW>OH("UC!%'4>_T"(45@(>DD6B5&",1R]%(U/J43A],JSKG1:;[WS%!)(O
M^.S)]%N7PH)*WJ9$B3<6%;7B%!%H3;RTGD>I$O@V09G;*/ID,]<3^=K[7#%[
M#"[\,.W_<0'C&5R=27=7Z*1F74F5I,6YDZB@7+G%%,I*GX5G2;8QDU8 UR>C
MN1XO:DNE;Q=KPH<N+YP8I0&]0>M( .\)TS:DG'S(K VC6ERLU=C%@4+160F!
MQ)@DZGI5 B@*\0>1D3$ E+<)77WOVKUO=5'-^?;]R\47":O:J_=A.)Y,NPU8
M+BHFAVO*FC"62S:)8"0$;P@SUI@,*J#7WH0R]Y'TR5+O 6$V$E2+V\)KC<&U
M*WEFQ !%4])E3ZP3F6C'!1-0S(RPD]NUM0I_)I?H2W_TWXH<KU9($X?D**Y+
M!(]B8Y*@*@R$&F8\U=YPUV:%C^/ITTFZ(1\>*>/95  UJ\"FEY >66$4S IJ
M%1$RH(T4O2/>:T^4$]([-,ZX;U1>^A2D/IV5]2E100SW6/'WU_<WZA"_KM6*
MX/0,__RP?W1V>OS^^./^R=[9 ?[T+I07]R1XXD-;-"=8!7^E+@4?IY,\G)?2
MO$$HQ4PB>9)#0'T6%2?62$.2-H'F9%!S-BLJ6F+8/,!Q56CX'E^+Q77W)1H
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M?_1"H'TJX=V!J5];E#6[F#VV%XO,Y[OX(F.&<T0%@I;2&D"7)## +PUGSJE
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M*+_;_W7_\/ACE\=TE3U[ C-T@LH \?0.OL!H<E$\I?6=AHT>5\LWJ+?F2B[
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MS%8Q?VG>S.K]/J3Q8+2(&2_O+U/$]ZSD-,U2X<X8H2HI(T$KR=&T1)O5,&K
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MB%XJ1387>XW$]AM<KT=HPL5%>\R/*23<M./)'>[F&(3,00!/MO0$YZ4M?.#
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M""4ZK:@-!DA,#(03')Q&%\UKE11GZ/S+.I=0SZ$(I0HCVDB\IR(4A985M8F
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M:JH855S622]KB[3__:P?#FQ)O%8*K$*X!]OP>L$P)9R*-D 2O+2!T18<.N^
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M=TC_WC1*21CNBK*!I>0K+"T90-3,(S>6"^<#3#)?Z+$Y!"WDW:$[^.9Q2D.
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M!4<VJV.QS&,TM \@\&*\Z56 V&P)4Q70W[?7<R\J/Y;*^TU/"GP]KPNU*L=
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M%TSG;'17R:*U/*>C0-Q=7/GQ[.M76/Y8G!_2<?N0KA0_\U7S(M5Q;^U:P7J
M +;*6R,6M-QEKDW69#3 C<VZF"2+T9*'&\I;QP&8X#;BV>GI197VN[*=**XI
MY-6OC)^.#J)(AG1>6PPS^?->(3)A?2Q:^%HW=7_7#<,7<FC ?O$FS+N!7.CP
MQ$IA$R^"01*5CR]8VF5D8 HA<DLR,[+/[<PP?-,'A?=IC]L)@@XZ[#$EYV=4
MU49VEYV=2DJ-P'P5F5;1,Z@SX%.4UF5+F[GM-&.GQW*FNC(Y)NN]?[LXEKN4
M\\3!)<D&G<?T'WVIX"L==?3(0E3DW4L30YUY";H/W\1O,.X_!W-O5K&]R^ZM
MG?LHN+XQ,?5K&?.\E=D<LJ:^8ZHZK.I^KGD.,):Q1753:?JA6#$ZD&# ,5^<
M9=JJS#QWGJ7",SD]'E#=4U?6T5CO'3=71VZ\8Q3<P6A_GD>U/>?=M[J@RXE2
MU@4K.:^3R60=5&;)"Y+(8LD^1%F0Q-4WIMR&=(359MTU?E/]V4'JZA /?<#5
M>CFK+-0;:/\@S:P^?/S'!3BER1UQRC$M*R61IW4#UY$A%X8\%A4*[U,-?RNL
M?]M30[5UV)M>S]/B*YDZK#>R>7.5B(1[ZV14]0;2&::%4PQBIAC-2&\CIU"M
M]$GAW +JW]%%:\UUX)>Z =K/6<YW@^L:--P*[WZ\_V;*'&8D!VABNCWHDO<U
MYA2B#LP6$YA&&QF SO7VDG;>+$PQ?7RD>S"3.]SL^[&2,0KHPC*V0GK@%SJ4
M7^)W/%U\JQ@O4M07AZ@,"7)6I;8TTCZ*IM#B":)U&GTPPO>Z;!@ ;GH/J*$Z
MK[LR3771X]( 3^E'G__$.2[AE( ^RU])XN2";7AU+K"N+L#:%+G143"7"H'U
M=0J"3X$5@REQ:[,,?2[U1L%\3";43S_W37/U^^7V=9=P$V(D6F2MQ^A:9##L
MW1.6&NPAC*V" V>U1B>M=49JXQ%,#)%;34>;U"7?Q*>U#XQ[I]P*4.DIL%1&
M-_J\/-;>-).9$"Y+<,'F?&0L4<V*"_9&<)ZG66VZOU>OY^>1UEM<ORM_+)8%
M9Y7[9O4LUFTFK4^"SS72UJQH):JS)%GT4C&9M0VE1-"J4ZO<).L[PJ1+6ZMO
MQB/0SVQZN#9-5WGBBHL6C*'#-!6FR2TC@?O,DE52*RC1^3[7Q6W7\8",O:.U
M=?T@1IG*4=WZ[5S.?^+L\Y?:.OZ=7-#/Y'+B,LU6^'XY2WA2*#[113H&F'+-
M\0,+412&2OC(HZF3O8_L,G#T(O_]R32]>>QK9!WRLVVUL;72S0]?4N!8B:DV
ME%0GJ(H!$SA36M7;DV09@0)FI',0@A1%^@=PTMRYT']_5]V/HK;&UH/MK-[Q
M599-S"_/EK/YYW/</^DXKUX%GE-9W2ATCA!U*,QJ10YQX)[%7!2SI1BTMF01
M.P4IK9;P@+Z'1G'(O2C_F.A97_V_L]GZQ^LY+>-L<VANIBM]^@+SW9YETEFC
M38HY5SW+4#@+H0##*#@I0"42]W$=#2-7> _?P/T88:MMOZ<%/> OY>Z#3R"M
M-W/%<G"1@C22@8<86"BI3@,)O-=%Z=&(X-_?VD.RP1Z!33,>!L%ST$!GOQ$!
M&,5JNDYK\2P9&Z6*-@359W[>4R13.\CENA>5'V<#D)*@O/*1I)?I*.2E%EYS
MQT"FP$/.3N<^Y$E'U@ TJ27<VO0S1B-'E3B]I19VR)K^W?2S1]//*&.9HF]B
M'TT_%"OVPH/PUC(1=)VB%@L+)B%#'I.VF5N.??;*AV.]HYI^CLYXQRAXTJ8?
MB1)X]I+)2M"MN2@DI!A9LJBRD87<YS[9\,?>]#-*XX.;?L:HJ^&E?Z7=^43?
MXD8 O]I%LD])T/H8%/K6M%.*>24D*SD@+3%%W.X8V\E?=/W)3]@&&HBZ,7_5
MIX\?*.(NB^77.JOK'->.+J++%J+@R2)IS2JI.NR"%DZ+E\Q+3:N69*!J"*?5
MJ)<^=7/IIJ#&\Z8^O/OT8@32 ES&(!4#Q373!G1MXI5,Z2 L!!GR]HB_G:8T
M[JU/W)8ZJJCA_>9F9A5^@^5&5"/PI@@<C73,J.S(^&D'#2079A,4)1,&$](
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MA#&R[F !%R,1KB5 3++%JV@8SQ1+:QL$"T4JAH$G:Q5$MYU1:&0"-P Z&C:
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M*[]ANK#E(:":5S#>"&?Z"L9#];3H)>3&]8LW@^,N4. <*G\EU-F]@G I'NO
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MN6L6V=@T!9;@;-R ?9O2#P][I(%&&I(E C^)="D2:Z T>@V<)6%E\L/,+!U
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MW#1>9:L%,RO)8!7)T7@#O4P\0 _*AWCNY-T&T:">P%-,+^,'].-J _$]##W
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MGS$N"(\@22B%*(Z8WLQ$")* ,BHB)#4F\]7Z1.CHE'K5NA,M[3G<ZG/>:.'
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M(S'8B PV,MN[A2R /NYOZQ>^@2?P8>2.)ZOH J&]/ZU?*$?RHG7\&)T<9O;
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MFU-<7NOF)[Z17V7V+#]I:<]K;^A?T]5#D_#TC!7ES^8BT?_C4F_1*&40>5A
M&B8>#+7=X/L\"67DY#FV['=JE%.+754I:02ORI=L\O(VPCO>G;$="CL/Z0
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M'\PVY\<9T#H:9XS6<@;6>H):4=#6U/AG7NNZ9M5>[;PA1J%O2[!7&<>V%8<
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M<:#D*/9RO%,&%&>@]J<Y<6^J:Q&,JJ!XJYIXZ4\V*51D?KM4JV\TESLK]/*
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M)2;'>^C#@*HD(3[ED<]M#WXL^YP:*=5B[^"BQ49T^Z,+6^2/GP(-@.? =-1
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M)+<\T31#G_$D2+ ;R[6188@"-X&8!W*5%(X;L]"A8<16WWA.-C\/_W;W4X[
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M\3T$8T\:&"(0OI\852OOZF1I/+"7$6@A>Q.]F<-I1@.G@C0Q!UCC8Q\:WP'
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M:,&!%!O4<@,EN+DY9X!VO[$\+H:3[][WP)T!#>;9 8 ##&,#),V-X7$1G<D
M-O@P1S9[S6'J,'4-&IG-O#57J&W26KQU$A]'CB,;_Z)".R6*J+DH#SAEH8.@
MJZH@HX1$$(>,PPCSP.?$$7%B?)31U]G2N#CZS7%>?_(5EVBQ@9)[$(&\#[05
M$9\,WZPTK'%\"]UI)/P^AH,H^&0L9R)@ TQ'Y]U.;,Q8]_TF?@;G=BISA'&[
MWQF8BB/-TI)_3K]Q=B6_FNPA)6M>59(^?U*GU_]JYPK^.\?Y_??-BKLB$D1@
MN9U@0A)Q$L.8\ @B[ GJAA[R[&I2#9)B:0QMSL&G@6^V>YX<THE9NY(?:@7
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M/<Y /1P[5=1]3CM,^W;.X3!W^9EG6&9R YIR>*S<A$Y'M<-UZ(3&9W,G.AV
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M*(C-MH=[Y9*39CH 1SM>/?.\E-:-=J+9 /XC+;0+#6Y[<GU/RT?P#>?I9EN
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M 4,G!..>([S?U;S'!9WJ'IP*=#\];%7\R//TFSXONMY4B2XK7\U5R) ?>"*
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MHX@ZB2OL:GUT=;<T>R/^+7#>J_)1R3W( [03[7Z;9%P,ISYR:0%W!C289P<
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M#A,181BPT FP_%^?!XT;P)R O[[(_Q\%N>$.?LSO=NI=NY05_**$_57!>'D
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M4&7FV:V[;,3IR3I>,^-&0D/A/;2GV@WJ#T;VWXZ"[4U875#KE;^\!!B5SKI
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M@D/I5-KFX A36^8;?])63.^*#_NA/+[.3P9H+%^;.S9>"[U5_Y,7^?ZWC[;
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M0"$N.9?4\^!Z>+"IT>=65E +VS&[H15B5Z.P'^ &-P,[8-;!XCL.1L\V7LN
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M%!,8)B2!B,E4LT.F($(9QBQ50>)6-,IEL*G11$/>36%NCQB08] >=^7W"=C
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MRU(?TW_H;X($4BEI>GGHG:2E2-5[3+\;)TYG4@?F5:LH>*4I*%4%'XRRO\W
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M]"DE2R/(1*R@C+A$"@>)4L+SYN/HH%.SI[8RVZ AT]A]T=*:O3O8H>!IQDD
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M&3&/(0HQ@3@F >2,IC3E. D8=FK+>G[,I2T1;TEU#QY;N8&>=<!WDCMV8;6
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MQ51X=GT:)I5R<4O)L5H0N]/]JXY9FOV1M^0QJ_7IB>!7H#W<:2C',=UMFC?
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MBP8[J_B\9+#[[4-=Z*X-NBZ:MZG:,_6 I1A+C\,HU15<N(\@#6,/2LR(%'%
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M@:?..M[DY59*P/;4Z)ATOYM'7N2PT7U0,X_I7@0[[EW$]$[M&/4W_;@"6_V
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MG9AK*YA4]I\[@<E.(FT "N]6KRU]N:[@B_]VC_*!QBC06A.)T:XTX]+H^4L
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M>O4.POQ1'@)7'4W1<J++68L,,A!O(Y#H1'#EETS7.>%:3T\S%JL;EWM_F3>
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M0]P['[$U2$'0A-:3)%C<%,%0T^JL29:*::NBY[3.'<(?T];W06T52'6LD@9
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M AD_4RHYC!3!EHX/WF7<I9,VQ)56$ %T=AP"PTBS"L:V(++O?@>=HJV6<AK
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MJ\<]P\K.9,*W.8P3I+_LV6IR>N''JX&4Y=A^,AJFNPFJGQ[Q<#^LTH_N(?H
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M5[ R4TR #3H!R8IE9#-%XM%^$ TI08XIQUSG4L:.!/=K]EO$WFM[1R4@]'U
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ML1;I^I@\2RE' LDG(F7B)$A)"<I2.A>9 %ZGPNP'A+525]LQ()X-3NQ..PV
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M2S8:-I7;8/#E HQ#J[J%@.2>^8\P/QV7VR E6O\;)(RN[F_1S5 VP[$?QW+
M M,\F5Z5#@<HH(<?3U;5V:L+=T_$(@&<T4D3*A/N8)(;8AFS1*6(KKI55F\V
ML7N/%5"5P7Z3A =8&^W HZE5\PZFPZ^+L/!T7,+2A3A.Q_>B>2R9E0CNE?7
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MQ:*#E(JII7P:?.(%I#79J2*+]VT2%X;3..^[SL2H:ZRB#L#WY#,$B<N03Y"
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MUA4"=SSQ241;A+%@4FWES2F0<+6*RG,;A$A<*M,Z)#RIE_91NA_STCY&$1V
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M#'&:D<+&0@&DTL:ES)10K<;B[4OSZ8=.<\-\E-9/%M]U,Y\)IKDO10 SM4S
MF$0^'4D9<\@VB9!RZ,F:5YI/WX>9$]^CM3X>W_X*WTO\5(GXV%<WHV?IOR\7
MFT5==EW'0=7!&\L+DA$14Q^E%_GZE?I=/%]\NGJO/O)4B4E(G"4Y8'KA'N7%
MOU@RZ!B!!ZS=L94#;R2'(AT/,F(NH7%HU_+%_VGSM+5'_URNX@;7WVIH]7KY
M]?*"_GFU3/1;6Q5=A5P!)>,Z.0@N(J@4#<1 )B1*$; (7F)IW-IH(DXZ"0,.
M1>*C8>T<"N_ ";KE__GW:[;K>?=JC?]]6:?>;"]3B^/>&2W ())?9R5Q$TL
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M2D'4^1ZMKT*>H*^31YX>'+0&"NT)IG?CGY_YN^DQZA*QY1RD;!0%0CI"D**
MR2S*8(D_WQBM0\CL)&*=$"=#@M9)E-83(K>[>+.5F+P^ X@BP04:$*'0_@T^
M@0OD6RC!-;I"YXUMC+^?B>H$;=-#X3'0':B7&2&V65^<O:^E(U=!EBY<2V/
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M;C)JGMJ\[.Y/\]\FL;3!EC@2$CKPR_;@]"W)_II9S67Q+"%@"JKF+VJ(-E-
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MKW[^@X<^6:RQ6!@D*0GMT46(7 6P'K,N(7C?*"OS*:JZM#5C4/'XR^N!*NC
M%_[!R^_AXG*]]<7>E9LAG3OXH[ 1G1:)6".KJ@16_C0#=%+6VU)72INY*F,I
MG?=IHRGL&JCJY,Z^VY?L%ZOE9G6^R-LL>!+&Q;4P]G_A/VR]MN?G?FPW/F$E
M+R+Q"#;4WB^B*/ L> A92W3"&,_;M/]KY\._7M)G76X'RV[+7$/FK-A4@]U4
MJFM*6Y9%BE)CLC)8I3UO<]NT@Y@^S],1&-CENQ\B\ Z.T1>TY.+B54CU.N/[
MMJ5:0!/1&DETBU Y8! Q6HA**A1*FVC:#"#ZF9;Y$7.0>E>3RKH[M%SW8' E
M8#;> &:;09F2P"7)P16-1CE#P7&;#/Q=U,R+F$,U_"1@]A!W!Y!YC]]6Y]\6
MRT_WF;ENLR&\BN3?84ULL?76M(#GCH,QVH5L5+2-CJ<GR>H)1/MH_:>QWE.I
MH ,\W749/]+O;#<9XYZCB!*R4A2=,&4@((DHE"B#5D'DV.;A?Q<U\\=O4QY:
M!\N[0\Q<[RD*))E#%4FY1+MB6-^5309=>WUX-)A4FT>SW?3,:W4.U_,O@+.'
MT#N S@=,%"WDRL1-9R@A=?*U61B9R9J+&2#$S*!@$$Y;'[UOTP/E)U+Z LP^
M^OVI(?,APNX +?]<;GYB(1MCE906#!EA4!9I#_F"=>1'P.2SE*+-)<,.8N8]
MFAH@YE"!=X"9^P?VUNQZ39#W=%3[1,)03'KP3DN(7A:E5-!6MRDE^9F6>1.J
MIW9F#I1U=VAY&[[<["*-L;C$$HA"6%<LU8J\;.H$0<L9YBQLFUN;QRCJZ>YF
MO*:?!,Z>8I^Y,N.1,/"W2_Q?ETLD[<IK ZI+=C$5 5DF,LB:_+_(:X 8E#+(
M8K%R2)G&T/5Z LJ^FETU%O/,T*GO=&]68?G\9V[TS36"P=HRLT 0*H#BJ,'S
M8@"594%RIZ08,G/@UROU%%Y/ )>)13M[H^I=_+Q=?=MR<H<G6YBSF8[MK:>F
MT L**I,#E$9CB%Z$AY-M!L/EY]5Z<F(:0>9 $<\]V0*7B]7Z.OS3_Z;9V]4%
M;G:SE5(TQ$: HG+-1. "8E .?#$YJY1SL8/ZG0]?<MZ*L,GATTK8/6'(<*%O
MV'J%<7T9UM^)+7LS#\+DZ()&0%^[Y&21P66D/ZQ76;O@A QC,?3TDO/6@+7%
MT(3"[@E#^M_L+5O/+C]=;B[N,*51&T^&%'CA="9K5F?$.@G6A^"U$<@?WNH,
ML4*/+SAOS5=K&S21H&=W?NZQI=P/MJX].G?KT27CE:2SF(5ZY24-.,812D)R
M^IV."NU8]#R^W+RE76VQ,Y&0N[ [6SZJ,:W[X.MZ<7[G(':,L1AS+4W3GIPY
MPR&@C'001W1!Z:"U&(R8)Q::MVRK$5:F$FP_*/&,$2^_87KHL"E&UA*]!A>9
M)H=-,7 A"M"<9:9)B!Z'C(<:L-0@I/A31,HDPNT(*_=P;V[F'FJG+)<(S&A7
MYUM:B@ZM !Y1,9>]U,R-!,JN=89=[K&3A,G!<NW$7]ERXW0%_?\*RP?>NU&J
MR,09V%![<C-?(.;H04J?@\PN&)G&X>21E88AY73N@2>6;3_VQ++[W-SX6X$+
ME+7LD>7:ID&K %Z0B>1$2I R119_5< P;*5A2#F=*^")9=L/4O0CW*"-WKMB
M06QQ;Q)Q4T7FC \V*J4%#AE4]^N5AB'E=&Y^)Y9M/T@QV[/TSN61O[F -,@I
M=$- '6KO%\$@^,1 )/+4BY+%1#,.*H\M-0PKIW;-.YUT^P'+%?1WL,.XD254
MVUC3B51DBK"O!3GI+A69$5F(^]B5?<%R:O>YTTFW'[#8+?9_#W<Y<3&[I#,'
M5)R#2I[,HZ O12'32<>IL%Z-]%1^7F481$[MRG82F?:##KWEY/84E>R:F^WP
M9U?SRYRIN1E81\J2N()FRC+'+1VS(RW)[I6&H>34+F<GDVUO2/EA%B6_F2 M
MF,G<!%!2"?HCUJ)X)B':G(S3.N*(M\0GEQJ&E9.\G)U$NC.#Y6I*RYVN!C>6
MT1/0F8D@,B,64"D(1D>(GNF<7=8N#GGL>>3CAX'B=.YAIY!B=WFZ;VXG"2>7
MC(].0?%1@[*60U0I00@9$_U#).@?(4WWS:CAW$<*>J;.[]Y/ZK->RNYFY*9Y
M\_MP@1\N:N.,/W"=JJ(^X9D.M*4$QSIWBGAC%L$;,IA1>#I(N;>VQ",@ZBD:
M>\KPW1,43P)M,OUTB+T78;W^OEA^>O:ECBD[0T'"0>.!^YI$'[FF\UA&0!Y=
MDC9ZVZCZ[2FJ>DH);H&O W30P5%X]S _RR*%I'D$V@*.K+OV%":B 88,,>4@
M6HUKO$M%3_G T^!E;QE/UHIV&GS<SB4PY"NZQ &+X>3VB]J4(%I@UCKEBRXE
MM'&3=A#3DXLT/5KVD7@7Q]1=)MZNEND''_6\92"-9Z!29/5V(8 D]Q&#-K[D
M-N[0;GIZRON='CQ[RGU"_!RK:]^+U3=<!CJ*5U^^GB_",N'$;?H>7Z!M7[Z!
MC+5MQ!=K5I54B>+Z;$#Q3'B,*9,M"L:GDI),[;S*XS3BB\I+%A&!O+< *JC:
M$<H72#9:;X21Z-KU&CR%1GQC,#"D$=\8@7?@)>]H':8"FF24!XF\OLZZ "[0
MN8Q%VNQT8O[AN+3_08WX1JGWUXWXQLBZ.[1<7[DFPT46+H(LMJ8>UO:\7@D(
ML78/2SXDWL9I/HE&?*,T/*01WQAQ=_&.=5TRL;,+G"1[JYT1D(VF[:2$ 9]5
M!E88XSFXD/.0\NU?+M03+/;1XV-U* <+M0.C\G2?0!URT#(Y"#)F,K@V0]1%
MD[^//FP[=O,V/?8.;]78[.IO,CQ-KX(.\/18]*F4#+KV>J)P,=2F7KF.2A+$
M2S:2*V2^44>L0][ CMJP\1#G9@JISWQ</;C]OHY0KVZ_GWVCX+0*Z=5J_1[I
M9Q:IOK>$[]MQVF=TN#,GLX+$:CF7H,WGHJ%#OS 35)!./YRNM_,<VY^"GCSE
M/96_.KHFNL1;O>3:O%K\18?[Y[#^A/7[Z_ )WU=MGAF3-!><;'%$2^RQ"#%H
M#CI%3M]*+(4A!9E[+-V3N6J%L.EDWR6T?ERV7;N/;_ N?\BXS\$&(&)R[;IA
M(?H<@1=A2F!9<#ZD/F*?M?M\&IL67!-*__2FSSP:M"QP,_7DF2%K-9XZ,YK=
MQA-GO-(Y:0M%%3H4"V8((FHH5CB*#D3D^ACC%%M>='OM%9W[B8(41\;9: :!
M49#B##D#% @%E8Z1X=;O1?<8# RYZ!XC\ ZBPAU7<YR7Z$+-\0LEUS*D"*'V
MNS/.RABX,S8?X^*RSXON4>K]]47W&%EWAY;K&Q:AK$]!(=3)\+2#DH ZM1F$
MLUZXXGPV;:SH25QTC]+PD(ON,>+N #)/WZ$QG[GVA@&*$D$Q1F&IUO6*CL(&
M9YP)V&;HPZE-G!FE]5'7F&-4T &>WN %?=B[<L7+;3&D=87) #8E39NL6++/
M1H#0PN=L6)*F49K1#FHZO 0_!#T'"[P#T.SH/^XL2TDX 3Q5D3A=[;*C<)8)
M&UDQ,CPL%)NWJ_]1;[P/\7(.E'5W:+E3195IJR S&5AD=2ASL!"SEN!11".=
M)VZ.,;ZSXZ[^HS0]M*O_&+&?2E?_P(TPR3K@I;:#CLE C%F!L-I+JXJP8DC1
M^XEW]1^EV7VZ^H\1<_]=_5'6\SHC%+0(RK,,@6</BDY<0VY<R/IOW=5_7[A,
M+-K9&\4-;#GO:^R9Z$!12!99Z=KE.=<IE3%;U#F3?R_WA,O)=/6?$C('BKC;
MK+,%;F[8<:KV(#)@<VT&D6@7.)D"$$O66I-<"J,[(>]>JJ<RG@G@,K5PN\#*
M4XUZ!4/GG%*0#(]D):V&J*(&Z[11"JT.=F33N ,Z(!^_L]-A.)E*L!W$2O\[
MK!<U9*S%UML(P&1>1/"I)MB1122*:[*4KMD A>6B7; /#IV)8J2'E/1T(!T>
M51\DY\YP<KV')(\BB\@!@]FVEN#@A;? E.&*:>?H+\V1TD,<?9ANGP#*'H+N
M "JOD,0=SE]=+O/F92F8+A;?\,.?X6MEZ6:JJ&5:"6Y E#I22?, T=0&X-$F
M\KL\.6&N"78&$-</F/;1_ZJM,CK U\O+]2JOSL_#^F8T5W8670G@E:H17W#@
MT$C0$;T)012NV@SK?$C)O&'WQ,@Y2,PS^[\OPC+D\#PL_XL^[EE*^/6B)JC=
MP3R:C&S;(EPE<M-<\>!-,J ]1Z9T"2$-B91^N="\7LQ$D)A>I!V8D>=A<X]Z
M+"HR-.!MJ%FP08#C*0%FZ[C/7I<BFAB1^W3,&U=/;$(.$/',!N2&\G?K/]:+
M+W>9*-9;89T!J6R=ATXQI&,D'@)XU+[FA.@A(V$>76#>@'E"@S&-"&?$P69]
M<?8^+#]=^?0^<%5\=,##MO%85A!UT%!=)T3KI2Z#FBK0I]ZQ#?350[MP;]F>
MKMGV#X+WEV0/ZK^]V DR&"/ UGLC502"E[0/@G+(,2LDUJ<%P)SAR $J>ZCT
M/>0WL]I_7RP77RZ_7!,>-5.!:(1B/(5'+A/8L]-@HG(N\A*-'91I,DCQ]Y:>
M6?7[*&XUA13G5G_XZR[A3NBB= !>2GTG4G1:)4]*$RI;'XQR<5!][3#UWUUZ
MGG!R,O7O+<4.@H/:ENOBNBW71_J=J^089YEPD2)>25I35B9P(BC(R4JI30DB
MM0D1=E'3T\/*X=?C!\N[0\Q<^\_>:>LRJP5PI3XUU5: A2.@,5)X*07'-E>=
MN^F9]W;S<#W_ CA["+T#Z%P_/-]IT!Y$-I%1C)12'0 2ZY1XFRP486510M!.
M:V-K?B*E+\#LH]_5E,+N "W_7&Y^8B&YI%P2KK9Z,Z "EQ <CU"[OT<LT0O7
MIA!C!S'S7H,W0,RA N\ ,Q\NXP;_^Y+D]_);/;%_V%ZEO8^QIC\0]+D,$'T@
M9X_K8K1#%D0;W#Q"T"#L'&G,T^%NS112[Q,\U[O**@H/A)3@8Z["(1L:I=Q.
M,8NF9"--HR9YCY(T[W$UB<)_#:(]I-\?C&Z>%2DN##J3N^?KA)*8-'B4&2(O
M.J7(94)_# CUX.U,I.JG ;2'W#L SV/-3*QBB?2;P=HZH94+#S$Q TQ;U)A+
M2.(8=6!O1K4_.]($NJF+P?:3>@?@J83?5$#>EL]>W4\]7ZW7JS]K*4KX2O]R
M\?TL>=0BJ@QU=!)MC"C(:GL&1NN0N.;>N4;3$D90V5-!T)ZP>!C)M])15SVK
MGIW3IR[#!=8"A;>7U1*_*[^%[YL_UHO5^N/J0_J,^?(<\^_AXG)-K+Y>OOPK
MX6;SKM!/+-/B:SB_:ACWD;"W^;PZSV<<I8U)*) ZUL0<M.!T02@JVLB-3E8-
MF9G8G-">JI(.PVQ_>NT7Y _8N^'_!YNJU#8:D0%%YW6VH4K@ZR'EB7>'=4I=
M=H?!]U<D])1JWA28D^JB@W/]/JMT:N#U4*^0;>(J&>#&&U"V2 C;2H] 9X63
MRFE_C+99/RCJ*9%CFO-Z$MEWAZ'G8;/8?"!:0GZWO)L-Q<\<.A],": UB4@I
MB1"*PIK_6IABDO@Z1O> QRGLZ4FP!<8FTDU71^5-%\W?PS+77_K^QQJ_7C?]
M_3'V\BU>O B;SW^L5PDQDT^Q^HKKB^_/EOG99H,7;U;TY^9U>;%8I\LOFVUB
M[N9WO#B+F2-#F\$+(6DKDA9"R@:$EY9YE[V-0[H4')'DGNY_ISZ*^]'UZ6^!
MU]>CTA+%C-N/^UD@-AKK4W3@R&&FTT=S<$%J8!B+D"2@89/"CT)L3[=&7<!^
M8OV>(.#?E1>KY69UOLAU!/)5L%@E].I\]><.:3@5F,C6@PBY=C*H'>!T[;AL
MZF,DLUCX^$N %I0.@KK[.T.]H69/$.</-O[VD/L0SG>><1*#BXB$6ZTI/(W,
M0?!,@5#!.UF?+\R0!CJ-R1R$</]W1G@KG787+CXYJUYBUI[%#%+ZVF=?1HAH
M*+RK':N%CLS[014#!P:,3]$X[!F!G0)6&RMH]J91#Z[UELO+[37>^F+Q?[<*
MJQS>X2TDZ04%OV!-K'U(Z.B(W/AZ'Q,*2IO%H!%TXU8=!J>3>)9J+/*N#FKB
M8;'*BW0];>C_OPQK6N;\^UU>S[()#G-UMY4RY(;D##%P#:BYS9Q%'P4;#:@A
M*P\#U8F^&TTN^@Z.R+LSS<]XX"@Y%M"6D?<JO &G/4)4W-+1CRJG-EUB[E(Q
M#$(G\<)SL)![ ,B.I_[W6/.<%LM//S_V*RN+MRJ1-;7$G:,#.Y2@2?%&6AZ)
M-]FFO\<X.H>![*3>>!HJJE,8_G-YN<%\P]&+U9<OBXOM^Q;>/>G)XB;.#0.1
M,@=5YZQ[FR0DK[4.PAET;9JD[4WR,'">U./0<=0WLZ.VB\G;Y_I7J_7K95IC
MY3"<W^['S9E!+:/. ;#81.>!DA DKVT6.!T&KC#CRP!?;:_%AR'M9)YPVBO@
M%!%V]S+S6?[/RTV]R'S^^N-OS\Y*D84"Z 0FUX'-SGEPM3&S2RP[4H#'06^.
M$Y,U#)4G\\(RI]*Z"ET'3J&TJN2,*,$RQ4 QC."\D."#5Y(XM$'O/U]V@AF@
M_,0?/"84?Y?P^KBBG72/I^O4Y#-,/C)F(B3-R=*S(""D6L8LK+6I8+)E_W>W
M1Y<=!JH3?V.81NA=XNGF6OK>).;KABEG*KJ0559U(',=:9D\^%PT1".D5<J[
M$L;?M U9>5B"]DF\!AQ!]*<]K7C;P[SEB.)["QQQ+O'CC+4=1IRTI+C1*#KC
MDB";E!Q$Y C"A*A0*1'DH 9Q>[WV'6<8<4%!.XX7L*X.62DBT3%.NR.8Y)'I
MR)EO,Z;O5(81C\' D&'$8P3>P87:CH%BP4AKBO:0>-DV#:YUJ[7PV9M,_^F4
M<YL^)GN.Z3OJ,.)1ZOWUF+XQLNX.+7>&<Q1K''<J@]\.IV1%0-39@T8K>#'6
M"-NF(OQDQO2-TO30,7UCQ-[%?)OK U\YJZ\._=NI8.ZZQMVAXT4*A.!KPER0
M'$+V$J2EZ#,:1V2E 9[TP.5Z@LF^>GUL)M)$0NX"-UL^+&/$RN]$RF?B1=UT
M]9%2!:<$)*-J*[(JJ\(LE"RDCC9DKH9<7OYJG9XJ82=#RD1B[0(BUZBO,YYN
M4/\*X_HRK+\36_::+2,#ER(QR+)FH$M5:@L- \G&1(((,@ZZZAZQ9$^5JE.;
MF F%W8%WL[/3H61<FBA+G:>[S0N+$+D(!(DD?72*_,%&F0S[=A ]ZMCJ0_SA
M@^7=(69N>_]8X7G.$*(GL6@?P64KP*ODZ MMR.,["FIZ\(8/U_.P#J)CA-X!
M='YN:BFU<4*X##99LLFAYH2A3& "3])QX:5IU)KM)#J(CM+O+SN(CA%V!VC9
MU= R:LE4R>3&B]HF2L4"(3 ZPTN,-@;.C&P3=9]*!]%#$'.HP#O S/T#^SUF
M_/*U:N0J@WEKAH64.I=@(*3(0/D<($BD0SRBY](5&]0QNF[LHJTGQWGJR[^#
M==$]NJYW(!KG=2@&F*^O<UYK\'4#Q62L$-H(M,?HP+&;NIYN?PY'Q"C [:&>
M[B'W;GDS ,,(.M,YN919,JQ5MW5R"9,@A8E!9I?*4<KX'B6P9^#M@XQ1T-M/
M3=VC[^.?JYO;U<""E3F"X4K62>4D-=3;*B"=HA:,'Z63U:,$]G2+<'3T[:>F
M'H::787-D:$(7@!+F6)GD6J]1B$P"&]MP"!$'(2M4Y]IMX\KMK\D>U#_-6IY
MC-EBKG/=)#&.24!@Y!<(87D06 P?-F7D%&?:C5+9(S/MQLBOJZ%F067/&-,0
M0\WW5H)![<X'P6E17$@ZJT%C'QH--6L^TVZ4XAX=:C9&BMVY'&]N\RN-LTH7
MQT [F4#5X;R^)M<JVB HC<BHV]PO'])"_:BCS::+U?>3>E<YS'><H/4BW:FK
M>_&Y[K#%\L5J>4&KGUDM%!,F@/&H0,DZ<J>.?.12>I]],<*.[SXX=/6>HJ(]
ME?YH*G,3#71GH)YLW<)92C(("\;5>1BY*' Q"-!2!V62RC(<PV8=W%OGZ&TK
M]D%@8_W,VEIG-V_WVAEC"KP$B"97,1%/47%5!WVI:&3B(K:I]3ZHE?31>UE,
MAZL]9=^!_7I_VPKM7;G7GR/+Z+-4Y!YB'?_DK 1O@P<9LW)12N2ES92UQRCJ
M*0:?!D.3R+X##/TC+):;JR:_[Y8O_[I8+#]=+C:?*V=7G5#/N. YD]L).;KZ
MUIR)(24E**ZC8U)3\-KFH?:7I/7DN$^#JFFU,1Y>_@I>2_Q4S]>V%\_W7<DS
M%:4I4M%&L<;46],$,8<$7&7%K$,??+MZI@$$]MDI?+IC<!K-=&#1!K+UTR"<
M^I/X!?-9#(PXP@2:)9(D5PJ\HZ!&"S16<TU^P3$\L/&4]]G5^P@0G4:7)UI@
M>YOKTZ[$=O<2QRBR'<!<VS);+9TK44<0GJ7:]9W0ZW,!5*8$Z8QTJEW@?YPR
MVV1,5CPH*$PJ\EC)TKL8$:((3GM=F$ON"/:NWS+;,1@84F8[1N ='*@[4Z!1
MI>(3Q<9YVWQ6DT$/M#A(5R0/7BGNVM1F[UU:<-12VU$J'E):,$;>'6+F.C4B
MHA'<& _!DP.IMB4\T0FPP6WSF8/B["BHZ2&'[G ]#RLM&"/T#J"S*W>Y3IXP
MGJ2B71T>'53MF"+K.X,+,2CAO6XS=7G?9/%CEQ>,TO& 9/$Q N_P/OU'],$T
M3S8:#A%M+5T7&@)+ 9)EF1&34;LV%N>0Q^:C5L$=<E1-(?73?&S.A4>+.4!1
M-M=+$0HL!3F&]7M,10HW\X-+@K_]8_,HI1_^V#Q& R<7VO\'+CY]OL#\[*II
MV-5[9WWY7)6;=]")(_T1*[8-_/=EO>T]0#0AQ9 =)"%KR:<T$ LF*%':XD.H
M19\G=@_P0-!WW]?/)";CK>1@=$TU*[+VI NN-OS7MG#T*K1QN'Y!V/R6[T!L
M[#I!IU+$R5FY9Y\^K;=/3=>3P1>X6=U[39W8Q@U>KZV%VX_MQO;-ID#_<2@\
MA#J)7=!I&CWDJ .=W]8)UJX)UO3V[:XT?TCY[J/][8O!U8 ),ASORBNB(YS_
M'PSK,Q&8T\998"A4+>])X'B*4)Q57C*/TK>1QZ&4]VDA1Z#KJ<DSS579P?W'
M"'Y?+]^25?CX)YY_P]_)+?Z\.>.(16;'Z 1*B;QB+R%RS<"*F#6Z4K1K4SUX
M$-GS1\7S@?9 )9X:8NN6_/CGZHR5;(ID!9B+=01 H? MI@+"!>]%8CG[=KV)
MQE([?P[DG/C<1V4G"4O"&9Y%[9";J"!LD]A]TO0WGT$Z%K 4#"ZU:W\TGM[Y
M4RMGA^9HM9TB.%^M+M=G.BC!G8C@G=*@E!/@B'Y GHKC)3@Z&?K 9B5W_OS,
MN:$Y6FDGB<S%-SPS.F=5C "C:=,I$2U$*>AO+O LO#"Y45'?7N3.G\PY.S+'
M*NVTD/FLT+*W?+)D,?-Z+.10>WEZ!L%J =9:\K"UTS*V:>2S+\7S9W+.A\_]
M5=<!1.^_9;T(Z_7WQ?+3=7D1#Z)X&>D,L(P$R'F])Y:)&+)9.^*/Q6/,L[A/
MU2"H-1T7-C'4)E/!_G#:#I*:'D[_7(:K,=V8J\PJ0W^L\<OB\LNSY39YX_5F
M<UF'HKU8;2XV;_'B#%%'KD2"F'0MB]0.O$P(!H,M(DB.XAB]I$83/@B43<>-
M-05E6T4>6O;SL<UD=LS9H/8& M?D8F2BGOQA\H5]-,K8D#AO?^$S[':\Z<BQ
MAB?K*!E/9MZ.]5KXPV]X2T:=UOF&$[\//K%"VQ?!H:RU?0,,1FB#I?:PDPQ4
MJ//4C7.$(Z4=LS&SAL.3CE/KX'..,94,AM?J7%^C<ETSWCB/N6A1Y,.!&__#
M:AW&8&!(K<,8@7?GOV\SLET(20N*BD.V9)PIY@#''+&1#?<LFH+F&(6I?=8Y
MC%+OKT>*C9%U=VBY.Z D4##!&5*8ROE5 Z>89:8_/'E;LC"'QXCT.AXI-DK3
M@T>*C1![%W-_ME6-=1#-;Y?X[.MZ<4YJU=<I^$HS='6^!'I#]M<BN7&,=EID
M3BMFL@IJ^#"Q)Q;J"1K[ZG+W<*@)!#LS2I[5@43O\=OJ_-MB^>D%+;ZH_6H6
MYXN+[]?<>)T*UT&"R((B0YX3^%JG7RR/3J.)7I0!,/GU2O/G:$R*DXE%V\%I
MM+.>S!;%4LP*K$D&5*RC:HRKU1U,BZB8MZ*-]W(:(Z .\5\.EG>'F+G>5,QE
M(VCW@,50F]4Z [$V5M-*!9&#EXAM&DB=3)WF*#T/J],<(_0.H+.K;)!,:HY6
M*&#14_3(<G7HB(\2DF'!EZ1SFX>V4ZG3'*7C 76:8P3> 68^7,8-_O<ER>_E
MMVJ#;W83U\P6:3RDY-C5!6@(48%#I@WCUOG0)MOZ$8+FS_>;\J":0NI]@N=Z
M5R5$YR+QD R21Q_K+ YKZ,O(D<L@C-%MCJM'29K7^$RB\%^#: _I]P>CFX)W
MX1W+/ +S2E$807^C"((DY9-$7T>]I#9^\DYRNH///JI^&D![R+T#\-R/$[>;
M2@>*,YE/-=.T=N5/##QR"X6S5)C4&4N;=\V?:9D_%WC*8^M 67>'EAL7D#LF
MD$ROQH3$@Y% 6 ^@"[,*K54FEB/@I8=SZE -/PF8/<3= 62>OI%BV@LOLR?3
M*RA\L(F#B];6!OOH2TD!=9MWA<-O!H\$HGVT_E-KYZE4T &>'FO685U)5I8$
MGEER!:4C5U (#T$6F2+:HKUI@J1#^N(<=0C+=$^;^TF]._ \WB'8*Q^%)XY0
M^]I"**OZK,<@&(E,2*9(;D< TV&]FX_>+V<4&/;LW3Q&,QT [EXRFTH^&&<S
M9,TB*)0:?-021*K-?+V3&MOT81Z=,'CTJ2J'0&=O&4_8YZU!RN ?+]]^>/WN
M[;.WO_WQ[L/']R\_OGZ_S:U[^?L?;][]GY<OG[]\^_+5ZX]_O'GV]L,>^8*C
M/GZR9,']F9HH4_#%ZLM77&ZN +_,[_%BL<:*Q1VI8\G%&#E&.B%KHV]7+#C&
M,LCBD4Q-#$FVN4(90>2A!NH/6N=JE7<7GW']QXH^]G:YY[C$LKC8_%CV(ZGA
M.?W^?YTE<@Z92!YJ,_W:QR="9%:05UIRK%=O/+2IW-R7XIF=^D:X>V@,CZ+/
MGOLRC;$P6[]XGV3K/1:9Q83N8G &0UJDY>@U@\AKG&FCO[JF%]&ZY&I!'#MY
M0_HA?<9\>8[OREN\V6C;:I>M#G[LLY)%4G449M9U<QM;:)^E"%D9[E3,QN4V
M-QX#"3P=,SD&53_=W3?0UM_%*E8=K):UB'55I7,UJ7V1[DAI_RJ5-G3,8EOW
M%-,,YI<EG90/=7@;-W2T%PZ^\ 04)J&4424=&SWHS&%^?R/Q+S%?Z^&/\["\
MX^]<[>\S)X7$.L)'\)KLA*H6S*8$N02./'@F7)M(?!29IV.*QR#L<5,\M>8Z
MN/_Y(;7*SH]D.\4E^?5$MHB!CBYCZ%@1"#(*SY3!@-BF:FLW/3._SK<#P$\/
M(0=KHTM,7;\199VB31)!:.U ^9C 8\C@!*I@4$33J&7-8Q3-BZLIM/U+ .TA
M^@X@='U+<+7#[FVZZT?!K(,-7#H0P<?Z:IU(2%R#PR0*<U)GWB8![5>4]0:I
M??2_^\IF&F5T *['+YX>9]&*+$PR ;SQ""HX"<Y+#SFH[(7GPO@V#MD>Q,[[
M@M($@JU5U@$J[\OM X5NF]7Z3?VUJKAZ, 2FLU J RNZSO6,KK:9\,"+SI['
MJ(MND^O_2]+F1=Q<_MFA.NH==-?[%B7&;(N&&(.DV(EV5% N@BY<I,2X<*E-
M=#Z N)Y.VX/A, 9L>^AF1KAM&RZMOY_]\\,9HJCS.BQDJT3M#6_(/DL#:(ST
M0IL2RE,'Z0;3OWU:??O_KC_Q"DS77VQQM$70C_4Z!L@^*EP=),\.#,ZKU1H7
MG[:^Y/4QS;T1.=:DBF+HF.:F9KA; 2EFP9(05N<V>7$_D=*3WS0=5J:1? ?0
M^?EP_W&VO[E-U"G9%5M<!JWK,[%DN19,V/I6C/295F,C1WT0>?.6N1W/49I>
M5UT"\ .NORVNF@:>H64RH$M@16TI%Y('GV*LU:8)ZSN<C6UN))XD:^Y$S,EA
M\$N@[:N3+@%V,YELRXT6BG-!Y'.%)"?/"WC.%$@7 B=W4A;7YOKT:;KF3M@\
M/L3VUDJ7&'OYUU=,=>(C7ERNE^^V'L*SS08O-F=61VL,1^)-DK\1,H>@,X)%
M6YCE,03'CX2XQZF<NW3\^/B;2&/]M*W]F<5G5^UZMVK<MBI?K>\8]JLZH;-B
MN4I:%'!\.QZ'I!HD,>M842PKZV.S]IG[T#MWL>CQ@3JY%KLTH+N3:\YB<DPG
MR:"XH$ E<IT=DANB@ZLEV#SP1F.-AE(X=P78\?$X@:9Z;N+\X=^?O7_Y_-F'
ME[^]>/=[315[]O'UN[=[9,$]\D&3I;$-(72JSLNWH'I7[F8,O<?S>H9M<RH_
M?";$QK#!_,?U=(P?C<*EU\DX#CD1])2R EP=PQ:4E=):[J5MM(D/HOM@(S=T
M]>=W5_^1EHK,FYB3I<UD4MU1Y(8$X2"KH@5:E81OU/7Y,,)G#I>/A]6?;.41
M%=YS'O)NR[1W'<:3']?8G#:LK3@0J'2@6L*#)3^OMB*N'E^,6H% 9*BSD+%1
M=N&\1O7']>O=M>NBK\@O?KBYGJW78?D)KR@X/[]^"'A7?OS@PT_9//^^3;FX
M7R%@H^&><PXERMH^H0YC5L*#]U$%P1GMS3;/M[.P>](&?,R^>#Q+N5=P=1"[
M_1#2;D:?I8O%M\7%]P=<*J.T,A2A<@P:5$TBB@DE<!%58B4EXQNU*MN+WIDO
M9'O8 \W4>WJ^RP2C>P9^<&-_YCB#>@Y#K]<L.YD39*YR?3/EX((@,#NI2PA:
MN]2HR4\GGLTC&^_.<?/\^\^GT9]AG:\>G85!VN@&P5MB4L5BP&&='J@QL**=
M;E4B,!D+)^V!C,'O:.O;! 0=>!7;F\7PY:IZP\@<O0T&>,BZ#G%R=)C0L<*4
MY-H[D65IXRO<I:*7>JFC N%AU<*^6ND(4==I7T*&Z)/G@"D@**D31)0,HM<Z
MFV*5TFURFN[3,2^J]M?G(\#80[@S#Z=Y]V6YB)>;U\O:;(P<H<J)8%S=-DID
M2-YKA,#JVZ^H0K%.0O#1"!])4M;^PM/[]2I]@& ?W:V:"')&2&S6%V<?%Q?5
MT+Y>9HIL\F4XWVX/P24F&Q@45FK;\2#KF"\ZU:/ES$AKDQID,&B%.\:"OGIH
M*!XEH9>*D#E.H&GTTANP_F-Q\7GK19+\-I\77S^N7M+>N>W_*BQSLC[;9U;J
M39"UX+G5%,8;'=&3O0Z#[G3W@]S3Q,UCLR:"P5.@FE G,Q]M;U=+_/+U?/4=
M\;?%&A/]Y$UQ*2JKBU1@0R)A)51DXUD $XI"(64P#X&U\U1[=(&.P#&E.E=3
MR[8#M_B7QOPQ6_[F-I]$<V=+BA:<2 *4$@:\<PF8M2*:3 RWFCIQ,.V]U [,
M&=0=&0&GC/FWEW6+7ZMK\^SRXO-JO?B_F,\25_^/O2]M<RK)T?U%FAO[\C&!
MK!KF4B0#5/?<3_G$H@!/)S9C.ZEB?OU5V,Y].[9/^!Q7]]/S,$!2)[2\H9 4
M"JFP8(CMQ"THKP4)@#:]5YK[E*R+?&1;X"E6!DYS'!B+?6V%7H Q@IU!;'^;
M33\M9^D?K\/WR3)<K#GZ2#"8_\#\RVS^R^7R<HYO%XO+0*'>N2A"&AZ1HKE4
MQPD@^5TR%Y""N!8F<&';M#;<FM2!PZ=AD=U6L2- [MY;]R3G2?U/KB1S:Q,;
M:V) QX"'FA)A04,4GH12FV%DPVB3LW%:]Z>9&MCS.7([WQ-8!@X0=Q;#ZL'S
M+$_*9%WD\DN8S'\+\W_@\F_AXA+?3;Y-EF?3D^F4 K!?Z6O+<Z&\9 (M&,\C
M*$=2<1P]",DLJBA-,EWRJ(>C>-B')0/MCQ&#XJ]PQ&QLQ8\PN:A1&YVY:SE(
MG6)FV563D4 A&@BUL[$V*KJ0HQ"BS3"U5AP-^PKFV ^7/F R@NURNLF/;5ZG
M/2Z6][/I#UPL,:\DL/A<'_3<+Y-\/UO^/UQ^Q#3[,ET=L=8E% P9H."D':WH
MB%76 JMCRY*+637RQYJQU&G#F+_HAAD'4/[*.V;]0(\,R>:OZK_CY\2!)<4X
M<$J1IYHXZ4P8"26[Q'E&=,>VC1[EL]/>LO_:6X>&U/&5_7ZZ_/8MS'_.RDVU
MWVTQU18"TT7O-<';K=JX8'@/$8RCFIB+R%'$U7 /5GN[): ]9" S--GJ@HHU
M:K\QDFKB3A;A]ON5^WO^9F3*N9-2"(4!7/8<E(P.0AW1F*(P-AO"M6DS,K,)
M.T==9;P-KI^N,AX*'"-POM:WJ5<-XYG-]#\>(+@Z(#DZ!!^EI--,1R^RL$&U
MZ3QVAXRQU!P/!HM97SH: <!VO^._87N:[U5KH@TBZ$"^8;&&MKW,X)AUD K+
M*G@7L-&XRA;<# OW/<"U;0:HM:9'@/9KDU&O',]68YTW!5)HK#>T)#AD%,XP
M9<!)@1 I2/!1%"3QM@T[[Y,T\IJ'YFAY*F;<2W4CP.!'"FKGD]K5;<7*[Q2E
M+CY^^GW#C%1TVEAI08DZR\"1G )3$9!Q30>2](6UR;H_2];(JQ0.C<7^5#@"
M/+Z=4G1-VXK\^=4D]-M=[9DS5D19Z_:L!L6MA! S M?"F<BX<:5-,NX9HL;R
MX& L[F=?^ALO%#<[UL:<?%0>3-$>%)H((:A<:^MIPV:NBVYS1#]+UK#'=&_*
M[P:J'30Q EC5<C(BX"L= F_P!U[,OE>>-EG!C=$6/H6<9:G7_+0#41<2%K%D
MK$+G-7=:M+%T'8@;)<1V@<+#8[17O>P,M1\XC[.^ FJ\H!]]^16G. \7Q-I)
M_C:93FI"K#Y W'"WV+!G4F1:10XVE3JSM#:D=,E#T9@2,R8+WZ:-Q%9D#GOD
MM@-@.UV- HK]>"@W5WXJVA!YTH2I.M>MNBI.(ATHQL6BN*LUN,-=S79G9"SO
M:\;B00Z)DQ&X!QO.*)A[E/&-%3@W@IO$:.>'Q.N("4]AG10>)(9(N]_%5AY"
M-_J&=1(&A=#]?'S_^CSVJH"'JEAE1S9=TMK6!G1;^Z 5 CN(8QQU A9#26@D
M6!XL*!8]!&88D)_C8U+22]5F,.A8Z@3V?9+*6?8JH /-/6WZ(FK39.<@:1.%
MC,9[V4: _^HZMBU^VW4=VP8$8_!/[EP!2A&DDRZ"4[F0"$N] F06@DB>^9RM
MRFU:1(VR!N"@4'CVWG\;O8P 5$WN5!QW@3MC@'M5ATW& EXG!&2TN4VFG8YM
ML/E7O_??"ER'N/??1M,C0/O3E\<"16#9"1"U#E\Q7DBH,4(R*+,6)3/I_G7O
M?TBT=+[WWT9U []I_3SYMA;8S2UQ=BEQD@>$0ONZ#NZ@")<+*-DCB21%O%]P
M\NC;TX=?_@O>U>^"GQ[$/C1H/GW\@/,RFW^KK0_6?#Q2>'!5=> =H9]D)).L
M[_!(4"0L 4Z0FYT$;0;9I7O65HN._+G^0:'63%D#H_#CV>?76W!6 A/1"PE!
M,@5*!U5K%05(Y;D)7OA\O_/*HS#<;M61/XL_) X;JFOHOA!(ZEB)=@O^4@P,
MM;"@9;:TT<C2>Y(CF!2*% F]OC_0X_$.#SNL/?+GYH<$97/5C2#$Z.%)I0^U
M20L6<-9Z4 [KBT6=@7.;1;#>Y#RR?FW;7:D>01?@??)!!T; ,6-^'<<M5ATD
M%F^GZRO ][@\*[_,Y@4GM>?7K5D5+M<J6@5%25X+V01$1V>6R,KX4F)0LM&H
MD(/P-_* OV?4]K5IVD'H+[>QSFVQT02MH>A4R,L3C!3D,B0CA9*A1.O:O!OL
MEX\CW2@-D=IT,VT%FV/8-$^>_8^R_W><?/E:VT_\P'GX@J=_XCQ-%OB!W%4\
M+TX+\@XL!$RYOCD*X",O@)*[R**6Z =JCM4?DR-/)![!=AL(<,>P%_>1S.J'
M;\(2:S._51N_<Y1%!^T92"7K:ZYD@(@*0/&C#=X+7D2;:YP#,SKRC.L1[,D!
M@3>&?5FS++6;,N8WE_/)],N:SW5SOWO)F'7[OR>5Q#!$Y0L8)<GI]\Q!S$6"
M*46C,27SV"@HZXN%(SW?>HJ[!@'"&'; KG(__9_+R?+GVRFQ?;DZW,^67W'^
M^6N8/NX])Y45FB3!VNH]^\+ ^Q( (V>D,)E(/>,ZDK;D<.!P;!@ ]W7<M$33
M/]$N>_F YDCRR4Q"]C92$$LR<R%Z\"69$HIGK5X-CT8$ Y]S_U3[M%\\COG9
MR<GKU[__]ON[D\^G;\X^__OIQ_K:XN/IOY^^__3V;Z?OSCY]VN$YR<O?[.V9
MR);D]_3\HX)OCE\)?Y,?N'[7NH+[Y_#G-<P58XH'2=&/0025@P!G*LPQJ!"C
MX4&W>:+0@;@>)OD\6&*VQ,\DWE?T[_YQSIW66&HO%NL"J&@T.,9PU>JJ\)*0
MML[!F+]-V;#.3M^X>6003W]Z.6JKM;H&WN4I7-<O'\Z"/<;* >V8B=R$I#1H
M45\D6Z<@I.#IS%9<N<C)9SU:.W93<'"2TN6WR]7CIY5G\,CB[V:+]2/MF^VD
M4\H)LR?J4ZBM!"(XS#5RYZ'PG(IVK5O4[D3X^*W@-JA[^H59>ZT>M9&\?DU;
MY3*;5K=X]KS,JK1V?V;<F*##F>0>!7= 2XZN>%[S\48$!TIE"]$C[:Z2$PM:
M,_K-L5KR;7;Z.<^AF*03!,<,J) $>)X-I! 9R\)8ED0306Q#Y?AM]#9X>O#H
MLI6^QI TNVIQM$XZW-B(U1M ]#Y[91%T"76:LL@0M'(@!9>!6R&D:.0S/$?6
MP*\DFZ'AP75)7ZH9 <[N\; I[B8Z4[(J <I<.PB9"-X'3?LS)48\,>%"FY>0
MCY$S].5";^J^_YQQ;]F/ $"WMMWG>9@N+M:*R?]]N5A6J5T]T%2F2/0,3. )
M%"=?W+'$H3@>:<L5)ALUM^M&W\ =D_8'PM-'8U]:&1?6WF"93#&_PBG]9EG?
MIBP><&=-B%ZBA.(C&7D;&'A)W&6#HK"0D<<VONIV= Y[)],4>WUK:5P8?,K-
MV#"F14XI20,6$TG.\3H\-B-D5$RCBVCU8!'"&-[L-D5>C[HY#M!5W_;==3E0
M9K)(%C.4$&J.WA4(27D(*@1A<Q1!#AJ=OAO'8[&#Q0Q-%3@"@*ZN[+_.+DA=
MBZMK\G1QF>L=_VR^4N=R.9_$R^4J33I[/R.>ITNB@K[XY>V4*,'%\KQP51(S
MY(!(8E@EM.#K-1;3R7(OA&.-LDO]T'\4 ?".&'NL9O"P"N^QCW*#1/G'TT^G
M)Q]?__O)^S=O3FN&]\-OI^\_[Y#@?N)#O26FNQ#:4T+Y\:;N-T4\R6?CBJG)
MODR_<%5S?QYT,BZ7@):;V&2W/T]77R,&;G]ZNJHUNB34?YJ5Y1^TGV^Z)]Y<
M&C'-F4TV0S2K*0V17.'"(R1G=#3!R]+H*G!GDH>U>#WBZZEY!&V5..:;O\?M
MQ,XU$<]^KK%Q:UC]\ ($A6(B<1: 5)_(9Q0>G. ,C),B69^MY&W:.+0Q<:L&
M'NM[R]JV^YF1'?>NPWFQF L%^=8[VA0E!8C(&$5>)A;&$$4.+P!HU[5';:*V
MP<>=+BJME7!\ENGZ/OU*).&.2':O.-AKN<:6;1>F#V/YI..A1$G!A=9T C/I
M(0:!=6!*<5FJX'*;5YCM+-^S>^W#?)8OTW+3_/I<R9!TS1-HZSPH0;]S47$P
MHKZ8]S$HU:79U!9+CMK.;8.&.RW,&HE\Z$9ZS['UGY?A@N+IDP7YE;4YUCG2
M&6$\1<7))@<*D8-#[H$I.C4BNE TVQ=+]Q<=-B\W!)KV$OL(4G#/,G?ZYR8Y
M<Y+^YW)"Q+V=TNY)N%C4-OWG-@4;ZYM1@>M,$'D&W&@RK0%-S#ERT:99]QY$
M#WMYT0"AAU;D[IB=+<-%6Q=O53)Y^E]U9LOIV_>OS\C7.=TEF?;X=WISRCJ0
MV9.WM<KHKI.XA(NK:737>./<.2;1@I#U/1Q:#]YD2:<@0<W[J(-MLX&?IVM?
MFW;WZZL_;99X+/.BC9*:<0E!A%*K&1#J$!&0,G@6. ;3Z'GG5F0.ZZ?UB*/[
M=JN=LL8<C#YJ G;.DCWWM;96JV&.[ 7,:9^*"<C 9DY(D,70F94R"%.R888E
M)]N4AK6U73<O2%;KO)]-9]^Q=KZMUU]US<>3-$P)*[@MD'-9C462$'U@$"T&
M<B&B2XV&4.Q&[ZBMV3;(>OH!4#/U'9U9N\XVW3;N[W&/W-I.R[0UA%LQ>1@+
MF3!:RS$!RS&!2J: 9U[2#K9.:!]386VJ>=I:R%_#9%HK$C8)G,^S=Y/EY,M*
MEY]PN;Q855V?4P!E<LD((@5%C@(*"-$HD*JHI"QGX?X4@9Z8[T3>J.W?-KBY
M;__Z5\[VYLZOM^D4OZQ(Z"U5\NIR,9FN0N9O<3)=:ZN&TXO)_?F%Y^2&(E,4
MPVN5:Z%@"A!"H) ^.:.2)P&'-B^7N],X;*JN(00;J6D$N;JKS74VI=#H^VS-
MT%DY62QPN>#GZ(./@F(OHSA%85DF\,(J8-);@9$+(]ITE'V>KF$S;@>P=3VH
M8SQ&[O$TXG6Z\-P)HV/$ K$X3EPE,MV"6;">*Y&RRD(>LC3AFK!A!_@T1%F?
M"AF!#7L^+#IG%.QX6Q0(5QAY!F2,0_%8.S#8&'E&UC(9]R1=PT[B:8BN'M6Q
MMPT;Z'[@?9A7UG]@S_'H@^^V#4"?9^- $:?SG#O.(4E<W2,A1*X"R)2S3SG6
M#B9'%'&N2J;N)G0>K+%^Y*$,[85(/B0&7_OH1@8NN;IC4G9H>&TZV*50K<MB
MXXX=MT# G<JTWL4\@K.NCD C?_"F1>3J[;=W/,<8/&1=>_QD0P<V$P8$8G2>
M82Z-!C\\2LXP:&JD\EG?\A\!B&X/@R#IT%D=;OYF]4J;]EUM([IYHQB*5*:H
M!!J#!64%@RBS NESTBXK6WR;UP!;$CJL&>L!&O??ZC74T\!U9[]-+G"QG$UQ
MT];V.KGW&N?D:TPW%7574Q?KX#LT'H(4 E31M5Z8XA.3L'C-=7*ARQCAK18=
M^ E=2]7/#J&'H0>SOG 4O+M^?)B"$27E -QHBG5<<13WHH.@I8D&36)>]^!H
MO1OVH7';X[&=Q$=P7+Z0E,M"V&QE &U$[3W+,[@@ZLZ0M/>RXM:VZ0[<0XYT
M$"]L1R!LERK=1BOC?L^[#L<_G_S7Z2[=RV__U[UE"YXDJ:><P!HRG\.?-_5:
MU^&@D^BK'0*F30%E)*_-#SB(R&I=6/%9M=ENSQ"UKX5YY-,WA1PV)4U;(8(7
MBA@FIY$\2/H%M2O2Z5*WS:$8'DFU35_XN&]3>M/#F MJ;FW>'O*4SWVMA;TY
M2$[R67PQQ143KC9?J9W*JC<< YTN*9+O3<=6X&V*! ]A?S9']*9-UKE++,CD
M,\1<6R QH\$77;OW(^TN3$IHWI;7NP2-V.IL@8HGK<X>TA^!FWS-QD=,LVF:
M7$Q6FGF"NY/E+TCJ"A>UJ^4E??GGS7]/$>BY]4H5;B(44]_0Y4#,>RE Z!B4
M-9Z)^U%9W]#K@XUA*V*: _;@FAXXJ7!:"J;E=1.C#0=WI5!E/<?E.L(Y^3:[
MG"[/A34)=6*0<HZTDWF$(&P$C!1LBV"Y0O[".;O'\L-6R_0-PD/I8;P6E?[B
M]6Q:;]:1_A(7Y\R*S+R+($5<O0\M)$9A(.F(1: -RC4.B9XG<-A"F@-;P;VT
MTV,FHIV%VYCW7^C/TR\K_I>7\^G5'@M229LQU@:J I32%# %+H'3;[67268I
M>[)USQ(R;'W-4%:O/]T<P5'[]\GR:^W\MV9UU<J/_NWW,/WY9O)CDBD2O&)<
M!I8UK^4#RI/(I27A>R] U[L1IE6(]]O([PS*SD1U JCYJP&TC<[&>UB__EIO
M[=Y.3Z>A3A2]<GIEUL$@\^#(YZ!#H7 (5FM(,97 =9$9&V<1NI#9":+V6"#:
M7E/CJ;GNLA4?'S][^F>M :;_X"I\6^]&%Y,QFLX*=%96+P8A:N'!U/8CV6II
M5)LJVKXYZ81I=VR8'E3?(["^;S;+UHE.JQO .M=XK=6+B]D?ZS8ZWG'4HH#+
MG':RHM_%)%VM7O"URX!YT/JO)PAW(*X3*OVQH;)OK0SLD_X^G=.&^C*=_.^*
MI<V&65SWF[YJ)GTRS1]P&BZ6-?PK5GM?8@%F:OCGC(48;:!#I' ?K9#.=:GC
MW67M;NER=BRH.H@*1F#+GN9Q+<YKQHC):WY3FE]B/K=)&!&=!H^<(CR4]#NA
M'<C$M2I18$EM;FSV(+H;3(_N6N=0:APO8C]_#<N_SRXO\EL*\-+RVD>Y=JU3
M\DXR SZ92%S6"2N\:,@\!>Z,$#FUZ16U&[W=<'ITMSD'4-X((/H&TQS)]WT[
M?6I?+C[2SV?3$"]^?I@M%I-:"QDL3]X; [+(0'(E-$7+,D0?I34LR,C;M'S8
MB=QN #V:FY[#J6X$^+QU>1J^;7H,G"Z6DV^TU\[*%5>UX/$<>;8B>@4,)0>5
MO"1W)B-X3<<&,Q(YMFG"TIW&;D@\WBN??I4TYFJQ.B#\P^G'3_]^\O%TA_*P
M._]Y;_5@3Q/54P'8:9A/*9I8?,#Y*FMRC1YF>2BV5A2C(/18*<$QE^N<2JMC
M4H[.O39IL"<HVCM1>.^[-_6.WMA@!:,P*48&2C,'GCD!///HBG(8&J5+GB1I
MX-FH?6#B0=ZN%_$?BP'9N1OE(Q]I8DP:]IY\$C[68M:D$B"?N5[*YD@JEXX$
M$%A4UF9CVU2ZM3(I-^\_[J_P*BPFJ78=F5Q<KJY8[G0LS,4PX3GY:<&NQFQ2
MT!OK[S03R6OCT;6Y$]N1X)&:HVWP]'2OR7:J.Q9C=26+67D=+M+E>G#U[(%@
M=B^=WV.Q)L9O'X:;^UU9<"G1@+"&8"63@*BR 8TZ)Y.]]/<G3XS<2+['Y<TD
MS',AM97,T9Y5]=%*<19\;2+G:J,O.NP3MVW>^-PA8Z0&;1O=WS=HNXMY!#F!
MO^/DRU<RMB<_<!Z^X/O+^@C[K*RDLSB[7"Z685HO/5:V^3RCBBQ["Q&U Y6Y
M 8_) 2-[SP1&%5B;!I%;D3GPC/D6&&NGIO%B<.,&/."1!)EX3$*"3;Y.3:^S
M:JS(=8XNXSXY*0,>$H5/$3KPQ/D#XK 758T B8]ZI.?*BX1)D8_+701E#">3
M7@H$@::$D+)J=.'Y*#G#5KHW0=7^8A\A=C9[XEP8E!&=@.)$=0A2!N=S E.R
M9.3.QM#H!O()@H8M6C\(?G81_;&$C#V\IW[V<TW"OH.\J'X26BXE+A@I/T5F
MR!W2M1-H+&!SM"B]+;)1Z[KVV:^3Z7*2*]I)MI\P7<XGM=IC/3<-\R^T_5ZO
MIGB'=>>2!ZG@53<>U%%)SB,()5<#<AUM$Z8@>&N2\$&&1I/8^^5CI*'E-NA[
M.E=V<$6/X$3=D^=7/Q__P*IGGL1B'%<<4-@ZB[JV\/!.@O#>6Z=%E(TF]C9D
M:M@-,"16[S<U' EP1KN'WH=O^&;V+4RFY^1CEY"")JAJ3UYV8B1G*P%S%7,6
MC#@\X$:XH6S@YHAC@5 G:.^HSQ'@\]-REOYQ^ZW(AXLPW;2"5-*@S]:!B+3[
M51U,[%6P4#Q/1EEN-&L#S6>(&B,J=]7^?6>C)U4,_:J7(J#93\05.V??5QU,
M/T^^K5\E?43RRB;U[=WJQ[]/)\M%J'7\\S*;?ZN/19[\9U==4+G"6LY/[IRN
M-1/*@ _> ?U=3DK88O1+\5=[*H?-@#=!Z<A4.S#(M^!*%)&2,AZB*ID<*57
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MDL>DO1%MKDD?I^>8;.0VN'E@(_?7QH!)G\5\><O*OPX+7)4F""N,%=H#!JE
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MK6"Q!L1ZF0%5WX^B9KM+;=!YJ:E65LY_GK\^.:<H%B./MG8/R!3&ISI<QDO
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M5M),%"4L6)<05*R7[-9[X"@4$DB\%FT2Y&-HN.7(,JOB**B1G#:)=ZS6PD5
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MB0PRRZR+S*78+E,&7UAF%.?9+LJ;M9'DSJ#X@?,XZ]=^/&9R;^ZMDPH%O0Z
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M;U]F/_[/YHMKZ['YP\IXK%!RL]YP+Q/[!<..$AR#SD_.I2S(K0H@8LVFV5C
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M=CA.CCZ/63WT=+N_^0B=/L5)N "3S\"A4.B][=/BW^.\//@ZVJNSTUH#]#?
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MRH!@T>DE"$-4PZE4GI+JK;UF6F(U3"[[7%:\WHJ*\ O6JF!O!=/8W7"M0!C
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M_68W;?ZYW+2[$DN=7G4G$G>_:H6TK56X?X8'(1IEXX=8FFRY'>5[81-10EQ
MXG-;X#]NU_"Y,J4_A['O:\[(,&%X8=[ASC=!",7!87(M>5]69#2/,,GM[.4
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M$-B/T':2+_#R6(SMD/?K(N?B^U2MP1JJ'.I>4D-DX?G"K:8[62@CCJ)S8L^
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MP;PI3>'B=/:Z"Y6K5!U%KX5F/HS"@>18F]J%XN!\9> 3@E72ZFAAR?QJQDN
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M!:)\-C*(LN>=DJ)!U#DQ;=*.4\ 7V[A4O18-@_LN5&$!_!B1S,@,X_()\(C
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MG/C=NCB8JE/9A\I<@9<Q8V$A<)JPD%3,3N)&'3H02/=!#K]%0_I>ZO"9J3^
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MYK]U>>&[DV%)S7%R;EW/C2MQ(-EE]WAEKSGD-\]*Y>&N704B!*(FY40T!\A
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M5X0CQM;?2)(6I+/ZAJ+3--1K$5-F\NC4PRO1F2'-#P.T"G*A/A:+;F&_P)N
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M&XXD^;W!P  YK)DQC][Y#9@U=6%<5-9>]TQ5*E?'R0LA9 ACKJ VJ/&J*\L
M_= @IC%BQI$?<5-.[F=(QY78.N];P3;C[/TOAF=7W'&Z$@J^%.N\BT4JG1)3
M=TQFJF,SV'Y@FUQ[C@2'+\8H*T:!R=IPN?<TZ5-XZX'7I BQY9\L2QY.T^.)
M()/)<^3X$4A ;JY1T89VBI#Q..P SDSJ@_^-9>&<U!R+7PW?O_^&T>LA%W*>
M6"-BH"!E"+#">IO&,[SN5XI*#JGO-3:=YU4 2;) 0:+$[18>CDX9)6M/;WR5
M!E^6.*QH&H+'3 PN/#;L:U?!T<(Q4.'LX@K@(/;I^$-:3S,U%#3?%X4Z-@Z
MD!]NQ_KTI0M?6F*T#;A4:S87C2?;DIB\[;K>"\X[X.!&3BZA(;/?5#9WQ-\6
M[<I;6?*9-1@B5-#&L5(#^6N9P00Q[XB\UF[Y9^(>4[?$8_'>'UOY__D2W(-\
M!%4B??)D1__NTJM#73SZ@)XPDH@'-AP?"(^4VGQJ(5LQ8P8'4((&55W;V":U
M<3%'Q!PO\_4Q.:?;N3^?8@\L.((%VX==[?%.(V@P,HX5MFW)8:5_X*BOXV\#
M0\AD0G5"X"O;"!B;R: 9X_S9</Z?L@!<N\+69J/&-*3'F%I2*G#B2N4U$CAG
M S;^NUXT+8@*]AY?-)LPQ#@P;K9.'T<MP[EC@'5I_>H%@<EFP\FX+TIR;&P2
MYU]D.-_>:#*>_?/UFU]_?O'\QQ>O7KR^>+];+?UT%>",6/8P+A7Q(4BU ,.?
M,TU$0L3NZB!R<)$N04O7IBHR6WVWLA'G7M-.9SW9=G 8"JJ.<'0$R_0W:E9-
MJQ<)6!>PQXIF+JD><FK44-DN69G2W6M>U/D1NQZ(TIM5:IVOX%.VUS<;,ZM_
MZ33ZG8G)5_#/O%V4W_]_4$L#!!0    ( #&*JE2$J%K*C0@  %4G   4
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M]EC#J#O-C:.686\<N]=JPV@UVM]E]KXQK" ;K:<'VS3J'>=!9LT\O#K$2*+
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MR<TJW[[LWWC[N/'ZOWCJ'RWRGT_V_P502P,$%     @ ,8JJ5"L]<R]&!@
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MRHU?"O)?_7TC^]*R_P]02P$"% ,4    "  QBJI4#D9FBAI"! "E-2L $
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M &)H8RTR,#(R,#,S,5]L86(N>&UL4$L! A0#%     @ ,8JJ5.[5;Z)Z[P
M@KD* !0              ( !5JH& &)H8RTR,#(R,#,S,5]P<F4N>&UL4$L!
M A0#%     @ ,8JJ5'\323,8.   >UD! !X              ( ! IH' &5X
M:&EB:70Q,#$S9F]R;6]F<G-U9W)A;G1A+FAT;5!+ 0(4 Q0    ( #&*JE09
M8EV[LSH  '2% 0 >              "  5;2!P!E>&AI8FET,3 Q-&9O<FUO
M9F]P=&EO;F=R82YH=&U02P$"% ,4    "  QBJI4A*A:RHT(  !5)P  %
M            @ %%#0@ 97AH:6)I=#,Q,7$Q,C R,BYH=&U02P$"% ,4
M"  QBJI4JLR</IT(  !K)P  %               @ $$%@@ 97AH:6)I=#,Q
M,G$Q,C R,BYH=&U02P$"% ,4    "  QBJI4"8II_S &  "9&0  %
M        @ '3'@@ 97AH:6)I=#,R,7$Q,C R,BYH=&U02P$"% ,4    "  Q
MBJI4*SUS+T8&  #$&0  %               @ $U)0@ 97AH:6)I=#,R,G$Q
>,C R,BYH=&U02P4&      P #  D P  K2L(

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
